PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DAJ	Hirsh, I; Vaissler, A; Chernin, J; Segol, O; Pizov, R				Hirsh, Irina; Vaissler, Alexander; Chernin, Josef; Segol, Ori; Pizov, Reuven			Fentanyl or tramadol, with midazolam, for outpatient colonoscopy: Analgesia, sedation, and safety	DIGESTIVE DISEASES AND SCIENCES			English	Article						gastrointestinal endoscopy; ambulatory analgesia; sedation; fentanyl; tramadol	RANDOMIZED CONTROLLED-TRIAL; GASTROINTESTINAL ENDOSCOPY; PAIN	The present study determined the acceptability of colonoscopy in outpatients treated with tramadol or fentanyl for analgesia and sedation. One hundred fifty patients were randomly assigned to receive midazolam, 0.05 mg/kg, and fentanyl, 2 mu g/kg, intravenously (group 1), midazolam, 0.05 mg/kg, and tramadol, 1 mg/kg, per os (group 2), or midazolam, 0.05 mg/kg, and tramadol, 2 mg/kg, per os (group 3). Pain severity, level of sedation, cardiorespiratory parameters, and procedure-related side effects and complications were registered and analyzed. No significant cardiorespiratory disturbances were observed. Sedation level during the procedure was similar in all groups. Pain severity values measured during the procedure was significantly higher in groups 2 and 3 than in group 1 (P < 0.001). Both hospital and home adverse events occurred more frequently in groups 2 and 3 compared to group 1 (P < 0.03). The patients receiving fentanyl-based analgesia tolerated colonoscopy better than patients treated with tramadol.	Technion Israel Inst Technol, Dept Anesthesiol & Crit Care Med, Lady Davies Carmel Med Ctr, IL-34362 Haifa, Israel; Technion Israel Inst Technol, Lady Davies Carmel Med Ctr, Dept Gastroenterol, IL-34362 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-34362 Haifa, Israel	Hirsh, I (reprint author), Technion Israel Inst Technol, Dept Anesthesiol & Crit Care Med, Lady Davies Carmel Med Ctr, 7 Michal St, IL-34362 Haifa, Israel.	hi767682@yahoo.com					ARROWSMITH JB, 1991, GASTROINTEST ENDOSC, V37, P421, DOI 10.1016/S0016-5107(91)70773-6; CHAPMAN CR, 2001, BONICAS MANAGEMENT P, P311; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; DANESHMEND TK, 1991, GUT, V32, P12, DOI 10.1136/gut.32.1.12; DAYER P, 1994, DRUGS, V47, P3, DOI 10.2165/00003495-199400471-00003; Duthie DJR, 1998, BRIT J ANAESTH, V81, P51; Eckardt VF, 1999, GASTROINTEST ENDOSC, V49, P560, DOI 10.1016/S0016-5107(99)70382-2; FLEISCHER D, 1989, GASTROINTEST ENDOSC, V35, P262, DOI 10.1016/S0016-5107(89)72773-5; Froehlich F, 1997, GASTROINTEST ENDOSC, V45, P1, DOI 10.1016/S0016-5107(97)70295-5; FUKUDA K, 2004, MILLERS ANESTHESIA; GROSSI L, 1940, DIGEST DIS SCI, V49, P1642; HERMAN LL, 1993, GASTROINTEST ENDOSC, V39, P388, DOI 10.1016/S0016-5107(93)70111-X; KNEEF EB, 1990, GASTROINTEST ENDOSC, V36, pS13; le Roux P J, 2000, Curr Opin Anaesthesiol, V13, P457, DOI 10.1097/00001503-200008000-00010; LEHMANN KA, 1994, DRUGS, V47, P19, DOI 10.2165/00003495-199400471-00005; Lewis KS, 1997, AM J HEALTH-SYST PH, V54, P643, DOI 10.1093/ajhp/54.6.643; Rawal N, 1992, PRACTICAL MANAGEMENT, P367; Rex DK, 1999, GASTROINTEST ENDOSC, V49, P554, DOI 10.1016/S0016-5107(99)70381-0; RISTIKANKARE M, 1999, GASTROINTEST ENDOSC, V49, P556; Roelofse JA, 1999, EUR J ANAESTH, V16, P441, DOI 10.1046/j.1365-2346.1999.00505.x; SUNSHINE A, 1994, DRUGS, V47, P8, DOI 10.2165/00003495-199400471-00004; Terruzzi V, 2001, GASTROINTEST ENDOSC, V54, P169, DOI 10.1067/mge.2001.113923	22	14	14	0	1	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0163-2116	1573-2568		DIGEST DIS SCI	Dig. Dis. Sci.	NOV	2006	51	11					1946	1951		10.1007/s10620-006-9413-9			6	Gastroenterology & Hepatology	Gastroenterology & Hepatology	109QM	WOS:000242323500010	17009113				2020-06-30	J	Webster, LR				Webster, Lynn R.			Fentanyl buccal tablets	EXPERT OPINION ON INVESTIGATIONAL DRUGS			English	Article						breakthrough pain; chronic non-malignant pain; chronic pain; effervescent; fentanyl buccal tablets	BREAKTHROUGH PAIN; CANCER-PATIENTS; PREVALENCE; CITRATE	Fentanyl buccal tablets (FBT) are designed to manage the breakthrough pain associated with chronic pain with an enhanced rate and extent of fentanyl absorption through the buccal mucosa. The formulation incorporates an effervescent reaction to produce large shifts in pH that enhance absorption. Results from studies of safety and tolerability have shown FBT to be effective and well tolerated in opioid-tolerant chronic pain patients. Adverse events were similar to those seen with other opioids and included nausea and somnolence. Adverse events were common but mild or moderate in most cases and did not cause a high drop-out rate. In addition to the treatment of breakthrough pain, FBT could be clinically efficacious for the treatment of brief, anticipated painful events. The abuse liability of FBT is unknown and caution should be used in prescribing FBT to patients with histories of substance abuse.	Lifetree Clin Res & Pain Clin, Salt Lake City, UT USA	Webster, LR (reprint author), Lifetree Clin Res & Pain Clin, Salt Lake City, UT USA.	lynnw@lifetreepain.com					DARWISH M, 2006, J PAIN S4, V7, pS35; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; HALE ME, 2006, ANN M AM AC PAIN MED; Pather SI, 2001, DRUG DELIV TECH, V1, P54; PORTENOY R, 2006, J PAIN S4, V7, pS35; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; SEGAL T, 2006, J PAIN S4, V7, pS35; TAYLOR D, 2006, J PAIN S2, V7, pS2; WEBSTER L, 2006, J PAIN S2, V7, pS52	13	9	10	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1354-3784	1744-7658		EXPERT OPIN INV DRUG	Expert Opin. Investig. Drugs	NOV	2006	15	11					1469	1473		10.1517/13543784.15.11.1469			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	102DK	WOS:000241791000014	17040204				2020-06-30	J	Kayacan, N; Ertugrul, F; Cete, N; Coskunfirat, N; Akar, M; Karsli, B; Erman, M				Kayacan, N.; Ertugrul, F.; Cete, N.; Coskunfirat, N.; Akar, M.; Karsli, B.; Erman, M.			Comparison of epidural and combined spinal-epidural analgesia in the management of labour without pain	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						labour analgesia; epidural analgesia; combined spinal-epidural analgesia; local anaesthetics; opioids		The effects of combined spinal-epidural analgesia (CSEA) and epidural analgesia (EA) were studied in 50 healthy parturients randomly allocated to receive bupivacaine plus fentanyl either epidurally, or intrathecally and epidurally. Significant differences from baseline values were seen in systolic blood pressure at all time-points except for 4 h in the EA group and at 3 and 4 h in the CSEA group. Significant differences from baseline values were seen in diastolic blood pressure at 1, 2, 3 and 4 h in the EA group, whereas no significant differences from baseline were seen in the CSEA group. Pain scores in both groups were significantly decreased compared with baseline and all scores, except at 2h, were significantly lower in the CSEA group compared with the EA group. The duration of labour and total amount of drugs used were significantly decreased and cervical dilatation was faster with CSEA compared with EA. In conclusion, CSEA was associated with more rapid onset of analgesia and faster progress in cervical dilatation compared with EA, and can be used safely for labour analgesia.	Akdeniz Univ, Fac Med, Dept Anaesthesiol & Reanimat, TR-07070 Antalya, Turkey; Akdeniz Univ, Dept Obstet & Gynaecol, TR-07070 Antalya, Turkey	Kayacan, N (reprint author), Akdeniz Univ, Fac Med, Dept Anaesthesiol & Reanimat, TR-07070 Antalya, Turkey.	nurtenkaycacan@yahoo.com	Coskunfirat, Nesil/C-4777-2016; Erman Akar, Munire/C-5390-2016; Ertugrul, Fatma/C-5401-2016; Karsli, Bilge/C-2468-2016	Coskunfirat, Nesil/0000-0003-0179-0043; Erman Akar, Munire/0000-0002-3856-3787; 			Cascio M, 1997, CAN J ANAESTH, V44, P605, DOI 10.1007/BF03015443; COLLIS RE, 1995, LANCET, V345, P1413, DOI 10.1016/S0140-6736(95)92602-X; GORTON H, 2000, CURR ANAESTH CRIT CA, V11, P92; Hughes D, 2003, COCHRANE DB SYST REV, V4; LEDERMAN RP, 1978, AM J OBSTET GYNECOL, V132, P495, DOI 10.1016/0002-9378(78)90742-1; Mattingly Jay E, 2003, Paediatr Drugs, V5, P615, DOI 10.2165/00148581-200305090-00004; Morgan GE, 2002, CLIN ANAESTHESIOL, P1; Tan T. K., 1998, Annals Academy of Medicine Singapore, V27, P235; THORP JA, 1993, AM J OBSTET GYNECOL, V169, P851, DOI 10.1016/0002-9378(93)90015-B; Tsen LC, 1999, ANESTHESIOLOGY, V91, P920, DOI 10.1097/00000542-199910000-00010; WILLDECKLUND G, 1979, ACTA ANAESTH SCAND, V23, P519, DOI 10.1111/j.1399-6576.1979.tb01482.x	11	8	12	0	8	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0300-0605	1473-2300		J INT MED RES	J. Int. Med. Res.	NOV-DEC	2006	34	6					596	602		10.1177/147323000603400604			7	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	129XW	WOS:000243764400004	17294991	Bronze			2020-06-30	J	Masri, R; Trageser, JC; Bezdudnaya, T; Li, Y; Keller, A				Masri, Radi; Trageser, Jason C.; Bezdudnaya, Tatiana; Li, Ying; Keller, Asaf			Cholinergic regulation of the posterior medial thalamic nucleus	JOURNAL OF NEUROPHYSIOLOGY			English	Article							EXCITATORY SYNAPTIC-TRANSMISSION; SOMATIC SENSORY RESPONSES; PRESYNAPTIC INHIBITION; ROSTRAL SECTOR; BRAIN-STEM; GROUP POM; INFORMATION; HIPPOCAMPUS; MODULATION; ACTIVATION	We previously showed that the GABAergic nucleus zona incerta (ZI) suppresses vibrissae-evoked responses in the posterior medial (POm) thalamus of the rodent somatosensory system. We proposed that this inhibitory incertothalamic pathway regulates POm responses during different behavioral states. Here we tested the hypothesis that this pathway is modulated by the ascending brain stem cholinergic system, which regulates sleep-wake cycles and states of vigilance. We demonstrate that cholinergic inputs facilitate POm responses to vibrissae stimulation. Activation of the cholinergic system by stimulation of brain stem cholinergic nuclei (laterodorsal tegmental and the pedunculopontine tegmental) or by tail pinch significantly increased the magnitude of POm responses to vibrissae stimulation. Microiontophoresis of the muscarinic receptor agonist carbachol enhanced POm responses to vibrissae stimulation. Application of carbachol to an in vitro slice preparation reduced the frequency but not the amplitude of miniature inhibitory postsynaptic currents, indicating a presynaptic site of action for carbachol. We conclude that the cholinergic system facilitates POm responses by suppressing GABAergic inputs from ZI. We propose the state-dependent gating hypothesis, which asserts that differing behavioral states, regulated by the brain stem cholinergic system, modulate the flow of information through POm.	Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA	Keller, A (reprint author), Univ Maryland, Sch Med, Dept Anat & Neurobiol, 20 Penn St, Baltimore, MD 21201 USA.	akeller@umaryland.edu		Keller, Asaf/0000-0001-8727-663X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-31078, R01 NS031078, R01 NS051799, F31 NS-046123, NS-051799, F31 NS046123]		Baba H, 1998, J PHYSIOL-LONDON, V508, P83, DOI 10.1111/j.1469-7793.1998.083br.x; Barnabi F, 2001, AM J PHYSIOL-REG I, V281, pR1665; Bartho P, 2002, EUR J NEUROSCI, V16, P999, DOI 10.1046/j.1460-9568.2002.02157.x; Bokor H, 2005, NEURON, V45, P929, DOI 10.1016/j.neuron.2005.01.048; Castro-Alamancos MA, 2004, PROG NEUROBIOL, V74, P213, DOI 10.1016/j.pneurobio.2004.09.002; Castro-Alamancos MA, 2002, J PHYSIOL-LONDON, V541, P319, DOI 10.1113/jphysiol.2002.016857; Cox CL, 2000, NEURON, V27, P597, DOI 10.1016/S0896-6273(00)00069-6; DIAMOND ME, 1992, J COMP NEUROL, V319, P66, DOI 10.1002/cne.903190108; DIAMOND ME, 1992, J COMP NEUROL, V318, P462, DOI 10.1002/cne.903180410; Friedberg MH, 1999, J NEUROPHYSIOL, V81, P2243; Fuentealba P, 2005, PROG NEUROBIOL, V75, P125, DOI 10.1016/j.pneurobio.2005.01.002; HALLANGER AE, 1987, J COMP NEUROL, V262, P105, DOI 10.1002/cne.902620109; Kayama Y, 1991, Fukushima J Med Sci, V37, P75; Lavallee P, 2005, J NEUROSCI, V25, P7489, DOI 10.1523/JNEUROSCI.2301-05.2005; LUPICA CR, 1992, J NEUROSCI, V12, P3753; MASRI RM, 2005, SOC NEUR ABSTR 17317, V35; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90066-8; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; SCANZIANI M, 1995, NEUROPHARMACOLOGY, V34, P1549, DOI 10.1016/0028-3908(95)00119-Q; Sherman SM, 1996, J NEUROPHYSIOL, V76, P1367; SHERMAN SM, 2005, EXPLORING THALAMUS I, P504; SHERMANSM, 2001, EXPLORING THALAMUS; Sosnik R, 2001, J NEUROPHYSIOL, V86, P339; Steriade M, 2003, NEURON, V37, P563, DOI 10.1016/S0896-6273(03)00065-5; STERIADE M, 1988, PHYSIOL REV, V68, P649; Steriade M, 2004, PROG BRAIN RES, V145, P179, DOI 10.1016/S0079-6123(03)45013-9; Timofeeva E, 2005, J NEUROSCI, V25, P9135, DOI 10.1523/JNEUROSCI.3073-05.2005; Trageser JC, 2006, J NEUROPHYSIOL, V96, P1456, DOI 10.1152/jn.00423.2006; Trageser JC, 2004, J NEUROSCI, V24, P8911, DOI 10.1523/JNEUROSCI.3218-04.2004; VARELA C, 2004, [No title captured], V34	30	26	26	0	2	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077	1522-1598		J NEUROPHYSIOL	J. Neurophysiol.	NOV	2006	96	5					2265	2273		10.1152/jn.00476.2006			9	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	095SP	WOS:000241328900011	16870838	Green Accepted			2020-06-30	J	Kwak, HJ; Kim, JY; Kwak, YL; Park, WS; Lee, KC				Kwak, Hyun J.; Kim, Ji Y.; Kwak, Young L.; Park, Won S.; Lee, Kyung C.			Comparison of a bolus of fentanyl with an infusion of alfentanil during target-controlled propofol infusion in third molar extraction under conscious sedation	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							MONITORED ANESTHESIA CARE; PATIENT-CONTROLLED PROPOFOL; INTRAVENOUS SEDATION; MIDAZOLAM; ANALGESIA; RECOVERY; SURGERY; PHARMACOKINETICS; SCALE	Purpose: This study was designed to compare hemodynamic changes, respiratory depression, and patient satisfaction between a bolus of fentanyl and an infusion of alfentanil during target-controlled propofol infusion in third molar extraction under conscious sedation. Patients and Methods: Forty patients were randomly assigned to receive either a bolus of fentanyl (n = 24) or an infusion of alfentanil (n = 16) in combination with target-controlled propofol infusion. Hemodynamic changes, respiratory depression, sedation, and cooperation scores were recorded during surgery and patient satisfaction scores were assessed after surgery. Results: Changes in mean blood pressure, heart rate, or oxygen saturation within and between the groups were not significant throughout the procedure. There were no significant differences in sedation, cooperation, and patient satisfaction scores between the 2 groups. Conclusion: Because there was no difference in hemodynamic variables and patient satisfaction scores between a bolus of fentanyl and an infusion of alfentanil during target-controlled propofol infusion, both combinations are suitable for conscious sedation in third molar extraction.	Gachon Univ Med & Sci, Gil Med Ctr, Gachon Med Sch, Dept Anesthesiol & Pain Med, Inchon 405760, South Korea; Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Seoul, South Korea; Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Seoul, South Korea	Lee, KC (reprint author), Gachon Univ Med & Sci, Gil Med Ctr, Gachon Med Sch, Dept Anesthesiol & Pain Med, 1198 Guwol Dong, Inchon 405760, South Korea.	leekc@gilhospital.com		Kwak, Young-Lan/0000-0002-2984-9927			Avramov MN, 1997, ANESTH ANALG, V85, P566, DOI 10.1097/00000539-199709000-00015; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; BOSEK V, 1992, J CLIN ANESTH, V4, P480, DOI 10.1016/0952-8180(92)90223-N; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; COOPER GM, 1983, BRIT J ANAESTH, V55, pS179; Dexter F, 1997, ANESTHESIOLOGY, V87, P865, DOI 10.1097/00000542-199710000-00021; Dilger JA, 2004, CAN J ANAESTH, V51, P20, DOI 10.1007/BF03018541; Dionne RA, 2001, J AM DENT ASSOC, V132, P740, DOI 10.14219/jada.archive.2001.0271; GILL SS, 1990, BRIT J ANAESTH, V65, P760, DOI 10.1093/bja/65.6.760; HUGHES MA, 1992, ANESTHESIOLOGY, V76, P334, DOI 10.1097/00000542-199203000-00003; JENSTRUP M, 1990, BRIT J ANAESTH, V64, P717, DOI 10.1093/bja/64.6.717; KAY B, 1983, BRIT J ANAESTH, V55, pS169; Mertens MJ, 2004, ANESTHESIOLOGY, V100, P795, DOI 10.1097/00000542-200404000-00008; OCONNOR M, 1983, BR J ANAESTH S2, V55, P217; Oei-Lim VLB, 1998, BRIT J ANAESTH, V80, P324; OSBORNE GA, 1994, ANAESTHESIA, V49, P287, DOI 10.1111/j.1365-2044.1994.tb14175.x; OSBORNE GA, 1991, ANAESTHESIA, V46, P553, DOI 10.1111/j.1365-2044.1991.tb09654.x; Parworth LP, 1998, J ORAL MAXIL SURG, V56, P447, DOI 10.1016/S0278-2391(98)90710-8; Pavlin DJ, 1996, ANESTHESIOLOGY, V84, P23, DOI 10.1097/00000542-199601000-00004; SANDIN R, 1993, BRIT J ANAESTH, V71, P782, DOI 10.1093/bja/71.6.782; Sandler NA, 2001, J ORAL MAXIL SURG, V59, P603, DOI 10.1053/joms.2001.23366; SCAMMAN FL, 1984, ACTA ANAESTH SCAND, V28, P63, DOI 10.1111/j.1399-6576.1984.tb02013.x; SHAFER SL, 1992, J PHARMACOKINET BIOP, V20, P147, DOI 10.1007/BF01070999; SHERRY E, 1992, ANAESTHESIA, V47, P477, DOI 10.1111/j.1365-2044.1992.tb02268.x; SMITH I, 1994, ANESTHESIOLOGY, V81, P1005; TAYLOR IN, 1992, BRIT J ANAESTH, V69, P168, DOI 10.1093/bja/69.2.168; White P F, 1991, J Clin Anesth, V3, P32, DOI 10.1016/0952-8180(91)90203-Y; WHITE PF, 1986, ANESTHESIOLOGY, V64, P99, DOI 10.1097/00000542-198601000-00018	28	5	5	1	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391			J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	NOV	2006	64	11					1577	1582		10.1016/j.joms.2005.11.112			6	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	100SS	WOS:000241689600002	17052581				2020-06-30	J	Yassen, A; Kan, JM; Olofsen, E; Suidgeest, E; Dahan, A; Danhof, M				Yassen, Ashraf; Kan, Jingmin; Olofsen, Erik; Suidgeest, Ernst; Dahan, Albert; Danhof, Meindert			Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							MU-OPIOID RECEPTOR; VENTILATORY RESPONSE; IN-VIVO; NORBUPRENORPHINE; PHARMACOLOGY; METABOLITE; KINETICS; MORPHINE; BINDING	The purpose of this investigation was to develop a mechanismbased pharmacokinetic/pharmacodynamic (PK/PD) model to predict the time course of respiratory depression following administration of opioids in rats. The proposed model is based on receptor theory and aims at the separate characterization of biophase distribution and receptor association/dissociation kinetics as determinants of hysteresis between plasma concentration and effect. Individual concentration time courses of buprenorphine and fentanyl were determined in conjunction with continuous monitoring of respiratory depression. Buprenorphine and fentanyl were administered intravenously in various doses. For buprenorphine hysteresis was best described by a combined biophase distribution-receptor association/ dissociation model with a linear transducer function. The values of the parameter estimates of the rate constants for biophase distribution (k(eo)), receptor association (k(on)), and dissociation (k(off)) were 0.0348 min(-1) [95% confidence interval (CI), 0.0193-0.0503 min(-1)], 0.57 ml/ng/min (95% CI, 0.38-0.76 ml/ng/min), and 0.0903 min(-1) (95% CI, 0.035-0.196 min(-1)), respectively. The values of the equilibrium dissociation constant and intrinsic activity were 0.16 ng/ml and 0.48 (95% CI, 0.45-0.51), respectively. The value of the K-d is close to reported estimates of receptor affinity in vitro confirming the validity of the mechanism-based PK/PD model. For fentanyl, unrealistically high estimates of the rate constants for receptor association and dissociation were obtained, indicating that hysteresis is caused solely by biophase distribution kinetics. This is consistent with fentanyl's fast receptor association/dissociation kinetics in vitro. As a result, the mechanism-based PK/PD model of fentanyl could be reduced to a biophase distribution model with fractional sigmoid E-max pharmacodynamic model.	Leiden Amsterdam Ctr Drug Res, Gorlaeus Labs, Div Pharmacol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Dept Anesthesiol, Med Ctr, Leiden, Netherlands	Danhof, M (reprint author), Leiden Amsterdam Ctr Drug Res, Gorlaeus Labs, Div Pharmacol, POB 9502, NL-2300 RA Leiden, Netherlands.	m.danhof@lacdr.leidenuniv.nl	Dahan, Albert/B-8845-2008	Dahan, Albert/0000-0003-3161-3945			Bailey PL, 2000, NEW ENGL J MED, V343, P1228, DOI 10.1056/NEJM200010263431705; BAXTER AD, 1994, CAN J ANAESTH, V41, P87, DOI 10.1007/BF03009796; BEAL SL, 1999, NONMEM USERS GUIDE; BLACK JW, 1983, PROC R SOC SER B-BIO, V220, P141, DOI 10.1098/rspb.1983.0093; BOAS RA, 1985, BRIT J ANAESTH, V57, P192, DOI 10.1093/bja/57.2.192; Cassel JA, 2005, EUR J PHARMACOL, V520, P29, DOI 10.1016/j.ejphar.2005.08.008; CLARK AJ, 1937, HEFFNERS HDB EXPT PH, V4, P38; COWAN A, 1977, BRIT J PHARMACOL, V60, P547, DOI 10.1111/j.1476-5381.1977.tb07533.x; Cox EH, 1998, J PHARMACOL EXP THER, V284, P1095; Cox EH, 1999, ANESTHESIOLOGY, V90, P535, DOI 10.1097/00000542-199902000-00030; Dahan A, 2005, BRIT J ANAESTH, V94, P825, DOI 10.1093/bja/aei145; Dahan A, 1996, BRIT J ANAESTH, V76, P747; Danhof M, 2005, PHARM RES, V22, P1432, DOI 10.1007/s11095-005-5882-3; Ette EL, 2003, J CLIN PHARMACOL, V43, P610, DOI 10.1177/0091270003253624; GAL TJ, 1989, CLIN PHARMACOL THER, V45, P66, DOI 10.1038/clpt.1989.10; Galynker I, 1996, NUCL MED BIOL, V23, P325, DOI 10.1016/0969-8051(95)02087-X; Huang P, 2001, J PHARMACOL EXP THER, V297, P688; Inturrisi CE, 2002, CLIN J PAIN, V18, pS3, DOI 10.1097/00002508-200207001-00002; Jonker DM, 2005, PHARMACOL THERAPEUT, V106, P1, DOI 10.1016/j.pharmthera.2004.10.014; Joranson DE, 2000, JAMA-J AM MED ASSOC, V283, P1710, DOI 10.1001/jama.283.13.1710; Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6; Megarbane B, 2006, TOXICOL APPL PHARM, V212, P256, DOI 10.1016/j.taap.2005.08.002; OHTANI M, 1995, J PHARMACOL EXP THER, V272, P505; Ohtani M, 1997, J PHARMACOL EXP THER, V281, P428; Pasternak GW, 2004, NEUROPHARMACOLOGY, V47, P312, DOI 10.1016/j.neuropharm.2004.07.004; Romberg R, 2003, BRIT J ANAESTH, V91, P862, DOI 10.1093/bja/aeg279; ROTHMAN RB, 1995, SYNAPSE, V21, P60, DOI 10.1002/syn.890210109; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; Selley DE, 1997, MOL PHARMACOL, V51, P87; SHEINER LB, 1979, CLIN PHARMACOL THER, V25, P358; Shimada S, 1996, BIOL PHARM BULL, V19, P430; SHIUE CY, 1991, NUCL MED BIOL, V18, P281; Snyder SH, 2003, TRENDS PHARMACOL SCI, V24, P198, DOI 10.1016/S0165-6147(03)00066-X; STANSKI DR, 1992, ANNU REV PHARMACOL, V32, P423, DOI 10.1146/annurev.pharmtox.32.1.423; VanderGraaf PH, 1997, INT J CLIN PHARM TH, V35, P442; Visser SAG, 2002, J PHARMACOL EXP THER, V302, P1158, DOI 10.1124/jpet.302.3.1158; Yassen A, 2005, J PHARMACOL EXP THER, V313, P1136, DOI 10.1124/jpet.104.082560; Yassen A, 2006, ANESTHESIOLOGY, V104, P1232, DOI 10.1097/00000542-200606000-00019; Zhang LP, 2003, J PHARMACOKINET PHAR, V30, P387, DOI 10.1023/B:JOPA.0000012998.04442.1f; Zuideveld KP, 2004, J PHARMACOL EXP THER, V308, P1012, DOI 10.1124/jpet.103.059030	40	32	34	0	8	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	NOV	2006	319	2					682	692		10.1124/jpet.106.107953			11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	096UY	WOS:000241403500020	16855177				2020-06-30	J	Hamabe, W; Maeda, T; Fukazawa, Y; Kumamoto, K; Shang, LQ; Yamamoto, A; Yamamoto, C; Tokuyama, S; Kishioka, S				Hamabe, Wakako; Maeda, Takehiko; Fukazawa, Yohji; Kumamoto, Kazumasa; Shang, Lu Qing; Yamamoto, Akihiro; Yamamoto, Chizuko; Tokuyama, Shogo; Kishioka, Shiroh			P-glycoprotein ATPase activating effect of opioid analgesics and their P-glycoprotein-dependent antinociception in mice	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						opioid analgesics; antinociception; blood-brain barrier; P-glycoprotein ATPase activity; mdr1a deficient mice	BLOOD-BRAIN-BARRIER; MULTIDRUG TRANSPORTER; ENDOTHELIAL-CELLS; MORPHINE; PURIFICATION; RAT; RECONSTITUTION; CAPILLARIES; INHIBITION; HYDROLYSIS	It is well known that opioid analgesics exert central antinociceptive actions. However, in vivo and in vitro studies have shown that some opioid analgesics given systemically have limited access to the central nervous system because of the blood-brain barrier (BBB). P-glycoprotein (P-gp), an ATP-dependent drug efflux transporter, is one component of the BBB. In this report, we assessed the antinociceptive effect of morphine, fentanyl, and meperidine in P-gp deficient (mdr1 a KO) mice, and compared these effects with those in wild type (WT) mice. The antinociceptive effects of morphine and fentanyl in mdr1 a KO mice were significantly greater than those in WT mice. However, there was no clear difference in the antinociceptive effects of meperidine in the two genotypes. In addition, we determined the effect of opioid analgesics on P-gp ATPase activity, which is requisite for drug transport, using mouse brain capillary endothelial cells. In our observations, morphine and fentanyl, but not meperidine, significantly increased P-gp ATPase activity, and the drugs' concentration-response curves were bell-shaped, reaching a peak at a concentration of 1 mu M. These results suggest that P-gp ATPase activity may be, at least in part, involved in the antinociceptive potencies of those opioid analgesics that are substrates for P-gp. (c) 2006 Elsevier Inc. All rights reserved.	Wakayama Med Univ, Dept Pharmacol, Wakayama, Wakayama 6418509, Japan; Kobe Gakuin Univ, Fac Pharmaceut Sci, Dept Clin Chem, Nishi Ku, Kobe, Hyogo 6512180, Japan	Kishioka, S (reprint author), Wakayama Med Univ, Dept Pharmacol, 811-1 Kimiidera, Wakayama, Wakayama 6418509, Japan.	kishioka@wakayama-med.ac.jp		Maeda, Takehiko/0000-0002-3184-0999			Abbruscato TJ, 1997, J PHARMACOL EXP THER, V280, P402; Al-Shawi MK, 2005, J BIOENERG BIOMEMBR, V37, P489, DOI 10.1007/s10863-005-9497-5; Al-Shawi MK, 2003, J BIOL CHEM, V278, P52629, DOI 10.1074/jbc.M308175200; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; Bauer B, 2005, EXP BIOL MED, V230, P118; BOADO RJ, 1991, J NEUROCHEM, V57, P2136, DOI 10.1111/j.1471-4159.1991.tb06433.x; CALLAGHAN R, 1993, J BIOL CHEM, V268, P16059; CIRELLA VN, 1987, ANESTH ANALG, V66, P703; Dagenais C, 2004, BIOCHEM PHARMACOL, V67, P269, DOI 10.1016/j.bcp.2003.08.027; DALLAIRE L, 1991, BIOCHEM J, V276, P745, DOI 10.1042/bj2760745; de Boer AG, 2003, ANNU REV PHARMACOL, V43, P629, DOI 10.1146/annurev.pharmtox.43.100901.140204; Dong MQ, 1996, J BIOL CHEM, V271, P28875, DOI 10.1074/jbc.271.46.28875; ECKER G, 1995, WIEN KLIN WOCHENSCHR, V107, P681; Emmerson PJ, 1996, J PHARMACOL EXP THER, V278, P1121; Fromm MF, 2004, TRENDS PHARMACOL SCI, V25, P423, DOI 10.1016/j.tips.2004.06.002; Garrigos M, 1997, EUR J BIOCHEM, V244, P664, DOI 10.1111/j.1432-1033.1997.00664.x; Garrigues A, 2002, P NATL ACAD SCI USA, V99, P10347, DOI 10.1073/pnas.162366399; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gourlay G, 2005, SUPPORT CARE CANCER, V13, P153, DOI 10.1007/s00520-004-0690-6; He L, 2002, ACTA PHARMACOL SIN, V23, P423; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; Idriss HT, 2000, J PHYSIOL-LONDON, V524, P629, DOI 10.1111/j.1469-7793.2000.00629.x; King M, 2001, NAT NEUROSCI, V4, P268, DOI 10.1038/85115; Letrent SP, 1999, DRUG METAB DISPOS, V27, P827; Lotsch J, 2004, CLIN PHARMACOKINET, V43, P983; MIYAMOTO Y, 1991, BRAIN RES, V552, P136, DOI 10.1016/0006-8993(91)90671-H; Regina A, 1998, J NEUROCHEM, V71, P705; Rodriguez M, 2004, J PHARM PHARMACOL, V56, P367, DOI 10.1211/0022357022782; ROY SD, 1989, PHARM RES-DORDR, V6, P825, DOI 10.1023/A:1015944018555; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Shimizu N, 2004, J PHARMACOL SCI, V94, P240, DOI 10.1254/jphs.94.240; TAKAGI H, 1966, JPN J PHARMACOL, V16, P287, DOI 10.1254/jjp.16.287; Thompson SJ, 2000, ANESTHESIOLOGY, V92, P1392, DOI 10.1097/00000542-200005000-00030; Tombline G, 2004, J BIOL CHEM, V279, P5363, DOI 10.1074/jbc.M311964200; Tsuji A, 1997, Nihon Rinsho, V55, P1059; Wandel C, 2002, ANESTHESIOLOGY, V96, P913, DOI 10.1097/00000542-200204000-00019; Zong J, 2000, PHARMACEUT RES, V17, P749, DOI 10.1023/A:1007546719287	38	41	45	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	NOV	2006	85	3					629	636		10.1016/j.pbb.2006.10.018			8	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	134ZD	WOS:000244122500018	17134744				2020-06-30	J	Hartrick, CT; Bourne, MH; Gargiulo, K; Damaraju, CV; Vallow, S; Hewitt, DJ				Hartrick, Craig T.; Bourne, Michael H.; Gargiulo, Kathryn; Damaraju, C. V.; Vallow, Sue; Hewitt, David J.			Fentanyl iontophoretic transdermal system for acute-pain management after orthopedic surgery: A comparative study with morphine intravenous patient-controlled analgesia	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article; Proceedings Paper	59th Postgraduate Assembly of the New-York-State-Society-of-Anesthesiologists	DEC 09-13, 2005	New York, NY	New York State Soc Anesthesiologists		acute-pain management; fentanyl; multimodal therapy; patient-controlled analgesia; rofecoxib; total-hip replacement	POSTOPERATIVE PAIN	Background and Objectives: The fentanyl HCl iontophoretic transdermal system (ITS) has been demonstrated in clinical trials to be safe and effective for acute-pain management after several types of major surgery. The current study compared the efficacy, safety, and convenience of fentanyl ITS with morphine intravenous patient-controlled analgesia (IV PCA) for acute-pain management after unilateral total-hip replacement (THR). Methods: In this multicenter (52 sites), randomized, open-label, active-controlled, phase IIIb, study, patients (n = 799) received fentanyl ITS (40 mu g fentanyl [10-minute infusion/lockout], up to 6 doses/h) or morphine IV PCA (1-mg morphine bolus [5-minute lockout], up to 10 mg/h) after unilateral THR. The primary efficacy measure was success ratings ("excellent" or "good") on the patient global assessment (PGA) of the method of pain control in the first 24 hours. Pain intensity and adverse events were also assessed. Results: The PGA success ratings (83.0% v 82.2%; difference = 0.9%; 95% CI: -4.4% to 6.1%) and the mean last pain-intensity scores (3.0 v 3.0; difference = 0.0; 95% CI: -0.33 to 0.33) in the first 24 hours were statistically equivalent between fentanyl ITS and morphine IV PCA groups, respectively. The incidence of adverse events was similar between the groups. Conclusions: Results of this study demonstrate fentanyl ITS and a standard regimen of morphine IV PCA were comparable methods of pain control for management of acute postoperative pain after THR, on the basis of the PGA success ratings and pain intensity in the first 24 hours of treatment.	William Beaumont Hosp, Dept Anesthesiol, Royal Oak, MI 48073 USA; Univ Utah, Sch Med, Salt Lake City, UT USA; Salt Lake Orthopaed Clin, Salt Lake City, UT USA; Ortho McNeil Janssen Sci Affairs LLC, Raritan, NJ USA; Ortho McNeil Inc, Raritan, NJ USA	Hartrick, CT (reprint author), William Beaumont Hosp, Dept Anesthesiol, 3601 W 13 Mile Rd, Royal Oak, MI 48073 USA.	chartrick@beaumont.edu					BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; Kalia YN, 2004, ADV DRUG DELIVER REV, V56, P619, DOI 10.1016/j.addr.2003.10.026; Sinatra R, 2005, CLIN PHARMACOKINET, V44, P1; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x	5	67	69	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1098-7339			REGION ANESTH PAIN M	Region. Anesth. Pain Med.	NOV-DEC	2006	31	6					546	554		10.1016/j.rapm.2006.08.011			9	Anesthesiology	Anesthesiology	114XK	WOS:000242698700012	17138198				2020-06-30	J	Chan, JHH; Heilpern, GNA; Packham, I; Trehan, RK; Marsh, GDJ; Knibb, AA				Chan, Jason H. H.; Heilpern, Giles N. A.; Packham, Iain; Trehan, Ravi K.; Marsh, Gavin D. J.; Knibb, Aston A.			A prospective randomized double-blind trial of the use of intrathecal fentanyl in patients undergoing lumbar spinal surgery	SPINE			English	Article						intrathecal; fentanyl; analgesia; lumbar spine; randomized controlled trial	POSTOPERATIVE PAIN; MORPHINE; ANALGESIA	Study Design. A randomized, double-blind controlled study. Objective. To assess the efficacy and safety of intrathecal fentanyl in the relief of postoperative pain in patients undergoing lumbar spinal surgery. Summary of Background Data. Fentanyl has been used as a spinal analgesic in surgery and obstetrics with several studies promoting its efficacy and safety. There is no evidence in the literature about intrathecal fentanyl in lumbar spinal surgery. Previous studies have looked at the use of intrathecal morphine and conclude that it is effective but also associated with respiratory depression. Methods. Sixty patients undergoing posterior lumbar spine decompression with or without instrumented fusion were randomized to receive either 15 mu g of fentanyl intrathecally under direct vision or nothing just before wound closure. After surgery, all patients received intravenous (IV) morphine via patient-controlled analgesia system (PCA) syringe driver. Outcome measures included visual analogue scores (VAS) for pain, time to first bolus of IV morphine PCA, and total amount of morphine PCA used. Results. The patients who received fentanyl demonstrated a significant decrease in their mean pain VAS, an increase in the time to first PCA bolus, and a 41% reduction in the total PCA morphine received. No patients had respiratory compromise requiring treatment. There was no significant difference between the two groups with respect to age, gender, and case mix. Conclusion. Intrathecal fentanyl is effective at reducing pain and morphine PCA use after lumbar spinal surgery with minimal respiratory depression.	Mayday Univ Hosp, Thornton Heath, Dept Orthopaed, Thornton Heath, England; Mayday Univ Hosp, Thornton Heath, Dept Anaesthesia, Thornton Heath, England	Chan, JHH (reprint author), MRCS, 191A Tudor Dr, Kingston upon Thames KT2 5NU, Surrey, England.	jhhchan@hotmail.com					Arms DM, 1998, ORTHOPEDICS, V21, P539; BELZARENA SD, 1992, ANESTH ANALG, V74, P653; BERNARD JM, 1991, INT C COTR DUB INSTR; Boezaart AP, 1999, SPINE, V24, P1131, DOI 10.1097/00007632-199906010-00013; COUSINS MJ, 1984, ANESTHESIOLOGY, V61, P276; ETCHES RC, 1994, CAN J ANAESTH, V41, P125, DOI 10.1007/BF03009805; France JC, 1997, SPINE, V22, P2272, DOI 10.1097/00007632-199710010-00015; Grace D, 1996, ANESTH ANALG, V83, P1055, DOI 10.1097/00000539-199611000-00027; GRASS JA, 1992, J PAIN SYMPTOM MANAG, V7, P419, DOI 10.1016/0885-3924(92)90022-A; Greenbarg P E, 1988, J Spinal Disord, V1, P139; Hagg O, 2003, EUR SPINE J, V12, P12, DOI 10.1007/s00586-002-0464-0; Hamber EA, 1999, REGION ANESTH PAIN M, V24, P255; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; JACOBSON L, 1988, ANESTH ANALG, V67, P1082, DOI 10.1213/00000539-198867110-00011; JORDAN C, 1979, BRIT J ANAESTH, V51, P497, DOI 10.1093/bja/51.6.497; KARPOS PAG, 1994, J BONE JOINT SURG AM, V76A, P916, DOI 10.2106/00004623-199406000-00018; KIRSON LE, 1989, ANESTHESIOLOGY, V71, P192, DOI 10.1097/00000542-198908000-00004; KITAHATA LM, 1981, ANESTHESIOLOGY, V54, P153, DOI 10.1097/00000542-198102000-00010; Lim EHL, 2002, CAN J ANAESTH, V49, P57, DOI 10.1007/BF03020419; ONEILL P, 1985, J NEUROSURG, V63, P413, DOI 10.3171/jns.1985.63.3.0413; PAYNE R, 1987, ACTA ANAESTH SCAND, V31, P38, DOI 10.1111/j.1399-6576.1987.tb02668.x; REVILL SI, 1976, ANAESTHESIA, V31, P1191, DOI 10.1111/j.1365-2044.1976.tb11971.x; Shende D, 1998, ANAESTHESIA, V53, P706, DOI 10.1046/j.1365-2044.1998.329-az0482.x; Techanivate Anchalee, 2003, J Med Assoc Thai, V86, P262; Ummenhofer WC, 2000, ANESTHESIOLOGY, V92, P739, DOI 10.1097/00000542-200003000-00018; Urban MK, 2002, SPINE, V27, P535, DOI 10.1097/00007632-200203010-00015; YAKSH TL, 1981, PAIN, V11, P293, DOI 10.1016/0304-3959(81)90633-3; YEUNG JC, 1980, J PHARMACOL EXP THER, V215, P633	28	15	20	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	OCT 15	2006	31	22					2529	2533		10.1097/01.brs.0000241135.79983.52			5	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	098KK	WOS:000241519200003	17047539				2020-06-30	J	Lee, J; Oh, Y; Kim, C; Kim, S; Park, H; Kim, H				Lee, J.; Oh, Y.; Kim, C.; Kim, S.; Park, H.; Kim, H.			Fentanyl reduces desflurane-induced airway irritability following thiopental administration in children	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						airway irritation; anesthesia; anesthetics; complications; desflurane; fentanyl; inhalation; narcotics; pediatric	SEVOFLURANE ANESTHESIA; EMERGENCE AGITATION; INDUCTION; MAINTENANCE; REFLEXES; INFANTS	Background: Airway irritation is a major drawback of desflurane anesthesia. This study was designed to evaluate the effect of intravenous fentanyl given before thiopental induction on airway irritation caused by a stepwise increase in desflurane in children. Methods: Eighty children (2-8 years) were enrolled in a randomized, double-blind study. Forty received saline and 40 received 2 mu g/kg of fentanyl intravenously; this was followed by thiopental sodium 5 mg/kg in both groups. Patients were assistant-ventilated with desflurane 1%, which was then increased by 1% every six breaths up to 10%. During this period, cough, secretion, excitation and apnea were graded and the desflurane concentration at which airway irritation symptoms first occurred was recorded. The results were analyzed using Pearson's chi-squared test. Results: The incidence of typical airway irritation events was lower with fentanyl than with saline (cough, 2.5% vs. 42.5%; secretion, 27.5% vs. 82.5%; excitation, 10% vs. 82.5%; apnea, 20% vs. 65%; P < 0.05). The mean expired desflurane concentration at which the first airway irritation symptom occurred was greater with fentanyl than with saline (7.3% vs. 5.5%, P < 0.05). Conclusions: Intravenous fentanyl in children reduces airway complications caused by desflurane.	Seoul Natl Univ Hosp, Dept Anesthesiol, Coll Med, Seoul 110744, South Korea	Kim, H (reprint author), Seoul Natl Univ Hosp, Dept Anesthesiol, Coll Med, 28 Yeongeondong, Seoul 110744, South Korea.	dami0605@snu.ac.kr	Kim, Hee Soo/J-5453-2012				ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Bailey JM, 1997, ANESTH ANALG, V85, P681, DOI 10.1097/00000539-199709000-00036; Cohen IT, 2002, ANESTH ANALG, V94, P1178, DOI 10.1097/00000539-200205000-00023; Cohen IT, 2001, ANESTH ANALG, V93, P88; Demirbilek S, 2004, EUR J ANAESTH, V21, P538, DOI 10.1017/S0265021504007069; EGER EI, 1987, ANESTH ANALG, V66, P971; Joseph PC, 2001, CLIN ANESTH, P1199; Kamei J, 1996, PULM PHARMACOL THER, V9, P349, DOI 10.1006/pulp.1996.0046; Kong CF, 2000, BRIT J ANAESTH, V85, P364, DOI 10.1093/bja/85.3.364; Mckay RE, 2005, ANESTH ANALG, V100, P697, DOI 10.1213/01.ANE.0000146514.65070.AE; Tagaito Y, 1998, ANESTHESIOLOGY, V88, P1459, DOI 10.1097/00000542-199806000-00007; Tanaka S, 1996, ANESTH ANALG, V82, P821, DOI 10.1097/00000539-199604000-00025; TAYLOR RH, 1992, CAN J ANAESTH, V39, P6, DOI 10.1007/BF03008665; ZWASS MS, 1992, ANESTHESIOLOGY, V76, P373, DOI 10.1097/00000542-199203000-00009	14	6	7	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	OCT	2006	50	9					1161	1164		10.1111/j.1399-6576.2006.01134.x			4	Anesthesiology	Anesthesiology	086FX	WOS:000240660300019	16987347				2020-06-30	J	VanNatta, ME; Rex, DK				VanNatta, Megan E.; Rex, Douglas K.			Propofol alone titrated to deep sedation versus propofol in combination with opioids and/or benzodiazepines and titrated to moderate sedation for colonoscopy	AMERICAN JOURNAL OF GASTROENTEROLOGY			English	Article							NURSE-ADMINISTERED PROPOFOL; GASTROINTESTINAL ENDOSCOPY; REGISTERED NURSES; RANDOMIZED-TRIAL; GASTROENTEROLOGIST SUPERVISION; OUTPATIENT COLONOSCOPY; CONSCIOUS SEDATION; MIDAZOLAM; MEPERIDINE; ANESTHETIST	BACKGROUND: Propofol by nonanesthesiologists is controversial because the drug is commonly used to produce deep sedation or general anesthesia. Propofol in combination with opioids and/or benzodiazepines can be titrated to moderate sedation, which might be safer. AIM: To compare recovery time, patient satisfaction, and other end points with propofol alone titrated to deep sedation versus propofol combination therapy with opioids and/or benzodiazepines. METHOD: A randomized controlled clinical trial of propofol alone titrated to deep sedation versus fentanyl plus propofol versus midazolam plus propofol versus fentanyl plus midazolam plus propofol in 200 outpatients undergoing colonoscopy. Each combination regimen was titrated to moderate sedation. RESULTS: Patients receiving propofol alone received higher doses of propofol and had deeper sedation scores compared with combination therapy (both p < 0.001). Patients receiving combination regimens were discharged more quickly (median 13.0-14.7 versus 18.1 min) than those receiving propofol alone (p < 0.01). There were no differences in vital signs or oxygen saturations among the study arms. There were no significant differences in pain or satisfaction among the study arms in the recovery area. At a follow-up phone call, patients receiving fentanyl and propofol remembered more of the procedure than those in the other regimens (p < 0.005) and remembered more pain than those receiving propofol alone (p < 0.02). CONCLUSIONS: Propofol in combination with fentanyl and/or midazolam can be titrated to moderate levels of sedation without substantial loss of satisfaction and with shorter recovery times compared with propofol titrated to deep sedation throughout the procedure.	Indiana Univ, Sch Med, Dept Med, Div Gastroenterol, Indianapolis, IN 46202 USA	Rex, DK (reprint author), Indiana Univ, Sch Med, Dept Med, Div Gastroenterol, 550 N,Univ Blvd UH 4100, Indianapolis, IN 46202 USA.						Baptisia A, 2005, GASTROINTEST ENDOSC, V61, pAB108, DOI 10.1016/S0016-5107(05)00687-5; Chutkan R, 2004, GASTROINTEST ENDOSC, V60, P167, DOI 10.1016/S0016-5107(04)01699-2; Clarke AC, 2001, ENDOSCOPY, V33, P95; Cohen LB, 2004, GASTROINTEST ENDOSC, V59, P795, DOI 10.1016/S0016-5107(04)00349-9; Dewitt J, 2003, GASTROINTEST ENDOSC, V57, pAB78; Faulx AL, 2004, GASTROINTEST ENDOSC, V59, pAB131; Gonzalez-Huix F, 2004, GASTROINTEST ENDOSC, V59, pAB133; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Heuss LT, 2005, ENDOSCOPY, V37, P161, DOI 10.1055/s-2004-826143; Heuss LT, 2003, ALIMENT PHARM THER, V17, P1493, DOI 10.1046/j.1365-2036.2003.01608.x; Heuss LT, 2003, GASTROINTEST ENDOSC, V57, pAB105; Heuss LT, 2003, GASTROINTEST ENDOSC, V57, P664, DOI 10.1067/mge.2003.191; Heuss LT, 2003, AM J GASTROENTEROL, V98, P1751, DOI 10.1016/S0002-9270(03)00447-7; Kongkam P, 2004, GASTROINTEST ENDOSC, V59, pAB127; Koshy G, 2000, AM J GASTROENTEROL, V95, P1476; Kulling D, 2003, GASTROINTEST ENDOSC, V57, pAB78; Patel S, 2005, AM J GASTROENTEROL, V100, P2689, DOI 10.1111/j.1572-0241.2005.00320.x; Qadeer MA, 2005, CLIN GASTROENTEROL H, V3, P1049, DOI 10.1016/S1542-3565(05)00742-1; Rex DK, 2005, GASTROENTEROLOGY, V129, P1384, DOI 10.1053/j.gastro.2005.08.014; Rex DK, 2002, AM J GASTROENTEROL, V97, P1159; Rex Douglas K, 2003, Rev Gastroenterol Disord, V3, P70; Seeff LC, 2004, GASTROENTEROLOGY, V127, P1670, DOI 10.1053/j.gastro.2004.09.051; SIDAK Z, 1967, J AM STAT ASSOC, V62, P626, DOI 10.2307/2283989; Sipe BW, 2002, GASTROINTEST ENDOSC, V55, P815, DOI 10.1067/mge.2002.124636; Tohda G, 2005, GASTROINTEST ENDOSC, V61, pAB123, DOI 10.1016/S0016-5107(05)00746-7; Ulmer BJ, 2003, CLIN GASTROENTEROL H, V1, P425, DOI 10.1016/S1542-3565(03)00226-X; Vargo JJ, 2002, GASTROENTEROLOGY, V123, P8, DOI 10.1053/gast.2002.34232; VARGO JJ, 2005, [No title captured], V59, pAB132; Walker JA, 2003, AM J GASTROENTEROL, V98, P1744, DOI 10.1016/S0002-9270(03)00496-9; Weston BR, 2003, AM J GASTROENTEROL, V98, P2440, DOI 10.1016/S0002-9270(03)01701-5; Yusoff IF, 2004, GASTROINTEST ENDOSC, V60, P356, DOI 10.1016/S0016-5107(04)01711-0	31	136	144	0	4	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0002-9270			AM J GASTROENTEROL	Am. J. Gastroenterol.	OCT	2006	101	10					2209	2217		10.1111/j.1572-0241.2006.00760.x			9	Gastroenterology & Hepatology	Gastroenterology & Hepatology	089XL	WOS:000240915100009	17032185				2020-06-30	J	Burlacu, CL; Frizelle, HP; Moriarty, DC; Buggy, DJ				Burlacu, C. L.; Frizelle, H. P.; Moriarty, D. C.; Buggy, D. J.			Fentanyl and clonidine as adjunctive analgesics with levobupivacaine in paravertebral analgesia for breast surgery	ANAESTHESIA			English	Article							BRACHIAL-PLEXUS BLOCK; INTERCOSTAL NERVE BLOCK; EPIDURAL ANALGESIA; POSTOPERATIVE PAIN; ANESTHESIA; LIDOCAINE; PROLONGS; BUPIVACAINE; MEPIVACAINE; ROPIVACAINE	The addition of fentanyl or clonidine to levobupivacaine was evaluated in patients undergoing breast surgery under general anaesthesia with intra- and postoperative paravertebral analgesia. Patients were randomly allocated to four groups: Group L received 19 ml bolus levobupivacaine 0.25% plus 1 ml saline followed by an infusion of levobupivacaine 0.1%; Group LF received 19 ml bolus levobupivacaine 0.25% plus fentanyl 50 mu g followed by an infusion of levobupivacaine 0.05% with fentanyl 4 mu g.ml(-1); Group LC received 19 ml bolus levobupivacaine 0.25% plus clonidine 150 mu g followed by an infusion of levobupivacaine 0.05% with clonidine 3 ug.ml(-1)'; Group C (control) received general anaesthesia without paravertebral analgesia. All groups received postoperative i.v. morphine patient controlled analgesia (PCA). Although mean (SD) postoperative PCA morphine consumption was decreased in LF [7.9 (4.1) mg] and LC [5.9 (3.5) mg] vs L [27.7 (8.6) mg] or C patients [21.7 (5.5) mg], p < 0.01, paravertebral fentanyl and clonidine were associated with significantly increased vomiting and hypotension, respectively.	Mater Misericordiae Univ Hosp, Dept Anaesthesia Intens Care & Pain Med, Dublin 7, Ireland	Burlacu, CL (reprint author), Mater Misericordiae Univ Hosp, Dept Anaesthesia Intens Care & Pain Med, Eccles St, Dublin 7, Ireland.	crina@ireland.com		Buggy, Donal/0000-0003-3922-4397			Adam F, 1999, ANESTH ANALG, V89, P444, DOI 10.1097/00000539-199908000-00036; BERRISFORD RG, 1993, BRIT J ANAESTH, V70, P201, DOI 10.1093/bja/70.2.201; Bimston DN, 1999, SURGERY, V126, P650, DOI 10.1016/S0039-6060(99)70118-2; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; EASON MJ, 1979, ANAESTHESIA, V34, P638, DOI 10.1111/j.1365-2044.1979.tb06363.x; Eisenach JC, 1996, ANESTHESIOLOGY, V85, P655, DOI 10.1097/00000542-199609000-00026; GAUMANN D, 1992, ANESTH ANALG, V75, P69; GAUMANN DM, 1992, ANESTH ANALG, V74, P719; GISSEN AJ, 1987, ANESTH ANALG, V66, P1272; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Gristwood R W, 1999, Expert Opin Investig Drugs, V8, P861, DOI 10.1517/13543784.8.6.861; Kampe S, 2004, CURR MED RES OPIN, V20, P199, DOI 10.1185/030079903125002874; Karmakar MK, 2001, ANESTHESIOLOGY, V95, P771, DOI 10.1097/00000542-200109000-00033; KHASAR SG, 1995, NEUROSCIENCE, V66, P427, DOI 10.1016/0306-4522(94)00562-J; Klein SM, 2000, ANESTH ANALG, V90, P1402, DOI 10.1097/00000539-200006000-00026; LIU S, 1995, ANESTHESIOLOGY, V82, P1353, DOI 10.1097/00000542-199506000-00005; Liu SS, 2003, ANESTH ANALG, V96, P263, DOI 10.1097/00000539-200301000-00053; Nishikawa K, 2000, ANESTH ANALG, V91, P384, DOI 10.1097/00000539-200008000-00028; Polley LS, 2003, ANESTHESIOLOGY, V99, P1354, DOI 10.1097/00000542-200312000-00017; Polley LS, 1999, ANESTHESIOLOGY, V90, P944, DOI 10.1097/00000542-199904000-00003; PURCELLJONES G, 1989, ANESTH ANALG, V68, P32; SINGELYN FJ, 1992, REGION ANESTH, V17, P148; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; Tschernko EM, 1998, ANESTH ANALG, V87, P107, DOI 10.1097/00000539-199807000-00023; TUCKER GT, 1972, ANESTHESIOLOGY, V37, P277, DOI 10.1097/00000542-197209000-00003; UNNERSTALL JR, 1984, BRAIN RES REV, V7, P69, DOI 10.1016/0165-0173(84)90030-4	26	42	43	2	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	OCT	2006	61	10					932	937		10.1111/j.1365-2044.2006.04793.x			6	Anesthesiology	Anesthesiology	095AZ	WOS:000241281900003	16978305				2020-06-30	J	van Twest, RM				van Twest, R. M.			Bispectral index guided timing of intubation without neuromuscular blockade during sevoflurane induction of anaesthesia in adults	ANAESTHESIA AND INTENSIVE CARE			English	Article						bispectral index monitoring (BIS); endotracheal intubation; sevoflurane induction; inhalational anaesthesia	INHALATION INDUCTION; TRACHEAL INTUBATION; VITAL CAPACITY; NITROUS-OXIDE; PROPOFOL	The aim of this study was to assess the effectiveness of bispectral index monitoring (BIS) as a guide to the timing of intubation during sevoflurane induction of anaesthesia without the use of neuromuscular blocking agents in adults, and specifically, whether a target BIS value of 25 provides better intubating conditions than a target BIS of 40. Forty patients were randomized into one of two groups, a target BIS 25 (n = 21) ora target BIS 40 (n = 19). Patients received premedication with midazolam 20 mu g/kg and fentanyl 0.5 mu g/kg. Sevoflurane induction of anaesthesia was initiated and titrated to reach the target BIS value and maintained within the target range for two minutes. The trachea was then intubated, with intubating conditions being assessed using a standardized scale. The BIS 25 group had a superior median intubating score of 4 (range 3-9, [IQR 4-5]) vs the BIS 40 group with a median of 7(5-10, [6-9], P < 0.001). The time to reach target BIS values was not statistically different (BIS 25 group 6.6 min, BIS 40 group 5.1 min, P = 0.054). End-tidal sevoflurane concentration upon reaching the target BIS was higher in the BIS 25 group (5.3% +/- 1.2%) vs the BIS 40 group (3.5% +/- 0.95) (P < 0.001). There was no statistical difference in haemodynamic parameters between groups. A target BIS value of 25 provides good to excellent intubating conditions and better intubating conditions than a target BIS of 40 during sevoflurane induction of anaesthesia without the use of neuromuscular blocking agents.	Gold Coast Hosp, Dept Anaesthet, Southport, Qld, Australia	van Twest, RM (reprint author), Princess Alexandra Hosp, Dept Anaesthet, Ipswich Rd, Brisbane, Qld 4102, Australia.						CASAER M, 1998, EUR J ANAESTH, V15, P776; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; Goodwin N, 2004, ANAESTHESIA, V59, P15, DOI 10.1111/j.1365-2044.2004.03481.x; Hall JE, 1997, ANAESTHESIA, V52, P410, DOI 10.1111/j.1365-2044.1997.091-az0086.x; Iamaroon A, 2001, ANESTH ANALG, V92, P523, DOI 10.1213/00000539-200102000-00045; KIMURA T, 1994, ANESTH ANALG, V79, P378; MacIntyre PA, 1998, EUR J ANAESTH, V15, P462; Muzi M, 1997, ANESTH ANALG, V85, P1143, DOI 10.1097/00000539-199711000-00034; Myles PS, 2004, LANCET, V363, P1757, DOI 10.1016/S0140-6736(04)16300-9; Philip BK, 1999, ANESTH ANALG, V89, P623, DOI 10.1097/00000539-199909000-00014; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; Thwaites A, 1997, BRIT J ANAESTH, V78, P356; Weber F, 2003, ANAESTHESIA, V58, P749, DOI 10.1046/j.1365-2044.2003.03261.x; Woods AW, 2005, BRIT J ANAESTH, V94, P150, DOI 10.1093/bja/aei006; Yamaguchi H, 2003, ENVIRON TOXICOL PHAR, V15, P1, DOI 10.1016/j.etap.2003.08.004; Yogendran S, 2005, CAN J ANAESTH, V52, P45, DOI 10.1007/BF03018579	16	7	7	0	0	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2021, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	OCT	2006	34	5					606	612		10.1177/0310057X0603400517			7	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	112LF	WOS:000242526700007	17061635	Bronze			2020-06-30	J	Lessa, MA; Tibirica, E				Lessa, Marcos A.; Tibirica, Eduardo			Pharmacologic evidence for the involvement of central and peripheral opiold receptors in the card ioprotective effects of fentanyl	ANESTHESIA AND ANALGESIA			English	Article							ISCHEMIA-REPERFUSION INJURY; MYOCARDIAL-ISCHEMIA; INFARCTION; HEART; PROTECTION; NALOXONE; OPIOIDS; AGENTS; DOGS; RATS	BACKGROUND: We investigated the involvement of central and peripheral opioid receptors (OR) in the cardioprotective effects of fentanyl (FENT) in a model of myocardial ischemia/reperfusion injury associated with pharmacologically induced sympathetic overactivity in anesthetized rabbits. METHODS: Central sympathetic stimulation was achieved through intracerebroventricular injection Of L-glutamate in animals submitted to 35 min of coronary occlusion followed by 120 min of reperfusion. Rabbits received naloxone HCl intracerebroventricularly or naloxone methiodide IV, a quaternary compound that does not cross the blood-brain barrier, 5 min before FENT treatment (5 or 50 mu g/kg, IV). RESULTS: Infarct area was reduced only by FENT 50 (from 51% +/- 2% to 24% +/- 2%). This protective effect was abolished by peripheral (42% +/- 4%), but not central, OR blockade (32% +/- 3%). The number of premature ventricular complexes during the ischemic period (54 +/- 3) was reduced by FENT 50 (19 +/- 7), an effect blunted by central (40 +/- 3) but not peripheral (18 +/- 7) blockade of OR. During reperfusion, the number of premature ventricular complexes (134 +/- 50) was reduced to 9 5 by FENT 50 and was prevented by central (42 +/- 4) as well as peripheral (20 +/- 11) OR blockade. The mortality rate (50%) and incidence of ventricular tachycardia (55%) were completely abolished by FENT 50. CONCLUSIONS: We conclude that fentanyl's effects for limiting myocardial ischemic injury are mediated via peripheral ORs while opioid's antiarrhythmic actions are mediated via central OR agonism.	Fiocruz MS, Dept Physiol & Pharmacodynam, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil	Tibirica, E (reprint author), Fiocruz MS, Dept Physiol & Pharmacodynam, Inst Oswaldo Cruz, Ave Brasil 4365 Manguinhos,CP 926, BR-21045900 Rio De Janeiro, Brazil.	etibi@ioc.fiocruz.br					Chien GL, 1996, J MOL CELL CARDIOL, V28, P1895, DOI 10.1006/jmcc.1996.0182; DASKALOPOULOS NT, 1975, EUR J PHARMACOL, V33, P91, DOI 10.1016/0014-2999(75)90142-9; FLACKE JW, 1983, ANESTH ANALG, V62, P305; FLACKE JW, 1985, ANESTH ANALG, V64, P1053; GAUTRET B, 1985, J CARDIOVASC PHARM, V7, P649, DOI 10.1097/00005344-198507000-00006; GGE JC, 1997, ANESTHESIOL CLIN N A, V1, P65; GILES T, 1983, EUR J PHARMACOL, V95, P247, DOI 10.1016/0014-2999(83)90641-6; Groban L, 2004, ANESTH ANALG, V98, P903, DOI 10.1213/01.ANE.0000105878.96434.05; Kato R, 2002, CAN J ANAESTH, V49, P777, DOI 10.1007/BF03017409; Kato R, 2000, BRIT J ANAESTH, V84, P608, DOI 10.1093/bja/84.5.608; Kevin LG, 2005, ANESTH ANALG, V101, P1275, DOI 10.1213/01.ANE.0000180999.81013.D0; Komatsu T, 1992, J Cardiothorac Vasc Anesth, V6, P444, DOI 10.1016/1053-0770(92)90011-U; LATSON TW, 1992, J CLIN ANESTH, V4, P265, DOI 10.1016/0952-8180(92)90127-M; LAUBIE M, 1983, EUR J PHARMACOL, V91, P431, DOI 10.1016/0014-2999(83)90167-X; Lessa MA, 2004, ACTA ANAESTH SCAND, V48, P1115, DOI 10.1111/j.1399-6576.2004.00472.x; Lishmanov YB, 2004, B EXP BIOL MED+, V138, P107; MAXWELL MP, 1987, CARDIOVASC RES, V21, P737, DOI 10.1093/cvr/21.10.737; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Okubo S, 2004, AM J PHYSIOL-HEART C, V287, pH1786, DOI 10.1152/ajpheart.01143.2003; Pugsley MK, 2002, PHARMACOL THERAPEUT, V93, P51, DOI 10.1016/S0163-7258(02)00165-1; SAINI V, 1988, AM HEART J, V115, P598, DOI 10.1016/0002-8703(88)90810-1; SAWYER CH, 1954, J COMP NEUROL, V101, P801, DOI 10.1002/cne.901010307; SCHOMIG A, 1995, HERZ, V20, P169; Schultz JE, 2001, PHARMACOL THERAPEUT, V89, P123, DOI 10.1016/S0163-7258(00)00106-6; Schultz JEJ, 1996, CIRC RES, V78, P1100, DOI 10.1161/01.RES.78.6.1100; Villemagne PSR, 2002, EUR J NUCL MED MOL I, V29, P1385, DOI 10.1007/s00259-002-0897-z	26	14	20	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	OCT	2006	103	4					815	821		10.1213/01.ane.0000237284.30817.f6			7	Anesthesiology	Anesthesiology	087RL	WOS:000240759800003	17000787				2020-06-30	J	Miller, P; Mack, CD; Sammer, M; Rozet, I; Lee, LA; Muangman, S; Wang, M; Hollingworth, W; Lam, AM; Vavilala, MS				Miller, Patrick; Mack, Christopher D.; Sammer, Marla; Rozet, Irene; Lee, Lorri A.; Muangman, Saipin; Wang, Marjorie; Hollingworth, Will; Lam, Arthur M.; Vavilala, Monica S.			The incidence and risk factors for hypotension during emergent decompressive craniotomy in children with traumatic brain injury	ANESTHESIA AND ANALGESIA			English	Article							ACUTE SUBDURAL-HEMATOMA; SEVERE HEAD-INJURY; SURGICAL EVACUATION; BLOOD-PRESSURE; SURGERY	We conducted a retrospective cohort study in children < 13 yr with traumatic brain injury (TBI) at a Level 1 pediatric trauma center to describe risk factors for intraoperative hypotension (IH) during emergent decompressive craniotomy. Between 1994 and 2004, 108 children underwent emergent decompressive craniotomy for TBI. Overall, 56 (52%) patients had IH. Independent risk factors for IH were each 10 mL estimated blood loss/kg (ARR 1.15 95% CI 1.08-1.22), each mm of computed tomography (CT) midline shift (ARR 1.04 95%CI 1.01-1.07), each 10 mL of CT lesion volume (ARR 1.03 95%CI 1.01-1.05), and emergency department (ED) hypotension (5/5 patients with ED hypotension had IH). CT midline shift >= 4 mm predicted IH (ARR 1.67 95% CI 1.06-2.63), independent of blood loss. IH occurred frequently during emergent decompressive craniotomy in children with TBI. ED hypotension, blood loss, CT lesion volume, and CT midline shift predicted IH. Anesthesiologists can expect children with preoperative CT midline shift >= 4 mm to have IH during this procedure.	Univ Washington, Harborview Med Ctr, Dept Anesthesiol, Seattle, WA 98104 USA; Univ Washington, Dept Pediat, Seattle, WA 98104 USA; Univ Washington, Dept Radiol, Seattle, WA 98104 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98104 USA; Harborview Injury Prevent & Res Ctr, Seattle, WA USA	Vavilala, MS (reprint author), Univ Washington, Harborview Med Ctr, Dept Anesthesiol, 325 9Th Ave,Box 359724, Seattle, WA 98104 USA.	vavilala@u.washington.edu		Hollingworth, William/0000-0002-0840-6254	PHS HHSUnited States Public Health Service [K23044632]		Adelson P David, 2003, Pediatr Crit Care Med, V4, pS12; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chesnut RM, 1997, J TRAUMA, V42, pS4, DOI 10.1097/00005373-199705001-00002; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Gopinath SP, 1996, ANESTH ANALG, V83, P1014, DOI 10.1097/00000539-199611000-00020; HAGLUND MM, 1996, ANESTH ANALG, V83, P1014; HORAN M J, 1987, Pediatrics, V79, P1; Kawaguchi M, 1996, J NEUROSURG ANESTH, V8, P117, DOI 10.1097/00008506-199604000-00003; Kinoshita K, 2004, RESUSCITATION, V60, P151, DOI 10.1016/j.resuscitation.2003.07.005; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Meyer PG, 2005, CHILD NERV SYST, V21, P133, DOI 10.1007/s00381-004-1016-1; OSTEBEE A, 1995, CALCULUS GRAPHICAL N, V2; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Ransom GH, 2003, CHILD ABUSE NEGLECT, V27, P381, DOI 10.1016/S0145-2134(03)00025-5; UCHIDA M, 1982, CRIT CARE MED, V10, P5, DOI 10.1097/00003246-198201000-00002; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	21	13	14	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	OCT	2006	103	4					869	875		10.1213/01.ane.0000237327.12205.dc			7	Anesthesiology	Anesthesiology	087RL	WOS:000240759800014	17000796				2020-06-30	J	Roy, JD; Massicotte, L; Sassine, MP; Seal, RF; Roy, A				Roy, Jean-Denis; Massicotte, Luc; Sassine, Marie-Pascale; Seal, Robert F.; Roy, Andre			A comparison of intrathecal morphine/fentanyl and patient-controlled analgesia with patient-controlled analgesia alone for analgesia after liver resection	ANESTHESIA AND ANALGESIA			English	Article							INCREASED PROTHROMBIN TIME; DONOR RIGHT HEPATECTOMY; EPIDURAL CATHETER; PROPHYLAXIS; ANESTHESIA	Continuous epidural anesthesia and analgesia may be considered in liver resection, but is often avoided because of the potential development of coagulopathies and the risk of epidural hematoma. In this prospective, randomized, double-blind study we compared postoperative morphine consumption via patient-controlled analgesia after liver surgery between two groups of patients: patients receiving a preoperative dose of intrathecal morphine (0.5 mg) and fentanyl (15 mu g) (treatment group) and patients receiving a sham intrathecal injection (placebo group). Forty patients scheduled for major liver resection (>= two segments) were enrolled. The primary outcome measure was patient-controlled analgesia morphine consumption. Secondary outcomes were evaluation of pain at rest and with movement, scored on a visual analog scale with assessment of sedation, nausea, pruritus, and respiratory frequency. Outcome measures were recorded at 6, 12, 18, 24, and 48 h postspinal anesthesia or simulation. Patients in the placebo group consumed approximately three times more morphine during each time interval than patients in the treatment group (at 48 h: 124 +/- 30 vs 47 21 mg, P < 0.0001). Pain evaluation on the visual analog scale was lower for the first 18 h in the treatment group. There was no difference in the incidence of side effects in both groups. Intrathecal morphine (0.5 mg) and fentanyl (15 mu g) given before liver surgery significantly decreased postoperative morphine consumption compared to placebo without any increase in side effects.	CHUM, Hop St Luc, Dept Anesthesiol, Montreal, PQ H2X 3J4, Canada; CHUM, Hop St Luc, Dept Epidemiol & Biostat, Montreal, PQ H2X 3J4, Canada; Univ Alberta, Dept Anesthesiol & Pain Med, Edmonton, AB, Canada; CHUM, Hop St Luc, Dept Surg, Hepatobiliary Serv, Montreal, PQ H2X 3J4, Canada	Massicotte, L (reprint author), CHUM, Hop St Luc, Dept Anesthesiol, 1058 St Denis, Montreal, PQ H2X 3J4, Canada.	luc.massicotte@umontreal.ca					Ayanoglu HO, 2003, TRANSPLANT P, V35, P2970, DOI 10.1016/j.transproceed.2003.10.090; BAILEY PL, 2005, ANESTHESIA, P379; Bogra J, 2005, BMC ANESTHESIOL, V5, P5, DOI DOI 10.1186/1471-2253-5-5; Borromeo CJ, 2000, ANESTH ANALG, V91, P1139, DOI 10.1097/00000539-200011000-00018; Celeski D C, 1999, AANA J, V67, P239; Choiniere M, 1996, J PAIN SYMPTOM MANAG, V11, P299, DOI 10.1016/0885-3924(95)00204-9; Cywinski JB, 2004, ANESTH ANALG, V99, P1747, DOI 10.1213/01.ANE.0000136423.17446.5D; Fournier R, 2000, ANESTH ANALG, V90, P918, DOI 10.1213/00000539-200004000-00026; Horlocker TT, 1997, ANESTH ANALG, V85, P874, DOI 10.1097/00000539-199710000-00031; Jain K, 2004, INT J OBSTET ANESTH, V13, P215, DOI 10.1016/j.ijoa.2004.04.006; Lentschener C, 2002, EUR J ANAESTH, V19, P780, DOI 10.1017/S0265021502001266; Massicotte L, 2006, LIVER TRANSPLANT, V12, P117, DOI 10.1002/lt.20559; Matot I, 2002, ANESTH ANALG, V95, P1179, DOI 10.1097/00000539-200211000-00009; Melzack R, 1989, J Pain Symptom Manage, V4, P157, DOI 10.1016/0885-3924(89)90010-9; Parlow JL, 2004, ANESTH ANALG, V98, P1072, DOI 10.1213/01.ANE.0000105880.59649.5C; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Redai I, 2004, SURG CLIN N AM, V84, P401, DOI 10.1016/S0039-6109(03)00229-9; Schumann R, 2004, LIVER TRANSPLANT, V10, P363, DOI 10.1002/lt.20059; Siniscalchi A, 2004, LIVER TRANSPLANT, V10, P1144, DOI 10.1002/lt.20235; Swart M, 1997, ANAESTHESIA, V52, P373, DOI 10.1111/j.1365-2044.1997.az0083c.x; Tsui SL, 2004, ANAESTH INTENS CARE, V32, P630, DOI 10.1177/0310057X0403200503	21	25	28	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	OCT	2006	103	4					990	994		10.1213/01.ane.0000238040.41872.7e			5	Anesthesiology	Anesthesiology	087RL	WOS:000240759800037	17000818				2020-06-30	J	Hanazaki, M; Taga, N; Nakatsuka, H; Yokoyama, M; Morita, K; Shirakawa, Y; Yamatsuji, T; Naomoto, Y; Hiraki, T				Hanazaki, Motohiko; Taga, Naoyuki; Nakatsuka, Hideki; Yokoyama, Masataka; Morita, Kiyoshi; Shirakawa, Yasuhiro; Yamatsuji, Tomoki; Naomoto, Yoshio; Hiraki, Takao			Anesthetic management of radiofrequency ablation of mediastinal metastatic lymph nodes adjacent to the trachea	ANESTHESIA AND ANALGESIA			English	Letter							TUMORS		Okayama Univ, Sch Med, Dept Anesthesiol & Resuscitol, Okayama 700, Japan; Okayama Univ, Sch Med, Dept Surg Gastroenterol Transplant & Surg Oncol, Okayama 700, Japan; Okayama Univ, Sch Med, Dept Radiol, Okayama 700, Japan	Hanazaki, M (reprint author), Okayama Univ, Sch Med, Dept Anesthesiol & Resuscitol, Okayama 700, Japan.	motohiko@hanazaki.com	Hanazaki, Motohiko/B-1028-2008; Shirakawa, Yasuhiro/B-2351-2011	Hanazaki, Motohiko/0000-0002-0498-7215; 			Rossi S, 1998, AM J ROENTGENOL, V170, P1015, DOI 10.2214/ajr.170.4.9530052; Sawada M, 2002, ANESTH ANALG, V94, P1416; Yasui K, 2004, RADIOLOGY, V231, P850, DOI 10.1148/radiol.2313030347	3	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	OCT	2006	103	4					1041	1042		10.1213/01.ane.0000239053.40982.0f			2	Anesthesiology	Anesthesiology	087RL	WOS:000240759800053	17000832				2020-06-30	J	Renna, M; Gillbe, C				Renna, Maurizio; Gillbe, Charles			BIS and the electromyogram	ANESTHESIA AND ANALGESIA			English	Letter									Royal Brompton Hosp, Dept Anaesthesia, London SW3 6LY, England	Renna, M (reprint author), Royal Brompton Hosp, Dept Anaesthesia, London SW3 6LY, England.	maurizio.renna@imperial.ac.uk					Liu N, 2005, ANESTH ANALG, V101, P1713, DOI 10.1213/01.ANE.0000184038.49429.8F; Renna Maurizio, 2002, J Clin Monit Comput, V17, P377, DOI 10.1023/A:1024210405543	2	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	OCT	2006	103	4					1049	1049		10.1213/01.ane.0000239044.54218.46			1	Anesthesiology	Anesthesiology	087RL	WOS:000240759800066	17000842				2020-06-30	J	Moss, IR; Brown, KA; Laferriere, A				Moss, Immanuela Rave; Brown, Karen A.; Laferriere, Andre			Recurrent hypoxia in rats during development increases subsequent respiratory sensitivity to fentanyl	ANESTHESIOLOGY			English	Article							OBSTRUCTIVE SLEEP-APNEA; CHILDREN; ADENOTONSILLECTOMY	Background: In children with a history of significant obstructive sleep apnea who undergo adenotonsillectomy, postsurgical administration of opiates has been alleged to be associated with an increased risk for respiratory complications, including respiratory depression. The authors hypothesize that this association is due to an effect of recurrent hypoxemia that accompanies more severe obstructive sleep apnea on altered responsiveness to subsequent exogenous opiates. Methods: The current study was designed to test the effect of recurrent hypoxia. in the developing rat on respiratory responses to subsequent administration of the mu-opioid agonist fentanyl. Rats were exposed to 12% oxygen balance nitrogen for 7 h daily for 17 days, from postnatal day 17 to 33, a period equivalent to human childhood. After 17 additional days in room air, rats were given a fentanyl dose and tested for their respiratory response to fentanyl using a whole body plethysmograph. Rats undergoing similar protocols without recurrent hypoxia served as controls. Results: As compared with controls, rats preexposed to recurrent hypoxia displayed a more profound depression with fentanyl in minute ventilation, respiratory frequency, tidal volume, and tidal volume divided by inspiratory time that represents respiratory drive. These results indicated an increased respiratory sensitivity to fentanyl after recurrent hypoxia. Conclusions. Previous recurrent hypoxia increases respiratory sensitivity to subsequent opiate agonists. If these findings are applicable to humans, opiate dosing in children must be adjusted depending on history of recurrent hypoxemia to avoid respiratory depression.	McGill Univ, Montreal Childrens Hosp, Res Inst, Dept Pediat, Montreal, PQ H3H 1P3, Canada; McGill Univ, Montreal Childrens Hosp, Res Inst, Dept Physiol, Montreal, PQ H3H 1P3, Canada; McGill Univ, Montreal Childrens Hosp, Ctr Hlth, Div Pediat Anesthesia, Montreal, PQ H3H 1P3, Canada; McGill Univ, Ctr Hlth, Inst Res, Montreal, PQ H3H 1P3, Canada	Moss, IR (reprint author), McGill Univ, Montreal Childrens Hosp, Res Inst, Dept Pediat, 2300 Tupper St,Room A-707, Montreal, PQ H3H 1P3, Canada.	immanuela.moss@mcgill.ca	Brown, Karen/AAE-1816-2020				Brown KA, 2003, ANESTHESIOLOGY, V99, P586, DOI 10.1097/00000542-200309000-00013; Brown KA, 2006, ANESTHESIOLOGY, V105, P665, DOI 10.1097/00000542-200610000-00009; EPSTEIN RA, 1980, J APPL PHYSIOL, V49, P1107; Feldman JL, 2005, RESP PHYSIOL NEUROBI, V147, P131, DOI 10.1016/j.resp.2005.03.014; Kinkead R, 2001, J APPL PHYSIOL, V90, P1729; Laferriere A, 2005, DEV BRAIN RES, V156, P210, DOI 10.1016/j.devbrainres.2005.03.002; McGuire M, 2002, J APPL PHYSIOL, V93, P2155, DOI 10.1152/japplphysiol.00405.2002; Moss IR, 2006, PEDIATR RES, V59, P525, DOI 10.1203/01.pdr.0000203104.45807.23; Moss IR, 2002, RESP PHYSIOL NEUROBI, V131, P15, DOI 10.1016/S1569-9048(02)00034-4; Nixon GM, 2004, PEDIATRICS, V113, pE19, DOI 10.1542/peds.113.1.e19; ROSEN GM, 1994, PEDIATRICS, V93, P784; White DA, 2005, EUR J PHARMACOL, V528, P119, DOI 10.1016/j.ejphar.2005.10.026; Wilson K, 2002, ANESTHESIOLOGY, V96, P313, DOI 10.1097/00000542-200202000-00015	13	41	41	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	OCT	2006	105	4					715	718		10.1097/00000542-200610000-00017			4	Anesthesiology	Anesthesiology	090EC	WOS:000240932400016	17006070				2020-06-30	J	Jugovac, I; Imas, O; Hudetz, AG				Jugovac, Izabela; Imas, Olga; Hudetz, Anthony G.			Supraspinal anesthesia - Behavioral and electroencephalographic effects of intracerebroventricularly infused pentobarbital, propofol, fentanyl, and midazolam	ANESTHESIOLOGY			English	Article							MORPHINE-INDUCED ANTINOCICEPTION; HORN NEURONAL RESPONSES; CEREBRAL-BLOOD-FLOW; SPINAL-CORD; OPIOID RECEPTORS; ELECTRICAL-STIMULATION; INTRATHECAL MIDAZOLAM; INDUCED HYPERALGESIA; NOXIOUS-STIMULATION; GABA(A) RECEPTORS	Background: Anesthetic endpoints of unconsciousness and immobility result from agent effects on both brain and spinal cord that are difficult to separate during systemic administration. To investigate cerebral mechanism of anesthetic-induced unconsciousness, the authors studied behavioral and electrophysiologic effects of four anesthetics infused intracerebroventricularly to conscious rats. The authors aimed to produce progressively increasing anesthetic depths, indicated by electroencephalographic synchronization and behavioral change. Methods: During anesthesia, rats were equipped with intracerebroventricular infusion catheters, hind-paw stimulation, and epidural electrodes to record the electroencephalogram from the somatosensory cortex. Silicone bolus was injected into the fourth ventricle to minimize drug distribution to the spinal cord. 60 min later, 50-min infusion of pentobarbital (6.0 mg/h), fentanyl (0.75 mu g/h), propofol (3.0 mg/h), or midazolam. (0.24 mg/h) was initiated. Vibrissal, olfactory, corneal, and tail-pinch responses were tested every 10 min. Results: All agents depressed vibrissal, olfactory, and corneal responses; propofol and pentobarbital produced the strongest effect. All agents except propofol depressed tail-pinch response; fentanyl and pentobarbital produced the strongest effect. All agents except midazolam increased delta power. Pentobarbital enhanced theta power. All agents except fentanyl enhanced a and beta power. Pentobarbital and midazolam slightly increased, whereas fentanyl decreased, gamma power. Pentobarbital increased and midazolam decreased somatosensory evoked potential; these changes were small and apparently unrelated to behavior. Conclusions. Alpha and beta power increase may reflect sedative component of anesthesia. Simultaneous delta, alpha, and beta power increase may correlate with loss of consciousness. Theta and delta power increase may reflect surgical anesthesia. Opioid-induced gamma power decrease may reflect suppression of pain perception. Pentobarbital-, fentanyl-, and midazolam-induced immobility to noxious stimulation may be mediated supraspinally.	Med Coll Wisconsin, Dept Anesthesiol, Milwaukee, WI 53226 USA	Hudetz, AG (reprint author), Med Coll Wisconsin, Dept Anesthesiol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	ahudetz@mcw.edu			NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 56398]		Adler LJ, 1997, ANESTH ANALG, V84, P120, DOI 10.1097/00000539-199701000-00023; Alkire MT, 2000, CONSCIOUS COGN, V9, P370, DOI 10.1006/ccog.1999.0423; ANGEL A, 1970, J PHYSIOL-LONDON, V210, pP167; Antognini JF, 2000, CAN J ANAESTH, V47, P273, DOI 10.1007/BF03018926; Antognini JF, 2000, ANESTH ANALG, V91, P1282, DOI 10.1097/00000539-200011000-00043; Antognini JF, 1997, MED HYPOTHESES, V48, P83, DOI 10.1016/S0306-9877(97)90028-1; ANTOGNINI JF, 1993, ANESTHESIOLOGY, V79, P1244, DOI 10.1097/00000542-199312000-00015; Antognini JF, 2004, NEUROSCI LETT, V361, P94, DOI 10.1016/j.neulet.2003.12.024; Antognini JF, 2003, ANESTH ANALG, V96, P999, DOI 10.1213/01.ANE.0000052514.69682.6E; Antognini JF, 2003, BRIT J ANAESTH, V91, P233, DOI 10.1093/bja/aeg168; Antognini JF, 2002, ANESTHESIOLOGY, V96, P980, DOI 10.1097/00000542-200204000-00028; ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; Backman SB, 2004, PROG BRAIN RES, V145, P197, DOI 10.1016/S0079-6123(03)45014-0; BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; Billard V, 1997, CLIN PHARMACOL THER, V61, P45, DOI 10.1016/S0009-9236(97)90181-8; Bol CJJG, 1999, J PHARMACOL EXP THER, V291, P153; Bol CJJG, 2000, J PHARMACOL EXP THER, V294, P347; Booth CM, 2004, JAMA-J AM MED ASSOC, V291, P870, DOI 10.1001/jama.291.7.870; BORGES M, 1994, ANESTHESIOLOGY, V81, P1511, DOI 10.1097/00000542-199412000-00027; CAUDLE RM, 1990, J PHARMACOL EXP THER, V252, P1361; CHAILLET P, 1983, LIFE SCI, V33, P2105, DOI 10.1016/0024-3205(83)90334-X; COLLIER C, 1991, ANAESTH INTENS CARE, V19, P573, DOI 10.1177/0310057X9101900416; DAUGE V, 1987, EUR J PHARMACOL, V141, P171, DOI 10.1016/0014-2999(87)90260-3; Devor M, 2001, PAIN, V94, P101, DOI 10.1016/S0304-3959(01)00345-1; Dong YF, 1999, NEUROSCI LETT, V271, P17, DOI 10.1016/S0304-3940(99)00506-6; EDWARDS M, 1990, ANESTHESIOLOGY, V73, P273, DOI 10.1097/00000542-199008000-00015; FANG FG, 1986, J PHARMACOL EXP THER, V238, P1039; Faulkner HJ, 1998, BRIT J PHARMACOL, V125, P483, DOI 10.1038/sj.bjp.0702113; Faulkner HJ, 1999, BRIT J PHARMACOL, V128, P1813, DOI 10.1038/sj.bjp.0702948; Feshchenko VA, 1997, NEUROPSYCHOBIOLOGY, V35, P211, DOI 10.1159/000119347; Fiset P, 1999, J NEUROSCI, V19, P5506; Flood P, 2000, ANESTHESIOLOGY, V92, P1418, DOI 10.1097/00000542-200005000-00033; GAMRANI H, 1986, BRAIN RES, V364, P30, DOI 10.1016/0006-8993(86)90984-4; Goodchild CS, 1996, BRIT J ANAESTH, V77, P758; HAFFMANS J, 1983, J NEURAL TRANSM, V57, P1, DOI 10.1007/BF01250043; Hirata H, 2003, J NEUROPHYSIOL, V90, P2837, DOI 10.1152/jn.00544.2003; Huang X, 2001, NEUROSCI LETT, V299, P189, DOI 10.1016/S0304-3940(01)01497-5; Hudetz AG, 2003, ANESTHESIOLOGY, V99, P1125, DOI 10.1097/00000542-200311000-00019; IKONOMIDOUTURSKI C, 1987, NEUROSCIENCE, V20, P671, DOI 10.1016/0306-4522(87)90118-7; John ER, 2002, BRAIN RES REV, V39, P1, DOI 10.1016/S0165-0173(02)00142-X; John ER, 2005, ANESTHESIOLOGY, V102, P447, DOI 10.1097/00000542-200502000-00030; John ER, 2001, CONSCIOUS COGN, V10, P165, DOI 10.1006/ccog.2001.0507; KOFKE WA, 1992, ANESTH ANALG, V75, P953; Kuizenga K, 2001, BRIT J ANAESTH, V86, P354, DOI 10.1093/bja/86.3.354; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; LEE PHK, 1989, J NEUROSCI, V9, P692; LUGER TJ, 1995, EUR J PHARMACOL, V275, P153, DOI 10.1016/0014-2999(94)00759-Z; Ma JY, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-02-j0004.2002; MANTEGAZZA P, 1982, BRIT J PHARMACOL, V75, P569, DOI 10.1111/j.1476-5381.1982.tb09175.x; McKernan RM, 2000, NAT NEUROSCI, V3, P587, DOI 10.1038/75761; MIASKOWSKI C, 1991, EUR J PHARMACOL, V205, P247, DOI 10.1016/0014-2999(91)90905-6; MILLER R, 1994, [No title captured]; Mortazavi S, 1999, ANESTHESIOLOGY, V90, P1070, DOI 10.1097/00000542-199904000-00021; Narita M, 2002, LIFE SCI, V70, P2341, DOI 10.1016/S0024-3205(01)01550-8; Nishiyama T, 2001, ANESTH ANALG, V93, P1025, DOI 10.1097/00000539-200110000-00045; NIV D, 1988, ANESTH ANALG, V67, P1169; OTSUKA T, 1991, AM J PHYSIOL, V261, pH110; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pirker S, 2000, NEUROSCIENCE, V101, P815, DOI 10.1016/S0306-4522(00)00442-5; PORRECA F, 1984, J PHARMACOL EXP THER, V230, P341; RADY JJ, 1993, PHARMACOL BIOCHEM BE, V46, P331, DOI 10.1016/0091-3057(93)90361-V; RAMPIL I, 1997, NEUROANESTHESIA NEUR; RAMPIL IJ, 1993, ANESTHESIOLOGY, V78, P707, DOI 10.1097/00000542-199304000-00014; RATTAN AK, 1991, ANESTH ANALG, V73, P124; Rudolph U, 2004, NAT REV NEUROSCI, V5, P709, DOI 10.1038/nrn1496; Rudolph U, 2004, ANNU REV PHARMACOL, V44, P475, DOI 10.1146/annurev.pharmtox.44.101802.121429; Rudolph U, 1999, NATURE, V401, P796, DOI 10.1038/44579; Saravanakumar K, 2005, PEDIATR ANESTH, V15, P597, DOI 10.1111/j.1460-9592.2005.01493.x; Schramm BM, 2002, ANESTH ANALG, V94, P1237, DOI 10.1097/00000539-200205000-00034; Segal M, 1988, NIDA Res Monogr, V82, P133; Sinz EH, 2000, ANESTH ANALG, V91, P1443, DOI 10.1097/00000539-200012000-00027; SNEAD OC, 1982, NEUROPHARMACOLOGY, V21, P1137, DOI 10.1016/0028-3908(82)90171-X; SPANDE TF, 1992, J NAT PROD, V55, P707, DOI 10.1021/np50084a002; Stabernack C, 2005, ANESTH ANALG, V100, P128, DOI 10.1213/01.ANE.0000139353.97950.FA; Steriade M, 2003, FRONT BIOSCI-LANDMRK, V8, pD878, DOI 10.2741/1043; Sudo M, 2001, ACTA ANAESTH SCAND, V45, P823, DOI 10.1034/j.1399-6576.2001.045007823.x; Sukhotinsky I, 2005, J COMP NEUROL, V489, P425, DOI 10.1002/cne.20636; Taira Y, 2000, BRIT J ANAESTH, V85, P881, DOI 10.1093/bja/85.6.881; Tassonyi E, 2002, BRAIN RES BULL, V57, P133, DOI 10.1016/S0361-9230(01)00740-7; Tatsuo MAKF, 1999, EUR J PHARMACOL, V370, P9, DOI 10.1016/S0014-2999(99)00096-5; TOMMASINO C, 1984, ANESTHESIOLOGY, V60, P283, DOI 10.1097/00000542-198404000-00003; Tononi Giulio, 2004, BMC Neurosci, V5, P42, DOI 10.1186/1471-2202-5-42; Veselis RA, 2004, ANESTH ANALG, V99, P399; Veselis RA, 1997, ANESTHESIOLOGY, V87, P1106, DOI 10.1097/00000542-199711000-00015; WANG FS, 1993, J PHARMACOL EXP THER, V265, P1361; Wang QY, 2004, ACTA PHARMACOL SIN, V25, P1619; YOUNG B, 2003, [No title captured], P13; ZIEGLGANSBERGER W, 1979, SCIENCE, V205, P415, DOI 10.1126/science.451610	88	24	24	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	OCT	2006	105	4					764	778		10.1097/00000542-200610000-00023			15	Anesthesiology	Anesthesiology	090EC	WOS:000240932400022	17006076				2020-06-30	J	Gupta, A; Fant, F; Axelsson, K; Sandblom, D; Rykowski, J; Johansson, JE; Andersson, SO				Gupta, Anil; Fant, Federica; Axelsson, Kjell; Sandblom, Dag; Rykowski, Jan; Johansson, Jan-Erik; Andersson, Swen-Olof			Postoperative analgesia after radical retropubic prostatectomy: A double-blind comparison between low thoracic epidural and patient-controlled intravenous analgesia	ANESTHESIOLOGY			English	Article							HEALTH-RELATED QUALITY; RANDOMIZED TRIAL; MAJOR SURGERY; GENERAL-ANESTHESIA; PAIN MANAGEMENT; OF-LIFE; RECOVERY; FENTANYL; INFUSION; EFFICACY	Background: Postoperative pain after radical retropubic prostatectomy can be severe unless adequately treated. Low thoracic epidural analgesia and patient-controlled intravenous analgesia were compared in this double-blind, randomized study. Methods: Sixty patients were randomly assigned to receive either low thoracic epidural analgesia (group E) or patient-controlled intravenous analgesia (group P) for postoperative pain relief. All patients had general anesthesia combined with thoracic epidural analgesia during the operation. Postoperatively, patients in group E received an infusion of 1 mg/ml ropivacaine, 2 mu g/ml fentanyl, and 2 mu g/ml adrenaline, 10 ml/h during 48 h epidurally, and a placebo patient-controlled intravenous analgesia pump intravenously. Patients in group P received a patient-controlled intravenous analgesia pump with morphine intravenously and 10 ml/h placebo epidurally. Pain, the primary outcome variable, was measured using the numeric rating scale at rest (incision pain and "deep" visceral pain) and on coughing. Secondary outcome variables included gastrointestinal function, respiratory function, mobilization, and full recovery. Health-related quality of fife was measured using the Short Form-36 questionnaire, and plasma concentration of fentanyl was measured in five patients to exclude a systemic effect of fentanyl. Results. Incisional pain and pain on coughing were lower in group E compared with group P at 2-24 h, as was deep pain between 3 and 24 h postoperatively (P < 0.05). Maximum expiratory pressure was greater in group E at 4 and 24 h (P < 0.05) compared with group P. No difference in time to home discharge was found between the groups. The mean plasma fentanyl concentration varied from 0.2 to 0.3 ng/ml during 0-48 h postoperatively. At 1 month, the scores on emotional role, physical functioning, and general health of the Short Form-36 were higher in group E compared with group P. However, no group X time interaction was found in the Short Form-36. Conclusions: The authors found evidence for better pain relief and improved expiratory muscle function in patients receiving low thoracic epidural analgesia compared with patient-controlled analgesia for radical retropubic prostatectomy. Low thoracic epidural analgesia can be recommended as a good method for postoperative analgesia after abdominal surgery.	Orebro Univ Hosp, Dept Med, Div Anesthesiol & Intens Care, SE-70185 Orebro, Sweden; Orebro Univ Hosp, Div Urol, SE-70185 Orebro, Sweden	Gupta, A (reprint author), Orebro Univ Hosp, Dept Med, Div Anesthesiol & Intens Care, SE-70185 Orebro, Sweden.	anil.gupta@orebroll.se					Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; Basse L, 2000, ANN SURG, V232, P51, DOI 10.1097/00000658-200007000-00008; Beattie WS, 2001, ANESTH ANALG, V93, P853, DOI 10.1097/00000539-200110000-00010; Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; Bonnet F, 2005, BRIT J ANAESTH, V95, P52, DOI 10.1093/bja/aei038; Carli F, 2002, ANESTHESIOLOGY, V97, P540, DOI 10.1097/00000542-200209000-00005; Gardner TA, 2000, CANCER-AM CANCER SOC, V89, P424, DOI 10.1002/1097-0142(20000715)89:2<424::AID-CNCR30>3.0.CO;2-6; Ginosar Y, 2003, ANESTH ANALG, V97, P1439, DOI 10.1213/01.ANE.0000081792.84877.A2; Gottschalk A, 1998, JAMA-J AM MED ASSOC, V279, P1076, DOI 10.1001/jama.279.14.1076; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Gupta A, 1993, Int J Obstet Anesth, V2, P129, DOI 10.1016/0959-289X(93)90004-2; Haythornthwaite JA, 1998, J UROLOGY, V160, P1761, DOI 10.1016/S0022-5347(01)62400-5; Kehlet H, 2003, LANCET, V362, P1921, DOI 10.1016/S0140-6736(03)14966-5; Kehlet H, 2002, AM J SURG, V183, P630, DOI 10.1016/S0002-9610(02)00866-8; LIU S, 1995, ANESTHESIOLOGY, V82, P1474, DOI 10.1097/00000542-199506000-00019; Macrae WA, 2001, BRIT J ANAESTH, V87, P88, DOI 10.1093/bja/87.1.88; Moen V, 2004, ANESTHESIOLOGY, V101, P950, DOI 10.1097/00000542-200410000-00021; Niemi G, 1998, ACTA ANAESTH SCAND, V42, P897, DOI 10.1111/j.1399-6576.1998.tb05348.x; Norris EJ, 2001, ANESTHESIOLOGY, V95, P1054, DOI 10.1097/00000542-200111000-00006; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; Phillips DM, 2000, JAMA-J AM MED ASSOC, V284, P428, DOI 10.1001/jama.284.4.428; Rigg JRA, 2002, LANCET, V359, P1276, DOI 10.1016/S0140-6736(02)08266-1; RINGQVIST T, 1966, VENTILATORY CAPACITY, P23; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; Schuster M, 2004, ANESTH ANALG, V98, P708; Senagore AJ, 2003, BRIT J SURG, V90, P1195, DOI 10.1002/bjs.4223; SHIR Y, 1995, UROLOGY, V45, P993, DOI 10.1016/S0090-4295(99)80120-4; SHIR Y, 1994, ANESTHESIOLOGY, V80, P49, DOI 10.1097/00000542-199401000-00011; Stevens RA, 1998, UROLOGY, V52, P213, DOI 10.1016/S0090-4295(98)00147-2; Tramer MR, 1997, BRIT J ANAESTH, V78, P642, DOI 10.1093/bja/78.6.642; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x; WALSH PC, 1980, UROL CLIN N AM, V7, P583; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE, 1993, SF 36 HLTH SURVEY MA; Wigfull J, 2001, ANAESTHESIA, V56, P70, DOI 10.1046/j.1365-2044.2001.01763-6.x; Wu CL, 2003, ANESTH ANALG, V97, P1078, DOI 10.1213/01.ANE.0000081722.09164.D5	36	32	33	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	OCT	2006	105	4					784	793		10.1097/00000542-200610000-00025			10	Anesthesiology	Anesthesiology	090EC	WOS:000240932400024	17006078				2020-06-30	J	Di Liddo, L; D'Angelo, A; Nguyen, B; Bailey, B; Amre, D; Stanciu, C				Di Liddo, Lydia; D'Angelo, Antonio; Nguyen, Bao; Bailey, Benoit; Amre, Devendra; Stanciu, Constantin			Etomidate versus midazolam for procedural sedation in pediatric outpatients: A randomized controlled trial	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	83rd Annual Meeting of the Canadian-Paediatric-Society	JUN 13-17, 2006	St Johns, CANADA	Canadian Paediat Soc			TOTAL INTRAVENOUS ANESTHESIA; RAPID-SEQUENCE INTUBATION; VISUAL ANALOG SCALE; EMERGENCY; CHILDREN; PAIN; ANALGESIA; RELIABILITY; VALIDITY; SAFETY	Study objective: Midazolam is widely used for procedural sedation and analgesia. Etomidate has been studied mostly in adults. Our objective is to compare the efficacy of etomidate and midazolam for achieving procedural sedation and analgesia in children. Methods: A randomized, double-blind, emergency department and orthopedic clinic-based trial was carried out among patients aged 2 to 18 years with displaced extremity fractures. Patients were administered 1 mu g/kg of fentanyl and either 0.2 mg/kg of etomidate or 0.1 mg/kg of midazolam. Adequate sedation was defined, for the purpose of this study, as a score of 4 or more on the Ramsay Sedation Scale. The primary outcome was induction and recovery time. The rates of adverse events, success of fracture reduction, and parent and physician satisfaction were also compared. Results: From April to August 2004, 100 of 128 eligible patients were enrolled (age 8.7 +/- 3.7 years; 50% male patients). A higher proportion of patients attained adequate sedation among those who received etomidate: 46 of 50 (92%) versus 18 of 50 (36%) (Delta 56%; 95% confidence interval [CI] 38% to 69%). Time taken for induction (hazard ratio 4.9; 95% CI 2.2 to 10.9) and time taken for recovery (hazard ratio 2.8; 95% CI 1.5 to 5.1) were lower among patients who received etomidate. The rates of adverse events were similar in both groups, except for myoclonus and pain at the injection site, which was more frequent in the etomidate group. Conclusion: Induction and recovery times are shorter with etomidate compared with midazolam. At the dosages used for procedural sedation and analgesia among children with displaced extremity fracture, etomidate has higher efficacy in comparison with midazolam.	Ctr Hosp Univ St Justine, Dept Pediat, Div Emergency Med, Montreal, PQ H3T 1C5, Canada; Ctr Hosp Univ St Justine, Dept Pharm, Montreal, PQ H3T 1C5, Canada; Ctr Hosp Univ St Justine, Res Ctr, Montreal, PQ H3T 1C5, Canada; Ctr Hosp Univ St Justine, Dept Pediat, Div Clin Pharmacol, Montreal, PQ H3T 1C5, Canada; Ctr Hosp Univ St Justine, Dept Surg, Div Orthoped, Montreal, PQ H3T 1C5, Canada	Di Liddo, L (reprint author), Ctr Hosp Univ St Justine, Dept Pediat, Div Emergency Med, 3175 Chemin Cote St Catherine, Montreal, PQ H3T 1C5, Canada.	diliddolydia@hotmail.com	AMRE, DEVENDRA K/D-4988-2015				Algren JT, 1996, PEDIATR EMERG CARE, V12, P435, DOI 10.1097/00006565-199612000-00013; AMBUEL B, 1992, J PEDIATR PSYCHOL, V17, P95, DOI 10.1093/jpepsy/17.1.95; Bergen Joseph M., 1997, Journal of Emergency Medicine, V15, P221, DOI 10.1016/S0736-4679(96)00350-2; Bijur PE, 2001, ACAD EMERG MED, V8, P1153, DOI 10.1111/j.1553-2712.2001.tb01132.x; Burton JH, 2002, ANN EMERG MED, V40, P496, DOI 10.1067/mem.2002.126607; COTE CJ, 1994, PEDIATR CLIN N AM, V41, P31; De Jonghe B, 2000, INTENS CARE MED, V26, P275, DOI 10.1007/s001340051150; Dickinson R, 2001, ACAD EMERG MED, V8, P74, DOI 10.1111/j.1553-2712.2001.tb00558.x; Falk J, 2004, ANN PHARMACOTHER, V38, P1272, DOI 10.1345/aph.1E008; Gallagher EJ, 2002, AM J EMERG MED, V20, P287, DOI 10.1053/ajem.2002.33778; Gross JB, 1996, ANESTHESIOLOGY, V84, P459; Guldner G, 2003, ACAD EMERG MED, V10, P134, DOI 10.1111/j.1553-2712.2003.tb00030.x; Havel CJ, 1999, ACAD EMERG MED, V6, P989, DOI 10.1111/j.1553-2712.1999.tb01180.x; Jagoda AS, 1998, ANN EMERG MED, V31, P663, DOI 10.1016/S0196-0644(98)70216-1; KAUFFMAN RE, 1992, PEDIATRICS, V89, P1110; Kennedy RM, 1998, PEDIATRICS, V102, P956, DOI 10.1542/peds.102.4.956; Kienstra AJ, 2004, PEDIATR EMERG CARE, V20, P499, DOI 10.1097/01.pec.0000136065.22328.df; Krauss B, 2000, NEW ENGL J MED, V342, P938, DOI 10.1056/NEJM200003303421306; MCDOWALL RH, 1995, J CLIN ANESTH, V7, P273, DOI 10.1016/0952-8180(95)00017-C; Moro-Sutherland DM, 2000, ACAD EMERG MED, V7, P1370, DOI 10.1111/j.1553-2712.2000.tb00494.x; Morton NS, 1998, PAEDIATR ANAESTH, V8, P189, DOI 10.1046/j.1460-9592.1998.00759.x; Nordt Sean Patrick, 1997, Journal of Emergency Medicine, V15, P357; OHARA M, 1987, J PEDIATR ORTHOPED, V7, P78, DOI 10.1097/01241398-198701000-00016; Pena BMG, 1999, ANN EMERG MED, V34, P483, DOI 10.1016/S0196-0644(99)80050-X; Petrack EM, 1997, PEDIATRICS, V99, P711, DOI 10.1542/peds.99.5.711; Powell CV, 2001, ANN EMERG MED, V37, P28; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Rothermel LK, 2003, CURR OPIN PEDIATR, V15, P200, DOI 10.1097/00008480-200304000-00011; Rupprecht T, 2000, ACTA PAEDIATR, V89, P1077, DOI 10.1080/713794566; SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5; Shields R E, 1997, Crit Care Nurs Clin North Am, V9, P281; SIEVERS TD, 1991, PEDIATRICS, V88, P1172; Smith GA, 1997, CLIN PEDIATR, V36, P17, DOI 10.1177/000992289703600103; Sokolove PE, 2000, PEDIATR EMERG CARE, V16, P18, DOI 10.1097/00006565-200002000-00005; van Dijk M, 2000, PAIN, V84, P367, DOI 10.1016/S0304-3959(99)00239-0	35	33	33	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	OCT	2006	48	4					433	440		10.1016/j.annemergmed.2006.03.004			8	Emergency Medicine	Emergency Medicine	089NB	WOS:000240886200014	16997680				2020-06-30	J	Van Nimmen, NFJ; Poels, KLC; Veulemans, HAF				Nimmen, N. F. J. Van; Poels, K. L. C.; Veulemans, H. A. F.			Identification of exposure pathways for opioid narcotic analgesics in pharmaceutical production workers	ANNALS OF OCCUPATIONAL HYGIENE			English	Article						active pharmaceutical ingredients (APIs); biological monitoring; dermal; fentanyl; inhalation; production workers	SPECTROMETRIC SCREENING METHOD; CLINICAL PHARMACOKINETICS; OCCUPATIONAL-EXPOSURE; DERMAL EXPOSURE; PLANT WORKERS; FENTANYL; SUFENTANIL; ALFENTANIL; PERFORMANCE; LIMITS	The protection of workers from the potential harmful effects of active pharmaceutical ingredients (APIs) poses a significant challenge for the drug manufacturing industry. The actual pathways through which pharmaceutical production workers are exposed to potent drugs and the processes resulting in actual uptake are up till now virtually unknown. In this study, a detailed exposure assessment survey was conducted in a pharmaceutical 'primary manufacturing' production facility during which environmental and biological exposure monitoring for potent opioid narcotic drugs was performed. On the occasion of multiple consecutive production days, personal half-shift air samples were collected and hand wipes were taken at the end of each half-shift and analysed for fentanyl. All environmental samples showed detectable amounts of fentanyl (> 0.1 ng per sample), indicating a potential for both inhalation and dermal exposure. Spatial distribution of fentanyl dermal contamination was further investigated by means of patch samplers placed on five anatomical regions of the body. Body locations showing the highest level of fentanyl contamination were identified as the hands, the neck and lower arms. The effective uptake of fentanyl was demonstrated by the detection of this opioid in urine samples of the workers involved. Individual and group-level analysis of combined external and internal fentanyl exposure measures revealed a positive and significant correlation between fentanyl hand exposure and urinary excretion, while it seemed that the effect of inhalation exposure was largely due to its correlation with dermal exposure. The results of the established individual linear and mixed effects models strongly suggest that in most workers the dermal pathway is actually the primary route of fentanyl exposure.	Katholieke Univ Leuven, Dept Occupat Environm & Insurance Med, Lab Occupat Hyg & Toxicol, B-3000 Louvain, Belgium	Van Nimmen, NFJ (reprint author), Katholieke Univ Leuven, Dept Occupat Environm & Insurance Med, Lab Occupat Hyg & Toxicol, Kapucijnenvoer 35, B-3000 Louvain, Belgium.	nadine.vannimmen@med.kuleuven.be					BERNER B, 1994, CLIN PHARMACOKINET, V26, P121, DOI 10.2165/00003088-199426020-00005; Binks SP, 2003, OCCUP MED-OXFORD, V53, P363, DOI 10.1093/occmed/kqg116; Bos PMJ, 1998, OCCUP ENVIRON MED, V55, P795, DOI 10.1136/oem.55.12.795; *CEN, 2005, WORKPL EXP MEAS DERM; DELUCA R, 2004, MONOGRAPH OCCUPATION; *EPA, 1989, EPA600889043; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Kenny LC, 1997, ANN OCCUP HYG, V41, P135, DOI 10.1016/S0003-4878(96)00034-8; Ku R. H., 2000, CHEM HLTH SAF    JAN, P34; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; McClean MD, 2004, ANN OCCUP HYG, V48, P663, DOI 10.1093/annhyg/meh062; Morgan Michael S., 1997, Environmental Health Perspectives, V105, P105, DOI 10.2307/3433400; Naumann BD, 1996, AM IND HYG ASSOC J, V57, P33, DOI 10.1202/0002-8894(1996)057<0033:PECLFP>2.0.CO;2; Schneider T, 1999, OCCUP ENVIRON MED, V56, P765, DOI 10.1136/oem.56.11.765; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; SESSINK PJM, 1994, J OCCUP ENVIRON MED, V36, P79; SESSINK PJM, 1994, INT ARCH OCC ENV HEA, V65, P401, DOI 10.1007/BF00383251; Van Nimmen NFJ, 2004, J CHROMATOGR B, V804, P375, DOI 10.1016/j.jchromb.2004.01.044; Van Nimmen NFJ, 2004, J CHROMATOGR A, V1035, P249, DOI 10.1016/j.chroma.2004.02.074; VINCENT JH, 1999, PARTICLE SIZE SELECT, P130; WILLENS JS, 1993, HEART LUNG, V22, P239	22	11	11	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0003-4878			ANN OCCUP HYG	Ann. Occup. Hyg.	OCT	2006	50	7					665	677		10.1093/annhyg/mel028			13	Public, Environmental & Occupational Health; Toxicology	Public, Environmental & Occupational Health; Toxicology	092IV	WOS:000241091100004	16757512	Bronze			2020-06-30	J	Dardonville, C; Fernandez-Fernandez, C; Gibbons, SL; Ryan, GJ; Jagerovic, N; Gabilondo, AM; Meana, JJ; Callado, LF				Dardonville, Christophe; Fernandez-Fernandez, Cristina; Gibbons, Sarah-Louise; Ryan, Gary J.; Jagerovic, Nadine; Gabilondo, Ane M.; Javier Meana, J.; Callado, Luis F.			Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I-2-imidazoline binding sites	BIOORGANIC & MEDICINAL CHEMISTRY			English	Article						I-2-imidazoline binding site affinity; mu-opioid agonist; alkane guanidine; analgesia; dual acting drug; opioid tolerance; opioid withdrawal; human brain; BU224	POSTMORTEM HUMAN BRAIN; INDUCED ANTINOCICEPTION; LIGANDS; MORPHINE; ATTENUATION; IDAZOXAN; AFFINITY; AGONIST; TOLERANCE; AGMATINE	Two series of fentanyl-derived hybrid molecules bearing potent I-2-Imidazoline binding site (IBS) ligands (i.e., guanidine and BU224 moieties) linked with an aliphatic (m = 2, 3, 4, 6, 7, 8, 9 and 12 methylene units) or aromatic spacer were prepared. Their affinities for the mu-opioid receptors and for the I-2-IBS were determined through competition binding studies on human postmortem brain membranes. Whereas the BU224 hybrid molecules bound to the mu-opioid receptor and the I-2-IBS in the micromolar to low micromolar range, the alkaneguanidine series exhibited remarkable affinities in the nanomolar range for both receptors. [S-35]GTP gamma S functional assays were performed on human postmortem brain membranes with selected ligands from each series (4f and 8g) showing the highest dual affinity for the mu-opioid receptor and I-2-IBS affinities. Both compounds displayed agonist properties: at the mu-opioid receptor for the alkaneguanidine derivative 4f (spacer: six methylene units) and at a G-protein coupled receptor (GPCR) which remains to be determined for 8g. The lack of analgesic properties of 4f in vivo (i.e., hot plate and writhing tests in mice), discordant with the good in vitro binding data (K-i mu = 1.04 +/- 0.28 nM, K-i I-2 = 409 +/- 238 nM), may possibly be due to the low intrinsic efficacy of the compound. Alternatively, a low access to the central nervous system for this kind of hybrid molecules cannot be ruled out. Two new compounds reported here (9f and 13), which were not dual acting, are worth mentioning for their outstanding binding affinities; 9f bound to the mu-opioid receptor with a picomolar affinity (K-i = 0.0098 +/- 0.0033 nM), whereas 13 presented an I-2-IBS affinity (K-i = 18 +/- 11 nM) similar to the reference compound BU224. (c) 2006 Elsevier Ltd. All rights reserved.	CSIC, Inst Quim Med, E-28006 Madrid, Spain; Univ Basque Country, Dept Farmacol, Euskal Herriko Unibertsitatea, E-48940 Leioa, Spain	Dardonville, C (reprint author), CSIC, Inst Quim Med, Juan Cierva 3, E-28006 Madrid, Spain.	dardonville@iqm.csic.es	Gabilondo, Ane M./C-4417-2015; Callado, Luis F/A-7024-2008	Gabilondo, Ane M./0000-0002-1892-3861; Callado, Luis F/0000-0001-9941-012X; MEANA, JOSE JAVIER/0000-0002-7913-6714; Jagerovic, Nadine/0000-0003-2642-6969; , Christophe/0000-0001-5395-1932; CALLADO HERNANDO, LUIS FELIPE/0000-0002-5564-3447			Boronat MA, 1998, BRIT J PHARMACOL, V125, P175, DOI 10.1038/sj.bjp.0702031; Boronat MA, 1999, ANN NY ACAD SCI, V881, P359, DOI 10.1111/j.1749-6632.1999.tb09380.x; Dardonville C, 2004, MED RES REV, V24, P639, DOI 10.1002/med.20007; Dardonville C, 2004, BIOORG MED CHEM LETT, V14, P491, DOI 10.1016/j.bmcl.2003.10.048; Dardonville C, 2002, BIOORGAN MED CHEM, V10, P1525, DOI 10.1016/S0968-0896(01)00420-5; Diaz A, 1997, EUR J PHARMACOL, V333, P9, DOI 10.1016/S0014-2999(97)01118-7; GABILONDO AM, 1994, PSYCHOPHARMACOLOGY, V115, P135, DOI 10.1007/BF02244763; Gonzalez-Maeso J, 2000, EUR J PHARMACOL, V390, P25, DOI 10.1016/S0014-2999(99)00827-4; Gonzalez-Maeso J, 2002, EUR J PHARMACOL, V452, P21, DOI 10.1016/S0014-2999(02)02242-2; KANEKO C, 1979, CHEM PHARM BULL, V27, P946; MartinGomez JI, 1996, NEUROREPORT, V7, P1393, DOI 10.1097/00001756-199605310-00013; Miralles A, 2005, EUR J PHARMACOL, V518, P234, DOI 10.1016/j.ejphar.2005.06.023; MIRALLES A, 1993, J PHARMACOL EXP THER, V264, P1187; Montero A, 2002, BIOORGAN MED CHEM, V10, P1009, DOI 10.1016/S0968-0896(01)00356-X; Morgan AD, 2002, PHARMACOL BIOCHEM BE, V72, P873, DOI 10.1016/S0091-3057(02)00774-8; Morphy R, 2005, J MED CHEM, V48, P6523, DOI 10.1021/jm058225d; POSS MA, 1992, TETRAHEDRON LETT, V33, P5933, DOI 10.1016/S0040-4039(00)61092-4; Ruiz-Durantez E, 2003, BRIT J PHARMACOL, V138, P494, DOI 10.1038/sj.bjp.0705052; Sanchez-Blazquez P, 2000, BRIT J PHARMACOL, V130, P146, DOI 10.1038/sj.bjp.0703294; Su RB, 2003, ACTA PHARMACOL SIN, V24, P631	20	42	42	1	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0968-0896			BIOORGAN MED CHEM	Bioorg. Med. Chem.	OCT 1	2006	14	19					6570	6580		10.1016/j.bmc.2006.06.007			11	Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry, Organic	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry	086CK	WOS:000240650500011	16797997				2020-06-30	J	Schmidt, B; Roth, B; Stutzer, H; Benz-Bohm, G				Schmidt, Beate; Roth, Bernhard; Stuetzer, Hartmut; Benz-Bohm, Gabriele			Prospective sonographic evaluation of fentanyl side effects on the neonatal gallbladder	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						opioid; pain; biliary system; ultrasound; neonatal	INTENSIVE-CARE-UNIT; COMMON BILE-DUCT; PHARMACOLOGICAL-TREATMENT; PARENTERAL-NUTRITION; RANDOMIZED-TRIAL; ANALGESIA; SEDATION; MORPHINE; PAIN; PRETERM	Objective: In an effort to minimise the stress and pain of mechanically ventilated neonates, the application of opioids has increased markedly. Abdominal adverse effects of opioid analgesics are constipation and increased pressure in the biliary system. Our aim was to evaluate the impact of continuous intravenous infusion of fentanyl on the volume of the neonatal gallbladder and to assess potential gastrointestinal side effects. Methods: We prospectively matched pairs of 40 mechanically ventilated neonates (28-42 gestational weeks) under total parenteral nutrition and midazolam sedation. One group (20 patients) received continuous fentanyl infusions (dose 0.5-2 mu g kg(-1) h(-1)) the other group (20 patients) served as controls. Sonographic measurements of gallbladder length, depth and width were performed to calculate gallbladder volume using the ellipsoid method. Repeated ultrasound images, date of meconium release and serum bilirubin levels were documented. Results: Fentanyl application was not associated with gallbladder sludge/stones, gallbladder hydrops, hyperbilirubinemia or prolonged meconium release. Neonatal gallbladder length, width and volume did not differ significantly (data expressed as mean, standard deviation, median, interquartile range: length (cm) 3.16 +/- 0.68, 3.3, 0.675 vs 3.06 +/- 0.62, 3.3, 1.1; P=0.645; width (cm) 1.02 +/- 0.23, 1.0, 0.28 vs 0.89 +/- 0.27, 0.9, 0.38, P=0.12; volume (cm(3)) 1.52 +/- 0.67, 1.7, 0.86 vs 1.22 +/- 0.77, 1.09, 1.19, P=0.20). Conclusion: In our study fentanyl caused no major complications in the biliary system and intestine of ventilated preterm and term neonates. Sonographic investigations of the gallbladder under fentanyl treatment may be dispensable. Further investigations are required to assess adverse gastrointestinal effects.	Univ Cologne, Childrens Hosp, Dept Neonatol, D-50937 Cologne, Germany; Univ Cologne, Inst Med Stat Informat & Epidemiol, D-5000 Cologne 41, Germany; Univ Cologne, Dept Radiol, D-5000 Cologne 41, Germany	Schmidt, B (reprint author), Univ Cologne, Childrens Hosp, Dept Neonatol, Kerpenerstr 62, D-50937 Cologne, Germany.	beate.schmidt@uk-koeln.de					Akinci SB, 2005, PEDIATR ANESTH, V15, P870, DOI 10.1111/j.1460-9592.2005.01574.x; Allegaert K, 2003, EUR J CLIN PHARMACOL, V59, P87, DOI 10.1007/s00228-003-0585-3; ANAND KJS, 1987, LANCET, V1, P62; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; Angeles DM, 2005, PEDIATR RES, V57, P873, DOI 10.1203/01.PDR.0000157676.45088.8C; ARAD I, 1989, J PERINAT MED, V17, P337; Aranda JV, 2005, CLIN THER, V27, P877, DOI 10.1016/j.clinthera.2005.06.019; Aretz S, 2004, BIOL NEONATE, V85, P243, DOI 10.1159/000076238; Blauer T, 1998, CLIN J PAIN, V14, P39, DOI 10.1097/00002508-199803000-00006; Carbajal R, 2006, ARCH PEDIATRIE, V13, P211, DOI 10.1016/j.arcped.2005.12.007; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; FIGUEROACOLON R, 1990, J PEDIATR GASTR NUTR, V10, P234, DOI 10.1097/00005176-199002000-00015; Guinsburg R, 1998, J PEDIATR-US, V132, P954, DOI 10.1016/S0022-3476(98)70390-7; HARTWIG S, 1991, EUR J PEDIATR, V150, P784, DOI 10.1007/BF02026712; HYNYNEN MJ, 1986, ANESTH ANALG, V65, P370; JAWAHEER G, 1995, ARCH DIS CHILD-FETAL, V72, pF200, DOI 10.1136/fn.72.3.F200; Lee J, 2004, IMMUNOPHARM IMMUNOT, V26, P17, DOI 10.1081/IPH-120029941; MALAVE A, 1992, LIFE SCI, V51, P513, DOI 10.1016/0024-3205(92)90028-N; MATOS C, 1987, J ULTRAS MED, V6, P243, DOI 10.7863/jum.1987.6.5.243; MCCAMMON RL, 1984, ANESTH ANALG, V63, P139; Menon G, 1998, SEMIN PERINATOL, V22, P417, DOI 10.1016/S0146-0005(98)80057-8; PETERS H, 1983, J ULTRASOUND MED S, V2, P141; Radbruch Lukas, 2004, Keio J Med, V53, P23, DOI 10.2302/kjm.53.23; ROTH B, 1991, DEV PHARMACOL THERAP, V17, P121, DOI 10.1159/000457510; Saarenmaa E, 1999, J PEDIATR-US, V134, P144, DOI 10.1016/S0022-3476(99)70407-5; SCHLESINGER AE, 1988, PEDIATR RADIOL, V18, P235, DOI 10.1007/BF02390403; Tibboel D, 2005, SEMIN FETAL NEONAT M, V10, P195, DOI 10.1016/j.siny.2004.11.002; TREMBLAY PR, 1973, CAN ANAESTH SOC J, V20, P747, DOI 10.1007/BF03025675; VIEIRA ZEG, 1994, INT J CLIN PHARM TH, V32, P274; Wielenga J M, 2004, Neonatal Netw, V23, P39	30	2	2	0	2	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0031-6970			EUR J CLIN PHARMACOL	Eur. J. Clin. Pharmacol.	OCT	2006	62	10					823	827		10.1007/s00228-006-0170-7			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	092NN	WOS:000241104200005	16896787				2020-06-30	J	Sahin, AS; Duman, A; Gunaydin, IG; Sahin, TK; Gormus, N; Duman, I				Sahin, Ayse Saide; Duman, Ates; Gunaydin, Ishak Gursel; Sahin, Tahir Kemal; Gormus, Niyazi; Duman, Ipek			Effect of cooling on the responses of human saphenous vein to fentanyl, remifentanil and sufentanil	FUNDAMENTAL & CLINICAL PHARMACOLOGY			English	Article						cooling; fentanyl; human saphenous vein; remifentanil; sufentanil	HUMAN RIGHT ATRIA; CORONARY-ARTERY; IN-VITRO; VASCULAR-TONE; ENDOTHELIUM; ALFENTANIL; VASORELAXATION; HYPOTHERMIA; REACTIVITY; MECHANISMS	We studied the vasodilatory effects of fentanyl, remifentanil and sufentanil on the human saphenous vein strips at 37, 32 and 28 degrees C. Fentanyl produced concentration-dependent relaxation of human saphenous vein strips precontracted with 5-hydroxytryptamine (5-HT) at every temperature studied. Compared with vein strips at 37 degrees C, relaxant responses to each one concentration of fentanyl were significantly reduced at 32 and 28 degrees C. Remifentanil relaxed vein strips in a concentration-dependent way and the relaxation for all concentrations were significantly greater at 32 and 28 degrees C compared with 37 degrees C. Sufentanil produced concentration-dependent relaxation in saphenous vein strips precontracted with 5-HT. These relaxant responses were similar at 32 degrees C compared with 37 degrees C. When bath temperature was lowered from 37 to 28 degrees C, the relaxant responses to sufentanil were significantly reduced. In summary, the present study suggests that cooling reduces the relaxation caused by fentanyl and sufentanil on human saphenous veins but augments the relaxation with remifentanil. The augmented vasodilatory effect of remifentanil with cooling may be useful on systemic vascular resistance and organ preservation under hypothermic conditions like cardiopulmonary bypass surgery.	Selcuk Univ, Meram Med Fac, Dept Pharmacol, Konya, Turkey; Selcuk Univ, Meram Med Fac, Dept Anesthesia & Intens Care, Konya, Turkey; Selcuk Univ, Meram Med Fac, Dept Forens Med, Konya, Turkey; Selcuk Univ, Meram Med Fac, Dept Publ Hlth, Konya, Turkey; Selcuk Univ, Meram Med Fac, Dept Cardiovasc Surg, Konya, Turkey	Sahin, AS (reprint author), Selcuk Univ, Meram Med Fac, Dept Pharmacol, Konya, Turkey.	aysesaide@gmail.com	DUMAN, IPEK/AAB-9235-2020; Sahin, Tahir Kemal/AAQ-6915-2020	Sahin, Tahir Kemal/0000-0002-4836-1759			BLAISE GA, 1990, ANESTHESIOLOGY, V72, P535, DOI 10.1097/00000542-199003000-00023; BODELSSON M, 1991, J CARDIOVASC SURG, V32, P288; CHAMBERS CE, 1999, CARDIAC ANESTHESIA, P62; Duman A, 2003, J CARDIOTHOR VASC AN, V17, P465, DOI 10.1016/S1053-0770(03)00151-4; FEUERSTEIN G, 1987, CIRCULATION, V75, P125; Hanouz JL, 2001, ANESTH ANALG, V93, P543, DOI 10.1097/00000539-200109000-00005; HARKER CT, 1990, J VASC SURG, V12, P45, DOI 10.1067/mva.1990.20311; KARASAWA F, 1993, BRIT J ANAESTH, V71, P877, DOI 10.1093/bja/71.6.877; KARASAWA F, 1993, CLIN EXP PHARMACOL P, V20, P705, DOI 10.1111/j.1440-1681.1993.tb01655.x; Kazmaier S, 2000, BRIT J ANAESTH, V84, P578, DOI 10.1093/bja/84.5.578; Klockgether-Radke AP, 2000, ACTA ANAESTH SCAND, V44, P1134, DOI 10.1034/j.1399-6576.2000.440917.x; MONITTO CL, 1993, ANESTH ANALG, V76, P985; Sahin AE, 2005, J CARDIOTHOR VASC AN, V19, P197, DOI 10.1053/j.jvca.2005.01.031; Sahin AS, 2005, FUND CLIN PHARMACOL, V19, P341, DOI 10.1111/j.1472-8206.2005.00330.x; Suzuki S, 2000, RESPIRATION, V67, P189, DOI 10.1159/000029485; Unlugenc H, 2003, ACTA ANAESTH SCAND, V47, P65, DOI 10.1034/j.1399-6576.2003.470111.x; Weisser J, 2001, BASIC RES CARDIOL, V96, P198, DOI 10.1007/s003950170071; Yamada Shinichi, 2004, Kurume Medical Journal, V51, P1	18	1	3	1	3	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0767-3981			FUND CLIN PHARMACOL	Fundam. Clin. Pharmacol.	OCT	2006	20	5					473	476		10.1111/j.1472-8206.2006.00434.x			4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	083XW	WOS:000240493500005	16968417				2020-06-30	J	Teoh, WHL; Thomas, E; Tan, HM				Teoh, W. H. L.; Thomas, E.; Tan, H. M.			Ultra-low dose combined spinal-epidural anesthesia with intrathecal bupivacaine 3.75 mg for cesarean delivery: a randomized controlled trial	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						low dose spinal anesthesia; combined spinal-epidural; regional anesthesia; cesarean; hypotension	SUBARACHNOID BLOCK; SECTION; FENTANYL	Background: We wished to investigate the feasibility of an ultra low-dose combined spinal-epidural technique in providing surgical anesthesia for uncomplicated cesarean deliveries in a randomized, double-blind controlled trial. Method: Forty-four normotensive, non-obese patients were randomized to receive either intrathecal hyperbaric bupivacaine 3.75 mg (low dose group, n=22) or 9 mg (conventional group, n=22), in addition to intrathecal fentanyl 25 mu g, morphine 100 mu g, and epidural 1.5% lidocaine 3 mL. Sensorimotor anesthesia and hemodynamic data were assessed at 2.5-min intervals for the first 15 min. Results: The maximal sensory block achieved in the low-dose group was significantly lower than that in the conventional group (median T3, [range T2-T6] vs. T2 [C2-T6], P<0.001) with a longer time taken to reach maximal sensory block. The low-dose group had less motor block, faster sensory regression to T10 dermatome and faster motor recovery to Bromage 0 (all P<0.001). The block failed to reach T6 bilaterally within 10 min in one patient in the low-dose group and two in the conventional group, with no significant difference in the need for epidural supplementation before or after delivery of the baby. The low-dose group experienced less hypotension (14% vs. 73%, P<0.001) with less ephedrine usage (0.68 vs. 17.5 mg, P<0.001). There was no difference in operating conditions and other side effects (shivering, pruritus). Conclusion: We conclude that this technique results in a significantly lower incidence of maternal hypotension and has a role in high-risk parturients in whom maintenance of stable hemodynamics is imperative. (C) 2006 Elsevier Ltd. All rights reserved.	KK Womens & Childrens Hosp, Dept Womens Anesthesia, Singapore 229899, Singapore	Teoh, WHL (reprint author), KK Womens & Childrens Hosp, Dept Womens Anesthesia, 100 Bukit Timah Rd, Singapore 229899, Singapore.	teohwendy@yahoo.com		Teoh, Wendy/0000-0001-9594-3009			Ben-David B, 2000, REGION ANESTH PAIN M, V25, P235, DOI 10.1016/S1098-7339(00)90004-X; BLUMGART CH, 1992, BRIT J ANAESTH, V69, P457, DOI 10.1093/bja/69.5.457; Carpenter RL, 1998, ANESTHESIOLOGY, V89, P24, DOI 10.1097/00000542-199807000-00007; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; Ginosar Y, 2004, ANESTHESIOLOGY, V100, P676, DOI 10.1097/00000542-200403000-00031; Goy RWL, 2004, ANESTH ANALG, V98, P491, DOI 10.1213/01.ANE.0000097182.DE; Hamlyn EL, 2005, INT J OBSTET ANESTH, V14, P355, DOI 10.1016/j.ijoa.2005.01.001; Leeda M, 2002, ANESTHESIOLOGY, V96, P1310, DOI 10.1097/00000542-200206000-00008; Lim Y, 2004, INT J OBSTET ANESTH, V13, P198, DOI 10.1016/j.ijoa.2004.03.007; Loke GPY, 2002, ANAESTHESIA, V57, P169, DOI 10.1046/j.1365-2044.2002.02227.x; PopitzBergez FA, 1997, REGION ANESTH, V22, P363, DOI 10.1016/S1098-7339(97)80013-2; Reyes M, 2004, INT J OBSTET ANESTH, V13, P99, DOI 10.1016/j.ijoa.2003.09.004; Richardson MG, 1996, REGION ANESTH, V21, P119; Vercauteren MP, 1998, ANESTH ANALG, V86, P989, DOI 10.1097/00000539-199805000-00014	14	36	36	0	2	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	OCT	2006	15	4					273	278		10.1016/j.ijoa.2006.03.004			6	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	101BY	WOS:000241715100002	16774830				2020-06-30	J	Stone, JP; Tiwari, VR; Shetty, DY; Dodd, PH; Jenkins, JG				Stone, J. P.; Tiwari, V. R.; Shetty, D. Y.; Dodd, P. H.; Jenkins, J. G.			Injectate temperature and discomfort during epidural injection	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Letter							ANESTHESIA; ADRENALINE; FENTANYL; PAIN		Royal Surrey Cty Hosp, Dept Anaesthesia, Guildford, Surrey, England	Stone, JP (reprint author), Royal Surrey Cty Hosp, Dept Anaesthesia, Guildford, Surrey, England.	garethjenkins@doctors.org.uk					ALONSO PE, 1993, BRIT J PLAST SURG, V46, P76, DOI 10.1016/0007-1226(93)90070-R; DAWSON PJ, 1992, BRIT J ANAESTH, V68, P414, DOI 10.1093/bja/68.4.414; KAMAYA H, 1983, ANESTH ANALG, V62, P1025; SHEHABI Y, 1990, ANAESTH INTENS CARE, V18, P31, DOI 10.1177/0310057X9001800106; Ursell PG, 1996, OPHTHALMOLOGY, V103, P839; WALMSLEY AJ, 1986, BRIT J ANAESTH, V58, P1130, DOI 10.1093/bja/58.10.1130	6	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	OCT	2006	15	4					342	343		10.1016/j.ijoa.2006.06.008			2	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	101BY	WOS:000241715100027	16949272				2020-06-30	J	Martin, TL; Woodall, KL; McLellan, BA				Martin, Teri L.; Woodall, Karen L.; McLellan, Barry A.			Fentanyl-related deaths in Ontario, Canada: Toxicological findings and circumstances, of death in 112 cases (2002-2004)	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							TRANSDERMAL FENTANYL; ABUSE; MISUSE; PATCH; PAIN		Ctr Forens Sci, Toxicol Sect, Toronto, ON M7A 2G8, Canada; Off Chief Coroner, Toronto, ON M7A 2G9, Canada	Martin, TL (reprint author), Ctr Forens Sci, Toxicol Sect, 25 Grosvenor St, Toronto, ON M7A 2G8, Canada.	teri.martin@jus.gov.on.ca					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; Arvanitis ML, 2002, AM J EMERG MED, V20, P58, DOI 10.1053/ajem.2002.29562; Bleeker CP, 2001, EUR J PAIN-LONDON, V5, P325, DOI 10.1053/eujp.2000.0220; CHATURVEDI AK, 1990, J ANAL TOXICOL, V14, P385, DOI 10.1093/jat/14.6.385; Coon TP, 2005, ANN EMERG MED, V46, P473, DOI 10.1016/j.annemergmed.2005.06.450; DUTHIE DJR, 1988, BRIT J ANAESTH, V60, P614, DOI 10.1093/bja/60.6.614; ECKENHOFF JE, 1960, CLIN PHARMACOL THER, V1, P483; GARRIOTT JC, 1984, J ANAL TOXICOL, V8, P288, DOI 10.1093/jat/8.6.288; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; *JANSS INC, 2004, [No title captured]; KOVES EM, 1985, J FORENSIC SCI, V30, P692; Kramer Christopher, 1998, Journal of the American Osteopathic Association, V98, P385; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Liappas IA, 2004, J PSYCHOPHARMACOL, V18, P277, DOI 10.1177/0269881104042634; Lilleng PK, 2004, J FORENSIC SCI, V49, P1364; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; MATEJCZYK RJ, 1988, J ANAL TOXICOL, V12, P236, DOI 10.1093/jat/12.4.236; Olkkola KT, 1999, ANESTHESIOLOGY, V91, P681, DOI 10.1097/00000542-199909000-00020; PARE EM, 1987, J ANAL TOXICOL, V11, P272, DOI 10.1093/jat/11.6.272; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; Purucker M, 2000, ANN EMERG MED, V35, P314, DOI 10.1016/S0196-0644(00)70091-6; RAYMOND B, 2004, CANADIAN ADVERSE REA, V14, P1; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; Regnard C, 2003, PALLIATIVE MED, V17, P714, DOI 10.1191/0269216303pm838cr; Tateishi T, 1996, ANESTH ANALG, V82, P167; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; Weemhoff JL, 2003, J PHARM PHARMACOL, V55, P381, DOI 10.1211/002235702739; WOODALL KL, 2006, P AM AC FOR SCI 58 A, V12, P361	29	83	85	0	32	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	OCT	2006	30	8					603	610		10.1093/jat/30.8.603			8	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	093NY	WOS:000241176200019	17132259	Bronze			2020-06-30	J	Kelly, JJ; Donath, S; Jamsen, K; Chalkiadis, GA				Kelly, J. J.; Donath, Susan; Jamsen, Kris; Chalkiadis, G. A.			Postoperative sleep disturbance in pediatric patients using patient-controlled devices (PCA)	PEDIATRIC ANESTHESIA			English	Article						patient-controlled analgesia; sleep disturbance	LOWER ABDOMINAL-SURGERY; CONTROLLED ANALGESIA; CHILDREN; PAIN	Background : Sleep disturbance has not been well quantified in pediatric postoperative management, yet has broad implications in pain management as well as upon the physical and psychological well-being of the young patient admitted for surgery. We aimed to describe sleep disturbance in this population using patient-controlled analgesia (PCA) and then identify the predictors of disturbed sleep. Methods: A retrospective audit and analysis of sleep disturbance in postoperative pediatric patients using PCA devices were performed in a postoperative surgical ward population of a major tertiary referral center. PCA presses were used as a proxy measure of sleep. The description of the sleep disturbance included an unadjusted and adjusted analysis of the proposed predictors of sleep disturbance: age, sex, nature of presentation, operation type, PCA opioid type, presence of background infusion, postoperative night number, and adjuvant medication. All data were entered into an ACCESS database developed for the audit and analyzed using STATA 8.0. Results: The first 126 children prescribed PCA devices in the year 2004 were audited. One-third of patients in the population prescribed PCA experienced sleep disturbance. Observed predictors of sleep disturbance include older children (OR: 0.86, P = 0.001) and those receiving a background infusion (OR: 0.19, P = 0.002).Other predictors were not significant. Conclusions: Sleep disruption is common in children-prescribed PCA opioid analgesia. Older children and those receiving a background infusion were observed to experience less sleep. Other proposed predictors were not found to be reliable. Further investigation into the predictors of disturbed sleep in the postoperative patient is warranted.	Royal Childrens Hosp, Dept Gen Med, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Clin Epidemiol & Biostat Unit, Melbourne, Vic, Australia; Royal Childrens Hosp, Dept Anaesthesia, Parkville, Vic 3052, Australia	Kelly, JJ (reprint author), Royal Childrens Hosp, Dept Gen Med, Flemington Rd, Parkville, Vic 3052, Australia.	julian.kelly@rch.org.au		Donath, Susan/0000-0003-2489-3977			BRIMACOMBE J, 1993, ANAESTHESIA, V48, P527, DOI 10.1111/j.1365-2044.1993.tb07078.x; CLOSS SJ, 1992, INT J NURS STUD, V29, P381, DOI 10.1016/0020-7489(92)90016-A; DOYLE E, 1993, BRIT J ANAESTH, V71, P670, DOI 10.1093/bja/71.5.670; DOYLE E, 1993, BRIT J ANAESTH, V71, P818, DOI 10.1093/bja/71.6.818; Kain ZN, 2003, J CLIN ANESTH, V15, P505, DOI 10.1016/j.jclinane.2003.02.002; KNIGHT JC, 1994, [No title captured], V4, P45; KNILL RL, 1990, ANESTHESIOLOGY, V73, P52, DOI 10.1097/00000542-199007000-00009; Lewin DS, 1999, J DEV BEHAV PEDIATR, V20, P244, DOI 10.1097/00004703-199908000-00007; McDonald AJ, 2001, PEDIATR DRUGS, V3, P273, DOI 10.2165/00128072-200103040-00004; Rosenberg J, 2001, SLEEP MED REV, V5, P129, DOI 10.1053/smrv.2000.0121; RosenbergAdamsen S, 1996, BRIT J ANAESTH, V76, P552	11	7	7	0	3	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	OCT	2006	16	10					1051	1056		10.1111/j.1460-9592.2006.01932.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	084JF	WOS:000240528500009	16972835				2020-06-30	J	Kaplanian, S; Chambers, NA				Kaplanian, Serge; Chambers, Neil A.			Anesthesia in a child with newly diagnosed Hypertrophic Cardiomyopathy	PEDIATRIC ANESTHESIA			English	Article						cardiac arrest; pediatric; torsade de pointes; Hypertrophic Cardiomyopathy	VENTRICULAR-FIBRILLATION	We report the initial resuscitation and subsequent management of a child with newly diagnosed Hypertrophic Cardiomyopathy (HCM), which presented as an out of hospital cardiac arrest. HCM is an autosomal dominant condition that is uncommonly encountered in the pediatric setting and is an important cause of sudden death. Here, we describe the safe use of an anesthetic technique for insertion of an implantable cardioverter-defibrillator that ensured strict hemodynamic stability and modest bradycardia.	Princess Margaret Hosp Children, Dept Anesthesia, Perth, WA, Australia	Chambers, NA (reprint author), Princess Margaret Hosp Children, Dept Anesthesia, Perth, WA, Australia.	chambey@bigpond.com					CODD MB, 1989, CIRCULATION, V80, P564, DOI 10.1161/01.CIR.80.3.564; Dessertenne F, 1966, Arch Mal Coeur Vaiss, V59, P263; GHAZALA Q, 2004, J EMERGENCY MED, V26, P65; Harley ID, 1996, BRIT J ANAESTH, V77, P675; LINIER W, 1984, ANESTHESIOLOGY, V60, P61; LOUBSER P, 1984, ANESTHESIOLOGY, V60, P228, DOI 10.1097/00000542-198403000-00010; Maron BJ, 2004, PEDIATR CLIN N AM, V51, P1305, DOI 10.1016/j.pcl.2004.04.017; MOGAYZEL C, 1995, ANN EMERG MED, V25, P484, DOI 10.1016/S0196-0644(95)70263-6; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; ROBERTS WC, 1975, HUM PATHOL, V6, P287, DOI 10.1016/S0046-8177(75)90003-9; Ruppel R, 1998, J AM COLL CARDIOL, V32, P1724, DOI 10.1016/S0735-1097(98)00430-6; Schindler MB, 1996, NEW ENGL J MED, V335, P1473, DOI 10.1056/NEJM199611143352001; STOELTING RK, 2002, ANESTHESIA COEXISTIN, P120	13	2	2	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	OCT	2006	16	10					1080	1083		10.1111/j.1460-9592.2006.01922.x			4	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	084JF	WOS:000240528500015	16972841				2020-06-30	J	Pershad, J; Todd, K; Waters, T				Pershad, Jay; Todd, Kevin; Waters, Teresa			Cost-effectiveness analysis of sedation and analgesia regimens during fracture manipulation in the pediatric emergency department	PEDIATRIC EMERGENCY CARE			English	Article						analysis; sedation and analgesia; fracture manipulation	INTRAVENOUS REGIONAL ANESTHESIA; PROCEDURAL SEDATION; KETAMINE SEDATION; FOREARM FRACTURES; PROPOFOL SEDATION; DOUBLE-BLIND; CHILDREN; MIDAZOLAM; BLOCK; TRIAL	Objective: To conduct a cost-effectiveness analysis, from a hospital's perspective, of 4 procedural sedation and analgesia (PSA) regimens to facilitate forearm fracture manipulation in the pediatric emergency department (ED): deep sedation with ketamine/midazolarn (K/M) administration, propofol/fentanyl administration, fentanyl/midazolam (F/M) administration, and axillary block. Design/Methods: We constructed a decision analytic model using relevant probabilities from published studies of pediatric patients who underwent fracture manipulation in the EDs. Total costs were calculated by assessing ED resource utilization associated with uncomplicated PSA and with PSA complicated by adverse events. Costs of consumable equipment were considered to be fixed. Total sedation time, personnel time, and drug costs were considered variable. We assumed that all PSA regimens provided effective relief from procedural distress. Failure rates for axillary block were estimated based on reports in the literature. When patients experienced emesis, recovery agitation, respiratory depression, lidocaine toxicity, or regional block failure, we assumed that the patients would require I additional hour of ED stay. Sensitivity analyses of all key variables in the model were performed to identify those that may result in a change in the preferred option. Monte Carlo simulations were performed to assess model robustness. Results: Under baseline assumptions, the propofol/fentanyl regimen was the most cost-effective choice (expected cost, US $84.06), followed by axillary block (US $88.18), K/M (US $105.32), and F/M (US $159.79), respectively. Varying the fixed and variable costs by 50% to 200% of their baseline values did not alter the ranking. When ketamine and propofol were administered without adjunctive midazolam and fentanyl, respectively, propofol remained the optimum choice. With total PSA,time as the outcome measure, the incremental cost-effectiveness ratios were US $8.1 and US $24.9 per hour of ED time saved, for propofol/fentanyl versus axillary block and for axillary block versus K/M, respectively. Conclusions: Among PSA regimens during forearm fracture manipulation in the pediatric ED, propofol/fentanyl is the most cost-effective regimen followed by axillary block, K/M, and F/M.	Lebonheur Childrens Hosp & Med Ctr, Dept Pediat, Div Emergency Med, Memphis, TN 38103 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Div Emergency Med, Memphis, TN 38163 USA; St Jude Childrens Res Ctr, Dept Anesthesia, Memphis, TN USA; Univ Tennessee, Ctr Hlth Serv Res, Dept Prevent Med, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA	Pershad, J (reprint author), Lebonheur Childrens Hosp & Med Ctr, Dept Pediat, Div Emergency Med, 50 N Dunlap St, Memphis, TN 38103 USA.	pershadj@lebonheur.org					Bassett KE, 2003, ANN EMERG MED, V42, P773, DOI 10.1016/S0196-0644(03)00619-X; BOLTE RG, 1994, J PEDIATR ORTHOPED, V14, P534, DOI 10.1097/01241398-199407000-00022; CRAMER KE, 1995, J ORTHOP TRAUMA, V9, P407, DOI 10.1097/00005131-199505000-00008; EMSC Grant Panel Pharmacologic Ag, 2004, J PEDIATR SURG, V39, P1472, DOI 10.1016/j.jpedsurg.2004.07.002; Fombeur PO, 2002, AM J HEALTH-SYST PH, V59, P1344, DOI 10.1093/ajhp/59.14.1344; Godambe SA, 2003, PEDIATRICS, V112, P116, DOI 10.1542/peds.112.1.116; Guenther E, 2003, ANN EMERG MED, V42, P783, DOI 10.1016/S0196-0644(03)00634-6; Havel CJ, 1999, ACAD EMERG MED, V6, P989, DOI 10.1111/j.1553-2712.1999.tb01180.x; HENNRIKUS WL, 1995, J BONE JOINT SURG AM, V77A, P335, DOI 10.2106/00004623-199503000-00001; JULIANO PJ, 1992, J PEDIATR ORTHOPED, V12, P633; Kennedy RM, 1998, PEDIATRICS, V102, P956, DOI 10.1542/peds.102.4.956; Krauss B, 2000, NEW ENGL J MED, V342, P938, DOI 10.1056/NEJM200003303421306; KRIWANEK KL, 2005, PED AC SOC M MAY WAS; Mackay CA, 1997, J ACCID EMERG MED, V14, P226; McCollam JS, 1999, CRIT CARE MED, V27, P2454, DOI 10.1097/00003246-199911000-00022; Pena BMG, 1999, ANN EMERG MED, V34, P483, DOI 10.1016/S0196-0644(99)80050-X; ROSENBERG MK, 1994, ANESTH ANALG, V79, P852; Sherwin TS, 2000, ANN EMERG MED, V35, P229, DOI 10.1016/S0196-0644(00)70073-4; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; Skokan EG, 2001, CLIN PEDIATR, V40, P663, DOI 10.1177/000992280104001204; Sung Y F, 1991, J Clin Anesth, V3, P391, DOI 10.1016/0952-8180(91)90182-M; Wathen JE, 2000, ANN EMERG MED, V36, P579, DOI 10.1067/mem.2000.111131; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253	23	17	17	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-5161	1535-1815		PEDIATR EMERG CARE	Pediatr. Emerg. Care	OCT	2006	22	10					729	736		10.1097/01.pec.0000220523.01364.ef			8	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	096HQ	WOS:000241368600007	17047473				2020-06-30	J	Roberts, KD; Leone, TA; Edwards, WH; Rich, WD; Finer, NN				Roberts, Kari D.; Leone, Tina A.; Edwards, William H.; Rich, Wade D.; Finer, Neil N.			Premedication for nonemergent neonatal intubations: A randomized, controlled trial comparing atropine and fentanyl to atropine, fentanyl, and mivacurium	PEDIATRICS			English	Article						intubation; premedication; atropine; fentanyl; mivacurium; muscle relaxant; hypoxia; infant; neonate	NASOTRACHEAL INTUBATION; ENDOTRACHEAL INTUBATION; TRACHEAL INTUBATION; PHYSIOLOGICAL-CHANGES; PRESSURE; INFANTS; RESPONSES; AWAKE; SUCCINYLCHOLINE; FACILITATION	OBJECTIVE. The purpose of this work was to investigate whether using a muscle relaxant would improve intubation conditions in infants, thereby decreasing the incidence and duration of hypoxia and time and number of attempts needed to successfully complete the intubation procedure. PATIENTS/METHODS. This was a prospective, randomized, controlled, 2-center trial. Infants requiring nonemergent intubation were randomly assigned to receive atropine and fentanyl or atropine, fentanyl, and mivacurium before intubation. Incidence and duration of hypoxia were determined at oxygen saturation thresholds of <= 85%, <= 75%, <= 60%, and <= 40%. Videotape was reviewed to determine the time and number of intubation attempts and duration of action of mivacurium. RESULTS. Analysis of 41 infants showed that incidence of oxygen saturation <= 60% of any duration was significantly less in the mivacurium group (55% vs 24%). The incidence of saturation level of any duration <= 85%, 75%, and 40%; cumulative time >= 30 seconds; and time below the thresholds were not significantly different. Total procedure time (472 vs 144 seconds) and total laryngoscope time (148 vs 61 seconds) were shorter in the mivacurium group. Successful intubation was achieved in >= 2 attempts significantly more often in the mivacurium group (35% vs 71%). CONCLUSIONS. Premedication with atropine, fentanyl, and mivacurium compared with atropine and fentanyl without a muscle relaxant decreases the time and number of attempts needed to successfully intubate while significantly reducing the incidence of severe desaturation. Premedication including a short-acting muscle relaxant should be considered for all nonemergent intubations in the NICU.	Dartmouth Hitchcock Med Ctr, Div Neonatol, Lebanon, NH 03766 USA; Univ Calif San Diego, Med Ctr, Div Neonatol, San Diego, CA 92103 USA	Roberts, KD (reprint author), Univ Minnesota, Childrens Hosp, MMC 39,420 Delaware St SE, Minneapolis, MN 55455 USA.	rober694@umn.edu					Andriessen P, 2004, PEDIATR RES, V56, P939, DOI 10.1203/01.PDR.0000145257.75072.BB; BARRINGTON KJ, 1989, CRIT CARE MED, V17, P1293, DOI 10.1097/00003246-198912000-00009; Barrington KJ, 1998, AM J PERINAT, V15, P213, DOI 10.1055/s-2007-993928; Bhutada A, 2000, ARCH DIS CHILD-FETAL, V82, pF34, DOI 10.1136/fn.82.1.F34; Cook DR, 2000, ANESTH ANALG, V90, pS24, DOI 10.1097/00000539-200005001-00006; Cook-Sather SD, 1998, ANESTH ANALG, V86, P945, DOI 10.1097/00000539-199805000-00006; Dempsey EM, 2006, ARCH DIS CHILD-FETAL, V91, pF279, DOI 10.1136/adc.2005.087213; FRIESEN RH, 1987, ANESTH ANALG, V66, P874; GIBBONS PA, 1986, ANESTH ANALG, V65, pS58; Hall RW, 2005, PEDIATRICS, V115, P1351, DOI 10.1542/peds.2004-1398; KELLY MA, 1984, J PEDIATR-US, V105, P303, DOI 10.1016/S0022-3476(84)80137-7; Khammash Hatem M., 1993, Pediatric Research, V33, p218A; KONG AS, 1992, ANAESTHESIA, V47, P896, DOI 10.1111/j.1365-2044.1992.tb03159.x; Lemons JA, 2000, PEDIATRICS, V105, P454; MARSHALL TA, 1984, CRIT CARE MED, V12, P501, DOI 10.1097/00003246-198406000-00006; MILLAR C, 1994, CAN J ANAESTH, V41, P281, DOI 10.1007/BF03009904; Oei J, 2002, J PAEDIATR CHILD H, V38, P146, DOI 10.1046/j.1440-1754.2002.00726.x; POKELA ML, 1994, ACTA PAEDIATR, V83, P151, DOI 10.1111/j.1651-2227.1994.tb13040.x; RAJU TNK, 1980, J PEDIATR-US, V96, P860, DOI 10.1016/S0022-3476(80)80558-0; Saarenmaa E, 1999, J PEDIATR-US, V134, P144, DOI 10.1016/S0022-3476(99)70407-5; Sarkar S, 2006, J PERINATOL, V26, P286, DOI 10.1038/sj.jp.7211499; Simon L, 2004, CRIT CARE MED, V32, P565, DOI 10.1097/01.CCM.0000108883.58081.E3; STOW PJ, 1988, BRIT J ANAESTH, V60, P167, DOI 10.1093/bja/60.2.167; Vogel S, 2000, PEDIATR RES, V47, p438A; Whyte S, 2000, ARCH DIS CHILD-FETAL, V82, pF38, DOI 10.1136/fn.82.1.F38; ZIEGLER JW, 1992, AM J DIS CHILD, V146, P147, DOI 10.1001/archpedi.1992.02160140013008; 2004, SUCCINYLCHOLINE CHLO	27	71	73	0	2	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	OCT	2006	118	4					1583	1591		10.1542/peds.2006-0590			9	Pediatrics	Pediatrics	090NZ	WOS:000240959300031	17015550	Green Published			2020-06-30	J	Petrov, RR; Vardanyan, RS; Lee, YS; Ma, SW; Davis, P; Begay, LJ; Lai, JY; Porreca, F; Hruby, VJ				Petrov, Ravil R.; Vardanyan, Ruben S.; Lee, Yeon S.; Ma, Shou-wu; Davis, Peg; Begay, Lucinda J.; Lai, Josephine Y.; Porreca, Frank; Hruby, Victor J.			Synthesis and evaluation of 3-aminopropionyl substituted fentanyl analogues for opioid activity	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						fentanyl derivatives; opioid agonists; enkephalin analogue	PHARMACOLOGICAL EVALUATION; ANALGESIC ACTIVITY; RECEPTOR; LIGANDS; DERIVATIVES; AFFINITY; AGONIST; POTENT; ANTAGONISTS; PEPTIDE	An enkephalin analogue coupled to 'aminofentanyl' has been synthesized and tested for biological activities at the mu and delta opioid receptors. Aminofentanyl which represents a structural derivative of fentanyl has been synthesized by acylation of 1-(2-phenethyl)-4-(N-anilino)piperidine with phthaloyl protected beta-alaninyl chloride in the presence of DIPEA, followed by deprotection with hydrazine hydrate. Aminofentanyl has also been successfully acylated with ethyl isocyanate, various acid anhydrides, to further investigate structure-activity relationships of these new fentanyl derivatives. Among the new derivatives compound 7 which carries a Tyr-D-Ala-Gly-Phe opioid message sequence showed good opioid affinity (1 nM at both delta and mu opioid receptors) and bioactivity (34.9 nM in MVD and 42 nM in GPI/LMMP bioassays). (c) 2006 Elsevier Ltd. All rights reserved.	Univ Arizona, Dept Chem, Tucson, AZ 85721 USA; Univ Arizona, Dept Pharmacol, Tucson, AZ 85721 USA	Hruby, VJ (reprint author), Univ Arizona, Dept Chem, Tucson, AZ 85721 USA.	hruby@u.arizona.edu	Vardanyan, Ruben S/G-8173-2016		NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R37 DA012394, R01 DA013449, P01 DA006284]		BAGLEY JR, 1989, J MED CHEM, V32, P663, DOI 10.1021/jm00123a028; BAGLEY JR, 1988, Patent No. 277794; Bowdle TA, 1998, DRUG SAFETY, V19, P173, DOI 10.2165/00002018-199819030-00002; ESSAWI MYH, 1983, J MED CHEM, V26, P348, DOI 10.1021/jm00357a007; FANG SN, 1983, ACTA PHARMACOL SINIC, V18, P823; FELDMAN PL, 1991, J MED CHEM, V34, P2202, DOI 10.1021/jm00111a041; Feldman PL, 1990, Patent No. [EP 383579, 383579]; HUANG BS, 1985, Patent No. 160422; Janssen A. J., 1964, US Patent, Patent No. [3,141,823, 3141823]; Janssen P. A. J, 1979, US Patent, Patent No. [4179569, US4179569A]; Janssen PAJ, 1964, N-(1Aralkyl-4piperidyl) alkanoic acid anilides, Patent No. [FR M2430, 2430]; JANSSENS F, 1986, J MED CHEM, V29, P2290, DOI 10.1021/jm00161a027; KRAMER TH, 1993, J PHARMACOL EXP THER, V266, P577; KUDZMA LV, 1988, Patent No. 4791121; LALINDE N, 1990, J MED CHEM, V33, P2876, DOI 10.1021/jm00172a032; Lee K, 1998, BIOORG MED CHEM LETT, V8, P2563, DOI 10.1016/S0960-894X(98)00456-9; LEYSEN JE, 1978, CHARACTERISTICS FUNC, P479; Lipkowski AW, 1999, BIOORG MED CHEM LETT, V9, P2763, DOI 10.1016/S0960-894X(99)00464-3; MARYANOFF BE, 1982, J MED CHEM, V25, P913, DOI 10.1021/jm00350a006; MCCONNELL RI, 2003, Patent No. 1312923; MISICKA A, 1992, LIFE SCI, V51, P1025, DOI 10.1016/0024-3205(92)90501-F; Montero A, 2002, BIOORGAN MED CHEM, V10, P1009, DOI 10.1016/S0968-0896(01)00356-X; Petrov RR, 2006, ACTA CRYSTALLOGR E, V62, pO2815, DOI 10.1107/S1600536806021817; POLT R, 1994, P NATL ACAD SCI USA, V91, P7114, DOI 10.1073/pnas.91.15.7114; RILEY TN, 1973, J PHARM SCI, V62, P983, DOI 10.1002/jps.2600620627; ROTHMAN RB, 1991, LIFE SCI, V48, P111; Schiller PW, 2003, LIFE SCI, V73, P691, DOI 10.1016/S0024-3205(03)00389-8; SCHILLER PW, 1989, J MED CHEM, V32, P698, DOI 10.1021/jm00123a035; STEPHEN WH, 1999, ORG P DEV, V3, P241; Van Daele G.H.P, 1976, Ger. Pat., Patent No. [2.610.228, 2610228]; VANBEVER WFM, 1976, ARZNEIMITTELFORSCH, V26, P1548; VARTANYAN RS, 1989, KHIM FARM ZH+, V23, P573; VARTANYAN RS, 1989, KHIM FARM ZH+, V23, P562; VARTANYAN SA, 1985, Patent No. 736583; YEADON M, 1988, NEUROPHARMACOLOGY, V27, P345, DOI 10.1016/0028-3908(88)90141-4	35	22	23	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X			BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	SEP 15	2006	16	18					4946	4950		10.1016/j.bmcl.2006.06.040			5	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	082OD	WOS:000240395300049	16828552	Green Accepted			2020-06-30	J	Agarwal, S; Nag, P; Sikora, S; Prasad, TL; Kumar, S; Gupta, RK				Agarwal, S.; Nag, P.; Sikora, S.; Prasad, T. L.; Kumar, S.; Gupta, R. K.			Fentanyl-augmented MRCP	ABDOMINAL IMAGING			English	Article						magnetic resonance cholangiopancreatography; fentanyl; morphine; billary; pancreatic	MAGNETIC-RESONANCE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; COMMON BILE-DUCT; PANCREATIC DUCT; INTRAVENOUS MORPHINE; SECRETIN STIMULATION; ACUTE CHOLECYSTITIS; ERCP; CHOLEDOCHOLITHIASIS; CHOLANGIOGRAPHY	Background: Drugs such as secretin and morphine have been used to augment the visualization of magnetic resonance cholangiopancreatography (MRCP). This study investigated the effectiveness of intravenous administration of a synthetic opioid, fentanyl, in improving the MRCP image quality. Methods: Thirty consecutive patients with a provisional diagnosis of benign biliary and/or pancreatic disease underwent MRCP. Coronal single-shot fast spin-echo heavily T2-weighted dynamic MRCP images were generated before and at every minute for 10 min after intravenous administration of fentanyl citrate at a dose of 1.0 mu g/kg. Pre- and postinjection images were compared and analyzed qualitatively and quantitatively. Results: Qualitatively, visualization of intrahepatic bile ducts, common bile duct, and main pancreatic duct improved after fentanyl injection in five (16%), 11 (37%), and 19 (63%) patients, respectively. The pancreatobiliary junction and common channel were visualized better after fentanyl injection in eight of the 18 patients (44%). Quantitatively, signal intensity and diameters of the intrahepatic ducts, common bile duct, and main pancreatic duct measured at corresponding points on pre- and postinjection images showed an increase above preinjection values in 28 (93%), 27 (90%), and 21 (70%) and in 18 (60%), 26 (86%), and 22 (73%), respectively, and these changes were highly significant at all sites (p < 0.001). Conclusions: Intravenous administration of fentanyl before MRCP improves qualitative and quantitative visualization of the ductal system anatomy that may be of value in clinical diagnosis and management.	Sanjay Gandhi Postgrad Inst Med Sci, Dept Radiodiag, Lucknow 226014, Uttar Pradesh, India; Sanjay Gandhi Postgrad Inst Med Sci, Dept Surg Gastroenterol, Lucknow 226014, Uttar Pradesh, India	Gupta, RK (reprint author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Radiodiag, Raebareli Rd, Lucknow 226014, Uttar Pradesh, India.	rgupta@sgpg.ac.in					Adamek HE, 1998, GUT, V43, P680, DOI 10.1136/gut.43.5.680; BRICE J, 1999, DIAGN IMAGING SAN S, pIR36; Calvo MM, 2002, AM J GASTROENTEROL, V97, P347; Chan JHM, 2000, ABDOM IMAGING, V25, P405, DOI 10.1007/s002610000018; Chaudhary A, 2002, BRIT J SURG, V89, P433, DOI 10.1046/j.0007-1323.2002.02066.x; ECONOMOU G, 1971, GUT, V12, P218, DOI 10.1136/gut.12.3.218; Fukukura Y, 2002, RADIOLOGY, V222, P674, DOI 10.1148/radiol.2223010684; Gutstein HB, 2001, GOODMAN GILMANS PHAR, P595; Hintze RE, 1997, ENDOSCOPY, V29, P182, DOI 10.1055/s-2007-1004160; Hosoki T, 2004, ACTA RADIOL, V45, P375, DOI 10.1080/02841850410005462; Irie H, 1998, AM J ROENTGENOL, V171, P1381, DOI 10.2214/ajr.171.5.9798883; Irie H, 1998, RADIOLOGY, V206, P379, DOI 10.1148/radiology.206.2.9457189; Kats J, 2003, DIGEST SURG, V20, P32, DOI 10.1159/000068863; Kejriwal R, 2004, ANZ J SURG, V74, P619, DOI 10.1111/j.1445-1433.2004.03114.x; KESLAR PJ, 1987, CLIN NUCL MED, V12, P592, DOI 10.1097/00003072-198708000-00002; KIM EE, 1986, AM J ROENTGENOL, V147, P1177, DOI 10.2214/ajr.147.6.1177; Ly JN, 2002, RADIOL CLIN N AM, V40, P1289, DOI 10.1016/S0033-8389(02)00056-8; Mariani A, 2003, GASTROINTEST ENDOSC, V58, P847, DOI 10.1016/S0016-5107(03)02303-4; Matos C, 1997, RADIOLOGY, V203, P435, DOI 10.1148/radiology.203.2.9114101; Matos Celso, 2002, Radiographics, V22, pe2; Oates E, 1996, J NUCL MED, V37, P267; RADNAY PA, 1980, ANAESTHESIST, V29, P26; Rosch T, 2002, GASTROINTEST ENDOSC, V55, P870, DOI 10.1067/mge.2002.124206; Sharma SK, 2003, SURG ENDOSC, V17, P868, DOI 10.1007/s00464-002-8704-2; Sho M, 1998, AM J SURG, V176, P279, DOI 10.1016/S0002-9610(98)00148-2; Sica GT, 1999, RADIOLOGY, V210, P605, DOI 10.1148/radiology.210.3.r99fe55605; Silva AC, 2004, RADIOGRAPHICS, V24, P677, DOI 10.1148/rg.243035087; STOELTING RK, 1999, PHARM PHYSL ANESTHET, P77; Taylor ACF, 2002, GASTROINTEST ENDOSC, V55, P17, DOI 10.1067/mge.2002.120324; Vitellas KM, 2000, RADIOGRAPHICS, V20, P939, DOI 10.1148/radiographics.20.4.g00jl23939; WALLNER BK, 1991, RADIOLOGY, V181, P805, DOI 10.1148/radiology.181.3.1947101; ZIMMON DS, 1975, GASTROENTEROLOGY, V69, P303	32	15	15	0	1	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0942-8925			ABDOM IMAGING	Abdom. Imaging	SEP-OCT	2006	31	5					582	587		10.1007/s00261-005-0155-5			6	Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical Imaging	Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical Imaging	124YD	WOS:000243407800012	16465580				2020-06-30	J	Prakash, S; Arora, D; Prakash, S; Bhartiya, V; Singh, R				Prakash, S.; Arora, D.; Prakash, S.; Bhartiya, V.; Singh, R.			A combination of fentanyl-midazolam-propofol provides better intubating conditions than fentanyl-lignocaine-propofol in the absence of neuromuscular blocking agents	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						anaesthesia; intravenous; intubation tracheal; technique	DIFFICULT TRACHEAL INTUBATION; MUSCLE-RELAXANTS; INDUCTION; ALFENTANIL; ANESTHESIA; LIDOCAINE; REMIFENTANIL; THIOPENTONE; INJECTION; DRUGS	Background: The use of propofol and adjuvants such as opioids, benzodiazepines and local anaesthetic agents, may provide adequate conditions for tracheal intubation without the need for neuromuscular blocking agents. In this randomized, double-blind study, intubating conditions after induction of anaesthesia with propofol, midazolam and fentanyl were compared with those after propofol, lignocaine and fentanyl. Methods: In 80 ASA I/II adult patients undergoing elective gynaecological surgery, intubating conditions were compared after induction of anaesthesia with a fentanyl 2 mu g/kg, midazolam 0.03 mg/kg, propofol 2.5 mg/kg combination (group FMP) vs. a fentanyl 2 mu g/kg, lignocaine 1.5 mg/kg, propofol 2.5 mg/kg combination (group FLP). Intubating conditions were assessed using a qualitative scoring system. Results: Intubation was successful in all patients in group FMP and in 87.5% of patients in group FLP; (P = 0.021). Overall, intubating conditions were clinically acceptable in 77.5% and 55% of patients in group FMP and group FLP, respectively (P = 0.033). Conclusion: We conclude that the fentanyl, midazolam, propofol combination more reliably provides acceptable conditions for intubation than the fentanyl, lignocaine, propofol combination. Intubation was successful in all patients receiving the fentanyl, midazolam, propofol combination.	Vardhman Mahavir Med Coll, Dept Anaesthesia & Intens Care, New Delhi, India; Safdarjang Hosp, New Delhi, India	Prakash, S (reprint author), 155-3 Basant Lane,Railway Colony, New Delhi 110055, India.	drsunilprakash@gmail.com; drsunilprakash@gmail.com					BARKER P, 1992, BRIT J ANAESTH, V69, P23, DOI 10.1093/bja/69.1.23; BENSHLOMO I, 1990, BRIT J ANAESTH, V64, P45, DOI 10.1093/bja/64.1.45; BOWDLE TA, 1995, WYLIE CHURCHILLDAVID, P900; CORMACK RS, 1984, ANAESTHESIA, V39, P1105, DOI 10.1111/j.1365-2044.1984.tb08932.x; DAVIDSON JAH, 1993, BRIT J ANAESTH, V70, P163, DOI 10.1093/bja/70.2.163; GRANGE CS, 1993, EUR J ANAESTH, V10, P9; Grant S, 1998, BRIT J ANAESTH, V81, P540, DOI 10.1093/bja/81.4.540; HILLER A, 1993, ACTA ANAESTH SCAND, V37, P725, DOI 10.1111/j.1399-6576.1993.tb03798.x; HIMES RS, 1977, ANESTHESIOLOGY, V47, P437, DOI 10.1097/00000542-197711000-00010; HOVORKA J, 1991, ACTA ANAESTH SCAND, V35, P326, DOI 10.1111/j.1399-6576.1991.tb03298.x; Jabbour-Khoury SI, 2003, CAN J ANAESTH, V50, P116, DOI 10.1007/BF03017841; JOLLY ER, 1956, J PHARMACOL EXP THER, V116, P273; Kazama T, 1997, ANESTHESIOLOGY, V87, P213, DOI 10.1097/00000542-199708000-00007; Keaveny J P, 1988, Anaesthesia, V43 Suppl, P80, DOI 10.1111/j.1365-2044.1988.tb09079.x; Klemola UM, 2000, ACTA ANAESTH SCAND, V44, P465, DOI 10.1034/j.1399-6576.2000.440419.x; LEWIS C B, 1948, Anaesthesia, V3, P113, DOI 10.1111/j.1365-2044.1948.tb06759.x; MULHOLLAND D, 1991, ANAESTHESIA, V46, P312, DOI 10.1111/j.1365-2044.1991.tb11506.x; POULTON TJ, 1979, ANESTHESIOLOGY, V50, P470, DOI 10.1097/00000542-197905000-00018; SAARNIVAARA L, 1991, ACTA ANAESTH SCAND, V35, P19, DOI 10.1111/j.1399-6576.1991.tb03235.x; SAMSOON GLT, 1987, ANAESTHESIA, V42, P487, DOI 10.1111/j.1365-2044.1987.tb04039.x; SHORT TG, 1991, BRIT J ANAESTH, V67, P539, DOI 10.1093/bja/67.5.539; Stevens JB, 1998, ANESTH ANALG, V86, P45, DOI 10.1097/00000539-199801000-00009; Trabold F, 2004, ACTA ANAESTH SCAND, V48, P35, DOI 10.1111/j.1399-6576.2004.00259.x; VibyMogensen J, 1996, ACTA ANAESTH SCAND, V40, P59, DOI 10.1111/j.1399-6576.1996.tb04389.x; Woods AW, 2005, BRIT J ANAESTH, V94, P150, DOI 10.1093/bja/aei006; YUKIOKA H, 1985, ANESTH ANALG, V64, P1189	26	5	6	0	1	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	SEP	2006	50	8					999	1004		10.1111/j.1399-6576.2006.01093.x			6	Anesthesiology	Anesthesiology	076EF	WOS:000239939100015	16923097				2020-06-30	J	Puolakka, PAE; Puura, AIE; Pirhonen, RA; Ranta, AU; Autio, V; Lindgren, L; Rorarius, MGF				Puolakka, P. A. E.; Puura, A. I. E.; Pirhonen, R. A.; Ranta, A. U.; Autio, V.; Lindgren, L.; Rorarius, M. G. F.			Lack of analgesic effect of parecoxib following laparoscopic cholecystectomy	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						cyclo-oxygenase-2 inhibitor; non-steroidal anti-inflammatory drug; parecoxib; visceral pain	UP ORAL VALDECOXIB; POSTOPERATIVE PAIN; COX-2 INHIBITORS; SODIUM; KETOROLAC; EFFICACY; SAFETY; MANAGEMENT; QUALITY; COXIBS	Background: The cyclo-oxygenase-2 inhibitor, parecoxib, can be administered parenterally. The recommended dose for post-operative use is 40 mg twice daily, which may not be the appropriate dose for the treatment of visceral pain. We studied the effect of a single dose of parecoxib of either 40 or 80 mg in laparoscopic cholecystectomy, and its effect on opioid-induced side-effects. Methods: Seventy-three patients scheduled for elective laparoscopic cholecystectomy were enrolled in this prospective, randomized, double-blind study. Patients were randomized into three groups: a placebo-treated control group, a 40-mg parecoxib-treated group (P40) and an 80-mg parecoxib-treated group (P80). We recorded the cumulative fentanyl consumption during the first 20 h post-operatively by patient-controlled analgesia equipment, the pain scores during rest, coughing and mobilization (visual analogue scale, 0-10), the worst pain during the first 2 h post-operatively and in the following 18 h, and the side-effects by questionnaire. Results: No significant differences in fentanyl consumption between the three groups could be detected. The worst pain experienced between 2 and 20 h post-operatively on the ward was significantly lower in the P80 group than in the control group. Conclusions: The recommended dose of parecoxib, 40 mg, is not effective for the treatment of pain during the early post-operative period after laparoscopic cholecystectomy. Doubling the dose to 80 mg seems to improve the results.	Univ Hosp Tampere, Dept Anaesthesiol & Intens Care, Tampere 33521, Finland; Dist Hosp, Dept Anaesthesiol, Valkeakoski, Finland; Dist Hosp, Dept Anaesthesiol, Vammala, Finland; Dist Hosp, Dept Surg, Valkeakoski, Finland; Univ Tampere, Tampere Sch Publ Hlth, Tampere, Finland; Tampere Univ Hosp, Res Unit, Tampere, Finland; Tampere Univ, Sch Med, FIN-33101 Tampere, Finland	Puolakka, PAE (reprint author), Univ Hosp Tampere, Dept Anaesthesiol & Intens Care, POB 2000, Tampere 33521, Finland.	piapuolakka@kolumbus.fi					Alexander JI, 1997, BRIT J ANAESTH, V79, P369, DOI 10.1093/bja/79.3.369; Altman DG, 1999, PRACTICAL STAT MED R; Barton SF, 2002, ANESTHESIOLOGY, V97, P306, DOI 10.1097/00000542-200208000-00004; Bisgaard T, 2001, PAIN, V90, P261, DOI 10.1016/S0304-3959(00)00406-1; BLACKBURN A, 1995, J CLIN ANESTH, V7, P103, DOI 10.1016/0952-8180(94)00040-B; Brune K, 2004, SCAND J RHEUMATOL, V33, P1, DOI 10.1080/03009740310004766; Daniels SE, 2001, CLIN THER, V23, P1018, DOI 10.1016/S0149-2918(01)80088-6; Desjardins PJ, 2001, ANESTH ANALG, V93, P721, DOI 10.1097/00000539-200109000-00036; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; Gajraj NM, 2003, ANESTH ANALG, V96, P1720, DOI 10.1213/01.ANE.0000061461.55712.C5; Gan TJ, 2004, ACTA ANAESTH SCAND, V48, P1194, DOI 10.1111/j.1399-6576.2004.00495.x; Gan TJ, 2004, ANESTH ANALG, V98, P1665, DOI 10.1213/01.ANE.0000117001.44280.F3; Gilron I, 2003, ANESTHESIOLOGY, V99, P1198, DOI 10.1097/00000542-200311000-00029; Hubbard RC, 2003, BRIT J ANAESTH, V90, P166, DOI 10.1093/bja/aeg038; Joshi GP, 2004, ANESTH ANALG, V98, P336, DOI 10.1213/01.ANE.0000093390.94921.4A; Kranke P, 2004, ANESTH ANALG, V99, P797, DOI 10.1213/01.ANE.0000133139.68208.92; Malan TP, 2003, ANESTHESIOLOGY, V98, P950, DOI 10.1097/00000542-200304000-00023; Mutapi F, 2002, LANCET INFECT DIS, V2, P219, DOI 10.1016/S1473-3099(02)00240-2; Ng A, 2004, BRIT J ANAESTH, V92, P846, DOI 10.1093/bja/aeh161; Ng A, 2003, BRIT J ANAESTH, V90, P746, DOI 10.1093/bja/aeg139; Ott E, 2003, J THORAC CARDIOV SUR, V125, P1481, DOI 10.1016/S0022-5223(03)00125-9; Romsing J, 2005, ACTA ANAESTH SCAND, V49, P133, DOI 10.1111/j.1399-6576.2005.00614.x; Romsing J, 2004, ACTA ANAESTH SCAND, V48, P525, DOI 10.1111/j.0001-5172.2004.00379.x; RORARIUS MGF, 1993, ACTA U TAMPER SER A, V368, P12; SCHEININ B, 1995, ACTA ANAESTH SCAND, V39, P195, DOI 10.1111/j.1399-6576.1995.tb04042.x; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; Straube S, 2005, ACTA ANAESTH SCAND, V49, P601, DOI 10.1111/j.1399-6576.2005.00666.x; Tang J, 2002, ANESTHESIOLOGY, V96, P1305, DOI 10.1097/00000542-200206000-00007	28	23	28	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	SEP	2006	50	8					1027	1032		10.1111/j.1399-6576.2006.01116.x			6	Anesthesiology	Anesthesiology	076EF	WOS:000239939100019	16923101				2020-06-30	J	Farag, E; Chelune, GJ; Schubert, A; Mascha, EJ				Farag, Ehab; Chelune, Gordon J.; Schubert, Armin; Mascha, Edward J.			Is depth of anesthesia, as assessed by the bispectral index, related to postoperative cognitive dysfunction and recovery?	ANESTHESIA AND ANALGESIA			English	Article							ACUTE CONFUSIONAL STATES; CORONARY-ARTERY-BYPASS; FEMORAL-NECK FRACTURES; TRAUMATIC HEAD-INJURY; MULTIPLE-SCLEROSIS; ELDERLY PATIENTS; DELIRIUM; SURGERY; PATIENT; SCORES	We randomized 74 patients to either a lower Bispectral Index (BIS) regimen (median BIS, 38.9) or a higher BIS regimen (mean BIS, 50.7) during the surgical procedure. Preoperatively and 4-6 wk after surgery, the patients' cognitive status was assessed with a cognitive test battery consisting of processing speed index, working memory index, and verbal memory index. Processing speed index was 113.7 +/- 1.5 (mean +/- SE) in the lower BIS group versus 107.9 +/- 1.4 in the higher BIS group (P = 0.006). No difference was observed in the other two test battery components. Somewhat deeper levels of anesthesia were therefore associated with better cognitive function 4-6 wk postoperatively, particularly with respect to the ability to process information.	Case Western Reserve Univ, Dept Gen Anesthesiol & Outcomes Res, Cleveland Clin Lerner Coll Med, Cleveland, OH 44106 USA; Univ Utah, Dept Neurol, Ctr Alzheimers Care Imaging & Res, Salt Lake City, UT USA; Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA	Schubert, A (reprint author), Cleveland Clin, Dept Gen Anesthesiol, 9500 Euclid Ave,E31, Cleveland, OH 44195 USA.	schubea@ccf.org	Schubert, Armin/D-3589-2011				Alkire MT, 1998, ANESTHESIOLOGY, V89, P323, DOI 10.1097/00000542-199808000-00007; Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; BARRETT J, 2000, J INT NEUROPSYCH SOC, V6, P147; BEDFORD PD, 1955, LANCET, V2, P259; BERGGREN D, 1987, ANESTH ANALG, V66, P497; Blanck TJJ, 2000, ANESTHESIOLOGY, V93, P1285, DOI 10.1097/00000542-200011000-00023; Burrow B, 2001, ANAESTH INTENS CARE, V29, P239, DOI 10.1177/0310057X0102900303; CHELUNE GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; CHELUNE GJ, 1999, J INT NEUROPSYCH SOC, V5, P109; Chelune GJ, 2003, ASSESSING RELIABLE N; DeLuca J, 2004, J CLIN EXP NEUROPSYC, V26, P550, DOI 10.1080/13803390490496641; Dodds C, 1998, BRIT J ANAESTH, V81, P449, DOI 10.1093/bja/81.3.449; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Donders J, 1996, CHILD NEUROPSYCHOL, V2, P185, DOI 10.1080/09297049608402251; EDMONDS HL, 1998, ANESTH ANALG, V86, DOI UNSP SCA13; Fernandez CR, 2003, J CLIN ANESTH, V15, P52, DOI 10.1016/S0952-8180(02)00483-X; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gibson G E, 1991, Int Psychogeriatr, V3, P373, DOI 10.1017/S1041610291000820; Goldstein MZ, 2000, AM J GERIAT PSYCHIAT, V8, P35, DOI 10.1097/00019442-200002000-00005; GUSTAFSON Y, 1991, J AM GERIATR SOC, V39, P655, DOI 10.1111/j.1532-5415.1991.tb03618.x; Heaton R, 2003, DEMOGRAPHIC EFFECTS; HIRSCH JA, 1984, NEUROCHEM RES, V9, P1039, DOI 10.1007/BF00964800; Hoffman N, 2000, ARCH CLIN NEUROPSYCH, V15, P47, DOI 10.1016/S0887-6177(98)00156-5; Kneebone AC, 1998, ANN THORAC SURG, V65, P1320, DOI 10.1016/S0003-4975(98)00158-1; LINEWEAVER TT, 2003, USE WAIS 3 WMS 3 CON; LIPOWSKI ZJ, 1989, NEW ENGL J MED, V320, P578; LIPOWSKI ZJ, 1983, AM J PSYCHIAT, V140, P1426; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V271, P134, DOI 10.1001/jama.271.2.134; Marrie RA, 2003, MULT SCLER, V9, P621, DOI 10.1191/1352458503ms971oa; McKhann GM, 1997, ANN THORAC SURG, V63, P510; MCSWEENY AJ, 1993, CLIN NEUROPSYCHOL, V7, P300, DOI DOI 10.1080/13854049308401901; MIAO N, 1995, ANESTHESIOLOGY, V83, P593, DOI 10.1097/00000542-199509000-00019; MOLLER JT, 1998, LANCET, V351, P861; MURRAY AM, 1993, J GERONTOL, V48, pM181, DOI 10.1093/geronj/48.5.M181; OKEEFE ST, 1994, BRIT J ANAESTH, V73, P673, DOI 10.1093/bja/73.5.673; Rasmussen LS, 1999, BRIT J ANAESTH, V83, P585; Ritchie K, 1997, Int Psychogeriatr, V9, P309, DOI 10.1017/S1041610297004468; ROSENBERG J, 1993, SURGERY, V114, P76; SAVAGEAU JA, 1982, J THORAC CARDIOV SUR, V84, P595; Sawrie S M, 1996, J Int Neuropsychol Soc, V2, P556; Schubert A, 1996, ANESTHESIOLOGY, V85, P513, DOI 10.1097/00000542-199609000-00010; Taylor MJ, 2001, J INT NEUROPSYCH SOC, V7, P867, DOI 10.1017/S1355617701777107; TOWNES BD, 1989, J THORAC CARDIOV SUR, V98, P774; TUNE L, 1992, AM J PSYCHIAT, V149, P1393; Violet JM, 1997, ANESTHESIOLOGY, V86, P866, DOI 10.1097/00000542-199704000-00017; Warner DS, 2000, ANESTHESIOLOGY, V92, P1226; WECHSLER D, 1997, WWS 3 TEST ADM SCORI; WECHSLER D, 1997, WAIS 3 ADM SCORING M; WETHERELL A, 1980, BRIT J CLIN PHARMACO, V10, P627, DOI 10.1111/j.1365-2125.1980.tb00525.x; WILLIAMSRUSSO P, 1995, JAMA-J AM MED ASSOC, V274, P44, DOI 10.1001/jama.274.1.44; Yoshitani K, 2001, ANESTH ANALG, V92, P1370; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7	52	78	95	3	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	SEP	2006	103	3					633	640		10.1213/01.ane.0000228870.48028.b5			8	Anesthesiology	Anesthesiology	077SG	WOS:000240049800020	16931673				2020-06-30	J	Morimoto, Y; Hagihira, S; Yamashita, S; Lida, Y; Matsumoto, M; Tsuruta, S; Sakabe, T				Morimoto, Yasuhiro; Hagihira, Satoshi; Yamashita, Satoshi; Lida, Yasuhiko; Matsumoto, Mishiya; Tsuruta, Syunsuke; Sakabe, Takefumi			Changes in electroencephalographic bicoherence during sevoflurane anesthesia combined with intravenous fentanyl	ANESTHESIA AND ANALGESIA			English	Article							ISOFLURANE ANESTHESIA; BISPECTRAL ANALYSIS	With the introduction of bispectral index (BIS) as a measure of a patient's sedation during general anesthesia, attention has been directed toward bispectral analysis of electroencephalography (EEG). In the present study we evaluated the relationship between EEG bicoherence and sevoflurane concentration. Sixteen ASA physical status I-II patients scheduled for elective abdominal surgery were enrolled in the study. Anesthesia was induced with 5% sevoflurane and maintained with sevoflurane and oxygen (50%). just before surgery, W fentanyl (2 mu g/kg) was given and then ox continuously infused (2 mu g . kg(-1) . h(-1)). Using software we developed, EEG bicoherence, BIS, and 95% spectral edge frequency (SEF95) were recorded at end-tidal sevoflurane concentrations of 0.5%, 0.8%, 1.1%, 1.4%, 1.7%, 2.0%, and 2.3%. Under light anesthesia, EEG bicoherence values were low. With increasing sevoflurane concentrations, 2 peaks of bicoherence emerged along the diagonal lime (f1 = f2). Both the first (at around 4 Hz) and second (at around 10 Hz) grew higher (37.7% +/- 7.5% and 35.1% +/- 9.0%, respectively) as the sevoflurane concentration increased to 1.4%. However, the first peak leveled off whereas the second tended to decrease slightly with further increases in sevoflurane concentration. The BIS value decreased as the sevoflurane concentration increased and leveled off at 1.4% and higher concentrations of sevoflurane. The SEF 95 also decreased as the sevoflurane concentration increased up to 2.3%. Thus the distribution pattern of the two bicoherence peaks is likely to be better than BIS of the anesthetic effect of sevoflurane during surgery.	Yamaguchi Univ, Sch Med, Dept Anesthesiol Resuscitol, Ube, Yamaguchi 7558505, Japan; Osaka Univ, Dept Anesthesiol, Grad Sch Med, Suita, Osaka 565, Japan	Morimoto, Y (reprint author), Yamaguchi Univ, Sch Med, Dept Anesthesiol Resuscitol, 1-1-1 Minami Kogushi Ube, Ube, Yamaguchi 7558505, Japan.	yamorimo@nifty.com					Hagihira S, 2004, ANESTHESIOLOGY, V100, P818, DOI 10.1097/00000542-200404000-00011; Hagihira S, 2002, ANESTHESIOLOGY, V97, P1409, DOI 10.1097/00000542-200212000-00012; Hagihira S, 2001, ANESTH ANALG, V93, P966, DOI 10.1097/00000539-200110000-00032; Johansen JW, 2000, ANESTHESIOLOGY, V93, P1336, DOI 10.1097/00000542-200011000-00029; Katoh T, 1998, ANESTHESIOLOGY, V88, P642, DOI 10.1097/00000542-199803000-00014; Kurehara Koukichi, 2002, Masui, V51, P642; Morimoto Y, 2004, ANESTH ANALG, V98, P1336, DOI 10.1213/01.ANE.0000105867.17108.B6; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; SCHWENDER D, 1998, ANAESTHESIA, V53, P225; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; SIGL JC, 1994, J CLIN MONITOR, V10, P392, DOI 10.1007/BF01618421; STERIADE M, 1993, J NEUROSCI, V13, P3266	12	17	18	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	SEP	2006	103	3					641	645		10.1213/01.ane.0000229699.99371.3c			5	Anesthesiology	Anesthesiology	077SG	WOS:000240049800021	16931674				2020-06-30	J	Hashimoto, T; Saito, Y; Yamada, K; Hara, N; Kirihara, Y; Tsuchiya, M				Hashimoto, Tatsuya; Saito, Yoji; Yamada, Kazuo; Hara, Nobumasa; Kirihara, Yumiko; Tsuchiya, Mikako			Enhancement of morphine analgesic effect with induction of mu-opioid receptor endocytosis in rats	ANESTHESIOLOGY			English	Article; Proceedings Paper	11th World Congress on Pain	AUG 21-26, 2005	Sydney, AUSTRALIA	Int Assoc Study Pain, US Canc Pain Relief Comm, Natl Canc Inst			PROTEIN-COUPLED RECEPTORS; DORSAL-HORN NEURONS; BETA-ARRESTIN; CANCER PAIN; SPINAL-CORD; DOSE RATIO; DESENSITIZATION; INTERNALIZATION; TOLERANCE; TRAFFICKING	Background Morphine can desensitize mu-opioid receptor (MOR), but it does not cause internalization of the receptor after binding. Acute desensitization of MOR impairs the efficiency of signaling, whereas the receptor internalization restores the cell responsiveness to the agonists. Thereby, the property of morphine may limit the analgesic effects of this opiate drug. it has been shown that [D-Ala(2),McPhe(4) Gly-ol(5)]enkephalin (DAMGO), a potent MOR agonist inducing the internalization, facilitates morphine to internalize MOR, suggesting that MOR agonists with low relative activity versus endocytosis (RAVE) values such as DAMGO can potentiate analgesic effects of morphine through stimulating MOR internalization. The authors examined whether the acute analgesic effect of morphine can be potentiated by low relative activity versus endocytosis agonists DAMGO and fentanyl. Methods: Rats injected intrathecally with opioids were subjected to a hot plate test for antinociceptive effect. Immuno-stained spinal dorsal horn was analyzed by confocal microscopy. Results. Fentanyl induced MOR internalization to a lesser extent than DAMGO at equianalgesic doses. Coadministration of fentanyl promoted morphine-induced MOR internalization. The analgesic effect of morphine was greatly potentiated together with decrease in the relative activity versus endocytosis value when MOR internalization was induced by coadministration of a subanalgesic dose of DAMGO or fentanyl. In contrast, the combination of DAMGO and fentanyl increased neither the analgesic effect nor the internalization of MOR. Conclusions: The results suggest that the coadministration of morphine with MOR-internalizing agonist is clinically applicable to develop successful pain-management regimens to achieve satisfactory analgesia using less morphine.	Shimane Univ, Fac Med, Dept Anesthesiol, Izumo, Shimane 6938501, Japan	Hashimoto, T (reprint author), Shimane Univ, Fac Med, Dept Anesthesiol, 89-1 Enya, Izumo, Shimane 6938501, Japan.	hashit@med.shimane-u.ac.jp					ARDEN JR, 1995, J NEUROCHEM, V65, P1636; ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; Bailey CP, 2003, J NEUROSCI, V23, P10515; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Bohn LM, 2004, MOL PHARMACOL, V66, P106, DOI 10.1124/mol.66.1.106; Bolan EA, 2002, J PHARMACOL EXP THER, V303, P557, DOI 10.1124/jpet.102.035881; CHAKRABARTI S, 1995, MOL BRAIN RES, V30, P269, DOI 10.1016/0169-328X(95)00014-J; Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; Haberstock-Debic H, 2003, J NEUROSCI, V23, P4324; He L, 2002, CELL, V108, P271, DOI 10.1016/S0092-8674(02)00613-X; Keith DE, 1998, MOL PHARMACOL, V53, P377; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; Kirihara Y, 2003, ANESTHESIOLOGY, V99, P961, DOI 10.1097/00000542-200310000-00032; Koch T, 2005, MOL PHARMACOL, V67, P280, DOI 10.1124/mol.104.004994; Lawlor PG, 1998, CANCER, V82, P1167, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.3.CO;2-8; Marvizon JCG, 1999, NEUROREPORT, V10, P2329, DOI 10.1097/00001756-199908020-00020; Mason N, 2001, BRIT J ANAESTH, V86, P236, DOI 10.1093/bja/86.2.236; Minnis JG, 2003, NEUROSCIENCE, V119, P33, DOI 10.1016/S0306-4522(03)00135-0; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Ripamonti C, 1998, J CLIN ONCOL, V16, P3216, DOI 10.1200/JCO.1998.16.10.3216; Saito Y, 1995, PAIN, V63, P303, DOI 10.1016/0304-3959(95)00055-0; Schulz S, 2004, EMBO J, V23, P3282, DOI 10.1038/sj.emboj.7600334; SIMON EJ, 1986, ANN NY ACAD SCI, V463, P31, DOI 10.1111/j.1749-6632.1986.tb21501.x; Song BB, 2003, J NEUROSCI, V23, P1847; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; TANAKA M, 1991, REGION ANESTH, V16, P214; Trafton JA, 2000, J NEUROSCI, V20, P8578; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; YU SS, 1993, J BIOL CHEM, V268, P337; Zaki PA, 2000, J PHARMACOL EXP THER, V292, P1127; Zuo ZY, 2005, ANESTH ANALG, V101, P728, DOI 10.1213/01.ANE.0000160588.32007.AD	36	22	27	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	SEP	2006	105	3					574	580		10.1097/00000542-200609000-00023			7	Anesthesiology	Anesthesiology	078OE	WOS:000240112300021	16931992				2020-06-30	J	Allen, JW; Horais, KA; Tozier, NA; Yaksh, TL				Allen, Jeffrey W.; Horais, Kjersti A.; Tozier, Nicolle A.; Yaksh, Tony L.			Opiate pharmacology of intrathecal granulomas	ANESTHESIOLOGY			English	Article; Proceedings Paper	34th Annual Meeting of the Society-for-Neuroscience	OCT 23-27, 2004	San Diego, CA	Soc Neurosci			SPINAL-CORD COMPRESSION; MORPHINE THERAPY; SHEEP MODEL; CATHETER GRANULOMAS; INFLAMMATORY MASS; DRUG INFUSION; HUMAN-SKIN; DOGS; HYDROMORPHONE; SYSTEMS	Background: Chronic intrathecal morphine infusion produces intradural granulomas. The authors examined a variety of opioids infused intrathecal for analgesic activity and toxicity. Methods: Two sets of experiments were undertaken in dogs with chronic intrathecal catheters: (1) Six-hour intrathecal infusions were used to determine the full analgesic dose and the maximum tolerated dose. (2) To establish toxicity, the maximum tolerated dose was given for up to 28 days by continuous intrathecal infusion. Drugs examined were morphine sulfate, hydromorphone, D/L-methadone, L-methadone, D-methadone, fentanyl, [d-Ala(2),N-Me-Phe(4),Gly(4)-ol]-enkephalin (DAMGO), naloxone, or saline. Results: Analgesia and tolerability: Six-hour intrathecal infusion of agonists resulted in a time-dependent increase in thermal escape latency. At higher concentrations, dose-limiting motor dysfunction and sedation occurred, and hypersensitivity occurred. The concentrations, in mg/ml, for full analgesic dose/maximum tolerated dose were as follows: morphine, 0.9/12.0; hydromorphone, 1-0/3.0; D/L-methadone, 2.8/3; L-methadone, 1.0/> 1.0; fentanyl, 0-3/2.0; DAMGO, 0.1/> 2.0; D-methadone, > 1/ > 1; naloxone, > 10/ > 10. Spinal patbology: Chronic intrathecal infusion of the maximum tolerated dose revealed 100% intradural granuloma formation after morphine, hydromorphone, L-methadone, and naloxone. DAMGO induced a mass in only a single animal (one of three). D/L- and D-methadone produced intradural granulomas but were also associated with parenchymal necrosis. Saline and fentanyl. animals displayed no granulomas. Conclusions. Intrathecal opiate-induced granulomas are not strictly dependent on opioid receptor activation. Therefore, opiates at equianalgesic doses present different risks for granuloma formation. importantly, D/L- and D-methadone also resulted in parenchymal necrosis, an affect associated with the N-Methyl-D-aspartate antagonist action of the D-isomer.	Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA	Yaksh, TL (reprint author), Univ Calif San Diego, Dept Anesthesiol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	tyaksh@ucsd.edu	Yaksh, Tony/D-4119-2009		NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [5P20MH060975]; PHS HHSUnited States Public Health Service [NIDA-15353]		ALDRETE JA, 1994, ANESTHESIOLOGY, V81, P1542, DOI 10.1097/00000542-199412000-00032; Allen JW, 2006, ANESTHESIOLOGY, V105, P581, DOI 10.1097/00000542-200609000-00024; Allen JW, 2004, METH MOLEC MED, P11; Artico M, 2001, MICROSC RES TECHNIQ, V53, P212, DOI 10.1002/jemt.1085; Bejjani GK, 1997, SURG NEUROL, V48, P288, DOI 10.1016/S0090-3019(96)00466-1; Blount JP, 1996, J NEUROSURG, V84, P272, DOI 10.3171/jns.1996.84.2.0272; Blunk JA, 2004, ANESTH ANALG, V98, P364, DOI 10.1213/01.ANE.0000097168.32472.0D; Bradding P, 1999, CRIT REV ONCOL HEMAT, V31, P119, DOI 10.1016/S1040-8428(99)00010-4; Cabbell KL, 1998, NEUROSURGERY, V42, P1176, DOI 10.1097/00006123-199805000-00142; Callahan RJ, 2004, ANESTH ANALG, V98, P653, DOI 10.1213/01.ANE.0000099723.75548.DF; Coffey RJ, 2002, NEUROSURGERY, V50, P78, DOI 10.1097/00006123-200201000-00014; COOMBS DW, 1994, ANESTH ANALG, V78, P674; DOUCETTE R, 1987, J COMP NEUROL, V261, P583, DOI 10.1002/cne.902610409; FELDBERG W, 1951, J PHYSIOL-LONDON, V114, P490, DOI 10.1113/jphysiol.1951.sp004639; Gradert TL, 2003, ANESTHESIOLOGY, V99, P188, DOI 10.1097/00000542-200307000-00029; Hassenbusch SJ, 1999, NEUROMODULATION, V2, P230, DOI 10.1046/j.1525-1403.1999.00230.x; HERMENS JM, 1985, ANESTHESIOLOGY, V62, P124, DOI 10.1097/00000542-198502000-00005; Horais K, 2003, TOXICOL SCI, V71, P263, DOI 10.1093/toxsci/71.2.263; Inturrisi C E, 2005, Minerva Anestesiol, V71, P435; Johansen MJ, 2004, PAIN MED, V5, P14, DOI 10.1111/j.1526-4637.2004.04010.x; Langsam A, 1999, NEUROSURGERY, V44, P689, DOI 10.1097/00006123-199903000-00159; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Miele VJ, 2006, EUR J PAIN, V10, P251, DOI 10.1016/j.ejpain.2005.05.002; Murray A, 2005, J PAIN SYMPTOM MANAG, V29, pS57, DOI 10.1016/j.jpainsymman.2005.01.007; NORTH RB, 1991, NEUROSURGERY, V29, P778, DOI 10.1227/00006123-199111000-00025; ROY SD, 1988, PHARMACEUT RES, V5, P580, DOI 10.1023/A:1015994030251; SABBE MB, 1994, ANESTHESIOLOGY, V81, P899, DOI 10.1097/00000542-199410000-00017; Schuchard M, 1998, NEUROMODULATION, V1, P137, DOI 10.1111/j.1525-1403.1998.tb00007.x; Stefano GB, 1998, J NEUROIMMUNOL, V83, P70, DOI 10.1016/S0165-5728(97)00223-3; STEVENS CW, 1989, J PHARMACOL EXP THER, V251, P216; Theoharides TC, 2005, BRAIN RES REV, V49, P65, DOI 10.1016/j.brainresrev.2004.11.006; Toombs JD, 2005, ANESTHESIOLOGY, V102, P687, DOI 10.1097/00000542-200503000-00031; Yaksh TL, 2002, PAIN MED, V3, P300, DOI 10.1046/j.1526-4637.2002.02048.x; Yaksh TL, 2003, ANESTHESIOLOGY, V99, P174, DOI 10.1097/00000542-200307000-00028; Yaksh TL, 1997, FUND APPL TOXICOL, V38, P89, DOI 10.1006/faat.1997.2314; YAKSH TL, 1983, J PHARMACOL EXP THER, V226, P303; YAKSH TL, 1987, ACTA ANAESTH SCAND, V31, P25, DOI 10.1111/j.1399-6576.1987.tb02667.x; YAKSH TL, 1981, ANESTHESIOLOGY, V54, P451, DOI 10.1097/00000542-198106000-00004; Yaksh TL, 1999, TRENDS PHARMACOL SCI, V20, P329, DOI 10.1016/S0165-6147(99)01370-X	39	49	49	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	SEP	2006	105	3					590	598		10.1097/00000542-200609000-00025			9	Anesthesiology	Anesthesiology	078OE	WOS:000240112300023	16931994				2020-06-30	J	Charalambous, CP; Tryfonidis, M; Alvi, F; Kumar, R; Hirst, P				Charalambous, Charalambos P.; Tryfonidis, Marios; Alvi, Farhan; Kumar, Raj; Hirst, Philip			Purely intra-articular versus general anesthesia for proposed arthroscopic partial meniscectomy of the knee: A randomized controlled trial	ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY			English	Article						arthroscopy; intra-articular; knee; local anesthesia; partial meniscectomy	LOCAL-ANESTHESIA	Purpose: The aim of this study was to compare intra-articular anesthesia alone versus general anesthesia with regard to case of the procedure, level of postoperative pain, and patient satisfaction when partial meniscectomy is anticipated. Methods: We prospectively randomized to general anesthesia or to intra-articular anesthesia 107 patients who were about to undergo knee arthroscopy, in whom partial meniscal resection was anticipated on the basis of clinical or radiologic grounds. Technical difficulty of the procedure, level of postoperative pain and nausea, and overall patient satisfaction were assessed. Results: The ease of obtaining arthroscopic views, the adequacy of these views, and the ease of performing partial meniscal resection or another procedure were similar in both groups according to scores assigned by the operating surgeon. Pain at 6 hours postoperatively was significantly less in the intra-articular anesthesia group but was similar in the 2 groups at 24 and 48 hours. Patients who were given intra-articular anesthesia reported higher satisfaction rates in understanding the underlying disease of the knee. Conclusions: We propose that intra-articular anesthesia alone can be effectively used in knee arthroscopies in which partial meniscal resection is anticipated. Level of Evidence: Level 1, high-quality randomized controlled therapeutic trial.	Manchester Royal Infirm, Dept Orthopaed, Manchester M13 9WL, Lancs, England	Charalambous, CP (reprint author), Flat 204,159 Hathersage Rd, Manchester M13 0HX, Lancs, England.	bcharalambos@hotmail.com					BUCKLEY JR, 1989, J BONE JOINT SURG BR, V71, P126; ERIKSSON E, 1986, ORTHOPEDICS, V9, P186; Forssblad M, 1999, KNEE SURG SPORT TR A, V7, P323, DOI 10.1007/s001670050171; HULTIN J, 1992, ARTHROSCOPY, V8, P239, DOI 10.1016/0749-8063(92)90043-B; Jacobson E, 2002, AM J SPORT MED, V30, P61, DOI 10.1177/03635465020300012401; Jacobson E, 2000, ARTHROSCOPY, V16, P183, DOI 10.1016/S0749-8063(00)90034-3; LITNER S, 1996, ARTHROSCOPY, V12, P482; TEGNER Y, 1985, CLIN ORTHOP RELAT R, P43; Williams CRP, 1997, ANN ROY COLL SURG, V79, P345	9	1	1	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0749-8063			ARTHROSCOPY	Arthroscopy	SEP	2006	22	9					972	977		10.1016/j.arthro.2006.04.108			6	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	087BU	WOS:000240718100011	16952727				2020-06-30	J	Fettes, PDW; Moore, CS; Whiteside, JB; Mcleod, GA; Wildsmith, JAW				Fettes, P. D. W.; Moore, C. S.; Whiteside, J. B.; Mcleod, G. A.; Wildsmith, J. A. W.			Intermittent vs continuous administration of epidural ropivacaine with fentanyl for analgesia during labour	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetic techniques, epidural; analgesia, obstetric; drug delivery, infusion; drug delivery, bolus; regional anaesthesia	CONTINUOUS-INFUSION; SURGERY; BOLUSES	Background. Many years ago regular intermittent bolus administration of epidural local anaesthetic solution was recognized to produce more effective analgesia than continuous infusion, but only recently has the development of suitable pumps allowed the former technique's wider evaluation. Methods. In this randomized, double-blind trial, 40 primigravid patients had a lumbar epidural catheter inserted, and plain ropivacaine 0.2% 15-20 ml was titrated until analgesia and bilateral sensory block to T10 were produced (time zero). Patients were then given either an infusion of ropivacaine 2 mg ml(-1) with fentanyl 2 mu g ml(-1) at 10 ml h(-1), or hourly boluses of 10 ml of the same solution. Pain, sensory block and motor block were measured frequently. If requested, additional 10 ml boluses of the study mixture were given for analgesia. Results. There were no differences between the two groups in patient characteristics, obstetric/neonatal outcome, or in sensory or motor block. A total of 12 (60%) patients in the continuous group required one or more additional boluses compared with 4 (20%) patients in the intermittent group (95% CI 9.6-61.7%, P=0.02). Therefore the intermittent group received a lower total drug dose than the infusion group (P=0.02). Duration of uninterrupted analgesia (time to first rescue bolus) was longer in the intermittent group (P < 0.02). Conclusions. The intermittent group required fewer supplementary injections and less drug to maintain similar pain scores, sensory and motor block compared with the continuous group. This represents a more efficacious mode of analgesia.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Anaesthesia, Dundee DD1 9SY, Scotland	Fettes, PDW (reprint author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Anaesthesia, Dundee DD1 9SY, Scotland.	pdwfettes@doctors.org.uk	mcleod, graeme/C-3405-2012	mcleod, graeme/0000-0001-5931-1362			Chua SMH, 2004, CAN J ANAESTH, V51, P581, DOI 10.1007/BF03018402; Duncan LA, 1998, BRIT J ANAESTH, V80, P7; Hogan Q, 2002, REGION ANESTH PAIN M, V27, P150, DOI 10.1053/rapm.2002.29748; Lim Y, 2005, INT J OBSTET ANESTH, V14, P305, DOI 10.1016/j.ijoa.2005.05.004; MORGENSEN T, 1988, BRIT J ANAESTH, V60, P515; RAJ PP, 1987, ANESTH ANALG, V66, P401, DOI 10.1213/00000539-198705000-00005; SCOTT DB, 1982, REGION ANESTH PAIN M, V7, P135; Ueda K, 2005, ANESTHESIOLOGY, V103, P126, DOI 10.1097/00000542-200507000-00019; van der Vyver M, 2002, BRIT J ANAESTH, V89, P459, DOI 10.1093/bja/aef217	9	57	63	1	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	SEP	2006	97	3					359	364		10.1093/bja/ael157			6	Anesthesiology	Anesthesiology	075QN	WOS:000239900400014	16849382	Bronze			2020-06-30	J	Sen, S; Ugur, B; Aydin, ON; Ogurlu, M; Gezer, E; Savk, O				Sen, S.; Ugur, B.; Aydin, O. N.; Ogurlu, M.; Gezer, E.; Savk, O.			The analgesic effect of lornoxicam when added to lidocaine for intravenous regional anaesthesia	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetic techniques, regional, i.v.; anaesthetics local, lidocaine; analgesia, postoperative; analgesics, NSAIDs; lornoxicam; pain, postoperative; pain, tourniquet pain	POSTOPERATIVE ANALGESIA; ANIMAL-MODEL; PAIN; KETOROLAC; INFILTRATION; PRILOCAINE; RAT; ISCHEMIA; SURGERY; BLOCK	Background. The aim of the study was to evaluate the effect of lornoxicam (L) on sensory and motor block onset time, tourniquet pain, and postoperative analgesia, when added to lidocaine in intravenous regional anaesthesia (IVRA). Methods. Forty-five patients undergoing hand surgery were randomly and blindly divided into three groups as to receive either i.v. saline and IVRA with lidocaine 0.5% (Control group, n=15), i.v. saline and IVRA lidocaine 0.5% with lornoxicam (L-IVRA group, n=15), or intravenous lornoxicam and IVRA lidocaine 0.5% (L-IV group, n=15). Sensory and motor blocks onset time, and tourniquet pain was measured after tourniquet application at 5, 10, 20, and 30 min, and analgesic use were recorded during operation. After the tourniquet deflation, at 1, 30 min, and 2, 4 h, visual analogue scales score, the time to first analgesic requirement, total analgesic consumption in first 24 h, and side effects were noted. Results. Sensory and motor block onset times were shorter and the recovery time prolonged in the Group L-IVRA compared with the other group (P=0.001). A decreased tourniquet pain, a prolonged time first analgesic requirement [229 (85) min vs 28 (20) and 95 (24) min, P=0.0038) and less postoperative analgesic requirements during 24 h were found in Group L-IVRA compared with the other groups (P < 0.05). Conclusions. The addition of lornoxicam to lidocaine for intravenous regional anaesthesia shortens the onset of sensory and motor block, decreases tourniquet pain and improves postoperative analgesia without causing any side effect.	Adnan Menderes Univ, Fac Med, Dept Anaesthesiol & Reanimat, Aydin, Turkey; Adnan Menderes Univ, Fac Med, Dept Anaesthesiol & Reanimat Algol, Aydin, Turkey; Adnan Menderes Univ, Fac Med, Dept Orthopaed & Traumatol, Aydin, Turkey	Sen, S (reprint author), Adnan Menderes Univ, Fac Med, Dept Anaesthesiol & Reanimat, Aydin, Turkey.	drseldasen@yahoo.com					ARMSTRONG P, 1990, ANAESTHESIA, V45, P11, DOI 10.1111/j.1365-2044.1990.tb14494.x; Balfour JA, 1996, DRUGS, V51, P639, DOI 10.2165/00003495-199651040-00008; BENDAVID B, 1995, BRIT J ANAESTH, V75, P409, DOI 10.1093/bja/75.4.409; BIAS W, 1996, BR J CLIN PRACT, V50, P197; Brill S, 2004, ACTA ANAESTH SCAND, V48, P117, DOI 10.1111/j.1399-6576.2004.00280.x; Buritova J, 1998, INFLAMM RES, V47, P18, DOI 10.1007/s000110050245; CHABEL C, 1990, ANESTHESIOLOGY, V72, P1038, DOI 10.1097/00000542-199006000-00014; Choyce A, 2002, CAN J ANAESTH, V49, P32, DOI 10.1007/BF03020416; Coderre TJ, 2004, PAIN, V112, P94, DOI 10.1016/j.pain.2004.08.001; Corpataux JB, 1997, ANESTH ANALG, V84, P1081, DOI 10.1097/00000539-199705000-00023; Dallel R, 2001, EUR NEUROL, V45, P126, DOI 10.1159/000052109; Deciga-Campos M, 2004, EUR J PHARMACOL, V484, P193, DOI 10.1016/j.ejphar.2003.11.021; Estebe JP, 2003, REGION ANESTH PAIN M, V28, P120, DOI 10.1053/rapm.2003.50123; Gokin AP, 2001, ANESTHESIOLOGY, V95, P1441, DOI 10.1097/00000542-200112000-00025; Jones NC, 1996, ANAESTHESIA, V51, P446, DOI 10.1111/j.1365-2044.1996.tb07789.x; Karamanlioglu B, 2005, CAN J ANAESTH, V52, P1047, DOI 10.1007/BF03021603; Memis D, 2004, ANESTH ANALG, V98, P835; REUBEN SS, 1995, ANESTH ANALG, V81, P110, DOI 10.1097/00000539-199507000-00022; Reuben SS, 1996, REGION ANESTH, V21, P565; Rokyta R, 2003, NEUROENDOCRINOL LETT, V24, P304; Rosenow DE, 1998, ANESTH ANALG, V86, P1045, DOI 10.1097/00000539-199805000-00026; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; Steinberg RB, 1998, ANESTH ANALG, V86, P791, DOI 10.1097/00000539-199804000-00021; Van Antwerpen P, 2004, EUR J PHARMACOL, V496, P55, DOI 10.1016/j.ejphar.2004.06.017	24	25	26	1	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	SEP	2006	97	3					408	413		10.1093/bja/ael170			6	Anesthesiology	Anesthesiology	075QN	WOS:000239900400022	16845131	Bronze			2020-06-30	J	Musel, AL; Warshaw, EM				Musel, Andrea L.; Warshaw, Erin M.			Cutaneous reactions to transdermal therapeutic systems	DERMATITIS			English	Review							ALLERGIC CONTACT-DERMATITIS; LIDOCAINE PATCH 5-PERCENT; ADVERSE SKIN REACTIONS; DRUG DELIVERY SYSTEMS; LONG-TERM TREATMENT; QUALITY-OF-LIFE; SMOKING CESSATION; NICOTINE PATCH; DOUBLE-BLIND; CANCER PAIN	Transdermal therapeutic systems have been increasingly used in the past two decades. However, cutaneous side effects are fairly common and may result in poor patient compliance. This review article summarizes the spectrum of reactions due to transdermal therapeutic systems and provides a current list of known allergens.	Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; Minneapolis Vet Affairs Med Ctr, Minneapolis, MN 55455 USA	Musel, AL (reprint author), Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA.						ABELIN T, 1989, METHOD FIND EXP CLIN, V11, P205; ABELIN T, 1989, LANCET, V1, P7; Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Amkraut AA, 1996, J AM ACAD DERMATOL, V35, P27, DOI 10.1016/S0190-9622(96)90491-0; [Anonymous], 1991, JAMA, V266, P3133; Barbano RL, 2004, ARCH NEUROL-CHICAGO, V61, P914, DOI 10.1001/archneur.61.6.914; Batta K, 1998, BRIT MED J, V316, P149; BERTI JJ, 1995, MAYO CLIN PROC, V70, P581, DOI 10.4065/70.6.581; BIRCHER AJ, 1991, CONTACT DERMATITIS, V25, P230, DOI 10.1111/j.1600-0536.1991.tb01850.x; Boehncke WH, 1996, CONTACT DERMATITIS, V35, P187, DOI 10.1111/j.1600-0536.1996.tb02350.x; BOEKHORST JC, 1983, LANCET, V2, P1031; Buckley DA, 1998, CONTACT DERMATITIS, V39, P91, DOI 10.1111/j.1600-0536.1998.tb05847.x; Burkman RT, 2004, AM J OBSTET GYNECOL, V190, pS49, DOI 10.1016/j.ajog.2004.01.060; CARMICHAEL AJ, 1992, CONTACT DERMATITIS, V26, P194, DOI 10.1111/j.1600-0536.1992.tb00293.x; CARMICHAEL AJ, 1989, CONTACT DERMATITIS, V21, P113, DOI 10.1111/j.1600-0536.1989.tb04712.x; CARMICHAEL AJ, 1994, DRUG SAFETY, V10, P151, DOI 10.2165/00002018-199410020-00004; CORAZZA M, 1995, CONTACT DERMATITIS, V32, P246, DOI 10.1111/j.1600-0536.1995.tb00683.x; DAUGHTON DM, 1991, ARCH INTERN MED, V151, P749, DOI 10.1001/archinte.151.4.749; DAVIS GF, 1987, CURR THER RES CLIN E, V42, P712; de Cetina TC, 1999, INT J GYNECOL OBSTET, V64, P71; DEGROOT AC, 1994, PATCH TESTING, P10; DICK JBC, 1987, LANCET, V1, P516; DILANDRO A, 1989, CONTACT DERMATITIS, V21, P115, DOI 10.1111/j.1600-0536.1989.tb04713.x; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; DWYER CM, 1994, CONTACT DERMATITIS, V30, P309, DOI 10.1111/j.1600-0536.1994.tb00612.x; EICHELBERG D, 1989, METHOD FIND EXP CLIN, V11, P223; FARM G, 1993, CONTACT DERMATITIS, V29, P214, DOI 10.1111/j.1600-0536.1993.tb03545.x; FILLINGIM JM, 1989, CLIN THER, V11, P398; FISCHER RG, 1985, SOUTHERN MED J, V78, P1523, DOI 10.1097/00007611-198512000-00033; FISHER AA, 1984, CUTIS, V34, P526; Foti C, 2003, CONTACT DERMATITIS, V49, P312, DOI 10.1111/j.0105-1873.2003.0251i.x; Gammaitoni AR, 2002, ANN PHARMACOTHER, V36, P236; Gammaitoni AR, 2002, AM J HEALTH-SYST PH, V59, P2215, DOI 10.1093/ajhp/59.22.2215; GORDON CR, 1989, BRIT MED J, V298, P1220, DOI 10.1136/bmj.298.6682.1220; GREBE SKG, 1993, ARCH DERMATOL, V129, P379, DOI 10.1001/archderm.1993.01680240125023; GROTH H, 1983, LANCET, V2, P850; HOGAN DJ, 1990, J AM ACAD DERMATOL, V22, P811, DOI 10.1016/0190-9622(90)70113-V; HOLDINESS MR, 1989, CONTACT DERMATITIS, V20, P3, DOI 10.1111/j.1600-0536.1989.tb03087.x; HOMICK JL, 1983, AVIAT SPACE ENVIR MD, V54, P994; HORNING JR, 1988, CHEST, V93, P941, DOI 10.1378/chest.93.5.941; HURKMANS JFGM, 1985, BRIT J DERMATOL, V112, P461, DOI 10.1111/j.1365-2133.1985.tb02321.x; HURT RD, 1990, MAYO CLIN PROC, V65, P1529, DOI 10.1016/S0025-6196(12)62186-7; ITO MK, 1991, AM J MED, V91, pS42, DOI 10.1016/0002-9343(91)90062-3; Jordan W P Jr, 1997, Am J Contact Dermat, V8, P108; JORDAN WP, 1992, J FAM PRACTICE, V34, P709; Kanny G, 2003, ALLERGY, V58, P535, DOI 10.1034/j.1398-9995.2003.00073.x; KLIGMAN AM, 1966, J INVEST DERMATOL, V47, P393, DOI 10.1038/jid.1966.160; Koch P, 2001, CONTACT DERMATITIS, V44, P112, DOI 10.1034/j.1600-0536.2001.44020914.x; KORNITZER M, 1995, PREV MED, V24, P41, DOI 10.1006/pmed.1995.1006; Kounis NG, 1996, BRIT J CLIN PRACT, V50, P437; Lamb Steven R, 2004, Dermatitis, V15, P78, DOI 10.2310/6620.2004.03033; LETENDRE PW, 1984, DRUG INTEL CLIN PHAR, V18, P69; LITT JZ, 1997, DRUG ERUPTION REFERE, P184; Machet L, 1999, DERMATOLOGY, V198, P106, DOI 10.1159/000018082; MAIBACH H, 1985, CONTACT DERMATITIS, V12, P192, DOI 10.1111/j.1600-0536.1985.tb01104.x; MAIBACH HI, 1987, CONTACT DERMATITIS, V16, P1, DOI 10.1111/j.1600-0536.1987.tb02607.x; Mancuso G, 2001, J EUR ACAD DERMATOL, V15, P70, DOI 10.1046/j.1468-3083.2001.00203.x; MCBURNEY EI, 1989, J AM ACAD DERMATOL, V20, P508, DOI 10.1016/S0190-9622(89)80093-3; McGriff NJ, 2001, PHARMACOTHERAPY, V21, P1425, DOI 10.1592/phco.21.17.1425.34428; Meier T, 2003, PAIN, V106, P151, DOI 10.1016/S0304-3959(03)00317-8; MEIKLE AW, 1997, P 79 M END SOC JUN 1; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; MULLIGAN SC, 1990, CLIN PHARMACOL THER, V47, P331, DOI 10.1038/clpt.1990.36; MURRAY KB, 1984, NEW ENGL J MED, V310, P721; Okazawa H, 1998, CONTACT DERMATITIS, V38, P233, DOI 10.1111/j.1600-0536.1998.tb05729.x; Panhans-Gross A, 2000, CONTACT DERMATITIS, V43, P368; PATRUNO C, 1994, CONTACT DERMATITIS, V31, P124, DOI 10.1111/j.1600-0536.1994.tb01939.x; PECQUET C, 1992, CONTACT DERMATITIS, V27, P275, DOI 10.1111/j.1600-0536.1992.tb03276.x; Perez-Calderon R, 2002, CONTACT DERMATITIS, V46, P303, DOI 10.1034/j.1600-0536.2002.460513.x; PLACE VA, 1985, AM J OBSTET GYNECOL, V152, P1092, DOI 10.1016/0002-9378(85)90568-X; Polster AM, 1999, CUTIS, V63, P154; POUL J, 1993, BRIT J RHEUMATOL, V32, P1000; PRIETO RD, 1994, ANN ALLERGY, V72, P344; RILLIET A, 1980, DERMATOLOGICA, V161, P361, DOI 10.1159/000250391; ROSE JE, 1990, CLIN PHARMACOL THER, V47, P323, DOI 10.1038/clpt.1990.35; ROSENFELD AS, 1984, AM HEART J, V108, P1061, DOI 10.1016/0002-8703(84)90488-5; Ross D, 1997, BRIT MED J, V315, P288, DOI 10.1136/bmj.315.7103.288; SAUSKER WF, 1978, JAMA-J AM MED ASSOC, V239, P1743; SCHWARTZ BK, 1988, CONTACT DERMATITIS, V18, P106, DOI 10.1111/j.1600-0536.1988.tb02753.x; Shouls J, 2001, CONTACT DERMATITIS, V45, P124, DOI 10.1034/j.1600-0536.2001.045002124.x; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; SMITH EW, 1992, SKIN PHARMACOL, V5, P69; STOUKIDES CA, 1992, CLIN PHARMACY, V11, P222; TOPAZ O, 1987, ANN ALLERGY, V59, P365; TORRES V, 1992, CONTACT DERMATITIS, V26, P53, DOI 10.1111/j.1600-0536.1992.tb00873.x; TROZAK DJ, 1985, J AM ACAD DERMATOL, V13, P247, DOI 10.1016/S0190-9622(85)70167-3; VAILLANT L, 1990, CONTACT DERMATITIS, V23, P142, DOI 10.1111/j.1600-0536.1990.tb04774.x; VANDERWILLIGEN AH, 1988, J AM ACAD DERMATOL, V18, P146, DOI 10.1016/S0190-9622(88)80056-2; VANDERWILLIGEN AH, 1987, CONTACT DERMATITIS, V17, P56, DOI 10.1111/j.1600-0536.1987.tb02656.x; VINCENZI C, 1993, CONTACT DERMATITIS, V29, P104, DOI 10.1111/j.1600-0536.1993.tb03500.x; VonBahr B, 1997, CONTACT DERMATITIS, V37, P44, DOI 10.1111/j.1600-0536.1997.tb00382.x; WEBER MA, 1984, AM HEART J, V108, P231, DOI 10.1016/0002-8703(84)90580-5; WHITE TM, 1986, WESTERN J MED, V145, P104; Wilson DE, 1998, CLIN THER, V20, P299, DOI 10.1016/S0149-2918(98)80093-3; Wolf R, 1998, CLIN DERMATOL, V16, P617, DOI 10.1016/S0738-081X(98)00047-9	95	23	23	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1710-3568	2162-5220		DERMATITIS	Dermatitis	SEP	2006	17	3					109	122		10.2310/6620.2006.05051			14	Dermatology	Dermatology	102AZ	WOS:000241784400001	16956462				2020-06-30	J	Yazbeck-Karam, VG; Aouad, MT; Bleik, JH; Baraka, AS				Yazbeck-Karam, V. G.; Aouad, M. T.; Bleik, J. H.; Baraka, A. S.			Propofol-remifentanil-based anaesthesia vs. sevoflurane-fentanyl-based anaesthesia for immediate postoperative ophthalmic evaluation following strabismus surgery	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthetics inhalational, sevoflurane; anaesthetics intravenous, propofol; analgesics opioid, fentanyl, remifentanil; surgical techniques, ophthalmic, strabismus surgery; postoperative recovery period	SACCADIC EYE-MOVEMENTS; TOTAL INTRAVENOUS ANESTHESIA; FACTORIAL DESIGN; PEAK VELOCITY; NAUSEA; ADJUSTMENT; RECOVERY; SUTURES; EMESIS; TRIAL	Background and objective: Following strabismus surgery, immediate postoperative ophthalmic evaluation may be desired. Thus, an anaesthetic technique allowing rapid recovery of ocular motility is required. Saccadic eye movements Is a biophysical monitor of ocular motility and may be used to assess recovery from anaesthesia. The aim of this study is to compare the time to the recovery of saccadic eye movements in patients, following one of two anaesthetic techniques: Propofol-remifentanil-based anaesthesia vs. sevoflurane-fentanyl-based anaesthesia. Methods: Fifty adult patients undergoing strabismus surgery were randomly assigned to one of two groups: patients in Group R received induction and maintenance of anaesthesia with propofol and remifentanil, while patients in Group S received induction of anaesthesia with propofol and fentanyl and maintenance of anaesthesia with sevoflurane. Recovery from anaesthesia was measured from the time all anaesthetics were turned off and was assessed every 2 min. Recovery time was attained when patients were able to generate brisk saccadic eye movements. At recovery time, the ophthalmic evaluation was started. Results: The mean recovery time of saccadic eye movements was significantly shorter in the Group R when compared to the Group S (12.1 +/- 4.3 min vs. 21.5 +/- 4.7 min respectively, P < 0.0001). More patients in Group S experienced nausea and vomiting postoperatively as compared to Group R (9/25 vs. 2/25, respectively, P = 0.037). Conclusions: Propofol-remifentanil-based anaesthesia may be a useful technique in strabismus surgery when immediate postoperative ophthalmic evaluation is desired. When compared to sevoflurane maintenance of anaesthesia, it allows for a more rapid recovery from anaesthesia as judged by recovery of saccadic eye movements and a decreased incidence of postoperative nausea and vomiting.	Amer Univ Beirut, Dept Anesthesiol, Med Ctr, Beirut, Lebanon; Rizk Hosp, Dept Anesthesiol, Beirut, Lebanon; Rizk Hosp, Dept Ophthalmol, Beirut, Lebanon	Yazbeck-Karam, VG (reprint author), Amer Univ Beirut, Dept Anesthesiol, Med Ctr, POB 11 0236, Beirut, Lebanon.	gvabirad@inco.com.lb	yazbeck karam, vanda/J-5898-2018	yazbeck karam, vanda/0000-0001-8049-6816			AANTAA R, 1991, PHARMACOL TOXICOL, V68, P394, DOI 10.1111/j.1600-0773.1991.tb01259.x; Apfel CC, 2005, ANAESTHESIST, V54, P201, DOI 10.1007/s00101-005-0803-8; Apfel CC, 2002, BRIT J ANAESTH, V88, P659, DOI 10.1093/bja/88.5.659; Biallas R, 2003, ANAESTHESIST, V52, P586, DOI 10.1007/s00101-003-0516-9; Bleik JH, 2004, J AAPOS, V8, P528, DOI 10.1016/j.jaapos.2004.08.004; Carpenter RHS, 2002, ANAESTHESIA, V57, P855, DOI 10.1046/j.1365-2044.2002.02780.x; Chhabra A, 2005, REGION ANESTH PAIN M, V30, P43, DOI 10.1016/j.rapm.2004.08.023; Cogen MS, 2002, J AAPOS, V6, P241, DOI 10.1067/mpa.2002.123398; GAO F, 1991, EUR J ANAESTH, V8, P267; Hackner C, 2003, BRIT J ANAESTH, V91, P580, DOI 10.1093/bja/aeg223; Khan OA, 2000, ANAESTHESIA, V55, P877, DOI 10.1046/j.1365-2044.2000.01529.x; LABORIT G, 1977, REV EEG NEUROPHYSIOL, V7, P70, DOI 10.1016/S0370-4475(77)80037-3; LERMAN J, 1992, [No title captured], V69, P24; Madan R, 2005, ANESTH ANALG, V100, P1622, DOI 10.1213/01.ANE.0000150977.14607.E1; METZ HS, 1979, ANN OPHTHALMOL, V11, P1593; Montes FR, 2002, J CLIN ANESTH, V14, P324, DOI 10.1016/S0952-8180(02)00367-7; Nouraei SAR, 2003, BRIT J ANAESTH, V91, P175, DOI 10.1093/bja/aeg158; O'Hare RA, 2001, BRIT J ANAESTH, V86, P361, DOI 10.1093/bja/86.3.361; Ohmi G, 1999, JPN J OPHTHALMOL, V43, P522, DOI 10.1016/S0021-5155(99)00114-8; Patil BB, 2002, OPHTHALMIC ANAESTHESIA, P23; PAUT O, 1995, ACTA ANAESTH SCAND, V39, P1117, DOI 10.1111/j.1399-6576.1995.tb04241.x; Rossiter JD, 2006, EYE, V20, P55, DOI 10.1038/sj.eye.6701789; Rubsam B, 2000, Strabismus, V8, P287, DOI 10.1076/stra.8.4.287.688; SCOTT WE, 1977, J PEDIATR OPHTHALMOL, V14, P71; Standl T, 1996, ACTA ANAESTH SCAND, V40, P729, DOI 10.1111/j.1399-6576.1996.tb04519.x; Tramer M, 1997, BRIT J ANAESTH, V78, P256; Treschan TA, 2005, ANESTHESIOLOGY, V103, P6, DOI 10.1097/00000542-200507000-00005; VANDENBERG AA, 1989, ANAESTHESIA, V44, P110; Velez FG, 2001, J AAPOS, V5, P178, DOI 10.1067/mpa.2001.114661; WARD JB, 1995, OPHTHALMOLOGY, V102, P122; YOSHIZUMI J, 1991, BRIT J ANAESTH, V67, P735, DOI 10.1093/bja/67.6.735; YOSHIZUMI J, 1993, BRIT J ANAESTH, V71, P839, DOI 10.1093/bja/71.6.839	32	7	8	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	SEP	2006	23	9					743	747		10.1017/S0265021506000457			5	Anesthesiology	Anesthesiology	079BZ	WOS:000240151800003	16884553				2020-06-30	J	Cillo, JE; Finn, R				Cillo, Joseph E., Jr.; Finn, Richard			Hemodynamics in elderly coronary artery disease patients undergoing propofol sedation	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							MYOCARDIAL ISCHEMIA; MIDAZOLAM; SURGERY	Purpose: The purpose of this study was to evaluate noninvasive intraoperative hemodynamics in an elderly population with coronary artery disease (CAD) undergoing midazolam/fentanyl intravenous sedation-analgesia, with or without propofol for dentoalveolar surgery. Patients and Methods: A retrospective chart analysis of 24 consecutive male patients aged 60 years or greater, with coronary artery disease, undergoing midazolam/fentanyl intravenous sedation-analgesia with or without propofol for dentoalveolar surgery. Data recorded included noninvasive baseline and intraoperative hemodynamic measurements at 5-minute intervals for systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), pulse pressure (PP), and pulse (P). Results: The addition of propofol to elderly CAD patients resulted in statistically significant lower averages for SBP (126.1 mm Hg vs 131.3 mm Hg, P < .01), DBP (64.1 mm Hg vs 74.3 mm Hg, P < .001), MAP (84.3 mm Hg vs 94.2 mm Hg, P < .001) and PP (57.7 mm Hg vs 61.8 mm Hg, P = .01) with statistically insignificant differences in pulse (74.2 beats per minute vs 75.8 beats per minute, P = .1). Baseline changes in elderly CAD patients who received propofol were within +/- 20% (range: -13.8% to +6.9%). Conclusion: Midazolam/fentanyl intravenous sedation provided stable intraoperative hemodynamics in elderly CAD patients. The addition of propofol to elderly CAD patients also resulted in stable intraoperative hemodynamics and may be a safe adjunct to intravenous sedation in elderly CAD patients. (c) 2006 American Association of Oral and Maxillofacial Surgeons.	Allegheny Gen Hosp, Dept Oral & Maxillofacial Surg, Pittsburgh, PA 15212 USA; Univ Texas, SW Med Ctr, Parkland Mem Hosp, Dept Oral & Maxillofacial Surg, Dallas, TX 75230 USA; Univ Texas, SW Med Ctr, Dept Surg, Div Oral & Maxillofacial Surg, Dallas, TX 75230 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75230 USA; Vet Adm N Texas Hlth Care Syst, Dallas, TX USA	Cillo, JE (reprint author), Allegheny Gen Hosp, Dept Oral & Maxillofacial Surg, 320 E N Ave,Suite 0107, Pittsburgh, PA 15212 USA.	jecdna@aol.com					Benetos A, 1997, J HYPERTENS, V15, pS89, DOI 10.1097/00004872-199715022-00009; BERNE RM, 1986, CARDIOVASCULAR PHYSL; Campbell R L, 1997, Anesth Prog, V44, P64; CORIAT P, 1982, ACTA ANAESTH SCAND, V26, P287, DOI 10.1111/j.1399-6576.1982.tb01768.x; DIERDORF SF, 2002, ANESTHESIA COEXISTIN, P15; FAIRFIELD JE, 1991, BRIT J ANAESTH, V67, P618, DOI 10.1093/bja/67.5.618; Johns FR, 1998, J ORAL MAXIL SURG, V56, P1124, DOI 10.1016/S0278-2391(98)90749-2; KNIGHT AA, 1988, ANESTHESIOLOGY, V68, P681, DOI 10.1097/00000542-198805000-00005; Maneglia R, 1988, Anaesthesia, V43 Suppl, P109, DOI 10.1111/j.1365-2044.1988.tb09090.x; MARTY J, 1986, ANESTHESIOLOGY, V64, P206, DOI 10.1097/00000542-198602000-00013; Merin R G, 1990, J Card Surg, V5, P247; MORGAN GE, 1992, CLIN ANAESTHESIOL, P347; Ong CKS, 2004, ANESTH ANALG, V98, P1289, DOI 10.1213/01.ANE.0000111107.18755.CC; Parworth LP, 1998, J ORAL MAXIL SURG, V56, P447, DOI 10.1016/S0278-2391(98)90710-8; Perrott DH, 2003, J ORAL MAXILLOFAC SU, V61, P995; Reinhart DJ, 1997, J CLIN ANESTH, V9, P130, DOI 10.1016/S0952-8180(97)00237-7; Sarasin DS, 1996, J ORAL MAXIL SURG, V54, P1187, DOI 10.1016/S0278-2391(96)90348-1; SCHWAB RL, 1990, J PERS EVAL EDUC, V4, P5; STARY HC, 1995, CIRCULATION, V92, P1362; STOELTING RK, 1994, BASICS ANESTHESIA, P251; *US CENS BUR, 2000, 38 US CENS BUR POP D; Yamasaki N, 2003, INTERNAL MED, V42, P383, DOI 10.2169/internalmedicine.42.383	22	6	6	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	SEP	2006	64	9					1338	1342		10.1016/j.joms.2006.05.018			5	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	078OW	WOS:000240114100003	16916666				2020-06-30	J	Zylicz, Z; Plaat, LLRVD				Zylicz, Zbigniew; van Rijn-van der Plaat, Lia Lens			Fentanyl may increase breathlessness in a patient with motor neuron disease	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Letter							INDUCED MUSCLE RIGIDITY; INFANT		St Elizabeth Hospice, Ipswich, Suffolk, England; Nicholas Copernicus Univ, Bydgoszcz, Poland; St Peter & St James Hospice, Lewis, Scotland	Zylicz, Z (reprint author), St Elizabeth Hospice, Ipswich, Suffolk, England.						ASKGAARD B, 1977, ACTA ANAESTH SCAND, V21, P1, DOI 10.1111/j.1399-6576.1977.tb01185.x; Glick C, 1996, SOUTHERN MED J, V89, P1119, DOI 10.1097/00007611-199611000-00023; JENNINGS AL, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002066; Lindemann R, 1998, EUR J PEDIATR, V157, P1012, DOI 10.1007/s004310050988; LUI PW, 1992, EUR J ANAESTH, V9, P419; Mayumi T, 1990, J Anesth, V4, P82, DOI 10.1007/s0054000040082; Muller P, 2000, AM J PERINAT, V17, P23, DOI 10.1055/s-2000-7289; Rosenberg M, 1977, Anesth Prog, V24, P50; SANFORD TJ, 1994, J CLIN ANESTH, V6, P473, DOI 10.1016/0952-8180(94)90087-6; SILBERT BS, 1987, ANESTH ANALG, V66, P1338, DOI 10.1213/00000539-198712000-00029; vanLemmen RJ, 1996, EUR J PEDIATR, V155, P1067, DOI 10.1007/s004310050538	11	6	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	SEP	2006	32	3					199	200		10.1016/j.jpainsymman.2006.05.001			2	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	084KJ	WOS:000240531500002	16939840	Bronze			2020-06-30	J	Cole, A; Mutlow, A; Isaza, R; Carpenter, JW; Koch, DE; Hunter, RP; Dresser, BL				Cole, Alexander; Mutlow, Adrian; Isaza, Ramiro; Carpenter, James W.; Koch, David E.; Hunter, Robert P.; Dresser, Betsy L.			Pharmacokinetics and pharmacodynamics of carfentanil and naltrexone in female common eland (Taurotragus oryx)	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Article						carfentanil; eland; naltrexone; pharmacokinetics; renarcotization; Tourotragus oryx	GOATS CAPRA-HIRCUS; BISON BISON-BISON; CHEMICAL IMMOBILIZATION; XYLAZINE; CITRATE; PLASMA; HYDROCHLORIDE; DISPOSITION; DETOMIDINE; ETORPHINE	The pharmacokinetic parameters of carfentanil and naltrexone were determined in the common eland (Taurotragus oryx). Six adult females were immobilized with xylazine (0.23 +/- 0.03 mg/kg i.m.) and carfentanil (0.0169 +/- 0.0005 mg/kg i.m.) for a 45-min period, during which time routine health care procedures were performed. Heart and respiration rates and body temperatures were monitored throughout the immobilization period. A single intramuscular injection of naltrexone (1.66 +/- 0.08 mg/kg i.m.) was sufficient for reversal. The eland were intermittently restrained in a hydraulic squeeze chute for serial blood sample collection via jugular venipuncture during immobilization and up to 48 hr post-immobilization. The quantification of carfentanil and naltrexone in the plasma was performed by liquid chromatography and mass spectroscopy methods. Carfentanil was rapidly absorbed following administration, with the peak plasma concentration (C-max) at 13.8 min. Naltrexone was readily absorbed and reached C-max at 23.4 +/- 416.8 min after administration. All animals stood 2.7 +/- 2.2 min after naltrexone administration. Carfentanil has a half-life of 7.7 hr, whereas naltrexone has a much shorter half-life of 3.7 hr. Although respiratory rates appeared to fluctuate widely among animals, heart rates and body temperature remained stable throughout the immobilization. Renarcotization was not noted as a major complication.	Audubon Nat Inst Ctr Res Endagered Species, New Orleans, LA 70131 USA; Kansas State Univ, Coll Vet Med, Dept Clin Sci, Manhattan, KS 66506 USA; Kansas State Univ, Coll Vet Med, Dept Anat & Physiol, Manhattan, KS 66506 USA; Univ Florida, Coll Vet Med, Dept Small Anim Clin Sci, Gainesville, FL 32610 USA	Cole, A (reprint author), Audubon Nat Inst Ctr Res Endagered Species, 14001 River Rd, New Orleans, LA 70131 USA.		Hunter, Robert P/A-2306-2008	Hunter, Robert P/0000-0003-1224-2376			Allen JL, 1996, J ZOO WILDLIFE MED, V27, P496; AMASS KD, 2004, CHEM IMMOBILIZATION; Caulkett NA, 2000, CAN J VET RES, V64, P64; CHENEY CS, 1988, J S AFR VET ASSOC, V59, P13; CHIANG CN, 1984, CLIN PHARMACOL THER, V36, P704, DOI 10.1038/clpt.1984.243; CITINO SB, 2003, ZOO WILD ANIMAL MED, P660; CORNICK JL, 1992, J AM VET MED ASSOC, V200, P1661; CRABTREE BL, 1984, CLIN PHARMACY, V3, P273; Delvaux H, 1999, J WILDLIFE DIS, V35, P38, DOI 10.7589/0090-3558-35.1.38; GIBALDI M, 1982, [No title captured], P409; HAIGH JC, 1990, J ZOO WILDLIFE MED, V21, P391; HAIGH JC, 1995, J WILDLIFE DIS, V31, P37, DOI 10.7589/0090-3558-31.1.37; Heard DJ, 1996, AM J VET RES, V57, P87; Howard LL, 2004, J ZOO WILDLIFE MED, V35, P312, DOI 10.1638/03-090; Hunter RP, 2003, J CHROMATOGR B, V793, P351, DOI 10.1016/S1570-0232(03)00351-9; KOCK MD, 1987, J WILDLIFE DIS, V23, P625, DOI 10.7589/0090-3558-23.4.625; KREEGER TJ, 1997, HDB WILDLIFE CHEM IM, P151; Miller MW, 1996, J WILDLIFE DIS, V32, P234, DOI 10.7589/0090-3558-32.2.234; Mutlow A, 2004, J ZOO WILDLIFE MED, V35, P489, DOI 10.1638/03-074; NEILSON L, 1996, LUMB JONES VET ANEST, P736; NEILSON L, 1999, CHEM IMMOBILIZATION, P261; Pollock CG, 2003, J ZOO WILDLIFE MED, V34, P408, DOI 10.1638/01-061; Porter SJ, 2002, ADDICT BIOL, V7, P219, DOI 10.1080/135562102200120442; RAATH JP, 1992, J S AFR VET ASSOC, V63, P138; RAMSAY EC, 1995, J WILDLIFE DIS, V31, P391, DOI 10.7589/0090-3558-31.3.391; REUNING RH, 1979, J PHARM SCI, V68, P411, DOI 10.1002/jps.2600680405; RIVIERE JE, 1999, COMP PHARMACOKINETIC; Schumacher J, 1997, J ZOO WILDLIFE MED, V28, P166; Schumacher J, 1997, AM J VET RES, V58, P157; Sleeman JM, 1997, J ZOO WILDLIFE MED, V28, P158; WALL ME, 1984, DRUG METAB DISPOS, V12, P677; WALL ME, 1981, DRUG METAB DISPOS, V9, P369; YOBURN BC, 1986, J PHARMACOL EXP THER, V237, P126	33	12	12	0	11	AMER ASSOC ZOO VETERINARIANS	MEDIA	6 NORTH PENNELL ROAD, MEDIA, PA 19063 USA	1042-7260			J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	SEP	2006	37	3					318	326		10.1638/05-070.1			9	Veterinary Sciences	Veterinary Sciences	084XC	WOS:000240566700013	17319131				2020-06-30	J	Storms, TN; Schumacher, J; Osborn, DA; Miller, KV; Ramsay, EC				Storms, Timothy N.; Schumacher, Juergen; Osborn, David A.; Miller, Karl V.; Ramsay, Edward C.			Effects of ketamine on carfentanil and xylazine immobilization of white-tailed deer (Odocoileus virginianus)	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Article						cervid; carfentanil; ketamine; Odocoileus virginianus; optimal dosage; white-tailed deer	MEDETOMIDINE; COMBINATION; ANESTHESIA; GAZELLA; A3080	Using a crossover design, the effects of the addition of ketamine to a previously determined optimal hand-injected immobilization dosage of carfentanil/xylazine were evaluated in 11 adult white-tailed deer (Odocoileus virginianus). Two i.m. ketamine dosages were evaluated: 0.15 mg/kg (low ketamine) and 0.30 mg/kg (high ketamine). Each deer was immobilized twice 2 wk apart. Inductions were video recorded and reviewed by observers, who had been blinded to drugs and dosages, who rated qualitative aspects. There were significant (P < 0.05) dosage-dependent decreases in heart rate, SaO(2), and arterial pH, and a significant dosage-dependent increase in PaCO2. Induction times with both dosages were more rapid (mean 2.3 +/- 0.9 min for low ketamine and 2.3 +/- 0.6 min for high ketamine) than those reported for the same carfentanil/xylazine dosage used without ketamine. Mean quality ratings, though improved compared to those reported for carfentanil/xylazine alone, were considered "undesirable" for both dosages. Hyperthermia (temperature > 41 degrees C) was noted in 13 of 22 immobilizations. Arterial pH and PaO2 increased significantly from 10 to 20 min postrecumbency, but acidernia (pH < 7.3) was present throughout immobilization periods for all deer. There were ketamine dosage-dependent increases in respiratory components of this acidernia compared with that associated with carfentanil/xylazine alone. Possible hypoxemia was present at both sampling times for both groups, while hypercapnea (PaCO2 > 60 min Hg) was present for the high-ketamine group only. Reversal times for naltrexone and yohimbine were rapid (mean 2.9 +/- 0.7 min for low ketamine and 3.3 +/- 0.8 min for high ketamine), with no evidence of renarcotization. Although the addition of ketamine to carfentanil/xylazine caused faster inductions and improved induction qualities, it also produced an increased incidence of hyperthermia, acidemia, hypoxemia, and hypercapnea. Supplemental oxygen and close monitoring of body temperature is recommended when using this immobilization regimen.	Dallas Zoo, Dallas, TX 75203 USA; Univ Tennessee, Coll Vet Med, Dept Small Anim Clin Sci, Knoxville, TN 37996 USA; Univ Georgia, Warnell Sch Forest Resources, Athens, GA 30602 USA	Storms, TN (reprint author), Dallas Zoo, 650 S RL Thornton Freeway, Dallas, TX 75203 USA.			Schumacher, Juergen/0000-0003-3973-7248			Citino SB, 2002, J WILDLIFE DIS, V38, P457, DOI 10.7589/0090-3558-38.2.457; Citino SB, 2001, J S AFR VET ASSOC, V72, P29; Grobler D, 2001, J S AFR VET ASSOC, V72, P81; KARESH WB, 1986, J ZOO WILDLIFE MED, V17, P58, DOI 10.2307/20094795; LIN HC, 1996, LUMB JONES VET ANEST, P241; Miller-Edge M., 1994, Proceedings American Association of Zoo Veterinarians and Association of Reptilian and Amphibian Veterinarians Annual Conference Pittsburgh, USA, 22-27, October, 1994., P192; Moresco A, 2001, J ZOO WILDLIFE MED, V32, P81, DOI 10.1638/1042-7260(2001)032[0081:UONTRC]2.0.CO;2; Schumacher J, 1997, J ZOO WILDLIFE MED, V28, P166; Snyder SB, 1992, P AM ASS ZOO VET AM, P253; Storms TN, 2005, J WILDLIFE DIS, V41, P559, DOI 10.7589/0090-3558-41.3.559	10	10	10	0	4	AMER ASSOC ZOO VETERINARIANS	MEDIA	6 NORTH PENNELL ROAD, MEDIA, PA 19063 USA	1042-7260			J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	SEP	2006	37	3					347	353		10.1638/05-079.1			7	Veterinary Sciences	Veterinary Sciences	084XC	WOS:000240566700016	17319134				2020-06-30	J	Steagall, PVM; Teixeira, FJ; Minto, BW; Campagnol, D; Correa, MA				Steagall, Paulo V. M.; Teixeira, Francisco J.; Minto, Bruno W.; Campagnol, Daniela; Correa, Mariana A.			Evaluation of the isoflurane-sparing effects of lidocaine and fentanyl during surgery in dogs	JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Fall Meeting of the Association-of-Veterinary-Anaesthetists	SEP, 2005	Newmarket, ENGLAND	Assoc Vet Anaesthetists			MINIMUM ALVEOLAR CONCENTRATION; INTRAVENOUS LIDOCAINE; ANESTHETIC POTENCY; NITROUS-OXIDE; COMBINATION; HALOTHANE; REDUCTION; PHARMACOKINETICS; BUPIVACAINE; ENFLURANE	Objective-To evaluate the isoflurane-sparing effects of lidocaine and fentanyl administered by constant rate infusion (CRI) during surgery in dogs. Design-Randomized prospective study. Animals-24 female dogs undergoing unilateral mastectomy because of mammary neoplasia. Procedures-After premedication with acepromazine and morphine and anesthetic induction with ketamine and diazepam, anesthesia in dogs (n = 8/group) was maintained with isoflurane combined with either saline (0.9% NaCl) solution (control), liclocaine (1.5 mg/kg [0.68 mg/lb], IV bolus, followed by 250 mu g/kg/min [113 mu g/lb/min], CRI), or fentanyl (5 mu g/kg [2.27 mu g/lb], IV bolus, followed by 0.5 mu g/kg/min [0.23 mu g/lb/min], CRI). Positive-pressure ventilation was used to maintain eucapnia. An anesthetist unaware of treatment, endtidal isoflurane (ETiso) concentration, and vaporizer concentrations adjusted a nonprecision vaporizer to maintain surgical depth of anesthesia. Cardiopulmonary variables and ETiso values were monitored before and after beginning surgery. Results-Heart rate was lower in the fentanyl group. Mean arterial pressure did not differ among groups after surgery commenced. In the control group, mean +/- SD ETiso values ranged from 1.16 +/- 0.35% to 1.94 +/- 0.96%. Fentanyl significantly reduced isoflurane requirements during surgical stimulation by 54% to 66%, whereas the reduction in ETiso concentration (34% to 44%) observed in the lidocaine group was not significant. Conclusions and Clinical Relevance-Administration of fentanyl resulted in greater isoflurane sparing effect than did liclocaine. However, it appeared that the low heart rate induced by fentanyl may partially offset the improvement in mean arterial pressure that would be expected with reduced isoflurane requirements.	Sao Paulo State Univ, Dept Vet Surg & Anesthesiol, Sch Vet Med & Anim Sci, BR-18618000 Botucatu, SP, Brazil	Teixeira, FJ (reprint author), Sao Paulo State Univ, Dept Vet Surg & Anesthesiol, Sch Vet Med & Anim Sci, BR-18618000 Botucatu, SP, Brazil.		campagnol, daniela/I-6084-2012; Steagall, Paulo/W-6043-2019; minto, bruno w/G-1186-2012; Teixeira-Neto, Francisco Jose/B-7722-2012	Steagall, Paulo/0000-0003-4150-6043; minto, bruno w/0000-0002-8808-4127; Teixeira-Neto, Francisco Jose/0000-0002-3002-8093			COTE E, 2005, VET INTERNAL MED, P1040; Criado AB, 2003, VET ANAESTH ANALG, V30, P250, DOI 10.1046/j.1467-2995.2003.00123.x; Doherty TJ, 1998, EQUINE VET J, V30, P300, DOI 10.1111/j.2042-3306.1998.tb04101.x; Dyson DH, 1999, CAN VET J, V40, P327; EGER EI, 1965, ANESTHESIOLOGY, V26, P756, DOI 10.1097/00000542-196511000-00010; EGER EI, 1965, ANESTHESIOLOGY, V26, P764, DOI 10.1097/00000542-196511000-00011; HALL LW, 2001, APPARATUS ADM ANAEST, P197; Hellyer PW, 2001, AM J VET RES, V62, P555, DOI 10.2460/ajvr.2001.62.555; HIMES RS, 1977, ANESTHESIOLOGY, V47, P437, DOI 10.1097/00000542-197711000-00010; ILKIW JE, 1994, CAN J VET RES, V58, P248; Ilkiw JE, 1999, CLIN TECH SMALL AN P, V14, P27, DOI 10.1016/S1096-2867(99)80024-3; LIU PL, 1983, ANESTH ANALG, V62, P375; MCEWAN AI, 1993, ANESTHESIOLOGY, V78, P864, DOI 10.1097/00000542-199305000-00009; MOON PF, 1995, ANESTHESIOLOGY, V83, P535, DOI 10.1097/00000542-199509000-00012; MOTOMURA S, 1984, ANESTH ANALG, V63, P47; Muir WW, 2003, AM J VET RES, V64, P1155, DOI 10.2460/ajvr.2003.64.1155; MURPHY MR, 1979, ANESTHESIOLOGY, V50, P13, DOI 10.1097/00000542-197901000-00004; MURPHY MR, 1982, ANESTHESIOLOGY, V57, P485, DOI 10.1097/00000542-198212000-00009; Ngo LY, 1997, J PHARM SCI-US, V86, P944, DOI 10.1021/js960399i; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P757, DOI 10.1016/S0195-5616(08)70005-6; Pypendop BH, 2005, ANESTH ANALG, V100, P97, DOI 10.1213/01.ANE.0000139350.88158.38; REGAN MJ, 1967, ANESTHESIOLOGY, V28, P689, DOI 10.1097/00000542-196707000-00015; Skarda RT, 1996, LUMB JONES VET ANEST, P426; Steffey E.P., 1996, LUMB JONES VET ANEST, P297; STEFFEY EP, 1977, AM J VET RES, V38, P1833; Torske KE, 1998, CAN VET J, V39, P361; Valverde A, 2004, VET ANAESTH ANALG, V31, P264, DOI 10.1111/j.1467-2995.2004.00165.x	27	47	47	0	11	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0003-1488			JAVMA-J AM VET MED A	JAVMA-J. Am. Vet. Med. Assoc.	AUG 15	2006	229	4					522	527		10.2460/javma.229.4.522			6	Veterinary Sciences	Veterinary Sciences	073MX	WOS:000239748400018	16910849				2020-06-30	J	Orbach-Zinger, S; Friedman, L; Avramovich, A; Ilgiaeva, N; Orvieto, R; Sulkes, J; Eidelman, LA				Orbach-Zinger, S.; Friedman, L.; Avramovich, A.; Ilgiaeva, N.; Orvieto, R.; Sulkes, J.; Eidelman, L. A.			Risk factors for failure to extend labor epidural analgesia to epidural anesthesia for Cesarean section	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						Cesarean section; epidural analgesia; epidural fanesthesia; general anesthesia; labor	DELIVERY; LIDOCAINE; EFFICACY; BLOCKADE	Aim: To identify parturients at risk of inability to extend labor epidural analgesia in whom alternative methods of anesthesia should be considered for Cesarean section (CS). Methods: For 6 months, we prospectively studied women undergoing CS with a functioning epidural catheter in place from the delivery ward. All parturients received the same epidural protocol: bolus of bupivacaine 0.1% and fentanyl, followed by bupivacaine 0.1% and fentanyl (2 mu g/ml) 10-15 ml/h and an additional 5 ml of bupivacaine 0.125% as top-up according to patient request. Sixteen milliliters of lidocaine 2%, 1 ml of bicarbonate and 100 mu g of fentanyl were given for CS. Failed epidural analgesia was defined as the need to convert to general anesthesia. Results: Of the 101 parturients studied, 20 (19.8%) required conversion to general anesthesia. In univariate analysis, the likelihood of failed epidural anesthesia was inversely correlated with parturient age (P = 0.014) and directly correlated with pre-pregnancy weight (P = 0.019), weight at the end of pregnancy (P = 0.003), body mass index at the end of pregnancy (P = 0.0004), gestational week (P = 0.008), number of top-ups (P = 0.0004) and visual analog scale (VAS) score 2 h before CS (P = 0.03). In multivariate analysis, the number of top-ups in the delivery ward was the best predictor of epidural anesthesia failure (odds ratio, 4.39; P = 0.005). Conclusion: Younger, more obese parturients at a higher gestational week, requiring more top-ups during labor and having a higher VAS score in the 2 h before CS are at risk for inability to extend labor epidural analgesia to epidural anesthesia for CS.	Rabin Med Ctr, Dept Anesthesiol, IL-49100 Petah Tiqwa, Israel; Rabin Med Ctr, Dept Gynecol & Obstet, IL-49100 Petah Tiqwa, Israel; Rabin Med Ctr, Dept Epidemiol, IL-49100 Petah Tiqwa, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Eidelman, LA (reprint author), Rabin Med Ctr, Dept Anesthesiol, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.	leidelman@clalit.org.il					BOURNE TM, 1997, [No title captured], V52, P896; BRULL SJ, 1991, BRIT J ANAESTH, V66, P651, DOI 10.1093/bja/66.6.651; CRAWFORD JS, 1986, ANAESTHESIA, V41, P1039, DOI 10.1111/j.1365-2044.1986.tb12751.x; CROSBY ET, 1990, CAN J ANAESTH, V37, P789, DOI 10.1007/BF03006538; Gaiser RR, 1998, INT J OBSTET ANESTH, V7, P27, DOI 10.1016/S0959-289X(98)80025-3; Garry M, 2002, INT J OBSTET ANESTH, V11, P9, DOI 10.1054/ijoa.2001.0903; Hawkins JL, 1997, ANESTHESIOLOGY, V86, P277, DOI 10.1097/00000542-199702000-00002; Lam DTC, 2001, ANAESTHESIA, V56, P790; Lucas DN, 1999, ANAESTHESIA, V54, P1173, DOI 10.1046/j.1365-2044.1999.01108.x; Michlin R, 2000, ISRAEL MED ASSOC J, V2, P10; Morgan PJ, 2000, CAN J ANAESTH, V47, P956, DOI 10.1007/BF03024865; Price M L, 1991, Int J Obstet Anesth, V1, P13, DOI 10.1016/0959-289X(91)90024-K; Riley ET, 2002, INT J OBSTET ANESTH, V11, P81, DOI 10.1054/ijoa.2001.0927; RILEY ET, 1995, ANESTH ANALG, V80, P709, DOI 10.1097/00000539-199504000-00010; Russell I F, 1995, Int J Obstet Anesth, V4, P71, DOI 10.1016/0959-289X(95)82995-M; Tortosa JC, 2003, BRIT J ANAESTH, V91, P532, DOI 10.1093/bja/aeg214; Tully L, 2002, EUR J OBSTET GYN R B, V102, P120, DOI 10.1016/S0301-2115(01)00589-9; Wee MYK, 2005, INT J OBSTET ANESTH, V14, P147, DOI 10.1016/j.ijoa.2004.09.008	18	12	12	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	AUG	2006	50	7					793	797		10.1111/j.1399-6576.2006.01083.x			5	Anesthesiology	Anesthesiology	061NG	WOS:000238878700004	16879460				2020-06-30	J	Atallah, MM; Shorrab, AA; Mageed, YMA; Demian, AD				Atallah, M. M.; Shorrab, A. A.; Abdel Mageed, Y. M.; Demian, A. D.			Low-dose bupivacaine spinal anaesthesia for percutaneous nephrolithotomy: the suitability and impact of adding intrathecal fentanyl	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						anaesthetic technique; bupivacaine; fentanyl; low-dose spinal anaesthesia; percutaneous nephrolithotomy; spinal anaesthetics; surgery	HYPERBARIC BUPIVACAINE; SPREAD; MG	Background: Unilateral spinal anaesthesia has been used for lower limb surgery with a stable cardiovascular state and a short recovery unit stay. We sought to test the suitability of low-dose bupivacaine spinal anaesthesia for percutaneous nephrolithotomy, a procedure hitherto performed under general anaesthesia. Furthermore, we hypothesized that adding intrathecal fentanyl to bupivacaine may improve the quality of anaesthesia. Methods: We randomly allocated, through computer-generated randomization, 108 patients subjected to percutaneous nephrolithotomy to receive either 7.5 mg of hyperbaric bupivacaine 5 mg/ml alone or with the addition of 10 mu g of fentanyl. Drugs were given at the L-2-L-3 interspace with the patient in the lateral decubitus position. The patients remained in this position for 10 min, after which the sensory and motor blocks were assessed. Intra-operative analgesic supplementation, when deemed necessary, was achieved with intravenous fentanyl boluses (25 mu g). Results: The sensory and motor blocks after intrathecal bupivacaine and bupivacaine-fentanyl were similar. Sensory block, in both groups, reached the fifth and eighth thoracic dermatomes on the operative and non-operative sides, respectively. Deep motor block occurred on the operative side in all patients and in nearly 50% of patients on the non-operative side. The patients in the bupivacaine-fentanyl group required less intra-operative and post-operative analgesics, and both patients and endoscopists were better satisfied. Conclusion: This study demonstrated, for the first time, that intrathecal low-dose bupivacaine and fentanyl offers a reliable neuraxial block for patients subjected to percutaneous nephrolithotomy, with stable haemodynamics, good post-operative analgesia and acceptable patient and endoscopist satisfaction.	Mansoura Univ, Urol & Nephrol Ctr, Mansoura, Egypt	Atallah, MM (reprint author), Mansoura Univ, Urol & Nephrol Ctr, Mansoura, Egypt.	atallah_36@hotmail.com					Andreoni C, 2002, J ENDOUROL, V16, P721, DOI 10.1089/08927790260472863; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; BROMAGE PR, 1965, ACTA ANAESTH SCAND, VS, P55; BUCHNER A, USE GPOWER; Casati A, 1998, BRIT J ANAESTH, V81, P355, DOI 10.1093/bja/81.3.355; Casati A, 1998, CAN J ANAESTH, V45, P850, DOI 10.1007/BF03012218; Casati A, 1999, REGION ANESTH PAIN M, V24, P214, DOI 10.1016/S1098-7339(99)90130-X; Enk D, 1998, Curr Opin Anaesthesiol, V11, P511, DOI 10.1097/00001503-199810000-00011; Enk D, 2001, REGION ANESTH PAIN M, V26, P420, DOI 10.1053/rapm.2001.26489; Esmaoglu A, 1998, ACTA ANAESTH SCAND, V42, P1083, DOI 10.1111/j.1399-6576.1998.tb05380.x; Fanelli G, 2000, CAN J ANAESTH, V47, P746, DOI 10.1007/BF03019476; GENTILI ME, 1995, REGION ANESTH, V20, P169; Gravenstein D, 2000, Anesthesiol Clin North Am, V18, P953, DOI 10.1016/S0889-8537(05)70203-0; Kararmaz A, 2003, ANAESTHESIA, V58, P526, DOI 10.1046/j.1365-2044.2003.03153.x; Korhonen AM, 2003, ACTA ANAESTH SCAND, V47, P342, DOI 10.1034/j.1399-6576.2003.00092.x; Korhonen AM, 2003, ACTA ANAESTH SCAND, V47, P1292, DOI 10.1046/j.1399-6576.2003.00206.x; Kuusniemi KS, 2000, REGION ANESTH PAIN M, V25, P605, DOI 10.1053/rapm.2000.8500; Kuusniemi KS, 1999, EUR J ANAESTH, V16, P2, DOI 10.1046/j.1365-2346.1999.00414.x; Lee YY, 2005, EUR J ANAESTH, V22, P899, DOI 10.1017/S0265021505001523; LIU S, 1995, ANESTH ANALG, V80, P730, DOI 10.1097/00000539-199504000-00014; Nakamura T, 2001, CAN J ANAESTH, V48, P993, DOI 10.1007/BF03016590; Parlow JL, 1999, CAN J ANAESTH, V46, P66, DOI 10.1007/BF03012518; Patterson L, 2001, CAN J ANAESTH, V48, P768, DOI 10.1007/BF03016692; SEGURA JW, 1994, J UROLOGY, V151, P1648, DOI 10.1016/S0022-5347(17)35330-2; TEJWANI GA, 1992, ANESTH ANALG, V74, P726; Valanne JV, 2001, ANESTH ANALG, V93, P1377, DOI 10.1097/00000539-200112000-00005	26	12	13	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	AUG	2006	50	7					798	803		10.1111/j.1399-6576.2006.01063.x			6	Anesthesiology	Anesthesiology	061NG	WOS:000238878700005	16879461				2020-06-30	J	Kardos, A; Foldesi, C; Nagy, A; Saringer, A; Kiss, A; Kiss, G; Marschalko, P; Szabo, M				Kardos, A.; Foldesi, C.; Nagy, A.; Saringer, A.; Kiss, A.; Kiss, G.; Marschalko, P.; Szabo, M.			Trendelenburg positioning does not prevent a decrease in cardiac output after induction of anaesthesia with propofol in children	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						pediatric; Trendelenburg position; cardiac output; impedance cardiography	IMPEDANCE CARDIOGRAPHY; STROKE VOLUME; THORACIC BIOIMPEDANCE; TIME; PRESSURE; SURGERY	Background and objective: Induction of anaesthesia may cause decreased cardiac output and blood pressure. Head-down tilt is often the first clinical step to treat hypotension. The objective of this randomized single centre study was to determine, with the use of impedance cardiography (ICG), whether Trendelenburg positioning modifies the haemodynamic response to propofol/fentanyl induction of anaesthesia in ASA I children. Methods: Thirty ASA I children aged between 7 and 16 years scheduled for elective minor orthopaedic surgery were included. After intravenous induction with propofol and fentanyl in the head-down group (HDG, n = 15), 5 min of 20 degrees head-down tilt was applied. In the supine group (SG, n = 15), no change in the supine position was made. Heart rate (HR), mean arterial blood pressure (MABP), end-tidal carbon dioxide (ETCO2), stroke volume index (SVI), cardiac index (CI), systemic vascular resistance index (SVRI) and Heather index (HI) were recorded before (B), at 3 (A(3)), 5 (A(5)) and 8 (A(8)) minutes after induction in each group. Results: After induction, a significant decrease in CI, MABP, HR and HI was recorded in both groups. In the study group, significantly lower values of HR (66 vs. 78 beat/min) and higher values of SVI (42.9 vs. 40.6 ml/min/m(2)) were measured at A(3) compared with the control group. After induction, no difference in CI and SVRI was found between the two groups. Results: The present study shows that cardiac performance is not improved by Trendelenburg positioning after propofol/fentanyl induction of anaesthesia in children.	HEIM PAL Childrens Hosp, Paediat Intens Care Unit, H-1086 Budapest, Hungary; HEIM PAL Childrens Hosp, Dept Orthopaed Surg, H-1086 Budapest, Hungary; HEIM PAL Childrens Hosp, Gottsegen Gyorgy Natl Inst Cardiol, H-1086 Budapest, Hungary	Kardos, A (reprint author), HEIM PAL Childrens Hosp, Paediat Intens Care Unit, Ulloi Str 89, H-1086 Budapest, Hungary.	dr.kardos@axelero.hu					AUN CST, 1993, BRIT J ANAESTH, V70, P482; BERNSTEIN DP, 1986, CRIT CARE MED, V14, P898, DOI 10.1097/00003246-198610000-00015; BRADEN DS, 1990, AM HEART J, V120, P1166, DOI 10.1016/0002-8703(90)90132-H; Braga ADD, 2001, EUR J ANAESTH, V18, P384, DOI 10.1046/j.0265-0215.2001.00861.x; CASTOR G, 1990, CRIT CARE MED, V18, P544, DOI 10.1097/00003246-199005000-00017; Cybulski G, 2004, MED BIOL ENG COMPUT, V42, P707, DOI 10.1007/BF02347554; Ebert TJ, 2005, ANESTHESIOLOGY, V103, P20, DOI 10.1097/00000542-200507000-00007; Fahrenberg J, 1997, J MED ENG TECHNOL, V21, P15, DOI 10.3109/03091909709030298; HIRVONEN EA, 1995, ACTA ANAESTH SCAND, V39, P949, DOI 10.1111/j.1399-6576.1995.tb04203.x; INTRONA RPS, 1988, CRIT CARE MED, V16, P1101, DOI 10.1097/00003246-198811000-00004; KUBICEK WG, 1970, ANN NY ACAD SCI, V170, P724, DOI 10.1111/j.1749-6632.1970.tb17735.x; Manner T, 1998, PAEDIATR ANAESTH, V8, P25, DOI 10.1046/j.1460-9592.1998.00699.x; Mezzacappa ES, 1999, INT J PSYCHOPHYSIOL, V31, P189, DOI 10.1016/S0167-8760(98)00058-0; MULIER JP, 1991, ANESTH ANALG, V72, P28; OCONNELL AJ, 1991, ANAESTH INTENS CARE, V19, P434, DOI 10.1177/0310057X9101900323; Pianosi P, 1996, AM J CARDIOL, V77, P745, DOI 10.1016/S0002-9149(97)89210-7; Pianosi PT, 1997, CHEST, V111, P333, DOI 10.1378/chest.111.2.333; Reuter DA, 2003, EUR J ANAESTH, V20, P17, DOI 10.1097/00003643-200301000-00003; TERAI C, 1995, AM J EMERG MED, V13, P255, DOI 10.1016/0735-6757(95)90194-9; Turner RJ, 1998, BRIT J ANAESTH, V80, P737, DOI 10.1093/bja/80.6.737; VANAKEN H, 1988, ANESTHESIOLOGY, V68, P157; WILCOX S, 1988, ANESTH ANALG, V67, P574	22	8	10	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	AUG	2006	50	7					869	874		10.1111/j.1399-6576.2006.01073.x			6	Anesthesiology	Anesthesiology	061NG	WOS:000238878700015	16879471				2020-06-30	J	Gross, ER; Hsu, AK; Gross, GJ				Gross, Eric R.; Hsu, Anna K.; Gross, Garrett J.			The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3 beta	AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY			English	Article						Janus-activated kinase; glycogen synthase kinase; opioids; morphine; infarct size	GLYCOGEN-SYNTHASE KINASE-3-BETA; SIGNAL TRANSDUCER; UP-REGULATION; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTION FACTOR; ACTIVATION; APOPTOSIS; P53; ISCHEMIA/REPERFUSION; PROTECTION	We examined the role for the JAK/STAT signaling pathway in acute opioid-induced cardioprotection (OIC) and whether opioid-induced glycogen synthase kinase-3 beta (GSK-3 beta) inhibition is mediated by the JAK/STAT pathway. Rats underwent 30 min of ischemia and either 5 min or 2 h of reperfusion, followed by tissue isolation for molecular analysis or infarct size assessment, respectively. Rats were treated with vehicle, morphine (300 mu g/kg), the delta-opioid agonist fentanyl isothiocynate (FIT, 10 mu g/kg), or the GSK inhibitor SB-216763 (SB21, 600 mu g/kg) 10 min before ischemia. Five minutes before opioid or SB21 treatment, some rats received the putative JAK2 inhibitor AG-490 (3 mg/kg) or the putative JAK3 inhibitor ZM-449829 (3 mg/kg). H9C2 cardiomyoblast cells were also used to investigate FIT-induced signaling (1 mu M) in vitro via molecular analysis. Morphine induced the phosphorylation of JAK2, yet not JAK1, in the area at risk. Morphine, FIT, and SB21 also reduced infarct size compared with vehicle ( water) when administered before ischemia [43.0 +/- 2.8, 39.1 +/- 3.1, and 42.1 +/- 2.5 (* P < 0.001, respectively) vs. 58.1 +/- 1.3%, respectively]. AG-490 abrogated OIC, whereas ZM-449829 had no effect on OIC. Cardioprotection was afforded by SB21 even in the presence of AG-490. Morphine phosphorylated STAT3, Akt, and GSK-3 beta, and phosphorylation was abrogated by AG-490. FIT stimulation of H9C2 cells also caused a time-dependent phosphorylation of STAT3, Akt, and GSK-3 beta, and this effect was abrogated by AG-490. STAT3 phosphorylation was also dependent on phosphatidylinositol 3-kinase (PI3K) activation in both tissue and H9C2 cells. These data suggest that OIC occurs via the JAK2 regulation of PI3K pathway-dependent STAT3, Akt, and GSK-3 beta, with GSK-3 beta contributing a central role in acute OIC.	Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA	Gross, GJ (reprint author), Med Coll Wisconsin, Dept Pharmacol & Toxicol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	ggross@mcw.edu			NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL-08311]		Bolli R, 2003, TRENDS CARDIOVAS MED, V13, P72, DOI 10.1016/S1050-1738(02)00230-X; Booz GW, 2002, J MOL CELL CARDIOL, V34, P1443, DOI 10.1006/jmcc.2002.2076; Carvalho CRO, 2003, ENDOCRINOLOGY, V144, P638, DOI 10.1210/en.2002-220706; Cieslik K, 2001, J BIOL CHEM, V276, P1211, DOI 10.1074/jbc.M005305200; Fryer RM, 2001, J PHARMACOL EXP THER, V299, P477; Gross ER, 2004, CIRC RES, V94, P960, DOI 10.1161/01.RES.0000122392.33172.09; Hattori R, 2001, J MOL CELL CARDIOL, V33, P1929, DOI 10.1006/jmcc.2001.1456; Hilfiker-Kleiner D, 2004, CIRC RES, V95, P187, DOI 10.1161/01.RES.0000134921.50377.61; Ichikawa Y, 2003, J MOL CELL CARDIOL, V35, pA21; Juhaszova M, 2004, J CLIN INVEST, V113, P1535, DOI 10.1172/JCI200419906; Kunisada K, 2000, P NATL ACAD SCI USA, V97, P315, DOI 10.1073/pnas.97.1.315; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lo RKH, 2004, MOL PHARMACOL, V65, P1427, DOI 10.1124/mol.65.6.1427; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Mocanu MM, 2003, FEBS LETT, V555, P302, DOI 10.1016/S0014-5793(03)01260-2; Negoro S, 2001, CIRCULATION, V104, P979, DOI 10.1161/hc3401.095947; Negoro S, 2000, CARDIOVASC RES, V47, P797, DOI 10.1016/S0008-6363(00)00138-3; Nguyen MHH, 2001, J BIOL CHEM, V276, P32704, DOI 10.1074/jbc.M103100200; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; Stephanou A, 2002, FASEB J, V16, P1841, DOI 10.1096/fj.02-0150fje; Stephanou A, 2001, J BIOL CHEM, V276, P28340, DOI 10.1074/jbc.M101177200; Stephanou A, 2000, J BIOL CHEM, V275, P10002, DOI 10.1074/jbc.275.14.10002; Suzuki S, 2003, BIOCHEM BIOPH RES CO, V308, P802, DOI 10.1016/S0006-291X(03)01472-4; Takahashi T, 1999, CIRC RES, V85, P884; Tsang A, 2004, CIRC RES, V95, P230, DOI 10.1161/01.RES.0000138303.76488.fe; Turenne GA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-12; Verma A, 2003, CANCER METAST REV, V22, P423, DOI 10.1023/A:1023805715476; Wang LH, 1999, J IMMUNOL, V162, P3897; Watcharasit P, 2003, J BIOL CHEM, V278, P48872, DOI 10.1074/jbc.M305870200; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Wen TC, 2001, NEUROSCI LETT, V303, P153, DOI 10.1016/S0304-3940(01)01711-6; Xuan YT, 2001, P NATL ACAD SCI USA, V98, P9050, DOI 10.1073/pnas.161283798; Yoshioka S, 2004, LIFE SCI, V74, P2097, DOI 10.1016/j.lfs.2003.07.057; Zhang XC, 2005, J BIOL CHEM, V280, P8714, DOI 10.1074/jbc.M408092200; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	36	131	142	0	12	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6135	1522-1539		AM J PHYSIOL-HEART C	Am. J. Physiol.-Heart Circul. Physiol.	AUG	2006	291	2					H827	H834		10.1152/ajpheart.00003.2006			8	Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease	Cardiovascular System & Cardiology; Physiology	063LS	WOS:000239020300040	16517948				2020-06-30	J	Sivathondan, D				Sivathondan, D.			Myotonic dystrophy and pain management of a patient undergoing total abdominal hysterectomy in a Metropolitan General Hospital	ANAESTHESIA AND INTENSIVE CARE			English	Article						myotonic dystrophy, pain management	ANESTHESIA; SURGERY	Patients with myotonic dystrophy presenting for surgery are exposed to the adverse effects of anaesthetics, especially if the condition has not been diagnosed. Respiratory depression due to increased sensitivity to anaesthetic and opioid drugs is of major concern in patients undergoing major surgery. Meticulous pre- and postoperative management, including pain management, is necessary to avoid morbidity and mortality.	Canterbury Hosp, Dept Anaesthesia, Sydney, NSW, Australia	Sivathondan, D (reprint author), 157 Blvd, Strathfield, NSW 2135, Australia.						ADAMS C, GENEREVIEWS; Bennun M, 2000, BRIT J ANAESTH, V85, P407, DOI 10.1093/bja/85.3.407; Bird T., GENEREVIEWS; BOULY A, 1991, ANAESTHESIA, V46, P705, DOI 10.1111/j.1365-2044.1991.tb09752.x; Boyle R, 1999, ANAESTH INTENS CARE, V27, P301, DOI 10.1177/0310057X9902700315; Colovic V, 2002, PAEDIATR ANAESTH, V12, P351, DOI 10.1046/j.1460-9592.2002.00812.x; DALAL FY, 1972, CAN ANAESTH SOC J, V19, P436, DOI 10.1007/BF03005968; GARDNERMEDWIN D, 1980, BRIT MED BULL, V36, P109, DOI 10.1093/oxfordjournals.bmb.a071623; Imison AR, 2001, ANAESTH INTENS CARE, V29, P34, DOI 10.1177/0310057X0102900106; Jenkins JA, 2004, PEDIATR ANESTH, V14, P693, DOI 10.1111/j.1460-9592.2004.01280.x; Macintyre PE, 2006, MED J AUSTRALIA, V184, P101, DOI 10.5694/j.1326-5377.2006.tb00144.x; Mathieu J, 1997, NEUROLOGY, V49, P1646, DOI 10.1212/WNL.49.6.1646; Merefield DC, 1997, ANAESTH INTENS CARE, V25, P93; NIGHTINGALE P, 1985, BRIT J ANAESTH, V57, P1131, DOI 10.1093/bja/57.11.1131; PIERCE JW, 1965, GUT, V6, P392, DOI 10.1136/gut.6.4.392; SWASH M, 1997, NEUROMUSCULAR DIS PR; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026	17	2	3	0	1	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2021, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	AUG	2006	34	4					506	509		10.1177/0310057X0603400404			4	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	084YA	WOS:000240569100020	16913352	Bronze			2020-06-30	J	Cucchiaro, G; Adzick, SN; Rose, JB; Maxwell, L; Watcha, M				Cucchiaro, Giovanni; Adzick, Scott N.; Rose, John B.; Maxwell, Lynne; Watcha, Mehernoor			A comparison of epidural bupivacaine-fentanyl and bupivacaine-clonidine in children undergoing the nuss procedure	ANESTHESIA AND ANALGESIA			English	Article							SOLE ANALGESIC AGENT; POSTOPERATIVE ANALGESIA; ABDOMINAL-SURGERY; DOUBLE-BLIND; DOSE-RESPONSE; INFUSION; MORPHINE; LABOR; ROPIVACAINE; SUFENTANIL	The administration of epidural opioids, though effective for producing analgesia, has severe side effects in most patients. It is unknown whether clonidine can effectively replace opioids and cause fewer side effects. We compared, in this randomized trial, the incidence of vomiting and pruritus as well as the analgesic profile of three different combinations of bupivacame, fentanyl, and clonidine administered epidurally in patients undergoing the Nuss procedure: bupivacaine + fentanyl, bupivacaine + clonidine, bupivacaine + fentanyl + clonidine. The incidence of side effects was significantly less in the bupivacaine + clonidine group (33%) compared with the bupivacaine + fentanyl (92%) and bupivacaine + fentanyl + clonidine (73%) groups (P = 0.004). Quality of postoperative analgesia was similar in the three groups. No significant complications were observed. In conclusion, clonidine is an effective and safe alternative to epidural opioids.	Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Surg, Philadelphia, PA 19104 USA	Cucchiaro, G (reprint author), Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, 34th St & Civic Ctr Blvd, Philadelphia, PA 19104 USA.	cucchiaro@email.chop.edu		Maxwell, Lynne/0000-0002-4406-9232			BAILEY PL, 1991, ANESTHESIOLOGY, V74, P43, DOI 10.1097/00000542-199101000-00008; Chassard D, 1996, BRIT J ANAESTH, V77, P458, DOI 10.1093/bja/77.4.458; Claes B, 1998, REGION ANESTH PAIN M, V23, P540, DOI 10.1016/S1098-7339(98)90078-5; COOPER DW, 1993, BRIT J ANAESTH, V70, P503, DOI 10.1093/bja/70.5.503; Cucchiaro G, 2006, ANESTH ANALG, V102, P1376, DOI 10.1213/01.ane.0000204251.36881.80; Cucchiaro G, 2003, PAEDIATR ANAESTH, V13, P318, DOI 10.1046/j.1460-9592.2003.01010.x; Curatolo M, 2000, ANESTHESIOLOGY, V92, P325, DOI 10.1097/00000542-200002000-00012; De Kock M, 1999, ANESTHESIOLOGY, V90, P1354, DOI 10.1097/00000542-199905000-00020; De Negri P, 2001, ANESTH ANALG, V93, P71; DeKock M, 1997, ANESTHESIOLOGY, V86, P285, DOI 10.1097/00000542-199702000-00003; Dobrydnjov I, 2005, ACTA ANAESTH SCAND, V49, P538, DOI 10.1111/j.1399-6576.2005.00638.x; Eberhart LHJ, 2002, BRIT J ANAESTH, V89, P760, DOI 10.1093/bja/aef261; EISENACH JC, 1995, PAIN, V61, P391, DOI 10.1016/0304-3959(94)00209-W; Gan TJ, 2001, ANESTH ANALG, V92, P393, DOI 10.1213/00000539-200102000-00022; Gedney JA, 1998, ANAESTHESIA, V53, P1148, DOI 10.1046/j.1365-2044.1998.00636.x; Kizilarslan S, 2000, EUR J ANAESTH, V17, P692, DOI 10.1046/j.1365-2346.2000.00740.x; Klamt JG, 2003, J CLIN ANESTH, V15, P510, DOI 10.1016/j.jclinane.2003.02.005; Macario A, 1999, ANESTH ANALG, V88, P1085, DOI 10.1097/00000539-199905000-00023; Nuss D, 1998, J PEDIATR SURG, V33, P545, DOI 10.1016/S0022-3468(98)90314-1; Ozalp G, 1998, CAN J ANAESTH, V45, P938; Paech MJ, 1997, ANESTH ANALG, V84, P1323, DOI 10.1097/00000539-199706000-00027; RAVITCH MM, 1958, SURG GYNECOL OBSTET, V106, P618; ROCKEMANN MG, 1995, ANESTH ANALG, V80, P869, DOI 10.1097/00000539-199505000-00003; Roelants F, 2005, ANESTHESIOLOGY, V102, P1205, DOI 10.1097/00000542-200506000-00021; Sjostrom S, 1998, ACTA ANAESTH SCAND, V42, P776, DOI 10.1111/j.1399-6576.1998.tb05321.x	25	28	29	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	AUG	2006	103	2					322	327		10.1213/01.ane.0000221047.68114.ad			6	Anesthesiology	Anesthesiology	065SA	WOS:000239178400013	16861412				2020-06-30	J	Thomasy, SM; Steffey, EP; Mama, KR; Solano, A; Stanley, SD				Thomasy, S. M.; Steffey, E. P.; Mama, K. R.; Solano, A.; Stanley, S. D.			The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetics volatile; isoflurane; analgesics opioid; fentanyl; MAC; horse; potency; anaesthetic	HALOTHANE; ANESTHESIA; DOGS; ALFENTANIL; ENFLURANE	Background. Fentanyl decreases the minimum alveolar concentration (MAC) of inhaled anaesthetics and has been used clinically to reduce the requirements of other anaesthetic drugs in humans and small animals. We hypothesized that i.v. fentanyl would decrease the MAC of isoflurane in horses in a dose-dependent manner. Methods. Following determination of baseline MAC of isoflurane, fentanyl was administered i.v. to target plasma concentrations of 1, 8 and 16 ng ml(-1). Each horse was randomly assigned two of three target concentrations administered in ascending order. Loading and infusion doses for each horse were determined from previously derived individual pharmacokinetic values. Isoflurane MAC determination began 45 min after fentanyl administration at each target fentanyl concentration. Venous blood was collected at fixed intervals during the infusion for measurement of plasma fentanyl concentrations. Results. Mean actual fentanyl plasma concentrations were 0 (baseline), and 0.72 (SD 0.26), 8.43 (3.22), and 13.31 (6.66) ng ml(-1) for the target concentrations of 1, 8 and 16 ng ml(-1), respectively. The corresponding isoflurane MAC values were a baseline of 1.57 (0.23), and 1.51 (0.24), 1.41 (0.23) and 1.37 (0.09)%, respectively. The fentanyl concentrations of 0.72 and 8.43 ng ml(-1) did not significantly alter the MAC of isoflurane, but an 18 (7)% ISO-MAC reduction was observed at the 13.31 ng ml(-1) concentration. Conclusions. These results cautiously encourage further study of fentanyl as an opioid anaesthetic adjunct to inhalant anaesthesia in horses.	Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA; Univ Calif Davis, KL Maddy Equiner Analyt Chem Lab, Calif Anim Hlth & Food Safety Lab, Davis, CA 95616 USA; Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Clin Sci, Ft Collins, CO 80523 USA	Steffey, EP (reprint author), Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA.	epsteffey@ucdavis.edu					EISELE JH, 1967, ANESTHESIOLOGY, V28, P856, DOI 10.1097/00000542-196709000-00019; Hellyer PW, 2001, AM J VET RES, V62, P555, DOI 10.2460/ajvr.2001.62.555; ILKIW JE, 1994, CAN J VET RES, V58, P248; Ilkiw JE, 1999, CLIN TECH SMALL AN P, V14, P27, DOI 10.1016/S1096-2867(99)80024-3; Johnson CB, 1997, RES VET SCI, V62, P159, DOI 10.1016/S0034-5288(97)90139-9; KAMERLING SG, 1985, GEN PHARMACOL, V16, P253, DOI 10.1016/0306-3623(85)90078-3; LEHMANN K A, 1988, Acta Anaesthesiologica Belgica, V39, P11; Maxwell LK, 2003, EQUINE VET J, V35, P484, DOI 10.2746/042516403775600415; MCEWAN AI, 1993, ANESTHESIOLOGY, V78, P864, DOI 10.1097/00000542-199305000-00009; MOON PF, 1995, ANESTHESIOLOGY, V83, P535, DOI 10.1097/00000542-199509000-00012; PASCOE PJ, 1993, AM J VET RES, V54, P1327; STEFFEY EP, 1987, J VET PHARMACOL THER, V10, P290, DOI 10.1111/j.1365-2885.1987.tb00104.x; STEFFEY EP, 1987, AM J VET RES, V48, P7; STEFFEY EP, 1980, AM J VET RES, V41, P821; STEFFEY EP, 1977, AM J VET RES, V38, P1037; STEFFEY EP, 1974, ANESTHESIOLOGY, V41, P392, DOI 10.1097/00000542-197410000-00017; Steffey EP, 2003, AM J VET RES, V64, P166, DOI 10.2460/ajvr.2003.64.166; Thomasy SM, 2004, J VET INTERN MED, V18, P550, DOI 10.1892/0891-6640(2004)18&lt;550:TFCWNA&gt;2.0.CO;2; THOMASY SM, 2006, UNPUB EQUINE VET J; WHITEHAIR KJ, 1993, AM J VET RES, V54, P1693	20	34	35	1	7	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	AUG	2006	97	2					232	237		10.1093/bja/ael116			6	Anesthesiology	Anesthesiology	070EK	WOS:000239502900019	16720675	Bronze			2020-06-30	J	Davies, AN				Davies, Andrew N.			Cancer-related breakthrough pain	BRITISH JOURNAL OF HOSPITAL MEDICINE			English	Article							ORAL TRANSMUCOSAL FENTANYL; INCIDENT PAIN; DOSE-TITRATION; CITRATE; MANAGEMENT; MORPHINE; MULTICENTER; PREVALENCE; TRIAL	Breakthrough pain is a common problem in patients with cancer, and is associated with significant morbidity among this group of patients. This review examines the different types of breakthrough pain, and the various options for the management of breakthrough pain.	Royal Marsden Hosp, Sutton SM2 5PT, Surrey, England	Davies, AN (reprint author), Royal Marsden Hosp, Downs Rd, Sutton SM2 5PT, Surrey, England.						Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Davies AN, 1997, J PALLIATIVE CARE, V13, P50, DOI 10.1177/082585979701300210; del Rosario MAB, 2001, J PAIN SYMPTOM MANAG, V21, P439, DOI 10.1016/S0885-3924(01)00254-8; Enting RH, 2005, J PAIN SYMPTOM MANAG, V29, P213, DOI 10.1016/j.jpainsymman.2004.05.010; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136; Gardner-Nix J, 2001, J PAIN SYMPTOM MANAG, V22, P627, DOI 10.1016/S0885-3924(01)00321-9; Hanks G., 2001, EUR J PALLIAT CARE, V8, P6; Hanks GW, 2004, PALLIATIVE MED, V18, P698, DOI 10.1191/0269216304pm966oa; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V28, P505, DOI 10.1016/j.jpainsymman.2004.02.024; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V27, P352, DOI 10.1016/j.jpainsymman.2003.09.006; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Parlow JL, 2005, PALLIATIVE MED, V19, P3, DOI 10.1191/0269216305pm958oa; Pavis H, 2002, J PAIN SYMPTOM MANAG, V24, P598, DOI 10.1016/S0885-3924(02)00522-5; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 2004, OXFORD TXB PALLIATIV, P438; Simmonds MA, 1999, ONCOLOGY-NY, V13, P1103; Sloman R, 1994, Contemp Nurse, V3, P6; TWYCROSS R, 1998, PALLIATIVE CARE FORM; TWYCROSS RG, 1978, MANAGEMENT TERMINAL; World Health Organization, 1996, CANC PAIN REL; Zeppetella G, 2000, PALLIATIVE MED, V14, P57, DOI 10.1191/026921600668793500; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5	26	10	12	0	1	MA HEALTHCARE LTD	LONDON	ST JUDES CHURCH, DULWICH ROAD, LONDON SE24 0PB, ENGLAND	1462-3935			BRIT J HOSP MED	Br. J. Hosp. Med.	AUG	2006	67	8					414	416		10.12968/hmed.2006.67.8.21960			3	Medicine, General & Internal	General & Internal Medicine	073DQ	WOS:000239723400006	16918095				2020-06-30	J	Oshima, T; Kasuya, Y; Okumura, Y; Murakami, T; Dohi, S				Oshima, Tsutomu; Kasuya, Yoshiko; Okumura, Yasuhisa; Murakami, Tatsuo; Dohi, Shuji			Identification of independent risk factors for fentanyl-induced cough	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							REFLEX SENSITIVITY; INHALED CAPSAICIN; BRONCHOCONSTRICTION; BOLUS; HUMANS	Purpose: To determine how the probability of fentanyl-induced cough is affected by patient characteristics and/or anesthetic technique. Methods: We analyzed data from a cohort of 1,311 adult patients undergoing elective surgery under general anesthesia, accompanied by iv fentanyl. The following data were collected: patient demographics, history of cigarette smoking, presence of bronchial asthma or chronic obstructive pulmonary disease, administration of angiotensin converting enzyme inhibitors; and anesthetic technique, including: preanesthetic anxiolytic medication, prior use of atropine, epidural lidocaine, a priming dose of vecuronium, and the dose of iv fentanyl. Associations between individual variables in the clinical evaluation model and the likelihood of fentanyl-induced cough were characterized by calculating odds ratios. Multiple logistic regression analysis was used to examine the independent contribution of each variable while controlling for all variables. Results: Fentanyl-induced cough was independently associated with the following: aging, cigarette smoking, a prior epidural injection of lidocaine, and a priming dose of vecuronium. Fentanyl-induced cough was unaffected by gender, the presence of either bronchial asthma or chronic obstructive pulmonary disease, or prior use of atropine. Conclusions: Fentanyl-induced cough may be suppressed by aging, cigarette smoking, prior epidural injection of lidocaine, or a priming dose of vecuronium. These findings may allow insights into the mechanism of this phenomenon, thereby leading to its prevention.	Gifu Univ, Sch Med, Dept Anesthesia, Gifu 500, Japan	Oshima, T (reprint author), Teikyo Univ, Sch Med, Ichihara Hosp, Dept Anesthesia, 3426-3 Anesaki, Chiba 2990111, Japan.	oshimat@med.teikyo-u.ac.jp					Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; BICKERMAN HA, 1954, AM J MED SCI, V228, P156, DOI 10.1097/00000441-195408000-00005; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; CHRISTENSEN V, 1978, ACTA ANAESTH SCAND, P84; Dicpinigaitis PV, 2003, CHEST, V123, P685, DOI 10.1378/chest.123.3.685; Dicpinigaitis PV, 1999, AM J RESP CRIT CARE, V159, P1660, DOI 10.1164/ajrccm.159.5.9810060; DIEPINIGAITIS PV, 1998, CHEST, V113, P1319; Doherty MJ, 2000, THORAX, V55, P643, DOI 10.1136/thorax.55.8.643; Fujimura M, 1996, EUR RESPIR J, V9, P1624, DOI 10.1183/09031936.96.09081624; FULLER RW, 1985, J APPL PHYSIOL, V58, P1080; Irwin RS, 2002, AM J RESP CRIT CARE, V165, P1469, DOI 10.1164/rccm.2110097; ISRAILI ZH, 1992, ANN INTERN MED, V117, P234, DOI 10.7326/0003-4819-117-3-234; KARLSSON JA, 1988, J APPL PHYSIOL, V65, P1007; OCONNELL F, 1994, J APPL PHYSIOL, V76, P1082; Pandey CK, 2004, ANESTH ANALG, V99, P1696, DOI 10.1213/01.ANE.0000136967.82197.82; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; PONTOPPIDAN H, 1960, JAMA-J AM MED ASSOC, V174, P2209, DOI 10.1001/jama.1960.03030180029007; SHEPPARD D, 1983, AM REV RESPIR DIS, V127, P691; Tweed WA, 2001, ANESTH ANALG, V92, P1442; WIDDICOMBE JG, 1995, EUR RESPIR J, V8, P1193, DOI 10.1183/09031936.95.08071193	20	23	35	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	AUG	2006	53	8					753	758		10.1007/BF03022790			6	Anesthesiology	Anesthesiology	069LI	WOS:000239447600003	16873340	Bronze			2020-06-30	J	Kjaer, M; Comerford, M; Kondilis, L; DiMaria, L; Abramovitz, S; Kiselev, M; Samuels, J; Gadalla, F; Leighton, BL				Kjaer, Maus; Comerford, Michele; Kondilis, Linda; DiMaria, Lauren; Abramovitz, Sharon; Kiselev, Michael; Samuels, Jon; Gadalla, Farida; Leighton, Barbara L.			Oral sodium citrate increases nausea amongst elective cesarean delivery patients	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							SPINAL-ANESTHESIA; SECTION; PREVENTION; METOCLOPRAMIDE; HYPOTENSION; FAMOTIDINE; DEATHS; TRIAL	Purpose: Historically, aspiration of gastric contents with subsequent pneumonia was a major cause of anesthesia-related maternal mortality. Before elective Cesarean delivery gastric fluid can be neutralized with histamine-2 blockers or with oral sodium citrate. Although sodium citrate is commonly used, many patients dislike its taste. We designed this study to determine whether or not patients are more likely to experience nausea during Cesarean delivery when sodium citrate is administered preoperatively. Methods: One hundred and twenty-three healthy women carrying a singleton fetus and scheduled for elective Cesarean delivery under spinal anesthesia were randomized to receive either sodium citrate 30 mL po and saline 2 mL iv (sodium citrate group), or water 30 mL po and famotidine 20 mg iv (famotidine group). Spinal anesthesia consisted of 1.6 mL of 0.75% bupivacaine (12 mg), fentanyl 20 mu g, and preservative-free. morphine 200 mu g. Patients were asked to rate the degree of nausea present at one and five minutes after spinal placement, at the time of uterine exteriorization, and upon arrival to the recovery room. At each time point, the patient's systolic blood pressure and heart rate were recorded. Results: At all recorded intervals, the average degree of nausea was greater in the sodium citrate group compared to the famotidine group. The frequency of nausea was also greater in the sodium citrate group compared with the famotidine group (37% vs 14% respectively, P < 0.05) five minutes after establishment of spinal anesthesia. The frequencies of nausea were not significantly different between groups at other time periods. Conclusion: Nausea is more common during Cesarean delivery in women who receive oral sodium citrate rather than iv famotidine for aspiration prophylaxis.	Cornell Univ, Weill Med Coll, Dept Anesthesiol, New York, NY 10021 USA	Kjaer, M (reprint author), Cornell Univ, Weill Med Coll, Dept Anesthesiol, 525 E 68th St,M-325, New York, NY 10021 USA.	kkjaer@hotmail.com		Samuels, Jon/0000-0002-7040-1366			Cooper GM, 2005, BRIT J ANAESTH, V94, P417, DOI 10.1093/bja/aei066; DEWAN DM, 1985, ANESTH ANALG, V64, P34; Dindelli M, 1991, Ann Ostet Ginecol Med Perinat, V112, P376; Doi H, 1991, J Anesth, V5, P276, DOI 10.1007/s0054010050276; Elhakim M, 2005, BRIT J ANAESTH, V95, P811, DOI 10.1093/bja/aei260; Fujii Y, 1998, ACTA ANAESTH SCAND, V42, P921, DOI 10.1111/j.1399-6576.1998.tb05350.x; Garry M, 2002, INT J OBSTET ANESTH, V11, P9, DOI 10.1054/ijoa.2001.0903; Hagberg C, 2001, ISRAEL MED ASSOC J, V3, P653; Hawkins JL, 1997, ANESTHESIOLOGY, V86, P277, DOI 10.1097/00000542-199702000-00002; James LP, 1998, J CLIN PHARMACOL, V38, P1089; Lin C J, 1996, Acta Anaesthesiol Sin, V34, P179; Orenstein SR, 2003, ALIMENT PHARM THER, V17, P1097, DOI 10.1046/j.1365-2036.2003.01559.x; Palmer A W, 1991, Nurse Anesth, V2, P126; RILEY ET, 1995, ANESTH ANALG, V81, P838, DOI 10.1097/00000539-199510000-00031; ROUT CC, 1993, ANESTHESIOLOGY, V79, P262, DOI 10.1097/00000542-199308000-00011; Schneck H, 1999, ANESTH ANALG, V88, P63, DOI 10.1097/00000539-199901000-00012; Stein DJ, 1997, ANESTH ANALG, V84, P342, DOI 10.1097/00000539-199702000-00018; Wong CA, 2002, ANESTHESIOLOGY, V96, P1395, DOI 10.1097/00000542-200206000-00019	18	5	5	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	AUG	2006	53	8					776	780		10.1007/BF03022794			5	Anesthesiology	Anesthesiology	069LI	WOS:000239447600007	16873344	Bronze			2020-06-30	J	Sittl, R; Nuijten, M; Nautrup, BP				Sittl, Reinhard; Nuijten, Mark; Nautrup, Barbara Poulsen			Patterns of dosage changes with transidermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: A retrospective data analysis in Germany	CLINICAL THERAPEUTICS			English	Article						cancer pain; noncancer pain; transdermal; buprenorphine; fentanyl; tolerance; dosage stability	LONG-TERM MANAGEMENT; OPIOID TOLERANCE; ROTATION; COHORT	Background: Previous studies have suggested that buprenorphine may have a low association with tolerance development compared with other strong opioids. In a previous study by our group, mean cohort and intraindividual dosage increases over an entire course of treatment and on a per-day basis were significantly lower with transdermal (TD) buprenorphine than with TD fentanyl. However, no information concerning the relationship between qualitative and quantitative dose changes is available. Objective: The aim of this study was to compare TD buprenorphine and TD fentanyl with respect to dosage increases, dosage stability, and the nature of dosage changes. Methods: This retrospective analysis used data from the IMS Disease Analyzer-Mediplus database, which contains patient-related data documented by 400 medical practices in Germany. Data from patients with noncancer or cancer Pain treated with TD buprenorphine or TD fentanyl for at least 3 months between May 2002 and April 2005 were analyzed. Daily dosages were directly determined from the prescribed patch strength, taking into account the possibility of multiple patches applied simultaneously. To determine dosage stability, patients were classified based on the type of dosage change (stable, increase, alternating, or decrease) of the prescribed dosages. From the prescribed daily dosages, mean percentage increases were calculated on a per-patient basis for the entire treatment period and per day, and these were assessed in relation to the type of dosage change. Results: In total, 631 patients with noncancer pain and 605 patients with cancer pain were included in the analysis (782 women, 454 men; mean age, 76.3 years [range, 29-100 years]). Treatment Indications included osteoarthritis, low back pain, osteoporosis (noncancer groups), and neoplasm (cancer groups). Patients had similar analgesic premedication requirements based on steps 1 to 3 of the World Health Organization analgesic ladder. Comedication requirements for breakthrough pain were also similar between the TD buprenorphine and TD fentanyl groups. The mean percentage increases per day were 0.10% (TD buprenorphine) and 0.25% (TD fentanyl) in the noncancer groups and 0.19% (TD buprenorphine) and 0.47% (TD fentanyl) in the cancer groups (both, P < 0.05). A significantly larger proportion of patients receiving TD buprenorphine had stable dosages over the entire treatment period compared with patients receiving TD fentanyl (noncancer groups: 56.9% vs 41.6%; cancer groups: 50.0% vs 26.2% [both, P < 0.05]). Compared with TD buprenorphine, the proportion of patients with alternating dosage changes was significantly greater in patients receiving TD fentanyl (noncancer groups: 22.7% vs 13.1%; cancer groups: 30.6% vs 11.8% [both, P < 0.05]). Conclusions: In this retrospective data analysis, compared with TD buprenorphine, the increase in mean daily dosage was significantly greater in patients treated with TD fentanyl. Also, compared with TD buprenorphine, alternating dosage changes were seen in a significantly greater proportion of patients receiving TD fentanyl. On the other hand, a significantly greater proportion of patients treated with TD buprenorphine had stable dosages over their entire treatment periods.	Grunenthal GmbH, D-52099 Aachen, Germany; Univ Erlangen Nurnberg, Pain Clin, Erlangen, Germany; Erasmus Univ, Rotterdam, Netherlands	Nautrup, BP (reprint author), Grunenthal GmbH, D-52099 Aachen, Germany.	barbara.poulsen-nautrup@grunenthal.com					Ackerman Stacey J, 2003, J Manag Care Pharm, V9, P223; ARMITAGE P, 1994, STAT METHODS MED RES; Buntin-Mushock C, 2005, ANESTH ANALG, V100, P1740, DOI 10.1213/01.ANE.0000152191.29311.9B; Davies J, 2000, Int J Palliat Nurs, V6, P162; Dietlein G, 2002, INT J CLIN PHARM TH, V40, P130; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; *EUR AG EV MED PRO, 2002, INT C HARM WHO GUID; *EUR PHAR MARK RES, 2004, AN CLASS SYST; Gasquet I, 2005, PHARMACOEPIDEM DR S, V14, P805, DOI 10.1002/pds.1122; Griessinger N, 2005, CURR MED RES OPIN, V21, P1147, DOI 10.1185/030079905X53315; *GRUN GMBH, 2003, TRANST TRANSD BUPR P; *JANSS PHARM INC, 2001, DUR TRANSD FENT PACK; Kieffer BL, 2002, CELL, V108, P587, DOI 10.1016/S0092-8674(02)00666-9; Koppert W, 2005, PAIN, V118, P15, DOI 10.1016/j.pain.2005.06.030; Korte W, 1996, J PAIN SYMPTOM MANAG, V11, P139, DOI 10.1016/0885-3924(95)00162-X; Likar R, 2006, CLIN THER, V28, P943, DOI 10.1016/j.clinthera.2006.06.012; Maier C, 2005, SCHMERZ, V19, P410, DOI 10.1007/s00482-005-0432-9; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; Mercadante S, 2006, EUR J PAIN, V10, P153, DOI 10.1016/j.ejpain.2005.02.006; Milligan K, 2001, J PAIN, V2, P197, DOI 10.1054/jpai.2001.25352; Moryl N, 2002, PAIN, V96, P325, DOI 10.1016/S0304-3959(01)00465-1; Motheral B, 2003, VALUE HEALTH, V6, P90, DOI 10.1046/j.1524-4733.2003.00242.x; Mystakidou K, 2003, INT J CANCER, V107, P486, DOI 10.1002/ijc.11416; Mystakidou K, 2003, J PAIN, V4, P298, DOI 10.1016/S1526-5900(03)00632-1; Radbruch L, 2001, PALLIATIVE MED, V15, P309, DOI 10.1191/026921601678320296; Sittl R, 2005, CLIN THER, V27, P1022, DOI 10.1016/j.clinthera.2005.06.024; Sittl R, 2005, CLIN THER, V27, P225, DOI 10.1016/j.clinthera.2005.02.012; World Health Organization, 2004, INT STAT CLASSIFICAT; World Health Organization, 1990, CANC PAIN REL PALL C; Zaki PA, 2000, J PHARMACOL EXP THER, V292, P1127; ZENZ M, 1992, J PAIN SYMPTOM MANAG, V7, P69, DOI 10.1016/0885-3924(92)90116-Y; Zuo ZY, 2005, ANESTH ANALG, V101, P728, DOI 10.1213/01.ANE.0000160588.32007.AD	32	20	22	1	3	ELSEVIER	BRIDGEWATER	685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA	0149-2918			CLIN THER	Clin. Ther.	AUG	2006	28	8					1144	1154		10.1016/j.clinthera.2006.08.002			11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	084GP	WOS:000240521000007	16982291				2020-06-30	J	Otis, J; Rothman, M				Otis, James; Rothman, Margaret			A Phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic non-malignant pain	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						duragesic; fentanyl; opioid; pain; transdermal	RELEASE ORAL MORPHINE; EFFICACY; MANAGEMENT; TRIAL	Background: The transdermal fentanyl delivery system (fentanyl TTS; Duragesic) is currently widely available in patch strengths of 25, 50, 75, and 100 mu g/h. However, a lower dose of 12 mu g/h would allow optimal titration and fine tuning of the analgesic effect, and may be beneficial in certain patient populations such as the elderly or opioid-naive. A 12 mu g/h fentanyl TTS patch has been developed, and the clinical efficacy and safety tested in this single-arm, non-randomized, open-label, multicenter, 28-day trial in opioid-exposed and -naive patients with moderate to severe pain for at least 6 months. Patients: Patients were treated with fentanyl TTS for 28 days in an intent-to-treat manner starting at 12 mu g/h (one patch), titrated upwards in increments of 12 mu g/h to a maximum dose of 36 mu g/h (three patches). Results: A total of 227 patients were enrolled. The majority of patients with a 'global assessment of therapy' of fair/poor at baseline (63.4%) improved to good/very good, while 28.9% of patients with an assessment of good/very good at baseline worsened to fair/poor at endpoint. The average pain intensity levels for the efficacy evaluable population steadily decreased over the course of the trial. The adverse event (AE) profile of fentanyl TTS in this trial was generally similar to that identified in previous fentanyl TTS trials, and no unexpected safety issues or AEs were noted. Furthermore, the drop-out rate in this trial was lower than has been noted in previous trials. Conclusion: This trial demonstrated that the lower 12 mu g/h dose of fentanyl TTS provided a therapeutic benefit in non-malignant chronic pain, with a similar AE rate but a lower drop-out rate than that seen in trials at higher doses. This lower dose may, therefore, be of particular benefit to elderly or opioid-naive patients.	BUMC, Pain Management Grp, Dept Neurol, Boston, MA 02118 USA; Johnson & Johnson Pharmaceut Serv LLC, Raritan, NJ 08869 USA	Otis, J (reprint author), BUMC, Pain Management Grp, Dept Neurol, 715 Albany St C3, Boston, MA 02118 USA.	James.Otis@bmc.org					Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Andrews C, 1983, CLIN ANAESTHESIOL, V1, P97; MIGUEL R, 1995, ANESTHESIOLOGY, V83, P470, DOI 10.1097/00000542-199509000-00005; Milligan K, 2001, J PAIN, V2, P197, DOI 10.1054/jpai.2001.25352; Pavelka K, 2004, CURR MED RES OPIN, V20, P1967, DOI 10.1185/030079904X14120; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; SOUTHAM MA, 1995, ANTI-CANCER DRUG, V6, P29, DOI 10.1097/00001813-199504003-00005; TARVER SD, 1990, ADV ANESTHESIA, V7, P337; Woodroffe MA, 1997, CAN FAM PHYSICIAN, V43, P268	10	11	14	0	1	LIBRAPHARM	NEWBURY	29-35  VENTURE WEST, NEW GREENHAM PARK, NEWBURY RG19 6HX, BERKSHIRE, ENGLAND	0300-7995			CURR MED RES OPIN	Curr. Med. Res. Opin.	AUG	2006	22	8					1493	1501		10.1185/030079906X115540			9	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	068EW	WOS:000239356300007	16870074				2020-06-30	J	Hernandez-Gancedo, C; Pestana, D; Pena, N; Royo, C; Perez-Chrzanowska, H; Criado, A				Hernandez-Gancedo, C.; Pestana, D.; Pena, N.; Royo, C.; Perez-Chrzanowska, H.; Criado, A.			Monitoring sedation in critically ill patients: bispectral index, Ramsay and observer scales	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						intensive care; sedation, propofol, miclazolam, fentanyl; monitoring, bispectral index, sedation scoring	INTENSIVE-CARE-UNIT; MECHANICAL VENTILATION; ICU PATIENTS; MIDAZOLAM; PROPOFOL; ALFENTANIL; ANESTHESIA; DEPTH	Background and objective: Sedation is commonly required by critically ill patients and inadequate sedation may be hazardous. Traditionally, subjective scales have been used for monitoring sedation. Bispectral index has been proposed, although its utility in the intensive care unit is debated. Our aim was to evaluate the depth of sedation in intubated surgical critically ill patients by means of two sedation scales (Ramsay and Observer's Assessment of Alertness and Sedation) and bispectral index. Methods: Sedation was assessed prospectively in 50 postoperative intubated patients requiring at least 24 h of sedation (35 propofol, 15 midazolam/fentanyl), every 8 h for a 24-h period. The bispectral index value recorded was the mean value obtained during a 10-min observation period, whenever the quality signal index was above 7 5 916 and the electromyographic signal was below 25%. Results: Most of the patients (78%) were oversedated (bispectral index < 60). The three sedation scores (global data) correlated significantly (P < 0.001). This correlation was lost in the midazolam group in which the patients were also significantly more sedated than the propofol group (P = 0.001). The correlation between the bispectral index and the scales in the midazolam group reappeared when the measurements with a Ramsay = 6 or an Observer's Assessment of Alertness and Sedation = 1 were excluded. Conclusions: Sedation should be monitored routinely in intensive care units. The Ramsay and the Observer's Assessment of Alertness and Sedation scales showed equal efficacy. Bispectral index might prove useful for discriminating between deeper levels of sedation.	Univ Madrid, Hosp La Paz, Serv Anestesia Reanimac, Residencia Gen, Madrid 28046, Spain	Hernandez-Gancedo, C (reprint author), Univ Madrid, Hosp La Paz, Serv Anestesia Reanimac, Residencia Gen, Paseo Castellana 261, Madrid 28046, Spain.	mhgancedo@hotmail.com		CRIADO PORTAL, ANTONIO JOSE/0000-0002-5292-4155			Andrzejowski J, 2000, ANAESTHESIA, V55, P761, DOI 10.1046/j.1365-2044.2000.01532.x; AVRAMOV MN, 1995, CRIT CARE CLIN, V11, P802; Bailey JM, 2001, ANESTHESIOLOGY, V95, P281, DOI 10.1097/00000542-200108000-00005; Barr J, 2001, ANESTHESIOLOGY, V95, P286, DOI 10.1097/00000542-200108000-00007; Brocas E, 2002, INTENS CARE MED, V28, P211, DOI 10.1007/s00134-001-1189-y; Bruhn J, 2000, ANESTHESIOLOGY, V92, P1485, DOI 10.1097/00000542-200005000-00042; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; De Jonghe B, 2000, INTENS CARE MED, V26, P275, DOI 10.1007/s001340051150; Frenzel D, 2002, INTENS CARE MED, V28, P178, DOI 10.1007/s00134-001-1183-4; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; HANSENFLASCHEN J, 1994, CRIT CARE MED, V22, P732; Hirota K, 1999, EUR J ANAESTH, V16, P779; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Liu J, 1996, ANESTHESIOLOGY, V84, P64, DOI 10.1097/00000542-199601000-00007; Liu J, 1997, ANESTH ANALG, V84, P185, DOI 10.1097/00000539-199701000-00033; MEYER TJ, 1994, CHEST, V105, P1211, DOI 10.1378/chest.105.4.1211; Nasraway SA, 2002, CRIT CARE MED, V30, P1483, DOI 10.1097/00003246-200207000-00014; Ostermann ME, 2000, JAMA-J AM MED ASSOC, V283, P1451, DOI 10.1001/jama.283.11.1451; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Rello J, 1999, AM J RESP CRIT CARE, V159, P1742, DOI 10.1164/ajrccm.159.6.9808030; Sebel PS, 1997, ANESTH ANALG, V84, P891, DOI 10.1097/00000539-199704000-00035; Simmons LE, 1999, CRIT CARE MED, V27, P1499, DOI 10.1097/00003246-199908000-00016; Soliman HM, 2001, BRIT J ANAESTH, V87, P186, DOI 10.1093/bja/87.2.186; Sydow M, 1999, INTENS CARE MED, V25, P634, DOI 10.1007/s001340050917; Young C, 2000, CRIT CARE MED, V28, P854, DOI 10.1097/00003246-200003000-00041	27	29	30	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	AUG	2006	23	8					649	653		10.1017/S0265021506000056			5	Anesthesiology	Anesthesiology	068UV	WOS:000239400900003	16438768				2020-06-30	J	Hura, G; Knapik, P; Misiolek, H; Krakus, A; Karpe, J				Hura, G.; Knapik, P.; Misiolek, H.; Krakus, A.; Karpe, J.			Sensory blockade after thoracic paravertebral injection of ropivacaine or bupivacaine	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthetics local, ropivacaine, bupivacaine; anaesthesia conduction, nerve block, paravertebral; surgical procedures, operative, mastectomy	0.5-PERCENT ROPIVACAINE; BREAST-CANCER; SURGICAL-MANAGEMENT; GENERAL-ANESTHESIA; 0.75-PERCENT	Background and objective: No clinical trials comparing the characteristics of sensory blockade caused by various local anaesthetics in thoracic paravertebral blockade have been published. The aim of this prospective study was a clinical assessment of sensory blockade after paravertebral injection of ropivacaine or bupivacaine in patients undergoing modified radical mastectomy. Methods: Seventy ASA I-II patients were randomized to receive a single injection of ropivacaine 0.5% (n = 35) or bupivacaine 0.5% (n = 35) at the T4 level. General anaesthesia with propofol and fentanyl was provided during the procedure and patients were not intubated. The following parameters were analysed: duration and dynamics of the sensory blockade and the patient's and surgeon's assessment. Results: Both ropivacaine and bupivacaine provided a similar level of analgesia. Ropivacaine was characterized by more rapid onset - after only 5 min 53% of patients in this group had the extent of sensory blockade wide enough to perform modified radical mastectomy in comparison to only 20% after bupivacaine (P < 0.01). The initial spread of sensory blockade (> 9 segments blocked) was noted more often in the ropivacaine group (88% vs. 65%, P < 0.05), lasted longer and appeared to be wider than sensory blockade produced by bupiva-Caine. Regression of sensory blockade was initially similar, but after 24 h sensory blockade in the ropivacaine group still had a potential to provide analgesia for modified radical mastectomy in 815 of patients in comparison to only 50% of such patients in the bupivacaine group (P < 0.05). Degree of postoperative pain, performance of the cardiovascular system, consumption of medications and complications were all similar between the study groups. Conclusions: Both agents provide satisfactory conditions for mastectomy, but ropivacaine seems to be superior to bupivacaine for thoracic paravertebral blockade during breast cancer surgery.	Ctr Oncol, Dept Anaesthesiol, Bielsko Biala, Poland; Med Univ Silesia, Clin Dept Anaesthesiol, Zabrze, Poland	Hura, G (reprint author), Ejdervej 15, DK-6400 Sonderborg, Denmark.	ghura@wp.pl		Knapik, Piotr/0000-0002-1058-1502			AKERMAN B, 1988, ACTA ANAESTH SCAND, V32, P571, DOI 10.1111/j.1399-6576.1988.tb02788.x; Bertini L, 1999, REGION ANESTH PAIN M, V24, P514, DOI 10.1016/S1098-7339(99)90041-X; Breivik EK, 2000, CLIN J PAIN, V16, P22, DOI 10.1097/00002508-200003000-00005; BROWN DL, 1990, ANESTHESIOLOGY, V72, P633, DOI 10.1097/00000542-199004000-00010; Buckenmaier CC, 2002, ACTA ANAESTH SCAND, V46, P1042, DOI 10.1034/j.1399-6576.2002.460820.x; Buckenmaier CC, 2002, CAN J ANAESTH, V49, P571, DOI 10.1007/BF03017383; Casati A, 2000, Minerva Anestesiol, V66, P39; Coveney E, 1998, ANN SURG, V227, P496, DOI 10.1097/00000658-199804000-00008; D'Ercole FJ, 1999, ANESTH ANALG, V88, P1351, DOI 10.1097/00000539-199906000-00029; EASON MJ, 1979, ANAESTHESIA, V34, P638, DOI 10.1111/j.1365-2044.1979.tb06363.x; Greengrass R, 1996, CAN J ANAESTH, V43, P858, DOI 10.1007/BF03013039; Greengrass Roy, 2002, Best Pract Res Clin Anaesthesiol, V16, P271, DOI 10.1053/bean.2002.0238; GRIFFIN RP, 1995, BRIT J ANAESTH, V74, P512, DOI 10.1093/bja/74.5.512; HICKEY R, 1991, ANESTHESIOLOGY, V74, P639, DOI 10.1097/00000542-199104000-00002; Karmakar MK, 2000, BRIT J ANAESTH, V84, P263; Karmakar MK, 2001, ANESTHESIOLOGY, V95, P771, DOI 10.1097/00000542-200109000-00033; Klein SM, 2000, ANESTH ANALG, V90, P1402, DOI 10.1097/00000539-200006000-00026; Klein SM, 1998, ANESTH ANALG, V87, P1316, DOI 10.1097/00000539-199812000-00019; McClellan KJ, 2000, DRUGS, V60, P1065, DOI 10.2165/00003495-200060050-00007; McGlade DP, 1998, ANAESTH INTENS CARE, V26, P515, DOI 10.1177/0310057X9802600507; Naguib M, 1998, DRUG SAFETY, V18, P221, DOI 10.2165/00002018-199818040-00001; Najarian MM, 2003, AM SURGEON, V69, P213; Pusch F, 1999, ACTA ANAESTH SCAND, V43, P770, DOI 10.1034/j.1399-6576.1999.430714.x; RICHARDSON J, 1995, ACTA ANAESTH SCAND, V39, P1005, DOI 10.1111/j.1399-6576.1995.tb04219.x; RICHARDSON J, 2001, HIGHLIGHTS REGIONAL, V10, P113; VAINIONPAA VA, 1995, ANESTH ANALG, V81, P534, DOI 10.1097/00000539-199509000-00019; Wang R D, 2001, Expert Opin Pharmacother, V2, P2051, DOI 10.1517/14656566.2.12.2051; WELTZ CR, 1995, ANN SURG, V222, P19, DOI 10.1097/00000658-199507000-00004	28	21	22	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	AUG	2006	23	8					658	664		10.1017/S0265021506000561			7	Anesthesiology	Anesthesiology	068UV	WOS:000239400900005	16805930				2020-06-30	J	Motamed, C; Merle, JC; Combes, X; Yakhou, L; Vodinh, J; Duvaldestin, P				Motamed, C.; Merle, J. C.; Combes, X.; Yakhou, L.; Vodinh, J.; Duvaldestin, P.			The effect of fentanyl and remifentanil, with or without ketoprofen, on pain after thyroid surgery: a randomized-controlled trial	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						surgery, thyroid; analgesics opioid, fentanyl, remifentanil; pain, postoperative; anti-inflammatory agents; non-steroidal; ketoprofen	ACUTE OPIOID TOLERANCE; POSTOPERATIVE PAIN; INTRAOPERATIVE REMIFENTANIL; GENERAL-ANESTHESIA; ABDOMINAL-SURGERY; SUFENTANIL; MANAGEMENT; IBUPROFEN; RECOVERY; EFFICACY	Background and objectives: This study was designed to quantify the additional postoperative analgesic efficacy of a single dose of ketoprofen in patients undergoing thyroid surgery using two different intraoperative analgesic regimens. Methods: One hundred and twenty patients were randomly assigned to one of four groups: intraoperative fentanyl or remifentanil with or without ketoprofen (n = 30 for each group). Intravenous ketoprofen (1.5 mg kg(-1)) or saline was administered 45 min before the end of surgery. Pain scores, opiold demand and length of stay in the postanaesthesia care unit were assessed in a blinded manner. Results: Patients receiving intraoperative fentanyl with saline had significantly lower visual analogue scale pain scores in the postanaesthesia care unit compared with those receiving intruoperative remifentaril with saline (55 +/- 10 mm vs. 80 +/- 18 mm, P < 0.05) and they stayed shorter in the postanaesthesia care unit (86 +/- 24 min vs. 126 coproduct 37 min). In conjunction with intraoperative fentanyl, ketoprofen significantly decreased postoperative pain scores (40 +/- 10 mm, P < 0.05 compared with fentanyl alone) and opioid demand (4 of 30 patients vs. 14 of 30 patients compared with fentanyl alone, P < 0.05). Patients receiving intraoperative remifentanil had no additional analgesic benefit with ketoprofen. Conclusion: After thyroid surgery, patients receiving intraoperative fentanyl had lower pain scores and needed less rescue analgesia compared with patients receiving intraoperative remifentanil. The adjunction of ketoprofen further improved analgesia in patients who received intraoperative fentanyl only.	Univ Paris 12, Hop Henri Mondor, Serv Anesthesie Reanimat, AP HP, F-94010 Creteil, France	Motamed, C (reprint author), Inst Gustave Roussy, Serv Anesthesie, Rue Camille Desmoulins, F-94080 Villejuif, France.	motamed@igr.fr					Abbas S. M., 2004, JPMA Journal of the Pakistan Medical Association, V54, P319; Albrecht S, 1999, ANESTH ANALG, V89, pS40; Albrecht S, 2000, ANAESTHESIA, V55, P315, DOI 10.1046/j.1365-2044.2000.01122.x; Aunac S, 2002, ANESTH ANALG, V95, P746, DOI 10.1097/00000539-200209000-00039; Basto ER, 2001, ANESTH ANALG, V92, P1052; Beers RA, 2000, ANESTH ANALG, V91, P1420, DOI 10.1097/00000539-200012000-00022; Betancourt JW, 2004, J PERIODONTOL, V75, P872, DOI 10.1902/jop.2004.75.6.872; Burkle H, 1996, ANESTH ANALG, V83, P646, DOI 10.1097/00000539-199609000-00038; Cafiero T, 2004, Minerva Anestesiol, V70, P661; Casati A, 2000, ANESTH ANALG, V91, P1269, DOI 10.1097/00000539-200011000-00040; Cortinez LI, 2001, BRIT J ANAESTH, V87, P866, DOI 10.1093/bja/87.6.866; Damen SL, 2004, J LAPAROENDOSC ADV A, V14, P87, DOI 10.1089/109264204322973853; Davis PJ, 2000, ANESTH ANALG, V90, P863, DOI 10.1213/00000539-200004000-00017; Defechereux T, 1999, J ALTERN COMPLEM MED, V5, P509, DOI 10.1089/acm.1999.5.509; Defechereux T, 2000, ANN CHIR, V125, P539, DOI 10.1016/S0003-3944(00)00238-8; DERSHWITZ M, 1995, ANESTH ANALG, V81, P619, DOI 10.1097/00000539-199509000-00035; Dirks J, 2002, ANESTHESIOLOGY, V97, P1591, DOI 10.1097/00000542-200212000-00035; Doyle PW, 2001, EUR J ANAESTH, V18, P13, DOI 10.1046/j.1365-2346.2001.00763.x; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Guo ZY, 2003, CHINESE MED J-PEKING, V116, P1386; Hachenberg T, 2000, Anaesthesiol Reanim, V25, P144; Hiller A, 2004, ACTA ANAESTH SCAND, V48, P1185, DOI 10.1111/j.1399-6576.2004.00473.x; Karamanlioglu B, 2003, EUR J ANAESTH, V20, P490, DOI 10.1097/00003643-200306000-00013; Motamed C, 2004, BRIT J ANAESTH, V93, P306, DOI 10.1093/bja/aeh583; OWEN H, 1986, BRIT J ANAESTH, V58, P1371, DOI 10.1093/bja/58.12.1371; Shafer S L, 1998, Acta Anaesthesiol Belg, V49, P91; SUNSHINE A, 1993, CLIN PHARMACOL THER, V54, P546, DOI 10.1038/clpt.1993.187; Vach B, 2002, Rozhl Chir, V81, P519	28	4	5	0	3	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	AUG	2006	23	8					665	669		10.1017/S0265021506000391			5	Anesthesiology	Anesthesiology	068UV	WOS:000239400900006	16805931				2020-06-30	J	Schumacher, PM; Stadler, KS; Wirz, R; Leibundgut, D; Pfister, CA; Zbinden, AM				Schumacher, P. M.; Stadler, K. S.; Wirz, R.; Leibundgut, D.; Pfister, C. A.; Zbinden, A. M.			Model-based control of neuromuscular block using mivacurium: design and clinical verification	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthesia general; neuromuscular blockade, monitoring, automation, closed-loop; control; neuromuscular blocking agents; mivacurium; electromyography; computer simulation	LOOP FEEDBACK-CONTROL; CONTINUOUS-INFUSION; YOUNG-ADULT; PHARMACODYNAMICS; PHARMACOKINETICS; VECURONIUM; PHARMACOLOGY; PERFORMANCE; ATRACURIUM	Background. Short-acting agents for neuromuscular block (NMB) require frequent dosing adjustments for individual patient's needs. In this study, we verified a new closed-loop controller for mivacurium dosing in clinical trials. Methods: Fifteen patients were studied. T1% measured with electromyography was used as input signal for the model-based controller. After induction of propofol/opiate anaesthesia, stabilization of baseline electromyography signal was awaited and a bolus of 0.3 mg kg(-1) mivacurium was then administered to facilitate endotracheal intubation. Closed-loop infusion was started thereafter, targeting a neuromuscular block of 90%. Setpoint deviation, the number of manual interventions and surgeon's complaints were recorded. Drug use and its variability between and within patients were evaluated. Results: Median time of closed-loop control for the I 1 patients included in the data processing was 135 [89-336] min (median [range]). Four patients had to be excluded because of sensor problems. Mean absolute deviation from setpoint was 1.8 +/- 0.9 T1%. Neither manual interventions nor complaints from the surgeons were recorded. Mean necessary mivacurium infusion rate was 7.0 +/- 2.2 mu g kg(-1) min(-1). Intrapatient variability of mean infusion rates over 30-min interval showed high differences up to a factor of 1.8 between highest and lowest requirement in the same patient. Conclusions: Neuromuscular block can precisely be controlled with mivacurium using our model-based controller. The amount of mivacurium needed to maintain T1% at defined constant levels differed largely between and within patients. Closed-loop control seems therefore advantageous to automatically maintain neuromuscular block at constant levels.	Univ Hosp Bern, Dept Anesthesiol, CH-3010 Bern, Switzerland; Swiss Fed Inst Technol, Automat Control Lab, Zurich, Switzerland	Schumacher, PM (reprint author), Univ Hosp Bern, Dept Anesthesiol, CH-3010 Bern, Switzerland.	peter.schumacher@dkf.unibe.ch		Stadler, Konrad Shedden/0000-0003-0316-2657			ALI HH, 1988, BRIT J ANAESTH, V61, P541, DOI 10.1093/bja/61.5.541; Arbous MS, 2005, ANESTHESIOLOGY, V102, P257, DOI 10.1097/00000542-200502000-00005; BRANDOM BW, 1989, BRIT J ANAESTH, V62, P488, DOI 10.1093/bja/62.5.488; CALDWELL JE, 1995, INT ANESTHESIOL CLIN, V33, P39, DOI 10.1097/00004311-199500000-00003; COOK DR, 1992, BRIT J ANAESTH, V69, P580, DOI 10.1093/bja/69.6.580; DEMEY JC, 1995, ANAESTHESIA, V50, P947, DOI 10.1111/j.1365-2044.1995.tb05925.x; ERIKSSON LI, 1993, ANESTHESIOLOGY, V78, P693, DOI 10.1097/00000542-199304000-00012; Ezzine S, 2002, ANESTHESIOLOGY, V97, P622, DOI 10.1097/00000542-200209000-00016; Geldner G, 1999, ANAESTHESIST, V48, P157, DOI 10.1007/s001010050682; Kansanaho M, 1996, INT J CLIN MONIT COM, V13, P217, DOI 10.1023/A:1016956507342; LIEN CA, 1994, ANESTHESIOLOGY, V80, P1296, DOI 10.1097/00000542-199406000-00017; MADDINENI VR, 1994, BRIT J ANAESTH, V73, P608, DOI 10.1093/bja/73.5.608; MERETOJA OA, 1993, BRIT J ANAESTH, V71, P232, DOI 10.1093/bja/71.2.232; OLKKOLA KT, 1991, ACTA ANAESTH SCAND, V35, P420, DOI 10.1111/j.1399-6576.1991.tb03321.x; OLKKOLA KT, 1991, EUR J ANAESTH, V8, P7; Ostergaard D, 2002, ACTA ANAESTH SCAND, V46, P684, DOI 10.1034/j.1399-6576.2002.460609.x; Pellissier D, 1995, ANN FR ANESTH, V14, P467, DOI 10.1016/S0750-7658(05)80486-1; Powers D M, 1992, J Clin Anesth, V4, P123, DOI 10.1016/0952-8180(92)90028-Y; SAVARESE JJ, 1988, ANESTHESIOLOGY, V68, P723, DOI 10.1097/00000542-198805000-00010; SCHUMACHER PM, 2003, WORLD C MED PHYS BIO; STADLER KS, 2003, EUR CONTR C ECC; VARVEL JR, 1992, J PHARMACOKINET BIOP, V20, P63, DOI 10.1007/BF01143186; Viby-Mogensen J, 2000, ACTA ANAESTH SCAND, V44, P1169, DOI 10.1034/j.1399-6576.2000.441002.x; Viby-Mogensen J, 2000, BRIT J ANAESTH, V84, P301; Viby-Mongensen J, 2000, ANESTHESIA, P1351; VibyMogensen J, 1996, ACTA ANAESTH SCAND, V40, P59, DOI 10.1111/j.1399-6576.1996.tb04389.x	26	8	8	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	AUG	2006	23	8					691	699		10.1017/S0265021506000524			9	Anesthesiology	Anesthesiology	068UV	WOS:000239400900011	16805935				2020-06-30	J	Murphy, GS; Szokol, JW; Marymont, JH; Avram, MJ; Vender, JS				Murphy, Glenn S.; Szokol, Joseph W.; Marymont, Jesse H.; Avram, Michael J.; Vender, Jeffery S.			Opioids and cardioprotection: The impact of morphine and fentanyl on recovery of ventricular function after cardiopulmonary bypass	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						anesthetic preconditioning; morphine; fentanyl; myocardial performance index; cardioprotection	CORONARY-ARTERY-BYPASS; K-ATP CHANNELS; MYOCARDIAL PERFORMANCE INDEX; CARDIAC TROPONIN-I; INTACT RAT-HEART; DIASTOLIC DYSFUNCTION; PROGNOSTIC VALUE; SURGERY; SEVOFLURANE; RECEPTORS	Objectives: Experimental studies have shown that opioids protect the myocardium from ischemic injury and that opioid cardioprotection is enhanced by the coadministration of volatile anesthetics. Previous data suggest that morphine produces a more potent cardioprotective effect than fentanyl. The present study investigated the effect of the choice of intraoperative opioid (morphine or fentanyl) on recovery of myocardial function after coronary artery bypass graft (CABG) surgery. Design: Prospective, randomized study. Setting: University hospital. Participants: Forty-six patients undergoing CABG surgery. Interventions: Patients were randomly assigned to receive either morphine (40 mg) or fentanyl (1,000 mu g) before cardiopulmonary bypass (CPB). Global cardiac function was assessed intraoperatively using the myocardial performance index (MPI), which combines echocardiographic parameters of both systolic and diastolic function. Measurements and Main Results: The MPI (median [range]) was increased after CPB in the fentanyl group, indicating a significant worsening of global left ventricular function (0.43 [0.28-0.54] baseline; 0.49 [0.32-0.64] 15 minutes post-CPB; 0.51 [0.36-0.63] end of operation; p < 0.05 post-CPB compared with baseline). The MPI improved in the morphine group after CPB (0.44 [0.32-0.64] baseline; 0.36 [0.24-0.45] 15 minutes post-CPB; 0.34 [0.20-0.46] end of operation; p < 0.05 post-CPB compared with baseline and the fentanyl group). Conclusions: In patients undergoing CPB, global ventricular function is enhanced by the administration of morphine prior to the ischemic insult of cardioplegic arrest. (C) 2006 Elsevier Inc. All rights reserved.	Northwestern Univ, Feinberg Sch Med, Evanston NW Healthcare, Dept Anesthesiol, Evanston, IL 60201 USA	Murphy, GS (reprint author), Northwestern Univ, Feinberg Sch Med, Evanston NW Healthcare, Dept Anesthesiol, 2650 Ridge Ave, Evanston, IL 60201 USA.	gmurphy@enh.org	Avram, Michael/M-7681-2019				Al-Mukhaini M, 2003, Eur J Echocardiogr, V4, P128; Ascione L, 2003, J AM SOC ECHOCARDIOG, V16, P1019, DOI 10.1016/S0894-7317(03)00589-3; Bein B, 2005, ANESTH ANALG, V100, P610, DOI 10.1213/01.ANE.0000145012.27484.A7; Bell SP, 2000, J AM COLL CARDIOL, V36, P2296, DOI 10.1016/S0735-1097(00)01011-1; Benedict PE, 1999, CIRCULATION, V100, P357; Bernard F, 2001, ANESTH ANALG, V92, P291, DOI 10.1213/00000539-200102000-00002; Chello M, 2001, EUR J CARDIO-THORAC, V20, P140, DOI 10.1016/S1010-7940(01)00754-0; De Hert SG, 2002, ANESTHESIOLOGY, V97, P42, DOI 10.1097/00000542-200207000-00007; Dujardin KS, 1998, AM J CARDIOL, V82, P1071, DOI 10.1016/S0002-9149(98)00559-1; Eidem BW, 2000, AM J CARDIOL, V86, P654, DOI 10.1016/S0002-9149(00)01047-X; Fellahi JL, 2003, ANESTHESIOLOGY, V99, P270, DOI 10.1097/00000542-200308000-00007; FLACKE JW, 1987, ANESTH ANALG, V66, P723; Julier K, 2003, ANESTHESIOLOGY, V98, P1315, DOI 10.1097/00000542-200306000-00004; Lasocki S, 2002, ANESTHESIOLOGY, V97, P405, DOI 10.1097/00000542-200208000-00018; Liang BT, 1999, CIRC RES, V84, P1396; LOWENSTEIN E, 1969, NEW ENGL J MED, V281, P1389, DOI 10.1056/NEJM196912182812503; Ludwig LM, 2003, ANESTHESIOLOGY, V98, P705, DOI 10.1097/00000542-200303000-00019; MACLEOD BA, 1983, ANESTHESIOLOGY, V58, P44, DOI 10.1097/00000542-198301000-00008; Mathur S, 1999, ANESTHESIOLOGY, V91, P1349, DOI 10.1097/00000542-199911000-00027; McPherson BC, 2001, CIRCULATION, V103, P290; Morimoto K, 1998, SURG TODAY, V28, P23, DOI 10.1007/BF02483604; OCANA M, 1990, EUR J PHARMACOL, V186, P377, DOI 10.1016/0014-2999(90)90466-J; Poelaert J, 2004, ACTA ANAESTH SCAND, V48, P973, DOI 10.1111/j.0001-5172.2004.00466.x; RAFFA RB, 1995, BRAIN RES, V677, P277, DOI 10.1016/0006-8993(95)00164-L; Rakowski H, 1996, J Am Soc Echocardiogr, V9, P736, DOI 10.1016/S0894-7317(96)90076-0; Schultz JE, 1998, CIRCULATION, V97, P1282, DOI 10.1161/01.CIR.97.13.1282; Schultz JEJ, 1998, AM J PHYSIOL-HEART C, V274, pH909, DOI 10.1152/ajpheart.1998.274.3.H909; Schultz JEJ, 1996, CIRC RES, V78, P1100, DOI 10.1161/01.RES.78.6.1100; Schultz JJ, 1997, J MOL CELL CARDIOL, V29, P2187, DOI 10.1006/jmcc.1997.0454; Tei C, 1995, J Cardiol, V26, P357; Tei C, 1997, J AM SOC ECHOCARDIOG, V10, P169, DOI 10.1016/S0894-7317(97)70090-7; Tei C, 1995, J CARDIOL, V26, P396; Ulucam M, 2004, ADV THER, V21, P96, DOI 10.1007/BF02850337; Warner M A, 1991, J Cardiothorac Vasc Anesth, V5, P481, DOI 10.1016/1053-0770(91)90123-B; WHITE JL, 1994, BRIT J ANAESTH, V73, P214, DOI 10.1093/bja/73.2.214; WUSTER M, 1979, NEUROSCI LETT, V15, P193, DOI 10.1016/0304-3940(79)96112-3; Yamada H, 2002, J AM SOC ECHOCARDIOG, V15, P1238, DOI 10.1067/mje.2002.124877; Zaugg M, 2003, BRIT J ANAESTH, V91, P551, DOI 10.1093/bja/aeg205	38	55	59	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770	1532-8422		J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	AUG	2006	20	4					493	502		10.1053/j.jvca.2005.07.036			10	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	073SU	WOS:000239763700004	16884978				2020-06-30	J	Kawamura, T; Kadosaki, M; Nara, N; Kaise, A; Suzuki, H; Endo, S; Wei, JC; Inada, K				Kawamura, Takae; Kadosaki, Mamoru; Nara, Noriko; Kaise, Atsushi; Suzuki, Hirotaka; Endo, Shigeatu; Wei, Jicheng; Inada, Katsuya			Effects of sevoflurane on cytokine balance in patients undergoing coronary artery bypass graft surgery	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						coronary artery bypass graft; cytokine balance; sevoflurane; myocardial reperfusion injury; inflammatory response; myocardial protection	TUMOR-NECROSIS-FACTOR; MYOCARDIAL REPERFUSION INJURY; CARDIAC-SURGERY; NITRIC-OXIDE; VOLATILE ANESTHETICS; RAT LUNGS; HALOTHANE; ISCHEMIA; ADHESION; INTERLEUKIN-10	Objective: The effects of sevoflurane on proinflammatory cytokines related to ischemic-reperfusion injury are not clear. The hypothesis was tested that sevoflurane decreases myocardial ischemic-reperfusion injury by suppressing proinflammatory cytokines. Design: Prospective, randomized study. Setting: A medical university heart center. Participants: Twenty-three patients undergoing coronary artery by-pass surgery allocated randomly into 2 groups Interventions: Anesthesia for 23 patients undergoing coronary artery bypass surgery was maintained using either fentanyl (30 mu g/kg) with propofol (2-8 mg/kg/h) in the control group (n = 10) or fentanyl (30 mu g/kg) with 0.5% to 1.0% sevoflurane in the sevoflurane group (n = 13). Measurements and Main Results: Interleukin (IL)-6, IL-8, IL-10, and IL-1 receptor antagonist (IL-1ra) were measured by enzyme-linked immunosorbent assay. Troponin-T and creatine kinase-MB isoenzyme (CK-MB) were measured by enzyme immunoassay and ultraviolet absorption spectrophotometry, respectively. Serum IL-6 and IL-8 concentrations in both groups increased significantly over baseline from 60 minutes after declamping the aorta (p < 0.001). The increases were greater in the control group than in the sevoflurane group (p < 0.05). Serum IL-10 and IL-1ra concentrations in both groups increased significantly over baseline from 60 minutes after declamping the aorta (p < 0.001). There were no differences between the two groups. Serum troponin-T and CK-MB concentrations increased significantly in both groups from 60 minutes after declamping the aorta (p < 0.001); the increases were greater in the control group (p < 0.05). Conclusion: Sevoflurane suppressed the production of IL-6 and IL-8, but not IL-10 and IL-1ra. Changes in the balance between pro- and anti-inflammatory cytokines may be one of the most important mechanisms of myocardial protection caused by sevoflurane. (C) 2006 Elsevier Inc. All rights reserved.	Sendai Med Ctr, Dept Anesthesiol, Miyagino Ku, Sendai, Miyagi 9838520, Japan; Iwate Med Univ, Mem Heart Ctr, Dept Anesthesiol, Morioka, Iwate, Japan; Iwate Med Univ, Dept Crit Care Med, Morioka, Iwate, Japan; Iwate Med Univ, Dept Biol, Morioka, Iwate, Japan	Kawamura, T (reprint author), Sendai Med Ctr, Dept Anesthesiol, Miyagino Ku, 2-8-8 Miyagino, Sendai, Miyagi 9838520, Japan.	tkawamura@snh.go.jp		Suzuki, Hirotaka/0000-0001-8486-1294			BARTH J, 1987, ACTA ANAESTH SCAND, V31, P740, DOI 10.1111/j.1399-6576.1987.tb02656.x; BRAUNWALD E, 1982, CIRCULATION, V66, P1146, DOI 10.1161/01.CIR.66.6.1146; CASSATELLA MA, 1994, J EXP MED, V179, P1695, DOI 10.1084/jem.179.5.1695; Colletti LM, 1998, SHOCK, V10, P182, DOI 10.1097/00024382-199809000-00006; Cope DK, 1997, ANESTHESIOLOGY, V86, P699, DOI 10.1097/00000542-199703000-00023; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; FINKEL MS, 1996, [No title captured], V1, P203; Garcia C, 2005, BRIT J ANAESTH, V94, P159, DOI 10.1093/bja/aei026; JENNINGS RB, 1985, CIRC RES, V56, P262, DOI 10.1161/01.RES.56.2.262; Julier K, 2003, ANESTHESIOLOGY, V98, P1315, DOI 10.1097/00000542-200306000-00004; Kawamura T, 1996, CAN J ANAESTH, V43, P456, DOI 10.1007/BF03018106; Kawamura T, 2000, CRIT CARE MED, V28, P2201, DOI 10.1097/00003246-200007000-00004; Kawamura T, 1997, CAN J ANAESTH, V44, P38, DOI 10.1007/BF03014322; Kawamura T, 1999, CRIT CARE MED, V27, P545, DOI 10.1097/00003246-199903000-00033; KAWAMURA T, 1993, CAN J ANAESTH, V40, P1016, DOI 10.1007/BF03009470; Khimenko PL, 1998, J APPL PHYSIOL, V85, P2005; Kowalski C, 1997, ANESTHESIOLOGY, V86, P188, DOI 10.1097/00000542-199701000-00023; Liu RY, 2000, ANESTHESIOLOGY, V92, P833, DOI 10.1097/00000542-200003000-00027; Mathur S, 1997, ANESTHESIOLOGY, V87, P1460, DOI 10.1097/00000542-199712000-00025; METINKO AP, 1991, FASEB J*, V704, P1941; MITSUHATA H, 1995, INT J IMMUNOPHARMACO, V17, P529, DOI 10.1016/0192-0561(95)00026-X; Nader ND, 2004, J CARDIOTHOR VASC AN, V18, P269, DOI 10.1053/j.jvca.2004.03.004; Novalija E, 1999, ANESTHESIOLOGY, V91, P701, DOI 10.1097/00000542-199909000-00023; PACCAUD JP, 1990, BIOCHEM BIOPH RES CO, V166, P187, DOI 10.1016/0006-291X(90)91929-M; Preckel B, 1998, ANESTH ANALG, V87, P1221, DOI 10.1097/00000539-199812000-00001; Sharma SK, 2000, CIRCULATION, V102, P166, DOI 10.1161/01.CIR.102.2.166; TAIT AR, 1993, ANESTH ANALG, V76, P1106; Tassiopoulos AK, 1998, EUR J VASC ENDOVASC, V16, P36, DOI 10.1016/S1078-5884(98)80089-0; Toller WG, 1999, ANESTHESIOLOGY, V91, P1437, DOI 10.1097/00000542-199911000-00037; Yang ZQ, 2000, CIRCULATION, V101, P1019, DOI 10.1161/01.CIR.101.9.1019	31	41	51	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	1053-0770			J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	AUG	2006	20	4					503	508		10.1053/j.jvca.2006.01.011			6	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	073SU	WOS:000239763700005	16884979				2020-06-30	J	Morita, T; Tei, Y				Morita, Tatsuya; Tei, You			Skin reaction to both morphine and fentanyl attenuated by steroids and antihistaminics	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Letter									Seirei Mikatahara Gen Hosp, Shizuoka, Japan	Morita, T (reprint author), Seirei Mikatahara Gen Hosp, Shizuoka, Japan.						FISHER MM, 1991, CLIN REV ALLERG, V9, P309; GINSBERG GS, 1985, DRUG THER, V15, P147; STOUKIDES CA, 1992, CLIN PHARMACY, V11, P222	3	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924			J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	AUG	2006	32	2					100	101		10.1016/j.jpainsymman.2006.04.002			2	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	074TV	WOS:000239835600002	16877172	Bronze			2020-06-30	J	van Rijswijk, R				van Rijswijk, Rein			A delirious patient with opioid intoxication after chewing a fentanyl patch	JOURNAL OF THE AMERICAN GERIATRICS SOCIETY			English	Letter							OVERDOSE; ABUSE		Amphia Hosp, Dept Internal Med, Breda, Netherlands	van Rijswijk, R (reprint author), Amphia Hosp, Dept Internal Med, Breda, Netherlands.						Edinboro LE, 1997, J FORENSIC SCI, V42, P741; Frolich M, 2001, ANESTH ANALG, V93, P647; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; ROSE PG, 1993, ANESTH ANALG, V77, P390, DOI 10.1213/00000539-199377020-00029; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11	6	5	5	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0002-8614			J AM GERIATR SOC	J. Am. Geriatr. Soc.	AUG	2006	54	8					1298	1299		10.1111/j.1532-5415.2006.00832.x			2	Geriatrics & Gerontology; Gerontology	Geriatrics & Gerontology	076MC	WOS:000239961400029	16914008				2020-06-30	J	Muenster, T; Schmidt, J; Wick, S; Forst, J; Schmitt, HJ				Muenster, Tino; Schmidt, Joachim; Wick, Stefanie; Forst, Juergen; Schmitt, Hubert J.			Rocuronium 0.3 mg(.)kg(-1) (ED95) induces a normal peak effect but an altered time course of neuromuscular block in patients with Duchenne's muscular dystrophy	PEDIATRIC ANESTHESIA			English	Article						Duchenne's muscular dystrophy; neuromuscular transmission; neuromuscular blocking agents; neuromuscular monitoring	MUSCLE-RELAXATION; DURATION; ONSET; MIVACURIUM; VECURONIUM; ANESTHESIA; PROTEINS	Background: In patients with Duchenne's muscular dystrophy (DMD) recovery from neuromuscular block is delayed. It has been assumed that this is because of a higher potency of muscle relaxants in this patient cohort. We determined the peak effect, and the time course of action of rocuronium 0.3 mg.kg(-1) (ED95) in DMD patients. Methods: Twenty-four patients (12 with DMD and 12 controls; aged 10-18 years) were studied. All patients were anesthetized with propofol and fentanyl/remifentanil. Neuromuscular transmission was monitored by acceleromyography. After induction all patients received a single dose of rocuronium 0.3 mg.kg(-1). The complete time course of action as onset, peak effect and spontaneous recovery was recorded. Results: The onset time (s) to maximum block was significantly (P < 0.01) prolonged in DMD patients (median: 315; range: 120-465) compared with controls (195, 75-270). The peak effect (% twitch depression relative to baseline) was not different between the groups (DMD: 59-100; controls: 28-100). In the DMD group, recovery was significantly (P < 0.01) delayed compared with controls at all recorded time points. The clinical duration (min) was 40.3 (22-89) in the DMD group vs 9.8 (6-17) in the control group (P < 0.01). Conclusions: The similar peak effect in both groups does not confirm the thesis of rocuronium having a higher potency in DMD patients. The documented very long recovery after the ED95 of rocuronium emphasizes the need for careful assessment of neuromuscular function in DMD patients.	Univ Erlangen Nurnberg, Dept Anaesthesiol, D-91054 Erlangen, Germany; Univ Erlangen Nurnberg, Dept Orthopaed, D-91054 Erlangen, Germany	Schmitt, HJ (reprint author), Univ Erlangen Nurnberg, Dept Anaesthesiol, Krankenhausstr 12, D-91054 Erlangen, Germany.	hubert.schmitt@kfa.imed.uni-erlangen.de					BEWICK GS, 1992, NEUROREPORT, V3, P857, DOI 10.1097/00001756-199210000-00009; Blake DJ, 2000, TRENDS NEUROSCI, V23, P92, DOI 10.1016/S0166-2236(99)01510-6; BUZELLO W, 1988, BRIT J ANAESTH, V60, P228, DOI 10.1093/bja/60.2.228; Compton AG, 2005, J NEUROPATH EXP NEUR, V64, P350, DOI 10.1093/jnen/64.4.350; FOLDES FF, 1991, ANESTHESIOLOGY, V75, P191, DOI 10.1097/00000542-199108000-00004; Grady RM, 2000, NEURON, V25, P279, DOI 10.1016/S0896-6273(00)80894-6; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HUANG FY, 1990, ANAESTH SIN, V28, P223; Kumar N, 1996, BRIT J ANAESTH, V77, P488, DOI 10.1093/bja/77.4.488; MEISTELMAN C, 1992, CAN J ANAESTH, V39, P665, DOI 10.1007/BF03008227; OZAWA E, 1995, HUM MOL GENET, V4, P1711, DOI 10.1093/hmg/4.suppl_1.1711; Ririe DG, 1998, ANESTHESIOLOGY, V88, P351, DOI 10.1097/00000542-199802000-00013; Sanfilippo M, 1997, ACTA ANAESTH SCAND, V41, P1365, DOI 10.1111/j.1399-6576.1997.tb04659.x; Schmidt J, 2005, BRIT J ANAESTH, V95, P769, DOI 10.1093/bja/aei249; Schultz P, 2001, ACTA ANAESTH SCAND, V45, P612, DOI 10.1034/j.1399-6576.2001.045005612.x; Tobias J. D., 1994, PAEDIATR ANAESTH, V4, P57; Uslu M, 1999, ANESTH ANALG, V89, P340, DOI 10.1097/00000539-199908000-00017; VibyMogensen J, 1996, ACTA ANAESTH SCAND, V40, P59, DOI 10.1111/j.1399-6576.1996.tb04389.x; Wick S, 2005, ANESTHESIOLOGY, V102, P915, DOI 10.1097/00000542-200505000-00009; Woolf RL, 1997, ANESTHESIOLOGY, V87, P1368, DOI 10.1097/00000542-199712000-00016	20	17	18	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	AUG	2006	16	8					840	845		10.1111/j.1460-9592.2006.01870.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	064UW	WOS:000239115900006	16884467				2020-06-30	J	Stienen, PJ; van Oostrom, H; van den Bos, R; de Groot, HNM; Hellebrekers, LJ				Stienen, Peter J.; van Oostrom, Hugo; van den Bos, Ruud; de Groot, Harry N. M.; Hellebrekers, Ludo J.			Vertex-recorded, rather than primary somatosensory cortex-recorded, somatosensory-evoked potentials signal unpleasantness of noxious stimuli in the rat	BRAIN RESEARCH BULLETIN			English	Article						SEP; nociceptive system; pain; analgesia; auditory-evoked potential; fentanyl	PEDUNCULOPONTINE NUCLEUS; FIELD POTENTIALS; PAIN PERCEPTION; AUDITORY INPUT; MODULATION; RESPONSES; SI; MECHANISMS; BRAIN; NOCICEPTORS	In the present study, we investigated in the rat whether vertex- or primary somatosensory cortex-recorded somatosensory-evoked potentials (Vx-SEP/SI-SEP, respectively) signal unpleasantness of noxious stimuli. Therefore, initially we characterised fentanyl effects (0, 20, 40 or 50 mu g/kg/h) on somatosensory and auditory processing by recording Vx-/SI-SEPs and vertex- and primary auditory cortex-recorded auditory-evoked potentials (Vx-/Al-AEPs, respectively). Subsequently, in a separate experiment, the animals were subjected to a Pavlovian fear-conditioning paradigm. The noxious stimuli applied to evoke Vx-/SI-SEPs (unconditioned stimulus (US)) were paired to a tone (conditioned stimulus (CS)) under 'steady state' conditions of 0, 20, 40 or 50 mu g/kg/h fentanyl. Vx-/SI-SEPs were recorded simultaneously during these trials. After CS-US presentation, CS-induced fear-conditioned behaviour was analysed in relation to the SEPs recorded during CS-US presentation and the AEPs recorded in the first experiment. While the SI-SEP and AI-AEP were minimally but significantly affected, fentanyl dose-dependently decreased the Vx-SEP and Vx-AEP. The decrease of the Vx-SEP and Vx-AEP was parallelled by the dose-dependent decrease of the amount of CS-induced fear-conditioned behaviour. These results suggest that the dose-dependent decrease of the Vx-SEP amplitude, rather than of the SI-SEP, indicates that the US was experienced as less unpleasant. Next to an altered US processing, altered CS processing contributed to the decrease of the amount of CS-induced fear-conditioned behaviour as indicated by the dose-dependent decrease of the Vx-AEP. (c) 2006 Elsevier Inc. All rights reserved.	Univ Utrecht, Fac Vet Med, Sect Anaesthesiol & Neurophysiol, Dept Clin Sci Compan Anim, NL-3508 TD Utrecht, Netherlands; Univ Utrecht, Fac Vet Med, Sect Anesthesiol, Dept Equine Sci, NL-3508 TD Utrecht, Netherlands; Univ Utrecht, Fac Med Vet, Dept Anim Sci & Soc, NL-3508 TD Utrecht, Netherlands; Univ Utrecht, Rudolf Magnus Inst Neurosci, Utrecht, Netherlands	Stienen, PJ (reprint author), Univ Utrecht, Fac Vet Med, Sect Anaesthesiol & Neurophysiol, Dept Clin Sci Compan Anim, POB 80-154, NL-3508 TD Utrecht, Netherlands.	P.Stienen@vet.uu.nl					Arendt-Nielsen L, 1994, Acta Anaesthesiol Scand Suppl, V101, P7; Banoub M, 2003, ANESTHESIOLOGY, V99, P716, DOI 10.1097/00000542-200309000-00029; BARTH DS, 1990, J NEUROPHYSIOL, V64, P1527; BJERRING P, 1988, J NEUROL NEUROSUR PS, V51, P43, DOI 10.1136/jnnp.51.1.43; Bromm B, 1998, ELECTROEN CLIN NEURO, V107, P227, DOI 10.1016/S0013-4694(98)00075-3; Casey KL, 2000, J NEUROPHYSIOL, V84, P525; CHAPIN JK, 1984, J COMP NEUROL, V229, P199, DOI 10.1002/cne.902290206; De Ribeaupierre F., 1997, CENTRAL AUDITORY SYS, P317; FANSELOW MS, 1979, J COMP PHYSIOL PSYCH, V93, P736, DOI 10.1037/h0077609; Garcia-Rill E, 2004, PROG BRAIN RES, V143, P283, DOI 10.1016/S0079-6123(03)43027-6; Haberham ZL, 1999, LAB ANIM, V33, P47, DOI 10.1258/002367799780578570; Haberham ZL, 2000, BRAIN RES, V873, P287, DOI 10.1016/S0006-8993(00)02504-X; Heppelmann B, 2001, EXP BRAIN RES, V141, P501, DOI 10.1007/s002210100888; Iannetti GD, 2004, CLIN NEUROPHYSIOL, V115, P2629, DOI 10.1016/j.clinph.2004.05.023; Kakigi R, 2000, J CLIN NEUROPHYSIOL, V17, P295, DOI 10.1097/00004691-200005000-00007; Kalliomaki J, 1998, PAIN, V77, P323, DOI 10.1016/S0304-3959(98)00115-8; KOLPAKOV VG, 1977, BEHAVIOUR, V62, P190, DOI 10.1163/156853977X00108; LeDoux J, 2003, CELL MOL NEUROBIOL, V23, P727, DOI 10.1023/A:1025048802629; Maes JHR, 1997, PHARMACOL BIOCHEM BE, V58, P305, DOI 10.1016/S0091-3057(97)00240-2; Maren S, 2001, ANNU REV NEUROSCI, V24, P897, DOI 10.1146/annurev.neuro.24.1.897; Millan MJ, 1999, PROG NEUROBIOL, V57, P1, DOI 10.1016/S0301-0082(98)00048-3; MIYAZATO H, 1995, BRAIN RES BULL, V37, P247, DOI 10.1016/0361-9230(95)00003-W; Miyazato H, 1999, NEUROSCIENCE, V92, P911, DOI 10.1016/S0306-4522(98)00762-3; Miyazato H, 2000, BRAIN RES BULL, V51, P387, DOI 10.1016/S0361-9230(99)00257-9; Ohara S, 2004, PAIN, V110, P318, DOI 10.1016/j.pain.2004.04.009; Overton DA, 1985, CONTEXT LEARNING, P357; Price DD, 2000, SCIENCE, V288, P1769, DOI 10.1126/science.288.5472.1769; REESE NB, 1995, BRAIN RES BULL, V37, P257, DOI 10.1016/0361-9230(95)00002-V; REESE NB, 1995, BRAIN RES BULL, V37, P265, DOI 10.1016/0361-9230(95)00001-U; Schnitzler A, 2000, J CLIN NEUROPHYSIOL, V17, P592, DOI 10.1097/00004691-200011000-00005; SCHOUENBORG J, 1986, BRAIN RES, V397, P86, DOI 10.1016/0006-8993(86)91371-5; Sewards TV, 2002, BRAIN RES BULL, V59, P163, DOI 10.1016/S0361-9230(02)00864-X; Shaw FZ, 1999, BRAIN RES, V824, P183, DOI 10.1016/S0006-8993(99)01185-3; Silbert SC, 2003, J NEUROSCI, V23, P34; Skinner RD, 2004, PROG BRAIN RES, V143, P291, DOI 10.1016/S0079-6123(03)43028-8; Stienen PJ, 2005, BRAIN RES BULL, V67, P269, DOI 10.1016/j.brainresbull.2005.06.038; Stienen PJ, 2004, BRAIN RES, V1030, P256, DOI 10.1016/j.brainres.2004.10.014; Stienen PJ, 2003, J NEUROSCI METH, V126, P79, DOI 10.1016/S0165-0270(03)00070-0; Teneud L, 2000, BRAIN RES, V884, P196, DOI 10.1016/S0006-8993(00)02983-8; van Oostrom H, 2005, BRAIN RES PROTOC, V15, P14, DOI 10.1016/j.brainresprot.2005.02.001; Yeomans DC, 1996, PAIN, V66, P253, DOI 10.1016/0304-3959(96)03082-5; Yeomans DC, 1996, PAIN, V68, P133, DOI 10.1016/S0304-3959(96)03176-4	42	11	11	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230			BRAIN RES BULL	Brain Res. Bull.	JUL 31	2006	70	3					203	212		10.1016/j.brainresbull.2006.06.003			10	Neurosciences	Neurosciences & Neurology	072OF	WOS:000239682000002	16861104	Green Published			2020-06-30	J	Schroeder, MB; Riters, LV				Schroeder, Molly B.; Riters, Lauren V.			Pharmacological manipulations of dopamine and opioids have differential effects on sexually motivated song in male European starlings	PHYSIOLOGY & BEHAVIOR			English	Article						song; vocal communication; sexual behavior; motivation; reward; dopamine; opioids; songbird	MEDIAL PREOPTIC AREA; ENDOGENOUS OPIOIDS; CONSUMMATORY ASPECTS; NUCLEUS-ACCUMBENS; CATECHOLAMINERGIC INPUTS; RECEPTOR AGONISTS; MALE-RATS; BEHAVIOR; INVOLVEMENT; LESIONS	Vocal communication is common among social vertebrates, though little is known about the neural mechanisms regulating the motivation to communicate. This study examined a possible role for dopamine and opioids in sexually motivated song in male European starlings. The dopamine reuptake inhibitor GBR-12909 increased singing behavior, whereas the D1 dopamine receptor antagonist SCH-23390 decreased song, suggesting a role for dopamine in the motivation to sing. In contrast, the opioid agonist fentanyl decreased song, and the antagonist naloxone has previously been shown to increase song, findings consistent with a role for opioids in reward associated with song production. These results suggest that dopamine and opioids play opposing roles in the regulation of the motivation to communicate. (c) 2006 Elsevier Inc. All rights reserved.	Univ Wisconsin, Dept Zool, Madison, WI 53706 USA	Riters, LV (reprint author), Univ Wisconsin, Dept Zool, 361 Birge Hall,430 Lincoln Dr, Madison, WI 53706 USA.	LVRiters@wisc.edu			NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01-MH 65645, R01 MH065645]		AGMO A, 1988, PHARMACOL BIOCHEM BE, V30, P1021, DOI 10.1016/0091-3057(88)90135-9; Appeltants D, 2000, J CHEM NEUROANAT, V18, P117, DOI 10.1016/S0891-0618(99)00054-X; Appeltants D, 2002, NEUROREPORT, V13, P649, DOI 10.1097/00001756-200204160-00023; AYROMLOOI J, 1980, J REPROD MED, V24, P23; Ball GF, 2002, FRONT NEUROENDOCRIN, V23, P137, DOI 10.1006/frne.2002.0230; Balthazart J, 1997, PHYSIOL BEHAV, V62, P571, DOI 10.1016/S0031-9384(97)00163-7; Bass AH, 2003, PROG NEUROBIOL, V69, P1, DOI 10.1016/S0301-0082(03)00004-2; Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8; Berridge KC, 2004, PHYSIOL BEHAV, V81, P179, DOI 10.1016/j.physbeh.2004.02.004; Berridge KC, 2003, BRAIN COGNITION, V52, P106, DOI 10.1016/S0278-2626(03)00014-9; BITRAN D, 1988, BRAIN RES BULL, V20, P323, DOI 10.1016/0361-9230(88)90062-7; BLACKBURN JR, 1992, PROG NEUROBIOL, V39, P247, DOI 10.1016/0301-0082(92)90018-A; BLACKBURN JR, 1989, BEHAV NEUROSCI, V103, P15, DOI 10.1037/0735-7044.103.1.15; BOTTJER SW, 1984, SCIENCE, V224, P901, DOI 10.1126/science.6719123; Bottjer SW, 1997, J NEUROBIOL, V33, P602, DOI 10.1002/(SICI)1097-4695(19971105)33:5<602::AID-NEU8>3.0.CO;2-8; Brenowitz EA, 1997, J NEUROBIOL, V33, P517, DOI 10.1002/(SICI)1097-4695(19971105)33:5<517::AID-NEU3>3.0.CO;2-7; Buchanan KL, 2003, P ROY SOC B-BIOL SCI, V270, P1149, DOI 10.1098/rspb.2003.2330; Burgdorf J, 2001, PHYSIOL BEHAV, V72, P167, DOI 10.1016/S0031-9384(00)00411-X; Carden SE, 1996, BEHAV NEUROSCI, V110, P324, DOI 10.1037/0735-7044.110.2.324; Castagna C, 1997, PHARMACOL BIOCHEM BE, V58, P403, DOI 10.1016/S0091-3057(97)00243-8; CASTO JM, 1994, J NEUROBIOL, V25, P767, DOI 10.1002/neu.480250703; CATCHPOLE C, 1995, BIRD SONG BIOL THEME, V8; CUTHILL I, 1985, ANIM BEHAV, V33, P326, DOI 10.1016/S0003-3472(85)80146-9; DAMASSA DA, 1977, HORM BEHAV, V8, P275, DOI 10.1016/0018-506X(77)90002-2; DELANEROLLE NC, 1978, J COMP PHYSIOL PSYCH, V92, P416, DOI 10.1037/h0077486; Duffy DL, 2000, BEHAV ECOL, V11, P654, DOI 10.1093/beheco/11.6.654; Duffy DL, 2002, P ROY SOC B-BIOL SCI, V269, P847, DOI 10.1098/rspb.2002.1956; EENS M, 1995, BEHAV ECOL SOCIOBIOL, V36, P71, DOI 10.1007/s002650050126; EENS M, 1993, BEHAVIOUR, V125, P51, DOI 10.1163/156853993X00182; EENS M, 1994, BELG J ZOOL, V124, P167; EENS M, 1990, BIRD STUDY, V37, P48, DOI 10.1080/00063659009477038; Eens M, 1997, ADV STUD BEHAV, V26, P355, DOI 10.1016/S0065-3454(08)60384-8; FALK H, 1988, BIOL REPROD, V39, P1004, DOI 10.1095/biolreprod39.5.1004; Fibiger H C, 1992, Clin Neuropharmacol, V15 Suppl 1 Pt A, p566A; GULLEDGE CC, 1995, J COMP NEUROL, V356, P408, DOI 10.1002/cne.903560308; Gulledge CC, 1999, J COMP NEUROL, V404, P505; HARDING CF, 2004, [No title captured]; Heimovics SA, 2005, J NEUROBIOL, V65, P207, DOI 10.1002/neu.20181; HUGHES AM, 1990, PSYCHOPHARMACOLOGY, V102, P243, DOI 10.1007/BF02245929; HULL EM, 1986, BRAIN RES, V370, P73, DOI 10.1016/0006-8993(86)91106-6; HULL EM, 1995, J NEUROSCI, V15, P7465; HULL EM, 1990, BRAIN RES, V512, P1, DOI 10.1016/0006-8993(90)91162-A; KALIVAS PW, 1993, BRAIN RES REV, V18, P75, DOI 10.1016/0165-0173(93)90008-N; Kelley AE, 2002, J NEUROSCI, V22, P3306; Kelley AE, 1996, J PHARMACOL EXP THER, V278, P1499; Kelley DB, 2004, CURR OPIN NEUROBIOL, V14, P751, DOI 10.1016/j.conb.2004.10.015; Koob GF, 1996, MOL PSYCHIATR, V1, P186; Kotegawa T, 1997, J EXP ZOOL, V277, P146, DOI 10.1002/(SICI)1097-010X(19970201)277:2&lt;146::AID-JEZ6&gt;3.0.CO;2-P; Laurent V, 2002, P NATL ACAD SCI USA, V99, P3087, DOI 10.1073/pnas.261715099; LEHNER P, 1996, HDB ETHOLOGICAL METH; LEWIS JW, 1981, J COMP NEUROL, V196, P347, DOI 10.1002/cne.901960212; Maney DL, 2003, J NEUROBIOL, V56, P163, DOI 10.1002/neu.10227; Margoliash D, 1997, J NEUROBIOL, V33, P671, DOI 10.1002/(SICI)1097-4695(19971105)33:5<671::AID-NEU12>3.0.CO;2-C; MAS M, 1995, EUR J PHARMACOL, V280, P331, DOI 10.1016/0014-2999(95)00270-U; Meisel Robert L., 1994, P3; MOSES J, 1995, PHARMACOL BIOCHEM BE, V51, P681, DOI 10.1016/0091-3057(94)00437-N; NORDEEN KW, 1993, BEHAV NEURAL BIOL, V59, P79, DOI 10.1016/0163-1047(93)91215-9; NOTTEBOHM F, 1976, J COMP NEUROL, V165, P457, DOI 10.1002/cne.901650405; PFAFF DW, 1999, DRIVE NEUROBIOLOGICA; PFAUS JG, 1995, BRAIN RES, V693, P21, DOI 10.1016/0006-8993(95)00679-K; PFAUS JG, 1992, HORM BEHAV, V26, P457, DOI 10.1016/0018-506X(92)90014-M; Pfaus JG, 2004, ANN REV SEX RES, V14, P1; PFAUS JG, 1989, PSYCHOPHARMACOLOGY, V98, P363, DOI 10.1007/BF00451688; PFAUS JG, 1991, BEHAV NEUROSCI, V105, P727, DOI 10.1037/0735-7044.105.5.727; Pinxten R, 1997, ANIM BEHAV, V54, P45, DOI 10.1006/anbe.1996.0432; Riters LV, 2000, HORM BEHAV, V38, P250, DOI 10.1006/hbeh.2000.1623; Riters LV, 1999, HORM BEHAV, V36, P276, DOI 10.1006/hbeh.1999.1549; Riters LV, 2004, CELL TISSUE RES, V316, P35, DOI 10.1007/s00441-003-0838-6; Riters LV, 2005, BEHAV NEUROSCI, V119, P245, DOI 10.1037/0735-7044.119.1.245; Riters LV, 2004, BEHAV BRAIN RES, V155, P307, DOI 10.1016/j.bbr.2004.05.002; Riters LV, 1999, PHYSIOL BEHAV, V66, P763, DOI 10.1016/S0031-9384(99)00014-1; Robbins TW, 1996, CURR OPIN NEUROBIOL, V6, P228, DOI 10.1016/S0959-4388(96)80077-8; RODRIGUEZMANZO G, 1995, PSYCHOPHARMACOLOGY, V122, P131, DOI 10.1007/BF02246087; Schultz W, 2002, NEURON, V36, P241, DOI 10.1016/S0896-6273(02)00967-4; Seyfarth RM, 2003, ANNU REV PSYCHOL, V54, P145, DOI 10.1146/annurev.psych.54.101601.145121; SOHRABJI F, 1990, BEHAV NEURAL BIOL, V53, P51, DOI 10.1016/0163-1047(90)90797-A; Soma KK, 2001, GEN COMP ENDOCR, V123, P144, DOI 10.1006/gcen.2001.7657; Van Ree JM, 2000, EUR J PHARMACOL, V405, P89, DOI 10.1016/S0014-2999(00)00544-6; vanFurth WR, 1996, BRAIN RES, V729, P20, DOI 10.1016/S0006-8993(96)00225-9; VANFURTH WR, 1994, AM J PHYSIOL, V266, pR606; vanFurth WR, 1995, BRAIN RES REV, V21, P162, DOI 10.1016/0165-0173(96)82985-7; VANFURTH WR, 1995, BEHAV NEUROSCI, V109, P123, DOI 10.1037/0735-7044.109.1.123; Vates GE, 1997, J COMP NEUROL, V380, P275; Wild JM, 1997, J COMP NEUROL, V377, P392, DOI 10.1002/(SICI)1096-9861(19970120)377:3<392::AID-CNE7>3.0.CO;2-Y; WINSLOW JT, 1991, BEHAV NEUROSCI, V105, P253, DOI 10.1037/0735-7044.105.2.253; Wise RA, 2004, AM J PHYSIOL-REG I, V286, pR13, DOI 10.1152/ajpregu.00590.2003	86	43	43	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0031-9384			PHYSIOL BEHAV	Physiol. Behav.	JUL 30	2006	88	4-5					575	584		10.1016/j.physbeh.2006.05.011			10	Psychology, Biological; Behavioral Sciences	Psychology; Behavioral Sciences	075BL	WOS:000239857100037	16784760				2020-06-30	J	Poveda, R; Fernandez-Duenas, V; Fernandez, A; Sanchez, S; Puig, MM; Planas, E				Poveda, Raquel; Fernandez-Duenas, Victor; Fernandez, Alejandro; Sanchez, Silvia; Puig, Margarita M.; Planas, Eulalia			Synergistic interaction between fentanyl and the histamine H-3 receptor agonist R-(alpha)-methylhistamine, on the inhibition of nociception and plasma extravasation in mice	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						fentanyl; histamine H-3 receptor agonist; nociception; plasma extravasation; synergy	INFLAMMATION; OPIOIDS	Here we report a synergistic interaction between fentanyl and the histamine H-3 receptor agonist R-(alpha)-methylhistamine on the inhibition of nociception and plasma extravasation in mice. Chronic inflammation was induced by subplantar injection of Complete Freund's Adjuvant into the right hind paw, and the effect of the drugs was evaluated 7 days later. Nociception and plasma extravasation were assessed by hot-plate and Evans blue tests respectively. Subcutaneous administration of fentanyl (0.01-0.1 mg/kg) induced dose-related anti-nociceptive and anti-extravasation effects (E-max=100% and 62%, respectively). R-(alpha)-methylhistamine administration (0.3-3 mg/kg) showed a dose-related inhibitory effect on extravasation (E-max=65%) but not on nociception. To analyze possible interaction between these two drugs, a dose-response curve to fentanyl plus a fixed dose of R-((x)-methylhistamine (0.5 mg/kg) was obtained. The dose-response curve for the combined treatment showed a shift to the left compared with that for fentanyl alone. Our results confirm that fentanyl and R-(alpha)-methylbistamine interact in a synergic way, inhibiting nociception and plasma extravasation. (c) 2006 Elsevier B.V All rights reserved.	Univ Barcelona, Sch Med, Dept Pathol & Expt Therapeut, Pharmacol Unit,Hosp Llobregat, Lhospitalet De Llobregat 08907, Spain; Univ Autonoma Barcelona, Hosp Univ Del Mar, Dept Anaesthesiol, Sch Med, Barcelona, Spain	Planas, E (reprint author), Univ Barcelona, Sch Med, Dept Pathol & Expt Therapeut, Pharmacol Unit,Hosp Llobregat, Campus Univ Bellvitge,Feixa Llarga S-N, Lhospitalet De Llobregat 08907, Spain.	eplanas@ub.edu	Fernandez-Duenas, Victor/E-5337-2014	Fernandez-Duenas, Victor/0000-0001-7834-2965			Amano R, 2001, NEUROSCI RES, V41, P201, DOI 10.1016/S0168-0102(01)00275-9; Cannon KE, 2003, EUR J PHARMACOL, V470, P139, DOI 10.1016/S0014-2999(03)01737-0; Krause M, 2001, CURR MED CHEM, V8, P1329, DOI 10.2174/0929867013372274; Le Loet X, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-31; Mcleod RL, 1998, J PHARMACOL EXP THER, V287, P43; OHKUBO T, 1995, EUR J PHARMACOL, V273, P83, DOI 10.1016/0014-2999(94)00668-W; OWEN SM, 1994, AGENTS ACTIONS, V41, pC62, DOI 10.1007/BF02007768; Romero A, 2005, EUR J PHARMACOL, V511, P207, DOI 10.1016/j.ejphar.2005.02.004; Rouleau A, 2000, J PHARMACOL EXP THER, V295, P219; Stein C, 2001, Z RHEUMATOL, V60, P416, DOI 10.1007/s003930170004; TALLARIDA RJ, 1992, PAIN, V49, P93, DOI 10.1016/0304-3959(92)90193-F; TALLARIDA RJ, 2001, PHARM PRO PHARM ANAL; UDAKA K, 1970, P SOC EXP BIOL MED, V133, P1384; YONEHARA N, 1992, REGUL PEPTIDES, V38, P13, DOI 10.1016/0167-0115(92)90068-6	14	6	6	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999			EUR J PHARMACOL	Eur. J. Pharmacol.	JUL 10	2006	541	1-2					53	56		10.1016/j.ejphar.2006.05.008			4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	060LM	WOS:000238803700009	16762339				2020-06-30	J	Subramony, JA; Sharma, A; Phipps, JB				Subramony, J. Anand; Sharma, Ashutosh; Phipps, J. B.			Microprocessor controlled transdermal drug delivery	INTERNATIONAL JOURNAL OF PHARMACEUTICS			English	Review						transdermal; iontophoresis; controller; lidocaine; fentanyl; drug delivery	ELECTROTRANSPORT SYSTEM; LIDOCAINE; CHILDREN; IONTOPHORESIS; ANESTHETICS; PAIN	Transdermal drug delivery via iontophoresis is reviewed with special focus on the delivery of lidocaine for local anesthesia and fentanyl for patient controlled acute therapy such as postoperative pain. The role of the microprocessor controller in achieving dosimetry, alternating/reverse polarity, pre-programmed, and sensor-based delivery is highlighted. Unique features such as the use of tactile signaling, telemetry control, and pulsatile waveforms in iontophoretic drug delivery are described briefly. (c) 2006 Elsevier B.V. All rights reserved.	ALZA Corp, Mountain View, CA 94043 USA; Vyteris Inc, Fair Lawn, NJ 07410 USA	Subramony, JA (reprint author), ALZA Corp, 1900 Charleston Rd, Mountain View, CA 94043 USA.	asubramo@alzus.jnj.com					ASHBURN M, 1997, CLIN J PAIN, V13, P1322; BANGA AK, 1998, ELECT ASSISTED TRANS; BROWN CR, 1998, P 17 ANN SCI M AM PA, P192; Eichenfield LF, 2002, PEDIATRICS, V109, P1093, DOI 10.1542/peds.109.6.1093; FOGT EJ, 1984, Patent No. 4444193; Gary A. L, 1993, Patent No. [5213568, US5213568A]; GIBSON LE, 1959, PEDIATRICS, V23, P54; Gupta SK, 1998, J PHARM SCI, V87, P976, DOI 10.1021/js970437d; Gupta SK, 1999, J PHARM SCI, V88, P835, DOI 10.1021/js980258b; Kleiber C, 2002, PEDIATRICS, V110, P758, DOI 10.1542/peds.110.4.758; LATTIN GA, 1998, Patent No. 5843014; LATTIN GA, 1983, Patent No. 4406658; LATTIN GA, 1996, Patent No. 5551953; LEDUC S, 1908, ELECT IONS THEIR USE; Lener EV, 1997, DERMATOL SURG, V23, P673, DOI 10.1111/j.1524-4725.1997.tb00388.x; MCNICHOLS LA, 1997, Patent No. 5697896; MCNICHOLS LA, 1991, Patent No. 5047007; MCNICHOLS LA, 1994, Patent No. 5314502; MILLOT P, 2000, Patent No. 6167302; PHIPPS JB, 2002, ENCY PHARM TECHNOLOG, P1573; SORENSON PD, 2001, Patent No. 6175763; TAPPER R, 1982, Patent No. 4340047; TAPPER R, 1989, Patent No. 4822334; TAPPER R, 1993, Patent No. 5224927; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Wallace MS, 2001, REGION ANESTH PAIN M, V26, P229, DOI 10.1053/rapm.2001.22633; WOODHOUSE A, 1997, ANALGESIA, V3, P1; YEUNG WH, 1984, CLIN PEDIATR, V23, P603, DOI 10.1177/000992288402301101; Zempsky WT, 1998, J PEDIATR-US, V132, P1061, DOI 10.1016/S0022-3476(98)70413-5	29	37	41	1	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0378-5173	1873-3476		INT J PHARMACEUT	Int. J. Pharm.	JUL 6	2006	317	1					1	6		10.1016/j.ijpharm.2006.03.053			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	062RB	WOS:000238961100001	16713690				2020-06-30	J	Puura, A; Puolakka, P; Rorarius, M; Salmelin, R; Lindgren, L				Puura, A.; Puolakka, P.; Rorarius, M.; Salmelin, R.; Lindgren, L.			Etoricoxib pre-medication for post-operative pain after laparoscopic cholecystectomy	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						clinical trial; cumulative fentanyl; etoricoxib; laparoscopic cholecystectomy; nausea; outcome; post-operative pain; pre-operatively; side-effects; surgery	COX-2 INHIBITORS; ANALGESIA; NSAIDS	Background: Etoricoxib alleviates and prevents acute pain. The hypothesis of our study was that the pre-operative use of etoricoxib would reduce the post-operative need for additional pain treatment. Methods: In this double-blind, randomized and active placebo-controlled study, 75 patients were pre-medicated 1.5 h before elective laparoscopic cholecystectomy with 120 mg of etoricoxib (E120 group), the same dose of etoricoxib combined with I g of paracetamol (E + P group) or placebo (Pla group). To alleviate post-operative pain, a patient-controlled analgesia (PCA) device was programmed to deliver 50 mu g of fentanyl intravenously (lockout time, 5 min). The pain intensity and nausea were assessed using a visual analogue scale (VAS). The number of patients with post-operative nausea and vomiting was recorded. Blood loss was compared between the groups. Because the operations are almost blood-less, the operation time was also recorded to compare the possible effect on bleeding time. Results: Pre-medication with etoricoxib or etoricoxib plus paracetamol had a statistically significant fentanyl-sparing effect 2-20 h post-operatively compared with placebo (P = 0.001). No significant differences were demonstrated in fentanyl-sparing effect between the E120 and E + P groups. No significant differences in pain intensity were found between the three study groups. No significant differences were observed between the groups with regard to nausea, blood loss, duration of anaesthesia or duration of surgery. Conclusion: Etoricoxib is suitable for pre-medication before laparoscopic cholecystectomy as it reduces the need for postoperative opioids. Opioid-related side-effects, however, were not reduced in the present study, despite the observed opioid-sparing effect of etoricoxib and combined etoricoxib and paracetamol.	Dist Hosp Valkeakoski, Dept Anaesthesiol, Tampere, Finland; Med Ctr Mehilainen, Tampere, Finland; Tampere Univ Hosp, Dept Child Psychiat, Tampere, Finland; Univ Tampere, Sch Med, FIN-33101 Tampere, Finland; Univ Tampere, Sch Publ Hlth, FIN-33101 Tampere, Finland	Puura, A (reprint author), Katajatie 19 B, FIN-36200 Kangasala, Finland.	arto.puura@mehilainen.fi					BARDEN J, 2003, COCHRANE DB SYST REV, V2; BARDEN J, 2003, BMC ANESTHESIOL, V3, P1; Barden Jodie, 2002, BMC Anesthesiol, V2, P4, DOI 10.1186/1471-2253-2-4; Cochrane DJ, 2002, DRUGS, V62, P2637, DOI 10.2165/00003495-200262180-00006; Dallob A, 2003, J CLIN PHARMACOL, V43, P573, DOI 10.1177/0091270003253703; Hyllested M, 2002, BRIT J ANAESTH, V88, P199, DOI 10.1093/bja/88.2.199; Kehlet H, 2001, BRIT J ANAESTH, V87, P62, DOI 10.1093/bja/87.1.62; McQuay HJ, 2000, EVIDENCE BASED RESOURCE IN ANAESTHESIA AND ANALGESIA, P87; Romsing J, 2005, ACTA ANAESTH SCAND, V49, P133, DOI 10.1111/j.1399-6576.2005.00614.x; Romsing J, 2004, ACTA ANAESTH SCAND, V48, P525, DOI 10.1111/j.0001-5172.2004.00379.x; ROMUNDSTAD L, 2005, EUR J PAIN; RORARIUS MGF, 1993, BRIT J ANAESTH, V70, P293, DOI 10.1093/bja/70.3.293; RORARIUS MGF, 2006, ACTA U TAMPERENSIS A, V10, P177; VANE JR, 1971, NATURE-NEW BIOL, V231, P231	14	36	41	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JUL	2006	50	6					688	693		10.1111/j.1399-6576.2006.01049.x			6	Anesthesiology	Anesthesiology	064AE	WOS:000239060800008	16987363				2020-06-30	J	Anderson, RE; Jakobsson, JG				Anderson, R. E.; Jakobsson, J. G.			Cerebral state index response to incision: a clinical study in day-surgical patients	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						ambulatory surgical procedures; intra-operative monitoring; propofol	BISPECTRAL INDEX; GENERAL-ANESTHESIA; AWARENESS; PROPOFOL; CONSUMPTION; SEVOFLURANE; ISOFLURANE; INDUCTION; RECOVERY; SEDATION	Background: Inadequate anaesthesia, with somatic/autonomic response or awareness, is often revealed at intubation and surgical incision. Anaesthetic depth monitors should be able to prevent this risk. This explorative study examined the ability of the cerebral state monitor to predict autonomic/somatic responses to incision. Methods: Forty-two ASA I-II day-surgical patients [19 men and 23 females; mean age 52 (29-79) years, mean weight 77 (50-118) kg] were induced clinically with fentanyl/propofol with sevoflurane after placement of the laryngeal mask airway. The cerebral state index (CSI (TM)) was blindly recorded 4 min prior to and 4 min after incision. Results: During the 4 min prior to incision, the mean CSI (TM) was 45 (16-62) and increased by 9 (-13-40) when the mean value for the first 4 min after incision was subtracted from the value prior to incision, corresponding to a relative change of 21% (-21-118). The change in CSI (TM) did not show any consistent relation to the value before incision. Five patients showed minor movements after incision and six patients had > 25% increase in blood pressure. Neither CSI (TM) nor the change in index differed between patients who did or did not respond somatically or autonomically to incision. The last CSI (TM) value just prior to incision was 44 for nonresponders and 40 and 42 for somatic and autonomic responders, respectively. Conclusion: The CSI (TM) in the majority of patients was within acceptable ranges during clinically adjusted anaesthesia prior to incision but seems not to be able to reliably predict an autonomic or somatic response to incision.	Karolinska Hosp, Dept Cardiothorac Anaesthet & Intens Care, S-10401 Stockholm, Sweden; Karolinska Inst, Dept Anaesthesiol & Intens Care, Stockholm, Sweden	Jakobsson, JG (reprint author), Sabbatsbergs Hosp, Dept Anesthesiol, S-11324 Stockholm, Sweden.	jan.jakobsson@kirurgi.ki.se					Anderson RE, 2005, ACTA ANAESTH SCAND, V49, P750, DOI 10.1111/j.1399-6576.2005.00737.x; Barr G, 2000, ACTA ANAESTH SCAND, V44, P807, DOI 10.1034/j.1399-6576.2000.440707.x; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Ekman A, 2004, ACTA ANAESTH SCAND, V48, P20, DOI 10.1111/j.1399-6576.2004.00260.x; EVANS JM, 1987, BRIT J ANAESTH, V59, P1346, DOI 10.1093/bja/59.11.1346; Holmstrom A, 2005, ACTA ANAESTH SCAND, V49, P754, DOI 10.1111/j.1399-6576.2005.00697.x; Jensen EW, 2004, ACTA ANAESTH SCAND, V48, P1260, DOI 10.1111/j.1399-6576.2004.00521.x; Katoh T, 1998, ANESTHESIOLOGY, V88, P642, DOI 10.1097/00000542-199803000-00014; Liu SS, 2004, ANESTHESIOLOGY, V101, P311, DOI 10.1097/00000542-200408000-00010; Maattanen H, 2002, ACTA ANAESTH SCAND, V46, P882, DOI 10.1034/j.1399-6576.2002.460720.x; McCulloch TJ, 2005, ANESTH ANALG, V100, P1221, DOI 10.1213/01.ANE.0000149022.48021.24; Myles PS, 2004, LANCET, V363, P1757, DOI 10.1016/S0140-6736(04)16300-9; Recart A, 2003, ANESTH ANALG, V97, P1667, DOI 10.1213/01.ANE.0000087041.63034.8C; Rinaldi S, 2005, ACTA ANAESTH SCAND, V49, P692, DOI 10.1111/j.1399-6576.2005.00658.x; Sebel PS, 2004, ANESTH ANALG, V99, P833, DOI 10.1213/01.ANE.0000130261.90896.6C; SHIM CY, 1972, ANESTHESIOLOGY, V36, P146, DOI 10.1097/00000542-197202000-00014; Struys MMRF, 2003, ANESTHESIOLOGY, V99, P802, DOI 10.1097/00000542-200310000-00010; VERNON JM, 1995, ANESTH ANALG, V80, P780, DOI 10.1097/00000539-199504000-00023; White PF, 2004, ANESTHESIOLOGY, V100, P811, DOI 10.1097/00000542-200404000-00010	19	6	8	0	1	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JUL	2006	50	6					749	753		10.1111/j.1399-6576.2006.01028.x			5	Anesthesiology	Anesthesiology	064AE	WOS:000239060800018	16987372				2020-06-30	J	Dempsey, EM; Al Hazzani, F; Faucher, D; Barrington, KJ				Dempsey, E. M.; Al Hazzani, F.; Faucher, D.; Barrington, K. J.			Facilitation of neonatal endotracheal intubation with mivacurium and fentanyl in the neonatal intensive care unit	ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION			English	Article							RANDOMIZED CONTROLLED-TRIAL; TRACHEAL INTUBATION; PREMEDICATION; PRETERM; INFANTS	Background: Endotracheal intubation in the neonate is painful and is associated with adverse physiological effects. Some premedication regimens have been shown to reduce these effects, but the optimal regimen is not yet determined. Method: Data on semi-elective intubations were prospectively collected in the neonatal intensive care unit over a six month period. Patients received 20 mu g/kg atropine, 200 mu g/kg mivacurium (a non-depolarising muscle relaxant) followed by 5 mu g/kg fentanyl. Results: Thirty three patients were electively intubated during this time period. The primary reason for intubation was surfactant administration (53%). Median (range) birth weight, gestational age, and age at intubation were 1360 9 (675-4200), 29 weeks (25-38), and 33 hours (1-624) respectively. Twenty two of the infants were intubated on the first attempt. Median duration from initial insertion of the laryngoscope to successful intubation was 60 seconds (15 seconds to 20 minutes). In 18 cases, the first attempt was by a trainee with no previous successful intubation experience, 10 of whom intubated within two attempts. Muscle relaxation occurred at a mean (SD) of 94 (51) seconds, and mean (range) time to return of spontaneous movements was 937 seconds (480-1800). Intubation conditions were scored as excellent using a validated intubation scale. Conclusion: Effective analgesia can be administered and intubation performed with some brief desaturations, even when junior personnel are being taught their first intubation. In this first report of mivacurium for intubation in the newborn, effective bag and mask ventilation was easily achieved during muscle relaxation and was associated with excellent intubation conditions, permitting a high success rate for inexperienced personnel.	McGill Univ, Ctr Hlth, Dept Pediat, Montreal, PQ, Canada; McGill Univ, Ctr Hlth, Dept Obstet Gynaecol, Montreal, PQ, Canada	Dempsey, EM (reprint author), Coombe Womens Hosp, Dept Neonatol, Dublin 8, Ireland.	edempsey@coombe.ie	Hazzani, Fahad Al/S-8170-2016; Dempsey, Eugene Michael/H-8051-2015	Hazzani, Fahad Al/0000-0001-8995-9418; Dempsey, Eugene Michael/0000-0002-6266-3462			Barrington KJ, 1998, AM J PERINAT, V15, P213, DOI 10.1055/s-2007-993928; Bhutada A, 2000, ARCH DIS CHILD-FETAL, V82, pF34, DOI 10.1136/fn.82.1.F34; COOK DR, 1995, ACTA ANAESTH SCAND, V39, P35, DOI 10.1111/j.1399-6576.1995.tb04307.x; Duncan HP, 2001, PAEDIATR ANAESTH, V11, P135, DOI 10.1046/j.1460-9592.2001.00535.x; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; Falck AJ, 2003, PEDIATRICS, V112, P1242, DOI 10.1542/peds.112.6.1242; FERNANDEZ CV, 1994, CAN MED ASSOC J, V150, P499; FRIESEN RH, 1987, ANESTH ANALG, V66, P874; GOLDBERG ME, 1989, ANESTH ANALG, V69, P93; Hancock S, 2000, ARCH DIS CHILD-FETAL, V83, pF77; Konrad C, 1998, ANESTH ANALG, V86, P635; LEMYRE B, 2004, PEDIATRICS, V4, P20; Leone TA, 2005, J PEDIATR-US, V146, P638, DOI 10.1016/j.jpeds.2005.01.029; McAllister JD, 1999, PEDIATR CLIN N AM, V46, P1249, DOI 10.1016/S0031-3955(05)70185-1; Oei J, 2002, J PAEDIATR CHILD H, V38, P146, DOI 10.1046/j.1440-1754.2002.00726.x; POKELA ML, 1994, ACTA PAEDIATR, V83, P151, DOI 10.1111/j.1651-2227.1994.tb13040.x; Shah V, 2002, CLIN PERINATOL, V29, P535, DOI 10.1016/S0095-5108(02)00019-2; Vogel S, 2000, PEDIATR RES, V47, p438A; Whyte S, 2000, ARCH DIS CHILD-FETAL, V82, pF38, DOI 10.1136/fn.82.1.F38	19	39	39	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1359-2998			ARCH DIS CHILD-FETAL	Arch. Dis. Child.-Fetal Neonatal Ed.	JUL	2006	91	4					F279	F282		10.1136/adc.2005.087213			4	Pediatrics	Pediatrics	061BI	WOS:000238845800010	16464937	Green Published			2020-06-30	J	Chinellato, A; Terrazzani, G; Debetto, P; Zambon, P; Guzzinati, S; Walley, T; Giusti, P				Chinellato, Alessandro; Terrazzani, Gianni; Debetto, Patrizia; Zambon, Paola; Guzzinati, Stefano; Walley, Tom; Giusti, Pietro			Retrospective analysis of opioid prescriptions in cancer patients in a northern Italian Region	BRITISH JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						cancer pain; morphine; opioid prescribing; transdermal fentanyl	PAIN; OUTPATIENTS; MORPHINE	We evaluated patterns of use of opioids in palliative care across one region in Italy by cross-referencing a cancer registry with unique patient identifiers, with prescription databases. There were 90 803 patients in the registry, of whom 39 597 died during the study period. Only 8539 (21%) of these were prescribed opioids at the time of their death. Prescribed daily doses of oral morphine used (45 mg) and of buprenorphine (0.71 mg) were low compared with injected morphine (28.6 mg, equivalent to approximately 90 mg of oral morphine) and especially with doses of transdermal fentanyl (1.13 mg, equivalent to approximately 180 mg morphine). The reasons for this acceptance of transdermal fentanyl and reluctance to use oral morphine are unclear, but it seems that more effort in educating healthcare professionals and patients about the use of morphine would be useful. The use of more detailed prescribing data such as prescribed or received daily doses can add to our understanding of headline prescribing data.	Univ Padua, Dept Pharmacol & Anaesthesiol E Meneghetti, I-35131 Padua, Italy; Off Pharmaceut Serv, Treviso, Italy; Registro Tumori Veneto, Serv Epidemiol Tumori, Padua, Italy; Univ Liverpool, Dept Pharmacol & Therapeut, Prescribing Res Grp, Liverpool, Merseyside, England	Giusti, P (reprint author), Univ Padua, Dept Pharmacol & Anaesthesiol E Meneghetti, Largo Meneghetti 2, I-35131 Padua, Italy.	pietro.giusti@unipd.it	Guzzinati, Stefano/K-4987-2012	guzzinati, stefano/0000-0002-4908-5506; GIUSTi, Pietro/0000-0001-9352-4046			*BRIT NAT FORM, 2005, BMA, V44, P14; Chinellato A, 2003, LANCET, V362, P78, DOI 10.1016/S0140-6736(03)13819-6; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; *INCB, 2001, [No title captured]; McCaffery M, 1996, NURS OUTLOOK, V44, P184, DOI 10.1016/S0029-6554(96)80039-X; McNamara P, 2002, PALLIATIVE MED, V16, P425, DOI 10.1191/0269216302pm536oa; Mercadante S, 1996, J PAIN SYMPTOM MANAG, V11, P108, DOI 10.1016/0885-3924(95)00147-6; Mercadante S, 2000, SUPPORT CARE CANCER, V8, P123, DOI 10.1007/s005200050026; Mercadante S, 2002, LANCET, V360, P1254, DOI 10.1016/S0140-6736(02)11261-X; Salvato C, 2003, PHARMACOL RES, V48, P75, DOI 10.1016/S1043-6618(03)00060-4; Vainio A, 1998, ACTA ONCOL, V37, P743, DOI 10.1080/028418698430142; *WHO, 2002, WHO COLL CTR DRUG ST; *WHO, 2005, [No title captured]; World Health Organization, 1996, CANC PAIN REL	14	14	14	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0306-5251	1365-2125		BRIT J CLIN PHARMACO	Br. J. Clin. Pharmacol.	JUL	2006	62	1					130	133		10.1111/j.1365-2125.2006.02600.x			4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	055XW	WOS:000238485500013	16842385	Green Published			2020-06-30	J	Mystakidou, K; Katsouda, E; Parpa, E; Vlahos, L; Tsiatas, ML				Mystakidou, Kyriaki; Katsouda, Emmanuela; Parpa, Efi; Vlahos, Lambros; Tsiatas, Marinos L.			Oral transmucosal fentanyl citrate: Overview of pharmacological and clinical characteristics	DRUG DELIVERY			English	Article						breakthrough pain; cancer; oral transmucosal fentanyl citrate	BREAKTHROUGH CANCER PAIN; DOSE-TITRATION; TRANSDERMAL FENTANYL; CASE SERIES; PHARMACOKINETICS; MANAGEMENT; MORPHINE; MULTICENTER; TRIAL	Oral transmucosal fentanyl citrate ( OTFC; brand name Actiq(R), Cephalon, UT) is a new opioid formulation that incorporates fentanyl into a lozenge and allows drug delivery through the buccal mucosa. This kind of absorption avoids first-pass metabolism, yielding a bioavailability substantially greater than oral administration. OTFC has a rapid onset of action and a short duration of effect. These characteristics, which resemble the course of a typical breakthrough pain episode, resulted in making OTFC the first opioid analgesic formulation specifically developed and approved for control of breakthrough pain in cancer patients. Apart from that, OTFC has been used in a variety of clinical situations of noncancer pain. This review article presents the synthesis; clinical pharmacology; pharmacokinetic and pharmacodynamic properties, toxicity, and clinical efficacy of this novel agent.	Univ Athens, Dept Radiol, Pain Relief & Palliat Care Unit, Athens, Greece; Univ Athens, Dept Clin Therapeut, Athens, Greece	Mystakidou, K (reprint author), Univ Athens, Areteion Hosp, Sch Med, Dept Radiol,Pain Relief & Palliat Care Unit, 27 Korinthias St, Athens 11526, Hellas, Greece.	mistakidou@yahoo.com					Burton AW, 2004, CLIN J PAIN, V20, P195, DOI 10.1097/00002508-200405000-00011; CARTWRIGHT P, 1983, ANESTH ANALG, V62, P966; *CEPH INC, 2003, ACT SUMM PROD CHAR; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; COHEN MR, 1982, PSYCHIAT RES, V6, P7, DOI 10.1016/0165-1781(82)90032-4; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Hanks GW, 2004, PALLIATIVE MED, V18, P698, DOI 10.1191/0269216304pm966oa; Landy SH, 2004, HEADACHE, V44, P762, DOI 10.1111/j.1526-4610.2004.04142.x; Lee M, 2003, J PAIN SYMPTOM MANAG, V26, P743, DOI 10.1016/S0885-3924(03)00241-0; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; McMenamin Erin, 2002, Expert Rev Neurother, V2, P625, DOI 10.1586/14737175.2.5.625; MEULDERMANS WEG, 1982, ARCH INT PHARMACOD T, V257, P4; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; SCHECHTER NL, 1995, PEDIATRICS, V95, P335; Shaiova L, 2004, J NATL MED ASSOC, V96, P984; Sharar S. R., 2002, Journal of Burn Care & Rehabilitation, V23, P27, DOI 10.1097/00004630-200201000-00006; Sharer SR, 1998, J BURN CARE REHABIL, V19, P516, DOI 10.1097/00004630-199811000-00010; Simmonds MA, 1999, ONCOLOGY-NY, V13, P1103; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; TAMSEN A, 1982, PAIN, V13, P171, DOI 10.1016/0304-3959(82)90027-6	27	33	34	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1071-7544	1521-0464		DRUG DELIV	Drug Deliv.	JUL-AUG	2006	13	4					269	276		10.1080/10717540500394661			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	047VH	WOS:000237906300004	16766468				2020-06-30	J	Katz, NP; Buse, DC; Budman, SH; Venuti, SW; Fernandez, KC; Benoit, C; Bianchi, R; Cooper, D; Jasinski, DR; Smith, DE; Butler, SF				Katz, N. P.; Buse, D. C.; Budman, S. H.; Venuti, S. Wing; Fernandez, K. C.; Benoit, C.; Bianchi, R.; Cooper, D.; Jasinski, D. R.; Smith, D. E.; Butler, S. F.			Development and preliminary experience with an ease of extractability rating system for prescription opioids	DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY			English	Article						extractability; substance abuse; opioid; narcotic; Controlled Substances Act		One important factor in the abuse potential of an opioid product is the ease with which active drug can be extracted. There are currently no standards for testing or reporting extractability. This article describes the development of an Extractability Rating System for use by the pharmaceutical industry and regulators. Despite several limitations, this effort serves as a call for standardized testing and reporting so that products can be accurately rated, and should help establish goals for drug developers who wish to develop "abuse-resistant" opioid products.	Inflexxion Inc, Newton, MA 02464 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA; Harvard Univ, Sch Med, Boston, MA USA; Prescript Drug Res Ctr, Fairfax, VA USA; Signature Consulting, Rockville, MD USA; Johns Hopkins Bayview Med Ctr, Baltimore, MD USA; Haight Ashbury Free Clin, San Francisco, CA USA	Fernandez, KC (reprint author), Inflexxion Inc, 320 Needham St,Suite 100, Newton, MA 02464 USA.	kfernandez@inflexxion.com	Butler, Stephen/AAK-7902-2020; Sharry, John A Mac/B-5509-2011	Butler, Stephen/0000-0002-6132-5883; Sharry, John A Mac/0000-0002-9528-6261			*AM PAIN SOC, 2004, PRINC AN US TREATM A; Bigne J.E., 2002, QUALITATIVE MARKET R, V5, P87, DOI DOI 10.1108/13522750210423724; Butler SF, 2004, ADDICTION, V99, P413, DOI 10.1111/j.1360-0443.2004.00705.x; *DRUG AB WARN NETW, 2002, ED TRENDS DAWN FIN E; Jackson KM, 2002, ORGAN RES METHODS, V5, P307, DOI 10.1177/109442802237114; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.1.30; Siegel S, 1956, NONPARAMETRIC STAT B; *SUBST AB MENT HLT, 2002, 2002 LAT NAT SURV DR; Tracey TJG, 2003, PSYCHOTHER RES, V13, P401, DOI 10.1093/ptr/kpg041; TROCHIM WMK, 1989, EVAL PROGRAM PLANN, V12, P1, DOI 10.1016/0149-7189(89)90016-5; Weller S. C., 1988, SYSTEMATIC DATA COLL, V10; West DC, 2002, MED EDUC, V36, P820, DOI 10.1046/j.1365-2923.2002.01292.x	13	19	19	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0363-9045	1520-5762		DRUG DEV IND PHARM	Drug Dev. Ind. Pharm.	JUL	2006	32	6					727	746		10.1080/03639040500529093			20	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	059WA	WOS:000238761700009	16885128				2020-06-30	J	Erkent, U; Iskit, AB; Onur, R; Ilhan, M				Erkent, U.; Iskit, A. B.; Onur, R.; Ilhan, M.			The effect of nitric oxide on fentanyl and haloperidol-induced catalepsy in mice	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article; Proceedings Paper	Meeting of the Turkish-Pharmacology-Society/17th National Congress of Pharmacology/1st Clinical Pharmacology Symposium	OCT 17-21, 2003	Belek, TURKEY	Turkish Pharmacol Soc		fentanyl; haloperidol; nitric oxide opioid; dopamine; catalepsy	IN-VIVO; STRIATAL DOPAMINE; MOTOR-ACTIVITY; SYNTHASE; RAT; RELEASE; INVOLVEMENT; RECEPTORS; INHIBITION; GLUTAMATE	Background and objectives: This study was designed to investigate the role of nitric oxide on catalepsy induced by fentanyl and haloperidol. Methods: Male albino mice were treated either with fentanyl (0.1-0.2 mg kg(-1), s.c.) or haloperidol (0.5-2 mg kg(-1), i.p.). The non-selective nitric oxide synthase inhibitor, N-G-nitro-L-arginine (10 mg kg(-1), i.p.), selective neuronal nitric oxide synthase inhibitor, 7-nitroindazole (3 mg kg(-1), i.p.), and I nitric oxide donors, L-arginine (30-300 mg kg(-1), i p.) and D-arginine (3 0 mg kg(-1) i.p.), were applied 20 min prior to fentanyl or haloperidol injection. A mu-opioid receptor antagonist naloxone (1 mg kg(-1), i. p.) was also given in some groups. The cataleptic status of mice was assessed by placing animals in a rearing position in the cage. If the mouse maintained cataleptic posture for more than 20 s, it was scored as cataleptic and duration of catalepsy was expressed in terms of minutes. Results: Both NG-nitro-L-arginine and 7-nitroindazole prolonged fentanyl-induced catalepsy (fentanyl: 3.6 +/- 0.8 min; fentanyl + N-G-nitro-L-arginine: 77.4 +/- 14.6 min, fentanyl + 7-nitroindazole: 56.0 +/- 10.4 min; n = 6; P < 0.01). This effect was reversed by L-arginine and naloxone, but not by D-arginine. Nitric oxide synthase inhibitors also prolonged the cataleptic action of haloperldol but to a lesser extent (haloperidol: 72.0 +/- 6.3 min; haloperidol + N-G-nitro-L-arginine: 98.5 6.3 min, haloperidol + 7-nitroindazole: 89.6 +/- 2.2 min; n = 6; P < 0.05). The prolongation of haloperidol-induced catalepsy with nitric oxide synthase inhibitors was not reversed by L-arginine. Conclusion: These results suggest a common mechanism between p-oploid receptors and the nitric oxide system in the development of fentanyl-induced catalepsy in mice different from haloperidol-induced catalepsy.	Univ Hacettepe, Fac Med, Dept Pharmacol, TR-06100 Ankara, Turkey	Iskit, AB (reprint author), Univ Hacettepe, Fac Med, Dept Pharmacol, TR-06100 Ankara, Turkey.	alperi@hacettepe.edu.tr					ABEKAWA T, 1994, BRAIN RES, V666, P147, DOI 10.1016/0006-8993(94)90298-4; Adams MR, 1997, P NATL ACAD SCI USA, V94, P12157, DOI 10.1073/pnas.94.22.12157; Afify EA, 2001, PHARMACOL RES, V44, P533, DOI 10.1006/phrs.2001.0887; Araki T, 2001, EUR NEUROPSYCHOPHARM, V11, P125, DOI 10.1016/S0924-977X(01)00077-3; BANERJEE U, 1968, BRIT J PHARMACOL, V33, P544, DOI 10.1111/j.1476-5381.1968.tb00503.x; Bashkatova V, 2004, EXP NEUROL, V186, P235, DOI 10.1016/j.expneurol.2003.12.005; Buyukuysal RL, 1997, FUNDAM CLIN PHARM, V11, P528; Chen SW, 1996, EUR J PHARMACOL, V312, P241, DOI 10.1016/0014-2999(96)00571-7; Dall'Igna OP, 2001, EUR J PHARMACOL, V432, P29, DOI 10.1016/S0014-2999(01)01457-1; Del Bel EA, 2000, PSYCHOPHARMACOLOGY, V147, P356, DOI 10.1007/s002130050003; Del Bel EA, 2002, PSYCHOPHARMACOLOGY, V161, P32, DOI 10.1007/s00213-002-1009-2; Desvignes C, 1999, NEUROSCI LETT, V261, P175, DOI 10.1016/S0304-3940(99)00026-9; Dzoljic E, 1997, BEHAV BRAIN RES, V87, P209, DOI 10.1016/S0166-4328(97)02281-X; EZRINWATERS C, 1977, EUR J PHARMACOL, V41, P321, DOI 10.1016/0014-2999(77)90325-9; Gupta M, 2001, METHOD FIND EXP CLIN, V23, P497, DOI 10.1358/mf.2001.23.9.662138; HAVEMANN U, 1980, N-S ARCH PHARMACOL, V313, P139, DOI 10.1007/BF00498570; Ignarro I.J., 1990, ANN REV PHARM TOXICO, V30, P535; Kiss JP, 2004, NEUROCHEM INT, V45, P485, DOI 10.1016/j.neuint.2003.11.004; Liang LP, 1998, BRAIN RES, V800, P181, DOI 10.1016/S0006-8993(98)00452-1; LING GSF, 1982, NEUROSCI LETT, V32, P193, DOI 10.1016/0304-3940(82)90273-7; MALEC D, 1977, POL J PHARMACOL PHAR, V29, P177; Marras RA, 1995, NEUROREPORT, V7, P158, DOI 10.1097/00001756-199512290-00038; Morris BJ, 1997, NEUROPHARMACOLOGY, V36, P1589, DOI 10.1016/S0028-3908(97)00159-7; NODA Y, 1995, EUR J PHARMACOL, V286, P291, DOI 10.1016/0014-2999(95)00464-X; Pires JGP, 1998, BRAZ J MED BIOL RES, V31, P417, DOI 10.1590/S0100-879X1998000300014; PORRECA F, 1992, J PHARMACOL EXP THER, V263, P147; SANBERG PR, 1988, BEHAV NEUROSCI, V102, P748, DOI 10.1037/0735-7044.102.5.748; SANDI C, 1995, EUR J PHARMACOL, V277, P89, DOI 10.1016/0014-2999(95)00068-V; SANDOR NT, 1995, BRAIN RES BULL, V36, P483, DOI 10.1016/0361-9230(94)00229-T; Segovia G, 1998, BRAIN RES BULL, V45, P275, DOI 10.1016/S0361-9230(97)00402-4; STARR MS, 1995, EUR J PHARMACOL, V277, P151, DOI 10.1016/0014-2999(95)00063-Q; VANDERWENDE C, 1979, NEUROPHARMACOLOGY, V18, P633, DOI 10.1016/0028-3908(79)90117-5; WAUQUIER A, 1975, PSYCHOPHARMACOLOGIA, V41, P229, DOI 10.1007/BF00428929; West AR, 2000, J NEUROPHYSIOL, V83, P1796; West AR, 1997, NEUROPHARMACOLOGY, V36, P1571, DOI 10.1016/S0028-3908(97)00148-2; Zarrindast MR, 2003, EUR J PHARMACOL, V482, P205, DOI 10.1016/j.ejphar.2003.10.006	36	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	JUL	2006	23	7					580	585		10.1017/S0265021506000226			6	Anesthesiology	Anesthesiology	059SI	WOS:000238752100007	16507184				2020-06-30	J	Kostopanagiotou, G; Markantonis, SL; Arkadopoulos, N; Andreadou, I; Charalambidis, G; Chondroudaki, J; Costopanagiotou, C; Smyrniotis, V				Kostopanagiotou, G.; Markantonis, S. L.; Arkadopoulos, N.; Andreadou, I.; Charalambidis, G.; Chondroudaki, J.; Costopanagiotou, C.; Smyrniotis, V.			The effect of acutely induced hepatic failure on remifentanil and fentanyl blood levels in a pig model	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						acute liver failure; opioid analgesics; fentanyl; remifentanil; pharmacokinetics; pig model	ACUTE LIVER-FAILURE; INTRACRANIAL-PRESSURE; HEMORRHAGIC-SHOCK; PHARMACOKINETICS; PHARMACODYNAMICS; TRANSPLANTATION; DISEASE; DOGS	Background and objective: Opioids and especially fentanyl are widely used during the intensive care unit management of intracranial pressure in fulminant hepatic failure patients as well as during and after liver transplantation. The newer synthetic opioid remifentanil is also increasingly being used in critical care patients. Due to a lack of data relating to the influence of acute hepatic failure on remifentanil and fentanyl pharmacokinetics, this study was designed in order to determine the impact of this condition on the blood levels of these opioids using a pig model. Methods: Twenty pigs were randomly assigned to one of two groups: A group with surgically induced acute hepatic failure by hepatic devascularization (acute hepatic failure, n = 10) and a control group (SHAM, n = 10), subjected to a SHAM operation. Postoperatively, five animals in each group were administered remifentanil (1 mu g kg(-1) min(-1)) or fentanyl (0.2 mu g kg(-1) min(-1)) by continuous intravenous infusion. Blood samples for determination of drug concentrations were withdrawn at Oh and 0.5, 1, 5, 7, 9h after initiation of dosing. Results: Significantly higher blood concentrations were found in animals with acute hepatic failure compared to SHAM-operated animals receiving remifentanil at 5 h (P = 0.003), 7 h (P = 0.007) and 9 h (P = 0.004) and fentanyl at 7 h (P < 0.0005) and 9 h (P = 0.05). The small number and the great variability in drug concentrations did not allow a detailed kinetic analysis to be performed. Approximate clearance values were found to be greater for the SHAM compared with the acute hepatic failure animals for both fentanyl and remifentanil. Conclusions: Hepatic devascularization in our porcine acute hepatic failure model, appears to have significantly altered the disposition of fentanyl and unexpectedly remifentanil. These changes were thought to be brought about by severe disruption of blood flow and biotransformation in the liver, as well as by haemodynamic changes in the acute hepatic failure animals.	Univ Athens, Lab Biopharmaceut & Pharmacokinet, Sch Pharm, GR-15771 Athens, Greece; Univ Athens, Sch Med, Attikon Hosp, Dept Anaesthesiol 2, Haidari, Greece; Univ Athens, Sch Med, Dept Surg 2, Athens, Greece	Markantonis, SL (reprint author), Univ Athens, Lab Biopharmaceut & Pharmacokinet, Sch Pharm, GR-15771 Athens, Greece.	kyroudi@pharm.uoa.gr	Andreadou, Ioanna/AAF-7284-2019				ASCHER NL, 1993, ARCH SURG-CHICAGO, V128, P677; BOOS DL, 1989, MANUAL NEUROANAESTHE, P37; CARACENI P, 1995, LANCET, V345, P163, DOI 10.1016/S0140-6736(95)90171-X; Chism JP, 1996, DRUG METAB DISPOS, V24, P34; Dershwitz M, 1996, ANESTHESIOLOGY, V84, P812, DOI 10.1097/00000542-199604000-00008; Egan TD, 1999, ANESTHESIOLOGY, V91, P156, DOI 10.1097/00000542-199907000-00024; Eisenhuber E, 1998, WIEN KLIN WOCHENSCHR, V110, P564; FINGEROTE RJ, 1993, AM J GASTROENTEROL, V88, P1000; GILLESPIE TJ, 1981, J ANAL TOXICOL, V5, P133, DOI 10.1093/jat/5.3.133; HABERER JP, 1982, BRIT J ANAESTH, V54, P1267, DOI 10.1093/bja/54.12.1267; HANID MA, 1979, GASTROENTEROLOGY, V76, P123; Hoke JF, 1997, J PHARMACOL EXP THER, V281, P226; HUDSON RJ, 1986, ANESTHESIOLOGY, V64, P334, DOI 10.1097/00000542-198603000-00006; Johnson KB, 2001, ANESTHESIOLOGY, V94, P322, DOI 10.1097/00000542-200102000-00023; Kostopanagiotou G, 2003, HEPATOLOGY, V37, P1130, DOI 10.1053/jhep.2003.50185; LEE WM, 1993, NEW ENGL J MED, V329, P1862, DOI 10.1056/NEJM199312163292508; MARKS RM, 1973, ANN INTERN MED, V78, P173, DOI 10.7326/0003-4819-78-2-173; MOSS E, 1978, BRIT J ANAESTH, V50, P779, DOI 10.1093/bja/50.8.779; MUNOZ SJ, 1993, SEMIN LIVER DIS, V13, P395; Navapurkar VU, 1998, BRIT J ANAESTH, V81, P881; Newsham IF, 2000, NEURO-ONCOLOGY, V2, P1, DOI 10.1093/neuonc/2.1.1; NISFELDT BB, 1976, BR J ANESTH, V48, P963; SAKABE T, 1997, ANAESTHESIA NEUROSUR, P152; Schiodt FV, 1999, LIVER TRANSPLANT SUR, V5, P29, DOI 10.1002/lt.500050102; SELINGER K, 1994, J PHARMACEUT BIOMED, V12, P243, DOI 10.1016/0731-7085(94)90035-3; Tegeder I, 1999, CLIN PHARMACOKINET, V37, P17, DOI 10.2165/00003088-199937010-00002; WENDON J, 1995, ACUTE LIVER FAILURE, P93	27	9	9	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	JUL	2006	23	7					598	604		10.1017/S0265021506000135			7	Anesthesiology	Anesthesiology	059SI	WOS:000238752100011	16507181				2020-06-30	J	Hess, PE; Pratt, SD; Oriol, NE				Hess, P. E.; Pratt, S. D.; Oriol, N. E.			An analysis of the need for anesthetic interventions with differing concentrations of labor epidural bupivacaine: an observational study	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						obstetric anesthesia; epidural analgesia; bupivacaine; pain treatment; treatment complications; fentanyl; epinephrine	MATERNAL PREPREGNANCY OVERWEIGHT; OBSTETRIC ANESTHESIA; ANALGESIA; FENTANYL; OBESITY; PAIN	Background: Labor epidural analgesia techniques using lower concentrations of bupivacaine are designed to maintain pain control with fewer side effects such as hypotension and motor block. However, the increase in sensation may allow breakthrough pain resulting in the need for additional interventions. We examined the number of interventions, both for analgesia and for treatment of side effects, required when using three concentrations of bupivacaine. Methods: Retrospective observational investigation examining 4493 women who received epidural analgesia during two periods. In the first period, higher concentrations of bupivacaine were used (0.125% and 0.0625%, both with fentanyl 2 mu g/mL). In the second period, a very low concentration was used (0.04% plus fentanyl 1.7 mu g/mL and epinephrine 1.7 mu g/mL). Outcomes were compared using univariate tests, and multivariate Poisson regression was used to identify independent factors influencing interventions. Results: The frequencies of interventions were similar for women receiving bupivacaine concentrations of 0.04% (1.4 +/- 2.0) and 0.125% (1.5 +/- 2.0), while women receiving the 0.0625% solution required more interventions (1.8 +/- 2.3; P < 0.001). Women who received 0.04% or 0.0625% bupivacaine required more treatment of breakthrough pain (P < 0.002), while those receiving 0.125% bupivacaine required more treatment for hypotension and motor block (P < 0.05). Multivariate Poisson regression showed that duration of treatment, maternal age and body mass index were independent factors for the number of interventions. Conclusions: Neither the total interventions nor intervention rate per hour varied significantly with the concentrations of bupivacaine used in this study. Lower concentrations produced fewer side effects including hypotension, while the higher concentration resulted in less breakthrough pain. (C) 2006 Published by Elsevier Ltd.	Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02215 USA	Hess, PE (reprint author), Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, East Campus,St-308,330 Brookline Ave, Boston, MA 02215 USA.	phess@bidmc.harvard.edu	Hess, Philip/A-8577-2013	Hess, Philip/0000-0002-1206-0102			Bell ED, 2000, ANESTHESIOLOGY, V92, P851, DOI 10.1097/00000542-200003000-00029; BREEN TW, 1993, ANESTH ANALG, V77, P919; Bujold E, 2005, AM J OBSTET GYNECOL, V193, P1517, DOI 10.1016/j.ajog.2005.03.041; CHESTNUT DH, 1988, ANESTHESIOLOGY, V68, P754, DOI 10.1097/00000542-198805000-00013; COHEN SE, 1987, ANESTHESIOLOGY, V67, P403, DOI 10.1097/00000542-198709000-00020; COUSINS MJ, 1984, ANESTHESIOLOGY, V61, P276; CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; Dempsey JC, 2005, J MATERN-FETAL NEO M, V17, P179, DOI 10.1080/14767050500073456; ELLIOTT RD, 1991, CAN J ANAESTH, V38, P303, DOI 10.1007/BF03007619; Hawkins JL, 1997, ANESTHESIOLOGY, V87, P135, DOI 10.1097/00000542-199707000-00018; Hess PE, 2001, ANESTH ANALG, V93, P414; Lyons G, 1997, BRIT J ANAESTH, V78, P493; MacArthur C, 2002, ANESTHESIOLOGY, V97, P1567; MURPHY JD, 1991, BRIT MED J, V302, P564, DOI 10.1136/bmj.302.6776.564; NOBLE HA, 1991, ANAESTHESIA, V46, P549, DOI 10.1111/j.1365-2044.1991.tb09653.x; Polley LS, 2002, ANESTHESIOLOGY, V96, P1123, DOI 10.1097/00000542-200205000-00015; Seoud MAF, 2002, AM J PERINAT, V19, P1, DOI 10.1055/s-2002-20175; Vahratian A, 2004, OBSTET GYNECOL, V104, P943, DOI 10.1097/01.AOG.0000142713.53197.91; Yentis SM, 1999, ANAESTHESIA, V54, P958, DOI 10.1046/j.1365-2044.1999.01064.x	19	4	5	0	1	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JUL	2006	15	3					195	200		10.1016/j.ijoa.2005.12.006			6	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	065NH	WOS:000239166100003	16798443				2020-06-30	J	Evron, S; Muzikant, G; Rigini, N; Khazin, V; Sessler, DI; Sadan, O; Ezri, T				Evron, S.; Muzikant, G.; Rigini, N.; Khazin, V.; Sessler, D. I.; Sadan, O.; Ezri, T.			Patient-controlled epidural analgesia: the role of epidural fentanyl in peripartum urinary retention	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						anesthesia; obstetrics; epidural analgesia; patient-controlled analgesia; urinary retention; urinary bladder catheterization; urinary infection	VOIDING DIFFICULTIES; POSTPARTUM PERIOD; VAGINAL DELIVERY; BLADDER VOLUME; FOLLOW-UP; LABOR; BUPIVACAINE; WOMEN; 0.125-PERCENT; PREVALENCE	Background: Urinary bladder function is impaired during labor and delivery, predisposing to urinary retention. The effect of low-dose epidural opioid on bladder function remains unclear. We tested the hypothesis that adding low-dose fentanyl to epidural ropivacaine for patient-controlled labor analgesia does not promote urinary retention. Methods: Laboring women who requested patient-controlled epidural analgesia were randomly assigned in a double blind study to 0.2% ropivacaine (R-group, n = 100) or 0.2% ropivacaine with fentanyl 2 mu g/mL (RF-group, n = 98). Urinary bladder distension was assessed clinically every hour. The post-void residual urine volume was measured by ultrasonography. Urine volume exceeding 100 mL was drained by catheterization. Bladder volume of >= 300 mL, as determined by catheterization was considered as evidence of urinary retention. Results: Thirty percent of the patients in each group developed urinary retention during labor. There was no statistically significant difference between the groups. There was an excellent correlation between bladder volume as estimated by ultrasonography and that by catheterization: catheterization volume = 0.93 x ultrasound volume + 25; r(2) = 0.83. The bias (mean error) was -1 +/- 99 mL and the precision (average absolute error) between the ultrasound estimate and actual bladder volume determined by catheterization was 58 79 mL. Conclusion: Addition of fentanyl to patient-controlled epidural analgesia did not increase the risk of urinary retention. Ultrasound measurements were effective and reliable in assessing urinary bladder volumes during labor. (C) 2006 Elsevier Ltd. All rights reserved.	Tel Aviv Univ, Sackler Fac Med, Edith Wolfson Med Ctr, Dept Anesthesia,Obstet Anesthesia Unit, IL-58100 Holon, Israel; Tel Aviv Univ, Sackler Fac Med, Edith Wolfson Med Ctr, Dept Obstet & Gynecol, IL-58100 Holon, Israel; Univ Louisville, Dept Anesthesiol & Pharmacol, Louisville, KY 40292 USA; Outcomes Res Inst, Louisville, KY USA	Ezri, T (reprint author), Tel Aviv Univ, Sackler Fac Med, Edith Wolfson Med Ctr, Dept Anesthesia,Obstet Anesthesia Unit, IL-58100 Holon, Israel.	tezri@netvision.net.il	Sessler, Daniel/D-3504-2011	Sessler, Daniel/0000-0001-9932-3077	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 061655]		ABOULEISH E, 1991, ANESTHESIOLOGY, V74, P711, DOI 10.1097/00000542-199104000-00015; ANDERSON JB, 1991, BMJ-BRIT MED J, V302, P894, DOI 10.1136/bmj.302.6781.894; ANDOLF E, 1994, GYNECOL OBSTET INVES, V38, P51, DOI 10.1159/000292445; CARDOZO L, 1993, ULTRASOUND OBST GYN, P1675; Cohen SE, 2000, ANESTHESIOLOGY, V92, P387, DOI 10.1097/00000542-200002000-00019; CRAWFORD JS, 1972, BRIT J ANAESTH, V44, P66, DOI 10.1093/bja/44.1.66; Evron S, 2004, INT J OBSTET ANESTH, V13, P5, DOI 10.1016/S0959-289X(03)00092-X; EVRON S, 1985, PAIN, V23, P135, DOI 10.1016/0304-3959(85)90055-7; Gyampoh B, 2004, BJOG-INT J OBSTET GY, V111, P103, DOI 10.1046/j.1471-0528.2003.00025.x; HERPOLSHEIMER A, 1994, OBSTET GYNECOL, V84, P931; HINMAN F, 1976, SURG GYNECOL OBSTET, V142, P901; HOLMES JH, 1967, J UROLOGY, V97, P654, DOI 10.1016/S0022-5347(17)63094-5; Howell CJ, 2001, BRIT J OBSTET GYNAEC, V108, P27, DOI 10.1016/S0306-5456(00)00012-7; IOSIF S, 1980, AM J OBSTET GYNECOL, V137, P696, DOI 10.1016/S0002-9378(15)33243-9; Jain S, 2003, INT J GYNECOL OBSTET, V83, P19, DOI 10.1016/S0020-7292(03)00201-7; Liang CC, 2002, INT J OBSTET ANESTH, V11, P164, DOI 10.1054/ijoa.2002.0951; LOSE G, 1987, OBSTET GYNECOL, V69, P33; O'Grady F, 1966, Br J Urol, V38, P156, DOI 10.1111/j.1464-410X.1966.tb09694.x; SMITH NKG, 1990, AGE AGEING, V19, P337, DOI 10.1093/ageing/19.5.337; STANTON SL, 1983, OBSTET GYNECOL, V61, P144; WEIL A, 1983, BRIT J OBSTET GYNAEC, V90, P428, DOI 10.1111/j.1471-0528.1983.tb08938.x; WEISSMAN A, 1995, ULTRASOUND OBST GYN, V6, P130, DOI 10.1046/j.1469-0705.1995.06020130.x; Yip SK, 2004, ACTA OBSTET GYN SCAN, V83, P881, DOI 10.1111/j.0001-6349.2004.00460.x; Yip SK, 2002, AM J OBSTET GYNECOL, V187, P648, DOI 10.1067/mob.2002.125278; Yip SK, 1997, ACTA OBSTET GYN SCAN, V76, P667, DOI 10.3109/00016349709024608; YOUNIS MN, 1983, INT J GYNECOL OBSTET, V21, P477, DOI 10.1016/0020-7292(83)90038-3	26	8	8	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JUL	2006	15	3					206	211		10.1016/j.ijoa.2005.10.019			6	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	065NH	WOS:000239166100005	16798445				2020-06-30	J	Paech, M				Paech, Michael			Solutions for patient-controlled epidural analgesia	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Letter							LABOR; BUPIVACAINE; FENTANYL		Univ Western Australia, Perth, WA 6009, Australia	Paech, M (reprint author), Univ Western Australia, Perth, WA 6009, Australia.	michael.paech@health.wa.gov.au		PAECH, MICHAEL/0000-0001-9023-6575			Carvalho B, 2005, INT J OBSTET ANESTH, V14, P223, DOI 10.1016/j.ijoa.2005.02.003; FERRANTE FM, 1995, CLIN J PAIN, V11, P121, DOI 10.1097/00002508-199506000-00006; Paech M J, 1993, Int J Obstet Anesth, V2, P65, DOI 10.1016/0959-289X(93)90081-R; Paech MJ, 2000, REGION ANESTH PAIN M, V25, P34, DOI 10.1016/S1098-7339(00)80008-5; Pirbudak L, 2002, EUR J ANAESTH, V19, P271, DOI 10.1017/S0265021502000431	5	0	0	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JUL	2006	15	3					262	262		10.1016/j.ijoa.2006.03.002			1	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	065NH	WOS:000239166100027	16798466				2020-06-30	J	Bianchi, RP				Bianchi, RP			Letter to the editor - Comparison of fentanyl extraction from two different transdermal patches	JOURNAL OF FORENSIC SCIENCES			English	Letter										Bianchi, RP (reprint author), 5502 Chestermill Court, Fairfax, VA 22030 USA.							0	2	3	0	3	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0022-1198			J FORENSIC SCI	J. Forensic Sci.	JUL	2006	51	4					939	939		10.1111/j.1556-4029.2006.00190.x			1	Medicine, Legal	Legal Medicine	060GI	WOS:000238790200035	16882245				2020-06-30	J	Bilgin, H; Mogol, EB; Bekar, A; Iscimen, R; Korfali, G				Bilgin, H; Mogol, EB; Bekar, A; Iscimen, R; Korfali, G			A comparison of effects of alfentanil, fentanyl, and remifentanil on hemodynamic and respiratory parameters during stereotactic brain biopsy	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						fentanyl; alfentanil; remifentanil; stereotactic brain biopsy; hemodynamic parameters; respiratory parameters	MONITORED ANESTHESIA CARE; OUTPATIENT ANESTHESIA; MIDAZOLAM; SEDATION; INFUSION; PHARMACODYNAMICS; PHARMACOKINETICS; CRANIOTOMY; DEPRESSION; SURGERY	The aim of this study was to compare the effects of 3 different sedative-analgesic regimens in patients with intracranial mass lesions undergoing stereotactic brain biopsy. A 135 outpatients with American Society of Anesthesiologists I to II were divided into 3 groups: group A (n = 45) received a loading dose of IV alfentanil 7.5 mu g/kg followed by infusion rate of 0.25 mu g/kg/min; group F (n = 45) received a bolus dose of 1 mu g/kg IV fentanyl and repeated as needed; and group R (n = 45) received infusion of 0.05 mu g/kg/min remifentanil. Target level of sedation was 3 to 4 of the Ramsay Sedation Scale. Systolic and diastolic blood pressure, heart rate, respiratory rate, peripheric oxygen saturation (SpO(2)), and end-tidal carbon dioxide were recorded at different stages of the procedures. The patients in group F had significantly lower mean heart rate than those in groups A and R, but this was not in the limits of the bradycardia. The patients in group A had significantly lower mean SpO(2) than those in the other groups, but mean SpO(2) values did not drop below 94%. There were no significant differences in end-tidal carbon dioxide and respiratory rate values among the groups. Our results suggest that all 3 regimens have relatively similar hemodynamic and respiratory responses. The use of bolus fentanyl technique caused less hemodynamic stability. The continuous infusion technique of remifentanil or alfentanil provided better control on hemodynamic parameters.	Uludag Univ, Tip Fak, Anestezyiol Reanimasyon AD, TR-16059 Bursa, Turkey; Uludag Univ, Fac Med, Dept Anesthesiol & Intens, Bursa, Turkey; Uludag Univ, Fac Med, Dept Neurosurg, Bursa, Turkey	Bilgin, H (reprint author), Uludag Univ, Tip Fak, Anestezyiol Reanimasyon AD, TR-16059 Bursa, Turkey.	hbilgin@uludag.edu.tr	Bilgin, Hulya/A-7338-2016	Bilgin, Hulya/0000-0001-6639-5533			Avramov MN, 1996, ANESTHESIOLOGY, V85, P1283, DOI 10.1097/00000542-199612000-00009; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; Balakrishnan G, 2000, ANESTH ANALG, V91, P163, DOI 10.1097/00000539-200007000-00030; BENSHLOMO I, 1990, BRIT J ANAESTH, V64, P45, DOI 10.1093/bja/64.1.45; BLACK TE, 1984, ANAESTHESIA, V39, P546, DOI 10.1111/j.1365-2044.1984.tb07358.x; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; CONNELLY NR, 1990, ANESTH ANALG, V70, P299; Dershwitz M, 1996, ANESTHESIOLOGY, V84, P812, DOI 10.1097/00000542-199604000-00008; GLASS PSA, 1993, ANESTH ANALG, V77, P1031; Gold MI, 1997, ANESTHESIOLOGY, V87, P51, DOI 10.1097/00000542-199707000-00007; Guy J, 1997, ANESTHESIOLOGY, V86, P514, DOI 10.1097/00000542-199703000-00002; JAFFE RS, 1989, ANESTHESIOLOGY, V70, P151, DOI 10.1097/00000542-198901000-00031; JANCZUR EA, 1990, ANESTH ANALG, V71, P312; Jhaveri R, 1997, ANESTHESIOLOGY, V87, P253, DOI 10.1097/00000542-199708000-00011; Johnson Joel O, 2002, Anesthesiol Clin North Am, V20, P361, DOI 10.1016/S0889-8537(01)00006-2; KISSIN I, 1990, ANESTH ANALG, V71, P65; KISSIN I, 1987, ANESTH ANALG, V66, P97; Lauer KK, 1997, CAN J ANAESTH, V44, P929, DOI 10.1007/BF03011963; Litman RS, 2000, J PAIN SYMPTOM MANAG, V19, P468, DOI 10.1016/S0885-3924(00)00141-X; MAHLA ME, 1988, ANESTHESIOLOGY, V69, P593, DOI 10.1097/00000542-198810000-00021; PINSKER MC, 1986, ANESTH ANALG, V65, P819; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; SEBEL PS, 1982, BRIT J ANAESTH, V54, P1185, DOI 10.1093/bja/54.11.1185; TUCKER MR, 1986, J ORAL MAXIL SURG, V44, P688; Twersky RS, 2001, J CLIN ANESTH, V13, P407, DOI 10.1016/S0952-8180(01)00292-6; URQUHART ML, 1989, ANESTH ANALG, V68, P249; WEIL JV, 1975, NEW ENGL J MED, V292, P1103, DOI 10.1056/NEJM197505222922106; WELLING EC, 1989, ANESTH ANALG, V68, P57; White P F, 1991, J Clin Anesth, V3, P32, DOI 10.1016/0952-8180(91)90203-Y; WHITE PF, 1983, ANESTHESIOLOGY, V59, P294, DOI 10.1097/00000542-198310000-00005; WHITE PF, 1986, ANESTHESIOLOGY, V64, P99, DOI 10.1097/00000542-198601000-00018	31	17	20	2	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JUL	2006	18	3					179	184		10.1097/01.ana.0000210998.10410.2e			6	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	059FQ	WOS:000238719100003	16799344				2020-06-30	J	Chapalain-Pargade, S; Laville, I; Paci, A; Chachaty, E; Mercier, L; Bourget, P				Chapalain-Pargade, Sophie; Laville, Isabelle; Paci, Angelo; Chachaty, Elisabeth; Mercier, Lionel; Bourget, Philippe			Microbiological and physicochemical stability of fentanyl and sufentanil solutions for patient-controlled delivery systems	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						analgesics; microbiological stability; physicochemical stability; patient-controlled delivery system; quality assurance; clinical pharmacy	PORTABLE PUMP RESERVOIR; CANCER PAIN RELIEF; POLYPROPYLENE SYRINGES; MORPHINE-SULFATE; INFUSION PUMPS; CITRATE; GLASS; HYDROCHLORIDE; COMPATIBILITY; CONTAINERS	The aim of this study was to assess the microbiological and physicochemical stability of opioid solutions containing fentanyl or sufentanil and thereby determine the feasibility of extending the expiration dates after mixing. Five systems containing fentanyl or sufentanil solutions at 50 mu g/mL in portable patient-controlled analgesia (PCA) systems were filled and stored at room temperature for 14 days. They were sampled immediately after preparation, at day 3, and each day of the following weeks. Microbiological stability was assessed by performing sterility tests. The physicochemical study was performed by determining aspect, pH, and osmolality evolution. All samples were tested for appearance, change in color, and loss of concentration using an analytical method. There was no significant change in pH and osmolality values of any solutions. No precipitation or change in color was observed in any of the sample solutions. There was no significant loss of fentanyl or sufentanil over 14 days (4.3% and 4.1%, respectively). This study indicates that both drug solutions in the PCA systems are stable for a minimum of 14 days at room temperature.	Inst Gustave Roussy, Dept Clin Pharm, F-94805 Villejuif, France; Inst Gustave Roussy, Dept Med Microbiol, F-94805 Villejuif, France	Paci, A (reprint author), Inst Gustave Roussy, Dept Clin Pharm, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	apaci@igr.fr		PACI, Angelo/0000-0002-4849-0825			ALLEN LV, 1990, AM J HOSP PHARM, V47, P1572, DOI 10.1093/ajhp/47.7.1572; Boitquin L, 2004, J PAIN SYMPTOM MANAG, V28, P4, DOI 10.1016/j.jpainsymman.2004.04.003; Boitquin LP, 2004, ANN PHARMACOTHER, V38, P1836, DOI 10.1345/aph.1D564; Brodner G, 2002, EUR J ANAESTH, V19, P295; CPMP/ICH, 1994, CPMPICH38195; *CPMP ICH, 1996, CPMPICH28195; Enting RH, 2002, CANCER-AM CANCER SOC, V94, P3049, DOI 10.1002/cncr.10518; FORREST WH, 1970, ANESTHESIOLOGY, V33, P363, DOI 10.1097/00000542-197009000-00023; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Jappinen A, 2003, EUR J PHARM SCI, V19, P31, DOI 10.1016/S0928-0987(03)00041-1; KOWALSKI SR, 1990, AM J HOSP PHARM, V47, P1584, DOI 10.1093/ajhp/47.7.1584; KOWALUK EA, 1982, AM J HOSP PHARM, V39, P460, DOI 10.1093/ajhp/39.3.460; Le Hoang M. D., 1998, Journal de Pharmacie Clinique, V17, P35; MCGRADY EM, 1993, ACTA ANAESTH SCAND, V37, P594; NAHATA MC, 1992, AM J HOSP PHARM, V49, P2785, DOI 10.1093/ajhp/49.11.2785; OHLSSON L, 1992, PAIN, V48, P349, DOI 10.1016/0304-3959(92)90083-N; OHLSSON LJ, 1995, ANN PHARMACOTHER, V29, P972, DOI 10.1177/106002809502901002; Oustric-Mendes AC, 1997, J CLIN PHARM THER, V22, P283, DOI 10.1046/j.1365-2710.1997.10475104.x; Peterson GM, 1998, J CLIN PHARM THER, V23, P67, DOI 10.1046/j.1365-2710.1998.00141.x; ROOS PJ, 1992, PHARM WEEKBLAD, V14, P23, DOI 10.1007/BF01989221; ROOS PJ, 1992, PHARM WEEKBLAD, V14, P196, DOI 10.1007/BF01962538; STILES ML, 1989, AM J HOSP PHARM, V46, P1404, DOI 10.1093/ajhp/46.7.1404; TOBIAS JD, 1992, CLIN PEDIATR, V31, P177, DOI 10.1177/000992289203100310; TRISSEL LA, 1988, AM J HOSP PHARM, V45, P1569, DOI 10.1093/ajhp/45.7.1569; *US PHARM CONV, 2002, US PHARM, V25, P2256; Vermeire A, 1997, INT J PHARM, V146, P213, DOI 10.1016/S0378-5173(96)04813-2; Vermeire A, 1999, INT J PHARMACEUT, V187, P17, DOI 10.1016/S0378-5173(99)00181-7; World Health Organization, 1998, CANC PAIN REL PALL C; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M; 2005, EUROPEAN PHARMACOPOE, P153	30	2	2	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924			J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	JUL	2006	32	1					90	97		10.1016/j.jpainsymman.2006.01.006			8	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	065KO	WOS:000239159000012	16824989	Bronze			2020-06-30	J	Christoph, T; Schiene, K; Englberger, W; Parsons, CG; Chizh, BA				Christoph, Thomas; Schiene, Klaus; Englberger, Werner; Parsons, Chris G.; Chizh, Boris A.			The antiallodynic effect of NMDA antagonists in neuropathic pain outlasts the duration of the in vivo NMDA antagonism	NEUROPHARMACOLOGY			English	Article						neuropathic pain; NMDA antagonist; opioid; spinal cord; allodynia; dorsal horn neuron; iontophoresis	D-ASPARTATE RECEPTOR; DOUBLE-BLIND; INTRADERMAL CAPSAICIN; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; EVOKED PAIN; KETAMINE; HYPERALGESIA; MORPHINE; RAT	Clinical reports have described a long-lasting relief in neuropathic pain patients treated with NMDA receptor antagonists; it is unclear, however, what mediates this effect. In this work, we have used two NMDA antagonists of different class to investigate if the antiallodynic effects in a rat neuropathy model can outlast their in vivo NMDA antagonism. Both the uncompetitive NMDA antagonist ketamine and the glycine(B) antagonist MRZ 2/576 inhibited neuronal responses to iontophoretic NMDA in anaesthetised rats with the time course consistent with their known pharmacokinetics (t(1/2) similar to 10-12 min, similar in control and nerve-injured rats). Surprisingly, the antiallodynic effects of the same doses of the NMDA antagonists in the neuropathic pain model were long-lasting (> 3 h with ketamine, > 24 h with MRZ 2/576). The effect of ketamine was further prolonged (> 24 h) when combined with a short-acting opioid, fentanyl, which only produced a short effect (similar to 40 min) when given alone. The duration of centrally mediated side effects of ketamine and MRZ 2/576 was short, similar to the in vivo NMDA antagonism. We speculate that NMDA receptor blockade may down-regulate the central sensitisation triggered by nerve injury, resulting in a long-lasting antiallodynic effect. Development of short-acting NMDA antagonists could represent a strategy for improving their tolerability. (c) 2006 Elsevier Ltd. All rights reserved.	Grunenthal GmbH Res Ctr, Dept Pharmacol, D-52078 Aachen, Germany; Grunenthal GmbH Res Ctr, Dept Mol Pharmacol, D-52078 Aachen, Germany; Merz Pharmaceut, Dept Pharmacol, D-60318 Frankfurt, Germany	Chizh, BA (reprint author), Addenbrookes Hosp, Addenbrookes Ctr Clin Invest, GlaxoSmithKline, Hills Rd, Cambridge CB2 2GG, England.	boris.a.chizh@gsk.com		Parsons, Christopher/0000-0002-3122-8572			Aida S, 2000, ANESTHESIOLOGY, V92, P1624, DOI 10.1097/00000542-200006000-00020; Belozertseva IV, 2000, N-S ARCH PHARMACOL, V361, P279, DOI 10.1007/s002109900179; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; Burton AW, 1999, REGION ANESTH PAIN M, V24, P208, DOI 10.1016/S1098-7339(99)90129-3; Chizh BA, 1997, NEUROSCIENCE, V80, P251, DOI 10.1016/S0306-4522(97)00119-X; Chizh BA, 2005, CURR PHARM DESIGN, V11, P2977, DOI 10.2174/1381612054865082; CHIZH BA, 2002, THERAPEUTIC POTENTIA, P263; CHIZH BA, 2001, SOC NEUR ABSTR, DOI UNSP 27.53.14; COHEN ML, 1973, ANESTHESIOLOGY, V39, P370, DOI 10.1097/00000542-197310000-00003; Correll GE, 2004, PAIN MED, V5, P263, DOI 10.1111/j.1526-4637.2004.04043.x; Danysz W, 1998, AMINO ACIDS, V14, P235, DOI 10.1007/BF01345268; Danysz W, 2005, NEUROPHARMACOLOGY, V48, P360, DOI 10.1016/j.neuropharm.2004.11.005; Danysz W, 1998, PHARMACOL REV, V50, P597; Eide PK, 1997, PAIN, V72, P289, DOI 10.1097/00006396-199708000-00042; EIDE PK, 1995, NEUROSURGERY, V37, P1080, DOI 10.1227/00006123-199512000-00007; Eisenberg E, 1998, PAIN, V74, P337, DOI 10.1016/S0304-3959(97)00198-X; Fields HL, 1998, NEUROBIOL DIS, V5, P209, DOI 10.1006/nbdi.1998.0204; Fisher K, 2000, J PAIN SYMPTOM MANAG, V20, P358, DOI 10.1016/S0885-3924(00)00213-X; Fu ES, 1997, ANESTH ANALG, V84, P1086, DOI 10.1097/00000539-199705000-00024; Gottrup H, 2000, BRIT J ANAESTH, V84, P155; Hesselink MB, 1999, J PHARMACOL EXP THER, V290, P543; Jaksch W, 2002, ANESTH ANALG, V94, P981, DOI 10.1097/00000539-200204000-00038; Koppert W, 2001, ANESTHESIOLOGY, V95, P395, DOI 10.1097/00000542-200108000-00022; MALMBERG AB, 1995, BRIT J PHARMACOL, V114, P1069, DOI 10.1111/j.1476-5381.1995.tb13315.x; Mathisen LC, 1999, ACTA ANAESTH SCAND, V43, P220, DOI 10.1034/j.1399-6576.1999.430218.x; MAX MB, 1995, CLIN NEUROPHARMACOL, V18, P360, DOI 10.1097/00002826-199508000-00008; PARK KM, 1995, PAIN, V63, P163, DOI 10.1016/0304-3959(95)00029-R; Parsons CG, 1997, J PHARMACOL EXP THER, V283, P1264; Parsons CG, 2001, EUR J PHARMACOL, V429, P71, DOI 10.1016/S0014-2999(01)01307-3; Parsons CG, 2000, AMINO ACIDS, V19, P157, DOI 10.1007/s007260070044; Petersen KL, 2000, PAIN, V88, P125, DOI 10.1016/S0304-3959(00)00311-0; Pud D, 1998, PAIN, V75, P349, DOI 10.1016/S0304-3959(98)00014-1; Rabben T, 1999, J PHARMACOL EXP THER, V289, P1060; Sang CN, 2000, J PAIN SYMPTOM MANAG, V19, pS21; Sweetman S., 2005, MARTINDALE COMPLETE; TVERSKOY M, 1994, ANESTH ANALG, V78, P205, DOI 10.1213/00000539-199402000-00002; UEDA M, 1995, NEUROPHARMACOLOGY, V34, P303, DOI 10.1016/0028-3908(94)00160-T; Wallace MS, 2002, CLIN J PAIN, V18, P373, DOI 10.1097/00002508-200211000-00005; WANG J, 2005, IASP 2005 11 WORLD C; Warncke T, 1997, PAIN, V72, P99, DOI 10.1016/S0304-3959(97)00006-7	40	38	40	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908			NEUROPHARMACOLOGY	Neuropharmacology	JUL	2006	51	1					12	17		10.1016/j.neuropharm.2006.02.007			6	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	064PC	WOS:000239100600002	16616769				2020-06-30	J	Weschules, DJ; Bain, KT; Reifsnyder, J; McMath, JA; Kupperman, DE; Gallagher, RM; Hauck, WW; Knowlton, CH				Weschules, Douglas J.; Bain, Kevin T.; Reifsnyder, JoAnne; McMath, Jill A.; Kupperman, David E.; Gallagher, Rollin M.; Hauck, Walter W.; Knowlton, Calvin H.			Toward evidence-based prescribing at end of life: A comparative analysis of sustained-release morphine, oxycodone, and transdermal fentanyl, with pain, constipation, and caregiver interaction outcomes in hospice patients	PAIN MEDICINE			English	Article; Proceedings Paper	20th Annual Meeting of the American-Academy-of-Pain-Medicine	MAR 04-07, 2004	Orlando, FL	Amer Acad Pain Med		opioid analgesics; pain; morphine; oxycodone; fentanyl; hospice	CANCER PAIN; INTRAVENOUS MORPHINE; PHARMACOLOGICAL-PROPERTIES; THERAPEUTIC-EFFICACY; ORAL MORPHINE; DOUBLE-BLIND; MYOCLONUS; OPIOIDS; MORPHINE-6-GLUCURONIDE; HYPERALGESIA	Objective. The primary goal of this investigation was to examine selected outcomes in hospice patients who are prescribed one of three sustained-release opioid preparations. The outcomes examined include: pain score, constipation severity, and ability of the patient to communicate with caregivers. Patients and Settings. This study included 12,000 terminally ill patients consecutively admitted to hospices and receiving pharmaceutical care services between the period of July 1 and December 31, 2002. Design. We retrospectively examined prescribing patterns of sustained-release morphine, oxycodone, and transdermal fentanyl. We compared individual opioids on the aforementioned outcome markers, as well as patient gender, terminal diagnosis, and median length of stay. Results. Patients prescribed a sustained-release opioid had similar average ratings of pain and constipation severity, regardless of the agent chosen. Patients prescribed transdermal fentanyl were reported to have more difficulty communicating with friends and family when compared with patients prescribed either morphine or oxycodone. On average, patients prescribed transdermal fentanyl had a shorter length of stay on hospice as compared with those receiving morphine or oxycodone. Conclusion. There was no difference in observed pain or constipation severity among patients prescribed sustained-release opioid preparations. Patients receiving fentanyl were likely to have been prescribed the medication due to advanced illness and associated dysphagia. Diminished ability to communicate with caregivers and a shorter hospice course would be consistent with this profile. Further investigation is warranted to examine the correlation between a patient's ability to interact with caregivers and pain control achieved.	excelleRx Inc, Philadelphia, PA 19102 USA; Univ Penn, Vet Adm Med Ctr, Philadelphia Dept Psychiat, Philadelphia, PA 19104 USA; Univ Penn, Vet Adm Med Ctr, Philadelphia Dept Anesthesia, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Div Clin Pharmacol, Biostat Sect, Philadelphia, PA 19107 USA	Weschules, DJ (reprint author), excelleRx Inc, 1601 Cherry St,Suite 1700, Philadelphia, PA 19102 USA.	dweschules@excellerx.com					Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; BASTA S, 1998, J PHARM CARE PAIN SY, V6, P21; BONICA JJ, 2001, BONICAS MANAGEMENT P, P3; Bruera E, 1998, J CLIN ONCOL, V16, P3222, DOI 10.1200/JCO.1998.16.10.3222; CHEN ZR, 1991, LIFE SCI, V48, P2165, DOI 10.1016/0024-3205(91)90150-A; CHRISTENSEN CB, 1987, PHARMACOL TOXICOL, V60, P75, DOI 10.1111/j.1600-0773.1987.tb01724.x; CURTIS GB, 1999, EUR J CLIN PHARMACOL, V55, P435; Gammaitoni AR, 2000, PAIN MED, V1, P317, DOI 10.1046/j.1526-4637.2000.00043.x; Guo H, 2001, J PAIN SYMPTOM MANAG, V22, P637, DOI 10.1016/S0885-3924(01)00296-2; Hall S, 2003, PAIN MED, V4, P125, DOI 10.1046/j.1526-4637.2003.03020.x; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; HEDNER T, 1987, SCAND J GASTROENTERO, V22, P27, DOI 10.3109/00365528709090997; Heiskanen T, 1997, PAIN, V73, P37, DOI 10.1016/S0304-3959(97)00072-9; Hunt R, 1999, J PAIN SYMPTOM MANAG, V18, P111, DOI 10.1016/S0885-3924(99)00051-2; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; KALSO E, 1991, ACTA ANAESTH SCAND, V35, P642, DOI 10.1111/j.1399-6576.1991.tb03364.x; KALSO E, 1990, CLIN PHARMACOL THER, V47, P639, DOI 10.1038/clpt.1990.85; Lyss AP, 1997, SEMIN ONCOL, V24, P28; MACDONALD N, 1993, PAIN, V53, P353, DOI 10.1016/0304-3959(93)90232-E; Megens AAHP, 1998, J PAIN SYMPTOM MANAG, V15, P253, DOI 10.1016/S0885-3924(97)00371-0; MORLEY JS, 1992, LANCET, V340, P1045, DOI 10.1016/0140-6736(92)93067-W; Mucci-LoRusso P, 1998, EUR J PAIN-LONDON, V2, P239, DOI 10.1016/S1090-3801(98)90020-9; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; PASTERNAK GW, 1987, LIFE SCI, V41, P2845, DOI 10.1016/0024-3205(87)90431-0; PATT RB, 1996, AM PAIN SOC B, V6, P1; POTTER JM, 1989, BRIT MED J, V299, P150, DOI 10.1136/bmj.299.6692.150; POYHIA R, 1993, J PAIN SYMPTOM MANAG, V8, P63, DOI 10.1016/0885-3924(93)90101-Z; Rischitelli DG, 2002, PHARMACOTHERAPY, V22, P898, DOI 10.1592/phco.22.11.898.33628; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; SJOGREN P, 1993, ACTA ANAESTH SCAND, V37, P780, DOI 10.1111/j.1399-6576.1993.tb03809.x; Sjogren P, 1998, ACTA ANAESTH SCAND, V42, P1070, DOI 10.1111/j.1399-6576.1998.tb05378.x; SJOGREN P, 1993, PAIN, V55, P93, DOI 10.1016/0304-3959(93)90188-U; Weschules DJ, 2003, PAIN MED, V4, P269, DOI 10.1046/j.1526-4637.2003.03031.x; *WHO, 1996, [No title captured], V804; Wong J O, 1997, Acta Anaesthesiol Sin, V35, P25; YAKASH TL, 1986, ANESTHESIOLOGY, V64, P590	37	19	19	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1526-2375			PAIN MED	Pain Med.	JUL-AUG	2006	7	4					320	329		10.1111/j.1526-4637.2006.00184.x			10	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	065LS	WOS:000239162000008	16898943				2020-06-30	J	Woloszczuk-Gebicka, B; Wyska, E; Grabowski, T; Swierczewska, A; Sawicka, R				Woloszczuk-Gebicka, Bogumila; Wyska, Elzbieta; Grabowski, Tomasz; Swierczewska, Anna; Sawicka, Renata			Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children	PEDIATRIC ANESTHESIA			English	Article						neuromuscular blocking drugs, nondepolarizing : rocuronium; anesthetics, inhalational : sevoflurane; synergism; pharmacokinetics; pharmacodynamics; pharmacokinetic-pharmacodynamic modeling	TARGET-CONTROLLED INFUSION; TIME-COURSE; BROMIDE ORG-9426; DOSE-RESPONSE; ISOFLURANE; HALOTHANE; PROPOFOL; VECURONIUM; DESFLURANE; INFANTS	Background: The aim of this study was to compare pharmacokinetics and pharmacokinetic-pharmacodynamic (PK-PD) relationship of rocuronium in children anesthetized with nitrous oxide (N2O) and fentanyl or with N2O and sevoflurane. Methods: Twenty-four children (3-11 years old, ASA PS I or II) were randomized to receive N2O/O-2-fentanyl or N2O/O-2-sevoflurane (one MAC) anesthesia. Neuromuscular transmission was monitored electromyographically. Initial bolus dose of rocuronium, 0.6 mg.kg(-1) was followed by continuous infusion, targeting at steady-state 95% T1 depression. Neuromuscular transmission was allowed to recover spontaneously. Plasma samples were collected at the moment of discontinuation of infusion, and 10, 20, 30, 50, 60 and 75 min afterwards. Concentrations of rocuronium were measured using high-performance liquid chromatography with electrochemical detection (HPLC-EC). Rocuronium PK was described by a two-compartment model and PD parameters were estimated using effect compartment and sigmoidal E-max models. Results: No differences in rocuronium PK parameters were observed between study groups. Clearance was 3.91 +/- 2.07 and 3.62 +/- 0.80 ml.min(-1).kg(-1) in sevoflurane and fentanyl groups, respectively (P < 0.65). Effect compartment concentrations corresponding to 50% inhibition of T1 (EC50) were 1.41 +/- 0.45 and 2.32 +/- 1.00 mu g.ml(-1) (P < 0.02), and rate constants for equilibration between plasma and effect compartment (k(eo)) values were 0.10 +/- 0.04 and 0.24 +/- 0.14 min(-1) (P < 0.009) in sevoflurane and fentanyl groups, respectively. Conclusions: Disposition of rocuronium was similar under stable N2O-fentanyl and N2O-sevoflurane anesthesia. Sevoflurane reduced rocuronium requirements as well as decreased EC50 relevant to inhibition of T1 and rocuronium transfer to effect compartment. Therefore, the potentiating effect of sevoflurane seems to be mainly of PD origin, probably due to an increased sensitivity of the neuromuscular junction.	Childrens Mem Hlth Inst, Dept Anaesthesiol & Intens Therapy, Warsaw, Poland; Jagiellonian Univ, Collegium Medicum, Dept Pharmacokinet & Phys Pharm, Krakow, Poland; Ctr Pharmacokinet Res Filab, Lajski, Poland	Woloszczuk-Gebicka, B (reprint author), Warsaw Med Univ, Dept Paediat Anaesthesis, Marszalkowska 24, PL-00556 Warsaw, Poland.	bogumila.gebicka@acn.waw.pl	Grabowski, Tomasz/AAE-6300-2020	Grabowski, Tomasz/0000-0002-3077-9698; Wyska, Elzbieta/0000-0002-4798-0574			COOPER RA, 1993, BRIT J ANAESTH, V71, P222, DOI 10.1093/bja/71.2.222; DARGENIO DZ, 1997, ADAPT 2 US GUIDE; Dragne A, 2002, CAN J ANAESTH, V49, P353, DOI 10.1007/BF03017322; DUCHARME J, 1992, J CHROMATOGR-BIOMED, V573, P79, DOI 10.1016/0378-4347(92)80477-8; Jellish WS, 2000, ANESTH ANALG, V91, P1250; Kansanaho M, 1997, EUR J ANAESTH, V14, P488, DOI 10.1046/j.1365-2346.1997.00171.x; KATOH T, 1992, BRIT J ANAESTH, V68, P139, DOI 10.1093/bja/68.2.139; Kumar N, 1996, BRIT J ANAESTH, V77, P488, DOI 10.1093/bja/77.4.488; LARIJANI GE, 1995, PHARMACOTHERAPY, V15, P36; Lowry DW, 1998, ANESTH ANALG, V87, P936, DOI 10.1097/00000539-199810000-00036; Meretoja OA, 1996, BRIT J ANAESTH, V76, P235; Morita T, 1997, ANAESTHESIA, V52, P538, DOI 10.1111/j.1365-2222.1997.119-az0123.x; OKELLY B, 1994, EUR J ANAESTH, P57; OLKKOLA KT, 1994, EUR J ANAESTH S, V9, P57; ORIS B, 1993, ANESTH ANALG, V77, P570; Reid JE, 2001, CAN J ANAESTH, V48, P351, DOI 10.1007/BF03014962; Saldien V, 2003, ANESTH ANALG, V97, P44, DOI 10.1213/01.ANE.0000066262.32103.60; SHEINER LB, 1979, CLIN PHARMACOL THER, V25, P358; SZENOHRADSZKY J, 1992, ANESTHESIOLOGY, V77, P899, DOI 10.1097/00000542-199211000-00010; VANDENBROEK L, 1994, J CLIN ANESTH, V6, P288, DOI 10.1016/0952-8180(94)90075-2; Vermeyen KM, 2003, BRIT J ANAESTH, V90, P183, DOI 10.1093/bja/aeg043; VibyMogensen J, 1996, ACTA ANAESTH SCAND, V40, P59, DOI 10.1111/j.1399-6576.1996.tb04389.x; VUKSANAJ D, 1995, ANESTHESIOLOGY, V82, P1104, DOI 10.1097/00000542-199505000-00003; Wierda JMKH, 1997, BRIT J ANAESTH, V78, P690, DOI 10.1093/bja/78.6.690; Woloszczuk-Gebicka B, 2001, ACTA ANAESTH SCAND, V45, P73, DOI 10.1034/j.1399-6576.2001.450112.x; Wulf H, 1998, CAN J ANAESTH, V45, P526, DOI 10.1007/BF03012702; Xue FS, 1998, ANAESTHESIA, V53, P25, DOI 10.1046/j.1365-2044.1998.00278.x	27	7	14	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	JUL	2006	16	7					761	768		10.1111/j.1460-9592.2005.01840.x			8	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	066CV	WOS:000239208200008	16879519				2020-06-30	J	Burgoyne, LL; Hoffer, FA; de Armendi, AJ				Burgoyne, Laura L.; Hoffer, Fredric A.; de Armendi, Alberto J.			Anesthesia for a patient with bilateral undrained pneumothoraces	PEDIATRIC ANESTHESIA			English	Letter									St Jude Childrens Res Hosp, Div Anesthesiol, Memphis, TN 38105 USA	Burgoyne, LL (reprint author), St Jude Childrens Res Hosp, Div Anesthesiol, 332 N Lauderdale St, Memphis, TN 38105 USA.	Laura.Burgoyne@stjude.org		Burgoyne, Laura/0000-0003-1088-1641			CROFTS SL, 1991, ANAESTHESIA, V46, P192, DOI 10.1111/j.1365-2044.1991.tb09407.x; EGER EI, 1965, ANESTHESIOLOGY, V26, P61, DOI 10.1097/00000542-196501000-00011; HUNTER AR, 1955, P ROY SOC MED, V48, P765, DOI 10.1177/003591575504801003	3	0	0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	JUL	2006	16	7					802	803		10.1111/j.1460-9592.2006.01888.x			2	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	066CV	WOS:000239208200017	16879528				2020-06-30	J	Sano, T; Nishimura, R; Kanazawa, H; Igarashi, E; Nagata, Y; Mochizuki, M; Sasaki, N				Sano, T; Nishimura, R; Kanazawa, H; Igarashi, E; Nagata, Y; Mochizuki, M; Sasaki, N			Pharmacokinetics of fentanyl after single intravenous injection and constant rate infusion in dogs	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						constant rate infusion; dogs; fentanyl; pharmacokinetics	LUMBOSACRAL EPIDURAL SPACE; ANALGESIA; MORPHINE; CATS; PHARMACODYNAMICS; MEDETOMIDINE; ISOFLURANE; ENFLURANE; RECEPTOR; SURGERY	Objective To determine the plasma concentration and define the pharmacokinetic characteristics of fentanyl (10 mu g kg(-1)) administered as a single intravenous (IV) injection followed by: (a) no further drug; or (b) a constant rate infusion (CRI) of fentanyl 10 mu g kg(-1) hour(-1) lasting 1, 3 or 4 hours in dogs. Animals Fourteen healthy adult beagles (seven males and seven females). Experimental design Randomized cross-over design. Materials and methods Dogs were randomly assigned to four treatment groups. Drugs were administered to each dog in a randomized cross-over design with at least a 14-day washout interval between experiments. All dogs received an IV loading dose of fentanyl (10 mu g kg(-1)). One group received no further fentanyl. In others, the loading dose was followed by a CRI of fentanyl (10 mu g kg(-1) hour(-1)) for 1, 3 or 4 hours. Blood samples were collected and plasma fentanyl concentrations determined using high-performance liquid chromatography-mass spectrometry. Plasma pharmacokinetic estimates were obtained by plotting plasma concentrations versus time data and by fitting the change in concentration to a pharmacokinetic model, using a purpose-built program written by the Graduate School of Pharmaceutical Sciences (Kyoto University) in Visual Basic (VBA) on Excel (Microsoft Corporation). Results Plasma fentanyl concentration decreased rapidly after single IV injection: the plasma concentration-time curve best fitted a two-compartment model. Pharmacokinetic variables for IV injection were characterized by a short distribution half-time (t(1/2 alpha) was 4.5 minutes), a relatively long elimination half time (t(1/2 beta) was 45.7 minutes), a large volume of distribution (approximately 5 L kg(-1)) and high total body clearance (77.9 mL minute(-1) kg(-1)). Stable plasma fentanyl levels were obtained in all CRI groups although pharmacokinetic variables were influenced by the duration of administration. Conclusions and clinical relevance While this study clarified the pharmacokinetic features of rapid IV fentanyl injection and CRI in dogs, the plasma concentration achieving analgesia was not and so further research is needed. Further studies on the effects of other sedatives and/or anaesthetics on fentanyl's disposition are also required as the drug is commonly used with other agents.	Univ Tokyo, Grad Sch Agr & Life Sci, Lab Vet Surg, Tokyo, Japan; Kyoritsu Coll Pharmaceut Sci, Lab Phys Pharmaceut Chem, Tokyo, Japan	Sano, T (reprint author), Kitasato Univ, Sch Vet Med, Dept Vet Med, Lab Vet Radiol & Radiat Biol, Higashi 23 bancho 35-1, Towada, Aomori 0348628, Japan.	tsano@vmas.kitasato-u.ac.jp		Kanazawa, Hideko/0000-0003-2550-470X			ADAM HK, 1980, BRIT J ANAESTH, V52, P743, DOI 10.1093/bja/52.8.743; BOAS RA, 1985, BRIT J ANAESTH, V57, P192, DOI 10.1093/bja/57.2.192; BOVILL JG, 1980, BRIT J ANAESTH, V52, P795, DOI 10.1093/bja/52.8.795; CLOTZ MA, 1991, CLIN PHARMACY, V10, P581; DUKE T, 1994, VET SURG, V23, P143, DOI 10.1111/j.1532-950X.1994.tb00459.x; DUKE T, 1994, VET SURG, V23, P149, DOI 10.1111/j.1532-950X.1994.tb00460.x; FREYE E, 1991, PHARMACEUT RES, V8, P196, DOI 10.1023/A:1015887919560; Hayashi K, 1998, Masui, V47, P420; HOLLEY FO, 1988, BRIT J ANAESTH, V60, P608, DOI 10.1093/bja/60.6.608; HUG CC, 1981, ANESTHESIOLOGY, V55, P369, DOI 10.1097/00000542-198110000-00006; HUGHES MA, 1992, ANESTHESIOLOGY, V76, P334, DOI 10.1097/00000542-199203000-00003; Lee DD, 2000, AM J VET RES, V61, P672, DOI 10.2460/ajvr.2000.61.672; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; MURPHY MR, 1983, ANESTHESIOLOGY, V59, P537, DOI 10.1097/00000542-198312000-00009; MURPHY MR, 1979, ANESTHESIOLOGY, V50, P13, DOI 10.1097/00000542-197901000-00004; Mutoh T, 1997, AM J VET RES, V58, P885; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P757, DOI 10.1016/S0195-5616(08)70005-6; Rajan V, 1998, BIOL NEONATE, V74, P39, DOI 10.1159/000014009; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; ROERIG DL, 1987, ANESTHESIOLOGY, V67, P466, DOI 10.1097/00000542-198710000-00004; Saijo H, 2001, Masui, V50, P528; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; SMITH I, 1994, ANESTHESIOLOGY, V81, P1005; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; VILLIGER JW, 1983, NEUROPHARMACOLOGY, V22, P447, DOI 10.1016/0028-3908(83)90162-4; YAKSH TL, 1986, ANESTHESIOLOGY, V64, P54, DOI 10.1097/00000542-198601000-00009; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879, DOI 10.1248/bpb1978.4.879	28	64	64	0	20	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1467-2987			VET ANAESTH ANALG	Vet. Anaesth. Analg.	JUL	2006	33	4					266	273		10.1111/j.1467-2995.2005.00266.x			8	Veterinary Sciences	Veterinary Sciences	048UM	WOS:000237972000010	16764592				2020-06-30	J	Oztekin, DS; Oztekin, I; Issever, H; Goksel, O; Cinar, B; Canik, S				Oztekin, Deniz Scher; Oztekin, Ilhan; Issever, Halim; Goksel, Onur; Cinar, Bayer; Canik, Sevim			Postoperative effects of opioid analgesics administered via continuous perfusion and patient controlled analgesia after open heart surgery	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Article						morphine; fentanyl; meperidine; remifentanil; tramadol; opioid	TRAMADOL; MORPHINE; PAIN; INFUSION; PCA; FENTANYL; NAUSEA	Critical care nurses and physicians are familiar with the principles of patient controlled analgesia and the opioid analgesics' regimens and observations necessary for pain control in the postoperative cardiac surgical patients. The objective of the study was to compare the effects of morphine, fentanyl, meperidine, remifentanil and tramadol which were administered by patient controlled analgesia and continuous intravenous infusion combination on the various parameters. This study was designed as prospective randomised trial. Fifty patients undergone open heart surgery with sternotomy were entered equally into five randomized groups. Visual analog scale was used by researcher nurse to assess the patient' pain status. Respiratory rate, heart rate and blood gases (pO(2), pCO(2), SaO(2)), radial arterial blood pressures were measured in the first 24 hrs postoperatively. Bolus requirements were determined by physicians and side effects of the analgesics were documented. Fentanyl group showed statistically higher levels of mean pO(2) (p=0.002). Meperidine had the lowest number of bolus doses (p=0.001). There were no significant differences between the groups for pain management except higher visual analog scales on tramadol. Headache, stomachache and, palpitations were observed in our patients. Remifentanil, meperidine, fentanyl and morphine showed similar effect with each other for pain relief except tramadol.	Istanbul Univ, Florence Nightingale Sch Nursing, TR-34360 Istanbul, Turkey; Siyami Ersek Thorac & Cardiovasc Surg Ctr, Istanbul, Turkey; Istanbul Univ, Istanbul Fac Med, Dept Publ Hlth, Istanbul, Turkey	Oztekin, DS (reprint author), Tutuncu Mehmet Efendi Cad Iffet AP 40-3 Goztepe, TR-34726 Kadikoy, Turkey.	dnzoztekin@hotmail.com	Oztekin, Seher Deniz/C-9708-2019	Oztekin, Seher Deniz/0000-0001-5215-7913			Barilaro C, 2001, Minerva Anestesiol, V67, P171; Brix-Christensen V, 1997, INT J CARDIOL, V62, P191, DOI 10.1016/S0167-5273(97)00229-5; CAMBITZI J, 2000, POSTOPERATIVE PAIN M, P466; CHRUBASIK J, 1992, EUR J ANAESTH, V9, P23; ERSEK M, 2004, PAIN MED SURG NURSIN, V1, P131; Foubert Jan, 2005, Eur J Oncol Nurs, V9, P21, DOI 10.1016/j.ejon.2004.03.006; GRANT RP, 1992, CAN J ANAESTH, V39, P214, DOI 10.1007/BF03008779; Gust R, 1999, CRIT CARE MED, V27, P2218, DOI 10.1097/00003246-199910000-00025; Hopkins D, 1998, CAN J ANAESTH, V45, P435, DOI 10.1007/BF03012579; JOSHI GP, 1998, PATIENT CONTROLLED A, P577; KRENN H, 2000, EUR J PAIN, V5, P219; KUGUOGLU SY, 1998, STUDY WHICH USED MCG; MELZACK R, 1992, PAIN, P152; Naguib M, 1998, CAN J ANAESTH, V45, P1168, DOI 10.1007/BF03012458; Ng KFJ, 1998, EUR J ANAESTH, V15, P565, DOI 10.1046/j.1365-2346.1998.00354.x; OWEN H, 1989, ANAESTHESIA, V44, P11, DOI 10.1111/j.1365-2044.1989.tb11088.x; PARKER RK, 1991, JAMA-J AM MED ASSOC, V266, P1947, DOI 10.1001/jama.266.14.1947; PUNTILLO KA, 1998, PAIN ANALGESIA SEDAT, P61; SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5; SEARLE NR, 1994, CAN J ANAESTH, V41, P198, DOI 10.1007/BF03009831; Silvasti M, 2000, EUR J ANAESTH, V17, P448, DOI 10.1046/j.1365-2346.2000.00710.x; van den Berg AA, 1999, ACTA ANAESTH SCAND, V43, P28, DOI 10.1034/j.1399-6576.1999.430107.x; WHITE WD, 1979, BRIT MED J, V2, P166, DOI 10.1136/bmj.2.6183.166; Wilder-Smith CH, 1999, ANESTHESIOLOGY, V91, P639, DOI 10.1097/00000542-199909000-00013	24	6	6	0	4	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	JUL	2006	126	7					499	504		10.1248/yakushi.126.499			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	070SP	WOS:000239544500007	16819272	Bronze			2020-06-30	J	Mao, CL; Zientek, KD; Colahan, PT; Kuo, MY; Liu, CH; Lee, KM; Chou, CC				Mao, Chi-Liang; Zientek, Keith D.; Colahan, Patrick T.; Kuo, Mei-Yueh; Liu, Chi-Ho; Lee, Kuo-Ming; Chou, Chi-Chung			Development of an enzyme-linked immunosorbent assay for fentanyl and applications of fentanyl antibody-coated nanoparticles for sample preparation	JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS			English	Article						fentanyl; enzyme immunoassay; antibody-coated magnetic nanoparticles; capillary electrophoresis	GAS-CHROMATOGRAPHY; MAGNETIC NANOPARTICLES; LIQUID-CHROMATOGRAPHY; TRANSDERMAL FENTANYL; HUMAN PLASMA; SUFENTANIL; ALFENTANIL; EXTRACTION; EFFICACY; URINE	A sensitive enzyme-linked immunosorbent assay (ELISA) was developed for the detection of fentanyl in serum and urine. The ELISA used an indirect competitive method produced by coating the plate with thyroglobulin conjugated with fentanyl hapten. Antibodies against fentanyl-hemocyanin were detected by a goat-anti-rabbit antibody conjugated with alkaline phosphatase. Calibration standard curves ranged from 0.5 ng/ml to 50 mu g/ml (IC50 = 10 ng/ml), and the limits of detection were 0.5 and 1.0 ng/ml for serum and urine, respectively. The intra- and inter-assay variations were less than 8% and 10%, respectively. The antibody produced against fentanyl completely cross-reacted with p-fluorofentanyl, thienylfentanyl and 3-methylthienylfentanyl, cross-reacted highly with carfentanil (85%), but was considered non-cross-reactive with a-methylfentanyl (5%), sufentanil (< 1%), alfentanil (< 1%) and lofentanil (< 1 %). Nano-sized iron oxide magnetic particles coated with the developed fentanyl antibody were capable of specific binding and releasing of fentanyl from urine samples. This enabled the drug to be effectively pre-concentrated and decreased the limit of detection by approximately one order of magnitude. The analytical background noise was significantly reduced to enable fentanyl detection at concentrations originally below chromatographic limit of detection. The change of platform for antibody binding with nanoparticles demonstrated a novel use of antibodies for sample preparation and should facilitate drug screening by traditional ELISA. (c) 2006 Elsevier B.V. All rights reserved.	Natl Chung Hsing Univ, Coll Vet Med, Vet Med Teaching Hosp, Taichung 40227, Taiwan; Natl Chung Hsing Univ, Coll Vet Med, Dept Vet Med, Taichung 40227, Taiwan; Univ Florida, Coll Vet Med, Dept Large Anim Clin Sci, Racing Lab, Gainesville, FL 32610 USA	Chou, CC (reprint author), Natl Chung Hsing Univ, Coll Vet Med, Vet Med Teaching Hosp, 250-1 Kuokuang Rd, Taichung 40227, Taiwan.	ccchou@nchu.edu.tw		Chou, Chi-Chung/0000-0002-4622-2552			Bjorksten AR, 2002, J CHROMATOGR B, V775, P97, DOI 10.1016/S1570-0232(02)00178-2; CATHERINE CB, 2003, J PHYS D, V36, pR198; Choi HS, 2001, J CHROMATOGR B, V765, P63, DOI 10.1016/S0378-4347(01)00405-4; Day J, 2003, J ANAL TOXICOL, V27, P513, DOI 10.1093/jat/27.7.513; DELBEKE FT, 1989, J VET PHARMACOL THER, V12, P1, DOI 10.1111/j.1365-2885.1989.tb00633.x; Emerich DF, 2003, EXPERT OPIN BIOL TH, V3, P655, DOI 10.1517/eobt.3.4.655.21202; Foley PL, 2001, COMPARATIVE MED, V51, P239; HAMMARGREN WR, 1988, J ANAL TOXICOL, V12, P183, DOI 10.1093/jat/12.4.183; Harkins JD, 1997, J VET PHARMACOL THER, V20, P396, DOI 10.1046/j.1365-2885.1997.00089.x; Hayashi Y, 2004, ANAL CHEM, V76, P1295, DOI 10.1021/ac0302859; HENDERSON GL, 1990, J ANAL TOXICOL, V14, P172, DOI 10.1093/jat/14.3.172; JANSSEN PA, 1984, [No title captured]; Jia HF, 2003, BIOTECHNOL BIOENG, V84, P406, DOI 10.1002/bit.10781; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Kumar K, 1996, J PHARMACEUT BIOMED, V14, P667, DOI 10.1016/0731-7085(95)01685-6; Lambropoulos J, 2000, J PHARMACEUT BIOMED, V23, P421, DOI 10.1016/S0731-7085(00)00312-5; Lingeman H, 1997, J CHROMATOGR B, V689, P221, DOI 10.1016/S0378-4347(96)00363-5; MAKOWSKI GS, 1995, ANN CLIN LAB SCI, V25, P169; Maxwell LK, 2003, EQUINE VET J, V35, P484, DOI 10.2746/042516403775600415; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Pankhurst QA, 2003, J PHYS D APPL PHYS, V36, pR167, DOI 10.1088/0022-3727/36/13/201; Papich MG, 1997, SEMIN VET MED SURG, V12, P80, DOI 10.1016/S1096-2867(97)80005-9; Paradis C, 2002, THER DRUG MONIT, V24, P768, DOI 10.1097/00007691-200212000-00014; Pascoe PJ, 2003, VET ANAESTH ANALG, V30, P165, DOI 10.1046/j.1467-2995.2003.00134.x; Portier EJG, 1999, J CHROMATOGR B, V723, P313, DOI 10.1016/S0378-4347(98)00518-0; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; RUNAGYUTTIKARN W, 1990, J ANAL TOXICOL, V14, P160, DOI 10.1093/jat/14.3.160; Salata O.V., 2004, J NANOBIOTECHNOL, V2, P3, DOI [DOI 10.1186/1477-3155-2-3, 10.1186/1477-3155-2-3]; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; Sevarino FB, 1997, J CLIN ANESTH, V9, P173, DOI 10.1016/S0952-8180(97)00043-3; Shou WZ, 2001, RAPID COMMUN MASS SP, V15, P466, DOI 10.1002/rcm.255; Souverain S, 2004, J CHROMATOGR B, V801, P141, DOI 10.1016/j.jchromb.2003.11.043; Tartaj P, 2003, J PHYS D APPL PHYS, V36, pR182, DOI 10.1088/0022-3727/36/13/202; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; TOBIN T, 1987, RES COMMUN CHEM PATH, V52, P408; WATTS VW, 1990, J ANAL TOXICOL, V14, P266, DOI 10.1093/jat/14.5.266; Wegner K., 2002, Proceedings of the 48th Annual Convention of the American Association of Equine Practitioners, Orlando, Florida, USA, 4-8 December 2002, P291; WOESTENBORGHS RJH, 1994, ANESTHESIOLOGY, V80, P666, DOI 10.1097/00000542-199403000-00025; Zhao ZJ, 2001, J MOL RECOGNIT, V14, P300, DOI 10.1002/jmr.541	39	13	13	1	21	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0731-7085	1873-264X		J PHARMACEUT BIOMED	J. Pharm. Biomed. Anal.	JUN 16	2006	41	4					1332	1341		10.1016/j.jpba.2006.03.009			10	Chemistry, Analytical; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	055ZV	WOS:000238491100035	16621415				2020-06-30	J	Maltepe, F; Kocaayan, E; Ugurlu, BS; Akdeniz, B; Guneri, S				Maltepe, F.; Kocaayan, E.; Ugurlu, B. S.; Akdeniz, B.; Guneri, S.			Comparison of remifentanil and fentanyl in anaesthesia for elective cardioversion	ANAESTHESIA AND INTENSIVE CARE			English	Article						remifentanil; fentanyl; cardioversion; propofol; sedation; recovery	PROPOFOL; MIDAZOLAM; SEDATION; CONSCIOUSNESS; ETOMIDATE	This prospective, randomized, double-blind study was designed to compare the recovery characteristics of remifentanil and fentanyl in combination with propofol for direct current cardioversion. Patients undergoing elective cardioversion received either intravenous fentanyl 1 mu g/kg (n=33) or remifentanil 0.25 mu g/kg (n=30) and propofol was titrated to a Ramsay sedation score of 5 by slow intravenous injection. Heart rate, systolic, diastolic and mean blood pressures decreased significantly following sedation in both groups but did not show a significant difference between the groups. Time to answer a question (306 +/- 83 vs 383 +/- 131s, mean +/- SD, P=0.014) and time to sit up (412 +/- 90 vs 511 +/- 126s, P=0.002) were significantly shorter in the remifentanil group compared to the fentanyl group. Side-effects and patient discomfort were similar for both groups. Remifentanil can be used as a suitable supplement to propofol for direct current cardioversion and may provide a faster recovery profile than fentanyl.	Dokuz Eylul Univ, Sch Med, Dept Anesthesiol & Reanimat, Izmir, Turkey; Dokuz Eylul Univ, Sch Med, Dept Cardiovasc Surg, Izmir, Turkey; Dokuz Eylul Univ, Sch Med, Dept Cardiol, Izmir, Turkey	Maltepe, F (reprint author), Dokuz Eylul Univ, Tip Fak, Anestezi Reanimasyon Anabilim Dali, TR-35340 Izmir, Turkey.						Bailey P.L., 2000, ANESTHESIA, P273; Burkle H, 1996, ANESTH ANALG, V83, P646, DOI 10.1097/00000539-199609000-00038; Canessa R, 1991, J Cardiothorac Vasc Anesth, V5, P566, DOI 10.1016/1053-0770(91)90007-G; FENNELLY ME, 1992, BRIT J ANAESTH, V68, P303, DOI 10.1093/bja/68.3.303; GALE DW, 1993, CRIT CARE MED, V21, P1509, DOI 10.1097/00003246-199310000-00019; GUPTA A, 1990, ANAESTHESIA, V45, P872, DOI 10.1111/j.1365-2044.1990.tb14576.x; Harrison SJ, 2002, HEART, V88, P117, DOI 10.1136/heart.88.2.117; Herregods LL, 2003, J CLIN ANESTH, V15, P91, DOI 10.1016/S0952-8180(02)00520-2; HULLANDER RM, 1993, ANESTH ANALG, V77, P690; James S, 2003, ANAESTHESIA, V58, P291, DOI 10.1046/j.1365-2044.2003.306519.x; Karthikeyan S, 2002, ANAESTHESIA, V57, P1114, DOI 10.1046/j.1365-2044.2002.02782_3.x; Lee MPL, 2001, ANESTH ANALG, V93, P359, DOI 10.1097/00000539-200108000-00025; Litman RS, 2000, J PAIN SYMPTOM MANAG, V19, P468, DOI 10.1016/S0885-3924(00)00141-X; Lysakowski C, 2001, BRIT J ANAESTH, V86, P523, DOI 10.1093/bja/86.4.523; Recart A, 2003, ANESTH ANALG, V96, P1047, DOI 10.1213/01.ANE.0000054002.65040.B3; Stoneham MD, 1996, ANAESTHESIA, V51, P565, DOI 10.1111/j.1365-2044.1996.tb12566.x; Trabold F, 2004, ACTA ANAESTH SCAND, V48, P35, DOI 10.1111/j.1399-6576.2004.00259.x; Vuyk J, 1997, ANESTHESIOLOGY, V87, P1549, DOI 10.1097/00000542-199712000-00033; WESTMORELAND CL, 1993, ANESTHESIOLOGY, V79, P893, DOI 10.1097/00000542-199311000-00005	19	9	11	0	0	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2021, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	JUN	2006	34	3					353	357		10.1177/0310057X0603400309			5	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	068ZH	WOS:000239413600012	16802490	Bronze			2020-06-30	J	Lake, APJ; Coates, OL				Lake, A. P. J.; Coates, O. L.			Mixed opioid - Mixed message?	ANAESTHESIA AND INTENSIVE CARE			English	Article						MOP-R; MOP; opioid receptor; analgesia; mu receptor	INDUCED RESPIRATORY DEPRESSION; RECEPTOR; FENTANYL	By exposing the mu-receptor (MOP-R) to more than one exogenous ligand, the administration during general anaesthesia of more than one opioid with principal action on the receptor may confound and lead to complications or unexpected outcomes. The giving of such a 'mixed message' can result in respiratory depression, excess sedation and delayed recovery to an unusual degree. We present a case of apparent extreme opioid sensitivity and discuss a possible mechanism. Such occurrences may be more common than previously realised.	Glan Clwyd Gen Hosp, Dept Anaesthesia, Bodelwyddan LL18 5UJ, Denbigh, Wales	Lake, APJ (reprint author), Glan Clwyd Gen Hosp, Dept Anaesthesia, Bodelwyddan LL18 5UJ, Denbigh, Wales.						Bot G, 1998, J PHARMACOL EXP THER, V285, P1207; Bowdle TA, 1998, DRUG SAFETY, V19, P173, DOI 10.2165/00002018-199819030-00002; GAL TJ, 1989, CLIN PHARMACOL THER, V45, P66, DOI 10.1038/clpt.1989.10; Gharagozlou Parham, 2003, BMC Pharmacol, V3, P1, DOI 10.1186/1471-2210-3-1; Kvam TM, 2004, J MOL MED, V82, P250, DOI 10.1007/s00109-003-0514-z; METZGER TG, 1995, FEBS LETT, V375, P1, DOI 10.1016/0014-5793(95)01185-H; Pogozheva ID, 1998, BIOPHYS J, V75, P612, DOI 10.1016/S0006-3495(98)77552-6; SHOOK JE, 1990, AM REV RESPIR DIS, V142, P895, DOI 10.1164/ajrccm/142.4.895; Subramanian G, 2000, J MED CHEM, V43, P381, DOI 10.1021/jm9903702; Waldhoer M, 2004, ANNU REV BIOCHEM, V73, P953, DOI 10.1146/annurev.biochem.73.011303.073940	10	0	0	0	2	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2021, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	JUN	2006	34	3					369	371		10.1177/0310057X0603400304			3	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	068ZH	WOS:000239413600015	16802493	Bronze			2020-06-30	J	Zimmermann, M				Zimmermann, M			Medico-legal aspects of the use of fentanyl patches	ANAESTHESIST			English	Article						generic fentanyl patches; pain therapy; effective dose; side-effects; responsibility		The use of fentanyl patches has become accepted as standard in Germany for the treatment of chronic and cancer pain. Recently generic fentanyl patches were launched but in contrast to the original patches the new patches are without labels concerning the concentration. There is not only a difference of ca 30% in the fentanyl concentration among the different generic patches, there is also a variation in the size. Especially in hospitals, nursing homes or in emergency cases the dose of the patches cannot be distinguished by doctors, nurses or other healthcare providers which can lead to overdoses or to withdrawl reactions with one of the strongest opioids available. In cases where problems occur the prescribing doctor will be held responsible.	Univ Frankfurt Klinikum, Klin Anasthesiol Intensivmed & Schmerztherapie, D-60590 Frankfurt, Germany	Zimmermann, M (reprint author), Univ Frankfurt Klinikum, Klin Anasthesiol Intensivmed & Schmerztherapie, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	M.Zimmermann@em.uni-frankfurt.de					GROND S, 2005, KLINIKARZT, V34, P10; Jage J, 2006, SCHMERZ, V20, P79, DOI 10.1007/s00482-006-0467-6	2	1	1	0	1	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0003-2417			ANAESTHESIST	Anaesthesist	JUN	2006	55	6					706	707		10.1007/s00101-006-1022-7			2	Anesthesiology	Anesthesiology	053PP	WOS:000238317400012	16609884				2020-06-30	J	Silbert, BS; Scott, DA; Evered, LA; Lewis, MS; Kalpokas, M; Maruff, P; Myles, PS; Jamrozik, K				Silbert, Brendan S.; Scott, David A.; Evered, Lisbeth A.; Lewis, Matthew S.; Kalpokas, Mario; Maruff, Paul; Myles, Paul S.; Jamrozik, Konrad			A comparison of the effect of high- and low-dose fentanyl on the incidence of postoperative cognitive dysfunction after coronary artery bypass surgery in the elderly	ANESTHESIOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 22-26, 2005	Las Vegas, NV	Amer Soc Anesthesiologists			CARDIOPULMONARY BYPASS; CARDIAC-SURGERY; GRAFT-SURGERY; CONTROLLED-TRIAL; OUTCOMES; POPULATIONS; EXTUBATION; MANAGEMENT; MORBIDITY; ISCHEMIA	Background. Postoperative cognitive dysfunction (POCD) after coronary artery bypass graft surgery is a common complication for which, despite many clinical investigations, no definitive etiology has been found. The current use of both high and low-dose fentanyl as anesthetic techniques allowed us to investigate the effect of fentanyl on the incidence of POCD. Methods. Three hundred fifty patients scheduled to undergo elective coronary artery bypass graft surgery were randomized to receive either high-dose fentanyl (50 mu g/kg) or low-dose fentanyl (10 mu g/kg) as the basis of the anesthetic. All patients underwent neuropsychological testing before surgery and at 1 week, 3 months, and 12 months after surgery. Results. One hundred sixty-eight patients in the low-dose group and 158 patients in the high-dose group were included in the final analysis. Neuropsychological testing was performed on 88%, 93%, and 92% of patients at 1 week, 3 months, and 12 months, respectively. There was no difference between group mean scores at any of the three testing times. Analysis of individual patients by the 20% rule did not detect any differences between groups. The one SD rule, which has fewer false-positive results, detected significantly more patients with POCD in the low-dose group than in the high-dose group at 1 week (23.6% vs. 13.7%; P = 0.03) but not at the other testing times. Patients with POCD spent an average of 1.2 days longer in the hospital than those without POCD (P = 0.021). Conclusions: High-dose fentanyl is not associated with a difference in the incidence of POCD at 3 or 12 months after surgery. Low-dose fentanyl leads to shorter postoperative ventilation times and may be associated with a greater incidence of POCD 1 week after surgery. Early POCD is associated with an increased duration of stay in the hospital.	St Vincents Hosp, Dept Anaesthesia, Ctr Anaesthesia & Cognit Funct, Fitzroy, Vic 3065, Australia; La Trobe Univ, Sch Psychol Sci, Melbourne, Vic, Australia; Alfred Hosp, Dept Anesthesia & Perioperat Med, Melbourne, Vic, Australia; Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia; Univ Queensland, Sch Populat Hlth, Brisbane, Qld, Australia	Silbert, BS (reprint author), St Vincents Hosp, Dept Anaesthesia, Ctr Anaesthesia & Cognit Funct, POB 2900, Fitzroy, Vic 3065, Australia.	silberbs@svhm.org.au		Myles, Paul/0000-0002-3324-5456; Evered, Lisbeth/0000-0002-9051-7913; Lewis, Matthew/0000-0001-7973-0716; Maruff, Paul/0000-0002-6947-9537			ARIS A, 1986, J THORAC CARDIOV SUR, V91, P526; BLAUTH CI, 1990, J THORAC CARDIOV SUR, V99, P61; Cheng DCH, 1996, ANESTHESIOLOGY, V85, P1300, DOI 10.1097/00000542-199612000-00011; Collie A, 1999, AUST NZ J PSYCHIAT, V33, P568, DOI 10.1080/j.1440-1614.1999.00570.x; Keizer AMA, 2005, ACTA ANAESTH SCAND, V49, P1232, DOI 10.1111/j.1399-6576.2005.00835.x; Kofke WA, 1996, ANESTH ANALG, V83, P1298, DOI 10.1097/00000539-199612000-00029; Kofke WA, 2002, ANESTH ANALG, V94, P1229, DOI 10.1097/00000539-200205000-00033; Lewis MS, 2006, ACTA ANAESTH SCAND, V50, P50, DOI 10.1111/j.1399-6576.2006.00893.x; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LOWENSTEIN E, 1969, NEW ENGL J MED, V281, P1389, DOI 10.1056/NEJM196912182812503; MCCORMACK HM, 1988, PSYCHOL MED, V18, P1007, DOI 10.1017/S0033291700009934; McKhann GM, 1997, ANN THORAC SURG, V63, P510; Millar K, 2001, BRIT J ANAESTH, V86, P63, DOI 10.1093/bja/86.1.63; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Mora CT, 1996, J THORAC CARDIOV SUR, V112, P514, DOI 10.1016/S0022-5223(96)70280-5; Morimoto Y, 1997, J NEUROSURG ANESTH, V9, P316, DOI 10.1097/00008506-199710000-00005; MURKIN JM, 1995, ANN THORAC SURG, V59, P1289, DOI 10.1016/0003-4975(95)00106-U; MURKIN JM, 1995, J THORAC CARDIOV SUR, V110, P340, DOI 10.1016/S0022-5223(95)70229-6; NELSON H, 1992, NATL ADULT READING T; Newman MF, 2001, NEW ENGL J MED, V344, P395, DOI 10.1056/NEJM200102083440601; Newman S, 1999, HEART, V82, P541, DOI 10.1136/hrt.82.5.541; Rasmussen LS, 2005, ACTA ANAESTH SCAND, V49, P1225, DOI 10.1111/j.1399-6576.2005.00791.x; Rasmussen LS, 2001, ACTA ANAESTH SCAND, V45, P275, DOI 10.1034/j.1399-6576.2001.045003275.x; Scott DA, 2002, J CARDIOTHOR VASC AN, V16, P715, DOI 10.1053/jcan.2002.128413; Selnes OA, 2002, CURR OPIN PSYCHIATR, V15, P285, DOI 10.1097/00001504-200205000-00010; SHAW PJ, 1987, STROKE, V18, P700, DOI 10.1161/01.STR.18.4.700; Silbert BS, 1998, CHEST, V113, P1481, DOI 10.1378/chest.113.6.1481; Sloviter RS, 1996, J COMP NEUROL, V366, P516, DOI 10.1002/(SICI)1096-9861(19960311)366:3<516::AID-CNE10>3.0.CO;2-N; Symes E, 2000, AUST NZ J PSYCHIAT, V34, P770, DOI 10.1080/j.1440-1614.2000.00808.x; Van Dijk D, 2002, JAMA-J AM MED ASSOC, V287, P1405, DOI 10.1001/jama.287.11.1405; van Dijk D, 2000, J THORAC CARDIOV SUR, V120, P632, DOI 10.1067/mtc.2000.108901	31	58	73	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	JUN	2006	104	6					1137	1145		10.1097/00000542-200606000-00007			9	Anesthesiology	Anesthesiology	047HD	WOS:000237869500006	16732083				2020-06-30	J	Veyckemans, F				Veyckemans, F.			Sedation in children: how and for who?	ARCHIVES DE PEDIATRIE			French	Article; Proceedings Paper	Congress of the Societes-de-Pediatrie	JUN 14-17, 2006	Lyon, FRANCE	Soc Pediat, Soc Francaise Pediat, Assoc Pediat Langue Francaise		sedation; monitoring; child			Clin Univ St Luc, Anesthesiol Serv, B-1200 Brussels, Belgium	Veyckemans, F (reprint author), Clin Univ St Luc, Anesthesiol Serv, 10-1821,Ave Hippocrate, B-1200 Brussels, Belgium.	veyckemans@anes.ucl.ac.be					Boulland P, 2005, ANN FR ANESTH, V24, P1305, DOI 10.1016/j.annfar.2005.05.018; Cravero JP, 2004, ANESTH ANALG, V99, P1355, DOI 10.1213/01.ANE.0000134810.60270.E8; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Hall RW, 2005, PEDIATRICS, V115, P1351, DOI 10.1542/peds.2004-1398; Wolf AR, 2004, PEDIATR ANESTH, V14, P435, DOI 10.1111/j.1460-9592.2004.01332.x	5	1	1	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	PARIS	23 RUE LINOIS, 75724 PARIS, FRANCE	0929-693X			ARCH PEDIATRIE	Arch. Pediatr.	JUN	2006	13	6					835	837		10.1016/j.arcped.2006.03.131			3	Pediatrics	Pediatrics	054IW	WOS:000238371000136	16697580				2020-06-30	J	Langford, R; McKenna, F; Ratcliffe, S; Vojtassak, J; Richarz, U				Langford, Richard; McKenna, Frank; Ratcliffe, Stuart; Vojtassak, Jozef; Richarz, Ute			Transdermal fentanyl for improvement of pain and functioning in osteoarthritis - A randomized, placebo-controlled trial	ARTHRITIS AND RHEUMATISM			English	Article							CHRONIC NONCANCER PAIN; RELEASE ORAL MORPHINE; LOW-BACK-PAIN; DOUBLE-BLIND; STANDING-COMMITTEE; TASK-FORCE; KNEE; MANAGEMENT; HIP; RECOMMENDATIONS	Objective. Although common treatments for osteo-arthritis (OA) pain, such as nonsteroidal antiinflammatory drugs (NSAIDs), simple analgesics, and weak opioids, provide relief in some cases, they fail to control pain or are poorly tolerated in many cases. Strong opioids have been used to successfully treat several types of noncancer pain but have rarely been tested in controlled studies. Therefore, we tested the effects of transdermal fentanyl (TDF) in patients with moderate-to-severe OA pain, in a placebo-controlled study. Methods. The cohort comprised patients with radiologically confirmed OA of the hip or knee (meeting the American College of Rheumatology criteria) requiring joint replacement and with moderate-to-severe pain that had been inadequately controlled by weak opioids. The patients were randomized to receive TDF or placebo for 6 weeks after a 1-week pretreatment run-in phase. During study treatment, previously prescribed NSAIDs and simple analgesics were continued, but weak opioids were discontinued. All patients had access to paracetamol and metoclopramide. Pain was recorded on a visual analog scale (VAS), and function was assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Results. Data were available for 399 patients (202 receiving TDF, 197 receiving placebo), of whom 199 (50%) completed the study. TDF provided significantly better pain relief than placebo, as demonstrated by the primary outcome measure (area under the curve for VAS scores -20 in the TDF group versus -14.6 in the placebo group; P = 0.007). TDF was also associated with significantly better overall WOMAC scores and pain scores. The most common adverse events were nausea, vomiting, and somnolence, and these occurred more often in the TDF group. Conclusion. TDF can reduce pain and improve function in patients with knee or hip OA.	Barts & London NHS Trust, Pain Res Grp, London, England; Trafford Gen Hosp, Manchester, Lancs, England; Comenius Univ, Ruzinov Hosp, Bratislava, Slovakia; Janssen Cilag Baar, Baar, Switzerland	Richarz, U (reprint author), Sihlbruggstr 111, CH-6341 Baar, Switzerland.	urichar1@jacch.jnj.com					Allan L, 2005, SPINE, V30, P2484, DOI 10.1097/01.brs.0000186860.23078.a8; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; ALTMAN R, 1991, ARTHRITIS RHEUM, V34, P505, DOI 10.1002/art.1780340502; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; *AM AC PAIN MED, 2004, AM PAIN SOC AM SOC A; Babul N, 2004, J PAIN SYMPTOM MANAG, V28, P59, DOI 10.1016/j.jpainsymman.2003.11.006; Becker JC, 2004, BRIT J CLIN PHARMACO, V58, P587, DOI 10.1111/j.1365-2125.2004.02198.x; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Bilfinger TV, 1998, INT J CARDIOL, V64, pS61, DOI 10.1016/S0167-5273(98)00037-0; BolnotDelmas D, 1996, PAIN, V64, P99, DOI 10.1016/0304-3959(95)00075-5; Bookwala J, 2003, PSYCHOL AGING, V18, P844, DOI 10.1037/0882-7974.18.4.844; Caldwell JR, 1999, J RHEUMATOL, V26, P862; Caldwell JR, 2002, J PAIN SYMPTOM MANAG, V23, P278, DOI 10.1016/S0885-3924(02)00383-4; Corti MC, 2003, AGING CLIN EXP RES, V15, P359, DOI 10.1007/BF03327356; Dieppe PA, 2005, LANCET, V365, P965, DOI 10.1016/S0140-6736(05)71086-2; GOSSOP M, 1990, ADDICT BEHAV, V15, P487, DOI 10.1016/0306-4603(90)90036-W; Hawkey CJ, 1999, LANCET, V353, P307, DOI 10.1016/S0140-6736(98)12154-2; Jordan KM, 2003, ANN RHEUM DIS, V62, P1145, DOI 10.1136/ard.2003.011742; Juni P, 2004, LANCET, V364, P2021, DOI 10.1016/S0140-6736(04)17514-4; Kalso E, 2004, PAIN, V112, P372, DOI 10.1016/j.pain.2004.09.019; Kalso E, 2003, EUR J PAIN, V7, P381, DOI 10.1016/S1090-3801(02)00143-X; Kennedy D, 2003, PHYSIOTHER CAN, V55, P160; Laporte JR, 2004, DRUG SAFETY, V27, P411, DOI 10.2165/00002018-200427060-00005; Lipman A G, 2001, Curr Rheumatol Rep, V3, P513, DOI 10.1007/s11926-001-0066-6; McNicol E, 2003, J PAIN, V4, P231, DOI 10.1016/S1526-5900(03)00556-X; McQuay H, 1999, LANCET, V353, P2229, DOI 10.1016/S0140-6736(99)03528-X; McQuay HJ, 2003, J PAIN SYMPTOM MANAG, V25, P395, DOI 10.1016/S0885-3924(03)00099-X; Milligan K, 2001, J PAIN, V2, P197, DOI 10.1054/jpai.2001.25352; Otis JAD, 2005, ANN RHEUM DIS, V64, P528; Peloso PM, 2000, J RHEUMATOL, V27, P764; Simpson KH, 2004, BRIT J ANAESTH, V92, P326, DOI 10.1093/bja/aeh059; Simpson RK, 1997, J PAIN SYMPTOM MANAG, V14, P218, DOI 10.1016/S0885-3924(97)00183-8; Stratford PW, 2004, BMC MUSCULOSKEL DIS, V5, DOI 10.1186/1471-2474-5-17; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Woolf AD, 2003, B WORLD HEALTH ORGAN, V81, P646; Zhang W, 2005, ANN RHEUM DIS, V64, P669, DOI 10.1136/ard.2004.028886	36	61	65	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0004-3591	1529-0131		ARTHRITIS RHEUM-US	Arthritis Rheum.	JUN	2006	54	6					1829	1837		10.1002/art.21884			9	Rheumatology	Rheumatology	052AT	WOS:000238203600015	16729276				2020-06-30	J	Nitsun, M; Szokol, JW; Saleh, HJ; Murphy, GS; Vender, JS; Luong, L; Raikoff, K; Avram, MJ				Nitsun, Martin; Szokol, Joseph W.; Saleh, H. Jacob; Murphy, Glenn S.; Vender, Jeffery S.; Luong, Lynn; Raikoff, Kiril; Avram, Michael J.			Pharmacokinetics of midazolam, propofol, and fentanyl transfer to human breast milk	CLINICAL PHARMACOLOGY & THERAPEUTICS			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; FLUORESCENCE DETECTION; DRUG EXCRETION; ANESTHESIA; KINETICS; WOMEN; PHARMACODYNAMICS; COLOSTRUM; INFANT; VOLUME	Background and objectives. Lactating women undergoing operations requiring general anesthesia are advised to pump and discard their milk for 24 hours after the procedure. Data on anesthetic drug transfer into breast milk are limited. This study determined the pharmacokinetics of midazolam, propofol, and fentanyl transfer into milk to provide caregivers with data regarding the safety of breast milk after administration of these drugs. Methods. Five lactating women participated in this study after providing institutionally approved written informed consent. Patients underwent premedication with midazolam before induction of anesthesia with propofol and fentanyl. Anesthesia was maintained with a potent volatile anesthetic. Milk and blood were collected before drug administration. Milk was collected 5, 7, 9, 11, and 24 hours after drug administration. Venous blood was collected at intervals up to 7 hours. Plasma and milk midazolam, propofol, and fentanyl concentrations were measured by HPLC with tandem mass spectrometric or fluorescence detection. The pharmacokinetics of drug transfer into milk was modeled with plasma pharmacokinetics. Results. Plasma midazolam, propofol, and fentanyl pharmacokinetics were consistent with reports of others. In 24 hours of milk collection, averages of 0.005% (range, 0.002%-0.013%) of the maternal midazolam dose, 0.027% (0.004%-0.082%) of the propofol dose, and 0.033% (0.006%-0.073%) of the fentanyl dose were collected in milk, representing averages of 0.009%, 0.025%, and 0.039% of the respective elimination clearances. Conclusion: The amount of midazolam, propofol, and fentanyl excreted into milk within 24 hours of induction of anesthesia provides insufficient justification for interrupting breast-feeding.	Northwestern Univ, Feinberg Sch Med, Dept Anesthesiol, Chicago, IL 60611 USA; Northwestern Univ, Dept Obstet & Gynecol, Chicago, IL USA; Northwestern Univ, Feinberg Sch Med, Dept Anesthesiol, Chicago, IL USA; Northwestern Univ, Feinberg Sch Med, Mary Beth Donnelley Clin Pharmacol Core Facil, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA	Avram, MJ (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Anesthesiol, 303 E Chicago Ave,Ward 13-199, Chicago, IL 60611 USA.	mja190@northwestern.edu	Avram, Michael/M-7681-2019				AVRAM MJ, 1983, CLIN PHARMACOL THER, V34, P505, DOI 10.1038/clpt.1983.205; Barrett PHR, 1998, METABOLISM, V47, P484, DOI 10.1016/S0026-0495(98)90064-6; Begg Evan J, 2002, J Hum Lact, V18, P323, DOI 10.1177/089033402237904; BOND GM, 1992, ANAESTH INTENS CARE, V20, P426, DOI 10.1177/0310057X9202000404; Borgatta L, 1997, J CLIN PHARMACOL, V37, P186, DOI 10.1002/j.1552-4604.1997.tb04780.x; DAILLAND P, 1989, ANESTHESIOLOGY, V71, P827, DOI 10.1097/00000542-198912000-00003; GARZONE PD, 1989, CLIN PHARMACOKINET, V16, P337, DOI 10.2165/00003088-198916060-00002; GREEN D, 1982, EARLY HUM DEV, V6, P153, DOI 10.1016/0378-3782(82)90102-5; Ibrahim A, 2002, ANESTHESIOLOGY, V96, P88, DOI 10.1097/00000542-200201000-00020; Ito S, 2000, NEW ENGL J MED, V343, P118, DOI 10.1056/NEJM200007133430208; Ito S, 2003, ADV DRUG DELIVER REV, V55, P617, DOI 10.1016/S0169-409X(03)00034-6; JELLIFFE DB, 1978, AM J CLIN NUTR, V31, P492; KANTO J, 1989, CLIN PHARMACOKINET, V17, P308, DOI 10.2165/00003088-198917050-00002; Knibbe CAJ, 1998, J CHROMATOGR B, V706, P305, DOI 10.1016/S0378-4347(97)00571-9; KOSKA AJ, 1981, CLIN PHARMACOL THER, V29, P100, DOI 10.1038/clpt.1981.16; Lang C, 2003, ANAESTHESIST, V52, P934, DOI 10.1007/s00101-003-0571-2; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P442; MATHESON I, 1990, BRIT J CLIN PHARMACO, V30, P787, DOI 10.1111/j.1365-2125.1990.tb05443.x; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; MCKENZIE SA, 1975, ARCH DIS CHILD, V50, P894, DOI 10.1136/adc.50.11.894; MORETTI ME, 1995, AM J OBSTET GYNECOL, V173, P1625, DOI 10.1016/0002-9378(95)90662-2; PLUMMER GF, 1987, J CHROMATOGR-BIOMED, V421, P171, DOI 10.1016/0378-4347(87)80394-8; SAINT L, 1984, BRIT J NUTR, V52, P87, DOI 10.1079/BJN19840074; SHAFER A, 1988, ANESTHESIOLOGY, V69, P348, DOI 10.1097/00000542-198809000-00011; SMITH MT, 1981, EUR J CLIN PHARMACOL, V19, P171; STEC GP, 1980, CLIN PHARMACOL THER, V28, P404, DOI 10.1038/clpt.1980.180; STEER PL, 1992, CAN J ANAESTH, V39, P231, DOI 10.1007/BF03008782; TACKLEY RM, 1989, BRIT J ANAESTH, V62, P46, DOI 10.1093/bja/62.1.46; UHL K, 2002, AM FAM PHYSICIAN, V179, P172; WILSON JT, 1980, CLIN PHARMACOKINET, V5, P1, DOI 10.2165/00003088-198005010-00001	30	38	40	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0009-9236	1532-6535		CLIN PHARMACOL THER	Clin. Pharmacol. Ther.	JUN	2006	79	6					549	557		10.1016/j.clpt.2006.02.010			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	052WB	WOS:000238263500006	16765143				2020-06-30	J	Reinoso-Barbero, E; Martinez-Garcia, E; Hernandez-Gancedo, MC; Simon, AM				Reinoso-Barbero, E.; Martinez-Garcia, E.; Hernandez-Gancedo, M. C.; Simon, A. M.			The effect of epidural bupivacaine on maintenance requirements of sevoflurane evaluated by bispectral index in children	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						ANALGESICS OPIOID, fentanyl; ANAESTHETICS INHALATIONAL, sevoflurane; ANAESTHESIA GENERAL, bispectral index monitoring; CHILDREN; EPIDURAL ANALGESIA, bupivacaine; SURGERY, ORTHOPAEDIC; ELECTROENCEPHALOGRAPHY	END-TIDAL SEVOFLURANE; ANESTHESIA; FENTANYL; INDUCTION; RESPONSES; LIDOCAINE; INCISION; MONITOR; STATES; BLOCK	Background and objective: Combined (local and general) anaesthesia or Balanced (intravenous analgesics and inhalational hypnotics) anaesthesia are commonly used in paediatrics. The authors have investigated the influence of both types of anaesthesia on the requirements of sevoflurane to maintain an adequate level of hypnosis as measured by Bispectral index (at around 50) monitoring in paediatric orthopaedic patients. Methods: Twenty-six orthopaedic surgery patients aged 2-15 yr were randomized to receive, during general sevoflurane anaesthesia, 5 mu g kg(-1) of intravenous fentanyl (Balanced anaesthesia group) or 1 mL kg(-1) of caudal-epidural bupivacaine 0.25% (Combined anaesthesia group). The end-tidal sevoflurane concentration was adjusted every 5 min in order to maintain Bispectral index values at around 50. Results: Patients showed very similar Bispectral index values (P > 0.05) in both the Combined and the Balanced groups before anaesthesia (96.7 +/- 2.7 vs. 96.9 +/- 1.8), after induction (48.5 +/- 2.9 vs. 49.8 +/- 3.6) and after administration of analgesia (50.9 +/- 3.8 vs. 50.3 +/- 4.3). The sevoflurane end-tidal concentration requirements were similar in both the Combined and Balanced groups before administration of analgesia (2.1 +/- 0.2 vs. 2.1 +/- 0.4, P = 0.9415), but lower end-tidal concentrations were required by the Combined group than by the Balanced group (0.81 +/- 0.4 vs. 1.5 +/- 0.5, P < 0.0001) in the first 20 min after administration of analgesia. Conclusion: Combined anaesthesia with epidural bupivacaine maintains the same Bispectral index values as Balanced anaesthesia during orthopaedic surgery in children without fentanyl and with a lower sevoflurane requirement.	Hosp Univ La Paz, Unidad Dolor Infantil, Dept Anesthesiol, Madrid 28036, Spain; Univ Autonoma Madrid, Sch Med, Dept Surg, Madrid, Spain; Univ Navarra Clin, Dept Anesthesiol, Pamplona, Spain	Reinoso-Barbero, E (reprint author), Hosp Univ La Paz, Unidad Dolor Infantil, Dept Anesthesiol, Paseo Castellana 261, Madrid 28036, Spain.	franreinoso@terra.es	Martinez, Ernesto/AAA-7796-2019	Martinez, Ernesto/0000-0002-3291-7855; Antonio, Martinez-Simon/0000-0002-3039-4798			Agarwal A, 2004, ANESTH ANALG, V99, P1684, DOI 10.1213/01.ANE.0000136422.70531.5A; Barr G, 2000, ACTA ANAESTH SCAND, V44, P807, DOI 10.1034/j.1399-6576.2000.440707.x; BENDAVID B, 1995, ANESTH ANALG, V81, P525, DOI 10.1097/00000539-199509000-00017; Casati L, 2002, ANESTH ANALG, V94, P1331, DOI 10.1097/00000539-200205000-00053; DEDEYNE C, 1998, ANESTHESIOLOGY, V89, pA3; Degoute CS, 2001, BRIT J ANAESTH, V86, P209, DOI 10.1093/bja/86.2.209; Denman WT, 2000, ANESTH ANALG, V90, P872, DOI 10.1213/00000539-200004000-00018; Eappen S, 1998, ANESTHESIOLOGY, V88, P1036, DOI 10.1097/00000542-199804000-00024; FLASHION R, 1997, [No title captured], V86, P613; GASS PS, 1997, ANESTHESIOLOGY, V86, P836; GENTILI M, 1998, BRIT J ANAESTH, V81, P1970; Hodgson PS, 2001, ANESTHESIOLOGY, V94, P799, DOI 10.1097/00000542-200105000-00018; INAGAKI Y, 1994, ANESTH ANALG, V79, P386; JOHANSEN JW, 1998, ANESTH ANALG, V86, pS406; Katoh T, 2000, BRIT J ANAESTH, V84, P63; Kihara S, 2000, ANESTH ANALG, V91, P305, DOI 10.1097/00000539-200008000-00012; LAINER WL, 1994, ANESTHESIOLOGY, V80, P392; Olofsen E, 1999, ANESTHESIOLOGY, V90, P1345, DOI 10.1097/00000542-199905000-00019; Reinoso-Barbero F, 2002, CAN J ANAESTH, V49, P67, DOI 10.1007/BF03020421; REINOSOBARBERO F, 1995, ANESTHESIOLOGY, V82, P144, DOI 10.1097/00000542-199501000-00019; ROIZEN MF, 1981, ANESTHESIOLOGY, V54, P390, DOI 10.1097/00000542-198105000-00008; Rosen David A., 1999, Anesthesiology (Hagerstown), V91, pA1244; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; Sebel PS, 2004, ANESTH ANALG, V99, P833, DOI 10.1213/01.ANE.0000130261.90896.6C; Watcha M. F., 1999, Anesthesiology (Hagerstown), V91, pA1266	25	11	13	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	JUN	2006	23	6					460	464		10.1017/S0265021506000330			5	Anesthesiology	Anesthesiology	052OL	WOS:000238242900003	16507194				2020-06-30	J	Gursoy, S; Bagcivan, I; Yildirim, MK; Berkan, O; Kaya, T				Gursoy, S; Bagcivan, I; Yildirim, MK; Berkan, O; Kaya, T			Vasorelaxant effect of opioid analgesics on the isolated human radial artery	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article							PATIENT-CONTROLLED ANALGESIA; CORONARY-ARTERY; FENTANYL; BYPASS; SURGERY; GRAFTS; REVASCULARIZATION; VASOREACTIVITY; CONTRACTILITY; ENDOTHELIUM	Background and objective: Arterial grafts are prone to vasospasm. Opiold analgesics are commonly used in the perioperative course of cardiac surgical procedures. Therefore, we investigated the direct effects of morphine, meperidine, fentanyl and remifentanil on the human radial artery. Methods: Radial artery segments, obtained from 20 patients, were precontracted with phenylephrine. Using the organ bath technique, the endothelium-independent vasodilatation was tested in vitro by addition of cumulative concentrations of morphine, meperidine, fentanyl and remifentanil in separate organ baths, in the presence or absence of naloxone. Indomethacin and N-G-nitro-L-arginine methyl ester was added to all organ bath in order to determine the effects of prostaglandins and nitric oxide, respectively. Results: Morphine (10(-8)-10(-4) mol L-1), meperidine (10(-10)-10(-6) mol L-1), fentanyl (10(-10)-10(-6) mol L-1) and remifentanil (10(-8)-10(-4) mol L-1) caused a concentration-dependent vasorelaxation in the human being artery rings. The relaxations in the presence of naloxane did not change. The maximal relaxant effects of meperidine and fentanyl were significantly greater than those of morphine and remifentanil (P < 0.05). Conclusions: These findings indicate that morphine, meperidine, fentanyl and remifentanil produce concentration-dependent and endothelium-independent relaxations in human being radial artery rings. Meperidine and fentanyl are more potent relaxant agents than morphine and remifentanil in the human being radial artery in vitro.	Cumhuriyet Univ, Sch Med, Dept Anesthesiol, TR-58140 Sivas, Turkey; Cumhuriyet Univ, Sch Med, Dept Pharmacol, TR-58140 Sivas, Turkey; Cumhuriyet Univ, Sch Med, Dept Cardiothorac Surg, TR-58140 Sivas, Turkey	Gursoy, S (reprint author), Cumhuriyet Univ, Sch Med, Dept Anesthesiol, TR-58140 Sivas, Turkey.	sgursoy@cumhuriyet.edu.tr					ACAR C, 1991, SURG RADIOL ANAT, V13, P283, DOI 10.1007/BF01627759; ACAR C, 1992, ANN THORAC SURG, V54, P652, DOI 10.1016/0003-4975(92)91007-V; Barner H B, 1996, Semin Thorac Cardiovasc Surg, V8, P3; BLAISE GA, 1990, ANESTHESIOLOGY, V72, P535, DOI 10.1097/00000542-199003000-00023; BOVILL JG, 1984, ANESTHESIOLOGY, V61, P731; BUGGEASP.B, 1973, CARDIOVASC RES, V7, P528, DOI 10.1093/cvr/7.4.528; Carpentier A, 1973, ANN THORAC SURG, V16, P11; CHARDIGNY C, 1993, CIRCULATION, V88, P115; Conant AR, 2003, J THORAC CARDIOV SUR, V126, P448, DOI 10.1016/S0022-5223(03)00388-X; DIETL CA, 1995, ANN THORAC SURG, V60, P102; FISK RL, 1976, ANN THORAC SURG, V21, P513, DOI 10.1016/S0003-4975(10)63919-7; Gurbet A, 2004, J CARDIOTHOR VASC AN, V18, P755, DOI 10.1053/j.jvca.2004.08.014; He GW, 1997, ANN THORAC SURG, V63, P1346, DOI 10.1016/S0003-4975(97)00106-9; HE GW, 1995, J THORAC CARDIOV SUR, V109, P707, DOI 10.1016/S0022-5223(95)70352-7; He GW, 1996, ANN THORAC SURG, V61, P610, DOI 10.1016/0003-4975(95)00920-5; He GW, 2001, J THORAC CARDIOV SUR, V121, P431, DOI 10.1067/mtc.2001.113593; KARASAWA F, 1993, BRIT J ANAESTH, V71, P877, DOI 10.1093/bja/71.6.877; KARASAWA F, 1993, CLIN EXP PHARMACOL P, V20, P705, DOI 10.1111/j.1440-1681.1993.tb01655.x; LOWENSTEIN E, 1969, NEW ENGL J MED, V281, P1389, DOI 10.1056/NEJM196912182812503; Manasse E, 1996, ANN THORAC SURG, V62, P1076, DOI 10.1016/0003-4975(96)00594-2; REYES AT, 1995, ANN THORAC SURG, V59, P118, DOI 10.1016/0003-4975(94)00673-U; Rosenfeldt FL, 1999, ANN THORAC SURG, V67, P878, DOI 10.1016/S0003-4975(98)01299-5; SEARLE NR, 1994, CAN J ANAESTH, V41, P198, DOI 10.1007/BF03009831; SHIBATA O, 1995, CAN J ANAESTH, V42, P1164, DOI 10.1007/BF03015106; TODA N, 1977, ANESTHESIOLOGY, V46, P411, DOI 10.1097/00000542-197706000-00007; WHITE DA, 1990, ANESTH ANALG, V71, P29; YAMANOUE T, 1993, ANESTH ANALG, V76, P382; YAMANOUE T, 1992, ANESTH ANALG, V74, P889	28	15	21	0	3	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	JUN	2006	23	6					496	500		10.1017/S0265021506000172			5	Anesthesiology	Anesthesiology	052OL	WOS:000238242900010	16507200				2020-06-30	J	Hallberg, P; Marten, L; Wadelius, M				Hallberg, Par; Marten, Leif; Wadelius, Mia			Possible fluconazole-fentanyl interaction - a case report	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY			English	Letter									Med Prod Agcy, Pharmacovigilance Unit, S-75103 Uppsala, Sweden; Mora Hosp, Unit Palliat Care, Mora, Sweden; Univ Uppsala Hosp, Dept Clin Pharmacol, S-75014 Uppsala, Sweden	Hallberg, P (reprint author), Med Prod Agcy, Pharmacovigilance Unit, POB 26, S-75103 Uppsala, Sweden.	par.hallberg@mpa.se	Wadelius, Mia/C-7740-2016	Wadelius, Mia/0000-0002-6368-2622; Hallberg, Par/0000-0003-3465-3280			Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Katz HI, 1999, BRIT J DERMATOL, V141, P26; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; MERCADANTE S, 2002, J PAIN SYMPTOM MANAG, V3, P281; Olkkola KT, 1999, ANESTHESIOLOGY, V91, P681, DOI 10.1097/00000542-199909000-00020; Palkama VJ, 1998, ANESTH ANALG, V87, P190, DOI 10.1097/00000539-199807000-00039; Palkama VJ, 1998, BRIT J ANAESTH, V81, P598, DOI 10.1093/bja/81.4.598; Pickeral T., 2000, NATL SOC EXPERIMENTA, V25, P7; PORTA PL, 1993, HIST EC IDEAS, V1, P43	11	24	24	0	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0031-6970	1432-1041		EUR J CLIN PHARMACOL	Eur. J. Clin. Pharmacol.	JUN	2006	62	6					491	492		10.1007/s00228-006-0120-4			2	Pharmacology & Pharmacy	Pharmacology & Pharmacy	051CE	WOS:000238137300012	16758267				2020-06-30	J	Wang, LQ; Bernert, JT				Wang, Lanqing; Bernert, John T.			Analysis of 13 fentanils, including sufentanil and carfentanil, in human urine by liquid chromatography-atmospheric-pressure ionization-tandem mass spectrometry	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							ELECTROSPRAY-IONIZATION; HUMAN PLASMA; REMIFENTANIL; PHARMACOKINETICS; ABUSE; METABOLITES; ALFENTANIL; EXTRACTION; DEATH; BLOOD		Ctr Dis Control & Prevent, Emergency Response & Air Toxicants Branch, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA	Bernert, JT (reprint author), Ctr Dis Control & Prevent, Emergency Response & Air Toxicants Branch, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Highway NE,Mailstop F-47, Atlanta, GA 30341 USA.	jtb2@cdc.gov					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; Annesley TM, 2003, CLIN CHEM, V49, P1041, DOI 10.1373/49.7.1041; Bender J, 1999, J PHARMACEUT BIOMED, V21, P559, DOI 10.1016/S0731-7085(99)00151-X; Benijts T, 2004, J CHROMATOGR A, V1029, P153, DOI 10.1016/j.chroma.2003.12.022; Booth JV, 2002, ANESTH ANALG, V95, P1024, DOI 10.1213/01.ANE.0000026379.66419.DB; Day J, 2003, J ANAL TOXICOL, V27, P513, DOI 10.1093/jat/27.7.513; GARRIOTT JC, 1984, J ANAL TOXICOL, V8, P288, DOI 10.1093/jat/8.6.288; GLASS PS, 1999, ANESTH ANALG, V89, P7; GLASS PSA, 1995, J CLIN ANESTH, V7, P558, DOI 10.1016/0952-8180(95)00127-1; GROSSE CM, 1994, J PHARMACEUT BIOMED, V12, P195, DOI 10.1016/0731-7085(94)90030-2; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Hoke JF, 1997, J PHARMACOL EXP THER, V281, P226; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; LAKOSKI JM, 2000, ADVANTAGES LIMITATIO, P49; Lehner AF, 2000, J ANAL TOXICOL, V24, P309, DOI 10.1093/jat/24.5.309; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; Martens-Lobenhoffer J, 2002, J CHROMATOGR B, V769, P227, DOI 10.1016/S1570-0232(01)00569-4; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Meert TF, 1996, PHARM WORLD SCI, V18, P1, DOI 10.1007/BF00449683; Michelsen LG, 1996, J CLIN ANESTH, V8, P679, DOI 10.1016/S0952-8180(96)00179-1; *NAT RES COUNC, 1999, CHEM BIOL TERR RES D, P262; PARE EM, 1987, J ANAL TOXICOL, V11, P272, DOI 10.1093/jat/11.6.272; POKLIS A, 1995, CLIN TOXICOL, V33, P439; Sachs H, 1996, INT J LEGAL MED, V109, P213, DOI 10.1007/BF01225521; Shou WZ, 2001, RAPID COMMUN MASS SP, V15, P466, DOI 10.1002/rcm.255; SILVERSTEIN JH, 1993, ANESTH ANALG, V76, P618; Taylor J. K., 1987, QUALITY ASSURANCE CH; Valaer AK, 1997, J CHROMATOGR SCI, V35, P461, DOI 10.1093/chromsci/35.10.461	28	25	28	0	13	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	JUN	2006	30	5					335	341		10.1093/jat/30.5.335			7	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	057ML	WOS:000238599800009	16839472	Bronze			2020-06-30	J	Zwiers, WJ; Blodgett, TM; Vallejo, MC; Finegold, H				Zwiers, William J.; Blodgett, Todd M.; Vallejo, Manuel C.; Finegold, Helene			Successful vaginal delivery for a parturient with complete aortic coarctation	JOURNAL OF CLINICAL ANESTHESIA			English	Article						vaginal delivery; parturient; aortic coarctation	PREGNANCY	This report describes the case of a parturient with complete coarctation of the aorta that was diagnosed during pregnancy. The use of invasive monitoring and the choice of labor analgesia for vaginal delivery are reviewed. Management of patients with complex cardiac anomalies requires consultation among cardiologist, obstetricians, and anesthesiologists to ensure good outcome for the mother and baby. (C) 2006 Elsevier Inc. All rights reserved.	Univ Pittsburgh, Sch Nursing, Sch Nurse Anesthesia, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Radiol, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA	Finegold, H (reprint author), Magee Womens Hosp, Pittsburgh, PA 15213 USA.	finegoldh@anes.upmc.edu	Vallejo, Manuel C/X-5544-2019	Vallejo, Manuel C/0000-0002-1240-3670			Dessole S, 2000, ARCH GYNECOL OBSTET, V263, P145, DOI 10.1007/PL00007472; GARCIA-MACHADO R, 1988, Archivos del Instituto de Cardiologia de Mexico, V58, P203; GOODWIN JF, 1961, CLIN OBSTET GYNECOL, V4, P645, DOI 10.1097/00003081-196109000-00004; Janku K, 2000, Ceska Gynekol, V65, P236; MANGANO DT, 2002, SNIDER LEVINSONS ANE, P469; Togal T, 2002, EUR J ANAESTH, V19, P768, DOI 10.1017/S0265021502271239; Venning S, 2003, J ROY SOC MED, V96, P234, DOI 10.1258/jrsm.96.5.234; Zeira M., 1993, Harefuah, V124, P756; ZEIRA M, 1993, HAREFUAH, V124, P796; ZEIRA M, 1993, HAREFUAH, V124, P795	10	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	JUN	2006	18	4					300	303		10.1016/j.jclinane.2005.10.004			4	Anesthesiology	Anesthesiology	065DN	WOS:000239139700011	16797434				2020-06-30	J	Marier, JF; Lor, M; Potvin, D; DiMarco, M; Morelli, G; Saedder, EA				Marier, Jean-Francois; Lor, Mary; Potvin, Diane; DiMarco, Marika; Morelli, Gaetano; Saedder, Eva Aggerholm			Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects	JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						fentanyl; matrix transdermal delivery system; pharmacokinetics; tolerability	PRESSURE-SENSITIVE ADHESIVES; PHARMACOLOGICAL-PROPERTIES; THERAPEUTIC-EFFICACY; DRUG-DELIVERY; 3A4	A novel transdermal formulation of fentanyl-containing dipropylene glycol droplets dispersed in a silicone matrix with a rate-con trolling membrane was developed. Healthy male subjects (n = 24) received repeated 72-hour applications of fentanyl (50 mu g/h) as the novel matrix and the conventional reservoir formulations in a randomized, 2-way crossover study. Blood samples were collected, and serum concentrations of fentanyl were assayed using liquid chromatography with mass spectrometry detection. The mean area under the curve (AUC tau) and peak concentrations (C-max) of the matrix formulation were 84838 pg(.)h/mL and 1680 pg/mL, respectively. Ratio and 90% confidence intervals of AUC tau and C-max between the 2 formulations were within 80% to 125%. Adherence of the matrix formulation was higher than the reservoir formulation (62.5 vs 56.2%, P < .0001), without affecting skin irritation. Vital signs and adverse events of the 2 formulations were similar in nature and frequency. The novel matrix formulation displayed enhanced adherence and resulted in similar pharmocokinetics and tolerability as the reservoir formulation.	Int Med Affairs, Nycomed, DK-4000 Roskilde, Denmark; MDS Pharma Serv, Montreal, PQ, Canada	Saedder, EA (reprint author), Int Med Affairs, Nycomed, Langebjerg 1,Postbus 88, DK-4000 Roskilde, Denmark.	evs@nycomed.com	Saedder, Eva Aggerholm/AAI-8590-2020	Saedder, Eva/0000-0003-4905-1004			Auclair B, 1998, THER DRUG MONIT, V20, P607, DOI 10.1097/00007691-199812000-00004; BERNER B, 1994, CLIN PHARMACOKINET, V26, P121, DOI 10.2165/00003088-199426020-00005; Evans HC, 2003, DRUGS, V63, P1999, DOI 10.2165/00003495-200363190-00003; FISET P, 1995, ANESTHESIOLOGY, V83, P459, DOI 10.1097/00000542-199509000-00004; Freynhagen R, 2005, J PAIN SYMPTOM MANAG, V30, P289, DOI 10.1016/j.jpainsymman.2005.03.015; Gourlay G K, 2001, Lancet Oncol, V2, P165, DOI 10.1016/S1470-2045(00)00258-8; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; GUPTA SK, 1992, J PAIN SYMPTOM MANAG, V7, pS17, DOI 10.1016/0885-3924(92)90049-N; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; KAIKO RF, 1995, J CLIN PHARMACOL, V35, P499, DOI 10.1002/j.1552-4604.1995.tb04094.x; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lambropoulos J, 1999, J PHARMACEUT BIOMED, V20, P705, DOI 10.1016/S0731-7085(99)00077-1; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; PLEZIA PM, 1989, PHARMACOTHERAPY, V9, P2; RANADE VV, 1991, J CLIN PHARMACOL, V31, P401, DOI 10.1002/j.1552-4604.1991.tb01895.x; Roy SD, 1996, J PHARM SCI, V85, P491, DOI 10.1021/js950415w; SITRUKWARE R, 1995, J STEROID BIOCHEM, V53, P247, DOI 10.1016/0960-0760(95)00055-5; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; Tan HS, 1999, PHARM SCI TECHNOL TO, V2, P60, DOI 10.1016/S1461-5347(99)00119-4; Tateishi T, 1996, ANESTH ANALG, V82, P167; Towzer T. N., 1995, CLIN PHARMACOKINET, P367; *US DEP HHS, 1999, SKIN IRR SENS TEST G; *US FOOD DRUG ADM, [No title captured]; *US FOOD DRUG ADM, [No title captured]; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; *WORLD MED ASS DEC, 1996, REC GUID PHYS BIOM R	28	25	27	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0091-2700	1552-4604		J CLIN PHARMACOL	J. Clin. Pharmacol.	JUN	2006	46	6					642	653		10.1177/0091270006286901			12	Pharmacology & Pharmacy	Pharmacology & Pharmacy	045YK	WOS:000237778400006	16707411				2020-06-30	J	Kundra, P; Sivashanmugam, T; Ravishankar, M				Kundra, P; Sivashanmugam, T; Ravishankar, M			Effect of needle insertion site on ilioinguinal-iliohypogastric nerve block in children	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						anesthetic techniques; regional; ilioinguinal-iliohypogastric nerve block	ANALGESIA; BUPIVACAINE; PAIN	Background: Three different sites of needle insertion have been proposed for ilioinguinal-iliohypogastric (ILIH) nerve block. This double-blind study was designed to assess the quality of analgesia produced from these different sites. Methods: One hundred and thirty-two children of ASA grade I and II were randomly allocated into four groups to receive no nerve block (control group, n = 30) or ILIH block at 1 cm inferio-medial to the anterior superior iliac spine (ASIS) in group IM (n = 34), 1-2 cm medial to the ASIS in group M (n = 34) and 2 cm superio-medial to the ASIS in group SM (n = 34) with 0.25 ml/kg of 0.25% bupivacaine after induction of anaesthesia. Pain was assessed using the All India Institute of Medical Sciences (AIIMS) pain discomfort scale (APDS) score. The amount and pattern of fentanyl consumed over the ensuing 24-h period was noted. Results: APDS score and fentanyl requirement were similar in all the study groups but significantly higher until 8 h after surgery in the control group, P < 0.05. Twenty-two out of 102 children in the study groups and all patients in the control group received additional fentanyl during the post-operative period. Only 6 out of 22 children required additional fentanyl supplementation beyond the 30-min interval. Overall failure rate of ILIH nerve block was 6%. Conclusion: ILIH block can be successfully accomplished from any point if the needle bevel lies between the two muscle planes above and below the internal oblique.	Jawaharlal Inst Postgrad Med Educ & Res, Dept Anaesthesiol & Crit Care, Pondicherry, India	Kundra, P (reprint author), DII 21, JIPMER Campus, Pondicherry 605006, India.	p_kundra@hotmail.com					Avsar FM, 2002, J SURG RES, V107, P179, DOI 10.1006/jsre.2002.6479; BROWN TCK, 1992, TXB ANESTHESIA CHILD, P130; EPSTEIN RH, 1988, ANESTHESIOLOGY, V69, P773, DOI 10.1097/00000542-198811000-00025; FISHER QA, 1993, ANESTH ANALG, V76, P173; HINKLE AJ, 1987, ANESTHESIOLOGY, V67, P411, DOI 10.1097/00000542-198709000-00022; Kokki H, 2000, PAEDIATR ANAESTH, V10, P413, DOI 10.1046/j.1460-9592.2000.00498.x; Kundra P, 1998, ANESTH ANALG, V87, P52, DOI 10.1097/00000539-199807000-00012; MARKHAM SJ, 1986, ANAESTHESIA, V41, P1098, DOI 10.1111/j.1365-2044.1986.tb12956.x; RICE LJ, 1996, SMITHS ANESTHESIA IN, P410; SHANDLING B, 1980, J PEDIATR SURG, V15, P477, DOI 10.1016/S0022-3468(80)80757-3; SPLINTER WM, 1995, CAN J ANAESTH, V42, P197, DOI 10.1007/BF03010675; Whiteside JL, 2003, AM J OBSTET GYNECOL, V189, P1574, DOI 10.1016/S0002-9378(03)00934-7	12	11	13	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAY	2006	50	5					622	626		10.1111/j.1399-6576.2006.001017.x			5	Anesthesiology	Anesthesiology	036HK	WOS:000237062000017	16643234				2020-06-30	J	Frakes, MA; Lord, WR; Kociszewski, C; Wedel, SK				Frakes, MA; Lord, WR; Kociszewski, C; Wedel, SK			Efficacy of fentanyl analgesia for trauma in critical care transport	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							ABDOMINAL-PAIN; EMERGENCY; TRIAL	Introduction: Pain relief is one of the most important interventions for out-of-hospital patient care providers. This paper documents the need for and benefits from the administration of fentanyl to trauma patients during critical care transport. Methods: We underwent a retrospective review of the transport charts of 100 trauma patients who received fentanyl analgesia during transport and who were able to use a numeric response scale to rate their pain from 0 to 10. Results: Mean initial pain report was 7.6 +/- 2.2 units, relieved to 3.7 +/- 2.8 units by a mean total fentanyl dose of 1.6 +/- 0.8 mu g/kg (P <.001). Neither initial pain level nor pain relief differed between male and female patients, but did differ between patients originating at the site of injury and those transferred between hospitals. Fentanyl dose correlated poorly with the magnitude of pain relief (r = 0.22), but a dose greater than 2 mu g/kg provided more relief than lower doses (5.1 +/- 2.1 vs 3.6 +/- 2.4, P <.02). Conclusion: Fentanyl analgesia from these critical care transport teams provided significant pain relief to trauma patients. Pain reduction was greater for patients who received more than 2.0 mu g/kg of fentanyl. (C) 2006 Elsevier Inc. All rights reserved.	Hartford Hosp, LIFE STAR, Hartford, CT 06102 USA; Boston MedFlight, Bedford, MA 01730 USA	Frakes, MA (reprint author), Hartford Hosp, LIFE STAR, POB 5037, Hartford, CT 06102 USA.	mfrakes@harthosp.org					Abbuhl Frederick B, 2003, Prehosp Emerg Care, V7, P445; Alonso-Serra Hector M, 2003, Prehosp Emerg Care, V7, P482; Aronson AA, 2004, CHEST, V126, p907S, DOI 10.1378/chest.126.4_MeetingAbstracts.907S; Blettery B, 1996, REAN URG, V5, P691; Braude Darren, 2004, Prehosp Emerg Care, V8, P441, DOI 10.1016/j.prehos.2004.07.001; DeVellis P, 1998, Prehosp Emerg Care, V2, P293, DOI 10.1080/10903129808958883; Devellis P, 1998, PEDIATR EMERG CARE, V14, P321; DICKINSON ET, 2004, PREHOSP EMERG CARE, V8, P103; Eder SC, 2003, AM J EMERG MED, V21, P253, DOI 10.1016/S0735-6757(03)00041-X; Fosnocht DE, 2005, AM J EMERG MED, V23, P55, DOI 10.1016/j.ajem.2004.09.024; Fosnocht DE, 2001, AM J EMERG MED, V19, P399, DOI 10.1053/ajem.2001.24462; Fullerton-Gleason Lynne, 2002, Prehosp Emerg Care, V6, P411, DOI 10.1080/10903120290938049; HARRISON TH, 2000, ANN EMERG MED, V36, P4; *JOINT COMM ACCR H, 2004, CURR UNDERSTANDING A; KATZUNG BG, 2001, [No title captured]; Kim MK, 2002, ACAD EMERG MED, V9, P281, DOI 10.1111/j.1553-2712.2002.tb01319.x; Maio RF, 1999, ANN EMERG MED, V33, P423, DOI 10.1016/S0196-0644(99)70307-0; McEachin Christine Clara, 2002, Prehosp Emerg Care, V6, P406, DOI 10.1080/10903120290938030; *NAT PHARM COUNC I, 2004, IMPR QUAL PAIN MAN M; O'Brien RG, 1993, APPL ANAL VARIANCE B; Ricard-Hibon A, 1999, ANN EMERG MED, V34, P738, DOI 10.1016/S0196-0644(99)70099-5; Scott IE, 1994, BRIT J NURSING, V3, P494; Thomas SH, 2005, J EMERG MED, V29, P179, DOI 10.1016/j.jemermed.2005.02.007; Thomas SH, 2004, J EMERG MED, V26, P389, DOI 10.1016/j.jemermed.2003.11.020; Thomas SH, 2003, J AM COLL SURGEONS, V196, P18, DOI 10.1016/S1072-7515(02)01480-1; THOMAS SH, 1996, AIR MED J, V15, P57; Thomee V., 1990, HDB NUMERICAL ANAL, P5; Todd KH, 1996, ACAD EMERG MED, V3, P142, DOI 10.1111/j.1553-2712.1996.tb03402.x; US Department of Health and Human Services, 1992, AC PAIN MAN OP MED P; WHITE FG, 1904, [No title captured], V3, P8	30	23	23	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0735-6757			AM J EMERG MED	Am. J. Emerg. Med.	MAY	2006	24	3					286	289		10.1016/j.ajem.2005.11.021			4	Emergency Medicine	Emergency Medicine	041CS	WOS:000237431500005	16635698				2020-06-30	J	Lalley, PM				Lalley, PM			Opiate slowing of feline respiratory rhythm and effects on putative medullary phase-regulating neurons	AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY			English	Article						fentanyl; medullary respiratory neurons; phrenic nerve activity; naloxonazine; naltrindole	PRE-BOTZINGER COMPLEX; DELTA-OPIOID RECEPTORS; MEDIATED DEPRESSION; POTASSIUM CURRENTS; CALCIUM CURRENTS; NUCLEUS AMBIGUUS; CAT; GENERATION; RAT; NETWORK	Opiates have effects on respiratory neurons that depress tidal volume and air exchange, reduce chest wall compliance, and slow rhythm. The most dose-sensitive opioid effect is slowing of the respiratory rhythm through mechanisms that have not been thoroughly investigated. An in vivo dose-response analysis was performed on medullary respiratory neurons of adult cats to investigate two untested hypotheses related to mechanisms of opioid-mediated rhythm slowing: 1) Opiates suppress intrinsic conductances that limit discharge duration in medullary inspiratory and expiratory neurons, and 2) opiates delay the onset and lengthen the duration of discharges postsynaptically in phase-regulating postinspiratory and late-inspiratory neurons. In anesthetized and unanesthetized decerebrate cats, a threshold dose ( 3 mu g/kg) of the mu-opioid receptor agonist fentanyl slowed respiratory rhythm by prolonging discharges of inspiratory and expiratory bulbospinal neurons. Additional doses ( 2 - 4 mu g/kg) of fentanyl also lengthened the interburst silent periods in each type of neuron and delayed the rate of membrane depolarization to firing threshold without altering synaptic drive potential amplitude, input resistance, peak action potential frequency, action potential shape, or afterhyperpolarization. Fentanyl also prolonged discharges of postinspiratory and late-inspiratory neurons in doses that slowed the rhythm of inspiratory and expiratory neurons without altering peak membrane depolarization and hyperpolarization, input resistance, or action potential properties. The temporal changes evoked in the tested neurons can explain the slowing of network respiratory rhythm, but the lack of significant, direct opioid-mediated membrane effects suggests that actions emanating from other types of upstream bulbar respiratory neurons account for rhythm slowing.	Univ Wisconsin, Dept Physiol, Med Sci Ctr, Madison, WI 53706 USA	Lalley, PM (reprint author), Univ Wisconsin, Dept Physiol, Med Sci Ctr, 1300 Univ Ave, Madison, WI 53706 USA.	pmlalley@facstaff.wisc.edu			NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL-65526]		BALLANTYNE D, 1986, J PHYSIOL-LONDON, V370, P433, DOI 10.1113/jphysiol.1986.sp015943; Ballanyi K, 1997, J PHYSIOL-LONDON, V504, P127, DOI 10.1111/j.1469-7793.1997.127bf.x; Bennett JA, 1997, ANESTHESIOLOGY, V87, P1070, DOI 10.1097/00000542-199711000-00010; BOWDLE TA, 1998, DRUG SAFETY, V19, P193; CHOW CM, 1984, J APPL PHYSIOL, V56, P1278; COHEN MI, 1979, PHYSIOL REV, V59, P1105; DASHWOOD MR, 1983, ARCH INT PHARMACOD T, V266, P77; DELGADOGARCIA JM, 1983, BRAIN RES, V277, P231, DOI 10.1016/0006-8993(83)90930-7; DELPIERRE S, 1995, NEUROSCI LETT, V186, P69, DOI 10.1016/0304-3940(95)11266-Y; DRUMMOND GB, 1983, BRIT J ANAESTH, V55, P825, DOI 10.1093/bja/55.9.825; DUBOSE RA, 1997, INT ASS STUDY PA JUL, P2; FELDMAN JL, 1992, J PHYSIOL-LONDON, V450, P303, DOI 10.1113/jphysiol.1992.sp019128; FONE KCF, 1986, BRIT J PHARMACOL, V89, P67, DOI 10.1111/j.1476-5381.1986.tb11121.x; Gray PA, 1999, SCIENCE, V286, P1566, DOI 10.1126/science.286.5444.1566; GRUNSTEIN MM, 1982, J APPL PHYSIOL, V53, P1063; GUTSTEIN HB, 2001, GOODMAN GILMANS PHAR, P569; Haji A, 2003, NEUROSCI LETT, V351, P37, DOI 10.1016/S0304-3940(03)00951-0; Haji A, 2002, J NEUROPHYSIOL, V87, P1057, DOI 10.1152/jn.00470.2001; HASSEN AH, 1984, NEUROPHARMACOLOGY, V23, P407, DOI 10.1016/0028-3908(84)90248-X; Hayashi F, 1996, J NEUROSCI, V16, P6526; Howard RS, 1990, J PHYSL, V437, P181; HURLE MA, 1983, LIFE SCI, V33, P571, DOI 10.1016/0024-3205(83)90567-2; HURLE MA, 1985, NEUROPHARMACOLOGY, V24, P597, DOI 10.1016/0028-3908(85)90100-5; JAFFE J H, 1990, P485; Jolas T, 1997, BRAIN RES, V755, P229, DOI 10.1016/S0006-8993(97)00103-0; KIRSTEN EB, 1978, J PHARMACOL METHOD, V1, P263, DOI 10.1016/0160-5402(78)90057-8; KLAGES S, 1993, J NEUROPHYSIOL, V70, P1307; LALLEY PM, 1994, NEUROSCI LETT, V172, P59, DOI 10.1016/0304-3940(94)90662-9; Lalley PM, 2005, RESP PHYSIOL NEUROBI, V145, P13, DOI 10.1016/j.resp.2004.11.001; Lalley PM, 2003, AM J PHYSIOL-REG I, V285, pR1287, DOI 10.1152/ajpregu.00199.2003; Lonergan T, 2003, RESP PHYSIOL NEUROBI, V138, P165, DOI 10.1016/S1569-9048(03)00173-3; Lonergan T, 2003, NEUROSCIENCE, V121, P959, DOI 10.1016/S0306-4522(03)00591-8; Manzke T, 2003, SCIENCE, V301, P226, DOI 10.1126/science.1084674; Martin-Schild S, 1999, J COMP NEUROL, V405, P450, DOI 10.1002/(SICI)1096-9861(19990322)405:4<450::AID-CNE2>3.0.CO;2-#; MARTY J, 1981, ACTA ANAESTH SCAND, V25, P293, DOI 10.1111/j.1399-6576.1981.tb01654.x; Mellen NM, 2003, NEURON, V37, P821, DOI 10.1016/S0896-6273(03)00092-8; MORINSURUN MP, 1984, EUR J PHARMACOL, V98, P241, DOI 10.1016/0014-2999(84)90595-8; Niedhart P., 1989, ACTA ANAESTH SCAND, V33, P1; Pierrefiche O, 1998, J PHYSIOL-LONDON, V509, P245, DOI 10.1111/j.1469-7793.1998.245bo.x; PIERREFICHE O, 1995, NEUROSCI LETT, V184, P101, DOI 10.1016/0304-3940(94)11179-M; Richter D W, 1992, Curr Opin Neurobiol, V2, P788, DOI 10.1016/0959-4388(92)90135-8; RICHTER DW, 1993, J PHYSIOL-LONDON, V470, P23, DOI 10.1113/jphysiol.1993.sp019844; Richter DW, 2000, NEUROSCIENTIST, V6, P181, DOI 10.1177/107385840000600309; RICHTER DW, 1996, [No title captured], V2, P2079, DOI DOI 10.1007/978-3-642-60946-6_106; Rybak IA, 2004, RESP PHYSIOL NEUROBI, V143, P307, DOI 10.1016/j.resp.2004.03.020; SALES N, 1985, BRAIN RES, V344, P382, DOI 10.1016/0006-8993(85)90820-0; SANTIAGO TV, 1985, J APPL PHYSIOL, V59, P1675; SCHMID K, 1985, PFLUG ARCH EUR J PHY, V403, P58, DOI 10.1007/BF00583283; SCHWARZACHER SW, 1995, J NEUROPHYSIOL, V73, P1452; Shook J.E., 1990, AM REV RESPIR DIS, V33, P1; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; STEFANI A, 1994, BRAIN RES, V642, P339, DOI 10.1016/0006-8993(94)90940-7; TAKEDA EK, 1987, PFLUGERS ARCH, V409, P367; Takeda S, 2001, ANESTHESIOLOGY, V95, P740, DOI 10.1097/00000542-200109000-00029; Vasilakos K, 2005, J NEUROBIOL, V62, P369, DOI 10.1002/neu.20102; von Euler C., 1986, HDB PHYSL RESPIRATOR, VII, P1; Wilken B, 1997, J PEDIATR-US, V130, P89, DOI 10.1016/S0022-3476(97)70315-9; WILLIAMS JT, 1988, J NEUROSCI, V8, P4299; YAN S, 1995, BRAIN RES, V687, P217, DOI 10.1016/0006-8993(95)00541-W; YEADON M, 1989, PROG NEUROBIOL, V33, P1, DOI 10.1016/0301-0082(89)90033-6; YOUNES M, 1978, J APPL PHYSIOL, V44, P596	61	23	23	1	1	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6119			AM J PHYSIOL-REG I	Am. J. Physiol.-Regul. Integr. Comp. Physiol.	MAY	2006	290	5					R1387	R1396		10.1152/ajpregu.00530.2005			10	Physiology	Physiology	030VY	WOS:000236664400027	16284086				2020-06-30	J	Ito, H; Sobue, K; Hirate, H; Sugiura, T; So, M; Azami, T; Sasano, H; Katsuya, H				Ito, H; Sobue, K; Hirate, H; Sugiura, T; So, M; Azami, T; Sasano, H; Katsuya, H			Use of ketamine to facilitate opioid withdrawal in a child	ANESTHESIOLOGY			English	Letter							MORPHINE-TOLERANCE; NMDA; DEPENDENCE		Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi, Japan	Ito, H (reprint author), Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi, Japan.	hiroitou@sunprom.med.nagoya-cu.ac.jp					Bisaga A, 2001, PSYCHOPHARMACOLOGY, V157, P1, DOI 10.1007/s002130100739; Freye E, 2005, NEUROPHYSIOL CLIN, V35, P25, DOI 10.1016/j.neucli.2004.11.001; Herlenius E, 2004, EXP NEUROL, V190, pS8, DOI 10.1016/j.expneurol.2004.03.027; MARK CM, 1993, PEDIATRICS, V91, P369; SIREAR R, 2000, INT J DEV NEUROSCI, V130, P121; TRUJILLO KA, 1991, SCIENCE, V251, P85, DOI 10.1126/science.1824728; Zhu HB, 2003, PAIN, V104, P437, DOI 10.1016/S0304-3959(03)00051-4	7	5	5	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	MAY	2006	104	5					1113	1113		10.1097/00000542-200605000-00043			1	Anesthesiology	Anesthesiology	040JS	WOS:000237375400042	16645479				2020-06-30	J	Dosen-Micovic, L; Ivanovic, M; Micovic, V				Dosen-Micovic, L; Ivanovic, M; Micovic, V			Steric interactions and the activity of fentanyl analogs at the mu-opioid receptor	BIOORGANIC & MEDICINAL CHEMISTRY			English	Article						molecural modeling; fentanyl analogs; ligand-receptor interactions; docking simulation	DISTANCE GEOMETRY CALCULATIONS; PROTEIN-COUPLED RECEPTORS; SINGLE AMINO-ACID; PHARMACOLOGICAL EVALUATION; CONFORMATIONAL-ANALYSIS; MUTAGENESIS REVEALS; PEPTIDE RECEPTOR; OPIATE RECEPTOR; BINDING; DOCKING	Fentanyl is a highly potent and clinically widely used narcotic analgesic. The synthesis of its analogs remains a challenge in the attempt to develop highly selective p-opioid receptor agonists with specific pharmacological properties. In this paper, the use of flexible molecular docking in a Study of the formation of complexes between a series of active fentanyl analogs and the mu-opioid receptor is described. The optimal position and orientation Of fourteen fentanyl analogs in the binding pocket of the mu-receptor were determined. The major receptor amino acids and the ligand functional groups participating in the complex formation were identified. Stereochemical effects on the potency and binding are explained. The proposed model of ligand-receptor binding is in agreement with point mutation experiments explaining the role of the amino acids: Asp147, Tyr148, Asn230, His297, Trp318, His319, Cys321, and Tyr326 in the complex formation. In addition, the following amino acids were identified as being important for ligand binding or receptor activation: Ile322, Gly325, Val300, Met203, Leu200, Val143, and Ile144. (c) 2005 Elsevier Ltd. All rights reserved.	Univ Belgrade, Fac Chem, Belgrade 11000, Serbia Monteneg; ICTM, Ctr Chem, Belgrade, Serbia Monteneg	Dosen-Micovic, L (reprint author), Univ Belgrade, Fac Chem, POB 158, Belgrade 11000, Serbia Monteneg.	lmicovic@chem.bg.ac.yu	Micovic, Vladimir/R-4240-2018; Ivanovic, Milovan/R-5245-2016	Micovic, Vladimir/0000-0002-0973-4823; Ivanovic, Milovan/0000-0002-2534-4673			Aburi M, 2004, PROTEIN SCI, V13, P1997, DOI 10.1110/ps.04720304; BeckSickinger AG, 1996, DRUG DISCOV TODAY, V1, P502, DOI 10.1016/S1359-6446(96)10042-8; Bikker JA, 1998, J MED CHEM, V41, P2911, DOI 10.1021/jm970767a; Blake AD, 1997, J BIOL CHEM, V272, P782, DOI 10.1074/jbc.272.2.782; Bot G, 1998, J NEUROCHEM, V70, P358; Bot G, 1998, J PHARMACOL EXP THER, V285, P1207; BRINE GA, 1995, J MED CHEM, V38, P1547, DOI 10.1021/jm00009a015; CASY AF, 1986, OPIOID ANAGESICS; Chaipatikul V, 2003, J PHARMACOL EXP THER, V305, P909, DOI 10.1124/jpet.102.046219; Chaturvedi K, 2000, MOL BRAIN RES, V76, P64, DOI 10.1016/S0169-328X(99)00332-0; Claude PA, 1996, P NATL ACAD SCI USA, V93, P5715, DOI 10.1073/pnas.93.12.5715; Decaillot FM, 2003, NAT STRUCT BIOL, V10, P629, DOI 10.1038/nsb950; Dhawan BN, 1996, PHARMACOL REV, V48, P567; DosenMicovic L, 1996, ELECTRON J THEOR CH, V1, P199, DOI 10.1002/ejtc.29; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FERNANDEZ MJ, 1992, J CHEM SOC PERK T 2, P687, DOI 10.1039/p29920000687; Filizola M, 1998, J COMPUT AID MOL DES, V12, P111, DOI 10.1023/A:1007969112988; Flower DR, 1999, BBA-REV BIOMEMBRANES, V1422, P207, DOI 10.1016/S0304-4157(99)00006-4; FUKUDA K, 1995, J BIOL CHEM, V270, P6702, DOI 10.1074/jbc.270.12.6702; Gilson MK, 2003, J CHEM INF COMP SCI, V43, P1982, DOI 10.1021/ci034148o; GLASS PSA, 1995, J CLIN ANESTH, V7, P558, DOI 10.1016/0952-8180(95)00127-1; HEERDING J, 1994, REGUL PEPTIDES, V54, P119, DOI 10.1016/0167-0115(94)90418-9; IVANOVIC MD, 1998, THESIS U BELGRADE; Janssen P. A. J., 1968, DRUGS AFFECTING CENT, V2, P25; Kanematsu Ken, 2001, Current Medicinal Chemistry - Central Nervous System Agents, V1, P1, DOI 10.2174/1568015013358716; KONG HY, 1993, J BIOL CHEM, V268, P23055; KUDZMA LV, 1989, J MED CHEM, V32, P2534, DOI 10.1021/jm00132a007; Lavecchia A, 2000, J MED CHEM, V43, P2124, DOI 10.1021/jm991161k; Li J, 2001, BIOCHEMISTRY-US, V40, P12039, DOI 10.1021/bi0100945; LOBBEZOO MW, 1980, EUR J MED CHEM, V15, P357; Lu YF, 1998, SYNAPSE, V28, P117, DOI 10.1002/(SICI)1098-2396(199802)28:2<117::AID-SYN2>3.3.CO;2-8; Mansour A, 1997, J NEUROCHEM, V68, P344, DOI 10.1046/j.1471-4159.1997.68010344.x; MARTIN WR, 1983, PHARMACOL REV, V35, P283; MARYANOFF BE, 1982, J MED CHEM, V25, P913, DOI 10.1021/jm00350a006; McFadyen I, 2002, PROGR MED CHEM, V40, P107, DOI 10.1016/S0079-6468(08)70083-3; Metzger TG, 2001, J MED CHEM, V44, P857, DOI 10.1021/jm000381r; Micovic IV, 2000, BIOORG MED CHEM LETT, V10, P2011, DOI 10.1016/S0960-894X(00)00394-2; Micovic IV, 1998, J SERB CHEM SOC, V63, P93; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Mosberg HI, 2002, J PEPT RES, V60, P329, DOI 10.1034/j.1399-3011.2002.21061.x; Pil J, 2003, J PHARMACOL EXP THER, V304, P924, DOI 10.1124/jpet.102.040113; Pogozheva ID, 1997, BIOPHYS J, V72, P1963, DOI 10.1016/S0006-3495(97)78842-8; Pogozheva ID, 1998, BIOPHYS J, V75, P612, DOI 10.1016/S0006-3495(98)77552-6; Seki T, 1998, EUR J PHARMACOL, V350, P301, DOI 10.1016/S0014-2999(98)00240-4; Subramanian G, 1998, J MED CHEM, V41, P4777, DOI 10.1021/jm9803166; Subramanian G, 2000, J MED CHEM, V43, P381, DOI 10.1021/jm9903702; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; Ulens C, 2000, J PHARMACOL EXP THER, V294, P1024; VANBEVER WF, 1974, J MED CHEM, V17, P1047, DOI 10.1021/jm00256a003; VANBEVER WFM, 1976, ARZNEIMITTELFORSCH, V26, P1548; VANDAELE PGH, 1976, ARZNEIMITTELFORSCH, V26, P1521; WANG ZX, 1995, J MED CHEM, V38, P3652, DOI 10.1021/jm00018a026; WANG ZX, 1993, ACTA PHARMACOL SINIC, V28, P905; Xu H, 1999, SYNAPSE, V32, P23, DOI 10.1002/(SICI)1098-2396(199904)32:1<23::AID-SYN3>3.0.CO;2-N; Xu W, 2000, BIOCHEMISTRY-US, V39, P13904, DOI 10.1021/bi001099p; Zhu JM, 1996, FEBS LETT, V384, P198, DOI 10.1016/0014-5793(96)00312-2	56	28	30	0	18	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0968-0896	1464-3391		BIOORGAN MED CHEM	Bioorg. Med. Chem.	MAY 1	2006	14	9					2887	2895		10.1016/j.bmc.2005.12.010			9	Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry, Organic	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry	029UZ	WOS:000236591200002	16376082				2020-06-30	J	Alhashemi, JA; Kaki, AM				Alhashemi, JA; Kaki, AM			Anesthesiologist-controlled versus patient-controlled propofol sedation for shockwave lithotripsy	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							WAVE LITHOTRIPSY; CONTROLLED ANALGESIA; REMIFENTANIL; MIDAZOLAM; ALFENTANIL; INFUSION	Purpose: To compare anesthesiologist-controlled sedation (ACS) with patient-controlled sedation (PCS), with respect to propofol requirements, sedation, and recovery, in patients undergoing extracorporeal shockwave lithotripsy for urinary calculi. Methods: Sixty-four patients were randomized, in this double-blind study, to receive propofol sedation according to one of two regimens: infusion of 200 mu g(.)kg(-1.)min(-1) for ten minutes reduced thereafter to 50-150 mu g(.)kg(-1.)min(-1) titrated by an anesthesiologist, according to patient response (group ACS), or propofol administered by patient-controlled analgesia (bolus dose 300 mu g(.)kg(-1), lockout interval three minutes, no basal infusion), (group PCS). All patients received midazolam 10 mu g(.)kg(-1) iv and fentanyl 1 mu g(.)kg(-1) iv preoperatively, followed by fentanyl infused at a rate of 0.5 mu g(.)kg(-1.)hr(-1) throughout the procedure. Sedation and analgesia were assessed using the A-line ARX index and visual analogue scale, respectively. Psychomotor recovery and readiness for recovery room discharge were assessed using the Trieger dot test and postanesthesia discharge score, respectively. Patient satisfaction was assessed on a seven-point scale (1-7). Results: In comparison to group PCS, patients in group ACS received more propofol (398 +/- 162 mg vs 199 +/- 68 mg, P < 0.001), were more sedated (A-line ARX index: 35 +/- 16 vs 73 +/- 16, P < 0.001), experienced less pain (visual analogue scale: 0 0 vs 3 +/- 1, P < 0.001), and were more satisfied (median [Q1, Q3]: 7 [7, 7] vs 6 [6, 7], P < 0.001). In contrast, patients in group PCS had faster psychomotor recovery (Trieger dot test median [Q1, Q3]: 8 [4, 16] vs 16 [12, 26] dots missed, P = 0.002) and achieved postanesthesia discharge score >= 9 earlier (median [Q1, Q3]: 40 [35, 60] vs 88 [75, 100] min, P < 0.001) compared with group ACS. Conclusion: In comparison to PCS for patients undergoing extracorporeal shockwave lithotripsy, propofol/fentanyl ACS is associated with increased propofol administration, deeper sedation levels, and greater patient comfort. However, ACS is associated with slower recovery and a longer time to meet discharge criteria, when compared to PCS.	King Abdulaziz Univ Hosp, Dept Anesthesia & Crit Care, Jeddah 21418, Saudi Arabia	Alhashemi, JA (reprint author), King Abdulaziz Univ Hosp, Dept Anesthesia & Crit Care, POB 31648, Jeddah 21418, Saudi Arabia.	jalhashemi@kau.edu.sa					Alhashemi JA, 2004, CAN J ANAESTH, V51, P342, DOI 10.1007/BF03018237; Beloeil H, 2002, BRIT J ANAESTH, V89, P567, DOI 10.1093/bja/aef202; Bright E, 2003, ENDOSCOPY, V35, P683; Burmeister MA, 2002, ANAESTHESIA, V57, P877, DOI 10.1046/j.1365-2044.2002.02820.x; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Chin CM, 1997, BRIT J UROL, V79, P848, DOI 10.1046/j.1464-410X.1997.00212.x; CHUNG F, 1995, J CLIN ANESTH, V7, P500, DOI 10.1016/0952-8180(95)00130-A; Ge SJ, 2002, BRIT J ANAESTH, V89, P260, DOI 10.1093/bja/aef187; Joo HS, 2001, ANESTH ANALG, V93, P1227, DOI 10.1097/00000539-200111000-00037; KORTIS HI, 1995, J CLIN ANESTH, V7, P205, DOI 10.1016/0952-8180(95)00008-6; NEWMAN MG, 1969, ANESTH ANAL CURR RES, V48, P136, DOI 10.1213/00000539-196948010-00028; STREINER DL, 1995, HLTH MEASUREMENT SCA, V28, P53; Suttner S, 1999, ANESTH ANALG, V88, P77, DOI 10.1097/00000539-199901000-00015	13	20	21	0	0	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	MAY	2006	53	5					449	455		10.1007/BF03022616			7	Anesthesiology	Anesthesiology	041XY	WOS:000237491700005	16636028	Bronze			2020-06-30	J	Darwish, M; Kirby, M; Robertson, P; Tracewell, W; Jiang, JG				Darwish, M; Kirby, M; Robertson, P; Tracewell, W; Jiang, JG			Pharmacokinetic properties of fentanyl effervescent buccal tablets: A phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 mu g in healthy adult volunteers	CLINICAL THERAPEUTICS			English	Article						analgesics; dose proportionality; dose response; fentanyl effervescent buccal tablet; pharmacokinetics	CANCER PAIN; TRANSDERMAL FENTANYL; BREAKTHROUGH PAIN; PROPORTIONALITY; CITRATE	Background: The fentanyl effervescent buccal tablet (FEBT) is designed to enhance the rate and extent of the absorption of fentanyl, an oploid, through the buccal mucosa. Objectives: The purposes of this study were to assess the dose proportionality of FEBT in healthy volunteers over the potential therapeutic dose range (100800 mu g) and characterize the pharmacokinetic (PK) profile of 4 doses (100, 200, 400, and 800 mu g) of FEBT. Methods: This Phase 1, randomized, open-label, 4-period crossover study was conducted at Radiant Research, Honolulu, Hawaii. Healthy adult volunteers with intolerance to opiolds were randomly assigned to receive I of 4 single-dose sequences of FEBT: 100, 200, 400, and 800 mu g (selected to encompass the anticipated therapeutic dose range), with each successive administration separated by a washout period of >= 7 days. Naltrexone hydrochloride (50-mg tablet) was administered similar to 15 and 3 hours before and 9 hours after FEBT administration to block opioid receptor-mediated effects of fentanyl. Plasma fentanyl concentrations were measured from venous samples obtained over 72 hours after FEBT administration. Early fentanyl exposure was assessed using AUC from time 0 to 0.75 hour (the median T-max of the reference dose [100 mu g]) (AUC(0-Tmax)). Adverse events (AEs) were monitored and recorded throughout the study by medically qualified personnel. Results: Thirty-two subjects (26 men, 6 women; mean [SD] age, 29.3 [7.2] years [range, 19-44 years]; mean [SD] weight, 74.7 [10.7] kg) were enrolled. Median T-max was between 35 and 45 minutes after FEBT administration. AUC(0-infinity) and C-max increased approximately linearly with increasing doses of FEBT. Mean plasma fentanyl concentrations decreased from C-max in a blexponential manner at the 100- and 200-mu g doses and decreased in a triexponential manner at the 800-mu g dose. Despite the triexponential decrease in the mean profile observed with the 400-mu g dose, a bi-exponential decrease was observed in approximately half of the individual profiles. AUC(0-Tmax') ranged from 0.09 mu g (.) h/mL with the 100-mu g dose to 0.52 ng (.) h/mL with the 800-mu g dose. The most commonly reported AEs in the 100-, 200-, 400-, and 800-mu g dose groups were as follows: application-site erythema, 3, 3, 4, and 3 subjects, respectively; nausea, 3, 2, 5, and 4 subjects; somnolence, 3, 2, 3, and 2 subjects; and headache, 3, 2, 1, and 4 subjects. None of the AEs were serious. Conclusions: In this study of the dose proportionality of FEBT in healthy volunteers, the PK profile of FEBT was characterized by a high early systemic exposure of fentanyl (0.09-0.52 ng (.) h/mL). Dose-dependent parameters (C(ma)x and AUC) increased in an approximately dose-proportional manner from 100 to 800 mu g FEBT.	Cephalon Inc, Dept Clin Pharmacol, Frazer, PA 19355 USA; Cephalon Inc, Dept Drug Safety & Disposit, W Chester, PA USA; Cephalon Inc, Dept Biometr, Frazer, PA 19355 USA	Darwish, M (reprint author), Cephalon Inc, Dept Clin Pharmacol, 41 Moores Rd, Frazer, PA 19355 USA.	mdarwish@cephalon.com					BENNETT D, 2005, [No title captured], V30, P354; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Darwish M, 2005, CLIN PHARMACOKINET, V44, P1279, DOI 10.2165/00003088-200544120-00006; *EUR AG EV MED PRO, ICH TOP E, V6; HUDSON RJ, 1986, ANESTHESIOLOGY, V64, P334, DOI 10.1097/00000542-198603000-00006; HUG CC, 1981, ANESTHESIOLOGY, V55, P369, DOI 10.1097/00000542-198110000-00006; Lor M, 2005, CLIN PHARMACOL THER, V77, pP76, DOI 10.1016/j.clpt.2004.12.181; Mercadante S, 2005, J PAIN SYMPTOM MANAG, V30, P485, DOI 10.1016/j.jpainsymman.2005.04.014; Mercadante S, 1999, ONCOLOGY-NY, V13, P215; PAYNE R, 1992, J PAIN SYMPTOM MANAG, V7, pS40, DOI 10.1016/0885-3924(92)90052-J; Rees Elizabeth, 2002, Int J Palliat Nurs, V8, P304; Smith BP, 2000, PHARMACEUT RES, V17, P1278, DOI 10.1023/A:1026451721686; Stanley TH, 2005, J PAIN SYMPTOM MANAG, V29, pS67, DOI 10.1016/j.jpainsymman.2005.01.009; Zeppetella G, 2001, PALLIATIVE MED, V15, P323, DOI 10.1191/026921601678320304	14	34	38	0	6	EXCERPTA MEDICA INC	NEW YORK	650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA	0149-2918			CLIN THER	Clin. Ther.	MAY	2006	28	5					707	714		10.1016/j.clinthera.2006.05.015			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	051OC	WOS:000238169400007	16861092				2020-06-30	J	Darwish, M; Tempero, K; Kirby, M; Thompson, J				Darwish, M; Tempero, K; Kirby, M; Thompson, J			Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1080 mu g versus oral transmucosal fentanyl citrate 1600 mu g and dose proportionality of FEBT 270 to 1300 mu g: A single-dose, randomized, open-label, three-period study in healthy adult volunteers	CLINICAL THERAPEUTICS			English	Article						fentanyl; fentanyl effervescent buccal tablet; oral transmucosal fentanyl citrate; pharmacokinetics; effervescence	PERMEABILITY	Background: The fentanyl effervescent buccal tablet (FEBT) was designed to enhance the rate and extent of absorption of fentanyl through the buccal mucosa. FEBT is being investigated for the management of breakthrough pain. Objectives: The primary objective of this study was to compare the relative bloavailability of FEBT 1080 mu g with that of oral transmucosal fentanyl citrate (OTFC (R)) 1600 mu g, and the secondary objective was to assess the dose proportionality of FEBT 270 to 1300 mu g in healthy adult volunteers. Methods: This single-dose, randomized, open-label, 3 period study was conducted by MDS Pharma Services, Lincoln, Nebraska. Non-oploid-tolerant healthy adult volunteers were included. In periods I and 2 (relative-bioavailability analysis), subjects were randomly assigned to 1 of 2 administration sequences: single-dose FEBT 1080 mu g followed by single-dose OTFC 1600 jag, or vice versa; in period 3 (doseproportionality analysis), they were randomly assigned to receive a single dose of FEBT 270, 810, or 1300 mu g. Subjects were instructed to place FEBT between the gum and cheek above an upper molar tooth and allow it to disintegrate for 10 minutes. Subjects were instructed to place the OTFC lozenge between the cheek and lower gum and move the unit from side to side using the handle and allow the unit to dissolve for 15 minutes. All subjects received naltrexone 50 mg PO at 15 and 3 hours before and 12 hours after fentanyl administration, except those receiving FEBT 270 pg, who were not given naltrexone at 12 hours. For the measurement of serum concentrations of fentanyl, venous blood samples were collected before and up to 36 hours after study drug administration. For tolerability analysis, continuous pulse oximetry, 12-lead electrocardiography, clinical laboratory analysis, and physical examination, including vital-sign measurements, were performed; the oral mucosa was inspected; and spontaneous reporting was employed. Results: A total of 42 subjects were enrolled (25 women, 17 men; mean [SDI age, 27 [11] years; mean [SD] weight, 68.4 [8.7] kg); 39 completed the study. Total systemic exposure (as measured using AUC(0-infinity)) was statistically similar between FEBT 1080 pg and OTFC 1600 pg (mean [SD], 18.0 [5.4] vs 18.0 [7.1] ng (.) h/mL). However, the mean (SD) C-max with FEBT 1080 pg was 2.7 (0.9) ng/mL compared with 2.2 (0.7) ng/mL with OTFC 1,600 pg (P = NS), and the T-max of 1.0 hour with FEBT was significantly less compared with OTFC (2.0 hours; P < 0.001). Similarly, mean (SD) early systemic exposure (AUC(0-Tmax'); ie, AUC from time 0 to 1 hour [the median T-max of the reference dose of FEBT [810 mu g]) was significantly greater with FEBT compared with OTFC (1.5 [0.5] vs 0.8 [0.4] ng (.) h/mL; P < 0.001). Exploratory analyses suggested dose proportionality as assessed using AUC(0-infinity) and AUC(0-Tmax') over the range of FEBT 270 to 1300 mu g.	Cephalon Inc, Frazer, PA 19355 USA; CIMA Labs, Eden Prairie, MN USA	Darwish, M (reprint author), Cephalon Inc, 41 Moores Rd, Frazer, PA 19355 USA.	mdarwish@cephalon.com					BENNETT D, 2005, [No title captured], V30, P354; *CEPH INC, 2004, ACT OR TRANSM FENT C; Darwish M, 2005, CLIN PHARMACOKINET, V44, P1279, DOI 10.2165/00003088-200544120-00006; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Eichman JD, 1998, PHARM RES-DORDR, V15, P925, DOI 10.1023/A:1011936901638; Eichman JD, 1997, EUR J PHARM BIOPHARM, V44, P33, DOI 10.1016/S0939-6411(97)00099-4; *EUR AG EV MD PROD, 2002, ICH TOP E, V6; FINE PG, 1991, PAIN, V45, P149, DOI 10.1016/0304-3959(91)90181-V; Pather SI, 2001, DRUG DELIV TECH, V1, P54; Smith BP, 2000, PHARMACEUT RES, V17, P1278, DOI 10.1023/A:1026451721686; Stanley TH, 2005, J PAIN SYMPTOM MANAG, V29, pS67, DOI 10.1016/j.jpainsymman.2005.01.009; US Department of Health and Human Services. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER), GUID IND STAT APPR E; *US FDA, CAT FDA APPR DRUG PR; 1983, [No title captured], V64, P3	14	40	43	1	1	EXCERPTA MEDICA INC	NEW YORK	650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA	0149-2918			CLIN THER	Clin. Ther.	MAY	2006	28	5					715	724		10.1016/j.clinthera.2006.05.016			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	051OC	WOS:000238169400008	16861093				2020-06-30	J	Richman, PS; Baram, D; Varela, M; Glass, PS				Richman, PS; Baram, D; Varela, M; Glass, PS			Sedation during mechanical ventilation: A trial of benzodiazepine and opiate in combination	CRITICAL CARE MEDICINE			English	Article						sedation; mechanical ventilation; midazolam; fentanyl; benzodiazepine; opiate	INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; MIDAZOLAM INFUSIONS; PROPOFOL; ANALGESICS; LORAZEPAM; PATIENT; EFFICACY; AGENTS; SCALE	Objective: To compare the efficacy of continuous intravenous sedation with midazolam alone vs. midazolam plus fentanyl ("cosedation") during mechanical ventilation. Design: A randomized, prospective, controlled trial. Setting. A ten-bed medical intensive care unit at a university hospital. Patients: Thirty patients with respiratory failure who were expected to require >48 hrs of mechanical ventilation and who were receiving a sedative regimen that did not include opiate pain control. Interventions. An intravenous infusion of either midazolam alone or co-sedation was administered by a nurse-implemented protocol to achieve a target Ramsay Sedation Score set by the patient's physician. Study duration was 3 days, with a brief daily "wake-up." Measurements and Main Results: We recorded the number of hours/day that patients were "off-target" with their Ramsay Sedation Scores, the number of dose titrations per day, the incidence of patient-ventilator asynchrony, and the time required to achieve adequate sedation as measures of sedative efficacy. We also recorded sedative cost in U.S. dollars and adverse events including hypotension, hypoventilation, ileus, and coma. Compared with the midazolam-only group, the co-sedation group had fewer hours per day with an "off-target" Ramsay Score (4.2 +/- 2.4 and 9.1 +/- 4.9, respectively, p <.002). Fewer episodes per day of patient-ventilator asynchrony were noted in the co-sedation group compared with midazolam-only (0.4 +/- 0.1 and 1.0 +/- 0.2, respectively, p <.05). Co-sedation also showed nonsignificant trends toward a shorter time to achieve sedation, a need for fewer dose titrations per day, and a lower total sedative drug cost. There was a trend toward more episodes of ileus with co-sedation compared with midazolam-only (2 vs. 0). Conclusions: In mechanically ventilated patients, co-sedation with midazolam and fentanyl by constant infusion provides more reliable sedation and is easier to titrate than midazolam alone, without significant difference in the rate of adverse events.	SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pharm, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Anesthesiol, Stony Brook, NY 11794 USA	Richman, PS (reprint author), SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA.						AITKENHEAD AR, 1989, LANCET, V2, P704, DOI 10.1016/S0140-6736(89)90770-8; BARR J, 1995, CRIT CARE CLIN, V11, P827; BarrientosVega R, 1997, CRIT CARE MED, V25, P33, DOI 10.1097/00003246-199701000-00009; BURNS AM, 1992, DRUGS, V43, P507, DOI 10.2165/00003495-199243040-00007; Carroll K C, 1999, Am J Crit Care, V8, P105; Cernaianu AC, 1996, CRIT CARE MED, V24, P222, DOI 10.1097/00003246-199602000-00007; Christensen BV, 1999, INTENS CARE MED, V25, P186, DOI 10.1007/s001340050814; DUTHIE DJR, 1995, EUR J ANAESTH, V12, P21; Gilliland HEM, 1996, ANAESTHESIA, V51, P808, DOI 10.1111/j.1365-2044.1996.tb12605.x; GLASS P, 1992, ANESTHESIA ANALGESIA, V74, pS111; HANSENFLASCHEN J, 1994, CRIT CARE MED, V22, P732; HIGGINS TL, 1994, CRIT CARE MED, V22, P1415, DOI 10.1097/00003246-199409000-00011; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Kress JP, 2002, AM J RESP CRIT CARE, V166, P1024, DOI 10.1164/rccm.200204-270CC; McCollam JS, 1999, CRIT CARE MED, V27, P2454, DOI 10.1097/00003246-199911000-00022; Merkel S I, 1997, Pediatr Nurs, V23, P293; Novaes MAFP, 1999, INTENS CARE MED, V25, P1421, DOI 10.1007/s001340051091; POHLMAN AS, 1994, CRIT CARE MED, V22, P1241, DOI 10.1097/00003246-199408000-00007; PUNTILLO KA, 1990, HEART LUNG, V19, P526; Puntillo KA, 1997, CRIT CARE MED, V25, P1159, DOI 10.1097/00003246-199707000-00017; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Rhoney Denise H, 2003, J Intensive Care Med, V18, P139, DOI 10.1177/0885066603251200; Riker RR, 1999, CRIT CARE MED, V27, P1325, DOI 10.1097/00003246-199907000-00022; RONAN KP, 1995, CRIT CARE MED, V23, P286, DOI 10.1097/00003246-199502000-00014; SHAFER A, 1990, CRIT CARE MED, V18, P1039, DOI 10.1097/00003246-199009000-00024; Shafer A, 1998, CRIT CARE MED, V26, P947, DOI 10.1097/00003246-199805000-00034; SHELLY MP, 1991, EUR J ANAESTH, V8, P21; SIVAM SP, 1985, LIFE SCI, V37, P199, DOI 10.1016/0024-3205(85)90645-9; Soliman HM, 2001, BRIT J ANAESTH, V87, P186, DOI 10.1093/bja/87.2.186; VINIK HR, 1989, ANESTH ANALG, V69, P213; Wagner BKJ, 1997, CLIN PHARMACOKINET, V33, P426, DOI 10.2165/00003088-199733060-00003; Weinbroum AA, 1997, INTENS CARE MED, V23, P1258, DOI 10.1007/s001340050495; Wittbrodt ET, 1999, CRIT CARE MED, V27, P1384, DOI 10.1097/00003246-199907000-00037	35	40	46	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	MAY	2006	34	5					1395	1401		10.1097/01.CCM.0000215454.50964.F8			7	Critical Care Medicine	General & Internal Medicine	038PV	WOS:000237235900014	16540957				2020-06-30	J	Crippen, D				Crippen, D			Comfortably numb in the intensive care unit	CRITICAL CARE MEDICINE			English	Editorial Material							CONTINUOUS INTRAVENOUS-INFUSION; SEDATION; MIDAZOLAM; FENTANYL; PATIENT; ICU		Univ Pittsburgh, Med Ctr, Dept Crit Care Med, Neurovasc ICU, Pittsburgh, PA 15260 USA	Crippen, D (reprint author), Univ Pittsburgh, Med Ctr, Dept Crit Care Med, Neurovasc ICU, Pittsburgh, PA 15260 USA.						Barr J, 2001, ANESTHESIOLOGY, V95, P286, DOI 10.1097/00000542-200108000-00007; BRUDER N, 1994, CRIT CARE MED, V22, P1114, DOI 10.1097/00003246-199407000-00011; Crippen D, 2000, CRIT CARE, V4, P81, DOI 10.1186/cc661; Fragen RJ, 1997, CLIN THER, V19, P405, DOI 10.1016/S0149-2918(97)80126-9; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Kovoor P, 1997, PACE, V20, P2765, DOI 10.1111/j.1540-8159.1997.tb05434.x; MICHALK S, 1988, INTENS CARE MED, V15, P37; Milgrom P, 1993, Anesth Prog, V40, P57; Miner JR, 2002, ACAD EMERG MED, V9, P275, DOI 10.1197/aemj.9.4.275; Richman PS, 2006, CRIT CARE MED, V34, P1395, DOI 10.1097/01.CCM.0000215454.50964.F8; Shiu KK, 2005, CHEST, V128, P3773, DOI 10.1378/chest.128.5.3773; WALSH M, 1991, ANN EMERG MED, V20, P913, DOI 10.1016/S0196-0644(05)81439-8	12	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	MAY	2006	34	5					1558	1559		10.1097/01.CCM.0000216195.30750.8D			2	Critical Care Medicine	General & Internal Medicine	038PV	WOS:000237235900045	16633258				2020-06-30	J	Kostopanagiotou, G; Pandazi, A; Kontogiannopoulou, SMS; Matsota, P; Niokou, D; Kitsou, M; Crepi, E; Christodoulaki, K; Grigoropoulou, I				Kostopanagiotou, G; Pandazi, A; Kontogiannopoulou, SMS; Matsota, P; Niokou, D; Kitsou, M; Crepi, E; Christodoulaki, K; Grigoropoulou, I			The impact of intraoperative propofol administration in the prevention of postoperative pruritus induced by epidural morphine	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthesia epidural; side-effects; pruritus; opioids; morphine; anaesthetics intravenous; propofol	OPIOID-INDUCED PRURITUS; INTRATHECAL MORPHINE; NAUSEA	Background and objective: We examined the efficacy of intraoperative propofol administration to prevent pruritus induced by epidural morphine. Methods: Seventy patients ASA I-II undergoing combined epidural and general anaesthesia for hysterectomy were randomly assigned to two groups, Group P where anaesthesia was induced with propofol and fentanyl and maintained with propofol-nitrous oxide and Group S in which anaesthesia was induced with thiopental and fentanyl and maintained with sevoflurane-nitrous oxide. All patients received a ropivacaine epidural bolus with 3 mg morphine I h before the end of surgery. The incidence and severity of pruritus were evaluated every 4 h for the first 12 h postoperatively by blinded observers. Results: The total incidence of pruritus was significantly higher (P = 0.024) in Group S (65.6%) compared to Group P (29%) between 4 and 8 h postoperatively. There were also significantly more patients (P = 0.03) reporting severe pruritus in Group S (22%) compared to Group P (0). Conclusion: Propofol-based general anaesthesia compared to thiopental-sevoflurane-based anaesthesia reduces the incidence and severity of pruritus induced by a single injection of 3 mg epidural morphine with ropivacaine.	Univ Athens, Sch Med, Attikon Hosp, Clin Anaesthesiol 2, GR-11527 Athens, Greece	Pandazi, A (reprint author), Bouboulinas 35, Athens 17675, Greece.	pa0240@ee.teiath.gr	Matsota, Paraskevi/AAD-8073-2019	Matsota, Paraskevi/0000-0003-0971-4483; Pandazi, Ageliki/0000-0002-6187-6431			BALLANTYNE JC, 1988, PAIN, V33, P149, DOI 10.1016/0304-3959(88)90085-1; Beilin Y, 1998, ANESTH ANALG, V86, P310, DOI 10.1097/00000539-199802000-00018; BORGEAT A, 1992, ANESTHESIOLOGY, V76, P510, DOI 10.1097/00000542-199204000-00004; BORGEAT A, 1994, ANESTHESIOLOGY, V80, P642; Gan TJ, 1996, ANESTHESIOLOGY, V85, P1036, DOI 10.1097/00000542-199611000-00011; Grattidge P, 1998, ACTA ANAESTH SCAND, V42, P124, DOI 10.1111/j.1399-6576.1998.tb05092.x; Horta ML, 2000, ANESTH ANALG, V90, P638, DOI 10.1097/00000539-200003000-00025; Kjellberg F, 2001, EUR J ANAESTH, V18, P346, DOI 10.1046/j.0265-0215.2000.00826.x; SAIAH M, 1994, ANESTH ANALG, V78, P1110; Szarvas S, 2003, J CLIN ANESTH, V15, P234, DOI 10.1016/S0952-8180(02)00501-9; TORN K, 1994, BRIT J ANAESTH, V73, P411, DOI 10.1093/bja/73.3.411; Warwick JP, 1997, ANAESTHESIA, V52, P270, DOI 10.1111/j.1365-2044.1997.069-az0060.x; Yeh HM, 2000, ANESTH ANALG, V91, P172, DOI 10.1097/00000539-200007000-00032	13	8	9	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	MAY	2006	23	5					418	421		10.1017/S0265021505001912			4	Anesthesiology	Anesthesiology	040VF	WOS:000237408100008	16469206				2020-06-30	J	Naja, MZ; Al-Tannir, MA; Maaliki, H; El-Rajab, M; Ziade, MF; Zeidan, A				Naja, MZ; Al-Tannir, MA; Maaliki, H; El-Rajab, M; Ziade, MF; Zeidan, A			Nerve-stimulator-guided repeated pudendal nerve block for treatment of pudendal neuralgia	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Letter							PROSPECTIVE RANDOMIZED-TRIAL; GENERAL-ANESTHESIA; PAIN; SURGERY		Makassed Gen Hosp, Anaesthesia & Pain Med Dept, Beirut 11072210, Lebanon; Makassed Gen Hosp, Res Dept, Beirut 11072210, Lebanon; Makassed Gen Hosp, Dept Pediat, Beirut 11072210, Lebanon; Sahel Gen Hosp, Dept Anaesthesiol, Beirut, Lebanon; Lebanese Univ, Fac Publ Hlth, Beirut, Lebanon	Naja, MZ (reprint author), Makassed Gen Hosp, Anaesthesia & Pain Med Dept, POB 11-6 301, Beirut 11072210, Lebanon.	zouhnaja@yahoo.com		Al-Tannir, Mohamad/0000-0002-7739-8446			FRICTON JR, 1994, BAILLIERE CLIN RHEUM, V8, P857, DOI 10.1016/S0950-3579(05)80052-4; Hong CZ, 1998, ARCH PHYS MED REHAB, V79, P863, DOI 10.1016/S0003-9993(98)90371-9; Mauillon J, 1999, DIS COLON RECTUM, V42, P186, DOI 10.1007/BF02237125; Naja MZ, 2003, EUR J ANAESTH, V20, P897, DOI 10.1097/00003643-200311000-00007; Naja MZ, 2003, ANAESTHESIA, V58, P1007, DOI 10.1046/j.1365-2044.2003.03401.x; Naja Z., 2000, Middle East Journal of Anesthesiology, V15, P559; NEILL ME, 1982, J ROY SOC MED, V75, P96; Pisani R, 1997, SCAND J UROL NEPHROL, V31, P407, DOI 10.3109/00365599709030631; Thoumas D, 1999, ABDOM IMAGING, V24, P309, DOI 10.1007/s002619900503; Wesselmann U, 1997, PAIN, V73, P269, DOI 10.1016/S0304-3959(97)00076-6	10	11	11	0	0	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	MAY	2006	23	5					442	444		10.1017/S026502150623028X			3	Anesthesiology	Anesthesiology	040VF	WOS:000237408100014	16573866				2020-06-30	J	Ng, KFJ; Yuen, TST; Ng, VMW				Ng, Kwok F. J.; Yuen, Timmy S. T.; Ng, Vivian M. W.			A comparison of postoperative cognitive function and pain relief with fentanyl or tramadol patient-controled analgesia	JOURNAL OF CLINICAL ANESTHESIA			English	Article						analgesia; patient-controlled; analgesics; opioid; fentanyl; tramadol; mental processes, cognition; drug effects	MORPHINE; DELIRIUM; ASSOCIATION; NAUSEA	Study Objective: The use of different opioids for patient-controlled analgesia (PCA) may affect postoperative cognitive function differently. Patient-controlled analgesia fentanyl has been shown to preserve cognitive function better than morphine. The effect of PCA tramadol on cognitive function is unknown. This study aims to compare postoperative cognitive function and analgesia of PCA fentanyl or tramadol. Design: Prospective randomized double-blinded study. Setting: Metropolitan teaching hospital. Patients: 30 ASA physical status I, II, and III patients undergoing lower abdominal operations. Interventions: Patients received standard general anesthesia for their operations. Postoperatively, patients received either fentanyl (group F, 10 mu g bolus, n = 17) or tramadol (group T, 20 mg bolus, n = 13) for PCA. Group F patients also received fentanyl boluses and group T patients received tramadol boluses intraoperatively. Measurements: Cognitive function was measured using Mini-Mental State Examination and Benton Visual Retention Test (BVRT) preoperatively and on days 1 and 2. Pain was measured by numerical rating scale. Results: No differences were found in postoperative Mini-Mental State Examination or BVRT scores, but significantly fewer (29.4%; 95% confidence interval [CI], 13.3%-53.1%) group F patients were able to complete BVRT compared with group T patients (84.6%; 95% Cl, 57.8%-95.7%; 95% Cl of difference, 19.4%-74.8%) (P = 0.010) on day 1. In the first 24 hours, group F and group T patients had similar analgesia at rest, but group T patients had better analgesia during cough (mean Numeric Rating Scale, 7.6; 95% Cl, 7.0-8.2 vs 6.0; 95% Cl, 4.8-7.2, group F vs group T) (P = 0.018; 95% CI of difference, 0.4-2.8). No differences were found in frequency of side effects or patient satisfaction. Conclusions: Tramadol or fentanyl PCA has similar cognitive effects on days 1 and 2; however, patients receiving tramadol PCA are more motivated to undergo cognitively demanding tasks and have slightly better analgesia on postoperative day 1. (C) 2006 Elsevier Inc. All rights reserved.	Univ Hong Kong, Dept Anaesthesiol, Hong Kong, Hong Kong, Peoples R China; Queen Mary Hosp, Dept Anaesthesiol, Hong Kong, Hong Kong, Peoples R China	Ng, KFJ (reprint author), Univ Hong Kong, Queen Mary Hosp, Dept Anaesthesiol, Hong Kong, Hong Kong, Peoples R China.	jkfng@hkucc.hku.hk					Chiu HF, 1994, J HK COLL PSYCHIAT S, V4, p25S; Coman E, 1999, CLIN NEUROPSYCHOL, V13, P66, DOI 10.1076/clin.13.1.66.1972; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; GALASKO D, 1993, NEUROLOGY, V43, P1559, DOI 10.1212/WNL.43.8.1559; Herrick IA, 1996, ANAESTHESIA, V51, P356, DOI 10.1111/j.1365-2044.1996.tb07748.x; HOUMES RJM, 1992, ANESTH ANALG, V74, P510; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; LEE CR, 1993, DRUGS, V46, P313, DOI 10.2165/00003495-199346020-00008; LIPOWSKI ZJ, 1989, NEW ENGL J MED, V320, P578; Lynch EP, 1998, ANESTH ANALG, V86, P781; Marcantonio ER, 1998, AM J MED, V105, P380, DOI 10.1016/S0002-9343(98)00292-7; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Ng KFJ, 1997, CAN J ANAESTH, V44, P810, DOI 10.1007/BF03013155; Ng KFJ, 1998, EUR J ANAESTH, V15, P565, DOI 10.1046/j.1365-2346.1998.00354.x; Pang WW, 2000, CAN J ANAESTH, V47, P968, DOI 10.1007/BF03024867; PRESTON KL, 1991, DRUG ALCOHOL DEPEN, V27, P7, DOI 10.1016/0376-8716(91)90081-9; Rapp SE, 1996, ANESTH ANALG, V82, P1043, DOI 10.1097/00000539-199605000-00029; Sacerdote P, 2000, ANESTH ANALG, V90, P1411, DOI 10.1097/00000539-200006000-00028; Silvasti M, 2000, EUR J ANAESTH, V17, P448, DOI 10.1046/j.1365-2346.2000.00710.x; Unger JM, 1999, J AM GERIATR SOC, V47, P559, DOI 10.1111/j.1532-5415.1999.tb02570.x; WILLIAMSRUSSO P, 1992, J AM GERIATR SOC, V40, P759, DOI 10.1111/j.1532-5415.1992.tb01846.x; Wyatt JK, 1999, AM J PHYSIOL-REG I, V277, pR1152; Yoshitani K, 2001, ANESTH ANALG, V92, P1370	23	22	23	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	MAY	2006	18	3					205	210		10.1016/j.jclinane.2005.08.004			6	Anesthesiology	Anesthesiology	050ZR	WOS:000238130400008	16731323				2020-06-30	J	Elkassabany, N; Tetzlaff, JE; Argalious, M				Elkassabany, Nabil; Tetzlaff, John E.; Argalious, Maged			Anesthetic management of a patient with stiff person syndrome	JOURNAL OF CLINICAL ANESTHESIA			English	Editorial Material						regional anesthesia; stiff person syndrome; paravertebral block	BABY SYNDROME	We describe the successful anesthetic management of a patient with stiff-person syndrome (SPS) undergoing a right inguinal hernia repair, using a somatic paravertebral block supplemented with conscious sedation. We also present the implications of general anesthesia in patients with SPS. The use of regional anesthetic techniques in patients with SPS has the advantage of avoiding exposure to muscle relaxants. The use of general anesthesia in patients with SPS carries the risk of postoperative hypotonia due to enhancement of gamma-aminobutyric acid action on synaptic transmission by drugs that have a gamma-aminobutyric acid agonistic action. (C) 2006 Elsevier Inc. All rights reserved.	Cleveland Clin Fdn, Dept Gen Anesthesiol & Crit Care Med, Cleveland, OH 44195 USA	Argalious, M (reprint author), Cleveland Clin Fdn, Dept Gen Anesthesiol & Crit Care Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.	argalim@ccf.org					Bouw J, 2003, ANESTH ANALG, V97, P486, DOI 10.1213/01.ANE.0000072701.97699.79; COOK WP, 1986, ANESTHESIOLOGY, V65, P525, DOI 10.1097/00000542-198611000-00015; Dalakas MC, 2000, NEUROLOGY, V55, P1531, DOI 10.1212/WNL.55.10.1531; GOMAR C, 1994, ANESTHESIOLOGY, V81, P1306, DOI 10.1097/00000542-199411000-00035; Haslam N, 2002, ANAESTHESIA, V57, P298, DOI 10.1111/j.1365-2044.2002.2520_24.x; JOHNSON JO, 1995, ANESTH ANALG, V80, P612, DOI 10.1097/00000539-199503000-00032; Layzer R B, 1988, N Engl J Med, V318, P1060, DOI 10.1056/NEJM198804213181610; Levy Lucien M., 1999, Annals of Internal Medicine, V131, P522; LORISH TR, 1989, MAYO CLIN PROC, V64, P629, DOI 10.1016/S0025-6196(12)65339-7; Murphy C, 2000, PAEDIATR ANAESTH, V10, P567, DOI 10.1046/j.1460-9592.2000.00573.x; Obara M, 2002, ANAESTHESIA, V57, P511; PIOVANO C, 2002, MINERVA ANESTHESIOL, V68, P865; Sugimura M, 2002, PHARMACOL BIOCHEM BE, V72, P111, DOI 10.1016/S0091-3057(01)00728-6	13	9	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	MAY	2006	18	3					218	220		10.1016/j.jclinane.2005.06.009			3	Anesthesiology	Anesthesiology	050ZR	WOS:000238130400011	16731326				2020-06-30	J	Musshoff, F; Trafkowski, J; Kuepper, U; Madea, B				Musshoff, F.; Trafkowski, J.; Kuepper, U.; Madea, B.			An automated and fully validated LC-MS/MS procedure for the simultaneous determination of 11 opioids used in palliative care, with 5 of their metabolites	JOURNAL OF MASS SPECTROMETRY			English	Article						LC-MS/MS; opioids; blood plasma; solid-phase extraction; drug monitoring	PERFORMANCE LIQUID-CHROMATOGRAPHY; TANDEM MASS-SPECTROMETRY; SOLID-PHASE EXTRACTION; HUMAN PLASMA; ELECTROSPRAY-IONIZATION; ELECTROCHEMICAL DETECTION; BODY-FLUIDS; HUMAN SERUM; QUANTITATIVE-DETERMINATION; FORENSIC TOXICOLOGY	A fully validated liquid chromatographic procedure coupled with electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) is presented for quantitative determination of the opioids buprenorphine, codeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, oxymorphone, piritramide, tilidine, and tramadol together with their metabolites bisnortilidine, morphine-glucuronides, norfentanyl, and nortilidine in blood plasma after an automatically performed solid-phase extraction (SPE). Separation was achieved in 35 min on a Phenomenex C12 MAX-RP column (4 gm, 150 x 2 mm) using a gradient of ammonium formiate buffer (pH 3.5) and acetonitrile. The validation data were within the required limits. The assay was successfully applied to authentic plasma samples, allowing confirmation of the diagnosis of overdose situations as well as monitoring of patients' compliance, especially in patients under palliative care. Copyright (c) 2006 John Wiley & Sons, Ltd.	Univ Bonn, Inst Forens Sci, D-53111 Bonn, Germany	Musshoff, F (reprint author), Univ Bonn, Inst Forens Sci, Stiftspl 12, D-53111 Bonn, Germany.	f.musshoff@uni-bonn.de					Blanchet M, 1999, J CHROMATOGR A, V854, P93, DOI 10.1016/S0021-9673(99)00666-4; Bogusz MJ, 1998, J ANAL TOXICOL, V22, P549, DOI 10.1093/jat/22.7.549; Bogusz MJ, 1997, J CHROMATOGR B, V703, P115, DOI 10.1016/S0378-4347(97)00384-8; Bostrom E, 2004, RAPID COMMUN MASS SP, V18, P2565, DOI 10.1002/rcm.1658; BOUQUILLON AI, 1992, J CHROMATOGR-BIOMED, V577, P354, DOI 10.1016/0378-4347(92)80258-R; Brooks KE, 1996, J ANAL TOXICOL, V20, P269, DOI 10.1093/jat/20.4.269; Ceccato A, 2000, J CHROMATOGR B, V748, P65, DOI 10.1016/S0378-4347(00)00318-2; Ceccato A, 2003, J PHARMACEUT BIOMED, V32, P619, DOI 10.1016/S0731-7085(03)00169-9; Chen YL, 2002, J CHROMATOGR B, V769, P55, DOI 10.1016/S1570-0232(01)00616-X; Cheremina O, 2005, BIOMED CHROMATOGR, V19, P777, DOI 10.1002/bmc.516; Dawson M, 2002, J CHROMATOGR SCI, V40, P40, DOI 10.1093/chromsci/40.1.40; Day J, 2003, J ANAL TOXICOL, V27, P513, DOI 10.1093/jat/27.7.513; Dienes-Nagy A, 1999, J CHROMATOGR A, V854, P109, DOI 10.1016/S0021-9673(99)00750-5; Edwards SR, 2005, J CHROMATOGR B, V814, P241, DOI 10.1016/j.jchromb.2004.10.035; FENTON J, 1994, J ANAL TOXICOL, V18, P159, DOI 10.1093/jat/18.3.159; Gaulier JM, 2000, J FORENSIC SCI, V45, P226; George S, 2004, FORENSIC SCI INT, V143, P121, DOI 10.1016/j.forsciint.2004.03.024; Gopal S, 2001, EUR J PHARM BIOPHARM, V51, P147, DOI 10.1016/S0939-6411(00)00135-1; He HB, 1998, J CHROMATOGR B, V708, P185, DOI 10.1016/S0378-4347(97)00655-5; HO ST, 1991, J CHROMATOGR-BIOMED, V570, P339, DOI 10.1016/0378-4347(91)80537-M; Hoja H, 1997, J ANAL TOXICOL, V21, P160, DOI 10.1093/jat/21.2.160; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; Kokubun H, 2005, ANAL SCI, V21, P337, DOI 10.2116/analsci.21.337; Kuhlman JJ, 1996, J ANAL TOXICOL, V20, P229, DOI 10.1093/jat/20.4.229; Lagrange F, 1998, J PHARMACEUT BIOMED, V16, P1295, DOI 10.1016/S0731-7085(97)00139-8; Lewis RJ, 2005, J CHROMATOGR B, V822, P137, DOI 10.1016/j.jchromb.2005.05.031; Liang HR, 2004, J CHROMATOGR B, V806, P191, DOI 10.1016/j.jchromb.2004.03.059; Malonne H, 2004, BRIT J CLIN PHARMACO, V57, P270, DOI 10.1111/j.1365-2125.2003.02013.x; Martens-Lobenhoffer J, 2003, J CHROMATOGR B, V783, P53, DOI 10.1016/S1570-0232(02)00488-9; Meng QC, 2000, J CHROMATOGR B, V742, P115, DOI 10.1016/S0378-4347(00)00146-8; Moody DE, 1997, J ANAL TOXICOL, V21, P406, DOI 10.1093/jat/21.6.406; Moody DE, 2002, ANAL BIOCHEM, V306, P31, DOI 10.1006/abio.2002.5673; Murphy CM, 2005, J MASS SPECTROM, V40, P70, DOI 10.1002/jms.776; Musshoff F, 2004, J CHROMATOGR B, V811, P47, DOI 10.1016/j.jchromb.2004.03.072; Musshoff F, 2005, FORENSIC SCI INT, V154, P247, DOI 10.1016/j.forsciint.2004.10.012; MUSSHOFF F, 2006, UNPUB ENANTIOMERIC D; PACIFICI R, 1995, J CHROMATOGR B, V664, P329, DOI 10.1016/0378-4347(94)00496-R; Pascual JA, 1999, J CHROMATOGR B, V724, P295, DOI 10.1016/S0378-4347(99)00015-8; Peters F. T., 2004, TOXICHEM KRIMTECH, V1, P146; Pirnay S, 2004, J CHROMATOGR B, V807, P335, DOI 10.1016/j.jchromb.2004.04.029; Polettini A, 2001, J CHROMATOGR B, V754, P447, DOI 10.1016/S0378-4347(01)00029-9; Ropero-Miller JD, 2002, J ANAL TOXICOL, V26, P524, DOI 10.1093/jat/26.7.524; Schanzle G, 1999, J CHROMATOGR B, V721, P55, DOI 10.1016/S0378-4347(98)00438-1; Schmitt G, 2003, METHODENVALIDIERUNG; Scislowski M, 2005, J ANAL TOXICOL, V29, P249, DOI 10.1093/jat/29.4.249; Thieme D, 2003, ANAL CHIM ACTA, V492, P171, DOI 10.1016/S0003-2670(03)00563-4; Tracqui A, 1997, J FORENSIC SCI, V42, P111; Tyrefors N, 1996, J CHROMATOGR A, V729, P279, DOI 10.1016/0021-9673(95)01090-4; WANG WL, 1994, J CHROMATOGR B, V660, P279, DOI 10.1016/0378-4347(94)00309-2; Weng ND, 1999, J CHROMATOGR B, V735, P255, DOI 10.1016/S0378-4347(99)00429-6; Weng ND, 2000, J PHARMACEUT BIOMED, V23, P697, DOI 10.1016/S0731-7085(00)00352-6; Wright AWE, 1998, J CHROMATOGR B, V712, P169, DOI 10.1016/S0378-4347(98)00146-7; WRIGHT AWE, 1994, THER DRUG MONIT, V16, P200, DOI 10.1097/00007691-199404000-00016; Zheng M, 1998, J PHARMACEUT BIOMED, V16, P971, DOI 10.1016/S0731-7085(97)00094-0; Zheng M, 2002, XENOBIOTICA, V32, P141, DOI 10.1080/00498250110091767; Zuccaro P, 1997, J ANAL TOXICOL, V21, P268, DOI 10.1093/jat/21.4.268	57	93	95	2	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1076-5174	1096-9888		J MASS SPECTROM	J. Mass Spectrom.	MAY	2006	41	5					633	640		10.1002/jms.1021			8	Biochemical Research Methods; Chemistry, Analytical; Spectroscopy	Biochemistry & Molecular Biology; Chemistry; Spectroscopy	061JD	WOS:000238867100008	16541404				2020-06-30	J	Sasson, M; Shvartzman, P				Sasson, Menahem; Shvartzman, Pesach			Fentanyl patch sufficient analgesia for only one day	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Letter							RELEASE ORAL MORPHINE; TRANSDERMAL FENTANYL; CANCER PAIN; EFFICACY		Ben Gurion Univ Negev, Sial Res Ctr Family Med & Primary Care, IL-84105 Beer Sheva, Israel; Clalit Hlth Serv So Dist, Beer Sheva, Israel	Sasson, M (reprint author), Ben Gurion Univ Negev, Sial Res Ctr Family Med & Primary Care, IL-84105 Beer Sheva, Israel.		SHVARTZMAN, PESACH/F-2134-2012				Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; [Anonymous], 2005, FDA Consum, V39, P3; *MOSB INC, 2005, [No title captured]; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Radbruch L, 2001, PALLIATIVE MED, V15, P309, DOI 10.1191/026921601678320296	6	2	2	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	MAY	2006	31	5					389	391		10.1016/j.jpainsymman.2005.12.015			3	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	052CF	WOS:000238207700008	16716868	Bronze			2020-06-30	J	Llanes, LR; Fassbender, K; Baracos, VE; Watanabe, S				Llanes, Lea Renina; Fassbender, Konrad; Baracos, Vickie E.; Watanabe, Sharon			Drug utilization review on a tertiary palliative care unit	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						drug utilization review; palliative care unit; fentanyl; ondansetron; total parenteral nutrition	TOTAL PARENTERAL-NUTRITION; ADVANCED CANCER-PATIENTS; SUBCUTANEOUS FENTANYL; BOWEL OBSTRUCTION; CHRONIC NAUSEA; RENAL-FAILURE; DOUBLE-BLIND; PAIN; HOME; RECOMMENDATIONS	Drugs are indispensable for the management of symptoms in palliative care patients, and account for a significant proportion of expenditures on a Tertiary Palliative Care Unit (TPCU). Drug expenditures for Edmonton's TPCU increased by 40% in 2002 compared to 2001. Fifty-five percent of the increase was attributable to injectable fentanyl, oral and injectable ondansetron, and total parenteral nutrition (TPN). As there zoos no increase in the unit cost of these drags between 2001 and 2002, the increased expenditures reflected increased utilization. The hypothesis of this study was that the increased utilization of these drugs reflected, appropriate prescribing. The objective was to compare the indications for prescribing these drugs in 2002 against evidence-and consensus-based criteria. Patients who received these drugs while admitted to the TPCU from January 1 to December 31, 2002 were identified through the pharmacy database. Evidence- and consensus-based criteria, for drug utilization were developed. Prescribing indications were retrospectively compared against the criteria. Drug prescriptions were categorized as follows: (1) meeting criteria, (2) riot meeting criteria, or (3) uncertain. The drugs under study were prescribed during 48 out of 234 admissions to the TPCU in 2002. Prescriptions for fentanyl met criteria in 26 of 29 cases. Indications were unsuccessful therapy with morphine, hydromorphone, and oxycodone (20), requirement for rabid titration front-fentanyl patch (5), renal failure (2), and sublingual administration for breakthrough pain. (1). Prescriptions for ondansetron met criteria in 19 of 21 cases. Indications were nausea refractory to metoclopramide and dexamethasone (13), and nausea related to radiotherapy or chemotherapy (6). Prescriptions for TPN met criteria for initiation in only one of five cases. However, in all cases, TPN had been started prior to admission. In cases where death was considered imminent, TPN was continued pending consultation with the patient and family regarding discontinuation. These data indicate that the increased prescribing of fentanyl and ondansetron. on. the TPCU satisfied evidence- and consensus-based criteria in most cases, apparently justifying the associated increase in drug expenditures. This type of analysis may be useful whenever increased drug utilization requires review. A cost, effectiveness analysis would be the next step in evaluating the costs vs. the benefits. The issue of discontinuing TPN in palliative care patients requires further investigation. (C) 2006 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.	Grey Nuns Community Hosp, Tertiary Palliat Care Unit, Edmonton, AB T6L 5X8, Canada; Univ Alberta, Dept Oncol, Div Palliat Care Med, Edmonton, AB, Canada; Univ Alberta, Dept Agr Food & Nutr Sci, Edmonton, AB, Canada; Alberta Canc Board Palliat Care Res Initiat, Edmonton, AB, Canada	Watanabe, S (reprint author), Grey Nuns Community Hosp, Tertiary Palliat Care Unit, 1100 Youville Dr W,Room 4324, Edmonton, AB T6L 5X8, Canada.	swatanab@cha.ab.ca		Baracos, Vickie/0000-0002-9609-1001			Anderson F, 1996, J PALLIAT CARE, V12, P5, DOI 10.1177/082585979601200102; Bechel D L, 2000, Jt Comm J Qual Improv, V26, P400; Bozzetti F, 2002, CLIN NUTR, V21, P281, DOI 10.1054/clnu.2002.0560; Bruera E, 1996, J PAIN SYMPTOM MANAG, V11, P147, DOI 10.1016/0885-3924(95)00161-1; BRUERA E, 1995, J PAIN SYMPTOM MANAG, V10, P348, DOI 10.1016/0885-3924(95)00052-Z; Bruera E, 2000, J PAIN SYMPTOM MANAG, V19, P427, DOI 10.1016/S0885-3924(00)00138-X; Bruera E, 1991, J Palliat Care, V7, P6; Dean M, 2004, J PAIN SYMPTOM MANAG, V28, P497, DOI 10.1016/j.jpainsymman.2004.02.021; Downie J, 2004, J PALLIATIVE CARE, V20, P143, DOI 10.1177/082585970402000305; Ferris FD, 2002, MODEL GUIDE HOSPICE; Gralla RJ, 1999, J CLIN ONCOL, V17, P2971, DOI 10.1200/JCO.1999.17.9.2971; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Hardy J, 2002, SUPPORT CARE CANCER, V10, P231, DOI 10.1007/s00520-001-0332-1; Hoda D, 2005, CANCER-AM CANCER SOC, V103, P863, DOI 10.1002/cncr.20824; Lundholm K, 2004, CANCER-AM CANCER SOC, V100, P1967, DOI 10.1002/cncr.20160; Mangione-Smith R, 2002, HEALTH SERV RES, V37, P1603, DOI 10.1111/1475-6773.10482; McKinlay AW, 2004, P NUTR SOC, V63, P431, DOI 10.1079/PNS2004377; Mercadante S, 1997, J PAIN SYMPTOM MANAG, V13, P241, DOI 10.1016/S0885-3924(97)00076-6; PAIX A, 1995, PAIN, V63, P263, DOI 10.1016/0304-3959(95)00084-6; PAYNE R, 1995, ANTI-CANCER DRUG, V6, P50, DOI 10.1097/00001813-199504003-00009; POPIELA T, 1989, EUR J CANCER CLIN ON, V25, P1823; *REG PALL CAR PROG, HOM PAR NUTR CANC SE; Ripamonti C, 2001, SUPPORT CARE CANCER, V9, P223, DOI 10.1007/s005200000198; Van Gossum A, 1999, CLIN NUTR, V18, P135, DOI 10.1016/S0261-5614(99)80002-8; Watanabe S, 1998, J PAIN SYMPTOM MANAG, V16, P323, DOI 10.1016/S0885-3924(98)00095-5; WEISS SM, 1982, CANCER, V50, P1210, DOI 10.1002/1097-0142(19820915)50:6<1210::AID-CNCR2820500632>3.0.CO;2-3; Zeppetella G, 2001, PALLIATIVE MED, V15, P323, DOI 10.1191/026921601678320304	27	3	3	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	MAY	2006	31	5					457	464		10.1016/j.jpainsymman.2005.08.017			8	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	052CF	WOS:000238207700016	16716876	Bronze			2020-06-30	J	Waara-Wolleat, KL; Hildebrand, KR; Stewart, GR				Waara-Wolleat, KL; Hildebrand, KR; Stewart, GR			A review of intrathecal fentanyl and sufentanil for the treatment of chronic pain	PAIN MEDICINE			English	Review						fentanyl; infusion; intraspinal; intrathecal; pain; sufentanil	INTRASPINAL DRUG-DELIVERY; CHRONIC NONMALIGNANT PAIN; BUPIVACAINE HYDROCHLORIDE; INFUSION SYSTEM; PUMP RESERVOIRS; SHEEP MODEL; STABILITY; MORPHINE; THERAPY; OPIOIDS	Intrathecal infusion of morphine using implantable pumps is an accepted practice for long-term management of chronic pain. Despite clinical benefit, development of tolerance and side-effects associated with intrathecal morphine has prompted investigators to explore alternative opioids such as the potent anilinopiperidine analogs, fentanyl, and sufentanil. Relevant preclinical and clinical literature from the MEDLINE database was used primarily for this review. In vitro, both compounds are stable in solution, but studies have not been conducted using implantable pumps under simulated use conditions (e.g., long-term stability at body temperature). Preclinical studies of limited duration have demonstrated efficacy, but safety-toxicology studies have been limited to intermittent boluses of sufentanil only. Few clinical reports on the use of intrathecal sufentanil or fentanyl for chronic pain are available. Although results confirm potency and efficacy with intrathecal administration, further studies are needed to support the long-term use of either opioid in chronic pain management.	Univ Minnesota, Coll Pharm, Minneapolis, MN 55455 USA; Medtronic Inc, Minneapolis, MN USA	Waara-Wolleat, KL (reprint author), 2520 Pilot Knob Rd,Suite 100, Mendota Hts, MN 55120 USA.	waar0002@umn.edu					Abram SE, 1997, ANESTHESIOLOGY, V87, P127, DOI 10.1097/00000542-199707000-00017; Ahmed SU, 2005, NEUROMODULATION, V8, P112, DOI 10.1111/j.1525-1403.2005.00227.x; Aldrete JA, 2000, EUR J PAIN, V4, P361, DOI 10.1053/eujp.2000.0199; ALLEN LV, 1990, AM J HOSP PHARM, V47, P1572, DOI 10.1093/ajhp/47.7.1572; ALLEN LV, 1993, AM J HOSP PHARM, V50, P714, DOI 10.1093/ajhp/50.4.714; Boitquin LP, 2004, ANN PHARMACOTHER, V38, P1836, DOI 10.1345/aph.1D564; Brodner G, 2002, EUR J ANAESTH, V19, P295; Capogna G, 2003, ANESTH ANALG, V96, P1178, DOI 10.1213/01.ANE.0000054003.03645.CF; Cherry DA, 2003, PAIN, V102, P163, DOI 10.1016/S0304-3959(02)00371-8; de Leon-Casasola OA, 2004, CANCER INVEST, V22, P630, DOI 10.1081/CNV-200027166; DICKENSON AH, 1991, BRIT MED BULL, V47, P690, DOI 10.1093/oxfordjournals.bmb.a072501; DIRIG DM, 1995, PAIN, V62, P321, DOI 10.1016/0304-3959(95)00006-E; Gerber Helmut R, 2003, Best Pract Res Clin Anaesthesiol, V17, P429, DOI 10.1016/S1521-6896(03)00014-4; Gradert TL, 2003, ANESTHESIOLOGY, V99, P188, DOI 10.1097/00000542-200307000-00029; Hamber EA, 1999, REGION ANESTH PAIN M, V24, P255; HANSDOTTIR V, 1991, ANESTHESIOLOGY, V74, P264, DOI 10.1097/00000542-199102000-00012; Hassenbusch SJ, 2004, J PAIN SYMPTOM MANAG, V27, P540, DOI 10.1016/j.jpainsymman.2004.03.001; HASSENBUSCH SJ, 1995, J PAIN SYMPTOM MANAG, V10, P527, DOI 10.1016/0885-3924(95)00087-F; Hassenbusch SJ, 2000, J PAIN SYMPTOM MANAG, V20, pS4, DOI 10.1016/S0885-3924(00)00203-7; Hildebrand KR, 2001, J PAIN SYMPTOM MANAG, V22, P1042, DOI 10.1016/S0885-3924(01)00364-5; JAFFE J H, 1990, P485; Johansen MJ, 2004, PAIN MED, V5, P14, DOI 10.1111/j.1526-4637.2004.04010.x; Krames ES, 1996, J PAIN SYMPTOM MANAG, V11, P333, DOI 10.1016/0885-3924(96)00010-3; Maeyaert J, 2003, NEUROMODULATION, V6, P133, DOI 10.1046/j.1525-1403.2003.03021.x; Miguel R, 2000, Cancer Control, V7, P149; Mueller-Schwefe G, 1999, NEUROMODULATION, V2, P77, DOI 10.1046/j.1525-1403.1999.00077.x; Paice J, 1995, CANC PAIN MANAGEMENT, P131; RAWAL N, 1991, ANESTHESIOLOGY, V75, P1025, DOI 10.1097/00000542-199112000-00015; SABBE MB, 1994, ANESTHESIOLOGY, V81, P899, DOI 10.1097/00000542-199410000-00017; SOSNOWSKI M, 1990, ANESTHESIOLOGY, V73, P1141, DOI 10.1097/00000542-199012000-00012; STEVENS CW, 1989, J PHARMACOL EXP THER, V250, P1; Thimineur MA, 2004, PAIN, V109, P242, DOI 10.1016/j.pain.2004.01.003; TU YH, 1990, AM J HOSP PHARM, V47, P2037, DOI 10.1093/ajhp/47.9.2037; Ummenhofer WC, 2000, ANESTHESIOLOGY, V92, P739, DOI 10.1097/00000542-200003000-00018; VANDEWALLE J, 1976, ACTA ANAESTH BELG, V27, P129; Willis KD, 1999, NEUROMODULATION, V2, P241, DOI 10.1046/j.1525-1403.1999.00241.x; Wilson KM, 1998, J PAIN SYMPTOM MANAG, V16, P52, DOI 10.1016/S0885-3924(98)00024-4; Yaksh TL, 2002, PAIN MED, V3, P300, DOI 10.1046/j.1526-4637.2002.02048.x; Yaksh TL, 2003, ANESTHESIOLOGY, V99, P174, DOI 10.1097/00000542-200307000-00028; YAKSH TL, 1986, ANESTHESIOLOGY, V64, P54, DOI 10.1097/00000542-198601000-00009	40	23	27	0	7	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	MAY-JUN	2006	7	3					251	259		10.1111/j.1526-4637.2006.00155.x			9	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	040QZ	WOS:000237396800008	16712626	Other Gold			2020-06-30	J	Antila, H; Manner, T; Kuurila, K; Salantera, S; Kujala, R; Aantaa, R				Antila, H; Manner, T; Kuurila, K; Salantera, S; Kujala, R; Aantaa, R			Ketoprofen and tramadol for analgesia during early recovery after tonsillectomy in children	PEDIATRIC ANESTHESIA			English	Article						analgesia; postoperative; nonsteroidal anti-inflammatory agents; ketoprofen; tramadol	POSTOPERATIVE NAUSEA; PAIN RELIEF; PHARMACOKINETICS; RISK	Background: Pain following tonsillectomy is often intense. Nonsteroidal anti-inflammatory drugs and opioids are effective, but both can cause adverse effects. Tramadol may be a viable alternative for post-tonsillectomy pain. This study was designed to compare the analgesic effects of ketoprofen and tramadol during the early recovery period after tonsillectomy. Methods: Forty-five ASA class I children (9-15 years) were randomized to receive either saline, ketoprofen (2 mg.kg(-1)) or tramadol (1 mg.kg(-1)) after induction of anesthesia. Upon completion of surgery, the study treatment was continued as a 6 h intravenous (i.v.) infusion of another dose of saline, ketoprofen (2 mg.kg(-1)) or tramadol (1 mg.kg(-1)). Postoperatively, each patient received rescue analgesia with patient-controlled analgesia (PCA) device programmed to deliver 0.5 mu g.kg(-1) bolus doses of fentanyl. Postoperative pain was assessed using Visual Analog Scale (VAS) during swallowing. Intraoperative blood loss was measured. Results: The total number of requests of PCA-fentanyl was significantly less in ketoprofen group compared with tramadol and placebo groups (P = 0.035 and P = 0.049, respectively, in pairwise comparisons) and the VAS scores for pain were significantly lower in ketoprofen group compared with tramadol (P = 0.044) or placebo groups (P = 0.018) during the first six postoperative hours. Measured intraoperative blood loss was greater in ketoprofen-treated patients than in those receiving placebo (P = 0.029). Conclusion: A dose of 4 mg.kg(-1) of i.v. ketoprofen provided good pain relief with moderate supplemental PCA-fentanyl requirements during the first six postoperative hours after tonsillectomy in children whereas the effects of 2 mg.kg(-1) of i.v. tramadol did not differ from those of placebo.	Turku Univ, Dept Anaesthesiol & Intens Care, FIN-20521 Turku, Finland; Cent Hosp Vaasa, Dept Otorhinolaryngol, Vaasa, Finland; Turku Univ, Dept Nursing Sci, Turku, Finland	Aantaa, R (reprint author), Turku Univ, Dept Anaesthesiol & Intens Care, POB 52, FIN-20521 Turku, Finland.	riku.aantaa@tyks.fi	Salantera, Sanna/B-7073-2008	Salantera, Sanna/0000-0003-2529-6699			[Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373; Budd K, 1999, BRIT J ANAESTH, V82, P493; Cardwell M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003591.pub2; Courtney MJ, 2001, ARCH OTOLARYNGOL, V127, P385, DOI 10.1001/archotol.127.4.385; DEBRUYNE D, 1987, CLIN PHARMACOKINET, V12, P214, DOI 10.2165/00003088-198712030-00003; Eberhart LHJ, 2004, ANESTH ANALG, V99, P1630, DOI 10.1213/01.ANE.0000135639.57715.6C; Engelhardt T, 2003, PAEDIATR ANAESTH, V13, P249, DOI 10.1046/j.1460-9592.2003.00983.x; Hamunen K, 2005, PAIN, V116, P146, DOI 10.1016/j.pain.2005.04.004; Kokki H, 2002, PAEDIATR ANAESTH, V12, P162, DOI 10.1046/j.1460-9592.2002.00804.x; Kokki H, 1998, BRIT J ANAESTH, V81, P870; Kokki H, 2003, CLIN PHARMACOKINET, V42, P373, DOI 10.2165/00003088-200342040-00005; Kokki Hannu, 2003, Paediatr Drugs, V5, P103, DOI 10.2165/00148581-200305020-00004; McDonald AJ, 2001, PEDIATR DRUGS, V3, P273, DOI 10.2165/00128072-200103040-00004; Moiniche S, 2003, ANESTH ANALG, V96, P68, DOI 10.1213/01.ANE.0000040583.65135.57; Mukherjee K, 2001, ANAESTHESIA, V56, P1193; Ozer Z, 2003, EUR J ANAESTH, V20, P920; Rose JB, 1999, BRIT J ANAESTH, V83, P104; Sachse C, 1997, AM J HUM GENET, V60, P284; Salonen A, 2002, LARYNGOSCOPE, V112, P94, DOI 10.1097/00005537-200201000-00017; Salonen A, 2002, INT J PEDIATR OTORHI, V62, P143, DOI 10.1016/S0165-5876(01)00610-3; Stamer UM, 2003, PAIN, V105, P231, DOI 10.1016/S0304-3959(03)00212-4; van den Berg AA, 1999, ACTA ANAESTH SCAND, V43, P28, DOI 10.1034/j.1399-6576.1999.430107.x; Warnock FF, 1998, PAIN, V75, P37, DOI 10.1016/S0304-3959(97)00202-9	23	24	24	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	MAY	2006	16	5					548	553		10.1111/j.1460-9592.2005.01819.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	032JB	WOS:000236769600008	16677265				2020-06-30	J	Mistraletti, G; De la Cuadra-Fontaine, JC; Asenjo, FJ; Donatelli, F; Wykes, L; Schricker, T; Carli, F				Mistraletti, Giovanni; De la Cuadra-Fontaine, Juan Carlos; Asenjo, Francisco J.; Donatelli, Francesco; Wykes, Linda; Schricker, Thomas; Carli, Franco			Comparison of analgesic methods for total knee arthroplasty: Metabolic effect of exogenous glucose	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article						total knee arthroplasty; pain; stable isotopes; analgesia; epidural; patient-controlled analgesia; continuous peripheral nerve block	INSULIN-RESISTANCE; EPIDURAL-ANESTHESIA; INTEGRATED ANALYSIS; POSTOPERATIVE PAIN; PROTEIN-METABOLISM; LOCAL-ANESTHESIA; BOWEL FUNCTION; NERVE BLOCK; SURGERY; INFUSION	Background and Objectives: This study was set up to assess whether postoperative suppression of gluconeogenesis by dextrose infusion would be influenced by continuous peripheral nerve block (CPNB) with local anesthetics, in comparison with epidural and with intravenous analgesia. Methods: Twenty-seven patients, undergoing elective primary total knee arthroplasty for ostcoarthritis, were randomly allocated to one of the three groups of 9 patients each: patient controlled analgesia (PCA) with i.v. morphine, epidural with bupivacaine 0.1% and fentanyl 3 mu g/ml, or continuous femoral and sciatic blocks with ropivacaine 0.2%. Endogenous glucose production, an index of gluconeogenesis, and glucose clearance, an index of whole body glucose uptake, were assessed on the second postoperative day by measuring [6,6-(2H)(2)] glucose kinetics after an overnight fast (fasted state), and during a 3-h period infusion of dextrose at 4 mg/kg/min (fed state). Visual analog scale (VAS) at rest and at knee flexion, use of morphine, mobilization, nutritional intake, and bowel function were also collected. Results: Endogenous glucose production was totally suppressed by 3 h of dextrose infusion in all 3 groups (P < .001) while glucose clearance was unchanged. Blood glucose and insulin increased (P < .001), while glucagon decreased, with the greatest change in the epidural group (P < .05). VAS at rest and at knee flexion was significantly lower in patients receiving epidural and CPNB compared to i.v. morphine (P < .05). Restoration of bowel function, assessed as return of bowel movements, was faster in the CPNB group (P < .05). Conclusion: Excellent analgesia was achieved in the epidural and continuous nerve block groups. Postoperative gluconeogenesis was totally suppressed by dextrose infusion independent of the analgesia technique with no change in glucose utilization.	McGill Univ, Ctr Hlth, Dept Anesthesia, Montreal, PQ H3G 1A4, Canada; McGill Univ, Sch Dietet & Human Nutr, Montreal, PQ, Canada	Carli, F (reprint author), McGill Univ, Ctr Hlth, Dept Anesthesia, 1650,Cedar Ave,Room D10-144, Montreal, PQ H3G 1A4, Canada.	Franco.Carli@mcgill.ca	Mistraletti, Giovanni/O-5859-2017	Mistraletti, Giovanni/0000-0001-8322-1623			Adams HA, 2002, EUR J ANAESTH, V19, P658, DOI 10.1017/S0265021502001084; Capdevila X, 1999, ANESTHESIOLOGY, V91, P8, DOI 10.1097/00000542-199907000-00006; Carli F, 2005, ARCH SURG-CHICAGO, V140, P593, DOI 10.1001/archsurg.140.6.593; Carli F, 2001, DIS COLON RECTUM, V44, P1083, DOI 10.1007/BF02234626; Carli F, 2000, NUTRITION, V16, P777, DOI 10.1016/S0899-9007(00)00385-3; CHOI PT, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD003071, 10.1002/14651858.cd003071]; Davies AF, 2004, BRIT J ANAESTH, V93, P368, DOI 10.1093/bja/aeh224; de Benedetto P, 2001, ANESTH ANALG, V93, P1040, DOI 10.1097/00000539-200110000-00049; GIESECKE K, 1988, BRIT J ANAESTH, V61, P652, DOI 10.1093/bja/61.6.652; Glantz L, 2000, ANESTH ANALG, V91, P1415, DOI 10.1097/00000539-200012000-00021; Greisen J, 2001, ANESTHESIOLOGY, V95, P578, DOI 10.1097/00000542-200109000-00007; Holte K, 2002, CLIN NUTR, V21, P199, DOI 10.1054/clnu.2001.0514; Keyl C, 1996, ANESTH ANALG, V82, P113, DOI 10.1097/00000539-199601000-00020; KINNEY JM, 1983, NUTR SUPPORT SERIOUS, P5; LJUNGQVIST O, 1994, J AM COLL SURGEONS, V178, P329; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; PITHER CE, 1988, BRIT J ANAESTH, V60, P730, DOI 10.1093/bja/60.6.730; Schricker T, 2000, AM J PHYSIOL-ENDOC M, V279, pE646; Schricker T, 2004, ANN SURG, V240, P916, DOI 10.1097/01.sla.0000143249.93856.66; Schricker T, 1999, ANESTHESIOLOGY, V90, P1636, DOI 10.1097/00000542-199906000-00020; Schricker T, 2000, ANESTHESIOLOGY, V92, P62, DOI 10.1097/00000542-200001000-00015; Schricker Thomas, 2004, JPEN J Parenter Enteral Nutr, V28, P149, DOI 10.1177/0148607104028003149; SHAW JHF, 1989, ANN SURG, V209, P63, DOI 10.1097/00000658-198901000-00010; SHAW JHF, 1985, SURGERY, V97, P557; Singelyn FJ, 1998, ANESTH ANALG, V87, P88, DOI 10.1097/00000539-199807000-00019; THORELL A, 1994, BRIT J SURG, V81, P59, DOI 10.1002/bjs.1800810120; Vloka JD, 1999, ANESTH ANALG, V89, P1467, DOI 10.1097/00000539-199912000-00028; Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487; WOLFE RR, 1979, METABOLISM, V28, P210, DOI 10.1016/0026-0495(79)90066-0; WOLFE RR, 1993, CLIN NUTR PARENTERAL, P113; Wu CT, 2005, ANESTH ANALG, V100, P448, DOI 10.1213/01.ANE.0000142551.92340.CC	31	10	13	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1098-7339	1532-8651		REGION ANESTH PAIN M	Region. Anesth. Pain Med.	MAY-JUN	2006	31	3					260	269		10.1016/j.rapm.2006.02.005			10	Anesthesiology	Anesthesiology	046OW	WOS:000237821900014	16701193				2020-06-30	J	Ripamonti, C; Fagnoni, E; Campa, T; Brunelli, C; De Conno, F				Ripamonti, C; Fagnoni, E; Campa, T; Brunelli, C; De Conno, F			Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy	SUPPORTIVE CARE IN CANCER			English	Editorial Material						cancer; pain; oral morphine; transdermal fentanyl; switching; titration; settings of care; opioid administration	RELEASE ORAL MORPHINE; QUALITY-OF-LIFE; POSTOPERATIVE PAIN; OPIOIDS; PHARMACOKINETICS; EFFICACY; CODEINE; TRIAL		Natl Canc Inst, Rehabil & Palliat Care Operat Unit, I-20133 Milan, Italy	Ripamonti, C (reprint author), Natl Canc Inst, Rehabil & Palliat Care Operat Unit, Via Venezian 1, I-20133 Milan, Italy.	carla.ripamonti@istitutotumori.mi.it	Ripamonti, Carla/C-4557-2017; Brunelli, Cinzia/B-9361-2017	Ripamonti, Carla/0000-0001-5495-5054; Brunelli, Cinzia/0000-0003-3905-1289			Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Burza M, 1998, Clin Ter, V149, P277; Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542; Chinellato A, 2003, LANCET, V362, P78, DOI 10.1016/S0140-6736(03)13819-6; De Conno F, 2005, PALLIATIVE MED, V19, P179, DOI 10.1191/0269216305pm1002oa; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Genf World Health Organization, 1986, CANC PAIN REL; Gourlay G K, 2001, Lancet Oncol, V2, P165, DOI 10.1016/S1470-2045(00)00258-8; GOURLAY GK, 1989, PAIN, V37, P193, DOI 10.1016/0304-3959(89)90130-9; GOURLAY GK, 1990, PAIN, V40, P21, DOI 10.1016/0304-3959(90)91046-L; Hanks GW, 1996, BRIT MED J, V312, P823; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; HOLLEY FO, 1988, BRIT J ANAESTH, V60, P608, DOI 10.1093/bja/60.6.608; JACOX A, 1994, [No title captured]; JANSSEN LP, 2005, IMPORTANT DRUG WARNI; KORKE W, 1996, J PAIN SYMPTOM MANAG, V11, P139; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Megens AAHP, 1998, J PAIN SYMPTOM MANAG, V15, P253, DOI 10.1016/S0885-3924(97)00371-0; Mystakidou K, 2001, ANTICANCER RES, V21, P2225; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; Radbruch L, 2000, PALLIATIVE MED, V14, P111, DOI 10.1191/026921600671594561; Radbruch L, 2002, J PAIN SYMPTOM MANAG, V24, P183, DOI 10.1016/S0885-3924(02)00445-1; *SIGN, 2000, CANC PAIN GUID; Skaer TL, 2004, DRUGS, V64, P2629, DOI 10.2165/00003495-200464230-00002; Tawfik MO, 2004, CURR MED RES OPIN, V20, P259, DOI 10.1185/030079903125003026; van Seventer R, 2003, CURR MED RES OPIN, V19, P457, DOI 10.1185/030079903125002045; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Vielvoye-Kerkmeer APE, 2000, J PAIN SYMPTOM MANAG, V19, P185, DOI 10.1016/S0885-3924(99)00152-9; *WHO, 1999, MOD LIST ESS DRUGS E; World Health Organization, 1996, CANC PAIN REL	31	31	33	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	MAY	2006	14	5					400	407		10.1007/s00520-005-0918-0			8	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	037ZV	WOS:000237187800002	16485087				2020-06-30	J	Liehmann, L; Mosing, M; Auer, U				Liehmann, L; Mosing, M; Auer, U			A comparison of cardiorespiratory variables during isoflurane-fentanyl and propofol-fentanyl anaesthesia for surgery in injured cats	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						anaesthesia; cats; fentanyl; injured; isoflurane; propofol	MINIMUM ALVEOLAR CONCENTRATION; BLOOD-PRESSURE MEASUREMENT; HALOTHANE ANESTHESIA; ANALGESIC DRUGS; DOGS; ALFENTANIL; REDUCTION; INDUCTION; INFUSION; SYSTEM	Objective To compare haemodynamic and respiratory variables during isoflurane-fentanyl (IF) and propofol-fentanyl (PF) anaesthesia for surgery in injured cats. Study design Prospective. randomized, controlled clinical study. Animals Thirty-three client-owned injured cats undergoing orthopaedic surgery. Materials and methods Pre-anaesthetic medication was intravenous midazolam 1 mg kg(-1), butorphanol 0.4 mg kg(-1) and ketamine 2 mg kg(-1). Anaesthesia was induced with propofol (P) and maintained with either: (a) a continuous rate infusion (CRI) of fentanyl (F) 0.02 mg kg(-1) hour(-1) and isoflurane (initial end-tidal concentration of 1%), (b) a fentanyl CRI (dose as before) and sevoflurane (initial end-tidal concentration of 2%) or (c) a CRI of propofol (12 mg kg(-1) hour(-1)). All three techniques were given to effect until surgical anaesthesia was achieved. Heart rate and rhythm (ECG), mean arterial blood pressure. respiratory rate, tidal volume and end-tidal CO2 concentration were recorded. Venous blood gas analysis was performed before and after sedation, and at the end of anaesthesia. Blood chemistry and blood cell counts were assessed before, at the end of, and 24 hours after anaesthesia. The variables recorded from cats anaesthetized with IF and PF were compared. Results Mean end-expiratory isoflurane concentration was 1.19 +/- 0.19%. The propofol infusion rate was 11.4 +/- 0.8 mg kg(-1) hour(-1). No significant differences between the two groups in heart rate were identified; no cardiac dysrhythmias were recorded. Mean arterial blood pressure was significantly lower in IF cats during skin incision (p=0.01), during surgery without intense surgical stimulation (p<0.01) and during surgery with intense surgical stimulation (p=0.01). Nine of 11 cats in the IF group were markedly hypotensive (34-49 mmHg) while seven of 11 cats in group PF were mildly hypotensive (49-59 mmHg). One of 11 cats in group IF and nine of 11 cats in group PF required intermittent positive pressure ventilation (IPPV) to maintain end-tidal CO2 levels below 6.66 kPa (50 mmHg). Conclusion and clinical relevance Despite the necessity to ventilate the lungs of cats in the PF group, arterial blood pressure was better maintained. Propofol-fentanyl anaesthesia is better for surgery in injured cats providing the means to impose IPPV are available.	Univ Vet Med, Clin Surg Ophthalmol & Dent, Clin Dept Small Anim & Horses, Vienna, Austria; Univ Vet Med, Clin Anaesthesia & Perioperat Intens Care, Vienna, Austria	Liehmann, L (reprint author), Univ Vet Med Vienna, Dept Surg & Ophthalmol, Vet Pl 1, A-1210 Vienna, Austria.	lea.liehmann@vu-wien.ac.at		Ulrike, Auer/0000-0003-0390-2678; Mosing, Martina/0000-0002-6190-5642			Bednarski R.M., 1996, LUMB JONES VET ANEST, P591; Beths T, 2001, VET REC, V148, P198, DOI 10.1136/vr.148.7.198; BINNS SH, 1995, J VET INTERN MED, V9, P405, DOI 10.1111/j.1939-1676.1995.tb03301.x; Branson KR, 1997, VET SURG, V26, P347, DOI 10.1111/j.1532-950X.1997.tb01510.x; BRANSON KR, 1994, J AM VET MED ASSOC, V204, P1888; BREARLEY JC, 1988, J SMALL ANIM PRACT, V29, P315, DOI 10.1111/j.1748-5827.1988.tb02290.x; BRUSSEL T, 1989, ANESTH ANALG, V69, P35; Caulkett NA, 1998, VET SURG, V27, P370, DOI 10.1111/j.1532-950X.1998.tb00143.x; DAVIS LE, 1968, J AM VET MED ASSOC, V153, P1161; EBERT TJ, 1992, ANESTHESIOLOGY, V76, P725, DOI 10.1097/00000542-199205000-00010; EGER EI, 1984, BRIT J ANAESTH, V56, pS71; GEEL JK, 1991, J S AFR VET ASSOC, V62, P118; HALL LW, 1987, J SMALL ANIM PRACT, V28, P623, DOI 10.1111/j.1748-5827.1987.tb01277.x; HALL RI, 1987, ANESTH ANALG, V66, P1287; Hikasa Y, 1996, VET SURG, V25, P234, DOI 10.1111/j.1532-950X.1996.tb01407.x; Hikasa Y, 1998, J VET MED A, V45, P559, DOI 10.1111/j.1439-0442.1998.tb00860.x; HORNE MM, 1994, VET SURG, V23, P241, DOI 10.1111/j.1532-950X.1994.tb00478.x; Ilkiw JE, 1997, AM J VET RES, V58, P1274; JONES RS, 1990, VET ANN, V30, P300; KEEGAN RD, 1993, VET SURG, V22, P537, DOI 10.1111/j.1532-950X.1993.tb00434.x; Lalley PM, 2003, AM J PHYSIOL-REG I, V285, pR1287, DOI 10.1152/ajpregu.00199.2003; Lee DD, 2000, AM J VET RES, V61, P672, DOI 10.2460/ajvr.2000.61.672; MCEWAN AI, 1993, ANESTHESIOLOGY, V78, P864, DOI 10.1097/00000542-199305000-00009; Mendes GM, 2003, J AM VET MED ASSOC, V223, P1608, DOI 10.2460/javma.2003.223.1608; MICHELL AR, 1994, ANAESTHESIA CAT, P12; MORGAN DWT, 1989, VET REC, V124, P31, DOI 10.1136/vr.124.2.31; Muir WW, 2002, AM J VET RES, V63, P1241, DOI 10.2460/ajvr.2002.63.1241; MURPHY MR, 1982, ANESTHESIOLOGY, V57, P485, DOI 10.1097/00000542-198212000-00009; NOLAN A, 1993, BRIT J ANAESTH, V70, P546, DOI 10.1093/bja/70.5.546; OTTO KA, 1994, S REPORT ANIMAL PAIN, P147; Pascoe PJ, 1997, AM J VET RES, V58, P1267; POTERACK KA, 1991, ANESTH ANALG, V73, P64; ROBERTSON SA, 1992, AM J VET RES, V53, P1027; ROBINSON BJ, 1994, BRIT J ANAESTH, V73, P167, DOI 10.1093/bja/73.2.167; Robinson BJ, 1997, ANESTHESIOLOGY, V86, P64, DOI 10.1097/00000542-199701000-00010; Sander C, 1996, KLEINTIERPRAXIS, V41, P5; SEBEL PS, 1992, ANESTHESIOLOGY, V76, P52, DOI 10.1097/00000542-199201000-00008; SELLGREN J, 1992, ACTA ANAESTH SCAND, V36, P784, DOI 10.1111/j.1399-6576.1992.tb03565.x; Short CE, 1999, VET CLIN N AM-SMALL, V29, P747, DOI 10.1016/S0195-5616(99)50059-4; STEFFEY EP, 1977, AM J VET RES, V38, P1833; Takeda S, 2001, ANESTHESIOLOGY, V95, P740, DOI 10.1097/00000542-200109000-00029; TAVAT S, 1956, ARCH INT PHARMACOD T, V108, P92; TRIM CM, 1994, ANAESTHESIA CAT, P213; WEAVER BMQ, 1990, VET REC, V126, P617; WESTMORELAND CL, 1994, ANESTH ANALG, V78, P23; WILLETTE RN, 1987, J PHARMACOL EXP THER, V240, P352; WISKOCIL L, 2001, THESIS U VET MED VIE; YASTER M, 1994, ANESTHESIOLOGY, V80, P364, DOI 10.1097/00000542-199402000-00016	48	25	25	0	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	MAY	2006	33	3					158	168		10.1111/j.1467-2995.2005.00251.x			11	Veterinary Sciences	Veterinary Sciences	040OL	WOS:000237389200004	16634941				2020-06-30	J	Chen, SR; Pan, HL				Chen, SR; Pan, HL			Blocking mu opioid receptors in the spinal cord prevents the analgesic action by subsequent systemic opioids	BRAIN RESEARCH			English	Article						spinal cord; dorsal horn; pain; opioid	DORSAL-HORN; PERIAQUEDUCTAL GRAY; SUBSTANTIA-GELATINOSA; SUPRASPINAL ACTIONS; OPIATE RECEPTORS; NEUROPATHIC PAIN; MICRO-INJECTION; RAPHE MAGNUS; WHOLE-CELL; MORPHINE	Systemically administered mu opioids may produce analgesia through inhibition of the ascending nociceptive transmission and activation of descending pathways. However, the relative importance of the spinal and supraspinal sites in the analgesic action of systemic opioids remains uncertain. It has been shown that systemic morphine can inhibit dorsal horn neurons independent of the descending system. In this study, we determined the extent to which spinal p opioid receptors mediate the analgesic effect of systemic p opioids. Rats were instrumented with an intrathecal catheter with the tip placed in the lumbar spinal cord. Nociception was measured by testing the paw withdrawal threshold in response to a noxious radiant heat or pressure stimulus. Surprisingly, intrathecal pretreatment with naloxone or H-D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP, a specific A opioid receptor antagonist) completely blocked the inhibitory effect of intravenous morphine on mechanical nociception. Intrathecal naloxone or CTAP also abolished the effect of intravenous morphine on the withdrawal latency of the hindpaw, but not the forepaw, measured with a radiant heat stimulus. Furthermore, the inhibitory effect of subcutaneous fentanyl on mechanical nociception was eliminated by CTAP injected intrathecally. Intrathecal CTAP similarly abolished the effect of subcutaneous fentanyl on thermal nociception of the hindpaw but not the forepaw. Therefore, this study provides new information that when spinal p opioid receptors are blocked, subsequent systemic administration of mu opioids fails to produce an analgesic effect. This finding highlights the important role of mu opioid receptors in the spinal cord in the antinociceptive action of opioids. (c) 2006 Elsevier B.V. All rights reserved.	Penn State Univ, Coll Med, Dept Anesthesiol, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Dept Neural & Behav Sci, Hershey, PA 17033 USA	Pan, HL (reprint author), Univ Texas, MD Anderson Canc Ctr, Dept Anesthesiol & Pain Med, 1400 Holcombe Blvd,Unit 409, Houston, TX 77030 USA.	huilinpan@mdanderson.org		Pan, Hui-Lin/0000-0001-8444-3770	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM64830]; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS45602]		ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; ATWEH SF, 1977, BRAIN RES, V124, P53, DOI 10.1016/0006-8993(77)90863-0; BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; BASBAUM AI, 1976, P NATL ACAD SCI USA, V73, P4685, DOI 10.1073/pnas.73.12.4685; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Chen SR, 2003, ANESTHESIOLOGY, V99, P1409, DOI 10.1097/00000542-200312000-00026; Chen SR, 2002, J NEUROPHYSIOL, V87, P2726, DOI 10.1152/jn.2002.87.6.2726; Chen SR, 2001, ANESTHESIOLOGY, V95, P525, DOI 10.1097/00000542-200108000-00039; CHEN SR, IN PRESS J NEUROPHYS; Chen YP, 2005, J PHARMACOL EXP THER, V314, P611, DOI 10.1124/jpet.105.085563; CHITOUR D, 1986, BRAIN RES, V377, P397, DOI 10.1016/0006-8993(86)90889-9; DawsonBasoa M, 1997, BRAIN RES, V757, P37, DOI 10.1016/S0006-8993(97)00092-9; DICKENSON AH, 1987, J PHYSIOL-LONDON, V384, P81, DOI 10.1113/jphysiol.1987.sp016444; DOSTROVSKY JO, 1983, J NEUROPHYSIOL, V49, P948; Finnegan TF, 2004, J PHARMACOL EXP THER, V309, P476, DOI 10.1124/jpet.103.064808; Gao KM, 1998, J NEUROSCI, V18, P1860; JACQUET YF, 1973, SCIENCE, V182, P490, DOI 10.1126/science.182.4111.490; Kalyuzhny AE, 1996, J NEUROSCI, V16, P6490; KITAHATA LM, 1974, ANESTHESIOLOGY, V41, P39, DOI 10.1097/00000542-197407000-00008; Kohno T, 1999, J PHYSIOL-LONDON, V518, P803, DOI 10.1111/j.1469-7793.1999.0803p.x; LEBARS D, 1975, BRAIN RES, V98, P261, DOI 10.1016/0006-8993(75)90005-0; LEVY RA, 1979, EUR J PHARMACOL, V57, P43, DOI 10.1016/0014-2999(79)90102-X; Light AR, 1999, J NEUROPHYSIOL, V82, P3316; Lin Q, 1996, J PHARMACOL EXP THER, V276, P958; MAGNUSON DSK, 1991, J NEUROPHYSIOL, V66, P1941; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; MOISES HC, 1994, J NEUROSCI, V14, P5903; Porreca F, 2001, J NEUROSCI, V21, P5281, DOI 10.1523/JNEUROSCI.21-14-05281.2001; Schneider SP, 1998, J NEUROPHYSIOL, V80, P2954; SHARPE LG, 1974, BEHAV BIOL, V11, P303, DOI 10.1016/S0091-6773(74)90548-3; SINCLAIR JG, 1986, GEN PHARMACOL, V17, P351, DOI 10.1016/0306-3623(86)90053-4; SINCLAIR JG, 1988, PAIN, V33, P357, DOI 10.1016/0304-3959(88)90296-5; SOJA PJ, 1983, SOMATOSENS RES, V1, P83, DOI 10.3109/07367228309144542; TSOU K, 1964, SCI SINICA, V13, P1099; URBAN MO, 1994, BRAIN RES, V652, P9, DOI 10.1016/0006-8993(94)90311-5; VANDENHOOGEN RHWM, 1987, ANESTHESIOLOGY, V66, P186, DOI 10.1097/00000542-198702000-00013; Wu ZZ, 2004, J PHARMACOL EXP THER, V311, P939, DOI 10.1124/jpet.104.073429; YAKSH TL, 1977, J PHARMACOL EXP THER, V202, P411; YAKSH TL, 1985, ANNU REV PHARMACOL, V25, P433, DOI 10.1146/annurev.pharmtox.25.1.433; YEUNG JC, 1980, J PHARMACOL EXP THER, V215, P633	40	51	54	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 7	2006	1081						119	125		10.1016/j.brainres.2006.01.053			7	Neurosciences	Neurosciences & Neurology	036TQ	WOS:000237098900015	16499888				2020-06-30	J	Fujiwara, Y; Asakura, Y; Shibata, Y; Nishiwaki, K; Komatsu, T				Fujiwara, Y; Asakura, Y; Shibata, Y; Nishiwaki, K; Komatsu, T			A marked decrease in heart rate variability associated with junctional rhythm during anesthesia with sevoflurane and fentanyl	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						junctional rhythm; entropy; heart rate variability		Heart rate variability (HRV) was investigated using a new technique for time series analysis combining the maximum entropy method and non-linear least squares method - the 'MemCalc method'-in patients undergoing general anesthesia with sevoflurane and fentanyl for elective surgery. As the occurrence of junctional rhythm coincided with the measurement of these variables in two patients, we successfully evaluated the entropy, low (LF) and high (HF) frequency component of the HRV during junctional rhythm and found that the occurrence of junctional rhythm is associated with marked decreases in the entropy, LF and HF of HRV. When evaluating autonomic control of the heart using HRV analysis, the decrease in HRV caused by the occurrence of junctional rhythm must be taken into account.	Aichi Med Univ, Dept Anesthesiol, Nagakute, Aichi 4801195, Japan; Nagoya Univ, Grad Sch Med, Dept Anesthesiol, Nagoya, Aichi, Japan	Fujiwara, Y (reprint author), Aichi Med Univ, Dept Anesthesiol, 21 Yazako Nagakute, Nagakute, Aichi 4801195, Japan.	yyoshiff@aichi-med-u.ac.jp	Nishiwaki, Kimitoshi/I-7238-2014				AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045; PINCUS SM, 1994, AM J PHYSIOL, V266, pH1643, DOI 10.1152/ajpheart.1994.266.4.H1643; SAITO K, 1994, RECENT ADV TIME SERI, P11; Sawada Y, 1997, MED BIOL ENG COMPUT, V35, P318, DOI 10.1007/BF02534083	4	8	12	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	APR	2006	50	4					509	511		10.1111/j.1399-6576.2006.00989.x			3	Anesthesiology	Anesthesiology	022QE	WOS:000236069900016	16548866				2020-06-30	J	Knuttgen, D; Wolf, M; Trojan, S; Wappler, F				Knuttgen, D; Wolf, M; Trojan, S; Wappler, F			Respiratory sinus arrhythmia as predictor of blood pressure stability during anaesthetic induction in diabetics	ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE			German	Article						diabetes mellitus; respiratory sinus arrhythmia; heart rate variation; general anaesthesia; hypotension	CARDIOVASCULAR AUTONOMIC FUNCTION; HEART-RATE VARIATION; ORTHOSTATIC HYPOTENSION; NEUROPATHY; MELLITUS; DYSFUNCTION; RESPONSES; DISEASE; TESTS	Objective: Diabetics with cardiovascular autonomous neuropathy (CAN) can show severe hypotension during the course of anaesthesia. To improve the safety of anaesthesia, pre-operative evaluation of this concomitant disorder is recommended. The conventional test battery described by Ewing and Clarke to diagnose CAN is relatively time-consuming and complex. The aim of this study was to evaluate whether patients at risk could be reliably identified with less diagnostic effort. Methods: Fifty patients with diabetes mellitus undergoing an ophthalmosurgical procedure were investigated. To evaluate their cardiovascular reflex status, the following tests were performed one day before surgery: determination of heart rate variation (HRV) under deep respiration (6 breaths/min), and the response of heart rate (max/ min 30:15 ratio) and blood pressure after getting up from a supine position. Anaesthesia was induced with thiopental and fentanyl and maintained with enflurane/N2O; vecuronium was administered for tracheal intubation. Patients whose systolic blood pressure fell below 90 mmHg during the induction phase were assigned to Group H (hypotensive), the remaining patients to Group N (non-hypotensive). The groups were compared regarding the pre-operatively collected variables. Results: The demographic data were comparable in the two groups with exception of the length of diabetes. Regarding blood pressure reaction during orthostatic load, there was no significant difference between the groups. In contrast, the parameters of HRV under deep respiration (with exception of the "mean circular resultant") and the max/min 30:15 ratio were significantly lower in patients of Group H than in Group N. The best differentiation between the groups offered the E/I ratio (= quotient resulting from the longest R-R interval during expiration (E) and the shortest R-R interval during inspiration (1) under deep breathing) as a measure of respiratory sinus arrhythmia. The incidence of hypotension during anaesthetic induction in patients with a normal E/I ratio was 8.7 %, but in patients with a pathologically reduced E/I ratio 51.9 % (p=0.0019). The sensitivity of this test concerning hypotension that occurred was 87.5 %, the specificity 61.7 %. Conclusion: The available results prove the close connection between the preoperatively measured breadth of respiratory sinus arrhythmia and blood pressure response during anaesthetic induction. Patients at risk of hypotension can be identified reliably and quickly during pre-operative screening with the help of a single, simple test procedure.	Univ Witten Herdecke, Lehrstuhl Anasthesiol 2, Klin Anasthesiol & Operat Intensivmed, Kliniken Stadt Koln gGmbH,Krankenhaus Merheim, D-51109 Cologne, Germany	Knuttgen, D (reprint author), Univ Witten Herdecke, Lehrstuhl Anasthesiol 2, Klin Anasthesiol & Operat Intensivmed, Kliniken Stadt Koln gGmbH,Krankenhaus Merheim, Ostmerheimerstr 200, D-51109 Cologne, Germany.	knuettgend@kliniken-koeln.de					Birand, 1998, Int J Angiol, V7, P244, DOI 10.1007/s005479900105; BURGOS LG, 1989, ANESTHESIOLOGY, V70, P591, DOI 10.1097/00000542-198904000-00006; Claus D, 1994, Clin Auton Res, V4, P117, DOI 10.1007/BF01845775; Dutsch M, 2001, FORTSCHR NEUROL PSYC, V69, P423, DOI 10.1055/s-2001-16907; EMMETT RS, 2002, COCHRANE DB SYST REV, V3, P2251; EWING DJ, 1982, BRIT MED J, V285, P916, DOI 10.1136/bmj.285.6346.916; HILSTED J, 1981, J CLIN INVEST, V68, P1427, DOI 10.1172/JCI110394; Howorka K, 1998, J AUTONOM NERV SYST, V69, P164, DOI 10.1016/S0165-1838(98)00015-0; JORGENSEN BG, 1995, ACTA ANAESTH SCAND, V39, P560, DOI 10.1111/j.1399-6576.1995.tb04120.x; KAHN JK, 1986, DIABETES CARE, V9, P89; Keyl C, 1999, ANESTH ANALG, V88, P985, DOI 10.1097/00000539-199905000-00004; Knuttgen D, 2005, ANAESTHESIST, V54, P442, DOI 10.1007/s00101-005-0837-y; KNUTTGEN D, 1990, KLIN WOCHENSCHR, V68, P1168, DOI 10.1007/BF01815272; KUNTTGEN D, 1990, ANASTH INTENSIVTHER, V25, P256; LATSON TW, 1994, ANESTHESIOLOGY, V80, P326, DOI 10.1097/00000542-199402000-00013; Ley SC, 2005, ANASTH INTENSIV NOTF, V40, P230, DOI 10.1055/s-2004-826125; LINSTEDT U, 1993, ANAESTHESIST, V42, P521; MORIARTY KT, 1991, J NEUROL NEUROSUR PS, V54, P938, DOI 10.1136/jnnp.54.10.938-a; PIRART J, 1978, DIABETES CARE, V1, P168, DOI DOI 10.2337/DIACARE.1.3.1; Ralley Fiona E., 1996, Canadian Journal of Anaesthesia, V43, pR14; Schatz IJ, 1996, NEUROLOGY, V46, P1470, DOI 10.1212/wnl.46.5.1470; Scherpereel PA, 2001, EUR J ANAESTH, V18, P277, DOI 10.1046/j.0265-0215.2001.00876.x; SCHNELL O, 1995, DIABETOLOGIA, V38, P1345; THOMAS AN, 1989, CAN J ANAESTH, V36, P590, DOI 10.1007/BF03005391; TRIANTAFILLOU AN, 1986, ANESTH ANALG, V65, P1237; VOHRA A, 1993, BRIT J ANAESTH, V71, P258, DOI 10.1093/bja/71.2.258; ZIEGLER D, 1992, DIABETIC MED, V9, P166, DOI 10.1111/j.1464-5491.1992.tb01754.x; ZOLA B, 1986, J CLIN ENDOCR METAB, V63, P208, DOI 10.1210/jcem-63-1-208	28	1	1	0	2	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0939-2661			ANASTH INTENSIV NOTF	Anasthesiol. Intensivmed. NotfMed. Schmerzther.	APR	2006	41	4					233	240		10.1055/s-2006-925230			8	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	039UC	WOS:000237331800007	16636948				2020-06-30	J	Roussier, M; Mahul, P; Pascal, J; Baylot, D; Prades, JM; Auboyer, C; Molliex, S				Roussier, M; Mahul, P; Pascal, J; Baylot, D; Prades, JM; Auboyer, C; Molliex, S			Patient-controlled cervical epidural fentanyl compared with patient-controlled i.v. fentanyl for pain after pharyngolaryngeal surgery	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetic techniques, epidural; analgesia, patient-controlled; analgesia, postoperative; analgesics opioid, fentanyl; surgery, otolaryngological	INTRAVENOUS FENTANYL; POSTTHORACOTOMY PAIN; CONTROLLED ANALGESIA; CESAREAN-SECTION; ANESTHESIA; LUMBAR; THORACOTOMY; INFUSIONS; PULMONARY; EFFICACY	Background. Analgesia after pharyngolaryngeal surgery is commonly provided through the i.v. route. The aim of the study was to compare cervical epidural administration of fentanyl with the i.v. route for postoperative analgesia after pharyngolaryngeal surgery. Methods. In a randomized double-blind study 42 patients received fentanyl via patient-controlled analgesia (PCA) either through the i.v. route (PCA-IV group, n=22) or through the cervical epidural route (PCA-Epid group, n=20). Identical PCA settings were used in the two groups (bolus dose: 1.5 mu g kg(-1), bolus: 25 mu g, lockout interval: 10 min, maximum cumulative dose: 400 mu g per 4 h). Analgesia at rest and during swallowing was evaluated using a visual analogue scale. Results. Analgesia at rest was better in the PCA-Epid groupthan in the PCA-IV group but only 2 and 6 h after surgery (P < 0.02). There was no difference in analgesia during swallowing. Cumulative doses of fentanyl were similar {PCA-Epid group: 1412 mu g (912), PCA-IV group: 1287 mu g (1200) [median (IQR)]}. The Pa-o2 showed a significant decrease between the preoperative and postoperative period, but this decrease was identical in the two groups [PCA-IV-group: 11.47 (2.4) kPa vs 8.27 (0.9) kPa; PCA-Epid group: 11.33 (1.9) kPa vs 9.20 (2.4) kPa for preoperative and postoperative period respectively]. Conclusions. The study results show that cervical epidural analgesia provides marginally better pain relief at rest with no decrease in the fentanyl consumption. The use of the cervical epidural administration of fentanyl is questionable because of the possible complications of the technique.	Ctr Hosp St Etienne, Hop Bellevue, Dept Anesthesie Reanimat, F-42055 St Etienne 2, France; Ctr Hosp St Etienne, Hop Bellevue, Serv Otorhinolaryngol, F-42055 St Etienne, France; Univ St Etienne, F-42055 St Etienne 2, France	Roussier, M (reprint author), Ctr Hosp St Etienne, Hop Bellevue, Dept Anesthesie Reanimat, F-42055 St Etienne 2, France.	marc.roussier@chu-st-etienne.fr					BAXTER AD, 1994, CAN J ANAESTH, V41, P184, DOI 10.1007/BF03009829; BERNARDS CM, 1992, ANESTHESIOLOGY, V77, P750, DOI 10.1097/00000542-199210000-00020; Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; BONNET F, 1990, CAN J ANAESTH, V37, P353, DOI 10.1007/BF03005590; Capdevila X, 1998, ANESTH ANALG, V86, P1033, DOI 10.1097/00000539-199805000-00024; CHANEY MA, 1995, CAN J ANAESTH, V42, P891, DOI 10.1007/BF03011037; COOPER DW, 1995, BRIT J ANAESTH, V74, P184, DOI 10.1093/bja/74.2.184; ELLIS DJ, 1990, ANESTHESIOLOGY, V72, P981, DOI 10.1097/00000542-199006000-00006; Funayama T, 2003, CAN J ANAESTH, V50, P454, DOI 10.1007/BF03021056; GLASS PSA, 1992, ANESTH ANALG, V74, P345; GRANT RP, 1992, CAN J ANAESTH, V39, P214, DOI 10.1007/BF03008779; GUINARD JP, 1992, ANESTHESIOLOGY, V77, P1108, DOI 10.1097/00000542-199212000-00011; HARRISON DM, 1988, ANESTHESIOLOGY, V68, P454, DOI 10.1097/00000542-198803000-00025; HARUKUNI I, 1995, ANESTH ANALG, V81, P1169, DOI 10.1097/00000539-199512000-00009; LOPER KA, 1990, ANESTH ANALG, V70, P72; MCELLISTREM RF, 1993, CAN J ANAESTH, V40, P165, DOI 10.1007/BF03011315; Mu LC, 2000, ANAT REC, V258, P406, DOI 10.1002/(SICI)1097-0185(20000401)258:4<406::AID-AR9>3.0.CO;2-5; SALOMAKI TE, 1991, ANESTHESIOLOGY, V75, P790, DOI 10.1097/00000542-199111000-00010; SALOMAKI TE, 1993, ANESTHESIOLOGY, V79, P672; SANDLER AN, 1992, ANESTHESIOLOGY, V77, P626, DOI 10.1097/00000542-199210000-00003; TAKASAKI M, 1980, BRIT J ANAESTH, V52, P1271, DOI 10.1093/bja/52.12.1271; WITTICH DJ, 1984, LARYNGOSCOPE, V94, P615	22	12	12	2	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	APR	2006	96	4					492	496		10.1093/bja/ael025			5	Anesthesiology	Anesthesiology	025FY	WOS:000236251900014	16476697	Bronze			2020-06-30	J	Eroglu, A				Eroglu, A			A comparison of patient-controlled subacromial and i.v. analgesia after open acromioplasty surgery	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesia, patient-controlled; analgesic techniques, i.v., subacromial; analgesics opioid, fentanyl; anaesthetics local, ropivacaine; surgery, acromioplasty	CONTROLLED INTERSCALENE ANALGESIA; BRACHIAL-PLEXUS ANESTHESIA; MAJOR SHOULDER SURGERY; INTRABURSAL OXYCODONE; BUPIVACAINE; ROPIVACAINE; INFUSION; FENTANYL; BLOCK	Background. The aim of this study was to compare three patient-controlled analgesia (PCA) techniques for pain relief after acromioplasty. These techniques included use of subacromial ropivacaine, subacromial fentanyl or i.v. fentanyl. Methods. Forty-eight patients scheduled for open acromioplasty surgery were prospectively randomized to receive ropivacaine 0.2% (Group R) or fentanyl 4 mu g ml(-1) (Group F) for subacromial analgesia, or fentanyl 4 mu g ml(-1) (Group C) for i.v. analgesia. All patients received background infusion at a rate of 5 ml h(-1) plus a PCA bolus dose of 3 ml with a lockout time of 20 min. In addition, rescue analgesia with tramadol 50-100 mg i.v. was available on demand. Pain relief was regularly assessed using a visual analogue scale (0-10 cm) and side-effects were noted. Results. The postoperative pain scores at 2, 4, 6 and 12 h after the start of PCA were higher in Group F compared with Group R and Group C (P < 0.001), However, the pain scores at the other time points were similar between the three groups. Pain scores, incremental dose requested and received, total volume of analgesic solution infused and rescue tramadol were similar between Group R and Group C. Specific side-effects were similar in the three groups. Conclusion. The PCA techniques using subacromial ropivacaine or fentanyl i.v. provided similar and adequate pain relief and minimal side-effects after open acromioplasty surgery. The PCA using subacromial fentanyl was not as effective as either subacromial ropivacaine or i.v. fentanyl.	Karadeniz Tech Univ, Dept Anaesthesiol, Fac Med, Trabzon, Turkey	Eroglu, A (reprint author), Karadeniz Tech Univ, Dept Anaesthesiol, Fac Med, Trabzon, Turkey.	aheroglu@hotmail.com	Eroglu, Ahmet/B-1414-2012	Eroglu, Ahmet/0000-0002-0396-1582			Axelsson K, 2003, ACTA ANAESTH SCAND, V47, P993, DOI 10.1034/j.1399-6576.2003.00146.x; Borgeat A, 2003, ANESTHESIOLOGY, V99, P436, DOI 10.1097/00000542-200308000-00026; Borgeat A, 1997, ANESTHESIOLOGY, V87, P1343, DOI 10.1097/00000542-199712000-00013; Borgeat A, 2001, ANESTH ANALG, V92, P218; Borgeat A, 1998, BRIT J ANAESTH, V81, P603, DOI 10.1093/bja/81.4.603; Boss AP, 2004, J SHOULDER ELB SURG, V13, P630, DOI 10.1016/j.jse.2004.04.005; Brown SL, 2004, ANESTHESIOLOGY, V100, P1305, DOI 10.1097/00000542-200405000-00036; Camu F, 1998, ANESTH ANALG, V87, P890, DOI 10.1097/00000539-199810000-00027; Casati A, 2003, ANESTH ANALG, V96, P253, DOI 10.1097/00000539-200301000-00051; DAWSONSAUNDERS B, 1994, BASIS CLIN BIOSTATIS, P119; Delaunay L, 2005, REGION ANESTH PAIN M, V30, P117, DOI 10.1016/j.rapm.2004.11.004; Ekatodramis G, 2003, ANESTHESIOLOGY, V98, P143, DOI 10.1097/00000542-200301000-00023; Eroglu A, 2004, REGION ANESTH PAIN M, V29, P539, DOI 10.1016/j.rapm.2004.07.224; Harvey GP, 2004, ARTHROSCOPY, V20, P451, DOI 10.1016/j.arthro.2004.03.004; JINYOUNG P, 2002, REG ANESTH PAIN MED, V27, P145; Laurila PA, 2002, ACTA ANAESTH SCAND, V46, P1031, DOI 10.1034/j.1399-6576.2002.460818.x; LAWRENCE AJ, 1992, EUR J CLIN PHARMACOL, V43, P351, DOI 10.1007/BF02220608; Mallon WJ, 2000, J SHOULDER ELB SURG, V9, P85; Muittari P, 1998, REGION ANESTH PAIN M, V23, P474, DOI 10.1016/S1098-7339(98)90030-X; Muittari PA, 1999, J CLIN ANESTH, V11, P11, DOI 10.1016/S0952-8180(98)00122-6; Prakash S, 2004, ANESTH ANALG, V99, P552, DOI 10.1213/01.ANE.0000125110.56886.90; Woodhouse A, 2000, REGION ANESTH PAIN M, V25, P259, DOI 10.1016/S1098-7339(00)90008-7	22	8	9	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	APR	2006	96	4					497	501		10.1093/bja/ael018			5	Anesthesiology	Anesthesiology	025FY	WOS:000236251900015	16464979	Bronze			2020-06-30	J	Villeneuve, V; Kaufman, I; Weeks, S; Deschamps, A				Villeneuve, V; Kaufman, I; Weeks, S; Deschamps, A			Anesthetic management of a labouring parturient with urticaria pigmentosa	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							SYSTEMIC MASTOCYTOSIS; INTRATHECAL TACHYPHYLAXIS; EPIDURAL ANALGESIA; CANCER-PATIENTS; PREGNANCY; FENTANYL; ALLERGY; PATIENT; PAIN	Purpose: To report the anesthetic management of labour pain and Cesarean section in a patient with urticaria pigmentosa at risk for systemic mastocytosis. Clinical: A 37-yr-old patient with a history of urticaria pigmentosa and an allergic reaction to a local anesthetic agent was seen in consultation at 36 weeks gestation. She previously tested negative for an allergy test to lidocaine. Recommendations to avoid systemic mastocytosis included: avoidance of histamine-releasing drugs, using lidocaine for labour epidural, and regional anesthesia in case of a Cesarean section. The patient presented at term in]about. Intravenous fentanyl was used for early labour, followed by a combined spinal-epidural. The spinal contained lidocaine and fentanyl, but because of pruritus, the epidural infusion contained lidocaine only. Most likely because of tachyphylaxis to lidocaine, an epidural bolus of lidocaine with epinephrine failed to provide adequate anesthesia for a Cesarean section. The block was supplemented with nitrous oxide by mask, with fentanyl postdelivery. Postoperative pain control was managed with an epidural infusion of lidocaine and fentanyl for three days. The patient was discharged without complications four days postsurgery. Conclusion: Proper allergy testing prior to pregnancy is important to help the management of labour pain and anesthesia for Cesarean section in a patient at risk for systemic mastocytosis.	Royal Victoria Hosp, Montreal, PQ H3T 1A1, Canada; Univ Sherbrooke, CUSE, Sherbrooke, PQ J1K 2R1, Canada; McGill Univ, Ctr Hlth, Montreal, PQ H3A 2T5, Canada	Deschamps, A (reprint author), Royal Victoria Hosp, 687 Pine Ave W,Room S5-05, Montreal, PQ H3T 1A1, Canada.	alain.deschamps@staff.mcgill.ca					Arias M, 2004, SPINE, V29, pE161, DOI 10.1097/00007632-200404150-00025; Balestrieri PJ, 2003, ANESTH ANALG, V96, P1489, DOI 10.1213/01.ANE.0000058843.24914.C7; BERNSTEIN I, 1995, J ALLERGY CLIN IMMUN, V96, P707; Browne IM, 2001, AM J OBSTET GYNECOL, V185, P1253, DOI 10.1067/mob.2001.115115; CHOI RH, 1997, LIFE SCI, V61, P177; COLLADA JCG, 2000, [No title captured], V47, P326; COLLIS RE, 1995, LANCET, V345, P1413, DOI 10.1016/S0140-6736(95)92602-X; DeBalli P, 2003, CNS DRUGS, V17, P889, DOI 10.2165/00023210-200317120-00003; DESBOROUGH JP, 1990, BRIT J ANAESTH, V65, P833, DOI 10.1093/bja/65.6.833; Greenblatt E P, 1990, J Clin Anesth, V2, P108, DOI 10.1016/0952-8180(90)90063-9; Hepner DL, 2003, ANESTH ANALG, V97, P1853, DOI 10.1213/01.ANE.0000077681.55641.69; Herman NL, 1999, ANESTH ANALG, V89, P378, DOI 10.1097/00000539-199908000-00024; HORAN RF, 1991, J INVEST DERMATOL, V96, pS5, DOI 10.1111/1523-1747.ep12468899; HOSKING MP, 1987, ANESTH ANALG, V66, P344; JAMES PD, 1987, CAN J ANAESTH, V34, P522, DOI 10.1007/BF03014363; Kan RE, 1998, ANESTHESIOLOGY, V88, P1467, DOI 10.1097/00000542-199806000-00008; LONGLEY J, 1995, J AM ACAD DERMATOL, V32, P545, DOI 10.1016/0190-9622(95)90336-4; Mercadante S, 2003, ANESTH ANALG, V97, P187, DOI 10.1213/01.ANE.0000067403.15926.BD; METCALFE DD, 1991, [No title captured], V96, P55; MILASZKIEWICZ R, 1992, ANAESTHESIA, V47, P1042, DOI 10.1111/j.1365-2044.1992.tb04198.x; Palmer CM, 1998, ANESTHESIOLOGY, V88, P355, DOI 10.1097/00000542-199802000-00014; Tirel O, 2001, ANN FR ANESTH, V20, P874, DOI 10.1016/S0750-7658(01)00536-6; Vaughan STA, 1998, ANAESTHESIA, V53, P804, DOI 10.1046/j.1365-2044.1998.00536.x; Worobec AS, 2000, OBSTET GYNECOL, V95, P391, DOI 10.1016/S0029-7844(99)00591-8; Yang CP, 2004, ANESTH ANALG, V98, P557, DOI 10.1213/01.ANE.0000077713.21575.07	25	19	19	0	1	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	APR	2006	53	4					380	384		10.1007/BF03022503			5	Anesthesiology	Anesthesiology	029XA	WOS:000236596500010	16575037	Bronze			2020-06-30	J	Slappendel, R; Simpson, K; Dubois, D; Keininger, DL				Slappendel, R; Simpson, K; Dubois, D; Keininger, DL			Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain	EUROPEAN JOURNAL OF PAIN			English	Article						PAC-SYM; opioid; constipation; pain; assessment	RELEASE ORAL MORPHINE; TRANSDERMAL FENTANYL; MANAGEMENT; CANCER	Background: The Patient Assessment of Constipation symptoms (PAC-SYM) questionnaire is a 12-item self-report instrument divided into abdominal, rectal and stool domains. Aims: This study aimed to (1) evaluate the psychometric properties of PAC-SYM in assessing the symptoms and severity of opioid-induced constipation; (2) test for differences in opioid-induced constipation between Durogesic (R) fentanyl transdermal reservoir (TDF) and oral sustained-release morphine (SRM) in patients with chronic low back pain (CLBP). Methods: In a 13-month, open-label, parallel-group Study, 680 patients were randomised to receive either TDF (n = 338) or SRM (n = 342) for CLBP. Assessments were recorded at Visit I (baseline), Visit 5 (Day 29) and Visit 17 (Month 13). Concurrent validity, clinical validity and responsiveness of PAC-SYM were determined based on patients confirmation of constipation (CC) scores. Differences in PAC-SYM scores between treatment groups were also evaluated. Results: The study included 677 patients, of whom 638 were opioid-naive. Mean PAC-SYM scores for constipated patients were Substantially higher than for non-constipated patients, demonstrating good clinical validity for PAC-SYM. The PAC-SYM Could detect changes in bowel function over the treatment period, indicating responsiveness. Homogeneity of each symptom domain exceeded Cronbach's alpha coefficient of 0.70, suggesting good internal consistency and reliability. Changes in mean PAC-SYM scores from baseline to Visit 5 and Visit 17 were significantly lower for the TDF group than for the SRM group, indicating that the TDF group experienced less severe constipation. Conclusion: PAC-SYM is a reliable, valid and responsive measure of the presence and severity of opioid-induced constipation symptoms. (c) 2005 European Federation of Chapters of the international Association for the Study of Pain. Published by Elsevier Ltd. All rights reserved.	Sint Maartensklin, Dept Anesthesiol, NL-6500 GM Nijmegen, Netherlands; St James Hosp, Leeds, W Yorkshire, England; Johnson & Johnson Pharmaceut Serv, Beerse, Belgium; MAPI Values, Boston, MA USA	Slappendel, R (reprint author), Sint Maartensklin, Dept Anesthesiol, POB 9011, NL-6500 GM Nijmegen, Netherlands.	r.slappendel@maatensklini.nl					Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Balint G, 2002, CLIN RHEUMATOL, V21, pS17, DOI 10.1007/s100670200032; Beller EM, 2002, MED J AUSTRALIA, V177, P565, DOI 10.5694/j.1326-5377.2002.tb04955.x; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Frank L, 1999, SCAND J GASTROENTERO, V34, P870, DOI 10.1080/003655299750025327; Frank L, 2001, GERONTOLOGIST, V41, P778, DOI 10.1093/geront/41.6.778; Gammaitoni AR, 2003, PAIN MED, V4, P21, DOI 10.1046/j.1526-4637.2003.03002.x; GLARE P, 1992, J PAIN SYMPTOM MANAG, V7, P369, DOI 10.1016/0885-3924(92)90092-V; Herndon CM, 2002, PHARMACOTHERAPY, V22, P240, DOI 10.1592/phco.22.3.240.33552; Jovey Roman D, 2003, Pain Res Manag, V8 Suppl A, p3A; Kalso E, 2003, EUR J PAIN, V7, P381, DOI 10.1016/S1090-3801(02)00143-X; Kurz A, 2003, DRUGS, V63, P649, DOI 10.2165/00003495-200363070-00003; LIKERT R, 1932, ARCH PSYCHOL, V55; Linton SJ, 1998, PAIN, V75, P163; MCMILLAN SC, 1989, CANCER NURS, V12, P183, DOI 10.1097/00002820-198906000-00012; Nicholson B, 2003, DRUGS, V63, P17, DOI 10.2165/00003495-200363010-00002; Osterberg A, 1996, SCAND J GASTROENTERO, V31, P575, DOI 10.3109/00365529609009130; *PAIN SOC, 2004, [No title captured]; Passik SD, 2000, ADV THER, V17, P70, DOI 10.1007/BF02854840; PEDHAZUR EJ, 1991, MEASUREMENT DESIGN A, P653; Petticrew M, 1997, HEALTH TECHNOL ASSES, V1, P1; Portenoy R. K., 1994, Annals Academy of Medicine Singapore, V23, P160; Radbruch L, 2000, PALLIATIVE MED, V14, P111, DOI 10.1191/026921600671594561; Rashiq S, 2003, PAIN, V106, P119, DOI 10.1016/S0304-3959(03)00299-9; Ruoff GE, 2003, CLIN THER, V25, P1123, DOI 10.1016/S0149-2918(03)80071-1; Schug Stephan A, 2003, Best Pract Res Clin Anaesthesiol, V17, P91, DOI 10.1053/bean.2003.0267; Simpson RK, 1997, J PAIN SYMPTOM MANAG, V14, P218, DOI 10.1016/S0885-3924(97)00183-8; Talley Nicholas J, 2004, Rev Gastroenterol Disord, V4 Suppl 2, pS3; THOMPSON WG, 1992, [No title captured], V5, P75; Vallerand AH, 2003, NURS CLIN N AM, V38, P435, DOI 10.1016/S0029-6465(02)00094-4; ZENZ M, 1992, J PAIN SYMPTOM MANAG, V7, P69, DOI 10.1016/0885-3924(92)90116-Y; Zuurmond W W, 2002, Acta Anaesthesiol Belg, V53, P193	33	78	78	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801	1532-2149		EUR J PAIN	Eur. J. Pain	APR	2006	10	3					209	217		10.1016/j.ejpain.2005.03.008			9	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	024KL	WOS:000236193800005	15914049				2020-06-30	J	Goring-Morris, J; Russell, IF				Goring-Morris, J; Russell, IF			A randomised comparison of 0.5% bupivacaine with a lidocaine/epinephrine/fentanyl mixture for epidural top-up for emergency caesarean section after "low dose" epidural for labour	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						anaesthesia; obstetric; epidural; local anaesthetics; bupivacaine; lidocaine	ANALGESIA; ADRENALINE; ANESTHESIA; OBESITY; SPREAD	Background: When extending a fentanyl-containing, low-dose labour epidural for emergency caesarean section it has been shown that there is no difference in time to surgical readiness between plain bupivacaine 0.5% and mixtures of lidocaine/epinephrine or lidocaine/bupivacaine/epinephrine. However, it is not known whether adding fentanyl to the lidocaine/epinephrine mixture would increase speed of onset or improve the efficacy of the mixture when topping up for an emergency caesarean section. Methods: In a prospective, single blind study we compared plain 0.5% bupivacaine with a lidocaine/epinephrine/fentanyl mixture for extending previous low-dose epidural analgesia for emergency caesarean section in 68 patients. Results: There was a significantly longer median preparation time for the mixture than for the single drug (3.0 v 1.25 min: P < 0.0005). The median onset time for block of T7 to touch from the start of the top-up was 13.8 min for the mixture and 17.5 min for plain bupivacaine. This difference was not statistically significant and was offset by the longer preparation time. No general anaesthetics were required for poor blocks and the need for other intraoperative supplementation was not significantly different between the groups (bupivacaine 5/34, lidocaine mixture 2/26). Conclusions: The use of a lidocaine/epinephrine/fentanyl mixture conferred no clear statistically significant benefit over the use of plain 0.5% bupivacaine when used to extend fentanyl containing low-dose labour epidural analgesia for emergency caesarean section, but the lidocaine solution is cheaper and less toxic than the alternatives. (c) 2006 Elsevier Ltd. All rights reserved.	Hull Royal Infirm, Dept Anaesthesia, Kingston Upon Hull HU3 2JZ, N Humberside, England	Russell, IF (reprint author), Hull Royal Infirm, Dept Anaesthesia, Anlaby Rd, Kingston Upon Hull HU3 2JZ, N Humberside, England.	i.f.russell@hull.ac.uk					CURATOLO M, 1994, ACTA ANAESTH SCAND, V38, P625; HODGKINSON R, 1981, ANESTH ANALG, V60, P421; HODGKINSON R, 1980, ANESTH ANALG, V59, P89; HOWELL P, 1990, BRIT J ANAESTH, V65, P648, DOI 10.1093/bja/65.5.648; LAISHLEY RS, 1988, BRIT J ANAESTH, V60, P180, DOI 10.1093/bja/60.2.180; Lam DTC, 2001, ANAESTHESIA, V56, P790; Lucas DN, 2000, J ROY SOC MED, V93, P346, DOI 10.1177/014107680009300703; Lucas DN, 2000, BRIT J ANAESTH, V84, P494; Lucas DN, 1999, ANAESTHESIA, V54, P1173, DOI 10.1046/j.1365-2044.1999.01108.x; NORTON AC, 1988, ANAESTHESIA, V43, P844; Sanders RD, 2004, ANAESTHESIA, V59, P988, DOI 10.1111/j.1365-2044.2004.03753.x; Shibli KU, 2000, INT J OBSTET ANESTH, V9, P160, DOI 10.1054/ijoa.1999.0382; Thomas J., 2001, ROYAL COLL OBSTET GY; Tortosa JC, 2003, BRIT J ANAESTH, V91, P532, DOI 10.1093/bja/aeg214; 1989, REPORT HLTH SOCIAL S, P140; 2004, WHY MOTHERS DIE 2000, P122	16	15	17	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	APR	2006	15	2					109	114		10.1016/j.ijoa.2005.11.005			6	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	032PX	WOS:000236787900004	16488138				2020-06-30	J	Wilson, D; Pettifer, GR; Hosgood, G				Wilson, D; Pettifer, GR; Hosgood, G			Effect of transidermally administered fentanyl on minimum alveolar concentration of isoflurane in normothermic and hypothermic dogs	JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION			English	Article; Proceedings Paper	29th Annual Meeting of the American-College-of -Veterinary-Anesthesiologists/International-Veterinary-Academy-of-Pain-Management	OCT, 2004	Phoenix, AZ	Amer Coll Vet Anesthesiologists, Int Vet Acad Pain Management			TRANSDERMAL FENTANYL; SERUM CONCENTRATIONS; ANESTHETIC POTENCY; PHARMACOKINETICS; MORPHINE; TEMPERATURE; ANALGESIA; RABBITS; PATCHES; SWINE	Objective-To determine whether the minimum alveolar concentration (MAC) of isoflurane was altered by transdermal administration of fentanyl in normothermic and hypothermic dogs. Design-Randomized complete block crossover design. Animals-6 mature healthy dogs. Procedure-Dogs received each of 4 treatments in random order. Following induction of anesthesia, normothermia was maintained in dogs that were treated with a fentanyl patch (F-NORM) or sham patch (C-NORM), or hypothermia was maintained in dogs that were treated with a fentanyl patch (F-HYPO) or sham patch (C-HYPO). The appropriate patch was applied 24 hours prior to induction of anesthesia. Anesthesia was induced with isoflurane in oxygen; the dogs were intubated and mechanically ventilated. Target esophageal temperatures were maintained within 1 degrees C of baseline values (normothermia) or at 34.5 degrees C (94.1 degrees F, hypothermia) for 1 hour prior to starting MAC determinations. Supramaximal stimulation was achieved with an electrical stimulator attached to needle electrodes placed in the buccal mucosa of the lower jaw of the dog. Results-Mean MAC +/- SEM of isoflurane during C-NORM, C-HYPO, FLNORM, and F-HYPO treatments were 1.20 +/- 0.17, 0.89 +/- 0.18, 0.76 +/- 0.10, and 0.81 +/- 0,17, respectively. The mean MAC during C-NORM was significantly higher than values for the other treatments. There was no significant difference in mean MAC among the C-HYPC, F-NORM, and F-HYPO treatments. Conclusions and Clinical Relevance-Data suggest that transdermal administration of fentanyl significantly reduces isoflurane requirements in normothermic dogs. The isoflurane MAC-sparing effects of transdermal fentanyl are not apparent in hypothermic dogs.	MedVet Med Ctr Pets, Worthington, OH 43085 USA; Louisiana State Univ, Sch Vet Med, Dept Vet Clin Sci, Baton Rouge, LA 70803 USA	Wilson, D (reprint author), MedVet Med Ctr Pets, 300 E Wilson Bridge Rd, Worthington, OH 43085 USA.			Hosgood, Giselle/0000-0002-8851-8597			ANTOGNINI JF, 1993, ANESTHESIOLOGY, V78, P1152, DOI 10.1097/00000542-199306000-00020; Bailey P.L., 2000, ANESTHESIA, P273; BENTLEY JB, 1982, ANESTH ANALG, V61, P968; Carroll GL, 1999, AM J VET RES, V60, P986; EGER EI, 1965, ANESTHESIOLOGY, V26, P756, DOI 10.1097/00000542-196511000-00010; Egger CM, 1998, VET SURG, V27, P159, DOI 10.1111/j.1532-950X.1998.tb00114.x; Foley PL, 2001, COMPARATIVE MED, V51, P239; Franks JN, 2000, J AM VET MED ASSOC, V217, P1013, DOI 10.2460/javma.2000.217.1013; FUNG DL, 1980, J CLIN PHARMACOL, V20, P652, DOI 10.1002/j.1552-4604.1980.tb01682.x; GELMAN S, 1984, ANESTHESIOLOGY, V61, P726, DOI 10.1097/00000542-198412000-00017; Harvey-Clark CJ, 2000, LAB ANIM-UK, V34, P386, DOI 10.1258/002367700780387750; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Muir WW, 2003, AM J VET RES, V64, P1155, DOI 10.2460/ajvr.2003.64.1155; MURPHY MR, 1982, ANESTHESIOLOGY, V57, P485, DOI 10.1097/00000542-198212000-00009; Pettifer GR, 2004, VET ANAESTH ANALG, V31, P109, DOI 10.1111/j.1467-2987.2004.00158.x; Pettifer GR, 2003, AM J VET RES, V64, P1557, DOI 10.2460/ajvr.2003.64.1557; QUASHA AL, 1980, ANESTHESIOLOGY, V53, P315, DOI 10.1097/00000542-198010000-00008; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; SCHLEIMER R, 1998, CLIN PHARMACOL THER, V23, P188; SCHUTTLER J, 1984, ANESTHESIOLOGY, V61, P315, DOI 10.1097/00000542-198409000-00010; STEFFEY EP, 1994, J VET PHARMACOL THER, V17, P202, DOI 10.1111/j.1365-2885.1994.tb00234.x; STEWART J, 1995, CALCULUS EARLY TRANS, P459; Valverde A, 2003, AM J VET RES, V64, P957, DOI 10.2460/ajvr.2003.64.957; WILKINSON GR, 1975, DRUG METAB REV, V4, P139, DOI 10.3109/03602537508993754; YACKEY M, 2004, VET ANAESTH ANALG, V29, P1	25	16	16	0	4	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0003-1488			JAVMA-J AM VET MED A	JAVMA-J. Am. Vet. Med. Assoc.	APR 1	2006	228	7					1042	1046		10.2460/javma.228.7.1042			5	Veterinary Sciences	Veterinary Sciences	028VS	WOS:000236517500021	16579782				2020-06-30	J	Sekimoto, K; Nishikawa, K; Ishizeki, J; Kubo, K; Saito, S; Goto, F				Sekimoto, K; Nishikawa, K; Ishizeki, J; Kubo, K; Saito, S; Goto, F			The effects of volatile anesthetics on intraoperative monitoring of myogenic motor-evoked potentials to pranscranial electrical stimulation and on partial neuromuscular blockade during propofol/fentanyl/nitrous oxide anesthesia in humans	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						motor-evoked potentials; volatile anesthetics; neuromuscular blockade; muscle relaxant	TOTAL INTRAVENOUS ANESTHESIA; NITROUS-OXIDE; ISOFLURANE; SURGERY; RESPONSES; HALOTHANE; AMPLITUDE; PROPOFOL; CORTEX; SINGLE	The aim of the present study was to compare the influence of volatile anesthetics on transcranial motor-evoked potentials (tcMEP) in humans anesthetized with propofol/fentanyl/nitrous oxide and on partial neuromuscular blockade (NMB). The authors studied 35 ASA I and II patients who were undergoing elective craniotomy and brain tumor resection. The patients were randomized to one of three groups to receive halothane (HAL), isoflurane (ISO), or sevoflurane (SEV). Anesthetic depth was initially adjusted using the bispectral index to 40 +/- 5, and NMB was adjusted to 40%-50% of one twitch of train of four (T1) after recovery from intubation. MEPs with train of five square-wave pulses were elicited using screw electrodes placed in the skull over C3-C4. After craniotomy, the inhalational agent was introduced at 0.5 MAC and then 1.0 MAC (20 minutes each), and the effects on MEPs, NMB, and hemodynamic variables were studied. A decrease in BIS and systolic blood pressure was observed with all agents. Both SEV and ISO at 1.0 MAC significantly decreased train-of-four ratio from 38.4 +/- 18.1 at control to 19.0 +/- 9.7 and from 35.3 +/- 12.4 to 26.1 +/- 13.7, respectively (P<0.001), but not HAL at 1.0 MAC. The amplitudes of tcMEPs were significantly reduced by all agents at 1.0 MAC with the effect being less in HAL at 0.5 MAC. We have shown that HAL had a lesser suppressive effect on MEPs than either ISO or SEV at 0.5 MAC, which was partially due to a lesser degree of NMB.	Gunma Univ, Dept Anesthesiol, Grad Sch Med, Maebashi, Gumma 3718511, Japan	Nishikawa, K (reprint author), Gunma Univ, Dept Anesthesiol, Grad Sch Med, 3-39-22 Showa Machi, Maebashi, Gumma 3718511, Japan.	nishikaw@med.gunma-u.ac.jp		Nishikawa, Koichi/0000-0002-9256-334X			ADAMS DC, 1993, ANESTH ANALG, V77, P913; CALANCIE B, 1991, J NEUROSURG, V74, P897, DOI 10.3171/jns.1991.74.6.0897; Haghighi SS, 1996, J NEUROSURG ANESTH, V8, P47, DOI 10.1097/00008506-199601000-00011; HAGHIGHI SS, 1990, NEUROSURGERY, V26, P993, DOI 10.1227/00006123-199006000-00012; JELLINEK D, 1991, NEUROSURGERY, V29, P551, DOI 10.1227/00006123-199110000-00011; KALKMAN CJ, 1992, ANESTHESIOLOGY, V76, P502, DOI 10.1097/00000542-199204000-00003; KALKMAN CJ, 1995, ANESTHESIOLOGY, V83, P270, DOI 10.1097/00000542-199508000-00006; KALKMAN CJ, 1992, ANESTH ANALG, V75, P584; Kawaguchi M, 1998, J NEUROSURG ANESTH, V10, P131, DOI 10.1097/00008506-199807000-00001; LOUGHNAN BA, 1989, BRIT J ANAESTH, V63, P561, DOI 10.1093/bja/63.5.561; Scheufler KM, 2002, J NEUROSURG, V96, P571, DOI 10.3171/jns.2002.96.3.0571; Sihle-Wissel M, 2000, BRIT J ANAESTH, V85, P465, DOI 10.1093/bja/85.3.465; Sloan TB, 2002, J CLIN NEUROPHYSIOL, V19, P430, DOI 10.1097/00004691-200210000-00006; TANIGUCHI M, 1993, NEUROSURGERY, V33, P407; TANIGUCHI M, 1992, NEUROSURGERY, V31, P891, DOI 10.1227/00006123-199211000-00010; TANIGUCHI M, 1993, NEUROSURGERY, V32, P219, DOI 10.1227/00006123-199302000-00011; Ubags LH, 1998, NEUROSURGERY, V43, P90, DOI 10.1097/00006123-199807000-00058; van Dongen EP, 1999, ANESTH ANALG, V88, P22, DOI 10.1097/00000539-199901000-00005; Watanabe K, 2004, J NEUROSURG, V100, P155, DOI 10.3171/jns.2004.100.1.0155; ZENTNER J, 1992, NEUROSURGERY, V31, P298, DOI 10.1227/00006123-199208000-00015	20	32	35	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	APR	2006	18	2					106	111		10.1097/00008506-200604000-00003			6	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	035OB	WOS:000237009800003	16628063				2020-06-30	J	Cillo, JE; Finn, R				Cillo, JE; Finn, R			Correlation and comparison of body mass index on hemodynamics in hypertensive and normotensive patients undergoing intravenous sedation	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							MYOCARDIAL ISCHEMIA; PULSE PRESSURE; SLEEP-APNEA; OBESITY; DISEASE; PREVALENCE; OVERWEIGHT; RISK	Purpose: The purpose of this project was to retrospectively compare and correlate body mass index (BMI) and hemodynamics in hypertensive and normotensive patients undergoing intravenous sedation for dentoalveolar surgery. Patients and Methods: A retrospective chart analysis of 263 consecutive male patients undergoing intravenous (IV) sedation for dentoalveolar surgery was divided into 5 BMI groups: underweight, normal weight, overweight, obese, extremely obese. Data recorded were noninvasive baseline and intraoperative hemodynamic measurements at 5-minute intervals for systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), pulse pressure (PP), and pulse (P). Statistical analysis of mean values between groups was carried out using multivariate linear regression analysis, Pearson's correlation coefficient, and Student's t test and found significant for P <.05. Results: Average hemodynamic values for normotensive patients were significantly lower for all groups except for pulse in the normal group, pulse in the obese group, and DBP in the extremely obese group. For normotensive patients, there were statistically significant strong positive correlation for elevated BMI and increased baseline changes in SBP and PP. For the hypertensive group, there was a statistically significant moderate positive correlation for elevated BMI and increased baseline changes in PP and statistically significant strong positive correlation for baseline changes in MAP. Baseline changes were significant for greater increases in SBP and decreases in DBP and MAP in the underweight hypertensive group. Significant increases from baseline in the normotensive group were for PP in the normal BMI group and for pulse in the obese group. All baseline changes, with the exception of normotensive underweight SBP (+26.7%) and hypertensive PP (+23.9%), were within +/- 20% of baseline (range, -12.2% to +17.4%). Conclusion: In general, normotensive patients in this study had lower average hemodynamic values than hypertensive patients in all BMI groups. Great variability was seen in baseline changes for all BMI groups, but a substantial majority of changes were within 20% of baseline. There were statistically significant moderate and positive correlations in BMI for changes from baseline for several hemodynamic measurements. Intravenous sedation for oral and maxillofacial surgery procedures maintains a stable hemodynamic state in hypertensive and normotensive patients regardless of BMI. (c) 2006 American Association of Oral and Maxillofacial Surgeons J Oral Maxillofac Surg 64.583-588, 2006.	Univ Texas, SW Med Ctr, Dept OMFS, Parkland Mem Hosp, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Surg, Div Oral & Maxillofacial Surg, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75235 USA; Vet Adm N Texas Hlth Care Syst, Dallas, TX USA	Cillo, JE (reprint author), Univ Texas, SW Med Ctr, Dept OMFS, Parkland Mem Hosp, 2526 Harry Hines Blvd, Dallas, TX 75235 USA.	jecdna@aol.com					AGARWAL N, 1982, SURGERY, V92, P226; ALAUDDIN A, 1990, SURGERY, V108, P809; BEARD CM, 1992, INT J EPIDEMIOL, V21, P656, DOI 10.1093/ije/21.4.656; BIRO P, 1995, J CLIN ANESTH, V7, P417, DOI 10.1016/0952-8180(95)00036-H; CORIAT P, 1982, ACTA ANAESTH SCAND, V26, P287, DOI 10.1111/j.1399-6576.1982.tb01768.x; DIERDORF SF, 2002, ANESTHESIA COEXISTIN, P15; Dixon JB, 2003, CHEST, V123, P1134, DOI 10.1378/chest.123.4.1134; Dominguez-Cherit G, 1998, WORLD J SURG, V22, P969, DOI 10.1007/s002689900501; GROSSMAN E, 1991, AM J CARDIOL, V68, P57, DOI 10.1016/0002-9149(91)90710-3; Jung RT, 1997, BRIT MED BULL, V53, P307, DOI 10.1093/oxfordjournals.bmb.a011615; KANAZAWA T, 1990, J CARDIOVASC PHARM, V16, pS9; KANNEL WB, 1991, J CLIN EPIDEMIOL, V44, P183, DOI 10.1016/0895-4356(91)90265-B; KANNEL WB, 1990, J AM COLL CARDIOL, V15, P206, DOI 10.1016/0735-1097(90)90203-2; KASPER EK, 1992, AM J CARDIOL, V70, P921, DOI 10.1016/0002-9149(92)90739-L; Kempers KG, 2000, J ORAL MAXIL SURG, V58, P137, DOI 10.1016/S0278-2391(00)90326-4; KNIGHT AA, 1988, ANESTHESIOLOGY, V68, P681, DOI 10.1097/00000542-198805000-00005; KNOWLER WC, 1981, AM J EPIDEMIOL, V113, P144, DOI 10.1093/oxfordjournals.aje.a113079; Kuroki Hisanaga, 2003, Leg Med (Tokyo), V5 Suppl 1, pS307, DOI 10.1016/S1344-6223(02)00157-8; Laurent P, 2003, AM J HYPERTENS, V16, P363, DOI 10.1016/S0895-7061(03)00063-3; MORGAN GE, 1992, CLIN ANAESTHESIOL, P345; Morgan S, 1999, BRIT MED J, V318, P368, DOI 10.1136/bmj.318.7180.368; *NHANES, 2000, PREV OV OB AD 1999 2; Nishimura Y, 2003, ACTA OTO-LARYNGOL, V123, P22, DOI 10.1080/0365523031000052; Pascual M, 2003, HEART, V89, P1152, DOI 10.1136/heart.89.10.1152; Pelosi P, 1998, ANESTH ANALG, V87, P654, DOI 10.1097/00000539-199809000-00031; Polednak AP, 2003, CANCER DETECT PREV, V27, P415, DOI 10.1016/j.cdp.2003.09.002; ROY WL, 1979, ANESTHESIOLOGY, V51, P393, DOI 10.1097/00000542-197911000-00005; SAFAR ME, 1989, J HYPERTENS, V7, P769, DOI 10.1097/00004872-198910000-00001; Seidell JC, 1996, ARCH INTERN MED, V156, P958, DOI 10.1001/archinte.156.9.958; STOELTING RK, 1994, BASICS ANESTHESIA, P251; STUNKARD AJ, 1988, MED J AUSTRALIA, V148, pS21; VANITALLIE TB, 1985, ANN INTERN MED, V103, P983, DOI 10.7326/0003-4819-103-6-983	32	7	7	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	APR	2006	64	4					583	588		10.1016/j.joms.2005.12.009			6	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	031CT	WOS:000236682400004	16546636				2020-06-30	J	Kim, TH				Kim, Tae-Hoon			Safety and effectiveness of moderate sedation for radiologic non-vascular intervention	KOREAN JOURNAL OF RADIOLOGY			English	Article						anesthesia; abdomen, interventional procedures	CONSCIOUS SEDATION; PROCEDURAL SEDATION; MIDAZOLAM-FENTANYL; ANALGESIA; ANESTHESIA; DIAZEPAM; PAIN; ARTERIOGRAPHY; SATISFACTION; GUIDELINES	Objective: The purpose of this study was to prospectively characterize the safety and effectiveness of moderate sedation/analgesia for performing radiologic non-vascular abdominal intervention. Materials and Methods: During a 3-month period, a total of 63 adult patients with a mean age of 64 years (range: 27-82) underwent moderate sedation for 72 radiologic non-vascular interventional procedures. A combination of fentanyl citrate and midazolam hydrochloride, based on the patient's body weight, was intravenously administered until the patient was drowsy and tranquil. The adverse events associated with this moderate sedation were assessed. The visual analog scale format was used to measure the subjective feelings of the patient's pre-procedural anxiety and intraprocedural pain. Results: The mean total dose per kilogram of body weight of fentanyl used in PTBD was 1.148 mu g, it was 1.157 mu g for PTGBD, 1 mu g for AD, 1 mu g for PCN, 1.641 mu g for TDC, 1 mu g for DJS, 2 mu g for BS, 1 mu g for GS and 2 mu g for RFA. The mean total dose per kilogram of body weight of midazolam was 0.035 mg in PTBD, PTGBD, AD, PCN, DJS, GS and RFA, 0.039 mg in TDC, and 0.043 mg in BS. A temporary reduction of systolic blood pressure to less than 80 mmHg was observed during 5 procedures (6.9%), whereas a temporary elevation of systolic blood pressure above 150 mmHg was observed during 10 procedures (13.8%). A reduction of arterial oxygen saturation to less than 90% was observed during 14 procedures (19.4%). None of the patients required pharmacologic reversal agents or cardiopulmonary resuscitation. The mean anxiety score recorded before all procedures was 5.2 (distressing). The mean pain score during the procedure, which was recorded after all procedures, was 2.9 (mild). Conclusion: Moderate sedation allows performance of safe and effective radiologic non-vascular intervention, and it is also easy for an interventional radiologist to use. The patients should be continuously monitored to check their vital signs and arterial oxygen saturation during the procedures.	Dankook Univ Hosp, Dept Radiol, Cheonan 330715, Chungnam, South Korea	Kim, TH (reprint author), Dankook Univ Hosp, Dept Radiol, 16-5 Anseodong, Cheonan 330715, Chungnam, South Korea.	radiology@dankook.ac.kr					Arepally A, 2001, CARDIOVASC INTER RAD, V24, P185, DOI 10.1007/s002700002549; AYRESMITH G, 1987, RADIOLOGY, V164, P285, DOI 10.1148/radiology.164.1.3588922; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; BENSHLOMO I, 1990, BRIT J ANAESTH, V64, P45, DOI 10.1093/bja/64.1.45; Bluemke DA, 2000, RADIOLOGY, V216, P645, DOI 10.1148/radiology.216.3.r00se45645; Cote CJ, 2001, J PEDIATR-US, V139, P15, DOI 10.1067/mpd.2001.116049; CRAGG AH, 1991, AM J ROENTGENOL, V157, P173, DOI 10.2214/ajr.157.1.2048514; Green SM, 2002, ANN EMERG MED, V39, P433, DOI 10.1067/mem.2002.122770; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; HARSHFIELD DL, 1993, AM J ROENTGENOL, V161, P1057, DOI 10.2214/ajr.161.5.7903843; Innes G, 1999, J EMERG MED, V17, P145, DOI 10.1016/S0736-4679(98)00135-8; Kennedy PT, 2000, RADIOLOGY, V216, P660, DOI 10.1148/radiology.216.3.r00se04660; Krauss B, 2000, NEW ENGL J MED, V342, P938, DOI 10.1056/NEJM200003303421306; Lang EV, 1998, J VASC INTERV RADIOL, V9, P407, DOI 10.1016/S1051-0443(98)70291-X; LIND LJ, 1987, CARDIOVASC INTER RAD, V10, P247, DOI 10.1007/BF02578002; LUNDGREN S, 1983, J ORAL MAXIL SURG, V41, P99, DOI 10.1016/0278-2391(83)90215-X; Martin ML, 2003, J VASC INTERV RADIOL, V14, P1119, DOI 10.1097/01.RVI.0000086536.86489.82; MCDERMOTT VGM, 1993, BRIT J RADIOL, V66, P667, DOI 10.1259/0007-1285-66-788-667; Michalodimitrakis M, 1999, AM J FOREN MED PATH, V20, P93, DOI 10.1097/00000433-199903000-00022; MILLER DL, 1987, RADIOLOGY, V162, P195, DOI 10.1148/radiology.162.1.3786761; MONK TG, 1994, MINIM INVASIV THER, V3, P17; Mueller PR, 2000, RADIOLOGY, V215, P684, DOI 10.1148/radiology.215.3.r00jn33684; Murphy MF, 1996, ANN EMERG MED, V27, P461, DOI 10.1016/S0196-0644(96)70232-9; SACCHETTI A, 1994, ANN EMERG MED, V23, P237, DOI 10.1016/S0196-0644(94)70037-0; Skehan SJ, 2000, RADIOLOGY, V216, P653, DOI 10.1148/radiology.216.3.r00se09653; Wagner HJ, 1996, J VASC INTERV RADIOL, V7, P673, DOI 10.1016/S1051-0443(96)70827-8; WHITWAM JG, 1993, ANAESTHESIA, V48, P937; YASTER M, 1990, PEDIATRICS, V86, P463	28	5	6	0	2	KOREAN RADIOLOGICAL SOC	SEOUL	121-8 YANGJAE-DONG, SEOCHO-GU, SEOUL 137-130, SOUTH KOREA	1229-6929	2005-8330		KOREAN J RADIOL	Korean J. Radiol.	APR-JUN	2006	7	2					125	130		10.3348/kjr.2006.7.2.125			6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	055UO	WOS:000238476200007	16799273	Other Gold, Green Published			2020-06-30	J	Gupta, A; Kaur, R; Malhotra, R; Kale, S				Gupta, A; Kaur, R; Malhotra, R; Kale, S			Comparative evaluation of different doses of propofol preceded by fentanyl on intubating conditions and pressor response during tracheal intubation without muscle relaxants	PEDIATRIC ANESTHESIA			English	Article						tracheal intubation; propofol; fentanyl; intubating conditions; pressor response	PEDIATRIC-PATIENTS; ANESTHESIA; CHILDREN; ALFENTANIL; REMIFENTANIL; INDUCTION; SUXAMETHONIUM; COMBINATION	Background: The aim of our study was to determine the optimal dose of propofol preceded by fentanyl for successful tracheal intubation and to see its effectiveness in blunting pressor response in children aged 3-10 years. Methods: This prospective, double blind, randomized study was conducted on 60 ASA grade I and II children, between 3 and 10 years undergoing elective surgery who were divided into three groups of 20 each. The children received different doses of propofol (group I, 2.5 mg.kg(-1); group II, 3.0 mg.kg(-1); group III, 3.5 mg.kg(-1)) preceded by a fixed dose of fentanyl (3.0 mu g.kg(-1)) 3 min earlier. The tracheal intubating conditions were graded based on scoring system devised by Helbo-Hensen et al. with Steyn modification which includes five criteria; ease of laryngoscopy, degree of coughing, position of vocal cords, jaw relaxation, and limb movement and graded on a 4-point scale. Heart rate (HR), mean arterial pressure (MAP), and oxygen saturation changes were also noted. Results: Tracheal intubating conditions were acceptable in 25% of the patients in group I, while significantly higher (P < 0.001) in group II (80%) and in group III (90%). The pressor response was not effectively blunted in group I (17% increase in HR), while effectively blunted in groups II and III. A fall in cardiac output was seen in group III indicated by a decrease in MAP (16%) and HR (11%). No airway complications were noted. Conclusions: Propofol 3 mg.kg(-1) (group II) preceded by fentanyl 3 mu g.kg(-1) is the optimal dose combination in our study. It provides acceptable intubating conditions in 80% patients, blunts pressor response to intubation without significant cardiovascular depression.	Safdarjang Hosp, Dept Anaesthesia, Delhi, India; Maulana Azad Med Coll, Dept Anaesthesia, Delhi, India	Gupta, A (reprint author), B-229, Delhi 110034, India.	dr_akhi1@rediffmail.com					Abouleish A, 1999, ANESTH ANALG, V89, P1328, DOI 10.1097/00000539-199911000-00055; ALCOCK R, 1993, BRIT J ANAESTH, V70, P34, DOI 10.1093/bja/70.1.34; Blair JM, 2004, ANAESTHESIA, V59, P27, DOI 10.1111/j.1365-2044.2004.03524.x; BORGEAT A, 1992, ANESTH ANALG, V74, P539; Braga ADD, 2001, EUR J ANAESTH, V18, P384, DOI 10.1046/j.0265-0215.2001.00861.x; BRYSON HM, 1995, DRUGS, V50, P513, DOI 10.2165/00003495-199550030-00008; DEUTSCHMAN CS, 1994, ANESTH ANALG, V79, P373; Erhan E, 2003, EUR J ANAESTH, V20, P37, DOI 10.1097/00003643-200301000-00007; HELBOHANSEN S, 1988, ACTA ANAESTH SCAND, V32, P41; HOPKINS PM, 1995, BRIT J ANAESTH, V75, P675, DOI 10.1093/bja/75.6.675; Klemola UM, 2000, CAN J ANAESTH, V47, P854, DOI 10.1007/BF03019664; Robinson DN, 1998, PAEDIATR ANAESTH, V8, P467; RUNCIE CJ, 1993, BRIT J ANAESTH, V70, P192, DOI 10.1093/bja/70.2.192; SAARNIVAARA L, 1991, ACTA ANAESTH SCAND, V35, P19, DOI 10.1111/j.1399-6576.1991.tb03235.x; SCHELLER MS, 1992, ANESTH ANALG, V75, P788; SCHRUM SE, 1994, ANESTH ANALG, V78, P482; Simon L, 2002, PAEDIATR ANAESTH, V12, P36, DOI 10.1046/j.1460-9592.2002.00727.x; STEYN MP, 1994, BRIT J ANAESTH, V72, P403, DOI 10.1093/bja/72.4.403; Woods AW, 2005, BRIT J ANAESTH, V94, P150, DOI 10.1093/bja/aei006	19	30	32	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	APR	2006	16	4					399	405		10.1111/j.1460-9592.2005.01783.x			7	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	022AA	WOS:000236025800005	16618293				2020-06-30	J	Baumgarten, RK; Wesen, CA; Boccaccio, JE				Baumgarten, RK; Wesen, CA; Boccaccio, JE			Regional anesthesia has a role in hernia surgery	WORLD JOURNAL OF SURGERY			English	Letter							REPAIR		Farms Anesthesia & Pain Management, Grosse Pointe Farms, MI 48236 USA; St Johns Hosp, Dept Surg, Detroit, MI USA	Baumgarten, RK (reprint author), Farms Anesthesia & Pain Management, Grosse Pointe Farms, MI 48236 USA.	rkbaumgarten@comcast.net					Kehlet H, 2005, WORLD J SURG, V29, P1058, DOI 10.1007/s00268-005-7969-8; LeBlanc KA, 2005, J AM COLL SURGEONS, V200, P198, DOI 10.1016/j.jamcollsurg.2004.10.011; LIU S, 1995, ANESTH ANALG, V80, P730, DOI 10.1097/00000539-199504000-00014; Naja M. Z., 2001, Middle East Journal of Anesthesiology, V16, P201; Naja ZM, 2005, ANESTHESIOLOGY, V103, P600, DOI 10.1097/00000542-200509000-00024; PALA Y, 2005, REG ANESTH PAIN M S5, V30, P15; Santanen U, 2004, ACTA ANAESTH SCAND, V48, P474, DOI 10.1111/j.0001-5172.2004.00345.x; Weltz CR, 2003, WORLD J SURG, V27, P425, DOI 10.1007/s00268-002-6661-5	8	1	1	0	0	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0364-2313			WORLD J SURG	World J.Surg.	APR	2006	30	4					639	640		10.1007/s00268-005-0624-6			2	Surgery	Surgery	030FC	WOS:000236618600026	16547616				2020-06-30	J	Skaer, TL				Skaer, Tracy L.			Transdermal opioids for cancer pain	HEALTH AND QUALITY OF LIFE OUTCOMES			English	Review							DOUBLE-BLIND; THERAPEUTIC SYSTEM; ORAL MORPHINE; DOSE RATIO; FENTANYL; BUPRENORPHINE; MULTICENTER; EFFICACY; TOLERABILITY; DEPRESSION	Patients with moderate to severe malignancy-related pain frequently require the use of opioid pharmacotherapy. Unfortunately, many cancer patients continue to be prescribed subtherapeutic doses of pain medications resulting in undo suffering and diminished quality of life. The choice of analgesic pharmacotherapy should be individualized and based on the intensity and etiology of pain reported by the patient. Health care providers must be able to readily quantify the relative analgesic potency when converting from one opioid to another or from one route of administration to another. Transdermal fentanyl is effective and well tolerated pharmacotherapy for the cancer pain patients. However, clinicians need to be cognizant that the U.S./U.K. manufacturer's recommendations for equilalagesic dosing of transdermal fentanyl may result in initial doses that produce subtherapeutic levels and unrelieved pain in some patients. A more aggressive dosing algorithm for transdermal fentanyl using a 2: 1 (mg/day of oral morphine: mcg/hr of transdermal fentanyl) conversion ratio that considers both a review of the literature and clinical experience should help clinicians individualize cancer pain pharmacotherapy. Transdermal buprenorphine is now being prescribed in Europe and Australia for chronic and cancer pain management. Buprenorphine's mixed agonist/antagonist activity, dosage ceiling, and high affinity to the opiate receptor limits its use to those patients who do not already require large daily doses of opioids. Thus, buprenorphine may not be an appropriate medication for some patients with advanced unremitting cancer pain.	Washington State Univ, Coll Pharm, Pullman, WA 99164 USA	Skaer, TL (reprint author), Washington State Univ, Coll Pharm, Wegner Hall Room 105,POB 646510, Pullman, WA 99164 USA.	tskaer@wsu.edu					AHMEDZAI S, 1994, J DRUG DEV, V6, P93; Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; ARNER S, 1988, PAIN, V33, P11, DOI 10.1016/0304-3959(88)90198-4; Bohme K, 2003, PAIN CLINIC, V15, P193, DOI 10.1163/156856903321579334; Bohme K, 2002, CLIN RHEUMATOL, V21, pS13, DOI 10.1007/s100670200031; Breitbart W, 2000, ONCOLOGY-NY, V14, P695; Bucher JA, 1999, CANCER PRACT, V7, P71, DOI 10.1046/j.1523-5394.1999.07207.x; Budd K, 2003, INT J CLIN PRACT, P9; CHERNY NI, 1994, CA-CANCER J CLIN, V44, P262, DOI 10.3322/canjclin.44.5.263; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; Cleary J F, 1997, Semin Oncol, V24, pS16; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Evans HC, 2003, DRUGS, V63, P1999, DOI 10.2165/00003495-200363190-00003; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; GROND S, 1994, J PAIN SYMPTOM MANAG, V9, P372, DOI 10.1016/0885-3924(94)90174-0; HANKS GW, 1995, ANTI-CANCER DRUG, V6, P14, DOI 10.1097/00001813-199504003-00003; HIGGS CMB, 1995, J PAIN SYMPTOM MANAG, V10, P4, DOI 10.1016/0885-3924(94)00060-X; *JANSS PHARM, 2001, DUR FENT TRANSD SYST; Johnson RE, 2005, J PAIN SYMPTOM MANAG, V29, P297, DOI 10.1016/j.jpainsymman.2004.07.005; Kongsgaard UE, 1998, EUR J PAIN-LONDON, V2, P53, DOI 10.1016/S1090-3801(98)90046-5; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Lawlor P, 1997, PAIN, V72, P79, DOI 10.1016/S0304-3959(97)00018-3; Lawlor PG, 1998, CANCER, V82, P1167, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.3.CO;2-8; Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Muriel C, 2005, CLIN THER, V27, P451, DOI 10.1016/j.clinthera.2005.04.007; Mystakidou K, 2005, QUAL LIFE RES, V14, P1825, DOI 10.1007/s11136-005-4324-3; Mystakidou K, 2004, J PAIN, V5, P119, DOI 10.1016/j.jpain.2003.12.003; PAYNE R, 1995, ANTI-CANCER DRUG, V6, P50, DOI 10.1097/00001813-199504003-00009; Portenoy RK, 1996, J PAIN SYMPTOM MANAG, V11, P203, DOI 10.1016/0885-3924(95)00187-5; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; Radbruch L, 2003, INT J CLIN PRACT, P19; Radbruch L, 2003, INT J CLIN PRACT, P15; Radbruch Lukas, 2004, Keio J Med, V53, P23, DOI 10.2302/kjm.53.23; Reddick BK, 2005, J PSYCHOSOC ONCOL, V23, P137, DOI 10.1300/J077v23n02_09; SCHUG SA, 1991, DRUGS, V42, P228, DOI 10.2165/00003495-199142020-00005; Simmonds M A, 1997, Semin Oncol, V24, pS16; Sittl R, 2003, CLIN THER, V25, P150, DOI 10.1016/S0149-2918(03)90019-1; Sittl Reinhard, 2005, Expert Rev Neurother, V5, P315, DOI 10.1586/14737175.5.3.315; Sorge J, 2004, CLIN THER, V26, P1808, DOI 10.1016/j.clinthera.2004.11.008; SOUTHAM MA, 1995, ANTI-CANCER DRUG, V6, P29, DOI 10.1097/00001813-199504003-00005; Wong J O, 1997, Acta Anaesthesiol Sin, V35, P25; World Health Organization, 1996, CANC PAIN REL GUID O; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M; ZENZ M, 1994, J PAIN SYMPTOM MANAG, V9, P54, DOI 10.1016/0885-3924(94)90149-X; ZENZ M, 1992, J PAIN SYMPTOM MANAG, V7, P69, DOI 10.1016/0885-3924(92)90116-Y; ZHUKOVSKY DS, 1995, J PAIN SYMPTOM MANAG, V10, P113, DOI 10.1016/0885-3924(94)00072-S	48	19	22	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1477-7525		HEALTH QUAL LIFE OUT	Health Qual. Life Outcomes	MAR 31	2006	4								24	10.1186/1477-7525-4-24			9	Health Care Sciences & Services; Health Policy & Services	Health Care Sciences & Services	091LL	WOS:000241029300001	16573839	DOAJ Gold, Green Published			2020-06-30	J	Statler, KD; Alexander, H; Vayni, V; Holubkov, R; Dixon, CE; Clark, RSB; Jenkins, L; Kochanek, PM				Statler, KD; Alexander, H; Vayni, V; Holubkov, R; Dixon, CE; Clark, RSB; Jenkins, L; Kochanek, PM			Isoflurane exerts neuroprotective actions at or near the time of severe traumatic brain injury	BRAIN RESEARCH			English	Article						anaesthesia; traumatic brain injury; fentanyl; rat; narcotic; hippocampus; head injury; contusion; controlled cortical impact	CONTROLLED CORTICAL IMPACT; CEREBRAL-BLOOD-FLOW; ENDOGENOUS OPIOIDS; FENTANYL; ANESTHESIA; RATS; AUTOREGULATION; ISCHEMIA; DEFICITS; MICE	Isoflurane improves outcome vs. fentanyl anesthesia, in experimental traumatic brain injury (TBI). We assessed the temporal profile of isoflurane neuroprotection and tested whether isoflurane confers benefit at the time of TBI. Adult, male rats were randomized to isoflurane (1%) or fentanyl (10 mcg/kg iv bolus then 50 mcg/kg/h) for 30 min pre-TBI. Anesthesia was discontinued, rats recovered to tail pinch, and TBI was delivered by controlled cortical impact. Immediately post-TBI, rats were randomized to 1 h of isoflurane, fentanyl, or no additional anesthesia, creating 6 anesthetic groups (isoflurane:isoflurane, isoflurane:fentanyl, isoflurane: none, fentanyl:isoflurane, fentanyl:fentanyl, fentanyl:none). Beam balance, beam walking, and Morris water maze (MWM) performances were assessed over post-trauma d1-20. Contusion volume and hippocampal survival were assessed on d21. Rats receiving isoflurane pre- and post-TBI exhibited better beam walking and MWM performances than rats treated with fentanyl pre- and any treatment post-TBI. All rats pretreated with isoflurane had better CA3 neuronal survival than rats receiving fentanyl pre- and post-TBI. In rats pretreated with fentanyl, post-traumatic isoflurane failed to affect function but improved CA3 neuronal survival vs. rats given fentanyl pre- and post-TBI. Posttraumatic isoflurane did not alter histopathological outcomes in rats pretreated with isoflurane. Rats receiving fentanyl pre- and post-TBI had the worst CA1 neuronal survival of all groups. our data support isoflurane neuroprotection, even when used at the lowest feasible level before TBI (i.e., when discontinued with recovery to tail pinch immediately before injury). Investigators using isoflurane must consider its beneficial effects in the design and interpretation of experimental TBI research. (c) 2006 Elsevier B.V. All rights reserved.	Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT 84158 USA; Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA; Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA	Statler, KD (reprint author), Univ Utah, Sch Med, Dept Pediat, POB 581289, Salt Lake City, UT 84158 USA.	kim.statler@hsc.utah.edu; alexanderHL@anes.upmc.edu; vagnva@anes.upmc.edu; rholubkov@hrc.utah.edu; dixonec@upmc.edu; clarkrs@ccm.upmc.edu; ljenkins@pitt.edu; kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32-HD40686]; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318]		BICKLER PE, 1994, ANESTHESIOLOGY, V81, P1461, DOI 10.1097/00000542-199412000-00022; Bickler PE, 2003, ANESTH ANALG, V97, P564, DOI 10.1213/01.ANE.0000068880.82739.7B; Chapman SB, 2000, J COMMUN DISORD, V33, P333, DOI 10.1016/S0021-9924(00)00029-0; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Elsersy H, 2004, ANESTHESIOLOGY, V100, P1160, DOI 10.1097/00000542-200405000-00018; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; HAYES RL, 1990, J NEUROSURG, V72, P252, DOI 10.3171/jns.1990.72.2.0252; Hendrich KS, 2001, MAGNET RESON MED, V46, P202, DOI 10.1002/mrm.1178; HERNANDEZ MJ, 1978, STROKE, V9, P150, DOI 10.1161/01.STR.9.2.150; HOFFMAN WE, 1991, ANESTH ANALG, V73, P753; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Kawaguchi M, 2004, ANESTH ANALG, V98, P798; Kawaguchi M, 2000, ANESTHESIOLOGY, V92, P1335, DOI 10.1097/00000542-200005000-00023; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kofke WA, 1996, ANESTH ANALG, V83, P141, DOI 10.1097/00000539-199607000-00025; Kozlowski DA, 2004, J NEUROTRAUM, V21, P513, DOI 10.1089/089771504774129856; Lenz C, 1998, ANESTHESIOLOGY, V89, P1480, DOI 10.1097/00000542-199812000-00026; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; Miura Y, 1999, ANESTH ANALG, V88, P787, DOI 10.1097/00000539-199904000-00020; Nikolaishvili L S, 2004, Neurosci Behav Physiol, V34, P467, DOI 10.1023/B:NEAB.0000022631.46176.6b; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PATEL PM, 1993, J CEREB BLOOD FLOW M, pS685; SAFO Y, 1985, ACTA ANAESTH SCAND, V29, P594, DOI 10.1111/j.1399-6576.1985.tb02261.x; Soonthon-Brant V, 1999, ANESTH ANALG, V88, P49, DOI 10.1097/00000539-199901000-00010; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Statler KD, 2003, BRAIN RES, V994, P37, DOI 10.1016/j.brainres.2003.09.042; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; TEMPELHOFF R, 1992, J NEUROSURG, V77, P201, DOI 10.3171/jns.1992.77.2.0201; Varma MR, 2002, BRAIN RES, V951, P191, DOI 10.1016/S0006-8993(02)03161-X; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002	31	64	64	1	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 3	2006	1076						216	224		10.1016/j.brainres.2005.12.106			9	Neurosciences	Neurosciences & Neurology	031GL	WOS:000236692500025	16473332				2020-06-30	J	Arai, YCP; Ogata, J; Fukunaga, K; Shimazu, A; Fujioka, A; Uchida, T				Arai, YCP; Ogata, J; Fukunaga, K; Shimazu, A; Fujioka, A; Uchida, T			The effect of intrathecal fentanyl added to hyperbaric bupivacaine on maternal respiratory function during Cesarean section	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						Cesarean section; intrathecal fentanyl; respiratory physiology; subarachnoid blockade	SPINAL-ANESTHESIA; SUBARACHNOID BLOCK; BARICITY	Background: Subarachnoid blockade with local anesthetics induces respiratory depression. Although the addition of fentanyl to bupivacaine has become popular in subarachnoid blockade for Cesarean section, there is no information on the effect of intrathecal fentanyl on maternal spirometric respiratory function in parturients undergoing Cesarean section. Methods: We tested the effect of the addition of intrathecal fentanyl to hyperbaric bupivacaine on maternal spirometric performance in 40 consenting parturients undergoing Cesarean section. The parturients were randomized into two groups: those receiving 2.0 ml of hyperbaric bupivacaine 0.5% and 0.4 ml of saline intrathecally and those receiving 2.0 ml of hyperbaric bupivacaine and 0.4 ml of fentanyl (20 mu g) intrathecally. We performed spirometry on arriving at the operation room and 15 min after subarachnoid blockade. Results: Subarachnoid blockade with bupivacaine significantly decreased the peak expiratory flow rate, but did not induce significant changes in vital capacity and forced vital capacity. The addition of intrathecal fentanyl to bupivacaine improved the quality of subarachnoid blockade, but did not lead to a deterioration in respiratory function compared with intrathecal bupivacaine alone. Conclusions: The addition of intrathecal fentanyl to hyperbaric bupivacaine did not lead to a deterioration in maternal spirometric respiratory function in parturients undergoing Cesarean section.	Ehime Rosai Hosp, Dept Anesthesiol, Niihama, Ehime, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Anesthesiol, Fukuoka, Japan; Kochi Med Sch, Dept Anesthesiol, Kochi, Japan; Univ Texas, Med Branch, Off Biostat, Galveston, TX 77550 USA	Arai, YCP (reprint author), Aichi Med Univ, Ctr Multidisciplinary Pain, 21 Karimata, Nagakute, Aichi 4801195, Japan.	arainon@aichi-med-u.ac.jp					Burns SM, 2001, ANAESTHESIA, V56, P794; CHAMBERS WA, 1981, BRIT J ANAESTH, V53, P279, DOI 10.1093/bja/53.3.279; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; Conn D A, 1993, Int J Obstet Anesth, V2, P12, DOI 10.1016/0959-289X(93)90023-B; Cowan CM, 2002, BRIT J ANAESTH, V89, P452; GAMIL M, 1989, BRIT J ANAESTH, V62, P415, DOI 10.1093/bja/62.4.415; HARROPGRIFFITHS AW, 1991, ANAESTHESIA, V46, P11, DOI 10.1111/j.1365-2044.1991.tb09304.x; Kelly MC, 1996, ANAESTHESIA, V51, P1120, DOI 10.1111/j.1365-2044.1996.tb15046.x; Parlow JL, 1999, CAN J ANAESTH, V46, P66, DOI 10.1007/BF03012518; SANDERSON P, 1994, BRIT J ANAESTH, V73, P744, DOI 10.1093/bja/73.6.744; Shende D, 1998, ANAESTHESIA, V53, P706, DOI 10.1046/j.1365-2044.1998.329-az0482.x; Siddik-Sayyid SM, 2002, ANESTH ANALG, V95, P209, DOI 10.1097/00000539-200207000-00037; von Ungern-Sternberg BS, 2004, ANAESTHESIA, V59, P743, DOI 10.1111/j.1365-2044.2004.03832.x; von Ungern-Sternberg BS, 2004, ANAESTHESIA, V59, P350, DOI 10.1111/j.1365-2044.2004.03667.x	14	7	7	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAR	2006	50	3					364	367		10.1111/j.1399-6576.2006.00961.x			4	Anesthesiology	Anesthesiology	012PS	WOS:000235352000014	16480472				2020-06-30	J	Asai, T				Asai, T			Unexpected subglottic stenosis in an infant	ANAESTHESIA			English	Letter									Kansai Med Univ, Moriguchi, Osaka 5708507, Japan	Asai, T (reprint author), Kansai Med Univ, Moriguchi, Osaka 5708507, Japan.	asait@takii.kmu.ac.jp						0	1	1	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0003-2409			ANAESTHESIA	Anaesthesia	MAR	2006	61	3					302	303		10.1111/j.1365-2044.2006.04563.x			2	Anesthesiology	Anesthesiology	019BP	WOS:000235810900028	16480368				2020-06-30	J	Topcu, I; Ekici, NZ; Isik, R; Sakarya, M				Topcu, I; Ekici, NZ; Isik, R; Sakarya, M			The effects of tramadol and fentanyl on gastrointestinal motility in septic rats	ANESTHESIA AND ANALGESIA			English	Article							INTESTINAL INFLAMMATION; ANALGESIC TRAMADOL; MORPHINE; TRANSIT; OPIOIDS; SEPSIS; MU; ANTINOCICEPTION; COLONIZATION; INHIBITION	In this study, we investigated the effects of tramadol and fentanyl on gastrointestinal transit (GIT) during acute systemic inflammation in an experimental model of cecal ligation and perforation (CLP). One-hundred-twenty male Swiss-Albino rats were divided randomly into 6 groups: Group I = sham-operated + saline; Group II = sham-operated + fentanyl; Group III = sham-operated + tramadol; Group IV = CLP + saline; Group V = CLP + fentanyl; Group VI CLP + tramadol. Suspension of charcoal was administered as an intragastric meal to measure the GIT. GIT% (mean +/- SD) were 46.1% +/- 9.8%, 43.2% +/- 9.8%, 45.9% +/- 10.2%, 33.2% +/- 9.2%, 24.9% +/- 4.1%, and 31.8% +/- 8.4% in Groups I, II, III, IV, V, and VI, respectively. GIT% was significantly less in Group V than in Groups 1, 11, 111, and IV (P < 0.05). The Group VI mean value was significantly lower than those of Groups I, II, and III (P < 0.05) but not different from those of Groups W and V (P > 0.05). The antitransit effect of fentanyl was shown to have increased in the experimental sepsis model, but no decrease in GIT was obtained with tramadol. This was thought to be the result of an associated endogenic opioid system activation and receptor upregulation in sepsis.	Celal Bayar Univ, Dept Anesthesiol & Intens Care, Manisa, Turkey	Topcu, I (reprint author), Guzelyurt Mah Ingolstadt Cad,Anadolu Konutlari 11, TR-45030 Manisa, Turkey.	topcuismet@yahoo.com					Asai T, 1997, BRIT J ANAESTH, V78, P301; Crighton IM, 1998, ANESTH ANALG, V87, P445, DOI 10.1097/00000539-199808000-00040; Cullen JJ, 1999, J SURG RES, V81, P81, DOI 10.1006/jsre.1998.5452; DeLuca A, 1996, PHARMACOL THERAPEUT, V69, P103, DOI 10.1016/0163-7258(95)02053-5; DOOLEY CP, 1988, DIGEST DIS SCI, V33, P598, DOI 10.1007/BF01798363; DRIESSEN B, 1993, BRIT J PHARMACOL, V108, P806, DOI 10.1111/j.1476-5381.1993.tb12882.x; Fruhwald S, 2004, NEUROGASTROENT MOTIL, V16, P213, DOI 10.1111/j.1365-2982.2004.00509.x; HILLMAN KM, 1982, CRIT CARE MED, V10, P444, DOI 10.1097/00003246-198207000-00005; INGLIS TJJ, 1993, LANCET, V341, P911, DOI 10.1016/0140-6736(93)91208-4; JENNINGS G, 1995, CLIN NUTR, V14, P35, DOI 10.1016/S0261-5614(06)80008-7; KROMER W, 1989, LIFE SCI, V44, P579, DOI 10.1016/0024-3205(89)90190-2; Lydon AM, 1999, CAN J ANAESTH, V46, P544, DOI 10.1007/BF03013544; MANARA L, 1985, ANNU REV PHARMACOL, V25, P249, DOI 10.1146/annurev.pa.25.040185.001341; MARSHALL JC, 1993, ANN SURG, V218, P111, DOI 10.1097/00000658-199308000-00001; Marshall JC, 1998, SEPSIS, V2, P187; Murphy DB, 1997, ANESTHESIOLOGY, V87, P765, DOI 10.1097/00000542-199710000-00008; Murphy DB, 1997, ANAESTHESIA, V52, P1224, DOI 10.1111/j.1365-2044.1997.214-az0349.x; NIMMO WS, 1975, BRIT J CLIN PHARMACO, V2, P509, DOI 10.1111/j.1365-2125.1975.tb00568.x; Planas E, 2003, EUR J PHARMACOL, V482, P223, DOI 10.1016/j.ejphar.2003.09.048; Pol O, 1996, PHARMACOLOGY, V53, P180, DOI 10.1159/000139429; Pol O, 1996, PHARMACOLOGY, V53, P340, DOI 10.1159/000139449; POL O, 1994, J PHARMACOL EXP THER, V270, P386; RAFFA RB, 1992, J PHARMACOL EXP THER, V260, P275; SAKARYA M, 2001, [No title captured], V12, P61; SIMON R, 1987, ARCH SURG-CHICAGO, V122, P78; STEIN C, 1993, ANESTH ANALG, V76, P182; STEIN C, 1989, J PHARMACOL EXP THER, V248, P1269; Thorn SE, 1996, ACTA ANAESTH SCAND, V40, P177, DOI 10.1111/j.1399-6576.1996.tb04417.x; VICKERS MD, 1992, ANAESTHESIA, V47, P291, DOI 10.1111/j.1365-2044.1992.tb02166.x; VILLAR J, 1994, CRIT CARE MED, V22, P914; WICHTERMAN KA, 1980, J SURG RES, V29, P189, DOI 10.1016/0022-4804(80)90037-2; Wilder-Smith CH, 1999, ANESTHESIOLOGY, V91, P639, DOI 10.1097/00000542-199909000-00013; Wilder-Smith CH, 2001, PAIN, V91, P23, DOI 10.1016/S0304-3959(00)00414-0; WilderSmith CH, 1997, BRIT J CLIN PHARMACO, V43, P71, DOI 10.1111/j.1365-2125.1997.tb00035.x; Yuan CS, 1999, NEUROPHARMACOLOGY, V38, P425, DOI 10.1016/S0028-3908(98)00192-0	35	14	14	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAR	2006	102	3					876	881		10.1213/01.ane.0000196506.28780.94			6	Anesthesiology	Anesthesiology	015OK	WOS:000235560500033	16492844				2020-06-30	J	Bruijnzeel, AW; Lewis, B; Bajpai, LK; Morey, TE; Dennis, DM; Gold, M				Bruijnzeel, AW; Lewis, B; Bajpai, LK; Morey, TE; Dennis, DM; Gold, M			Severe deficit in brain reward function associated with fentanyl withdrawal in rats	BIOLOGICAL PSYCHIATRY			English	Article						fentanyl; dependence; mu-opioid receptor; naloxone; reward; withdrawal	EXTRACORPOREAL MEMBRANE-OXYGENATION; OPIATE WITHDRAWAL; NICOTINE WITHDRAWAL; OPIOID ANALGESICS; MEDICAL USE; DEPENDENCE; TOLERANCE; NALOXONE; TRENDS; ABUSE	During the last decade, there has been a strong increase in the use of the mu-opioid receptor agonist fentanyl. The aim of these studies was to investigate the effects of fentanyl withdrawal on brain reward function and somatic withdrawal signs. Fentanyl and saline were chronically administered via minipumps. An intracranial self-stimulation procedure was used to provide a measure of brain reward function. Somatic signs were recorded from a checklist of opioid abstinence signs. The opioid receptor antagonist naloxone induced a dose-dependent elevation in brain reward thresholds and somatic withdrawal signs in fentanyl-treated rats. Discontinuation of fentanyl administration resulted in a time-dependent elevation of brain reward thresholds and somatic withdrawal signs. These findings indicate that fentanyl withdrawal is associated with affective and somatic withdrawal signs. The severity of the deficit in brain reward function in this animal model suggests that affective fentanyl withdrawal symptoms may be a strong deterrent to abstinence.	Univ Florida, McKnight Brain Inst, Dept Psychiat, Coll Med, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Anesthesiol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Pharmacol & Expt Therapeut, Gainesville, FL 32610 USA	Bruijnzeel, AW (reprint author), Univ Florida, McKnight Brain Inst, Dept Psychiat, Coll Med, POB 100256, Gainesville, FL 32610 USA.	awbruijn@psychiatry.ufl.edu					ARNOLD JH, 1991, J PEDIATR-US, V119, P639, DOI 10.1016/S0022-3476(05)82419-9; ARNOLD JH, 1990, ANESTHESIOLOGY, V73, P1136, DOI 10.1097/00000542-199012000-00011; Barr AM, 2002, TRENDS PHARMACOL SCI, V23, P475, DOI 10.1016/S0165-6147(02)02086-2; BRUIJNEEL AW, IN PRESS BRAIN RES B; Bruijnzeel AW, 2004, NEUROPHARMACOLOGY, V47, P572, DOI 10.1016/j.neuropharm.2004.05.005; Cryan JF, 2003, BIOL PSYCHIAT, V54, P49, DOI 10.1016/S0006-3223(02)01730-4; Dominguez KD, 2003, ANN PHARMACOTHER, V37, P473, DOI 10.1345/aph.1C324; DWOSKIN LP, 1983, EUR J PHARMACOL, V90, P269, DOI 10.1016/0014-2999(83)90248-0; Epping-Jordan MP, 1998, NATURE, V393, P76; ERPELS F A, 1987, Acta Anaesthesiologica Belgica, V38, P231; Franck L S, 1998, Am J Crit Care, V7, P364; Franck Linda S, 2004, Intensive Crit Care Nurs, V20, P344, DOI 10.1016/j.iccn.2004.07.008; GELLERT VF, 1977, J PHARMACOL EXP THER, V201, P44; GELLERT VF, 1978, J PHARMACOL EXP THER, V205, P536; Gilson AM, 2004, J PAIN SYMPTOM MANAG, V28, P176, DOI 10.1016/j.jpainsymman.2004.01.003; Gourlay G K, 2001, Lancet Oncol, V2, P165, DOI 10.1016/S1470-2045(00)00258-8; HIGGINS GA, 1994, PHARMACOL BIOCHEM BE, V48, P1, DOI 10.1016/0091-3057(94)90489-8; Joranson DE, 2000, JAMA-J AM MED ASSOC, V283, P1710, DOI 10.1001/jama.283.13.1710; Koob GF, 1997, PHARMACOL BIOCHEM BE, V57, P513, DOI 10.1016/S0091-3057(96)00438-8; KORNETSKY C, 1979, FED PROC, V38, P2473; LEUSCHEN MP, 1993, J THORAC CARDIOV SUR, V105, P885; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Schulteis G, 2000, NATURE, V405, P1013; SCHULTEIS G, 1995, P NATL ACAD SCI USA, V92, P5880, DOI 10.1073/pnas.92.13.5880; SCHULTEIS G, 1994, J PHARMACOL EXP THER, V271, P1391; STINUS L, 1990, NEUROSCIENCE, V37, P767, DOI 10.1016/0306-4522(90)90106-E; Thornton SR, 1997, J PHARMACOL EXP THER, V281, P514	27	25	26	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0006-3223	1873-2402		BIOL PSYCHIAT	Biol. Psychiatry	MAR 1	2006	59	5					477	480		10.1016/j.biopsych.2005.07.020			4	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	019PY	WOS:000235850400014	16169528				2020-06-30	J	Ferguson, LM; Drummond, GB				Ferguson, LM; Drummond, GB			Acute effects of fentanyl on breathing pattern in anaesthetized subjects	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesics opioid; fentanyl; ventilation; anaesthetics; effects of respiration; ventilation; analgesics; effects of respiration; ventilation; pattern	RESPIRATORY RHYTHM; NEURONS; BRAIN; FREQUENCY; RECEPTORS; PROPOFOL; MORPHINE; MEDULLA; AGONIST	Background. The predominant effect of opioids on respiratory pattern during anaesthesia is an increase in the duration of expiration ( an effect on 'timing'), but there may also be changes in tidal volume ( an effect on 'drive'). Timing and drive are controlled by separate neuronal systems, but are infrequently considered individually. The effects of opioids on breathing are not well characterized clinically because changes in carbon dioxide and anaesthetic levels usually occur at the same time, and can obscure the effects of the opioid. Methods. To study these effects in isolation, we established stable mild hypercapnia in female patients breathing spontaneously during sevoflurane anaesthesia, and then gave fentanyl 0.5 mg kg(-1) i.v. End-tidal carbon dioxide and sevoflurane concentrations were maintained constant, and the changes in timing of inspiration, expiration and tidal volume were measured. Results. The duration of inspiration increased by 30%, and the duration of expiration increased by 95%. Tidal volume increased in proportion to inspiratory duration, and the pattern of flow during the breath was recognizably changed, with a reduction in the rate of increase of flow at the onset of inspiration. Conclusions. Small doses of opioid given when anaesthesia and carbon dioxide are stable affect respiratory timing predominantly, but in addition changes in the pattern of motor output can be detected.	Univ Edinburgh, Dept Anaesthesia Crit Care & Pain Med, Edinburgh EH16 4SA, Midlothian, Scotland	Drummond, GB (reprint author), Univ Edinburgh, Dept Anaesthesia Crit Care & Pain Med, 51 Little France Crescent, Edinburgh EH16 4SA, Midlothian, Scotland.	g.b.drummond@ed.ac.uk					CLARK FJ, 1972, J PHYSIOL-LONDON, V222, P267, DOI 10.1113/jphysiol.1972.sp009797; Dahan A, 1998, ANESTHESIOLOGY, V88, P903, DOI 10.1097/00000542-199804000-00009; DRUMMOND GB, 1983, BRIT J ANAESTH, V55, P825, DOI 10.1093/bja/55.9.825; GOODMAN NW, 1989, BRIT J ANAESTH, V63, P548, DOI 10.1093/bja/63.5.548; Gray PA, 1999, SCIENCE, V286, P1566, DOI 10.1126/science.286.5444.1566; GREER JJ, 1995, J PHYSIOL-LONDON, V485, P845, DOI 10.1113/jphysiol.1995.sp020774; Haji A, 2003, NEUROSCI LETT, V351, P37, DOI 10.1016/S0304-3940(03)00951-0; Haji A, 2003, NEUROPHARMACOLOGY, V45, P368, DOI 10.1016/S0028-3908(03)00154-0; Janczewski WA, 2002, J PHYSIOL-LONDON, V545, P1017, DOI 10.1113/jphysiol.2002.023408; Laferriere A, 1999, DEV BRAIN RES, V112, P1, DOI 10.1016/S0165-3806(98)00149-7; Lalley PM, 2003, AM J PHYSIOL-REG I, V285, pR1287, DOI 10.1152/ajpregu.00199.2003; Lonergan T, 2003, RESP PHYSIOL NEUROBI, V138, P165, DOI 10.1016/S1569-9048(03)00173-3; McCrimmon DR, 2003, AM J PHYSIOL-REG I, V285, pR1274, DOI 10.1152/ajpregu.00428.2003; Mellen NM, 2003, NEURON, V37, P821, DOI 10.1016/S0896-6273(03)00092-8; NEWSOMDAVIS J, 1975, J PHYSIOL-LONDON, V245, P481; O'Keeffe KM, 2005, RESP PHYSIOL NEUROBI, V146, P147, DOI 10.1016/j.resp.2004.12.003; Rafferty GF, 1996, J APPL PHYSIOL, V81, P1744; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; Smart JA, 2000, BRIT J ANAESTH, V84, P735; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; Strickland TL, 2001, BRIT J ANAESTH, V86, P639, DOI 10.1093/bja/86.5.639; Tanabe A, 2005, NEUROSCI LETT, V375, P19, DOI 10.1016/j.neulet.2004.10.058; Upton RN, 2004, BRIT J ANAESTH, V93, P687, DOI 10.1093/bja/aeh261; Waters CM, 1999, J PHARMACOL EXP THER, V288, P157; Wu MF, 2005, RESP PHYSIOL NEUROBI, V146, P33, DOI 10.1016/j.resp.2004.11.005	25	19	20	1	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	MAR	2006	96	3					384	390		10.1093/bja/ael011			7	Anesthesiology	Anesthesiology	013UE	WOS:000235434500016	16449234	Bronze			2020-06-30	J	Iida, H; Matsuura, S; Shirakami, G; Tanimoto, K; Fukuda, K				Iida, H; Matsuura, S; Shirakami, G; Tanimoto, K; Fukuda, K			Differential effects of intravenous anesthetics on ciliary motility in cultured rat tracheal epithelial cells	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							IN-VITRO; BEAT FREQUENCY; MUCOCILIARY CLEARANCE; TRANSPORT; PROPOFOL; MUCUS; ISOFLURANE; HALOTHANE; ENFLURANE; MORPHINE	Purpose: It has been shown that airway ciliary function is impaired by several anesthetic or sedative drugs, which may predispose anesthetized or intensive care patients to respiratory complications, such as hypoxemia, atelectasis and pulmonary infection. We studied the effects of midazolam, propofol, dexmedetomidine, ketamine, fentanyl, thiopental and pentobarbital on ciliary beat frequency (CBF) in isolated and cultured rat tracheal epithelial (RTE) cells, to investigate their direct CBF action removing influences of non-epithelial cells. Methods: Rat tracheal epithelial cells were purely isolated from tracheas of adult male Sprague-Dawley rats. After 14 to 21 days of culture, the images of motile cilia were videotaped using a phase-contrast microscope. Baseline CBF and CBF 30 or 50 min after administration of vehicle or one of the above agents were computer-analyzed. Results: Midazolam (0.3-10 mu M), propofol (1-100 mu M), dexmedetomidine (1-100 nM), fentanyl (0.1-10 nM) and thiopental (30-300 mu M) had no effect on CBE Ketamine at a supraclinical dose (1000 mu M) increased CBF (22 +/- 13, mean standard deviation, % increase from baseline; baseline = 100%) significantly (P < 0.01). Fentanyl at a high clinical dose (100 nM) increased CBF significantly (10 +/- 9%). Pentobarbital decreased CBF dose-dependently (100 mu M, -2 +/- 6%; 300 mu M, - 14 +/- 18%; 1000 mu M, -75 +/- 5%) and reversibly (P < 0.01). Conclusion: These results show that midazolam, propofol, dexmedetomidine and thiopental have no direct action on CBF in isolated RTE cells, whereas high doses of ketamine and fentanyl have direct ciliostimulatory actions and pentobarbital has a direct cilioinhibitory action.	Kyoto Univ Hosp, Dept Anesthesia, Kyoto 6068507, Japan	Shirakami, G (reprint author), Kyoto Univ Hosp, Dept Anesthesia, Kyoto 6068507, Japan.	gshi@kuhp.kyoto-u.ac.jp					Boek WM, 1999, ACTA OTO-LARYNGOL, V119, P93; Bullock R, 1995, TXT CRITICAL CARE, P1449; CURTIS LN, 1992, J PHARMACOL TOXICOL, V28, P1, DOI 10.1016/1056-8719(92)90058-9; DORMEHL IC, 1991, J MED PRIMATOL, V20, P235; Fakuda K., 2005, MILLERS ANESTHESIA, P379; Farber NE, 2005, MILLERS ANESTHESIA, P155; FORBES AR, 1977, ANESTHESIOLOGY, V46, P319, DOI 10.1097/00000542-197705000-00002; FORBES AR, 1979, ANESTH ANALG, V58, P387; Ham HCL, 1998, INTENS CARE MED, V24, P791, DOI 10.1007/s001340050667; HASANI A, 1992, THORAX, V47, P298, DOI 10.1136/thx.47.4.298; HENTHORN TK, 1994, PHARM BASIS ANESTHES, P307; Ingels K. J. A. O., 1992, Rhinology (Utrecht), V30, P149; IRAVANI J, 1975, RESPIRATION, V32, P157; Johnston M, 1997, ACTA OTO-LARYNGOL, V117, P856, DOI 10.3109/00016489709114214; KAARTINEN L, 1993, IN VITRO CELL DEV-AN, V29A, P481, DOI 10.1007/BF02639383; KARTTUNEN P, 1991, ARZNEIMITTEL-FORSCH, V41-2, P1095; KING M, 1979, J APPL PHYSIOL, V46, P504; Konrad F, 1998, ANASTH INTENSIV NOTF, V33, P171, DOI 10.1055/s-2007-994232; LANDA JF, 1975, J APPL PHYSIOL, V38, P946; Lee RMKW, 1997, LUNG SCI FDN, P459; MORIYAMA S, 1990, ACTA ANAESTH SCAND, V34, P523, DOI 10.1111/j.1399-6576.1990.tb03138.x; OHMOTO N, 1995, J PHYS SOC JPN, V64, P1104; OSTROWSKI LE, 1995, METHOD CELL BIOL, V47, P57, DOI 10.1016/S0091-679X(08)60791-8; PATRICK G, 1977, J APPL PHYSIOL, V42, P451; PHILLIPS PP, 1990, OTOLARYNG HEAD NECK, V103, P558, DOI 10.1177/019459989010300406; Raphael JH, 1996, BRIT J ANAESTH, V76, P116; Raphael JH, 1997, BRIT J ANAESTH, V79, P473, DOI 10.1093/bja/79.4.473; REVES JG, 2005, MILLERS ANESTHESIA, P317; Salathe Matthias, 2002, Journal of Allergy and Clinical Immunology, V110, pS275, DOI 10.1067/mai.2002.129412; Sato M, 2003, ANESTH ANALG, V97, P1353, DOI 10.1213/01.ANE.0000085662.20562.F5; Selwyn DA, 1996, BRIT J ANAESTH, V76, P274; Shirakami G, 2000, ANESTHESIOLOGY, V93, P482, DOI 10.1097/00000542-200008000-00028; Wang L, 2003, J APPL PHYSIOL, V94, P2375, DOI 10.1152/japplphysiol.00741.2002; Wanner A, 1996, AM J RESP CRIT CARE, V154, P1868, DOI 10.1164/ajrccm.154.6.8970383	34	14	16	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	MAR	2006	53	3					242	249		10.1007/BF03022209			8	Anesthesiology	Anesthesiology	017MF	WOS:000235697000005	16527787				2020-06-30	J	Angle, PJ; Hussain, K; Morgan, A; Halpern, SH; Van der Vyver, M; Yee, J				Angle, PJ; Hussain, K; Morgan, A; Halpern, SH; Van der Vyver, M; Yee, J			High quality labour analgesia using small gauge epidural, needles and catheters	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							POSTDURAL PUNCTURE HEADACHE; DURAL PUNCTURE; MANAGEMENT; DESIGN	Purpose: Inadvertent epidural needle punctures represent the leading cause of severe postdural puncture headache (PDPH) in parturients. Use of small gauge (G) epidural needles for continuous analgesia has received little attention despite possible important reductions in PDPH. We report the first study to examine the feasibility of using small G Tuohy needles and 23 G catheters for labour analgesia. Methods: Healthy parturients :5 6 cm dilated were recruited. Epidural analgesia was established using a 19 G Tuohy epidural needle, a 23 G single port 40 cm catheter and bupivacaine 0.08% with fentanyl 2 mu g.mL(-1) (15-20 mL). Breakthrough pain was treated by protocol. There was no formal in-training period for anesthesiologists. The primary outcome was the combined failure rate for initiation (failed needle/catheter placement or failed block <= 30 min of drug administration). Secondary outcomes included late block failure (> 30 min), recognized dural puncture, PDPH, patient assessment of analgesia within 24 hr of delivery, complications and anesthesiologist satisfaction. Results: Twenty-seven parturients were recruited. Successful blocks were initiated and maintained in 24/27 who rated overall analgesia from good to excellent (19/24 very good to excellent). Three block failures occurred at the initiation phase only (two unilateral, one absent). There was no evidence of catheter kinking after placement. One patient developed PDPH after unrecognized dural puncture which was self-treated with acetaminophen for four days, followed by complete symptom resolution. Conclusion: It is feasible to provide high quality labour analgesia using small G epidural needles and catheters. The effect of small G epidural needles on PDPH warrants future study.	Univ Toronto, Sunnybrook & Womens Coll Hosp, Dept Anesthesia, Toronto, ON, Canada; Univ Toronto, Sunnybrook & Womens Coll Hosp, Dept Res Design & Biostat, Toronto, ON, Canada	Angle, PJ (reprint author), Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Anesthesia, Womens Coll Campus,76 Grenville St, Toronto, ON M5S 1B2, Canada.	pamela.angle@sw.ca	Halpern, Stephen H/K-8304-2012				Aida S, 1998, ANESTHESIOLOGY, V88, P76, DOI 10.1097/00000542-199801000-00014; Angle P, 2005, CAN J ANAESTH, V52, P397, DOI 10.1007/BF03016283; Angle P, 1999, CAN J ANAESTH, V46, P861, DOI 10.1007/BF03012976; Angle PJ, 2003, ANESTHESIOLOGY, V99, P1376, DOI 10.1097/00000542-200312000-00021; ANGLE PJ, 2004, ANESTHESIOLOGY, V101, pA36; Fleiss J.L., 1981, STAT METHODS RATES P, P14; HALPERN S, 1994, ANESTHESIOLOGY, V81, P1376, DOI 10.1097/00000542-199412000-00012; Holst D, 1998, ANESTH ANALG, V87, P1331; Paech M, 2001, INT J OBSTET ANESTH, V10, P162, DOI 10.1054/ijoa.2000.0825; PURDIE NL, 2004, ANESTHESIOLOGY, V101, pA36; RASMUSSEN BS, 1989, ANAESTHESIA, V44, P571, DOI 10.1111/j.1365-2044.1989.tb11444.x; Safa-Tisseront V, 2001, ANESTHESIOLOGY, V95, P334, DOI 10.1097/00000542-200108000-00012; Sage FJ, 2000, PAEDIATR ANAESTH, V10, P279, DOI 10.1046/j.1460-9592.2000.00507.x; STRIDE PC, 1993, ANAESTHESIA, V48, P247, DOI 10.1111/j.1365-2044.1993.tb06913.x	14	5	6	0	1	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	MAR	2006	53	3					263	267		10.1007/BF03022213			5	Anesthesiology	Anesthesiology	017MF	WOS:000235697000009	16527791				2020-06-30	J	McBain, J; Lemire, EG; Campbell, DC				McBain, J; Lemire, EG; Campbell, DC			Epidural labour analgesia in a parturient with Noonan syndrome: a case report	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							HYPERTROPHIC SUBAORTIC STENOSIS; CESAREAN-SECTION; INTRATHECAL INJECTION; RESPIRATORY ARREST; ANESTHESIA; PATIENT; CARDIOMYOPATHY; BUPIVACAINE; SUFENTANIL	Purpose: Noonan syndrome is a relatively uncommon genetic disorder with implications for anesthesia due to multiple organ system involvement. Pregnancy presents additional concerns and there are only four reported cases of anesthesia for Cesarean delivery in parturients with Noonan syndrome. We describe the first reported management of labour analgesia in a parturient with Noonan syndrome culminating in vaginal delivery. Clinical features: A 21-yr-old parturient with Noonan syndrome received patient-controlled epidural analgesia for labour at 39 weeks gestation. Meticulous attention to the anesthetic technique resulted in good analgesia, and a successful outcome for mother and child. The different approaches to labour analgesia in parturients, with particular attention to combined spinal epidural vs epidural analgesia in this setting are discussed. Conclusion: Parturients; with Noonan syndrome can present with an array of anomalies that may present difficulties to the anesthesiologist including a difficult airway, cardiopulmonary abnormalities, exaggerated lumbar lordosis and short stature. Careful preoperative consultation and determination of the degree of associated anomalies will help to prepare the anesthesiologist for potential problems.	Univ Saskatchewan, Coll Med, Dept Anesthesia, Royal Univ Hosp, Saskatoon, SK S7N 0W8, Canada; Univ Saskatchewan, Coll Med, Dept Pediat, Royal Univ Hosp, Saskatoon, SK S7N 0W8, Canada	Campbell, DC (reprint author), Univ Saskatchewan, Coll Med, Dept Anesthesia, Royal Univ Hosp, 103 Hosp Dr, Saskatoon, SK S7N 0W8, Canada.	david.campbell@saskatoonhealthregion.ca					Autore C, 1999, ANESTHESIOLOGY, V90, P1205, DOI 10.1097/00000542-199904000-00036; Bertola Débora R., 2003, Rev. Hosp. Clin., V58, P5, DOI 10.1590/S0041-87812003000100002; CAMPBELL AM, 1992, ANAESTHESIA, V47, P131, DOI 10.1111/j.1365-2044.1992.tb02010.x; Campbell DC, 2000, ANESTH ANALG, V90, P1384, DOI 10.1097/00000539-200006000-00023; Campbell DC, 2000, SEMIN ANESTH, V19, P149; CAMPBELL DC, 1997, REGION ANESTH PAIN M, V1, P114; DADABHOY ZP, 1988, ANESTHESIOLOGY, V68, P636, DOI 10.1097/00000542-198804000-00031; Grange CS, 1998, CAN J ANAESTH, V45, P332, DOI 10.1007/BF03012024; Greenhalgh CA, 1996, ANAESTHESIA, V51, P173, DOI 10.1111/j.1365-2044.1996.tb07708.x; Halpern SH, 2004, ANESTH ANALG, V99, P1532, DOI 10.1213/01.ANE.0000136850.08972.07; Ho KM, 1997, ANESTHESIOLOGY, V87, P168, DOI 10.1097/00000542-199707000-00024; Ho WL, 2003, PEDIATR RADIOL, V33, P200, DOI 10.1007/s00247-002-0768-6; JAMIESON CR, 1994, NAT GENET, V8, P357, DOI 10.1038/ng1294-357; Katsiris S, 1998, CAN J ANAESTH, V45, P880, DOI 10.1007/BF03012223; Lee CK, 2001, J BONE JOINT SURG AM, V83A, P1495, DOI 10.2106/00004623-200110000-00006; LOUBSER P, 1984, ANESTHESIOLOGY, V60, P228, DOI 10.1097/00000542-198403000-00010; Magboul Magboul M. A., 2000, Middle East Journal of Anesthesiology, V15, P611; McLure HA, 1996, BRIT J ANAESTH, V77, P665; MINNICH ME, 1987, ANESTHESIOLOGY, V67, P590, DOI 10.1097/00000542-198710000-00029; Noonan JA, 2003, AM J MED GENET A, V123A, P68, DOI 10.1002/ajmg.a.20502; NOONAN JA, 1963, J PEDIATR-US, V63, P468; Pan PH, 2004, INT J OBSTET ANESTH, V13, P227, DOI 10.1016/j.ijoa.2004.04.008; SHARLAND M, 1992, ARCH DIS CHILD, V67, P178, DOI 10.1136/adc.67.2.178; Stewart KI, 2004, ANESTHESIOLOGY, V100, pB10; Tartaglia M, 2002, AM J HUM GENET, V70, P1555, DOI 10.1086/340847; Thaman R, 2003, HEART, V89, P752, DOI 10.1136/heart.89.7.752	26	2	3	0	2	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	MAR	2006	53	3					274	278		10.1007/BF03022215			5	Anesthesiology	Anesthesiology	017MF	WOS:000235697000011	16527793				2020-06-30	J	Schmid-Grendelmeier, P; Pokorny, R; Gasser, UE; Richarz, U				Schmid-Grendelmeier, P; Pokorny, R; Gasser, UE; Richarz, U			A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						buprenorphine; erythema; fentanyl; transdermal delivery system	RELEASE ORAL MORPHINE; CHRONIC NONCANCER PAIN; CANCER PAIN; DOUBLE-BLIND; OPEN-LABEL; MULTICENTER; EFFICACY; OSTEOARTHRITIS; TOLERABILITY; MODERATE	Objective: Establishing local tolerability of transdermal opioid systems is important as more systems become available for use in a range of indications. We compared the skin irritation potential of a single application of transdermal fentanyl (Durogesic* D-trans dagger; DDTDF) and transdermal buprenorphine (Transtec double dagger; TDB) patches in healthy volunteers. Methods: 46 healthy males and females (mean age [range]: 59.6 [50-69] years) with healthy skin received a single dose of both the DDTDF 25 mu g/h patch and the TDB 35 mu g/h patch in a randomised order under naltrexone cover. The incidence and severity of erythema was assessed at various timepoints after patch removal. Results: There was a non-significant trend towards a higher incidence of erythema 60 min after patch removal with TDB compared with DDTDF. The severity of erythema at 60 min and the incidence of erythema at 72 h after patch removal were significantly higher with TDB than with DDTDF (p = 0.01 and 22% versus 4.9%, p = 0.04, respectively). In general, the results from the chromametric assessment of treated skin were in agreement. The incidence of topical adverse events (AEs) was lower with DDTDF than with TDB (one versus six events) and subjects preferred the DDTDF patch and felt it was less noticeable on the skin. The DDTDF patch was considered less painful to remove, and, consistent with that, the TDB patch was judged to have better adhesion. Twenty-one subjects reported systemic AEs with DDTDF plus naltrexone and 22 with TDB plus naltrexone, most of which were considered treatment-related, 34 and 60 AEs, respectively. Conclusions: Local tolerability of transdermal opioid systems should be considered when making a therapeutic choice. Even after a single application in healthy volunteers, differences in local tolerability, assessed both clinically and by chromametry, and patch comfort were shown between DDTDF and TDB, in favour of DDTDF.	Janssen Cilag AG, CH-6341 Baar, Switzerland; Univ Zurich Hosp, CH-8091 Zurich, Switzerland; Swiss Pharma Contract, Allschwil, Switzerland; ClinRes GmbH, Aesch, Switzerland	Richarz, U (reprint author), Janssen Cilag AG, Sihlbruggstr 111, CH-6341 Baar, Switzerland.	URICHAR1@JACCH.JNJ.com					Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; Clarys P, 2000, SKIN RES TECHNOL, V6, P230, DOI 10.1034/j.1600-0846.2000.006004230.x; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Elliott JC, 2003, J INVEST DERMATOL, V121, P1053, DOI 10.1046/j.1523-1747.2003.12569.x; Le Loet X, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-31; Melgosa AMC, 2005, ALLERGY, V60, P1217, DOI 10.1111/j.1398-9995.2005.00883.x; Milligan K, 2001, J PAIN, V2, P197, DOI 10.1054/jpai.2001.25352; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Muriel C, 2005, CLIN THER, V27, P451, DOI 10.1016/j.clinthera.2005.04.007; Pavelka K, 2004, CURR MED RES OPIN, V20, P1967, DOI 10.1185/030079904X14120; Sathyan G, 2005, CURR MED RES OPIN, V21, P1961, DOI 10.1185/030079905X65259; Sittl R, 2003, CLIN THER, V25, P150, DOI 10.1016/S0149-2918(03)90019-1; Sorge J, 2004, CLIN THER, V26, P1808, DOI 10.1016/j.clinthera.2004.11.008; van Seventer R, 2003, CURR MED RES OPIN, V19, P457, DOI 10.1185/030079903125002045; 1999, GUIDANCE IND SKIN IR	17	14	14	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.	MAR	2006	22	3					501	509		10.1185/030079906X89829			9	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	027BA	WOS:000236387000007	16574034				2020-06-30	J	Anderson, RE; Jakobsson, JG				Anderson, RE; Jakobsson, JG			Cerebral state monitor, a new small handheld EEG monitor for determining depth of anaesthesia: a clinical comparison with the bispectral index during day-surgery	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthesia general; awareness; monitoring; depth of anaesthesia; bispectral index; cerebral state index; surgery ambulatory; anaesthetics; propofol; sevoflurane; desflurane	SPECTRAL ENTROPY; NITROUS-OXIDE; PROPOFOL; REMIFENTANIL; SEVOFLURANE; SEDATION; INDUCTION	Background and objective: The cerebral state index (CSI (TM)) derived from a new small handheld electroencephalogram monitor was studied during routine day surgical anaesthesia titrated according to the bispectral index (BIS (TM)). The objective was to determine the degree of agreement between the two monitors. Methods: Anaesthesia was induced with propofol and fentanyl (0.1 mg) in 38 patients undergoing general anaesthesia for routine day-surgery. Maintenance anaesthesia (sevoflurane (20/38), desflurane (10/38) or propofol (8/38)) titrated by BIS XP (Aspect Medical, Natwick, MA, USA) and BIS and CSI (cerebral State Monitor, Danmeter; Odense, Denmark) index values were recorded every minute. No patient received muscle relaxation. Observer's Assessment of Alertness/Sedation rating scale was used to assess level of sedation. Results: Pair-wise recordings (914) of CSI and BIS were collected. The indices showed similar pattern and decreased with increasing level of sedation, however with large ranges for each level of sedation. Median indices were similar during surgery (BIS: 50 (14-89); CSI: 51 (7-88)) and both indices increased (P < 0.01) when minor movements occurred (BIS 65 (40-83); CST 67 (40-89)). During maintenance of anaesthesia CSI > 20% from BIS-Index in 24% of readings, and on rare occasions CSI indices deviated > 100% from the BIS reading. When BIS < 40, CSI decreased slower than BIS and with wider spreading. Conclusions: When used for day-surgery anaesthesia without muscle relaxation, CSI and BIS show similar patterns and numerical values but with the incidence of occasionally large discrepancies between pair-wise readings. Which monitor is the more dependable remains to be established and cannot be implied from this initial explorative study.	Karolinska Hosp, Dept Cardiothorac Anaesthet & Intens Care, S-10401 Stockholm, Sweden; Karolinska Inst, Dept Anaesthesiol & Intens Care, Stockholm, Sweden	Jakobsson, JG (reprint author), Sabbatsbergs Hosp, Dept Anaesthesiol, S-11324 Stockholm, Sweden.	jan.jakobsson@kirurgi.ki.se					Alkire MT, 1998, ANESTHESIOLOGY, V89, P323, DOI 10.1097/00000542-199808000-00007; Anderson RE, 2005, ACTA ANAESTH SCAND, V49, P750, DOI 10.1111/j.1399-6576.2005.00737.x; Assareh H, 2002, ACTA ANAESTH SCAND, V46, P495, DOI 10.1034/j.1399-6576.2002.460504.x; Barr G, 2000, ACTA ANAESTH SCAND, V44, P807, DOI 10.1034/j.1399-6576.2000.440707.x; Barr G, 1999, BRIT J ANAESTH, V82, P827; Barr G, 2001, ANAESTHESIA, V56, P888, DOI 10.1046/j.1365-2044.2001.02059-3.x; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Dahaba AA, 2004, ANESTH ANALG, V99, P781, DOI 10.1213/01.ANE.0000132997.19872.BC; Degoute CS, 2001, BRIT J ANAESTH, V86, P209, DOI 10.1093/bja/86.2.209; Ellerkmann RK, 2004, ANESTHESIOLOGY, V101, P1275; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; Johansen JW, 2000, ANESTHESIOLOGY, V93, P1336, DOI 10.1097/00000542-200011000-00029; Katoh T, 1998, ANESTHESIOLOGY, V88, P642, DOI 10.1097/00000542-199803000-00014; Kearse LA, 1998, ANESTHESIOLOGY, V88, P25, DOI 10.1097/00000542-199801000-00007; Kreuer S, 2004, ACTA ANAESTH SCAND, V48, P1168, DOI 10.1111/j.1399-6576.2004.00498.x; Liu J, 1997, ANESTH ANALG, V84, P185, DOI 10.1097/00000539-199701000-00033; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P671, DOI 10.1097/00000542-199809000-00017; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; Recart A, 2003, ANESTH ANALG, V97, P1667, DOI 10.1213/01.ANE.0000087041.63034.8C; Schmidt GN, 2004, ANESTHESIOLOGY, V101, P1283; Schneider G, 2004, EUR J ANAESTH, V21, P6, DOI 10.1017/S0265021504001024; Schwab HS, 2004, ANESTH ANALG, V99, P1723, DOI 10.1213/01.ANE.0000136467.47996.70; Vanluchene ALG, 2004, BRIT J ANAESTH, V93, P645, DOI 10.1093/bja/aeh251	23	27	39	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	MAR	2006	23	3					208	212		10.1017/S0265021505002206			5	Anesthesiology	Anesthesiology	015PF	WOS:000235562600005	16430792				2020-06-30	J	Polack, PO; Charpier, S				Polack, PO; Charpier, S			Intracellular activity of cortical and thalamic neurones during high-voltage rhythmic spike discharge in Long-Evans rats in vivo	JOURNAL OF PHYSIOLOGY-LONDON			English	Article							GENETICALLY-DETERMINED SPIKE; ACTIVATED CATION CURRENT; ABSENCE EPILEPSY; WAVE DISCHARGES; SOMATOSENSORY SYSTEM; STRIATAL NEURONS; WAG/RIJ STRAIN; AWAKE RATS; OSCILLATIONS; SEIZURES	Spontaneous high-voltage rhythmic spike (HVRS) discharges at 6-12 Hz have been widely described in the electrocorticogram (EcoG) of Long-Evans rats. These ECoG oscillations have been proposed to reflect a state of attentive immobility allowing the optimization of sensory integration within the corticothalamic pathway. This hypothesis has been challenged by recent studies emphasizing similarities between HVRS discharges and spike-and-wave discharges (SWDs) in well-established rat genetic models of absence epilepsy. Here, we made in vivo intracellular recordings to determine, for the first time, the cellular mechanisms responsible for the synchronized oscillations in the corticothalamic loop during HVRS discharges in the Long-Evans rats. We show that HVRS discharges are associated in corticothalamic neurones with rhythmic suprathreshold synaptic depolarizations superimposed on a tonic hyperpolarization, likely due to a process of synaptic disfacilitation. Simultaneously, thalamocortical neurones exhibit a large-amplitude 'croissant'-shaped membrane hyperpolarization with a voltage sensitivity suggesting a potassium-dependent mechanism. This thalamic hyperpolarizing envelope was associated with a membrane oscillation resulting from interactions between excitatory synaptic inputs, a chloride-dependent inhibitory conductance and voltage-gated intrinsic currents. These cortical and thalamic cellular mechanisms underlying HVRS activity in Long-Evans rats are remarkably similar to those previously described in the thalamocortical networks during SWDs. Thus, the present study provides an additional support to the hypothesis that HVRS activity in Long-Evans rats is an absence-like seizure activity.	Coll France, INSERM, U667, F-75231 Paris 05, France; Univ Paris 06, F-75005 Paris, France	Charpier, S (reprint author), Coll France, INSERM, U667, 11 Pl Marcelin Berthelot, F-75231 Paris 05, France.	stephane.charpier@college-de-france.fr		Polack, Pierre-Olivier/0000-0003-1716-6595			BAL T, 1995, J PHYSIOL-LONDON, V483, P665, DOI 10.1113/jphysiol.1995.sp020613; Basar E, 2000, INT J PSYCHOPHYSIOL, V35, P95, DOI 10.1016/S0167-8760(99)00047-1; Bruno RM, 2003, J NEUROSCI, V23, P9565; Bullock TH, 1997, P NATL ACAD SCI USA, V94, P1, DOI 10.1073/pnas.94.1.1; BUZSAKI G, 1994, [No title captured]; Charpier S, 1999, NEUROPHARMACOLOGY, V38, P1699, DOI 10.1016/S0028-3908(99)00139-2; COENEN AML, 1991, NEUROSCI BIOBEHAV R, V15, P259, DOI 10.1016/S0149-7634(05)80005-3; Coenen AML, 2003, BEHAV GENET, V33, P635, DOI 10.1023/A:1026179013847; Danober L, 1998, PROG NEUROBIOL, V55, P27, DOI 10.1016/S0301-0082(97)00091-9; Destexhe A, 2003, PHYSIOL REV, V83, P1401, DOI 10.1152/physrev.00012.2003; DESTEXHE A, 2001, THALAMOCORTICAL ASSE; DRINKENBURG WHIM, 1993, PHYSIOL BEHAV, V54, P779, DOI 10.1016/0031-9384(93)90092-T; Engel AK, 2001, NAT REV NEUROSCI, V2, P704, DOI 10.1038/35094565; Fanselow EE, 2001, P NATL ACAD SCI USA, V98, P15330, DOI 10.1073/pnas.261273898; Fanselow EE, 1999, J NEUROSCI, V19, P7603, DOI 10.1523/JNEUROSCI.19-17-07603.1999; Feldman M.L., 1984, CEREB CORTEX, V1, P123; Fontanini A, 2005, J NEUROPHYSIOL, V93, P2832, DOI 10.1152/jn.01035.2004; Fricker D, 1999, J PHYSIOL-LONDON, V517, P791, DOI 10.1111/j.1469-7793.1999.0791s.x; GASTAUT MH, 1952, REV NEUROL, V87, P176; Gutnick Michael J., 1995, P33; Hutchison WD, 2004, J NEUROSCI, V24, P9240, DOI 10.1523/JNEUROSCI.3366-04.2004; KAPLAN BJ, 1979, BRAIN RES BULL, V4, P431, DOI 10.1016/S0361-9230(79)80021-0; KAPLAN BJ, 1985, EXP NEUROL, V88, P425, DOI 10.1016/0014-4886(85)90204-3; Mahon S, 2003, J PHYSIOL-LONDON, V550, P947, DOI 10.1113/jphysiol.2003.043125; Mahon S, 2001, CEREB CORTEX, V11, P360, DOI 10.1093/cercor/11.4.360; MARESCAUX C, 1992, EPILEPSY RES, P335; McCormick DA, 2001, ANNU REV PHYSIOL, V63, P815, DOI 10.1146/annurev.physiol.63.1.815; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P291, DOI 10.1113/jphysiol.1990.sp018331; MOUNTCASTLE VB, 1998, PERCEPTUAL NEUROSCIE; NEAFSEY EJ, 1986, BRAIN RES REV, V11, P77, DOI 10.1016/0165-0173(86)90011-1; Neckelmann D, 2000, NEUROSCIENCE, V96, P475, DOI 10.1016/S0306-4522(99)00571-0; Nicolelis MAL, 2002, NAT NEUROSCI, V5, P517, DOI 10.1038/nn0602-517; NICOLELIS MAL, 1995, SCIENCE, V268, P1353, DOI 10.1126/science.7761855; Niedermeyer E, 1999, ITAL J NEUROL SCI, V20, P7, DOI 10.1007/s100720050004; PANAYIOTOPOULOS CP, 1997, [No title captured], P2327; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.physiol.58.1.299; PAXINOS G, 1986, BRAIN STEREOTAXIC CO; Paz JT, 2005, J NEUROSCI, V25, P2092, DOI 10.1523/JNEUROSCI.4689-04.2005; PFURTSCHELLER G, 1992, NEUROREPORT, V3, P1057, DOI 10.1097/00001756-199212000-00006; Pinault D, 1998, J PHYSIOL-LONDON, V509, P449, DOI 10.1111/j.1469-7793.1998.449bn.x; Pinault D, 2003, J PHYSIOL-LONDON, V552, P881, DOI 10.1113/jphysiol.2003.046573; RALL W, 1969, BIOPHYS J, V9, P1483, DOI 10.1016/S0006-3495(69)86467-2; Rouiller EM, 2000, BRAIN RES BULL, V53, P727, DOI 10.1016/S0361-9230(00)00364-6; Salenius S, 2003, CURR OPIN NEUROBIOL, V13, P678, DOI 10.1016/j.conb.2003.10.008; Sauve K, 1999, CONSCIOUS COGN, V8, P213, DOI 10.1006/ccog.1999.0383; SAWYER SF, 1989, J COMP NEUROL, V286, P1, DOI 10.1002/cne.902860102; SEMBA K, 1984, NEUROSCIENCE, V12, P761, DOI 10.1016/0306-4522(84)90168-4; SEMBA K, 1980, BRAIN RES, V195, P281, DOI 10.1016/0006-8993(80)90065-7; Shaw FZ, 2005, J NEUROPHYSIOL, V93, P2435, DOI 10.1152/jn.00999.2004; Shaw FZ, 2004, J NEUROPHYSIOL, V91, P63, DOI 10.1152/jn.00487.2003; Sherman SM, 2001, TRENDS NEUROSCI, V24, P122, DOI 10.1016/S0166-2236(00)01714-8; SIMONS DJ, 1989, J NEUROPHYSIOL, V61, P311; Slaght S, 2004, J NEUROSCI, V24, P6816, DOI 10.1523/JNEUROSCI.1449-04.2004; Slaght SJ, 2002, EPILEPTIC DISORD, V4, pS9; Slaght SNJ, 2002, J NEUROSCI, V22, P2323, DOI 10.1523/JNEUROSCI.22-06-02323.2002; Snead O C 3rd, 1999, Adv Neurol, V79, P253; Steriade M, 2000, NEUROSCIENCE, V101, P243, DOI 10.1016/S0306-4522(00)00353-5; STERIADE M, 1995, J NEUROSCI, V15, P623; Steriade M, 2004, NAT REV NEUROSCI, V5, P121, DOI 10.1038/nrn1325; Steriade M, 1997, THALAMUS ORG FUNCTIO; Steriade M., 2003, NEURONAL SUBSTRATES; Timofeev I, 2004, NEUROSCIENCE, V123, P299, DOI 10.1016/j.neuroscience.2003.08.051; Timofeev I, 2002, NEUROSCIENCE, V114, P1115, DOI 10.1016/S0306-4522(02)00300-7; Timofeev I, 1998, J NEUROPHYSIOL, V80, P1495; VERGNES M, 1982, NEUROSCI LETT, V33, P97, DOI 10.1016/0304-3940(82)90136-7; Ward LM, 2003, TRENDS COGN SCI, V7, P553, DOI 10.1016/j.tics.2003.10.012; Wiest MC, 2003, NAT NEUROSCI, V6, P913, DOI 10.1038/nn1107; ZILLES K, 1985, [No title captured]	68	43	45	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3751	1469-7793		J PHYSIOL-LONDON	J. Physiol.-London	MAR 1	2006	571	2					461	476		10.1113/jphysiol.2005.100925			16	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	020FN	WOS:000235893900016	16410284	Green Published			2020-06-30	J	Chao, A; Huang, CH; Pryor, JP; Reilly, PM; Schwab, CW				Chao, A; Huang, CH; Pryor, JP; Reilly, PM; Schwab, CW			Analgesic use in intubated patients during acute resuscitation	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						analgesia; pain; pain relief; endotracheal intubation; wounds and injuries; trauma; acute Resuscitation	INADEQUATE EMERGENCY; TRAUMA PATIENTS; PAIN ASSESSMENT; RISK FACTOR; ETHNICITY	Background. Pain relief can often be overlooked during a busy trauma resuscitation, especially in patients who are intubated. We sought to investigate qualitative and quantitative aspects of analgesic use in intubated patients during the acute phase of resuscitation. Methods: We evaluated a retrospective cohort of consecutive adult patients who were intubated during the acute trauma resuscitation (first 6 hours) from January 2001 to May 2002 at a Level I trauma center in the United States. Patient demographics, injuries, vital signs, medications, trauma bay procedures, and disposition status were analyzed. Analgesia was recorded as the type of analgesic, route of administration, elapsed time to receive the first analgesic, total dosage, and time intervals between two successive doses. Fisher's exact test, X-2 test, and ANOVA were used to analyze data. Results: A total of 120 patients were included. Sixty-one (51%) patients received analgesia during their stay in the emergency department. Using logistic regression analysis, patients who more likely to receive analgesia were those who did not require immediate surgical operation and were transferred to the intensive care unit (odds ratio [OR] = 3.91; 95% CI = 1.75-8.76) and those who were admitted during the hours of 8 AM to 6 Pm (OR= 3.17; CI = 1.40-7.16). Among those patients receiving analgesia, 30 (25%) patients received analgesia within 30 minutes upon arrival. The mean time of receiving the first analgesia dose was 57 minutes. The average morphine equivalent dose given to the patients was 15.7 mg. The most frequently given single dose was 100 mu g of intravenous fentanyl. Most of the analgesics (37%) were given between 30 to 60 minutes apart. Conclusion: Our findings suggest that patients who are intubated during the acute resuscitation probably receive inadequate analgesia. The inadequacy appears to be in the timing and repetition of administration, rather than the dose. Patients who were transferred early to the intensive care unit were more likely to receive analgesics.	Natl Taiwan Univ Hosp, Dept Anesthesiol, Taipei, Taiwan; Univ Penn, Sch Med, Div Traumatol & Surg Crit Care, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA	Pryor, JP (reprint author), Div Traumatol & Surg Crit Care, 3440 Mkt St, Philadelphia, PA 19104 USA.	pryorj@uphs.upenn.edu		Chao, Anne/0000-0002-7170-3817; HUANG, CHI-HSIANG/0000-0001-5357-0451			Blauer T, 1998, CLIN J PAIN, V14, P39, DOI 10.1097/00002508-199803000-00006; Gelinas C, 2004, AM J CRIT CARE, V13, P126; Gill M, 2004, AM J EMERG MED, V22, P76, DOI 10.1016/j.ajem.2003.12.006; Hedderich R, 1999, CRIT CARE CLIN, V15, P167, DOI 10.1016/S0749-0704(05)70046-4; Jones JS, 1996, AM J EMERG MED, V14, P157, DOI 10.1016/S0735-6757(96)90123-0; KUCHINSKI J, 1991, Journal of Emergency Medicine, V9, P9, DOI 10.1016/0736-4679(91)90524-J; MorganJones R, 1996, INJURY, V27, P539, DOI 10.1016/S0020-1383(96)00094-0; ROTONDO MF, 1993, J TRAUMA, V34, P242, DOI 10.1097/00005373-199302000-00012; SELBST SM, 1990, ANN EMERG MED, V19, P1010, DOI 10.1016/S0196-0644(05)82565-X; Suominen P, 2004, PEDIATR ANESTH, V14, P336, DOI 10.1046/j.1460-9592.2003.01241.x; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; Todd KH, 2000, ANN EMERG MED, V35, P11, DOI 10.1016/S0196-0644(00)70099-0; Zohar Z, 2001, J TRAUMA, V51, P767, DOI 10.1097/00005373-200110000-00024	13	17	18	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2006	60	3					579	582		10.1097/01.ta.0000195644.58761.93			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	026WX	WOS:000236374900025	16531857				2020-06-30	J	Gordon, DB				Gordon, DB			Oral transmucosal fentanyl citrate for cancer breakthrough pain: A review	ONCOLOGY NURSING FORUM			English	Article							DOSE-TITRATION; MORPHINE; PHARMACOKINETICS; PREMEDICATION; PREVALENCE; ABSORPTION; MANAGEMENT; OTFC	Purpose/Objectives: To review the dose titration, efficacy, and safety of oral transmucosal fentanyl citrate (OTFC). Data Sources: Phase I and II clinical trial abstracts and evidence-based review articles. Data Synthesis: OTFC has an onset, peak, and duration of action similar to that of an IV dose of an opiod and has been demonstrated to be effective and well tolerated for the management of breakthrough pain in patients with cancer. Conclusions: Studies of OTFC demonstrate that it is easy to use, noninvasive, effective, safe, and acceptable to patients, caregivers, and healthcare providers. However, OTFC is expensive and approved for use only in opioid-tolerant patients with cancer. Implications for Nursing: Breakthrough pain in patients with cancer is a common problem with characteristics that make it difficult to treat. Oncology nurses should familiarize themselves with OTFC's unique characteristics to be able to best help patients manage their therapy.	Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA	Gordon, DB (reprint author), Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA.	db.gordon@hosp.wisc.edu					ADELUS S, 2002, INT C CANC NURS LOND; *AM PAN SOC, 2003, PRINC AN US TREATM A; ASHBURN MA, 1994, DRUG SAFETY, V11, P295, DOI 10.2165/00002018-199411050-00001; ASHBURN MA, 1990, CAN J ANAESTH, V37, P857, DOI 10.1007/BF03006621; ASHBY MA, 1992, PAIN, V51, P153, DOI 10.1016/0304-3959(92)90256-B; BASSKIN LE, 1999, AM J PAIN MANAGEMENT, V9, P129; BENNETT D, 2005, [No title captured], V30, P296; BENNETT D, 2005, [No title captured], V30, P354; BRUERA E, 1992, PAIN, V50, P75, DOI 10.1016/0304-3959(92)90114-Q; Burton AW, 2004, CLIN J PAIN, V20, P195, DOI 10.1097/00002508-200405000-00011; *CEPH, 2004, ACT PACK INS; *CEPH, 2005, CEPH ANN POS STAG 3; Chandler S, 1999, Am J Hosp Palliat Care, V16, P489, DOI 10.1177/104990919901600213; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Colleau SM, 2004, CANC PAIN RELEASE, V17, P1; Coluzzi PH, 1998, J PAIN SYMPTOM MANAG, V16, P184, DOI 10.1016/S0885-3924(98)00046-3; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Danjoux C., 2000, Clinical and Investigative Medicine, V23, pS23; Davis T, 1993, Hosp J, V9, P85, DOI 10.1300/J011v09n01_07; EGAN T, 2002, AM AC PAIN MAN ANN S; Ferrante FM, 1996, J PAIN SYMPTOM MANAG, V11, P265, DOI 10.1016/0885-3924(95)00201-4; Fine P G, 1998, J Palliat Med, V1, P55, DOI 10.1089/jpm.1998.1.55; Fine PG, 1998, J PAIN SYMPTOM MANAG, V16, P179, DOI 10.1016/S0885-3924(98)00045-1; FOLEY KM, 1993, NEUROL CLIN, V11, P503; Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136; Gomez-Batiste X, 2002, J PAIN SYMPTOM MANAG, V24, P45, DOI 10.1016/S0885-3924(02)00421-9; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P738, DOI 10.1097/00000542-200409000-00023; Lee M, 2003, J PAIN SYMPTOM MANAG, V26, P743, DOI 10.1016/S0885-3924(03)00241-0; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; LU J, 2003, AM SOC AN ANN M SAN; MAREK B, 2001, AM SOC CLIN ONC ANN; Mathey F, 2000, CR ACAD SCI II C, V3, P1; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; *MICR, 2004, MORPH; Mock DL, 1986, ANESTH ANALG, V65, pS102; Moore P A, 2000, Anesth Prog, V47, P29; Mystakidou Kyriaki, 2005, Am J Hosp Palliat Care, V22, P228, DOI 10.1177/104990910502200313; NELSON PS, 1989, ANESTHESIOLOGY, V70, P616, DOI 10.1097/00000542-198904000-00011; OSBORNE R, 1990, CLIN PHARMACOL THER, V47, P12, DOI 10.1038/clpt.1990.2; PANNUTI F, 1982, PHARMACOL RES COMMUN, V14, P369, DOI 10.1016/S0031-6989(82)80107-0; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; PORTENOY RK, 2002, 38 AM SOC CLIN ONC A; Rees Elizabeth, 2002, Int J Palliat Nurs, V8, P304; RHINER M, 1999, AM J NURS, V99, pS3; ROBISON JM, 1995, NURS CLIN N AM, V30, P725; Shaiova L, 2004, SUPPORT CARE CANCER, V12, P268, DOI 10.1007/s00520-004-0595-4; SIMMONDS MA, 1997, P AN M AM SOC CLIN, V16, P52; SQUIER CA, 1975, BRIT MED BULL, V31, P169, DOI 10.1093/oxfordjournals.bmb.a071275; STANLEY TH, 1989, ANESTH ANALG, V69, P21; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Streisand JB, 1996, ANESTHESIOLOGY, V85, pA322; STREISAND JB, 1993, ANESTHESIOLOGY, V79, pA369; *US FDA, 1998, FDA APPR ACTIQ MARK; WEINBERG DS, 1988, CLIN PHARMACOL THER, V44, P335, DOI 10.1038/clpt.1988.159; World Health Organization, 1996, CANC PAIN REL; Zimmer Ruth, 2001, Comprehensive Therapy, V27, P293, DOI 10.1007/s12019-001-0027-z	60	7	7	0	3	ONCOLOGY NURSING SOC	PITTSBURGH	125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA	0190-535X	1538-0688		ONCOL NURS FORUM	Oncol. Nurs. Forum	MAR	2006	33	2					257	264		10.1188/06.ONF.257-264			8	Oncology; Nursing	Oncology; Nursing	031II	WOS:000236697600009	16518441				2020-06-30	J	Ball, AM; Smith, KM				Ball, AM; Smith, KM			Postoperative pain management: Can transdermal patches help?	ORTHOPEDICS			English	Article							PATIENT-CONTROLLED ANALGESIA; ORTHOPEDIC-SURGERY; DOUBLE-BLIND; CLINICAL EFFICACY; CONTROLLED-TRIAL; FENTANYL; 5-PERCENT; PLACEBO; SAFETY; MULTICENTER		Univ Kentucky, Coll Pharm, Chandler Med Ctr, Lexington, KY 40536 USA	Smith, KM (reprint author), Univ Kentucky, Coll Pharm, Chandler Med Ctr, 800 Rose St,Rm C-117, Lexington, KY 40536 USA.						[Anonymous], 2003, AHFS DRUG INF; Ashburn MA, 2004, ANESTHESIOLOGY, V100, P1573; Bonica J. J., 1990, MANAGEMENT PAIN, V1; Burch F, 2004, OSTEOARTHR CARTILAGE, V12, P253, DOI 10.1016/j.joca.2003.10.007; CAPLAN RA, 1989, JAMA-J AM MED ASSOC, V261, P1036, DOI 10.1001/jama.261.7.1036; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; *END PHARM, 2005, LID LID TRANSD PACK; Galer BS, 2004, CURR MED RES OPIN, V20, pS5, DOI 10.1185/030079904X12933; Gammaitoni AR, 2003, J CLIN PHARMACOL, V43, P111, DOI 10.1177/0091270002239817; Griessinger N, 2005, CURR MED RES OPIN, V21, P1147, DOI 10.1185/030079905X53315; HARRIS SN, 1991, OBSTET GYNECOL, V78, P673; *JANSS PHAR PROD L, 2005, DUR FENT TRANSD PACK; Lauretti GR, 1999, ANESTHESIOLOGY, V90, P734, DOI 10.1097/00000542-199903000-00015; Lauretti GR, 2001, J CLIN ANESTH, V13, P576, DOI 10.1016/S0952-8180(01)00333-6; Meier T, 2003, PAIN, V106, P151, DOI 10.1016/S0304-3959(03)00317-8; *NOV CONS HLTH 1, 2004, TRANSD SCOP SCOP PAC; Owen MD, 1997, J CLIN ANESTH, V9, P8, DOI 10.1016/S0952-8180(96)00218-8; *PHARM M, 1999, MIN NITR TRANSD PACK; SEGAL IS, 1991, ANESTHESIOLOGY, V74, P220, DOI 10.1097/00000542-199102000-00005; Sevarino FB, 1997, J CLIN ANESTH, V9, P173, DOI 10.1016/S0952-8180(97)00043-3; Sinatra R, 2005, CLIN PHARMACOKINET, V44, P1; STROMBERG BV, 1991, AM SURGEON, V57, P712; VANBASTELAERE M, 1995, J CLIN ANESTH, V7, P26, DOI 10.1016/0952-8180(94)00000-T; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Wheatley GH, 2005, J THORAC CARDIOV SUR, V130, P464, DOI 10.1016/j.jtcvs.2005.02.011; Wong Nina N., 2001, Journal of Pharmacy Technology, V17, P84	26	2	2	0	3	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086 USA	0147-7447			ORTHOPEDICS	Orthopedics	MAR	2006	29	3					217	220		10.3928/01477447-20060301-13			4	Orthopedics	Orthopedics	020XS	WOS:000235947200006	16539198				2020-06-30	J	Tsutsumi, Y; Kanamori, H; Tanaka, J; Asaka, M; Imamura, M; Masauzi, N				Tsutsumi, Y; Kanamori, H; Tanaka, J; Asaka, M; Imamura, M; Masauzi, N			Withdrawal symptoms from transdermal fentanyl (TDF) after an allogeneic peripheral blood stem cell transplant (PBSCT)	PAIN MEDICINE			English	Article						fentanyl; pain; stem Cell; withdrawl; CYP3A4		A 47-year-old woman who underwent allogenic peripheral blood stem cell transplant developed withdrawal symptoms soon after Fentanyl 25 mcg/h patch was stopped, which has not been reported at this dose. Possible causes, such as the inhibition of CYP3A4 induced by cyclosporine causing elevations of serum fentanyl, are discussed.	Hakodate Municipal Hosp, Dept Internal Med, Hakodate, Hokkaido 0410821, Japan; Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan	Tsutsumi, Y (reprint author), Hakodate Municipal Hosp, Dept Internal Med, 1-10-1 Minato Cho, Hakodate, Hokkaido 0410821, Japan.	rtsutsu@nyc.odn.ne.jp	Asaka, Masahiro/A-5948-2012; Tanaka, Junji/A-4098-2012; Masauzi, Nobuo/E-1709-2012	Masauzi, Nobuo/0000-0002-4372-0169			Davies AN, 1996, PALLIATIVE MED, V10, P348; Gourlay G K, 2001, Lancet Oncol, V2, P165, DOI 10.1016/S1470-2045(00)00258-8; HIGGS CMB, 1995, J PAIN SYMPTOM MANAG, V10, P4, DOI 10.1016/0885-3924(94)00060-X; Hunt R, 1996, PALLIATIVE MED, V10, P347; Olkkola KT, 1999, ANESTHESIOLOGY, V91, P681, DOI 10.1097/00000542-199909000-00020; ZENZ M, 1994, J PAIN SYMPTOM MANAG, V9, P54, DOI 10.1016/0885-3924(94)90149-X	6	1	1	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	MAR-APR	2006	7	2					164	165		10.1111/j.1526-4637.2006.00107.x			2	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	024UE	WOS:000236220900009	16634729	Bronze			2020-06-30	J	Schmidt, J; Kroeber, S; Irouschek, A; Birkholz, T; Schroth, M; Albrecht, S				Schmidt, J; Kroeber, S; Irouschek, A; Birkholz, T; Schroth, M; Albrecht, S			Anesthetic management of patients with ornithine transcarbamylase deficiency	PEDIATRIC ANESTHESIA			English	Article						ornithine transcarbamylase deficiency; general anesthesia; perioperative management; hyperammonemia; alternative pathway therapy	HYPERAMMONEMIA; THERAPY; COMA	Ornithine transcarbamylase deficiency (OTCD) is the most common inborn error of the urea cycle. Several specific factors require care during anesthesia in patients with this condition to avoid metabolic decompensation with acute hyperammonemia and encephalopathy. We report monozygous twins with severe neonatal-onset OTCD undergoing general anesthesia twice each, with midazolam, s-ketamine, fentanyl and isoflurane in combination with surgical field infiltration with ropivacaine. Alternative pathway medication and high-caloric diet with 10% glucose solutions were continuously administered during the perioperative course. Both children were extubated within 10 min of the final suture, and their neurological state remained unchanged. Perioperatively, blood ammonia levels remained within the normal range.	Univ Erlangen Nurnberg, Dept Anesthesiol, D-91054 Erlangen, Germany; Univ Erlangen Nurnberg, Dept Pediat, Erlangen, Germany	Schmidt, J (reprint author), Univ Erlangen Nurnberg, Dept Anesthesiol, Krankenhausstr 12, D-91054 Erlangen, Germany.	joachim.schmidt@gmx.ch					ARN PH, 1990, NEW ENGL J MED, V322, P1652, DOI 10.1056/NEJM199006073222307; BATSHAW ML, 1982, ANN NEUROL, V11, P319, DOI 10.1002/ana.410110315; BAUM VC, 1999, ANESTHESIA GENETIC M, P225; Berry GT, 2001, J PEDIATR-US, V138, pS56, DOI 10.1067/mpd.2001.111837; BRUSILOW SW, 2001, [No title captured], P1909; Czock D, 2005, CLIN PHARMACOKINET, V44, P61, DOI 10.2165/00003088-200544010-00003; HONEYCUTT D, 1992, NEUROLOGY, V42, P666, DOI 10.1212/WNL.42.3.666; Iida R, 1996, Masui, V45, P642; Kasahara M, 1998, J PEDIATR SURG, V33, P1753, DOI 10.1016/S0022-3468(98)90278-0; Legras A, 2002, CRIT CARE MED, V30, P241, DOI 10.1097/00003246-200201000-00035; Michalak A, 1997, METAB BRAIN DIS, V12, P171; Perez Valdivieso J R, 2002, Rev Esp Anestesiol Reanim, V49, P219; Perpoint T, 2001, INTENS CARE MED, V27, P1962, DOI 10.1007/s00134-001-1148-7; Tazuke M, 1997, Masui, V46, P783; Trivedi M, 2001, J CLIN GASTROENTEROL, V32, P340, DOI 10.1097/00004836-200104000-00013; Wraith JE, 2001, ARCH DIS CHILD, V84, P84, DOI 10.1136/adc.84.1.84; Zenker M, 2005, AM J MED GENET A, V132A, P185, DOI 10.1002/ajmg.a.30414	17	10	10	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	MAR	2006	16	3					333	337		10.1111/j.1460-9592.2005.01695.x			5	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	012WJ	WOS:000235371300018	16490102				2020-06-30	J	Fujiwara, Y; Hirokawa, M; Wakao, Y; Itou, H; Komatsu, T				Fujiwara, Y; Hirokawa, M; Wakao, Y; Itou, H; Komatsu, T			Heart rate variability in a child with hereditary sensory autonomic neuropathy 2 (HSAN 2) during general anesthesia with propofol and fentanyl	PEDIATRIC ANESTHESIA			English	Letter							CONGENITAL INSENSITIVITY; PAIN		Aichi Med Univ, Dept Anesthesiol, Aichi 4801195, Japan; Kamiida Daichi Hosp, Dept Anesthesiol, Nagoya, Aichi 4620802, Japan	Fujiwara, Y (reprint author), Aichi Med Univ, Dept Anesthesiol, Aichi 4801195, Japan.	yyoshiff@aichi-med-u.ac.jp					DEUTSCHMAN CS, 1994, ANESTH ANALG, V79, P373; Houlden H, 2004, CURR OPIN NEUROL, V17, P569, DOI 10.1097/00019052-200410000-00007; Kanaya N, 2003, ANESTHESIOLOGY, V98, P34, DOI 10.1097/00000542-200301000-00009; Komatsu T, 1992, J Cardiothorac Vasc Anesth, V6, P444, DOI 10.1016/1053-0770(92)90011-U; KRITCHMAN MM, 1959, JAMA-J AM MED ASSOC, V170, P529, DOI 10.1001/jama.1959.03010050023005; Low PA, 2003, MUSCLE NERVE, V27, P646, DOI 10.1002/mus.10333; Nagasako EM, 2003, PAIN, V101, P213, DOI 10.1016/S0304-3959(02)00482-7; Rozentsveig V, 2004, PEDIATR ANESTH, V14, P344, DOI 10.1046/j.1460-9592.2003.01235.x; SAITO K, 1994, RECENT ADV TIME SERI, P11; Sawada Y, 1997, MED BIOL ENG COMPUT, V35, P318, DOI 10.1007/BF02534083	10	2	2	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	MAR	2006	16	3					363	366		10.1111/j.1460-9592.2005.01828.x			5	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	012WJ	WOS:000235371300031	16490115				2020-06-30	J	Sarvela, PJ; Halonen, PM; Soikkeli, AI; Kainu, JP; Korttila, KT				Sarvela, PJ; Halonen, PM; Soikkeli, AI; Kainu, JP; Korttila, KT			Ondansetron and tropisetron do not prevent intraspinal morphine- and fentanyl-induced pruritus in elective cesarean delivery	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						obstetrics; anesthesia; spinal; intrathecal; epidural; post-operative nausea and vomiting	INTRATHECAL MORPHINE; EPIDURAL MORPHINE; PROPHYLACTIC ONDANSETRON; NAUSEA	Although intraspinal morphine has been shown to be effective in providing analgesia after cesarean delivery, pruritus as a side-effect remains a common cause of dissatisfaction. The role of ondansetron has been studied in preventing pruritus but the results have been contradictory. We randomized 98 parturients undergoing elective cesarean section using combined spinal-epidural anesthesia into a double-blinded trial to receive tropisetron 5 mg (T group) or ondansetron 8 mg (O group) or placebo (NaCl group) after delivery, when intrathecal morphine 160 mu g and fentanyl 15 mu g were used for post-operative pain control. The patients additionally received ketoprofen 300 mg per day. Post-operative itching, nausea and vomiting, sedation and need for rescue analgesics were registered every 3 h up to 24 h, and all patients were interviewed on the first post-operative day. Seventy-six percent of the parturients in the placebo group, 87% in the ondansetron, and 79% in the tropisetron group had itching. The incidence of post-operative nausea and vomiting was 21%, 20% and 11% of the patients in the placebo, ondansetron and tropisetron groups, respectively. Medication for pruritus was needed by 31%, 23% and 39% of the patients in the placebo, ondansetron and tropisetron groups, respectively. In the post-operative questionnaire, the patients reported less post-operative nausea in the tropisetron group than in the placebo group (P < 0.01). Neither ondansetron nor tropisetron prevent itching caused by intrathecal morphine with fentanyl. However, tropisetron reduced post-operative nausea.	Univ Helsinki, Cent Hosp, Dept Anesthesia & Intens Care, FI-00029 Helsinki, Finland	Sarvela, PJ (reprint author), Univ Helsinki, Cent Hosp, Dept Anesthesia & Intens Care, Haartmaninkatu 2, FI-00029 Helsinki, Finland.	Johanna.sarvela@hus.fi					AYOUB CM, 2004, OBSTET ANESTHESIA PR, P472; Borgeat A, 1999, ANESTHESIOLOGY, V90, P432, DOI 10.1097/00000542-199902000-00017; Charuluxananan S, 2003, ANESTH ANALG, V96, P1789, DOI 10.1213/01.ANE.0000066015.21364.7D; Choi DH, 2000, ACTA ANAESTH SCAND, V44, P214, DOI 10.1034/j.1399-6576.2000.440214.x; Gurkan Y, 2002, ANESTH ANALG, V95, P1763, DOI 10.1213/01.ANE.0000033097.30674.02; Korhonen AM, 2003, ACTA ANAESTH SCAND, V47, P1292, DOI 10.1046/j.1399-6576.2003.00206.x; Sarvela J, 2002, ANESTH ANALG, V95, P436, DOI 10.1097/00000539-200208000-00037; Sarvela PJ, 1999, ANESTH ANALG, V89, P1257, DOI 10.1213/00000539-199911000-00033; Szarvas S, 2003, ANESTH ANALG, V97, P259, DOI 10.1213/01.ANE.0000066310.49139.2A; Szarvas S, 2003, J CLIN ANESTH, V15, P234, DOI 10.1016/S0952-8180(02)00501-9; Tzeng JI, 2003, CAN J ANAESTH, V50, P1023, DOI 10.1007/BF03018366; Wells J, 2004, INT J OBSTET ANESTH, V13, P35, DOI 10.1016/j.ijoa.2003.07.001; Yazigi A, 2002, J CLIN ANESTH, V14, P183, DOI 10.1016/S0952-8180(01)00381-6; Yeh HM, 2000, ANESTH ANALG, V91, P172, DOI 10.1097/00000539-200007000-00032	14	33	36	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	FEB	2006	50	2					239	244		10.1111/j.1399-6576.2006.00934.x			6	Anesthesiology	Anesthesiology	004EG	WOS:000234734200018	16430549				2020-06-30	J	Nikkola, E; Laara, A; Hinkka, S; Ekblad, U; Kero, P; Salonen, M				Nikkola, E; Laara, A; Hinkka, S; Ekblad, U; Kero, P; Salonen, M			Patient-controlled epidural analgesia in labor does not always improve maternal satisfaction	ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA			English	Article						fentanyl; labor; patient-controlled epidural analgesia; PCEA; satisfaction	CONTINUOUS-INFUSION; CHILDBIRTH; FENTANYL; BUPIVACAINE	Background. We investigated whether patient-controlled epidural analgesia in labor with bupivacaine and fentanyl provides more satisfaction to mothers than intermittent bolus epidural analgesia or patient-controlled epidural analgesia with plain bupivacaine. Methods. Ninety mothers with term, uncomplicated pregnancies were randomized to receive intermittent bolus epidural analgesia ( bupivacaine + fentanyl), patient-controlled epidural analgesia ( bupivacaine + fentanyl), or patient-controlled epidural analgesia ( bupivacaine). Pain during labor was evaluated with a visual analog scale. Obstetric and neonatal outcomes were recorded. After delivery, the mothers were given a questionnaire covering the following themes: experience of labor pain, feeling of control, fears and expectations associated with pregnancy/ with delivery/with becoming a mother, as well as pain, physical condition and emotions after delivery. To elaborate on these answers, 30 mothers were further randomized to a semistructured interview, in which the same topics were discussed. The main outcome measure was maternal satisfaction. Results. The intermittent bolus epidural analgesia group felt they could influence labor most ( p = 0.03), and in the interview they expressed most satisfaction. In this group, the total drug utilization was smallest ( bupivacaine: p< 0.0001 comparing all groups, fentanyl: p = 0.03 comparing the two fentanyl-receiving groups). No differences in pain occurred. Vomiting ( p = 0.04) and pruritus ( p< 0.0001) were more common or more severe in the groups receiving fentanyl. Conclusions. We found no advantages for patient-controlled epidural analgesia over intermittent bolus epidural analgesia in terms of maternal satisfaction.	Turku Univ Hosp, Dept Anesthesiol, FIN-20520 Turku, Finland; Turku Univ Hosp, Dept Pediat, FIN-20520 Turku, Finland; Turku Univ Hosp, Dept Obstet & Gynecol, FIN-20520 Turku, Finland; Univ Turku, Dept Biostat, Turku, Finland	Nikkola, E (reprint author), Ureheilukatu 16 B 39, Helsinki 00250, Finland.	eeva.nikkola@welho.com					AIKEN LR, 1996, PERS ASSESS, P132; BRAMADAT IJ, 1993, BIRTH-ISS PERINAT C, V20, P22, DOI 10.1111/j.1523-536X.1993.tb00175.x; Chumbley GM, 1999, ANAESTHESIA, V54, P386, DOI 10.1046/j.1365-2044.1999.00836.x; Chumbley GM, 1998, ANAESTHESIA, V53, P216, DOI 10.1046/j.1365-2044.1998.00314.x; DREW NC, 1989, BRIT J OBSTET GYNAEC, V96, P1084, DOI 10.1111/j.1471-0528.1989.tb03386.x; FRIEDMAN JMH, 1989, CONT APPROACHES PSYC, P83; GAMBLING DR, 1988, CAN J ANAESTH, V35, P249, DOI 10.1007/BF03010618; Hodnett ED, 2002, AM J OBSTET GYNECOL, V186, pS160, DOI 10.1067/mob.2002.121141; HOLLMEN A, 1977, ACTA ANAESTH SCAND, V21, P174, DOI 10.1111/j.1399-6576.1977.tb01207.x; JOHNSON LR, 1989, PAIN, V39, P17, DOI 10.1016/0304-3959(89)90170-X; JUSTINS DM, 1983, ANAESTHESIA, V38, P937, DOI 10.1111/j.1365-2044.1983.tb12022.x; KANTO J, 1983, BIOL RES PREG PERIN, V4, P172; LOFTUS JR, 1995, ANESTHESIOLOGY, V83, P300, DOI 10.1097/00000542-199508000-00010; MERTON RK, 1990, FOCUSED INTERVIEW MA, P1; Morgan PJ, 1999, INT J OBSTET ANESTH, V8, P165, DOI 10.1016/S0959-289X(99)80132-0; MURPHY JD, 1991, BRIT MED J, V302, P564, DOI 10.1136/bmj.302.6776.564; NIEMALA P, 1980, AITIYDEN HYVAKSYMINE, P1; NIEMELA P, 1985, VAUVA TULOSSA ELAMA, P1; Paech M, 1998, BAILLIERE CLIN OB GY, V12, P377, DOI 10.1016/S0950-3552(98)80073-4; Paech M J, 1996, Int J Obstet Anesth, V5, P115, DOI 10.1016/S0959-289X(96)80010-0; Ross A, 1998, BAILLIERE CLIN OB GY, V12, P499, DOI 10.1016/S0950-3552(98)80081-3; Taylor N, 1996, SOC SCI MED, V43, P1137, DOI 10.1016/0277-9536(96)00056-1; Taylor NM, 1996, ANAESTHESIA, V51, P525, DOI 10.1111/j.1365-2044.1996.tb12556.x; van der Vyver M, 2002, BRIT J ANAESTH, V89, P459, DOI 10.1093/bja/aef217	24	12	12	0	2	TAYLOR & FRANCIS AS	OSLO	PO BOX 12 POSTHUSET, NO-0051 OSLO, NORWAY	0001-6349			ACTA OBSTET GYN SCAN	Acta Obstet. Gynecol. Scand.	FEB	2006	85	2					188	194		10.1080/00016340500409935			7	Obstetrics & Gynecology	Obstetrics & Gynecology	017QP	WOS:000235708400011	16532913				2020-06-30	J	Freye, E; Hartung, E; Levy, JV				Freye, E; Hartung, E; Levy, JV			No potentiation of fentanyl by use of transdermal buprenorphine in patients undergoing fast-track anesthesia for open-heart surgery	ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE			German	Article						transdermal buprenorphine; fentanyl; opioid anesthesia; additive effects; open-heart surgery	RECEPTOR-BINDING; MU-OPIOIDS; MORPHINE; PAIN; NALBUPHINE; MANAGEMENT; KINETICS; RATS	Objective: Simultaneous use of opioids with a different pharmacological profile may lead to unexpected prolongation of effects. In an open label study possible overhang in post-operative respiratory effects and vigilance was determined in a group of patients (n = 22) carrying a transdermal buprenorphine patch for at least 2 months for treatment of chronic pain, undergoing a fentanyl-based fast-track enflurane anesthetic technique for open-heart operation. Data was compared with another randomised group (n = 21) undergoing similar open-heart procedures with no other opioid than fentanyl on board. Methods and Results: Following induction with fentanyl and a barbiturate, depth of anesthesia with enflurane (Fi 0.5) was guided using the bispectral index (BIS). Additional doses of fentanyl were given when blood pressure and/or heart-rate increased 20% above preinduction levels. Early postoperative extubation was initiated once the cardiovascular system was stable and there were no signs of respiratory impairment. Following a similar time of operation and anesthesia and a similar total dose of fentanyl (0.69mg +/- 0.23SD versus 0.67mg +/- 0.16SD), postoperatively, there were no significant differences between the buprenorphine- and the control group regarding the time till extubation (25.2 min +/- 6.1 versus 33.3 min +/- 5.0) and the arterial blood gases under oxygen inhalation (paO(2) 136 torr +/- 48 SD versus 128 torr +/- 35 SD; paCO(2) 43.3 torr +/- 3.3 SO versus 41.9 torr +/- 1.2 SD and the post-anesthetic vigilance and recovery score (6.8 +/- 1.0 versus 7.5 +/- 0.8) 60 minutes after end of anesthesia. Contary to the control group, there was a lower and significant (p < 0.01) incidence of PONV in patients with transdermal buprenorphine. Conclusion: Patients using a buprenorphine patch for the relief of chronic pain cannot be regarded as opioid naive. Due to adaptive mechanisms and the development of tolerance, there is no prolongation of the respiratory depression induced by intraoperative fentanyl. Long-term use of transdermal buprenorphine does not lead to potentiation or prolongation of opioid effects in cardiac Surgery patients.	Univ Kliniken Dusseldorf, Klin Gefasschirurg & Nierentransplantat, Dusseldorf, Germany; Univ Kliniken Dusseldorf, Anasthesiol Klin, Dusseldorf, Germany; Univ Pacific, Abt Pharmakol & Physiol, San Francisco, CA USA	Freye, E (reprint author), Deichstr 3A, D-41468 Neuss, Germany.	enno.freye@uni-duesseldorf.de					AKRAM A, 1997, INDIAN J PHYSL PHARM, V41, P361; ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Beltrutti D, 2000, PAIN CLINIC, V12, P121, DOI 10.1163/156856900750229889; BOAS RA, 1985, BRIT J ANAESTH, V57, P192, DOI 10.1093/bja/57.2.192; BRUERA E, 1989, PAIN, V39, P13, DOI 10.1016/0304-3959(89)90169-3; BULLINGHAM RES, 1980, CLIN PHARMACOL THER, V28, P667, DOI 10.1038/clpt.1980.219; CHEN ZR, 1991, LIFE SCI, V48, P2165, DOI 10.1016/0024-3205(91)90150-A; DECASTRO J, 1982, NEW DRUG SERIES, V1; DECASTRO J, 1975, ANTIMORPHINQUES ANES, V3, P47; FREYE E, 2004, OPIOIDE MED, P469; Hambrook J.M., 1976, OPIATES ENDOGENOUS O, P295; Khan FA, 1997, ANAESTHESIA, V52, P1095, DOI 10.1111/j.1365-2044.1997.211-az0347.x; KREEK MJ, 1973, JAMA-J AM MED ASSOC, V223, P665, DOI 10.1001/jama.223.6.665; LEHMANN KA, 1982, ANAESTHESIST, V31, P221; LEWIS JW, 1985, DRUG ALCOHOL DEPEN, V14, P363, DOI 10.1016/0376-8716(85)90067-5; MAGNAN J, 1982, N-S ARCH PHARMACOL, V319, P197, DOI 10.1007/BF00495865; MANNER T, 1987, BRIT J ANAESTH, V59, P978, DOI 10.1093/bja/59.8.978; Meert TF, 1996, PHARM WORLD SCI, V18, P1, DOI 10.1007/BF00449683; Morgan D, 1999, ANESTH ANALG, V88, P407, DOI 10.1097/00000539-199902000-00035; Okutani R, 1989, J Cardiothorac Anesth, V3, P401, DOI 10.1016/S0888-6296(89)97267-0; PORTENOY RK, 1987, MED CLIN N AM, V71, P303, DOI 10.1016/S0025-7125(16)30872-0; RAPP SE, 1995, PAIN, V61, P195, DOI 10.1016/0304-3959(94)00168-E; SADEE W, 1982, J PHARMACOL EXP THER, V223, P157; SCHMIDT WK, 1985, DRUG ALCOHOL DEPEN, V14, P339, DOI 10.1016/0376-8716(85)90066-3; Taub A., 1982, NARCOTIC ANALGESICS, P199; TUFANO R, 1986, 7 EUR C AN VIENN; TYERS MB, 1980, BRIT J PHARMACOL, V69, P503, DOI 10.1111/j.1476-5381.1980.tb07041.x; WALKER EA, 1995, J PHARMACOL EXP THER, V273, P1345; Walsh SL, 2003, DRUG ALCOHOL DEPEN, V70, pS13, DOI 10.1016/S0376-8716(03)00056-5; Yassen A, 2005, J PHARMACOL EXP THER, V313, P1136, DOI 10.1124/jpet.104.082560; YOUNG AM, 1991, J PHARMACOL EXP THER, V257, P795	31	0	1	0	2	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0939-2661			ANASTH INTENSIV NOTF	Anasthesiol. Intensivmed. NotfMed. Schmerzther.	FEB	2006	41	2					86	92		10.1055/s-2005-870501			7	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	020EQ	WOS:000235891600004	16493560				2020-06-30	J	Seyhan, TO; Tugrul, M; Sungur, MO; Kayacan, S; Telci, L; Pembeci, K; Akpir, K				Seyhan, TO; Tugrul, M; Sungur, MO; Kayacan, S; Telci, L; Pembeci, K; Akpir, K			Effects of three different dose regimens of magnesium on propofol requirements, haemodynamic variables and postoperative pain relief in gynaecological surgery	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetics i.v., propofol; magnesium sulphate; narcotics, morphine; neuromuscular block, atracuriurn	VOLATILE ANESTHETICS; SULFATE; INFUSION; RATS; TOLERANCE; RESPONSES; KETAMINE; MORPHINE; PART	Background. In this double-blind, randomized, placebo-controlled study we compared the effects of three different dose regimens of magnesium on intraoperative propofol and atracurium requirements, and postoperative morphine consumption in patients undergoing gynaecological surgery. Methods. Eighty women were allocated to four equal groups. The control group received normal saline; magnesium groups received 40 mg kg-l of magnesium before induction of anaesthesia, followed by i.v. infusion of normal saline, magnesium 10 mg kg(-1) h(-1) or magnesium 20 prig kg(-1) h(-1) for the next 4 h. Propofol infusion was targeted to keep bispectral index values between 45 and 55. Postoperative analgesia was achieved using PCA with morphine. Results. Magnesium groups required significantly less propofol [mean (SD) 121.5 (13.3), 102.2 (8.0) and 101.3 (9.7) mu g kg(-1) min(-1) respectively] than the control group (140.7 (16.5) mu g kg(-1) min(-1)). Atracurium use was significantly higher in the control group than magnesium groups [0.4 (0.06) vs 0.34 (0.06), 0.35 (0.04), 0.34 (0.06) mg kg(-1) h(-1) respectively]. Morphine consumption was significantly higher in control group than magnesium groups on the first postoperative day [0.88 (0.14) vs 0.73 (0.17), 0.59 (0.23), 0.53 (0.21) mg kg(-1) respectively]. The heart rate was lower in magnesium groups and 20 mg kg(-1) h(-1) infusion group demonstrated the lowest values. Conclusion. Magnesium 40 mg kg(-1) bolus followed by 10 mg kg(-1) h(-1) infusion leads to significant reductions in intraoperative propofol, atracurium and postoperative morphine consumption. Increasing magnesium dosage did not offer any advantages, but induced haemodynamic consequences.	Istanbul Univ, Fac Med, Dept Anaesthesiol, Istanbul, Turkey; Univ Louisville, Dept Anaesthesiol, Louisville, KY 40292 USA	Seyhan, TO (reprint author), IU Istanbul, Tip Fak Anesteziyoloji Anabilim Dali, Cerrahi Bilimler Binasi, TR-34093 Istanbul, Turkey.	tulay2000@e-kolay.net	Seyhan, Tulay Ozkan/AAB-6958-2019; Sungur, Mukadder Orhan/A-6574-2017; Tugrul, Mehmet/AAD-4954-2020	Seyhan, Tulay Ozkan/0000-0002-7070-8827; Sungur, Mukadder Orhan/0000-0002-0770-8904; 			ARNOLD A, 1995, ANAESTHESIA, V50, P203, DOI 10.1111/j.1365-2044.1995.tb04556.x; Begon S, 2002, ANESTHESIOLOGY, V96, P627, DOI 10.1097/00000542-200203000-00019; Choi JC, 2002, ANESTHESIOLOGY, V97, P1137, DOI 10.1097/00000542-200211000-00017; Dayicioglu V, 2003, HYPERTENS PREGNANCY, V22, P257, DOI 10.1081/PRG-120024029; FERIA M, 1993, PAIN, V53, P287, DOI 10.1016/0304-3959(93)90225-E; FUCHSBUDER T, 1995, BRIT J ANAESTH, V74, P404; Kara H, 2002, EUR J ANAESTH, V19, P52, DOI 10.1017/S026502150200008X; Kissin I, 2000, ANESTH ANALG, V91, P1483, DOI 10.1097/00000539-200012000-00035; Ko SH, 2001, ANESTHESIOLOGY, V95, P640, DOI 10.1097/00000542-200109000-00016; Koinig H, 1998, ANESTH ANALG, V87, P206, DOI 10.1097/00000539-199807000-00042; Kussman B, 1997, BRIT J ANAESTH, V79, P122; Levaux C, 2003, ANAESTHESIA, V58, P131, DOI 10.1046/j.1365-2044.2003.02999.x; Lu JF, 2000, CLIN PHARMACOKINET, V38, P305, DOI 10.2165/00003088-200038040-00002; MacIver MB, 1996, ANESTHESIOLOGY, V85, P823, DOI 10.1097/00000542-199610000-00018; McCarthy RJ, 1998, ANESTH ANALG, V86, P830, DOI 10.1097/00000539-199804000-00028; SANCHEZCAPUCHINO A, 1994, ANAESTHESIA, V49, P912, DOI 10.1111/j.1365-2044.1994.tb04275.x; Sasaki R, 2002, ANESTHESIOLOGY, V96, P681, DOI 10.1097/00000542-200203000-00026; Schulz-Stubner S, 2001, EUR J ANAESTH, V18, P723, DOI 10.1046/j.1365-2346.2001.00921.x; STUDY RE, 1994, ANESTHESIOLOGY, V81, P104, DOI 10.1097/00000542-199407000-00016; Takano Y, 2000, PAIN, V84, P175, DOI 10.1016/S0304-3959(99)00207-9; Telci L, 2002, BRIT J ANAESTH, V89, P594, DOI 10.1093/bja/aef238; Tramer MR, 1996, ANESTHESIOLOGY, V84, P340, DOI 10.1097/00000542-199602000-00011; Weissberg N, 1991, Magnes Res, V4, P49; Wilder-Smith OHG, 1998, ANESTH ANALG, V86, P95, DOI 10.1097/00000539-199801000-00019; WilderSmith CH, 1997, ACTA ANAESTH SCAND, V41, P1023, DOI 10.1111/j.1399-6576.1997.tb04830.x; XIAO WH, 1994, BRAIN RES, V666, P168, DOI 10.1016/0006-8993(94)90768-4	26	86	98	3	17	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	FEB	2006	96	2					247	252		10.1093/bja/aei291			6	Anesthesiology	Anesthesiology	011YY	WOS:000235306600018	16311277	Bronze			2020-06-30	J	Compton, WM; Volkow, ND				Compton, WM; Volkow, ND			Major increases in opioid analgesic abuse in the United States: Concerns and strategies	DRUG AND ALCOHOL DEPENDENCE			English	Editorial Material						prescription drug abuse; opioid analgesics; drug abuse; drug dependence; addiction	DEPENDENCE; PAIN; PSYCHOMOTOR; ADDICTION	The problem of abuse of and addiction to opioid analgesics has emerged as a major issue for the United States in the past decade and has worsened over the past few years. The increases in abLISO of these opioids appear to reflect, in part, changes in medication prescribing practices, changes in drug formulations its well as relatively easy access via the internet. Though the use of opioid analgesics for the treatment of acute pain appears to be generally benign, long-term administration of opioids has been associated with clinically meaningful rates of abuse or addiction. Important areas of research to help with the problem of opioid analgesic abuse include the identification of clinical practices that minimize the risks of addiction, the development of guidelines for early detection and management of addiction, the development of opioid analgesics that minimize the risks for abuse, and the development of safe and effective non-opioid analgesics. With high rates of abuse of opiate analgesics among teenagers in the United States, a particularly urgent priority is the investigation of best practices for treating pain in adolescents as well as the development of prevention strategies to reduce diversion and abuse. (c) 2005 Elsevier Ireland Ltd. All rights reserved.	NIDA, Bethesda, MD 20892 USA	Compton, WM (reprint author), NIDA, 6001 Execut Blvd,MSC 9589, Bethesda, MD 20892 USA.	wcompton@nida.nih.gov					[Anonymous], 1994, DIAGN STAT MAN MENT; Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244; Basile AS, 2002, P NATL ACAD SCI USA, V99, P11452, DOI 10.1073/pnas.162371899; BAUM C, 1987, PUBLIC HEALTH REP, V102, P426; Cowan DT, 2003, PAIN MED, V4, P340, DOI 10.1111/j.1526-4637.2003.03038.x; DEQUINCY T, 1998, [No title captured]; FISCHMAN MW, 1989, [No title captured]; FISHBAIN DA, 1992, CLIN J PAIN, V8, P77, DOI 10.1097/00002508-199206000-00003; Forman RF, 2003, JAMA-J AM MED ASSOC, V290, P889, DOI 10.1001/jama.290.7.889; Gureje O, 1998, JAMA-J AM MED ASSOC, V280, P147, DOI 10.1001/jama.280.2.147; Hancock Christie M, 2002, Clin J Oncol Nurs, V6, P109; Harstall C, 2003, PAIN CLIN UPDATES, V11, P1, DOI DOI 10.1016/S1070-7212(03)00004-6; JOHNSTON LD, 2004, MONITORING FUTURE NA, V1; Joranson DE, 2000, JAMA-J AM MED ASSOC, V283, P1710, DOI 10.1001/jama.283.13.1710; Katz NP, 2003, ANESTH ANALG, V97, P1097, DOI 10.1213/01.ANE.0000080159.83342.B5; *NAT CTR ADD SUBST, 2004, YOUV GOT DRUGS PRESC; PORTER J, 1980, NEW ENGL J MED, V302, P123; Rice A S, 2001, Curr Opin Investig Drugs, V2, P399; Siegal HA, 2003, AM FAM PHYSICIAN, V67, P942; Simoni-Wastila L, 2004, AM J PUBLIC HEALTH, V94, P266, DOI 10.2105/AJPH.94.2.266; *SUBST AB MENT HLT, 2004, MOR DAT DRUG AB WARN; *SUBST AB MENT HLT, 2003, EM DEP TRENDS DRUG A; Volkow ND, 2003, AM J PSYCHIAT, V160, P1909, DOI 10.1176/appi.ajp.160.11.1909; Zacny J, 2003, DRUG ALCOHOL DEPEN, V69, P215, DOI 10.1016/S0376-8716(03)00003-6; Zacny JP, 2003, PSYCHOPHARMACOLOGY, V170, P242, DOI 10.1007/s00213-003-1540-9; Zacny JP, 2003, PSYCHOPHARMACOLOGY, V165, P146, DOI 10.1007/s00213-002-1245-5	26	551	557	1	97	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716	1879-0046		DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	FEB 1	2006	81	2					103	107		10.1016/j.drugalcdep.2005.05.009			5	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	004WJ	WOS:000234783000001	16023304				2020-06-30	J	Chari, P; Ghai, B				Chari, P; Ghai, B			Comparison of butorphanol and thiopentone vs fentanyl and thiopentone for laryngeal mask airway insertion	JOURNAL OF CLINICAL ANESTHESIA			English	Article						equipment, laryngeal mask; anesthetic, intravenous, thiopentone; anesthetic, adjuvant, butorphanol, fentanyl	PROPOFOL; ANESTHESIA; INDUCTION; FACILITATE	Study Objective: To compare laryngeal mask airway (LMA) insertion conditions using a combination of butorphanol and thiopentone vs fentanyl and thiopentone. Design: Prospective, randomized, and double-blind study. Setting: Operating theater. Patients: One hundred four females, with American Society of Anesthesiologists grades I and II, diagnosed with carcinoma cervix scheduled for intracavitary implant placement, were recruited into the study. The patients were randomly divided into 2 groups of 52 each. Intervention: Anesthesia was induced with butorphanol (30 mu g kg(-1)) and thiopentone in group B and fentanyl (1.5 mu g kg(-1)) and thiopentone in group F, followed by LMA insertion. Anesthesia was maintained with O-2, N2O, and isoflurane with spontaneous ventilation. Measurements: Six variables were noted oil a 3-point scale: jaw relaxation (nil/slight/gross), ease of insertion (easy/difficult/impossible), swallowing (nil/slight/gross), coughing/gagging (nil/slight/gross), limb/head movement (nil/slight/gross), and laryngospasm (nil/slight/gross). Postoperatively, sedation score was assessed on a 4-point scale at 1/2 hour, 1 hour, and 2 hours. Main Results: The 2 groups were demographically similar. Incidence of full jaw relaxation at first attempt was significantly higher in group B vs F (48 vs 35 patients, P = 0.003). Insertion was easy in 48 vs 37 patients in group B and F, respectively (P = 0.017). The incidence of swallowing, patient movements, and laryngospasm was comparable among the groups. Coughing/gagging was significantly lower in group B (P = 0.008). Significantly more patients were sedated in group B at 1/2 hour ( P = 0.010) and 1 hour (P = 0.000). None of the patients were deeply sedated at 1 hour. At 2 hours, all patients were awake. Conclusion: The use of butorphanol and thiopentone as induction agents produced excellent LMA insertion conditions compared to fentanyl and thiopentone (98% vs 86% success rate with 92% vs 71 % easy insertion). (c) 2006 Elsevier Inc. All rights reserved.	Postgrad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Chandigarh 160012, India	Ghai, B (reprint author), Postgrad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Sector-12, Chandigarh 160012, India.	ghaibabita@hotmail.com					Bapat P, 1996, CAN J ANAESTH, V43, P564, DOI 10.1007/BF03011767; BROWN GW, 1995, ACTA ANAESTH SCAND, V39, P1103, DOI 10.1111/j.1399-6576.1995.tb04238.x; BROWN GW, 1991, ANAESTHESIA, V46, P771, DOI 10.1111/j.1365-2044.1991.tb09776.x; Cook TM, 1997, CAN J ANAESTH, V44, P569, DOI 10.1007/BF03011948; COOK TM, 1996, ANAESTHESIA, V51, P1187; Koh KF, 1999, CAN J ANAESTH, V46, P670, DOI 10.1007/BF03013956; Lee MPL, 2001, ANESTH ANALG, V93, P359, DOI 10.1097/00000539-200108000-00025; LINDGREN L, 1993, BRIT J ANAESTH, V70, P306, DOI 10.1093/bja/70.3.306; PACHTER IJ, 1985, DRUG ALCOHOL DEPEN, V14, P325, DOI 10.1016/0376-8716(85)90065-1; ROSOW C E, 1988, Acute Care, V12, P2; SCANLON P, 1993, CAN J ANAESTH, V40, P816, DOI 10.1007/BF03009250; Seavell CR, 1996, ANAESTHESIA, V51, P699, DOI 10.1111/j.1365-2044.1996.tb04660.x; SKLAR GS, 1989, DICP ANN PHARMAC, V23, P659, DOI 10.1177/106002808902300905; Vogelsang J, 1991, J Post Anesth Nurs, V6, P129; Yoshino A, 1999, BRIT J ANAESTH, V83, P279, DOI 10.1093/bja/83.2.279	15	6	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	FEB	2006	18	1					8	11		10.1016/j.jclinane.2005.04.007			4	Anesthesiology	Anesthesiology	024MG	WOS:000236198500003	16517325				2020-06-30	J	Feld, JM; Hoffman, WE; Stechert, MM; Hoffman, IW; Ananda, RC				Feld, JM; Hoffman, WE; Stechert, MM; Hoffman, IW; Ananda, RC			Fentanyl or dexmedetomidine combined with desflurane for bariatric surgery	JOURNAL OF CLINICAL ANESTHESIA			English	Article						obesity; fentanyl; dexmedetomidine; desflurane; pain, postoperative; morphine	OBSTRUCTIVE SLEEP-APNEA; GASTRIC BYPASS; BISPECTRAL INDEX; MORBID-OBESITY; RISK-FACTORS; PROPOFOL; REQUIREMENTS; REMIFENTANIL; VOLUNTEERS; ALFENTANIL	Study Objective: Because fentanyl has ventilatory depressing effects, alternative methods for analgesia may be beneficial for management of bariatric surgery. We evaluated whether dexmedetomidine infusion could replace fentanyl for facilitation of open gastric bypass surgery. Design: Randomized, single blinded, open label. Setting: University teaching hospital. Patients: Twenty bariatric patients with an average body mass index of 54 to 61 kg/m(2) undergoing surgery for open gastric bypass. Interventions: Patients were randomized to receive either fentanyl (0.5-mu g/kg bolus, 0.5 mu g (.) kg(-1) h(-1), n = 10) or dexmedetomidine (0.5-mu g/kg bolus, 0.4 mu g (.) kg(-1) (.) h(-1), n = 10) for intraoperative analgesia. In both groups, end-tidal desflurane was adjusted to maintain the bispectral index at 45 to 50. Measurements: In the operating room, blood pressure and heart rate were measured at 5-minute intervals. Bispectral index and end-tidal desflurane concentration were measured every hour. During recovery in the postanesthesia care unit, patient-evaluated pain scores and morphine use by patient-controlled analgesia pump were determined. Main Results: During surgery, desflurane concentrations necessary to maintain the bispectral index at 45 to 50 were decreased, and blood pressure and heart rate were lower with in the dexmedetomidine compared with fentanyl group. In the postanesthesia care unit, pain scores and morphine use were decreased in the dexmedetomidine group. Conclusions: Dexmedetomidine, when used to substitute for fentanyl during gastric bypass surgery, attenuates blood pressure and provides postoperative analgesia. (c) 2006 Elsevier Inc. All rights reserved.	Univ Illinois, Dept Anesthesiol, Chicago, IL 60612 USA	Hoffman, WE (reprint author), Univ Illinois, Dept Anesthesiol, Chicago, IL 60612 USA.	whoffman@uic.edu					Arain SR, 2004, ANESTH ANALG, V98, P153, DOI 10.1213/01.ANE.0000093225.39866.75; Barr G, 2000, ACTA ANAESTH SCAND, V44, P807, DOI 10.1034/j.1399-6576.2000.440707.x; Benumof Jonathan L, 2002, Anesthesiol Clin North Am, V20, P789, DOI 10.1016/S0889-8537(02)00020-2; CAMPBELL C, 1995, RESP PHYSIOL, V100, P107, DOI 10.1016/0034-5687(94)00119-K; Daniel M, 1998, ANESTHESIOLOGY, V88, P43, DOI 10.1097/00000542-199801000-00009; De Wolf AM, 2001, ANESTH ANALG, V93, P1205, DOI 10.1097/00000539-200111000-00031; Deveney CW, 2004, AM J SURG, V187, P655, DOI 10.1016/j.amjsurg.2004.01.001; Dutta S, 2001, J PHARM SCI-US, V90, P172, DOI 10.1002/1520-6017(200102)90:2<172::AID-JPS8>3.0.CO;2-J; ESCLAMADO RM, 1989, LARYNGOSCOPE, V99, P1125; Feld JM, 2003, CAN J ANAESTH, V50, P336, DOI 10.1007/BF03021029; Fernandez AZ, 2004, ANN SURG, V239, P698, DOI 10.1097/01.sla.0000124295.41578.ab; Gaszynski TM, 2004, OBES SURG, V14, P498, DOI 10.1381/096089204323013488; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; Holmes Johnnie, 2004, AANA J, V72, P126; Javaheri S, 2004, EUR HEART J, V25, P260, DOI 10.1016/j.ehj.2003.10.032; Kabon B, 2004, ANESTHESIOLOGY, V100, P274, DOI 10.1097/00000542-200402000-00015; Lysakowski C, 2001, BRIT J ANAESTH, V86, P523, DOI 10.1093/bja/86.4.523; Maze M, 2001, CRIT CARE CLIN, V17, P881, DOI 10.1016/S0749-0704(05)70185-8; Nguyen NT, 2001, J AM COLL SURGEONS, V192, P469, DOI 10.1016/S1072-7515(01)00822-5; PIVALIZZA EG, 1994, ANAESTH INTENS CARE, V22, P315; Renna Maurizio, 2002, J Clin Monit Comput, V17, P377, DOI 10.1023/A:1024210405543; Salihoglu Z, 2001, OBES SURG, V11, P496, DOI 10.1381/096089201321209413; Schneider MC, 1997, ACTA ANAESTH SCAND, V41, P163; Smith SC, 2004, OBES SURG, V14, P73, DOI 10.1381/096089204772787329; Thornton C, 1999, BRIT J ANAESTH, V83, P381; Ukleja A, 2004, J CLIN GASTROENTEROL, V38, P312, DOI 10.1097/00004836-200404000-00004; VILA P, 1994, ANAESTHESIA, V49, P909, DOI 10.1111/j.1365-2044.1994.tb04274.x	27	102	110	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	FEB	2006	18	1					24	28		10.1016/j.jclinane.2005.05.009			5	Anesthesiology	Anesthesiology	024MG	WOS:000236198500006	16517328				2020-06-30	J	Lacombe, GF; Leake, JL; Clokie, CM; Haas, DA				Lacombe, GF; Leake, JL; Clokie, CM; Haas, DA			Comparison of remifentanil with fentanyl for deep sedation in oral surgery	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							REGIONAL ANESTHESIA; PROPOFOL ANESTHESIA; AMBULATORY SURGERY; RECOVERY; ALFENTANIL; DESFLURANE; SEVOFLURANE; INDUCTION; PHARMACODYNAMICS; REQUIREMENTS	Purpose: The aim of this study was to compare recovery for oral surgery patients given a deep sedation regimen of midazolam, propofol, and remifentanil with a standard control of fentanyl in place of remifentanil. Materials and Methods: This investigation was designed as a randomized, prospective, single-blinded controlled study. Group 1, the control, received midazolam 0.03 mg/kg, fentanyl I mu g/kg, and propofol initially at 140 mu g/kg/min. Group 2 received midazolam 0.03 mg/kg, remifentanil: propofol (1:500) given at an initial propofol infusion rate of 40 mu g/kg/min. Outcome measures included time to response to verbal command, Aldrete score = 9, Postanesthesia Discharge Scoring System = 7, and assessment by the Digit Symbol Substitution Test. Results: Forty-seven subjects were entered in the study. Baseline findings were homogenous between the 2 groups. Subjects in group 2 recovered earlier (P < .005) and required less propofol for both the induction (0.8 +/- 0.4 versus 1.2 +/- 0.6 mg/kg; mean +/- SD, P < .01) and maintenance of deep sedation (46 +/- 9 versus 131 +/- 17 mu g/kg/min; P < .005). There were minor differences in vital signs. Conclusions: This study demonstrated that this remifentanil regimen provided significantly more rapid recovery and used significantly less propofol compared with the fentanyl regimen. (c) 2006 American Association of Oral and Maxillofacial Surgeons.	Univ Toronto, Fac Dent, Toronto, ON M5G 1G6, Canada	Haas, DA (reprint author), Univ Toronto, Fac Dent, 124 Edward St, Toronto, ON M5G 1G6, Canada.	daniel.haas@utoronto.ca					ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Andrews DT, 1997, ANESTH ANALG, V85, P414; CHUNG F, 1995, ANESTH ANALG, V80, P896, DOI 10.1097/00000539-199505000-00008; CLAEYS MA, 1988, BRIT J ANAESTH, V60, P3, DOI 10.1093/bja/60.1.3; CUNNINGHAM FE, 1993, ANESTHESIOLOGY, V79, pA712; Dershwitz M, 2002, J CLIN ANESTH, V14, P275, DOI 10.1016/S0952-8180(02)00353-7; DESMONTS JM, 1995, ANESTHESIOLOGY, V83, pA857; Fragen RJ, 2000, ANESTH ANALG, V90, P713, DOI 10.1097/00000539-200003000-00037; GLASS PSA, 1993, ANESTH ANALG, V77, P1031; Greilich PE, 2001, ANESTH ANALG, V92, P80; HINDMARCH I, 1980, BRIT J CLIN PHARMACO, V10, P189, DOI 10.1111/j.1365-2125.1980.tb01745.x; KAPILA A, 1995, ANESTHESIOLOGY, V83, P968, DOI 10.1097/00000542-199511000-00009; Kazama T, 2000, ANESTHESIOLOGY, V92, P1017, DOI 10.1097/00000542-200004000-00019; Koitabashi T, 2002, ANESTH ANALG, V94, P1530, DOI 10.1097/00000539-200206000-00028; LANGACKER P, 1996, PHYS REV D, V54, P1; Larsen B, 2000, ANESTH ANALG, V90, P168, DOI 10.1097/00000539-200001000-00035; Leslie K, 1996, ANESTHESIOLOGY, V84, P52, DOI 10.1097/00000542-199601000-00006; LETOURNEAU JE, 1983, ANESTH PROG, V152; Loop T, 2000, ANESTH ANALG, V91, P123, DOI 10.1097/00000539-200007000-00023; Marshall SI, 1999, ANESTH ANALG, V88, P508, DOI 10.1097/00000539-199903000-00008; Nakagawa M, 2000, CAN J ANAESTH, V47, P47, DOI 10.1007/BF03020731; Pelosi G, 1999, Minerva Anestesiol, V65, P791; Reyle-Hahn M, 2000, PAEDIATR ANAESTH, V10, P59, DOI 10.1046/j.1460-9592.2000.00440.x; SCHAFER SL, 1990, [No title captured], V73, P1091; SMITH I, 1994, ANESTHESIOLOGY, V81, P1005; Song D, 1998, ANESTH ANALG, V86, P267, DOI 10.1097/00000539-199802000-00009; STOKES DN, 1991, ANESTH ANALG, V72, P578; STONE BI, 1984, [No title captured], V18, P15; Vuyk J, 1997, ANESTHESIOLOGY, V87, P1549, DOI 10.1097/00000542-199712000-00033; WESTMORELAND CL, 1994, ANESTH ANALG, V78, P23; Wilder-Smith OHG, 2001, CAN J ANAESTH, V48, P439, DOI 10.1007/BF03028305; WRIGLEY SR, 1991, ANAESTHESIA, V46, P615, DOI 10.1111/j.1365-2044.1991.tb09706.x	32	11	15	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	FEB	2006	64	2					215	222		10.1016/j.joms.2005.10.026			8	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	005PV	WOS:000234837200010	16413892				2020-06-30	J	Girshin, M; Mukherjee, J; Clowney, R; Singer, LP; Wasnick, J				Girshin, M; Mukherjee, J; Clowney, R; Singer, LP; Wasnick, J			The postoperative cardiovascular arrest of a 5-year-old male: an initial presentation of Duchenne's muscular dystrophy	PEDIATRIC ANESTHESIA			English	Article						Duchenne's muscular dystrophy; hyperkalemia; cardiac arrest; anesthesia	MALIGNANT HYPERTHERMIA; CARDIAC-ARREST; ANESTHESIA; CHILDREN	Anesthesia may be administered to patients with Duchenne's muscular dystrophy, but cases are reported in which apparently healthy children suffer hyperkalemic cardiac arrest. We present the case of a 5-year-old boy whose muscular dystrophy was discovered following a fatal, perioperative cardiac arrest in the postanesthesia care unit.	Montefiore Med Ctr, Dept Anesthesiol, Bronx, NY 10467 USA; Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA; Montefiore Med Ctr, Childrens Hosp, Bronx, NY 10467 USA	Girshin, M (reprint author), Montefiore Med Ctr, Dept Anesthesiol, 111 E 210th St N4, Bronx, NY 10467 USA.	mgirshin@montefiore.org					BOIVIN P, 2003, BRIT J ANAESTH, V90, P800; Booker PD, 2003, BRIT J ANAESTH, V90, P349, DOI 10.1093/bja/aeg061; CONTRAN R, 1999, PATHOLOGIC BASIS DIS, P1281; Goresky GV, 1999, CAN J ANAESTH, V46, P525, DOI 10.1007/BF03013541; HEIMANPATTERSON TD, 1993, MED CLIN N AM, V77, P477, DOI 10.1016/S0025-7125(16)30265-6; JACKSON MJ, 1987, MUSCLE NERVE, V10, P15, DOI 10.1002/mus.880100105; Korones DN, 2001, AM J HEMATOL, V66, P46, DOI 10.1002/1096-8652(200101)66:1<46::AID-AJH1007>3.3.CO;2-F; Kunkel LM, 2005, AM J HUM GENET, V76, P205, DOI 10.1086/428143; LARCH M, 1997, CLIN PEDIATR, V36, P9; Morray JP, 2000, ANESTHESIOLOGY, V93, P6, DOI 10.1097/00000542-200007000-00007; Morris P, 1997, PAEDIATR ANAESTH, V7, P1, DOI 10.1046/j.1460-9592.1997.d01-41.x; Nathan A, 2005, ANESTH ANALG, V100, P672, DOI 10.1213/01.ANE.0000146533.21771.2F; PELUSO A, 1992, CAN J ANAESTH, V39, P1117, DOI 10.1007/BF03008386; Richards W C, 1972, Anaesth Intensive Care, V1, P150; SETHNA NF, 1988, ANESTHESIOLOGY, V68, P462, DOI 10.1097/00000542-198803000-00028; Takahashi Hidenori, 2002, Masui, V51, P190; VANESSEN A, 2004, THESIS, P49; Yotsukura M, 1999, AM HEART J, V137, P672, DOI 10.1016/S0002-8703(99)70221-8	18	22	22	0	1	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	FEB	2006	16	2					170	173		10.1111/j.1460-9592.2005.01698.x			4	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	003HI	WOS:000234672000011	16430414				2020-06-30	J	Soliman, LM; Mossad, EB				Soliman, LM; Mossad, EB			Thoracic epidural catheter in the management of a child with an anterior mediastinal mass: a case report and literature review	PEDIATRIC ANESTHESIA			English	Review						thoracotomy; mediastinal mass; thoracic epidural; pediatric	SPINAL-CORD INJURY; REGIONAL ANESTHESIA; COMPLICATIONS; ANALGESIA; HEMATOMA; SURGERY; PATIENT; AIRWAY; RISK	We describe a case of an anterior mediastinal mass compressing the right main bronchus that required a biopsy through a thoracotomy incision. The anesthetic management of these patients is associated with several risks and challenges, including potential airway compression and cardiovascular collapse. Inhalation induction and maintenance of spontaneous respiration is recommended to preserve normal transpulmonary pressure gradient and improve flow through conducting airways. We placed a thoracic epidural catheter under general anesthesia as the main analgesic technique in order to maintain spontaneous breathing. The use of regional anesthesia, especially continuous epidurals in pediatric cardiothoracic anesthesia have many theoretical advantages including attenuation of the neuroendocrine response, facilitation of rapid extubation and improved ventilatory mechanics secondary to decreased narcotic requirements. The absolute risk of nerve injury and epidural hematoma for this procedure is unknown and hard to define in this patient population. We reviewed multiple studies and case reports addressing its safety and reported side effects. Finally, we emphasize that a thoracic epidural anesthesia is a reasonable choice that can be applied carefully in special situations even for children under general anesthesia.	Cleveland Clin Fdn, Dept Cardiothorac Anesthesia G3, Div Anesthesia & Crit Care Med, Cleveland, OH 44195 USA	Mossad, EB (reprint author), Cleveland Clin Fdn, Dept Cardiothorac Anesthesia G3, Div Anesthesia & Crit Care Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.	mossade@ccf.org					AKHTAR TM, 1991, BRIT J ANAESTH, V67, P632, DOI 10.1093/bja/67.5.632; Auroy Y, 1997, ANESTHESIOLOGY, V87, P479, DOI 10.1097/00000542-199709000-00005; AZAROW KS, 1993, J THORAC CARDIOV SUR, V106, P67, DOI 10.1016/S0022-5223(19)33741-9; Breschan C, 2001, PAEDIATR ANAESTH, V11, P105, DOI 10.1046/j.1460-9592.2001.00593.x; Bromage PR, 1998, REGION ANESTH PAIN M, V23, P104, DOI 10.1016/S1098-7339(98)90120-1; Clement G, 1990, Agressologie, V31, P34; DECAMP M, 1996, MEDIASTINUM GLENNS T, P643; Ferrari L R, 1989, J Clin Anesth, V1, P460, DOI 10.1016/0952-8180(89)90012-3; FLANDINBLETY C, 1995, PAEDIATR ANAESTH, V5, P41, DOI 10.1111/j.1460-9592.1995.tb00239.x; FOO D, 1981, SURG NEUROL, V15, P389, DOI 10.1016/0090-3019(81)90178-6; Giaufre E, 1996, ANESTH ANALG, V83, P904, DOI 10.1097/00000539-199611000-00003; Hammer GB, 2004, PAEDIATR ANAESTH, V14, P95, DOI 10.1046/j.1460-9592.2003.01196.x; Ho AMH, 2000, CHEST, V117, P551, DOI 10.1378/chest.117.2.551; Horlocker TT, 2003, ANESTH ANALG, V96, P1547, DOI 10.1213/01.ANE.0000057600.31380.75; Horlocker TT, 2003, REGION ANESTH PAIN M, V28, P172, DOI 10.1053/rapm.2003.50046; Kasai T, 2003, ANESTH ANALG, V96, P65, DOI 10.1097/00000539-200301000-00014; Kitahara Y, 1996, Masui, V45, P115; Krane EJ, 1998, REGION ANESTH PAIN M, V23, P433, DOI 10.1016/S1098-7339(98)90023-2; Lyerly HK, 1988, PULMONARY DIS DISORD, V3, P2087; Pastor MC, 2003, J CARDIOTHOR VASC AN, V17, P154, DOI 10.1053/jcan.2003.39; Peterson KL, 2000, ANESTH ANALG, V90, P1014, DOI 10.1097/00000539-200005000-00002; PIETROPAOLI JA, 1993, J PEDIATR SURG, V28, P560, DOI 10.1016/0022-3468(93)90616-S; PIRO AJ, 1976, INT J RADIAT ONCOL, V1, P415, DOI 10.1016/0360-3016(76)90006-7; Polaner DM, 1996, ANESTH ANALG, V82, P208, DOI 10.1097/00000539-199601000-00037; PULLERITS J, 1989, CAN J ANAESTH, V36, P681, DOI 10.1007/BF03005421; RILEY RH, 1992, ANAESTH INTENS CARE, V20, P229, DOI 10.1177/0310057X9202000221; Rose JB, 2003, ANESTH ANALG, V96, P3, DOI 10.1097/00000539-200301000-00002; Rosen DA, 2004, ANESTH ANALG, V98, P966, DOI 10.1213/01.ANE.0000103267.37895.5B; SALOMKI TE, 1991, ANESTHESIOLOGY, V79, P672; Sanchez R, 1998, J CARDIOTHOR VASC AN, V12, P170, DOI 10.1016/S1053-0770(98)90326-3; Scott NB, 2001, ANESTH ANALG, V93, P528, DOI 10.1097/00000539-200109000-00003; SHAMBERGER RC, 1991, J PEDIATR SURG, V26, P138, DOI 10.1016/0022-3468(91)90894-Y; TOBIAS JD, 1993, CAN J ANAESTH, V40, P879, DOI 10.1007/BF03009262; VISWANATHAN S, 1995, J CLIN ANESTH, V7, P151, DOI 10.1016/0952-8180(94)00028-3; Wolf AR, 1998, PAEDIATR ANAESTH, V8, P305, DOI 10.1046/j.1460-9592.1998.00239.x; WOOD CE, 1994, CAN J ANAESTH, V41, P613, DOI 10.1007/BF03010002	36	7	7	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	FEB	2006	16	2					200	205		10.1111/j.1460-9592.2005.01638.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	003HI	WOS:000234672000018	16430421				2020-06-30	J	Sreevastava, DK; Setlur, R; Sharma, VK; Padmini, HS; Puri, B; Bhargava, AK				Sreevastava, DK; Setlur, R; Sharma, VK; Padmini, HS; Puri, B; Bhargava, AK			Anesthetic management of an infant with lupus and congenital complete heart block	PEDIATRIC ANESTHESIA			English	Letter									Armed Forces Med Coll, Dept Anaesthesiol, Pune 411040, Maharashtra, India	Sreevastava, DK (reprint author), Armed Forces Med Coll, Dept Anaesthesiol, Pune 411040, Maharashtra, India.	dksreevastava@hotmail.com	ekambaram, padmini/D-3530-2015	Setlur, Rangraj/0000-0003-2914-4748			Bennie RE, 1997, PAEDIATR ANAESTH, V7, P301, DOI 10.1046/j.1460-9592.1997.d01-87.x; Castilla M, 2004, PAEDIATR ANAESTH, V14, P172, DOI 10.1046/j.1460-9592.2003.01180.x; KITRIDOU RC, 1997, DUBOIS LUPUS ERYTHEM, P1023; LINTON DM, 1984, S AFR MED J, V66, P875; Mohan VK, 2003, ANAESTH INTENS CARE, V31, P667, DOI 10.1177/0310057X0303100611; WOOD M, 1997, PRACTICAL CARDIAC DI, P168	6	1	1	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	FEB	2006	16	2					216	217		10.1111/j.1460-9592.2005.01754.x			2	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	003HI	WOS:000234672000021	16430424				2020-06-30	J	Janczewski, WA; Feldman, JL				Janczewski, WA; Feldman, JL			Distinct rhythm generators for inspiration and expiration in the juvenile rat	JOURNAL OF PHYSIOLOGY-LONDON			English	Article							PRE-BOTZINGER COMPLEX; RESPIRATORY PATTERN GENERATOR; CEREBRAL BLOOD-FLOW; STEM-SPINAL-CORD; NEWBORN RAT; PREBOTZINGER COMPLEX; VENTROLATERAL MEDULLA; ABDOMINAL-MUSCLES; IN-VITRO; NEURONS	Inspiration and active expiration are commonly viewed as antagonistic phases of a unitary oscillator that generates respiratory rhythm. This view conflicts with observations we report here in juvenile rats, where by administration of fentanyl, a selective mu-opiate agonist, and induction of lung reflexes, we separately manipulated the frequency of inspirations and expirations. Moreover, completely transecting the brainstem at the caudal end of the facial nucleus abolished active expirations, while rhythmic inspirations continued. We hypothesize that inspiration and expiration are generated by coupled, anatomically separate rhythm generators, one generating active expiration located close to the facial nucleus in the region of the retrotrapezoid nucleus/parafacial respiratory group, the other generating inspiration located more caudally in the preBotzinger Complex.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA	Janczewski, WA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Box 951763,10833 LeConte Ave, Los Angeles, CA 90095 USA.	victoraj@mednet.ucla.edu		Feldman, Jack/0000-0003-3692-9412	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL 70029, R01 HL070029]		Alheid GF, 2002, J NEUROCYTOL, V31, P693, DOI 10.1023/A:1025799830302; Ballanyi K, 1999, PROG NEUROBIOL, V59, P583, DOI 10.1016/S0301-0082(99)00009-X; Ballanyi Klaus, 2004, Current Neuropharmacology, V2, P221, DOI 10.2174/1570159043476828; BIANCHI AL, 1995, PHYSIOL REV, V75, P1, DOI 10.1152/physrev.1995.75.1.1; Borday C, 2004, PROG BIOPHYS MOL BIO, V84, P89, DOI 10.1016/j.pbiomolbio.2003.11.002; Brainerd E. L., 1999, EXP BIOL ONLINE, V4, P11; CHERNICK V, 1982, SCIENCE, V216, P1252, DOI 10.1126/science.7200636; CONNELLY CA, 1990, AM J PHYSIOL, V258, pL33; del Toro ED, 2001, J NEUROSCI, V21, P5637; Drummond GB, 2003, BRIT J ANAESTH, V91, P73, DOI 10.1093/bja/aeg145; ELLENBERGER HH, 1990, BRAIN RES, V513, P35, DOI 10.1016/0006-8993(90)91086-V; ERRCHIDI S, 1991, J PHYSIOL-LONDON, V443, P477, DOI 10.1113/jphysiol.1991.sp018846; Ezure K, 2003, J NEUROSCI, V23, P8941; Feldman JL, 2003, ANNU REV NEUROSCI, V26, P239, DOI 10.1146/annurev.neuro.26.041002.131103; FELDMAN JL, 1975, BIOL CYBERN, V17, P39, DOI 10.1007/BF00326708; FELDMAN JL, 1986, [No title captured], V4, P463; Gray PA, 2001, NAT NEUROSCI, V4, P927, DOI 10.1038/nn0901-927; Gray PA, 1999, SCIENCE, V286, P1566, DOI 10.1126/science.286.5444.1566; Grillner S, 2002, BRAIN RES REV, V40, P92, DOI 10.1016/S0165-0173(02)00193-5; GRILLNER S, 1991, Current Biology, V1, P231, DOI 10.1016/0960-9822(91)90066-6; GRUNSTEIN MM, 1981, J APPL PHYSIOL, V51, P122; Guyenet PG, 2005, J NEUROSCI, V25, P8938, DOI 10.1523/JNEUROSCI.2415-05.2005; Haji A, 2003, NEUROPHARMACOLOGY, V45, P368, DOI 10.1016/S0028-3908(03)00154-0; HAZINSKI TA, 1981, J APPL PHYSIOL, V50, P713; Homi HM, 2003, ANESTHESIOLOGY, V99, P1145, DOI 10.1097/00000542-200311000-00022; HOWARD RS, 1991, J PHYSIOL-LONDON, V437, P181, DOI 10.1113/jphysiol.1991.sp018590; Jacquin TD, 1996, NEURON, V17, P747, DOI 10.1016/S0896-6273(00)80206-8; JANCZEWSKI WA, 1990, RESP PHYSIOL, V79, P163, DOI 10.1016/0034-5687(90)90016-R; JANCZEWSKI WA, 1984, RESP PHYSIOL, V57, P293, DOI 10.1016/0034-5687(84)90078-1; Janczewski WA, 2002, J PHYSIOL-LONDON, V545, P1017, DOI 10.1113/jphysiol.2002.023408; JANCZEWSKI WA, 2003, 2 2 DISTINC GENERATO; JANCZEWSKI WA, 2002, MU OPIOID RECEPTOR A; JANSEN AH, 1983, PHYSIOL REV, V63, P437; KATZ RI, 1993, J CLIN ANESTH, V5, P134, DOI 10.1016/0952-8180(93)90141-Z; KUDO N, 1987, NEUROSCI LETT, V75, P43, DOI 10.1016/0304-3940(87)90072-3; MADSEN JB, 1987, BRIT J ANAESTH, V59, P1204, DOI 10.1093/bja/59.10.1204; Manzke T, 2003, SCIENCE, V301, P226, DOI 10.1126/science.1084674; McKay LC, 2005, NAT NEUROSCI, V8, P1142, DOI 10.1038/nn1517; Mellen NM, 2003, NEURON, V37, P821, DOI 10.1016/S0896-6273(03)00092-8; Mulkey DK, 2004, NAT NEUROSCI, V7, P1360, DOI 10.1038/nn1357; ONIMARU H, 1988, BRAIN RES, V445, P314, DOI 10.1016/0006-8993(88)91194-8; Onimaru H, 2003, J NEUROSCI, V23, P1478; Onimaru H, 1997, JPN J PHYSIOL, V47, P385, DOI 10.2170/jjphysiol.47.385; PORTER R, 1970, BREATHING HERING BRE; Richter D W, 1992, Curr Opin Neurobiol, V2, P788, DOI 10.1016/0959-4388(92)90135-8; RICHTER DW, 1982, J EXP BIOL, V100, P93; RINGAERT KRA, 1988, ANESTH ANALG, V67, P383; Rybak IA, 1997, J NEUROPHYSIOL, V77, P2007; Sakamoto T, 2001, BRIT J ANAESTH, V86, P395, DOI 10.1093/bja/86.3.395; Schreihofer AM, 1999, J COMP NEUROL, V407, P583, DOI 10.1002/(SICI)1096-9861(19990517)407:4<583::AID-CNE8>3.0.CO;2-E; SCHWARZACHER SW, 1995, J NEUROPHYSIOL, V73, P1452; SEARS TA, 1982, NATURE, V299, P728, DOI 10.1038/299728a0; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; SOUTHALL DP, 1985, LANCET, V2, P571; Takeda S, 2001, ANESTHESIOLOGY, V95, P740, DOI 10.1097/00000542-200109000-00029; Tanabe A, 2005, NEUROSCI LETT, V375, P19, DOI 10.1016/j.neulet.2004.10.058; Vasilakos K, 2005, J NEUROBIOL, V62, P369, DOI 10.1002/neu.20102; Viemari JC, 2004, J NEUROPHYSIOL, V91, P746, DOI 10.1152/jn.01153.2002; Wenninger JM, 2004, J APPL PHYSIOL, V97, P1629, DOI 10.1152/japplphysiol.00953.2003; WIXSON SK, 1997, ANESTHESIA ANELGESIA	60	272	276	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3751	1469-7793		J PHYSIOL-LONDON	J. Physiol.-London	JAN 15	2006	570	2					407	420		10.1113/jphysiol.2005.098848			14	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	003HO	WOS:000234672600016	16293645	Green Published			2020-06-30	J	Guyenet, PG				Guyenet, PG			Novel two-rhythm generator theory of breathing in mammals	JOURNAL OF PHYSIOLOGY-LONDON			English	Editorial Material							RESPIRATORY RHYTHM		Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA	Guyenet, PG (reprint author), Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA.	pgg@virginia.edu					Guyenet PG, 2005, J NEUROSCI, V25, P8938, DOI 10.1523/JNEUROSCI.2415-05.2005; Janczewski WA, 2002, J PHYSIOL-LONDON, V545, P1017, DOI 10.1113/jphysiol.2002.023408; JANCZEWSKI WA, 2006, J PHYSL, V570, P405; Morrison SR, 2004, NEWS PHYSIOL SCI, V19, P67, DOI 10.1152/nips.01502.2003; Onimaru H, 2003, J NEUROSCI, V23, P1478; Pena F, 2004, NEURON, V43, P105, DOI 10.1016/j.neuron.2004.06.023; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; Vasilakos K, 2005, J NEUROBIOL, V62, P369, DOI 10.1002/neu.20102	8	0	0	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0022-3751			J PHYSIOL-LONDON	J. Physiol.-London	JAN 15	2006	570	2					CP2	CP2		10.1113/jphysiol.2005.101709			1	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	003HO	WOS:000234672600001		Green Published			2020-06-30	J	Rohm, KD; Piper, SN; Suttner, S; Schuler, S; Boldt, J				Rohm, KD; Piper, SN; Suttner, S; Schuler, S; Boldt, J			RETRACTED: Early recovery, cognitive function and costs of a desflurane inhalational vs. a total intravenous anaesthesia regimen in long-term surgery (Retracted article. See vol. 55, pg. 903, 2011)	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article; Proceedings Paper; Retracted Publication	28th Congress of the European-Society-of-Neuroradiology	SEP 11-14, 2003	Istanbul, TURKEY	European Soc Neuroradiol		cognitive function; recovery; MMST; desflurane; propofol; remifentanil; costs	PROPOFOL ANESTHESIA; ELDERLY-PATIENTS; GENERAL-ANESTHESIA; ISOFLURANE; REMIFENTANIL; SEVOFLURANE; COMBINATION; PROFILE	Background: The purpose of the study was to compare time of recovery, return of cognitive function, post-anaesthetic care unit (PACU) stay and costs of a propofol/remifentanil (TIVA) with a desflurane/fentanyl-based anaesthesia (desflurane group) in surgical procedures lasting more than 150 min. Methods: Forty-nine patients undergoing elective abdominal prostatectomy were allocated randomly to receive bispectal index (BIS)-controlled desflurane/fentanyl (n = 24) or propofol/remifentanil (n = 25). Awakening, clinical recovery, direct drug acquisition and post-operative pain treatment were documented. Cognitive skills were tested using the Mini-Mental Status (MMST) test. Results: Extubation was significantly faster with desflurane (6.9 +/- 3.5 min) than with TIVA (11.2 +/- 4.0 min) as well as times for stating name and date of birth (desflurane: 6.1 +/- 3.9 and 6.6 +/- 4.0 min; TIVA: 12.4 +/- 11.5 min and 13.4 +/- 11.3 min). There were no significant differences in PACU discharge times or MMS scores between the groups. Significantly more patients suffered post-operative nausea and vomiting (PONV) in the desflurane (33% vs. 0%) than the TIVA group. Overall costs were significantly higher in the TIVA (58.8 +/- 11.6) than in the desflurane group (35.0 +/- 5.7). Conclusion: Patients undergoing prolonged surgical procedures showed a faster early recovery after desflurane/fentanyl than using TIVA, whereas stay in the PACU and recovery of cognitive function were similar in both groups. Costs of a TIVA regimen were significantly higher than using a desflurane-based anaesthesia technique.	Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany	Boldt, J (reprint author), Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, Bremserstr 79, D-67063 Ludwigshafen, Germany.	BoldtJ@gmx.net					ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Apfelbaum JL, 1996, ANESTH ANALG, V83, P721, DOI 10.1097/00000539-199610000-00010; Bekker AY, 2000, ANESTH ANALG, V91, P117, DOI 10.1097/00000539-200007000-00022; Boldt J, 1998, ANESTH ANALG, V86, P504, DOI 10.1097/00000539-199803000-00010; Chen XG, 2001, ANESTH ANALG, V93, P1489, DOI 10.1097/00000539-200112000-00029; DEXTER F, 1995, ANESTHESIOLOGY, V83, P77; Dolk A, 2002, EUR J ANAESTH, V19, P88, DOI 10.1017/S0265021502000157; FOLSTEIN M, 1985, J AM GERIATR SOC, V33, P228, DOI 10.1111/j.1532-5415.1985.tb07109.x; Fredman B, 2002, ANESTH ANALG, V94, P560, DOI 10.1097/00000539-200203000-00015; Glass PSA, 1999, ANESTH ANALG, V89, pS7; Grundmann U, 2001, ACTA ANAESTH SCAND, V45, P320, DOI 10.1034/j.1399-6576.2001.045003320.x; Gupta A, 2004, ANESTH ANALG, V98, P632, DOI 10.1213/01.ANE.0000103187.70627.57; Hogue CW, 1996, ANESTH ANALG, V83, P279, DOI 10.1097/00000539-199608000-00014; Johansen JW, 2000, ANESTHESIOLOGY, V93, P1336, DOI 10.1097/00000542-200011000-00029; Juvin P, 1997, ANESTH ANALG, V85, P647, DOI 10.1097/00000539-199709000-00029; Larsen B, 2000, ANESTH ANALG, V90, P168, DOI 10.1097/00000539-200001000-00035; LEBENBOMMANSOUR MH, 1993, ANESTH ANALG, V76, P936; Luginbuhl M, 2003, ACTA ANAESTH SCAND, V47, P165, DOI 10.1034/j.1399-6576.2003.00041.x; PARIKH SS, 1995, ANESTH ANALG, V80, P1223, DOI 10.1097/00000539-199506000-00027; Rasmussen LS, 2003, ACTA ANAESTH SCAND, V47, P260, DOI 10.1034/j.1399-6576.2003.00057.x; Rasmussen LS, 2001, ACTA ANAESTH SCAND, V45, P275, DOI 10.1034/j.1399-6576.2001.045003275.x; Suttner SW, 2001, BRIT J ANAESTH, V87, P699, DOI 10.1093/bja/87.5.699; Watcha MF, 1997, ANESTHESIOLOGY, V86, P1170, DOI 10.1097/00000542-199705000-00021; WEISKOPF RB, 1993, ANESTHESIOLOGY, V79, P1413, DOI 10.1097/00000542-199312000-00033	24	28	33	0	27	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JAN	2006	50	1					14	18		10.1111/j.1399-6576.2006.00905.x			5	Anesthesiology	Anesthesiology	007XT	WOS:000235005500002	16451145				2020-06-30	J	Mishra, LD; Tiwari, A				Mishra, LD; Tiwari, A			Pain and emergence agitation in children	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Letter							FENTANYL; PHARMACODYNAMICS; INFANTS		Banaras Hindu Univ, Inst Med Sci, Dept Anaesthesiol, Varanasi 221005, Uttar Pradesh, India	Mishra, LD (reprint author), Banaras Hindu Univ, Inst Med Sci, Dept Anaesthesiol, Varanasi 221005, Uttar Pradesh, India.	ldmishra@rediffmail.com					Aouad MT, 2005, ACTA ANAESTH SCAND, V49, P300, DOI 10.1111/j.1399-6576.2005.00642.x; COOK BA, 1992, CLIN PEDIATR, V31, P137, DOI 10.1177/000992289203100302; HERTZKA RE, 1989, ANESTHESIOLOGY, V70, P213, DOI 10.1097/00000542-198902000-00006; HICKEY PR, 1985, ANESTH ANALG, V64, P483; OLKKOLA KT, 1995, CLIN PHARMACOKINET, V28, P385, DOI 10.2165/00003088-199528050-00004; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005	6	2	5	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JAN	2006	50	1					124	124		10.1111/j.1399-6576.2006.00889.x			1	Anesthesiology	Anesthesiology	007XT	WOS:000235005500021	16451163				2020-06-30	J	Usichenko, TI; Dinse, M; Lysenyuk, VP; Wendt, M; Pavlovic, D; Lehmann, C				Usichenko, Taras I.; Dinse, Michaela; Lysenyuk, Victor P.; Wendt, Michael; Pavlovic, Dragan; Lehmann, Christian			Auricular acupuncture reduces intraoperative fentanyl requirement during hip arthroplasty - A randomized double-blinded study	ACUPUNCTURE & ELECTRO-THERAPEUTICS RESEARCH			English	Article						auricular acupuncture; opioid analgesic requirement; general anesthesia; intraoperative fentanyl; randomized trial	PAIN; ANESTHESIA; POINTS	We studied whether auricular acupuncture reduces analgesic requirement during total hip arthroplasty. Sixty-four patients were enrolled in this patient/anesthesiologist-blinded study according to inclusion criteria. They were randomly assigned to receive acupuncture with indwelling fixed needles (points lung, shenmen, forehead and hip) or sham procedure (4 nonacupuncture points on the helix). Surgery was performed under standardized general anesthesia with volatile anesthetic isoflurane and opioid analgesic fentanyl, whereby isoflurane concentration was kept constant. Demographics, fentanyl requirement, duration of general anesthesia and success of patients' blinding were registered. Patients from the acupuncture group required 21% less fentanyl during surgery than those who received sham procedure. Other outcome measures were similar in both groups. Auricular acupuncture reduced fentanyl requirement compared to sham procedure during hip arthroplasty.	Ernst Moritz Arndt Univ Greifswald, Dept Anesthesiol & Intens Care Med, D-17487 Greifswald, Germany; Natl Med Univ, Dept Nonorthodox Med, Kiev, Ukraine; Dalhousie Univ, Dept Anesthesia, Halifax, NS B3H 3J5, Canada	Usichenko, TI (reprint author), Ernst Moritz Arndt Univ Greifswald, Dept Anesthesiol & Intens Care Med, Friedrich Loeffler Str 23B, D-17487 Greifswald, Germany.	taras@uni-greifswald.de	Lehmann, Christian/G-4837-2013				Ceccherelli F, 1999, ACUPUNCTURE ELECTRO, V24, P169, DOI 10.3727/036012999816356309; CLEMENTJONES V, 1980, LANCET, V2, P946; Grammel B., 1981, AKUPUNKTURARZT AURIK, V5, P160; LEBARS D, 1979, PAIN, V6, P283, DOI 10.1016/0304-3959(79)90049-6; Leibing E, 2002, PAIN, V96, P189, DOI 10.1016/S0304-3959(01)00444-4; LEWITH GT, 1983, PAIN, V16, P111, DOI 10.1016/0304-3959(83)90202-6; MacPherson H, 2001, COMPLEMENT THER MED, V9, P246, DOI 10.1054/ctim.2001.0488; MARGOLIN A, 1995, AM J CHINESE MED, V23, P105, DOI 10.1142/S0192415X95000146; Moher D, 2001, ANN INTERN MED, V134, P657, DOI 10.7326/0003-4819-134-8-200104170-00011; NOGIER PFM, 1972, [No title captured]; OLESON TD, 1980, PAIN, V8, P217, DOI 10.1016/0304-3959(88)90009-7; SAKU K, 1993, CLIN CARDIOL, V16, P415, DOI 10.1002/clc.4960160509; Sakurai M, 2003, ANESTH ANALG, V96, P493, DOI 10.1097/00000539-200302000-00036; Sator-Katzenschlager SM, 2006, HUM REPROD, V21, P2114, DOI 10.1093/humrep/del110; Sebel PS, 1997, ANESTH ANALG, V84, P891, DOI 10.1097/00000539-199704000-00035; Simmons M S, 1993, Anesth Prog, V40, P14; Taguchi A, 2002, ANAESTHESIA, V57, P1159, DOI 10.1046/j.1365-2044.2002.02832.x; Usichenko TI, 2005, PAIN, V114, P320, DOI 10.1016/j.pain.2004.08.021; Usichenko TI, 2003, ANAESTHESIA, V58, P928, DOI 10.1046/j.1365-2044.2003.03362_23.x; USICHENKO TI, 2003, ACUPUNCTURE ELECT TH, V23, P195; Vorob'ev V V, 2000, Vestn Khir Im I I Grek, V159, P48; Wang SM, 2001, ANESTH ANALG, V93, P1178, DOI 10.1097/00000539-200111000-00024	22	20	22	1	7	COGNIZANT COMMUNICATION CORP	PUTNAM VALLEY	18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA	0360-1293	2167-9010		ACUPUNCTURE ELECTRO	Acupunct. Electro-Ther. Res.		2006	31	3-4					213	221		10.3727/036012906815844265			9	Integrative & Complementary Medicine; Neurosciences	Integrative & Complementary Medicine; Neurosciences & Neurology	183EW	WOS:000247556500002	17608061				2020-06-30	J	Naja, MZ; Al-Tannir, M; Naja, H; Ziade, MD; Zeidan, A				Naja, MZ; Al-Tannir, M; Naja, H; Ziade, MD; Zeidan, A			Repeated nerve blocks with clonidine, fentanyl and bupivacaine for trigeminal neuralgia	ANAESTHESIA			English	Letter							PROSPECTIVE RANDOMIZED-TRIAL; GENERAL-ANESTHESIA; FACIAL-PAIN; ANALGESIA; SURGERY		Makassed Gen Hosp, Beirut, Lebanon; Lebanese Univ, Beirut, Lebanon; Gen Hosp, Beirut, Lebanon	Naja, MZ (reprint author), Makassed Gen Hosp, Beirut, Lebanon.	zouhnaja@yahoo.com		Al-Tannir, Mohamad/0000-0002-7739-8446			Delzell JE, 1999, ARCH FAM MED, V8, P264, DOI 10.1001/archfami.8.3.264; Fletcher D, 2000, FUNDAM CLIN PHARM, V14, P327, DOI 10.1111/j.1472-8206.2000.tb00413.x; Naja MZ, 2003, EUR J ANAESTH, V20, P897, DOI 10.1097/00003643-200311000-00007; Naja MZ, 2003, ANAESTHESIA, V58, P1007, DOI 10.1046/j.1365-2044.2003.03401.x; Naja Z, 2005, CAN J ANAESTH, V52, P62, DOI 10.1007/BF03018582; Naja Z., 2000, Middle East Journal of Anesthesiology, V15, P559; Singelyn FJ, 1996, ANESTH ANALG, V83, P1046, DOI 10.1097/00000539-199611000-00025; Zakrzewska JM, 2002, J NEUROL NEUROSUR PS, V72, P27	8	3	4	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0003-2409			ANAESTHESIA	Anaesthesia	JAN	2006	61	1					70	71		10.1111/j.1365-2044.2005.04486.x			2	Anesthesiology	Anesthesiology	000SI	WOS:000234482300025	16409356				2020-06-30	J	Viscusi, ER; Reynolds, L; Tait, S; Melson, T; Atkinson, LE				Viscusi, ER; Reynolds, L; Tait, S; Melson, T; Atkinson, LE			An iontophoretic fentanyl patient-activated analgesic delivery system for postoperative pain: A double-blind, placebo-controlled trial	ANESTHESIA AND ANALGESIA			English	Article							CONTROLLED TRANSDERMAL SYSTEM; ELECTROTRANSPORT SYSTEM; MORPHINE; PHARMACOKINETICS; EFFICACY; SAFETY	An iontophoretic fentanyl HCl patient-activated transdermal system (fentanyl HCI PATS) is under development for the treatment of acute postoperative pain. The fentanyl HCI PATS is a needle-free, credit card-sized, preprogrammed system that is applied to the patient's upper outer arm or chest. The fentanyl HCI PATS was demonstrated to be superior to placebo in a previous trial; however, the randomization scheme used and the lack of control of entry pain level may have contributed to the lack of robust findings. We compared the fentanyl HCl PATS with placebo for acute postoperative pain management in a larger trial that addressed the limitations of the previous study. Adult patients admitted to the postanesthesia care unit after major surgery were titrated to comfort with opioids and randomized 1:1 to receive the fentanyl HCl PATS 40 mu g or placebo for 24 hours. Supplemental IV fentanyl was available to patients upon request in both treatment groups for the first 3 hours after enrollment. The primary efficacy endpoint was the percentage of patients who discontinued participation in the study because of inadequate analgesia. Pain intensity scores, patient global assessments (PGA), and investigator global assessments (IGA) were collected. Four-hundred-eighty-four patients (PATS, n = 244; placebo, n = 240) were enrolled. Fewer patients receiving the fentanyl HCl PATS discontinued because of inadequate analgesia compared with placebo (28.7% versus 60.0%; P < 0.0001). Mean last pain intensity scores were 3.5 and 5.4 for the fentanyl HCl PATS and placebo groups, respectively. Patients (73.4%, PGA) and investigators (72.1%, IGA) considered the fentanyl HCl PATS a good or excellent method of pain control. Treatment-related adverse events were similar between groups. This study demonstrated the superiority of the iontophoretic fentanyl HCl PATS over placebo for acute postoperative pain management.	Thomas Jefferson Univ Hosp, Jefferson Med Coll, Dept Anesthesiol, Philadelphia, PA 19107 USA; Loma Linda Univ, Sch Med, Dept Anesthesiol, Loma Linda, CA 92350 USA; Sparks Reg Med Ctr, Dept Anesthesiol, Ft Smith, AR USA; Helen Keller Hosp, Dept Anesthesia, Sheffield, S Yorkshire, England; ALZA Corp, Clin Dev, Mountain View, CA USA	Viscusi, ER (reprint author), Thomas Jefferson Univ, Dept Anesthesiol, 111 S 11th St,Suite G 8490, Philadelphia, PA 19107 USA.	eugene.viscusi@jefferson.edu					Austrup ML, 1999, SURG CLIN N AM, V79, P253, DOI 10.1016/S0039-6109(05)70382-0; BENNETT RL, 1982, ANN SURG, V195, P700, DOI 10.1097/00000658-198206000-00004; Camu F, 1998, ANESTH ANALG, V87, P890, DOI 10.1097/00000539-199810000-00027; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Etches RC, 1999, SURG CLIN N AM, V79, P297, DOI 10.1016/S0039-6109(05)70384-4; ETCHES RC, 1994, CAN J ANAESTH, V41, P125, DOI 10.1007/BF03009805; Gupta SK, 1998, J CLIN PHARMACOL, V38, P951, DOI 10.1002/j.1552-4604.1998.tb04392.x; Gupta SK, 1998, J PHARM SCI, V87, P976, DOI 10.1021/js970437d; Gupta SK, 1999, J PHARM SCI, V88, P835, DOI 10.1021/js980258b; HOWELL PR, 1995, CAN J ANAESTH, V42, P41, DOI 10.1007/BF03010570; Lehmann KA, 1999, EUR SURG RES, V31, P112, DOI 10.1159/000008629; Macintyre PE, 2001, BRIT J ANAESTH, V87, P36, DOI 10.1093/bja/87.1.36; Sathyan G, 2005, CLIN PHARMACOKINET, V44, P7, DOI 10.2165/00003088-200544001-00003; Sathyan S, 2005, CLIN PHARMACOKINET, V44, P17, DOI 10.2165/00003088-200544001-00004; Vicente KJ, 2003, CAN J ANAESTH, V50, P328, DOI 10.1007/BF03021027; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; WELCHEW EA, 1983, ANAESTHESIA, V38, P19, DOI 10.1111/j.1365-2044.1983.tb10367.x	17	65	67	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JAN	2006	102	1					188	194		10.1213/01.ane.0000183649.58483.77			7	Anesthesiology	Anesthesiology	997VA	WOS:000234275700032	16368828				2020-06-30	J	Manninen, PH; Balki, M; Lukitto, K; Bernstein, M				Manninen, PH; Balki, M; Lukitto, K; Bernstein, M			Patient satisfaction with awake craniotomy for tumor surgery: A comparison of remifentanil and fentanyl in conjunction with propofol	ANESTHESIA AND ANALGESIA			English	Article							CONSCIOUS SEDATION; LOCAL-ANESTHESIA; LARYNGEAL MASK; AIRWAY	In this study we compared the effectiveness of the use of remifentanil to fentanyl in conjunction with propofol in providing conscious sedation for awake craniotomy for tumor surgery and to assess patient satisfaction with both techniques. The ability to maintain appropriate levels of sedation, adequate analgesia, and hemodynamic stability was assessed in 50 patients randomized to receive either fentanyl or remifentanil. All complications were documented. Patients were interviewed at I h, 4 h, and 24 h after surgery to note their recall of procedure and pain and their overall satisfaction. There were no differences in sedation and pain scores or in hemodynamic and respiratory variables between the two groups. The incidence of intraoperative complications was not different (fentanyl, 14; remifentanil, 16). Respiratory complications occurred in 9 (18%) patients (fentanyl 6, remifentanil 3). The recall and satisfaction scores were not different; 93% of all patients were completely satisfied at all interview times. The use of remifentanil infusion in conjunction with propofol is a good alternative to fentanyl and propofol for conscious sedation for the awake craniotomy and these techniques are both well accepted by the patient.	Univ Toronto, Dept Anesthesia, Toronto Western Hosp, Univ Hlth Network,Dept Anesthesia, Toronto, ON MST 258, Canada; Univ Toronto, Dept Neurosurg, Toronto Western Hosp, Univ Hlth Network,Dept Anesthesia, Toronto, ON MST 258, Canada	Manninen, PH (reprint author), Univ Toronto, Dept Anesthesia, Toronto Western Hosp, Univ Hlth Network,Dept Anesthesia, 399 Bathurst St, Toronto, ON MST 258, Canada.	manninen@uhn.on.ca	Balki, Mrinalini/A-2669-2015				Aglio LS, 2001, TECH NEUROSURG, V7, P52, DOI 10.1097/00127927-200103000-00007; Audu PB, 2004, J NEUROSURG ANESTH, V16, P144, DOI 10.1097/00008506-200404000-00006; Berkenstadt H, 2001, J NEUROSURG ANESTH, V13, P246, DOI 10.1097/00008506-200107000-00013; Blanshard HJ, 2001, ANESTH ANALG, V92, P89; CHEMIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Costello TG, 2004, J CLIN NEUROSCI, V11, P16, DOI 10.1016/j.jocn.2003.09.003; Danks RA, 1998, NEUROSURGERY, V42, P28, DOI 10.1097/00006123-199801000-00006; Fukaya C, 2001, J CLIN NEUROSCI, V8, P253, DOI 10.1054/jocn.2000.0866; Hans P, 2000, ANAESTHESIA, V55, P255, DOI 10.1046/j.1365-2044.2000.01277.x; Huncke K, 1998, NEUROSURGERY, V42, P1312, DOI 10.1097/00006123-199806000-00069; Johnson KB, 1998, J NEUROSURG ANESTH, V10, P25, DOI 10.1097/00008506-199801000-00006; Nikas DC, 2001, TECH NEUROSURG, V7, P70, DOI 10.1097/00127927-200103000-00009; Sarang A, 2003, BRIT J ANAESTH, V90, P161, DOI 10.1093/bja/aeg037; SILBERGELD DL, 1992, SURG NEUROL, V38, P271, DOI 10.1016/0090-3019(92)90038-O; Taylor MD, 1999, J NEUROSURG, V90, P35, DOI 10.3171/jns.1999.90.1.0035; Tongier WK, 2000, J CLIN ANESTH, V12, P592, DOI 10.1016/S0952-8180(00)00211-7	16	76	91	1	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JAN	2006	102	1					237	242		10.1213/01.ANE.0000181287.86811.5C			6	Anesthesiology	Anesthesiology	997VA	WOS:000234275700040	16368836				2020-06-30	J	Hansdottir, V; Philip, J; Olsen, MF; Eduard, C; Houltz, E; Ricksten, SE				Hansdottir, V; Philip, J; Olsen, MF; Eduard, C; Houltz, E; Ricksten, SE			Thoracic epidural versus intravenous patient-controlled analgesia after cardiac surgery - A randomized controlled trial on length of hospital stay and patient-perceived quality of recovery	ANESTHESIOLOGY			English	Article							CORONARY-ARTERY-DISEASE; UNSTABLE ANGINA-PECTORIS; BYPASS GRAFT-SURGERY; OFF-PUMP; ANESTHESIA; HEMATOMA; RISK	Background: Perioperative thoracic epidural analgesia reduces stress response and pain scores and may improve outcome after cardiac surgery. This prospective, randomized trial was designed to compare the effectiveness of patient-controlled thoracic epidural analgesia with patient-controlled analgesia with intravenous morphine on postoperative hospital length of stay and patients' perception of their quality of recovery after cardiac surgery. Methods: One hundred thirteen patients undergoing elective cardiac surgery were randomly assigned to receive either combined thoracic epidural analgesia and general anesthesia followed by patient-controlled thoracic epidural analgesia or general anesthesia followed by to patient-controlled analgesia with intravenous morphine. Postoperative length of stay, time to eligibility for hospital discharge, pain and sedation scores, degree of ambulation, lung volumes, and organ morbidities were evaluated. A validated quality of recovery score was used to measure postoperative health status. Results: Length of stay and time to eligibility for hospital discharge were similar between the groups. Study groups differed neither in postoperative global quality of recovery score nor in five dimensions of quality of recovery score. Time to extubation was shorter (P < 0.001) and consumption of anesthetics was lower in the patient-controlled thoracic epidural analgesia group. Pain relief, degree of sedation, ambulation, and lung volumes were similar between the study groups. There was a trend for lower incidences of pneumonia (P = 0.085) and confusion (P = 0.10) in the patient-controlled thoracic epidural analgesia group, whereas cardiac, renal, and neurologic outcomes were similar between the groups. Conclusions: In elective cardiac surgery, thoracic epidural analgesia combined with general anesthesia followed by patient-controlled thoracic epidural analgesia offers no major advantage with respect to hospital length of stay, quality of recovery, or morbidity when compared with general anesthesia alone followed by to patient-controlled analgesia with intravenous morphine.	Gothenburg Univ, Sahlgrenska Hosp, Dept Cardiothorac Anesthesia & Intens Care, S-41345 Gothenburg, Sweden; Gothenburg Univ, Sahlgrenska Hosp, Dept Physiotherapy, S-41345 Gothenburg, Sweden	Ricksten, SE (reprint author), Gothenburg Univ, Sahlgrenska Hosp, Dept Cardiothorac Anesthesia & Intens Care, S-41345 Gothenburg, Sweden.	sven-erik.ricksten@aniv.gu.se					BLOMBERG S, 1990, ANESTHESIOLOGY, V73, P840, DOI 10.1097/00000542-199011000-00008; BLOMBERG S, 1989, ANESTH ANALG, V69, P558; Bucerius J, 2005, ANN THORAC SURG, V79, P807, DOI 10.1016/j.athoracsur.2004.06.013; Castellano JM, 2000, CHEST, V117, P305, DOI 10.1378/chest.117.2.305; Fillinger MP, 2002, J CARDIOTHOR VASC AN, V16, P15, DOI 10.1053/jcan.2002.29639; Ho AMH, 2000, CHEST, V117, P551, DOI 10.1378/chest.117.2.551; Jideus L, 2001, ANN THORAC SURG, V72, P65, DOI 10.1016/S0003-4975(01)02631-5; Kehlet H, 1997, BRIT J ANAESTH, V78, P606; KOCK M, 1990, ANESTH ANALG, V71, P625; Lee JD, 2004, ANN THORAC SURG, V78, P1132, DOI 10.1016/j.athoracsur.2003.10.077; Liem T H, 1992, J Cardiothorac Vasc Anesth, V6, P156; Liu SS, 2004, ANESTHESIOLOGY, V101, P153, DOI 10.1097/00000542-200407000-00024; Loick HM, 1999, ANESTH ANALG, V88, P701, DOI 10.1097/00000539-199904000-00001; Myles PS, 2001, ANESTHESIOLOGY, V95, P862, DOI 10.1097/00000542-200110000-00013; Myles PS, 2000, BRIT J ANAESTH, V84, P11; O'Connor CJ, 2001, ANESTH ANALG, V93, P523, DOI 10.1097/00000539-200109000-00001; Olausson K, 1997, CIRCULATION, V96, P2178; Onorati F, 2005, ANN THORAC SURG, V79, P837, DOI 10.1016/j.athoracsur.2004.07.060; Priestley MC, 2002, ANESTH ANALG, V94, P275, DOI 10.1097/00000539-200202000-00009; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; RICKSTEN SE, 1986, CHEST, V89, P774, DOI 10.1378/chest.89.6.774; Rosen DA, 2004, ANESTH ANALG, V98, P966, DOI 10.1213/01.ANE.0000103267.37895.5B; Royse C, 2003, ANN THORAC SURG, V75, P93, DOI 10.1016/S0003-4975(02)04074-2; Scott NB, 2001, ANESTH ANALG, V93, P528, DOI 10.1097/00000539-200109000-00003; Stamou SC, 2004, EUR J CARDIO-THORAC, V26, P549, DOI 10.1016/j.ejcts.2004.05.031; Tenling A, 2000, ACTA ANAESTH SCAND, V44, P1071, DOI 10.1034/j.1399-6576.2000.440906.x; Wallentin L, 2000, LANCET, V356, P9, DOI 10.1016/S0140-6736(00)02427-2; Zamvar VY, 2002, HEART SURG FORUM, V5, P109	28	92	98	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	JAN	2006	104	1					142	151		10.1097/00000542-200601000-00020			10	Anesthesiology	Anesthesiology	000OR	WOS:000234472200019	16394700				2020-06-30	J	Bouchnak, M; Belhadj, N; Chaaoua, T; Azaiez, W; Hamdi, M; Maghrebi, H				Bouchnak, M; Belhadj, N; Chaaoua, T; Azaiez, W; Hamdi, M; Maghrebi, H			Spinal anaesthesia for Caesarean section: dose injection speed have an effect on the incidence of hypotension?	ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION			French	Article						spinal anaesthesia; Caesarean section; hypotension	SUBARACHNOID DISTRIBUTION; BUPIVACAINE 0.5-PERCENT; PLAIN BUPIVACAINE; DURATION; SPREAD; LEVEL	Objective. - To study effect of injection rate on spinal blockade and haemodynamic of spinal bupivacaine for Caesarean section. Study design. - Prospective and randomized. Patients and methods. - Sixty ASA I-II patients scheduled for elective Caesarean section were randomized to receive either fast (20 seconds, group R, n = 30) or slow (60 seconds, group L, n = 30) spinal injection of 10 mg of hyperbaric bupivacaine 0.5% associated with 25 mu g of fentanyl and 100 mu g of morphine. Sensory and motor blockade and haemodynamic parameters were recorded. Results. - Profiles of sensory and motor block were similar in both groups. Variations of arterial blood pressure and total dose of ephedrine were not different between R and L groups. However, the number of patient with systolic blood pressure lower than 100 mmHg were significantly lower in L group than in R group (p = 0.04). Incidences of adverse effects were similar in both groups. Conclusion. - Result of the present study suggests that a slow rate of injection would induce lower incidence of hypotension induced by spinal bupivacaine for Caesarean section. (C) 2005 Elsevier SAS. Tous droits reserves.	Ctr Matern & Neonatol Tunis, Serv Anesthesie Reanimat, Tunis 1007, Tunisia	Bouchnak, M (reprint author), Ctr Matern & Neonatol Tunis, Serv Anesthesie Reanimat, Rue Jabel Lakhdar, Tunis 1007, Tunisia.	mouradbouchnak@yahoo.fr	maghrebi, houcine/L-7853-2016				ATCHISON SR, 1989, ANESTH ANALG, V69, P496; BOURKE DL, 1995, ANESTH ANALG, V81, P427; Casati A, 1998, BRIT J ANAESTH, V81, P355, DOI 10.1093/bja/81.3.355; HORLOCKER TT, 1994, ANESTH ANALG, V79, P773; MCCLURE JH, 1982, BRIT J ANAESTH, V54, P917, DOI 10.1093/bja/54.9.917; NEIGH JL, 1970, ANESTH ANAL CURR RES, V49, P912; Simon L, 2000, INT J OBSTET ANESTH, V9, P10, DOI 10.1054/ijoa.1999.0348; SINGH S, 2002, CAN J ANESTH, V49, pA13; STIENSTRA R, 1990, REGION ANESTH, V15, P208; TUOMINEN M, 1992, BRIT J ANAESTH, V69, P148, DOI 10.1093/bja/69.2.148; VANGESSEL EF, 1993, ANESTH ANALG, V77, P483	11	6	8	0	1	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	PARIS	23 RUE LINOIS, 75724 PARIS, FRANCE	0750-7658			ANN FR ANESTH	Ann. Fr. Anest. Reanim.	JAN	2006	25	1					17	19		10.1016/j.annfar.2005.07.078			3	Anesthesiology	Anesthesiology	009VM	WOS:000235141500004	16226864				2020-06-30	J	Migita, RT; Klein, EJ; Garrison, MM				Migita, RT; Klein, EJ; Garrison, MM			Sedation and analgesia for pediatric fracture reduction in the emergency department - A systematic review	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Review							INTRAVENOUS REGIONAL ANESTHESIA; DOUBLE-BLIND; PROCEDURAL SEDATION; KETAMINE SEDATION; FOREARM FRACTURES; PAIN MANAGEMENT; NITROUS-OXIDE; CHILDREN; TRIAL; MIDAZOLAM	Objective: To assess the safety and efficacy of various forms of analgesia and sedation for fracture reduction in pediatric patients in the emergency department, as observed in randomized controlled trials in pediatric populations. Data Sources: Cochrane Controlled Trials Register, CINAHL (Cumulative Index to Nursing & Allied Health Literature), and MEDLINE. The search terms '' fractures,'' '' manipulation, orthopedic,'' '' an (a) esthetics,'' '' analgesics,'' and '' hypnotics and sedatives '' were used. Study Selection: Studies were included if they were randomized controlled trials studying sedative and/or analgesic regimens for fracture reductions in pediatric patients in the emergency department. The search yielded 915 references. From these, 8 studies including 1086 patients were selected. Data Extraction: Interventions studied included intravenous regional blocks (Bier blocks), nitrous oxide, and parenteral combinations. Data on measures of effectiveness and safety were extracted. Data Synthesis: Ketamine hydrochloride-midazolam hydrochloride was associated with less distress during reduction than fentanyl citrate-midazolam or propofolfentanyl. Patients receiving ketamine-miclazolam required significantly fewer airway interventions than those in whom either fentanyl-midazolam or propofolfentanyl were used. Data comparing Bier blocks with systemic forms of sedation or analgesia were limited. Conclusions: Ketamine-midazolam seems to be more effective and have fewer adverse events than fentanylmidazolam or propofol-fentanyl. Data on other forms of analgesia or sedation are too limited to make comparisons. More research is needed to define the regimen that maximizes safety, efficacy, and efficiency for fracture reduction in pediatric patients.	Childrens Hosp & Reg Med Ctr, Emergency Serv, Seattle, WA 98105 USA; Childrens Hosp & Reg Med Ctr, Div Emergency Med, Seattle, WA 98105 USA; Childrens Hosp & Reg Med Ctr, Div Gen Pediat, Seattle, WA 98105 USA; Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; Child Hlth Inst, Seattle, WA USA	Migita, RT (reprint author), Childrens Hosp & Reg Med Ctr, Emergency Serv, B-5520,4800 Sand Point Way NE, Seattle, WA 98105 USA.	russ.migita@seattlechildrens.org					Bratt HD, 1996, J PEDIATR ORTHOPED, V16, P660, DOI 10.1097/01241398-199609000-00021; Brown JC, 2003, ANN EMERG MED, V42, P197, DOI 10.1067/mem.2003.275; Cheng JCY, 1999, J PEDIATR ORTHOPED, V19, P344, DOI 10.1097/00004694-199905000-00011; Cimpello LB, 2004, PEDIATR EMERG CARE, V20, P228, DOI 10.1097/01.pec.0000121242.99242.e0; Davidson AJ, 2002, PAEDIATR ANAESTH, V12, P146, DOI 10.1046/j.1460-9592.2002.00772.x; EVANS JK, 1995, J PEDIATR ORTHOPED, V15, P73, DOI 10.1097/01241398-199501000-00016; Fosnocht DE, 2004, AM J EMERG MED, V22, P286, DOI 10.1016/j.ajem.2004.04.011; FRIEDLAND LR, 1994, ANN EMERG MED, V23, P203, DOI 10.1016/S0196-0644(94)70031-1; Godambe SA, 2003, PEDIATRICS, V112, P116, DOI 10.1542/peds.112.1.116; Green SM, 2004, ANN EMERG MED, V44, P460, DOI 10.1016/j.annemergmed.2004.06.006; Gregory PR, 1996, J PEDIATR ORTHOPED, V16, P187, DOI 10.1097/01241398-199603000-00010; Havel CJ, 1999, ACAD EMERG MED, V6, P989, DOI 10.1111/j.1553-2712.1999.tb01180.x; JAY SM, 1984, J CONSULT CLIN PSYCH, V52, P1106, DOI 10.1037/0022-006X.52.6.1106; JAY SM, 1983, [No title captured], V2, P133, DOI DOI 10.1037/0278-6133.2.2.133; Kennedy RM, 1998, PEDIATRICS, V102, P956, DOI 10.1542/peds.102.4.956; Kennedy Robert M, 2004, Paediatr Drugs, V6, P11; Krauss B, 1998, PEDIATR EMERG CARE, V14, P99, DOI 10.1097/00006565-199804000-00003; Landin LA, 1997, J PEDIATR ORTHOP B, V6, P79, DOI 10.1097/01202412-199704000-00002; LEBARON S, 1984, J CONSULT CLIN PSYCH, V52, P729, DOI 10.1037/0022-006X.52.5.729; LUHMANN JD, 2004, PED AC SOC ANN M MAY; Lyons RA, 2000, ARCH DIS CHILD, V82, P452, DOI 10.1136/adc.82.6.452; MCGRATH PJ, 1985, ADV PAIN RES THER, V9, P395; Petrack EM, 1997, PEDIATRICS, V99, P711, DOI 10.1542/peds.99.5.711; Pierce MC, 1997, ACAD EMERG MED, V4, P22, DOI 10.1111/j.1553-2712.1997.tb03638.x; Sherwin TS, 2000, ANN EMERG MED, V35, P229, DOI 10.1016/S0196-0644(00)70073-4; Stark AD, 2002, BRIT MED J, V324, P457, DOI 10.1136/bmj.324.7335.457; Wathen JE, 2000, ANN EMERG MED, V36, P579, DOI 10.1067/mem.2000.111131; Wattenmaker I, 1990, J Orthop Trauma, V4, P35; WILSON JE, 1989, AM J EMERG MED, V7, P620, DOI 10.1016/0735-6757(89)90286-6	29	39	40	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	1072-4710	1538-3628		ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	JAN	2006	160	1					46	51		10.1001/archpedi.160.1.46			6	Pediatrics	Pediatrics	999JN	WOS:000234385700006	16389210	Bronze			2020-06-30	J	Zohar, E; Luban, I; White, PF; Ramati, E; Shabat, S; Fredman, B				Zohar, E; Luban, I; White, PF; Ramati, E; Shabat, S; Fredman, B			Bispectral index monitoring does not improve early recovery of geriatric outpatients undergoing brief surgical procedures	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							NITROUS-OXIDE ANESTHESIA; FAST-TRACK ELIGIBILITY; AMBULATORY ANESTHESIA; LAPAROSCOPIC SURGERY; PROPOFOL; REQUIREMENTS; ALFENTANIL; DESFLURANE; TITRATION; CRITERIA	Purpose: To assess if titration of sevoflurane using the bispectral index (BIS) monitor improves the early and intermediate recovery in geriatric outpatients undergoing brief urologic procedures under general anesthesia without muscle relaxants. Methods: After a standardized induction with propofol and fentanyl, a laryngeal mask airway was inserted and sevoflurane was administered in combination with 60% nitrous oxide in oxygen for maintenance of anesthesia in spontaneously breathing outpatients. In the Control group (n = 25), sevoflurane and fentanyl were titrated according to standard clinical practice. In the BIS-directed group (n = 25), sevoflurane was titrated to maintain a BIS value between 50 and 60, and supplemental fentanyl, 25 jig iv boluses were administered to treat tachypnea. The intraoperative anesthetic and analgesic requirements, as well as the times to eye opening, removal of the laryngeal mask airway device, response to simple commands, orientation to person and place, and postanesthesia care unit discharge eligibility (fast-track score of 14) were assessed at specific time intervals. Results: The minimum alveolar concentration-hour of sevoflurane (0.25 +/- 0.15 and 0.31 +/- 0.2) and end-tidal concentrations of sevoflurane at the end of surgery (0.3 +/- 0.3 and 0.4 +/- 0.20%) did not differ significantly between the Control and BIS-directed groups, respectively. Although the percentage of patients requiring supplemental boluses of fentanyl was reduced in the BIS-directed group (16 vs 48%, P < 0.05), the intraoperative BIS values and recovery times were similar in the two groups. Conclusion: In this non-paralyzed elderly outpatient surgery population, the use of BIS monitoring for titrating the maintenance anesthetic (sevoflurane) failed to improve the early recovery process.	UT SW Med Ctr, Dept Anesthesiol & Pain Management, Dallas, TX 75390 USA; Meir Hosp, Dept Anesthesiol & Intens Care, Kefar Sava, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	White, PF (reprint author), UT SW Med Ctr, Dept Anesthesiol & Pain Management, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	paul.white@utsouthwestern.edu					Ahmad S, 2003, ANESTHESIOLOGY, V98, P849, DOI 10.1097/00000542-200304000-00010; Assareh H, 2002, ACTA ANAESTH SCAND, V46, P495, DOI 10.1034/j.1399-6576.2002.460504.x; Bruhn J, 2000, ANESTHESIOLOGY, V92, P1485, DOI 10.1097/00000542-200005000-00042; Drover DR, 2002, ANESTHESIOLOGY, V97, P82, DOI 10.1097/00000542-200207000-00012; Drummond JC, 2000, ANESTHESIOLOGY, V93, P876, DOI 10.1097/00000542-200009000-00039; Fredman B, 2002, ANESTH ANALG, V94, P560, DOI 10.1097/00000539-200203000-00015; Gan TJ, 1997, ANESTHESIOLOGY, V87, P808, DOI 10.1097/00000542-199710000-00014; Hodgson PS, 2001, ANESTHESIOLOGY, V94, P799, DOI 10.1097/00000542-200105000-00018; Liu SS, 2004, ANESTHESIOLOGY, V101, P311, DOI 10.1097/00000542-200408000-00010; Pavlin DJ, 2001, ANESTH ANALG, V93, P613, DOI 10.1097/00000539-200109000-00017; Recart A, 2003, ANESTH ANALG, V97, P1667, DOI 10.1213/01.ANE.0000087041.63034.8C; Recart A, 2003, ANESTHESIOLOGY, V99, P813, DOI 10.1097/00000542-200310000-00011; Song DJ, 1997, ANESTHESIOLOGY, V87, P842, DOI 10.1097/00000542-199710000-00018; Song DJ, 1998, ANESTH ANALG, V87, P1245, DOI 10.1097/00000539-199812000-00006; Vivien B, 2003, ANESTHESIOLOGY, V99, P9, DOI 10.1097/00000542-200307000-00006; White PF, 1999, J CLIN ANESTH, V11, P78; White PF, 1999, ANESTH ANALG, V88, P1069, DOI 10.1097/00000539-199905000-00018; White PF, 2004, ANESTHESIOLOGY, V100, P811, DOI 10.1097/00000542-200404000-00010; White PF, 2004, ANESTHESIOLOGY, V100, P194, DOI 10.1097/00000542-200401000-00039; Wong F, 2000, J PSYCHOSOM RES, V49, P13, DOI 10.1016/S0022-3999(99)00109-9	20	21	22	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	JAN	2006	53	1					20	25		10.1007/BF03021523			6	Anesthesiology	Anesthesiology	000OQ	WOS:000234472100004	16371605	Bronze			2020-06-30	J	Darwish, M; Kirby, M; Robertson, P; Hellriegel, E; Jiang, JG				Darwish, Mona; Kirby, Mary; Robertson, Philmore, Jr.; Hellriegel, Edward; Jiang, John G.			Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics	CLINICAL PHARMACOKINETICS			English	Article							PERMEABILITY; SURGERY	Background: The fentanyl buccal tablet (FBT) is designed to enhance the rate and extent of fentanyl absorption through the buccal mucosa. Aim: To evaluate the bioequivalence of mu g-equivalent doses of FBT administered as single and multiple tablets and assess differences in the arterial and venous pharmacokinetics of FBT in healthy volunteers. Methods: Twenty-seven healthy adults, aged 19-45 years, participated in the randomised, open-label, three-period, crossover study. In the first two periods, FBT was administered as four 100 mu g tablets simultaneously or one FBT 400 mu g to assess bioequivalence. Venous blood samples were obtained over a 72-hour period to measure plasma fentanyl concentrations. In the third period, arterial and venous blood samples were obtained simultaneously from before administration of one FBT 400 mu g through 4 hours after administration to evaluate the impact of arterial versus venous sampling on the pharmacokinetic profile. As subjects were not opioid tolerant, naltrexone was administered to block opioid receptor-mediated effects of fentanyl. Adverse events were recorded throughout. Results: Maximum plasma concentration (C-max) and area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)) on average were approximately 12% and 13% higher, respectively, for FBT administered as four 100 mu g tablets simultaneously compared with one FBT 400 mu g. Maximum plasma concentrations in the arterial circulation were approximately 60% higher and occurred 15 minutes earlier than those measured from the venous circulation. No serious adverse events were reported during the study. Conclusion: Despite small differences in C-max and AUC(infinity) (on average 12% and 13%, respectively), FBT administered as four 100 mu g tablets simultaneously compared with one 400 mu g tablet did not meet the criteria for bioequivalence. An increased surface area exposure with four tablets compared with one tablet may account for the slightly higher maximum concentrations observed with four 100 mu g tablets. A substantially higher C-max was reached earlier in the arterial than in the venous circulation.	Cephalon Inc, Clin Pharmacol, Malvern, PA 19355 USA; Cephalon Inc, Drug Safety & Disposit, Frazer, PA USA; Cephalon Inc, Biomet, Frazer, PA USA	Darwish, M (reprint author), Cephalon Inc, Clin Pharmacol, 41 Moores Rd, Malvern, PA 19355 USA.	mdarwish@cephalon.com					BENNETT D, 2005, [No title captured], V30, P354; BOER F, 1992, BRIT J ANAESTH, V68, P370, DOI 10.1093/bja/68.4.370; CHIOU WL, 1989, CLIN PHARMACOKINET, V17, P175, DOI 10.2165/00003088-198917030-00004; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Eichman JD, 1998, PHARM RES-DORDR, V15, P925, DOI 10.1023/A:1011936901638; Eichman JD, 1997, EUR J PHARM BIOPHARM, V44, P33, DOI 10.1016/S0939-6411(97)00099-4; HILL HF, 1990, PAIN, V43, P69, DOI 10.1016/0304-3959(90)90051-E; HUDSON RJ, 1986, ANESTHESIOLOGY, V64, P334, DOI 10.1097/00000542-198603000-00006; HUG CC, 1981, ANESTHESIOLOGY, V55, P369, DOI 10.1097/00000542-198110000-00006; Pather SI, 2001, DRUG DELIV TECH, V1, P54	10	30	34	0	3	ADIS INTERNATIONAL LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND	0312-5963			CLIN PHARMACOKINET	Clin. Pharmacokinet.		2006	45	8					843	850		10.2165/00003088-200645080-00006			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	077JA	WOS:000240023900006	16884321				2020-06-30	J	Zeppetela, G; Ribeiro, MDC				Zeppetela, G; Ribeiro, MDC			Opioids for the management of breakthrough (episodic) pain in cancer patients	COCHRANE DATABASE OF SYSTEMATIC REVIEWS			English	Review							TRANSMUCOSAL FENTANYL CITRATE; CLINICALLY IMPORTANT CHANGES; OUTCOME MEASURES; DOSE-TITRATION; MORPHINE; MULTICENTER; TRIAL; OTFC	Background Breakthrough pain is a transient increase in pain intensity over background pain. It is a common and distinct component of cancer pain that can have a negative impact for both the patient and carers' quality of life. Breakthrough pain is usually related to background pain and is typically of rapid onset, severe in intensity, and generally self-limiting with an average duration of 30 minutes. At present the current approach to managing breakthrough pain is using supplemental analgesia (also known as rescue medication) at a dose proportional to the total around-the-clock (ATC) opioid dose. Objectives This review explores and assesses the evidence for the use of opioids in the management of breakthrough pain in patients with cancer. Search strategy MEDLINE (1966 to 2005), EMBASE (1980 to 2005), CancerLit (1993 to 2005), CINAHL (1982 to 2005) and Cochrane databases were searched. Handsearching of medical journals and reference from key textbooks was undertaken and drug companies contacted for unpublished data. There was no language restriction. Date of most recent search: January 2005. Selection criteria Randomized controlled trials of opioids used as rescue medication against active or placebo comparator in patients with cancer pain were included. Outcome measures sought were reduction in pain intensity measured by an appropriate scale, adverse effects, attrition, patient satisfaction and quality of life. There were no language restrictions. Data collection and analysis Eligible studies were selected and examined independently by the two reviewers. Full text was retrieved if any uncertainty about eligibility remained. Non-English texts were screened. Quality assessment and data extraction were conducted using standardised data forms. Drug and placebo dose, titration, route and formulation were compared and detail of all outcome measures ( if available) recorded. Main results Four studies (393 participants) met the inclusion criteria, all were concerned with the use of oral transmucosal fentanyl citrate (OTFC) in the management of breakthrough pain. Two studies examined the titration of OTFC, one study compared OTFC to normal release morphine and one study compared OTFC to placebo. OTFC was shown to be an effective treatment for breakthrough pain. When compared to placebo and morphine, participants gave lower pain intensity scores and higher pain relief scores for OTFC at all time points. Global assessment scores also favoured OTFC. Authors' conclusions There is evidence that OTFC is an effective treatment in the management of breakthrough pain. The randomised trial literature for the management of breakthrough pain is small and no trials were found for other opioids. Given the importance of this subject, more trials need to be undertaken.	St Clare Hospice, Hastingwood CM17 9JX, Essex, England	Zeppetela, G (reprint author), St Clare Hospice, Hastingwood Rd, Hastingwood CM17 9JX, Essex, England.						BRUERA E, 1995, J PAIN SYMPTOM MANAG, V10, P348, DOI 10.1016/0885-3924(95)00052-Z; Caraceni A, 1999, PAIN, V82, P263, DOI 10.1016/S0304-3959(99)00073-1; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; CLEARY JF, 1997, [No title captured], V16, pA52; COLUZZI P, 1997, P AN M AM SOC CLIN, V16, pA52; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; COLUZZI PH, 2002, DOULEURS, V3, P26; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016/S0885-3924(03)00162-3; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136; Hanks G., 2001, EUR J PALLIAT CARE, V8, P6; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; McQuay HJ, 2003, J PAIN SYMPTOM MANAG, V25, P395, DOI 10.1016/S0885-3924(03)00099-X; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; PASQUALUCCI V, 1987, PAIN, V29, P273, DOI 10.1016/0304-3959(87)90042-X; Portenoy R K, 1997, Semin Oncol, V24, pS16; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; SAVARESE JJ, 1988, CLIN PHARMACOL THER, V43, P376, DOI 10.1038/clpt.1988.46; Shaiova L, 2004, SUPPORT CARE CANCER, V12, P268, DOI 10.1007/s00520-004-0595-4; SIMMONDS MA, 1997, P AN M AM SOC CLIN, V16, pA52; Zeppetella G, 2003, EXPERT OPIN PHARMACO, V4, P493, DOI 10.1517/14656566.4.4.493	27	67	68	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1469-493X	1361-6137		COCHRANE DB SYST REV	Cochrane Database Syst Rev.		2006		1							CD004311.pub2	10.1002/14651858.CD004311.pub2			16	Medicine, General & Internal	General & Internal Medicine	007OE	WOS:000234978200034					2020-06-30	J	Muellejans, B; Matthey, T; Scholpp, J; Schill, M				Muellejans, Bernd; Matthey, Thomas; Scholpp, Joachim; Schill, Markus			Sedation in the intensive care unit with remifentanil/propofol versus midazolam/fentanyl: a randomised, open-label, pharmacoeconomic trial	CRITICAL CARE			English	Article							ANALGESIA-BASED SEDATION; CRITICALLY-ILL PATIENTS; RENAL IMPAIRMENT; MAJOR METABOLITE; PHARMACOKINETICS; PATIENT; ICU; GUIDELINES; GI87084B; SAFETY	Introduction Remifentanil is an opioid with a unique pharmacokinetic profile. Its organ-independent elimination and short context-sensitive half time of 3 to 4 minutes lead to a highly predictable offset of action. We tested the hypothesis that with an analgesia-based sedation regimen with remifentanil and propofol, patients after cardiac surgery reach predefined criteria for discharge from the intensive care unit (ICU) sooner, resulting in shorter duration of time spent in the ICU, compared to a conventional regimen consisting of midazolam and fentanyl. In addition, the two regimens were compared regarding their costs. Methods In this prospective, open-label, randomised, single-centre study, a total of 80 patients ( 18 to 75 years old), who had undergone cardiac surgery, were postoperatively assigned to one of two treatment regimens for sedation in the ICU for 12 to 72 hours. Patients in the remifentanil/propofol group received remifentanil (6- max. 60 mu g kg(-1) h(-1); dose exceeds recommended labelling). Propofol (0.5 to 4.0 mg kg(-1) h(-1)) was supplemented only in the case of insufficient sedation at maximal remifentanil dose. Patients in the midazolam/fentanyl group received midazolam (0.02 to 0.2 mg kg(-1) h(-1)) and fentanyl (1.0 to 7.0 mu g kg(-1) h(-1)). For treatment of pain after extubation, both groups received morphine and/or non-opioid analgesics. Results The time intervals ( mean values +/- standard deviation) from arrival at the ICU until extubation (20.7 +/- 5.2 hours versus 24.2 h +/- 7.0 hours) and from arrival until eligible discharge from the ICU (46.1 +/- 22.0 hours versus 62.4 +/- 27.2 hours) were significantly ( p < 0.05) shorter in the remifentanil/propofol group. Overall costs of the ICU stay per patient were equal ( approximately E1,700 on average). Conclusion Compared with midazolam/fentanyl, a remifentanil-based regimen for analgesia and sedation supplemented with propofol significantly reduced the time on mechanical ventilation and allowed earlier discharge from the ICU, at equal overall costs.	Heart Ctr Mecklenburg Vorpommern, Dept Anaesthesiol & Intens Care Med, Mecklenburg, Germany; GlaxoSmithKline Inc, Dept Med, Munich, Germany	Muellejans, B (reprint author), Heart Ctr Mecklenburg Vorpommern, Dept Anaesthesiol & Intens Care Med, Mecklenburg, Germany.	dr.muellejans@drguth.de					Baillard CB, 2005, ANN FR ANESTH, V24, P480, DOI 10.1016/j.annfar.2005.02.027; BAUER P, 1994, BIOMETRICS, V50, P1029, DOI 10.2307/2533441; Breen D, 2004, CRIT CARE, V8, pR21, DOI 10.1186/cc2399; Breen D, 2005, CRIT CARE, V9, pR200, DOI 10.1186/cc3495; *BUND GES, 1995, LEITF EINF FALLP SON, P73; Carroll K C, 1999, Am J Crit Care, V8, P105; CHENG EY, 1995, CRIT CARE CLIN, V11, P1005; Cook DJ, 1998, ANN INTERN MED, V129, P433, DOI 10.7326/0003-4819-129-6-199809150-00002; Dahaba AA, 2004, ANESTHESIOLOGY, V101, P640, DOI 10.1097/00000542-200409000-00012; Dellinger RP, 2004, CRIT CARE MED, V32, P858, DOI 10.1097/01.CCM.0000117317.18092.E4; *DKG, 2002, DKG NT, V1, P435; *DKG, 2002, KALK FALLK HDB ANW K, P125; EGAN TD, 1993, ANESTHESIOLOGY, V79, P881, DOI 10.1097/00000542-199311000-00004; Ferguson J, 1997, J ADV NURS, V26, P1065, DOI 10.1111/j.1365-2648.1997.tb00796.x; HUGHES MA, 1992, ANESTHESIOLOGY, V76, P334, DOI 10.1097/00000542-199203000-00003; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Karabinis A, 2004, CRIT CARE, V8, pR268, DOI 10.1186/cc2896; LANE M, 2002, CARE CRIT ILL, V18, P140; MALACRIDA R, 1992, CRIT CARE MED, V20, P1123, DOI 10.1097/00003246-199208000-00010; MALBRAIN M, 2004, CRIT CARE S1, V8, pP238; MARTIN J, 2005, ANASTH INTENSIVMED S, V46, pS1; Muellejans B, 2004, CRIT CARE, V8, pR1, DOI 10.1186/cc2398; Navapurkar VU, 1998, BRIT J ANAESTH, V81, P881; Novaes MAFP, 1999, INTENS CARE MED, V25, P1421, DOI 10.1007/s001340051091; *OECD, 2004, OECD HLTH DAT 2004; Pitsiu M, 2004, BRIT J ANAESTH, V92, P493, DOI 10.1093/bja/aeh086; RAMSEY MAE, 2000, CLIN ANAESTHESIOL, V14, P419; ROLLAND S, 2005, STAT KRANKENHAUSDATE, P296; Schweickert WD, 2004, CRIT CARE MED, V32, P1272, DOI 10.1097/01.CCM.0000127263.54807.79; Scott LJ, 2005, DRUGS, V65, P1793, DOI 10.2165/00003495-200565130-00007; Soliman HM, 2001, BRIT J ANAESTH, V87, P186, DOI 10.1093/bja/87.2.186; *STAT BUND, 2005, STAT JB BUND DEUTSCH, P599; Tonner Peter H, 2003, Curr Opin Anaesthesiol, V16, P113; Vender Jeffery S, 2004, Crit Care Med, V32, pS554, DOI 10.1097/01.CCM.0000145907.86298.12; WESTMORELAND CL, 1993, ANESTHESIOLOGY, V79, P893, DOI 10.1097/00000542-199311000-00005; Wilhelm W, 1999, ANAESTHESIST, V48, P625, DOI 10.1007/s001010050762; WILHELM W, 2004, EUR J ANAESTH, V21, pA705; Young C, 2000, CRIT CARE MED, V28, P854, DOI 10.1097/00003246-200003000-00041	38	89	97	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2006	10	3							R91	10.1186/cc4939			9	Critical Care Medicine	General & Internal Medicine	083DQ	WOS:000240436500022	16780597	DOAJ Gold, Green Published			2020-06-30	J	Battershill, AJ; Keating, GM				Battershill, AJ; Keating, GM			Remifentanil - A review of its analgesic and sedative use in the intensive care unit	DRUGS			English	Review							CEREBRAL-BLOOD-FLOW; CRITICALLY-ILL PATIENTS; VENTILATOR-ASSOCIATED PNEUMONIA; INTRACRANIAL-PRESSURE; DOSE REMIFENTANIL; CONTINUOUS-INFUSION; RENAL IMPAIRMENT; MAJOR METABOLITE; NITROUS-OXIDE; PHARMACOKINETICS	Remifentanil (Ultiva (TM)), a 4-anilidopiperidine derivative of fentanyl, is an ultra-short-acting mu-opioid receptor agonist indicated to provide analgesia and sedation in mechanically ventilated intensive care unit (ICU) patients. Analgesia-based sedation with remifentanil is a useful option for mechanically ventilated patients in the ICU setting. Its unique properties (e.g. organ-independent metabolism, lack of accumulation, rapid offset of action) set it apart from other opioid agents. Remifentanil is at least as effective as comparator opioids such as fentanyl, morphine and sufentanil in providing pain relief and sedation in mechanically ventilated ICU patients. Moreover, it allows fast and predictable extubation, as well as being associated with a shorter duration of mechanical ventilation and quicker ICU discharge than comparators in some studies. In addition, remifentanil is generally well tolerated in this patient population. Thus, remifentanil is a welcome addition to the currently available pharmacological agents employed in the management of mechanically ventilated ICU patients.	Adis Int Ltd, Auckland 1311, New Zealand	Battershill, AJ (reprint author), Adis Int Ltd, 41 Centorian Dr,Privage Bag 65901,Mairangi Bay, Auckland 1311, New Zealand.						Akinci SB, 2005, PEDIATR ANESTH, V15, P870, DOI 10.1111/j.1460-9592.2005.01574.x; AMIN HM, 1995, J PHARMACOL EXP THER, V274, P34; Andel H, 2000, ANASTH INTENSIVMED, V41, P674; Annane D, 2005, LANCET, V365, P63, DOI 10.1016/S0140-6736(04)17667-8; Babenco HD, 2000, ANESTHESIOLOGY, V92, P393, DOI 10.1097/00000542-200002000-00020; Baillard CB, 2005, ANN FR ANESTH, V24, P480, DOI 10.1016/j.annfar.2005.02.027; Baker KZ, 1997, J NEUROSURG ANESTH, V9, P134, DOI 10.1097/00008506-199704000-00005; Black ML, 1999, ANESTHESIOLOGY, V90, P718, DOI 10.1097/00000542-199903000-00013; Bouillon T, 2002, ANESTHESIOLOGY, V97, P1350, DOI 10.1097/00000542-200212000-00005; Breen D, 2004, CRIT CARE, V8, pR21, DOI 10.1186/cc2399; Breen D, 2005, CRIT CARE, V9, pR200, DOI 10.1186/cc3495; Cavaliere F, 2002, CAN J ANAESTH, V49, P1088, DOI 10.1007/BF03017909; CHINACHOTI T, 2002, J MED ASS THAI S3, V85, P848; Cohen J, 2001, Curr Opin Crit Care, V7, P227, DOI 10.1097/00075198-200108000-00003; Cook DJ, 1998, ANN INTERN MED, V129, P433, DOI 10.7326/0003-4819-129-6-199809150-00002; Cox EH, 1999, ANESTHESIOLOGY, V90, P535, DOI 10.1097/00000542-199902000-00030; Curatolo M, 2000, BRIT J ANAESTH, V85, P529, DOI 10.1093/bja/85.4.529; Dahaba AA, 2004, ANESTHESIOLOGY, V101, P640, DOI 10.1097/00000542-200409000-00012; Dahaba AA, 2002, CAN J ANAESTH, V49, P369, DOI 10.1007/BF03017324; Davidson A., 2001, European Journal of Anaesthesiology, V18, P114; Dershwitz M, 1996, ANESTHESIOLOGY, V84, P812, DOI 10.1097/00000542-199604000-00008; Egan T D, 2000, Curr Opin Anaesthesiol, V13, P449, DOI 10.1097/00001503-200008000-00009; EGAN TD, 1995, CLIN PHARMACOKINET, V29, P80, DOI 10.2165/00003088-199529020-00003; Engelhard K, 2004, ACTA ANAESTH SCAND, V48, P396, DOI 10.1111/j.0001-5172.2004.00348.x; Glass PSA, 1999, ANESTHESIOLOGY, V90, P1556, DOI 10.1097/00000542-199906000-00010; GLASS PSA, 1993, ANESTH ANALG, V77, P1031; Gravel NR, 1999, CNS DRUGS, V11, P9, DOI 10.2165/00023210-199911010-00002; Gustorff B, 2001, ANESTH ANALG, V92, P369, DOI 10.1213/00000539-200102000-00017; HOFFMAN WE, 1993, ANESTHESIOLOGY, V79, P107, DOI 10.1097/00000542-199307000-00016; Hoke JF, 1997, J PHARMACOL EXP THER, V281, P226; Holzki J, 2004, PEDIATR ANESTH, V14, P265, DOI 10.1046/j.1460-9592.2003.01179.x; Howie MB, 2001, ANESTH ANALG, V92, P1084; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; JAMES MK, 1992, J PHARMACOL EXP THER, V263, P84; JAMES MK, 1991, J PHARMACOL EXP THER, V259, P712; Kan RE, 1998, ANESTHESIOLOGY, V88, P1467, DOI 10.1097/00000542-199806000-00008; Karabinis A, 2004, CRIT CARE, V8, pR268, DOI 10.1186/cc2896; Kazmaier S, 2000, BRIT J ANAESTH, V84, P578, DOI 10.1093/bja/84.5.578; Klimscha W, 2003, ANESTHESIOLOGY, V99, P834, DOI 10.1097/00000542-200310000-00014; Koitabashi T, 2002, ANESTH ANALG, V94, P1530, DOI 10.1097/00000539-200206000-00028; Leone M, 2004, ANESTH ANALG, V99, P1193, DOI 10.1213/01.ANE.0000132546.79769.91; Liu LL, 2003, DRUGS, V63, P755, DOI 10.2165/00003495-200363080-00003; Lorenz IH, 2000, BRIT J ANAESTH, V85, P199, DOI 10.1093/bja/85.2.199; Lorenz IH, 2000, ANESTH ANALG, V90, P609, DOI 10.1097/00000539-200003000-00020; Lotsch J, 2003, PAIN, V102, P151, DOI 10.1016/S0304-3959(02)00349-4; MacIntyre NR, 2001, CHEST, V120, p375S, DOI 10.1378/chest.120.6_suppl.375S; MALBRAIN M, 2005, ICU MANAGEMENT, V5, P22; Mason Paula, 2002, Intensive Crit Care Nurs, V18, P355, DOI 10.1016/S0964-3397(02)00087-3; MATTHEY T, 2004, INTENSIVE CARE M S1, V30, P174; Minto CF, 1997, ANESTHESIOLOGY, V86, P10, DOI 10.1097/00000542-199701000-00004; MORRISON L, 2000, 13 ANN C EUR SOC INT; Muellejans B, 2004, CRIT CARE, V8, pR1, DOI 10.1186/cc2398; MULLEJANS B, 2005, [No title captured]; Nieuwenhuijs DJF, 2003, ANESTHESIOLOGY, V98, P312, DOI 10.1097/00000542-200302000-00008; Noseir RK, 2003, ANESTH ANALG, V96, P1645, DOI 10.1213/01.ANE.0000061587.13631.67; Ostapkovich ND, 1998, ANESTHESIOLOGY, V89, P358, DOI 10.1097/00000542-199808000-00011; Paris A, 1998, ANESTH ANALG, V87, P569, DOI 10.1097/00000539-199809000-00013; Park G, 2002, Minerva Anestesiol, V68, P505; Park G., 2002, CURR ANAESTHES CRIT, V13, P313; Peterson MA, 2001, ANN ENTOMOL SOC AM, V94, P1, DOI 10.1603/0013-8746(2001)094[0001:BMAMEF]2.0.CO;2; Pitsiu M, 2004, BRIT J ANAESTH, V92, P493, DOI 10.1093/bja/aeh086; REEKER W, 1997, ANESTHESIOLOGY S, V3, P87; Rello J, 2001, CHEST, V120, P955, DOI 10.1378/chest.120.3.955; Ross AK, 2001, ANESTH ANALG, V93, P1393, DOI 10.1097/00000539-200112000-00008; Royston D, 1996, ANESTHESIOLOGY, V85, pA83; Samuelson Karin A, 2003, Intensive Crit Care Nurs, V19, P350; Scott LJ, 2005, DRUGS, V65, P1793, DOI 10.2165/00003495-200565130-00007; SEBEL PS, 1995, ANESTH ANALG, V80, P990, DOI 10.1097/00000539-199505000-00024; Shinohara K, 2000, CAN J ANAESTH, V47, P361, DOI 10.1007/BF03020954; Soltesz S, 2001, BRIT J ANAESTH, V86, P763, DOI 10.1093/bja/86.6.763; Stoppa F, 2004, Minerva Anestesiol, V70, P753; Tipps LB, 2000, NEUROSURGERY, V46, P596, DOI 10.1097/00006123-200003000-00015; Vender Jeffery S, 2004, Crit Care Med, V32, pS554, DOI 10.1097/01.CCM.0000145907.86298.12; Warren DK, 2003, CRIT CARE MED, V31, P1312, DOI 10.1097/01.CCM.0000063087.93157.06; WESTMORELAND CL, 1993, ANESTHESIOLOGY, V79, P893, DOI 10.1097/00000542-199311000-00005; Wilhelm W, 1999, ANAESTHESIST, V48, P625, DOI 10.1007/s001010050762; WILHELM W, 2004, EUR J ANAESTHESIOL S, V32, P21; Wolf AR, 2004, PEDIATR ANESTH, V14, P435, DOI 10.1111/j.1460-9592.2004.01332.x	78	39	54	0	10	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0012-6667	1179-1950		DRUGS	Drugs		2006	66	3					365	385		10.2165/00003495-200666030-00013			21	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	026WA	WOS:000236372500014	16526829				2020-06-30	J	Blick, SKA; Wagstaff, AJ				Blick, Stephanie K. A.; Wagstaff, Antona J.			Fentanyl buccal tablet - In breakthrough pain in opioid-tolerant patients with cancer	DRUGS			English	Article							HEALTHY ADULT VOLUNTEERS; DOSE PROPORTIONALITY; OPEN-LABEL; MU-G; PHARMACOKINETICS; ENHANCEMENT	The fentanyl buccal tablet (FBT) is a new formulation of fentanyl that uses an effervescent drug delivery system to enhance penetration across the buccal mucosa for the treatment of breakthrough pain in opioid-tolerant patients with cancer. Fentanyl is rapidly absorbed from FBT across the buccal mucosa and into the bloodstream. Fentanyl is more rapidly absorbed and bioavailability is higher from FBT than from the oral transmucosal fentanyl citrate formulation. In a well designed phase III trial in opioid-tolerant patients with cancer, a single dose of FBT 100-800 mu g provided clinically significant improvements in pain intensity from 15 to 60 minutes after the dose. Single FBT doses of 100-800 mu g were generally well tolerated; the majority of adverse events were mild to moderate in nature and typical of those associated with opioids.	Wolters Kluwer Hlth I Adis, Auckland 1311, New Zealand	Blick, SKA (reprint author), Wolters Kluwer Hlth I Adis, 41 Centorian Dr,Provate Bag 65901, Auckland 1311, New Zealand.	demail@adis.co.nz					BROWN JH, 1981, BRIT J ANAESTH, V53, P1033, DOI 10.1093/bja/53.10.1033; *CEPH INC, PRESCR INF FENT FENT; Darwish M, 2006, CLIN THER, V28, P707, DOI 10.1016/j.clinthera.2006.05.015; Darwish M, 2006, CLIN THER, V28, P715, DOI 10.1016/j.clinthera.2006.05.016; Darwish M, 2005, CLIN PHARMACOKINET, V44, P1279, DOI 10.2165/00003088-200544120-00006; DARWISH M, 2006, AM SOC HLTH SYST PHA; DARWISH M, IN PRES J CLIN PAHRM; Darwish M, 2006, CLIN PHARMACOKINET, V45, P843, DOI 10.2165/00003088-200645080-00006; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Eichman JD, 1998, PHARM RES-DORDR, V15, P925, DOI 10.1023/A:1011936901638; Fine PG, 2000, CNS DRUGS, V13, P313, DOI 10.2165/00023210-200013050-00002; HALE M, 2006, AM AC PAIN MED ANN M; HORVATH G, 1990, ANESTH ANALG, V70, P284; HORVATH G, 1992, LIFE SCI, V50, P215; HU C, 1992, LAB ANIM-UK, V26, P15, DOI 10.1258/002367792780809075; Mercadante S, 1998, CANCER TREAT REV, V24, P425, DOI 10.1016/S0305-7372(98)90005-6; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; NALAMACHU S, 2006, IMPACT FENTANYL EFFE; NALAMACHU S, 2006, EVALUATION PATIENTS; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; PORTENOY RK, 2006, FENTANYL BUCCAL TABL; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; REVES JG, 1984, ANESTH ANALG, V63, P97; SLATKIN N, 2006, AM SOC CLIN ONC 42 A, P484; WEBSTER L, 2006, J PAIN S2, V4, pS52; YASTER M, 1989, ANESTHESIOLOGY, V70, P461, DOI 10.1097/00000542-198903000-00016	26	21	22	0	2	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0012-6667	1179-1950		DRUGS	Drugs		2006	66	18					2387	2393		10.2165/00003495-200666180-00013			7	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	126CX	WOS:000243490900012	17181383				2020-06-30	J	Choi, DH; Ahn, HJ; Kim, JA				Choi, DH; Ahn, HJ; Kim, JA			Combined low-dose spinal-epidural anesthesia versus single-shot spinal anesthesia for elective cesarean delivery	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article; Proceedings Paper	1st World Congress on Regional Anaesthesia and Pain Therapy	2002	Barcelona, SPAIN			combined spinal-epidural anesthesia; spinal anesthesia; cesarean delivery	HYPERBARIC BUPIVACAINE; SECTION; FENTANYL; HYPOTENSION; BLOCK; PREVENTION; ANALGESIA; EXTENSION; INJECTION; MECHANISM	Combined spinal-epidural anesthesia balancing low-dose intrathecal bupivacaine/fentanyl and low-dose epidural bupivacaine may be more useful than single-shot spinal anesthesia for cesarean delivery in reducing incidences of adverse effects such as hypotension and nausea and in shortening motor recovery. Combined spinal-epidural anesthesia (n = 50) or spinal anesthesia (n = 50) was randomly performed in 100 parturients. Intrathecal bupivacaine 6 mg added by fentanyl 20 mu g followed after 5 min by 10 mL of 0.25% epidural bupivacaine were used for combined spinal-epidural and intrathecal bupivacaine 9 mg with fentanyl 20 mu g for spinal anesthesia. The initial sensory block level was higher in the spinal group (P < 0.001), although the maximum levels were the same (T3). Complete surgical anesthesia was achieved and no patient complained of intraoperative pain in either group. Patients in the spinal group had denser motor block in the extremities and a higher incidence of hypotension (P < 0.05) and nausea and vomiting (P < 0.05). Motor recovery was faster in the combined spinal-epidural group (P < 0.001). We concluded that combined spinal-epidural anesthesia using low-dose local anesthetic-opioid spinal anesthesia and routine epidural supplementation before surgery had some potential advantages over single-shot spinal anesthesia in the lower incidences of adverse effects and quicker recovery. (c) 2005 Elsevier Ltd. All rights reserved.	Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Anesthesiol & Pain Med, Seoul 135710, South Korea	Choi, DH (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Anesthesiol & Pain Med, 50 Ilwondong, Seoul 135710, South Korea.	dhchoi@smc.samsung.co.kr					AKERMAN B, 1988, ANESTH ANALG, V67, P943; Albright GA, 1999, REGION ANESTH PAIN M, V24, P117, DOI 10.1016/S1098-7339(99)90071-8; Asokumar B, 1998, ANESTH ANALG, V87, P1309, DOI 10.1097/00000539-199812000-00018; Ben-David B, 2000, REGION ANESTH PAIN M, V25, P235, DOI 10.1016/S1098-7339(00)90004-X; Birnbach DJ, 1999, ANESTH ANALG, V88, P971, DOI 10.1097/00000539-199905000-00001; BLUMGART CH, 1992, BRIT J ANAESTH, V69, P457, DOI 10.1093/bja/69.5.457; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; Choi DH, 2000, REGION ANESTH PAIN M, V25, P591, DOI 10.1053/rapm.2000.8934; CHOI DH, 2001, IMRAPT, V13, pA77; Cowan CM, 2002, BRIT J ANAESTH, V89, P452; DESIMONE CA, 1995, REGION ANESTH, V20, P90; FAN SZ, 1994, ANESTH ANALG, V78, P474; Gaiser RR, 2003, J CLIN ANESTH, V15, P474, DOI 10.1016/S0952-8180(03)00113-2; HUNT CO, 1989, ANESTHESIOLOGY, V71, P535, DOI 10.1097/00000542-198910000-00009; Kuczkowski KM, 2005, ACTA ANAESTH SCAND, V49, P722, DOI 10.1111/j.1399-6576.2005.00686.x; Lew E, 2004, ANESTH ANALG, V98, P810; RAWAL N, 1988, ACTA ANAESTH SCAND, V32, P61, DOI 10.1111/j.1399-6576.1988.tb02689.x; Rawal N, 2000, Anesthesiol Clin North Am, V18, P267, DOI 10.1016/S0889-8537(05)70164-4; RILEY ET, 1995, ANESTH ANALG, V81, P838, DOI 10.1097/00000539-199510000-00031; ROUT CC, 1994, INT ANESTHESIOL CLIN, V32, P117, DOI 10.1097/00004311-199400000-00010; Stienstra R, 1996, ANESTH ANALG, V83, P382, DOI 10.1097/00000539-199608000-00031; THOREN T, 1994, ANESTH ANALG, V78, P1087; Vercauteren MP, 2000, ANESTH ANALG, V90, P324, DOI 10.1097/00000539-200002000-00016; Vercauteren MP, 1998, ANESTH ANALG, V86, P989, DOI 10.1097/00000539-199805000-00014	24	31	33	1	7	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JAN	2006	15	1					13	17		10.1016/j.ijoa.2005.05.009			5	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	004QP	WOS:000234767600004	16256330				2020-06-30	J	Gold, MS; Melker, RJ; Dennis, DM; Morey, TE; Bajpai, LK; Pomm, R; Frost-Pineda, K				Gold, MS; Melker, RJ; Dennis, DM; Morey, TE; Bajpai, LK; Pomm, R; Frost-Pineda, K			Fentanyl abuse and dependence: Further evidence for second hand exposure hypothesis	JOURNAL OF ADDICTIVE DISEASES			English	Article						addiction; sensitization; second-hand exposure; opioid; anesthesiologists; physician addiction	OCCUPATIONAL MORTALITY	We have proposed a novel hypothesis regarding the potential role Of Occupational or second-hand exposure in physician substance use, abuse, and addiction. While only 5.6% of licensed physicians in Florida are anesthesiologists, nearly 25% of physicians followed for substance abuse/dependence are anesthesiologists. When we sort by drug of choice, anesthesiologists have more opioid abuse and dependence than other physicians and appropriate controls. Abuse of one opioid, fentanyl, appears to be increasing and has been noted among the State of Florida's causes of opioid deaths. Fentanyl and sufentanyl are commonly administered highly potent opioid analgesics, as much as 80-800 times as potent as morphine. We have recent data from the State of Florida impaired physicians database, which has allowed us to categorize all fentanyl abusing and/or dependent physicians. Just knowing that a physician abuses fentanyl gives you a good clue as to their specialty; 75% are anesthesiologists! While drug abuse researchers, oncologists and others who handle drugs of abuse everyday, have no greater incidence of opioid abuse or dependence, anesthesiologists are at the top of every list. Can this be due to just access and stress? We have proposed an alternative hypothesis of second hand exposure. To test this hypothesis, we developed a sensitive LC/MS/MS assay to measure the intravenous anesthetic and analgesic agents, propofol and fentanyl in air. Not only did we detect propofol and fentanyl in cardiovascular surgery operating room air, we also found the highest concentrations were close to the patient's mouth where anesthesiologists work for hours. Like tobacco, second hand opioid exposure can sensitize and change the brain making abuse, dependence and behavioral disorders more likely. Thus environmental exposure and sensitization may be an important risk factor in physician addiction. Second hand exposure may affect treatment outcome and explain anesthesiologist's inability to return to work in the operating room. We are developing an animal model for second hand exposure and additional studies of the operating room and cardiac anesthesiologists are underway.	Univ Florida, Coll Med, Div Addict Med, Dept Psychiat, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Div Addict Med, Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Div Addict Med, Dept Community Hlth & Family Med & Chief, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Anesthesiol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Pediat & Biomed Engn, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Anesthesiol & Pharmacol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Expt Therapeut, Gainesville, FL 32610 USA	Gold, MS (reprint author), Univ Florida, Coll Med, Div Addict Med, Dept Psychiat, POB 100183, Gainesville, FL 32610 USA.	msgold@psychiatry.ufl.edu		Frost-Pineda, Kimberly/0000-0001-8991-4148			Alexander BH, 2000, ANESTHESIOLOGY, V93, P922, DOI 10.1097/00000542-200010000-00008; DEFALQUE RJ, 1995, ANESTHESIOLOGY, V83, P1370, DOI 10.1097/00000542-199512000-00035; DIMICHWARD H, 1988, CAN J PUBLIC HEALTH, V79, P194; FISCHMAN MW, 1992, CIBA F SYMP, V166, P165; Gold M., 1982, AM PSYCH ASS ABSTR, V95, P275; Gold MS, 2004, INT J NEUROPSYCHOPH, V7, pS140; Gold MS, 2004, PSYCHIAT CLIN N AM, V27, P745, DOI 10.1016/j.psc.2004.07.006; GOLD MS, 2005, J DUAL DIAGN, V1, P15; GOLD MS, 2005, J DUAL DIAGN, V1, P5; GOLD MS, 2004, IS ADDICTION OCCUPAT; HARFORD TC, 1992, J STUD ALCOHOL, V53, P463, DOI 10.15288/jsa.1992.53.463; HEDBERG EB, 2002, ASA NEWSLETTER   MAY; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; LEIGH JP, 1993, ADDICTION, V88, P767, DOI 10.1111/j.1360-0443.1993.tb02091.x; Long C. W., 1849, SO MED SURG J, V5, P705; MANDELL W, 1992, ALCOHOL CLIN EXP RES, V16, P734, DOI 10.1111/j.1530-0277.1992.tb00670.x; Nusbaumer MR, 2002, AM J DRUG ALCOHOL AB, V28, P735, DOI 10.1081/ADA-120015879; Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI 10.1146/annurev.psych.54.101601.145237; Talbott G D, 1981, J Med Assoc Ga, V70, P545; Wyvell CL, 2001, J NEUROSCI, V21, P7831	20	37	42	0	4	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1055-0887	1545-0848		J ADDICT DIS	J. Addict. Dis.		2006	25	1					15	21		10.1300/J069v25n01_04			7	Substance Abuse	Substance Abuse	035UP	WOS:000237027500004	16597569				2020-06-30	J	Cohen, PJ				Cohen, Peter J.			Comments by Peter J. Cohen	JOURNAL OF ADDICTIVE DISEASES			English	Editorial Material							EXPOSURE; ABUSE		Georgetown Univ, Ctr Law, Phys Hlth Comm, Med Soc Dist Columbia, Washington, DC USA	Cohen, PJ (reprint author), Georgetown Univ, Ctr Law, Phys Hlth Comm, Med Soc Dist Columbia, Washington, DC USA.	ccohenp@aol.com					BAUCHOP T, 1989, BIOSYSTEMS, V23, P53, DOI 10.1016/0303-2647(89)90008-7; Domino KB, 2005, JAMA-J AM MED ASSOC, V293, P1453, DOI 10.1001/jama.293.12.1453; Ernst M, 1997, SEMIN NEUROSCI, V9, P120, DOI 10.1006/smns.1997.0112; Gold MS, 2006, J ADDICT DIS, V25, P15, DOI 10.1300/J069v25n01_04; Gold MS, 2004, PSYCHIAT CLIN N AM, V27, P745, DOI 10.1016/j.psc.2004.07.006; GOLD MS, 2005, INT J NEUROPSYCHOPHA, V7; Kintz P, 2005, FORENSIC SCI INT, V153, P81, DOI 10.1016/j.forsciint.2005.04.033; London E D, 1996, NIDA Res Monogr, V163, P146; Markel H, 2005, NEW ENGL J MED, V352, P966, DOI 10.1056/NEJMp048240; Zubieta JK, 2000, NEUROPSYCHOPHARMACOL, V23, P326, DOI 10.1016/S0893-133X(00)00110-X	10	2	2	0	2	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1055-0887	1545-0848		J ADDICT DIS	J. Addict. Dis.		2006	25	4					135	136		10.1300/J069v25n04_14			2	Substance Abuse	Substance Abuse	116YN	WOS:000242839800014	17088234				2020-06-30	J	Denisco, RA				Denisco, Richard A.			Comments by Richard A. Denisco	JOURNAL OF ADDICTIVE DISEASES			English	Editorial Material							ABUSE		NIDA, Div Epidemiol Serv & Prevent Res, Bethesda, MD 20892 USA	Denisco, RA (reprint author), NIDA, Div Epidemiol Serv & Prevent Res, Bethesda, MD 20892 USA.	deniscor@nida.nih.gov					Gold MS, 2006, J ADDICT DIS, V25, P15, DOI 10.1300/J069v25n01_04; Paris RT, 1999, J ADDICT DIS, V18, P1, DOI 10.1300/J069v18n01_01; Patterson P, 1993, OR Manager, V9, P9; PATTERSON P, 1993, OR MANAGER, V9, P1; PELTON C, 1991, J PSYCHOACTIVE DRUGS, V23, P427, DOI 10.1080/02791072.1991.10471613; *US OCC SAF HLTH A, AN GAS GUID WORKPL E	6	2	2	0	1	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1055-0887	1545-0848		J ADDICT DIS	J. Addict. Dis.		2006	25	4					137	137		10.1300/J069v25n04_15			1	Substance Abuse	Substance Abuse	116YN	WOS:000242839800015	17088235				2020-06-30	J	Gorman, E				Gorman, Eugene			Comments by Eugene Gorman	JOURNAL OF ADDICTIVE DISEASES			English	Editorial Material							SUBSTANCE-USE; PHYSICIANS; ANESTHESIOLOGISTS; EXPOSURE		Pascack Valley Hosp, Div Anesthesiol, Opiate Detoxificat Inst, Westwood, NJ 07675 USA	Gorman, E (reprint author), Pascack Valley Hosp, Div Anesthesiol, Opiate Detoxificat Inst, 250 Old Hook Rd, Westwood, NJ 07675 USA.	aba6@aol.com					Alexander BH, 2000, ANESTHESIOLOGY, V93, P922, DOI 10.1097/00000542-200010000-00008; Blondell R D, 1992, J Ky Med Assoc, V90, P62; Clay Steven W, 2003, J Am Osteopath Assoc, V103, P81; FISCHMAN MW, 1992, CIBA F SYMP, V166, P165; Gallegos K V, 1988, QRB Qual Rev Bull, V14, P116; Gold MS, 2006, J ADDICT DIS, V25, P15, DOI 10.1300/J069v25n01_04; Gold MS, 2004, PSYCHIAT CLIN N AM, V27, P745, DOI 10.1016/j.psc.2004.07.006; HERRINGTON RE, 1982, JAMA-J AM MED ASSOC, V257, P2253; Hughes PH, 1999, J ADDICT DIS, V18, P23, DOI 10.1300/J069v18n02_03; PELTON C, 1991, J PSYCHOACTIVE DRUGS, V23, P427, DOI 10.1080/02791072.1991.10471613; Talbott G D, 1986, Va Med, V113, P95	11	4	4	0	2	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1055-0887	1545-0848		J ADDICT DIS	J. Addict. Dis.		2006	25	4					139	140		10.1300/J069v25n04_16			2	Substance Abuse	Substance Abuse	116YN	WOS:000242839800016	17088236				2020-06-30	J	Boztug, N; Bigat, Z; Akyuz, M; Demir, S; Ertok, E				Boztug, N; Bigat, Z; Akyuz, M; Demir, S; Ertok, E			Does using the bispectral index (BIS) during craniotomy affect the quality of recovery?	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						bispectral index; anesthesia recovery period; sevoflurane; fentanyl	NITROUS-OXIDE ANESTHESIA; PROPOFOL/REMIFENTANIL ANESTHESIA; AMBULATORY ANESTHESIA; PROPOFOL; SEDATION; ALFENTANIL; EMERGENCE; TITRATION; DEPTH; ELECTROENCEPHALOGRAM	One of the aims of neuroanesthesia is to provide early postoperative recovery and neurologic examination in patients undergoing supratentorial surgery. Our aim was to investigate the role of using the bispectral index (BIS) in recovery from anesthesia and altering drug administration in patients undergoing craniotomy. Fifty American Society of Anesthesiologists' (ASA) physical status I-II patients undergoing craniotomy were included in the study. The patients were randomly divided into two groups, and all patients received standard induction drugs, and 0.8%-1.5% sevoflurane was used for maintenance of anesthesia. In the BIS-guided group, the concentration of sevoflurane was titrated to maintain BIS at 40-60. In the control group, the anesthesiologist was blind to BIS, and the concentration of sevoflurane was changed according to the patients' hemodynamic changes. The hemodynamic data, BIS values, and sevoflurane concentrations were recorded every 15 minutes. In addition, the BIS value was recorded by the primary anesthetist in the BIS-guided group and by another independent anesthetist in the control group. At the end of the study, recovery criteria and Aldrete recovery scores were recorded every 15 minutes. Neurologic assessments were performed when the Aldrete score was 9-10. BIS values were higher, and sevoflurane concentrations (P < 0.05) and total doses of fentanyl (P < 0.01) were lower, in the BIS-guided group. Times to first spontaneous breathing, eye opening, and extubation (P = 0.035, P = 0.001.. and P 0.0001, respectively) were significantly shorter in the BIS-guided group. Time to an Aldrete score of 9-10 and adequate neurologic assessment were similar between the groups. To conclusion, BIS monitoring by supratentorial craniotomy under general anesthesia reduced the maintenance anesthetic concentration and narcotic drug usage and lowered the recovery times from general anesthesia.	Akdeniz Univ Med Fac, Dept Anesthesiol & Reanimat & Neurosurg, Antalya, Turkey; Akdeniz Univ Med Fac, Dept Neurosurg, Antalya, Turkey	Boztug, N (reprint author), Akdeniz Univ Med Hosp, Dept Anesthesiol & Reanimat, Dumlupinar Kampusu, TR-07070 Antalya, Turkey.	nevalboztug@hotmail.com					Bannister CF, 2001, ANESTH ANALG, V92, P877; De Deyne C, 1998, INTENS CARE MED, V24, P1294, DOI 10.1007/s001340050765; Deogaonkar A, 2004, CRIT CARE MED, V32, P2403, DOI 10.1097/01.CCM.0000147442.14921.A5; Drover DR, 2002, ANESTHESIOLOGY, V97, P82, DOI 10.1097/00000542-200207000-00012; Drummond JC, 2000, ANESTHESIOLOGY, V93, P876, DOI 10.1097/00000542-200009000-00039; Gan TJ, 1997, ANESTHESIOLOGY, V87, P808, DOI 10.1097/00000542-199710000-00014; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; Guinard JP, 1998, ANESTHESIOLOGY, V89, pA104; Johansen JW, 2000, J CLIN ANESTH, V12, P433, DOI 10.1016/S0952-8180(00)00187-2; Liu J, 1997, ANESTH ANALG, V84, P185, DOI 10.1097/00000539-199701000-00033; MATTA BF, 2000, TXB NEUROANAESTHESIA, P76; Monk TG, 2005, ANESTH ANALG, V100, P4, DOI 10.1213/01.ANE.0000147519.82841.5E; Pavlin DJ, 2001, ANESTH ANALG, V93, P613, DOI 10.1097/00000539-200109000-00017; Recart A, 2003, ANESTH ANALG, V97, P1667, DOI 10.1213/01.ANE.0000087041.63034.8C; Recart A, 2003, ANESTHESIOLOGY, V99, P813, DOI 10.1097/00000542-200310000-00011; Schmidt GN, 2004, ANESTH ANALG, V98, P1346, DOI 10.1213/01.ANE.0000111209.44119.30; Schmidt GN, 2002, ANESTH ANALG, V95, P1324, DOI 10.1097/00000539-200211000-00042; SIGL JC, 1994, J CLIN MONITOR, V10, P392, DOI 10.1007/BF01618421; Simmons LE, 1999, CRIT CARE MED, V27, P1499, DOI 10.1097/00003246-199908000-00016; Song DJ, 1997, ANESTHESIOLOGY, V87, P842, DOI 10.1097/00000542-199710000-00018; Song DJ, 1998, ANESTH ANALG, V87, P1245, DOI 10.1097/00000539-199812000-00006; TODD MM, 1993, ANESTHESIOLOGY, V78, P1005, DOI 10.1097/00000542-199306000-00002; WALTERS FJM, 1999, BAILLIERE CLIN ANAES, V13, P531	23	22	26	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	2006	18	1					1	4		10.1097/01.ana.0000188028.80960.dd			4	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	000YF	WOS:000234497700001	16369133				2020-06-30	J	Tankisi, A; Rasmussen, M; Juul, N; Cold, GE				Tankisi, A; Rasmussen, M; Juul, N; Cold, GE			The effects of 10 degrees reverse Trendelenburg position on subdural intracranial pressure and cerebral perfusion pressure in patients subjected to craniotomy for cerebral aneurysm	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						intracranial pressure; cerebral perfusion pressure; craniotomy; reverse Trendelenburg position; intracranial aneurysm	CEREBROSPINAL-FLUID PRESSURE; INTRA-CRANICAL PRESSURE; END-EXPIRATORY PRESSURE; HEAD TRAUMA PATIENTS; BLOOD-FLOW; VENOUS OUTFLOW; BODY POSITION; SUBARACHNOID HEMORRHAGE; TACTILE ESTIMATION; POSTERIOR-FOSSA	The aim of the current study was to examine the effects of 10 degrees reverse Trendelenburg position (rTp) on subdural intracranial pressure (ICP), cerebral perfusion pressure (CPP), and dural tension. Additionally. the relationship between preoperative Hunt & Hess (H&H) grade and the subdural ICP in patients scheduled for cerebral aneurysm surgery was investigated. Twenty-eight Consecutive patients with a cerebral aneurysm were subjected to craniotomy in propofol/fentanyl or propofol/remifentanil anesthesia. Subdural ICP was measured after opening of the bone flap and exposure of dura. After reference measurements Of subdural ICP and mean arterial blood pressure (MABP),. the measurements were repeated during 10 degrees rTp. No significant differences between the anesthetic groups Were disclosed. During 10 degrees rTp.. a significant decrease in MABP, ICP, and jugular bulb pressure was observed whereas CPP remained unchanged. In H&H 0 patients (unruptured aneurysm), the ICP decreased from 2.9 +/- 2.6 mmHg to 0.4 +/- 2.2 mmHg at 10 degrees rTp. In H&H I to 11 patients, the ICP decreased from 9.3 +/- 3.8 mmHg to 4.6 +/- 3.3 mmHg at 10 degrees rTp. A significant difference in the mean baseline subdural ICP and Delta ICP (change in ICP) was found between patients with unruptured aneurysm and patients with subarachnoid hemorrhage (H&H I and II). Furthermore, the relationship between the subdural ICP at neutral position and Delta ICP was significant. In patients without intracranial hypertension, 10 degrees rTp decreases subdural ICP and dural tension in patients with ruptured as well as patients with unruptured cerebral aneurysm; CPP is unchanged.	Aarhus Univ Hosp, Dept Neuroanaesthesia, DK-8000 Aarhus C, Denmark	Tankisi, A (reprint author), Aarhus Univ Hosp, Dept Neuroanaesthesia, Norrebrogade 44,Bygning 10,7 Etage, DK-8000 Aarhus C, Denmark.	alpta@as.aaa.dk	Juul, Niels/AAF-1378-2020; Rasmussen, Mads/R-4876-2019	Rasmussen, Mads/0000-0002-0416-6767			ALBECK MJ, 1991, J NEUROSURG, V74, P597, DOI 10.3171/jns.1991.74.4.0597; ALPERIN N, 2004, 12 INT S INTR PRESS; AUER LM, 1990, NEUROSURGERY, V26, P804, DOI 10.1227/00006123-199005000-00012; Balakrishnan G, 2000, ANESTH ANALG, V91, P163, DOI 10.1097/00000539-200007000-00030; Bundgaard H, 1998, ACT NEUR S, V71, P276; Bundgaard H, 2000, BRIT J NEUROSURG, V14, P229; CALLIAUW L, 1987, ACTA NEUROCHIR, V85, P154, DOI 10.1007/BF01456112; Cirovic S, 2003, AVIAT SPACE ENVIR MD, V74, P125; Cold GE, 1996, BRIT J NEUROSURG, V10, P69; DAVENPORT A, 1990, CRIT CARE MED, V18, P286, DOI 10.1097/00003246-199003000-00008; Dawson EA, 2004, AM J PHYSIOL-REG I, V287, pR911, DOI 10.1152/ajpregu.00196.2004; Doepp F, 2004, NEURORADIOLOGY, V46, P565, DOI 10.1007/s00234-004-1213-3; DURWARD QJ, 1983, J NEUROSURG, V59, P938, DOI 10.3171/jns.1983.59.6.0938; FELDMAN Z, 1992, J NEUROSURG, V76, P207, DOI 10.3171/jns.1992.76.2.0207; Gisolf J, 2004, J PHYSIOL-LONDON, V560, P317, DOI 10.1113/jphysiol.2004.070409; Guy J, 1997, ANESTHESIOLOGY, V86, P514, DOI 10.1097/00000542-199703000-00002; HARTMANN A, 1980, INTRACRANIAL PRESSUR, V4, P220; HASE U, 1978, ACTA NEUROCHIR, V44, P69, DOI 10.1007/BF01401631; Haure P, 2003, J NEUROSURG ANESTH, V15, P297, DOI 10.1097/00008506-200310000-00001; HAYASHI M, 1977, J NEUROSURG, V46, P584, DOI 10.3171/jns.1977.46.5.0584; Holt JP, 1941, AM J PHYSIOL, V134, P0292; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; HUSEBY JS, 1981, J NEUROSURG, V55, P704, DOI 10.3171/jns.1981.55.5.0704; Jorgensen HA, 1999, BRIT J NEUROSURG, V13, P449; KOFKE WA, 1993, ANESTHESIOLOGY, V78, P620, DOI 10.1097/00000542-199303000-00050; LANGFITT TW, 1964, J NEUROSURG, V21, P989, DOI 10.3171/jns.1964.21.11.0989; Larsen JKR, 2002, J NEUROSURG ANESTH, V14, P16, DOI 10.1097/00008506-200201000-00004; Lovell AT, 2000, ANESTH ANALG, V90, P372, DOI 10.1097/00000539-200002000-00025; LUCE JM, 1982, J APPL PHYSIOL, V53, P1496; LUCE JM, 1982, J APPL PHYSIOL, V52, P231; MADSEN JB, 1991, FOCUS INFUSION, P162; MAGNAES B, 1978, SURG NEUROL, V10, P45; MAGNAES B, 1976, J NEUROSURG, V44, P687, DOI 10.3171/jns.1976.44.6.0687; MARMAROU A, 1975, J NEUROSURG, V43, P523, DOI 10.3171/jns.1975.43.5.0523; Mavrocordatos P, 2000, J NEUROSURG ANESTH, V12, P10, DOI 10.1097/00008506-200001000-00003; Meixensberger J, 1997, NEUROL RES, V19, P249, DOI 10.1080/01616412.1997.11740808; Moraine JJ, 2000, J NEUROSURG, V92, P606, DOI 10.3171/jns.2000.92.4.0606; Ng I, 2004, NEUROSURGERY, V54, P593, DOI 10.1227/01.NEU.0000108639.16783.39; Ostapkovich ND, 1998, ANESTHESIOLOGY, V89, P358, DOI 10.1097/00000542-199808000-00011; Petersen KD, 2003, ANESTHESIOLOGY, V98, P329, DOI 10.1097/00000542-200302000-00010; RAMANI R, 1992, J NEUROSURG ANESTH, V4, P110, DOI 10.1097/00008506-199204000-00006; Rasmussen M, 2004, J NEUROSURG, V101, P621, DOI 10.3171/jns.2004.101.4.0621; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; SCHNEIDER GH, 1993, ACTA NEUROCHIR, P107; Schwarz S, 2002, STROKE, V33, P497, DOI 10.1161/hs0202.102376; SPERRY RJ, 1992, ANESTHESIOLOGY, V77, P416, DOI 10.1097/00000542-199209000-00002; STEPHAN H, 1987, ANAESTHESIST, V36, P60; Tankisi A, 2002, ACTA NEUROCHIR, V144, P665, DOI 10.1007/s00701-002-0957-y; Valdueza JM, 2000, LANCET, V355, P200; Vandesteene A, 1988, Anaesthesia, V43 Suppl, P42, DOI 10.1111/j.1365-2044.1988.tb09067.x; VOLDBY B, 1982, J NEUROSURG, V56, P186, DOI 10.3171/jns.1982.56.2.0186; Watts ADJ, 1998, ANESTH ANALG, V87, P564, DOI 10.1097/00000539-199809000-00012; Yoshida A., 1993, INTRACRANIAL PRESSUR, P433	53	14	16	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	2006	18	1					11	17		10.1097/01.ana.0000192132.71560.28			7	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	000YF	WOS:000234497700003	16369135				2020-06-30	J	Statler, KD; Alexander, H; Vagni, V; Dixon, CE; Clark, RSB; Jenkins, L; Kochanek, PM				Statler, KD; Alexander, H; Vagni, V; Dixon, CE; Clark, RSB; Jenkins, L; Kochanek, PM			Comparison of seven anesthetic agents on outcome after experimental traumatic brain injury in adult, male rats	JOURNAL OF NEUROTRAUMA			English	Article						analgesia; benzodiazepine; controlled cortical impact; isoflurane; ketamine; narcotic; propofol; sedation	CEREBRAL-BLOOD-FLOW; PROPOFOL INFUSION; ENDOGENOUS OPIOIDS; NITROUS-OXIDE; ISOFLURANE ANESTHESIA; FOREBRAIN ISCHEMIA; GLOBAL-ISCHEMIA; KETAMINE; FENTANYL; NEUROPROTECTION	Isoflurane is commonly used in experimental traumatic brain injury (TBI), both before and early after injury, yet it is rarely used clinically. Narcotics and benzodiazepines are frequently used after injury in clinical TBI. We compared seven anesthetic/sedative agents applied after injury in the controlled cortical impact model: diazepam, fentanyl, isoflurane, ketamine, morphine, pentobarbital, and propofol. Our objective was to provide insight into the relative degrees of neuroprotection provided by these agents in a standard model of TBI. We hypothesized that the choice of anesthetic/sedative early after experimental TBI critically impacts outcome and that the agents most commonly used clinically may be less neuroprotective than isoflurane. Rats treated with isoflurane had the best cognitive recovery (p < 0.05) and hippocampal neuronal survival (p < 0.05). Conversely, rats treated with ketamine had the most hippocampal neuronal death (p < 0.05). Morphine or propofol, two agents commonly used clinically, were associated with the poorest motor function on post-trauma day 1-5 (p < 0.05). Our data support beneficial effects of isoflurane early after experimental TBI. Our data suggest that the early post-TBI use of isoflurane, despite practical logistical issues, could potentially provide clinical benefits in TBI-versus other commonly used sedatives or analgesics. Furthermore, the choice of post-injury sedation and analgesia could have important implications on attempts to translate novel therapies from bench to field or bedside.	Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA USA; Safar Ctr Resuscitat Res, Pittsburgh, PA USA	Statler, KD (reprint author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA.	kim.statler@hsc.utah.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32-HD40686]; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318]		Bayona NA, 2004, ANESTHESIOLOGY, V100, P1151, DOI 10.1097/00000542-200405000-00017; BICKLER PE, 1994, ANESTHESIOLOGY, V81, P1461, DOI 10.1097/00000542-199412000-00022; Bickler PE, 2003, ANESTH ANALG, V97, P564, DOI 10.1213/01.ANE.0000068880.82739.7B; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P527; BRAY RJ, 1995, ANAESTHESIA, V50, P94, DOI 10.1111/j.1365-2044.1995.tb04544.x; Cannon ML, 2001, J NEUROSURG, V95, P1053, DOI 10.3171/jns.2001.95.6.1053; CARLSSON C, 1981, ANESTHESIOLOGY, V54, P488, DOI 10.1097/00000542-198106000-00008; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; CAVAZZUTI M, 1987, J CEREBR BLOOD F MET, V7, P806, DOI 10.1038/jcbfm.1987.138; CORRIGALL WA, 1980, BRAIN RES, V192, P227, DOI 10.1016/0006-8993(80)91022-7; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; Elsersy H, 2004, ANESTHESIOLOGY, V100, P1160, DOI 10.1097/00000542-200405000-00018; Engelhard K, 2004, ANESTHESIOLOGY, V101, P912, DOI 10.1097/00000542-200410000-00016; Engelhard K, 2003, ANESTH ANALG, V96, P524, DOI 10.1097/00000539-200302000-00041; Ergun R, 2002, NEUROSURG REV, V25, P95, DOI 10.1007/s101430100171; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FISHBACK AS, 1995, NEUROSURGERY, V37, P969, DOI 10.1227/00006123-199511000-00017; FRENK H, 1983, BRAIN RES REV, V6, P197, DOI 10.1016/0165-0173(83)90039-5; Gelb AW, 2002, ANESTHESIOLOGY, V96, P1183, DOI 10.1097/00000542-200205000-00023; Gilron I, 1999, ANESTH ANALG, V89, P128, DOI 10.1097/00000539-199907000-00022; Grasshoff C, 2002, ANESTH ANALG, V95, P920, DOI 10.1213/01.ANE.0000025705.93185.09; HANSEN TD, 1989, BRIT J ANAESTH, V63, P290, DOI 10.1093/bja/63.3.290; HAYES RL, 1990, J NEUROSURG, V72, P252, DOI 10.3171/jns.1990.72.2.0252; Hendrich KS, 2001, MAGNET RESON MED, V46, P202, DOI 10.1002/mrm.1178; HERNANDEZ MJ, 1978, STROKE, V9, P150, DOI 10.1161/01.STR.9.2.150; Hill GE, 1998, ANESTH ANALG, V87, P1015, DOI 10.1097/00000539-199811000-00006; HOFFMAN WE, 1991, ANESTH ANALG, V73, P753; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Kang TM, 2002, ANN PHARMACOTHER, V36, P1453; Kawaguchi M, 2004, ANESTH ANALG, V98, P798; Kawaguchi M, 2000, ANESTHESIOLOGY, V92, P1335, DOI 10.1097/00000542-200005000-00023; KISSIN I, 1987, CAN J ANAESTH, V34, P146, DOI 10.1007/BF03015332; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kofke WA, 1996, ANESTH ANALG, V83, P141, DOI 10.1097/00000539-199607000-00025; LARSSON JE, 1994, BRIT J ANAESTH, V73, P692, DOI 10.1093/bja/73.5.692; Lenz C, 1998, ANESTHESIOLOGY, V89, P1480, DOI 10.1097/00000542-199812000-00026; Lingamaneni R, 2003, BRIT J ANAESTH, V90, P199, DOI 10.1093/bja/aeg040; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; McNamara RK, 1997, PHARMACOL BIOCHEM BE, V56, P383, DOI 10.1016/S0091-3057(96)00237-7; Miura Y, 1999, ANESTH ANALG, V88, P787, DOI 10.1097/00000539-199904000-00020; Miura Y, 1998, ANESTHESIOLOGY, V89, P391, DOI 10.1097/00000542-199808000-00016; MURR R, 1993, ANESTH ANALG, V77, P898; Nagase K, 2003, J NEUROSURG ANESTH, V15, P98, DOI 10.1097/00008506-200304000-00006; Neff SPW, 1997, ANAESTH INTENS CARE, V25, P581; Nemoto E M, 1983, Am J Emerg Med, V1, P175, DOI 10.1016/0735-6757(83)90086-4; Nikolaishvili L S, 2004, Neurosci Behav Physiol, V34, P467, DOI 10.1023/B:NEAB.0000022631.46176.6b; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PATEL PM, 1993, J CEREB BLOOD FLOW M, pS685; Proescholdt M, 2001, BRAIN RES, V904, P245, DOI 10.1016/S0006-8993(01)02465-9; Rudolph U, 2004, NAT REV NEUROSCI, V5, P709, DOI 10.1038/nrn1496; SAFO Y, 1985, ACTA ANAESTH SCAND, V29, P594, DOI 10.1111/j.1399-6576.1985.tb02261.x; SHAPIRA Y, 1993, J CEREBR BLOOD F MET, V13, P962, DOI 10.1038/jcbfm.1993.120; SHAPIRA Y, 1994, STROKE, V25, P1637, DOI 10.1161/01.STR.25.8.1637; SHIU GK, 1983, CRIT CARE MED, V11, P452, DOI 10.1097/00003246-198306000-00013; SHIU GK, 1981, J NEUROCHEM, V37, P1448, DOI 10.1111/j.1471-4159.1981.tb06314.x; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Soonthon-Brant V, 1999, ANESTH ANALG, V88, P49, DOI 10.1097/00000539-199901000-00010; Statler KD, 2003, BRAIN RES, V994, P37, DOI 10.1016/j.brainres.2003.09.042; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; Tecoult E, 2000, J NEUROSURG ANESTH, V12, P255, DOI 10.1097/00008506-200007000-00010; TEMPELHOFF R, 1992, J NEUROSURG, V77, P201, DOI 10.3171/jns.1992.77.2.0201; Warner DS, 1996, ANESTHESIOLOGY, V84, P1475, DOI 10.1097/00000542-199606000-00024; WERNER C, 1993, ANESTH ANALG, V76, P971; Yang CCH, 1996, AM J PHYSIOL-HEART C, V270, pH575	65	92	95	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2006	23	1					97	108		10.1089/neu.2006.23.97			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	009GP	WOS:000235100100008	16430376				2020-06-30	J	Malavasi, LM; Nyman, G; Augustsson, H; Jacobson, M; Jensen-Waern, M				Malavasi, LM; Nyman, G; Augustsson, H; Jacobson, M; Jensen-Waern, M			Effects of epidural morphine and transdermal fentanyl analgesia on physiology and behaviour after abdominal surgery in pigs	LABORATORY ANIMALS			English	Article						pig; pain; opioid; analgesia; pain assessment	BETA-ENDORPHIN; CORTISOL; PAIN; BUPRENORPHINE; MEDETOMIDINE; CANNULATION; STRESS; MODEL	The objective of this work was to evaluate the physiological and behavioural effects of opioid analgesic treatment in pigs subjected to abdominal surgery. Ten Swedish Landrace x Yorkshire pigs (20 +/- 4 kg b.w.) were submitted for intestinal cannulation. The pigs were allocated into two groups during one preoperative, one surgical and two postoperative days. All pigs were anaesthetized with medetomidine, tiletamine and zolazepam. One group was treated with epidural morphine (0.1 mg/kg) preoperatively, and transdermal fentanyl patches (50 mu g/kg/h) were applied behind the ear immediately after surgery. The other group received epidural saline (equivalent volume) and placebo patches. All pigs were regularly weighed and clinically examined and repeated blood samples were analysed for serum concentrations of cortisol, P-endorphin and fentanyl. Pre- and postoperative behaviours were evaluated by a swine specialist blinded to the treatment, three times a day, and were also videotape recorded for a total of 84 h per pig. No differences in behaviour were noted by the observer. During the first postoperative 12 h, treated pigs did not differ in activity compared with preoperative recordings, while untreated pigs were found to be less active. The treated group started to show interest in eating immediately after anaesthesia recovery, whereas the placebo group did not. During the 12-60 h postoperative period, the treated group had lower activity levels compared with the preoperative levels, which were similar to those in the placebo group. Treated pigs gained 0.5+/-0.2 kg during the subsequent two postoperative days, whereas the untreated pigs lost weight throughout the experiment. Cortisol concentration differed immediately after the surgery: Group P had 325+/-120 nmol/L and Group M 159+/-49 nmol/L. beta-endorphin concentration did not differ between groups. The highest serum fentanyl concentration (0.37+/-0.3 ng/mL) was measured 24 h postoperatively. Preoperative epidural morphine in combination with postoperative transdermal fentanyl resulted in earlier return to normal activity levels and an immediate weight gain after surgery.	Swedish Univ Agr Sci, Fac Vet Med, Dept Large Anim Clin Sci, SE-75007 Uppsala, Sweden	Malavasi, LM (reprint author), Swedish Univ Agr Sci, Fac Vet Med, Dept Large Anim Clin Sci, Box 7018, SE-75007 Uppsala, Sweden.	Lais.Malavasi@kv.slu.se		Sassner, Hanna/0000-0002-1460-0328			Benson GJ, 2000, VET SURG, V29, P85, DOI 10.1111/j.1532-950X.2000.00085.x; Branson K. R., 2001, Veterinary pharmacology and therapeutics, P268; Brennan TJ, 1997, ANESTHESIOLOGY, V87, P1517, DOI 10.1097/00000542-199712000-00031; Dennis S.G., 1983, P151; Fink R., 2001, PAIN MANAGEMENT ANIM, P53; Flecknell P.A., 1999, ANZCCART NEWS, V12, P1; FLECKNELL PA, 2001, PAIN MANAGEMENT ANIM, P1; Gerard H, 1996, VET RES, V27, P219; Gonyou HW, 1996, ADVANCES IN SWINE IN BIOMEDICAL RESEARCH, VOLS 1 AND 2, P485; Harvey-Clark CJ, 2000, LAB ANIM-UK, V34, P386, DOI 10.1258/002367700780387750; HERMANSEN K, 1986, ACTA PHARMACOL TOX, V59, P27; Jacobson M, 2001, COMPARATIVE MED, V51, P163; LIVINGSTON A, 2001, PAIN MANAGEMENT ANIM, P9; MARTIN P, 1986, MEASURING BEHAV; MARTIN RF, 1985, INTRO VET PHARM, P130; Mellor DJ, 2000, BIOLOGY OF ANIMAL STRESS, P171, DOI 10.1079/9780851993591.0171; Molony V, 1997, J ANIM SCI, V75, P266; Nolan A. M., 2001, PAIN MANAGEMENT ANIM, P21; PLUMB DC, 1999, VET DRUG HDB, P316; Rang H. P., 1996, PHARMACOLOGY, P609; Ranheim B, 2000, J VET PHARMACOL THER, V23, P379, DOI 10.1046/j.1365-2885.2000.00291.x; Riviere JE, 2001, ADV DRUG DELIVER REV, V50, P175, DOI 10.1016/S0169-409X(01)00157-0; ROBERTSON IS, 1994, RES VET SCI, V56, P8, DOI 10.1016/0034-5288(94)90189-9; ROOZEN AWN, 1995, AM J VET RES, V56, P1225; SANFORD J, 1986, Veterinary Record, V118, P334; SHORT CE, 1999, TXB PAIN, P1007; SNEDDON LU, 2001, PAIN FARM ANIMALS; STRANDE A, 1968, ACTA VET SCAND, V9, P41; Szeitz A, 1996, J CHROMATOGR B, V675, P33, DOI 10.1016/0378-4347(95)00350-9; VANLEEUWEN P, 1991, J ANIM PHYSIOL AN N, V65, P183, DOI 10.1111/j.1439-0396.1991.tb00256.x; Wilkinson AC, 2001, CONTEMP TOP LAB ANIM, V40, P12	31	30	30	0	10	ROYAL SOC MEDICINE PRESS LTD	LONDON	1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND	0023-6772			LAB ANIM-UK	Lab. Anim.	JAN	2006	40	1					16	27		10.1258/002367706775404453			12	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	004JB	WOS:000234748000003	16460586				2020-06-30	J	Leal, T; Lebacq, J; Vanbinst, R; Lederman, C; De Kock, M; Wallemacq, P				Leal, T; Lebacq, J; Vanbinst, R; Lederman, C; De Kock, M; Wallemacq, P			Successful protocol of anaesthesia for measuring transepithelial nasal potential difference in spontaneously breathing mice	LABORATORY ANIMALS			English	Article						nasal potential difference; cystic fibrosis; anaesthetics; combined; mass spectrometry; mice	CYSTIC-FIBROSIS MICE; DROPERIDOL; FENTANYL; MOUSE; RAT; EPITHELIUM; TRANSPORT; AMILORIDE; KETAMINE; DEFECTS	Numerous difficulties arise during in vivo measurements of transepithelial nasal potential difference (PD) in mice, such as inadequate duration and depth of anaesthesia, bronchoaspiration of solutions perfused in the nose, and respiratory and/or cardiovascular depression. Anaesthesia was induced in adult C57 mice with intraperitoneal injection of a combination of fentanyl, droperidol and medetomidine, each of these at either a small dose (0.20, 10 and 0.33 mg/kg, respectively) or at a large dose (0.40, 20 and 0.40 mg/kg, respectively), combined with a fixed dose of 0.375 mu g clonidine. In order to establish a pharmacokinetic-pharmacodynamic relationship, blood concentrations of the first three drugs were measured in 24 animals by liquid-chromatography tandem mass spectrometry. At the end of the experiment, naloxone, a competitive morphinic antagonist, and atipamezole, an alpha-2 adrenergic antagonist, were administered. Bronchoaspiration was prevented by tilting the animal head downwards and by absorbing the excess fluid from the opposite nostril and from the oral cavity. Optimal assessment of anaesthesia associated with regular respiration, loss of blink, pupillary and pedal withdrawal reflexes was obtained with doses of fentanyl, droperidol and medetomidine corresponding to 0.20, 20 and 0.40 mg/kg, respectively. Blood concentrations of fentanyl around 17 ng/mL induced loss of respiratory efforts and were followed by death during the experiment. Integrity of ion transport was demonstrated under continuous perfusion by successive depolarization after amiloride and repolarization after chloride-free solution. The combination investigated in this study lead to adequate surgical anaesthesia (stage III, plane 2) for prolonged nasal PD measurements in spontaneously breathing mice.	Catholic Univ Louvain, Dept Clin Chem, B-1200 Brussels, Belgium; Catholic Univ Louvain, Dept Physiol, B-1200 Brussels, Belgium; Catholic Univ Louvain, Dept Anaesthesiol, B-1200 Brussels, Belgium; Catholic Univ Louvain, Pain Clin, B-1200 Brussels, Belgium	Leal, T (reprint author), St Luc Univ Hosp, Dept Clin Chem, 10 Av Hippocrate, B-1200 Brussels, Belgium.	teresinha.leal@clin.ucl.ac.be					CHATURVEDI AK, 1990, J ANAL TOXICOL, V14, P385, DOI 10.1093/jat/14.6.385; Egan ME, 2004, SCIENCE, V304, P600, DOI 10.1126/science.1093941; Flanagan RJ, 1998, ANN CLIN BIOCHEM, V35, P261, DOI 10.1177/000456329803500210; FREYE E, 1976, PHARMACOLOGY, V14, P1, DOI 10.1159/000136573; Ghosal S, 1996, THORAX, V51, P1229, DOI 10.1136/thx.51.12.1229; Ghosal S, 2000, EUR RESPIR J, V15, P146, DOI 10.1034/j.1399-3003.2000.15a27.x; GRUBB BR, 1994, AM J PHYSIOL, V266, pC1478, DOI 10.1152/ajpcell.1994.266.5.C1478; Hardiman KM, 2001, AM J PHYSIOL-LUNG C, V281, pL722; Hellebrekers LJ, 1997, LAB ANIM-UK, V31, P58, DOI 10.1258/002367797780600215; Hem A, 1998, LAB ANIM-UK, V32, P364, DOI 10.1258/002367798780599866; Hill GE, 1999, CAN J ANAESTH, V46, P1172, DOI 10.1007/BF03015528; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES MR, 1995, HUM GENE THER, V6, P445, DOI 10.1089/hum.1995.6.4-445; Leal T, 2003, CLIN CHEM LAB MED, V41, P61, DOI 10.1515/CCLM.2003.011; LEAL T, 2003, J CYSTIC FIBROSIS, V2, pS14; MEERT TF, 1994, ANESTHESIOLOGY, V81, P677, DOI 10.1097/00000542-199409000-00022; MERY S, 1994, TOXICOL PATHOL, V22, P353, DOI 10.1177/019262339402200402; MIDDLETON PG, 1994, EUR RESPIR J, V7, P2050; Sato T, 1996, CAN J ANAESTH, V43, P172, DOI 10.1007/BF03011259; Shibata O, 2003, PHARMACOLOGY, V68, P24, DOI 10.1159/000068729; Smith SN, 1999, AM J RESP CELL MOL, V20, P129, DOI 10.1165/ajrcmb.20.1.3278; VANDOORNINCK JH, 1995, EMBO J, V14, P4403, DOI 10.1002/j.1460-2075.1995.tb00119.x; VIRTANEN R, 1989, ACTA VET SCAND, P29; Vuckovic S, 1998, JPN J PHARMACOL, V78, P523, DOI 10.1254/jjp.78.523; Wallemacq PE, 2003, CLIN CHEM LAB MED, V41, P921, DOI 10.1515/CCLM.2003.140	25	12	12	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0023-6772	1758-1117		LAB ANIM-UK	Lab. Anim.	JAN	2006	40	1					43	52		10.1258/002367706775404480			10	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	004JB	WOS:000234748000005	16460587				2020-06-30	J	McAuliffe, PF; Gold, MS; Bajpai, L; Merves, ML; Frost-Pineda, K; Pomm, RM; Goldberger, BA; Melker, RJ; Cendan, JC				McAuliffe, PF; Gold, MS; Bajpai, L; Merves, ML; Frost-Pineda, K; Pomm, RM; Goldberger, BA; Melker, RJ; Cendan, JC			Second-hand exposure to aerosolized intravenous anesthetics propofol and fentanyl may cause sensitization and subsequent opiate addiction among anesthesiologists and surgeons	MEDICAL HYPOTHESES			English	Article							NUCLEUS-ACCUMBENS; SUBSTANCE MISUSE; PHYSICIANS; ABUSE; NEUROBIOLOGY; AMPHETAMINE; NEOCORTEX; PROGRAMS	We hypothesize that aerosolization of anesthetics administered intravenously to patients in the operating room may be an unintended source of exposure to physicians. This may lead to inadvertent sensitization, which is associated with an increased risk for developing addiction. This may contribute to the over-representation of certain specialties among physicians with addiction. We retrospectively reviewed the de-identified demographic information of all licensed physicians treated for substance abuse in the State of Florida since 1980, to determine if medical specialty was associated with addiction in this group of individuals. Then, to identify the potential for exposure, two mass spectrometry assays were developed to detect two intravenously administered drugs, fentanyl and propofol, in air. Since 1980, 7.6% of licensed Florida physicians underwent treatment for addiction. Addiction in anesthesiologists was higher than expected. Opiate abuse was greater in anesthesiologists and surgeons compared to other specialties. Aerosolized fentanyl was detected in the air of the cardiothoracic operating room, in patients' expiratory circuits, and in the headspace above sharps boxes, but not in adjoining hallways. Aerosolized propofol was detected in the expirations of a patient undergoing transurethral prostatectomy. While access and stress may place anesthesiologists and surgeons at greater risk for substance abuse, an additional risk factor may be unintended occupational exposure to addictive drugs. This report provides preliminary evidence of detection of aerosolized intravenous anesthetics using two newly developed analytical methods. We conclude that the potential exists for chronic exposure to low levels of airborne intravenously administered drugs. Further studies are under way to determine the significance of this exposure. (c) 2005 Elsevier Ltd. All rights reserved.	Univ Florida, Coll Med, Dept Surg, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Psychiat, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Anesthesiol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA; Univ Florida, Coll Engn, State Florida Prof Resource Network, Gainesville, FL 32611 USA; Univ Florida, Coll Engn, Dept Biomed Engn, Gainesville, FL 32611 USA	McAuliffe, PF (reprint author), Univ Florida, Coll Med, Dept Surg, 1600 SW Archer Rd,POB 100286, Gainesville, FL 32610 USA.	mcaulp@surgery.ufl.edu; msgold@psychiatry.ufl.edu	Cendan, Juan C./F-2303-2011	Cendan, Juan C./0000-0002-2744-4838; Frost-Pineda, Kimberly/0000-0001-8991-4148	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM-08721-05]		*AM MED ASS, 2004, PHYS CHAR DISTR US C; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Baird WLM, 2000, ANAESTHESIA, V55, P943, DOI 10.1046/j.1365-2044.2000.01765.x; Bajpai L, 2004, J CHROMATOGR B, V810, P291, DOI 10.1016/j.jchromb.2004.08.023; Berry CB, 2000, ANAESTHESIA, V55, P946, DOI 10.1046/j.1365-2044.2000.01758.x; Booth JV, 2002, ANESTH ANALG, V95, P1024, DOI 10.1213/01.ANE.0000026379.66419.DB; BREWSTER JM, 1986, JAMA-J AM MED ASSOC, V255, P1913, DOI 10.1001/jama.255.14.1913; Bruijnzeel AW, 2004, PSYCHIAT CLIN N AM, V27, P661, DOI 10.1016/j.psc.2004.06.005; Castner SA, 1999, NEUROPSYCHOPHARMACOL, V20, P10, DOI 10.1016/S0893-133X(98)00050-5; Euliano TY, 2001, ADV PHYSIOL EDUC, V25, P36; Gold MS, 2004, PSYCHIAT CLIN N AM, V27, P745, DOI 10.1016/j.psc.2004.07.006; Gold MS, 2004, PSYCHIAT ANN, V34, P794, DOI 10.3928/0048-5713-20041001-21; GRAVENSTEIN JS, 1983, ANESTH ANALG, V62, P467; Harrison C, 1998, BRIT J ANAESTH, V81, P20; Harrison GR, 2003, BRIT J ANAESTH, V91, P797, DOI 10.1093/bja/aeg271; Hughes PH, 1999, J ADDICT DIS, V18, P23, DOI 10.1300/J069v18n02_03; Hulse Gary, 2004, Aust Fam Physician, V33, P703; Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560; Jones JW, 2004, SURGERY, V135, P449, DOI 10.1016/j.surg.2003.09.011; Klebaur JE, 2002, BRAIN RES, V930, P30, DOI 10.1016/S0006-8993(01)03400-X; Knight JR, 2004, JAMA-J AM MED ASSOC, V292, P1351, DOI 10.1001/jama.292.11.1351; Larsen S., 2003, Food Service Technology, V3, P151, DOI 10.1111/j.1471-5740.2003.00074.x; MANDELL W, 1992, ALCOHOL CLIN EXP RES, V16, P734, DOI 10.1111/j.1530-0277.1992.tb00670.x; Mansky PA, 1999, PSYCHIAT QUART, V70, P107, DOI 10.1023/A:1022197218945; MENK EJ, 1990, JAMA-J AM MED ASSOC, V263, P3060, DOI 10.1001/jama.263.22.3060; Nagashima K, 2005, ANESTHESIOLOGY, V103, P318, DOI 10.1097/00000542-200508000-00015; Nusbaumer MR, 2002, AM J DRUG ALCOHOL AB, V28, P735, DOI 10.1081/ADA-120015879; Robinson TE, 1999, SYNAPSE, V33, P160; Robinson TE, 2000, ADDICTION, V95, pS91; Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI 10.1146/annurev.psych.54.101601.145237; Travis J, 2004, SCIENCE, V306, P1126; Upton RN, 2005, ANESTHESIOLOGY, V103, P344, DOI 10.1097/00000542-200508000-00018; Verghese A, 2002, NEW ENGL J MED, V346, P1510, DOI 10.1056/NEJM200205163462002; WASHTON AM, 1984, J CLIN PSYCHIAT, V45, P39; Weng ND, 2002, J PHARMACEUT BIOMED, V28, P1115, DOI 10.1016/S0731-7085(02)00002-X	35	39	44	1	9	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877	1532-2777		MED HYPOTHESES	Med. Hypotheses		2006	66	5					874	882		10.1016/j.mehy.2005.10.030			9	Medicine, Research & Experimental	Research & Experimental Medicine	028BA	WOS:000236459100002	16431033				2020-06-30	J	Ceccarelli, I; De Padova, AM; Fiorenzani, P; Massafra, C; Aloisi, AM				Ceccarelli, I.; De Padova, A. M.; Fiorenzani, P.; Massafra, C.; Aloisi, A. M.			Single opioid administration modifies gonadal steroids in both the CNS and plasma of male rats	NEUROSCIENCE			English	Article						sex hormones; testosterone; estradiol; opioids; CNS	INDUCED NOCICEPTIVE RESPONSES; SEXUAL FUNCTION; FEMALE RATS; HORMONES; TRAMADOL; PAIN; TESTOSTERONE; BUPRENORPHINE; NEURONS; BRAIN	While morphine remains one of the most widely used opioids for the treatment of painful conditions, other opioids are also commonly employed. Because of the interactions between opiolds and gonadal hormones, in particular opioid-induced hypogonadism, this study investigated the effects of widely used opioids on plasma testosterone and estradiol levels and brain testosterone levels in male rats. Animals were s.c. injected with two concentrations of morphine (5 or 10 mg/kg), fentanyl (0.05 or 0.1 mg/kg), tramadol (10 or 40 mg/kg), buprenorphine (0.05 or 0.1 mg/kg) or saline (0.7 ml/kg). Four or 24 h after treatment, the rats were deeply anesthetized to collect blood samples from the abdominal aorta and to perfuse the brains with saline. Plasma and brain hormone levels were measured by radioimmunoassay. In rats studied 4 h after treatment, all the opioids except tramadol 10 mg/kg decreased plasma testosterone in comparison with saline administration. At the same time, plasma estradiol levels were lower than control in the groups treated with the low doses of morphine, tramadol and buprenorphine, while estradiol remained at control levels in the other groups. Twenty-four hours after treatment, plasma testosterone levels were different (higher) than control in the animals treated with the low doses of morphine, fentanyl and buprenorphine. Estradiol was lower than control in the low dose groups, while the high doses did not produce any changes with respect to control. Four hours after treatment, brain testosterone was drastically decreased in all groups except buprenorphine, in which it remained at control levels. All groups returned to control levels at 24 h after treatment. In conclusion, opioids exert important effects on plasma and CNS sex hormone levels. The different magnitude and time-course of the effects of the different opiates on testosterone and estradiol levels are likely due to their different mechanism of action. (c) 2006 Published by Elsevier Ltd on behalf of IBRO.	Univ Siena, Pain & Stress Neurophysiol Lab, Neurosci & Appl Physiol Sect, I-53100 Siena, Italy	Aloisi, AM (reprint author), Univ Siena, Pain & Stress Neurophysiol Lab, Neurosci & Appl Physiol Sect, Via Aldo Moro 2, I-53100 Siena, Italy.	aloisi@unisi.it	Ceccarelli, Ilaria/G-9462-2012; Aloisi, Anna Maria/E-7183-2013				ABRAHAM GE, 1975, J STEROID BIOCHEM, V6, P261, DOI 10.1016/0022-4731(75)90141-7; ADAMS ML, 1993, J PHARMACOL EXP THER, V266, P323; Aloisi AM, 2005, PAIN, V115, P142, DOI 10.1016/j.pain.2005.02.019; Aloisi AM, 2004, NEUROSCI LETT, V361, P262, DOI 10.1016/j.neulet.2003.12.023; Aloisi AM, 2003, CLIN J PAIN, V19, P168, DOI 10.1097/00002508-200305000-00004; ALOISI AM, 2006, HORM BEHAV      0116; AMOROSO S, 1988, EUR J PHARMACOL, V145, P257, DOI 10.1016/0014-2999(88)90427-X; BASBAUM AI, 1978, ANN NEUROL, V4, P451, DOI 10.1002/ana.410040511; Becker JB, 2005, ENDOCRINOLOGY, V146, P1650, DOI 10.1210/en.2004-1142; Bliesener N, 2005, J CLIN ENDOCR METAB, V90, P203, DOI 10.1210/jc.2004-0929; Ceccarelli I, 2003, PAIN, V104, P35, DOI 10.1016/S0304-3959(02)00460-8; Craft RM, 2004, EUR J PAIN, V8, P397, DOI 10.1016/j.ejpain.2004.01.003; DELITALA G, 1983, NEUROENDOCRINOLOGY, V37, P275, DOI 10.1159/000123558; FABBRI A, 1989, J STEROID BIOCHEM, V32, P145, DOI 10.1016/0022-4731(89)90155-6; Frye CA, 2001, COGN AFFECT BEHAV NE, V1, P371, DOI 10.3758/CABN.1.4.371; Gaumond I, 2005, BRAIN RES, V1052, P105, DOI 10.1016/j.brainres.2005.06.011; Gaumond I, 2002, BRAIN RES, V958, P139, DOI 10.1016/S0006-8993(02)03661-2; Gil D, 2004, HORM BEHAV, V45, P64, DOI 10.1016/j.yhbeh.2003.08.005; Gomez-Flores R, 2000, IMMUNOPHARMACOLOGY, V48, P145, DOI 10.1016/S0162-3109(00)00198-3; Gore AC, 2001, BRAIN RES REV, V37, P235, DOI 10.1016/S0165-0173(01)00121-7; Gourlay G, 2005, SUPPORT CARE CANCER, V13, P153, DOI 10.1007/s00520-004-0690-6; Hammond J, 2001, J NEUROCHEM, V77, P1319, DOI 10.1046/j.1471-4159.2001.00345.x; Hojo Y, 2004, P NATL ACAD SCI USA, V101, P865, DOI 10.1073/pnas.2630225100; Holloway CC, 2001, NAT NEUROSCI, V4, P170, DOI 10.1038/84001; Janson W., 2003, Current Pharmaceutical Biotechnology, V4, P270, DOI 10.2174/1389201033489766; Johnson RE, 2005, J PAIN SYMPTOM MANAG, V29, P297, DOI 10.1016/j.jpainsymman.2004.07.005; Kovelowski CJ, 1998, EUR J PAIN-LONDON, V2, P211, DOI 10.1016/S1090-3801(98)90017-9; MAUGET R, 1994, GEN COMP ENDOCR, V93, P36, DOI 10.1006/gcen.1994.1005; Meert TF, 2005, PHARMACOL BIOCHEM BE, V80, P309, DOI 10.1016/j.pbb.2004.12.002; Meethal SV, 2005, CELL MOL LIFE SCI, V62, P257, DOI 10.1007/s00018-004-4381-3; Megens AAHP, 1998, J PAIN SYMPTOM MANAG, V15, P253, DOI 10.1016/S0885-3924(97)00371-0; Oliva P, 2002, EUR J PHARMACOL, V445, P179, DOI 10.1016/S0014-2999(02)01647-3; PAICE JA, 1994, J PAIN SYMPTOM MANAG, V9, P126; Patchev VK, 2004, EXP GERONTOL, V39, P1651, DOI 10.1016/j.exger.2004.07.011; PIMPINELLI F, 2006, BRAIN RES       0105; Plassart-Schiess E, 2001, BRAIN RES REV, V37, P133, DOI 10.1016/S0165-0173(01)00113-8; Prange-Kiel J, 2003, HIPPOCAMPUS, V13, P226, DOI 10.1002/hipo.10075; RAFFA RB, 1993, J PHARMACOL EXP THER, V267, P331; Rajagopal A, 2003, PAIN MED, V4, P379, DOI 10.1111/j.1526-4637.2003.03041.x; Rasor J, 2005, J AM OSTEOPATH ASSOC, V105, pS2; Rojas-Corrales MO, 2002, LIFE SCI, V72, P143, DOI 10.1016/S0024-3205(02)02220-8; Sacerdote P, 1997, PAIN, V72, P325, DOI 10.1016/S0304-3959(97)00055-9; SEFTEL A, 2005, INT J IMPOT RES 0811; Simpson ER, 2004, SEMIN REPROD MED, V22, P11; Simpson ER, 2003, J STEROID BIOCHEM, V86, P225, DOI 10.1016/S0960-0760(03)00360-1; Stoffel EC, 2003, PAIN, V103, P285, DOI 10.1016/S0304-3959(02)00457-8; Tsai YC, 2001, PAIN, V92, P63, DOI 10.1016/S0304-3959(00)00472-3; Zaki PA, 2000, J PHARMACOL EXP THER, V292, P1127; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	49	48	49	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2006	140	3					929	937		10.1016/j.neuroscience.2006.02.044			9	Neurosciences	Neurosciences & Neurology	052KG	WOS:000238232000017	16580783				2020-06-30	J	Shah, S				Shah, S			Resolution of sweating after switching from transdermal fentanyl to oral morphine sulphate	PALLIATIVE MEDICINE			English	Letter							PAIN				s.shah43@ntlworld.com					ALLAN L, 2001, BRIT MED J, V322, P17; Catterall RA, 1997, PALLIATIVE MED, V11, P169; De Witte JL, 1998, ANESTH ANALG, V87, P173, DOI 10.1097/00000539-199807000-00036; LANGROD J, 1981, INT J ADDICT, V16, P947, DOI 10.3109/10826088109038903; McNicol E, 2003, J PAIN, V4, P231, DOI 10.1016/S1526-5900(03)00556-X; Menten J, 2002, CURR MED RES OPIN, V18, P488, DOI 10.1185/030079902125001272; Mercadante S, 1998, J PAIN SYMPTOM MANAG, V15, P214; Potter J, 2003, PALLIATIVE MED, V17, P310, DOI 10.1191/0269216303pm760oa	8	2	2	0	0	HODDER ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	0269-2163			PALLIATIVE MED	Palliat. Med.		2006	20	3					222	222		10.1191/0269216306pm1123xx			1	Health Care Sciences & Services; Public, Environmental & Occupational Health; Medicine, General & Internal	Health Care Sciences & Services; Public, Environmental & Occupational Health; General & Internal Medicine	038MD	WOS:000237224300012	16764230				2020-06-30	J	Wheeler, AD; Tobias, JD				Wheeler, Adam D.; Tobias, Joseph D.			Bradycardia during methadone therapy in an infant	PEDIATRIC CRITICAL CARE MEDICINE			English	Article							WITHDRAWAL; CHILDREN	Objectives., To report the occurrence of bradycardia associated with the use of methadone administered to prevent withdrawal in an infant with physical tolerance following long-term opioid therapy in the pediatric intensive care unit setting. Design: Retrospective case report. Patients and Results., Methadone (0.1 mg/kg) was administered to a 6-month-old infant following prolonged use of intravenous fentanyl for sedation during respiratory failure requiring mechanical ventilation. Approximately 30-60 mins after the first dosing of methadone, the infant's heart rate decreased from his baseline of 130-140 beats/min to 80-90 beats/min for 30 seconds. After the third dose of methadone, the heart rate decreased to a sinus bradycardia of 60-70 beats/min for 4 mins. The episodes resolved with tactile stimulation. Over the next 18 hrs, there were repeated episodes of bradycardia. None of these episodes were associated with hypotension, apnea, change in oxygen saturation, decreased peripheral perfusion, or other signs of hemodynamic instability. The methadone was withdrawn and the intravenous fentanyl infusion was restarted. Eight to 10 hrs after administration of the last dose of methadone, the episodes of bradycardia resolved and the patient remained in a normal sinus rhythm with a heart rate of 120-140 beats/min. Conclusion. Methadone's three-dimensional structure shares similarities with calcium channel antagonists. Although it has been reported in the adult literature, there are no previous reports of bradycardia occurring with methadone therapy in infants. Although there were no deleterious physiologic effects related to the bradycardia in our patient, methadone should be used cautiously in patients who may not tolerate alterations in heart rate.	Univ Missouri, Dept Anesthesiol, Columbia, MO 65211 USA; Univ Missouri, Dept Child Hlth, Columbia, MO 65201 USA	Wheeler, AD (reprint author), Univ Missouri, Dept Anesthesiol, Columbia, MO 65211 USA.						Karir V, 2002, PHARMACOTHERAPY, V22, P1196, DOI 10.1592/phco.22.13.1196.33511; KATZ R, 1994, CRIT CARE MED, V22, P763, DOI 10.1097/00003246-199405000-00009; METCALFE J, 1980, RESP PHYSIOL, V42, P383, DOI 10.1016/0034-5687(80)90127-9; Meyer M M, 2001, Pediatr Crit Care Med, V2, P329, DOI 10.1097/00130478-200110000-00009; PERNOLL ML, 1975, RESP PHYSIOL, V25, P295, DOI 10.1016/0034-5687(75)90005-5; SEYLER DE, 1983, FUND APPL TOXICOL, V3, P536, DOI 10.1016/S0272-0590(83)80101-8; Siddappa R, 2003, PAEDIATR ANAESTH, V13, P805, DOI 10.1046/j.1460-9592.2003.01153.x; TOBIAS JD, 1990, CRIT CARE MED, V18, P1292, DOI 10.1097/00003246-199011000-00024; Tobias JD, 1996, J INTENSIVE CARE MED, V11, P284	9	9	9	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1529-7535			PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JAN	2006	7	1					83	85		10.1097/01.PCC.0000192337.00842.1E			3	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	082UJ	WOS:000240412400016	16395081				2020-06-30	J	Kanowitz, A; Dunn, TM; Kanowitz, EM; Dunn, WW; VanBuskirk, K				Kanowitz, Arthur; Dunn, Thomas M.; Kanowitz, Elyse M.; Dunn, William W.; VanBuskirk, Kayleen			Safety and effectiveness of fentanyl administration for prehospital pain management	PREHOSPITAL EMERGENCY CARE			English	Article						fentanyl; pain; prehospital; safety; effectiveness		Objective. To determine the safety and effectiveness of fentanyl administration for prehospital pain management. Methods. This was a retrospective chart review of patients transported by ambulance during 2002 - 2003 who were administered fentanyl citrate in an out-of-hospital setting. Preand post-pain-management data were abstracted, including vital signs, verbal numeric pain scale scores, medications administered, and recovery interventions. In addition, the emergency department (ED) charts of a subgroup of these patients were reviewed for similar data elements. Results. Of 2,129 patients who received fentanyl for prehospital analgesia, only 12 (0.6%) had a vital sign abnormality that could have been caused by the administration of fentanyl. Only one (0.2%) of the 611 patients who had both field and ED charts reviewed had a vital sign abnormality that necessitated a recovery intervention. There were no admissions to the hospital, nor patient deaths, attributed to fentanyl use. There was a statistically significant improvement in subjective pain scale scores (8.4 to 3.7). Clinically, this correlates with improvement from severe to mild pain. Conclusion. This study showed that fentanyl was effective in decreasing pain scores without causing significant hypotension, respiratory depression, hypoxemia, or sedation. Thus, fentanyl citrate can be used safely and effectively for pain management in the out-of-hospital arena.	Pridemark Paramed Serv, Arvada, CO USA; Univ No Colorado, Dept Psychol, Greeley, CO 80639 USA; Pridemark Paradem Serv, Boulder, CO USA; Colorado Coll, Dept Biol, Colorado Springs, CO 80903 USA; Denver Hlth Med Ctr, Paramed Div, Denver, CO USA	Kanowitz, A (reprint author), 8 Red Birch, Littleton, CO 80127 USA.	kanowitzmd@aol.com					Alonso-Serra Hector M, 2003, Prehosp Emerg Care, V7, P482; Baskett PJF, 1999, ANN EMERG MED, V34, P784, DOI 10.1016/S0196-0644(99)70106-X; Braude Darren, 2004, Prehosp Emerg Care, V8, P441, DOI 10.1016/j.prehos.2004.07.001; BRUNS BM, 1992, AM J EMERG MED, V10, P53, DOI 10.1016/0735-6757(92)90127-J; Bulloch B, 2002, ACAD EMERG MED, V9, P199, DOI 10.1197/aemj.9.3.199; Cordell WH, 2002, AM J EMERG MED, V20, P165, DOI 10.1053/ajem.2002.32643; DeVellis P, 1998, Prehosp Emerg Care, V2, P293, DOI 10.1080/10903129808958883; Ducharme J, 1996, ANN EMERG MED, V27, P399, DOI 10.1016/S0196-0644(96)70214-7; FOSNOCHT DE, 2003, [No title captured], V10, P484; Fullerton-Gleason Lynne, 2002, Prehosp Emerg Care, V6, P411, DOI 10.1080/10903120290938049; Ho K, 1996, ANN EMERG MED, V27, P427, DOI 10.1016/S0196-0644(96)70223-8; Jagoda AS, 1998, ANN EMERG MED, V31, P663, DOI 10.1016/S0196-0644(98)70216-1; *JOINT COMM ACCR H, 1998, JCAHO PUBL; McEachin Christine Clara, 2002, Prehosp Emerg Care, V6, P406, DOI 10.1080/10903120290938030; Ricard-Hibon A, 1999, ANN EMERG MED, V34, P738, DOI 10.1016/S0196-0644(99)70099-5; Rupp T, 2004, ANN EMERG MED, V43, P494, DOI 10.1016/j.annemergmed.2003.11.019; Summers S, 2001, J Perianesth Nurs, V16, P35; Tanabe P, 1999, J Emerg Nurs, V25, P171, DOI 10.1016/S0099-1767(99)70200-X; VASSILIADIS J, 2003, EMERGEN MED, V14, P261; White L J, 2000, Prehosp Emerg Care, V4, P205, DOI 10.1080/10903120090941209; WILSON JE, 1989, AM J EMERG MED, V7, P620, DOI 10.1016/0735-6757(89)90286-6	21	53	54	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1090-3127	1545-0066		PREHOSP EMERG CARE	Prehosp. Emerg. Care	JAN-MAR	2006	10	1					1	7		10.1080/10903120500373264			7	Emergency Medicine; Public, Environmental & Occupational Health	Emergency Medicine; Public, Environmental & Occupational Health	110IX	WOS:000242373000001	16418084				2020-06-30	J	Finkel, JC; Finley, A; Greco, C; Weisman, SJ; Zeltzer, L				Finkel, JC; Finley, A; Greco, C; Weisman, SJ; Zeltzer, L			Transdermal fentanyl in the management of children with chronic severe pain - Results from an international study	CANCER			English	Article						chronic pain; transdermal; opioid; tolerability	CANCER PAIN; PERFORMANCE; ANALGESIA; EFFICACY; DRUG	BACKGROUND. The current study was conducted to assess the safety and tolerability of a transdermal fentanyl delivery system for the relief of chronic pain in a pediatric population, and also to validate titration recommendations and conversion to transdermal fentanyl from oral opioid therapy. METHODS. This 15-day (with 3-month extension), single-arm, open-label trial was conducted at 66 sites in 10 countries. A total of 199 pediatric patients (ages 2-16 years) with both malignant and nonmalignant conditions who were receiving oral or parenteral opioids for moderate to severe chronic pain were enrolled. Transdermal fentanyl doses were titrated upward according to the rescue medication consumed during the previous application period. Degree of pain was assessed by patients and parents/guardians using visual and numeric scales. Level of play and quality of life were assessed using the Play Performance Scale (PPS) and the Child Health Questionnaire (CHQ). Adverse events were monitored on Days 1-15. Hypoventilation and sedation were monitored every 4 hours during the first 72 hours of the study. RESULTS. A total of 173 patients completed the primary treatment period and 130 entered the extension phase. The average daily pain intensity scores were reported to have decreased by Day 16 and improvements in the mean PPS scores were observed to the end of the extension period. The CHQ scores demonstrated improvements in 11 of 12 domains after Month 1 of the extension period. CONCLUSIONS. Transdermal fentanyl was found to be a safe and well tolerated alternative to oral opioid treatment for children ages 2-16 years who were previously exposed to opioid therapy.	Childrens Natl Med Ctr, Anesthesia Pain Management Serv, Washington, DC 20010 USA; George Washington Univ, Dept Anesthesiol, Washington, DC USA; George Washington Univ, Dept Pediat, Washington, DC USA; Dalhousie Univ, Dept Anesthesia, Halifax, NS, Canada; Dalhousie Univ, Dept Psychol, Halifax, NS, Canada; IWK Hlth Ctr, Halifax, NS, Canada; Childrens Hosp, Pain Treatment Serv, Boston, MA 02115 USA; Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA; Med Coll Wisconsin, Dept Anesthesiol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Anesthesiol, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Biobehav Sci, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Pediat Pain Program, Los Angeles, CA USA	Finkel, JC (reprint author), Childrens Natl Med Ctr, Anesthesia Pain Management Serv, 111 Michigan Ave,NW, Washington, DC 20010 USA.	jfinkel@cnmc.org	Finley, Allen/AAD-7583-2020	Finley, Allen/0000-0003-4579-7749; Zeltzer, Lonnie/0000-0001-9306-9450			Adriaensen H, 2003, Acta Anaesthesiol Belg, V54, P37; Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; *ALZ CORP, 2002, DUR SUMM PROD CHAR; [Anonymous], 1990, SAS STAT US GUID VER, V1; ASHBURN MA, 1993, ANESTH ANALG, V76, P402; Ashburn MA, 1999, LANCET, V353, P1865, DOI 10.1016/S0140-6736(99)04088-X; Ball AJ, 1996, BRIT J HOSP MED, V55, P586; BERMAN D, 1992, BRIT J CANCER, V66, pS84; BERTI JJ, 1995, MAYO CLIN PROC, V70, P581, DOI 10.4065/70.6.581; Chambliss C Robert, 2002, Paediatr Drugs, V4, P737, DOI 10.2165/00148581-200204110-00005; Charmandari E, 2003, HORM RES, V59, P161, DOI 10.1159/000069325; Cummings EA, 1996, PAIN, V68, P25, DOI 10.1016/S0304-3959(96)03163-6; Eccleston C, 2003, BRIT MED J, V326, P1408, DOI 10.1136/bmj.326.7404.1408; Eccleston C, 2001, BRIT J ANAESTH, V87, P144, DOI 10.1093/bja/87.1.144; Enck R E, 2001, Am J Hosp Palliat Care, V18, P365, DOI 10.1177/104990910101800601; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; Gauthier JC, 1998, CLIN J PAIN, V14, P116, DOI 10.1097/00002508-199806000-00005; Glajchen M, 2001, J Am Board Fam Pract, V14, P211; GOLDMAN A, 1991, BRIT MED BULL, V47, P676, DOI 10.1093/oxfordjournals.bmb.a072500; Howard RF, 2003, JAMA-J AM MED ASSOC, V290, P2464, DOI 10.1001/jama.290.18.2464; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; LANDGRAF JM, 2000, CHQ USERS MANUAL; LANSKY LL, 1985, CANCER, V56, P1837, DOI 10.1002/1097-0142(19851001)56:7+<1837::AID-CNCR2820561324>3.0.CO;2-Z; LANSKY SB, 1987, CANCER, V60, P1651, DOI 10.1002/1097-0142(19871001)60:7<1651::AID-CNCR2820600738>3.0.CO;2-J; Larsson BA, 1999, ACTA PAEDIATR, V88, P1301, DOI 10.1080/080352599750029952; Noyes M, 2001, Am J Hosp Palliat Care, V18, P411, DOI 10.1177/104990910101800612; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; Peters JM, 1999, AM J GASTROENTEROL, V94, P1857; PURCELLJONES G, 1988, PAIN, V33, P181, DOI 10.1016/0304-3959(88)90089-9; *SAS I INC, 1990, SAS PROC GUID VERS 6; SCHECHTER NL, 1986, J DEV BEHAV PEDIATR, V7, P350; Vallerand AH, 2003, NURS CLIN N AM, V38, P435, DOI 10.1016/S0029-6465(02)00094-4; Weisman S J, 1991, Pediatr Rev, V12, P237, DOI 10.1542/pir.12-8-237; Weisman SJ, 1998, ARCH PEDIAT ADOL MED, V152, P147; WOLFE J, 2004, PALLIATIVE CARE CHIL; Yaster Myron, 2001, Indian Journal of Pediatrics, V68, P749, DOI 10.1007/BF02752416; Zarbock S F, 2000, Home Care Provid, V5, P181, DOI 10.1067/mhc.2000.110688	37	25	27	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0008-543X	1097-0142		CANCER-AM CANCER SOC	Cancer	DEC 15	2005	104	12					2847	2857		10.1002/cncr.21497			11	Oncology	Oncology	992JT	WOS:000233880900025	16284992				2020-06-30	J	Schmidt, J; Schroth, M; Irouschek, A; Birkholz, T; Kurzai, M; Krober, S; Meisner, M; Albrecht, S				Schmidt, J; Schroth, M; Irouschek, A; Birkholz, T; Kurzai, M; Krober, S; Meisner, M; Albrecht, S			Patients with ornithine transcarbamylase deficiency	ANAESTHESIST			German	Article						ornithine transcarbamylase deficiency; hyperammonemia; alternative pathway therapy; general anaesthesia	HYPERAMMONEMIC COMA; LATE-ONSET; DIAGNOSIS; WOMAN	Ornithine transcarbamylase deficiency (OTCD) is the most common inborn urea cycle disorder. Patients with OTCD are at risk of acute metabolic decompensation with hyperammonemia and subsequent encephalopathy, coma and death. Symptoms may be triggered by infections, drugs and stress, evoked by trauma, pain, fear, surgery and anaesthesia or by episodes of protein catabolism, i.e. fasting-induced, post partum or during gastrointestinal bleeding. Several specific considerations must be made for anaesthetic and intensive care management in patients with this disease in order to avoid metabolic decompensation. We report the intensive care management of the first manifestation of late-onset OTCD in a 16-year-old girl and a course of inconspicuous general anaesthesia with midazolam, s-ketamine, fentanyl and isoflurane in a 22-year-old girl with known OTCD.	FAU, Klin Anasthesiol, D-91054 Erlangen, Germany; FAU, Kinder & Jugendklin, Erlangen, Germany; Stadt Krankenhaus, Dresden, Germany	Schmidt, J (reprint author), FAU, Klin Anasthesiol, Krankenhausstr 12, D-91054 Erlangen, Germany.	joachim.schmidt@gmx.ch					ARN PH, 1990, NEW ENGL J MED, V322, P1652, DOI 10.1056/NEJM199006073222307; BATSHAW ML, 1982, ANN NEUROL, V11, P319, DOI 10.1002/ana.410110315; BAUM VC, 1999, ANESTHESIA GENETIC M, P225; Berry GT, 2001, J PEDIATR-US, V138, pS56, DOI 10.1067/mpd.2001.111837; BRUSILOW SW, 2001, [No title captured], P1909; Gaspari R, 2003, ANN EMERG MED, V41, P104, DOI 10.1067/mem.2003.6; GODDON N, 2003, EUR J PAEDIATR NEURO, V7, P115; Hubler A, 2001, Z GEBURTSH NEONATOL, V205, P236, DOI 10.1055/s-2001-19056; Iida R, 1996, Masui, V45, P642; Kasahara M, 1998, J PEDIATR SURG, V33, P1753, DOI 10.1016/S0022-3468(98)90278-0; Legras A, 2002, CRIT CARE MED, V30, P241, DOI 10.1097/00003246-200201000-00035; Michalak A, 1997, METAB BRAIN DIS, V12, P171; Perez Valdivieso J R, 2002, Rev Esp Anestesiol Reanim, V49, P219; Perpoint T, 2001, INTENS CARE MED, V27, P1962, DOI 10.1007/s00134-001-1148-7; Plochl E, 2001, KLIN PADIATR, V213, P261, DOI 10.1055/s-2001-17216; SCHWAB S, 1998, J NEUROL, V246, P609; Schwarz S, 1999, NERVENARZT, V70, P111, DOI 10.1007/s001150050410; Tazuke M, 1997, Masui, V46, P783; Trivedi M, 2001, J CLIN GASTROENTEROL, V32, P340, DOI 10.1097/00004836-200104000-00013; Wraith JE, 2001, ARCH DIS CHILD, V84, P84, DOI 10.1136/adc.84.1.84	20	3	3	0	0	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0003-2417			ANAESTHESIST	Anaesthesist	DEC	2005	54	12					1201	1208		10.1007/s00101-005-0911-5			8	Anesthesiology	Anesthesiology	993FH	WOS:000233939500006	16136341				2020-06-30	J	Cherng, CH; Yang, CP; Wong, CS				Cherng, CH; Yang, CP; Wong, CS			Epidural fentanyl speeds the onset of sensory and motor blocks during epidural ropivacaine anesthesia	ANESTHESIA AND ANALGESIA			English	Article							LOCAL-ANESTHETICS; ANALGESIA; BUPIVACAINE; SUFENTANIL; LIDOCAINE; MORPHINE; SPREAD; NERVE; RATS	In this study we examined the onset times of sensory and motor block during epidural ropivacaine anesthesia with and without the addition of fentanyl to the epidural solution. Forty-five young male patients undergoing knee arthroscopic surgery were randomly allocated into 3 groups of 15 patients each: epidural fentanyl (EF; epidural administration of 15 mL of 1% ropivacaine plus 100 mu g fentanyl followed by IV injection of 2 mL of normal saline); IV fentanyl (IF; epidural administration of 15 mL of 1% ropivacaine plus 2 mL of normal saline followed by IV injection of 100 mu g fentanyl); and control (C; epidural administration of 15 mL of 1% ropivacaine plus 2 mL, of normal saline followed by IV injection of 2 mL of normal saline). The sensory and motor blocks were assessed by pinprick and modified Bromage scale, respectively. The hemodynamic changes, postepidural shivering, and side effects of epidural fentanyl were also recorded. There was no difference in the distribution of age, weight, and height among the 3 groups. The onset time of sensory block to the T10 dermatome was significantly more rapid in the EF group (13.0 +/- 3.0 min) than in the IF group (16.2 +/- 3.5 min, P < 0.05) or C group (17.7 +/- 3.6 min, P < 0.05). The onset times of motor block up to Bromage scale 1 and 2 were significantly more rapid in the EF group (11.9 +/- 4.6 and 24.4 +/- 5.9 min) than in the IF group (16.9 +/- 4.7 and 30.8 +/- 5.6min,P < 0.05) or C group (18.3 +/- 4.9 and 32.7 +/- 5.7 min, P < 0.05). There was no difference in the incidence of shivering among the three groups. Pruritus was observed in three patients of the EF group and one patient of the IF group. No nausea, vomiting, respiratory depression, urinary retention, or hypotension was observed in any patient. We conclude that epidural administration of the mixture of 100 mu g fentanyl and 1% ropivacaine solution accelerated the onset of sensory and motor blocks during epidural ropivacaine anesthesia without significant fentanyl-related side effects.	Tri Serv Gen Hosp, Natl Def Med Ctr, Dept Anesthesiol, Taipei 114, Taiwan; Taoyuan Armed Forces Gen Hosp, Div Anesthesiol, Taoyuan, Taiwan	Cherng, CH (reprint author), Tri Serv Gen Hosp, Natl Def Med Ctr, Dept Anesthesiol, 325,Sec 2,Cheng Gung Rd,Nei Hu, Taipei 114, Taiwan.	cherng1018@yahoo.com.tw					Boidin M P, 1991, Acta Anaesthesiol Belg, V42, P93; Bourke GJ, 1985, INTERPRETATION USES, P312; Cherng CH, 2001, REGION ANESTH PAIN M, V26, P523, DOI 10.1053/rapm.2001.27852; Cousins M. J., 1998, NEURAL BLOCKADE CLIN, P243; DUGGAN AW, 1984, PHARMACOL REV, V35, P219; FASSOULAKI A, 1991, BRIT J ANAESTH, V67, P437, DOI 10.1093/bja/67.4.437; FIELDS HL, 1980, NATURE, V284, P351, DOI 10.1038/284351a0; FRANK GB, 1985, CAN J PHYSIOL PHARM, V63, P1023, DOI 10.1139/y85-168; FRAZIER DT, 1972, P SOC EXP BIOL MED, V139, P434; Ganidagli S, 2004, VET REC, V154, P329, DOI 10.1136/vr.154.11.329; Gautier P, 1999, ANESTHESIOLOGY, V90, P772, DOI 10.1097/00000542-199903000-00020; GISSEN AJ, 1987, ANESTH ANALG, V66, P1272; JOHNSON C, 1991, REGION ANESTH, V16, P228; KANEKO M, 1994, ANESTHESIOLOGY, V80, P137, DOI 10.1097/00000542-199401000-00021; Kasaba T, 1996, CAN J ANAESTH, V43, P1211, DOI 10.1007/BF03013426; LI YM, 1995, ANESTHESIOLOGY, V82, P166, DOI 10.1097/00000542-199501000-00021; POWER I, 1991, REGION ANESTH, V16, P204; SMITH B, 1987, LANCET, V1, P1497; Vercauteren M, 1997, PHARMACOL BIOCHEM BE, V58, P237, DOI 10.1016/S0091-3057(97)00011-7; WONG K, 1993, ANESTH ANALG, V76, P131	20	12	18	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	DEC	2005	101	6					1834	1837		10.1213/01.ANE.0000184131.06529.35			4	Anesthesiology	Anesthesiology	987IU	WOS:000233512400050	16301269				2020-06-30	J	Halpern, SH; Ioscovich, A				Halpern, SH; Ioscovich, A			Epidural analgesia and breastfeeding	ANESTHESIOLOGY			English	Editorial Material									Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Anesthesia, Toronto, ON, Canada	Halpern, SH (reprint author), Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Anesthesia, 100 Coll St, Toronto, ON, Canada.	stephen.halpern@sw.ca	Halpern, Stephen H/K-8304-2012				Beilin Y, 2005, ANESTHESIOLOGY, V103, P1211, DOI 10.1097/00000542-200512010-00016; Gartner LM, 1997, PEDIATRICS, V100, P1035; Porter J, 1998, ANESTHESIOLOGY, V89, P79, DOI 10.1097/00000542-199807000-00014; Scott J A, 1999, Breastfeed Rev, V7, P5	4	8	8	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	DEC	2005	103	6					1111	1112		10.1097/00000542-200512000-00002			2	Anesthesiology	Anesthesiology	989VS	WOS:000233702700001	16306720				2020-06-30	J	Takane, H; Nosaka, A; Wakushima, H; Hosokawa, K; Ieiri, I				Takane, H; Nosaka, A; Wakushima, H; Hosokawa, K; Ieiri, I			Rifampin reduces the analgesic effect of transdermal fentanyl	ANNALS OF PHARMACOTHERAPY			English	Letter									Tottori Univ, Fac Med, Dept Hosp Pharm, Yonago, Tottori 6838504, Japan; Tottori Univ, Fac Med, Dept Otorhinolaryngol, Yonago, Tottori 683, Japan; Tottori Univ, Fac Med, Dept Hosp Pharm, Yonago, Tottori 683, Japan	Takane, H (reprint author), Tottori Univ, Fac Med, Dept Hosp Pharm, 36-1,Nishimachi, Yonago, Tottori 6838504, Japan.	ieiri@grape.med.tottori-u.ac.jp					Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Kharasch ED, 1997, ANESTHESIOLOGY, V87, P36, DOI 10.1097/00000542-199707000-00006; Mercadante S, 2002, J PAIN SYMPTOM MANAG, V24, P284, DOI 10.1016/S0885-3924(02)00477-3; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154	5	10	10	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1060-0280	1542-6270		ANN PHARMACOTHER	Ann. Pharmacother.	DEC	2005	39	12					2139	2140		10.1345/aph.1G370			2	Pharmacology & Pharmacy	Pharmacology & Pharmacy	988ZW	WOS:000233643700029	16288064				2020-06-30	J	Diaz-del-Consuelo, I; Jacques, Y; Pizzolato, GP; Guy, RH; Falson, F				Diaz-del-Consuelo, I; Jacques, Y; Pizzolato, GP; Guy, RH; Falson, F			Comparison of the lipid composition of porcine buccal and esophageal permeability barriers	ARCHIVES OF ORAL BIOLOGY			English	Article						esophageal epithelium; buccal epithelium; membrane lipids; permeability; AMD-HPTLC	ORAL EPITHELIUM; ELECTRON-MICROSCOPY; EPIDERMIS; CHROMATOGRAPHY; INTEGRITY; DELIVERY; MUCOSA; WATER	Pig esophageal mucosa has been shown to be a useful and practical substitute for buccal mucosa in in vitro permeability studies in that it offers a Larger surface area and it is much easier to prepare. Further, the tissues demonstrate similar histological. characteristics. The objectives of this work were to characterize the lipid composition of the esophageal. mucosa, to compare it to that of the buccal. tissue, and to correlate lipid composition with the membranes' permeabitity to fentanyl. The major lipid classes of buccal. and esophageal. epithelia were separated and analysed by automated multiple development high-performance thin-layer chromatography (AMD-HPTLC). The two epithelia presented a very similar lipid pattern. In general, there were more polar lipids than non-polar; glycosylceramides were relatively abundant whereas the amount of ceramides present was very small. The flux of fentanyl. applied as the citrate in aqueous solution was comparable across the buccal. and esophageal. barriers. Lipid extraction provoked a significant increase in permeability. In conclusion, this research confirms the suitability of the esophageal. mucosa as a model for buccal. permeability studies. (c) 2005 Elsevier Ltd. All rights reserved.	Ctr Interuniv Rech & Enseignement Pharmapeptides, F-74160 Archamps, France; Univ Geneva, Sch Pharmaceut Sci, CH-1211 Geneva, Switzerland; Univ Lyon 1, ISPB, Lab Rech & Dev Pharm Galen Ind, F-69373 Lyon, France; Hop Cantonal Geneva, Unite Neuropathol, Dept Clin Pathol, CH-1211 Geneva, Switzerland; Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England	Jacques, Y (reprint author), Ctr Interuniv Rech & Enseignement Pharmapeptides, Campus Univ, F-74160 Archamps, France.	yves.jacques@pharm.unige.ch	Guy, Richard H/H-3471-2012	Guy, Richard/0000-0003-3227-9862			Chen S.-Y., 1984, STRUCTURE FUNCTION O, P7; CORBO DC, 1990, J PHARM SCI, V79, P202, DOI 10.1002/jps.2600790304; DELCONSUELO ID, 2003, CONTR REL SOC 30 ANN, P514; DEVRIES ME, 1991, CRIT REV THER DRUG, V8, P271; Ganem-Quintanar A, 1998, PHARM RES-DORDR, V15, P495, DOI 10.1023/A:1011949020351; HILL MW, 1982, HISTOCHEM J, V14, P641, DOI 10.1007/BF01011896; Hoogstraate AJ, 1997, EUR J PHARM SCI, V5, P189, DOI 10.1016/S0928-0987(97)00280-7; HOPWOOD D, 1995, DIGESTION, V56, P5, DOI 10.1159/000201294; HOPWOOD D, 1978, VIRCHOWS ARCH B, V26, P345; HOPWOOD D, 1991, HISTOCHEM J, V23, P409, DOI 10.1007/BF01042297; HOPWOOD D, 1977, HISTOCHEM J, V9, P153, DOI 10.1007/BF01003627; Law S, 1995, ARCH ORAL BIOL, V40, P1085, DOI 10.1016/0003-9969(95)00091-7; Morlock GE, 1996, J CHROMATOGR A, V754, P423, DOI 10.1016/S0021-9673(96)00536-5; NAIR M, 1993, INT J PHARM, V89, P41, DOI 10.1016/0378-5173(93)90306-Z; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; SCHWEITZER EJ, 1987, J LAB CLIN MED, V110, P172; Squier C A, 2001, J Natl Cancer Inst Monogr, P7; SQUIER CA, 1977, J ULTRA MOL STRUCT R, V60, P212, DOI 10.1016/S0022-5320(77)80066-X; SQUIER CA, 1991, ARCH ORAL BIOL, V36, P647, DOI 10.1016/0003-9969(91)90017-O; SQUIER CA, 1986, ARCH ORAL BIOL, V31, P741, DOI 10.1016/0003-9969(86)90006-3; SQUIER CA, 1991, J INVEST DERMATOL, V96, P123, DOI 10.1111/1523-1747.ep12515931; Thompson IOC, 2001, ARCH ORAL BIOL, V46, P1091, DOI 10.1016/S0003-9969(01)00082-6; TOBEY NA, 1995, DIGESTION, V56, P45, DOI 10.1159/000201301; WERTZ PW, 1986, COMP BIOCHEM PHYS B, V83, P529, DOI 10.1016/0305-0491(86)90291-9	24	35	36	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0003-9969	1879-1506		ARCH ORAL BIOL	Arch. Oral Biol.	DEC	2005	50	12					981	987		10.1016/j.archoralbio.2005.04.008			7	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	989QW	WOS:000233689800001	15955526				2020-06-30	J	Mehrotra, R				Mehrotra, R			General anesthesia for a patient with alternating hemiplegia of childhood	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Letter							CESAREAN-SECTION		Green Lane Hosp, Auckland 3, New Zealand	Mehrotra, R (reprint author), Green Lane Hosp, Auckland 3, New Zealand.	rina_london@yahoo.com					CASAER P, 1984, LANCET, V2, P579; Han TH, 2001, CAN J ANAESTH, V48, P1117, DOI 10.1007/BF03020379; Mikati MA, 2000, PEDIATR NEUROL, V23, P134, DOI 10.1016/S0887-8994(00)00157-0; Parris-Piper TW, 2002, INT J OBSTET ANESTH, V11, P317, DOI 10.1054/ijoa.2002.0986; VERRETT S, 1971, PEDIATRICS, V47, P675	5	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	DEC	2005	52	10					1103	1104		10.1007/BF03021614			2	Anesthesiology	Anesthesiology	997JC	WOS:000234240500018	16326684	Bronze			2020-06-30	J	Sathyan, G; Guo, C; Sivakumar, K; Gidwani, S; Gupta, S				Sathyan, G; Guo, C; Sivakumar, K; Gidwani, S; Gupta, S			Evaluation of the bioequivalence of two transdermal fentanyl systems following single and repeat applications	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						bioequivalence; fentanyl; transdermal	RELEASE ORAL MORPHINE; CHRONIC NONCANCER PAIN; CANCER PAIN; EFFICACY; PHARMACOKINETICS	Objective: Transdermal delivery of fentanyl has potential benefits over slow-release morphine, being largely preferred by patients owing to the combination of effective pain relief, a good safety profile and easy, pain-free dosing. The new drug-in-adhesive Durogesic* D-TRANS dagger fentanyl Matrix Delivery System (DDTDF) has improved pharmaceutical characteristics and patient acceptability compared to the original Durogesic transdermal reservoir system (fentanyl transdermal reservoir), whilst still providing reliable and consistent delivery of fentanyl. The bioequivalence of these two systems was evaluated in two studies. Research designs and methods: Eighty healthy volunteers received single (72h) or multiple (288h) applications of DDTDF and the transdermal reservoir system (100 pg/h) in two separate randomised, crossover bioequivalence studies. Bioequivalence was assessed by calculating the ratio of least squares means based on log-transformed data following single system application and at steady-state during the fourth application. Results: Both transdermal systems were bioequivalent with respect to all tested pharmacokinetic parameters. Inter-subject variability was comparable between the two systems and was greater than intra-subject variability. Transdermal delivery was well tolerated in both groups. Conclusions: The pharmacokinetic results demonstrate that DDTDF is bioequivalent to the original fentanyl transdermal reservoir system after single and multiple applications.	ALZA Corp, Mountain View, CA 94043 USA	Sathyan, G (reprint author), ALZA Corp, 1900 Charleston Rd, Mountain View, CA 94043 USA.	GSATHYAN@alzus.jnj.com					Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; ANDERSON LS, 2002, AAPS PHARMSCI, P4; ANDRESEN C, 2004, 3 WORLD C WORLD I PA, P288; Chow S, 1992, DESIGN ANAL BIOAVAIL, P70; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; *CPMP, 1999, NOT GUID MOD REL OR; ESTEVE M, 1991, ANESTHESIOLOGY, V75, pA705; *FDA, 2001, GUID IND STAT APPR E; GIDWANI S, 2004, 3 WORLD C WORLD I PA, P288; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; GUPTA SK, 2004, 3 WORLD C WORLD I PA, P288; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Mehdizadeh Amir, 2004, Acta Pharmaceutica (Zagreb), V54, P301; *MLIC, 1983, STATS B MET LIFE INS, V654, P2; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; SATHYAN G, 2004, 3 WORLD C WORLD I PA, P288; SCHUIRMANN DJ, 1987, J PHARMACOKINET BIOP, V15, P657, DOI 10.1007/BF01068419	18	17	17	0	5	LIBRAPHARM	NEWBURY	29-35  VENTURE WEST, NEW GREENHAM PARK, NEWBURY RG19 6HX, BERKSHIRE, ENGLAND	0300-7995			CURR MED RES OPIN	Curr. Med. Res. Opin.	DEC	2005	21	12					1961	1968		10.1185/030079905X65259			8	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	993XH	WOS:000233990300011	16368047				2020-06-30	J	Lee, YY; Muchhal, K; Chan, CK; Cheung, ASP				Lee, YY; Muchhal, K; Chan, CK; Cheung, ASP			Levobupivacaine and fentanyl for spinal anaesthesia: a randomized trial	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthetics, local, levobupivacaine; analgesics, opioid, fentanyl; anaesthetic techniques, anaesthesia, spinal; surgery, urological	RACEMIC BUPIVACAINE; EPIDURAL LEVOBUPIVACAINE; INTRATHECAL FENTANYL; CESAREAN DELIVERY; SURGERY; LABOR; ANALGESIA; POTENCIES; REPAIR	Background and objective: Levobupivacaine 0.5% and racemic bupivacaine 0.5% are equally effective in spinal anaesthesia. Fentanyl has been used as an adjunct to racemic bupivacaine in spinal anaesthesia. At the time this study was designed, there was no published study on the intrathecal use of 0.5% levobupivacaine with fentanyl. Methods: This prospective, randomized, double-blind study compared the clinical efficacy, motor block and haemodynamic effects of using 2.6 mL of 0.5% levobupivacaine alone (2 5 patients) and 2.3 mL of 0.5% levobupivacaine with fentanyl 15 mu g in 0.3 mL (25 patients) for spinal anaesthesia in urological surgery. The study solution was injected into the subarachnoid space at the L3-L4 interspace. Results: There were no significant differences between the two groups in the haemodynamic changes, and quality of sensory and motor block. Anaesthesia was adequate and patient satisfaction was good in all cases. Side-effects were minor and infrequent with both regimes. Conclusions: We conclude that 2.3 mL of 0.5% levobupivacaine with fentanyl 15 mu g is as effective as 2.6 mL of 0.5% levobupivacaine alone in spinal anaesthesia for urological surgery. Further studies may be directed to find the optimal combination of levobupivacaine and opioid with maximal haemodynamic stability and least motor block.	Kwong Wah Hosp, Dept Anaesthesiol & Operating Theatre Serv, Kowloon, Hong Kong, Peoples R China	Lee, YY (reprint author), Kwong Wah Hosp, Dept Anaesthesiol & Operating Theatre Serv, Waterloo Rd, Kowloon, Hong Kong, Peoples R China.	yylee@ha.org.hk					Bader AM, 1999, ANESTHESIOLOGY, V90, P1596, DOI 10.1097/00000542-199906000-00015; Ben-David B, 2000, ANESTHESIOLOGY, V92, P6, DOI 10.1097/00000542-200001000-00007; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; Cox CR, 1998, BRIT J ANAESTH, V80, P289; Glaser C, 2002, ANESTH ANALG, V94, P194, DOI 10.1097/00000539-200201000-00037; Goel S, 2003, EUR J ANAESTH, V20, P294, DOI 10.1097/00003643-200304000-00004; Kararmaz A, 2003, ANAESTHESIA, V58, P526, DOI 10.1046/j.1365-2044.2003.03153.x; Kopacz DJ, 2000, ANESTH ANALG, V90, P642, DOI 10.1097/00000539-200003000-00026; Korhonen AM, 2003, ACTA ANAESTH SCAND, V47, P342, DOI 10.1034/j.1399-6576.2003.00092.x; Kuusniemi KS, 2000, ANESTH ANALG, V91, P1452, DOI 10.1097/00000539-200012000-00029; Lacassie HJ, 2003, ANESTH ANALG, V97, P1509, DOI 10.1213/01.ANE.0000083375.48151.FF; Lee YY, 2003, ANAESTH INTENS CARE, V31, P637, DOI 10.1177/0310057X0303100604; Lyons G, 1998, BRIT J ANAESTH, V81, P899; Martyr JW, 2001, ANAESTH INTENS CARE, V29, P501, DOI 10.1177/0310057X0102900509; Robinson AP, 2001, ANESTH ANALG, V92, P410, DOI 10.1213/00000539-200102000-00025; Vercauteren MP, 2001, ANESTH ANALG, V93, P996, DOI 10.1097/00000539-200110000-00040	17	25	27	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	DEC	2005	22	12					899	903		10.1017/S0265021505001523			5	Anesthesiology	Anesthesiology	990BY	WOS:000233719400001	16318658				2020-06-30	J	Lafuente, MP; Franch, J; Durall, I; Diaz-Bertrana, MC; Marquez, RM				Lafuente, MP; Franch, J; Durall, I; Diaz-Bertrana, MC; Marquez, RM			Comparison between meloxicam and transdermally administered fentanyl for treatment of postoperative pain in dogs undergoing osteotomy of the tibia and fibula and placement of a uniplanar external distraction device	JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION			English	Article; Proceedings Paper	38th National Conference of the Spanish-Small-Animal-Veterinary-Association	OCT, 2003	Seville, SPAIN	Spanish Small Animals Vet Assoc			SERUM CONCENTRATIONS; ORTHOPEDIC-SURGERY; KETOPROFEN; CARPROFEN; OVARIOHYSTERECTOMY; BUTORPHANOL; ANALGESIA; EFFICACY; TEMPERATURE; OXYMORPHONE	Objective-To compare the efficacy of meloxicam administered perioperatively with transdermal administration of fentanyl via a patch placed preoperatively in dogs undergoing orthopedic surgery. Design-Prospective study. Animals-16 dogs. Procedure-Unilateral or bilateral osteotomy of the tibia and fibula was surgically performed, and a uniplanar external distraction device was placed in each limb. Postoperative pain and lameness were assessed 24, 48, and 72 hours after administration of the first of 3 doses of meloxicam (0.2 mg/kg [0.09 mg/lb], IV, given preoperatively, followed by 0.1 mg/kg [0.045 mg/lb], IV, after 24 hours, and 0.1 mg/kg, PO, after 48 hours) or preoperative placement of a transdermal fentanyl patch (50 mu g/h) left in place for 72 hours. Results-No significant differences in total pain scores were detected between groups. Mean +/- SID lameness scores assessed at 24 and 72 hours were lower in dogs in the meloxicam group than dogs in the fentanyl group. Lameness scores decreased with time in a similar manner in both treatment groups. Conclusions and Clinical Relevance-Perioperative administration of meloxicam or preoperative placement of a transdermal fentanyl patch provided effective and similar postoperative analgesia in dogs undergoing orthopedic surgery. However, because of its anti-inflammatory effects, treatment with meloxicam reduced the degree of lameness and resulted in rapid functional recovery of the limb.	Washington State Univ, Coll Vet Med, Dept Vet Clin Sci, Pullman, WA 99164 USA; Univ Autonoma Barcelona, Coll Vet Med, Dept Anim Med & Surg, Barcelona 08193, Spain	Lafuente, MP (reprint author), Washington State Univ, Coll Vet Med, Dept Vet Clin Sci, Pullman, WA 99164 USA.						Balmer TV, 1998, J SMALL ANIM PRACT, V39, P158, DOI 10.1111/j.1748-5827.1998.tb03623.x; Borer LR, 2003, AM J VET RES, V64, P1429, DOI 10.2460/ajvr.2003.64.1429; Brideau C, 2001, AM J VET RES, V62, P1755, DOI 10.2460/ajvr.2001.62.1755; Budsberg SC, 2002, AM J VET RES, V63, P1557, DOI 10.2460/ajvr.2002.63.1557; Busch U, 1998, DRUG METAB DISPOS, V26, P576; Conzemius MG, 1997, J AM VET MED ASSOC, V210, P1619; Cross AR, 1997, AM J VET RES, V58, P626; Dembo G, 2005, ANESTHESIOLOGY, V102, P409, DOI 10.1097/00000542-200502000-00026; Deneuche AJ, 2004, VET SURG, V33, P650, DOI 10.1111/j.1532-950X.2004.04088.x; Doig PA, 2000, CAN VET J, V41, P296; Egger CM, 1998, VET SURG, V27, P159, DOI 10.1111/j.1532-950X.1998.tb00114.x; Egger CM, 2003, VET ANAESTH ANALG, V30, P229, DOI 10.1046/j.1467-2995.2003.00109.x; Firth AM, 1999, J AM VET MED ASSOC, V214, P651; FORELL EB, 1993, J AM ANIM HOSP ASSOC, V29, P460; Forsyth SF, 1998, J SMALL ANIM PRACT, V39, P421, DOI 10.1111/j.1748-5827.1998.tb03748.x; Grisneaux E, 1999, J AM VET MED ASSOC, V215, P1105; Hanft G, 2001, INFLAMM RES, V50, pS35; Hansen BD, 1997, APPL ANIM BEHAV SCI, V51, P101, DOI 10.1016/S0168-1591(96)01079-9; Hellyer PW, 1998, COMP CONT EDUC PRACT, V20, P140; Hofmeister EH, 2004, J AM ANIM HOSP ASSOC, V40, P468, DOI 10.5326/0400468; Holton L, 2001, VET REC, V148, P525, DOI 10.1136/vr.148.17.525; Holton LL, 1998, J AM VET MED ASSOC, V212, P61; Holton LL, 1998, J SMALL ANIM PRACT, V39, P469, DOI 10.1111/j.1748-5827.1998.tb03681.x; Laredo FG, 2004, VET REC, V155, P667, DOI 10.1136/vr.155.21.667; Lascelles B D, 2001, J Small Anim Pract, V42, P587, DOI 10.1111/j.1748-5827.2001.tb06034.x; Marcelin-Jimenez G, 2005, BIOPHARM DRUG DISPOS, V26, P167, DOI 10.1002/bdd.446; Mathews KA, 1996, CAN VET J, V37, P557; Mathews KA, 2002, J VET EMERG CRIT CAR, V12, P89, DOI 10.1046/j.1435-6935.2002.00007.x; Mathews KA, 2001, AM J VET RES, V62, P882, DOI 10.2460/ajvr.2001.62.882; Melzack R, 2001, ANN NY ACAD SCI, V933, P157; Moiniche S, 1997, ACTA ANAESTH SCAND, V41, P785, DOI 10.1111/j.1399-6576.1997.tb04784.x; MORTON DB, 1985, VET REC, V116, P431, DOI 10.1136/vr.116.16.431; Nell T, 2002, J SMALL ANIM PRACT, V43, P208, DOI 10.1111/j.1748-5827.2002.tb00059.x; Paddleford R. R., 1999, Manual of small animal anesthesia., P12; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P757, DOI 10.1016/S0195-5616(08)70005-6; Pettifer GR, 2004, VET ANAESTH ANALG, V31, P109, DOI 10.1111/j.1467-2987.2004.00158.x; Pettifer GR, 2003, AM J VET RES, V64, P1557, DOI 10.2460/ajvr.2003.64.1557; Pibarot P, 1997, J AM VET MED ASSOC, V211, P438; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; Slingsby LS, 1998, VET REC, V143, P185, DOI 10.1136/vr.143.7.185; Slingsby LS, 2002, J SMALL ANIM PRACT, V43, P286, DOI 10.1111/j.1748-5827.2002.tb00074.x; Slingsby LS, 2000, J SMALL ANIM PRACT, V41, P447, DOI 10.1111/j.1748-5827.2000.tb03139.x; VANE JR, 1995, INFLAMM RES, V44, P1, DOI 10.1007/BF01630479; Yaksh TL, 2001, J NEUROSCI, V21, P5847	44	16	16	2	10	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0003-1488	1943-569X		JAVMA-J AM VET MED A	JAVMA-J. Am. Vet. Med. Assoc.	DEC 1	2005	227	11					1768	1774		10.2460/javma.2005.227.1768			7	Veterinary Sciences	Veterinary Sciences	989XN	WOS:000233707500017	16342525				2020-06-30	J	Thurlkill, RL; Cross, DA; Scholtz, JM; Pace, CN				Thurlkill, RL; Cross, DA; Scholtz, JM; Pace, CN			pKa of fentanyl varies with temperature: implications for acid-base management during extremes of body temperature	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						fentanyl; pKa; body temperature; acid-base	PLASMA-PROTEIN BINDING; SYSTEMIC HYPERTHERMIA; BLOOD; CANCER; AUTOREGULATION; VERTEBRATES; EXPERIENCE; BALANCE; VALUES; PH	Objective: The pKa of fentanyl has not been measured previously at varying extremes of body temperature. The goal of this laboratory investigation was to test the hypothesis that the pKa of fentanyl changes with temperature. Design: The investigation involved measuring the pKa values of aqueous fentanyl at varying temperatures. Setting: The investigation was conducted in a controlled laboratory environment. Participants: No human or animal subjects were involved. Interventions: Because no live subjects were involved in the investigation, no interventions were necessary. Measurements and Main Results: This paper reports the effect of temperature on the pKa of fentanyl. The pKa of aqueous fentanyl was measured at 15 degrees C, 25 degrees C, 37 degrees C, 42 degrees C, and 47.5 degrees C by potentiometric titration in 0.01 mmol/L of potassium chloride after extensive degassing. Data were analyzed using the least squares method with an appropriately fitting equation. The pKa of fentanyl was found to change in a similar manner to the neutral point of water at varying temperatures. Conclusions: This finding has implications for the bioavailability of fentanyl at extremes of body temperature in association with the clinical acid-base management of the patient. Clinical implications for differing methods of intraoperative acid-base management at varying temperatures are discussed. (C) 2005 Elsevier Inc. All rights reserved.	Texas A&M Univ, Scott & White Mem Hosp & Clin, Dept Anesthesiol, Temple, TX 76508 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Dept Med Biochem & Genet, College Stn, TX USA; Texas A&M Univ, Ctr Adv Biomol Res, College Stn, TX USA	Cross, DA (reprint author), Texas A&M Univ, Scott & White Mem Hosp & Clin, Dept Anesthesiol, 2401 S 31st St, Temple, TX 76508 USA.	dacross@swmail.sw.org			NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM-37039, GM-52483]		ALONSO K, 1994, AM J CLIN ONCOL-CANC, V17, P353, DOI 10.1097/00000421-199408000-00015; Ash SR, 1997, ASAIO J, V43, pM830; BOWER S, 1981, J PHARM PHARMACOL, V33, P507, DOI 10.1111/j.2042-7158.1981.tb13849.x; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P14985, DOI 10.1021/bi970071j; Cremer OL, 2004, ANESTHESIOLOGY, V100, P1101, DOI 10.1097/00000542-200405000-00011; EISLER K, 1985, ANAESTHESIST, V34, P299; GABRIELE P, 1990, CANCER, V66, P2191, DOI 10.1002/1097-0142(19901115)66:10<2191::AID-CNCR2820661025>3.0.CO;2-8; Hegewisch-Becker S, 2002, ANN ONCOL, V13, P1197, DOI 10.1093/annonc/mdf216; HERMAN TS, 1982, CANCER TREAT REP, V66, P259; Huang YW, 1995, METHOD ENZYMOL, V259, P19; Huyghues-Despointes BMP, 2003, J MOL BIOL, V325, P1093, DOI 10.1016/S0022-2836(02)01274-3; LEES DE, 1980, ANESTHESIOLOGY, V52, P418, DOI 10.1097/00000542-198005000-00008; MEULDERMANS WEG, 1982, ARCH INT PHARMACOD T, V257, P4; MURKIN JM, 1987, ANESTH ANALG, V66, P825; NOZAKI Y, 1967, [No title captured], V11, P715, DOI DOI 10.1016/S0076-6879(67)11088-4; PETTIGREW RT, 1974, BMJ-BRIT MED J, V4, P679, DOI 10.1136/bmj.4.5946.679; RAHN H, 1975, AM REV RESPIR DIS, V112, P165; RAHN H, 1978, RESP PHYSIOL, V33, P91, DOI 10.1016/0034-5687(78)90087-7; RAHN H, 1974, PNEUMONOLOGIE, V151, P87, DOI 10.1007/BF02097155; REEVES RB, 1969, FED PROC, V28, P1204; REEVES RB, 1977, ANNU REV PHYSIOL, V39, P559, DOI 10.1146/annurev.ph.39.030177.003015; REEVES RB, 1976, J APPL PHYSIOL, V40, P762; REEVES RB, 1972, RESP PHYSIOL, V14, P219, DOI 10.1016/0034-5687(72)90030-8; REEVES RB, 1976, J APPL PHYSIOL, V40, P752; ROSENTHAL TB, 1948, J BIOL CHEM, V173, P25; SMINIA P, 1994, INT J HYPERTHER, V10, P1, DOI 10.3109/02656739409009328; Somero G. N., 1985, ACID BASE REGULATION, P55; SOMERO GN, 1986, AM J PHYSIOL, V251, pR197; Stadie WC, 1924, J BIOL CHEM, V60, P191; SWAIN JA, 1991, AM J PHYSIOL, V260, pH1640; SWAN H, 1984, SURG GYNECOL OBSTET, V158, P391; Vertrees A, 1996, ASAIO J, V42, P250; Vertrees RA, 2002, PERFUSION-UK, V17, P279, DOI 10.1191/0267659102pf588oa; Zablow A, 1997, INT J HYPERTHER, V13, P577, DOI 10.3109/02656739709023558; Zwischenberger JB, 2001, ANN THORAC SURG, V72, P234, DOI 10.1016/S0003-4975(01)02673-X	35	15	15	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770	1532-8422		J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	DEC	2005	19	6					759	762		10.1053/j.jvca.2004.11.039			4	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	997PJ	WOS:000234258600011	16326301				2020-06-30	J	Mahfouz, AKM; Khalaf, MA				Mahfouz, AKM; Khalaf, MA			Comparative study of 2 anesthesia techniques for pediatric refractive surgery	JOURNAL OF CATARACT AND REFRACTIVE SURGERY			English	Article							PHOTOREFRACTIVE KERATECTOMY; KETAMINE SEDATION; DOUBLE-BLIND; CHILDREN; RECOVERY; SEVOFLURANE; PROPOFOL; TRIAL	PURPOSE: To compare the effectiveness of 2 anesthesia techniques for pediatric refractive surgery, propofol/fentanyl and ketamine/midazolam. SETTING: Department of Ophthalmology, Magraby Eye & Ear Center, Muscat, Oman. METHODS: This prospective clinical study was of children ranging in age range from 3 to 12 years who were followed for myopic anisometropia with amblyopia after failure of conventional correction or patients with superficial stromal corneal opacities. The children were scheduled to have refractive surgery under general anesthesia using propofol/fentanyl (P/F group) or ketamine/midazolam (K/M group). All drugs were administered intravenously. RESULTS: Thirty patients were included in the study and were divided randomly into 2 equal groups. Both groups were comparable in age, weight, sex, duration of anesthesia, and duration of surgery. Time to complete recovery was significantly shorter in the P/F group. The hemodynamic changes observed in this study were not of clinical significance. Three patients in the P/F group showed arterial oxygen (O-2) saturation of less than 90% and supplemental O-2 was given by nasal cannula. The incidence of postoperative agitation and vomiting was significantly higher in the K/M group, while the need for jaw thrust was significantly higher in the P/F group. The difference between both groups in the ophthalmologist satisfaction score was not significant. CONCLUSIONS: Propofol offered some advantages for brief procedures outside the traditional operating rooms. It is short acting, and has a rapid offset resulting in shorter postoperative monitoring and a smoother recovery profile. It has greater potential for respiratory depression than ketamine. Hence, greater vigilance and experience with the pediatric airway is recommended with its use.	Univ Alexandria, Dept Anesthesia, Alexandria, Egypt; Cairo Univ, Dept Ophthalmol, Cairo, Egypt	Mahfouz, AKM (reprint author), Magraby Eye & Ear Ctr, PO 513,PC 112, Ruwi, Oman.	abdulkaderm2000@hotmail.com					Astle WF, 2002, J CATARACT REFR SURG, V28, P932, DOI 10.1016/S0886-3350(02)01304-4; Autrata R, 2004, J CATARACT REFR SURG, V30, P1909, DOI 10.1016/j.jcrs.2004.02.047; Cook DR, 2001, ANESTH ANALG, V92, P1444; Davidorf JM, 2000, J CATARACT REFR SURG, V26, P1567, DOI 10.1016/S0886-3350(00)00719-7; Fitzpatrick R, 2004, QUAL LIFE RES, V13, P331, DOI 10.1023/B:QURE.0000018489.25151.e1; GARTRY D, 1991, BRIT J OPHTHALMOL, V75, P258, DOI 10.1136/bjo.75.5.258; Gullo A, 2006, MINERVA ANESTESIOL, V72, P1; Hertzog JH, 2000, PEDIATRICS, V106, P742, DOI 10.1542/peds.106.4.742; Hutchinson Amy K, 2003, Curr Opin Ophthalmol, V14, P267, DOI 10.1097/00055735-200310000-00007; Lerman J, 1996, ANESTHESIOLOGY, V84, P1332, DOI 10.1097/00000542-199606000-00009; Mazurek Michael S, 2004, Semin Pediatr Surg, V13, P166, DOI 10.1053/j.sempedsurg.2004.04.009; Nucci P, 2003, J CATARACT REFR SURG, V29, P889, DOI 10.1016/S0886-3350(03)00011-7; Paysse EA, 2003, J CATARACT REFR SURG, V29, P478, DOI 10.1016/s0886-3350(03)00010-5; REICH DL, 1989, CAN J ANAESTH, V36, P186, DOI 10.1007/BF03011442; Sherwin TS, 2000, ANN EMERG MED, V35, P229, DOI 10.1016/S0196-0644(00)70073-4; SINGH D, 1995, J CATARACT REFR SURG, V21, P630, DOI 10.1016/S0886-3350(13)80558-5; Tang J, 1999, ANESTHESIOLOGY, V91, P253, DOI 10.1097/00000542-199907000-00034; TROKEL SL, 1983, AM J OPHTHALMOL, V96, P710, DOI 10.1016/S0002-9394(14)71911-7; UKLU E, 2003, J CARDIOTHOR VASC AN, V17, P686; Wathen JE, 2000, ANN EMERG MED, V36, P579, DOI 10.1067/mem.2000.111131; Yildizdas D, 2004, PEDIATR EMERG CARE, V20, P162, DOI 10.1097/01.pec.0000117922.65522.26	21	5	6	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0886-3350	1873-4502		J CATARACT REFR SURG	J. Cataract. Refract. Surg.	DEC	2005	31	12					2345	2349		10.1016/j.jcrs.2005.08.054			5	Ophthalmology; Surgery	Ophthalmology; Surgery	015XS	WOS:000235585400038	16473229				2020-06-30	J	Kadoi, Y; Hinohara, H; Kunimoto, F; Saito, S; Goto, F				Kadoi, Y; Hinohara, H; Kunimoto, F; Saito, S; Goto, F			Fentanyl-induced hemodynamic changes after esophagectomy or cardiac surgery	JOURNAL OF CLINICAL ANESTHESIA			English	Article						propofol; fentanyl; cardiac surgery; combination; sedation	INTENSIVE-CARE-UNIT; SEDATION; MIDAZOLAM; PROPOFOL; SLEEP; TRIAL; ICU	Study Objective: The goal of this study was to characterize the hemodynamic response to propofol vspropofol with fentanyl when used for sedation after esopliagectomy or cardiac surgery. Design: Prospective, randomized, controlled study. Setting: University Hospital, Intensive Care Unit. Patients: Thirty patients undergoing elective cardiac surgery and 26 patients undergoing esophagectomy were examined. Intervention: Patients were randomized to receive propolol (0.5 mg/kg bolus over 10 minutes, followed by continuous infusion at I mg/kg per hour) with or without fentanyl (2,0 mu g/kg per hour) to achieve sedation overnight while in the intensive care unit. Randomization was performed in a double-blind manner. Measurement: Mean arterial pressure (MAP) was monitored throughout the treatment period, and sedation level was measured. Sedation level was targeted to achieve a Ramsay score of 4, Main Results: The number of patients experiencing a greater than 20% drop in baseline MAP was higher in cardiac patients receiving propofol alone (11 of 15 patients, 73%) than in cardiac patients receiving propofol with fentanyl (4 of 15 patients, 27%). Furthermore, the time of optimal sedation was lower in the cardiac patients who received propofol than in cardiac patients who received propofol with fentanyl group (propofol alone, 79%; propofol with fentanyl, 88%). In contrast, there was no difference in the number of esophagectomy patients experiencing it greater than 20% drop in baseline MAP or in the mean time of optimal sedation when comparing the 2 treatment regimens. Conclusions: Propofol has a differential effect on hemodynamics and sedation when comparing patients after cardiac surgery and esophagectomy. (c) 2005 Elsevier Inc. All rights reserved.	Gunma Univ Hosp, Dept Anesthesiol, Maebashi, Gumma 3718511, Japan; Gunma Univ Hosp, Dept Intens Care, Maebashi, Gumma 3718511, Japan; Gunma Univ, Dept Anesthesiol, Grad Sch Med, Maebashi, Gumma 3718511, Japan	Kadoi, Y (reprint author), Gunma Univ Hosp, Dept Anesthesiol, Maebashi, Gumma 3718511, Japan.	kadoi@med.gunma-u.ac.jp					BOYD O, 1993, CAN J ANAESTH, V40, P1142, DOI 10.1007/BF03009603; Carrasco G, 1998, CRIT CARE MED, V26, P844, DOI 10.1097/00003246-199805000-00015; Hall RI, 2001, CHEST, V119, P1151, DOI 10.1378/chest.119.4.1151; HIGGINS TL, 1994, CRIT CARE MED, V22, P1415, DOI 10.1097/00003246-199409000-00011; Izurieta R, 2002, CRIT CARE MED, V30, P2644, DOI 10.1097/00003246-200212000-00006; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; KRUEGER JM, 1990, CLIN IMMUNOL IMMUNOP, V57, P188, DOI 10.1016/0090-1229(90)90033-M; Ostermann ME, 2000, JAMA-J AM MED ASSOC, V283, P1451, DOI 10.1001/jama.283.11.1451; RONAN KP, 1995, CRIT CARE MED, V23, P286, DOI 10.1097/00003246-199502000-00014; SCHIFFMAN PL, 1983, CHEST, V84, P695, DOI 10.1378/chest.84.6.695; Searle NR, 1997, CAN J ANAESTH, V44, P629, DOI 10.1007/BF03015447; Soliman HM, 2001, BRIT J ANAESTH, V87, P186, DOI 10.1093/bja/87.2.186; TreggiariVenzi M, 1996, INTENS CARE MED, V22, P1186, DOI 10.1007/BF01709334; Walder B, 2002, ANAESTH INTENS CARE, V30, P171, DOI 10.1177/0310057X0203000208	14	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180			J CLIN ANESTH	J. Clin. Anesth.	DEC	2005	17	8					598	603		10.1016/j.jclinane.2005.04.004			6	Anesthesiology	Anesthesiology	000XW	WOS:000234496700005	16427529				2020-06-30	J	Ard, JL; Bekker, A; Frempong-Boadu, AK				Ard, JL; Bekker, A; Frempong-Boadu, AK			Anesthesia for an adult with mucopolysaccharidosis I	JOURNAL OF CLINICAL ANESTHESIA			English	Article						mucopolysaccharidosis I; Hurler syndrome; anesthesia	BONE-MARROW-TRANSPLANTATION; HURLER-SYNDROME; CHILDREN	We describe the anesthetic management difficulties of a man with mucopolysaccharidosis I. We also briefly review the anesthesia literature related to this disease, (c) 2005 Elsevier Inc. All rights reserved.	NYU, Med Ctr, Dept Anesthesiol, New York, NY 10016 USA; NYU, Med Ctr, Dept Neurosurg, New York, NY 10016 USA	Ard, JL (reprint author), NYU, Med Ctr, Dept Anesthesiol, New York, NY 10016 USA.			Frempong-Boadu, Anthony/0000-0001-5958-0757; Ard, John/0000-0001-8279-1712			BAINES D, 1983, ANAESTH INTENS CARE, V11, P198, DOI 10.1177/0310057X8301100303; BELANI KG, 1993, J PEDIATR SURG, V28, P403, DOI 10.1016/0022-3468(93)90240-L; Guffon N, 1998, J PEDIATR-US, V133, P119, DOI 10.1016/S0022-3476(98)70201-X; Kachur E, 2000, NEUROSURGERY, V47, P223, DOI 10.1097/00006123-200007000-00046; Kakkis ED, 2001, NEW ENGL J MED, V344, P182, DOI 10.1056/NEJM200101183440304; KEMPTHORNE PM, 1983, ANAESTH INTENS CARE, V11, P203, DOI 10.1177/0310057X8301100304; Khan FA, 2002, PAEDIATR ANAESTH, V12, P468, DOI 10.1046/j.1460-9592.2002.t01-4-00864.x; KING DH, 1984, ANAESTHESIA, V39, P126, DOI 10.1111/j.1365-2044.1984.tb09499.x; Moores C, 1996, ANAESTH INTENS CARE, V24, P459, DOI 10.1177/0310057X9602400408; SEMENZA GL, 1988, MEDICINE, V67, P209, DOI 10.1097/00005792-198807000-00002; SJOGREN P, 1987, ACTA ANAESTH SCAND, V31, P214, DOI 10.1111/j.1399-6576.1987.tb02553.x; WALKER RWM, 1994, ANAESTHESIA, V49, P1078, DOI 10.1111/j.1365-2044.1994.tb04360.x; WILDER RT, 1990, ANESTHESIOLOGY, V72, P205, DOI 10.1097/00000542-199001000-00033	13	15	18	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180			J CLIN ANESTH	J. Clin. Anesth.	DEC	2005	17	8					624	626		10.1016/j.jclinane.2005.01.012			3	Anesthesiology	Anesthesiology	000XW	WOS:000234496700011	16427535				2020-06-30	J	Davies, AN; Vriens, J				Davies, AN; Vriens, J			Oral transmucosal fentanyl citrate and xerostomia	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Letter							BETHANECHOL		Royal Marsden Hosp, Sutton, Surrey, England	Davies, AN (reprint author), Royal Marsden Hosp, Sutton, Surrey, England.						Davies A, 2005, ORAL CARE ADV DIS, P97; EPSTEIN JB, 1994, ORAL SURG ORAL MED O, V77, P610, DOI 10.1016/0030-4220(94)90320-4; EVERETT HC, 1975, AM J PSYCHIAT, V132, P1202; Hanks G., 2001, EUR J PALLIAT CARE, V8, P6; OLSSON H, 1991, SCAND J DENT RES, V99, P316; ROBBINS IJ, 1983, NEW ENGL J MED, V309, P985; TWYCROSS RG, 2002, [No title captured]	7	18	19	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924			J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	DEC	2005	30	6					496	497		10.1016/j.jpainsymman.2005.11.006			2	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	002IP	WOS:000234605300002	16376735	Bronze			2020-06-30	J	Del Consuelo, ID; Pizzolato, GP; Falson, F; Guy, RH; Jacques, Y				Del Consuelo, ID; Pizzolato, GP; Falson, F; Guy, RH; Jacques, Y			Evaluation of pig esophageal mucosa as a permeability barrier model for buccal tissue	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						esophageal mucosa; buccal mucosa; fentanyl permeability; epithelial barrier; freezing	INVITRO PERMEABILITY; DIFFUSION RATES; PERMEATION; EPITHELIUM; TRANSPORT; MEMBRANE; DELIVERY; DRUGS; WATER; SKIN	Porcine buccal mucosa is frequently used for in vitro drug absorption studies as its structure and permeability characteristics are close to those of human tissue. However, this tissue model suffers from practical disadvantages, including a limited surface area, damage caused by mastication, and a fastidious and time-consuming excision procedure. It has been hypothesized that such limitations may be overcome by replacing the buccal tissue with the pig esophageal mucosa. The latter has a very similar structure and is easier to separate from the underlying tissue; furthermore, its surface area is greater and is generally intact. The aims of this work, therefore, were (i) to perform histological studies on the two membranes; (ii) to compare the transport of fentanyl citrate across buccal and esophageal mucosae; and (iii) to evaluate the effects of freezing on the tissue permeability. The results show that their histology is comparable, that the permeability of fentanyl citrate across the two epithelial barriers is similar, and that freezing the tissues did not alter their permeability. (c) 2005 Wiley-Liss, Inc. and the American Pharmacists Association.	Pharmapeptide, Ctr Interuniv Rech & Enseignement, F-74160 Archamps, France; Univ Geneva, Sch Pharmaceut Sci, CH-1211 Geneva, Switzerland; Univ Lyon 1, ISPB, Lab Rech & Dev Pharmacie Galen Ind, F-69373 Lyon, France; Hop Cantonal Geneva, Unite Neuropathol, Dept Clin Pathol, CH-1211 Geneva, Switzerland	Jacques, Y (reprint author), Pharmapeptide, Ctr Interuniv Rech & Enseignement, F-74160 Archamps, France.	yves.jacques@pharm.unige.ch	Guy, Richard H/H-3471-2012	Guy, Richard/0000-0003-3227-9862			Artusi M, 2003, INT J PHARM, V250, P203, DOI 10.1016/S0378-5173(02)00545-8; Chen LLH, 1999, INT J PHARM, V184, P63, DOI 10.1016/S0378-5173(99)00091-5; DEVRIES ME, 1991, INT J PHARM, V76, P25, DOI 10.1016/0378-5173(91)90340-T; DOWTY ME, 1992, PHARM RES-DORDR, V9, P1113, DOI 10.1023/A:1015883217858; EGGERTH RM, 1987, P INT S CONTROL REL, V14, P180; GALEY WR, 1976, J INVEST DERMATOL, V67, P713, DOI 10.1111/1523-1747.ep12598596; GOLDEN GM, 1986, J INVEST DERMATOL, V86, P255, DOI 10.1111/1523-1747.ep12285373; HARRISON DJ, 1997, PHARMACOL RES S, pS660; HILL MW, 1982, HISTOCHEM J, V14, P641, DOI 10.1007/BF01011896; HOOGSTRAATE AJ, 1994, PHARMACEUT RES, V11, P83, DOI 10.1023/A:1018949828548; HOPWOOD D, 1978, VIRCHOWS ARCH B, V26, P345; HOPWOOD D, 1991, HISTOCHEM J, V23, P409, DOI 10.1007/BF01042297; Imbert D, 1998, J DENT RES, V77, P290; JACQUES Y, 1998, P 2 WORLD M APGI APV, P921; Long JD, 1999, AM J GASTROENTEROL, V94, P2818, DOI 10.1111/j.1572-0241.1999.1422_b.x; Moser K, 2001, J CONTROL RELEASE, V73, P245, DOI 10.1016/S0168-3659(01)00290-5; NAIR M, 1993, INT J PHARM, V89, P41, DOI 10.1016/0378-5173(93)90306-Z; NICOLAZZO AJ, 2003, J PHARM SCI, V92, P2408; Nielsen HM, 2000, INT J PHARM, V194, P155, DOI 10.1016/S0378-5173(99)00368-3; ORLANDO RC, 1992, GASTROENTEROLOGY, V102, P910, DOI 10.1016/0016-5085(92)90177-Z; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Poorkhalkali N, 1999, ANAT EMBRYOL, V200, P541, DOI 10.1007/s004290050302; Sandri G, 2004, EUR J PHARM SCI, V21, P351, DOI 10.1016/j.ejps.2003.10.028; Shojaei A H, 1998, J Pharm Pharm Sci, V1, P15; Spechler SJ, 1996, GASTROENTEROLOGY, V110, P614, DOI 10.1053/gast.1996.v110.agast960614; Squier C A, 2001, J Natl Cancer Inst Monogr, P7; SQUIER CA, 1977, J ULTRA MOL STRUCT R, V60, P212, DOI 10.1016/S0022-5320(77)80066-X; SQUIER CA, 1985, ARCH ORAL BIOL, V30, P485, DOI 10.1016/0003-9969(85)90095-0; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Tsutsumi K, 1999, INT J PHARM, V177, P7, DOI 10.1016/S0378-5173(98)00329-9; van der Bijl P, 1998, EUR J ORAL SCI, V106, P958, DOI 10.1046/j.0909-8836.1998.eos106509.x; Veuillez F, 2002, INT J PHARM, V231, P1, DOI 10.1016/S0378-5173(01)00850-X; Vicente Y, 2001, DIGEST DIS SCI, V46, P1899, DOI 10.1023/A:1010631030320; Young Simon A., 1998, Journal of Pharmacy and Pharmacology, V50, P167	34	50	50	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	DEC	2005	94	12					2777	2788		10.1002/jps.20409			12	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	990HH	WOS:000233733300017	16258996				2020-06-30	J	Martin, ML; Lennox, PH; Buckley, BT				Martin, ML; Lennox, PH; Buckley, BT			Pain and anxiety: Two problems, two solutions	JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY			English	Editorial Material							INTERVENTIONAL RADIOLOGIC PROCEDURES; CONSCIOUS SEDATION; IV SEDATION; ANALGESIA; MIDAZOLAM; FENTANYL; ARTERIOGRAPHY; ANGIOGRAPHY; PERCEPTION; SURGERY		Univ British Columbia Hosp, Dept Radiol, Vancouver, BC V6T 2B5, Canada; Vancouver Gen Hosp, Dept Anesthesia, Vancouver, BC, Canada	Martin, ML (reprint author), Univ British Columbia Hosp, Dept Radiol, 2211 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada.	m.l.martin@shaw.ca					ALABSI M, 1991, PAIN, V46, P43, DOI 10.1016/0304-3959(91)90032-S; ARNTZ A, 1994, PAIN, V56, P307, DOI 10.1016/0304-3959(94)90169-4; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; Baris S, 2001, CAN J CARDIOL, V17, P277; Bettmann MA, 1997, RADIOLOGY, V203, P611, DOI 10.1148/radiology.203.3.9169677; Bodden-Heidrich R, 2000, J Pediatr Adolesc Gynecol, V13, P139, DOI 10.1016/S1083-3188(00)00056-5; CRAGG AH, 1991, AM J ROENTGENOL, V157, P173, DOI 10.2214/ajr.157.1.2048514; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; HARSHFIELD DL, 1993, AM J ROENTGENOL, V161, P1057, DOI 10.2214/ajr.161.5.7903843; Jones A, 2002, SCAND J PSYCHOL, V43, P307, DOI 10.1111/1467-9450.00299; KATAYAMA H, 1990, RADIOLOGY, V175, P621, DOI 10.1148/radiology.175.3.2343107; Kennedy PT, 2000, RADIOLOGY, V216, P660, DOI 10.1148/radiology.216.3.r00se04660; Koch ME, 1998, ANESTHESIOLOGY, V89, P300, DOI 10.1097/00000542-199808000-00005; Lang EV, 1998, J VASC INTERV RADIOL, V9, P407, DOI 10.1016/S1051-0443(98)70291-X; LANG EV, 1994, AM J ROENTGENOL, V162, P1221, DOI 10.2214/ajr.162.5.8166014; Lang EV, 2000, LANCET, V355, P1486, DOI 10.1016/S0140-6736(00)02162-0; Lang EV, 2002, RADIOLOGY, V222, P375, DOI 10.1148/radiol.2222010528; Lang EV, 1996, INT J CLIN EXP HYP, V44, P106, DOI 10.1080/00207149608416074; Lepage C, 2001, ANESTH ANALG, V93, P912, DOI 10.1097/00000539-200110000-00022; LIEBLICH SE, 1991, J ORAL MAXIL SURG, V49, P792, DOI 10.1016/0278-2391(91)90003-5; LUYK NH, 1988, J ORAL MAXILLOFAC SU, V17, P347; Mueller PR, 2000, RADIOLOGY, V215, P684, DOI 10.1148/radiology.215.3.r00jn33684; Rhudy JL, 2000, PAIN, V84, P65, DOI 10.1016/S0304-3959(99)00183-9; SCHUPP C, 2002, J VASC INTERV RADIOL, V16, P1585; Wagner HJ, 1996, J VASC INTERV RADIOL, V7, P673, DOI 10.1016/S1051-0443(96)70827-8; WALDING MF, 1991, J ADV NURS, V16, P388, DOI 10.1111/j.1365-2648.1991.tb03427.x; White PF, 2002, ANESTH ANALG, V94, P577, DOI 10.1097/00000539-200203000-00019	27	6	6	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	1051-0443			J VASC INTERV RADIOL	J. Vasc. Interv. Radiol.	DEC	2005	16	12					1581	1584		10.1097/01.RVI.0000167588.84460.FD			4	Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease	Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology	997CE	WOS:000234221800003	16371521				2020-06-30	J	Schupp, CJ; Berbaum, K; Berbaum, M; Lang, EV				Schupp, CJ; Berbaum, K; Berbaum, M; Lang, EV			Pain and anxiety during interventional radiologic procedures: Effect of patients' state anxiety at baseline and modulation by nonpharmacologic analgesia adjuncts	JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY			English	Article							POSTOPERATIVE PAIN; MEDICAL PROCEDURES; TRAIT-ANXIETY; SEDATION; ADOLESCENTS; INFORMATION; PREDICTORS; ADJUSTMENT; CLINICIAN; SITUATION	PURPOSE: To assess how patients' underlying anxiety affects their experience of distress, use of resources, and responsiveness toward nonpharmacologic analgesia adjunct therapies during invasive procedures. MATERIALS AND METHODS: Two hundred thirty-six patients undergoing vascular and renal interventions, who had been randomized to receive during standard care treatment, structured empathic attention, or self-hypnotic relaxation, were divided into two groups: those with low state anxiety scores on the State-Trait Anxiety Inventory (STAI, scores < 43; n = 116) and those with high state anxiety scores (>= 43; n = 120). All had access to patient-controlled analgesia with fentanyl and midazolam. Every 15 minutes during the procedure, patients rated their anxiety and pain on a scale of 0-10 (0, no pain/anxiety at all; 10, worst possible pain/anxiety). Effects were assessed by analysis of variance and repeated-measures analysis. RESULTS: Patients with high state anxiety levels required significantly greater procedure time and medication. Empathic attention as well as hypnosis treatment reduced procedure time and medication use for all patients. These nonpharmacologic analgesia adjunct treatments also provided significantly better pain control than standard care for patients with low anxiety levels. Anxiety decreased over the time of the procedure; patients with high state anxiety levels experienced the most significant decreases in anxiety with nonpharmacologic adjuncts whereas patients with low state anxiety levels coped relatively well under all conditions. CONCLUSION: Patients' state anxiety level is a predictor of trends in procedural pain and anxiety, need for medication, and procedure duration. Low and high state anxiety groups profit from the use of nonpharmacologic analgesia adjuncts but those with high state anxiety levels have the most to gain.	Harvard Univ, Dept Radiol, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA; Univ Illinois, Chicago Hlth Res & Policy Ctr, Chicago, IL USA; Univ Iowa Hosp & Clin, Dept Radiol, Iowa City, IA 52242 USA	Lang, EV (reprint author), Harvard Univ, Dept Radiol, Beth Israel Deaconess Med Ctr, Sch Med, 330 Brookline Ave,WCC 308, Boston, MA 02215 USA.	elang@bidmc.harvard.edu		Berbaum, Kevin/0000-0003-0489-2360	NCCIH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine [K24 AT001074, R01 AT000002, 1K24 AT 01074-01, 1R01 AT 0002-05]		ALABSI M, 1991, PAIN, V46, P43, DOI 10.1016/0304-3959(91)90032-S; ARNTZ A, 1994, PAIN, V56, P307, DOI 10.1016/0304-3959(94)90169-4; AUERBACH SM, 1976, J CONSULT CLIN PSYCH, V44, P809, DOI 10.1037/0022-006X.44.5.809; AUERBACH SM, 1983, J PERS SOC PSYCHOL, V44, P1284, DOI 10.1037/0022-3514.44.6.1284; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; Benotsch EG, 2000, ANN BEHAV MED, V22, P199, DOI 10.1007/BF02895114; Bodden-Heidrich R, 2000, J Pediatr Adolesc Gynecol, V13, P139, DOI 10.1016/S1083-3188(00)00056-5; Breme K, 2000, SCHMERZ, V14, P137, DOI 10.1007/s004820070039; DIXON WB, 1992, MDP STAT SOFTWARE MA; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GIL KM, 1992, CLIN J PAIN, V8, P215, DOI 10.1097/00002508-199209000-00005; Hiew C Y, 1995, Australas Radiol, V39, P128, DOI 10.1111/j.1440-1673.1995.tb00256.x; HORNE DJD, 1994, BEHAV MED, V20, P5; JACOX A, 1992, J PAIN SYMPTOM MANAG, V7, P229; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; JOHNSON DT, 1968, J CLIN PSYCHOL, V24, P20, DOI 10.1002/1097-4679(196801)24:1<20::AID-JCLP2270240105>3.0.CO;2-9; Jones A, 2002, SCAND J PSYCHOL, V43, P307, DOI 10.1111/1467-9450.00299; KIRK RE, 1995, EXPT DESIGN PROCEDUR; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Lang EV, 1998, J VASC INTERV RADIOL, V9, P407, DOI 10.1016/S1051-0443(98)70291-X; Lang EV, 2000, LANCET, V355, P1486, DOI 10.1016/S0140-6736(00)02162-0; LANG EV, 1999, SEMIN INTERVENT RAD, V16, P189; Martin ML, 2003, J VASC INTERV RADIOL, V14, P1119, DOI 10.1097/01.RVI.0000086536.86489.82; Nelson FV, 1998, J PAIN SYMPTOM MANAG, V15, P102, DOI 10.1016/S0885-3924(98)80007-9; Okun A, 1996, PSYCHOL REP, V79, P1059, DOI 10.2466/pr0.1996.79.3.1059; PATTERSON DR, 1992, J CONSULT CLIN PSYCH, V60, P713, DOI 10.1037/0022-006X.60.5.713; Rhudy JL, 2000, PAIN, V84, P65, DOI 10.1016/S0304-3959(99)00183-9; Riley TR, 2002, DIGEST DIS SCI, V47, P2151; Schelling G, 1996, J UROLOGY, V155, P43, DOI 10.1016/S0022-5347(01)66534-0; Spielberger C. D., 1983, STATE TRAIT ANXIETY; Spielberger C. D., 1970, STATE TRAIT ANXIETY; Spielberger CD, 1989, STATE TRAIT ANXIETY; SYRJALA KL, 1992, PAIN, V48, P137, DOI 10.1016/0304-3959(92)90049-H; WALDING MF, 1991, J ADV NURS, V16, P388, DOI 10.1111/j.1365-2648.1991.tb03427.x	34	53	56	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1051-0443	1535-7732		J VASC INTERV RADIOL	J. Vasc. Interv. Radiol.	DEC	2005	16	12					1585	1592		10.1097/01.RVI.0000185418.82287.72			8	Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease	Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology	997CE	WOS:000234221800004	16371522				2020-06-30	J	Ingman, K; Hagelberg, N; Aalto, S; Nagren, K; Juhakoski, A; Karhuvaara, S; Kallio, A; Oikonen, V; Hietala, J; Scheinin, H				Ingman, K; Hagelberg, N; Aalto, S; Nagren, K; Juhakoski, A; Karhuvaara, S; Kallio, A; Oikonen, V; Hietala, J; Scheinin, H			Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing	NEUROPSYCHOPHARMACOLOGY			English	Article						mu-opioid receptor; opioid antagonists; alcoholism; nalmefene	ALCOHOL DEPENDENCE; DOPAMINE-D-2 RECEPTORS; ORAL NALMEFENE; DOUBLE-BLIND; IN-VIVO; NALTREXONE; BINDING; DRUGS; PET; PHARMACOLOGY	The opioid antagonist nalmefene offers an alternative to traditional pharmacological treatments for alcoholism. The present study was designed to investigate the relationship between nalmefene plasma concentration and central mu-opioid receptor occupancy after a clinically effective dose ( 20 mg, orally). Pharmacokinetics and mu-opioid receptor occupancy of nalmefene after single and repeated dosing over 7 days was studied in 12 healthy subjects. Serial blood samples were obtained after both dosings, and pharmacokinetic parameters for nalmefene and main metabolites were determined. Central mu-opioid receptor occupancy of nalmefene was measured with positron emission tomography ( PET) and [C-11] carfentanil at four time points ( 3, 26, 50, 74 h) after both dosings. Nalmefene was rapidly absorbed in all subjects. The mean t(1/2) of nalmefene was 13.4 h after single and repeated dosing. The accumulation of nalmefene and its main metabolites in plasma during the repeated dosing period was as expected for a drug with linear pharmacokinetics, and steady-state was reached for all analytes. Both nalmefene dosings resulted in a very high occupancy at mu-opioid receptors (87 - 100%), and the decline in the occupancy was similar after both dosings but clearly slower than the decline in the plasma concentration of nalmefene or metabolites. High nalmefene occupancy (83 - 100%) persisted at 26 h after the dosings. The prolonged mu-opioid receptor occupancy by nalmefene indicates slow dissociation of the drug from mu-opioid receptors. These results support the rational of administering nalmefene when needed before alcohol drinking, and they additionally suggest that a high mu-opioid receptor occupancy can be maintained when nalmefene is taken once daily.	Turku Univ, Turku PET Ctr, FIN-20521 Turku, Finland; Turku Univ, CRST, FIN-20521 Turku, Finland; Turku Univ, Biotie Therapies Corp, FIN-20521 Turku, Finland; Turku Univ, Dept Pharmacol & Clin Pharmacol, FIN-20521 Turku, Finland; Turku Univ, Cent Hosp, Dept Anaesthesia & Intens Care, FIN-20521 Turku, Finland; Turku Univ, Dept Psychiat, FIN-20521 Turku, Finland	Scheinin, H (reprint author), Turku Univ, Turku PET Ctr, POB 52, FIN-20521 Turku, Finland.	harry.scheinin@utu.fi	Nagren, Kjell/AAE-7039-2019; Aalto, Sargo/K-1757-2013	Aalto, Sargo/0000-0002-8924-5447; Scheinin, Harry/0000-0002-1171-3511; Oikonen, Vesa/0000-0002-1947-0219			[Anonymous], 2000, JAMA, V284, P3043; Anton RF, 2004, J CLIN PSYCHOPHARM, V24, P421, DOI 10.1097/01.jcp.0000130555.63254.73; Balldin J, 2003, ALCOHOL CLIN EXP RES, V27, P1142, DOI 10.1097/01.ALC.0000075548.83053.A9; Bencherif B, 2004, BIOL PSYCHIAT, V55, P255, DOI 10.1016/j.biopsych.2003.07.007; Ciccocioppo R, 2002, NEUROPSYCHOPHARMACOL, V27, P391, DOI 10.1016/S0893-133X(02)00302-0; Cowen MS, 1999, PROG NEURO-PSYCHOPH, V23, P1171, DOI 10.1016/S0278-5846(99)00060-3; *CPMP ICH, 1995, CPMPICH13595; CULPEPPERMORGAN JA, 1995, LIFE SCI, V56, P1187, DOI 10.1016/0024-3205(95)00057-D; DEHAVENHUDKINS DL, 1990, PHARMACOL BIOCHEM BE, V37, P497, DOI 10.1016/0091-3057(90)90019-E; Dhawan BN, 1996, PHARMACOL REV, V48, P567; DIXON R, 1987, J CLIN PHARMACOL, V27, P233, DOI 10.1002/j.1552-4604.1987.tb02191.x; Drobes DJ, 2004, ALCOHOL CLIN EXP RES, V28, P1362, DOI 10.1097/01.ALC.0000139704.88862.01; EMMERSON PJ, 1994, J PHARMACOL EXP THER, V271, P1630; Endres CJ, 2003, NUCL MED BIOL, V30, P177, DOI 10.1016/S0969-8051(02)00411-0; GAL TJ, 1986, CLIN PHARMACOL THER, V40, P537, DOI 10.1038/clpt.1986.220; Gastpar M, 2002, J CLIN PSYCHOPHARM, V22, P592, DOI 10.1097/00004714-200212000-00009; Gianoulakis C, 2004, CURR TOP MED CHEM, V4, P39, DOI 10.2174/1568026043451573; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; Herz A, 1997, PSYCHOPHARMACOLOGY, V129, P99, DOI 10.1007/s002130050169; Hietala J, 1999, ANN MED, V31, P438, DOI 10.3109/07853899908998802; June HL, 1998, ALCOHOL CLIN EXP RES, V22, P2174, DOI 10.1111/j.1530-0277.1998.tb05931.x; June HL, 2004, NEUROPSYCHOPHARMACOL, V29, P285, DOI 10.1038/sj.npp.1300338; Kapur S, 2000, J PSYCHIATR NEUROSCI, V25, P161; Kim S, 1997, J NUCL MED, V38, P1726; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; Kranzler HR, 2000, NEUROPSYCHOPHARMACOL, V22, P493, DOI 10.1016/S0893-133X(99)00135-9; Krystal JH, 2001, NEW ENGL J MED, V345, P1734, DOI 10.1056/NEJMoa011127; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; Mason BJ, 1999, ARCH GEN PSYCHIAT, V56, P719, DOI 10.1001/archpsyc.56.8.719; MASON BJ, 1994, ALCOHOL CLIN EXP RES, V18, P1162, DOI 10.1111/j.1530-0277.1994.tb00098.x; Melichar JK, 2005, J PHARMACOL EXP THER, V312, P309, DOI 10.1124/jpet.104.072686; MEYER MC, 1984, J CLIN PSYCHIAT, V45, P15; O'Malley SS, 2003, ARCH INTERN MED, V163, P1695, DOI 10.1001/archinte.163.14.1695; O'Malley SS, 2000, J CLIN PSYCHOPHARM, V20, P69, DOI 10.1097/00004714-200002000-00012; OMALLEY SS, 1995, J CLIN PSYCHIAT, V56, P30; Oncken C, 2001, PSYCHOPHARMACOLOGY, V154, P397, DOI 10.1007/s002130000666; Oswald LM, 2004, PHYSIOL BEHAV, V81, P339, DOI 10.1016/j.physbeh.2004.02.008; Seeman P, 1999, AM J PSYCHIAT, V156, P876, DOI 10.1176/ajp.156.6.876; SINCLAIR JD, 1990, ANN MED, V22, P357, DOI 10.3109/07853899009147920; Slifstein M, 2001, NUCL MED BIOL, V28, P595, DOI 10.1016/S0969-8051(01)00214-1; SRISURAPANONT M, 2002, [No title captured], V2, P1867; STAHL KD, 1977, EUR J PHARMACOL, V46, P199, DOI 10.1016/0014-2999(77)90334-X; Subramanian G, 2000, J MED CHEM, V43, P381, DOI 10.1021/jm9903702; VOLPICELLI JR, 1995, AM J PSYCHIAT, V152, P613	44	59	66	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	DEC	2005	30	12					2245	2253		10.1038/sj.npp.1300790			9	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	985JF	WOS:000233372800014	15956985	Bronze			2020-06-30	J	Kim, JG; Sohn, SK; Kim, DH; Baek, JH; Chae, YS; Bae, NY; Kim, SY; Lee, KB				Kim, JG; Sohn, SK; Kim, DH; Baek, JH; Chae, YS; Bae, NY; Kim, SY; Lee, KB			Effectiveness of transdermal fentanyl patch for treatment of acute pain due to oral mucositis in patients receiving stem cell transplantation	TRANSPLANTATION PROCEEDINGS			English	Article							BONE-MARROW-TRANSPLANTATION; CONTROLLED ANALGESIA; CANCER PAIN; CHEMOTHERAPY; MANAGEMENT; MORPHINE	The current study was performed to evaluate the effectiveness and safety of transdermal therapeutic system (TTS) fentanyl in the management of acute pain due to oral mucositis in patients receiving stem cell transplantation. A cohort of consecutive patients with painful oral mucositis were enrolled. Initially, 25 mu g/h of TTS fentanyl was administered for the treatment of oral mucositis pain. The pain score, based on a visual analogue scale, and mood and quality of sleep as determined by EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire, Cancer 30), were all recorded before the treatment, then 2, 6, and 10 days later. Twenty-two patients with hematologic malignancies were enrolled. Three patients were excluded from the response assessment, as their TTS fentanyl treatment was stopped owing to related complaints, including severe dizziness, severe vomiting, and an extensive body rash. The total duration of the treatment was 8 days (range, 6-15 days) and the total amount of TTS fentanyl administered per patient was 2.21 at 25 mu g/h and 0.63 at 50 mu g/h. Six (31.6%) of the remaining 19 patients required an escalated dose of TTS fentanyl at 50 mu g/h. The mean pain scores before treatment and 2, 6, and 10 days later were 6.68, 5.17, 3.42, and 2.13, respectively (P < .001). Eight (42.1%) and seven (36.8%) patients experienced improved sleep and mood after treatment, respectively. The TTS fentanyl was effective in both relieving oral mucositis pain with an excellent tolerability and improving the quality of life for hematological patients receiving high-dose chemotherapy with stem cell transplantation.	Kyungpook Natl Univ Hosp, Dept Hematol Oncol, Taegu, South Korea	Sohn, SK (reprint author), Kyungpook Natl Univ Hosp, Dept Hematol Oncol, 50 Samduk 2 Ga, Taegu, South Korea.	sksohn@knu.ac.kr					BEARMAN SI, 1988, J CLIN ONCOL, V6, P1562, DOI 10.1200/JCO.1988.6.10.1562; Bellm LA, 2000, SUPPORT CARE CANCER, V8, P33; Coda BA, 1997, PAIN, V72, P333, DOI 10.1016/S0304-3959(97)00059-6; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Epstein JB, 1999, ORAL SURG ORAL MED O, V88, P273; FINE P, 1997, SEMIN ONCOL, V24, P1620; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Kostler WJ, 2001, CA-CANCER J CLIN, V51, P290, DOI 10.3322/canjclin.51.5.290; MACKIE AM, 1991, PAIN, V46, P265, DOI 10.1016/0304-3959(91)90109-B; Payne R, 1998, SEMIN ONCOL, V25, P47; Pillitteri LC, 1998, BONE MARROW TRANSPL, V22, P495, DOI 10.1038/sj.bmt.1701370; Stiff P, 2001, BONE MARROW TRANSPL, V27, pS3, DOI 10.1038/sj.bmt.1702863; Strupp C, 2000, ONCOL REP, V7, P659; Wardley AM, 2000, BRIT J HAEMATOL, V110, P292, DOI 10.1046/j.1365-2141.2000.02202.x; WOO SB, 1993, CANCER, V72, P1612, DOI 10.1002/1097-0142(19930901)72:5<1612::AID-CNCR2820720520>3.0.CO;2-Q; Zucker TP, 1998, PAIN, V75, P305, DOI 10.1016/S0304-3959(98)00009-8	16	15	18	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0041-1345	1873-2623		TRANSPL P	Transplant. Proc.	DEC	2005	37	10					4488	4491		10.1016/j.transproceed.2005.11.038			4	Immunology; Surgery; Transplantation	Immunology; Surgery; Transplantation	999TH	WOS:000234412900087	16387151				2020-06-30	J	Cichewicz, DL; Welch, SP; Smith, FL				Cichewicz, DL; Welch, SP; Smith, FL			Enhancement of transdermal fentanyl and buprenorphine antinociception by transdermal Delta(9)-tetrahydrocannabinol	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						fentanyl; buprenorphine; Delta(9)-THC; antinociception; transdermal; (guinea pig)	MORPHINE ANTINOCICEPTION; SYNERGISTIC INTERACTIONS; POSTOPERATIVE PAIN; MULTICENTER; DEPENDENCE; EFFICACY; OPIOIDS; CANCER; OPIATE; TRIAL	Previous studies have demonstrated that Delta(9)-tetrahydrocannabinol (THC) enhances the antinociceptive potency of many opioids administered by a variety of different routes of administration. We hypothesized that THC would enhance fentanyl or buprenorphine analgesia via the transdermal route of administration. THC was first demonstrated to enhance opioid antinociception when both drugs were administered parenterally in a hairless guinea pig model using the pin prick test. A low dose of THC (50 mg/kg, i.p.) produced no antinociception. However, THC enhanced the potency of s.c. fentanyl by 6.7-fold, and s.c. buprenorphine in a non-parallel fashion. For the transdermal studies, THC, fentanyl or buprenorphine was applied by pipette to the skin of the dorsum between the fore- and hind-flanks and covered with individual Tegederm (TM) patches. THC (400 mg/kg) produced no antinociception. However, THC enhanced fentanyl's potency by 3.7-fold at 2-h, and 5.8-fold at 4-h. Buprenophine's potency was increased 8.2-fold at 2-h and 7.2-fold at 4-h when co-administered with THC. These results indicate that the enhancement of transdermal opioids by THC could lead to the design of ail effective combination analgesic patch. (c) 2005 Elsevier B.V. All rights reserved.	Virginia Commonwealth Univ, Med Ctr, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Philip Morris Inc, Richmond, VA 23261 USA	Smith, FL (reprint author), Virginia Commonwealth Univ, Med Ctr, Dept Pharmacol & Toxicol, POB 980613, Richmond, VA 23298 USA.	flsmith1@vcu.edu	Jansen, Nils/G-1835-2011		NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA-07027, K02-DA-00186, DA-01647-29, DA-05274]		Allan L, 2001, BRIT MED J, V322, P1; BLIGHT AR, 1990, J COMP NEUROL, V296, P614, DOI 10.1002/cne.902960408; Bliss CL, 1967, STAT BIOL, P439; BOAS RA, 1985, BRIT J ANAESTH, V57, P192, DOI 10.1093/bja/57.2.192; CAPLAN RA, 1990, ADV PAIN RES THER, V14, P233; Cichewicz DL, 1999, J PHARMACOL EXP THER, V289, P859; Cichewicz DL, 2004, LIFE SCI, V74, P1317, DOI 10.1016/j.lfs.2003.09.038; Cichewicz DL, 2003, J PHARMACOL EXP THER, V304, P1010, DOI 10.1124/jpet.102.045575; Colquhoun D., 1971, LECT BIOSTATISTICS I, P327; DECASTRO J, 1991, REGIONAL OPIOID ANAL, P131; DONNER B, 1995, ANTI-CANCER DRUG, V6, P39, DOI 10.1097/00001813-199504003-00007; Evans HC, 2003, DRUGS, V63, P1999, DOI 10.2165/00003495-200363190-00003; Gilberto DB, 2003, CONTEMP TOP LAB ANIM, V42, P21; GOURLAY GK, 1989, PAIN, V37, P193, DOI 10.1016/0304-3959(89)90130-9; Hains BC, 2000, EXP NEUROL, V164, P426, DOI 10.1006/exnr.2000.7439; Hayes BB, 2000, TOXICOL SCI, V56, P262, DOI 10.1093/toxsci/56.2.262; HEEL RC, 1979, DRUGS, V17, P81, DOI 10.2165/00003495-197917020-00001; Khodorova AB, 2000, ANESTH ANALG, V91, P410, DOI 10.1097/00000539-200008000-00034; Kramer S, 1996, VET REC, V138, P128, DOI 10.1136/vr.138.6.128; LEANDER JD, 1988, EUR J PHARMACOL, V151, P457, DOI 10.1016/0014-2999(88)90543-2; Ling W, 1998, ADDICTION, V93, P475, DOI 10.1046/j.1360-0443.1998.9344753.x; Litten RZ, 1999, J SUBST ABUSE TREAT, V16, P105, DOI 10.1016/S0740-5472(98)00028-2; Mason DJ, 1999, EUR J PHARMACOL, V378, P237, DOI 10.1016/S0014-2999(99)00479-3; MELLO NK, 1993, HARVARD REV PSYCHIAT, V1, P168, DOI 10.3109/10673229309017075; MIYAUCHI H, 1992, Journal of Dermatology (Tokyo), V19, P140; MORROW TJ, 1983, SOMATOSENS RES, V1, P151, DOI 10.3109/07367228309144546; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; Sittl R, 2003, CLIN THER, V25, P150, DOI 10.1016/S0149-2918(03)90019-1; Smith FL, 1998, PHARMACOL BIOCHEM BE, V60, P559, DOI 10.1016/S0091-3057(98)00012-4; STINCHCOMB AL, 1995, PHARMACEUT RES, V12, P1526, DOI 10.1023/A:1016299824162; Valverde O, 2001, EUR J NEUROSCI, V13, P1816, DOI 10.1046/j.0953-816x.2001.01558.x; Welch SP, 1999, BRAIN RES, V848, P183, DOI 10.1016/S0006-8993(99)01908-3; Yesilyurt O, 2003, PAIN, V105, P303, DOI 10.1016/S0304-3959(03)00245-8	33	21	21	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	NOV 21	2005	525	1-3					74	82		10.1016/j.ejphar.2005.09.039			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	989YZ	WOS:000233711400011	16288738				2020-06-30	J	Allan, L; Richarz, U; Simpson, K; Slappendel, R				Allan, L; Richarz, U; Simpson, K; Slappendel, R			Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain	SPINE			English	Article						opioid analgesics; low back pain; fentanyl; morphine	CHRONIC NONCANCER PAIN; CANCER-PATIENTS; MANAGEMENT; THERAPY; ANALGESIA; TRIAL; TERM	Study Design. Open, randomized, parallel group multicenter study. Objectives. To compare the efficacy and safety of transdermal fentanyl (TDF) and sustained release morphine (SRM) in strong-opioid naive patients with chronic low back pain (CLBP). Summary of Background Data. Most studies of TDF and SRM have involved patients already receiving strong opioids. This is the first large-scale study focusing on strong-opioid naive patients with CLBP. Methods. Adults with CLBP requiring regular strong opioid therapy received either TDF or SRM for 13 months. Starting doses were 25 mu g/hr fentanyl patches every 72 hours or 30 mg oral morphine every 12 hours. Doses were adjusted according to response. Participants assessed pain relief and bowel function using weekly diaries. Other assessments, including quality of life, disease progression, and side effects, were made by patients and investigators. Results. Data from 680 patients showed that TDF and SRM provided similar levels of pain relief, but TDF was associated with significantly less constipation than SRM, indicating a greater likelihood of satisfactory pain relief without unmanageable constipation for patients receiving TDF. Other ratings were similar for TDF and SRM, but TDF provided greater relief of pain at rest and at night. Conclusions. TDF and SRM provided equivalent levels of pain relief, but TDF was associated with less constipation. This study indicates that sustained-release strong opioids can safely be used in strong-opioid naive patients.	Northwick Pk & St Marks NHS Trust, Harrow HA1 3UJ, Middx, England; Janssen Cilag, Baar, Switzerland; St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England; Sint Maartensklin, Nijmegen, Netherlands	Allan, L (reprint author), Northwick Pk & St Marks NHS Trust, Harrow HA1 3UJ, Middx, England.	laurie.allan@datacam.net					AHMEDZAI S, 1994, J DRUG DEV, V6, P93; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Bowman J M, 1991, AAOHN J, V39, P381; Brown R L, 1996, J Am Board Fam Pract, V9, P191; Brussen J, 1996, BRIT MED J, V313, P1262, DOI 10.1136/bmj.313.7067.1262b; CHERKIN DC, 1995, SPINE, V20, P1, DOI 10.1097/00007632-199501000-00001; Chou R, 2003, J PAIN SYMPTOM MANAG, V26, P1026, DOI 10.1016/j.jpainsymman.2003.03.003; Deyo RA, 1998, SPINE, V23, P2003, DOI 10.1097/00007632-199809150-00018; Eriksen J, 2003, PAIN, V106, P221, DOI 10.1016/S0304-3959(03)00225-2; FORDYCE WE, 1986, J BEHAV MED, V9, P127, DOI 10.1007/BF00848473; Franco ML, 2002, PAIN CLINIC, V14, P99, DOI 10.1163/156856902760196315; Gatchel RJ, 2003, J OCCUP REHABIL, V13, P1, DOI 10.1023/A:1021823505774; Gatchel RJ, 1995, SPINE, V20, P2702, DOI 10.1097/00007632-199512150-00011; HANKS GW, 1982, LANCET, V1, P1410; Jamison RN, 1998, SPINE, V23, P2591, DOI 10.1097/00007632-199812010-00014; Kalso E, 2003, EUR J PAIN, V7, P381, DOI 10.1016/S1090-3801(02)00143-X; KOES BW, 1992, SPINE, V17, P28, DOI 10.1097/00007632-199201000-00005; Korte W, 1996, J PAIN SYMPTOM MANAG, V11, P139, DOI 10.1016/0885-3924(95)00162-X; Linton SJ, 1998, PAIN, V75, P163; LINTON SJ, 2000, SPINE, V25, P2831; McQuay H, 1999, LANCET, V353, P2229, DOI 10.1016/S0140-6736(99)03528-X; McQuay H, 2003, PAIN, V106, P213, DOI 10.1016/j.pain.2003.08.012; MJYSTAKIDOU K, 2000, ANTICANCER RES, V21, P2225; Rashiq S, 2003, PAIN, V106, P119, DOI 10.1016/S0304-3959(03)00299-9; Talbot L, 2003, BRIT MED J, V327, P985, DOI 10.1136/bmj.327.7421.985; TAYLOR VM, 1994, SPINE, V19, P1207, DOI 10.1097/00007632-199405310-00002; Todd KH, 1996, ACAD EMERG MED, V3, P142, DOI 10.1111/j.1553-2712.1996.tb03402.x; VAINIO A, 1995, LANCET, V346, P667, DOI 10.1016/S0140-6736(95)92281-4; van Tulder M. W., 2003, COCHRANE LIB; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	30	106	115	2	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0362-2436			SPINE	SPINE	NOV 15	2005	30	22					2484	2490		10.1097/01.brs.0000186860.23078.a8			7	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	985PF	WOS:000233389600002	16284584				2020-06-30	J	Lee, YY; Kee, WDN; Muchhal, K; Chan, CK				Lee, YY; Kee, WDN; Muchhal, K; Chan, CK			Randomized double-blind comparison of ropivacaine-fentanyl and bupivacaine-fentanyl for spinal anaesthesia for urological surgery	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						bupivacaine; motor block; ropivacaine; spinal anaesthesia	CESAREAN DELIVERY; INTRATHECAL ROPIVACAINE; HYPERBARIC ROPIVACAINE; PLAIN SOLUTIONS; 15 MG; ANALGESIA; LABOR; POTENCIES; NERVE	Backround: Early studies have suggested that ropivacaine causes less motor block than bupivacaine, which might be advantageous in spinal anaesthesia for short procedures. The aim of this study was to compare plain ropivacaine 10 mg and plain bupivacaine 10 mg, both with fentanyl 15 mu g, for spinal anaesthesia in urological surgery. Methods: This was a prospective randomized double-blind study. After written informed consent had been obtained, 34 ASA I-III patients scheduled for urological surgery were randomly assigned to receive intrathecal injection of either plain ropivacaine 10 mg with fentanyl 15 mu g (ropivacaine group) or plain bupivacaine 10 mg with fentanyl 15 mu g (bupivacaine group) using a combined spinal-epidural technique. Results: All patients achieved sensory block to the T10 dermatome or higher at 15 min after intrathecal injection. One patient in the ropivacaine group was excluded because of unexpectedly prolonged surgery. The primary outcome, the duration of motor block, was shorter in the ropivacaine group (median, 126 min; interquartile range, 93-162 min) compared with the bupivacaine group (median, 189 min; interquartile range, 157-234 min; difference between medians, 71 min; 95% confidence interval, 28-109 min; P = 0.003). The duration of complete motor block was also shorter in the ropivacaine group compared with the bupivacaine group. There was no difference in the onset time of motor block. The characteristics of sensory block and the haemodynamic changes were similar between the groups. Conclusions: Plain ropivacaine 10 mg plus fentanyl 15 mu g provided similar sensory anaesthesia, but with a shorter duration of motor block, compared with plain bupivacaine 10 mg plus fentanyl 15 mu g when used for spinal anaesthesia in urological surgery.	Kwong Wah Hosp, Dept Anaesthesiol & Operating Theatre Serv, Kowloon, Hong Kong, Peoples R China	Lee, YY (reprint author), Kwong Wah Hosp, Dept Anaesthesiol & Operating Theatre Serv, Waterloo Rd, Kowloon, Hong Kong, Peoples R China.	yylee@ha.org.hk	Ngan Kee, Warwick/J-8817-2013	Ngan Kee, Warwick/0000-0003-1000-7735			BADER AM, 1989, ANESTH ANALG, V68, P724; Ben-David B, 2000, ANESTHESIOLOGY, V92, P6, DOI 10.1097/00000542-200001000-00007; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; BROMAGE PR, 1965, ACTA ANAESTH SCAND, VS, P55; Camorcia M, 2005, ANESTHESIOLOGY, V102, P646, DOI 10.1097/00000542-200503000-00025; Capogna G, 1999, BRIT J ANAESTH, V82, P371, DOI 10.1093/bja/82.3.371; Danelli G, 2004, REGION ANESTH PAIN M, V29, P221, DOI 10.1016/j.rapm.2004.02.003; FELDMAN HS, 1988, ANESTH ANALG, V67, P1047, DOI 10.1213/00000539-198867110-00005; Fettes PDW, 2005, BRIT J ANAESTH, V94, P107, DOI 10.1093/bja/aei008; Gaiser RR, 2000, J CLIN ANESTH, V12, P476, DOI 10.1016/S0952-8180(00)00186-0; Ganapathy S, 2000, ANESTHESIOLOGY, V93, P1537, DOI 10.1097/00000542-200012000-00031; Gautier PE, 1999, ANESTHESIOLOGY, V91, P1239, DOI 10.1097/00000542-199911000-00013; Kallio H, 2005, REGION ANESTH PAIN M, V30, P48, DOI 10.1016/j.rapm.2004.11.002; Kallio H, 2004, BRIT J ANAESTH, V93, P664, DOI 10.1093/bja/aeh257; Kallio H, 2004, ANESTH ANALG, V99, P713, DOI 10.1213/01.ANE.0000129976.26455.32; Khaw KS, 2002, ANESTH ANALG, V94, P680, DOI 10.1097/00000539-200203000-00037; Khaw KS, 2001, ANESTHESIOLOGY, V95, P1346, DOI 10.1097/00000542-200112000-00011; Malinovsky JM, 2000, ANESTH ANALG, V91, P1457, DOI 10.1097/00000539-200012000-00030; McDonald SB, 1999, ANESTHESIOLOGY, V90, P971, DOI 10.1097/00000542-199904000-00007; McNab W, 2001, SOIL SEDIMENT CONTAM, V10, P1, DOI 10.1080/20015891109167; McNamee DA, 2002, BRIT J ANAESTH, V89, P702, DOI 10.1093/bja/aef259; Ogun CO, 2003, BRIT J ANAESTH, V90, P659, DOI 10.1093/bja/aeg123; Polley LS, 1999, ANESTHESIOLOGY, V90, P944, DOI 10.1097/00000542-199904000-00003; Wahedi W, 1996, ANAESTHESIST, V45, P737, DOI 10.1007/s001010050306; WILDSMITH JAW, 1989, BRIT J ANAESTH, V63, P444, DOI 10.1093/bja/63.4.444; Yegin A, 2005, ACTA ANAESTH SCAND, V49, P401, DOI 10.1111/j.1399-6576.2005.00607.x	26	16	20	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	NOV	2005	49	10					1477	1482		10.1111/j.1399-6576.2005.00864.x			6	Anesthesiology	Anesthesiology	973YC	WOS:000232557500012	16223393				2020-06-30	J	Ozalevli, M; Cetin, TO; Unlugenc, H; Guler, T; Isik, G				Ozalevli, M; Cetin, TO; Unlugenc, H; Guler, T; Isik, G			The effect of adding intrathecal magnesium sulphate to bupivacaine-fentanyl spinal anaesthesia	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						analgesic; bupivacaine; fentanyl; inorganic chemicals; local anaesthetics; magnesium sulphate; opioids; spinal anaesthesia	RESPIRATORY DEPRESSION; ANALGESIA; MORPHINE; KETAMINE; OPIOIDS; PAIN	Background: The addition of intrathecal (IT) magnesium to spinal fentanyl prolongs the duration of spinal analgesia for vaginal delivery. In this prospective, randomized, double-blind, controlled study, we investigated the effect of adding IT magnesium sulphate to bupivacaine-fentanyl spinal anaesthesia. Methods: One hundred and two ASA I or II adult patients undergoing lower extremity surgery were recruited. They were randomly allocated to receive 1.0 ml of preservative-free 0.9% sodium chloride (group S) or 50 mg of magnesium sulphate 5% (1.0 ml) (group M) following 10 mg of bupivacaine 0.5% plus 25 mu g of fentanyl intrathecally. We recorded the following: onset and duration of sensory block, the highest level of sensory block, the time to reach the highest dermatomal level of sensory block and to complete motor block recovery and the duration of spinal anaesthesia. Results: Magnesium caused a delay in the onset of both sensory and motor blockade. The highest level of sensory block was significantly lower in group M than in group S at 5, 10 and 15 min (P < 0.001). The median time to reach the highest dermatomal level of sensory block was 17 min in group M and 13 min in group S (P < 0.05). The mean degree of motor block was also lower in group M at 5, 10 and 15 min (P < 0.001). The median duration of spinal anaesthesia was longer in group M (P < 0.001). Conclusions: In patients undergoing lower extremity surgery, the addition of IT magnesium sulphate (50 mg) to spinal anaesthesia induced by bupivacaine and fentanyl significantly delayed the onset of both sensory and motor blockade, but also prolonged the period of anaesthesia without additional side-effects.	Cukurova Univ, Fac Med, Dept Anaesthesiol, TR-01330 Adana, Turkey	Ozalevli, M (reprint author), Cukurova Univ, Fac Med, Dept Anaesthesiol, TR-01330 Adana, Turkey.	ozalevli@cu.edu.tr	Unlugenc, Hakki/W-9586-2018	Unlugenc, Hakki/0000-0003-0164-8258			ASCHER P, 1987, TRENDS NEUROSCI, V10, P284, DOI 10.1016/0166-2236(87)90174-3; ASHBURN MA, 1994, CLIN J PAIN, V10, P52, DOI 10.1097/00002508-199403000-00007; BROCKWAY MS, 1990, BRIT J ANAESTH, V64, P243, DOI 10.1093/bja/64.2.243; Buvanendran A, 2002, ANESTH ANALG, V95, P661, DOI 10.1097/00000539-200209000-00031; CAMPORA E, 1991, J PAIN SYMPTOM MANAG, V6, P428, DOI 10.1016/0885-3924(91)90041-2; Dickenson AH, 1997, ACTA ANAESTH SCAND, V41, P112, DOI 10.1111/j.1399-6576.1997.tb04624.x; ETCHES RC, 1989, CAN J ANAESTH, V36, P165, DOI 10.1007/BF03011441; Hawksworth C, 1998, REGION ANESTH PAIN M, V23, P283, DOI 10.1016/S1098-7339(98)90056-6; Ko SH, 2001, ANESTHESIOLOGY, V95, P640, DOI 10.1097/00000542-200109000-00016; Kroin JS, 2000, ANESTH ANALG, V90, P913, DOI 10.1213/00000539-200004000-00025; LEJUSTE MJLR, 1985, S AFR MED J, V68, P367; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; SIMPSON JI, 1994, ANESTHESIOLOGY, V81, P1493, DOI 10.1097/00000542-199412000-00025; Togal T, 2004, EUR J ANAESTH, V21, P193, DOI 10.1017/S0265021504003059; Tramer MR, 1996, ANESTHESIOLOGY, V84, P340, DOI 10.1097/00000542-199602000-00011; VARASSI G, 1992, ANESTHESIA, V47, P558; Wilder-Smith OHG, 1998, ANESTH ANALG, V86, P95, DOI 10.1097/00000539-199801000-00019; Witlin AG, 1998, OBSTET GYNECOL, V92, P883, DOI 10.1016/S0029-7844(98)00277-4; XIAO WH, 1994, BRAIN RES, V666, P168, DOI 10.1016/0006-8993(94)90768-4; YAMAMOTO T, 1992, NEUROSCI LETT, V135, P67, DOI 10.1016/0304-3940(92)90137-V	20	66	69	0	3	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	NOV	2005	49	10					1514	1519		10.1111/j.1399-6576.2005.00793.x			6	Anesthesiology	Anesthesiology	973YC	WOS:000232557500018	16223399				2020-06-30	J	Taylor, S; Kirton, OC; Staff, I; Kozol, RA				Taylor, S; Kirton, OC; Staff, I; Kozol, RA			Postoperative day one: a high risk period, for respiratory events	AMERICAN JOURNAL OF SURGERY			English	Article; Proceedings Paper	29th Annual Surgical Symposium of the Association-of-VA-Surgeons	MAR 11-13, 2005	Salt Lake City, UT			postoperative; respiratory depression; narcotics; complications	SLEEP-APNEA SYNDROME; PAIN MANAGEMENT; EPIDURAL ANALGESIA; BUPIVACAINE; PATIENT; OPIOIDS; RELIEF; MORPHINE; FENTANYL	Background: In 2001, the Joint Commission on Accreditation of Healthcare Organizations released Pain Management Standards that has led to an increased focus on pain control. Since then the Institute for Safe Medication Practices has noted that overaggressive pain management has led to increases in oversedation and fatal respiratory depression. One of our previous studies found that postoperative patients may be reaching dangerously high levels of sedation as a result of pain management. Our hypothesis is that postoperative patients who have a respiratory event caused by analgesic use are more likely to have that event in the first postoperative day. Methods: We performed a retrospective case-control analysis identifying 62 postoperative patients who had a respiratory event. A respiratory event was defined as respiratory depression caused by narcotic use in the postoperative period that was reversed by naloxone. Sixty-two postoperative patients with no such event were chosen randomly and frequency matched based on surgical procedure and diagnosis-related group. Risk factors for an event were identified. Results: Of the cases, 77.4% had a respiratory event in the first 24 hours postoperatively. Significant risk factors for an event were as follows: 65 years of age or older, having chronic obstructive pulmonary disease, having 1 or more comorbidities, and being placed on hydromorphone. Conclusions: The first 24 hours after surgery represents a high-risk period for a respiratory event as a result of narcotic use. The realization of this risk can lead to the implementation of standards to increase patient safety in the first postoperative day. (c) 2005 Excerpta Medica Inc. All rights reserved.	Univ Connecticut, Sch Med, Dept Surg, Farmington, CT 06030 USA; Hartford Hosp, Dept Surg, Hartford, CT 06115 USA; Hartford Hosp, Res Program, Hartford, CT 06115 USA	Kozol, RA (reprint author), Univ Connecticut, Sch Med, Dept Surg, 263 Farmington Ave, Farmington, CT 06030 USA.	kozol@nso.uchc.edu					Austrup ML, 1999, SURG CLIN N AM, V79, P253, DOI 10.1016/S0039-6109(05)70382-0; Cashman JN, 2004, BRIT J ANAESTH, V93, P212, DOI 10.1093/bja/aeh180; De Kock M, 1991, Acta Anaesthesiol Belg, V42, P85; Etches RC, 1999, SURG CLIN N AM, V79, P297, DOI 10.1016/S0039-6109(05)70384-4; Fillingim RB, 2004, EUR J PAIN, V8, P413, DOI 10.1016/j.ejpain.2004.01.007; Flisberg P, 2003, ACTA ANAESTH SCAND, V47, P457, DOI 10.1034/j.1399-6576.2003.00104.x; Flisberg P, 2002, J CLIN ANESTH, V14, P129, DOI 10.1016/S0952-8180(01)00369-5; Gold MS, 1997, J CARDIOTHOR VASC AN, V11, P137, DOI 10.1016/S1053-0770(97)90202-0; Gordon Debra B, 2004, Pain Manag Nurs, V5, P53, DOI 10.1016/j.pmn.2004.04.001; Huang N, 2001, AM J SURG, V182, P440, DOI 10.1016/S0002-9610(01)00766-8; *I SAF MED PRACT, 2002, MED SAF AL PAIN SCAL; LAMARCHE Y, 1986, CAN J ANAESTH, V33, P231, DOI 10.1007/BF03010837; Li JMW, 2002, MED CLIN N AM, V86, P771, DOI 10.1016/S0025-7125(02)00025-1; Liu SS, 1998, ANESTHESIOLOGY, V88, P688, DOI 10.1097/00000542-199803000-00020; LOGAS WG, 1987, ANESTHESIOLOGY, V67, P787, DOI 10.1097/00000542-198711000-00026; Lynch M, 2001, J Intraven Nurs, V24, P85; Ostermeier AM, 1997, ANESTH ANALG, V85, P452, DOI 10.1097/00000539-199708000-00037; Parikh SN, 2002, J ARTHROPLASTY, V17, P635, DOI 10.1054/arth.2002.32701; Phillips DM, 2000, JAMA-J AM MED ASSOC, V284, P428, DOI 10.1001/jama.284.4.428; Quaranta AJ, 1997, CHEST, V111, P467, DOI 10.1378/chest.111.2.467; Ravenscroft P, 2000, CLIN EXP PHARMACOL P, V27, P529, DOI 10.1046/j.1440-1681.2000.03293.x; SCOTT DA, 1995, ANESTHESIOLOGY, V83, P727, DOI 10.1097/00000542-199510000-00012; Swarm RA, 2001, CURR PROB SURG, V38, P845, DOI 10.1067/msg.20011.118495; Taylor S, 2003, AM J SURG, V186, P472, DOI 10.1016/j.amjsurg.2003.07.021; WHIPPLE JK, 1994, ANN PHARMACOTHER, V28, P655, DOI 10.1177/106002809402800517	25	105	108	1	6	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	NOV	2005	190	5					752	756		10.1016/j.amjsurg.2005.07.015			5	Surgery	Surgery	979II	WOS:000232935200018	16226953				2020-06-30	J	Rundshagen, I; Schroder, T; Heinze, J; Prichep, L; John, ER; Kox, WJ				Rundshagen, I; Schroder, T; Heinze, J; Prichep, L; John, ER; Kox, WJ			Topographic electroencephalography: Endotracheal intubation during anaesthesia with propofol/fentanyl	ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE			German	Article							BISPECTRAL INDEX; TRACHEAL INTUBATION; ELECTRICAL-ACTIVITY; PROPOFOL; AWARENESS; LARYNGOSCOPY; SUPPRESSION; INDUCTION	Objective: We used quantitative analysis of the electroencephalogram (EEG) during routine clinical practice to assess the effect of tracheal intubation following induction of anesthesia with propofol and fentanyl. Methods: The topographic EEG was recorded from eight bipolar electrode derivations in 25 patients. Z-scores relative to age expected normative data were computed for relative power in the delta, theta, alpha and beta frequency bands. Multivariate statistics (Hotellings' t-sqare) were used to evaluate changes in regional brain electrical activity. Results: Tracheal intubation induced an increase in alpha and beta frequencies, while delta power was reduced (F-values: Delta: 7.68, p = 0.011; Alpha 31.93; p < 0.001; Beta 12.85, p = 0.001). The most pronounced regional effect was seen for the alpha frequency band with the largest increase in both fronto-temporal regions (F-value 33.89, p < 0.001). During clinical practice the patients received propofol 2.7 ( 1.2; minimum: 0.5, maximum 6.9) mg kg(-1) and fentanyl 2 (1; minimum 1, maximum 4) pg kg(-1). Vital parameters did not change during intubation. Conclusion: Individual titration of the dose of propofol and fentanyl as done during routine clinical practice is not sufficient to block the strong noxious stimulation of intubation. Tracheal intubation resulted in "classical" cortical arousal. it remains open whether this cortical wake-up phenomenon has a clinical impact.	Charite Univ Med Berlin, Klin Anasthesiol & Operat Intens Med, D-10117 Berlin, Germany; NYU, Sch Med, Dept Psychiat, Brain Res Labs, New York, NY 10016 USA; Univ Klinikum Munster, Munster, Germany	Rundshagen, I (reprint author), Charite Univ Med Berlin, Klin Anasthesiol & Operat Intens Med, Campus Mitte,Schumannstr 20-21, D-10117 Berlin, Germany.	ingrid.rundshagen@charite.de					Bischoff P, 2000, ANESTHESIOLOGY, V92, P1545, DOI 10.1097/00000542-200006000-00010; Bouillon TW, 2004, ANESTHESIOLOGY, V100, P1353, DOI 10.1097/00000542-200406000-00006; Gugino LA, 2001, BRIT J ANAESTH, V87, P421, DOI 10.1093/bja/87.3.421; John E.R., 1987, HDB ELECTROENCEPHALO, P449; Johnson BW, 2003, ANAESTH INTENS CARE, V31, P155, DOI 10.1177/0310057X0303100203; Kalkman CJ, 2002, ANESTHESIOLOGY, V96, P784, DOI 10.1097/00000542-200204000-00003; Kishimoto T, 1995, CLIN PHARMACOL THER, V58, P666, DOI 10.1016/0009-9236(95)90023-3; KOCHS E, 1994, ANESTHESIOLOGY, V80, P1026, DOI 10.1097/00000542-199405000-00012; Menigaux C, 2002, BRIT J ANAESTH, V89, P857, DOI 10.1093/bja/aef275; Mustola ST, 2003, ANESTH ANALG, V97, P1040, DOI 10.1213/01.ANE.0000080156.05749.17; Myles PS, 2004, LANCET, V363, P1757, DOI 10.1016/S0140-6736(04)16300-9; Raymondos K, 2003, EUR J ANAESTH, V20, P44, DOI 10.1097/00003643-200301000-00008; Rundshagen I, 2004, BRIT J ANAESTH, V92, P33, DOI 10.1093/bja/aeh020; Sandin RH, 2000, LANCET, V355, P707, DOI 10.1016/S0140-6736(99)11010-9; Schmidt GN, 2004, ANESTH ANALG, V98, P1346, DOI 10.1213/01.ANE.0000111209.44119.30; Schmidt N, 2004, ANASTH INTENSIV NOTF, V39, P33; Schneider G, 2004, ANESTHESIOLOGY, V101, P1105, DOI 10.1097/00000542-200411000-00009; Schneider G, 2002, J NEUROSURG ANESTH, V14, P7, DOI 10.1097/00008506-200201000-00002; WILDERSMITH OHG, 1995, BRIT J ANAESTH, V75, P441, DOI 10.1093/bja/75.4.441; WILHELM W, 2005, UBERWACHUNG NARKOSET	20	1	1	0	1	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0939-2661	1439-1074		ANASTH INTENSIV NOTF	Anasthesiol. Intensivmed. NotfMed. Schmerzther.	NOV	2005	40	11					633	639		10.1055/s-2005-870464			9	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	986XQ	WOS:000233483400002	16287023				2020-06-30	J	Chung, F; Kayumov, L; Sinclair, DR; Edward, R; Moller, HJ; Shapiro, CM				Chung, F; Kayumov, L; Sinclair, DR; Edward, R; Moller, HJ; Shapiro, CM			What is the driving performance of ambulatory surgical patients after general anesthesia?	ANESTHESIOLOGY			English	Article							EPWORTH SLEEPINESS SCALE; PROLONGED WAKEFULNESS; PSYCHOMOTOR-SKILLS; HOME-READINESS; RECOVERY; ALCOHOL; IMPAIRMENT; ANAESTHESIA; DIAZEPAM; FATIGUE	Background: Ambulatory surgical patients are advised to refrain from driving for 24 h postoperatively. However, currently there is no strong evidence to show that driving skills and alertness have resumed in patients by 24 h after general anesthesia. The purpose of this study was to determine whether impaired driver alertness had been restored to normal by 2 and 24 h after general anesthesia in patients who underwent ambulatory surgery. Methods: Twenty patients who underwent left knee arthroscopic surgery were studied. Their driving simulation performance, electroencephalographically verified parameters of sleepiness, subjective assessment of sleepiness, fatigue, alertness, and pain were measured preoperatively and 2 and 24 h postoperatively. The same measurements were performed in a matched control group of 20 healthy individuals. Results: Preoperatively, patients had significantly higher attention lapses and lower alertness levels versus normal controls. Significantly impaired driving skills and alertness, including longer reaction time, higher occurrence of attention lapses, and microsleep intrusions, were found 2 h postoperatively versus preoperatively. No significantly differences were found in any driving performance parameters or electroencephalographically verified parameters 24 h postoperatively versus preoperatively. Conclusions: Patients showed lower alertness levels and impaired driving skills preoperatively and 2 h postoperatively. Based on driving simulation performance and subjective assessments, patients are safe to drive 24 h after general anesthesia.	Univ Toronto, Dept Anesthesia, Toronto Western Hosp, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Psychiat, Toronto Western Hosp, Toronto, ON M5T 2S8, Canada; Miami Univ, Jackson Mem Hosp, Dept Anesthesiol, Miami, FL USA	Chung, F (reprint author), Univ Toronto, Dept Anesthesia, Toronto Western Hosp, 2-046,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	frances.chung@uhn.on.ca	Chung, Frances/F-5618-2015; Stevens, David/F-4683-2015	Chung, Frances/0000-0001-9576-3606; Stevens, David/0000-0002-8412-2202			Arnedt JT, 2001, ACCIDENT ANAL PREV, V33, P337, DOI 10.1016/S0001-4575(00)00047-6; Arnedt JT, 2000, J SLEEP RES, V9, P233; Banks S, 2004, SLEEP, V27, P1063, DOI 10.1093/sleep/27.6.1063; Chatoo K, 2004, SLEEP, V27, P351; Chervin RD, 1997, J PSYCHOSOM RES, V42, P145, DOI 10.1016/S0022-3999(96)00239-5; CHUNG F, 1995, J CLIN ANESTH, V7, P500, DOI 10.1016/0952-8180(95)00130-A; CHUNG F, 1995, ANESTH ANALG, V80, P896, DOI 10.1097/00000539-199505000-00008; Dawson D, 1997, NATURE, V388, P235, DOI 10.1038/40775; HANNINGTONKIFF JG, 1970, BMJ-BRIT MED J, V3, P132, DOI 10.1136/bmj.3.5715.132; HAWKS RL, 1985, JAMA-J AM MED ASSOC, V254, P2618; Horne JA, 2004, PSYCHOPHYSIOLOGY, V41, P161, DOI 10.1046/j.1469-8986.2003.00130.x; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; KAYUMOV L, 2004, SLEEP, V27, pA68; KORTTILA K, 1975, ANESTHESIOLOGY, V43, P291, DOI 10.1097/00000542-197509000-00003; KORTTILA K, 1975, BRIT J ANAESTH, V47, P457, DOI 10.1093/bja/47.4.457; KORTTILA K, 1975, ANESTHESIOLOGY, V42, P685, DOI 10.1097/00000542-197506000-00010; KORTTILA K, 1977, ANESTHESIOLOGY, V46, P20, DOI 10.1097/00000542-197701000-00006; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Moller HJ, 2004, SLEEP, V27, P351; NEWMAN MG, 1969, ANESTH ANAL CURR RES, V48, P136, DOI 10.1213/00000539-196948010-00028; RAU PS, 98S2P30 NAT HIGHW TR; Sinclair DR, 2003, CAN J ANAESTH, V50, P238, DOI 10.1007/BF03017791; Sjogren P, 2000, PAIN, V86, P237, DOI 10.1016/S0304-3959(00)00248-7; Van Dongen HPA, 2003, SLEEP, V26, P117, DOI 10.1093/sleep/26.2.117; VICKERS MD, 1965, BRIT J ANAESTH, V37, P296, DOI 10.1093/bja/37.5.296	25	24	25	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	NOV	2005	103	5					951	956		10.1097/00000542-200511000-00008			6	Anesthesiology	Anesthesiology	980LP	WOS:000233020300007	16249668				2020-06-30	J	Coon, TP; Miller, M; Kaylor, D; Jones-Spangle, K				Coon, TP; Miller, M; Kaylor, D; Jones-Spangle, K			Rectal insertion of fentanyl patches: A new route of toxicity	ANNALS OF EMERGENCY MEDICINE			English	Letter									Darnall Army Community Hosp, Ft Hood, TX 76544 USA	Coon, TP (reprint author), Darnall Army Community Hosp, Ft Hood, TX 76544 USA.						Ashburn MA, 2003, J PAIN, V4, P291, DOI 10.1016/S1526-5900(03)00618-7; Barrueto F, 2004, VET HUM TOXICOL, V46, P30; Edinboro LE, 1997, J FORENSIC SCI, V42, P741; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; *MYL TECHN, 2005, DRUG FORMULARY REV, V21, P24	5	26	27	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	NOV	2005	46	5					473	473		10.1016/j.annemergmed.2005.06.450			1	Emergency Medicine	Emergency Medicine	980AN	WOS:000232986400022	16271683				2020-06-30	J	Topacoglu, H; Karcioglu, O; Cimrin, AH; Arnold, J				Topacoglu, H; Karcioglu, O; Cimrin, AH; Arnold, J			Respiratory arrest after low-dose fentanyl	ANNALS OF SAUDI MEDICINE			English	Article							SEDATION; ANALGESIA; EMERGENCY		Dokuz Eylul Univ, Sch Med, Dept Emergency Med, TR-35340 Izmir, Turkey; Tufts Univ, Sch Med, Dept Emergency Med, Baystate Med Ctr, Springfield, MA 01199 USA	Topacoglu, H (reprint author), Dokuz Eylul Univ, Sch Med, Dept Emergency Med, TR-35340 Izmir, Turkey.	hakan.topacoglu@deu.edu.tr					BARAFF LJ, 1994, ANN EMERG MED, V24, P1170, DOI 10.1016/S0196-0644(05)83035-5; CHUDNOFSKY CR, 1989, ANN EMERG MED, V18, P635, DOI 10.1016/S0196-0644(89)80517-7; GARNER EG, 1994, J REPROD MED, V39, P818; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Jagoda AS, 1998, ANN EMERG MED, V31, P663, DOI 10.1016/S0196-0644(98)70216-1; Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507; Proudfoot Jeffrey, 1995, Emergency Medicine Clinics of North America, V13, P357; SACCHETTI A, 1994, ANN EMERG MED, V23, P237, DOI 10.1016/S0196-0644(94)70037-0; STREISAND JB, 1993, ANESTHESIOLOGY, V78, P4; 1998, MED LETT DRUGS THER, V40, P1033	10	2	2	0	1	K FAISAL SPEC HOSP RES CENTRE	RIYADH	PUBLICATIONS OFFICE PO BOX 3354, RIYADH 11211, SAUDI ARABIA	0256-4947			ANN SAUDI MED	Ann. Saudi Med.	NOV-DEC	2005	25	6					508	510		10.5144/0256-4947.2005.508			3	Medicine, General & Internal	General & Internal Medicine	005RT	WOS:000234842200014	16438465	Green Published			2020-06-30	J	Karkabi, S; Besser, M; Zinman, C				Karkabi, S; Besser, M; Zinman, C			Arthroscopic subacromial decompression performed under local anesthesia	ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY			English	Article						arthroscopy; shoulder; local anesthesia			Rambam Med Ctr, Unit Arthroscop Surg, Haifa, Israel	Karkabi, S (reprint author), POB 303, IL-20200 Shfar Am, Israel.	v_s_karkabi@hotmail.com						0	1	1	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0749-8063			ARTHROSCOPY	Arthroscopy	NOV	2005	21	11					1404	1404		10.1016/j.arthro.2005.08.029			1	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	992LO	WOS:000233885600033	16325101				2020-06-30	J	Karkabi, S; Besser, M; Zinman, C				Karkabi, S; Besser, M; Zinman, C			Arthroscopic subacromial decompression performed under local anesthesia	ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY			English	Article						arthroscopy; shoulder; local anesthesia		Shoulder arthroscopy is usually performed under general anesthesia or interscalene block. General anesthesia may be contraindicated and interscalene block sometimes fails. We had 8 patients who were at high-risk and, therefore, shoulder arthroscopy and decompression were performed under local anesthesia in the beach-chair position. We used 50 mL of 1% lidocaine; 30 mL were infiltrated into the skin and underlying tissues and into the glenohumeral joint, and the rest was infiltrated into the subacromial joint. Before the infiltration, all patients were given 5 mg midazolam and 0.1 mg fentanyl intravenously. All 8 patients were satisfied with the analgesia provided by the anesthesia. We conclude that arthroscopy and subacromial decompression can be readily performed under local anesthesia in combination with efficient sedation.	Rambam Med Ctr, Unit Arthroscop Surg, Haifa, Israel	Karkabi, S (reprint author), POB 303, IL-20200 Shfar Am, Israel.	v_s_karkabi@hotmail.com						0	0	1	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0749-8063	1526-3231		ARTHROSCOPY	Arthroscopy	NOV	2005	21	11							1404.e1	10.1016/j.arthro.2005.08.029			2	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	992LO	WOS:000233885600034					2020-06-30	J	Rauf, K; Vohra, A; Fernandez-Jimenez, P; O'Keeffe, N; Forrest, M				Rauf, K; Vohra, A; Fernandez-Jimenez, P; O'Keeffe, N; Forrest, M			Remifentanil infusion in association with fentanyl-propofol anaesthesia in patients undergoing cardiac surgery: effects on morphine requirement and postoperative analgesia	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesia; postoperative; analgesics opioid; remifentanil; surgery; cardiac	BYPASS GRAFT-SURGERY; ACUTE OPIOID TOLERANCE; INTRAOPERATIVE REMIFENTANIL; RAPID DEVELOPMENT; PAIN; PHARMACOKINETICS; SUFENTANIL; ALFENTANIL; MECHANISMS; EFFICACY	Background. We have prospectively assessed the effects of remifentanil on morphine requirement in the first hour after emerging from general anaesthesia after elective coronary artery bypass surgery and in the first 12 h postoperatively, and pain and agitation scores in the first hour after emerging from general anaesthesia. Methods. Twenty patients undergoing off-pump coronary artery bypass surgery, receiving standardized propofol-fentanyl-based anaesthesia, randomly received infusions of either remifentanil 0.1 mu g kg(-1) min(-1) (Group R, n=10) or saline (Group S, n=10), each infused at 0.12 ml kg(-1) h(-1). Propofol and trial drug infusion were continued into the postoperative period until the patients were ready to be woken up. Postoperative analgesia was provided with morphine infusion commenced immediately after operation, and was additionally nurse controlled on the basis of a visual analogue scale (VAS) score (0-10). Agitation score was recorded using a VAS of 0-3. Results. In the first hour after discontinuing propofol and trial infusion, morphine requirements were significantly higher in the remifentanil group (8.15 (sd 3.59) mg) compared with the saline group (3.29 (2.36) mg) (P < 0.01). There was no difference in the total morphine given during the period after stopping propofol or in the total requirement in the first 12 h postoperatively. There was no significant difference in either pain scores or agitation scores between the two groups. Conclusion. Use of remifentanil is associated with increased opioid requirement in the first hour after it has been discontinued.	Manchester Royal Infirm, Cent Manchester & Manchester Childrens Univ Hosp, Dept Anaesthesia, Manchester M13 9WL, Lancs, England	Vohra, A (reprint author), Manchester Royal Infirm, Cent Manchester & Manchester Childrens Univ Hosp, Dept Anaesthesia, Oxford Rd, Manchester M13 9WL, Lancs, England.	avohra@f2s.com	Vohra, Akbar/G-5960-2015	Vohra, Akbar/0000-0001-8148-8607			Albrecht S, 1999, ANESTH ANALG, V89, pS40; Cheng DCH, 2001, ANESTH ANALG, V92, P1094; Coriat P, 2001, ANESTH ANALG, V92, P1081; Cortinez LI, 2001, BRIT J ANAESTH, V87, P866, DOI 10.1093/bja/87.6.866; Egan T D, 2000, Curr Opin Anaesthesiol, V13, P449, DOI 10.1097/00001503-200008000-00009; Engoren M, 2001, ANESTH ANALG, V93, P859, DOI 10.1097/00000539-200110000-00011; Fletcher D, 2000, ANESTH ANALG, V90, P666, DOI 10.1097/00000539-200003000-00029; Glass PSA, 1999, ANESTH ANALG, V89, pS7; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Gustorff B., 2001, European Journal of Anaesthesiology, V18, P138; Hall AP, 2000, BRIT J ANAESTH, V84, P100; Howie MB, 2001, ANESTH ANALG, V92, P1084; Jordan B, 1998, BRIT J ANAESTH, V81, P12; KAPILA A, 1995, ANESTHESIOLOGY, V83, P968, DOI 10.1097/00000542-199511000-00009; Lehmann A, 2000, J CARDIOTHOR VASC AN, V14, P416, DOI 10.1053/jcan.2000.7945; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; Michelsen LG, 1996, J CLIN ANESTH, V8, P679, DOI 10.1016/S0952-8180(96)00179-1; Myles PS, 2002, ANESTH ANALG, V95, P805, DOI 10.1097/00000539-200210000-00004; Schraag S, 1999, ANESTH ANALG, V89, P753, DOI 10.1097/00000539-199909000-00042; Thompson JP, 1996, BRIT J ANAESTH, V76, P341; Vinik HR, 1998, ANESTH ANALG, V86, P1307, DOI 10.1097/00000539-199806000-00033	21	30	32	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	NOV	2005	95	5					611	615		10.1093/bja/aei237			5	Anesthesiology	Anesthesiology	974MM	WOS:000232595900006	16155034	Bronze			2020-06-30	J	Olivier, JF; Le, N; Choiniere, JL; Prieto, I; Basile, F; Hemmerling, T				Olivier, JF; Le, N; Choiniere, JL; Prieto, I; Basile, F; Hemmerling, T			Comparison of three different epidural solutions in off-pump cardiac surgery: pilot study	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthesia, general; analgesia, epidural; haemodynamics, side-effects; pain control, outcome; surgery, off-pump coronary artery bypass grafting	BYPASS GRAFT-SURGERY; ANESTHESIA; ANALGESIA; HEMATOMA	Background. Immediate extubation using thoracic epidural analgesia (TEA) has become more popular after off-pump coronary artery bypass grafting (OPCAB). In this randomized prospective double-blind study, we present the first comparison of preoperative and postoperative haemodynamics during different regimens of TEA for immediate extubation after cardiac surgery. Methods. Sixty patients undergoing OPCAB were enrolled in this study. TEA was installed > 1 h before application of heparin at levels T2-T4. Analgesia was provided by bupivacaine 0.25%, 8 ml, 15 min before surgery and extubation, and at 10 ml h(-1) during surgery and up to 72 h afterwards using one of the following regimens: bupivacaine 0.125% alone, bupivacaine 0.125% with fentanyl 3 mu g ml(-1) or bupivacaine 0.125% with clonidine 0.6 mu g ml(-1). Patients were block-randomized for one of the three treatments. Pain scores and infusion rates of TEA were assessed up to 48 h after surgery. Respiratory function was assessed by Pa-o2 and Pa-o2 immediately after surgery, and haemodynamic stability was recorded in the form of heart rate and diastolic and systolic blood pressure. Results. Patient characteristics, respiratory function and haemodynamic stability did not vary between the three groups. Pain control was very good and was not significantly different between the groups using similar infusion rates after surgery. Paraesthesia in dermatomes T1 or C8 occurred equally in all three groups. There was no neurological complication related to TEA in this study. Conclusions. We conclude that immediate extubation after OPCAB using TEA is feasible with different TEA regimens. Respiratory function, haemodynamic stability and pain control are not different between TEA with bupivacaine alone, bupivacaine with fentanyl or bupivacaine with clonidine.	Univ Montreal, Hotel Dieu Ctr Hosp, Perioperat Cardiac Res Grp, Dept Anesthesiol, Montreal, PQ, Canada	Hemmerling, T (reprint author), Univ Montreal, Hotel Dieu Ctr Hosp, Perioperat Cardiac Res Grp, Dept Anesthesiol, Montreal, PQ, Canada.	thomashemmerling@hotmail.com					Ganapathy S, 2001, HEART SURG FORUM, V4, P323; GHIGNONE M, 1987, CAN J ANAESTH, V34, P46, DOI 10.1007/BF03007681; Hemmerling TM, 2004, ANESTH ANALG, V99, P1267, DOI 10.1213/01.ANE.0000133950.13310.2A; Hemmerling TM, 2004, CAN J ANAESTH, V51, P163, DOI 10.1007/BF03018777; Hemmerling TM, 2003, ANESTH ANALG, V97, P601, DOI 10.1213/01.ANE.0000074531.64117.92; Ho AMH, 2000, CHEST, V117, P551, DOI 10.1378/chest.117.2.551; Horlocker Terese T., 2004, Regional Anesthesia and Pain Medicine, V29, P1, DOI 10.1016/j.rapm.2003.12.006; Ikeda Y, 2003, ANESTH ANALG, V97, P748, DOI 10.1213/01.ANE.0000075841.37183.A4; Joachimsson P O, 1989, J Cardiothorac Anesth, V3, P444, DOI 10.1016/S0888-6296(89)97603-5; Liem T H, 1992, J Cardiothorac Vasc Anesth, V6, P156; LIU S, 1995, ANESTHESIOLOGY, V82, P1474, DOI 10.1097/00000542-199506000-00019; MOORE CM, 1995, BRIT J ANAESTH, V75, P387, DOI 10.1093/bja/75.4.387; Ohashi Kenji, 2002, Osaka City Medical Journal, V48, P45; Pastor MC, 2003, J CARDIOTHOR VASC AN, V17, P154, DOI 10.1053/jcan.2003.39; Priestley MC, 2002, ANESTH ANALG, V94, P275, DOI 10.1097/00000539-200202000-00009; Rosen DA, 2004, ANESTH ANALG, V98, P966, DOI 10.1213/01.ANE.0000103267.37895.5B; Scott NB, 2001, ANESTH ANALG, V93, P528, DOI 10.1097/00000539-200109000-00003; STENSETH R, 1994, ACTA ANAESTH SCAND, V38, P826, DOI 10.1111/j.1399-6576.1994.tb04013.x; STENSETH R, 1995, J CARDIOTHOR VASC AN, V9, P503, DOI 10.1016/S1053-0770(05)80131-4; Turfrey DJ, 1997, ANAESTHESIA, V52, P914; Turfrey DJ, 1997, ANAESTHESIA, V52, P1090, DOI 10.1111/j.1365-2044.1997.260-az0397.x	21	13	13	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	NOV	2005	95	5					685	691		10.1093/bja/aei238			7	Anesthesiology	Anesthesiology	974MM	WOS:000232595900018	16183682	Bronze			2020-06-30	J	Borland, ML; Bergesio, R; Pascoe, EM; Turner, S; Woodger, S				Borland, ML; Bergesio, R; Pascoe, EM; Turner, S; Woodger, S			Intranasal fentanyl is an equivalent analgesic to oral morphine in paediatric burns patients for dressing changes: A randomised double blind crossover study	BURNS			English	Article						intranasal fentanyl; oral morphine; pediatric burns; burns dressings	POSTOPERATIVE PAIN; CHILDREN; DIAMORPHINE; EFFICACY; CITRATE; TRIAL; PCINA	Introduction: The ideal analgesic agent for burns wound dressings in paediatric patients would be one that is easy to administer, well tolerated, and produces rapid onset of analgesia with a short duration of action and minimal side-effects to allow rapid resumption of activities and oral intake. We compared our current treatment of oral morphine to intranasal fentanyl in an attempt to find an agent closer to the ideal. Methods: A randomised double blind two-treatment crossover study comparing intranasal administration of fentanyl (INF) to orally administered morphine (OM). Children with burn injury aged up to 15 years and weighing 10-75 kg were included. Primary end-point was pain scores. Secondary end-points were time to resumption of age-appropriate activities, time to resumption of fluid intake, sedation and cooperation. Routine observations and vital signs were also recorded. Results: Twenty-four patients were studied with a median age of 4.5 years (interquartile range 1.8-9.0 years) and a median weight of 18.4 kg (interquartile range 12.9-33.2 kg). Mean pain difference scores (OM-INF) ranged from -0.500 (95% CI = -1.653 to 0.653) at baseline to -0.625 (05% CI = -1.863 to 0.613) for a retrospective rating of worst pain experienced during the dressing procedure. All measurements were within a pre-defined range of equivalent efficacy. The median time to resumption of fluid intake was 108 min (range 44-175 min) with OM and 140 min (range 60-210 min) with INF. These differences were not statistically significant. Fewer patients experienced mild side-effects with INF compared to OM (n = 5 versus n = 10). No patients experienced depressed respirations or oxygen saturations. Summary: Intranasal fentanyl was shown to be equivalent to oral morphine in the provision of analgesia for burn wound dressing changes in this cohort of paediatric patients. It was concluded that intranasal fentanyl is a suitable analgesic agent for use in paediatric burns dressing changes either by itself or in combination with oral morphine as a top up titratable agent. (c) 2005 Elsevier Ltd and ISBI. All rights reserved.	Princess Margaret Hosp Children, Dept Emergency, Perth, WA 6840, Australia	Borland, ML (reprint author), Princess Margaret Hosp Children, Dept Emergency, GPO Box D184, Perth, WA 6840, Australia.	Meredith.Borland@health.wa.gov.au		Pascoe, Elaine/0000-0003-1653-5803			Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Finn J, 2004, BURNS, V30, P262, DOI 10.1016/j.burns.2003.10.017; Gill M, 2003, ANN EMERG MED, V41, P234, DOI 10.1067/mem.2003.53; Kendall JM, 2001, BMJ-BRIT MED J, V322, P261, DOI 10.1136/bmj.322.7281.261; Lim Stephen C. B., 2003, Journal of Pharmacy Practice and Research, V33, P59; ONeil G, 1997, ANAESTH INTENS CARE, V25, P408, DOI 10.1177/0310057X9702500414; Powell CV, 2001, ANN EMERG MED, V37, P28; Robert R, 2003, J BURN CARE REHABIL, V24, P351, DOI 10.1097/01.BCR.0000095504.69283.F2; Robertson J, 1993, Pediatr Nurs, V19, P209; SCHUTZMAN SA, 1994, ANN EMERG MED, V24, P1059, DOI 10.1016/S0196-0644(94)70234-9; Senn SJ, 2002, CROSS OVER TRIALS CL; SHARAR SR, 1998, J BURN CARE REHABIL, V19, P16; Striebel HW, 1996, J CLIN ANESTH, V8, P4, DOI 10.1016/0952-8180(95)00167-0; Toussaint S, 2000, CAN J ANAESTH, V47, P299, DOI 10.1007/BF03020941; Wilson JA, 1997, J ACCID EMERG MED, V14, P70; Younge P, 1999, EMERGEN MED, V11, P90; 1998, FED REG, V63	17	66	68	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0305-4179	1879-1409		BURNS	Burns	NOV	2005	31	7					831	837		10.1016/j.burns.2005.05.001			7	Critical Care Medicine; Dermatology; Surgery	General & Internal Medicine; Dermatology; Surgery	978GM	WOS:000232861600004	16005154				2020-06-30	J	Nieszkowska, A; Combes, A; Luyt, CE; Ksibi, H; Trouillet, JL; Gibert, C; Chastre, J				Nieszkowska, A; Combes, A; Luyt, CE; Ksibi, H; Trouillet, JL; Gibert, C; Chastre, J			Impact of tracheotomy on sedative administration, sedation level, and comfort of mechanically ventilated intensive care unit patients	CRITICAL CARE MEDICINE			English	Article						tracheotomy; respiration; artificial; hypnotics; sedatives; intensive care unit; outcome assessment	EARLY TRACHEOSTOMY; COMPLICATIONS; PERCEPTIONS; INTUBATION; GUIDELINES; STRESSORS; BLUNT; SCORE; ICU	Objective: To assess the impact of tracheotomy on sedative administration, sedation level, and autonomy of mechanically-ventilated intensive care unit (ICU) patients. Design, Setting, and Patients: In this observational study, the charts of all consecutive patients undergoing mechanical ventilation requiring tracheotomy over a 14-month period in our 18-bed tertiary care ICU were reviewed retrospectively. Patients' sedation levels (according to the Riker's 7-level sedation-agitation score) and intravenous (fentanyl and midazolam) and oral (clorazepate and haloperidol) sedative administration were measured daily during the 7 days before and after tracheotomy. We also recorded patients for whom chair positioning and oral alimentation became possible in the days following tracheotomy. Interventions: None. Measurements and Main Results: Tracheotomy was performed on 72 (23.1%) of the 312 patients undergoing mechanical ventilation for >= 48 hrs. After tracheotomy, median (25th, 75th percentiles) fentanyl and midazolam administration decreased from 866 (191, 1672) to 71 (3, 426) mu g/(patient center dot day) and from 44 (16, 128) to 7 (1, 42) mg/(patient center dot day) (p <.001), respectively. Concomitant median time spent heavily sedated decreased from 7 (3, 17) to 1 (0, 6) hrs/day (p <.001), with no increase in agitation time. During the 7 days following tracheotomy, partial oral alimentation became possible for 35 patients (48.6%) and out-of-bed positioning became possible for 16 patients (22.2%). Conclusion: On the basis of these observations, we conclude that tracheotomized mechanically ventilated ICU patients required less intravenous sedative administration, spent less time heavily sedated, and achieved more autonomy earlier.	Hop La Pitie Salpetriere, Serv Reanimat Med, Paris, France	Nieszkowska, A (reprint author), Hop La Pitie Salpetriere, Serv Reanimat Med, Paris, France.						Armstrong PA, 1998, SURGERY, V124, P763, DOI 10.1067/msy.1998.91224; ASTRACHAN DI, 1988, LARYNGOSCOPE, V98, P1165; Brook A D, 2000, Am J Crit Care, V9, P352; Cammarano WB, 1998, CRIT CARE MED, V26, P676, DOI 10.1097/00003246-199804000-00015; COCHRAN J, 1989, J ADV NURS, V14, P1038, DOI 10.1111/j.1365-2648.1989.tb01515.x; Combes A, 2003, CRIT CARE MED, V31, P1373, DOI 10.1097/01.CCM.0000065188.87029.C3; Cornock MA, 1998, J ADV NURS, V27, P518, DOI 10.1046/j.1365-2648.1998.00555.x; De Jonghe B, 2002, JAMA-J AM MED ASSOC, V288, P2859, DOI 10.1001/jama.288.22.2859; DELARMINAT V, 1995, CRIT CARE MED, V23, P486, DOI 10.1097/00003246-199503000-00012; Diehl JL, 1999, AM J RESP CRIT CARE, V159, P383, DOI 10.1164/ajrccm.159.2.9707046; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; Esteban A, 2000, AM J RESP CRIT CARE, V161, P1450, DOI 10.1164/ajrccm.161.5.9902018; Georges H, 2000, CHEST, V118, P767, DOI 10.1378/chest.118.3.767; Gois Cristiane Franca Lisboa, 2004, Rev. Latino-Am. Enfermagem, V12, P22, DOI 10.1590/S0104-11692004000100004; Heffner JE, 2003, CLIN CHEST MED, V24, P389, DOI 10.1016/S0272-5231(03)00044-3; Heffner JE, 2001, CHEST, V120, p477S, DOI 10.1378/chest.120.6_suppl.477S; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Kasper Christine E, 2002, AACN Clin Issues, V13, P237, DOI 10.1097/00044067-200205000-00009; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Leder SB, 2000, LARYNGOSCOPE, V110, P641, DOI 10.1097/00005537-200004000-00019; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LENTZ M, 1981, NURS CLIN N AM, V16, P729; LESNIK I, 1992, AM SURGEON, V58, P346; MacIntyre NR, 2001, CHEST, V120, p375S, DOI 10.1378/chest.120.6_suppl.375S; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; Novaes MAFP, 1997, INTENS CARE MED, V23, P1282, DOI 10.1007/s001340050500; Novaes MAFP, 1999, INTENS CARE MED, V25, P1421, DOI 10.1007/s001340051091; Riker RR, 1999, CRIT CARE MED, V27, P1325, DOI 10.1097/00003246-199907000-00022; RODRIGUEZ JL, 1990, SURGERY, V108, P655; Rumbak MJ, 2004, CRIT CARE MED, V32, P1689, DOI 10.1097/01.CCM.0000134835.05161.B6; Tolep K, 1996, CHEST, V109, P167, DOI 10.1378/chest.109.1.167; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; WEINBERG PF, 1984, AM REV RESPIR DIS, V130, P791; ZWILLICH CW, 1974, AM J MED, V57, P161, DOI 10.1016/0002-9343(74)90440-9	36	120	123	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	2005	33	11					2527	2533		10.1097/01.CCM.0000186898.58709.AA			7	Critical Care Medicine	General & Internal Medicine	999XC	WOS:000234423500012	16276177				2020-06-30	J	Asenjo, JF; Brecht, KM				Asenjo, JF; Brecht, KM			Opioids: Other routes for use in recovery room	CURRENT DRUG TARGETS			English	Review						opioids; pain; post anesthesia care unit (PACU); nasal; transdermic; oral transmucosal; iontophoresis	ORAL TRANSMUCOSAL FENTANYL; CONTROLLED INTRANASAL ANALGESIA; POSTOPERATIVE PAIN MANAGEMENT; BUTORPHANOL NASAL SPRAY; TRANSNASAL BUTORPHANOL; PHARMACOKINETIC INTERACTION; TRANSDERMAL FENTANYL; INTRAVENOUS MORPHINE; CONTROLLED-TRIAL; CITRATE	Opioids remain the main pharmacological tools for pain control in the postoperative patient. Recent concerns about chronic use of non-steroidal anti-inflammatory drugs have put extra pressure on health care workers to device and develop new medications and delivery methods to provide patients with appropriate pain relief after surgery. New technologies and better understanding of the pharmacology of the opioids administered by non-traditional ways will be reviewed in this manuscript. Understanding the anatomy of the nose cavity is important to use the inhaled way to deliver fentanyl, sufentanyl or butorphanol in surgical patients. High concentration and small volume are keys to good absorption and effect by nasal administration. Transdermal delivery of fentanyl has been used in chronic pain for some years. A new fentanyl self-administration method is in advanced trials for clinical use. It has a huge potential in giving good pain relief with lower side effects and more patient independence because of its reduced size and lack of tubing attached to it. Day surgery patients could be great candidates for this therapeutic alternative. Finally, oral transmucosal fentanyl is also in the market. Better suited to be used in controlling breakthrough pain in chronic settings, it has been so far marketed in the perioperative period. Side effects are a concern in its use for preoperative sedation in children. Large studies are now required for drugs approval and for new indications at regulatory agencies level. Good clinical judgment is more relevant now than ever before to avoid complications and new withdraw of old good medications inappropriately prescribed from the market place.	McGill Univ, Dept Anesthesia & Acute Pain Serv, Montreal, PQ, Canada; McGill Univ, Montreal Gen Hosp, Dept Nursing, Montreal, PQ H3G 1A4, Canada	Asenjo, JF (reprint author), McGill Univ, Dept Anesthesia & Acute Pain Serv, Montreal, PQ, Canada.	jfasenjog@yahoo.com					ABBOUD TK, 1991, ACTA ANAESTH SCAND, V35, P14, DOI 10.1111/j.1399-6576.1991.tb03234.x; *AM SOC AN, STAND POST CAR STAND; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; de Leon-Casasola Oscar A, 2002, Best Pract Res Clin Anaesthesiol, V16, P521, DOI 10.1053/bean.2002.0257; Dsida RM, 1998, ANESTH ANALG, V86, P66, DOI 10.1097/00000539-199801000-00013; Gardner-Nix J, 2001, J PAIN SYMPTOM MANAG, V22, P627, DOI 10.1016/S0885-3924(01)00321-9; GILLIS JC, 1995, DRUGS, V50, P157, DOI 10.2165/00003495-199550010-00010; Ginsberg B, 1998, PAEDIATR ANAESTH, V8, P413; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P738, DOI 10.1097/00000542-200409000-00023; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; LIND GH, 1991, ANN EMERG MED, V20, P1117, DOI 10.1016/S0196-0644(05)81387-3; LONGO V, 1989, BIOCHEM PHARMACOL, V38, P1867, DOI 10.1016/0006-2952(89)90424-3; LOWHAGEN P, 1994, NEUROPATH APPL NEURO, V20, P543, DOI 10.1111/j.1365-2990.1994.tb01008.x; Malviya S, 1997, J CLIN ANESTH, V9, P374, DOI 10.1016/S0952-8180(97)00064-0; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Oderda GM, 2003, J PAIN SYMPTOM MANAG, V25, P276, DOI 10.1016/S0885-3924(02)00691-7; PAYNE R, 1992, J PAIN SYMPTOM MA S3, V7, P40; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; RHONDA R, 2003, J BURN CARE REHABIL, V24, P351; SCHIERMEIER O, 2002, NATURE; Sharer SR, 1998, J BURN CARE REHABIL, V19, P516, DOI 10.1097/00004630-199811000-00010; Shyu WC, 1996, BRIT J CLIN PHARMACO, V42, P513, DOI 10.1046/j.1365-2125.1996.4592.x; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Striebel HW, 1996, ANESTH ANALG, V83, P548, DOI 10.1097/00000539-199609000-00019; STRIEBEL HW, 1995, CAN J ANAESTH, V42, P287, DOI 10.1007/BF03010704; Striebel HW, 1996, J CLIN ANESTH, V8, P4, DOI 10.1016/0952-8180(95)00167-0; TALMAGE DE, 2000, ANESTHESIOLOGY, V92, P665; Toussaint S, 2000, CAN J ANAESTH, V47, P299, DOI 10.1007/BF03020941; Vachharajani NN, 1997, J CLIN PHARMACOL, V37, P979, DOI 10.1002/j.1552-4604.1997.tb04273.x; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Wax PM, 2003, ANN EMERG MED, V41, P700, DOI 10.1067/mem.2003.148; WETCHLER BV, 1992, CURR THER RES CLIN E, V52, P571, DOI 10.1016/S0011-393X(05)80464-3; 1976, TXB HUMAN ANATOMY	35	2	2	0	8	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1389-4501			CURR DRUG TARGETS	Curr. Drug Targets	NOV	2005	6	7					773	779		10.2174/138945005774574443			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	972UI	WOS:000232478300008	16305455				2020-06-30	J	Disma, N; Astuto, M; Rizzo, G; Rosano, G; Naso, P; Aprile, G; Bonanno, G; Russo, A				Disma, N; Astuto, M; Rizzo, G; Rosano, G; Naso, P; Aprile, G; Bonanno, G; Russo, A			Propofol sedation with fentanyl or midazolam during oesophagogastroduodenoscopy in children	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						conscious sedation; child; propofol; midazolam; fentanyl; gastroscopy	GENERAL-ANESTHESIA; GASTROINTESTINAL ENDOSCOPY; SEVOFLURANE; PHARMACOKINETICS; HALOTHANE; RECOVERY	Background and objective: Sedation is commonly used to facilitate diagnostic procedures in children. The aim of our study was to investigate sedation in children using propofol alone or combined with fentanyl or midazolam with regard to efficacy, adverse reactions or side-effects related to the drugs, ease of operation for the endoscopist, and time to discharge from the post-anaesthesia care unit. Methods: We prospectively studied 240 children, aged 1-12 yr of age, undergoing endoscopic procedures of the upper gastrointestinal tract. The patients were given an oral premedication with midazolam (0.5 mg kg(-1)) and were then randomly allocated to one of the three study groups: propofol alone (Group P), propofol with fentanyl 1 mu g kg(-1) (Group PF) or propofol with midazolam 0.1 mg kg(-1) (Group PM). Additional doses of propofol given during the procedure were recorded. Adequacy of sedation and ease of procedure (easy, adequate, impossible) were evaluated by the endoscopist, who was blinded as to the drugs used. Results: The duration of the procedure and the recovery period were similar in the three groups. The number of patients requiring supplemental doses of propofol to permit safe completion of gastroscopy was 31 in Group P (= 39%; eight of these required two additional doses), 14 in Group PM (= 18%), and 11 in Group PF (=13%) (P < 0.05). There was a lower incidence of adverse events in Group PM and in Group PF than in Group P (P < 0.05). Conclusions: Propofol in combination with fentanyl or midazolam gives better sedation and ease of endoscopy than propofol alone.	Catania Univ, Policlin, Anesthesiol Unit, Catania, Italy; Catania Univ, Gastroenterol Unit, Catania, Italy	Disma, N (reprint author), Via Serve Divina Provv 16-A, I-95123 Catania, Italy.	nicoladisma@tin.it	Disma, Nicola/AAA-8868-2020; astuto, marinella/AAP-6994-2020	astuto, marinella/0000-0002-9365-1309; Disma, Nicola/0000-0002-2960-9333			ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Bishop PR, 2002, GASTROINTEST ENDOSC, V55, P624, DOI 10.1067/mge.2002.123417; CARLSSON U, 1995, ENDOSCOPY, V27, P240, DOI 10.1055/s-2007-1005678; Cohen LB, 2004, GASTROINTEST ENDOSC, V59, P795, DOI 10.1016/S0016-5107(04)00349-9; Elitsur Y, 2000, ENDOSCOPY, V32, P788, DOI 10.1055/s-2000-7713; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; HANNALLAH RS, 1994, CAN J ANAESTH, V41, P12, DOI 10.1007/BF03009654; HASSALL E, 1993, J PEDIATR GASTR NUTR, V16, P370, DOI 10.1097/00005176-199305000-00004; Koshy G, 2000, AM J GASTROENTEROL, V95, P1476; Malviya S, 2000, BRIT J ANAESTH, V84, P743; Martlew RA, 1996, BRIT J ANAESTH, V76, P308; Means LJ, 1996, PEDIATRICS, V98, P502; Meretoja OA, 1996, BRIT J ANAESTH, V76, P767; Montes RG, 2000, J PEDIATR GASTR NUTR, V31, P41, DOI 10.1097/00005176-200007000-00010; MORGAN DJ, 1990, BRIT J CLIN PHARMACO, V30, P144, DOI 10.1111/j.1365-2125.1990.tb03755.x; Picard V, 2000, ACTA ANAESTH SCAND, V44, P307, DOI 10.1034/j.1399-6576.2000.440315.x; Schwartz DA, 1998, ANESTH ANALG, V87, P757, DOI 10.1097/00000539-199810000-00003; SHAFER A, 1988, ANESTHESIOLOGY, V69, P348, DOI 10.1097/00000542-198809000-00011; SHORT TG, 1991, BRIT J ANAESTH, V67, P539, DOI 10.1093/bja/67.5.539; Smallman Bettina, 2002, Curr Opin Anaesthesiol, V15, P455, DOI 10.1097/00001503-200208000-00008; SQUIRES RH, 1995, GASTROINTEST ENDOSC, V41, P99, DOI 10.1016/S0016-5107(05)80589-9; Sury MRJ, 1999, LANCET, V353, P1667, DOI 10.1016/S0140-6736(98)08383-4; Vuyk J, 1997, J CLIN ANESTH, V9, pS23, DOI 10.1016/S0952-8180(97)00117-7	23	54	64	0	2	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	NOV	2005	22	11					848	852		10.1017/S0265021505001432			5	Anesthesiology	Anesthesiology	980EI	WOS:000232996400007	16225720				2020-06-30	J	Hung, WT; Chen, CC; Liou, CM; Tsai, WY				Hung, WT; Chen, CC; Liou, CM; Tsai, WY			The effects of tow-dose fentanyl on emergence agitation and quality of life in patients with moderate developmental disabilities	JOURNAL OF CLINICAL ANESTHESIA			English	Article						agitation; anesthesia; general; dental care; emergence agitation; opioids; pediatric patients; sevoflurane	PEDIATRIC AMBULATORY PATIENTS; SEVOFLURANE ANESTHESIA; RECOVERY CHARACTERISTICS; ISOFLURANE ANESTHESIA; HALOTHANE; PROPOFOL; CHILDREN; DESFLURANE; SURGERY; MAINTENANCE	Study Objective: To analyze whether emergence agitation could be reduced by using a low dosage of fentanyl without causing an increase in postoperative adverse effects and/or affecting the patient's quality of life after discharge. Design: Randomized, controlled crossover trial. Setting: University medical center. Patients: One hundred ten ASA physical status I and II ambulatory patients with moderate developmental disabilities who received anesthesia for dental care. Interventions: During their first visit, patients were randomly treated either with a placebo or a 1- to 1.5-mu g/kg dose of fentanyl before inserting a reinforced laryngeal mask airway and treated with the remaining method during their second visit 6 to 12 months later. Measurements: Measured variables included anesthetic and emergence period, the occurrence of emergence agitation, and postanesthetic adverse effects such as nausea and vomiting. After discharge, the patient's quality of life was evaluated based on disturbances in daily activity, eating habit, and sleeping behavior. Results were analyzed by Student t test and McNemar test (P < 0.05). Main Results: Between the two treatments, there was a significant difference in the frequency of emergence agitation (P = 0.04) but no postoperative adverse effects such as postoperative nausea and vomiting. We also found no significant disturbances in the patient's quality of life according to daily activity, eating habits, or sleeping behavior. Conclusion: Emergence agitation may be reduced by using 1 to 1.5 mu g/kg of fentanyl during induction while maintaining anesthesia by sevoflurane in patients with moderate developmental disabilities undergoing dental care, without causing an increase in postoperative adverse effects and affecting the patient's life quality after discharge. (c) 2005 Elsevier Inc. All fights reserved.	Chung Shan Med Univ, Sch Med, Dept Anesthesiol, Taichung 403, Taiwan; Chung Shan Med Univ, Dept Anesthesia, Taichung, Taiwan; Columbia Univ, Sch Publ Hlth, Div Biostat, New York, NY 10032 USA	Hung, WT (reprint author), Chung Shan Med Univ, Sch Med, Dept Anesthesiol, Taichung 403, Taiwan.	cshy029@csh.org.tw					Aono J, 1997, ANESTHESIOLOGY, V87, P1298, DOI 10.1097/00000542-199712000-00006; Cohen IT, 2002, ANESTH ANALG, V94, P1178, DOI 10.1097/00000539-200205000-00023; Cravero JP, 2003, ANESTH ANALG, V97, P364, DOI 10.1213/01.ANE.0000070227.78670.43; Dashfield AK, 1998, ANAESTHESIA, V53, P1062, DOI 10.1046/j.1365-2044.1998.00571.x; DAVIS PJ, 1994, ANESTHESIOLOGY, V80, P298, DOI 10.1097/00000542-199402000-00009; Dellasega C, 1993, J Neurosci Nurs, V25, P147; ERIKSSON H, 1995, ACTA ANAESTH SCAND, V39, P377, DOI 10.1111/j.1399-6576.1995.tb04081.x; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Hung Wei-Te, 2003, Acta Anaesthesiol Sin, V41, P65; JOHANNESSON GP, 1995, ACTA ANAESTH SCAND, V39, P546, DOI 10.1111/j.1399-6576.1995.tb04116.x; KINGSTON HGG, 1986, ANESTH ANALG, V65, P181; Lapin SL, 1999, PAEDIATR ANAESTH, V9, P299, DOI 10.1046/j.1460-9592.1999.00351.x; Moore JK, 2003, BRIT J ANAESTH, V90, P461, DOI 10.1093/bja/aeg098; Paris ST, 1997, BRIT J ANAESTH, V79, P280, DOI 10.1093/bja/79.3.280; Sneyd JR, 1998, EUR J ANAESTH, V15, P433, DOI 10.1097/00003643-199807000-00009; Soppitt AJ, 2000, J CLIN ANESTH, V12, P265, DOI 10.1016/S0952-8180(00)00151-3; Uezono S, 2000, ANESTH ANALG, V91, P563, DOI 10.1213/00000539-200009000-00012; Visser K, 2001, ANESTHESIOLOGY, V95, P616, DOI 10.1097/00000542-200109000-00012; Welborn LG, 1996, ANESTH ANALG, V83, P917, DOI 10.1097/00000539-199611000-00005	19	14	15	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	NOV	2005	17	7					494	498		10.1016/j.jclinane.2004.09.014			5	Anesthesiology	Anesthesiology	992NS	WOS:000233891400002	16297747				2020-06-30	J	Benitez-Rosario, MA; Martin, AS; Feria, M				Benitez-Rosario, MA; Martin, AS; Feria, M			Oral transmucosal fentanyl citrate in the management of dyspnea crisis in cancer patients	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Letter									Hosp La Candelaria, Palliat Care Unit, Tenerife, Spain; Hosp La Candelaria, Res Unit, Tenerife, Spain; Univ La Laguna, Dept Pharmacol, Tenerife, Spain	Benitez-Rosario, MA (reprint author), Hosp La Candelaria, Palliat Care Unit, Tenerife, Spain.		Benitez-Rosario, Miguel-Angel/I-3824-2019	Benitez-Rosario, Miguel-Angel/0000-0001-7706-3171			Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Coyne PJ, 2002, J PAIN SYMPTOM MANAG, V23, P157, DOI 10.1016/S0885-3924(01)00391-8; Dudgeon DJ, 2001, J PAIN SYMPTOM MANAG, V21, P95, DOI 10.1016/S0885-3924(00)00258-X; Jennings AL, 2002, THORAX, V57, P939, DOI 10.1136/thorax.57.11.939; MUERS MF, 1993, THORAX, V48, P339, DOI 10.1136/thx.48.4.339; Thomas Jay R, 2003, J Support Oncol, V1, P23	6	20	22	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924			J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	NOV	2005	30	5					395	397		10.1016/j.jpainsymman.2005.10.002			3	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	996LR	WOS:000234175900001	16310612	Bronze			2020-06-30	J	Naja, ZA; Ziade, FM; Al-Tannir, MA; Mansour, RMA; El-Rajab, MA				Naja, ZA; Ziade, FM; Al-Tannir, MA; Mansour, RMA; El-Rajab, MA			Addition of clonidine and fentanyl: comparison between three different regional anesthetic techniques in circumcision	PEDIATRIC ANESTHESIA			English	Article						ring block; dorsal penile block; postoperative pain; analgesics; circumcision	SUBCUTANEOUS RING BLOCK; DORSAL NERVE BLOCK; PENILE BLOCK; POSTOPERATIVE ANALGESIA; PAIN RELIEF; TOPICAL ANALGESIA; CHILDREN; MORPHINE; DURATION; PROLONGS	Background: Several techniques have been used for alleviating postcircumcision pain with regional anesthetics being more effective than systemic opioids. Our aim was to compare the effectiveness of dorsal penile block, ring block (RB) and dorsal penile block associated with RB in reducing postcircumcision pain in children. Methods: We conducted a prospective randomized double-blind clinical trial on 100 boys aged between 1 month and 5 years undergoing elective circumcision. Each 20 ml of local anesthetic mixture contained 9 ml lidocaine 1% without epinephrine, 9 ml bupivacaine 0.5%, 1 ml fentanyl (50 mu g.ml(-1)) and 1 ml clonidine (75 mu g.ml(-1)). They were allocated to one of three groups: 33 boys were given a RB with 1-1.5 ml (group 1), 32 had a dorsal penile block with 1.5-4 ml (group 2) and 35 had a combined ring and dorsal penile block with 2.5-5 ml of anesthetic mixture based on the child's age. Results : Ninety-one children (91%) completed the clinical trial (three failed blocks and six follow-up losses). The groups were similar with regard to age, weight, height, duration of surgery and hemodynamic status. The average pain scores were significantly higher with a RB compared with the other two groups (P < 0.05) for the first postoperative day. RB children and dorsal penile block children consumed significantly more analgesics for the first six postoperative hours (P < 0.05). The surgeon's satisfaction was significantly higher with the ring + dorsal penile block group (100%) compared with the other two groups (P = 0.032). Conclusion: Dorsal penile block plus RB technique is superior to dorsal penile block alone and RB alone in reducing postcircumcision pain in children.	Makassed Gen Hosp, Dept Anesthesia & Pain Med, Beirut 11072210, Lebanon; Lebanese Univ, Fac Publ Hlth, Beirut, Lebanon; Makassed Gen Hosp, Res Dept, Beirut 11072210, Lebanon; Makassed Gen Hosp, Dept Pediat, Beirut 11072210, Lebanon	Naja, ZA (reprint author), Makassed Gen Hosp, Dept Anesthesia & Pain Med, POB 11-6301, Beirut 11072210, Lebanon.	zouhnaja@yahoo.com		Ziade, Fouad/0000-0001-6663-3861; Al-Tannir, Mohamad/0000-0002-7739-8446			BRAMWELL RGB, 1982, ANAESTHESIA, V37, P1024, DOI 10.1111/j.1365-2044.1982.tb01717.x; BROADMAN LM, 1987, ANESTHESIOLOGY, V67, P399, DOI 10.1097/00000542-198709000-00019; CARLSSON P, 1984, ACTA ANAESTH SCAND, V28, P432, DOI 10.1111/j.1399-6576.1984.tb02093.x; CHAMBERS FA, 1994, BRIT J ANAESTH, V73, P437, DOI 10.1093/bja/73.4.437; Choi WY, 2003, ANESTH ANALG, V96, P396, DOI 10.1097/00000539-200302000-00018; DALENS B, 1989, ANESTH ANALG, V69, P41; El Saied AH, 2000, CAN J ANAESTH, V47, P962, DOI 10.1007/BF03024866; HANNALLAH RS, 1987, ANESTHESIOLOGY, V66, P832, DOI 10.1097/00000542-198706000-00023; Holder KJ, 1997, EUR J ANAESTH, V14, P495, DOI 10.1046/j.1365-2346.1997.00180.x; Irwin MG, 1996, ANAESTH INTENS CARE, V24, P365, DOI 10.1177/0310057X9602400311; Kundra P, 1998, ANESTH ANALG, V87, P52, DOI 10.1097/00000539-199807000-00012; LAU JTK, 1984, AM J SURG, V147, P797, DOI 10.1016/0002-9610(84)90204-6; MARTIN LVH, 1982, BRIT J ANAESTH, V54, P1263, DOI 10.1093/bja/54.12.1263; Naja M. Z., 2001, Middle East Journal of Anesthesiology, V16, P201; Naja MZ, 2003, ANAESTHESIA, V58, P1007, DOI 10.1046/j.1365-2044.2003.03401.x; Naja Z, 2002, EUR J ANAESTH, V19, P197, DOI 10.1017/S0265021502000352; Naja Z., 2000, Middle East Journal of Anesthesiology, V15, P559; SANCHEZ R, 1984, ANAESTHESIA, V39, P788, DOI 10.1111/j.1365-2044.1984.tb06525.x; SEROUR F, 1994, ANESTH ANALG, V79, P129; SEROUR F, 1995, J UROLOGY, V153, P474, DOI 10.1097/00005392-199502000-00062; Singelyn FJ, 1996, ANESTH ANALG, V83, P1046, DOI 10.1097/00000539-199611000-00025; Soh CR, 2003, PAEDIATR ANAESTH, V13, P329, DOI 10.1046/j.1460-9592.2003.01033.x; TREETRAKARN T, 1985, ANESTHESIOLOGY, V62, P519, DOI 10.1097/00000542-198504000-00027; Tverskoy M, 1998, ANESTH ANALG, V87, P1121, DOI 10.1097/00000539-199811000-00026; VATER M, 1985, ACTA ANAESTH SCAND, V29, P175, DOI 10.1111/j.1399-6576.1985.tb02180.x; Yang CC, 1998, BRIT J UROL, V82, P109; YEOMAN PM, 1983, ANAESTHESIA, V38, P862, DOI 10.1111/j.1365-2044.1983.tb12251.x	27	5	5	0	1	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	NOV	2005	15	11					964	970		10.1111/j.1460-9592.2005.01613.x			7	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	975JZ	WOS:000232659600010	16238558				2020-06-30	J	Weinbroum, AA				Weinbroum, AA			Superiority of postoperative epidural over intravenous patient-controlled analgesia in orthopedic oncologic patients	SURGERY			English	Article							GENERAL-ANESTHESIA; PAIN; DEXTROMETHORPHAN; ROPIVACAINE; MORPHINE; SURGERY; INFUSION; PHARMACOKINETICS; ATTENUATION; SUFENTANIL	Background. Surgery for bone malignancy is associated with intense postoperative pain. Patient-controlled epidural analgesia (PCEA) and intravenous patient-controlled analgesia (IV-PCA) are used currently for postoperative pain control. Methods. The degree of pain control after resection of bone malignancy under combined general and epidural anesthesia followed postoperatively by prospectively randomized PCEA (rolpvacaine 3.2 mg +/- fentanyl 8 mu g/dose) or IV-PCA (morphine 2 mg/dose) (n = 35/group) was assessed. Postoperative analgesia delivery cantinued for up to 96 h; intramuscular rescue with diclofenac 75 mg was also available. Results. The mean hourly pain score among the PCEA patients was 3.0 +/- 0.9, compared with 4.7 +/- 0.6 (P < .01) among the IV-PCA patients. All mean hourly pain scores in the PCEA patients, except for the first 2 hours of treatment, were less than 4/10, but they were higher in the IV-PCA patients. The demand for diclofenac was 2 times (n = 10) lower for the PCEA patients, compared with their IV counterparts (n = 20, P < .01); the same difference appllied to the overall side effects (n = 15 vs n = 30, P < .01). Self-rated wakefulness and feelings of well-being were better in the PCEA patients. Conclusions. Postolmrative ropivacaine + fentanyl via PCEA reduces pain better and affords better subjective feelings than IV morphine via PCA after resection of bone malignancy carried out under combined general and epidural anesthesia.	Tel Aviv Sourasky Med Ctr, Postanesthesia Care Unit, IL-64239 Tel Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Weinbroum, AA (reprint author), Tel Aviv Sourasky Med Ctr, Postanesthesia Care Unit, 6 Wiezman St, IL-64239 Tel Aviv, Israel.	draviw@tasmc.health.gov.il					Badner NH, 1996, CAN J ANAESTH, V43, P17, DOI 10.1007/BF03015952; Ballantyne JC, 2004, BRIT J ANAESTH, V92, P4, DOI 10.1093/bja/aeh005; Ben Abraham R, 2002, CLIN J PAIN, V18, P282; BRUSTER S, 1994, BRIT MED J, V309, P1542, DOI 10.1136/bmj.309.6968.1542; Chae BK, 1998, SURG TODAY, V28, P727, DOI 10.1007/BF02484619; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; Correll DJ, 2001, REGION ANESTH PAIN M, V26, P444, DOI 10.1053/rapm.2001.26219; Erichsen CJ, 1996, ANESTHESIOLOGY, V84, P834, DOI 10.1097/00000542-199604000-00010; Handley GH, 1997, REGION ANESTH, V22, P435, DOI 10.1016/S1098-7339(97)80030-2; HECKER BR, 1988, PAIN, V35, P115, DOI 10.1016/0304-3959(88)90283-7; Horlocker TT, 2003, REGION ANESTH PAIN M, V28, P172, DOI 10.1053/rapm.2003.50046; JORGENSEN H, 2000, [No title captured]; Kampe S, 2001, ANAESTHESIA, V56, P1189; LIU S, 1995, ANESTHESIOLOGY, V82, P1474, DOI 10.1097/00000542-199506000-00019; Mann C, 2000, ANESTHESIOLOGY, V92, P433, DOI 10.1097/00000542-200002000-00025; McBeath D M, 1995, CRNA, V6, P31; McClure JH, 1996, BRIT J ANAESTH, V76, P300; Petropoulos G., 2000, Clinical and Experimental Obstetrics and Gynecology, V27, P42; Rockemann MG, 1997, ANASTH INTENSIV NOTF, V32, P414, DOI 10.1055/s-2007-995082; Rose DK, 1997, ANESTH ANALG, V84, P764, DOI 10.1097/00000539-199704000-00012; Scott DA, 1997, ANESTH ANALG, V85, P1322, DOI 10.1097/00000539-199712000-00026; SCOTT NB, 1988, BRIT J SURG, V75, P299; Shmookler B, 2001, MUSCULOSKELETAL CANCER SURGERY: TREATMENT OF SARCOMAS AND ALLIED DISEASES, P3; SWENSON JD, 1994, ANESTH ANALG, V78, P215, DOI 10.1213/00000539-199402000-00004; Van Boerum DH, 2000, SPINE, V25, P2355, DOI 10.1097/00007632-200009150-00014; Weinbroum A, 2001, MUSCULOSKELETAL CANCER SURGERY: TREATMENT OF SARCOMAS AND ALLIED DISEASES, P569; Weinbroum AA, 2000, CAN J ANAESTH, V47, P585, DOI 10.1007/BF03018952; Weinbroum AA, 2003, ANESTH ANALG, V96, P789; Weinbroum AA, 2002, CANCER-AM CANCER SOC, V95, P1164, DOI 10.1002/cncr.10784; Weinbroum AA, 2001, ANAESTHESIA, V56, P616, DOI 10.1046/j.1365-2044.2001.02088.x; Weinbroum AA, 2001, CAN J ANAESTH, V48, P167, DOI 10.1007/BF03019730; Wulf H, 1999, ANESTH ANALG, V89, P111, DOI 10.1097/00000539-199907000-00019	32	19	21	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	NOV	2005	138	5					869	876		10.1016/j.surg.2005.05.004			8	Surgery	Surgery	989DL	WOS:000233653000010	16291387				2020-06-30	J	Ozyurt, G; Basagan-Mogol, E; Bilgin, H; Tokat, O				Ozyurt, G; Basagan-Mogol, E; Bilgin, H; Tokat, O			Spinal anesthesia in a patient with severe thoracolumbar kyphoscoliosis	TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE			English	Article						spinal anesthesia; thoracolumbar kyphoscoliosis		Patients with spine abnormalities, present unique challenges to the health care provider responsible for administrating sedation and anesthesia during surgical and technical procedures. Spinal deformities may cause difficulties with both tracheal intubation and regional anesthesia. This report describes the anesthetic management for two urological operations that were performed in a patient with extremely severe thoracolumbar kyphoscoliosis. After examining the risk factors, spinal block by injecting single dose local anesthetic solution to the intratechal space was chosen to provide anesthesia. It has been suggested that hyperbaric solution, which is of high density compared with cerebrospinal fluid, can safely produce blocks for many operations under spinal anesthesia. In the first procedure, intrathecal injection of 6 mg hyperbaric bupivacaine, a local anesthetic solution (1.2 ml total volume), resulted in inadequate motor and sensory blockade, but the successful motor and sensory blockade at the level of Th10 was achieved in a second attempt with 6.25 mg hypobaric bupivacaine (2 ml). Because of this unexpected effect of local anesthetic solution, in the second operation, the technique was changed to intrathecal injection of 12.5 mg hypobaric bupivacaine (4 ml), and the motor and sensory blockade at Th10 was achieved again. The patient reported satisfactory anesthesia each time, and developed no complications. In conclusion, spinal anesthesia can be successful even in cases of severe thoracolumbar kyphoscoliosis. (c) 2005 Tohoku University Medical Press.	Uludag Univ, Sch Med, Dept Anesthesiol & Reanimat, TR-16059 Bursa, Turkey	Ozyurt, G (reprint author), Uludag Univ, Sch Med, Dept Anesthesiol, TR-16059 Bursa, Turkey.	gurayten@uludag.edu.tr	Bilgin, Hulya/A-7338-2016	Bilgin, Hulya/0000-0001-6639-5533			De Wachter D S, 1997, Technol Health Care, V5, P437; DOUGLAS MJ, 1995, CAN J ANAESTH, V42, P362, DOI 10.1007/BF03010719; DRESNER MR, 1995, ANAESTHESIA, V50, P807, DOI 10.1111/j.1365-2044.1995.tb06146.x; FRIED MJ, 1996, INT PRACTICE ANAETHE; Hagberg C, 1999, ANESTHESIA PERIOPERA, P3; Hatzakorzian R, 2001, ANESTHESIOLOGY, V95, P266, DOI 10.1097/00000542-200107000-00041; Kanri T, 1990, Shigaku, V78, P377; KLEINMAN W, 2002, CLIN ANAESTHESIOL, P253; LUI ACP, 1991, CAN J ANAESTH, V38, P522, DOI 10.1007/BF03007593; MALLAMPATI SR, 1985, CAN ANAESTH SOC J, V32, P429, DOI 10.1007/BF03011357; MORAN DH, 1990, ANESTH ANALG, V70, P445; Sakura S, 2000, Masui, V49, P18	12	12	13	0	2	TOHOKU UNIV MEDICAL PRESS	SENDAI	2-1, SEIRYO-MACHI, AOBA-KU, SENDAI, MIYAGI 980-8575, JAPAN	0040-8727	1349-3329		TOHOKU J EXP MED	Tohoku J. Exp. Med.	NOV	2005	207	3					239	242		10.1620/tjem.207.239			4	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	970DY	WOS:000232286600009	16210836	Bronze			2020-06-30	J	Stienen, PJ; de Groot, HNM; Venker-van Haagen, AJ; van den Brom, WE; Hellebrekers, LJ				Stienen, PJ; de Groot, HNM; Venker-van Haagen, AJ; van den Brom, WE; Hellebrekers, LJ			Differences between somatosensory-evoked potentials recorded from the ventral posterolateral thalamic nucleus, primary somatosensory cortex and vertex in the rat	BRAIN RESEARCH BULLETIN			English	Article						SEP; somatosensory system; primary somatosensory processing; nociception; fentanyl; analgesia	FIELD POTENTIALS; OPIOID RECEPTORS; PEDUNCULOPONTINE NUCLEUS; STARTLE RESPONSE; AUDITORY INPUT; MODULATION; AROUSAL; LATENCY; PAIN; SI	Somatosensory-evoked potential (SEP) components recorded over the primary somatosensory cortex (SI) and vertex in the rat within the 10-30 ms latency range were characterised with respect to the anatomy and function of the primary somatosensory pathway. To this aim, these components were compared to SEP components in the similar latency range recorded from the ventral posterolateral thalamic (VPL) nucleus, a nucleus known to be part of the subcortical structure of the primary somatosensory pathway and were described with respect to their stimulus-response characteristics and their response to the mu-opioid agonist fentanyl. The VPL positive (P)11-negative (N)18-P22 and SI P13-N18-P22 differed with respect to peak occurrence (P11 versus P13, respectively) and waveform morphology, but did not differ with respect to stimulus-response characteristics and their response to fentanyl. When compared to the vertex P15-N19-P26, the VPL P11-N18-P22 and SI P13-N18-P22 complex follow a relatively fast acquisition in stimulus intensity-response and were affected significantly less to increasing stimulus frequencies and to fentanyl. These results demonstrated that when compared to the VPL-SEP and SI-SEP, the Vx-SEP was modulated differently by the experimental conditions. It is suggested that this may be related to involvement of neural structures within different functional somatosensory pathways. (c) 2005 Elsevier Inc. All rights reserved.	Univ Utrecht, Fac Vet Med, Dept Clin Sci Compan Anim, NL-3508 TD Utrecht, Netherlands; Univ Utrecht, Fac Vet Med, Dept Equine Sci, NL-3508 TD Utrecht, Netherlands	Stienen, PJ (reprint author), Univ Utrecht, Fac Vet Med, Dept Clin Sci Compan Anim, POB 80-154,Yalelaan 8, NL-3508 TD Utrecht, Netherlands.	P.Stienen@vet.uu.nl					ATWEH SF, 1983, BRIT MED BULL, V39, P47, DOI 10.1093/oxfordjournals.bmb.a071789; Banoub M, 2003, ANESTHESIOLOGY, V99, P716, DOI 10.1097/00000542-200309000-00029; BERRY MS, 1976, BRAIN RES, V105, P1, DOI 10.1016/0006-8993(76)90919-7; Bromm B, 1998, ELECTROEN CLIN NEURO, V107, P227, DOI 10.1016/S0013-4694(98)00075-3; Casey KL, 2000, J NEUROPHYSIOL, V84, P525; CHAPIN JK, 1984, J COMP NEUROL, V229, P199, DOI 10.1002/cne.902290206; Chen YY, 2004, J NEUROSCI METH, V139, P99, DOI 10.1016/j.jneumeth.2004.04.022; DAVIS M, 1982, J NEUROSCI, V2, P791; de Bruin NMWJ, 2001, BIOL PSYCHOL, V55, P195, DOI 10.1016/S0301-0511(00)00084-3; DI S, 1994, BRAIN RES, V642, P267, DOI 10.1016/0006-8993(94)90931-8; DI S, 1990, J NEUROPHYSIOL, V63, P832; FEHLINGS MG, 1988, ELECTROEN CLIN NEURO, V69, P65, DOI 10.1016/0013-4694(88)90036-3; Freeman S, 1996, EVOKED POTENTIAL, V100, P362, DOI 10.1016/0168-5597(96)95690-7; Garcia-Rill E, 2004, PROG BRAIN RES, V143, P283, DOI 10.1016/S0079-6123(03)43027-6; Haberham ZL, 2000, BRAIN RES, V873, P287, DOI 10.1016/S0006-8993(00)02504-X; Heppelmann B, 2001, EXP BRAIN RES, V141, P501, DOI 10.1007/s002210100888; Homma Y, 2003, BRAIN RES BULL, V61, P189, DOI 10.1016/S0361-9230(03)00116-3; ISON JR, 1973, PHYSIOL BEHAV, V10, P1035, DOI 10.1016/0031-9384(73)90185-6; JONES AKP, 1991, NEUROSCI LETT, V126, P25, DOI 10.1016/0304-3940(91)90362-W; Kalliomaki J, 1998, PAIN, V77, P323, DOI 10.1016/S0304-3959(98)00115-8; LEANDRI M, 1989, ANN NEUROL, V25, P527, DOI 10.1002/ana.410250522; Lee JC, 2001, CHINESE J PHYSIOL, V44, P89; Li L, 1999, NEUROSCIENCE, V90, P139, DOI 10.1016/S0306-4522(98)00436-9; Mantzaridis H, 1997, ANAESTHESIA, V52, P1030, DOI 10.1111/j.1365-2044.1997.185-az0327.x; Millan MJ, 1999, PROG NEUROBIOL, V57, P1, DOI 10.1016/S0301-0082(98)00048-3; Miyazato H, 1999, BRAIN RES BULL, V48, P545, DOI 10.1016/S0361-9230(99)00034-9; Miyazato H, 1999, BRAIN RES, V822, P60, DOI 10.1016/S0006-8993(99)01074-4; MIYAZATO H, 1995, BRAIN RES BULL, V37, P247, DOI 10.1016/0361-9230(95)00003-W; Miyazato H, 1996, NEUROSCIENCE, V75, P289, DOI 10.1016/0306-4522(96)00176-5; Miyazato H, 2000, BRAIN RES BULL, V51, P387, DOI 10.1016/S0361-9230(99)00257-9; Paxinos G., 1998, RAT BRAIN STEREOTAXI; REESE NB, 1995, BRAIN RES BULL, V37, P257, DOI 10.1016/0361-9230(95)00002-V; REESE NB, 1995, BRAIN RES BULL, V37, P265, DOI 10.1016/0361-9230(95)00001-U; RICHARDS CD, 1983, BRIT J ANAESTH, V55, P201, DOI 10.1093/bja/55.3.201; Salami M, 2003, P NATL ACAD SCI USA, V100, P6174, DOI 10.1073/pnas.0937380100; SAMRA SK, 1987, ANESTHESIOLOGY, V66, P29, DOI 10.1097/00000542-198701000-00006; SCHOUENBORG J, 1986, BRAIN RES, V397, P86, DOI 10.1016/0006-8993(86)91371-5; Shaw FZ, 2001, BRAIN RES, V911, P105, DOI 10.1016/S0006-8993(01)02686-5; Shaw FZ, 1999, BRAIN RES, V824, P183, DOI 10.1016/S0006-8993(99)01185-3; Shaw N A, 1987, Electromyogr Clin Neurophysiol, V27, P235; Silbert SC, 2003, J NEUROSCI, V23, P34; Skinner RD, 2004, PROG BRAIN RES, V143, P291, DOI 10.1016/S0079-6123(03)43028-8; Stienen PJ, 2004, BRAIN RES, V1030, P256, DOI 10.1016/j.brainres.2004.10.014; Stienen PJ, 2003, J NEUROSCI METH, V126, P79, DOI 10.1016/S0165-0270(03)00070-0; Teneud L, 2000, BRAIN RES, V884, P196, DOI 10.1016/S0006-8993(00)02983-8; Van der Werf YD, 2002, BRAIN RES REV, V39, P107, DOI 10.1016/S0165-0173(02)00181-9; VANROTTERDAM A, 1993, ELECTROENCEPHALOGRAP, P85; VOGT BA, 1995, EXP NEUROL, V135, P83, DOI 10.1006/exnr.1995.1069; WIEDERHOLT WC, 1977, ELECTROEN CLIN NEURO, V42, P456, DOI 10.1016/0013-4694(77)90209-7; Willis WD, 1997, J CLIN NEUROPHYSIOL, V14, P2, DOI 10.1097/00004691-199701000-00002; Yeomans JS, 2002, NEUROSCI BIOBEHAV R, V26, P1, DOI 10.1016/S0149-7634(01)00057-4	51	6	7	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230			BRAIN RES BULL	Brain Res. Bull.	OCT 30	2005	67	4					269	280		10.1016/j.brainresbull.2005.06.038			12	Neurosciences	Neurosciences & Neurology	973VO	WOS:000232550900003	16182934				2020-06-30	J	Chhajed, PN; Aboyoun, C; Chhajed, TP; Malouf, MA; Harrison, GA; Tamm, M; Leuppi, JD; Glanville, AR				Chhajed, PN; Aboyoun, C; Chhajed, TP; Malouf, MA; Harrison, GA; Tamm, M; Leuppi, JD; Glanville, AR			Sedative drug requirements during bronchoscopy are higher in cystic fibrosis after lung transplantation	TRANSPLANTATION			English	Article						bronchoscopy; midazolam; fentanyl; propofol; lung transplantation	FLEXIBLE BRONCHOSCOPY; NASOPHARYNGEAL TUBE; ACUTE HYPOXEMIA; MIDAZOLAM; MANAGEMENT; PROPOFOL; RECIPIENTS; INSERTION; BIOPSY	Background. We noted that patients with cystic fibrosis tended to need higher doses of sedatives during bronchoscopy. We undertook this study to assess the sedative drug doses administered during bronchoscopy in lung transplant recipients and to assess if there is a change in the dosage requirements over time following lung transplantation. Methods. In all, 773 transbronchial biopsy procedures performed via flexible bronchoscopy were analyzed in 140 consecutive lung transplant recipients. Conscious sedation was achieved with intermittent boluses of intravenous midazolam and fentanyl. Intravenous propofol boluses of 10 to 30 mg were administered when optimal sedation was not achieved with midazolam doses of 0.20 to 0.25 mg/kg and fentanyl 2 to 2.5 micrograms/kg. Results. Mean doses of midazolam and fentanyl administered were 0.15 +/- 0.07 mg/kg (range 0.02 to 0.44 mg/kg) and 1.8 +/- 0.8 micrograms/kg (range 0.1 to 6.67 micrograms/kg) respectively. Midazolam and fentanyl doses administered to patients with cystic fibrosis were the highest compared to those with other disease types (P<0.0001). Examining the sedative doses administered over time following transplantation, there was a significant linear (P<0.00 1) and quadratic (P=0.0023) effect of time for midazolam and a significant linear (P=0.003) and a trend (P=0.08) for a quadratic effect for fentanyl. Propofol was effectively used in seven lung transplant recipients in whom adequate sedation could not be achieved with high doses of midazolam and fentanyl. Conclusions. There is an increase in sedative drug requirement with time for both midazolam and fentanyl after transplantation, which is significantly higher in patients with cystic fibrosis.	St Vincents Hosp, Lung Transplant Unit, Sydney, NSW 2010, Australia; St Vincents Hosp, Dept Crit Care Med & Anaesthesia, Sydney, NSW 2010, Australia	Chhajed, PN (reprint author), Univ Basel Hosp, Petersgraben 4, CH-4031 Basel, Switzerland.	pchhajed@uhbs.ch	Leuppi, Jorg/W-6798-2019				Aboyoun CL, 2001, AM J RESP CRIT CARE, V164, P460, DOI 10.1164/ajrccm.164.3.2011152; Chhajed P N, 2002, Indian J Chest Dis Allied Sci, V44, P31; Chhajed PN, 2004, SEMIN RESP CRIT CARE, V25, P413, DOI 10.1055/s-2004-832714; Chhajed PN, 2003, CLIN CHEST MED, V24, P511, DOI 10.1016/S0272-5231(03)00050-9; Chhajed PN, 2003, INTERN MED J, V33, P317, DOI 10.1046/j.1445-5994.2003.00403.x; Chhajed PN, 2003, J HEART LUNG TRANSPL, V22, P195, DOI 10.1016/S1053-2498(02)00462-X; Chhajed PN, 2002, CHEST, V121, P1350, DOI 10.1378/chest.121.4.1350; DUNDEE JW, 1984, DRUGS, V28, P519, DOI 10.2165/00003495-198428060-00002; Ereth Mark H., 1994, P91; FABRE G, 1988, BIOCHEM PHARMACOL, V37, P4389, DOI 10.1016/0006-2952(88)90622-3; Graber RG, 1999, GASTROINTEST ENDOSC, V49, P803, DOI 10.1016/S0016-5107(99)70308-1; Heuss LT, 2003, GASTROINTEST ENDOSC, V57, P664, DOI 10.1067/mge.2003.191; Honeybourne D, 2001, THORAX, V56, pI1; Hopkins PM, 2002, J HEART LUNG TRANSPL, V21, P1062, DOI 10.1016/S1053-2498(02)00442-4; Hopkins PM, 2004, AM J RESP CRIT CARE, V170, P1022, DOI 10.1164/rccm.200302-165oc; Knoblanche GE, 2002, MED J AUSTRALIA, V176, P147, DOI 10.5694/j.1326-5377.2002.tb04341.x; KRONBACH T, 1989, MOL PHARMACOL, V36, P89; RANDELL T, 1992, ACTA ANAESTH SCAND, V36, P221, DOI 10.1111/j.1399-6576.1992.tb03453.x; Rey E, 1998, CLIN PHARMACOKINET, V35, P313, DOI 10.2165/00003088-199835040-00004; Stolz D, 2004, THORAX, V59, P773, DOI 10.1136/thx.2003.019836; Tamm M, 2004, AM J RESP CRIT CARE, V170, P1120, DOI 10.1164/rccm.200310-1405OC; TAN KKC, 1993, CLIN PHARMACOL THER, V53, P544, DOI 10.1038/clpt.1993.68; Williams TJ, 1999, RESP MED, V93, P361, DOI 10.1016/S0954-6111(99)90320-7	23	13	14	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0041-1337	1534-6080		TRANSPLANTATION	Transplantation	OCT 27	2005	80	8					1081	1085		10.1097/01.tp.0000176925.13074.90			5	Immunology; Surgery; Transplantation	Immunology; Surgery; Transplantation	985KF	WOS:000233375600013	16278589				2020-06-30	J	Royse, CE; Royse, AG; Deelen, DA				Royse, CE; Royse, AG; Deelen, DA			An audit of morphine versus fentanyl as an adjunct to ropivacaine 0.2% for high thoracic epidural analgesia	ANAESTHESIA AND INTENSIVE CARE			English	Article						anaesthetic, local : morphine; fentanyl; epidural; side-effects	INFUSION; BUPIVACAINE; DIFFERENCE; SURGERY; LUMBAR; SITE; PAIN	When used as an adjunct to local anaesthetic, opioid administered via the epidural route can improve the quality of analgesia. Reports of respiratory depression associated with epidural morphine use as a sole agent in the 1980s led to an increased use of lipophilic opioids, especially fentanyl. Although fentanyl is commonly used, controversy exists about its efficacy and site of action. It is possible that low-dose morphine may be more effective than fentanyl, without increasing the risk of respiratory depression. A retrospective audit was conducted of 200 consecutive patients undergoing coronary artery bypass surgery who received high thoracic epidural analgesia. One hundred patients who received fentanyl 2 mu g/ml with 0.2% ropivacaine, prior to a change in our technique, were audited, followed by 100 patients who received 20 mu g/ml morphine with 0.2% ropivacaine. Outcome measures included the incidence of Visual Analogue Score (VAS) 4110; infusion rate adjustments; and side-effects. Patients receiving fentanyl were more likely to experience pain >= 4/10 (P'=0.002); the infusion rate was higher (P'=0.024); required more rate adjustments (P'=0. 001); a greater need for noradrenaline (P' =0.001) and antiemetic drugs (P'= 0. 001). There were no significant differences between the groups for sedation scores or the incidence of respiratory depression. This audit suggests morphine 20 mu g/ml may be superior to fentanyl 2 mu g/ml, as an adjunct to 0.2% ropivacaine. We found a reduced number of infusion interventions and less inadequate patient analgesia.	Univ Melbourne, Dept Pharmacol, Melbourne, Vic, Australia; Royal Melbourne Hosp, Dept Anaesthesia & Pain Management, Melbourne, Vic, Australia; Royal Melbourne Hosp, Dept Cardiac Serv, Melbourne, Vic, Australia			; Royse, Alistair/A-6046-2008	Royse, Colin/0000-0002-2250-8927; Royse, Alistair/0000-0002-4449-663X			DELEONCASASOLA OA, 1994, ANESTHESIOLOGY, V81, P368, DOI 10.1097/00000542-199408000-00015; ELDOR J, 1985, Harefuah, V108, P441; FISCHER RL, 1988, ANESTH ANALG, V67, P559; FULLER JG, 1990, CAN J ANAESTH, V37, P636, DOI 10.1007/BF03006481; Ginosar Y, 2003, ANESTH ANALG, V97, P1428, DOI 10.1213/01.ANE.0000081793.60059.10; GOURLAY GK, 1985, PAIN, V23, P317, DOI 10.1016/0304-3959(85)90001-6; GOURLAY GK, 1989, PAIN, V38, P253, DOI 10.1016/0304-3959(89)90210-8; Higuchi H, 2005, ANESTHESIOLOGY, V102, P285, DOI 10.1097/00000542-200502000-00008; Husegaard H C, 1982, Ugeskr Laeger, V144, P2652; Ishihara H, 1983, Masui, V32, P241; Jensen F M, 1982, Ugeskr Laeger, V144, P2651; Macguire B, 2000, Ann Thorac Cardiovasc Surg, V6, P13; Mather LE, 2003, ANESTH ANALG, V97, P1211, DOI 10.1213/01.ANE.0000092951.32643.A6; Royse AG, 1999, ANN THORAC SURG, V68, P1612, DOI 10.1016/S0003-4975(99)00676-1; Royse C, 2003, ANN THORAC SURG, V75, P93, DOI 10.1016/S0003-4975(02)04074-2; SANDLER AN, 1986, CAN J ANAESTH, V33, P542, DOI 10.1007/BF03014258; Scott DA, 1999, ANESTH ANALG, V88, P857, DOI 10.1097/00000539-199904000-00033	17	6	9	0	0	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2021, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	OCT	2005	33	5					639	644		10.1177/0310057X0503300514			6	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	987HU	WOS:000233509800015	16235484	Bronze			2020-06-30	J	Erden, V; Yangin, Z; Erkalp, K; Delatioglu, H; Bahceci, F; Seyhan, A				Erden, V; Yangin, Z; Erkalp, K; Delatioglu, H; Bahceci, F; Seyhan, A			Increased progesterone production during the luteal phase of menstruation may decrease anesthetic requirement	ANESTHESIA AND ANALGESIA			English	Article							MINIMUM ALVEOLAR CONCENTRATION; BISPECTRAL INDEX; SEVOFLURANE REQUIREMENTS; ISOFLURANE; WOMEN; CYCLE; MEN; ALLOPREGNANOLONE; TITRATION; INCISION	Besides having important hormonal effects, progesterone has depressant and hypnotic effects on the brain. In this study, we compared women in the follicular phase with low progesterone levels and in the luteal phase with high progesterone levels regarding their anesthetic requirements. Twenty patients with menstrual cycle days from 1 to 10 (follicular group) and 20 patients with menstrual cycle days from 18 to 24 (luteal group) were included in the study. Anesthesia was induced with fentanyl and thiopental; relaxation was secured with rocuronium, and anesthesia was maintained with a mixture of nitrous oxide 2 L/min and oxygen 2 L/min plus sevoflurane. The delivered sevoflurane concentration was adjusted to sustain a constant bispectral index value that averaged 46 in both groups. To determine the progesterone levels, blood samples were taken from all patients before surgery. We found that progesterone levels were 0.86 +/- 0.30 ng/mL in the follicular group and 7.48 +/- 3.86 ng/mL in the luteal group. The minimum alveolar anesthetic concentration (MAC)-hour (MAC-h) value of sevoflurane in the follicular group (1.55 +/- 0.18 MAC-h) was significantly larger than in the luteal group (1.3 +/- 0.13 MAC-h) (P < 0.0001). The sevoflurane requirements were larger in the follicular group during the maintenance phase of anesthesia. In conclusion, high progesterone levels during the luteal phase might be the cause of decreased anesthetic requirement.	SSK Vakif Gureba Hosp, Dept Anesthesiol, Istanbul, Turkey; SSK Vakif Gureba Hosp, Dept Obstet Gynecol, Istanbul, Turkey	Yangin, Z (reprint author), Siyavuspasa Cad Lale Sok 8-20 Bahcelievler, Istanbul, Turkey.	zehrayangin@hotmail.com					BITRAN D, 1995, J NEUROENDOCRINOL, V7, P171, DOI 10.1111/j.1365-2826.1995.tb00744.x; Bruhn J, 2000, ANESTHESIOLOGY, V92, P1485, DOI 10.1097/00000542-200005000-00042; CARL P, 1990, ANAESTHESIA, V45, P189, DOI 10.1111/j.1365-2044.1990.tb14683.x; CHAN MTV, 1995, ANESTHESIOLOGY, V82, P1360, DOI 10.1097/00000542-199506000-00006; DATTA S, 1989, ANESTH ANALG, V68, P46; Eger EI, 2003, ANESTHESIOLOGY, V99, P1059, DOI 10.1097/00000542-200311000-00009; Eger EI, 2001, ANESTH ANALG, V93, P947, DOI 10.1097/00000539-200110000-00029; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRANKS NP, 1993, BRIT J ANAESTH, V71, P65, DOI 10.1093/bja/71.1.65; FRIESS E, 1997, [No title captured], V272, P885; GIN T, 1994, ANESTHESIOLOGY, V81, P829, DOI 10.1097/00000542-199410000-00009; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; Goldfien A., 1998, BASIC CLIN PHARM, P653; Hemmerling TM, 2002, ANESTH ANALG, V95, P322, DOI 10.1097/00000539-200208000-00014; HERZOG AG, 1995, NEUROLOGY, V45, P1660, DOI 10.1212/WNL.45.9.1660; Johansen JW, 2000, J CLIN ANESTH, V12, P433, DOI 10.1016/S0952-8180(00)00187-2; Katoh T, 1998, ANESTHESIOLOGY, V88, P18, DOI 10.1097/00000542-199801000-00006; Katoh T, 1999, ANESTHESIOLOGY, V90, P398, DOI 10.1097/00000542-199902000-00012; Krasowski MD, 1998, MOL PHARMACOL, V53, P530; Lancel M, 1997, J PHARMACOL EXP THER, V282, P1213; LANCEL M, 1996, [No title captured], V271, P763; Nadeson R, 2001, BRIT J ANAESTH, V86, P704, DOI 10.1093/bja/86.5.704; PALAHNIUK RJ, 1974, ANESTHESIOLOGY, V41, P82, DOI 10.1097/00000542-197407000-00021; PAUL SM, 1992, FASEB J, V6, P2311; Pavlin DJ, 2001, ANESTH ANALG, V93, P613, DOI 10.1097/00000539-200109000-00017; Pfleeger M, 1997, INT J PSYCHOPHYSIOL, V27, P161, DOI 10.1016/S0167-8760(97)00058-5; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; REGAN MJ, 1967, ANESTHESIOLOGY, V28, P689, DOI 10.1097/00000542-196707000-00015; Riley JL, 1999, PAIN, V81, P225, DOI 10.1016/S0304-3959(98)00258-9; Sebel PS, 1997, ANESTH ANALG, V84, P891, DOI 10.1097/00000539-199704000-00035; Soderpalm AHV, 2004, PSYCHONEUROENDOCRINO, V29, P339, DOI 10.1016/S0306-4530(03)00033-7; SPEROFF L, 2005, CLIN GYNECOLOGIC END, P1013; Speroff L., 1999, CLIN GYNECOLOGIC END, P31; Speroff L, 1999, CLIN GYNECOLOGIC END, P200; Tanifuji Y, 1988, Masui, V37, P1240; VEITH JL, 1984, PHYSIOL BEHAV, V32, P31, DOI 10.1016/0031-9384(84)90065-9; Wadhwa A, 2003, ANESTHESIOLOGY, V99, P1062, DOI 10.1097/00000542-200311000-00010; Wong J, 2002, CAN J ANAESTH, V49, P13, DOI 10.1007/BF03020413	39	30	36	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	OCT	2005	101	4					1007	1011		10.1213/01.ane.0000168271.76090.63			5	Anesthesiology	Anesthesiology	967TZ	WOS:000232115400013	16192510				2020-06-30	J	Richebe, P; Rivat, C; Creton, C; Laulin, JP; Maurette, P; Lemaire, M; Simonnet, G				Richebe, P; Rivat, C; Creton, C; Laulin, JP; Maurette, P; Lemaire, M; Simonnet, G			Nitrous oxide revisited - Evidence for potent antihyperalgesic properties	ANESTHESIOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 11-15, 2003	SAN FRANCISCO, CA	Amer Soc Anesthesiologists			LONG-LASTING HYPERALGESIA; AMINO-ACID RECEPTORS; POSTOPERATIVE PAIN; MORPHINE-TOLERANCE; DOSE KETAMINE; FISCHER RATS; REMIFENTANIL; FENTANYL; ANALGESIA; SENSITIVITY	Background: Although opioids are unsurpassed analgesics for surgery, they also induce an N-methyl-D-aspartate-dependent enhancement of postoperative hyperalgesia. Because nitrous oxide (N2O) has anti-V-methyl-D-aspartate properties, the purpose of this study was to evaluate nitrous oxide ability to prevent such an opioid-induced hyperalgesia in rats. Methods: First, preventive effects of 50/50% NZO-O-2 on the development of delayed hyperalgesia observed after inflammatory pain (hind paw carrageenan injection on D-0) were examined for several days. Second, the ability of nitrous oxide (10-40%) to limit opioid-induced hyperalgesia induced by fentanyl was evaluated in nonsuffering rats. Third, antihyperalgesic effects of various nitrous oxide concentrations (20-50%) were assessed in both inflammatory and incisional pain models in fentanyl-treated rats (4 x 100 mu g/kg subcutaneously). Finally, the analgesic effect of a single dose of morphine was evaluated 24 h after fentanyl administration and nitrous oxide (D-0) to assess its preventive effect on acute morphine tolerance in both nonsuffering and hind paw-incised rats. Results: When applied on D-0, nitrous oxide reduced delayed hyperalgesia induced by inflammation. Exposure to nitrous oxide on Do also reduced opioid-induced hyperalgesia in nonsuffering rats in a dose-dependent manner. In fentanyl-treated rats with inflammatory or incisional pain, nitrous oxide strongly limited both magnitude and duration of hyperalgesia. Moreover, nitrous oxide exposure on D-0 opposed development of acute tolerance to analgesic effects of morphine administered on D-1 in both nonsuffering and incised fentanyl-treated rats. Conclusions: Nitrous oxide, an N-methyl-D-aspartate receptor antagonist, prevented the enhancement of pain sensitivity induced by both nociceptive inputs and fentanyl and opposed acute morphine tolerance. Results suggest that perioperative nitrous oxide use reduces exaggerated postoperative pain and morphine consumption.	Univ Bordeaux 2, Lab Homeostasie Allostasie Pathol, EA 3666, F-33076 Bordeaux, France	Simonnet, G (reprint author), Univ Bordeaux 2, Lab Homeostasie Allostasie Pathol, EA 3666, 146,Rue Leo Saignat, F-33076 Bordeaux, France.	gsimonnet@yahoo.com	RIVAT, Cyril/B-5697-2008; Rivat, Cyril/F-8482-2019	Rivat, Cyril/0000-0002-7491-6113			Angst MS, 2003, PAIN, V106, P49, DOI 10.1016/S0304-3959(03)00276-8; Brennan TJ, 1996, PAIN, V64, P493, DOI 10.1016/0304-3959(95)01441-1; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Celerier E, 2001, J NEUROSCI, V21, P4074, DOI 10.1523/JNEUROSCI.21-11-04074.2001; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; CODERRE TJ, 1993, MOL NEUROBIOL, V7, P229, DOI 10.1007/BF02769177; Cooper DW, 1997, BRIT J ANAESTH, V78, P311; De Kock M, 2001, PAIN, V92, P373, DOI 10.1016/S0304-3959(01)00278-0; Fletcher D, 1997, PAIN, V69, P303, DOI 10.1016/S0304-3959(96)03227-7; Fujinaga M, 2002, MOL NEUROBIOL, V25, P167, DOI 10.1385/MN:25:2:167; GONSOWSKI CT, 1994, ANESTH ANALG, V79, P710; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Guignard B, 2002, ANESTH ANALG, V95, P103, DOI 10.1097/00000539-200207000-00018; Himmelseher S, 2005, ANESTHESIOLOGY, V102, P211, DOI 10.1097/00000542-200501000-00030; Jevtovic-Todorovic V, 1998, NAT MED, V4, P460, DOI 10.1038/nm0498-460; KAYSER V, 1987, PAIN, V28, P99, DOI 10.1016/0304-3959(87)91064-5; KAYSER V, 1990, BRAIN RES, V508, P329, DOI 10.1016/0006-8993(90)90418-B; Koppert W, 2003, ANESTHESIOLOGY, V99, P152, DOI 10.1097/00000542-200307000-00025; Laulin JP, 1999, NEUROSCIENCE, V89, P631, DOI 10.1016/S0306-4522(98)00652-6; Laulin JP, 1998, EUR J NEUROSCI, V10, P782, DOI 10.1046/j.1460-9568.1998.00083.x; Macrae WA, 2001, BRIT J ANAESTH, V87, P88, DOI 10.1093/bja/87.1.88; MAO J, 1994, J NEUROSCI, V14, P2301; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; McCartney CJL, 2004, ANESTH ANALG, V98, P1385, DOI 10.1213/01.ANE.0000108501.57073.38; Millan MJ, 1999, PROG NEUROBIOL, V57, P1, DOI 10.1016/S0301-0082(98)00048-3; Ohashi Y, 2003, ANESTHESIOLOGY, V99, P947, DOI 10.1097/00000542-200310000-00030; Orii R, 2003, ANESTHESIOLOGY, V98, P1223, DOI 10.1097/00000542-200305000-00026; Richebe P, 2005, ANESTHESIOLOGY, V102, P421, DOI 10.1097/00000542-200502000-00028; Rivat C, 2002, ANESTHESIOLOGY, V96, P381, DOI 10.1097/00000542-200202000-00025; Schmid RL, 1999, PAIN, V82, P111, DOI 10.1016/S0304-3959(99)00044-5; Simonnet G, 2003, NEUROREPORT, V14, P1, DOI 10.1097/00001756-200301200-00001; Stubhaug A, 1997, ACTA ANAESTH SCAND, V41, P1124, DOI 10.1111/j.1399-6576.1997.tb04854.x; Subramaniam K, 2004, ANESTH ANALG, V99, P482, DOI 10.1213/01.ANE.0000118109.12855.07; Vanderah TW, 2001, PAIN, V92, P5, DOI 10.1016/S0304-3959(01)00311-6; Vinik HR, 1998, ANESTH ANALG, V86, P1307, DOI 10.1097/00000539-199806000-00033; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765	36	52	56	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	OCT	2005	103	4					845	854		10.1097/00000542-200510000-00024			10	Anesthesiology	Anesthesiology	970PO	WOS:000232322300023	16192778				2020-06-30	J	Beale, N; Evans, B; Plaat, F; Columb, MO; Lyons, G; Stocks, GM				Beale, N; Evans, B; Plaat, F; Columb, MO; Lyons, G; Stocks, GM			Effect of epidural volume extension on dose requirement of intrathecal hyperbaric bupivacaine at Caesarean section	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetic techniques, epidural volume extension; anaesthetics local, intrathecal bupivacaine	SPINAL-ANESTHESIA; BLOCK; INJECTION; DELIVERY; LEVEL	Background. The technique of epidural volume extension (EVE) involves the injection of saline into the extradural space immediately following the intrathecal injection, as part of a combined spinal-epidural (CSE) anaesthetic. One of the suggested benefits of EVE is a reduction in local anaesthetic required. The aim of this study was to test this hypothesis by comparing the median effective doses (ED50) of hyperbaric bupivacaine with fentanyl 25 mg with and without EVE for Caesarean section. Methods. Sixty women were randomized to receive either CSE anaesthesia with EVE (EVE group) or no EVE (NEVE group). Using a double-blinded, up-down sequential technique, varying doses of bupivacaine with fentanyl 25 mu g were administered. ED50 was estimated from up-down reversals and probit regression. Results. The ED50 for bupivacaine was similar and not significantly different in the two groups (5.1 mg in the EVE and 6.1 mg in the NEVE group; difference 1.0 mg, 95% CI-0.12 to 2.2, P = 0.08). Conclusions. This study illustrates that whilst low doses of intrathecal bupivacaine can be effectively used for Caesarean section, at such doses EVE does not appear to offer reliable or clinically relevant reductions in dosing with intrathecal bupivacaine.	Queen Charlottes & Chelsea Hosp, London W6 0XG, England; S Manchester Univ Hosp, Manchester, Lancs, England; St Jamess Univ Hosp, Leeds, W Yorkshire, England	Stocks, GM (reprint author), Queen Charlottes & Chelsea Hosp, London W6 0XG, England.	gstocks@hhnt.org	Columb, Malachy/F-9588-2016	Columb, Malachy/0000-0001-7837-4262			Ben-David B, 2000, REGION ANESTH PAIN M, V25, P235, DOI 10.1016/S1098-7339(00)90004-X; BLUMGART CH, 1992, BRIT J ANAESTH, V69, P457, DOI 10.1093/bja/69.5.457; Lew E, 2004, ANESTH ANALG, V98, P810; LIU S, 1995, ANESTHESIOLOGY, V82, P60, DOI 10.1097/00000542-199501000-00009; Mardirosoff C, 1998, REGION ANESTH PAIN M, V23, P92, DOI 10.1016/S1098-7339(98)90117-1; Russell I F, 1995, Int J Obstet Anesth, V4, P71, DOI 10.1016/0959-289X(95)82995-M; Russell IF, 2004, INT J OBSTET ANESTH, V13, P146, DOI 10.1016/j.ijoa.2003.12.007; Stienstra R, 1999, ANESTH ANALG, V88, P810, DOI 10.1097/00000539-199904000-00024; Takiguchi T, 1997, ANESTH ANALG, V85, P1097, DOI 10.1097/00000539-199711000-00024; Vercauteren MP, 1998, ANESTH ANALG, V86, P989, DOI 10.1097/00000539-199805000-00014; Yamazaki Y, 2000, J Anesth, V14, P73, DOI 10.1007/s005400050070	11	34	48	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	OCT	2005	95	4					500	503		10.1093/bja/aei200			4	Anesthesiology	Anesthesiology	965AF	WOS:000231921400012	16040637	Green Published, Bronze			2020-06-30	J	Benrath, J; Brechtel, C; Sandkuhler, J				Benrath, J; Brechtel, C; Sandkuhler, J			Low dose of S(+)-ketamine prevents long-term potentiation in pain pathways under strong opioid analgesia in the rat spinal cord in vivo	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetics i.v., ketamine; analgesia, pre-emptive; analgesics, opioid, fentanyl; model, rat; spinal cord, c-fibres	D-ASPARTATE RECEPTOR; POSTOPERATIVE PAIN; PREEMPTIVE ANALGESIA; CENTRAL SENSITIZATION; LASTING HYPERALGESIA; ACUTE TOLERANCE; KETAMINE; MANAGEMENT; FENTANYL; SURGERY	Background. mu-Opioid receptor (MOR) agonists are strong antinociceptive drugs. Low, but not high doses of the MOR agonist fentanyl prevent synaptic long-term potentiation (LTP) in pain pathways. Block of spinal N-methyl-D-aspartate (NMDA) receptors prevent central sensitization. Here we tested whether the NMDA receptor antagonist S(+)-ketamine reduces C-fibre-evoked potentials and prevents induction of LTP despite high doses of fentanyl. Methods. C-fibre-evoked field potentials were recorded in the superficial laminae I/II of the rat lumbar spinal cord. High-frequency stimulation (HFS) was applied to the sciatic nerve at C-fibre strength to induce LTP. S(+)-ketamine 5 mg kg(-1) was given 1 h before or after HFS. S(+)-ketamine 5 mg kg(-1) and fentanyl as a bolus ( 40 mg kg(-1)) followed by an infusion (96 mu g kg(-1) h(-1)) were given before HFS to test the action of the combination of these drugs. Results. HFS potentiated C-fibre-evoked field potentials to mean 173 (SEM 15)% of control (n = 7) for at least 1 h. Low-dose S(+)-ketamine given before HFS blocked the induction of LTP. S(+)-ketamine given after HFS had no effect on the maintenance of LTP. Low-dose S(+)-ketamine prevented induction of LTP under fentanyl-infusion. Conclusions. Low-dose S(+)-ketamine does not affect C-fibre-evoked potentials alone but blocks LTP induction in pain pathways. In contrast, high doses of opioids strongly reduce C-fibre-evoked potentials, but do not fully prevent LTP induction. In this animal study the combination of S(+)-ketamine with fentanyl reveals both a reduction of C-fibre-evoked potentials and prevention of LTP and seem therefore a better choice for perioperative pain management compared with the sole administration.	Med Univ Wien, Abt Neurophysiol, Zentrum Hirnforschung, A-1090 Vienna, Austria; Heidelberg Univ, Inst Physiol & Pathophysiol, D-69120 Heidelberg, Germany; Med Univ Wien, Klin Abt Anasthesie & Allgemeine Intens Med B, A-1090 Vienna, Austria	Sandkuhler, J (reprint author), Med Univ Wien, Abt Neurophysiol, Zentrum Hirnforschung, Spitalgasse 4, A-1090 Vienna, Austria.	juergen.sandkuehler@meduniwien.ac.at	Sandkuhler, Jurgen/B-6648-2012	Sandkuhler, Jurgen/0000-0002-5209-485X			Benrath J, 2004, ANESTHESIOLOGY, V100, P1545, DOI 10.1097/00000542-200406000-00030; Benrath J, 2005, BRIT J ANAESTH, V95, P247, DOI 10.1093/bja/aei158; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Celerier E, 2001, J NEUROSCI, V21, P4074, DOI 10.1523/JNEUROSCI.21-11-04074.2001; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; Crombie IK, 1998, PAIN, V76, P167, DOI 10.1016/S0304-3959(98)00038-4; Elia N, 2005, PAIN, V113, P61, DOI 10.1016/j.pain.2004.09.036; Fisher K, 2000, J PAIN SYMPTOM MANAG, V20, P358, DOI 10.1016/S0885-3924(00)00213-X; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Hao JX, 1998, ACTA ANAESTH SCAND, V42, P435, DOI 10.1111/j.1399-6576.1998.tb05138.x; Hayes C, 2004, ANAESTH INTENS CARE, V32, P330, DOI 10.1177/0310057X0403200305; Hewitt DJ, 2000, CLIN J PAIN, V16, pS73, DOI 10.1097/00002508-200006001-00013; Himmelseher S, 2005, ANESTHESIOLOGY, V102, P211, DOI 10.1097/00000542-200501000-00030; Hocking G, 2003, ANESTH ANALG, V97, P1730, DOI 10.1213/01.ANE.0000086618.28845.9B; Ikeda H, 2003, SCIENCE, V299, P1237, DOI 10.1126/science.1080659; Joo G, 2000, ANESTHESIOLOGY, V93, P231, DOI 10.1097/00000542-200007000-00034; KATZ J, 1992, ANESTHESIOLOGY, V77, P439, DOI 10.1097/00000542-199209000-00006; Kissin I, 2000, ANESTHESIOLOGY, V93, P1138, DOI 10.1097/00000542-200010000-00040; Kissin I, 2000, ANESTH ANALG, V91, P1483, DOI 10.1097/00000539-200012000-00035; Lahtinen P, 2004, ANESTH ANALG, V99, P1295, DOI 10.1213/01.ANE.0000133913.07342.B9; Larcher A, 1998, NEUROSCIENCE, V84, P583, DOI 10.1016/S0306-4522(97)00556-3; Li XQ, 2001, MOL BRAIN RES, V86, P56, DOI 10.1016/S0169-328X(00)00260-6; LIU XG, 1995, NEUROSCI LETT, V191, P43, DOI 10.1016/0304-3940(95)11553-0; McCartney CJL, 2004, ANESTH ANALG, V98, P1385, DOI 10.1213/01.ANE.0000108501.57073.38; Moiniche S, 2002, ANESTHESIOLOGY, V96, P725, DOI 10.1097/00000542-200203000-00032; RANDIC M, 1993, J NEUROSCI, V13, P5228; Reeh P W, 2000, Prog Brain Res, V129, P39; Richebe P, 2005, ANESTHESIOLOGY, V102, P421, DOI 10.1097/00000542-200502000-00028; Rivat C, 2002, ANESTHESIOLOGY, V96, P381, DOI 10.1097/00000542-200202000-00025; Sandkuhler J, 2000, PAIN, V88, P113, DOI 10.1016/S0304-3959(00)00424-3; Schmid RL, 1999, PAIN, V82, P111, DOI 10.1016/S0304-3959(99)00044-5; Simonnet G, 2003, NEUROREPORT, V14, P1, DOI 10.1097/00001756-200301200-00001; Stubhaug A, 1997, ACTA ANAESTH SCAND, V41, P1124, DOI 10.1111/j.1399-6576.1997.tb04854.x; Subramaniam K, 2004, ANESTH ANALG, V99, P482, DOI 10.1213/01.ANE.0000118109.12855.07; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026	36	36	41	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	OCT	2005	95	4					518	523		10.1093/bja/aei215			6	Anesthesiology	Anesthesiology	965AF	WOS:000231921400016	16113037	Bronze			2020-06-30	J	Pandey, CK; Singhal, V; Kumar, M; Lakra, A; Ranjan, R; Pal, R; Raza, M; Singh, U; Singh, PK				Pandey, CK; Singhal, V; Kumar, M; Lakra, A; Ranjan, R; Pal, R; Raza, M; Singh, U; Singh, PK			Gabapentin provides effective postoperative analgesia whether administered pre-emptively or post-incision	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							INTRATHECAL GABAPENTIN; PAIN; RAT; SENSITIZATION; HYSTERECTOMY; MODEL	Purpose: We investigated the effects of pre-incision and post-incision administration of gabapentin on postoperative pain and fentanyl consumption associated with open donor nephrectomy. Methods: Sixty ASA I subjects were randomly allocated into three groups to receive gabapentin 600 mg two hours before surgery and placebo after surgical incision (pre-incision group), placebo two hours before surgery and gabapentin 600 mg after surgical incision (post-incision group), or placebo two hours before surgery and after surgical incision (placebo group). After surgery, pain was assessed using a visual analogue scale (VAS), (1-10 cm) at time points 0, 6, 12, 18, and 24 hr. Subjects received patient-controlled-analgesia (fentanyl 1.0 mu g(.)kg(-1) subject activated dose). Total fentanyl consumption in each group was recorded. Results: Subjects of pre-incision and post-incision groups had lower VAS scores at all time points (3.1 +/- 1.8, 2.9 +/- 1.3, 2.8 +/- 1.3, 2.5 +/- 0.9, 2.5 +/- 1.5 and 3.6 +/- 1.1, 3.0 +/- 1.2, 3.2 +/- 1.1, 2.9 +/- 1.0, 2.6 +/- 2.2) compared to placebo group (6.6 +/- 1.3, 5.0 +/- 1.0, 4.4 +/- 0.7, 4.2 +/- 0.8, 3.9 +/- 1.0). They also used less fentanyl (563.3 mu g +/- 252.8 and 624.0 mu g +/- 210.5 respectively) compared to placebo (924.7 mu g +/- 417.5), (P < 0.05). No difference in total fentanyl consumption and pain scores at any time points were observed between pre- and post-incision groups. Conclusion: Pre-incision administration of 600 mg gabapentin has no added benefit over post-incision administration in terms of pain scores and fentanyl consumption in subjects undergoing open donor nephrectomy.	Sanjay Gandhi Postgrad Inst Med Sci, Dept Anaesthesiol, Lucknow 226014, Uttar Pradesh, India; Sanjay Gandhi Postgrad Inst Med Sci, Dept Biostat, Lucknow 226014, Uttar Pradesh, India	Pandey, CK (reprint author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Anaesthesiol, Lucknow 226014, Uttar Pradesh, India.	ckpandey@sgpgi.ac.in					Cheng JK, 2000, ANESTHESIOLOGY, V92, P1126, DOI 10.1097/00000542-200004000-00031; Dirks J, 2002, ANESTHESIOLOGY, V97, P1591, DOI 10.1097/00000542-200212000-00035; Dirks J, 2002, ANESTHESIOLOGY, V97, P102, DOI 10.1097/00000542-200207000-00015; Dirks J, 2002, ANESTHESIOLOGY, V97, P560, DOI 10.1097/00000542-200209000-00007; Feng Y, 2003, ANESTHESIOLOGY, V98, P729, DOI 10.1097/00000542-200303000-00023; Field MJ, 1997, J PHARMACOL EXP THER, V282, P1242; Gee NS, 1996, J BIOL CHEM, V271, P5768, DOI 10.1074/jbc.271.10.5768; Hurley RW, 2002, ANESTHESIOLOGY, V97, P1263, DOI 10.1097/00000542-200211000-00033; Maneuf YP, 2001, BRIT J PHARMACOL, V134, P237, DOI 10.1038/sj.bjp.0704227; Rorarius MGF, 2004, PAIN, V110, P175, DOI 10.1016/j.pain.2004.03.023; Turan A, 2004, ANESTH ANALG, V98, P1370, DOI 10.1213/01.ANE.0000108964.70485.B2; Turan A, 2004, ANESTHESIOLOGY, V100, P935, DOI 10.1097/00000542-200404000-00025; Werner MU, 2001, REGION ANESTH PAIN M, V26, P322, DOI 10.1053/rapm.2001.25070; Yoon MH, 1999, ANESTHESIOLOGY, V91, P1006, DOI 10.1097/00000542-199910000-00021; Yoon MH, 1999, ANESTH ANALG, V89, P434, DOI 10.1097/00000539-199908000-00034	15	53	55	0	1	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	OCT	2005	52	8					827	831		10.1007/BF03021777			5	Anesthesiology	Anesthesiology	980ND	WOS:000233024300008	16189334	Bronze			2020-06-30	J	Muller-Busch, HC; Lindena, G; Tietze, K; Woskanjan, S				Muller-Busch, HC; Lindena, G; Tietze, K; Woskanjan, S			Opioid switch in palliative care, opioid choice by clinical need and opioid availability	EUROPEAN JOURNAL OF PAIN			English	Article						palliative care; pain treatment; strong opioids; opioid switch; opioid rotation; adverse events	RESPONSIVE CANCER PAIN; TOXICITY REDUCTION; MORPHINE; ROTATION; HYDROMORPHONE; STRATEGIES; MANAGEMENT; ANALGESIA; METHADONE; SYMPTOMS	Availability of different WHO-step 3 opioids has encouraged the discussion on their value and led to the concepts of opioid rotation. Rotation is suggested, when other measures fail to achieve optimal analgesia and tolerability in cancer pain treatment. Opioid use was assessed in a prospective cohort study of 412 palliative care patients from 14 inpatient and outpatient palliative care facilities in Germany. The most frequently used opioids at baseline were morphine and fentanyl. The most frequent changes in medication (N = 106) occurred from oral to parenteral morphine. Only in 49 cases true switches to other long acting opioids were recorded. This is far less than expected from other reports. True switches and adverse side effects were found to occur more frequently in inpatients, while efficacy problems were more frequently recorded in outpatients. There was no correlation between the opoid used at baseline and switch frequency, but numbers of cases receiving other opioids than fentanyl or morphine were low. Reasons for and frequencies of changes in medication were found to be largely shaped by the setting reflecting patients' needs and clinical necessities. Recommendation of first line therapy and availability of opioid formulations define the frequency of opioid use. This impedes evaluation of specific differences between the opioids. (c) 2004 European Federation of Chapters of the International Association for the Study of Pain. Published by Elsevier Ltd. All rights reserved.	PalliativZentrum Berlin Brandenburg, D-10557 Berlin, Germany; Gemeinschaftskrankenhaus Havelhoehe, Dept Palliat Med, D-14089 Berlin, Germany; Univ Witten Herdecke, D-58448 Witten, Germany; CLARA Clin Anal Res & Applicat, D-14532 Kleinmachnow, Germany	Muller-Busch, HC (reprint author), PalliativZentrum Berlin Brandenburg, D-10557 Berlin, Germany.	muebu@havelhoehe.de					Ashby MA, 1999, MED J AUSTRALIA, V170, P68, DOI 10.5694/j.1326-5377.1999.tb126885.x; Barnett M, 2001, POSTGRAD MED J, V77, P371, DOI 10.1136/pmj.77.908.371; Benedetti C, 2000, J PAIN SYMPTOM MANAG, V19, P410, DOI 10.1016/S0885-3924(00)00152-4; Berger A, 2004, ANN PHARMACOTHER, V38, P389, DOI 10.1345/aph.1D109; BROOKS DJ, 1995, PALLIATIVE MED, V9, P229, DOI 10.1177/026921639500900308; Bruera E, 2003, J PAIN SYMPTOM MANAG, V26, P818, DOI 10.1016/S0885-3924(03)00286-0; Bruera E, 1996, CANCER, V78, P852, DOI 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T; Cairns R, 2001, Int J Palliat Nurs, V7, P522; Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542; Davies J, 2000, Int J Palliat Nurs, V6, P470; DESTOUTZ ND, 1995, J PAIN SYMPTOM MANAG, V10, P378, DOI 10.1016/0885-3924(95)90924-C; Ellershaw JE, 2002, J PAIN SYMPTOM MANAG, V24, P398, DOI 10.1016/S0885-3924(02)00507-9; GOLDBERG RJ, 1986, J CHRON DIS, V39, P37, DOI 10.1016/0021-9681(86)90105-0; GUINDON C, 2001, EUR J PALL CARE, V8, P49; HANKS GW, 2001, BRIT J CANCER, V84, P1695; Indelicato RA, 2002, J CLIN ONCOL, V20, P348, DOI 10.1200/JCO.2002.20.1.348; Kefalianakis F, 2002, ANAESTHESIST, V51, P28, DOI 10.1007/s101-002-8368-9; Kloke M, 2000, SUPPORT CARE CANCER, V8, P479, DOI 10.1007/s005200000153; Kuin A, 2004, J PAIN SYMPTOM MANAG, V27, P53, DOI 10.1016/j.jpainsymman.2003.06.001; Lee MA, 2001, PALLIATIVE MED, V15, P26, DOI 10.1191/026921601669626431; Lindena G, 1998, SCHMERZ, V12, P195, DOI 10.1007/s004820050142; McNamara P, 2002, PALLIATIVE MED, V16, P425, DOI 10.1191/0269216302pm536oa; McNicol E, 2003, J PAIN, V4, P231, DOI 10.1016/S1526-5900(03)00556-X; Mercadante S, 2000, SUPPORT CARE CANCER, V8, P123, DOI 10.1007/s005200050026; Mercadante S, 2000, SUPPORT CARE CANCER, V8, P307, DOI 10.1007/s005209900110; Mercadante S, 2001, J PAIN SYMPTOM MANAG, V21, P338, DOI 10.1016/S0885-3924(01)00250-0; Mercadante S, 2001, J PAIN SYMPTOM MANAG, V21, P144, DOI 10.1016/S0885-3924(00)00228-1; Mercadante S, 2001, J CLIN ONCOL, V19, P2898, DOI 10.1200/JCO.2001.19.11.2898; Meuser T, 2001, PAIN, V93, P247, DOI 10.1016/S0304-3959(01)00324-4; MULLERBUSCH HC, 2002, 10 WORLD C PAIN SAN, V158; Nauck F, 2004, PALLIATIVE MED, V18, P100, DOI 10.1191/0269216304pm852oa; NAUCK F, 2002, [No title captured], V3, P41, DOI DOI 10.1055/S-2002-32625; Quigley C., 2002, COCHRANE LIB; Radbruch L, 2002, J PAIN SYMPTOM MANAG, V23, P471, DOI 10.1016/S0885-3924(02)00408-6; Rustoen T, 2003, J PAIN SYMPTOM MANAG, V26, P696, DOI 10.1016/S0885-3924(03)00239-2; SCHUELLER T, 2004, [No title captured], V27, P1; Thomsen AB, 1999, ACTA ANAESTH SCAND, V43, P918, DOI 10.1034/j.1399-6576.1999.430909.x; Warfield CA, 1998, CANCER-AM CANCER SOC, V82, P2299, DOI 10.1002/(SICI)1097-0142(19980615)82:12<2299::AID-CNCR1>3.0.CO;2-O	38	17	19	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801	1532-2149		EUR J PAIN	Eur. J. Pain	OCT	2005	9	5					571	579		10.1016/j.ejpain.2004.12.003			9	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	966WS	WOS:000232054100010	16139186				2020-06-30	J	Hess, PE; Snowman, CE; Wang, J				Hess, PE; Snowman, CE; Wang, J			Hypothermia after cesarean delivery and its reversal with lorazepam	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						obstetric anesthesia; morphine; lorazepam; hypothermia; cesarean delivery; medication side effect	SPINAL-ANESTHESIA; BODY-TEMPERATURE; SUBARACHNOID MORPHINE; BETA-ENDORPHIN; THRESHOLDS; INJECTION; PEPTIDES; RABBITS; OPIOIDS	Background: Intrathecal morphine can produce hypothermia in animals. This side effect has been reported in humans, but has not been thoroughly studied in obstetrics. Methods: We report a series of 14 patients with presumed morphine-induced hypothermia. All patients had post-cesarean temperatures <35.8 degrees C, and complained of associated symptoms of diaphoresis and subjective feeling of being hot. After collecting this series, we determined the incidence of this side effect in an observational study of 100 consecutive patients. All patients had spinal anesthesia with bupivacaine, morphine and fentanyl. Results: In the case series, four of 14 patients were treated conservatively, and 10 were given lorazepam. Those treated conservatively had 6h of hypothermia and symptoms; women given lorazepam had a cessation of symptoms and a rapid increase in temperature. In the observational study, 6% (95% Confidence Interval: 1-10%) experienced symptomatic hypothermia lasting for several hours after the end of surgery (120-360 min). We found no statistical association with any demographic or obstetric characteristic. Conclusion: We conclude that symptomatic hypothermia is an occasional side effect of cesarean section under spinal anesthesia. We believe this syndrome is due to intrathecal morphine. While the duration is limited to 6h, lorazepam appears to treat both hypothermia and symptoms. (c) 2005 Elsevier Ltd. All rights reserved.	Beth Israel Deaconess Med Ctr, Dept Anesthesia & Crit Care, Boston, MA 02215 USA	Hess, PE (reprint author), Beth Israel Deaconess Med Ctr, Dept Anesthesia & Crit Care, St-308 E Campus,330 Brookline Ave, Boston, MA 02215 USA.	phess@bidmc.harvard.edu	Hess, Philip/A-8577-2013	Hess, Philip/0000-0002-1206-0102			CAVICCHINI E, 1989, NEUROPEPTIDES, V14, P45, DOI 10.1016/0143-4179(89)90033-4; Chen XH, 2001, BRAIN RES, V904, P252, DOI 10.1016/S0006-8993(01)02467-2; CLARK SM, 1983, BRAIN RES BULL, V10, P305, DOI 10.1016/0361-9230(83)90095-3; CLARK WG, 1980, NEUROSCI BIOBEHAV R, V4, P175, DOI 10.1016/0149-7634(80)90015-9; CLARK WG, 1979, PHARMACOL BIOCHEM BE, V10, P609, DOI 10.1016/0091-3057(79)90241-7; Frank SM, 2000, ANESTHESIOLOGY, V92, P1330, DOI 10.1097/00000542-200005000-00022; GLYNBALLINGER JR, 1985, BRAIN RES, V333, P366, DOI 10.1016/0006-8993(85)91594-X; Horn EP, 2002, ANESTH ANALG, V94, P409, DOI 10.1097/00000539-200202000-00034; Ikeda T, 1997, ANN NY ACAD SCI, V813, P792, DOI 10.1111/j.1749-6632.1997.tb51783.x; KAVEE EH, 1991, REGION ANESTH, V16, P325; KURZ A, 1993, ANESTH ANALG, V77, P721; OZAKI M, 1994, ANESTHESIOLOGY, V81, P282, DOI 10.1097/00000542-199408000-00004; REZVANI AH, 1982, AM J PHYSIOL, V243, pR104; RIOGARCIA JD, 1990, EUR J PHARMACOL, V187, P495; Sayyid SS, 2003, REGION ANESTH PAIN M, V28, P140, DOI 10.1053/rapm.2003.50043; SPENCER RL, 1990, J PHARMACOL EXP THER, V252, P696; SU CF, 1987, J NEUROL, V235, P105, DOI 10.1007/BF00718020; Wishaw K, 1997, ANAESTH INTENS CARE, V25, P586	18	16	16	0	3	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	OCT	2005	14	4					279	283		10.1016/j.ijoa.2005.02.004			5	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	978LF	WOS:000232874100002	16143507				2020-06-30	J	Bolukbasi, D; Sener, EB; Sarihasan, B; Kocamanoglu, S; Tur, A				Bolukbasi, D; Sener, EB; Sarihasan, B; Kocamanoglu, S; Tur, A			Comparison of maternal and neonatal outcomes with epidural bupivacaine plus fentanyl and ropivacaine plus fentanyl for labor analgesia	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						epidural labor analgesia; ropivacaine; bupivacaine; efficacy; maternal and neonatal outcome	LOW-DOSE BUPIVACAINE; 0.125-PERCENT BUPIVACAINE; DELIVERY; MODE; 0.25-PERCENT; SUFENTANIL; POTENCIES; INFUSION; RELIEF; PAIN	Background: Several studies have been performed to find a safe method of labor analgesia with minimal side effects and toxicity in mother and fetus We aimed to compare the efficacy and side effects of epidural bupivacaine plus fentanyl and ropivacame plus fentanyl at low concentrations. Method: Forty ASA I-II parturients' were included in this prospective, double-blind, trial and randomized to receive either bupivacaine or ropivacame for labor analgesia Analgesia was initiated with 8 mL of 0.125% solution plus fentanyl 50 mu g and maintained with a continuous infusion of 0.0625% solution with fentanyl 2 mu g/mL. Results: There were no differences in pain scores, total dose of local anesthetics used, sensory or motor blockade, labor duration, mode of delivery, side effects, patient satisfaction, or neonatal outcome between the two local anesthetics at these dosages, but at the end of the second stage and delivery, adequate analgesia quality could not be ensured. Conclusion: We found no major advantage of continuous epidural infusion of ropivacame 00625% plus fentanyl 2 mu g/mL over bupivacaine 0.0625% plus fentanyl 2 mu g/mL for labor analgesia. We believe that different methods or dosages may be tried in order to improve comfort at the second stage of labor and the delivery. (c) 2005 Elsevier Ltd. All rights reserved.	Ondokuz Mayis Univ, Fac Med, Dept Anesthesiol, TR-55139 Kurupelit, Turkey	Sener, EB (reprint author), Ondokuz Mayis Univ, Fac Med, Dept Anesthesiol, TR-55139 Kurupelit, Turkey.	bengimd@hotmail.com	KOCAMANOGLU, Ismail Serhat/R-1994-2019				AMIELTISON C, 1982, ANESTHESIOLOGY, V56, P340, DOI 10.1097/00000542-198205000-00003; Bonica JJ, 1990, MANAGEMENT PAIN, P1313; Camann W, 2000, ANESTHESIOLOGY, V92, P3, DOI 10.1097/00000542-200001000-00006; Capogna G, 1999, BRIT J ANAESTH, V82, P371, DOI 10.1093/bja/82.3.371; Chestnut DH, 1997, REGION ANESTH, V22, P495; Fernandez-Guisasola J, 2001, ANESTH ANALG, V92, P1261, DOI 10.1097/00000539-200105000-00034; Gautier P, 1999, ANESTHESIOLOGY, V90, P772, DOI 10.1097/00000542-199903000-00020; Glosten B, 2000, ANESTHESIA, P2024; GOODFELLOW CF, 1983, BRIT J OBSTET GYNAEC, V90, P214, DOI 10.1111/j.1471-0528.1983.tb08611.x; Lyons G, 1997, BRIT J ANAESTH, V78, P493; MacArthur C, 2001, LANCET, V358, P19; Meister GC, 2000, ANESTH ANALG, V90, P632, DOI 10.1097/00000539-200003000-00024; MOIR DD, 1986, BRIT J ANAESTH, V58, P747, DOI 10.1093/bja/58.7.747; Mongelli M, 1997, ACTA OBSTET GYN SCAN, V76, P765, DOI 10.3109/00016349709024344; Muir HA, 1997, CAN J ANAESTH, V44, P599, DOI 10.1007/BF03015442; Owen MD, 1998, ANESTH ANALG, V86, P527, DOI 10.1097/00000539-199803000-00015; Polley LS, 1999, ANESTHESIOLOGY, V90, P944, DOI 10.1097/00000542-199904000-00003; Reynolds F, 2002, BJOG-INT J OBSTET GY, V109, P1344, DOI 10.1016/S1470-0328(02)01961-4; Russell R, 1996, ANAESTHESIA, V51, P266, DOI 10.1111/j.1365-2044.1996.tb13645.x; SHYKEN JM, 1990, AM J OBSTET GYNECOL, V163, P802, DOI 10.1016/0002-9378(90)91072-K; STIENSTRA R, 1995, ANESTH ANALG, V80, P285, DOI 10.1097/00000539-199502000-00014; STODDART AP, 1994, ANAESTHESIA, V49, P1087, DOI 10.1111/j.1365-2044.1994.tb04362.x; VERTOMMEN JD, 1991, ANESTHESIOLOGY, V74, P809, DOI 10.1097/00000542-199105000-00002; Writer WDR, 1998, BRIT J ANAESTH, V81, P713, DOI 10.1093/bja/81.5.713; YEOMANS ER, 1985, AM J OBSTET GYNECOL, V151, P798, DOI 10.1016/0002-9378(85)90523-X; Zlatnik F J, 1999, OBSTETRIC ANESTHESIA, P303	26	16	18	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	OCT	2005	14	4					288	293		10.1016/j.ijoa.2005.04.007			6	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	978LF	WOS:000232874100004	16140519				2020-06-30	J	Lim, Y; Sia, ATH; Ocampo, C				Lim, Y; Sia, ATH; Ocampo, C			Automated regular boluses for epidural analgesia: a comparison with continuous infusion	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						epidural analgesia; combined spinal epidural; continuous epidural infusion; epidural boluses	LABOR ANALGESIA; INTRATHECAL SUFENTANIL; SENSORY CHANGES; HYPOTENSION; BUPIVACAINE; CATHETERS	Background: Intermittent epidural bolus dosing is a method of drug delivery that can prolong the duration of labour analgesia induced by a combined spinal epidural (CSE). In this randomized, double-blinded study, we compared the analgesic efficacy of two drug delivery systems: regular intermittent epidural boluses and continuous epidural infusion and assessed the incidence of breakthrough pain after CSE. Methods: With the approval of the Hospital Ethics Committee, we recruited 60 parturients into this randomized controlled trial. A CSE was performed with intrathecal fentanyl 25 mu g in all patients. The parturients were then randomly allocated into two groups. The infusion group received a continuous epidural infusion of levobupivacaine 0.1% with fentanyl 2 mu g/mL at a rate of 10 mL/h. The bolus group received 5-mL epidural boluses every half hour. The sample size was computed to detect a 40% reduction in the rate of breakthrough pain. Results: The bolus group had a lower incidence of breakthrough pain than the infusion group (10% vs. 37%, P < 0.05). The bolus group also had significantly higher satisfaction scores for labour analgesia: 97 +/- 8 (mean +/- SD) vs. 89 +/- 7 (P < 0.05). Conclusion: Automated regular bolus delivery of epidural analgesia when compared with continuous infusion decreased the incidence of breakthrough pain and increased maternal satisfaction. In a busy obstetric unit, this may also serve to decrease the anesthetists' workload. (c) 2005 Elsevier Ltd. All rights reserved.	KK Womens & Childrens Hosp, Dept Anesthesia, Singapore 229899, Singapore	Lim, Y (reprint author), KK Womens & Childrens Hosp, Dept Anesthesia, 100 Burkit Timah Rd, Singapore 229899, Singapore.	yvel6@hotmail.com					Beilin Y, 2002, ANESTH ANALG, V94, P927, DOI 10.1097/00000539-200204000-00029; Chua SMH, 2004, CAN J ANAESTH, V51, P581, DOI 10.1007/BF03018402; DAngelo R, 1997, ANESTH ANALG, V84, P1276, DOI 10.1097/00000539-199706000-00019; Duncan LA, 1998, BRIT J ANAESTH, V80, P7; HICKS JA, 1988, ANAESTHESIA, V43, P289; Hogan Q, 2002, REGION ANESTH PAIN M, V27, P150, DOI 10.1053/rapm.2002.29748; Kaynar AM, 1999, ANESTH ANALG, V89, P534, DOI 10.1097/00000539-199908000-00063; Mardirosoff C, 1998, REGION ANESTH PAIN M, V23, P92, DOI 10.1016/S1098-7339(98)90117-1; POWER I, 1988, ANAESTHESIA, V43, P876; Riley ET, 1997, ANESTH ANALG, V84, P346, DOI 10.1097/00000539-199702000-00019; Riley ET, 1998, ANESTHESIOLOGY, V89, P73, DOI 10.1097/00000542-199807000-00013; SHANKAR KB, 2000, ANESTHESIOLOGY S, V93, pA1071; Sia AT, 1999, ANAESTH INTENS CARE, V27, P154, DOI 10.1177/0310057X9902700204; van der Vyver M, 2002, BRIT J ANAESTH, V89, P459, DOI 10.1093/bja/aef217	14	54	58	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	OCT	2005	14	4					305	309		10.1016/j.ijoa.2005.05.004			5	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	978LF	WOS:000232874100007	16154735				2020-06-30	J	Jin, M; Gock, SB; Jannetto, PJ; Jentzen, JM; Wong, SH				Jin, M; Gock, SB; Jannetto, PJ; Jentzen, JM; Wong, SH			Pharmacogenomics as molecular autopsy for forensic toxicology: Genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							ETHNIC-DIFFERENCES; CYP3A5; METABOLISM; POLYMORPHISM		Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA; Milwaukee Cty Med Examiner Off, Milwaukee, WI USA	Wong, SH (reprint author), Med Coll Wisconsin, Dept Pathol, 8701 W Watertown Plank Rd, Milwaukee, WI 53226 USA.	shwong@mcw.edu					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; Ball SE, 1999, CLIN PHARMACOL THER, V66, P288, DOI 10.1016/S0009-9236(99)70037-8; Gasche Y, 2004, NEW ENGL J MED, V351, P2827, DOI 10.1056/NEJMoa041888; Guitton J, 1997, BIOCHEM PHARMACOL, V53, P1613, DOI 10.1016/S0006-2952(96)00893-3; Huang WL, 2004, DRUG METAB DISPOS, V32, P1434, DOI 10.1124/dmd.104.001313; Hustert E, 2001, PHARMACOGENETICS, V11, P773, DOI 10.1097/00008571-200112000-00005; Jannetto PJ, 2002, J ANAL TOXICOL, V26, P438, DOI 10.1093/jat/26.7.438; JENTZEN JM, 2003, CLIN FORENSIC TO DEC, P1; Kuehl P, 2001, NAT GENET, V27, P383, DOI 10.1038/86882; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Lee SJ, 2003, PHARMACOGENETICS, V13, P461, DOI 10.1097/00008571-200308000-00004; LILLENG K, 2004, J FORENSIC SCI, V49, P1; Min DI, 2004, THER DRUG MONIT, V26, P524, DOI 10.1097/00007691-200410000-00010; Spurdle AB, 2002, PHARMACOGENETICS, V12, P355, DOI 10.1097/00008571-200207000-00003; Thummel KE, 1998, ANNU REV PHARMACOL, V38, P389, DOI 10.1146/annurev.pharmtox.38.1.389; Wong M, 2004, CLIN PHARMACOL THER, V75, P529, DOI 10.1016/j.clpt.2004.02.005; Wong SH, 2003, J FORENSIC SCI, V48, P1406; Zeigler-Johnson CM, 2002, HUM HERED, V54, P13, DOI 10.1159/000066695	20	53	57	0	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	OCT	2005	29	7					590	598		10.1093/jat/29.7.590			9	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	976XE	WOS:000232766100002	16419387	Bronze			2020-06-30	J	But, AK; Durmus, M; Toprak, HI; Ozturk, E; Demirbilek, S; Ersoy, MO				But, AK; Durmus, M; Toprak, HI; Ozturk, E; Demirbilek, S; Ersoy, MO			Hemodynamic, hepatorenal, and postoperative effects of desflurane-fentanyl and midazolam-fentanyl anesthesia in coronary artery bypass surgery	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						coronary artery bypass grafting; desilurane; midazolam; kidney; liver; postoperative effects		Objective: The purpose of this study was to compare the hemodynamic, hepatorenal, and postoperative effects of desflurane-fentanyl and midazolam-fentanyl anesthesia during coronary artery bypass surgery. Design: Prospective study. Setting: University hospital. Participants: Sixty patients undergoing elective coronary artery bypass grafting surgery with ejection fraction more than 45%. Interventions: Anesthesia was induced with etomidate, 0.2 mg/kg, and fentanyl, 5 mu g/kg, in group D (n = 30) and with midazolam, 0.1 to 0.3 mg/kg, and fentanyl, 5 mu g/kg, in group M (n = 30). Anesthesia was maintained with desflurane, 2% to 6%, and fentanyl, 15 to 25 mu g/kg, in group D and midazolam infusion, 0.1 to 0.5 mg/kg/h, and fentanyl, 15 to 25 mu g/kg, in group M. Measurements and Main Results: Hemodynamic monitoring included a 5-lead electrocardiogram, a radial artery catheter, and a pulmonary artery catheter. Data were obtained before induction of anesthesia (t(0)), after induction of anesthesia (t(1)), after intubation (t(2)), after surgical incision (t(3)), after sternotomy (t(4)), before cardiopulmonary bypass (t(5)), after protamine infusion (t(6)), and at the end of the surgery (t(7)). Blood samples were obtained to measure total bilirubin, aspartate aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase, creatinine, and blood urea nitrogen just before induction of anesthesia and at the first, fourth, and 14th days postoperatively. Conclusions: Intraoperative hemodynamic responses were similar in both groups, and transient hepatic and renal dysfunctions were observed in the postoperative period in both groups. The extubation and intensive care unit discharge times were found to be shorter in the desflurane-fentanyl group. (c) 2005 Elsevier Inc. All rights reserved.	Inonu Univ, Sch Med, Dept Anesthesiol, TR-44315 Malatya, Turkey	But, AK (reprint author), Inonu Univ, Sch Med, Dept Anesthesiol, T Ozal Tip Merkezi Anesteziyoloj, TR-44315 Malatya, Turkey.	kbut@inonu.edu.tr	Toprak, Huseyin Ilksen/AAN-4023-2020				DEBELLIS RJ, 2000, J INT CARE MED, V6, P273; Eger EI, 1997, ANESTH ANALG, V84, P160, DOI 10.1097/00000539-199701000-00029; el Azab S R, 2001, Acta Anaesthesiol Belg, V52, P281; Gueugniaud PY, 1997, ANESTHESIOLOGY, V87, P599, DOI 10.1097/00000542-199709000-00021; HILL DM, 1980, SOUTH MED J, V73, P906, DOI 10.1097/00007611-198007000-00023; Koizumi M, 1998, ANESTH ANALG, V86, P1177, DOI 10.1097/00000539-199806000-00007; Kubota T, 2000, Acta Anaesthesiol Belg, V51, P197; Latham P, 2000, J CARDIOTHOR VASC AN, V14, P645, DOI 10.1053/jcan.2000.18304; Lehmann A, 2000, J CARDIOTHOR VASC AN, V14, P416, DOI 10.1053/jcan.2000.7945; MARTIN JL, 1995, ANESTHESIOLOGY, V83, P1125, DOI 10.1097/00000542-199511000-00030; MERIN RG, 1991, ANESTHESIOLOGY, V74, P568, DOI 10.1097/00000542-199103000-00027; OLSSON R, 1984, SCAND J THORAC CARD, V18, P217, DOI 10.3109/14017438409109894; ORiordan J, 1997, BRIT J ANAESTH, V78, P95; Provenchere S, 2003, ANESTH ANALG, V96, P1258, DOI 10.1213/01.ANE.0000055803.92191.69; SCHMIDT CC, 1999, ANAESTHESIA, V54, P1204; Story DA, 2001, ANESTHESIOLOGY, V95, P842, DOI 10.1097/00000542-200110000-00010; THOMSON IR, 1991, ANESTHESIOLOGY, V75, P776, DOI 10.1097/00000542-199111000-00008; Tiainen P, 1998, BRIT J ANAESTH, V80, P87; vanderMaaten JMAA, 1996, J CARDIOTHOR VASC AN, V10, P356, DOI 10.1016/S1053-0770(96)80097-8; Wissing H, 2000, ACTA ANAESTH SCAND, V44, P1149, DOI 10.1034/j.1399-6576.2000.440920.x; ZALESKI L, 1993, ANESTH ANALG, V76, P353	21	1	2	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	1053-0770			J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	OCT	2005	19	5					597	602		10.1053/j.jvca.2004.10.009			6	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	980YP	WOS:000233054400006	16202892				2020-06-30	J	Rodgers, SF				Rodgers, SF			Safety of intravenous sedation administered by the operating oral surgeon: The first 7 years of office practice	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							SOUTHERN-CALIFORNIA-SOCIETY; OUTPATIENT ANESTHESIA; MAXILLOFACIAL-SURGEONS; MASSACHUSETTS EXPERIENCE; MORTALITY SURVEY; MORBIDITY	Purpose: Outpatient intravenous sedation by properly trained personnel provides a safe, cost-effective means of anesthesia for numerous surgical procedures. The goal of this study was to provide a 7-year summary (December 1994 through November 2001) of anesthesia-related problems that occurred in the practice of a single Midwestern board-certified oral and maxillofacial surgeon. Methods: The files of intravenous sedation cases from December 1994 through November 2001 were organized retrospectively. Results: A total of 2,889 sedations were performed by the surgeon during the 7-year period. There were 1,743 (about 60.33%) patients in ASA Class I, 1,139 (about 39.43%) in ASA Class II, and 7 (about 0.24%) in ASA Class III. There were a total of 70 patients who had 77 adverse events. Less than 3% of the sedation patients experienced complications. There were no deaths and no patients required emergency transport to a hospital. Conclusions: The administration of intravenous sedation by the operating surgeon for outpatient oral surgery procedures is safe and results in a low incidence of adverse events. In this series, a number of previously undiagnosed medical problems were discovered. The diagnosis and referral for management of these medical problems improved patient health. (c) 2005 American Association of Oral and Maxillofacial Surgeons	Newburgh Oral Surg, Newburgh, IN 47630 USA	Rodgers, SF (reprint author), Newburgh Oral Surg, PC,4855 Highway 261, Newburgh, IN 47630 USA.						*AAOMS, 1995, J ORAL MAXILLOFAC S5, V53; *AAOMS, 2001, J ORAL MAXILLOFAC SU; CHYE EPY, 1993, J ORAL MAXILLOFAC SU, V51, P848; D'Eramo EM, 2003, J ORAL MAXIL SURG, V61, P793, DOI 10.1016/S0278-2391(03)00238-6; D'Eramo EM, 1999, J ORAL MAXIL SURG, V57, P531, DOI 10.1016/S0278-2391(99)90069-1; DERAMO EM, 1992, J ORAL MAXIL SURG, V50, P700, DOI 10.1016/0278-2391(92)90101-5; DRISCOLL EJ, 1974, J ORAL SURG, V32, P733; Hunter MJ, 1997, J ORAL MAXIL SURG, V55, P684, DOI 10.1016/S0278-2391(97)90575-9; LYTLE JJ, 1974, J ORAL SURG, V32, P739; LYTLE JJ, 1989, J ORAL MAXIL SURG, V47, P834, DOI 10.1016/S0278-2391(89)80043-6; LYTLE JJ, 1980, J ORAL SURG, V38, P814; Perrott DH, 2003, J ORAL MAXIL SURG, V61, P983, DOI 10.1016/S0278-2391(03)00668-2	12	17	18	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0278-2391			J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	OCT	2005	63	10					1478	1483		10.1016/j.joms.2005.05.320			6	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	970FF	WOS:000232289900011	16182915				2020-06-30	J	Wolfe, LL; Miller, MW				Wolfe, LL; Miller, MW			Suspected secondary thiafentanil intoxication in a captive mountain lion (Puma concolor)	JOURNAL OF WILDLIFE DISEASES			English	Article						A3080; intoxication; mountain lion; opioid; puma; Puma concolor; secondary poisoning; thiafentanil	SPONGIFORM ENCEPHALOPATHY; PLUS XYLAZINE; WILD ANIMALS; MULE DEER; IMMOBILIZATION; A-3080; CATS	Inadvertent ingestion of thiafentanil oxalate by a captive adult female mountain lion (Puma concolor) caused a prolonged clinical syndrome that included sedation and depression, muscle tension, and myopathy that was incompletely antagonized by naltrexone HCl. A serum chemistry profile revealed markedly elevated creatinine phosphokinase (CK; 490,450 IU/l), alanine aminotransferase (ALT; 1,896 IU/l), and aspartate aminotransferase (AST, 4,321 IU/l) 2 days after onset. The affected animal's condition gradually improved over the next 15 days in response to supportive-therapy that included diazepam (5 mg as needed), Normasol R (R) (3 l/day), dexamethasone (tapering dose starting at 1 mg/kg), and ketoprofen (1 mg/kg). She eventually recovered completely. Based on these observations, carcasses of animals immobilized with thiafentanil should be marked and disposed of properly to preclude opportunities for secondary exposure and potential intoxication in scavenging species. In addition, caution is advised when using thiafentanil in animals that could be preyed upon before full metabolism of the drug.	Wildlife Res Ctr, Colorado Div Wildlife, Ft Collins, CO 80526 USA	Wolfe, LL (reprint author), Wildlife Res Ctr, Colorado Div Wildlife, 317 W Prospect Rd, Ft Collins, CO 80526 USA.	lisa.wolfe@state.co.us					*COL DEP PUBL HLTH, 2003, 2003 RAB SUMM; GRUFFYDDJONES TJ, 1992, J SMALL ANIM PRACT, V33, P471, DOI 10.1111/j.1748-5827.1992.tb01026.x; ISHAK K, 2004, [No title captured], P169; JANSSEN DL, 1993, J ZOO WILDLIFE MED, V24, P11; KIRKWOOD JK, 1994, VET REC, V135, P296, DOI 10.1136/vr.135.13.296; Kreeger TJ, 2001, J WILDLIFE MANAGE, V65, P25, DOI 10.2307/3803272; KREEGER TJ, 2002, HDB WILDLIFE CHEM IM, P38; Rupprecht Charles E., 2001, P3, DOI 10.1002/9780470344880.ch1; Ryder SJ, 2001, VET REC, V148, P437, DOI 10.1136/vr.148.14.437; Spraker T. R., 1982, CHEM IMMOBILIZATION, P83; STANLEY TH, 1988, J WILDLIFE MANAGE, V52, P577, DOI 10.2307/3800910; Wack RF, 2003, ZOO WILD ANIMAL MED, P491; WALLACH JD, 1967, J AM VET MED ASSOC, V151, P870; WILLIAMS ES, 1980, J WILDLIFE DIS, V16, P89, DOI 10.7589/0090-3558-16.1.89; WILLOUGHBY K, 1992, VET REC, V131, P431, DOI 10.1136/vr.131.19.431; Wolfe LL, 2004, J WILDLIFE DIS, V40, P282, DOI 10.7589/0090-3558-40.2.282; WYATT JM, 1991, VET REC, V129, P233, DOI 10.1136/vr.129.11.233	17	4	4	0	9	WILDLIFE DISEASE ASSOC, INC	LAWRENCE	810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA	0090-3558	1943-3700		J WILDLIFE DIS	J. Wildl. Dis.	OCT	2005	41	4					829	833		10.7589/0090-3558-41.4.829			5	Veterinary Sciences	Veterinary Sciences	013AB	WOS:000235380900025	16456179				2020-06-30	J	Kronen, PW; Levionnois, OL; Eckstein, FS; Moens, YPS				Kronen, PW; Levionnois, OL; Eckstein, FS; Moens, YPS			Prolonged recovery and respiratory depression after fentanyl infusion in a sheep undergoing mitral valve reconstruction	LABORATORY ANIMALS			English	Article						sheep; cardiopulmonary bypass; fentanyl infusion; recovery; naloxone	LUNG RECRUITMENT MANEUVER; PHARMACOKINETICS; ALFENTANIL; VOLUME	A sheep was anaesthetized for implantation of a novel device (MitroFast (R)) to replace the posterior leaflet of the mitral valve. Anaesthetic management included a balanced anaesthetic protocol and consisted of propofol or isoflurane combined with fentanyl infusion (0.15-0.4 mu g/kg/min). Deliberate hypothermia during cardiopulmonary bypass was set at 34.5-35.5 degrees C. Surgery proceeded uneventfully. Total time of aortic cross-clamping was 35 min and total time on extracorporeal circulation was 60 min. Visual inspection, intracardiac pressure testing and transesophageal echocardiography indicated proper functioning of the device. The anaesthetic period was uneventful, but recovery was prolonged with central nervous and respiratory depression and marked hypoxaemia. Administration of naloxone (1.5 mu g/kg, repeated twice at 15-20 min intervals) reversed the central nervous and attenuated the respiratory depressions. An initially low rate of urine production normalized after rewarming and a single intravenous administration of furosemide.	Univ Bern, Dept Clin Vet Med, Sect Anaesthesiol, CH-3012 Bern, Switzerland; Univ Hosp, Cardiovasc Surg Clin, Bern, Switzerland; Vet Univ Vienna, Clin Anaesthesiol & Perioperat Intens Care, A-1030 Vienna, Austria	Kronen, PW (reprint author), Univ Bern, Dept Clin Vet Med, Sect Anaesthesiol, Langgasstr 124, CH-3012 Bern, Switzerland.	peter.kronen@knp.unibe.ch		Levionnois, olivier/0000-0003-0253-4682			BAILEY PL, 2000, ANESTHESIA, V1, P273; Dagum P, 1999, CIRCULATION, V100, P70; Dyhr T, 2004, ACTA ANAESTH SCAND, V48, P187, DOI 10.1111/j.0001-5172.2004.00300.x; Dyhr T, 2002, ACTA ANAESTH SCAND, V46, P717, DOI 10.1034/j.1399-6576.2002.460615.x; EGAN TD, 1993, ANESTHESIOLOGY, V79, P881, DOI 10.1097/00000542-199311000-00004; Engoren MC, 1998, J CARDIOTHOR VASC AN, V12, P177, DOI 10.1016/S1053-0770(98)90328-7; GARIBALDI B, 2000, GUIDELINES USE ANEST, P8; GEDNEY JA, 1995, BRIT J ANAESTH, V75, P344, DOI 10.1093/bja/75.3.344; Green GR, 1999, CIRCULATION, V100, P95; Gruber EM, 2001, ANESTH ANALG, V92, P882; HALL RI, 1993, ANESTH ANALG, V76, P957; Hellyer P W, 2003, Vet Anaesth Analg, V30, P111, DOI 10.1046/j.1467-2995.2003.00133_26.x; Hellyer PW, 2003, VET ANAESTH ANALG, V30, P172, DOI 10.1046/j.1467-2995.2003.00143.x; ILKIW JE, 1991, AM J VET RES, V52, P581; Lai DT, 2002, EUR J CARDIO-THORAC, V22, P808, DOI 10.1016/S1010-7940(02)00530-4; LULLMANN H, 1985, BRIT J ANAESTH, V57, P1012, DOI 10.1093/bja/57.10.1012; Phillips A S, 1994, J Cardiothorac Vasc Anesth, V8, P289, DOI 10.1016/1053-0770(94)90240-2; Roytblat L, 1998, ANESTH ANALG, V87, P266, DOI 10.1097/00000539-199808000-00006; Russell D, 1997, BRIT J ANAESTH, V79, P456, DOI 10.1093/bja/79.4.456; SALDEN R, 1990, [No title captured]; Santeiro M L, 1997, J Perinatol, V17, P135; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; Timek TA, 2002, CIRCULATION, V106, pI27, DOI 10.1161/01.cir.0000032920.33237.c0; WATERMAN AE, 1990, VET ANAESTH ANALG, V17, P20	24	4	4	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0023-6772	1758-1117		LAB ANIM-UK	Lab. Anim.	OCT	2005	39	4					428	434		10.1258/002367705774286385			7	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	975IY	WOS:000232655400009	16197710	Bronze			2020-06-30	J	Akinci, SB; Kanbak, M; Guler, A; Aypar, U				Akinci, SB; Kanbak, M; Guler, A; Aypar, U			Remifentanil versus fentanyl for short-term analgesia-based sedation in mechanically ventilated postoperative children	PEDIATRIC ANESTHESIA			English	Article						children; mechanical ventilation; remifentanil; fentanyl; sedation	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROPOFOL INFUSION SYNDROME; CRITICALLY-ILL PATIENTS; SPINAL-FUSION; SURGERY; PHARMACOKINETICS; DICLOFENAC; MULTICENTER; SUFENTANIL; ALFENTANIL	Back-ground: Analgesia-based sedation techniques are becoming more established in the intensive care unit (ICU) setting. The aim of this study was to compare remifentanil and fentanyl infusions for postoperative analgesia in pediatric ICU patients. Methods: After receiving ethical committee approval, a prospective randomized, double-blind study was performed. Twenty-two postoperative orthopedic surgery patients received either remifentanil 0.1 mu g center dot kg(-1)center dot min(-1) or fentanyl 0.025 mu g center dot kg(-1)center dot min(-1) infusions diluted to the same volume. Analgesic infusion was titrated to predefined levels of analgesia [behavioral pain scale (BPS) score of 3]. Propofol was added if sedation was unsatisfactory after BPS score 3 had been achieved. Results: There were no differences in groups regarding demographics, tracheal extubation times, and pain scores of the patients. After cessation of the opioid infusion, the sedation scores and the heart rates were always higher in the remifentanil group compared with the fentanyl group. The incidences of nausea, vomiting, apnea, desaturation, reintubation within 24 h and constipation were also similar between the two groups. Conclusions: We conclude that a remifentanil infusion provides clinically comparable analgesia with a fentanyl infusion in mechanically ventilated postoperative pediatric patients. These two drugs are suitable for short-term analgesia-based sedation in pediatric postoperative ICU patients.	Hacettepe Univ, Sch Med, Dept Anesthesiol & Reanimat, TR-06100 Ankara, Turkey	Akinci, SB (reprint author), Hacettepe Univ, Sch Med, Dept Anesthesiol & Reanimat, TR-06100 Ankara, Turkey.	sedabanu@hacettepe.edu.tr	Kanbak, Meral/I-9839-2013	Kanbak, Meral/0000-0002-1727-2032			Beck A, 2003, ARCH ORTHOP TRAUM SU, V123, P327, DOI 10.1007/s00402-003-0537-5; BEYER JE, 1983, PAIN, V17, P71, DOI 10.1016/0304-3959(83)90129-X; Bowdle TA, 1996, ANESTH ANALG, V83, P1292, DOI 10.1097/00000539-199612000-00028; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; Chiaretti A, 2000, PEDIATR NEUROSURG, V33, P83, DOI 10.1159/000028981; CLOTZ MA, 1991, CLIN PHARMACY, V10, P581; Dimar JR, 1996, SPINE, V21, P1870, DOI 10.1097/00007632-199608150-00006; Dumont AS, 2000, J PHARMACOL TOX MET, V43, P31, DOI 10.1016/S1056-8719(00)00077-0; Egan T D, 2000, Curr Opin Anaesthesiol, V13, P449, DOI 10.1097/00001503-200008000-00009; EGAN TD, 1993, ANESTHESIOLOGY, V79, P881, DOI 10.1097/00000542-199311000-00004; GLASS PS, 1999, ANESTH ANALG, V89, P7; Glassman SD, 1998, SPINE, V23, P834, DOI 10.1097/00007632-199804010-00020; Holzki J, 2004, PEDIATR ANESTH, V14, P265, DOI 10.1046/j.1460-9592.2003.01179.x; KAPILA A, 1995, ANESTHESIOLOGY, V83, P968, DOI 10.1097/00000542-199511000-00009; Koch M, 2004, INTENS CARE MED, V30, P522, DOI 10.1007/s00134-003-2130-3; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Miranda DR, 1996, CRIT CARE MED, V24, P64, DOI 10.1097/00003246-199601000-00012; Morton NS, 1999, BRIT J ANAESTH, V82, P715; Muellejans B, 2004, CRIT CARE, V8, pR1, DOI 10.1186/cc2398; NILSSON OS, 1997, INT ORTHOP, V11, P283; Ozlu O, 2003, PAEDIATR ANAESTH, V13, P53, DOI 10.1046/j.1460-9592.2003.00965.x; Park G, 2002, Minerva Anestesiol, V68, P505; Payen JF, 2001, CRIT CARE MED, V29, P2258, DOI 10.1097/00003246-200112000-00004; Reuben SS, 1997, REGION ANESTH, V22, P343, DOI 10.1016/S1098-7339(97)80009-0; Riker RR, 1999, CRIT CARE MED, V27, P1325, DOI 10.1097/00003246-199907000-00022; Rosow CE, 1999, ANESTH ANALG, V89, pS1; Soltesz S, 2001, BRIT J ANAESTH, V86, P763, DOI 10.1093/bja/86.6.763; Van der Marel CD, 2004, PEDIATR ANESTH, V14, P443; Vasile B, 2003, INTENS CARE MED, V29, P1417, DOI 10.1007/s00134-003-1905-x; Vuori A, 2004, ACTA ANAESTH SCAND, V48, P738, DOI 10.1111/j.1399-6576.2004.00404.x; Wilhelm W, 1999, ANAESTHESIST, V48, P625, DOI 10.1007/s001010050762; Wolf AR, 2004, PEDIATR ANESTH, V14, P435, DOI 10.1111/j.1460-9592.2004.01332.x	33	15	15	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	OCT	2005	15	10					870	878		10.1111/j.1460-9592.2005.01574.x			9	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	972RW	WOS:000232471900009	16176316				2020-06-30	J	Gelfand, MJ; O'Hara, SM; Curtwright, LA; MacLean, JR				Gelfand, MJ; O'Hara, SM; Curtwright, LA; MacLean, JR			Pre-medication to block [F-18]FDG uptake in the brown adipose tissue of pediatric and adolescent patients	PEDIATRIC RADIOLOGY			English	Article						brown adipose tissue; neoplasm; FDG; PET	F-18-FDG PET/CT; USA-FAT; TEMPERATURE; MUSCLE	Background: Radiopharmaceutical uptake of [F-18]2-deoxy-2-glucose (FDG) in brown adipose tissue is noted on 15-20% of positron emission tomography (PET) scans in children and adolescents. One report suggests that moderate-dose oral diazepam can partly or completely block FDG uptake in brown adipose tissue. Objective: To determine whether [F-18]FDG uptake in brown adipose tissue can be adequately blocked by pre-medication other than moderate-dose oral diazepam. Materials and methods: One hundred and eighteen [F-18]FDG PET body imaging studies were performed in 69 pediatric patients with a variety of solid tumors. The mean age at the time of imaging was 12.9 years (range 1.2-22.6 years), and 33 studies were performed in patients younger than 10 years old. Seventy-six were performed in boys and 42 in girls. Patients were imaged using a dedicated PET camera. Pre-medication was given in 88 studies: 45 received intravenous fentanyl (0.75-1.0 mu g/kg), 34 received low-dose oral diazepam (0.06 mg/kg) and 9 received moderate-dose oral diazepam (0.10 mg/kg). Thirty patients received no pre-medication, 7 of whom were known to have received opiates for pain during the 12 h before the study. Six body regions in the neck and chest were reviewed for [F-18]FDG uptake in brown adipose tissue. Uptake of FDG in brown fat was visually graded: 0 for no FDG uptake, 1 for low-grade uptake, 2 for moderate uptake, and 3 for intense uptake. Visual grades 2 and 3 were considered to interfere potentially with image interpretation in the neck and chest. Data were analyzed by multivariate regression using a Poisson distribution. Results: [F-18]FDG uptake in brown adipose tissue was most often seen in the lateral neck region and superior and lateral to the lungs (in 36 and 39 studies, respectively). Uptake was also seen near the costovertebral junctions (15 studies), in the superior and central neck in 7 studies and in the anterior mediastinum in 2. Brown adipose tissue uptake was thought to interfere potentially with image interpretation (visual grades 2 and 3) in 19 studies-in 6 of 23 (26.1%) studies after no pre-medication and no opiates for pain, in 10 of 34 (29.4%) after low-dose oral diazepam, in 0 of 9 (0%) after moderate-dose oral diazepam, in 3 of 45 (6.7%) after intravenous fentanyl, and in 0 of 7 (0%) after opiates prescribed for pain. Intravenous fentanyl reduced the grade of brown adipose tissue compared to no drug (P=0.0039) and low-dose diazepam (P=0.0024). Low-dose diazepam had no effect when compared to no drug (P=0.984). There were inadequate data for statistical testing of moderate-dose valium and opiates prescribed for pain. Children younger than 10 years had lower uptake grades (P=0.019) than those older than 10 years. Summary: The frequency of interfering [F-18]FDG uptake in brown adipose tissue is reduced by intravenous fentanyl pre-medication, which appears to be an effective alternative to the existing standard pre-medication, moderate-dose oral diazepam.	Cincinnati Childrens Hosp, Med Ctr, Dept Radiol, Cincinnati, OH 45229 USA	Gelfand, MJ (reprint author), Cincinnati Childrens Hosp, Med Ctr, Dept Radiol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	michael.gelfand@cchmc.org					ALFONSI P, 1995, ANAESTHESIA, V50, P214, DOI 10.1111/j.1365-2044.1995.tb04559.x; Bar-Sever Z, 2004, J NUCL MED, V45, P136; Barrington SF, 1996, J NUCL MED, V37, P1127; Cohade C, 2003, J NUCL MED, V44, P1267; Cohade C, 2003, J NUCL MED, V44, P170; EGELHOFF JC, 1997, AJR, V168, P1250; Garcia CA, 2004, MOL IMAGING BIOL, V6, P368, DOI 10.1016/j.mibio.2004.08.003; Hany TF, 2002, EUR J NUCL MED MOL I, V29, P1393, DOI 10.1007/s00259-002-0902-6; Horn EP, 1998, ANESTHESIOLOGY, V88, P108, DOI 10.1097/00000542-199801000-00018; KAWATE T, 1996, PHYSIOL BEHAV, V59, P231; Kranke P, 2002, ANESTH ANALG, V94, P453, DOI 10.1097/00000539-200202000-00043; NANNI C, 2004, J NUCL MED, V45, P140; Okuyama C, 2002, J NUCL MED, V43, P1234; Powell RM, 2000, ANESTH ANALG, V90, P1423, DOI 10.1097/00000539-200006000-00032; Tatsumi M, 2004, J NUCL MED, V45, P1189; Truong MT, 2004, AM J ROENTGENOL, V183, P1127, DOI 10.2214/ajr.183.4.1831127; Yeung HWD, 2003, J NUCL MED, V44, P1789	17	95	97	0	7	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0301-0449			PEDIATR RADIOL	Pediatr. Radiol.	OCT	2005	35	10					984	990		10.1007/s00247-005-1505-8			7	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	965KP	WOS:000231949700005	15988582				2020-06-30	J	Sanborn, PA; Michna, E; Zurakowski, D; Burrows, PE; Fontaine, P; Connor, L; Mason, KP				Sanborn, PA; Michna, E; Zurakowski, D; Burrows, PE; Fontaine, P; Connor, L; Mason, KP			Adverse cardiovascular and events during respiratory sedation of pediatric patients for imaging examinations	RADIOLOGY			English	Article							CHLORAL HYDRATE SEDATION; CHILDREN; TOMOGRAPHY; RADIOLOGY; EFFICACY; INFANTS; SAFETY; CT	PURPOSE: To retrospectively identify factors associated with an increased risk of adverse cardiovascular or respiratory events during sedation of pediatric patients for imaging examinations. MATERIALS AND METHODS: This HIPAA-compliant study was institutional review All sedation was waived d. consen board approved; the requirement for informed information-including patient demographics, medications (doses and routes of administration), time required to sedate and before discharge, American Society of Anesthesiologists physical status classification, adverse events, and failed sedations-was maintained in a computerized database. A review of the data on all patients sedated between 1997 and 2003 for magnetic resonance imaging, computed tomography, and interventional radiology revealed associated adverse respiratory events in 70 patients. Adverse respiratory event was defined as oxygen desaturation of at least 5%, pulmonary aspiration, and need for airway resuscitation. vascular events were defined as cardiac arrest and hemodynamic Adverse cardi.. changes requiring medical therapy. Adverse events were compared between sedation regimens-which included fentanyl, chloral hydrate, pentobarbital, and midazolam hydrochloricle- by using the Fisher exact test. Multiple logistic regression analysis was applied to identify potential predictors of adverse events. RESULTS: Among 16 467 sedations performed, 70 (0.4%) were associated with adverse respiratory events: 58 cases of oxygen desaturation, two pulmonary aspirations, cases of airway resuscitation, and no cardiovascular events. Nearly 30% (n = 20) of the 70 patients who had an adverse event had a history of serious respiratory illness. Logistic regression analysis revealed that neither patient age, weight, or sex nor type of imaging procedure was associated with an increased risk of an adverse event. Use of a single sedation agent was associated with lower adverse event risk than was use of multiple agents (P <.001). CONCLUSION: Consideration should be given to using single agents, avoiding the use of multidrug sedation regimens, and recognizing that a history of pulmonary disease could be associated with an increased risk of adverse respiratory events despite a currently stable respiratory state. (c) RSNA, 2005.	Childrens Hosp, Dept Radiol, Boston, MA 02115 USA; Childrens Hosp, Dept Biostat, Boston, MA 02115 USA; Childrens Hosp, Dept Anaesthesia, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Anesthesia, Boston, MA 02115 USA	Mason, KP (reprint author), Childrens Hosp, Dept Radiol, 300 Longwood Ave, Boston, MA 02115 USA.	keira.mason@tch.harvard.edu					ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Armitage P, 2002, STAT METHODS MED RES; Chung T, 2000, PEDIATR RADIOL, V30, P332, DOI 10.1007/s002470050752; Cote CJ, 2000, PEDIATRICS, V105, P805, DOI 10.1542/peds.105.4.805; Cote CJ, 2000, PEDIATRICS, V106, P633, DOI 10.1542/peds.106.4.633; FERRERBRECHNER T, 1977, ANESTH ANALG, V56, P344; GREENBERG SB, 1993, AM J ROENTGENOL, V161, P639, DOI 10.2214/ajr.161.3.8352124; GREENBERG SB, 1991, J COMPUT ASSIST TOMO, V15, P467, DOI 10.1097/00004728-199105000-00023; Hoffman GM, 2002, PEDIATRICS, V109, P236, DOI 10.1542/peds.109.2.236; HOSMER D. W., 2000, APPL LOGISTIC REGRES; *JOINT COMM ACCR H, 2001, AN SED, P35; Karian VE, 2002, PEDIATR RADIOL, V32, P348, DOI 10.1007/s00247-001-0653-8; KAUFFMAN RE, 1993, PEDIATRICS, V92, P471; KAUFFMAN RE, 1992, PEDIATRICS, V89, P1110; Mason KP, 2004, RADIOLOGY, V230, P537, DOI 10.1148/radiol.2302030107; Mason KP, 2002, RADIOLOGY, V225, P457, DOI 10.1148/radiol.2252011786; Mason KP, 2001, AM J ROENTGENOL, V177, P427, DOI 10.2214/ajr.177.2.1770427; Medina LS, 2003, RADIOLOGY, V226, P297, DOI 10.1148/radiol.2262011537; Napoli KL, 1996, J PEDIATR-US, V129, P287, DOI 10.1016/S0022-3476(96)70256-1; RONCHERAOMS CL, 1994, J CLIN PHARM THER, V19, P239, DOI 10.1111/j.1365-2710.1994.tb00680.x; Ruess L, 2002, PEDIATR RADIOL, V32, P505, DOI 10.1007/s00247-002-0712-9; THOMPSON JR, 1982, RADIOLOGY, V143, P475, DOI 10.1148/radiology.143.2.7071350; Zeigler V L, 1997, Crit Care Nurs Clin North Am, V9, P381; CRNA PRACTICE CONSID	24	109	113	0	4	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	OCT	2005	237	1					288	294		10.1148/radiol.2371041415			7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	965RM	WOS:000231968000039	16183936				2020-06-30	J	Allaf, ME; Varkarakis, IM; Bhayani, SB; Inagaki, T; Kavoussi, LR; Solomon, SB				Allaf, ME; Varkarakis, IM; Bhayani, SB; Inagaki, T; Kavoussi, LR; Solomon, SB			Pain control requirements for percutaneous ablation of renal tumors: Cryoablation versus radiofrequency ablation - Initial observations	RADIOLOGY			English	Article							FOLLOW-UP; CRYOANALGESIA; RELIEF	PURPOSE: To retrospectively compare the pain control requirements of patients undergoing computed tomography (CT)-guided percutaneous radiofrequency (RF) ablation with those of patients undergoing CT-guided percutaneous cryoablation of small (<= 4-cm) renal tumors. MATERIALS AND METHODS: The study was HIPAA compliant and received institutional review board exemption; informed consent was not required. Medical and procedure records of patients who underwent RF ablation and cryoablation of renal tumors from June 19, 2003, to February 28, 2004, were retrospectively reviewed for clinical data, tumor characteristics, and anesthesia information. During the study period, 10 men (mean age, 66.5 years) underwent cryoablation of 11 renal lesions, and 14 patients (11 men, four women; mean age, 68.1 years) underwent RF ablation of 15 renal tumors. Analgesic and sedative requirements during the procedure were compared. Standard anesthesia consisted of 5 mL of 1% lidocaine injected locally, and conscious sedation consisted of 50 mu g of fentanyl and 1 mg of midazolam administered intravenously. The Fisher exact test and Student t test were used to compare clinical factors and drug requirements between the two groups. RESULTS: There was no difference in terms of patient demographics, tumor diameter, or distribution of central versus noncentral lesions between the two groups. Cryoablation was associated with a significantly lower dose of fentanyl (165.0 mu g [RF group] vs 75.0 mu g [cryoablation group]; P <.001) and midazolam (2.9 mg [RF group] vs 1.6 mg [cryoablation group]; P =.026). In the RF group, one patient required general anesthesia, one patient required supplemental narcotics (5 mg of oxycodone) and sedatives (1 mg lorezapam), and one patient became apneic for a brief interval after receiving additional narcotics for pain during the procedure. An additional RF session was terminated early in one patient because of pain, and further medication could not be administered owing to bradycardia. No patients in the cryoablation group required any additional or alternate anesthetics. CONCLUSION: Image-guided percutaneous cryoablation of small (<= 4-cm) renal lesions appears to require less analgesia than RF ablation. Prospective trials with validated pain scales are needed to examine this further.(c) RSNA, 2005.	Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA; Johns Hopkins Med Inst, Brady Urol Inst, Dept Urol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Russell H Morgan Dept Radiol, Baltimore, MD 21205 USA	Solomon, SB (reprint author), Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10021 USA.	solomons@mskcc.org					Bishoff JT, 1999, J ENDOUROL, V13, P233, DOI 10.1089/end.1999.13.233; Callesen T, 1998, ANESTH ANALG, V87, P896, DOI 10.1097/00000539-199810000-00028; DOUGLAS WW, 1955, J PHYSIOL-LONDON, V130, P53, DOI 10.1113/jphysiol.1955.sp005392; Fergany AF, 2000, J UROLOGY, V163, P442, DOI 10.1016/S0022-5347(05)67896-2; Goldberg SN, 2003, RADIOLOGY, V228, P335, DOI 10.1148/radiol.2282021787; Green CR, 2002, J NATL MED ASSOC, V94, P716; LI CL, 1958, AM J PHYSIOL, V194, P200; LLOYD JW, 1976, LANCET, V2, P932; LUNDBERG A, 1948, ACTA PHYSL SCAND S, V50, P1; ORR IA, 1981, BMJ-BRIT MED J, V283, P945, DOI 10.1136/bmj.283.6297.945; Pavlovich CP, 2002, J UROLOGY, V167, P10, DOI 10.1016/S0022-5347(05)65371-2; Su LM, 2003, UROLOGY, V61, P26, DOI 10.1016/S0090-4295(03)00118-3; Yohannes P, 2001, J ENDOUROL, V15, P845, DOI 10.1089/089277901753205870; Zhou LQ, 2003, CRYOBIOLOGY, V46, P26, DOI 10.1016/S0011-2240(02)00160-8	14	107	110	0	1	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	OCT	2005	237	1					366	370		10.1148/radiol.2371040829			5	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	965RM	WOS:000231968000052	16126920				2020-06-30	J	Topcu, I; Luleci, N; Tekin, S; Kefi, A; Erincler, T				Topcu, I; Luleci, N; Tekin, S; Kefi, A; Erincler, T			Effectiveness of clonidine and fentanyl addition to bupivacaine in postoperative patient controlled epidural analgesia	ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE			German	Article						postoperative analgesia; epidural analgesia; clonidine; fentanyl; nausea	DOUBLE-BLIND; ABDOMINAL-SURGERY; PAIN RELIEF; MORPHINE; INFUSION; REQUIREMENTS; ROPIVACAINE; TRIAL; PCA	Background and Objectives: The aim of this prospective randomized double-blinded study was to compare the analgesic and side-effects of bupivacaine in combination with clonidine or fentanyl during patient-controlled-epidural analgesia (PCEA) in the postoperative period after abdominal hysterectomy. Methods: 75 patients from 18 to 65 years of age with ASA status I - II were investigated. After preoperative epidural catheterization, the patients were operated in general anesthesia. After surgery, the patients were randomly allocated to 3 PCEA-groups: Group B 0.125% bupivacaine, Group F 0.125% bupivacaine plus 1 mu g x ml(-1) fentanyl, Group C 0.125% bupivacaine plus 0.75 mu g x ml(-1) clonidine (10 ml loading dose, 5 ml repetitive bolus dose, 10 min lockout time, 30 ml limit within 4h). During the following 24 hours, hemodynamic parameters, pain score using visual analog scale (VAS), total analgesic consumption, additional analgesic requirements, sedation, satisfaction, nausea scores and probable side-effects were evaluated. Results: Total analgesic consumption was not different between Group F and Group C, but lower than in Group B (p < 0.05). Additional analgesic use was not different between the groups. Group F and Group C had lower VAS-scores in 24 hours than Group B (p < 0.05). Hemodynamic and sedation scores of patients were not different. In Group C, incidence of nausea was lower and satisfaction of patients was higher (p < 0.05). Conclusions: Addition of clonidine or fentanyl to local anesthetics for PCEA can reduce the analgetic demand. Epidural clonidine can reduce postoperative nausea and is connected with higher patients' satisfaction.	Celal Bayar Univ, Fak Med, Abt Anasthesiol, TR-45010 Manisa, Turkey	Erincler, T (reprint author), Celal Bayar Univ, Tip Fk Anesteziyol AD, TR-45010 Manisa, Turkey.	tuna.ericler@bayar.edu.tr					ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Berti M, 2000, J CLIN ANESTH, V12, P292, DOI 10.1016/S0952-8180(00)00154-9; BLOOR BC, 1993, ANAESTHETIC PHARM RE, V1, P221; Cooper DW, 1996, BRIT J ANAESTH, V76, P611; DELAUNAY L, 1993, REGION ANESTH, V18, P176; DEVOS H, 1994, NEUROSCIENCE, V59, P589, DOI 10.1016/0306-4522(94)90179-1; EGAN KJ, 1994, CAN J ANAESTH, V41, P6, DOI 10.1007/BF03009653; EGBERT AM, 1990, ARCH INTERN MED, V150, P1897, DOI 10.1001/archinte.150.9.1897; Flisberg P, 2003, ACTA ANAESTH SCAND, V47, P457, DOI 10.1034/j.1399-6576.2003.00104.x; Jeffs SA, 2002, BRIT J ANAESTH, V89, P424, DOI 10.1093/bja/aef216; Kirdemir P, 2000, J CLIN ANESTH, V12, P543, DOI 10.1016/S0952-8180(00)00216-6; KLIMSCHA W, 1995, ANESTH ANALG, V80, P322, DOI 10.1097/00000539-199502000-00020; Mahon SV, 1999, ANAESTHESIA, V54, P641, DOI 10.1046/j.1365-2044.1999.00856.x; MIKAWA K, 1995, CAN J ANAESTH, V42, P977, DOI 10.1007/BF03011068; MOTSCH J, 1990, ANESTHESIOLOGY, V73, P1067, DOI 10.1097/00000542-199012000-00002; Nakayama M, 2001, J CLIN ANESTH, V13, P86, DOI 10.1016/S0952-8180(01)00218-5; Paech MJ, 1997, ANESTH ANALG, V84, P1323, DOI 10.1097/00000539-199706000-00027; Park J, 1996, CAN J ANAESTH, V43, P900, DOI 10.1007/BF03011802; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Rawal N, 1999, SURG CLIN N AM, V79, P313, DOI 10.1016/S0039-6109(05)70385-6; Rimaitis Kestutis, 2003, Medicina (Kaunas), V39, P129; Rockemann MG, 1997, ANASTH INTENSIV NOTF, V32, P414, DOI 10.1055/s-2007-995082; ROSTAING S, 1991, ANESTHESIOLOGY, V75, P420, DOI 10.1097/00000542-199109000-00007; SCOTT DA, 1995, ANESTH ANALG, V81, P982, DOI 10.1097/00000539-199511000-00015; Silvasti M, 2000, ACTA ANAESTH SCAND, V44, P37, DOI 10.1034/j.1399-6576.2000.440107.x; Standl T, 2003, CAN J ANAESTH, V50, P258, DOI 10.1007/BF03017795; Vallejo MC, 2000, CAN J ANAESTH, V47, P406, DOI 10.1007/BF03018968	27	2	2	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0939-2661	1439-1074		ANASTH INTENSIV NOTF	Anasthesiol. Intensivmed. NotfMed. Schmerzther.	SEP	2005	40	9					521	525		10.1055/s-2005-870397			5	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	968UY	WOS:000232189400003	16145639				2020-06-30	J	Reich, DL; Hossain, S; Krol, M; Baez, B; Patel, P; Bernstein, A; Bodian, CA				Reich, DL; Hossain, S; Krol, M; Baez, B; Patel, P; Bernstein, A; Bodian, CA			Predictors of hypotension after induction of general anesthesia	ANESTHESIA AND ANALGESIA			English	Article							ARTERY-BYPASS-SURGERY; MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; HANDWRITTEN; ASSOCIATION; MORTALITY; RECORDS	Hypotension after induction of general anesthesia is a common event. In the current investigation, we sought to identify the predictors of clinically significant hypotension after the induction of general anesthesia. Computerized anesthesia records of 4096 patients undergoing general anesthesia were queried for arterial blood pressure (BP), demographic information, preoperative drug history, and anesthetic induction regimen. The median BP was determined preinduction and for 0-5 and 5-10 min postinduction of anesthesia. Hypotension was defined as either: mean arterial blood pressure (MAP) decrease of > 40% and MAP < 70 mm Hg or MAP < 60 mm Hg. Overall, 9% of patients experienced severe hypotension 0 -10 min postinduction of general anesthesia. Hypotension was more prevalent in the second half of the 0 -10 min interval after anesthetic induction (P < 0.001). In 2406 patients with retrievable foutcome data, prolonged postoperative stay and/or death was more common in patients with versus those without postinduction hypotension (13.3% and 8.6%, respectively, multivariate P < 0.02). Statistically significant multivariate predictors of hypotension 0-10 min after anesthetic induction included: ASA III-V, baseline MAP < 70 mm Hg, age >= 50 yr, the use of propofol for induction of anesthesia, and increasing induction dosage of fentanyl. Smaller doses of propofol, etomidate, and thiopental were not associated with less hypotension. To avoid severe hypotension, alternatives to propofol anesthetic induction (e.g., etomidate) should be considered in patients older than 50 yr of age with ASA physical status >= 3. We conclude that it is advisable to avoid propofol induction in patients who present with baseline MAP < 70 mm Hg.	CUNY Mt Sinai Sch Med, Dept Anesthesiol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Biomath Sci, New York, NY 10029 USA	Reich, DL (reprint author), Mt Sinai Med Ctr, Dept Anesthesiol, Box 1010,1 Gustave L Levy Pl, New York, NY 10029 USA.	david.reich@msnyuhealth.org					Bennett-Guerrero E, 2001, ANESTHESIOLOGY, V94, P992, DOI 10.1097/00000542-200106000-00012; Benson M, 2000, J CLIN MONITOR COMP, V16, P183, DOI 10.1023/A:1009937510028; COLSON P, 1992, ANESTH ANALG, V74, P805; COOK RI, 1989, ANESTHESIOLOGY, V71, P385, DOI 10.1097/00000542-198909000-00013; CORIAT P, 1994, ANESTHESIOLOGY, V81, P299, DOI 10.1097/00000542-199408000-00006; GOLDMAN L, 1979, ANESTHESIOLOGY, V50, P285, DOI 10.1097/00000542-197904000-00002; Hollenberg JP, 1997, J CARDIOTHOR VASC AN, V11, P545, DOI 10.1016/S1053-0770(97)90001-X; HUG CC, 1993, ANESTH ANALG, V77, pS21; Jain U, 1997, ANESTHESIOLOGY, V86, P576, DOI 10.1097/00000542-199703000-00009; LEROU JG, 1988, J CLIN MONITOR, V41, P37; LOEB RG, 1993, ANESTH ANALG, V76, P337; Reich DL, 2000, ANESTH ANALG, V91, P612, DOI 10.1213/00000539-200009000-00022; Reich DL, 2003, J CARDIOTHOR VASC AN, V17, P699, DOI 10.1053/j.jvca.2003.09.010; Reich DL, 1999, ANESTH ANALG, V89, P814, DOI 10.1097/00000539-199910000-00002; WEINGER MB, 1994, ANESTHESIOLOGY, V80, P77, DOI 10.1097/00000542-199401000-00015	15	268	290	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	SEP	2005	101	3					622	628		10.1213/01.ANE.0000175214.38450.91			7	Anesthesiology	Anesthesiology	958HE	WOS:000231434500002	16115962				2020-06-30	J	Lin, JA; Yeh, CC; Lee, MS; Wu, CT; Lin, SL; Wong, CS				Lin, JA; Yeh, CC; Lee, MS; Wu, CT; Lin, SL; Wong, CS			Prolonged injection time and light smoking decrease the incidence of fentanyl-induced cough	ANESTHESIA AND ANALGESIA			English	Article							AIRWAY HYPERRESPONSIVENESS; CIGARETTE-SMOKE; RECEPTORS; RESPONSES; BOLUS; SENSITIVITY; ANESTHESIA; RABBIT	We designed this study to evaluate the effect of injection time and smoking on fentanyl-induced cough. Four-hundred-fifty ASA class I-II patients, aged 18-80 yr and weighing 40-90 kg, scheduled for elective surgery were included. All patients received fentanyl (100 mu g for patients weighing 40-69 kg and 150 mu g for patients weighing 70-90 kg for clinical convenience) via the proximal port of a peripheral IV line on the forearm. Patients were randomly assigned to 3 groups of 150 patients each. Patients in Group I received fentanyl injection over 2 s, whereas for patients in Groups II and III the fentanyl was injected at a constant rate over 15 s and 30 s, respectively. We recorded the number of coughs of each patient during and 30 s after fentanyl injection. The incidence of cough was 18% in group 1, 8% in Group 11, and 1.3% in Group 111, significantly less (P < 0.05) with a longer injection time. Current smokers had a less frequent incidence of cough than nonsmokers; however, this effect was only significant in light smokers (< 10 cigarettes per day or < 10 smoking years or < 10 packyears). In conclusion, a longer injection time reduces the incidence of fentanyl-induced cough, and light smoking may be a protective factor against fentanyl-induced cough.	Tri Serv Gen Hosp, Dept Anesthesiol, Taipei, Taiwan; Natl Def Univ, Natl Def Med Ctr, Taipei, Taiwan	Wong, CS (reprint author), Tri Serv Gen Hosp, Dept Anesthesiol, 325,Sect 2,Chenggung Rd,Neihu 114, Taipei, Taiwan.	w82556@ndmctsgh.edu.tw		Lin, Jui-An/0000-0003-0855-4828			Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; Bonham AC, 1996, J APPL PHYSIOL, V81, P1715; BOVILL JG, 1984, ANESTHESIOLOGY, V61, P731; Chang AB, 1997, AM J RESP CRIT CARE, V155, P1935, DOI 10.1164/ajrccm.155.6.9196099; Fox AJ, 1996, PULM PHARMACOL THER, V9, P335, DOI 10.1006/pulp.1996.0044; GRELL FL, 1970, ANESTH ANAL CURR RES, V49, P523; Hsiue Tzuen-Ren, 1993, Journal of the Formosan Medical Association, V92, P231; Karlsson JA, 1999, PULM PHARMACOL THER, V12, P215, DOI 10.1006/pupt.1999.0207; Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421; Lui PW, 1996, CAN J ANAESTH, V43, P1216; Millqvist E, 2001, RESP MED, V95, P19, DOI 10.1053/rmed.2000.0965; PAINTAL AS, 1969, J PHYSIOL-LONDON, V203, P511, DOI 10.1113/jphysiol.1969.sp008877; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; RAVI K, 1994, J APPL PHYSIOL, V77, P2633; SANTAMBROGIO FB, 1982, RESP PHYSIOL, V49, P49, DOI 10.1016/0034-5687(82)90103-7; Tweed WA, 2001, ANESTH ANALG, V92, P1442; Willemse BWM, 2004, EUR RESPIR J, V23, P464, DOI 10.1183/09031936.04.00012704; ZHANG Z, 1995, J PHYSIOL-LONDON, V484, P189, DOI 10.1113/jphysiol.1995.sp020658	19	50	72	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	SEP	2005	101	3					670	674		10.1213/01.ANE.0000159161.31276.DB			5	Anesthesiology	Anesthesiology	958HE	WOS:000231434500014	16115973				2020-06-30	J	Chassard, D; Allaouchiche, BA; Boselli, E				Chassard, D; Allaouchiche, BA; Boselli, E			Timing is everything - The pendulum swings on	ANESTHESIOLOGY			English	Editorial Material							ANALGESIA; CHRONOPHARMACOLOGY; CHRONOBIOLOGY; DURATION; PAIN		Hop Hotel Dieu, F-69288 Lyon, France	Chassard, D (reprint author), Hop Hotel Dieu, F-69288 Lyon, France.	dominique.chassard@chu-lyon.fr	Boselli, Emmanuel/A-9183-2015	Boselli, Emmanuel/0000-0002-4949-3518			BRUGUEROLLE B, 1988, ANN REV CHRONOPHARMA, V5, P227; Chassard D, 2004, ANESTHESIOLOGY, V100, P413; Debon R, 2004, ANESTHESIOLOGY, V101, P978, DOI 10.1097/00000542-200410000-00024; Debon R, 2002, ANESTHESIOLOGY, V96, P542, DOI 10.1097/00000542-200203000-00006; GRAVES DA, 1983, CLIN PHARMACY, V2, P49; LABRECQUE G, 1995, PHARMACOL THERAPEUT, V68, P129, DOI 10.1016/0163-7258(95)02003-9; LEMMER B, 1987, CHRONOBIOL INT, V4, P319, DOI 10.3109/07420528709083522; MORRIS RW, 1967, NATURE, V216, P494, DOI 10.1038/216494a0; MUNSON ES, 1970, ANESTHESIOLOGY, V32, P507, DOI 10.1097/00000542-197006000-00007; Pan PH, 2005, ANESTHESIOLOGY, V103, P595, DOI 10.1097/00000542-200509000-00023; PROCACCI P, 1974, CHRONOBIOLOGIA, V1, P77; Smolensky M.H., 1993, AM REV RESPIR DIS, V147, P2	12	2	2	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	SEP	2005	103	3					454	456		10.1097/00000542-200509000-00004			3	Anesthesiology	Anesthesiology	960EZ	WOS:000231574300003	16129967				2020-06-30	J	Pan, PH; Lee, S; Harris, L				Pan, PH; Lee, S; Harris, L			Chronobiology of subarachnoid fentanyl for labor analgesia	ANESTHESIOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 23-27, 2004	Las Vegas, NV	Amer Soc Anesthesiologists			INTRATHECAL SUFENTANIL; CIRCADIAN CHANGES; DURATION; CHRONOPHARMACOLOGY; PERCEPTION; THRESHOLD; MORPHINE; KINETICS; DRUG	Background: Chronobiology studies the recurrent biologic rhythms that directly affect how an organism interacts with its environment and how its environment affects the organism. The purpose of this study is to determine whether the time of administration influences the analgesic duration of the commonly used subarachnoid fentanyl for labor analgesia. Methods: After institutional review board approval and informed consent were obtained, 77 healthy milliparous women in active labor requesting neuraxial analgesia were assigned to one of two groups, based on the time of combined spinal-epidural analgesia placement: the day group, for the time period from 12:00 to 18:00, and the night group, for the period from 20:00 to 02:00. Combined spinal-epidural analgesia was performed with 20 fig subarachnoid fentanyl. An epidural catheter was inserted but not dosed until patients requested further analgesia. Dynamic data were recorded at 5-min intervals for 20 min initially and then every 15 min. The analgesic duration was defined as the time from subarachnoid fentanyl injection to the time the patient requested further analgesia. Results. Seventy evaluable patients completed the study, with 35 per group. Patient demographics, visual analog pain scale scores, and labor characteristics were similar between groups, but the duration (mean +/- SD) for subarachnoid fentanyl labor analgesia was 92 +/- 34 min for the day group and 67 +/- 21 min for the night group (P < 0.001). Conclusions: The results indicate that chronobiology of subarachnoid fentanyl plays a significant role of up to 27% difference in labor analgesic duration between the two administration time periods studied. Chronobiology should be incorporated in future comparative studies or analysis of previous studies on subarachnoid fentanyl.	Wake Forest Univ, Sch Med, Dept Anesthesiol, Winston Salem, NC 27157 USA	Pan, PH (reprint author), Wake Forest Univ, Sch Med, Dept Anesthesiol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	ppan@wfubmc.edu					Aya AGM, 2004, BRIT J ANAESTH, V93, P451, DOI 10.1093/bja/aeh223; BRUGUEROLLE B, 1987, J PHARM PHARMACOL, V39, P148, DOI 10.1111/j.2042-7158.1987.tb06966.x; BRUGUEROLLE B, 1988, ANN REV CHRONOPHARMA, V5, P277; Chassard D, 2004, ANESTHESIOLOGY, V100, P413; DeBalli P, 2003, CNS DRUGS, V17, P889, DOI 10.2165/00023210-200317120-00003; Debon R, 2004, ANESTHESIOLOGY, V101, P978, DOI 10.1097/00000542-200410000-00024; Debon R, 2002, ANESTHESIOLOGY, V96, P542, DOI 10.1097/00000542-200203000-00006; LEMMER B, 1994, ANN BIOL CLIN-PARIS, V52, P1; LEMMER B, 1989, CHRONOBIOL INT, V6, P157, DOI 10.3109/07420528909064626; Louvel D, 1996, GUT, V39, P741, DOI 10.1136/gut.39.5.741; Lu JK, 1997, ANESTH ANALG, V85, P372, DOI 10.1097/00000539-199708000-00023; Mandell GL, 1996, REGION ANESTH, V21, P103; MORRIS RW, 1967, NATURE, V216, P494, DOI 10.1038/216494a0; Nelson KE, 1999, ANESTHESIOLOGY, V91, P1293, DOI 10.1097/00000542-199911000-00020; Nelson KE, 2002, ANESTHESIOLOGY, V96, P1070, DOI 10.1097/00000542-200205000-00007; Nordin S, 2003, PSYCHOPHYSIOLOGY, V40, P612, DOI 10.1111/1469-8986.00062; Palmer CM, 1998, ANESTHESIOLOGY, V88, P355, DOI 10.1097/00000542-199802000-00014; PROCACCI P, 1974, CHRONOBIOLOGIA, V1, P77; REINBERG A, 1977, N-S ARCH PHARMACOL, V297, P149, DOI 10.1007/BF00499924; Ummenhofer WC, 2000, ANESTHESIOLOGY, V92, P739, DOI 10.1097/00000542-200003000-00018; VANCAUTER E, 1990, HORM RES, V34, P45, DOI 10.1159/000181794	21	18	18	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	SEP	2005	103	3					595	599		10.1097/00000542-200509000-00023			5	Anesthesiology	Anesthesiology	960EZ	WOS:000231574300021	16129985				2020-06-30	J	Carvalho, B; Durbin, M; Drover, DR; Cohen, SE; Ginosar, Y; Riley, ET				Carvalho, B; Durbin, M; Drover, DR; Cohen, SE; Ginosar, Y; Riley, ET			The ED50 and ED95 of intrathecal isobaric bupivacaine with opioids for cesarean delivery	ANESTHESIOLOGY			English	Article							HYPERBARIC BUPIVACAINE; SPINAL-ANESTHESIA; 0.5-PERCENT BUPIVACAINE; TERM PARTURIENT; DOUBLE-BLIND; SECTION; PLAIN; FENTANYL; ANALGESIA; SPREAD	Background: The ideal intrathecal isobaric bupivacaine dose for cesarean delivery anesthesia is uncertain. While small doses (5-9 mg) of bupivacaine may reduce side effects such as hypotension, they potentially increase spinal anesthetic failures. This study determined the ED50 and ED95 of intrathecal isobaric bupivacaine (with adjuvant opioids) for cesarean delivery. Methods: After institutional review board approval and written informed consent were obtained, 48 parturients undergoing elective cesarean delivery under combined spinal-epidural anesthesia were enrolled in this double-blind, randomized, dose-ranging study. Patients received a 5-, 6-, 7-, 8-, 9-, 10-, 11-, or 12-mg intrathecal isobaric bupivacaine dose with 10 mu g fentanyl and 200 mu g morphine. Overall anesthetic success was recorded when no intraoperative epidural supplement was required during the cesarean delivery. ED50 and ED95 values for overall anesthetic success were determined using a logistic regression model. Results: ED50 and ED95 values for overall anesthetic success were 7.25 and 13.0 mg, respectively. No advantages for low doses could be demonstrated with regard to hypotension, nausea, vomiting, pruritus, or maternal satisfaction, although this study was underpowered to detect significant differences in secondary outcome variables. Conclusions: The ED50 and ED95 values (7.25 and 13.0 mg, respectively) for intrathecal isobaric hupivacaine in this circumstance are similar to values the authors determined recently for hyperbaric bupivacaine using similar methodology. These ED50 and ED95 values are significantly higher than those advocated in previous reports in which success was claimed using lower intrathecal bupivacaine doses. The current study used stricter criteria to define "successful" anesthesia and support the use of larger bupivacaine doses to ensure adequate patient comfort.	Stanford Univ, Sch Med, Dept Anesthesia, Stanford, CA 94305 USA; Hadassah Hebrew Univ, Med Ctr, Dept Anesthesiol & Crit Care Med, Jerusalem, Israel	Carvalho, B (reprint author), Stanford Univ, Sch Med, Dept Anesthesia, H3580, Stanford, CA 94305 USA.	bcarvalho@stanford.edu					Ben-David B, 2000, REGION ANESTH PAIN M, V25, P235, DOI 10.1016/S1098-7339(00)90004-X; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; Connolly C, 2001, BRIT J ANAESTH, V86, P805, DOI 10.1093/bja/86.6.805; Critchley LAH, 1999, ANAESTHESIA, V54, P469, DOI 10.1046/j.1365-2044.1999.00841.x; Danelli G, 2001, Minerva Anestesiol, V67, P573; Dershwitz M, 1998, J CLIN ANESTH, V10, P314, DOI 10.1016/S0952-8180(98)00035-X; FAN SZ, 1994, ANESTH ANALG, V78, P474; FINUCANE BT, 1995, REGION ANESTH, V20, P87; Ginosar Y, 2004, ANESTHESIOLOGY, V100, P676, DOI 10.1097/00000542-200403000-00031; HARTWELL BL, 1991, REGION ANESTH, V16, P17; Kang F C, 1998, Acta Anaesthesiol Sin, V36, P207; Khaw KS, 2002, ANESTH ANALG, V94, P680, DOI 10.1097/00000539-200203000-00037; MCCULLOCH WJD, 1986, BRIT J ANAESTH, V58, P610, DOI 10.1093/bja/58.6.610; NORRIS MC, 1990, ANESTHESIOLOGY, V72, P478, DOI 10.1097/00000542-199003000-00015; PEDERSEN H, 1989, ANESTH ANALG, V69, P46; Richardson MG, 1997, ANESTH ANALG, V84, P95, DOI 10.1097/00000539-199701000-00018; Richardson MG, 1998, ANESTH ANALG, V87, P336, DOI 10.1097/00000539-199808000-00019; RUSSELL IF, 1987, BRIT J ANAESTH, V59, P347, DOI 10.1093/bja/59.3.347; Sarvela PJ, 1999, ANESTH ANALG, V89, P1257, DOI 10.1213/00000539-199911000-00033; Schnider TW, 1996, ANESTHESIOLOGY, V85, P502, DOI 10.1097/00000542-199609000-00009; STIENSTRA R, 1987, ANESTH ANALG, V66, P171; Stocks GM, 2001, ANESTHESIOLOGY, V94, P593, DOI 10.1097/00000542-200104000-00011; VANHEMELRIJCK J, 1994, ANESTHESIOLOGY, V80, P36; Vercauteren MP, 1998, ANESTH ANALG, V86, P989, DOI 10.1097/00000539-199805000-00014	24	54	60	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	SEP	2005	103	3					606	612		10.1097/00000542-200509000-00025			7	Anesthesiology	Anesthesiology	960EZ	WOS:000231574300023	16129987				2020-06-30	J	de Almeida, AN; Tavares, C; Tibano, A; Sasaki, S; Murata, KN; Marino, R				de Almeida, AN; Tavares, C; Tibano, A; Sasaki, S; Murata, KN; Marino, R			Dexmedetomidine for awake craniotomy without laryngeal mask	ARQUIVOS DE NEURO-PSIQUIATRIA			English	Article						awake craniotomy; dexmedetomidine; epilepsy surgery; cortical mapping; neuroanesthesia	SEIZURE THRESHOLD; ANESTHESIA; SEDATION; PROPOFOL; INFUSION; PATIENT	Objective: This paper reports the use of dexmedetomidine in three epileptic patients with cavernous angiomas that underwent awake surgery in order to map their speech areas. Method.-Loading dose of dexmedetomidine varied from 1 mu g/Kg/h to 3 mu g/Kg/h over 20 minutes and maintenance dose from 0.4 mu g/Kg/h to 0.8 mu g/Kg/h. Results: There was no occurrence of hemodynamic instability, convulsions or respiratory depression. Patients tolerated well the procedure. Conclusion: Dexmedetomidine was useful for awake craniotomy as it decreased patients' level of consciousness but did not produce agitation. Laryngeal mask was not necessary to keep air ventilation.	Hosp Sao Joaquim Real & Benemerita Sociedade Port, Inst Neurol Sao Paulo, Sao Paulo, Brazil	de Almeida, AN (reprint author), Rua Maestro Cardim 808, BR-01323001 Sao Paulo, Brazil.	almeidaan@globo.com	Almeida, Antonio/O-5506-2019; de Almeida, Antonio Nogueira/A-2957-2016	Almeida, Antonio/0000-0002-0796-7025; de Almeida, Antonio Nogueira/0000-0002-0796-7025			Arain SR, 2002, ANESTH ANALG, V95, P461, DOI 10.1097/00000539-200208000-00042; Ard J, 2003, J NEUROSURG ANESTH, V15, P263, DOI 10.1097/00008506-200307000-00015; Bekker AY, 2001, ANESTH ANALG, V92, P1251; Danks RA, 1998, NEUROSURGERY, V42, P28, DOI 10.1097/00006123-199801000-00006; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; Hans P, 2000, ANAESTHESIA, V55, P255, DOI 10.1046/j.1365-2044.2000.01277.x; MIRSKI MAZ, 1994, ANESTHESIOLOGY, V81, P1422, DOI 10.1097/00000542-199412000-00017; Miyazaki Y, 1999, BRIT J ANAESTH, V82, P935; Mizobe T, 1996, J CLIN INVEST, V98, P1076, DOI 10.1172/JCI118887; Prielipp RC, 2002, ANESTH ANALG, V95, P1052, DOI 10.1097/00000539-200210000-00048; Skirboll SS, 1996, NEUROSURGERY, V38, P678, DOI 10.1227/00006123-199604000-00008; Talke P, 1997, ANESTH ANALG, V85, P1136, DOI 10.1097/00000539-199711000-00033; Venn RM, 2001, BRIT J ANAESTH, V87, P684, DOI 10.1093/bja/87.5.684	14	15	15	0	2	ASSOC ARQUIVOS NEURO- PSIQUIATRIA	SAO PAULO SP	PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL	0004-282X	1678-4227		ARQ NEURO-PSIQUIAT	Arq. Neuro-Psiquiatr.	SEP	2005	63	3B					748	750		10.1590/S0004-282X2005000500005			3	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	972RY	WOS:000232472100005	16258649	DOAJ Gold			2020-06-30	J	Shibutani, K; Inchiosa, MA; Sawada, K; Bairamian, M				Shibutani, K; Inchiosa, MA; Sawada, K; Bairamian, M			Pharmacokinetic mass of fentanyl for postoperative analgesia in lean and obese patients	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesics; fentanyl; complications; obesity; pharmacokinetics; fentanyl		Background. We previously proposed dosing weights for fentanyl, termed 'pharmacokinetic mass', that span the total body weight (TBW) range from 40 to 2 10 kg. In this study, we examined the relationships among fentanyl doses needed to achieve postoperative analgesia, corresponding plasma fentanyl concentrations, and pharmacokinetic mass in lean and obese patients undergoing abdominal surgery. Methods. A total of 69 patients were studied, with TBW ranging from 48 to 181 kg. Fentanyl infusion was used during surgery. After surgery, fentanyl infusion rates were titrated to achieve analgesia without significant respiratory depression. Plasma fentanyl concentrations were measured when an apparent steady analgesic state was obtained. Comparisons were made for dosing requirements and effective plasma concentrations for 37 lean patients (body mass index < 30, TBW < 85 kg) and 33 obese patients (body mass index > 30, TBW >= 85 kg). Results. The average fentanyl dose (mu g h(-1)) required to achieve and maintain analgesia over the 4 In postoperative period had a non-linear relationship to TBW; in comparison, fentanyl dose had a strong linear relationship to pharmacokinetic mass: dose (mu g h(-1))=1.22xpharmacokinetic mass-7.5; r = 0.74 1, P < 0.00 1. Based on results from our earlier study, the corresponding values of TBW and pharmacokinetic mass are: 52 kg - 52 kg; 70 kg - 65 kg; 100 kg - 83 kg; 120 kg - 93 kg; 140 kg - 99 kg; 160 kg - 104 kg; 180 kg - 107 kg; 200 kg - 109 kg. In the group comparisons, there was no statistically significant difference in the postoperative fentanyl dose per unit of pharmacokinetic mass between lean and obese patients. The plasma concentration of fentanyl required for analgesia was approximately 1.5 ng ml(-1), and was similar in the two groups. Conclusion. The relationship between dose and pharmacokinetic mass, compared with that of dose vs TBW, may provide confidence for the use of pharmacokinetic mass as a dosing approximation for fentanyl. Fentanyl dose based on TBW may cause overdosing in obese patients.	New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA; New York Med Coll, Dept Anesthesiol, Valhalla, NY 10595 USA; Nagoya Univ, Dept Anesthesia & Intens Care, Nagoya, Aichi, Japan	Inchiosa, MA (reprint author), New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA.	mario_inchiosa@nymc.edu					Aubrun F, 2002, ANESTHESIOLOGY, V96, P17, DOI 10.1097/00000542-200201000-00009; Benumof JL, 2001, J CLIN ANESTH, V13, P144, DOI 10.1016/S0952-8180(01)00232-X; Bouillon T, 1998, ANESTHESIOLOGY, V89, P557, DOI 10.1097/00000542-199809000-00002; Rooke GA, 2002, ANESTHESIOLOGY, V96, P2, DOI 10.1097/00000542-200201000-00006; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; Shibutani K, 2004, ANESTHESIOLOGY, V101, P603, DOI 10.1097/00000542-200409000-00008	6	50	50	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	SEP	2005	95	3					377	383		10.1093/bja/aei195			7	Anesthesiology	Anesthesiology	961ZU	WOS:000231701600018	16024584	Bronze			2020-06-30	J	Freynhagen, R; von Giesen, HJ; Busche, P; Sabatowski, R; Konrad, C; Grond, S				Freynhagen, R; von Giesen, HJ; Busche, P; Sabatowski, R; Konrad, C; Grond, S			Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: A prospective, multicenter pilot study in outpatients with chronic pain	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						chronic pain; transdermal therapeutic systems; fentanyl; reservoir; matrix; opioid side effects	RELEASE ORAL MORPHINE; CHRONIC CANCER PAIN; LONG-TERM TREATMENT; OPIOIDS; VALIDATION; MANAGEMENT; EFFICACY	Matrix systems for transdermal fentanyl will replace the reservoir systems in Europe. In an industry-independent, prospective, multicenter pilot study, 46 outpatients with chronic pain were asked to assess pain intensity, sleep interference, adverse events, and multiple secondary parameters during administration of the last reservoir and the first two matrix patches. There was no difference in pain intensity, sleep interference, and, the rate of adverse events between both systems. Self assessment on a 6-step numeric rating scale (1 = very good, 6 = insufficient) comparing the two systems (reservoir vs. matrix) showed that skin compatibility (2.6 vs. 1.5), adhesive properties (3.2 vs. 1.8), wearability/comfort (2.8 vs. 1.5), and general satisfaction (2.5 vs. 1. 8) improved significantly with the new matrix technology. At study endpoint, 91% of patients preferred the matrix system,for future use. The new fentanyl matrix system is characterized by it high level of general satisfaction, ease of use, patient acceptance, and improved skin compatibility. Reservoir and matrix systems appear to have comparable efficacy and safety so that outpatients can be switched directly from the reservoir to the matrix system without difficulties and new dose titration.	Univ Klinikum Dusseldorf, Dept Anesthesiol Ambulanz Schmerztherapie, D-40001 Dusseldorf, Germany; Univ Dusseldorf, Dept Anesthesiol, D-4000 Dusseldorf, Germany; Univ Dusseldorf, Dept Neurol, D-4000 Dusseldorf, Germany; Univ Cologne, Cologne, Germany; Univ Mannheim, Dept Anesthesiol, Mannheim, Germany; Univ Halle, Dept Anesthesiol, Halle An Der Saale, Germany	Freynhagen, R (reprint author), Univ Klinikum Dusseldorf, Dept Anesthesiol Ambulanz Schmerztherapie, Postfach 10 10 07, D-40001 Dusseldorf, Germany.		Sabatowski, Rainer/K-3475-2019	Sabatowski, Rainer/0000-0003-2228-3147; Freynhagen, Rainer/0000-0002-3759-1508			Allan L, 2001, BRIT MED J, V322, P1; ANDRESEN C, 2004, 3 WORLD C WORLD I PA, P289; BERNER B, 1994, CLIN PHARMACOKINET, V26, P121, DOI 10.2165/00003088-199426020-00005; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; Dellemijn PLI, 1998, J PAIN SYMPTOM MANAG, V16, P220, DOI 10.1016/S0885-3924(98)00070-0; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; Elsner F, 1999, SCHMERZ, V13, P273, DOI 10.1007/s004820050210; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; GIDWANI S, 2004, 3 WORLD C WORLD I PA, P288; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; GUPTA SK, 2004, 3 WORLD C WORLD I PA, P289; HOLDINESS MR, 1989, CONTACT DERMATITIS, V20, P3, DOI 10.1111/j.1600-0536.1989.tb03087.x; Likar Rudolf, 2003, Wien Med Wochenschr, V153, P317, DOI 10.1046/j.1563-258X.2003.02120.x; MILOSLAVSKY M, 2004, 3 WORLD C WORLD I PA, P288; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Mystakidou K, 2004, J PAIN, V5, P119, DOI 10.1016/j.jpain.2003.12.003; Naik, 2000, Pharm Sci Technolo Today, V3, P318, DOI 10.1016/S1461-5347(00)00295-9; Newshan G, 2001, J PAIN SYMPTOM MANAG, V21, P69, DOI 10.1016/S0885-3924(00)00238-4; Nugent M, 2001, J PAIN SYMPTOM MANAG, V21, P385, DOI 10.1016/S0885-3924(01)00257-3; Radbruch L, 1999, J PAIN SYMPTOM MANAG, V18, P180, DOI 10.1016/S0885-3924(99)00064-0; Radbruch L, 2003, INT J CLIN PRACT, P19; Radbruch L, 2001, PALLIATIVE MED, V15, P309, DOI 10.1191/026921601678320296; Radbruch Lukas, 2004, Keio J Med, V53, P23, DOI 10.2302/kjm.53.23; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; van Seventer R, 2003, CURR MED RES OPIN, V19, P457, DOI 10.1185/030079903125002045; Vielvoye-Kerkmeer APE, 2000, J PAIN SYMPTOM MANAG, V19, P185, DOI 10.1016/S0885-3924(99)00152-9; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M	28	24	24	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	SEP	2005	30	3					289	297		10.1016/j.jpainsymman.2005.03.015			9	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	974CP	WOS:000232569200014	16183013	Bronze			2020-06-30	J	Tripi, PA; Palmer, JS; Thomas, S; Elder, JS				Tripi, PA; Palmer, JS; Thomas, S; Elder, JS			Clonidine increases duration of bupivacaine caudal analgesia for ureteroneocystostomy: A double-blind prospective trial	JOURNAL OF UROLOGY			English	Article						anesthesia, caudal; clonidine; bupivacaine; vesico-ureteral reflux; child	INTRAVESICAL URETERONEOCYSTOSTOMY; LOCAL-ANESTHETICS; CHILDREN; KETAMINE; MIDAZOLAM; BLOCKADE; REPAIR; RABBIT	Purpose: We evaluated whether clonidine, when added to bupivacaine, would significantly prolong caudal analgesia and decrease opioid requirements in children undergoing ureteroneocystostomy. Materials and Methods: A total of 35 children I to 10 years old undergoing ureteroneocystostomy received a standardized regimen of general anesthesia, and were randomized to receive a preincision caudal block consisting of either 1 ml/kg 0.125% bupivacaine (controls) or 1 ml/kg 0.125% bupivacaine with 1 mu g/kg clonidine (treatment group). Caudal solutions also contained 1:400,000 epinephrine. Following the surgical procedure a second caudal block was performed with half of the original dose of medications. Caregivers were blinded to which caudal solution was administered. Postoperative outcome measures included pain scores, morphine requirements, duration of caudal analgesia and sedation scores. Statistical analysis was performed using ANOVA. Results: The 2 study groups wore similar for mean age, weight and length of surgical procedure. Two patients in the control group were excluded because of protocol violation. Intravenous morphine requirements for rescue therapy were 0.02 mg/kg in the postanesthesia care unit and 0.1 mg/kg on postoperative day 1 for the treatment group, compared to 0.05 mg/kg and 0.2 mg/kg, respectively, for controls (p <0.05). Mean interval from anesthesia finish time to first administered dose of morphine was 8.0 hours for the treatment group and 3.9 hours for controls (p = 0.01). Five of 18 patients in the clonidine-bupivacaine group received no postoperative morphine, compared to 1 of 15 in the bupivacaine group. No patient had development of hemodynamic instability, respiratory depression or sedation requiring treatment. Conclusions: The addition of clonidine to bupivacaine significantly increases the duration of caudal analgesia and decreases postoperative morphine requirements in children undergoing ureteroneocystostomy.	Case Western Reserve Univ, Sch Med, Rainbow Babies & Childrens Hosp, Div Pediat Urol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Rainbow Babies & Childrens Hosp, Div Pediat Anesthesiol, Cleveland, OH 44106 USA	Elder, JS (reprint author), Case Western Reserve Univ, Sch Med, Rainbow Babies & Childrens Hosp, Div Pediat Urol, 11100 Euclid Ave,Suite 2311, Cleveland, OH 44106 USA.						Ansermino M, 2003, PAEDIATR ANAESTH, V13, P561, DOI 10.1046/j.1460-9592.2003.01048.x; BORGBJERG FM, 1994, ANESTH ANALG, V79, P105; BROADMAN L, 1999, TECH REG ANESTH PAIN, V3, P150; Constant I, 1998, BRIT J ANAESTH, V80, P294; COOK B, 1995, BRIT J ANAESTH, V75, P698, DOI 10.1093/bja/75.6.698; De Mey JC, 2000, EUR J ANAESTH, V17, P379, DOI 10.1046/j.1365-2346.2000.00690.x; De Negri P, 2001, PAEDIATR ANAESTH, V11, P679, DOI 10.1046/j.1460-9592.2001.00742.x; GORESKY GV, 1995, CAN J ANAESTH, V42, P755, DOI 10.1007/BF03011171; Ivani G, 1998, ACTA ANAESTH SCAND, V42, P306, DOI 10.1111/j.1399-6576.1998.tb04921.x; Joshi W, 2004, PEDIATR ANESTH, V14, P483, DOI 10.1111/j.1460-9592.2004.01229.x; MALINOVSKY JM, 1991, ANESTHESIOLOGY, V75, P91, DOI 10.1097/00000542-199107000-00015; Merguerian PA, 2004, J UROLOGY, V172, P1621, DOI 10.1097/01.ju.0000139953.04938.07; Merkel S I, 1997, Pediatr Nurs, V23, P293; Miller OF, 2002, J UROLOGY, V167, P2556, DOI 10.1016/S0022-5347(05)65036-7; WOLF AR, 1988, ANESTHESIOLOGY, V69, P102, DOI 10.1097/00000542-198807000-00017; Wong D L, 1988, Pediatr Nurs, V14, P9	16	23	24	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5347			J UROLOGY	J. Urol.	SEP	2005	174	3					1081	1083		10.1097/01.ju.0000169138.90628.b9			3	Urology & Nephrology	Urology & Nephrology	956BU	WOS:000231274700078	16094063				2020-06-30	J	Ross, AK; Hazlett, HC; Garrett, NT; Wilkerson, C; Piven, J				Ross, AK; Hazlett, HC; Garrett, NT; Wilkerson, C; Piven, J			Moderate sedation for MRI in young children with autism	PEDIATRIC RADIOLOGY			English	Article						autism; moderate sedation; pentobarbital; fentanyl	PEDIATRIC SEDATION; CHLORAL HYDRATE; ORAL KETAMINE; MANAGEMENT; RADIOLOGY; EFFICACY	Autism is a pervasive neurodevelopmental disorder. Because of the deficits associated with the condition, sedation of children with autism has been considered more challenging than sedation of other children. Objective: To test this hypothesis, we compared children with autism against clinical controls to determine differences in requirements for moderate sedation for MRI. Materials and methods: Children ages 18-36 months with autism (group 1, n = 41) and children with no autistic behavior (group 2, n = 42) were sedated with a combination of pentobarbital and fentanyl per sedation service protocol. The sedation nurse was consistent for all patients, and all were sedated to achieve a Modified Ramsay Score of 4. Demographics and doses of sedatives were recorded and compared. Results: There were no sedation failures in either group. Children in group 1 (autism) were significantly older than group 2 (32.02 +/- 3.6 months vs 28.16 +/- 6.7 months) and weighed significantly more (14.87 +/- 2.1 kg vs 13.42 +/- 2.2 kg). When compared on a per-kilogram basis, however, group 1 had a significantly lower fentanyl requirement than group 2 (1.25 +/- 0.55 mcg/kg vs 1.57 +/- 10.81 mcg/kg), but no significant difference was found in pentobarbital dosing between groups 1 and 2, respectively (4.92 +/- 0.92 mg/kg vs 5.21 +/- 1.6 mg/kg). Conclusion: Autistic children in this age range are not more difficult to sedate and do not require higher doses of sedative agents for noninvasive imaging studies.	Duke Univ, Med Ctr, Div Pediat Anesthesia, Durham, NC 27710 USA; Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC USA; Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA; Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC USA	Ross, AK (reprint author), Duke Univ, Med Ctr, Div Pediat Anesthesia, 3094, Durham, NC 27710 USA.	ross0016@mc.duke.edu	Warfield, Simon/B-3352-2009	Warfield, Simon/0000-0002-7659-3880	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5P30 HD03110]; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH61696]		[Anonymous], 1994, DIAGN STAT MAN MENT; BRAFF MH, 1979, J DENT CHILD, V46, P404; CONNOR L, 2003, AJR, V181, P1601; Cote CJ, 2000, PEDIATRICS, V105, P805, DOI 10.1542/peds.105.4.805; Cravero JP, 2004, ANESTH ANALG, V99, P1355, DOI 10.1213/01.ANE.0000134810.60270.E8; Davila J M, 1988, Spec Care Dentist, V8, P58, DOI 10.1111/j.1754-4505.1988.tb00692.x; DONAHUE PJ, 1992, ANESTHESIOLOGY, V77, P604, DOI 10.1097/00000542-199209000-00036; Frush DP, 1996, AM J ROENTGENOL, V167, P1381, DOI 10.2214/ajr.167.6.8956563; GUTSTEIN HB, 1992, ANESTHESIOLOGY, V76, P28, DOI 10.1097/00000542-199201000-00004; Hoffman GM, 2002, PEDIATRICS, V109, P236, DOI 10.1542/peds.109.2.236; Karian VE, 2002, PEDIATR RADIOL, V32, P348, DOI 10.1007/s00247-001-0653-8; Karian VE, 1999, PEDIATR RADIOL, V29, P869, DOI 10.1007/s002470050715; KAUFFMAN RE, 1992, PEDIATRICS, V89, P1110; Klein U, 1999, Spec Care Dentist, V19, P200, DOI 10.1111/j.1754-4505.1999.tb01386.x; KOPEL HM, 1977, J DENT CHILD, V44, P302; LORD C, 1989, J AUTISM DEV DISORD, V19, P185, DOI 10.1007/BF02211841; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Malviya S, 2004, PEDIATR ANESTH, V14, P589, DOI 10.1111/j.1460-9592.2004.01243.x; Mason KP, 2001, AM J ROENTGENOL, V177, P427, DOI 10.2214/ajr.177.2.1770427; MEHTA UC, 1994, DEV BHEAV PED, V25, P102; Rainey L, 1998, ANAESTH INTENS CARE, V26, P682, DOI 10.1177/0310057X9802600615; RUMM PD, 1990, SOUTHERN MED J, V83, P1040; Seid M, 1997, INT J PEDIATR OTORHI, V40, P107, DOI 10.1016/S0165-5876(97)01507-3; STRAIN JD, 1988, AM J ROENTGENOL, V151, P975, DOI 10.2214/ajr.151.5.975; Van der Walt JH, 2001, PAEDIATR ANAESTH, V11, P401, DOI 10.1046/j.1460-9592.2001.00688.x	25	17	18	0	3	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0301-0449			PEDIATR RADIOL	Pediatr. Radiol.	SEP	2005	35	9					867	871		10.1007/s00247-005-1499-2			5	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	956QA	WOS:000231313700006	15902433				2020-06-30	J	del Consuelo, ID; Falson, F; Guy, RH; Jacques, Y				del Consuelo, ID; Falson, F; Guy, RH; Jacques, Y			Transport of fentanyl through pig buccal and esophageal epithelia in vitro. Influence of concentration and vehicle pH	PHARMACEUTICAL RESEARCH			English	Article						buccal epithelium; diffusion; esophageal epithelium; fentanyl; permeability; transport	ORAL-MUCOSA; HORSERADISH-PEROXIDASE; NARCOTIC ANALGESICS; DELIVERY DEVICE; PERMEABILITY; ABSORPTION; SKIN; CITRATE; WATER; PAIN	Purpose. To validate pig esophageal epithelium as a model for the permeability barrier of the buccal mucosa, the transport of fentanyl across the two tissues was compared in vivo. Methods. The epithelia were separated by immersing the excised mucosae into an isotonic saline solution at 60-65 degrees C. Fentanyl was delivered as the citrate salt at a concentration of 1 or 2 mg/mL buffered at one of four pH values (between 6.0 and 7.4). Results. Across both barriers, drug transport increased proportionally with concentration as expected. However, drug flux was not linearly related to the unionized fraction of the drug; indeed, fentanyl delivery was significant even when 98.5% of the drug was in the ionized form. Conclusions. Buccal and esophageal fluxes were very similar under all conditions suggesting that the esophageal epithelium is a representative tool for buccal transport studies in vitro.	Pharmapeptides, Ctr Interuniv Rech & Enseignement, F-74160 Archamps, France; Univ Geneva, Sch Pharmaceut Sci, CH-1211 Geneva, Switzerland; Univ Lyon 1, Lab Rech & Dev Pharm Galen Ind ISPB, F-69373 Lyon, France; Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England	Jacques, Y (reprint author), Pharmapeptides, Ctr Interuniv Rech & Enseignement, Parc Affaires Int, F-74160 Archamps, France.	yves.jacques@pharm.unige.ch	Guy, Richard H/H-3471-2012	Guy, Richard/0000-0003-3227-9862			CASSIDY J, 1993, PHARMACEUT RES, V10, P126, DOI 10.1023/A:1018941517355; DELCONSUELO ID, IN PRESS J PHARM SCI; DELCONSUELO ID, IN PRESS ARCH ORAL B; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; HOOGSTRAATE AJ, 1994, PHARMACEUT RES, V11, P83, DOI 10.1023/A:1018949828548; Jacques Y, 1997, STP PHARMA SCI, V7, P289; LESCH CA, 1989, J DENT RES, V68, P1345, DOI 10.1177/00220345890680091101; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; MOFFAT AC, 1971, TOP MED CHEM, V4, P1; OBATA Y, 1993, INT J PHARM, V89, P191, DOI 10.1016/0378-5173(93)90243-9; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; ROY SD, 1989, PHARMACEUT RES, V6, P147, DOI 10.1023/A:1015932610010; ROY SD, 1990, PHARMACEUT RES, V7, P842, DOI 10.1023/A:1015912932416; Shojaei A H, 1998, J Pharm Pharm Sci, V1, P15; SIEGEL A, 1984, STRUCTURE FUNCTION O, P98; Squier C A, 2001, J Natl Cancer Inst Monogr, P7; SQUIER CA, 1973, J ULTRA MOL STRUCT R, V43, P160, DOI 10.1016/S0022-5320(73)90076-2; SQUIER CA, 1985, J INVEST DERMATOL, V84, P176, DOI 10.1111/1523-1747.ep12264711; SQUIER CA, 1991, J INVEST DERMATOL, V96, P123, DOI 10.1111/1523-1747.ep12515931; STREISAND JB, 1995, ANESTHESIOLOGY, V82, P759, DOI 10.1097/00000542-199503000-00018; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Valenta C, 2000, INT J PHARM, V197, P77, DOI 10.1016/S0378-5173(99)00453-6; WERTZ PW, 1991, CRIT REV THER DRUG, V8, P237	23	20	20	0	2	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0724-8741	1573-904X		PHARM RES-DORDR	Pharm. Res.	SEP	2005	22	9					1525	1529		10.1007/s11095-005-6020-y			5	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	958TW	WOS:000231472100012	16132365				2020-06-30	J	El Mouedden, M; Meert, TF				El Mouedden, M; Meert, TF			Evaluation of pain-related behavior, bone destruction and effectiveness of fentanyl, sufentanil, and morphine in a murine model of cancer pain	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						bone cancer; cancer pain; fentanyl; morphine; sufentanil; opioid; marine model; osteolysis; CT-scan; trabecular bone structure	SKELETAL COMPLICATIONS; BREAKTHROUGH PAIN; TUMOR-GROWTH; SPINAL-CORD; BISPHOSPHONATE; THERAPY; PATHOPHYSIOLOGY; REORGANIZATION; HYPERALGESIA; OSTEOCLASTS	The present study was conducted to evaluate the pain development and bone destruction during bone cancer growth in a murine model of bone cancer pain and to evaluate the analgesic efficacy of fentanyl, sufentanil, and morphine in this model. C3H/HeNCrl mice were inoculated into the intramedullary space of the femur with osteolytic NCTC 2472 fibrosarcoma cells, and followed during a 3-week period to assess pain behaviors (spontaneous lifting and limb-use during forced ambulation on rotarod) and bone destruction (parameters indicative of bone lesions determined by mu CT-scans of the tumor-bearing bones) during bone cancer growth. The results showed that in this murine model of cancer-induced bone pain, behavioural manifestations of pain emerge in parallel with the progression of bone destruction. The Subcutaneous administration of fentanyl (0.025-0.64 mg/kg), sufentanil (0.005-0.04 mg/kg), and morphine (2.5-40 mg/kg) oil the test days 15 and 22 post-inoculation reduced pain-related behaviors in a dose dependent manner. A complete relief from pain-related behaviors was achieved with the following doses: >= 0. 16 mg/kg fentanyl, 0.02 mg/kg sufentanil, and 20 mg/kg morphine. In conclusion, the results showed a clear link between tumor growth-induced bone destruction and behavioral pain manifestations, the latter was effectively controlled by the opioids fentanyl, sufentanil, and morphine. (c) 2005 Elsevier Inc. All rights reserved.	Johnson & Johnson Pharmaceut, Res & Dev, Div Janssen Pharmaceut, B-2340 Beerse, Belgium	El Mouedden, M (reprint author), Johnson & Johnson Pharmaceut, Res & Dev, Div Janssen Pharmaceut, NV Turnhoutseweg 30, B-2340 Beerse, Belgium.	melmoued@PRDBE.jnj.com					Berruti A, 1999, CLIN CHEM, V45, P1240; Cherny NI, 2000, CA-CANCER J CLIN, V50, P70, DOI 10.3322/canjclin.50.2.70; Clohisy DR, 2003, CANCER-AM CANCER SOC, V97, P866, DOI 10.1002/cncr.11144; Clohisy DR, 1998, J ORTHOPAED RES, V16, P660, DOI 10.1002/jor.1100160606; Clohisy DR, 1996, J ORTHOPAED RES, V14, P2, DOI 10.1002/jor.1100140103; Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.3.CO;2-Z; Coleman Robert E., 1998, Current Opinion in Oncology, V10, pS7; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; Honore P, 2000, NAT MED, V6, P521, DOI 10.1038/74999; Honore P, 2000, Prog Brain Res, V129, P389; Honore P, 2000, PAIN MED, V1, P303, DOI 10.1046/j.1526-4637.2000.00047.x; KANIS JA, 1991, BONE, V12, P13; Kehl LJ, 2003, PAIN, V103, P175, DOI 10.1016/S0304-3959(02)00450-5; Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505; Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z; Luger NM, 2001, CANCER RES, V61, P4038; Luger NM, 2002, PAIN, V99, P397, DOI 10.1016/S0304-3959(02)00102-1; Mantyh PW, 2002, NAT REV CANCER, V2, P201, DOI 10.1038/nrc747; Mantyh PW, 2002, PAIN, V96, P1, DOI 10.1016/S0304-3959(01)00482-1; Medhurst SJ, 2002, PAIN, V96, P129, DOI 10.1016/S0304-3959(01)00437-7; Menendez L, 2003, BRAIN RES, V969, P102, DOI 10.1016/S0006-8993(03)02284-4; Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304-3959(96)03267-8; Mercadante S, 1998, CANCER TREAT REV, V24, P425, DOI 10.1016/S0305-7372(98)90005-6; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Pelger RCM, 1998, BONE, V22, P403, DOI 10.1016/S8756-3282(97)00289-5; Peters CM, 2004, NEUROSCIENCE, V126, P1043, DOI 10.1016/j.neuroscience.2004.04.027; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0; Portenoy RK, 1999, ONCOLOGY-NY, V13, P25; Sabino MAC, 2002, CANCER RES, V62, P7343; Schwei MJ, 1999, J NEUROSCI, V19, P10886; Sevcik MA, 2005, PAIN, V115, P128, DOI 10.1016/j.pain.2005.02.022; Sevcik MA, 2004, PAIN, V111, P169, DOI 10.1016/j.pain.2004.06.015; Thurlimann B, 1996, DRUGS, V51, P383; Vermeirsch H, 2004, PHARMACOL BIOCHEM BE, V79, P243, DOI 10.1016/j.pbb.2004.07.011; Wacnik PW, 2001, J NEUROSCI, V21, P9355, DOI 10.1523/JNEUROSCI.21-23-09355.2001; Walker K, 2002, PAIN, V100, P219, DOI 10.1016/S0304-3959(02)00040-4	37	29	30	1	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	SEP	2005	82	1					109	119		10.1016/j.pbb.2005.07.016			11	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	977OH	WOS:000232812600014	16125759				2020-06-30	J	Pitimana-Aree, S; Visalyaputra, S; Komoltri, C; Muangman, S; Tiviraj, S; Puanchan, S; Immark, P				Pitimana-Aree, S; Visalyaputra, S; Komoltri, C; Muangman, S; Tiviraj, S; Puanchan, S; Immark, P			An economic evaluation of bupivacaine plus fentanyl versus ropivacaine alone for patient-controlled epidural analgesia after total-knee replacement procedure: A double-blinded randomized study	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article						patient-controlled epidural analgesia (PCEA); total-knee replacement; cost effectiveness; bupivacaine; ropivacaine; fentanyl	MAJOR ABDOMINAL-SURGERY; POSTOPERATIVE ANALGESIA; HIP-REPLACEMENT; 0.125-PERCENT BUPIVACAINE; 0.2-PERCENT ROPIVACAINE; ORTHOPEDIC-SURGERY; INFUSION; LABOR; PREVENTION; SUFENTANIL	Background and Objectives: Total-knee replacement (TKR) surgery is one of the most painful orthopedic procedures after surgery. Opioid has been commonly combined with a local anesthetic to improve the quality of pain relief, but the treatment has opioid-related side effects. This study compared the cost effectiveness of patient-controlled epidural analgesia (PCEA) with 0.0625% bupivacame plus fentanyl (BF) 3 mu g/mL versus 0.15% ropivacame alone (R) during the first 48 hours after TKR procedure. Methods: This prospective randomized double-blined study was performed on 70 patients who underwent unilateral TKR procedure and received either BF or R after surgery. Visual analog scale (VAS) pain score at rest and upon movement, side effects, and cost of treatment were compared. Results: Overall pain at rest and upon movement between groups was not significantly different (P = 0.58, 95% CI = 4.4 to -7.8 and P = 0.8, 95% CI = 6.4 to -8.2, respectively). Patients in the BF group experienced more pruritus and had more vomiting episodes than those in the R group (P = .015), whereas no difference occurred in other side effects. Nevertheless, patient satisfaction with pain management was higher in the BF group compared with that in the R,group. In addition, pain treatment with bupivacame and fentanyl was 18% less costly compared with ropivacaine alone. Conclusions: Considering the economic evaluation, we conclude that PCEA with 0.0625% bupivacaine plus fentanyl 3 mu g/mL is more cost effective and provides more patient satisfaction than PCEA with ropivacame alone. However, use of epidural ropivacame alone causes fewer opioid-related side effects, particularly pruritus and vomiting.	Mahidol Univ, Siriraj Hosp, Fac Med, Dept Anesthesiol, Bangkok 10700, Thailand; Mahidol Univ, Siriraj Hosp, Fac Med, Clin Epidemiol Unit, Bangkok 10700, Thailand	Pitimana-Aree, S (reprint author), Mahidol Univ, Siriraj Hosp, Fac Med, Dept Anesthesiol, 2 Prannok Rd, Bangkok 10700, Thailand.	sispm@mahidol.ac.th	pitimana-aree, siriporn/S-1736-2019				Badner NH, 1996, CAN J ANAESTH, V43, P17, DOI 10.1007/BF03015952; Berti M, 2000, J CLIN ANESTH, V12, P292, DOI 10.1016/S0952-8180(00)00154-9; Berti M, 2000, CAN J ANAESTH, V47, P27, DOI 10.1007/BF03020727; Bertini L, 2001, ACTA ANAESTH SCAND, V45, P782, DOI 10.1034/j.1399-6576.2001.045006782.x; Brodner G, 1999, ANESTH ANALG, V88, P128; Capogna G, 1999, BRIT J ANAESTH, V82, P371, DOI 10.1093/bja/82.3.371; ETCHES RC, 1995, ANESTH ANALG, V81, P1175, DOI 10.1097/00000539-199512000-00010; Finucane BT, 2001, ANESTH ANALG, V92, P1276, DOI 10.1097/00000539-200105000-00038; JOGENSEN H, 2000, BR J ANESTH, V84, P144; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; Kampe S, 1999, ANESTH ANALG, V89, P395, DOI 10.1097/00000539-199908000-00027; Lorenzini C, 2002, ANAESTHESIA, V57, P424, DOI 10.1046/j.0003-2409.2001.02393.x; LUI S, 1999, ANESTHESIOLOGY, V90, P72; McClure JH, 1996, BRIT J ANAESTH, V76, P300; Meister GC, 2000, ANESTH ANALG, V90, P632, DOI 10.1097/00000539-200003000-00024; Owen MD, 1998, ANESTH ANALG, V86, P527, DOI 10.1097/00000539-199803000-00015; Polley LS, 1999, ANESTHESIOLOGY, V90, P944, DOI 10.1097/00000542-199904000-00003; Pouzeratte Y, 2001, ANESTH ANALG, V93, P1587, DOI 10.1097/00000539-200112000-00055; Scott DA, 1999, ANESTH ANALG, V88, P857, DOI 10.1097/00000539-199904000-00033; Turner G, 1996, BRIT J ANAESTH, V76, P606; Wulf H, 1999, ANESTH ANALG, V89, P111, DOI 10.1097/00000539-199907000-00019	21	18	22	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1098-7339	1532-8651		REGION ANESTH PAIN M	Region. Anesth. Pain Med.	SEP-OCT	2005	30	5					446	451		10.1016/j.rapm.2005.05.010			6	Anesthesiology	Anesthesiology	964YA	WOS:000231915700005	16135348				2020-06-30	J	Henke, J; Astner, S; Brill, T; Eissner, B; Busch, R; Erhardt, W				Henke, J; Astner, S; Brill, T; Eissner, B; Busch, R; Erhardt, W			Comparative study of three intramuscular anaesthetic combinations (medetomidine/ketamine, medetomidine/fentanyl/midazolam and xylazine/ketamine) in rabbits	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						alpha(2)-agonist drugs; anaesthesia; fentanyl; intramuscular; ketamine; medetomidine; midazolam; rabbit; xylazine	TILETAMINE-ZOLAZEPAM; KETAMINE XYLAZINE; BUTORPHANOL; PROPOFOL; FENTANYL	Objective To compare the quality of surgical anaesthesia. and cardiorespiratory effects of three intra-muscular (IM) anaesthetic combinations in rabbits. Study design Prospective randomized cross-over experimental study. Animals Nineteen adult female chinchilla mixed-bred rabbits weighing 3.9 0.8 kg. Methods Rabbits were given one of three IM anaesthetic combinations: 0.25 mg kg(-1) medetomidine and 35.0 mg kg(-1) ketamine (M-K), 0.20 mg kg(-1) medetomidine and 0.02 mg kg(-1) fentanyl and 1.0 mg kg(-1) midazolam (M-F-Mz) and 4.0 mg kg(-1) xylazine and 50 mg kg(-1) ketamine (X-K). The effects of anaesthesia on nociceptive reflexes, circulatory and respiratory function were recorded. Statistical analyses involved repeated measures ANOVA with paired Student's t-test applied post hoc. P-values < 0.05 were considered as significant. Results Reflex loss was most rapid and complete in M-K recipients, whereas animals receiving M-F-Mz showed the longest tolerance of endotracheal intubation (78.1 +/- 36.5 minutes). Loss of righting reflex was significantly most rapid (p < 0.05) in the X-K group (114.7 +/- 24.0 minutes). Surgical anaesthesia was achieved in 16 of 19 animals receiving M-K, in 14 animals receiving M-F-Mz, and in seven animals with X-K, but only for a short period (7.1 +/- 11.6 minutes). This was significantly (p < 0.001) shorter than with M-K (38.7 +/- 30.0 minutes) and M-F-Mz (31.6 +/- 26.6 minutes). Heart rates were greatest in X-K recipients: lowest HR were seen in animals receiving M-F-Mz. Mean arterial blood pressure was significantly higher (about 88 mmHg) during the first hour in the M-K group. During recovery. the greatest hypotension was encountered in the X-K group; minimum values were 5 3 12 mmHg. Six of 19 animals in the Mz group showed a short period of apnoea (30 seconds) immediately after endotracheal intubation. Respiratory frequency was significantly lower in this group (p < 0.001). Highest values for arterial carbon dioxide partial pressures (PaCO2) (6.90 +/- 0.87 kPa: 52.5 +/- 6.5 mmHg) occurred after induction of anaesthesia in group M-F-Mz animals. There was a marked decrease in PaO2 in all three groups (the minimum value 5.28 +/- 0.65 kPa [39.7 +/- 4.9 mmHg] was observed with M-K immediately after injection). Arterial PO2 was between 26.0 and 43.0 kPa (196 and 324 mmHg) in all groups during O-2 delivery and decreased - but not < 7.9 8 kPa - on its withdrawal. Immediately after drug injection, pH. values fell in all groups, with lowest values after 30 minutes (7.23 +/- 0.03 with M-K, 7.28 +/- 0.05 with M-F-Mz. and 7.36 +/- 0.04 with X-K). The X-K animals showed significantly (p < 0.001) higher pH values than medetomidine recipients. During I hour of anaesthesia pH values in the medetomidine groups remained below those of the X-K group. Conclusions Surgical anaesthesia was induced in most animals receiving medetomidine-based combinations. Arterial blood pressure was maintained at baseline values for about I hour after M-K. Transient apnoca occurred with M-F-Mz and mandates respiratory function monitoring. Oxygen enrichment of inspired gases is necessary with all three combinations. Endotracheal intubation is essential in rabbits receiving M-F-Mz. Clinical relevance The quality of surgical anaesthesia was greatest with M-K. All combinations allowed recoveries of similar duration. It is theoretically possible to antagonize each component of the M-F-Mz combination.	Tech Univ Munich, Inst Expt Onkol & Therapieforsch, D-81695 Munich, Germany; Working Grp Expt Surg, Inst Expt Oncol & Therapeut Res, D-81695 Munich, Germany; Inst Med Stat & Epidemiol, Munich, Germany	Henke, J (reprint author), Tech Univ Munich, Inst Expt Onkol & Therapieforsch, Ismaningerstr 22, D-81695 Munich, Germany.	julia.henke@lrz.tu-muenchen.de					Avsaroglu H, 2003, VET REC, V152, P300, DOI 10.1136/vr.152.10.300; BROWN JH, 1980, BRIT J ANAESTH, V52, P1101, DOI 10.1093/bja/52.11.1101; Difilippo SM, 2004, CONTEMP TOP LAB ANIM, V43, P32; Dupras J, 2001, CAN VET J, V42, P455; Erhardt W, 1984, Tierarztl Prax, V12, P391; ERHARDT W, 1986, J ASS VET ANAESTHETI, V14, P90; FEHR M, 1984, KLEINTIERPRAXIS, V29, P313; FLECKNELL PA, 1983, LAB ANIM, V17, P104, DOI 10.1258/002367783780959420; Haberstroh J, 2004, ANASTHESIE ANALGESIE, P629; HALL LW, 2001, VET ANAESTHESIA; HARABACZ I, 1981, THESIS LMU MUNICH; Hedenqvist P, 2002, VET ANAESTH ANALG, V29, P14, DOI [10.1046/j.1467-2987.2001.00058.x, 10.1046/j.1467-2995.2001.00019.x]; Hellebrekers LJ, 1997, LAB ANIM-UK, V31, P58, DOI 10.1258/002367797780600215; Henke J, 1996, TIERARZTL PRAX, V24, P604; HENKE J, 1998, P AVA SPRING M ED, P70; HENKE J, 1995, TIERSCHUTZBEAUFTRAGT, V2, P171; HENKE J, 2000, P 7 WCVA BERN, P99; HENKE J, 1993, NEUE ASPEKTE VETERIN, P296; LIPMAN NS, 1990, LAB ANIM SCI, V40, P395; MARCUS R, 1976, BIOMETRIKA, V63, P655, DOI 10.1093/biomet/63.3.655; MARINI RP, 1992, LAB ANIM SCI, V42, P57; MERO M, 1989, ACTA VET SCAND, P135; PEETERS ME, 1988, LAB ANIM, V22, P355, DOI 10.1258/002367788780746197; POPILSKIS SJ, 1991, LAB ANIM SCI, V41, P51; ROBERTS U, 1993, NEUE ASPEKTE VETERIN, P295; SANFORD TD, 1980, LAB ANIM SCI, V30, P519; Scabell P, 1999, TIERAERZTL PRAX K H, V27, P231; SEDGWICK CJ, 1986, VET CLIN N AM-FOOD A, V2, P731, DOI 10.1016/S0749-0720(15)31214-7; VERSTEGEN J, 1991, VET REC, V128, P32, DOI 10.1136/vr.128.2.32	29	35	39	0	14	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	SEP	2005	32	5					261	270		10.1111/j.1467-2995.2005.00242.x			10	Veterinary Sciences	Veterinary Sciences	965EU	WOS:000231933900004	16135207				2020-06-30	J	Stephens, LC; Katz, SG				Stephens, LC; Katz, SG			Phentermine and anaesthesia	ANAESTHESIA AND INTENSIVE CARE			English	Article						phentermine; anti-obesity medication : anaesthesia; hypertension	FENFLURAMINE; HYPERTENSION	We describe the case of a woman who had two perioperative hypertensive crises that may have been due to her use of phentermine, a little-known sympathomimetic anti-obesity medication. The currently available anti-obesity medications are discussed: phentermine, diethylpropion, and sibutramine; all of which are sympathomimetics possessing noradrenaline and serotonin reuptake inhibitor activity. These medications should be discontinued one week preoperatively and have potential interactions with tramadol and antidepressants. The drug orlistat inhibits gastrointestinal lipase and may lead to fat soluble vitamin (A, D, E, and K) deficiency, so consideration should be given to checking coagulation status preoperatively.	Royal Hosp Women, Dept Anaesthesia, Sydney, NSW, Australia	Katz, SG (reprint author), Royal Hosp Women, Dept Anaesthesia, Barker St, Randwick, NSW 2031, Australia.						Bays Harold, 2002, Am J Cardiovasc Drugs, V2, P245, DOI 10.2165/00129784-200202040-00004; Curfman GD, 1997, NEW ENGL J MED, V337, P629, DOI 10.1056/NEJM199708283370909; DOUGLAS A, 1983, INT J OBESITY, V7, P591; Halpern A, 2003, Obes Rev, V4, P25, DOI 10.1046/j.1467-789X.2003.00083.x; Hirsch J, 2000, OBES RES, V8, P227, DOI 10.1038/oby.2000.26; Kilpatrick IC, 2001, INT J OBESITY, V25, P1454, DOI 10.1038/sj.ijo.0801732; Mark EJ, 1997, NEW ENGL J MED, V337, P602, DOI 10.1056/NEJM199708283370904; Spahn DR, 2004, BRIT J ANAESTH, V92, P461, DOI 10.1093/bja/aeh085; Stafford RS, 2003, ARCH INTERN MED, V163, P1046, DOI 10.1001/archinte.163.9.1046	9	3	3	0	0	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2021, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	AUG	2005	33	4					525	527		10.1177/0310057X0503300418			3	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	961TF	WOS:000231684000018	16119498	Bronze			2020-06-30	J	Munoz, HR; Altermatt, FR; Gonzalez, JA; Leon, PJ				Munoz, HR; Altermatt, FR; Gonzalez, JA; Leon, PJ			The effect of different isoflurane-fentanyl dose combinations on early recovery from anesthesia and postoperative adverse effects	ANESTHESIA AND ANALGESIA			English	Article							FAST ALVEOLAR WASHOUT; AWAKENING CONCENTRATION; PROPOFOL ANESTHESIA; REMIFENTANIL; SEVOFLURANE; ALFENTANIL; REDUCTION; ENFLURANE; SURGERY; SLOW	We evaluated the effect of different combinations of fentanyl-isoflurane on early recovery from anesthesia in 80 adult patients undergoing laparoscopic cholecystectomy. Anesthesia was induced with fentanyl 2 mu g/kg and thiopental 5 mg/kg. Nitrous oxide was not used and patients were randomly assigned to one of four groups: Group 1 (n = 20) received 0.6% end-tidal isoflurane plus fentanyl, Group 2 (n = 20) received 1.2% end-tidal isoflurane plus fentanyl, Group 3 (n = 20) received 1.8% endtidal isoflurane plus fentanyl, and Group 4 (n = 20) received only isoflurane. In Groups 1, 2 and 3 isoflurane concentration was kept constant and fentanyl was given as necessary to maintain the mean arterial blood pressure within +/- 10% of the minimum mean arterial blood pressure measured in the ward. In Group 4, isoflurane concentration was adjusted to maintain mean arterial blood pressure as above. At the end of skin closure isoflurane was discontinued and the time to spontaneous breathing (TSB), time to extubation (TE) and time to eye opening (TEO) were recorded. In the postanesthesia care unit, the degree of sedation, respiratory rate, Spo(2), emesis, pain, and morphine consumption were evaluated every 15 min for I h, and thereafter every 30 min until discharge. Fentanyl requirements were 8.3 +/- 4.5 mu g/kg (mean +/- SD) in Group 1, 3.8 +/- 1.3 mu g/kg in Group 2, and 3.0 +/- 0.7 mu g/kg in Group 3 (P < 0.001), whereas in Group 4 the mean endtidal concentration of isoflurane was 2.0% +/- 0.4%. Although the mean TSB was < 5.5 min in all groups, TE increased from 7.3 +/- 5.1 min in Group 1 to 20.6 +/- 10.7 min in Group 4 (P < 0.001), and TEO increased from 7.4 +/- 5.1 min in Group I to 25.8 +/- 9.4 min in Group 4 (P < 0.001). There were no differences among the groups in any of the variables measured in the postanesthesia care unit. This study shows that the combination of a small concentration of isoflurane and a relatively larger dose of fentanyl results in a faster recovery from anesthesia than the inverse combination of doses.	Pontificia Univ Catolica Chile, Escuela Med, Dept Anestesiol, Santiago, Chile	Munoz, HR (reprint author), Hosp Clin UC, Dept Anestesiol, Marcoleta 367,POB 114 D, Santiago, Chile.	hmunoz@med.puc.cl					Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Bailey JM, 1997, ANESTH ANALG, V85, P681, DOI 10.1097/00000539-199709000-00036; Breslin DS, 2001, ANAESTHESIA, V56, P114, DOI 10.1046/j.1365-2044.2001.01795.x; Chung F, 2000, ACTA ANAESTH SCAND, V44, P790, DOI 10.1034/j.1399-6576.2000.440704.x; GAUMANN DM, 1992, BRIT J ANAESTH, V68, P81, DOI 10.1093/bja/68.1.81; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; Glass PSA, 1998, ANESTHESIOLOGY, V88, P5, DOI 10.1097/00000542-199801000-00004; Goyagi T, 1998, ANESTH ANALG, V86, P410, DOI 10.1097/00000539-199802000-00036; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; KATOH T, 1994, BRIT J ANAESTH, V73, P322, DOI 10.1093/bja/73.3.322; KATOH T, 1993, ANESTH ANALG, V77, P1012; Lang E, 1996, ANESTHESIOLOGY, V85, P721, DOI 10.1097/00000542-199610000-00006; Lentschener C, 2003, ACTA ANAESTH SCAND, V47, P84, DOI 10.1034/j.1399-6576.2003.470115.x; MCEWAN AI, 1993, ANESTHESIOLOGY, V78, P864, DOI 10.1097/00000542-199305000-00009; McLeskey CH, 1999, CAN J ANAESTH, V46, pR80, DOI 10.1007/BF03013184; Mertens MJ, 2003, ANESTHESIOLOGY, V99, P347, DOI 10.1097/00000542-200308000-00016; O'Hare RA, 2001, BRIT J ANAESTH, V86, P361, DOI 10.1093/bja/86.3.361; SEBEL PS, 1992, ANESTHESIOLOGY, V76, P52, DOI 10.1097/00000542-199201000-00008; van Delden PG, 2002, ANAESTHESIA, V57, P212, DOI 10.1046/j.0003-2409.2001.02465.x; Vuyk J, 1997, ANESTHESIOLOGY, V87, P1549, DOI 10.1097/00000542-199712000-00033; VUYK J, 1995, ANESTHESIOLOGY, V83, P8, DOI 10.1097/00000542-199507000-00003; WESTMORELAND CL, 1994, ANESTH ANALG, V78, P23	22	2	2	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	AUG	2005	101	2					371	376		10.1213/01.ANE.0000156950.21292.1A			6	Anesthesiology	Anesthesiology	948TR	WOS:000230739100014	16037146				2020-06-30	J	Davis, JJ; Swenson, JD; Hall, RH; Dillon, JD; Johnson, KB; Egan, TD; Pace, NL; Niu, SY				Davis, JJ; Swenson, JD; Hall, RH; Dillon, JD; Johnson, KB; Egan, TD; Pace, NL; Niu, SY			Preoperative "fentanyl challenge" as a tool to estimate postoperative opioid dosing in chronic opioid-consuming patients	ANESTHESIA AND ANALGESIA			English	Article							ACUTE PAIN; MANAGEMENT	When opioids are used for postoperative pain control, it is useful to define the dose-response relationship for analgesia and respiratory depression. We studied 20 chronically opioid-consuming patients having elective multilevel spine fusion. Preoperatively, each patient received a fentanyl infusion of 2 mu g (.) kg(-1) (.) min(-1) until the respiratory rate was < 5 breaths/min. Pharmacokinetic simulations were used to estimate the effect site concentration at the time of respiratory depression and to predict the patient-controlled analgesia settings that would provide an effect-site fentanyl concentration that was 30% of the concentration associated with respiratory depression. Postoperatively, patient-controlled analgesia settings were adjusted to achieve 2-3 demand doses per hour. At steady-state patient-controlled analgesia settings, arterial blood gases and plasma fentanyl levels were measured. Sixteen patients required no adjustment or one patient-con trolled analgesia adjustment. The median arterial Pco(2) level was 41 mm Hg and the interquartile range was 39 - 46 nun Hg. Plasma fentanyl levels demonstrated a significant correlation to the estimated effect-site concentration associated with respiratory depression determined during the preoperative fentanyl challenge. A preoperative fentanyl challenge used with pharmacokinetic simulations may be a useful tool to individualize the administration of analgesics to chronically opioid-consuming patients.	Univ Utah, Med Ctr, Dept Anesthesiol, Salt Lake City, UT 84132 USA	Davis, JJ (reprint author), Univ Utah, Med Ctr, Dept Anesthesiol, 30 North 1900 East,Room 3C 444, Salt Lake City, UT 84132 USA.	jennifer.davis@hsc.utah.edu					BUTSCHER K, 1995, CAN J ANAESTH, V42, P461, DOI 10.1007/BF03011681; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; PASERO C, 1999, PAIN CLIN MANUAL, P161; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; RAPP SE, 1995, PAIN, V61, P195, DOI 10.1016/0304-3959(94)00168-E; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; Stamer UM, 1999, EUR J ANAESTH, V16, P103, DOI 10.1046/j.1365-2346.1999.00427.x; White JM, 1999, ADDICTION, V94, P961, DOI 10.1046/j.1360-0443.1999.9479612.x; Zagari MJ, 1996, PHARMACOECONOMICS, V10, P356, DOI 10.2165/00019053-199610040-00005	9	18	18	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	AUG	2005	101	2					389	395		10.1213/01.ANE.0000156563.25878.19			7	Anesthesiology	Anesthesiology	948TR	WOS:000230739100018	16037150				2020-06-30	J	Sohn, JT; Ding, XQ; McCune, DF; Perez, DM; Murray, PA				Sohn, JT; Ding, XQ; McCune, DF; Perez, DM; Murray, PA			Fentanyl attenuates alpha(1B)-adrenoceptor-mediated pulmonary artery contraction	ANESTHESIOLOGY			English	Article							VASCULAR SMOOTH-MUSCLE; ALPHA(1)-ADRENOCEPTOR SUBTYPES; SAPHENOUS-VEIN; RAT AORTA; RECEPTOR; ADRENOCEPTOR; MU; CHLOROETHYLCLONIDINE; ANTAGONISTS; DEPRESSION	Background: The authors tested the hypothesis that the intravenous anesthetic fentanyl would attenuate the pulmonary vasoconstrictor response to alpha(1)-adrenoceptor activation. They also investigated the alpha(1)-adrenoceptor subtypes that could potentially mediate this effect of fentanyl. Methods: Endothelium-denuded canine pulmonary arterial rings were suspended for isometric tension recording. Dose-response curves for the alpha(1)-adrenoceptor agonist phenylephrine were generated in the absence and presence of fentanyl. The effects of inhibiting alpha(2) (rauwolscine), alpha(1) (prazosin), alpha(1A) (5-methylurapidil), alpha(1B), (chloroethylclonidine), and alpha(1D) (BMY 7378) adrenoceptors on phenylephrine contraction were also investigated. Receptor "protection" studies were performed to investigate the specific role of alpha(1B) adrenoceptors in mediating fentanyl-induced changes in phenylephrine contraction. Finally, competition binding studies were performed in rat-1 fibroblasts stably transfected with human alpha(1)-adrenoceptor complementary DNAs corresponding to the alpha(1A)-, alpha(1B)-, or alpha(1D)-adrenoceptor subtypes to directly assess whether fentanyl can compete for the alpha(1)-adrenoceptor activation pocket. Results: Fentanyl attenuated phenylephrine contraction in a dose-dependent fashion. Rauwolscine had no effect on phenylephrine contraction. Phenylephrine contraction was inhibited by prazosin and abolished by chloroethylclonidine but was relatively resistant to inhibition by 5-methylurapidil and BMY 7378. Pretreatment with fentanyl before exposure to chloroethylclonidine increased the maximal contractile response to phenylephrine compared to chloroethylelonidine pretreatment alone. Competition binding studies revealed that fentanyl binds to all three alpha(1)-adrenoceptor subtypes, with a fivefold greater affinity for the alpha(1)-adrenoceptor compared with the alpha(1D)-adrenoceptor subtype. Conclusion: Phenylephrine-induced contraction is primarily mediated by alpha(1B)-adrenoceptor activation in canine pulmonary artery. Fentanyl attenuates phenylephrine contraction by binding to alpha(1B) adrenoceptors.	Cleveland Clin Fdn, Ctr Anesthesiol Res, Cleveland, OH 44195 USA; Gyeongsang Natl Univ, Coll Med, Inst Hlth Sci, Dept Anesthesia & Pain Med, Jinju, South Korea	Murray, PA (reprint author), Cleveland Clin Fdn, Ctr Anesthesiol Res, FF40,9500 Euclid Ave, Cleveland, OH 44195 USA.	murrayp@ccf.org			NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [F32 HL-71369, HL-61438, HL-38291]		ARTRU AA, 2001, CEREBROSPINAL FLUID, P84; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; Bot G, 1998, J PHARMACOL EXP THER, V285, P1207; Eckhart AD, 1997, P NATL ACAD SCI USA, V94, P9487, DOI 10.1073/pnas.94.17.9487; Errasti AE, 1999, BRIT J PHARMACOL, V126, P437, DOI 10.1038/sj.bjp.0702320; ETCHES RC, 1989, CAN J ANAESTH, V36, P165, DOI 10.1007/BF03011441; Flavahan NA, 1998, J CARDIOVASC PHARM, V32, P308, DOI 10.1097/00005344-199808000-00020; FREYE E, 1974, ANESTH ANALG, V53, P40; GIOANNINI TL, 1992, P NATL ACAD SCI USA, V89, P52, DOI 10.1073/pnas.89.1.52; GOETZ AS, 1995, EUR J PHARMACOL, V272, pR5, DOI 10.1016/0014-2999(94)00751-R; GRAVES CL, 1975, ANESTH ANALG, V54, P15; HIEBLE JP, 1995, PHARMACOL REV, V47, P267; HUG CC, 1979, ANESTHESIOLOGY, V50, P342, DOI 10.1097/00000542-197904000-00011; HWA J, 1996, AUTONOMIC CONTROL MY; KARASAWA F, 1993, BRIT J ANAESTH, V71, P877, DOI 10.1093/bja/71.6.877; Lagu B, 1999, J MED CHEM, V42, P4794, DOI 10.1021/jm990202+; Leech CJ, 1996, AM J PHYSIOL-HEART C, V270, pH710; LOW AM, 1994, BRIT J PHARMACOL, V113, P1263, DOI 10.1111/j.1476-5381.1994.tb17134.x; MONROE PJ, 1991, NEUROSCI LETT, V133, P229, DOI 10.1016/0304-3940(91)90576-F; PEREZ DM, 1994, MOL PHARMACOL, V46, P823; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; Perez-Rivera AA, 2004, J PHARMACOL EXP THER, V308, P350, DOI 10.1124/jpet.103.056184; Piascik MT, 2001, J PHARMACOL EXP THER, V298, P403; Piascik MT, 1995, J PHARMACOL EXP THER, V275, P1583; Saussy DL, 1996, J PHARMACOL EXP THER, V278, P136; STONE DJ, 1988, ANESTH ANALG, V67, P663; TODA N, 1977, ANESTHESIOLOGY, V46, P411, DOI 10.1097/00000542-197706000-00007; VARGAS HM, 1995, LIFE SCI, V57, P2291, DOI 10.1016/0024-3205(95)02224-7; Xiao L, 1998, EUR J PHARMACOL, V347, P319, DOI 10.1016/S0014-2999(98)00109-5; Yan M, 2001, LIFE SCI, V68, P1191, DOI 10.1016/S0024-3205(00)01027-4	30	12	14	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	AUG	2005	103	2					327	334		10.1097/00000542-200508000-00016			8	Anesthesiology	Anesthesiology	952EA	WOS:000230983800015	16052115				2020-06-30	J	Mathews, DM; Rahman, SS; Cirullo, PM; Malik, RJ				Mathews, DM; Rahman, SS; Cirullo, PM; Malik, RJ			Increases in bispectral index lead to interventions that prevent possible intraoperative awareness	BRITISH JOURNAL OF ANAESTHESIA			English	Article							ANESTHESIA; ALFENTANIL; PROPOFOL	In this case a woman underwent a cervical laminectomy with a total i.v. anaesthesia technique and during her care two problems occurred with propofol delivery. In both cases, bispectral index increases alerted caregivers to the decreased propofol delivery and allowed them to make corrections in a manner timely enough to prevent the occurrence of awareness during anaesthesia. The case illustrates how intraoperative processed electroencephalographic monitoring may decrease the incidence of recall of awareness following surgery.	St Vincents Manhattan & New York Med Coll, St Vincent Catholic Med Ctr, Dept Anesthesiol, Valhalla, NY 10595 USA	Mathews, DM (reprint author), St Vincents Manhattan & New York Med Coll, St Vincent Catholic Med Ctr, Dept Anesthesiol, Valhalla, NY 10595 USA.	dmathews@svcmcny.org					Bergman IJ, 2002, ANAESTHESIA, V57, P549, DOI 10.1046/j.1365-2044.2002.02565.x; BRICE DD, 1970, BRIT J ANAESTH, V42, P535, DOI 10.1093/bja/42.6.535; Domino KB, 1999, ANESTHESIOLOGY, V90, P1053, DOI 10.1097/00000542-199904000-00019; Ekman A, 2004, ACTA ANAESTH SCAND, V48, P20, DOI 10.1111/j.1399-6576.2004.00260.x; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; Lennmarken C, 2002, ACTA ANAESTH SCAND, V46, P229, DOI 10.1034/j.1399-6576.2002.t01-1-460301.x; Luginbuhl M, 2002, ANESTHESIOLOGY, V96, P241, DOI 10.1097/00000542-200201000-00038; Lysakowski C, 2001, BRIT J ANAESTH, V86, P523, DOI 10.1093/bja/86.4.523; Myles PS, 2004, LANCET, V363, P1757, DOI 10.1016/S0140-6736(04)16300-9; Osterman JE, 2001, GEN HOSP PSYCHIAT, V23, P198, DOI 10.1016/S0163-8343(01)00142-6; Sandin RH, 2000, LANCET, V355, P707, DOI 10.1016/S0140-6736(99)11010-9; Sebel PS, 2004, ANESTH ANALG, V99, P833, DOI 10.1213/01.ANE.0000130261.90896.6C	12	9	9	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	AUG	2005	95	2					193	196		10.1093/bja/aei162			4	Anesthesiology	Anesthesiology	945OZ	WOS:000230513300013	15923267	Bronze			2020-06-30	J	Preisman, S; Marks, R; Nahtomi-Shick, O; Sidi, A				Preisman, S; Marks, R; Nahtomi-Shick, O; Sidi, A			Preservation of static and dynamic cerebral autoregulation after mild hypothermic cardiopulmonary bypass	BRITISH JOURNAL OF ANAESTHESIA			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 14-18, 2000	SAN FRANCISCO, CA	Amer Soc Anesthesiologists		brain, blood flow; brain, cerebral autoregulation; surgery, cardiac	CARBON-DIOXIDE REACTIVITY; BLOOD-FLOW VELOCITY; AUTO-REGULATION; HUMANS; MANAGEMENT; PRESSURE; OUTCOMES; SURGERY; PACO2	Background. Dysfunction of cerebral autoregulation might contribute to neurological morbidity after cardiac surgery. In this study, our aim was to assess the preservation of cerebral autoregulation after cardiac surgery involving cardiopulmonary bypass (CPB). Methods. Dynamic and static components of cerebral autoregulation were evaluated in 12 patients undergoing coronary artery bypass graft surgery, anaesthetized with midazolam, fentanyl, and propofol, and using mild hypothermic CPB (31-33 degrees C). Arterial pressure (ABP), central venous pressure (CVP), and blood flow velocity in the middle cerebral artery (CBFV) were recorded. The cerebral perfusion pressure (CPP) was calculated as a difference between mean ABP and CVP. Rapid decrease of CPP was caused by a sudden change of patients' position from Trendelenburg to reverse Trendelenburg. Cerebral vascular resistance (CVR) was calculated by dividing CPP by CBFV. Index of static cerebral autoregulation (CAstat) was calculated as the change of CVR related to change of CPP during the manoeuvre. Dynamic rate of autoregulation (RoRdyn) was determined as the change in CVR per second during the first 4 s immediately after a decrease in CPP, related to the change of CPP. Measurements were obtained after induction of anaesthesia, and 15, 30, and 45 min after termination of CPB. Results. No significant changes were found in CAstat or RoRdyn after CPB. Significant changes in CVR could be explained by concomitant changes in body temperature and haematocrit. Conclusion. Autoregulation of cerebral blood flow remains preserved after mild hypothermic CPB.	Tel Aviv Univ, Sackler Sch Med, Chaim Sheba Med Ctr, Dept Anesthesiol & Intens Care, IL-69978 Tel Aviv, Israel	Preisman, S (reprint author), Tel Aviv Univ, Sackler Sch Med, Chaim Sheba Med Ctr, Dept Anesthesiol & Intens Care, IL-69978 Tel Aviv, Israel.	preisman@netvision.net.il					AASLID R, 1991, STROKE, V22, P1148, DOI 10.1161/01.STR.22.9.1148; AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Bruder N, 1998, ANESTH ANALG, V86, P320, DOI 10.1097/00000539-199802000-00020; CROUGHWELL N, 1990, CIRCULATION, V82, P407; Dawson SL, 2000, CEREBROVASC DIS, V10, P126, DOI 10.1159/000016041; Giller CA, 1997, NEUROL RES, V19, P634; Jones SC, 2002, ANESTHESIOLOGY, V97, P488, DOI 10.1097/00000542-200208000-00028; Lang EW, 2002, J NEUROL NEUROSUR PS, V72, P583, DOI 10.1136/jnnp.72.5.583; LUNDAR T, 1985, ANN THORAC SURG, V40, P582, DOI 10.1016/S0003-4975(10)60353-0; LUNDAR T, 1986, ANN THORAC SURG, V41, P525, DOI 10.1016/S0003-4975(10)63034-2; MCNEILL BR, 1990, CAN J ANAESTH, V37, P313, DOI 10.1007/BF03005581; MURKIN JM, 1987, ANESTH ANALG, V66, P825; MURKIN JM, 1995, J THORAC CARDIOV SUR, V110, P349, DOI 10.1016/S0022-5223(95)70230-X; NEWELL DW, 1994, STROKE, V25, P793, DOI 10.1161/01.STR.25.4.793; Nuttall GA, 1996, ANESTH ANALG, V82, P1146, DOI 10.1097/00000539-199606000-00008; Roach GW, 1996, NEW ENGL J MED, V335, P1857, DOI 10.1056/NEJM199612193352501; ROGERS AT, 1988, ANESTHESIOLOGY, V69, P547, DOI 10.1097/00000542-198810000-00015; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; ZAR J, 1984, BIOSTAT ANAL, P135	20	6	6	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	AUG	2005	95	2					207	211		10.1093/bja/aei147			5	Anesthesiology	Anesthesiology	945OZ	WOS:000230513300015	15863439	Bronze			2020-06-30	J	Madi-Jebara, S; Adaime, C; Yazigi, A; Haddad, F; Hayek, G; Sleilaty, G; Antakly, MC				Madi-Jebara, S; Adaime, C; Yazigi, A; Haddad, F; Hayek, G; Sleilaty, G; Antakly, MC			Thoracic epidural and intrathecal analgesia have similar effects on pain relief and respiratory function after thoracic surgery	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			French	Article							POSTTHORACOTOMY PAIN; SURGICAL-PATIENTS; DOSE-RESPONSE; MORPHINE; SUFENTANIL; BUPIVACAINE; COMBINATION; FENTANYL; EXPERIENCE; MANAGEMENT	Purpose: To compare in a prospective randomized trial the effects of thoracic epidural infusions of fentanyl (F) and bupivacaine (B) to intrathecal morphine (M) and sufentanil (S) on analgesia and respiratory function following thoracotomy. Patients and methods. 55 patients undergoing on elective postero-lateral thoracotomy were randomly assigned to one of two groups: Group 1 (n = 2 7): received intrathecol S (5 mu g) and M (0.5 mg) one hour before surgery, Group 11 (n = 28) received, after induction of anesthesia, an initial dose of 10 to 20 mL of a solution of B 0.25% and F2 mu g(.)mL(-1) via an epidural thoracic catheter previously inserted between T5 and T8. The some solution was infused during surgery. After surgery, patients received a continuous infusion of B 0.1% and F 2 mu g(.)mL(-1) with a bolus every 15 min if needed. Heart rate (HR), mean arterial pressure (MAP), SpO(2), PacO(2), respiratory rate (RR), forced expiratory volume in one second, peak expiratory flow rote and forced vital capacity were recorded at different times from the day before surgery till T48 = 48 hr after surgery Subjective pain was assessed using a 10 cm visual analogue scale (VAS) scoring at rest and during cough. Results. No significant difference was noted between both groups concerning VAS, HR, MAP SpO(2), PacO(2), and RR. Variations of the respirotory function tests were identical in both groups, Conclusion: This study shows that intrathecal M and S offer analgesia comparable to thoracic epidurol infusion of B and F.	Hop Hotel Dieu France, Dept Anesthesie Reanimat, Beirut, Lebanon	Madi-Jebara, S (reprint author), Hop Hotel Dieu France, Dept Anesthesie Reanimat, Beirut, Lebanon.	vix@dm.net.lb		Sleilaty, Ghassan/0000-0001-8490-6958			BAILEY PL, 1993, ANESTHESIOLOGY, V79, P49, DOI 10.1097/00000542-199307000-00010; Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; Benzon H T, 1993, J Cardiothorac Vasc Anesth, V7, P515, DOI 10.1016/1053-0770(93)90304-4; Bloch MB, 2002, ANESTH ANALG, V94, P523, DOI 10.1097/00000539-200203000-00009; Brodner G, 2000, ANESTH ANALG, V90, P649, DOI 10.1097/00000539-200003000-00027; Giebler RM, 1997, ANESTHESIOLOGY, V86, P55, DOI 10.1097/00000542-199701000-00009; GRAY JR, 1986, ANESTH ANALG, V65, P873; Gwirtz KH, 1999, ANESTH ANALG, V88, P599, DOI 10.1097/00000539-199903000-00026; Kaiser AM, 1998, ANN THORAC SURG, V66, P367, DOI 10.1016/S0003-4975(98)00448-2; KAVANAGH BP, 1994, ANESTHESIOLOGY, V81, P737, DOI 10.1097/00000542-199409000-00028; Kindler CH, 1998, ACTA ANAESTH SCAND, V42, P614, DOI 10.1111/j.1399-6576.1998.tb05291.x; Liu N, 2001, ANESTH ANALG, V92, P31; Liu SS, 1998, ANESTHESIOLOGY, V88, P688, DOI 10.1097/00000542-199803000-00020; LUBENOW TR, 1994, ANN THORAC SURG, V58, P924, DOI 10.1016/0003-4975(94)90435-9; Mason N, 2001, BRIT J ANAESTH, V86, P236, DOI 10.1093/bja/86.2.236; McCrory C, 2002, J CARDIOTHOR VASC AN, V16, P607, DOI 10.1053/jcan.2002.126957; MOURISSE J, 1992, ACTA ANAESTH SCAND, V36, P70, DOI 10.1111/j.1399-6576.1992.tb03425.x; PERTTUNEN K, 1995, BRIT J ANAESTH, V75, P541, DOI 10.1093/bja/75.5.541; RICHARDSON J, 1993, ANN THORAC SURG, V55, P377, DOI 10.1016/0003-4975(93)91002-5; Salzer GM, 1997, ANN THORAC SURG, V63, P1411, DOI 10.1016/S0003-4975(97)00081-7; Slinger PD, 1999, J CARDIOTHOR VASC AN, V13, P350, DOI 10.1016/S1053-0770(99)90276-8; SUDARSHAN G, 1995, BRIT J ANAESTH, V75, P19, DOI 10.1093/bja/75.1.19; TARKKILA P, 1995, ACTA ANAESTH SCAND, V39, P983, DOI 10.1111/j.1399-6576.1995.tb04210.x; Wong CA, 2000, ANESTHESIOLOGY, V92, P1553, DOI 10.1097/00000542-200006000-00011	24	6	6	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	AUG-SEP	2005	52	7					710	716		10.1007/BF03016558			7	Anesthesiology	Anesthesiology	962PA	WOS:000231743500009	16103383	Bronze			2020-06-30	J	McLeod, A; Roche, A; Fennelly, M				McLeod, A; Roche, A; Fennelly, M			Case series: Ultrasonography may assist epidural insertion in scoliosis patients	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							ULTRASOUND; ANESTHESIA; SPACE	Purpose: Epidural cannulation is a difficult technique in the patient undergoing scoliosis repair, due to axial rotation of the vertebral bodies, as well as angulation of the spinal processes. This case series was performed to investigate whether ultrasonography could facilitate epidural insertion in patients with scoliosis, by assessing the degree of vertebral body rotation. Clinical features: Eleven patients scheduled for corrective scoliosis surgery were studied. The spine was examined ultrasonically using a portable ultrasound system with a 38-mm linear probe in two-dimensional B mode. The angulation of the probe head (measured using an inclinometer held in alignment with its long axis) at which the echo signals from the laminae became level on the screen was taken to correspond to the degree of vertebral rotation. The least rotated (most neutral) vertebral interspace was located, and a supervised anesthesiology trainee then performed epidural catheter insertion, using a loss-of-resistance technique. Bupivacaine 0.125% with fentanyl 4 mu g(.)mL(-1) was infused after surgery, and successful epidural placement was indicated by the presence of effective analgesia and loss of sensation to cold stimuli. In ten patients, the neutral space could be identified, while in one, the least rotated space was measured at 15 degrees from the horizontal. Epidural catheterization was successful in eight of I I patients at the identified level. In two other patients, the space above was employed. The information was described as helpful in seven patients. Conclusion: We conclude that ultrasonography may have a potential role to facilitate insertion of epidural catheters in patients with scoliosis.	Royal Natl Orthopaed Hosp, Dept Anaesthesia, Stanmore HA7 4LP, Middx, England; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA	McLeod, A (reprint author), Queen Alexandra Hosp, Dept Anaesthet, Portsmouth PO6 3LY, Hants, England.	andrew.mcleod@porthosp.nhs.uk					Chan VWS, 2003, ANESTH ANALG, V97, P1514, DOI 10.1213/01.ANE.0000062519.61520.14; Chen CPC, 2004, ANESTHESIOLOGY, V101, P181, DOI 10.1097/00000542-200407000-00028; Cobb J., 1948, AM ACADEMY ORTHOPAED, V5, P261; CURRIE JM, 1984, BRIT J ANAESTH, V56, P345, DOI 10.1093/bja/56.4.345; Furness G, 2002, ANAESTHESIA, V57, P277, DOI 10.1046/j.1365-2044.2002.2403_4.x; Grau T, 2003, CAN J ANAESTH, V50, P1047, DOI 10.1007/BF03018371; Grau T, 2001, REGION ANESTH PAIN M, V26, P64, DOI 10.1053/rapm.2001.19633; Hatfield A, 1999, BRIT J ANAESTH, V83, P789; NASH CL, 1969, J BONE JOINT SURG AM, VA 51, P223, DOI 10.2106/00004623-196951020-00002; *NAT I CLIN EXC, [No title captured]; Sandhu NS, 2002, BRIT J ANAESTH, V89, P254, DOI 10.1093/bja/aef186; Scott DHT, 1999, BRIT J ANAESTH, V82, P820; SUZUKI S, 1989, J BONE JOINT SURG BR, V71, P252; Watson MJ, 2003, BRIT J ANAESTH, V90, P509, DOI 10.1093/bja/aeg096	14	43	44	0	2	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	AUG-SEP	2005	52	7					717	720		10.1007/BF03016559			4	Anesthesiology	Anesthesiology	962PA	WOS:000231743500010	16103384	Bronze			2020-06-30	J	Moises, ECD; Duarte, LD; Cavalli, RD; Lanchote, VL; Duarte, G; da Cunha, SP				Moises, ECD; Duarte, LD; Cavalli, RD; Lanchote, VL; Duarte, G; da Cunha, SP			Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						obstetrical analgesia; epidural route; fentanyl; pharmacokinetics; placental transfer	CESAREAN-SECTION; ANALGESIA; BUPIVACAINE; ALFENTANIL; SUFENTANIL	Background: Fentanyl is an opioid drug widely used as a co-adjuvant in abdominal delivery, a fact that justifies its pharmacokinetic study under these conditions. Objective: Our objective was to investigate the pharmacokinetics and placental transfer of fentanyl in parturients whose pregnancies were resolved by cesarian section with epidural anesthesia. Patients and methods: Ten clinically normal parturients who delivered at term received 5 ml of 2% lidocaine hydrochloride without a vasoconstrictor for skin and subcutaneous blockade, followed by epidural injection of 2 ml fentanyl citrate (0.05 mg/ml), 15 ml 0.5% bupivacaine hydrochloride with 1:200,000 epinephrine, and 10 ml 2% lidocaine hydrochloride without a vasoconstrictor. Maternal blood samples were collected at various times after injection (1-840 min), and the fentanyl plasma concentrations were determined by gas chromatography-mass spectrometry. Pharmacokinetic analysis was performed using the bi- or tricompartmental model. The fetal/maternal ratio of the plasma fentanyl was determined at birth. Results: The values of the pharmacokinetic parameters were: t(3/2)alpha = 13.5 min, t(1/2)beta = 192.5 min, t(1/2 gamma) = 620 min, AUC(0-infinity) = 137.404 ng.min per millilter, C-1/f = 464.984 ml/min, V-d/f = 299.974 l, C-l/f/kg = 6.875 ml/min per kilogram, and V-d/f/kg = 4.441 l/kg. The latency between drug administration and birth was 28.5 min, with a maternal and fetal plasma concentration of 0.310 and 0.245 ng/ml, respectively, at a median fetal/maternal ratio of 0.892. Conclusion: The study demonstrated a rapid passage of fentanyl from the epidural space to maternal blood and a significant transplacental transfer of maternal fentanyl of about 90%, which should serve as an alert to obstetricians.	Univ Sao Paulo, Univ Hosp, Fac Med Ribeirao Preto, Dept Gynecol & Obstet, BR-14049 Ribeirao Preto, Brazil; Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, Dept Clin Anal Toxicol & Food Sci, BR-14049 Ribeirao Preto, Brazil; Hosp Clin 8 Andar, Dept Obstet & Ginecol, BR-14049900 Ribeirao Preto, SP, Brazil	da Cunha, SP (reprint author), Univ Sao Paulo, Univ Hosp, Fac Med Ribeirao Preto, Dept Gynecol & Obstet, BR-14049 Ribeirao Preto, Brazil.	spdcunha@fmrp.usp.br	Lanchote, Vera Lucia/P-5925-2016; Moises, Elaine Christine Dantas/N-9522-2019; Cavalli, Ricardo C/G-2405-2012; Duarte, Geraldo/J-7906-2012; Lanchote, Vera/C-1987-2012; Moises, Elaine/A-5708-2015	Lanchote, Vera Lucia/0000-0002-0074-4953; Moises, Elaine Christine Dantas/0000-0001-9099-4544; Moises, Elaine/0000-0001-9099-4544; Cavalli, Ricardo/0000-0001-5010-4914			DESPRATS R, 1991, EUR J OBSTET GYN R B, V42, P89, DOI 10.1016/0028-2243(91)90167-J; GUTSTEIN HB, 2001, GOODMAN GILMANS PHAR, P569; HODGKINSON R, 1980, ANESTH ANALG, V59, P89; JUSTINS DM, 1983, ANAESTHESIA, V38, P937, DOI 10.1111/j.1365-2044.1983.tb12022.x; LEVEQUE C, 1987, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V16, P113; Little BB, 1999, OBSTET GYNECOL, V93, P858, DOI 10.1016/S0029-7844(98)00444-X; Loebstein R, 1997, CLIN PHARMACOKINET, V33, P328, DOI 10.2165/00003088-199733050-00002; Mathias RS, 2000, OBSTET BASICA, P1035; PASANEN M, 1990, DRUG METAB REV, V21, P427, DOI 10.3109/03602538909030305; REYNOLDS F, 1970, ANAESTHESIA, V25, P14, DOI 10.1111/j.1365-2044.1970.tb00154.x; SANDLER AN, 1992, ANESTHESIOLOGY, V77, P626, DOI 10.1097/00000542-199210000-00003; SANTOS AC, 2001, CLIN ANESTHESIA; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; Tegeder I, 1999, CLIN PHARMACOKINET, V37, P17, DOI 10.2165/00003088-199937010-00002; WILLENS JS, 1993, HEART LUNG, V22, P239	15	15	17	0	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0031-6970	1432-1041		EUR J CLIN PHARMACOL	Eur. J. Clin. Pharmacol.	AUG	2005	61	7					517	522		10.1007/s00228-005-0967-9			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	958TN	WOS:000231471200005	16021436				2020-06-30	J	Mercadante, S; Ferrera, P; Villari, P; Casuccio, A				Mercadante, S; Ferrera, P; Villari, P; Casuccio, A			Rapid switching between transdermal fentanyl and methadone in cancer patients	JOURNAL OF CLINICAL ONCOLOGY			English	Article							INTRAVENOUS METHADONE; OPIOID ROTATION; ORAL METHADONE; DOSE RATIO; PAIN; MORPHINE; HYDROMORPHONE; MANAGEMENT; CONVERSION; ANALGESIA	Purpose The aim of this study was to examine the clinical effects of switching from transdermal (TTS) fentanyl to methadone, or vice versa, in patients with a poor response to the previous opioid. Patients and Methods A prospective study was carried out on 31 patients who switched from TTS fentanyl to oral methadone, or vice versa, because of poor opioid response. A fixed conversion ratio of fentanyl to methadone of 1:20 was started and assisted by rescue doses of opioids, and then doses were changed according to clinical response. Pain and symptom intensity, expressed as distress score, were recorded before switching doses of the two opioids and after subsequent doses. The number of changes of the daily doses, time to achieve stabilization, and hospital stay were also recorded. Results Eighteen patients were switched from TTS fentanyl to methadone, and seven patients were switched from methadone to TTS fentanyl. A significant decrease in pain and symptom intensity, expressed as symptom distress score, was found within 24 hours after switching took place in both directions. Unsuccessful switching occurred in six patients, who were subsequently treated with an alternative therapy. Conclusion A rapid switching using an initial fixed ratio of fentanyl to methadone of 1:20 is an effective method to improve the balance between analgesia and adverse effects in cancer patients with poor response to the previous opioid. No relationship between the final opioid dose and the dose of the previous opioid has been found.	La Maddalena Canc Ctr, Anesthesia & Intens Care Unit, Pain Relief & Palliat Care Unit, I-90146 Palermo, Italy; Univ Palermo, Dept Ophthalmol, Palermo, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Anesthesia & Intens Care Unit, Pain Relief & Palliat Care Unit, Via San Lorenzo 312, I-90146 Palermo, Italy.	terapiadeldolore@la-maddalena.it	casuccio, alessandra/B-1730-2013	casuccio, alessandra/0000-0002-5676-9535			Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Benitez-Rosario MA, 2004, CANCER-AM CANCER SOC, V101, P2866, DOI 10.1002/cncr.20712; Bruera E, 1996, CANCER, V78, P852, DOI 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; GALER BS, 1992, PAIN, V49, P87, DOI 10.1016/0304-3959(92)90192-E; GOURLAY GK, 1986, PAIN, V25, P297, DOI 10.1016/0304-3959(86)90234-4; GOURLAY GK, 1990, PAIN, V42, P383, DOI 10.1016/0304-3959(90)91151-8; Kornick CA, 2001, CANCER, V92, P3056, DOI 10.1002/1097-0142(20011215)92:12<3056::AID-CNCR10166>3.0.CO;2-H; Korte W, 1996, J PAIN SYMPTOM MANAG, V11, P139, DOI 10.1016/0885-3924(95)00162-X; Lawlor PG, 1998, CANCER, V82, P1167, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.3.CO;2-8; Manfredi PL, 1997, PAIN, V70, P99, DOI 10.1016/S0304-3959(96)03313-1; Mercadante S, 1999, J CLIN ONCOL, V17, P3307, DOI 10.1200/JCO.1999.17.10.3307; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; Mercadante S, 1998, J CLIN ONCOL, V16, P3656, DOI 10.1200/JCO.1998.16.11.3656; Mercadante S, 2001, J CLIN ONCOL, V19, P2898, DOI 10.1200/JCO.2001.19.11.2898; Mercadante S, 1997, Eur J Pain, V1, P77, DOI 10.1016/S1090-3801(97)90064-1; MORLEY JS, 1997, PAIN, V73, P14; Moryl N, 2002, PAIN, V96, P325, DOI 10.1016/S0304-3959(01)00465-1; Ripamonti C, 1998, J CLIN ONCOL, V16, P3216, DOI 10.1200/JCO.1998.16.10.3216; Santiago-Palma J, 2001, CANCER, V92, P1919, DOI 10.1002/1097-0142(20011001)92:7<1919::AID-CNCR1710>3.0.CO;2-G; Tse DMW, 2003, PALLIATIVE MED, V17, P206, DOI 10.1191/0269216303pm696oa; Watanabe S, 1998, J PAIN SYMPTOM MANAG, V16, P323, DOI 10.1016/S0885-3924(98)00095-5	22	45	45	0	0	AMER SOC CLINICAL ONCOLOGY	ALEXANDRIA	2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA	0732-183X	1527-7755		J CLIN ONCOL	J. Clin. Oncol.	AUG 1	2005	23	22					5229	5234		10.1200/JCO.2005.13.128			6	Oncology	Oncology	952CL	WOS:000230979300062	16051965	Green Published			2020-06-30	J	Thomas, SH; Rago, O; Harrison, T; Biddinger, PD; Wedel, SK				Thomas, SH; Rago, O; Harrison, T; Biddinger, PD; Wedel, SK			Fentanyl trauma analgesia use in air medical scene transports	JOURNAL OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the National-Associational-of-EMS-Physicians	JAN 13-15, 2005	Naples, FL	Natl Assoc EMS Phys		fentanyl; prehospital; analgesia; helicopter; air medical transport	ACUTE PAIN MANAGEMENT; PEDIATRIC TRAUMA; ABDOMINAL-PAIN; EMERGENCY; CARE; MORPHINE; PROGRAM	This study assessed frequency, safety and efficacy of prehospital fentanyl analgesia during 6 months' adult and pediatric helicopter trauma scene transports (213 doses in 177 patients). We reviewed flight records for pain assessment and analgesia provision, effect, and complications. Analgesia was administered to 46/49 (93.9%) intubated patients. In non-intubated patients, pain assessment was documented in 112 of 128 (87.5%), and analgesia was offered, or there was no pain, in 97/128 (75.8%). Of the 67 non-intubated patients to whom analgesia was administered, post-analgesia pain assessment was documented in 62 (92.5%) and pain improved in 53 (79.1% of 67). Post-analgesia blood pressure dropped below 90 torr in 2/177 cases (1.1%, 95% confidence interval [CI] 0.1-4.0%). Post-analgesia SpO2 did not drop below 90% in any patients (95% CI 0-2.3%). In this study, prehospital providers performed well with respect to pain assessment and treatment. Fentanyl was provided frequently, with good effect and minimal cardiorespiratory consequence. (c) 2005 Elsevier Inc.	Massachusetts Gen Hosp, Dept Emergency Serv, Boston, MA 02114 USA; Boston MedFlight, Boston, MA USA; Harvard Univ, Sch Med, Div Emergency Med, Boston, MA 02115 USA; Boston Univ, Dept Surg, Sch Med, Boston, MA 02215 USA	Thomas, SH (reprint author), Massachusetts Gen Hosp, Dept Emergency Serv, Clin Bldg 115,55 Fruit St, Boston, MA 02114 USA.						Abbuhl Frederick B, 2003, Prehosp Emerg Care, V7, P445; Alonso-Serra Hector M, 2003, Prehosp Emerg Care, V7, P482; Baskett PJF, 1999, ANN EMERG MED, V34, P784, DOI 10.1016/S0196-0644(99)70106-X; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; DeVellis P, 1998, Prehosp Emerg Care, V2, P293, DOI 10.1080/10903129808958883; Devellis P, 1998, PEDIATR EMERG CARE, V14, P321; DICKINSON ET, 2004, PREHOSP EMERG CARE, V8, P103; Fullerton-Gleason Lynne, 2002, Prehosp Emerg Care, V6, P411, DOI 10.1080/10903120290938049; HARRISON T, 2000, ANN EMERG MED, V36, pS53; Helm M, 1996, ANAESTHESIST, V45, P1196, DOI 10.1007/s001010050358; Hyland-McGuire P, 1998, J ACCID EMERG MED, V15, P99; McEachin C, 2004, PREHOSP EMERG CARE, V8, P103; McEachin Christine Clara, 2002, Prehosp Emerg Care, V6, P406, DOI 10.1080/10903120290938030; Moller JC, 2002, PEDIATR EMERG CARE, V18, P424, DOI 10.1097/00006565-200212000-00005; Mulligan-Smith D, 2000, Prehosp Emerg Care, V4, P111, DOI 10.1080/10903120090941380; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Poirier MP, 2004, PEDIATR EMERG CARE, V20, P412, DOI 10.1097/01.pec.0000125666.81431.d2; Ricard-Hibon A, 2003, AM J EMERG MED, V21, P461, DOI 10.1016/S0735-6757(03)00095-0; Ricard-Hibon A, 1997, ANN FR ANESTH, V16, P945, DOI 10.1016/S0750-7658(97)82142-9; Ricard-Hibon A, 1999, ANN EMERG MED, V34, P738, DOI 10.1016/S0196-0644(99)70099-5; Silfvast T, 2001, Eur J Emerg Med, V8, P275, DOI 10.1097/00063110-200112000-00005; Silka PA, 2004, ACAD EMERG MED, V11, P264, DOI 10.1197/j.aem.2003.09.016; Tentillier E, 2000, ANN FR ANESTH, V19, P275; Thomas SH, 2003, BRIT J SURG, V90, P5, DOI 10.1002/bjs.4009; Thomas SH, 2003, J AM COLL SURGEONS, V196, P18, DOI 10.1016/S1072-7515(02)01480-1; THOMAS SH, 1996, AIR MED J, V15, P57; TREVOR AJ, 2004, BASIC CLIN PHARM, P401; Turturro Michael A, 2002, Prehosp Emerg Care, V6, P486, DOI 10.1080/10903120290938238; VASILIADIS J, 2002, EMERG MED FREMANTHE, V14, P261; Vergnion M, 2001, ANESTH ANALG, V92, P1543; White L J, 2000, Prehosp Emerg Care, V4, P205, DOI 10.1080/10903120090941209; Zohar Z, 2001, J TRAUMA, V51, P767, DOI 10.1097/00005373-200110000-00024	32	26	26	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0736-4679			J EMERG MED	J. Emerg. Med.	AUG	2005	29	2					179	187		10.1016/j.jemermed.2005.02.007			9	Emergency Medicine	Emergency Medicine	949FT	WOS:000230771200012	16029830				2020-06-30	J	Salim, R; Nachum, Z; Moscovici, R; Lavee, M; Shalev, E				Salim, R; Nachum, Z; Moscovici, R; Lavee, M; Shalev, E			Continuous compared with intermittent epidural infusion on progress of labor and patient satisfaction	OBSTETRICS AND GYNECOLOGY			English	Article							MIDWIFE TOP-UPS; CESAREAN DELIVERY; EXTRADURAL ANALGESIA; OPIOID ANALGESIA; TRIAL; WOMEN; ANESTHESIA; RATES; MODE	Objective: To compare continuous with intermittent epidural infusion on the duration of labor and patients' satisfaction in nulliparous women. Methods: Nulliparous women who requested epidural analgesia during labor were randomly allocated to receive either a continuous infusion of 0.125% bupivacaine with 2 mu g/mL fentanyl at a rate of 8 mL/h (group A) or intermittent bolus of 10 mL of 0.25% bupivacaine on demand (group B). Controls were nulliparous women who did not receive epidural analgesia (group C). Included were singleton term pregnancies with cervical dilatation between 2 cm and 5 cm. A comparison was made between the groups regarding the duration of the active phase and the second stage of labor and patients' satisfaction. Secondary outcomes investigated were the mode of delivery, analgesia-related complications, and intrapartum and postpartum complications. Cord pH and Apgar score measured neonatal outcome. Results: Sixty-three parturients were randomly assigned to receive continuous infusion, and 64 received intermittent bolus infusion. Sixty-three patients served as controls. Mean duration of the active phase and the second stage of labor were not statistically different between groups A and B. Each technique produced comparable analgesia, achieving equivalent maternal satisfaction, with no apparent complications. The active phase of labor was prolonged by an average of 60 minutes and the 2nd stage by an average of 36 minutes regardless of the type of epidural compared with controls. The mode of delivery and maternal and neonatal outcome were not significantly different among the 3 groups. Conclusion: This study provides evidence that both continuous and intermittent epidural infusion produce comparable analgesia achieving equivalent maternal satisfaction with no difference regarding the duration of labor between them. Although patients receiving epidural analgesia experienced longer labors compared with controls, both mothers and neonates were unharmed.	Haemek Med Ctr, Dept Obstet & Gynecol, IL-18101 Afula, Israel; Haemek Med Ctr, Dept Anesthesia, Afula, Israel; Rappaport Fac Med, Haifa, Israel	Shalev, E (reprint author), Haemek Med Ctr, Dept Obstet & Gynecol, IL-18101 Afula, Israel.	shaleve@tx.technion.ac.il	shalev, eliezer/C-8223-2014				Bofill JA, 1997, AM J OBSTET GYNECOL, V177, P1465, DOI 10.1016/S0002-9378(97)70092-9; Chestnut DH, 1997, ANESTHESIOLOGY, V86, P273, DOI 10.1097/00000542-199702000-00001; Clark A, 1998, AM J OBSTET GYNECOL, V179, P1527, DOI 10.1016/S0002-9378(98)70019-5; Collis RE, 1999, BRIT J ANAESTH, V82, P233, DOI 10.1093/bja/82.2.233; Driver I, 1996, EUR J ANAESTH, V13, P515, DOI 10.1046/j.1365-2346.1996.d01-388.x; Halonen P, 2004, ACTA ANAESTH SCAND, V48, P732, DOI 10.1111/j.0001-5172.2004.00413.x; Halpern SH, 1998, JAMA-J AM MED ASSOC, V280, P2105, DOI 10.1001/jama.280.24.2105; Hawkins JL, 1997, ANESTHESIOLOGY, V86, P277, DOI 10.1097/00000542-199702000-00002; Howell CJ, 2002, BRIT MED J, V325, P357, DOI 10.1136/bmj.325.7360.357; HOWELL CJ, 2000, [No title captured], DOI DOI 10.1002/14651858.CD000331; LAMONT RF, 1989, ANAESTHESIA, V44, P893, DOI 10.1111/j.1365-2044.1989.tb09142.x; Liu EHC, 2004, BMJ-BRIT MED J, V328, P1410, DOI 10.1136/bmj.38097.590810.7C; PURDIE J, 1992, BRIT J ANAESTH, V68, P580, DOI 10.1093/bja/68.6.580; Roberts CL, 2002, AUST NZ J OBSTET GYN, V42, P176, DOI 10.1111/j.0004-8666.2002.00176.x; Rust G, 2004, AM J OBSTET GYNECOL, V191, P456, DOI 10.1016/j.ajog.2004.03.005; TAN S, 1994, BRIT J ANAESTH, V73, P619, DOI 10.1093/bja/73.5.619; THORP JA, 1993, AM J OBSTET GYNECOL, V169, P851, DOI 10.1016/0002-9378(93)90015-B; Torvaldsen S, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004457.PUB2; Weber S E, 1996, J Obstet Gynecol Neonatal Nurs, V25, P67, DOI 10.1111/j.1552-6909.1996.tb02515.x; Zhang J, 1999, AM J OBSTET GYNECOL, V180, P970, DOI 10.1016/S0002-9378(99)70669-1	20	22	25	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0029-7844			OBSTET GYNECOL	Obstet. Gynecol.	AUG	2005	106	2					301	306		10.1097/01.AOG.0000171109.53832.8d			6	Obstetrics & Gynecology	Obstetrics & Gynecology	948LR	WOS:000230717800014	16055579				2020-06-30	J	Tammpere, A; Brusberg, M; Axenborg, J; Hirsch, I; Larsson, H; Lindstrom, E				Tammpere, A; Brusberg, M; Axenborg, J; Hirsch, I; Larsson, H; Lindstrom, E			Evaluation of pseudo-affective responses to noxious colorectal distension in rats by manometric recordings	PAIN			English	Article						colorectal distension; fentanyl; rat; visceral pain; visceromotor response	IRRITABLE-BOWEL-SYNDROME; OPIOID-RECEPTOR AGONISTS; VISCERAL HYPERALGESIA; ATTENUATE RESPONSES; ANESTHETIZED RAT; COLONIC MOTILITY; AFFERENT-FIBERS; MOTOR-ACTIVITY; STIMULUS; PAIN	Recordings of electromyographic (EMG) activity in the abdominal musculature are generally used to quantify the pseudo-affective visceromotor response induced by colorectal distension (CRD) in rodents. The present study describes a non-invasive, manometric method to quantify the magnitude of the abdominal contractions evoked by CRD. CRD-induced increases in EMG activity in female rats (electrical response) were compared to phasic changes in balloon pressure (mechanical response). A phasic increasing CRD paradigm from 10 to 80 mmHg with 10 mmHg intervals induced a clear stimulus-response relationship with a strong correlation (r(2)=0.93) between the electrical and mechanical responses. Twelve repeated phasic distensions at 80 mmHg increased the mechanical response by 133 +/- 53% (P < 0.01), while the electrical response only increased by 20 +/- 19% (P > 0.05), when comparing the last distension to the first. Atropine methyl bromide (1 mg/kg, i.v.) did not affect the mechanical response to distension at 80 mmHg, suggesting that colonic activity per se, does not contribute to the balloon pressure variations during CRD in the current experimental set-up. The p-opioid receptor agonist fentanyl at a dose of 1.5 mu g/kg (i.v.) significantly reduced the mechanical response to CRD (P < 0.01) while the electrical response was not affected. The present study shows that phasic bursts in EMG activity from the abdominal musculature occur simultaneously with balloon pressure variations, which may represent a non-invasive alternative to EMG recordings. Furthermore, the mechanical response is a more sensitive parameter for detecting both hyperalgesic and analgesic responses. (c) 2005 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	AstraZeneca R&D, Integrat Pharmacol, GI Biol, S-43183 Molndal, Sweden; AstraZeneca R&D, Discovery IS IT, S-43183 Molndal, Sweden	Lindstrom, E (reprint author), AstraZeneca R&D, Integrat Pharmacol, GI Biol, S-43183 Molndal, Sweden.	erik.a.lindstrom@astrazenca.com					BANNER SE, 1995, BRIT J PHARMACOL, V114, P558, DOI 10.1111/j.1476-5381.1995.tb13263.x; BRIGGS SL, 1995, PHARMACOL BIOCHEM BE, V52, P561, DOI 10.1016/0091-3057(95)00140-R; BURTON MB, 1995, BRAIN RES, V672, P77, DOI 10.1016/0006-8993(94)01382-R; Carini F, 2001, BRIT J PHARMACOL, V133, P1107, DOI 10.1038/sj.bjp.0704164; Castroman P, 2001, NEUROSCI LETT, V306, P97, DOI 10.1016/S0304-3940(01)01886-9; Chang L, 2000, GUT, V47, P497, DOI 10.1136/gut.47.4.497; COUNTINHO SV, 2002, AM J PHYSIOL-GASTR L, V282, pG307; DANZEBRINK RM, 1995, PAIN, V63, P39, DOI 10.1016/0304-3959(94)00275-J; GREENWOOD B, 1995, AM J PHYSIOL-GASTR L, V268, pG514; Gschossmann JM, 2001, NEUROGASTROENT MOTIL, V13, P229, DOI 10.1046/j.1365-2982.2001.00262.x; Hara K, 2004, ANESTH ANALG, V98, P1380, DOI 10.1213/01.AE.00001079935.84035.48; Kozlowski CM, 2000, NEUROGASTROENT MOTIL, V12, P239, DOI 10.1046/j.1365-2982.2000.00205.x; Larsson M, 2003, NEUROGASTROENT MOTIL, V15, P371, DOI 10.1046/j.1365-2982.2003.00418.x; Lembo T, 2000, PAIN, V87, P137, DOI 10.1016/S0304-3959(00)00282-7; MAGGI CA, 1987, AM J PHYSIOL, V252, pG447; Martin TJ, 1998, EUR J PHARMACOL, V357, P25, DOI 10.1016/S0014-2999(98)00531-7; MAYER EA, 1994, GASTROENTEROLOGY, V107, P271, DOI 10.1016/0016-5085(94)90086-8; Megens AAHP, 1998, J PAIN SYMPTOM MANAG, V15, P253, DOI 10.1016/S0885-3924(97)00371-0; MERTZ H, 1995, GASTROENTEROLOGY, V109, P40, DOI 10.1016/0016-5085(95)90267-8; MONNIKES H, 1993, PEPTIDES, V14, P743, DOI 10.1016/0196-9781(93)90107-R; MORTEAU O, 1994, DIGEST DIS SCI, V39, P1239, DOI 10.1007/BF02093789; Munakata J, 1997, GASTROENTEROLOGY, V112, P55, DOI 10.1016/S0016-5085(97)70219-1; Naliboff BD, 1997, GUT, V41, P505, DOI 10.1136/gut.41.4.505; NESS TJ, 1988, BRAIN RES, V450, P153, DOI 10.1016/0006-8993(88)91555-7; NESS TJ, 1990, PAIN, V43, P377, DOI 10.1016/0304-3959(90)90035-C; NIKLASSON LG, 1988, ACTA PHYSIOL SCAND, V134, P549, DOI 10.1111/j.1365-201X.1988.tb10634.x; OBrien MD, 1997, DIGEST DIS SCI, V42, P26, DOI 10.1023/A:1018868601475; RITCHIE J, 1973, GUT, V14, P125, DOI 10.1136/gut.14.2.125; Sengupta JN, 1996, GASTROENTEROLOGY, V111, P968, DOI 10.1016/S0016-5085(96)70064-1; Su X, 2000, J NEUROPHYSIOL, V83, P963; Sun Y, 2000, SCAND J GASTROENTERO, V35, P380, DOI 10.1080/003655200750023949; Tatewaki M, 2003, AM J PHYSIOL-REG I, V285, pR862, DOI 10.1152/ajpregu.00715.2002; TRAUB RJ, 1992, PAIN, V49, P393, DOI 10.1016/0304-3959(92)90247-9; Verne GN, 2001, PAIN, V93, P7, DOI 10.1016/S0304-3959(01)00285-8	34	40	40	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	AUG	2005	116	3					220	226		10.1016/j.pain.2005.04.012			7	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	951NP	WOS:000230937700009	15936885				2020-06-30	J	White, MC; Nolan, JA				White, MC; Nolan, JA			An evaluation of pain and postoperative nausea and vomiting following the introduction of guidelines for tonsillectomy	PEDIATRIC ANESTHESIA			English	Article						tonsillectomy; nausea; antiemetics; morphine; NSAIDS; pain	ANALGESIC EFFICACY; PEDIATRIC TONSILLECTOMY; ANTIINFLAMMATORY DRUGS; CONTROLLED-TRIALS; CHILDREN; ONDANSETRON; MORPHINE; ADENOTONSILLECTOMY; PLACEBO; DICLOFENAC	Background: Tonsillectomy and adenotonsillectomy have a high incidence of postoperative pain, and postoperative nausea and vomiting (PONV). Pain is traditionally controlled with morphine but this increases the risk of PONV and may cause respiratory depression. Antiemetics reduce PONV but their routine use has been questioned on safety grounds. Method: After determining the current anesthetic management of elective tonsillectomy and adenotonsillectomy patients in our hospital, guidelines were developed to avoid the routine use of morphine and antiemetics. The effect on pain and PONV was then evaluated over a 3 month period. Postoperative pain was scored using the Oucher visual analog scale and nausea scored using a five point scale. Results: We analysed 34 cases to determine our current practice and 37 cases to evaluate the effect of introducing guidelines. Postguidelines, the median Oucher pain score at 4 h was 10, and at 8, 12, 16 h was zero. Despite receiving no antiemetics, only two children vomited (5%) after introduction of guidelines. Conclusion: Guidelines which use a combination of paracetamol, nonsteroidal anti-inflammatory drugs and fentanyl, provide excellent analgesia with minimal PONV after elective tonsillectomy and adenotonsillectomy. As a result the routine use of morphine and antiemetics can be avoided.	Bristol Royal Hosp Children, Dept Anaesthesia, Bristol BS2 8BJ, Avon, England	Nolan, JA (reprint author), Bristol Royal Hosp Children, Dept Anaesthesia, Marlborough St, Bristol BS2 8BJ, Avon, England.	judith.nolan@ubht.swest.nhs.uk					Anderson B, 1996, ANAESTH INTENS CARE, V24, P669, DOI 10.1177/0310057X9602400606; Anderson BJ, 2000, ANAESTH INTENS CARE, V28, P155, DOI 10.1177/0310057X0002800205; *AUD COMM, 2001, DAY SURG REP AUD COM; Beyer J E, 1992, J Pediatr Nurs, V7, P335; BONE ME, 1988, ANAESTHESIA, V43, P277; Courtman SP, 1999, PAEDIATR ANAESTH, V9, P467, DOI 10.1046/j.1460-9592.1999.00416.x; EUSTACE N, 2004, ASS PAED AN ANN M ED; FURST SR, 1994, ANESTHESIOLOGY, V81, P799, DOI 10.1097/00000542-199410000-00005; GUNTER JB, 1995, ANESTH ANALG, V81, P1136, DOI 10.1097/00000539-199512000-00004; Hamid SK, 1998, ANESTH ANALG, V86, P496, DOI 10.1097/00000539-199803000-00008; Harley EH, 1998, OTOLARYNG HEAD NECK, V119, P492, DOI 10.1016/S0194-5998(98)70107-X; Herreen PG, 2001, ANAESTH INTENS CARE, V29, P421, DOI 10.1177/0310057X0102900415; JENKINS JA, 2004, ASS PAED AN ANN SCI; Kotiniemi LH, 1997, ANAESTHESIA, V52, P963, DOI 10.1111/j.1365-2044.1997.203-az0338.x; Marret E, 2003, ANESTHESIOLOGY, V98, P1497; MATHER SJ, 1995, PAEDIATR ANAESTH, V5, P185, DOI 10.1111/j.1460-9592.1995.tb00275.x; Moiniche S, 2003, ANESTH ANALG, V96, P68, DOI 10.1213/01.ANE.0000040583.65135.57; Morton NS, 1997, PAEDIATR ANAESTH, V7, P37, DOI 10.1046/j.1460-9592.1997.d01-39.x; Mukherjee K, 2001, ANAESTHESIA, V56, P1193; Pickering AE, 2002, BRIT J ANAESTH, V88, P72, DOI 10.1093/bja/88.1.72; Romsing J, 1998, ACTA ANAESTH SCAND, V42, P770, DOI 10.1111/j.1399-6576.1998.tb05320.x; Romsing J, 2000, ACTA ANAESTH SCAND, V44, P291, DOI 10.1034/j.1399-6576.2000.440312.x; Semple D, 1999, PAEDIATR ANAESTH, V9, P135, DOI 10.1046/j.1460-9592.1999.9220317.x; StCharles CS, 1997, OTOLARYNG HEAD NECK, V117, P76, DOI 10.1016/S0194-5998(97)70211-0; Steward DL, 2003, COCHRANE DB SYST REV; SUTTERS KA, 1995, PAIN, V61, P145, DOI 10.1016/0304-3959(94)00166-C; Tramer MR, 1997, ANESTHESIOLOGY, V87, P1277, DOI 10.1097/00000542-199712000-00004; Walker R, 1999, PAEDIATR ANAESTH, V9, P278; WATTERS CH, 1988, ANAESTHESIA, V43, P641, DOI 10.1111/j.1365-2044.1988.tb04147.x	29	35	36	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	AUG	2005	15	8					683	688		10.1111/j.1460-9592.2004.01516.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	946LC	WOS:000230572700010	16029404				2020-06-30	J	Konishi, H; Ishihara, C; Chiba, M; Endo, Y; Yamaji, A				Konishi, H; Ishihara, C; Chiba, M; Endo, Y; Yamaji, A			Pain recurrence on the third day after application of a transdermal fentanyl patch	PHARMACY WORLD & SCIENCE			English	Letter						fentanyl patch; pain control; pain recurrence; transdermal	HEAT		Shiga Univ Med Sci, Dept Hosp Pharm, Otsu, Shiga 5202192, Japan; Shiga Univ Med Sci, Dept Surg, Otsu, Shiga 5202192, Japan	Konishi, H (reprint author), Shiga Univ Med Sci, Dept Hosp Pharm, Otsu, Shiga 5202192, Japan.	konishi@belle.shiga-med.ac.jp					Ashburn MA, 2003, J PAIN, V4, P291, DOI 10.1016/S1526-5900(03)00618-7; Carter KA, 2003, AM J HEALTH-SYST PH, V60, P191, DOI 10.1093/ajhp/60.2.191; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001	3	2	2	0	1	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0928-1231			PHARM WORLD SCI	Pharm. World Sci.	AUG	2005	27	4					353	353		10.1007/s11096-005-5972-7			1	Pharmacology & Pharmacy	Pharmacology & Pharmacy	974SZ	WOS:000232613000019	16228637				2020-06-30	J	Schuler, M; Oster, R				Schuler, M; Oster, R			Increasing importance of opioids in geriatrics	SCHMERZ			German	Article						geriatrics; costs; opioids; prescriptions; budget	PAIN; THERAPY	Background. During the previous 20 years the prescription of opioids for medical use has increased steadily. Patients and professionals have great reservations about the use of opioids in the elderly. The aim of this study was to describe the changes in analgesic therapy in a geriatric clinic during the previous 10 years. Method. The quality and quantity of prescriptions for opioids as well as the costs of the analgesic therapy in a large geriatric clinic between 1994 and 2003 were analyzed. Results. The use of opioids increased steadily from 0.72 mg per day and patient in 1994 to 9.50 mg in 2003 (1320%). The introduction of sustained release tilidine/naloxone and tramadol led to a change of the prescribed forms but only to a slight increase in the total consumption of these drugs. In 1994 the average daily cost of analgesic therapy was 15 cents per patient compared with 46 cents in 2003. The percentage of analgesics in the pharmacological budget increased from 5.6 to 10.8%. Conclusion. Dealing with opioids should be a part of the training program for all members of the geriatric team. Analgesics have come-to play an important role in the pharmacological budget at least in this geriatric clinic.	Heidelberg Univ, Bethanien Krankenhaus, Geriatr Zentrum, D-69126 Heidelberg, Germany	Schuler, M (reprint author), Heidelberg Univ, Bethanien Krankenhaus, Geriatr Zentrum, Rohrbacher Str 149, D-69126 Heidelberg, Germany.	mschuler@bethanien-heidelberg.de					Austin CA, 1998, AGE AGEING, V27, P667, DOI 10.1093/ageing/27.6.667; BELLACH BM, 2000, BUNDESGESUNDHEITSBLA, V43, P424; BELLVILL.JW, 1971, J AMER MED ASSOC, V217, P1835, DOI 10.1001/jama.217.13.1835; BERGERT F, 2004, AZQ PMV, P1; Carr DB, 1999, LANCET, V353, P2051, DOI 10.1016/S0140-6736(99)03313-9; CHARETTE SL, 2000, HDB PAIN RELIEF OLDE, P165; Ferrell B, 2002, J AM GERIATR SOC, V50, pS205, DOI 10.1046/j.1532-5415.50.6s.1.x; FERRELL B, 1996, [No title captured]; *INT NARC CONTR BO, 2003, NAR DRUG EST WORLD R; Loick G, 2000, DEUT MED WOCHENSCHR, V125, P1216, DOI 10.1055/s-2000-7726; Macintyre PE, 1996, PAIN, V64, P357, DOI 10.1016/0304-3959(95)00128-X; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; McClean WJ, 2002, MED J AUSTRALIA, V177, P17, DOI 10.5694/j.1326-5377.2002.tb04620.x; McQuay H, 1999, LANCET, V353, P2229, DOI 10.1016/S0140-6736(99)03528-X; Nikolaus T, 1999, AGE AGEING, V28, P543, DOI 10.1093/ageing/28.6.543; PARMELEE PA, 1993, J AM GERIATR SOC, V41, P517, DOI 10.1111/j.1532-5415.1993.tb01888.x; Schuler M, 2004, SCHMERZ, V18, P269, DOI 10.1007/s00482-004-0313-7; Schuler M, 2002, SCHMERZ, V16, P171, DOI 10.1007/s00482-002-0143-4; Schuler M, 2001, Z GERONTOL GERIATR, V34, P376, DOI 10.1007/s003910170039; Specht-Leible N, 2003, UNFALLCHIRURG, V106, P207, DOI 10.1007/s00113-002-0545-x; SZETO HH, 1977, ANN INTERN MED, V86, P738, DOI 10.7326/0003-4819-86-6-738; Tegeder I, 1999, SCHMERZ, V13, P183, DOI 10.1007/s004820050197; Weiner DK, 2002, J AM GERIATR SOC, V50, P2035, DOI 10.1046/j.1532-5415.2002.50618.x; ZENZ M, 2001, [No title captured]	24	7	7	0	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0932-433X	1432-2129		SCHMERZ	Schmerz	AUG	2005	19	4					302	307		10.1007/s00482-004-0377-4			6	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	959AD	WOS:000231488400007	15580360				2020-06-30	J	Solassol, I; Bressolle, F; Caumette, L; Garcia, F; Poujol, S; Culine, W; Pinguet, F				Solassol, I; Bressolle, F; Caumette, L; Garcia, F; Poujol, S; Culine, W; Pinguet, F			Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients	THERAPEUTIC DRUG MONITORING			English	Article						fentanyl; transdermal applications; pharmacokinetics; cancer pain patients	PHARMACOLOGICAL-PROPERTIES; THERAPEUTIC-EFFICACY; POSTOPERATIVE PAIN; PLASMA	Perception of pain by the patient is frequently one of the early signs preceding a diagnosis of cancer and, later, a sinister sign of disease progression. Among opioid drugs, transdermal fentanyl has been evaluated in the treatment of moderate to severe cancer pain. The objective of this study was to investigate the intra- and inter-individual variabilities in pharmacokinetics after fentanyl drug delivery by the transdermal fentanyl patch delivery system in patients with cancer pain. As a first step, a liquid chromatography-mass spectrometry method was developed for the determination of the analgesic fentanyl in human plasma. This method was validated over the concentration range 0.15-100 ng/mL. The study group consisted of 29 inpatients (18 men and 11 women; age range 29-80 years). The initial transdermal fentanyl delivery rate was chosen depending on the patient's analgesic requirements. For 20 patients, the initial TTS fentanyl delivery rate was 25 or 50 mu g/h. For 6 patients, the initial delivery rate was 75-150 mu g/h. Two patients received up to 300 mu g/h fentanyl delivery rate, and 3 patients received up to 350 mu g/h fentanyl delivery rate. Fifteen of the 29 patients received rescue doses of subcutaneous or oral morphine, and 26 patients received paracetamol with codeine (30 mg per os). Blood samples were collected at the following intervals: 2-5, 22-26, or 45-47 hours following fentanyl patch application. The severity of pain experienced by the patient was assessed thrice daily using a visual analogue scale. The study period was 46 days. Large patient-to-patient variations in pharmacokinetic, parameters occurred, although intraindividual variability was limited. A mean bioavailability of 78% was estimated; the total clearance averaged 41 L/h. From 25 to 100 mu g/h fentanyl delivery rate, the pharmacokinetics was linear. At the 2 highest doses, an increase of total clearance was observed (> 60 Uh). For the whole group, transdermal fentanyl treatment provided good to excellent pain relief in the majority of patients.	Univ Montpellier 1, Pharmacocinet Clin Lab, Fac Pharm, F-34093 Montpellier, France; Ctr Val Aurelle Anticanc, Serv Pharm, Oncopharmacol Dept, F-34298 Montpellier, France; Ctr Val Aurelle Anticanc, Dept Med, F-34298 Montpellier, France	Bressolle, F (reprint author), Univ Montpellier 1, Pharmacocinet Clin Lab, Fac Pharm, BP 14491,15 Ave Ch Flahault, F-34093 Montpellier, France.	Fbressolle@aol.com					Ariano RE, 2001, J CLIN PHARMACOL, V41, P757, DOI 10.1177/00912700122010663; Ashburn MA, 2003, J PAIN, V4, P291, DOI 10.1016/S1526-5900(03)00618-7; BELL SD, 1989, CAN J ANAESTH, V36, P116; BROOME IJ, 1995, ANAESTHESIA, V50, P300, DOI 10.1111/j.1365-2044.1995.tb04603.x; DURCAN TG, 1995, BRIT J ANAESTH, V74, P139; ESTEVE M, 1991, ANESTHESIOLOGY, V75, pA705; Farenc C, 2000, COMPUT BIOMED RES, V33, P315, DOI 10.1006/cbmr.2000.1548; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Gourlay G K, 2001, Lancet Oncol, V2, P165, DOI 10.1016/S1470-2045(00)00258-8; GOURLAY GK, 1989, PAIN, V37, P193, DOI 10.1016/0304-3959(89)90130-9; GOURLAY GK, 1990, PAIN, V40, P21, DOI 10.1016/0304-3959(90)91046-L; GUPTA SK, 1992, [No title captured], V7, P17; HANNA MH, STUDY EXAMINE REPEAT; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Kumar K, 1996, J PHARMACEUT BIOMED, V14, P667, DOI 10.1016/0731-7085(95)01685-6; Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; PLEZIA PM, 1989, PHARMACOTHERAPY, V9, P2; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0; ROSE PG, 1993, ANESTH ANALG, V77, P390, DOI 10.1213/00000539-199377020-00029; Shou WZ, 2002, J PHARMACEUT BIOMED, V27, P143, DOI 10.1016/S0731-7085(01)00497-6; SOUTHAM MA, 1995, ANTI-CANCER DRUG, V6, P29, DOI 10.1097/00001813-199504003-00005; Tawfik MO, 2004, CURR MED RES OPIN, V20, P259, DOI 10.1185/030079903125003026; VANBASTELAERE M, 1993, BRIT J ANAESTH, V70, P75; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; VILLIGER JW, 1983, NEUROPHARMACOLOGY, V22, P447, DOI 10.1016/0028-3908(83)90162-4; 1999, PKFIT COMPUTER PROGR	29	37	38	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0163-4356	1536-3694		THER DRUG MONIT	Ther. Drug Monit.	AUG	2005	27	4					491	498		10.1097/01.ftd.0000160717.50704.42			8	Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology	Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology	952RW	WOS:000231024200016	16044107				2020-06-30	J	Sedgwick, JA; Schenbeck, JL; Eghtesady, P				Sedgwick, JA; Schenbeck, JL; Eghtesady, P			Harmful effects of fentanyl on the fetus and placenta?	AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY			English	Letter									Childrens Hosp, Med Ctr, Dept Cardiothorac Surg, Cincinnati, OH 45229 USA; Univ Cincinnati, Cincinnati, OH 45221 USA	Sedgwick, JA (reprint author), Childrens Hosp, Med Ctr, Dept Cardiothorac Surg, Cincinnati, OH 45229 USA.	pirooz.eghtesady@cchmc.org		Eghtesady, Pirooz/0000-0001-7161-8391			Kopecky EA, 2000, AM J OBSTET GYNECOL, V183, P424, DOI 10.1067/mob.2000.105746; Reddy V. Mohan, 1997, Current Opinion in Pediatrics, V9, P530; Smith RP, 2004, AM J OBSTET GYNECOL, V190, P836, DOI 10.1016/j.ajog.2003.09.064; TEIXEIRA JM, 1999, AM J OBSTET GYNECOL, V18, P1018	4	3	3	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9378	1097-6868		AM J OBSTET GYNECOL	Am. J. Obstet. Gynecol.	JUL	2005	193	1					303	304		10.1016/j.ajog.2005.01.084			2	Obstetrics & Gynecology	Obstetrics & Gynecology	948BR	WOS:000230691500047	16021095				2020-06-30	J	Lalley, PM				Lalley, PM			D-1-dopamine receptor agonists prevent and reverse opiate depression of breathing but not antinociception in the cat	AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY			English	Article						expiratory neuron discharges; fentanyl; nociceptive reflex; phrenic nerve activity; respiration and ventilation	RESPIRATORY NETWORK; PHRENIC-NERVE; NEURONS; FENTANYL; MORPHINE; ANESTHESIA; ANALGESIA; RHYTHM; MICE; CAMP	Opioids depress respiration and decrease chest wall compliance. A previous study in this laboratory showed that dopamine-D-1 receptor (D1R) agonists restored phrenic nerve activity after arrest by fentanyl in immobilized, mechanically ventilated cats. The reinstated phrenic nerve rhythm was slower than control, so it was not known whether D1R agonists can restore spontaneous breathing to levels that provide favorable alveolar gas exchange and blood oxygenation. It was also not known whether the agonists counteract opioid analgesia. In the present study, anesthetized, spontaneously breathing cats were given intravenous doses of fentanyl (18.0 +/- 3.4 mu g/kg) that severely depressed depth and rate of respiration, lowered arterial hemoglobin oxygenation (HbO(2)), elevated end-tidal carbon dioxide (ETCO2), and abolished the nociceptive hind limb crossed-extensor reflex. Fentanyl (30 mu g/kg) also evoked tonic discharges of caudal medullary expiratory neurons in paralyzed mechanically ventilated cats, which might explain decreased chest compliance. The selective D1R agonists 6-chloro APB (3 mg/kg) or dihydrexidine (DHD, 1 mg/kg) increased depth and rate of spontaneous breathing after opioid depression and returned HbO(2) and ETCO2 to control levels. Opioid arrest of the nociceptive reflex remained intact. Pretreatment with DHD prevented significant depression of spontaneous breathing by fentanyl (17.5 +/- 4.3 mu g/kg). Tonic firing evoked by fentanyl in expiratory neurons was converted to rhythmic respiratory discharges by DHD (1 mg/kg). The results suggest that D1R agonists might be therapeutically useful for the treatment of opioid disturbances of breathing without impeding analgesia.	Univ Wisconsin, Dept Physiol, Med Sci Ctr, Madison, WI 53706 USA	Lalley, PM (reprint author), Univ Wisconsin, Dept Physiol, Med Sci Ctr, 1300 Univ Ave, Madison, WI 53706 USA.	pmlalley@facstaff.wisc.edu			NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL-65526]		ARATA A, 1993, BRAIN RES, V605, P193, DOI 10.1016/0006-8993(93)91740-J; BALLANTYNE D, 1986, J PHYSIOL-LONDON, V370, P433, DOI 10.1113/jphysiol.1986.sp015943; Ballanyi K, 1997, J PHYSIOL-LONDON, V504, P127, DOI 10.1111/j.1469-7793.1997.127bf.x; Becker A, 2001, N-S ARCH PHARMACOL, V363, P562, DOI 10.1007/s002100100404; BEDFORD RF, 1975, ANESTHESIOLOGY, V43, P1, DOI 10.1097/00000542-197507000-00001; Bowdle TA, 1998, DRUG SAFETY, V19, P173, DOI 10.2165/00002018-199819030-00002; BURGESS KR, 1994, CRIT CARE MED, V22, P413, DOI 10.1097/00003246-199403000-00010; Dolan S, 2001, NEUROSCI LETT, V309, P157, DOI 10.1016/S0304-3940(01)02063-8; ELDRIDGE FL, 1971, AM J PHYSIOL, V221, P535; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; GUTSTEIN HB, 2001, GOODMAN GILMANS PHAR, P569; Hawk CT, 1999, FORMULARY LAB ANIMAL; HORITA A, 1976, PSYCHOPHARMACOLOGY, V49, P57; Howard RS, 1990, J PHYSL, V437, P181; JAFFE J H, 1990, P485; Karper PE, 2000, PHYSIOL BEHAV, V68, P585, DOI 10.1016/S0031-9384(99)00223-1; Lalley PM, 2004, RESP PHYSIOL NEUROBI, V139, P247, DOI 10.1016/j.resp.2003.10.007; Lalley PM, 2003, AM J PHYSIOL-REG I, V285, pR1287, DOI 10.1152/ajpregu.00199.2003; LALLEY PM, 1997, J NEUROPHYSIOL, V77, P1191; LAUBIE M, 1986, EUR J PHARMACOL, V122, P301, DOI 10.1016/0014-2999(86)90410-3; LONG S, 1986, PROG NEUROBIOL, V27, P101, DOI 10.1016/0301-0082(86)90007-9; LUNDBERG D, 1979, EUR J PHARMACOL, V54, P153, DOI 10.1016/0014-2999(79)90417-5; LUNDBERG D, 1982, ACTA PHYSIOL SCAND, V114, P81, DOI 10.1111/j.1748-1716.1982.tb06955.x; Manzke T, 2003, SCIENCE, V301, P226, DOI 10.1126/science.1084674; MORGAN MJ, 1991, PHARMACOL BIOCHEM BE, V40, P317, DOI 10.1016/0091-3057(91)90560-O; NADEAU RA, 1965, J APPL PHYSIOL, V20, P836; NICHOLS AJ, 1990, AM J HYPERTENS, V3, pA116; Niedhart P., 1989, ACTA ANAESTH SCAND, V33, P1; RIGG JRA, 1978, BRIT J ANAESTH, V50, P759, DOI 10.1093/bja/50.8.759; Shook J.E., 1990, AM REV RESPIR DIS, V33, P1; TABATABAI M, 1989, ANESTHESIOLOGY, V70, P489, DOI 10.1097/00000542-198903000-00020; Valero-Cabre A, 2002, J NEUROPHYSIOL, V87, P1763, DOI 10.1152/jn.00305.2001; WATLING A, 2001, SIGMA RBI HDB RECEPT, P231; YEADON M, 1989, PROG NEUROBIOL, V33, P1, DOI 10.1016/0301-0082(89)90033-6	34	21	24	0	4	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6119			AM J PHYSIOL-REG I	Am. J. Physiol.-Regul. Integr. Comp. Physiol.	JUL	2005	289	1					R45	R51		10.1152/ajpregu.00868.2004			7	Physiology	Physiology	935PI	WOS:000229793800008	15705800				2020-06-30	J	Grimm, KA; Tranquilli, WJ; Gross, DR; Sisson, DD; Bulmer, BJ; Benson, J; Greene, SA; Martin-Jimenez, T				Grimm, KA; Tranquilli, WJ; Gross, DR; Sisson, DD; Bulmer, BJ; Benson, J; Greene, SA; Martin-Jimenez, T			Cardiopulmonary effects of fentanyl in conscious dogs and dogs sedated with a continuous rate infusion of medetomidine	AMERICAN JOURNAL OF VETERINARY RESEARCH			English	Article; Proceedings Paper	8th World Congress of Veterinary Anesthesia	SEP, 2003	Knoxville, TN				DEXMEDETOMIDINE; XYLAZINE	Objective-To determine the hemodynamic consequences of the coadministration of a continuous rate infusion (CRI) of medetomidine with a fentanyl bolus in dogs. Animals-12 healthy sexually intact male dogs weighing 30.3 +/- 4.2 kg (mean +/- SD). Procedure-Dogs received either fentanyl alone (15.0 mu g/kg, IV bolus) or the same dose of fentanyl during an 11-hour CRI of medetomidine (1.5 mu g/kg/h, IV). Prior to drug administration, dogs were instrumented for measurement of cardiac output, left atrial pressure, and systemic arterial blood pressures. Additionally, blood samples were collected from the pulmonary artery and left atrium for blood gas analysis. Results-Medetomidine infusion reduced the cardiac index, heart rate, and O-2 delivery while increasing left atrial pressure. Subsequent fentanyl administration further decreased the cardiac index. The PaO2 was not significantly different between the 2 treatment groups; however, fentanyl transiently decreased PaO2 from baseline values in dogs receiving a CRI of medetomidine. Conclusions and Clinical Relevance-Because of the prolonged hemodynamic changes associated with the CRI of medetomidine, its safety should be further evaluated before being clinically implemented in dogs.	Univ Illinois, Coll Vet Med, Dept Vet Clin Med, Urbana, IL 61801 USA; Univ Illinois, Coll Vet Med, Dept Vet Biosci, Urbana, IL 61801 USA; Oregon State Univ, Coll Vet Med, Dept Clin Sci, Corvallis, OR 97331 USA; Kansas State Univ, Coll Vet Med, Dept Clin Sci, Manhattan, KS 66506 USA; Washington State Univ, Coll Vet Med, Dept Vet Clin Sci, Pullman, WA 99164 USA	Grimm, KA (reprint author), Univ Illinois, Coll Vet Med, Dept Vet Clin Med, Urbana, IL 61801 USA.						BENSON GJ, 1985, AM J VET RES, V46, P1896; BLOOR BC, 1992, J PHARMACOL EXP THER, V263, P690; COPLAND VS, 1987, AM J VET RES, V48, P1626; Cullen LK, 1996, BRIT VET J, V152, P519, DOI 10.1016/S0007-1935(96)80005-4; FLACKE JW, 1990, J CARDIOVASC PHARM, V16, P616, DOI 10.1097/00005344-199010000-00013; Flacke W E, 1993, J Cardiothorac Vasc Anesth, V7, P41, DOI 10.1016/1053-0770(93)90117-4; GAUTRET B, 1985, J CARDIOVASC PHARM, V7, P649, DOI 10.1097/00005344-198507000-00006; GLANTZ SA, 2000, PRIMER APPL REGRESSI, P339; Grimm KA, 2000, AM J VET RES, V61, P42, DOI 10.2460/ajvr.2000.61.42; INOUE K, 1980, N-S ARCH PHARMACOL, V312, P57, DOI 10.1007/BF00502575; JALONEN J, 1995, J CARDIOTHOR VASC AN, V9, P519, DOI 10.1016/S1053-0770(05)80134-X; KLIDE AM, 1975, AM J VET RES, V36, P931; Lamont LA, 2001, AM J VET RES, V62, P1745, DOI 10.2460/ajvr.2001.62.1745; Lawrence CJ, 1996, ANESTH ANALG, V83, P1160, DOI 10.1097/00000539-199612000-00005; MEERT TF, 1994, ANESTHESIOLOGY, V81, P677, DOI 10.1097/00000542-199409000-00022; PHILLIPS HR, 1982, AM J PHYSIOL, V243, pH488; Pypendop BH, 1998, VET SURG, V27, P612, DOI 10.1111/j.1532-950X.1998.tb00539.x; REITAN JA, 1978, ANESTH ANALG, V57, P31; SALMENPERA MT, 1994, ANESTHESIOLOGY, V80, P837, DOI 10.1097/00000542-199404000-00017; STOELTING PK, 1991, PHARM PHYSL ANESTHET, P685; TRANQUILLI WJ, 2004, [No title captured]; Weitz J D, 1991, Nurse Anesth, V2, P19; Willigers HM, 2003, ANESTH ANALG, V96, P657, DOI 10.1213/01.ANE.0000048708.75957.FF	23	27	27	0	1	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0002-9645			AM J VET RES	Am. J. Vet. Res.	JUL	2005	66	7					1222	1226		10.2460/ajvr.2005.66.1222			5	Veterinary Sciences	Veterinary Sciences	943OW	WOS:000230364600017	16111162				2020-06-30	J	Pandey, CK; Raza, M; Tripathi, M; Navkar, DV; Kumar, A; Singh, UK				Pandey, CK; Raza, M; Tripathi, M; Navkar, DV; Kumar, A; Singh, UK			The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barre syndrome patients in the intensive care unit	ANESTHESIA AND ANALGESIA			English	Article							RANDOMIZED CONTROLLED-TRIAL; POSTOPERATIVE PAIN; INFLAMMATORY PAIN; NEURALGIA; NEURONS; MODELS; RAT	We evaluated the effects of gabapentin and carbamazepine for pain relief in 36 Guillain-Barre syndrome patients. Patients were randomly assigned to receive gabapentin 300 mg, carbamazepine 100 mg, or matching placebo 3 times a day for 7 days. Fentanyl 2 mu g/kg was used as a supplementary analgesic on patient demand. The pain score was recorded by using a numeric pain rating scale of 0-10, and sedation was recorded with a Ramsay sedation scale of 1-6 before medications were given and then at 6-h intervals throughout the study period. Total daily fentanyl consumption was recorded each day for each patient. The results of the study demonstrated that patients in the gabapentin group had significantly lower (P < 0.05) median numeric pain rating scale scores (3.5, 2.5, 2.0, 2.0, 2.0, 2.0, and 2.0) compared with patients in the placebo group (6.0,6.0,6.0,6.0,6.0,6.0, and 6.0) and the carbamazepine group (6.0, 6.0, 5.0, 4.0, 4.0, 3.5, and 3.0). There was no significant difference in fentanyl consumption between the gabapentin and carbamazepine groups on Day 1 (340.1 +/- 34.3 mu g and 347.5 +/- 38.0 mu g, respectively), but consumption was significantly less in these 2 groups compared with the placebo group (590.4 +/- 35.0 mu g) (P < 0.05). For the rest of the study period, there was a significant difference in fentanyl consumption among all treatment groups, and it was minimal in the gabapentin group (P < 0.05). We conclude that gabapentin is more effective than carbamazepine for decreasing pain and fentanyl consumption.	Sanjay Gandhi Postgrad Inst Med Sci, Dept Anaesthesiol, Lucknow 226014, Uttar Pradesh, India; Sanjay Gandhi Postgrad Inst Med Sci, Dept Biostat, Lucknow 226014, Uttar Pradesh, India	Pandey, CK (reprint author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Anaesthesiol, Lucknow 226014, Uttar Pradesh, India.	ckpandey@sgpgi.ac.in	Tripathi, Mukesh/U-8188-2019				ALBRIGHT PS, 1983, EXP NEUROL, V79, P11, DOI 10.1016/0014-4886(83)90374-6; Backonja M, 1998, JAMA-J AM MED ASSOC, V280, P1831, DOI 10.1001/jama.280.21.1831; CONNELLY M, 1990, ANESTHESIOLOGY, V72, P381, DOI 10.1097/00000542-199002000-00026; Dirks J, 2002, ANESTHESIOLOGY, V97, P560, DOI 10.1097/00000542-200209000-00007; Fassoulaki A, 2002, ANESTH ANALG, V95, P985, DOI 10.1097/00000539-200210000-00036; Feng Y, 2003, ANESTHESIOLOGY, V98, P729, DOI 10.1097/00000542-200303000-00023; Field MJ, 2000, BRIT J PHARMACOL, V131, P282, DOI 10.1038/sj.bjp.0703604; FLINK K, 2000, BRIT J PHARMACOL, V130, P900; GENIS D, 1989, J NEUROL NEUROSUR PS, V52, P999, DOI 10.1136/jnnp.52.8.999; HENSCHEL EO, 1977, ANESTHESIOLOGY, V47, P228, DOI 10.1097/00000542-197708000-00013; Hutson SM, 1998, J NEUROCHEM, V71, P863; KAPETANOVIC IM, 1995, EPILEPSY RES, V20, P113, DOI 10.1016/0920-1211(94)00071-4; MACDONALD RL, 1988, J NEURAL TRANSM, V72, P173, DOI 10.1007/BF01243417; McGraw T, 1997, ANESTHESIOLOGY, V86, P988, DOI 10.1097/00000542-199704000-00029; McLean MJ, 1999, EPILEPSIA, V40, P965, DOI 10.1111/j.1528-1157.1999.tb00804.x; Moulin DE, 1997, NEUROLOGY, V48, P328, DOI 10.1212/WNL.48.2.328; Pandey CK, 2004, CAN J ANAESTH, V51, P358, DOI 10.1007/BF03018240; Pandey CK, 2002, ANESTH ANALG, V95, P1719, DOI 10.1097/00000539-200212000-00046; Patel S, 2001, PAIN, V90, P217, DOI 10.1016/S0304-3959(00)00404-8; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Rowbotham M, 1998, JAMA-J AM MED ASSOC, V280, P1837, DOI 10.1001/jama.280.21.1837; Sist T, 1997, NEUROLOGY, V48, P1467, DOI 10.1212/WNL.48.5.1467; Solaro C, 1998, NEUROLOGY, V51, P609, DOI 10.1212/WNL.51.2.609; STOELTING RK, 1999, [No title captured]; TRACEY DJ, 1991, NEUROSCIENCE, V40, P673, DOI 10.1016/0306-4522(91)90004-8; Tripathi M, 2000, CRIT CARE MED, V28, P655, DOI 10.1097/00003246-200003000-00009; Werner MU, 2001, REGION ANESTH PAIN M, V26, P322, DOI 10.1053/rapm.2001.25070	27	53	57	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUL	2005	101	1					220	225		10.1213/01.ANE.0000152186.89020.36			6	Anesthesiology	Anesthesiology	936XE	WOS:000229888000040	15976235				2020-06-30	J	Jordan, S; Emery, S; Bradshaw, C; Watkins, A; Friswell, W				Jordan, S; Emery, S; Bradshaw, C; Watkins, A; Friswell, W			The impact of intrapartum analgesia on infant feeding	BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY			English	Article							EPIDURAL ANALGESIA; PLACENTAL-TRANSFER; FENTANYL; BUPIVACAINE; LABOR; DELIVERY; QUALITY; COHORT	Objective To investigate the impact of intrapartum analgesia on infant feeding at hospital discharge. Design Retrospective cohort. Setting Maternity unit of a UK district general hospital. Population A random sample of 425 healthy primiparae delivering healthy singleton babies at term in 2000. Methods A random sample of primiparae delivering term neonates was identified from the birth register. We retrieved and analysed the corresponding joint midwifery/obstetric case notes. Main outcome measure Infant feeding method at discharge from hospital. Results Women [190/424 (45%)] were exclusively bottle feeding their babies at discharge from hospital. No one commenced breastfeeding after hospital discharge. Regression analysis revealed that the main determinants of bottle feeding were as follows: maternal age [odds ratio (OR) 0.90, 95% confidence interval [CI] 0.85-0.95 per year]; occupation (OR 0.63, 95% CI 0.40-0.99 for each category, unemployed, manual, non-manual); antenatal feeding intentions (OR 0.12, 95% CI 0.080-0.19 for each category, bottle feeding, undecided, breastfeeding); caesarean section (OR 0.25, 95% CI 0.13-0.47, caesarean or vaginal delivery); and dose of fentanyl administered intrapartum (OR 1.004, 95% CI 1.000-1.008, 90% CI 1.001-1.007 for each microgram administered, range 8-500 mu g). Conclusions A dose-response relationship between fentanyl and artificial feeding has not been reported elsewhere. When well-established determinants of infant feeding are accounted for, intrapartum fentanyl may impede establishment of breastfeeding, particularly at higher doses.	Univ Coll Swansea, Sch Hlth Sci, Swansea SA2 8PP, W Glam, Wales; Singleton Hosp, Swansea SA2 8QA, W Glam, Wales; Univ Coll Swansea, European Business Management Sch, Swansea, W Glam, Wales	Jordan, S (reprint author), Univ Coll Swansea, Sch Hlth Sci, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.		jordan, sue/O-1297-2019	jordan, sue/0000-0002-5691-2987; Watkins, Alan/0000-0003-3804-1943			Albani A, 1999, Minerva Anestesiol, V65, P625; Altman DG, 1991, PRACTICAL STAT MED R; American Academy of Pediatrics Committee on Drugs, 2001, Pediatrics, V108, P776; ARONSON J, 2003, BMJ-BRIT MED J, V327, P122; AURICHE M, 1993, DRUG SAFETY, V9, P230, DOI 10.2165/00002018-199309030-00008; BADER AM, 1995, ANESTH ANALG, V81, P829, DOI 10.1097/00000539-199510000-00029; BRADFORDHILL A, 1965, [No title captured], V58, P295; BRUCE NG, 1991, PUBLIC HEALTH, V105, P357, DOI 10.1016/S0033-3506(05)80595-5; BUZZETTI A, 2001, BMJ-BRIT MED J, V323, P1358; CARRIE LES, 1981, ANAESTHESIA, V36, P965, DOI 10.1111/j.1365-2044.1981.tb08658.x; Cattaneo A, 2001, BRIT MED J, V323, P1358, DOI 10.1136/bmj.323.7325.1358; Corrigan OP, 2002, SOC SCI MED, V55, P497, DOI 10.1016/S0277-9536(01)00183-6; DESPRATS R, 1991, EUR J OBSTET GYN R B, V42, P89, DOI 10.1016/0028-2243(91)90167-J; Donath SM, 2003, ACTA PAEDIATR, V92, P352, DOI 10.1080/08035250310009293; Fernando R, 1997, ANAESTHESIA, V52, P517, DOI 10.1111/j.1365-2044.1997.154-az0160.x; Fontaine P, 2000, J FAM PRACTICE, V49, P515; Glasziou P, 2004, BMJ-BRIT MED J, V328, P39, DOI 10.1136/bmj.328.7430.39; *GOV STAT SERV, 2003, NHS MAT STAT ENGL 20; Grimes DA, 2002, LANCET, V359, P57, DOI 10.1016/S0140-6736(02)07283-5; Halpern SH, 1999, BIRTH-ISS PERINAT C, V26, P83, DOI 10.1046/j.1523-536x.1999.00083.x; HAMLYN B, 2002, DEP HLTH INFANT FEED; Hannah ME, 2002, JAMA-J AM MED ASSOC, V287, P1822, DOI 10.1001/jama.287.14.1822; Hardman J. G., 2001, GOODMAN GILMANS PHAR, P1924; *HDA, 2003, EFF PUBL HLTH INT PR; HELBOHANSEN HS, 1995, BAILLIERE CLIN ANAES, V9, P675, DOI 10.1016/S0950-3501(95)80030-1; Hirose M, 1997, BRIT J ANAESTH, V79, P120; Hirose M, 1996, ANESTH ANALG, V82, P1166, DOI 10.1097/00000539-199606000-00011; Hoddinott P, 1999, BRIT MED J, V318, P30, DOI 10.1136/bmj.318.7175.30; Irl C, 2000, DRUG SAFETY, V22, P169, DOI 10.2165/00002018-200022030-00001; JORDAN S, 2002, PHARM MIDWIVES EVIDE; Kaufman DW, 2000, LANCET, V356, P1339, DOI 10.1016/S0140-6736(00)02826-9; Kiehl E M, 1996, J Hum Lact, V12, P201, DOI 10.1177/089033449601200317; KOEHNTOP DE, 1986, ANESTH ANALG, V65, P227; KOTELKO DM, 1995, ANESTHESIOLOGY, V83, pA928; KUHNERT BR, 1993, EFFECT BABY MATERNAL, P46; Kull I, 2002, ARCH DIS CHILD, V87, P478, DOI 10.1136/adc.87.6.478; Lieberman E, 2002, AM J OBSTET GYNECOL, V186, pS31, DOI 10.1067/mob.2002.122522; LOFTUS JR, 1995, ANESTHESIOLOGY, V83, P300, DOI 10.1097/00000542-199508000-00010; Morrell CJ, 2000, BRIT MED J, V321, P593, DOI 10.1136/bmj.321.7261.593; *NAT COLL CTR WOM, 2003, CAES SECT; Oddy WH, 2003, ARCH DIS CHILD, V88, P224, DOI 10.1136/adc.88.3.224; Porter J, 1998, ANESTHESIOLOGY, V89, P79, DOI 10.1097/00000542-199807000-00014; RAJAN L, 1994, MIDWIFERY, V10, P87, DOI 10.1016/S0266-6138(05)80250-5; Reynolds F, 2000, REGIONAL ANALGESIA IN OBSTETRICS, P237; Simpson JA, 2002, J CLIN PHARM THER, V27, P151, DOI 10.1046/j.1365-2710.2002.00399.x; STEER PL, 1992, CAN J ANAESTH, V39, P231, DOI 10.1007/BF03008782; Wiffen P., 2002, BANDOLIER EXTRA	47	49	50	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1470-0328	1471-0528		BJOG-INT J OBSTET GY	BJOG	JUL	2005	112	7					927	934		10.1111/j.1471-0528.2005.00548.x			8	Obstetrics & Gynecology	Obstetrics & Gynecology	934JI	WOS:000229704700013	15957994				2020-06-30	J	Meyer, D; Tobias, JD				Meyer, D; Tobias, JD			Adverse effects following the inadvertent administration of opioids to infants and children	CLINICAL PEDIATRICS			English	Article							INTRAVENOUS MORPHINE; NALOXONE; DRUGS	Regardless of the clinical scenario in which they are administered, opioids can have adverse effects in infants and children. These adverse effects may be particularly problematic when opioids are inadvertently administered since the clinical signs and symptoms may not be readily attributed to opioids without art appropriate history. The authors present 3 clinical scenarios in which adverse effects occurred related to the inadvertent administration of opioids when: (1) acetaminophen with codeine were administered instead of acetaminophen, (2) a mother was breast-feeding while taking opioids, and (3) a fentanyl patch was placed on a superficial injury. A thorough history and physical examination combined with urine/plasma drug screening resulted in the identification of the problem and its effective therapy.	Univ Missouri, Dept Anesthesiol, Columbia, MO 65212 USA; Univ Missouri, Sch Med, Columbia, MO USA; Univ Missouri, Dept Child Hlth, Columbia, MO 65212 USA	Tobias, JD (reprint author), Univ Missouri, Dept Anesthesiol, 3W40H,1 Hosp Dr, Columbia, MO 65212 USA.						American Academy of Pediatrics Committee on Drugs, 2001, Pediatrics, V108, P776; ATKINSON HC, 1988, CLIN PHARMACOKINET, V14, P217, DOI 10.2165/00003088-198814040-00003; Barton Erik D, 2002, Prehosp Emerg Care, V6, P54, DOI 10.1080/10903120290938797; CHAY PCW, 1992, CLIN PHARMACOL THER, V51, P334, DOI 10.1038/clpt.1992.30; CHOONARA IA, 1989, BRIT J CLIN PHARMACO, V28, P599, DOI 10.1111/j.1365-2125.1989.tb03548.x; Dale O, 2004, BRIT J CLIN PHARMACO, V58, P156, DOI 10.1111/j.1365-2125.2004.02116.x; GONZALEZ JP, 1988, DRUGS, V35, P192, DOI 10.2165/00003495-198835030-00002; Howard CR, 1999, CLIN PERINATOL, V26, P447; Kaplan JL, 1999, ANN EMERG MED, V34, P42, DOI 10.1016/S0196-0644(99)70270-2; LEWIS JM, 1984, AM J DIS CHILD, V138, P944, DOI 10.1001/archpedi.1984.02140480046014; LYNN AM, 1993, ANESTH ANALG, V77, P695; LYNN AM, 1987, ANESTHESIOLOGY, V66, P136, DOI 10.1097/00000542-198702000-00005; MAIO RF, 1987, ANN EMERG MED, V16, P572, DOI 10.1016/S0196-0644(87)80690-X; McCarthy J J, 2000, J Hum Lact, V16, P115, DOI 10.1177/089033440001600206; NICHOLS DG, 1993, ANESTHESIOLOGY, V79, P733; OLKKOLA KT, 1988, CLIN PHARMACOL THER, V44, P128, DOI 10.1038/clpt.1988.127; OSBORNE R, 1990, CLIN PHARMACOL THER, V47, P12, DOI 10.1038/clpt.1990.2; SMIALEK JE, 1977, JAMA-J AM MED ASSOC, V238, P2516, DOI 10.1001/jama.238.23.2516; TANDBERG D, 1982, ANN EMERG MED, V11, P443, DOI 10.1016/S0196-0644(82)80045-0; Wasiak J, 2002, MED J AUSTRALIA, V176, P495, DOI 10.5694/j.1326-5377.2002.tb04524.x; WAY WL, 1965, CLIN PHARMACOL THER, V6, P454; Williams DG, 2002, BRIT J ANAESTH, V89, P839, DOI 10.1093/bja/aef284	22	18	18	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0009-9228	1938-2707		CLIN PEDIATR	Clin. Pediatr.	JUL-AUG	2005	44	6					499	503		10.1177/000992280504400605			5	Pediatrics	Pediatrics	944QO	WOS:000230444100005	16015396				2020-06-30	J	Takizawa, D; Sato, E; Kurosaki, D; Hiraoka, H; Saito, S; Goto, F				Takizawa, D; Sato, E; Kurosaki, D; Hiraoka, H; Saito, S; Goto, F			Changes in unbound concentration of propofol during hemorrhage	CLINICAL PHARMACOLOGY & THERAPEUTICS			English	Letter							PHARMACODYNAMIC ANALYSIS; SHOCK		Gunma Univ, Grad Sch Med, Dept Anesthesiol, Maebashi, Gumma 371, Japan	Takizawa, D (reprint author), Gunma Univ, Grad Sch Med, Dept Anesthesiol, Maebashi, Gumma 371, Japan.	d-takiza@bf6.so-net.ne.jp					Hiraoka H, 2004, CLIN PHARMACOL THER, V75, P324, DOI 10.1016/j.clpt.2003.12.004; Johnson KB, 2004, ANESTHESIOLOGY, V101, P647, DOI 10.1097/00000542-200409000-00013; Johnson KB, 2003, ANESTHESIOLOGY, V99, P409, DOI 10.1097/00000542-200308000-00023	3	1	1	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0009-9236	1532-6535		CLIN PHARMACOL THER	Clin. Pharmacol. Ther.	JUL	2005	78	1					93	95		10.1016/j.clpt.2005.04.010			3	Pharmacology & Pharmacy	Pharmacology & Pharmacy	943VB	WOS:000230381700015	16003300				2020-06-30	J	Sittl, R; Nuijten, M; Nautrup, BP				Sittl, R; Nuijten, M; Nautrup, BP			Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: Results of a retrospective cohort study	CLINICAL THERAPEUTICS			English	Article; Proceedings Paper	10th Annual International Meeting of the International-Society-for-Pharmacoeconomics-and-Outcomes-Research	MAY 15-18, 2005	Washington, DC	Int Soc Pharmacoecon & Outcomes Res		analgesic; buprenorphine; tolerance; fentanyl transdermal	DOUBLE-BLIND; PHARMACOLOGICAL PROPERTIES; TERM; EFFICACY; MANAGEMENT; TOLERABILITY; MULTICENTER; MECHANISMS; TOLERANCE; MORPHINE	Background: During long-term therapy with strong oploids (step III opiolds according to the World Health Organization [WHO] analgesic ladder), dose increases are often necessary because of deterioration of the primary disease or development of tolerance. Objective: The purpose of this study was to compare changes in dosages of transdermal (TD) fentanyl and TD buprenorphine in patients with cancer and noncancer pain. Methods: In a retrospective study, patients with cancer and noricancer pain being treated with TD fentanyl or TD buprenorphine for at least 3 months between January 2001 and December 2003 were identified from the IMS Disease Analyzer-mediplus database, which contains all patient-related data documented from 400 medical practices in Germany. The indications for treatment were defined according to the International Classification of Diseases, 10th Revision, and included neoplasm (cancer groups), and osteoarthritis, low back pain, and osteoporosis (noncancer groups). The cohort patients were considered to have comparable pain intensity because they had received similar analgesic premedication classified according to steps I to III of the WHO analgesic ladder (cohort groups). The mean prescribed daily doses on first and last prescription were documented, and the mean percentile increases were calculated over the whole treatment duration and per day. Additionally, the mean percentile intraindividual increases (on a per-patient basis) were estimated. Results: The cohort groups consisted of 448 patients with noncancer pain and 446 patients with cancer pain (552 women and 342 men; mean age, 74 years; range, 25-101 years). The mean percentile increases in dosages over the whole treatment duration and adjusted per day were significantly higher in patients taking TD fentanyl (P < 0.05). Differences were even greater for the mean percentile intraindividual increases per day, which totaled 0.42% and 0.17% for cancer patients taking TD fentanyl and TD buprenorphine, respectively; corresponding values were 0.25% and 0.09% in noncancer patients (P < 0.001). Conclusions: This retrospective analysis showed a significantly higher increase in the mean daily doses of TD fentanyl as compared with TD buprenorphine. The results must be verified in prospective, randomized clinical studies.	Univ Erlangen Nurnberg, Pain Clin, Erlangen, Germany; MEDTAP Int, Amsterdam, Netherlands; Gruenenthal GMBH, Aachen, Germany	Nautrup, BP (reprint author), Univ Erlangen Nurnberg, Pain Clin, Erlangen, Germany.	barbara.poulsen-nautrup@grunenthal.de					Ackerman Stacey J, 2003, J Manag Care Pharm, V9, P223; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; ARMITAGE P, 1994, STAT METHODS MED RES; Bailey CP, 2005, CURR OPIN PHARMACOL, V5, P60, DOI 10.1016/j.coph.2004.08.012; Bohme K, 2003, PAIN CLINIC, V15, P193, DOI 10.1163/156856903321579334; Dietlein G, 2002, INT J CLIN PHARM TH, V40, P130; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; *EUR PHARM MARK RE, 2004, AN CLASS SYST; FINCO G, 1995, CHIR ITAL, V74, P20; Freye E, 2003, ANASTH INTENSIV NOTF, V38, P14, DOI 10.1055/s-2003-36558; HEEL RC, 1979, DRUGS, V17, P81, DOI 10.2165/00003495-197917020-00001; Hsu M M, 2000, Acta Anaesthesiol Sin, V38, P155; *JANSS PHARM PROD, 2001, DUR PACK INS; Korte W, 1996, J PAIN SYMPTOM MANAG, V11, P139, DOI 10.1016/0885-3924(95)00162-X; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; Milligan K, 2001, J PAIN, V2, P197, DOI 10.1054/jpai.2001.25352; Motheral B, 2003, VALUE HEALTH, V6, P90, DOI 10.1046/j.1524-4733.2003.00242.x; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Mystakidou K, 2003, INT J CANCER, V107, P486, DOI 10.1002/ijc.11416; Mystakidou K, 2003, J PAIN, V4, P298, DOI 10.1016/S1526-5900(03)00632-1; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; Radbruch L, 2001, PALLIATIVE MED, V15, P309, DOI 10.1191/026921601678320296; Robinson SE, 2002, CNS DRUG REV, V8, P377; SCHUG SA, 1991, DRUGS, V42, P228, DOI 10.2165/00003495-199142020-00005; Sittl R, 2005, CLIN THER, V27, P225, DOI 10.1016/j.clinthera.2005.02.012; Sittl R, 2003, CLIN THER, V25, P150, DOI 10.1016/S0149-2918(03)90019-1; Sorge J, 2004, CLIN THER, V26, P1808, DOI 10.1016/j.clinthera.2004.11.008; World Health Organization, 1990, CANC PAIN REL PALL C; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M; 2003, INT STAT CLASSIFICAT; 2003, TRANSTEC SUMMARY PRO	31	15	15	0	2	ELSEVIER	BRIDGEWATER	685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA	0149-2918	1879-114X		CLIN THER	Clin. Ther.	JUL	2005	27	7					1022	1031		10.1016/j.clinthera.2005.06.024			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	955UV	WOS:000231254000005	16154481				2020-06-30	J	Sen, S; Ozmert, G; Aydin, ON; Baran, N; Caliskan, E				Sen, S; Ozmert, G; Aydin, ON; Baran, N; Caliskan, E			The persisting analgesic effect of low-dose intravenous ketamine after spinal anaesthesia for Caesarean section	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthesia, conduction; anaesthesia, spinal; anaesthetics local, bupivacaine; anaesthetics intravenous, ketamine; analgesics opioid, fentanyl; anaesthesia obstetrical; pain, postoperative	PREEMPTIVE ANALGESIA; POSTOPERATIVE PAIN; ABDOMINAL-SURGERY; FENTANYL; TONSILLECTOMY; MANAGEMENT; MORPHINE	Background and objectives: To compare the analgesic effects of intrathecal fentanyl and low-dose intravenous ketamine as adjuvants to intrathecal bupivacaine for Caesarean section. Methods: Ninety elective Caesarean section patients were randomized into three groups. Spinal anaesthesia was performed with 15 mg hyperbaric bupivacaine in all groups. Ketamine (0.15 mg kg(-1)) or an equal volume of normal saline was given intravenously immediately after initiating spinal anaesthesia in the ketamine and control group, respectively. In the fentanyl group, 10 mu g fentanyl was added to the intrathecal bupivacaine. Arterial pressures, heart rate values, adverse effects, the time of first request for postoperative analgesia, visual analogue pain scores, total analgesic consumptions at 24 and 48 h were recorded in all patients. Results: The time to first request for analgesia was significantly longer in the ketamine (197 min) and fentanyl (165 min) groups compared to the control group (144 min). Postoperative pain scores were significantly lower in the ketamine group than in both other groups. Although the analgesic requirements during first 24 h were significantly lower in the ketamine group, there was no significant difference between the groups during the following 24 h. Conclusion: Intravenous low-dose ketamine combined with intrathecal bupivacaine for Caesarean section provides longer postoperative analgesia and lower postoperative analgesic consumption than bupivacaine alone suggesting a pre-emptive effect.	Adnan Menderes Univ, Fac Med, Dept Anaesthesiol & Reanimat, TR-09100 Aydin, Turkey; SSK Ankara Matern & Womens Hlth Teaching Hosp, Dept Anaesthesiol, Etlik, Turkey; Adnan Menderes Univ, Dept Anaesthesiol & Reanimat Algol, TR-09100 Aydin, Turkey; SSK Ankara Matern & Womens Hlth Teaching Hosp, Dept Gynecol & Obstet, Ankara, Turkey	Sen, S (reprint author), Adnan Menderes Univ, Fac Med, Dept Anaesthesiol & Reanimat, 1976 Sokal,2-10, TR-09100 Aydin, Turkey.	drseldasen@yahoo.com					Ben-David B, 2002, ANESTH ANALG, V95, P1596, DOI 10.1097/00000539-200212000-00023; De Kock M, 2001, PAIN, V92, P373, DOI 10.1016/S0304-3959(01)00278-0; Elia N, 2005, PAIN, V113, P61, DOI 10.1016/j.pain.2004.09.036; Fu ES, 1997, ANESTH ANALG, V84, P1086, DOI 10.1097/00000539-199705000-00024; Guillou N, 2003, ANESTH ANALG, V97, P843, DOI 10.1213/01.ANE.0000075837.67275.36; Gupta A, 2003, ACTA ANAESTH SCAND, V47, P13, DOI 10.1034/j.1399-6576.2003.470103.x; Himmelseher S, 2005, ANESTHESIOLOGY, V102, P211, DOI 10.1097/00000542-200501000-00030; Hirota K, 1996, BRIT J ANAESTH, V77, P441, DOI 10.1093/bja/77.4.441; Kararmaz A, 2003, ACTA ANAESTH SCAND, V47, P1096, DOI 10.1034/j.1399-6576.2003.00231.x; Kaube H, 2000, NEUROLOGY, V55, P139, DOI 10.1212/WNL.55.1.139; Kawamata T, 2000, ANESTHESIOLOGY, V93, P520, DOI 10.1097/00000542-200008000-00032; Kelly DJ, 2001, CAN J ANAESTH, V48, P1000, DOI 10.1007/BF03016591; Kissin I, 2000, ANESTHESIOLOGY, V93, P1138, DOI 10.1097/00000542-200010000-00040; Kohrs R, 1998, ANESTH ANALG, V87, P1186, DOI 10.1097/00000539-199811000-00039; Lee I O, 2001, Acta Anaesthesiol Sin, V39, P123; Marcus RJ, 2000, BRIT J ANAESTH, V84, P739; Meininger D, 2003, ANESTH ANALG, V96, P852, DOI 10.1213/01.ANE.0000049685.38809.7E; POCKETT S, 1995, ANESTH ANALG, V80, P173, DOI 10.1097/00000539-199501000-00026; Podder S, 2000, EUR J ANAESTH, V17, P319, DOI 10.1046/j.1365-2346.2000.00680.x; Roffey P, 2001, HEADACHE, V41, P733, DOI 10.1046/j.1526-4610.2001.041007733.x; Schmid RL, 1999, PAIN, V82, P111, DOI 10.1016/S0304-3959(99)00044-5; TVERSKOY M, 1994, ANESTH ANALG, V78, P205, DOI 10.1213/00000539-199402000-00002; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; Xie H, 2003, CLIN J PAIN, V19, P317, DOI 10.1097/00002508-200309000-00006	24	22	24	0	2	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	JUL	2005	22	7					518	523		10.1017/S026502150500089X			6	Anesthesiology	Anesthesiology	948HP	WOS:000230707000007	16045141				2020-06-30	J	Wiebe, ER; Trouton, KJ; Savoy, E				Wiebe, ER; Trouton, KJ; Savoy, E			Intra-cervical versus i.v. fentanyl for abortion	HUMAN REPRODUCTION			English	Article						abortion; fentanyl; pain; paracervical block; randomized controlled trial	PAIN; ANESTHESIA	BACKGROUND: The majority of abortions are performed using a para-cervical block (without general anaesthesia) and involve a significant amount of pain. If fentanyl was given with the lidocaine in the para-cervical block, it potentially could improve pain control while decreasing side effects and avoiding i.v. access for women having abortions. METHODS: This was a randomized double-blind placebo-controlled trial of two treatment arms: (i) para-cervical block with 100 mu g of fentanyl i.v; or (ii) para-cervical block with 100 mu g of fentanyl intra-cervically (i.c.) for first trimester abortion. The setting was a free-standing urban abortion clinic. The outcome measures were pain scores and side effects. RESULTS: A total of 104 women received the fentanyl i.v. and 98 received the fentanyl i.c. The two groups were similar with respect to age, gestational age, obstetric history, anxiety and depression. Pain scores (0-10) were 4.7 and 5.7 for dilation (P = 0.01) and 3.8 and 5.6 for suctioning (P < 0.001) in the i.v. and i.c. groups, respectively. Side effects were similar, but more women in the i.v. group received anti-emetics. More women in the i.c. group were dissatisfied with the pain control. CONCLUSION: I.v. fentanyl is more effective than i.c. fentanyl for pain control in abortion.	Univ British Columbia, Dept Family Practice, Vancouver, BC V5Z 1M9, Canada	Wiebe, ER (reprint author), 1013-750 W Broadway, Vancouver, BC V5Z 1H9, Canada.	ellenwiebe@telus.net					BELANGER E, 1989, PAIN, V36, P339, DOI 10.1016/0304-3959(89)90094-8; Borgatta L, 1997, J REPROD MED, V42, P287; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; Glantz JC, 2001, INT J GYNECOL OBSTET, V72, P171, DOI 10.1016/S0020-7292(00)00292-7; Jensen MP, 1998, CLIN J PAIN, V14, P343, DOI 10.1097/00002508-199812000-00012; Karakaya D, 2001, REGION ANESTH PAIN M, V26, P434, DOI 10.1053/rapm.2001.24675; Lichtenberg ES, 2001, CONTRACEPTION, V64, P345, DOI 10.1016/S0010-7824(01)00279-7; Rawling MJ, 2001, AM J OBSTET GYNECOL, V185, P103, DOI 10.1067/mob.2001.115860; Todd KH, 1996, ANN EMERG MED, V27, P485, DOI 10.1016/S0196-0644(96)70238-X; Todd KH, 1996, ACAD EMERG MED, V3, P142, DOI 10.1111/j.1553-2712.1996.tb03402.x; TUCKER N, 1993, CAN J OPHTHALMOL, V28, P167; Wiebe E, 2003, CONTRACEPTION, V67, P219, DOI 10.1016/S0010-7824(02)00516-4; WIEBE ER, 1992, AM J OBSTET GYNECOL, V167, P131, DOI 10.1016/S0002-9378(11)91645-7; Wiebe ER, 1996, INT J GYNECOL OBSTET, V55, P71, DOI 10.1016/0020-7292(96)02689-6; WIEBE ER, 1995, INT J GYNECOL OBSTET, V50, P41, DOI 10.1016/0020-7292(95)02416-A	15	6	7	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0268-1161	1460-2350		HUM REPROD	Hum. Reprod.	JUL	2005	20	7					2025	2028		10.1093/humrep/deh892			4	Obstetrics & Gynecology; Reproductive Biology	Obstetrics & Gynecology; Reproductive Biology	943NA	WOS:000230359600042	15831513	Bronze			2020-06-30	J	Gaiser, RR; McHugh, M; Cheek, TG; Gutsche, BB				Gaiser, RR; McHugh, M; Cheek, TG; Gutsche, BB			Predicting prolonged fetal heart rate deceleration following intrathecal fentanyl/bupivacaine	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						combined spinal-epidural; fetal heart rate; prolonged fetal heart rate deceleration; intrathecal opioid	LABOR ANALGESIA; BRADYCARDIA; SUFENTANIL; OPIOIDS	Background: Intrathecal opioids for labor analgesia are occasionally associated with fetal heart rate abnormalities. We wanted to identify risk factors for this occurrence. Methods: The fetal tracings of 151 consecutive patients were reviewed for the period including 30 min before and 60 min after combined spinal-epidural analgesia using intrathecal bupivacaine with fentanyl. Their progress of labor at injection was also recorded. Results: Lack of fetal head engagement (odds ratio 5.5, 95% Cl 2.1-14.2) and the presence of variable fetal heart rate decelerations (odds ratio 3.6, 95% Cl 1.6-8.4) were associated with prolonged fetal heart rate deceleration after combined spinal-epidural analgesia. Conclusion: This case-control study suggests that if the fetal head is not engaged or if the fetus is experiencing variable decelerations, there is an increased risk of prolonged fetal heart rate deceleration following intrathecal fentanyl/bupivacaine. This finding must now be confirmed in a cohort study. (c) 2005 Elsevier Ltd. All rights reserved.	Hosp Univ Penn, Dept Anesthesia, Philadelphia, PA 19104 USA	Gaiser, RR (reprint author), Hosp Univ Penn, Dept Anesthesia, 3400 Spruce St, Philadelphia, PA 19104 USA.	gaiserr@uphs.upenn.edu					BALL RH, 1992, AM J OBSTET GYNECOL, V166, P1683, DOI 10.1016/0002-9378(92)91557-Q; CLARKE VT, 1994, ANESTHESIOLOGY, V81, P1083, DOI 10.1097/00000542-199410000-00041; COHEN SE, 1993, ANESTH ANALG, V77, P1155; GARITE TJ, 2002, GABBE OBSTETRICS NOR, P413; Gramellini D, 2003, J Matern Fetal Neonatal Med, V14, P291, DOI 10.1080/713606706; Mardirosoff C, 2002, BJOG-INT J OBSTET GY, V109, P274, DOI 10.1016/S1470-0328(02)01380-0; Nielsen PE, 1996, ANESTH ANALG, V83, P742, DOI 10.1097/00000539-199610000-00014; Norris MC, 2000, INT J OBSTET ANESTH, V9, P264, DOI 10.1054/ijoa.2000.0746; Parer JT, 1997, AM J OBSTET GYNECOL, V177, P1385; Van de Velde M, 2004, ANESTH ANALG, V98, P1153, DOI 10.1213/01.ANE.0000101980.34587.66	10	15	15	0	1	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JUL	2005	14	3					208	211		10.1016/j.ijoa.2004.12.010			4	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	951FV	WOS:000230915700005	15935647				2020-06-30	J	Christelis, N; Harrad, J; Howell, PR				Christelis, N; Harrad, J; Howell, PR			A comparison of epidural ropivacaine 0.75% and bupivacaine 0.5% with fentanyl for elective caesarean section	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article; Proceedings Paper	Annual Meeting of the Obstetric-Anaesthetists-Association	MAY, 2002	NOTTINGHAM, ENGLAND	Obstetr Anaesthetist Assoc		anaesthesia, obstetrical; anaesthesia, epidural; caesarean section; anaesthesia, local : bupivacaine; anaesthesia, local : ropivacaine	PROFOUND MOTOR BLOCKADE; EXTRADURAL ANESTHESIA; REGIONAL ANESTHESIA; ANALGESIA; POTENCIES; TOXICITY; LABOR; LIDOCAINE; EFFICACY; MG	Background: Early studies suggested that ropivacaine had clinical advantages over bupivacaine with respect to cardiotoxicity and motor block, and that it was suitable for epidural caesarean section. This study was set up to compare epidural 0.75% ropivacaine with a popular bupivacaine/fentanyl mixture for elective caesarean section. Methods: Eighty women having elective caesarean section under epidural anaesthesia were randomly allocated to receive 20 mL of either 0.75% ropivacaine or 0.5% bupivacaine plus fentanyl 100 mu g. Supplementation with 2% plain lidocaine was used where necessary. Times were recorded for onset of sensory block, density and duration of motor block, and the need for supplementation. Results: There was no difference between the groups in the time (mean [SD]) to achieve sensory blockade to cold to T4 (ropivacaine 15.8 [5.61 min, bupivacaine/fentanyl 18.7 [9.11 min, P = 0.13) or to S I (ropivacaine 18.3 [4.6] min, bupivacaine/fentanyl 17.4 [7.6] min, P = 0.59), or in the need for supplementation. However, ropivacaine produced a motor block that was denser (median Bromage score ropivacaine 3, bupivacaine/fentanyl 1.5, P = 0.0041), and of longer duration (ropivacaine 237 [84] min, bupivacaine/fentanyl 144 [76] min, P < 0.0001). Conclusions: This study suggests that epidural 0.75% ropivacaine without opioid may be used as an alternative to bupivacaine 0.5% with fentanyl for elective caesarean section, but it does not induce anaesthesia any faster and may result in a denser, more prolonged, motor block. (c) 2005 Published by Elsevier Ltd.	St Marys Hosp, Dept Anaesthet, London W2 1NY, England; Cty Hosp, Hereford & Homerton Hosp, London, England	Christelis, N (reprint author), St Marys Hosp, Dept Anaesthet, Praed St, London W2 1NY, England.	nick.christelis@doctors.org.uk					Abouleish EI, 1998, BRIT J ANAESTH, V80, P843, DOI 10.1093/bja/80.6.843; ALAHUHTA S, 1995, ANESTHESIOLOGY, V83, P23, DOI 10.1097/00000542-199507000-00004; Baldwin ES, 2000, ANAESTHESIA, V55, P91, DOI 10.1046/j.1365-2044.2000.01247.x; Bjornestad E, 1999, ACTA ANAESTH SCAND, V43, P603, DOI 10.1034/j.1399-6576.1999.430602.x; Bourne TM, 1997, ANAESTHESIA, V52, P901, DOI 10.1111/j.1365-2044.1997.180-az0314.x; BROCKWAY MS, 1991, BRIT J ANAESTH, V66, P31, DOI 10.1093/bja/66.1.31; Buggy DJ, 2000, BRIT J ANAESTH, V85, P468, DOI 10.1093/bja/85.3.468; Buggy DJ, 1999, ANAESTHESIA, V54, P895; Capogna G, 1999, BRIT J ANAESTH, V82, P371, DOI 10.1093/bja/82.3.371; Crosby E, 1998, CAN J ANAESTH, V45, P1066, DOI 10.1007/BF03012393; DATTA S, 1995, ANESTHESIOLOGY, V82, P1346, DOI 10.1097/00000542-199506000-00004; GRIFFIN RP, 1995, BRIT J ANAESTH, V74, P512, DOI 10.1093/bja/74.5.512; Howell PR, 1999, INT J OBSTET ANESTH, V8, P30, DOI 10.1016/S0959-289X(99)80149-6; Irestedt L, 1997, ACTA ANAESTH SCAND, V41, P1149, DOI 10.1111/j.1399-6576.1997.tb04857.x; Knudsen K, 1997, BRIT J ANAESTH, V78, P507; Lacassie HJ, 2002, ANESTH ANALG, V95, P204, DOI 10.1097/00000539-200207000-00036; MORRISON LMM, 1994, BRIT J ANAESTH, V72, P164, DOI 10.1093/bja/72.2.164; Morton CPJ, 1997, BRIT J ANAESTH, V79, P3; Muller M, 2001, BRIT J ANAESTH, V87, P784, DOI 10.1093/bja/87.5.784; NANCARROW C, 1989, ANESTH ANALG, V69, P276; PITKANEN M, 1992, REGION ANESTH, V17, P183; Plowman AN, 1998, ANAESTH INTENS CARE, V26, P204, DOI 10.1177/0310057X9802600214; Polley LS, 1999, ANESTHESIOLOGY, V90, P944, DOI 10.1097/00000542-199904000-00003; Ruetsch YA, 1999, ANESTHESIOLOGY, V90, P1784, DOI 10.1097/00000542-199906000-00040; Russell IF, 1998, ANAESTHESIA, V53, P93; Santos AC, 2001, ANESTHESIOLOGY, V95, P1256, DOI 10.1097/00000542-200111000-00033; SCOTT DB, 1989, ANESTH ANALG, V69, P563, DOI 10.1213/00000539-198911000-00003; Shibli KU, 2000, INT J OBSTET ANESTH, V9, P160, DOI 10.1054/ijoa.1999.0382; VENEZIANI A, 2000, WORLD C AN MONTR	29	8	9	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JUL	2005	14	3					212	218		10.1016/j.ijoa.2005.01.002			7	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	951FV	WOS:000230915700006	15935650				2020-06-30	J	Romans, CW; Gordon, WJ; Robinson, DA; Evans, R; Conzemius, MG				Romans, CW; Gordon, WJ; Robinson, DA; Evans, R; Conzemius, MG			Effect of postoperative analgesic protocol on limb function following onychectomy in cats	JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION			English	Article; Proceedings Paper	31st Annual Conference of the Veterinary-Orthopedic-Society	FEB 22-27, 2004	Big Sky, MT	Vet Orthoped Soc			TRANSDERMAL FENTANYL PATCH; CATECHOLAMINE RESPONSE; FELINE ONYCHECTOMY; PAIN MANAGEMENT; GAIT ANALYSIS; DOGS; BUPIVACAINE; BUTORPHANOL; PLATFORM	Objective-To evaluate the analgesic effects of topical administration of bupivacaine, IM administration of butorphanol, and transdermal administration of fentanyl in cats undergoing onychectomy. Design-Prospective study. Animals-27 healthy adult cats. Procedure-Cats were randomly assigned to 1 of 3 treatment groups, and unilateral (left forefoot) onychectomy was performed. Gait analysis was performed before and 1, 2, 3, and 12 days after surgery. All forces were expressed as a percentage of the cat's body weight. Results-On day 2, peak vertical force (PVF) was significantly decreased in cats treated with bupivacaine, compared with cats treated with butorphanol or fentanyl. The ratio of left forelimb PVF to PVF of the other 3 limbs was significantly lower on day 2 in cats treated with bupivacaine than in cats treated with fentanyl. No significant differences in vertical impulse (VI) were found between groups on any day. Values for PVF VI, and the PVF ratio increased progressively following surgery. However, for all 3 groups, values were still significantly decreased, compared with baseline values, 12 days after surgery. Conclusions and Clinical Relevance-Results suggest that limb function following onychectomy is significantly better in cats treated with fentanyl transdermally or butorphanol IM than in cats treated with bupivacaine topically. Regardless of the analgesic regimen, limb function was still significantly reduced 12 days after surgery, suggesting that long-term analgesic treatment should be considered for cats undergoing onychectomy. Irrigation of the surgical incisions with bupivacaine prior to wound closure cannot be recommended as the sole method for providing postoperative analgesia in cats undergoing onychectomy.	Iowa State Univ, Dept Vet Clin Sci, Ames, IA 50011 USA; Iowa State Univ, Dept Vet Clin Sci, Ames, IA 50011 USA; Iowa State Univ, Dept Vet Diagnost, Ames, IA 50011 USA; Iowa State Univ, Dept Prod Anim Med, Coll Vet Med, Ames, IA 50011 USA	Conzemius, MG (reprint author), Iowa State Univ, Dept Vet Clin Sci, Ames, IA 50011 USA.			Robinson, Duane/0000-0002-3602-7032			Ansah OB, 2002, VET SURG, V31, P99, DOI 10.1053/jvet.2002.31047; BENSON GJ, 1991, VET SURG, V20, P222, DOI 10.1111/j.1532-950X.1991.tb00340.x; Besancon MF, 2003, VET COMP ORTHOPAED, V16, P153; Buback JL, 1996, VET SURG, V25, P380, DOI 10.1111/j.1532-950X.1996.tb01431.x; Cambridge AJ, 2000, J AM VET MED ASSOC, V217, P685, DOI 10.2460/javma.2000.217.685; Carroll GL, 1998, J AM VET MED ASSOC, V213, P246; Conzemius MG, 1997, J AM VET MED ASSOC, V210, P1619; CONZEMIUS MG, 1994, VET SURG, V23, P291, DOI 10.1111/j.1532-950X.1994.tb00487.x; DeCamp CE, 1997, VET CLIN N AM-SMALL, V27, P825, DOI 10.1016/S0195-5616(97)50082-9; Franks JN, 2000, J AM VET MED ASSOC, V217, P1013, DOI 10.2460/javma.2000.217.1013; Gellasch KL, 2002, J AM VET MED ASSOC, V220, P1020, DOI 10.2460/javma.2002.220.1020; Glerum LE, 2001, VET SURG, V30, P351, DOI 10.1053/jvet.2001.24387; HANSEN B, 1993, J AM VET MED ASSOC, V202, P1485; Kyles AE, 1996, AM J VET RES, V57, P715; Lamont LA, 2002, VET CLIN N AM-SMALL, V32, P747, DOI 10.1016/S0195-5616(02)00028-1; Lascelles BDX, 1999, VET REC, V145, P601, DOI 10.1136/vr.145.21.601; Lascelles D., 1997, In Practice, V19, P203; Lee DD, 2000, AM J VET RES, V61, P672, DOI 10.2460/ajvr.2000.61.672; LIN HC, 1993, AM J VET RES, V54, P1721; MARTINEZ SA, 1993, VET MED-US, V88, P516; Mison MB, 2002, J AM VET MED ASSOC, V221, P651, DOI 10.2460/javma.2002.221.651; Romans CW, 2004, AM J VET RES, V65, P1276, DOI 10.2460/ajvr.2004.65.1276; Sammarco JL, 1996, VET SURG, V25, P59, DOI 10.1111/j.1532-950X.1996.tb01377.x; ScherkNixon M, 1996, J AM ANIM HOSP ASSOC, V32, P19, DOI 10.5326/15473317-32-1-19; SCOTT DW, 1980, J AM ANIM HOSP ASSOC, V16, P331; TOBIAS KS, 1994, VET SURG, V23, P274, DOI 10.1111/j.1532-950X.1994.tb00482.x; WERNER BE, 1994, COMP CONT EDUC PRACT, V16, P493; Winkler KP, 1997, J AM ANIM HOSP ASSOC, V33, P346, DOI 10.5326/15473317-33-4-346; Wright BD, 2002, CLIN TECH SMALL AN P, V17, P151, DOI 10.1053/svms.2002.36609	29	39	39	0	22	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0003-1488			JAVMA-J AM VET MED A	JAVMA-J. Am. Vet. Med. Assoc.	JUL 1	2005	227	1					89	93		10.2460/javma.2005.227.89			5	Veterinary Sciences	Veterinary Sciences	945LT	WOS:000230504700026	16013541				2020-06-30	J	Sachdeva, DK; Stadnyk, JM				Sachdeva, DK; Stadnyk, JM			Are one or two dangerous? Opioid exposure in toddlers	JOURNAL OF EMERGENCY MEDICINE			English	Article						opioid; pediatric; overdose; toxicity; narcotics	DATA-COLLECTION SYSTEM; AMERICAN-ASSOCIATION; SURVEILLANCE SYSTEM; METHADONE INTOXICATION; TRANSDERMAL FENTANYL; ACCIDENTAL INGESTION; CHILD; TRAMADOL; NARCOTICS; NALOXONE	Ingestions of opioid analgesics by children may lead to significant toxicity as a result of depression of the respiratory and central nervous systems. A review of the medical literature was performed to determine whether low doses of opioids are dangerous in the pediatric population under 6 years old. Methadone was found to be the most toxic of the opioids; doses as low as a single tablet can lead to death. All children who have ingested any amount of methadone need to be observed in an Emergency Department (ED) for at least 6 h and considered for hospital admission. Most other opioids are better tolerated in ingestions as small as one or two tablets. Based on the limited data available for these opioids, we conclude that equianalgesic doses of 5 mg/kg of codeine or greater require 4 to 6 h of observation in the ED. Data for propoxyphene and all extended-release preparations are limited; their prolonged half-lives would suggest the need for longer observation periods. All opioid ingestions leading to respiratory depression or significant central nervous system depression require admission to an intensive care unit. (c) 2005 Elsevier Inc.	Ft Washington Hosp, Emergency Dept, Ft Washington, MD 20744 USA; Georgetown Univ, Dept Emergency Med, Washington, DC USA; George Washington Univ, Dept Emergency Med, Washington, DC USA	Sachdeva, DK (reprint author), Ft Washington Hosp, Emergency Dept, 11711 Livingston Rd, Ft Washington, MD 20744 USA.						ARONOW R, 1972, J AMER MED ASSOC, V219, P321, DOI 10.1001/jama.219.3.321; BINCHY JM, 1994, BRIT MED J, V308, P1335, DOI 10.1136/bmj.308.6940.1335; Brooks DE, 1999, VET HUM TOXICOL, V41, P388; Collins JJ, 1999, J PEDIATR-US, V134, P319, DOI 10.1016/S0022-3476(99)70457-9; DIMAIO D J, 1973, Journal of Forensic Sciences, V18, P130; ECKENHOFF JE, 1960, CLIN PHARMACOL THER, V1, P483; *FACTS COMP INC, 2003, DRUG FACTS COMP, P860; Ghuran A, 2000, HEART, V83, P627, DOI 10.1136/heart.83.6.627; GUTSTEIN HB, 2001, GOODMAN GILMANS PHAR, P569; HANDAL KA, 1983, ANN EMERG MED, V12, P438, DOI 10.1016/S0196-0644(83)80343-6; Hardwick WE, 1997, SOUTH MED J, V90, P962, DOI 10.1097/00007611-199709000-00023; Hollander JE, 1999, ACAD EMERG MED, V6, P887, DOI 10.1111/j.1553-2712.1999.tb01235.x; LEE KD, 1974, CLIN PEDIATR, V13, P66, DOI 10.1177/000992287401300110; LEWIS JM, 1984, AM J DIS CHILD, V138, P944, DOI 10.1001/archpedi.1984.02140480046014; LITOVITZ T, 1985, AM J EMERG MED, V3, P423, DOI 10.1016/0735-6757(85)90203-7; Litovitz TL, 1999, AM J EMERG MED, V17, P435, DOI 10.1016/S0735-6757(99)90254-1; LITOVITZ TL, 1995, AM J EMERG MED, V13, P551, DOI 10.1016/0735-6757(95)90171-X; LITOVITZ TL, 1993, AM J EMERG MED, V11, P494, DOI 10.1016/0735-6757(93)90093-Q; LITOVITZ TL, 1992, AM J EMERG MED, V10, P452, DOI 10.1016/0735-6757(92)90075-9; LITOVITZ TL, 1986, AM J EMERG MED, V4, P427, DOI 10.1016/0735-6757(86)90220-2; LITOVITZ TL, 1994, AM J EMERG MED, V12, P546, DOI 10.1016/0735-6757(94)90276-3; LITOVITZ TL, 1991, AM J EMERG MED, V9, P461, DOI 10.1016/0735-6757(91)90216-7; LITOVITZ TL, 1990, AM J EMERG MED, V8, P394, DOI 10.1016/0735-6757(90)90234-Q; LITOVITZ TL, 1987, AM J EMERG MED, V5, P405, DOI 10.1016/0735-6757(87)90393-7; Litovitz TL, 1997, AM J EMERG MED, V15, P447, DOI 10.1016/S0735-6757(97)90193-5; Litovitz TL, 2002, AM J EMERG MED, V20, P391, DOI 10.1053/ajem.2002.34955; Litovitz TL, 1996, AM J EMERG MED, V14, P487, DOI 10.1016/S0735-6757(96)90160-6; LITOVITZ TL, 1989, AM J EMERG MED, V7, P495, DOI 10.1016/0735-6757(89)90252-0; Litovitz TL, 2001, AM J EMERG MED, V19, P337, DOI 10.1053/ajem.2001.25272; Litovitz TL, 1998, AM J EMERG MED, V16, P443, DOI 10.1016/S0735-6757(98)90000-6; LITOVITZ TL, 1988, AM J EMERG MED, V6, P479, DOI 10.1016/0735-6757(88)90252-5; Litovitz TL, 2000, AM J EMERG MED, V18, P517, DOI 10.1053/ajem.2000.9261; Marinella MA, 1997, SOUTHERN MED J, V90, P556, DOI 10.1097/00007611-199705000-00022; MCCURLEY WS, 1969, PEDIATRICS, V43, P90; MORROW PL, 1987, AM J FOREN MED PATH, V8, P60, DOI 10.1097/00000433-198703000-00014; Nelson LS, 1998, GOLDFRANKS TOXICOLOG, P975; NG B, 1993, AM J DRUG ALCOHOL AB, V19, P153, DOI 10.3109/00952999309002676; Poklis A, 1995, FORENSIC SCI INT, V76, P55, DOI 10.1016/0379-0738(95)01797-6; RAFFA RB, 1992, J PHARMACOL EXP THER, V260, P275; ROBINSON LD, 1971, J PEDIATR-US, V79, P688, DOI 10.1016/S0022-3476(71)80325-6; Sachdeva DK, 1997, AM J EMERG MED, V15, P217, DOI 10.1016/S0735-6757(97)90116-9; Schwab J, 2001, CLIN PEDIATR, V40, P119, DOI 10.1177/000992280104000212; SESSO AM, 1975, CLIN PEDIATR, V14, P388, DOI 10.1177/000992287501400411; SEY MJ, 1971, PEDIATRICS, V48, P294; Spiller HA, 1997, J TOXICOL-CLIN TOXIC, V35, P361, DOI 10.3109/15563659709043367; Sporer KA, 2001, CHEST, V120, P1628, DOI 10.1378/chest.120.5.1628; Tong TF, 2001, PEDIATR INT, V43, P517, DOI 10.1046/j.1442-200X.2001.01427.x; VELTRI JC, 1984, AM J EMERG MED, V2, P420, DOI 10.1016/0735-6757(84)90046-9; VONMUHLENDAHL KE, 1976, LANCET, V7, P303; Watson WA, 2003, AM J EMERG MED, V21, P353, DOI 10.1016/S0735-6757(03)00088-3	50	28	29	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	JUL	2005	29	1					77	84		10.1016/j.jemermed.2004.12.015			8	Emergency Medicine	Emergency Medicine	938XA	WOS:000230035500016	15961014				2020-06-30	J	Boztug, N; Bigat, Z; Ertok, E; Erman, M				Boztug, N; Bigat, Z; Ertok, E; Erman, M			Intrathecal ropivacaine versus ropivacaine plus fentanyl for out-patient arthroscopic knee surgery	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						ropivacaine; fentanyl; anaesthesia; spinal; surgery; arthroscopy	CESAREAN DELIVERY; SYSTEMIC TOXICITY; SPINAL-ANESTHESIA; CONSCIOUS DOG; BUPIVACAINE; LIDOCAINE; MORPHINE	We evaluated the effects of low-dose intrathecal ropivacaine with or without fentanyl for arthroscopic knee surgery. Fifty patients were randomized in equal groups to receive an intrathecal solution (3 ml) containing either 10 mg isobaric ropivacaine or 8 mg isobaric ropivacaine plus 25 mu g fentanyl. Complete motor blockade occurred in 22 patients (88%) in both groups. The time taken to reach sensory blockade to T-10 and total motor blockade was shorter in the ropivacainetreated group, but differences were not statistically significant. The duration of sensory and motor blockade was shorter in the ropivacaine plus fentanyl-treated group. The cephalad spread of sensory blockade was higher with ropivacaine than with ropivacaine plus fentanyl. We conclude that although 25 mu g fentanyl added to 8 mg ropivacaine provided shorter motor and sensory blockade durations than 10 mg ropivacaine alone, small doses of ropivacaine plus fentanyl can be used safely for arthroscopic knee surgery.	Akdeniz Univ, Fac Med, Dept Anaesthesiol & Reanimat, TR-07070 Antalya, Turkey	Boztug, N (reprint author), Akdeniz Univ, Fac Med, Dept Anaesthesiol & Reanimat, Dumlupinar Kampusu, TR-07070 Antalya, Turkey.	nevctlboztug@hotmail.com					BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; Buckenmaier CC, 2002, ANESTH ANALG, V95, P1253, DOI 10.1097/00000539-200211000-00028; Chung CJ, 2002, REGION ANESTH PAIN M, V27, P600, DOI 10.1053/rapm.2002.36455; De Kock M, 2001, ANESTHESIOLOGY, V94, P574, DOI 10.1097/00000542-200104000-00008; FELDMAN HS, 1991, ANESTH ANALG, V73, P373; FELDMAN HS, 1989, ANESTH ANALG, V69, P794; Gautier PE, 1999, ANESTHESIOLOGY, V91, P1239, DOI 10.1097/00000542-199911000-00013; Goel S, 2003, EUR J ANAESTH, V20, P294, DOI 10.1097/00003643-200304000-00004; Hughes D, 2001, BRIT J ANAESTH, V87, P733, DOI 10.1093/bja/87.5.733; Khaw KS, 2002, ANESTH ANALG, V94, P680, DOI 10.1097/00000539-200203000-00037; Malinovsky JM, 2000, ANESTH ANALG, V91, P1457, DOI 10.1097/00000539-200012000-00030; Ogun CO, 2003, BRIT J ANAESTH, V90, P659, DOI 10.1093/bja/aeg123; PENNING JP, 1992, ANESTHESIOLOGY, V77, P1186, DOI 10.1097/00000542-199212000-00021; VANKLEEF JW, 1994, ANESTH ANALG, V78, P1125; Wahedi W, 1996, ANAESTHESIST, V45, P737, DOI 10.1007/s001010050306; WANG C, 1993, ANESTHESIOLOGY, V79, P766, DOI 10.1097/00000542-199310000-00019	16	3	4	0	3	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0300-0605	1473-2300		J INT MED RES	J. Int. Med. Res.	JUL-AUG	2005	33	4					365	371		10.1177/147323000503300401			7	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	951DP	WOS:000230909600001	16104439				2020-06-30	J	Magni, G; Baisi, E; La Rosa, I; Imperiale, C; Fabbrini, V; Pennacchiotti, ML; Rosa, G				Magni, G; Baisi, E; La Rosa, I; Imperiale, C; Fabbrini, V; Pennacchiotti, ML; Rosa, G			No difference in emergence time and early cognitive function between sevoflurane-fentanyl and propofol-remifentanil in patients undergoing craniotomy for supratentorial intracranial surgery	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						sevoflurane; remifentanil; propofol; neuroanesthesia; neurosurgery	CEREBRAL-BLOOD-FLOW; RECOVERY; ISOFLURANE; DESFLURANE; ANESTHESIA; AUTOREGULATION	Balanced anesthesia with sevoflurane-fentanyl has been widely accepted as anesthetic management for neurosurgery. Propofol-remifentanil regimen has been successfully used in various surgical settings, but a comprehensive comparison of sevoflurane-fentanyl and propofol-remifentanil anesthesia in patients undergoing craniotomy for supratentorial intracranial surgery has not yet been done. The aim of this prospective, randomized, open-label clinical trial was to compare clinical properties of sevoflurane-fentanyl with propofol remifentanil anesthesia in patients undergoing supratentorial intracranial surgery. The primary endpoint was to compare early postoperative recovery and cognitive functions within the two groups, we also evaluated hemodynamic events, vomiting, shivering, and pain. One hundred twenty patients (64 males; age 15-75 years) were randomized to either total intravenous anesthesia (group T) or sevoflurane anesthesia (group S). Emergence and extubation times and cognitive function (Short Orientation Memory Concentration Test [SOMCT]) were compared in the two groups. Brain swelling, incidence of hypotensive and hypertensive episodes, postoperative vomiting, shivering, and pain were also analyzed. The mean emergence time (12.2 +/- 4.9 minutes for group S versus 12.3 +/- 6.1 minutes for group T; P = 0.92) and extubation time (18.2 +/- 2.3 minutes for group S versus 18.3 +/- 2.1 minutes for group T P = 0.80) were similar in the two groups. Average SOMCT scores, both 15 minutes after extubation (25.6 +/- 4.9 in group S versus 23.9 +/- 7.5 in group T; P = 0.14) and 45 minutes after extubation (27.3 +/- 2.2 in group S versus 26.0 +/- 5.1 in group T; P = 0.07) were also comparable. Brain swelling was present in seven and five patients in groups S and T, respectively (P = 0.76). Hypotension was present in 12% (group S) and 28% (group T) of patients (P = 0.02). Hypertension was present in 17% of patients in group S and 40% of patients in group T (P = 0.0046). Shivering was present in 18% and 25% of patients in groups T and S (P = 0.37). Our study demonstrates that there is no patient benefit of using total intravenous anesthesia with an ultra-short-acting opioid over the conventional balanced volatile technique in terms of recovery and cognitive functions.	Univ Roma La Sapienza, Policlin Umberto I, Dept Anesthesia & Intens Care, I-00100 Rome, Italy	Magni, G (reprint author), Univ Roma La Sapienza, Policlin Umberto I, Dept Anesthesia & Intens Care, Viale Policlin 155, I-00100 Rome, Italy.	gmagni@yahoo.com					ALEXANDER SC, 1970, ANESTHESIOLOGY, V32, P60, DOI 10.1097/00000542-197001000-00013; Basali A, 2000, ANESTHESIOLOGY, V93, P48, DOI 10.1097/00000542-200007000-00012; Bedforth NM, 2000, ANESTH ANALG, V91, P152, DOI 10.1097/00000539-200007000-00028; Bendo AA, 2001, CLIN ANESTH, P743; Chen XG, 2001, ANESTH ANALG, V93, P1489, DOI 10.1097/00000539-200112000-00029; FIESCHI C, 1968, NEUROLOGY, V18, P1166, DOI 10.1212/WNL.18.12.1166; Gauthier A, 2002, ANESTH ANALG, V95, P1384, DOI 10.1097/00000539-200211000-00052; Guy J, 1997, ANESTHESIOLOGY, V86, P514, DOI 10.1097/00000542-199703000-00002; Hogue CW, 1996, ANESTH ANALG, V83, P279, DOI 10.1097/00000539-199608000-00014; KATZMAN R, 1983, AM J PSYCHIAT, V140, P734; KURODA K, 1982, ACTA NEUROL SCAND, V66, P160, DOI 10.1111/j.1600-0404.1982.tb04513.x; Larsen B, 2000, ANESTH ANALG, V90, P168, DOI 10.1097/00000539-200001000-00035; Lerman J, 1996, ANESTHESIOLOGY, V84, P1332, DOI 10.1097/00000542-199606000-00009; Minto CF, 2000, ANESTHESIOLOGY, V92, P1603, DOI 10.1097/00000542-200006000-00017; Ozkose Z, 2001, J NEUROSURG ANESTH, V13, P296, DOI 10.1097/00008506-200110000-00003; Philip BK, 1996, ANESTH ANALG, V83, P314, DOI 10.1097/00000539-199608000-00019; Robertson MS, 1998, GEOTIMES, V43, P4; ROSA G, 1995, ACTA ANAESTH SCAND, V39, P90, DOI 10.1111/j.1399-6576.1995.tb05598.x; SKINHOJ E, 1973, LANCET, V1, P461, DOI 10.1016/S0140-6736(73)91884-9; STRANDGAARD S, 1974, CIRC RES, V34, P435, DOI 10.1161/01.RES.34.4.435; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; Talke P, 2002, ANESTH ANALG, V95, P430, DOI 10.1097/00000539-200208000-00036; Tang J, 1999, ANESTHESIOLOGY, V91, P253, DOI 10.1097/00000542-199907000-00034; THOMEE R, 1995, SCAND J REHABIL MED, V27, P145; TODD MM, 1993, ANESTHESIOLOGY, V78, P1005, DOI 10.1097/00000542-199306000-00002; Vuyk J, 1997, ANESTHESIOLOGY, V87, P1549, DOI 10.1097/00000542-199712000-00033; WIESNER G, 1994, ANAESTHESIST, V43, P587, DOI 10.1007/s001010050097	27	64	69	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JUL	2005	17	3					134	138		10.1097/01.ana.0000167447.33969.16			5	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	949HK	WOS:000230775500003	16037733				2020-06-30	J	Peng, YR; Sun, WZ; Mok, MS				Peng, YR; Sun, WZ; Mok, MS			Mini-dose titration of the transdennal fentanyl patch - A novel approach by adjusting the area of absorption	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Letter							TRANSDERMAL FENTANYL; PAIN		Natl Taiwan Univ Hosp, Taipei, Taiwan; Taipei Med Univ, Taipei, Taiwan	Peng, YR (reprint author), Natl Taiwan Univ Hosp, Taipei, Taiwan.			SUN, WEI-ZEN/0000-0001-8543-2600			Collins JJ, 1999, J PEDIATR-US, V134, P319, DOI 10.1016/S0022-3476(99)70457-9; Hardwick WE, 1997, SOUTH MED J, V90, P962, DOI 10.1097/00007611-199709000-00023; Hunt A, 2001, PALLIATIVE MED, V15, P405, DOI 10.1191/026921601680419456; *JANSS PHARM, 2004, FULL US PRESCR INF D; *JANSS PHARM, 2000, FULL US PRESCR INF D; Mercadante S, 2001, J PAIN SYMPTOM MANAG, V21, P448, DOI 10.1016/S0885-3924(01)00289-5; PENG YR, 2002, ACTA ANAESTHESIOL SI, V40, pS102	7	3	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	JUL	2005	30	1					7	8		10.1016/j.jpainsymman.2005.05.002			2	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	956VA	WOS:000231326800005	16043001	Bronze			2020-06-30	J	Morita, T; Takigawa, C; Onishi, H; Tajima, T; Tani, K; Matsubara, T; Miyoshi, I; Ikenaga, M; Akechi, T; Uchitomi, Y				Morita, T; Takigawa, C; Onishi, H; Tajima, T; Tani, K; Matsubara, T; Miyoshi, I; Ikenaga, M; Akechi, T; Uchitomi, Y		Japan Pain Rehabilitation Palliati	Opioid rotation from morphine to fentanyl in delirious cancer patients: An open-label trial	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						palliative care; delirium; opioid rotation; morphine; fentanyl; neoplasm	TRANSDERMAL FENTANYL; PALLIATIVE CARE; PAIN MANAGEMENT; SUBSTITUTION; METHADONE; INFUSION; ANALGESIA; OXYCODONE; DISTRESS; SAFE	Although recent studies suggest that opioid rotation could be an effective morphine-induced delirium, there have been no prospective studies to investigate the treatment effects of opioid rotation using fentanyl.. The primary aim of this study was to clarify the efficacy of opioid rotation from morphine to fentanyl in symptom palliation of morphine-induced delirium. Twenty-one consecutive cancer patients with morphine-induced delirium underwent opioid rotation to fentanyl. Physicians recorded the symptom severity of delirium (the Memorial Delirium Assessment Scale, MDAS), pain, and other symptoms (categorical verbal scale from 0: none to 3: severe) and the Schedule for Team Assessment Scale (STAS) (from 0: none to 4: extreme); and Performance status at the time a study enrollment and three and seven days after. Of 21 patients recruited, one patient did not complete the study. In the remaining 20 patients, morphine was substituted with transdermal fentanyl in 9 patients and Parenteral fentanyl in 11 patients. Total opioid dose increased from 64 mg oral morphine equivalent/day (Day 0) to 98 mg/day (Day 7), and the median increase in total opioid dose was 42%. Treatment success, defined as an MDAS score below 10 and pain score of 2 or less, was obtained in 13 patients on Day 3 and 18 patients on Day 7. The mean MDAS score significantly decreased from 14 (Day 0) to 6.4 and 3.6 (Days 3 and 7, respectively, P < 0.001). Pain scores significantly decreased from 2.2 (Day 0) to 1.3 and 1.1 on the categorical verbal scale (Days 3 and 7, respectively, P < 0.001); from 2.6 (Day 0) to 1.6 and 1.3 on the STAS (Days 3 and 7,,respectively, P < 0.001). Symptom scores of dry mouth, nausea, and vomiting significantly decreased, and performance status significantly improved. Opioid rotation from morphine to fentanyl may be effective in alleviating delirium and pain in cancer patients with morphine-induced delirium. (c) 2005 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.	Seirei Mikatahara Hosp, Dept Palliat & Support Care, Palliat Care Team, Shizuoka 4338558, Japan; Seirei Hosp, Shizuoka 4338558, Japan; Keiyukai Sapporo Hosp, Dept Palliat Med, Sapporo, Hokkaido, Japan; Kanagawa Canc Ctr, Dept Psychiat, Kanagawa, Japan; Miyagi Canc Ctr, Dept Palliat Med, Miyagi, Japan; Saiseikai Cent Hosp, Dept Palliat Care, Fukui, Japan; Kawasaki Social Insurance Hosp, Palliat Care Unit, Kawasaki, Kanagawa, Japan; Kure Med Ctr, Natl Hosp Organ, Kure, Japan; Yodogawa Christians Hosp, Osaka, Japan; Nagoya City Univ, Sch Med, Dept Psychiat, Nagoya, Aichi 467, Japan; Natl Canc Ctr Res Inst E, PsychoOncol Div, Kashiwa, Chiba, Japan; Natl Canc Ctr, Hosp E, Div Psychiat, Kashiwa, Chiba, Japan	Morita, T (reprint author), Seirei Mikatahara Hosp, Dept Palliat & Support Care, Palliat Care Team, 3453 Mikatahara Cho, Shizuoka 4338558, Japan.		Uchitomi, Yosuke/E-1463-2015				Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; AOKI N, 1987, RES REPORT FISCAL YE, P37; Ashby MA, 1999, MED J AUSTRALIA, V170, P68, DOI 10.5694/j.1326-5377.1999.tb126885.x; Breitbart W, 2000, ONCOLOGY-NY, V14, P695; Breitbart W, 2002, PSYCHOSOMATICS, V43, P183, DOI 10.1176/appi.psy.43.3.183; Caraceni A, 2002, J PAIN SYMPTOM MANAG, V23, P239, DOI 10.1016/S0885-3924(01)00409-2; Carson MG, 2000, PALLIATIVE MED, V14, P25, DOI 10.1191/026921600677786382; Enting RH, 2002, CANCER-AM CANCER SOC, V94, P3049, DOI 10.1002/cncr.10518; Gagnon B, 1999, SUPPORT CARE CANCER, V7, P265, DOI 10.1007/s005200050259; Hunt R, 1999, J PAIN SYMPTOM MANAG, V18, P111, DOI 10.1016/S0885-3924(99)00051-2; Kloke M, 2000, SUPPORT CARE CANCER, V8, P479, DOI 10.1007/s005200000153; Kornick CA, 2001, CANCER, V92, P3056, DOI 10.1002/1097-0142(20011215)92:12<3056::AID-CNCR10166>3.0.CO;2-H; Lawlor PG, 2000, ARCH INTERN MED, V160, P786, DOI 10.1001/archinte.160.6.786; Maddocks I, 1996, J PAIN SYMPTOM MANAG, V12, P182, DOI 10.1016/0885-3924(96)00050-4; Matsuoka Y, 2001, GEN HOSP PSYCHIAT, V23, P36, DOI 10.1016/S0163-8343(00)00121-3; McNamara P, 2002, PALLIATIVE MED, V16, P425, DOI 10.1191/0269216302pm536oa; Mercadante S, 1999, J CLIN ONCOL, V17, P3307, DOI 10.1200/JCO.1999.17.10.3307; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; Mercadante S, 2001, J CLIN ONCOL, V19, P2898, DOI 10.1200/JCO.2001.19.11.2898; MIYASHITA M, 2003, JAP J HOSPICE PALLIA, V13, P109; Morita T, 1999, SUPPORT CARE CANCER, V7, P128, DOI 10.1007/s005200050242; Morita T, 2004, PSYCHOSOMATICS, V45, P107, DOI 10.1176/appi.psy.45.2.107; Morita T, 2001, J PAIN SYMPTOM MANAG, V22, P997, DOI 10.1016/S0885-3924(01)00360-8; Morita Tatsuya, 2003, J Palliat Med, V6, P557, DOI 10.1089/109662103768253669; PAIX A, 1995, PAIN, V63, P263, DOI 10.1016/0304-3959(95)00084-6; Pereira J, 1997, CANCER-AM CANCER SOC, V79, P835; Santiago-Palma J, 2001, CANCER, V92, P1919, DOI 10.1002/1097-0142(20011001)92:7<1919::AID-CNCR1710>3.0.CO;2-G; Watanabe S, 1998, J PAIN SYMPTOM MANAG, V16, P323, DOI 10.1016/S0885-3924(98)00095-5	28	51	53	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924			J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	JUL	2005	30	1					96	103		10.1016/j.jpainsymman.2004.12.010			8	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	956VA	WOS:000231326800017	16043013	Bronze			2020-06-30	J	Bailey, PD; Rose, JB; Keswani, SG; Adzick, NS; Galinkin, JL				Bailey, PD; Rose, JB; Keswani, SG; Adzick, NS; Galinkin, JL			Does the use of fentanyl in epidural solutions for postthoracotomy pain management in neonates affect surgical outcome?	JOURNAL OF PEDIATRIC SURGERY			English	Article						congenital cystic adenomatoid malformation of the lung; epidural analgesia; surgical outcomes	REGIONAL ANESTHESIA; INFANTS; ANALGESIA; CHILDREN; INFUSIONS; SURGERY; RELIEF	Background/Purpose: Continuous epidural analgesia is routinely used to manage pain in infants undergoing resection of a congenital cystic adenomatoid malformation (CCAM) of the lung. Our aim was to determine if there is a difference in the length of stay (LOS), supplemental analgesic requirements, pain control, and the incidence of adverse respiratory events in infants receiving the 2 standard epidural solutions commonly used: bupivacaine 0.1% and bupivacaine 0.1% with fentanyl 2 to 5 mu g/mL. Methods: We retrospectively reviewed the charts of infants who received epidural infusions containing bupivacaine 0.1% (n = 18) and bupivacaine 0.1% with fentanyl 2 to 5 mu g/mL (n = 10) after CCAM resection during a 12-month period. LOS, rescue opioid, and nonopioid analgesic use, incidence of respiratory depression, and-pain scores were recorded. Results: The LOS in patients receiving fentanyl in their epidural solution was 1 day longer than those receiving plain bupivacaine(median 4 vs 3 days, respectively). Nonopioid analgesic and rescue opioid use was greater in patients who did not have fentanyl in their epidural solutions. Pain ratings were not significantly different. The incidence of respiratory depression was greater in patients receiving epidural infusions containing fentanyl (50% vs 17%, respectively). Conclusion: The addition of fentanyl to epidural infusions of bupivacaine in infants undergoing thoracotomy for resection of CLAM may prolong recovery and increase the incidence of adverse respiratory events without providing a significant analgesic benefit. (c) 2005 Elsevier Inc. All rights reserved.	Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Surg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	Galinkin, JL (reprint author), Childrens Hosp, Dept Anesthesia, TCH Box B090, Denver, CO 80218 USA.	jeffrey.galinkin@uchsc.edu					Abu-Saad HH, 1998, SEMIN PERINATOL, V22, P402, DOI 10.1016/S0146-0005(98)80056-6; BOSENBERG AT, 1988, ANESTHESIOLOGY, V69, P265; Bosenberg AT, 1998, PAEDIATR ANAESTH, V8, P479, DOI 10.1046/j.1460-9592.1998.00322.x; COTE CJ, 1995, ANESTHESIOLOGY, V82, P809, DOI 10.1097/00000542-199504000-00002; Giaufre E, 1996, ANESTH ANALG, V83, P904, DOI 10.1097/00000539-199611000-00003; Horak E, 2003, CLIN PEDIATR, V42, P251, DOI 10.1177/000992280304200309; KRECHEL SW, 1995, PAEDIATR ANAESTH, V5, P53, DOI 10.1111/j.1460-9592.1995.tb00242.x; Lemons JA, 2000, PEDIATRICS, V105, P454; Raghavendran S, 2001, ANESTH ANALG, V93, P348, DOI 10.1097/00000539-200108000-00022; RASCH DK, 1990, CAN J ANAESTH, V37, P359, DOI 10.1007/BF03005591; TOBIAS JD, 1993, CAN J ANAESTH, V40, P879, DOI 10.1007/BF03009262; TOBIAS JD, 1993, CAN J ANAESTH, V40, P1065, DOI 10.1007/BF03009478; TRUOG R, 1989, CLIN PERINATOL, V16, P61; WOLF AR, 1993, BRIT J ANAESTH, V70, P10, DOI 10.1093/bja/70.1.10; WOOD CE, 1994, CAN J ANAESTH, V41, P613, DOI 10.1007/BF03010002	15	5	5	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468	1531-5037		J PEDIATR SURG	J. Pediatr. Surg.	JUL	2005	40	7					1118	1121		10.1016/j.jpedsurg.2005.03.053			4	Pediatrics; Surgery	Pediatrics; Surgery	962JZ	WOS:000231729000010	16034755				2020-06-30	J	Storms, TN; Schumacher, J; Zagaya, N; Osborn, DA; Miller, KV; Ramsay, EC				Storms, TN; Schumacher, J; Zagaya, N; Osborn, DA; Miller, KV; Ramsay, EC			Determination and evaluation of an optimal dosage of carfentanil and xylazine for the immobilization of white-tailed deer (Odocoileus virginianus)	JOURNAL OF WILDLIFE DISEASES			English	Article						carfentanil; cervid; iteration method; Odocoileus virginianus; optimal dosage; white-tailed deer; xylazine	MEDETOMIDINE-KETAMINE; CAPTIVE REINDEER; MULE DEER; ELK; COMBINATION; NALTREXONE; NALOXONE; WAPITI; MOOSE	Using an iteration method, optimal hand-injected immobilization dosages of carfentanil/xylazine (CAR/XYL) were determined for 13 adult white-tailed deer (Odocoileus virginianus). Deer were temporarily restrained in a squeeze chute and were repeatedly immobilized one to four times at 2-5-wk intervals from December 2002 to March 2003. A fixed ratio of 1mg CAR:10 mg XYL intramuscularly was used, increasing or decreasing the dosage until the optimal dosage (defined by an induction time < 3 min and PaCO2 < 60 mmHg) was reached for each animal. Inductions were videorecorded and reviewed by observers blinded to drugs and dosages, who rated qualitative aspects of each induction. There were significant (P < 0.05) dosage-dependent decreases in induction time, time to first effect, PaO2, SaO(2), and arterial pH, and significant dosage-dependent increases in PaCO2 and quality ratings. The median optimal dosage (mOD) was 0.03 (range, 0.015-0.06) mg/kg CAR+0.3 (range, 0.15-0.6) mg/kg XYL. Induction times using the mOD were rapid (median 3.0 min [range, 1.8-10.0]), but quality ratings were considered undesirable for nine of 13 deer. Increased rectal body temperatures of 40.6 +/- 0.5 C (mean +/- SD) were noted in all deer and hyperthermia (T > 41 C) was noted in three. There was a positive correlation between body temperature and induction time (r=0.44). Heart rates significantly decreased from 5 to 15 min postinduction and remained decreased at the 20-min reading; there was occasional bradycardia. There was a significant increase in pH from 10 to 20 min postinduction, but metabolic acidemia (pH < 7.3) persisted throughout the immobilization periods for all deer. Possible hypoxemia (SaO(2) and SPO2 < 90 mmHg but PaO2 > 60 mmHg),vas present after induction, while hypercapnea (PaCO2 > 60 mmHg) did not occur. Reversal times with naltrexone and yohimbine were rapid (mean 3.7 +/- 1.5 min) and uneventful, with no evidence of renarcotization. Although the median optimal dosage produced rapid inductions, no respiratory depression, complete reversal after antagonist administration, and no renarcotization, negative attributes included elevated body temperatures, acidemia, and undesirable induction qualities.	Univ Tennessee, Dept Small Anim Clin Sci, Coll Vet Med, Knoxville, TN 37996 USA; Univ Georgia, Warnell Sch Forest Resources, Athens, GA 30602 USA	Storms, TN (reprint author), Univ Tennessee, Dept Small Anim Clin Sci, Coll Vet Med, Knoxville, TN 37996 USA.	larktim@teleport.com		Schumacher, Juergen/0000-0003-3973-7248			BAILEY PL, 1985, J WILDLIFE MANAGE, V49, P931, DOI 10.2307/3801373; CAULKETT NA, 1994, J ZOO WILDLIFE MED, V25, P376; Caulkett NA, 2000, CAN J VET RES, V64, P64; Delvaux H, 1999, J WILDLIFE DIS, V35, P38, DOI 10.7589/0090-3558-35.1.38; Haigh J. C., 1993, FARMING WAPITI RED D, P67; HAIGH JC, 1991, J ZOO WILDLIFE MED, V22, P318; HAIGH JC, 1990, J ZOO WILDLIFE MED, V21, P391; JESSUP DA, 1984, J ZOO ANIM MED, V15, P8, DOI 10.2307/20094672; KARESH WB, 1986, J ZOO WILDLIFE MED, V17, P58, DOI 10.2307/20094795; KLEIN LV, 1989, J ZOO WILDLIFE MED, V20, P139; MEULEMAN T, 1984, J WILDLIFE MANAGE, V48, P258, DOI 10.2307/3808484; Moresco A, 2001, J ZOO WILDLIFE MED, V32, P81, DOI 10.1638/1042-7260(2001)032[0081:UONTRC]2.0.CO;2; Ryeng KA, 2001, AM J VET RES, V62, P119, DOI 10.2460/ajvr.2001.62.119; Ryeng KA, 2001, AM J VET RES, V62, P406, DOI 10.2460/ajvr.2001.62.406; Schumacher J, 1997, J ZOO WILDLIFE MED, V28, P166; Schumacher J, 1997, AM J VET RES, V58, P157; SMITH IL, 1993, J AM ASS ZOO VET, P420; STANLEY TH, 1988, J WILDLIFE MANAGE, V52, P577, DOI 10.2307/3800910	18	14	14	1	12	WILDLIFE DISEASE ASSOC, INC	LAWRENCE	810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA	0090-3558	1943-3700		J WILDLIFE DIS	J. Wildl. Dis.	JUL	2005	41	3					559	568		10.7589/0090-3558-41.3.559			10	Veterinary Sciences	Veterinary Sciences	980KH	WOS:000233016900011	16244066	Bronze			2020-06-30	J	Aronoff, GM; Brennan, MJ; Pritchard, DD; Ginsberg, B				Aronoff, GM; Brennan, MJ; Pritchard, DD; Ginsberg, B			Evidence-based oral transmucosal fentanyl citrate (OTFC (R)) dosing guidelines	PAIN MEDICINE			English	Article						opioid; fentanyl; oral transmucosal; dosing; guidelines	BREAKTHROUGH CANCER PAIN; DOSE-TITRATION; PHARMACOKINETICS; MORPHINE; ABSORPTION; TRIAL	Objectives. To review the evidence for dosing and efficacy of oral transmucosal fentanyl citrate in the management of pain and produce dosing guidelines. Design. The scientific literature pertaining to oral transmucosal fentanyl citrate was reviewed, focusing upon its pharmacology and clinical experience with use in cancer and noncancer pain. Emphasis was upon published, peer-reviewed English language articles. Results. Information was crucially examined and synthesized into guidelines for use and dosing of oral transmucosal fentanyl citrate in cancer and noncancer pain. Conclusions. Oral transmucosal fentanyl citrate is a potent opioid delivery system, which, when used appropriately, is an effective treatment option for pain. Adherence to guidelines should promote its safe and efficacious use in a variety of clinical pain management settings.	Presbyterian Orthoped Hosp, Carolina Pain Associates, Charlotte, NC USA; Pain Ctr Fairfield, Fairfield, CT USA; Statesville Pain Associates, Statesville, NC USA; Duke Univ, Med Ctr, Durham, NC USA	Aronoff, GM (reprint author), Metroview Bldg,1900 Randolph Rd,Suite 606, Charlotte, NC 28207 USA.	geraldaronoffmd@msn.com					[Anonymous], 2004, PRESCR INF ACT OR TR, P1151; Bailey PL, 2003, ANESTHESIOLOGY, V99, pA967; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; CLEARY JF, 1997, AM PAIN SOC ANN M NE; Coluzzi PH, 1998, J PAIN SYMPTOM MANAG, V16, P184, DOI 10.1016/S0885-3924(98)00046-3; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; DOLLERY C, 1991, THERAPEUTIC DRUGS, V1, pF26; Egan TD, 2000, ANESTHESIOLOGY, V92, P665, DOI 10.1097/00000542-200003000-00009; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; JAFFE JH, 1996, GOODMAN GILMANS PHAR, P485; Kramer TH, 1996, CLIN PHARMACOL THER, V59, pPI13; Landy SH, 2004, HEADACHE, V44, P762, DOI 10.1111/j.1526-4610.2004.04142.x; Lee M, 2003, J PAIN SYMPTOM MANAG, V26, P743, DOI 10.1016/S0885-3924(03)00241-0; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; MAX MB, 1999, [No title captured]; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; SCHECHTER NL, 1995, PEDIATRICS, V95, P335; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; Sharar S. R., 2002, Journal of Burn Care & Rehabilitation, V23, P27, DOI 10.1097/00004630-200201000-00006; SINGER RS, 2004, PAIN CLINIC, V6, P10; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; WEINBERG DS, 1988, CLIN PHARMACOL THER, V44, P335, DOI 10.1038/clpt.1988.159; Zhang H, 2002, CLIN PHARMACOKINET, V41, P661, DOI 10.2165/00003088-200241090-00003; ZHANG H, 1996, DRUGS PHARM SCI, V74, P51	27	25	29	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	JUL-AUG	2005	6	4					305	314		10.1111/j.1526-4637.2005.00045.x			10	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	951LE	WOS:000230930900008	16083461	Bronze			2020-06-30	J	Gorelick, DA; Kim, YK; Bencherif, B; Boyd, SJ; Nelson, R; Copersino, M; Endres, CJ; Dannals, RF; Frost, JJ				Gorelick, DA; Kim, YK; Bencherif, B; Boyd, SJ; Nelson, R; Copersino, M; Endres, CJ; Dannals, RF; Frost, JJ			Imaging brain mu-opioid receptors in abstinent cocaine users: Time course and relation to cocaine craving	BIOLOGICAL PSYCHIATRY			English	Article; Proceedings Paper	23rd Collegium-Internationale-Neuro-Psychopharmacologium Congress (CINP)	JUN 23, 2002	MONTREAL, CANADA			cocaine; craving; mu-opioid receptor; PETscan; carfentanil; abstinence	MESSENGER-RNA LEVELS; NUCLEUS-ACCUMBENS; DIFFERENTIAL REGULATION; GENE-EXPRESSION; RAT CNS; BINDING; PROENKEPHALIN; STRIATUM; REGIONS; OPIATE	Background: Cocaine treatment upregulates brain mu-opioid receptors (mOR) in animals. Human data regarding this phenomenon are limited. We previously used positron emission tomography (PET) with [C-11]-carfentanil to show increased mOR binding in brain regions of 10 cocaine-dependent men after 1 and 28 days of abstinence. Methods: Regional brain mOR binding potential (BP) was measured with [C-11]carfentanil PET scanning in 17 cocaine users over 12 weeks of abstinence on a research ward and in 16 healthy control subjects. Results. Mu-opioid receptor BP was increased in the frontal, anterior cingulate, anti lateral temporal cortex after 1 day of abstinence. Mu-opioid receptor BP remained elevated in the first two regions after I week and in the anterior cingulate and anterior frontal cortex after 12 weeks. Increased binding in some regions at 1 day and 1 week was positively correlated with self-reported cocaine craving. Mu-opioid receptor BP was significantly correlated with percentage of days with cocaine use and amount of cocaine used per day of use during the 2 weeks before admission and with urine benzoylecgonine concentration at the first PET scan. Conclusions. These results suggest that chronic cocaine use influences endogenous opioid systems in the human brain and might explain mechanisms of cocaine craving and reinforcement.	Natl Inst Drug Abuse, Intramural Res Program, NIH, Dept Hlth & Human Serv, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Radiol Sci, Baltimore, MD 21205 USA	Gorelick, DA (reprint author), Natl Inst Drug Abuse, Intramural Res Program, NIH, Dept Hlth & Human Serv, 5500 Nathan Shock Dr, Baltimore, MD 21224 USA.	dgorelic@intra.nida.nih.gov			Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA-09479]		*AM PSYCH AS, 1994, [No title captured]; Ambrose LM, 2004, ANAT REC PART A, V279A, P583, DOI 10.1002/ar.a.20054; Azaryan AV, 1996, NEUROCHEM RES, V21, P1411, DOI 10.1007/BF02532382; Azaryan AV, 1996, J NEUROCHEM, V66, P443; Azaryan AV, 1998, CAN J PHYSIOL PHARM, V76, P278, DOI 10.1139/cjpp-76-3-278; Bencherif B, 2004, BIOL PSYCHIAT, V55, P255, DOI 10.1016/j.biopsych.2003.07.007; BRANCH AD, 1992, MOL BRAIN RES, V14, P231, DOI 10.1016/0169-328X(92)90178-E; CHEN JF, 1993, NEUROSCIENCE, V54, P669, DOI 10.1016/0306-4522(93)90238-B; CHEN JF, 1994, NEUROCHEM INT, V25, P355, DOI 10.1016/0197-0186(94)90143-0; CLOW DW, 1991, NEUROPSYCHOPHARMACOL, V4, P71; CLOW DW, 1991, DEV BRAIN RES, V59, P179, DOI 10.1016/0165-3806(91)90098-4; Dackis CA, 2001, J SUBST ABUSE TREAT, V21, P111, DOI 10.1016/S0740-5472(01)00192-1; Daglish MRC, 2003, EUR NEUROPSYCHOPHARM, V13, P453, DOI 10.1016/j.euroneuro.2003.08.006; Daunais JB, 1997, PHARMACOL BIOCHEM BE, V57, P471, DOI 10.1016/S0091-3057(96)00432-7; DEROGATIS LR, 1983, MANUAL CLIN PSYCHOME, V2; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI DOI 10.1002/HBM.460020402; FROST JJ, 1985, J COMPUT ASSIST TOMO, V9, P231, DOI 10.1097/00004728-198503000-00001; GEORGE SR, 1987, PEPTIDES, V8, P487, DOI 10.1016/0196-9781(87)90014-3; Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642; HAMMER RP, 1989, SYNAPSE, V3, P55, DOI 10.1002/syn.890030108; HURD YL, 1993, SYNAPSE, V13, P357, DOI 10.1002/syn.890130408; ITZHAK Y, 1993, DRUG ALCOHOL DEPEN, V33, P53, DOI 10.1016/0376-8716(93)90033-M; Kalivas PW, 2003, PSYCHOPHARMACOLOGY, V168, P44, DOI 10.1007/s00213-003-1393-2; Kilts CD, 2004, AM J PSYCHIAT, V161, P233, DOI 10.1176/appi.ajp.161.2.233; LaForge KS, 2003, BRAIN RES BULL, V59, P353, DOI 10.1016/S0361-9230(02)00927-9; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; MCLELLAN AT, 1985, J NERV MENT DIS, V173, P412, DOI 10.1097/00005053-198507000-00005; Montoya ID, 2004, CLIN PHARMACOL THER, V75, P34, DOI 10.1016/j.clpt.2003.09.004; Nikulina EM, 1999, NEUROREPORT, V10, P3015, DOI 10.1097/00001756-199909290-00026; Olive MF, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-23-j0002.2001; Oswald LM, 2004, PHYSIOL BEHAV, V81, P339, DOI 10.1016/j.physbeh.2004.02.008; Persson AI, 2004, EUR J NEUROSCI, V19, P1847, DOI 10.1111/j.1460-9568.2004.03268.x; POLLARD H, 1978, NEUROSCI LETT, V7, P295, DOI 10.1016/0304-3940(78)90216-1; Preston KL, 2002, J ANAL TOXICOL, V26, P393, DOI 10.1093/jat/26.7.393; Preston KL, 1997, ADDICTION, V92, P717, DOI 10.1046/j.1360-0443.1997.9267178.x; Przewlocka B, 1995, EUR NEUROPSYCHOPHARM, V5, P465; ROBINS LN, 1982, PSYCHOL MED, V12, P855, DOI 10.1017/S0033291700049151; Rosin A, 2003, BRAIN RES, V978, P1, DOI 10.1016/S0006-8993(03)02674-X; Rosin A, 2000, BRAIN RES, V872, P102, DOI 10.1016/S0006-8993(00)02481-1; Roth-Deri I, 2003, J NEUROCHEM, V84, P930, DOI 10.1046/j.1471-4159.2003.01584.x; Sharpe LG, 2000, SYNAPSE, V37, P292, DOI 10.1002/1098-2396(20000915)37:4<292::AID-SYN6>3.0.CO;2-V; Steiner H, 1999, NEUROSCIENCE, V88, P795, DOI 10.1016/S0306-4522(98)00241-3; Turchan J, 1999, NEUROSCIENCE, V91, P971, DOI 10.1016/S0306-4522(98)00637-X; Unterwald EM, 2001, ANN NY ACAD SCI, V937, P74; UNTERWALD EM, 1992, BRAIN RES, V584, P314, DOI 10.1016/0006-8993(92)90912-S; Unterwald EM, 2001, BRAIN RES, V900, P103, DOI 10.1016/S0006-8993(01)02269-7; UNTERWALD EM, 1994, NEUROREPORT, V5, P1613, DOI 10.1097/00001756-199408150-00018; VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210; VOLKOW ND, 1992, SYNAPSE, V11, P184, DOI 10.1002/syn.890110303; WANG CH, 1987, NEUROTOXICOL TERATOL, V9, P301, DOI 10.1016/0892-0362(87)90019-5; Werme M, 2000, EUR J NEUROSCI, V12, P2967, DOI 10.1046/j.1460-9568.2000.00147.x; Worsley KJ, 1996, HUM BRAIN MAPP, V4, P58, DOI 10.1002/(SICI)1097-0193(1996)4:1<58::AID-HBM4>3.0.CO;2-O; Yuferov V, 1999, BRAIN RES BULL, V48, P109, DOI 10.1016/S0361-9230(98)00155-5; Yuferov V, 2003, SYNAPSE, V48, P157, DOI 10.1002/syn.10198; Zubieta JK, 2000, NEUROPSYCHOPHARMACOL, V23, P326, DOI 10.1016/S0893-133X(00)00110-X; Zubieta JK, 1999, AM J PSYCHIAT, V156, P842, DOI 10.1176/ajp.156.6.842; Zubieta JK, 1996, NAT MED, V2, P1225, DOI 10.1038/nm1196-1225	57	107	112	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0006-3223	1873-2402		BIOL PSYCHIAT	Biol. Psychiatry	JUN 15	2005	57	12					1573	1582		10.1016/j.biopsych.2005.02.026			10	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	938MO	WOS:000230007700014	15953495				2020-06-30	J	Le Loet, X; Pavelka, K; Richarz, U				Le Loet, X; Pavelka, K; Richarz, U			Transdermal fentanyl for the treatment of pain caused by osteoarthritis of the knee or hip: an open, multicentre study	BMC MUSCULOSKELETAL DISORDERS			English	Article							CHRONIC NONCANCER PAIN; RELEASE ORAL MORPHINE; DOUBLE-BLIND; BACK-PAIN; EFFICACY; OPIOIDS; TRIAL; MANAGEMENT; RECOMMENDATIONS; ARTHRITIS	Background: This study was designed to evaluate the utility of transdermal fentanyl (TDF, Durogesic(R)) for the treatment of pain due to osteoarthritis (OA) of the knee or hip, which was not adequately controlled by non-opioid analgesics or weak opioids. The second part of the trial, investigating TDF in patients with rheumatoid arthritis ( RA) is reported separately. Methods: Current analgesia was optimised during a 1-week run-in. Patients then received 28 days treatment with TDF starting at 25 mu g/hr, with the option to increase the dose until adequate pain control was achieved. Metoclopramide was taken during the first week and then as needed. Results: Of the 159 patients recruited, 75 with OA knee and 44 with OA hip completed the treatment phase, 30 knee and 18 hip patients entered the one-week taper-off phase. The most frequently used maximum dose of TDF was 25 mu g/hr. The number of patients with adequate pain control increased during the run-in period from 4% to 27%, and further increased during TDF treatment to 88% on day 28. From baseline to endpoint, there were significant reductions in pain ( p < 0.001) and improvements in functioning ( p < 0.001) and physical ( p < 0.001) and mental ( p < 0.05) health. Scores for 'pain right now' decreased significantly within 24 hours of starting TDF treatment. TDF was assessed favourably and 84% of patients would recommend it for OA-related pain. Nausea and vomiting were the most common adverse events ( reported by 32% and 26% of patients respectively), despite prophylaxis with metoclopramide, which showed limited efficacy in this setting. Conclusion: TDF significantly increased pain control, and improved functioning and quality of life. Metoclopramide appeared to be of limited value in preventing nausea and vomiting; more effective anti-emetic treatment may enable more people to benefit from strong opioids such as TDF. This study suggests that four weeks is a reasonable period to test the benefit of adding TDF to improve pain control in OA patients and that discontinuing therapy in cases of limited benefit creates no major obstacles.	Janssen Cilag Med Affairs Europe Middle E & Asia, Baar, Switzerland; Hop Rouen, Ctr Hosp Univ Rouen, Rouen, France; Inst Rheumatol, Prague, Czech Republic	Richarz, U (reprint author), Janssen Cilag Med Affairs Europe Middle E & Asia, Baar, Switzerland.	Xavier.Le-Loet@chu-rouen.fr; pavelka@revma.cz; urichar1@jacch.jnj.com	Vlak, Tonko/H-4906-2017; Pavelka, Karel/E-6578-2017	Vlak, Tonko/0000-0001-5415-7124; Pavelka, Karel/0000-0003-1952-8422			Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; ALLAN L, 2005, IN PRESS SPINE; Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905; *AM PAIN SOC, 2002, GUID MAN PAIN OST RH; *ARTHR RES CAMP, 2003, FACTF ARTHR GLANC; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Bellamy N, 1996, ARTHRITIS RHEUM, V39, P357, DOI 10.1002/art.1780390302; Bierma-Zeinstra S, 1999, J RHEUMATOL, V26, P1129; Caldwell JR, 1999, J RHEUMATOL, V26, P862; Caldwell JR, 2002, J PAIN SYMPTOM MANAG, V23, P278, DOI 10.1016/S0885-3924(02)00383-4; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Creamer P, 1998, CLIN GERIATR MED, V14, P435; Dellemijn PLI, 1998, J PAIN SYMPTOM MANAG, V16, P220, DOI 10.1016/S0885-3924(98)00070-0; GILLINGS D, 1991, DRUG INF J, V25, P411, DOI DOI 10.1177/009286159102500311; Graziotti PJ, 1997, MED J AUSTRALIA, V167, P30, DOI 10.5694/j.1326-5377.1997.tb138760.x; Haddox JD, 1997, PAIN FORUM, V6, P77; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Kalso E, 2003, EUR J PAIN, V7, P381, DOI 10.1016/S1090-3801(02)00143-X; Knott L, 2000, CURR MED RES OPIN, V16, P147, DOI 10.1185/0300799009117019; LAWRENCE JS, 1966, ANN RHEUM DIS, V25, P1; Milligan K, 2001, J PAIN, V2, P197, DOI 10.1054/jpai.2001.25352; Peloso PM, 2000, J RHEUMATOL, V27, P764; Pham T, 2003, J RHEUMATOL, V30, P1648; Pinals RS, 1996, DRUGS, V52, P14, DOI 10.2165/00003495-199600523-00004; Portenoy RK, 2000, J PAIN SYMPTOM MANAG, V19, pS16; Ringe JD, 2002, RHEUMATOL INT, V22, P199, DOI 10.1007/s00296-002-0217-8; ROTH SH, 1998, RESIDENT STAFF PHYSI, V44, P31; SCHUG SA, 1991, DRUGS, V42, P228, DOI 10.2165/00003495-199142020-00005; Simpson RK, 1997, J PAIN SYMPTOM MANAG, V14, P218, DOI 10.1016/S0885-3924(97)00183-8; THEODORIDIS T, 2002, Z ORTHOP, V140, P217; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WOLHEIM FA, 1996, DRUGS, V52, P27	33	15	15	0	1	BIOMED CENTRAL LTD	LONDON	MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND	1471-2474			BMC MUSCULOSKEL DIS	BMC Musculoskelet. Disord.	JUN 15	2005	6								31	10.1186/1471-2474-6-31			10	Orthopedics; Rheumatology	Orthopedics; Rheumatology	951BF	WOS:000230903200001	15958159	DOAJ Gold, Green Published			2020-06-30	J	Roback, MG; Wathen, JE; Bajaj, L; Bothner, JP				Roback, MG; Wathen, JE; Bajaj, L; Bothner, JP			Adverse events associated with procedural sedation and analgesia in a pediatric emergency department: A comparison of common parenteral drugs	ACADEMIC EMERGENCY MEDICINE			English	Article						pediatrics; sedation; adverse events	KETAMINE SEDATION; DOUBLE-BLIND; MIDAZOLAM; CHILDREN; CONVULSIONS; TRIAL; SAFE	Objectives: To compare the frequency and severity of adverse events associated with parenteral drugs commonly used for procedural sedation and analgesia (PSA) in a pediatric emergency department. Methods: A database of consecutive patients receiving parenteral PSA was prospectively generated with the intent of monitoring safety in the emergency department. Data were logged onto a dedicated sedation sheet. A retrospective analysis was performed; comparisons were made based on sedation drugs used. Results: A total of 2,609 patients from June 1, 1996, to September 16, 2003, received PSA by emergency physicians. Patients who received PSA nonparenterally (n = 109) were excluded. A total of 2,500 patients (2,279, intravenous; 221, intramuscular) remained for analysis. Age range was 19 days to 32 years (median, 6.7 years). A total of 1,511 (60.4%) were male. Four major drug combinations were identified: ketamine alone (n = 1,492; 59.7%), ketamine/midazolam (n = 299; 12.0%), midazolam/fentanyl (n = 336; 13.4%), and midazolam alone (n = 260; 10.4%). A total of 113 patients (4.5%) received various other combinations of drugs. A total of 458 adverse events were observed in 426 patients (17%). Respiratory adverse events occurred as follows: ketamine alone, 91 patients (6.1%); ketamine/midazolam, 30 patients (10%); midazolam/fentanyl, 65 patients (19.3%); midazolam alone, 15 patients (5.8%). Vomiting occurred as follows: ketamine alone, 151 patients (10.1%); ketamine/midazolam, 16 patients (5.4%); midazolam/fentanyl, six patients (1.8%); midazolam alone, two patients (0.8%). Conclusions: Drug types used in pediatric PSA are associated with different adverse event profiles. Patients receiving ketamine with or without midazolam experienced fewer respiratory adverse events but more vomiting than the commonly used combination of midazolam and fentanyl. Adverse events may occur in any patient receiving parenteral PSA.	Univ Colorado, Sect Emergency Med, Childrens Hosp, Sch Med, Denver, CO 80218 USA	Roback, MG (reprint author), Univ Colorado, Sect Emergency Med, Childrens Hosp, Sch Med, B251,1056 E 19th Ave, Denver, CO 80218 USA.	roback.mark@tchden.org					Agrawal D, 2003, ANN EMERG MED, V42, P636, DOI 10.1016/S0196-0644(03)00516-X; BURMEISTERROTHER R, 1993, ANAESTHESIA, V48, P82; CORSSEN G, 1988, INTRAVENOUS ANESTHES, P99; Cote CJ, 2000, PEDIATRICS, V105, P805, DOI 10.1542/peds.105.4.805; Cote CJ, 2000, PEDIATRICS, V106, P633, DOI 10.1542/peds.106.4.633; DOMINO EF, 1965, CLIN PHARMACOL THER, V6, P279; Green SM, 2004, ANN EMERG MED, V44, P460, DOI 10.1016/j.annemergmed.2004.06.006; GREEN SM, 1990, ANN EMERG MED, V19, P1033, DOI 10.1016/S0196-0644(05)82569-7; Kennedy RM, 2000, ANN EMERG MED, V35, P297, DOI 10.1016/S0196-0644(00)70085-0; Kennedy RM, 1998, PEDIATRICS, V102, P956, DOI 10.1542/peds.102.4.956; KHALIL SN, 1992, ANESTHESIOLOGY, V77, P915, DOI 10.1097/00000542-199211000-00013; Newman DH, 2003, ANN EMERG MED, V42, P627, DOI 10.1016/S0196-0644(03)00446-3; OLYNYK JK, 1989, MED J AUSTRALIA, V150, P466, DOI 10.5694/j.1326-5377.1989.tb136578.x; Pena BMG, 1999, ANN EMERG MED, V34, P483, DOI 10.1016/S0196-0644(99)80050-X; Pitetti RD, 2003, ARCH PEDIAT ADOL MED, V157, P1090, DOI 10.1001/archpedi.157.11.1090; Roback MG, 2004, ANN EMERG MED, V44, P454, DOI 10.1016/j.annemergmed.2004.03.015; Sherwin TS, 2000, ANN EMERG MED, V35, P229, DOI 10.1016/S0196-0644(00)70073-4; SPLINTER WM, 1995, CAN J ANAESTH, V42, P201, DOI 10.1007/BF03010676; THOMPSON GE, 1972, ANESTHESIOLOGY, V37, P662, DOI 10.1097/00000542-197212000-00024; Wathen JE, 2000, ANN EMERG MED, V36, P579, DOI 10.1067/mem.2000.111131; WHITE PF, 1982, ANESTHESIOLOGY, V56, P119, DOI 10.1097/00000542-198202000-00007	21	99	100	0	4	HANLEY & BELFUS INC	PHILADELPHIA	210 S 13TH ST, PHILADELPHIA, PA 19107 USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	JUN	2005	12	6					508	513		10.1197/j.aem.2004.12.009			6	Emergency Medicine	Emergency Medicine	933SO	WOS:000229653400005	15930401				2020-06-30	J	Koo, PJS				Koo, PJS			Postoperative pain management with a patient-controlled transdermal delivery system for fentanyl	AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY			English	Editorial Material						absorption; fentanyl hydrochloride; lontophoresis; opiates; pain; patient-controlled analgesia; surgery; toxicity	CONTROLLED ANALGESIA; EFFICACY; PHARMACOKINETICS; MORPHINE; SAFETY	Purpose. The efficacy and safety of fentanyl hydrochloride patient-controlled transdermal system (PCTS) for management of acute postoperative pain are discussed. Summary. Fentanyl hydrochloride PCTS is a self-contained, needle-free, credit-card-sized fentanyl-delivery system that is worn on the patient's arm or chest. The system uses iontophoretic technology to actively deliver preprogrammed doses of fentanyl into the systemic circulation when activated by the patient on demand. PCTS is as safe and effective as i.v. morphine patient-controlled analgesia and superior to placebo for managing acute postoperative pain. Fentanyl absorption from PCTS is clinically insignificant when the device is not activated. This contrasts with the transdermal fentanyl patch, which delivers fentanyl continuously for 72 hours via passive absorption and is indicated only for use in the management of chronic pain. Conclusion. Fentanyl hydrochloride PCTS is a self-contained iontophoretic fentanyl-delivery system that provides patients control over pain management and consistent management of pain without analgesic peaks and troughs.	Univ Calif San Francisco, Sch Pharm, Dept Clin Pharm & Pharmaceut Serv, San Francisco, CA 94143 USA	Koo, PJS (reprint author), Univ Calif San Francisco, Sch Pharm, Dept Clin Pharm & Pharmaceut Serv, C-152,Box 062,521 Parnassus Ave, San Francisco, CA 94143 USA.	pjkoo@value.net					ABBOTT PCA, 1997, HLTH DEVICES, V26, P389; ALBERT JM, 1988, DIS COLON RECTUM, V31, P83, DOI 10.1007/BF02562633; Austrup ML, 1999, SURG CLIN N AM, V79, P253, DOI 10.1016/S0039-6109(05)70382-0; BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; Bourne Michael H, 2004, Am J Orthop (Belle Mead NJ), V33, P128; Campbell L, 1998, Br J Nurs, V7, P1364; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Chumbley GM, 1999, ANAESTHESIA, V54, P386, DOI 10.1046/j.1365-2044.1999.00836.x; Chumbley GM, 1998, ANAESTHESIA, V53, P216, DOI 10.1046/j.1365-2044.1998.00314.x; COLWELL CW, 1995, J BONE JOINT SURG AM, V77A, P726, DOI 10.2106/00004623-199505000-00009; Eade D M, 1997, Nurs Manage, V28, P38; EISENACH JC, 1988, ANESTHESIOLOGY, V68, P444, DOI 10.1097/00000542-198803000-00023; Etches RC, 1999, SURG CLIN N AM, V79, P297, DOI 10.1016/S0039-6109(05)70384-4; FERRANTE FM, 1988, ANESTH ANALG, V67, P457; FLEMING BM, 1992, J PAIN SYMPTOM MANAG, V7, P463, DOI 10.1016/0885-3924(92)90132-2; Gupta SK, 2005, CLIN PHARMACOKINET, V44, P25, DOI 10.2165/00003088-200544001-00005; Gupta SK, 1998, J CLIN PHARMACOL, V38, P951, DOI 10.1002/j.1552-4604.1998.tb04392.x; Huang N, 2001, AM J SURG, V182, P440, DOI 10.1016/S0002-9610(01)00766-8; Jacox A, 1997, PHARMACOECONOMICS, V12, P109, DOI 10.2165/00019053-199712020-00002; Jain S, 1997, Chest Surg Clin N Am, V7, P773; Kaboli P, 2003, MED CLIN N AM, V87, P77, DOI 10.1016/S0025-7125(02)00144-X; Lehmann KA, 1999, EUR SURG RES, V31, P112, DOI 10.1159/000008629; MCGRATH D, 1989, PAIN, V37, P265, DOI 10.1016/0304-3959(89)90190-5; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Pettersson PH, 2000, ACTA ANAESTH SCAND, V44, P43, DOI 10.1034/j.1399-6576.2000.440108.x; Sathyan G, 2005, CLIN PHARMACOKINET, V44, P7, DOI 10.2165/00003088-200544001-00003; Sathyan S, 2005, CLIN PHARMACOKINET, V44, P17, DOI 10.2165/00003088-200544001-00004; SINATRA RS, 2002, J AM ACAD ORTHOP SUR, V10, P117; Snell CC, 1997, J ADV NURS, V25, P681, DOI 10.1046/j.1365-2648.1997.1997025681.x; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Vicente KJ, 2003, CAN J ANAESTH, V50, P328, DOI 10.1007/BF03021027; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; VISCUSI ER, 2003, ANN M AM SOC AN SAN; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x; WHEATLEY RG, 1991, BRIT J ANAESTH, V67, P353, DOI 10.1093/bja/67.3.353; Woodhouse A, 1996, PAIN, V64, P115, DOI 10.1016/0304-3959(95)00082-8	37	15	18	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1079-2082	1535-2900		AM J HEALTH-SYST PH	Am. J. Health-Syst. Pharm.	JUN 1	2005	62	11					1171	1176		10.1093/ajhp/62.11.1171			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	931WV	WOS:000229517100012	15914877				2020-06-30	J	Lee, DKT; Wang, DP; Harsono, R; Wong, CY				Lee, DKT; Wang, DP; Harsono, R; Wong, CY			Compatibility of fentanyl citrate, ketamine hydrochloride, and droperidol in 0.9% sodium chloride injection stored in polyvinyl chloride bags	AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY			English	Article							STABILITY		Natl Def Med Ctr, Sch Pharm, Taipei, Taiwan; Kaohsiung Vet Gen Hosp, Dept Pharm, Kaohsiung, Taiwan; Kaohsiung Vet Gen Hosp, Dept Orthopaed, Kaohsiung, Taiwan; Brookdale Univ Hosp & Med Ctr, Brooklyn, NY USA	Wang, DP (reprint author), Natl Def Med Ctr, Sch Pharm, Taipei, Taiwan.	dpw@ndmctsgh.edu.tw					ILLUM L, 1982, INT J PHARM, V10, P339, DOI 10.1016/0378-5173(82)90168-5; LACKNER TE, 1983, AM J HOSP PHARM, V40, P97, DOI 10.1093/ajhp/40.1.97; Lee Derek K. T., 2003, Chinese Pharmaceutical Journal (Taipei), V55, P147; RAY JB, 1983, AM J HOSP PHARM, V40, P94, DOI 10.1093/ajhp/40.1.94; 1994, US PHARMACOPEIA, P562	5	6	6	0	2	AMER SOC HEALTH-SYSTEM PHARMACISTS	BETHESDA	7272 WISCONSIN AVE, BETHESDA, MD 20814 USA	1079-2082	1535-2900		AM J HEALTH-SYST PH	Am. J. Health-Syst. Pharm.	JUN 1	2005	62	11					1190	1192		10.1093/ajhp/62.11.1190			3	Pharmacology & Pharmacy	Pharmacology & Pharmacy	931WV	WOS:000229517100015	15914879				2020-06-30	J	Gross, ER; Peart, JN; Hsu, AK; Auchampach, JA; Gross, GJ				Gross, ER; Peart, JN; Hsu, AK; Auchampach, JA; Gross, GJ			Extending the cardioprotective window using a novel delta-opioid agonist fentanyl isothiocyanate via the PI3-kinase pathway	AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY			English	Article						delayed cardioprotection; phosphatidylinositol 3-kinase; opioids; BW373U86; postconditioning	INDUCED DELAYED CARDIOPROTECTION; ISCHEMIA-REPERFUSION INJURY; GLYCOGEN-SYNTHASE KINASE-3-BETA; PROTEIN-KINASE-C; K-ATP CHANNELS; MYOCARDIAL PROTECTION; 2ND WINDOW; LATE-PHASE; IRREVERSIBLE LIGANDS; MU-OPIATE	Selective delta-opioid agonists produce delayed cardioprotection that lasts for 24-48 h in rats; however, the maximum length of the cardioprotective window is unclear. In this study, we attempted to prolong the cardioprotective window using a unique delta-opioid agonist, fentanyl isothiocyanate (FIT), which binds irreversibly to the delta-receptor, and determined the role of the phosphatidylinositol 3-kinase (PI3K) pathway as a trigger or end effector of FIT-induced cardioprotection. Initially, male rats were administered FIT (10 mu g/kg) 10 min before hearts were subjected to 30 min of ischemia and 2 h of reperfusion followed by infarct size (IS) assessment. Acute FIT administration reduced IS when given before ischemia, 5 min before reperfusion, or 10 s after reperfusion compared with control. IS reduction also occurred following a single dose of FIT at 48, 72, 96, and 120 h after administration vs. control, with the maximum effect observed at 96 h. FIT-induced IS reduction at 96 h was completely abolished when the irreversible PI3K inhibitor wortmannin (15 mu g/kg) was given before FIT during the trigger phase; however, the effect was only partially abrogated when wortmannin was given 96 h later. These data suggest that FIT has a prolonged cardioprotective window greater than that of any previously described cardioprotective agent that requires PI3K primarily in the trigger phase but also partially, as a mediator or end effector.	Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA	Gross, GJ (reprint author), Med Coll Wisconsin, Dept Pharmacol & Toxicol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	ggross@mcw.edu			NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL-074314, HL-08311]		Baines CP, 2001, BASIC RES CARDIOL, V96, P207, DOI 10.1007/s003950170051; Baxter GF, 1997, J CARDIOVASC PHARM, V29, P631, DOI 10.1097/00005344-199705000-00011; Baxter GF, 2001, BASIC RES CARDIOL, V96, P329, DOI 10.1007/s003950170041; Benedict PE, 1999, CIRCULATION, V100, P357; Bolli R, 1998, BASIC RES CARDIOL, V93, P325, DOI 10.1007/s003950050101; Bradbury DA, 2004, FEBS LETT, V560, P30, DOI 10.1016/S0014-5793(04)00064-X; BURKE TR, 1984, J MED CHEM, V27, P1570, DOI 10.1021/jm00378a008; Chen M, 2003, BRIT J PHARMACOL, V140, P750, DOI 10.1038/sj.bjp.0705475; Ebrahim Z, 2001, AM J PHYSIOL-HEART C, V281, pH1458; Fryer RM, 2001, BASIC RES CARDIOL, V96, P136, DOI 10.1007/s003950170063; Fryer RM, 1999, CIRC RES, V84, P846; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Gross ER, 2004, CIRC RES, V94, P960, DOI 10.1161/01.RES.0000122392.33172.09; Gross ER, 2004, J PHARMACOL EXP THER, V310, P185, DOI 10.1124/jpet.103.064667; Gross ER, 2003, J MOL CELL CARDIOL, V35, P985, DOI 10.1016/S0022-2828(03)00183-4; Gross GJ, 2003, J MOL CELL CARDIOL, V35, P709, DOI 10.1016/S0022-2828(03)00135-4; Hausenloy DJ, 2004, CARDIOVASC RES, V61, P448, DOI 10.1016/j.cardiores.2003.09.024; Jonassen AK, 2001, CIRC RES, V89, P1191, DOI 10.1161/hh2401.101385; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Juhaszova M, 2004, J CLIN INVEST, V113, P1535, DOI 10.1172/JCI200419906; Kato R, 2000, BRIT J ANAESTH, V84, P204; Kato R, 2000, BRIT J ANAESTH, V84, P608, DOI 10.1093/bja/84.5.608; Kin H, 2004, CARDIOVASC RES, V62, P74, DOI 10.1016/j.cardiores.2004.01.006; Kis A, 2003, J MOL CELL CARDIOL, V35, P1063, DOI 10.1016/S0022-2828(03)00208-6; Kodani E, 2002, AM J PHYSIOL-HEART C, V283, pH1943, DOI 10.1152/ajpheart.00150.2002; Lee HY, 2004, CLIN CANCER RES, V10, P1074, DOI 10.1158/1078-0432.CCR-0833-3; Loubani M, 2004, CARDIOVASC RES, V61, P600, DOI 10.1016/j.cardiores.2003.10.013; Matsui T, 2001, CIRCULATION, V104, P330; Meng F, 1996, EUR J PHARMACOL, V311, P285, DOI 10.1016/0014-2999(96)00431-1; Miao WF, 2000, J MOL CELL CARDIOL, V32, P2397, DOI 10.1006/jmcc.2000.1283; Patel HH, 2004, LIFE SCI, V75, P129, DOI 10.1016/j.lfs.2003.10.036; Patel HH, 2003, CIRC RES, V92, P676, DOI 10.1161/01.RES.0000065167.52922.F6; Patel HH, 2002, CIRC RES, V91, P186, DOI 10.1161/01.RES.0000029085.69891.F2; Patel HH, 2001, J MOL CELL CARDIOL, V33, P1455, DOI 10.1006/jmcc.2001.1408; Rao R, 2004, J BIOL CHEM, V279, P3949, DOI 10.1074/jbc.M309325200; RICE KC, 1983, SCIENCE, V220, P314, DOI 10.1126/science.6132444; Shinmura K, 2002, AM J PHYSIOL-HEART C, V283, pH2534, DOI 10.1152/ajpheart.00209.2002; Takashi E, 1999, CIRC RES, V85, P1146; Tang QB, 2001, CANCER RES, V61, P4329; Tong HY, 2002, CIRC RES, V90, P377, DOI 10.1161/01.RES.0000012567.95445.55; Waldhoer M, 2004, ANNU REV BIOCHEM, V73, P953, DOI 10.1146/annurev.biochem.73.011303.073940; Wang Y, 2004, CIRC RES, V95, P84, DOI 10.1161/01.RES.0000133679.38825.a6; Yang XM, 2004, J MOL CELL CARDIOL, V36, P411, DOI 10.1016/j.yjmcc.2003.12.008; Zhao ZQ, 2003, AM J PHYSIOL-HEART C, V285, pH579, DOI 10.1152/ajpheart.01064.2002; Zhu JM, 1996, J BIOL CHEM, V271, P1430, DOI 10.1074/jbc.271.3.1430	45	42	45	0	7	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6135	1522-1539		AM J PHYSIOL-HEART C	Am. J. Physiol.-Heart Circul. Physiol.	JUN	2005	288	6					H2744	H2749		10.1152/ajpheart.00918.2004			6	Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease	Cardiovascular System & Cardiology; Physiology	926RI	WOS:000229139900026	15653765				2020-06-30	J	Dahan, A; Yassen, A; Bijl, H; Romberg, R; Sarton, E; Teppema, L; Olofsen, E; Danhof, M				Dahan, A; Yassen, A; Bijl, H; Romberg, R; Sarton, E; Teppema, L; Olofsen, E; Danhof, M			Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesics, opioid; complications, opioid-induced respiratory depression; complications, respiratory depression; receptors, mu-opioid; ventilation, analgesics, effects of respiration	RECEPTOR; DEPRESSANT; PHARMACOLOGY; ALFENTANIL; MORPHINE; AGONIST; MICE	Background. There is evidence from animal studies suggesting the existence of a ceiling effect for buprenorphine-induced respiratory depression. To study whether an apparent ceiling effect exists for respiratory depression induced by buprenorphine, we compared the respiratory effects of buprenorphine and fentanyl in humans and rats. Methods. In healthy volunteers, the opioids were infused i.v. over 90 s and measurements of minute ventilation at a fixed end-tidal Pco(2) of 7 kPa were obtained for 7 h. Buprenorphine doses were 0.7, 1.4, 4.3 and 8.6 &mu; g kg(-1) (n=20 subjects) and fentanyl doses 1.1, 2.1, 2.9, 4.3 and 7.1 &mu; g kg(-1) (n=21). Seven subjects received placebo. In rats, both opioids were infused i.v. over 20 min, and arterial Pco(2) was measured 5, 10, 15 and 20 min after the start of fentanyl infusion and 30, 150, 270 and 390 min after the start of buprenorphine infusion. Doses tested were buprenorphine 0, 100, 300, 1000 and 3000 &mu; g kg(-1) and fentanyl 0, 50, 68 and 90 &mu; g kg(-1). Results. In humans, fentanyl produced a dose-dependent depression of minute ventilation with apnoea at doses &GE; 2.9 &mu; g kg(-1); buprenorphine caused depression of minute ventilation which levelled off at doses &GE; 3.0 &mu; g kg(-1) to about 50% of baseline. In rats, the relationship of arterial Pco(2) and fentanyl dose was linear, with maximum respiratory depression at 20 min (maximum Pa-co2 8.0 kPa). Irrespective of the time at which measurements were obtained, buprenorphine showed a non-linear effect on Pa-co2, with a ceiling effect at doses &GT; 1.4 &mu; g kg(-1). The effect on Pa-co2 was modest (maximum value measured, 5.5 kPa). Conclusions. Our data confirm a ceiling effect of buprenorphine but not fentanyl with respect to respiratory depression.	Leiden Univ, Med Ctr, Dept Anesthesiol, Anesthesia & Pain Res Unit, NL-2300 RC Leiden, Netherlands; Leiden Amsterdam Ctr Drug Res, Div Pharmacol, Gorlaeus Lab, Leiden, Netherlands	Dahan, A (reprint author), Leiden Univ, Med Ctr, Dept Anesthesiol, Anesthesia & Pain Res Unit, P5-Q,POB 9600, NL-2300 RC Leiden, Netherlands.	a.dahan@lumc.nl	Dahan, Albert/B-8845-2008	Dahan, Albert/0000-0003-3161-3945			BOAS RA, 1985, BRIT J ANAESTH, V57, P192, DOI 10.1093/bja/57.2.192; Bouillon T, 1999, ANESTHESIOLOGY, V91, P144, DOI 10.1097/00000542-199907000-00023; BOWDLE TA, 2003, WYLIE CHURCHILLDAVID, P543; Budd K, 2003, BRIT J ANAESTH, V90, P722, DOI 10.1093/bja/aeg133; COWAN A, 1977, BRIT J PHARMACOL, V60, P547, DOI 10.1111/j.1476-5381.1977.tb07533.x; Cowan Alan, 1995, P31; Dahan A, 2001, ANESTHESIOLOGY, V94, P824, DOI 10.1097/00000542-200105000-00021; DAHAN A, 1990, J PHYSIOL-LONDON, V428, P485, DOI 10.1113/jphysiol.1990.sp018223; Dahan A, 2004, ANESTHESIOLOGY, V101, P1201, DOI 10.1097/00000542-200411000-00021; DOXEY JC, 1982, BRIT J PHARMACOL, V75, pP118; Evans HC, 2003, DRUGS, V63, P1999, DOI 10.2165/00003495-200363190-00003; Johnson R E, 2000, Curr Psychiatry Rep, V2, P519, DOI 10.1007/s11920-000-0012-8; Kishioka S, 2000, EUR J PHARMACOL, V391, P289, DOI 10.1016/S0014-2999(00)00039-X; Lutfy K, 2003, J NEUROSCI, V23, P10331; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; Mildh LH, 2001, ANESTH ANALG, V93, P939, DOI 10.1097/00000539-200110000-00028; Reynaud M, 1998, AM J PSYCHIAT, V155, P448; Romberg R, 2003, BRIT J ANAESTH, V91, P862, DOI 10.1093/bja/aeg279; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; Takita K, 2003, BRIT J ANAESTH, V91, P385, DOI 10.1093/bja/aeg191; WALSH SL, 1994, CLIN PHARMACOL THER, V55, P569, DOI 10.1038/clpt.1994.71; WALSH SL, 1995, J PHARMACOL EXP THER, V274, P361; Waters CM, 1999, J PHARMACOL EXP THER, V288, P157; WEINHOLD LL, 1992, DRUG ALCOHOL DEPEN, V30, P263, DOI 10.1016/0376-8716(92)90061-G	24	155	162	2	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	JUN	2005	94	6					825	834		10.1093/bja/aei145			10	Anesthesiology	Anesthesiology	923SX	WOS:000228930700022	15833777	Bronze			2020-06-30	J	Ng, CH; Singh, B; Kang, DSC; Yeo, JF; Fei, YJ				Ng, CH; Singh, B; Kang, DSC; Yeo, JF; Fei, YJ			Dental anaesthesia in a patient with Noonan syndrome	BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY			English	Letter									Natl Univ Singapore, Dept Oral & Maxillofacial Surg, Singapore 119260, Singapore	Fei, YJ (reprint author), Natl Univ Singapore, Dept Oral & Maxillofacial Surg, 10 Kent Ridge, Singapore 119260, Singapore.	omsyeojf@nus.edu.sg					NOONAN JA, 1963, J PEDIATR-US, V63, P468	1	0	0	0	3	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0266-4356	1532-1940		BRIT J ORAL MAX SURG	Br. J. Oral Maxillofac. Surg.	JUN	2005	43	3					267	268		10.1016/j.bjoms.2004.09.010			2	Dentistry, Oral Surgery & Medicine; Surgery	Dentistry, Oral Surgery & Medicine; Surgery	932BB	WOS:000229528100020	15888370				2020-06-30	J	Okutomi, T; Saito, M; Amano, K; Fukuoka, K; Hoka, S				Okutomi, T; Saito, M; Amano, K; Fukuoka, K; Hoka, S			Labour analgesia guided by echocardiography in a parturient with primary dilated cardiomyopathy	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							INTRATHECAL FENTANYL; CESAREAN-SECTION; SUFENTANIL; ANESTHESIA; PATIENT	Purpose: To evaluate the effects of intrathecal analgesics on cardiac function during labour analgesia using echocardiography in a parturient with idiopathic dilated cardiomyopathy (DCM). Clinical features: Induction of labour was planned in a 35-yr-old primiparous woman suffering from DCM. In order to stabilize hemodynamics in this patient, we induced continuous spinal analgesia with an infusion of fentanyl and epinephrine. Although her analgesia was well maintained for three hours during the first stage of labour, the patient complained of pain towards the second stage of labour. At this point, we administered bupivacaine intrathecally to alleviate her pain. Transthoracic echocardiography showed that the left ventricular end-diastolic and systolic dimensions, as well as the ejection fraction were not impaired by use of these analgesic medications. Conclusion: Measurement of left ventricular dimensions by echocardiography allowed us to monitor the patient's response to intrathecal analgesic medications. In this patient with DCM, analgesia with intrathecal fentanyl and bupivacaine was well tolerated.	Kitasato Univ, Dept Anesthesiol, Sch Med, Kanagawa 2288555, Japan; Kitasato Univ, Dept Obstet, Sch Med, Kanagawa 2288555, Japan; Kitasato Univ, Div Clin Lab, Sch Med, Kanagawa 2288555, Japan	Okutomi, T (reprint author), Kitasato Univ, Dept Anesthesiol, Sch Med, 1-15-1 Kitasato, Kanagawa 2288555, Japan.	toshiyukiokutomi@hotmail.com					Bernstein PS, 2001, AM J PERINAT, V18, P163, DOI 10.1055/s-2001-14525; BROMAGE PR, 1983, ANESTHESIOLOGY, V58, P257, DOI 10.1097/00000542-198303000-00010; DOI YL, 1991, AM J CARDIOL, V67, P188, DOI 10.1016/0002-9149(91)90443-O; Gaiser RR, 1998, J CLIN ANESTH, V10, P488, DOI 10.1016/S0952-8180(98)00076-2; GAMBLING DR, 1987, CAN J ANAESTH, V34, P505, DOI 10.1007/BF03014358; HONET JE, 1992, ANESTH ANALG, V75, P734; KDOI Y, 1996, MASUI, V45, P1002; KURODA T, 1989, JPN J MED, V28, P180, DOI 10.2169/internalmedicine1962.28.180; Muralidhar V, 1999, REGION ANESTH PAIN M, V24, P417; Shnaider R, 2001, CAN J ANAESTH, V48, P681, DOI 10.1007/BF03016203	10	9	10	0	1	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	JUN-JUL	2005	52	6					622	625		10.1007/BF03015773			4	Anesthesiology	Anesthesiology	947QQ	WOS:000230661600012	15983149	Bronze			2020-06-30	J	Micek, ST; Anand, NJ; Laible, BR; Shannon, WD; Kollef, MH				Micek, ST; Anand, NJ; Laible, BR; Shannon, WD; Kollef, MH			Delirium as detected by the CAM-ICU predicts restraint use among mechanically ventilated medical patients	CRITICAL CARE MEDICINE			English	Article							INTENSIVE-CARE-UNIT; CONFUSION ASSESSMENT METHOD; CRITICALLY ILL PATIENTS; SEDATION; MORTALITY; DIAGNOSIS; PROTOCOL; REMOVAL	Objective: The first goal of this investigation was to identify individuals with delirium defined by the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) among medical patients with respiratory failure. Our second goal was to compare clinical interventions including use of continuous sedation infusions, the number of ventilator-free days, ICU length of stay, hospital mortality, and use of physical restraints in mechanically ventilated patients with and without delirium. Design: A prospective, single-center, observational cohort study. Setting. The medical intensive care unit (19 beds) of an urban teaching hospital. Patients: Adult, intubated, and mechanically ventilated patients. Interventions: Daily evaluation with the CAM-ICU, outcomes assessment, and prospective data collection. Measurements and Main Results: Among 93 patients evaluated using the CAM-ICU, 44 patients (47%) developed delirium (CAM-ICU+) for >= 1 day while in the intensive care unit. Twenty-two patients (24%) had no episodes of delirium recorded (CAM-ICU-), and 27 (29%) remained comatose until extubation or death. A statistically greater number of patients with delirium (CAM-ICU+) received continuous infusions of midazolam (59% vs. 32%, p < .05) or fentanyl (57% vs. 32%, p < .05) and physical soft-limb restraints (77% vs. 50%, p < .05) compared with patients without delirium (CAM-ICU-). Conclusions: The identification of delirium using the CAM-ICU was associated with greater use of continuous sedation infusions and physical restraints. Additional studies are required to determine how the use of these specific interventions influences the occurrence and the natural history of delirium among critically ill patients.	Washington Univ, Sch Med, Div Pulm & Crit Care, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Gen Med Sci & Biostat, St Louis, MO 63110 USA; Barnes Jewish Hosp, Dept Pharm, St Louis, MO 63110 USA; S Dakota State Univ, Coll Pharm, Sioux Falls, SD USA	Kollef, MH (reprint author), Washington Univ, Sch Med, Div Pulm & Crit Care, Campus Box 8052,660 S Euclid Ave, St Louis, MO 63110 USA.	mkollef@im.wustl.edu					Bergeron N, 2002, CRIT CARE, V6, P181; Boulain T, 1998, AM J RESP CRIT CARE, V157, P1131, DOI 10.1164/ajrccm.157.4.9702083; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; BRUDER N, 1994, CRIT CARE MED, V22, P1114, DOI 10.1097/00003246-199407000-00011; Carrion MI, 2000, CRIT CARE MED, V28, P63, DOI 10.1097/00003246-200001000-00010; CARROLL Q, 1996, CLIN NURSE SPEC, V10, P220; Dolan MM, 2000, J GERONTOL A-BIOL, V55, pM527, DOI 10.1093/gerona/55.9.M527; Dubois MJ, 2001, INTENS CARE MED, V27, P1297, DOI 10.1007/s001340101017; Ely EW, 2004, CRIT CARE MED, V32, P106, DOI 10.1097/01.CCM.0000098033.94737.84; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; Ely EW, 2001, INTENS CARE MED, V27, P1892, DOI 10.1007/s00134-001-1132-2; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Ely EW, 2001, SEMIN RESP CRIT CARE, V22, P115, DOI 10.1055/s-2001-13826; Evans D, 2002, J ADV NURS, V40, P616, DOI 10.1046/j.1365-2648.2002.02422.x; Fraser GL, 2001, PHARMACOTHERAPY, V21, P1, DOI 10.1592/phco.21.1.1.34444; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; Jackson JC, 2003, CRIT CARE MED, V31, P1226, DOI 10.1097/01.CCM.0000059996.30263.94; Katz IR, 2001, AM J GERIAT PSYCHIAT, V9, P148, DOI 10.1176/appi.ajgp.9.2.148; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kollef MH, 1997, CRIT CARE MED, V25, P567, DOI 10.1097/00003246-199704000-00004; Maccioli GA, 2003, CRIT CARE MED, V31, P2665, DOI 10.1097/01.CCM.0000095463.72353.AD; MAZZEO AJ, 1995, CRIT CARE CLIN, V11, P937; Ostermann ME, 2000, JAMA-J AM MED ASSOC, V283, P1451, DOI 10.1001/jama.283.11.1451; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Reigle J, 1996, AACN Clin Issues, V7, P585, DOI 10.1097/00044067-199611000-00014; Sanders AB, 2002, ANN EMERG MED, V39, P338, DOI 10.1067/mem.2002.122273	28	86	90	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUN	2005	33	6					1260	1265		10.1097/01.CCM.0000164540.58515.BF			6	Critical Care Medicine	General & Internal Medicine	939HU	WOS:000230064100011	15942341				2020-06-30	J	Kosinski, MR; Schein, JR; Vallow, SM; Ascher, S; Hartle, C; Shikiar, R; Frank, L; Margolis, MK; Vorsanger, G				Kosinski, MR; Schein, JR; Vallow, SM; Ascher, S; Hartle, C; Shikiar, R; Frank, L; Margolis, MK; Vorsanger, G			An observational study of health-related quality of life and pain outcomes in chronic low back pain patients treated with fentanyl transdermal system	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						chronic low back pain; health related quality of life; opioid therapy	CHRONIC NONMALIGNANT PAIN; LONG-TERM TREATMENT; MAINE LUMBAR SPINE; CANCER PAIN; ORAL MORPHINE; NEUROPATHIC PAIN; SURVEY SF-36; NONSURGICAL MANAGEMENT; POSTHERPETIC NEURALGIA; RHEUMATOID-ARTHRITIS	Background: The analgesic effect of long-acting opioids, such as transdermal fentanyl, has been demonstrated in patients with cancer, neuropathic pain and chronic low back pain (CLBP). However, the broader effect of long-acting opioids on the patient's health-related quality of life (HRQoL) is less well known. Objective: To evaluate HRQoL outcomes in CLBP patients treated with transdermal fentanyl. Research design and methods: An observational study was conducted at 17 clinical centers in the US. Eligible patients had CLBP diagnosis for at least 3 months and were taking short-acting opioids chronically, and then initiated transdermal fentanyl treatment. Patients completed the Treatment Outcomes in Pain Survey (TOPS), which includes the SF-36 Health Survey, at baseline and >= 9 weeks of treatment. The HRQoL burden of CLBP was determined by comparing CLBP patients' SF-36 scores to the general US population and low back pain patient norms. HRQoL outcomes were determined by comparing baseline and follow-up TOPS and SF-36 scores. Additionally, HRQoL outcomes were evaluated across patient groups stratified by changes in pain intensity ratings as measured by an 11-point numerical rating scale. Results: At baseline CLBP patients (N = 131) scored one-to-two standard deviations (SD) below age and gender adjusted SF-36 general population norms (MANOVA F = 127.1, p < 0.0001) and significantly lower than low back pain norms (MANOVA F = 125.3, p < 0.0001). At follow-up, significant improvement (p < 0.05) was observed on six of the SF-36 scales and both SF-36 summary measures and five of the six TOPS pain-related scales. The magnitude of change in scores in effect size units among these scales ranged from 0.17 to 0.80, which are considered small to large effect size changes. HRQoL score improvement was greatest among patients experiencing the greatest pain relief. Conclusion: CLBP patients who chronically used short-acting opioids showed tremendous HRQoL burden. Favorable HRQoL outcomes were observed among patients who reported pain relief.	Janssen Med Affairs LLC, Titusville, NJ USA; QualityMetric Inc, Lincoln, RI USA; MEDTAP Int Inc, Bethesda, MD USA	Kosinski, MR (reprint author), 640 George Washington Highway, Lincoln, RI 02865 USA.	mkosinski@qualitymetric.com					Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Allan L, 2001, BRIT MED J, V322, P1; Andersson Gunnar B. J., 1997, P93; Aparasu R, 1999, J PAIN SYMPTOM MANAG, V18, P280, DOI 10.1016/S0885-3924(99)00085-8; ARKINSTALL W, 1995, PAIN, V62, P169, DOI 10.1016/0304-3959(94)00262-D; Arnold LM, 2000, J AFFECT DISORDERS, V57, P235, DOI 10.1016/S0165-0327(99)00042-7; Atlas SJ, 1996, SPINE, V21, P1787, DOI 10.1097/00007632-199608010-00012; Atlas SJ, 2001, SPINE, V26, P1179, DOI 10.1097/00007632-200105150-00017; Becker N, 1997, PAIN, V73, P393, DOI 10.1016/S0304-3959(97)00126-7; Bombardier C, 2000, SPINE, V25, P3100, DOI 10.1097/00007632-200012150-00003; Borenstein David, 1996, Current Opinion in Rheumatology, V8, P124, DOI 10.1097/00002281-199603000-00007; BORENSTEIN DG, 1994, LOW BACK PAIN MED DI; BRANCH CL, 1994, AAFP HOME STUDY SELF, P11; Bronfort G, 1999, PAIN, V83, P201, DOI 10.1016/S0304-3959(99)00103-7; CHERKIN DC, 1994, SPINE, V19, P1201, DOI 10.1097/00007632-199405310-00001; Cherkin DC, 1998, SPINE, V23, P607, DOI 10.1097/00007632-199803010-00015; Cohen J, 1988, STAT POWER ANAL BEHA; Cuijpers P, 1999, Int Psychogeriatr, V11, P445, DOI 10.1017/S1041610299006067; Dellemijn PLI, 1998, J PAIN SYMPTOM MANAG, V16, P220, DOI 10.1016/S0885-3924(98)00070-0; Dellemijn PLI, 1997, LANCET, V349, P753, DOI 10.1016/S0140-6736(96)09024-1; Deyo RA, 1998, SCI AM, V279, P48, DOI 10.1038/scientificamerican0898-48; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; Ehrich EW, 2001, AM J MANAG CARE, V7, P609; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; FRYMOYER JW, 1991, ORTHOP CLIN N AM, V22, P263; FRYMOYER JW, 1997, [No title captured]; Garratt A M, 1994, Qual Health Care, V3, P186, DOI 10.1136/qshc.3.4.186; Ghoname ESA, 1999, JAMA-J AM MED ASSOC, V281, P818, DOI 10.1001/jama.281.9.818; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Gureje O, 1998, JAMA-J AM MED ASSOC, V280, P147, DOI 10.1001/jama.280.2.147; Hacker RJ, 2000, SPINE, V25, P2646, DOI 10.1097/00007632-200010150-00017; Hagen KB, 1997, J RHEUMATOL, V24, P1703; HART LG, 1995, SPINE, V20, P11, DOI 10.1097/00007632-199501000-00003; Hashemi L, 1998, J OCCUP ENVIRON MED, V40, P1110; Hodselmans AP, 2001, ARCH PHYS MED REHAB, V82, P1099, DOI 10.1053/apmr.2001.23899; Hotelling H, 1931, ANN MATH STAT, V2, P360, DOI 10.1214/aoms/1177732979; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; *JOINT COMM ACCR H, 2000, PAIN ASS MAN ORG APP, P13; KATZ NP, 2001, 20 ANN SCI M AM PAIN; Kosinski M, 2002, AM J MANAG CARE, V8, P231; LANSKY D, 1992, MED CARE S, V30, P57; Leggett S, 1999, SPINE, V24, P889, DOI 10.1097/00007632-199905010-00010; LeidigBruckner G, 1997, J BONE MINER RES, V12, P663, DOI 10.1359/jbmr.1997.12.4.663; Linton SJ, 1998, PAIN, V75, P163; Mannix LK, 1999, HEADACHE, V39, P326, DOI 10.1046/j.1526-4610.1999.3905326.x; Mayer TG, 1988, FUNCTIONAL RESTORATI; McCarberg B H, 2001, Am J Ther, V8, P181, DOI 10.1097/00045391-200105000-00006; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; MCNAIRY SL, 1984, PAIN, V18, P169, DOI 10.1016/0304-3959(84)90884-4; Milligan K, 2001, J PAIN, V2, P197, DOI 10.1054/jpai.2001.25352; Moulin DE, 1996, LANCET, V347, P143, DOI 10.1016/S0140-6736(96)90339-6; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; POPE MH, 1990, SURG ROUNDS ORTHOP, V4, P35; Portenoy RK, 1996, PAIN RES MANAGE, V1, P17; Rogers WH, 2000, PAIN MED, V1, P55, DOI 10.1046/j.1526-4637.2000.99101.x; Rogers WH, 2000, PAIN MED, V1, P44, DOI 10.1046/j.1526-4637.2000.99102.x; Rowbotham M, 1998, JAMA-J AM MED ASSOC, V280, P1837, DOI 10.1001/jama.280.21.1837; RUDY TE, 1988, PAIN, V35, P129, DOI 10.1016/0304-3959(88)90220-5; Skevington SM, 1998, PAIN, V76, P395, DOI 10.1016/S0304-3959(98)00072-4; Stratford PW, 1996, PHYS THER, V76, P359, DOI 10.1093/ptj/76.4.359; TURK DC, 1992, HDB PAIN ASSESSMENT, P3; Ware JE, 1999, HEPATOLOGY, V30, P550, DOI 10.1002/hep.510300203; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE, 2001, SF 36 PHYS MENTAL HL; Ware JE, 1993, SF 36 HLTH SURVEY MA; Ware Jr JE, 1994, SF 36 PHYS MENTAL HL; Watson CPN, 1998, NEUROLOGY, V50, P1837; Won A, 1999, J AM GERIATR SOC, V47, P936, DOI 10.1111/j.1532-5415.1999.tb01287.x; Zhao SZ, 1999, CLIN THER, V21, P205, DOI 10.1016/S0149-2918(00)88279-X	73	31	32	0	1	LIBRAPHARM	NEWBURY	C/O DR. PETER L CLARKE, 26-32 VENTURE WEST, NEW GREENHAM PARK, NEWBURY RG19 6HX, BERKSHIRE, ENGLAND	0300-7995			CURR MED RES OPIN	Curr. Med. Res. Opin.	JUN	2005	21	6					849	862		10.1185/030079905X46377			14	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	937GH	WOS:000229912100005	15969885				2020-06-30	J	van der Zwan, T; Baerts, WDM; Perez, RSGM; de Lange, JJ				van der Zwan, T; Baerts, WDM; Perez, RSGM; de Lange, JJ			Postoperative condition after the use of remifentanil with a small dose of piritramide compared with a fentanyl-based protocol in patients undergoing craniotomy	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						pain, postoperative; analgesics opioid, remifentanil, fentanyl, piritramide; neurosurgical procedures, craniotomy	CEREBRAL-BLOOD-FLOW; SUPRATENTORIAL CRANIOTOMY; PROPOFOL ANESTHESIA; ALFENTANIL; REACTIVITY; SURGERY; LESIONS	Background and objective: The use of remifentanil requires other analgesics for postoperative pain relief compared to fentanyl in patients undergoing craniotomy. This could possibly reduce the postoperative advantages of this short-acting opioid. Methods: We compared remifentanil and fentanyl-based anaesthesia in a randomized observer and patient blinded trial on patients, undergoing an elective craniotomy. Twenty patients received anaesthesia using remifentanil with a small dose of piritramide (0.1 mg kg(-1)) after closure of the dura mater. Twenty patients underwent a fentanyl-based protocol. In both groups, anaesthesia was induced with thiopental and rocuronium, and maintained with 0.6-1 minimum alveolar concentration (MAC) isoflurane in a nitrous oxide/oxygen mixture 2: 1 and rocuronium. Patients received 1 g of paracetamol rectally postoperatively. A visual analogue scale (VAS) for pain, the Glasgow Coma Score, a modified Aldrete Score, arterial carbon dioxide tension (PaCO2) and piritramide consumption were evaluated every half an hour postoperatively. Results: No significant differences were found for pain, Aldrete or Glasgow Coma scores or for PaCO2 between the groups when controlled for age, although the pain and Glasgow Coma Scores were consistently higher and PaCO2 lower in the remifentanil group. Furthermore, 13 out of 20 patients in the remifentanil group requested extra piritramide as opposed to 7 out of 2 0 in the fentanyl group (P = 0.11). Conclusions: Despite the intraoperative use of piritramide in the remifentanil group, patients experienced more pain postoperatively. A significant influence of age on pain intensity was found. The use of remifentanil with a small dose of piritramide of 0.1 mg kg(-1) has no evident advantage over the use of fentanyl considering the postoperative conditions after craniotomy.	VU Univ Med Ctr, Dept Anesthesiol, NL-1007 MB Amsterdam, Netherlands; HAGA Hosp, The Hague, Netherlands	van der Zwan, T (reprint author), VU Univ Med Ctr, Dept Anesthesiol, 7 D166,POB 7057, NL-1007 MB Amsterdam, Netherlands.	tvdzwan@kabelfoon.nl					Baker KZ, 1997, J NEUROSURG ANESTH, V9, P134, DOI 10.1097/00008506-199704000-00005; Balakrishnan G, 2000, ANESTH ANALG, V91, P163, DOI 10.1097/00000539-200007000-00030; Coles JP, 2000, J NEUROSURG ANESTH, V12, P15, DOI 10.1097/00008506-200001000-00004; Gerlach K, 2003, EUR J ANAESTH, V20, P813, DOI 10.1097/00003643-200310000-00007; Guy J, 1997, ANESTHESIOLOGY, V86, P514, DOI 10.1097/00000542-199703000-00002; Ostapkovich ND, 1998, ANESTHESIOLOGY, V89, P358, DOI 10.1097/00000542-199808000-00011; Sneyd JR, 1998, BRIT J ANAESTH, V81, P361, DOI 10.1093/bja/81.3.361; Talke P, 2002, ANESTH ANALG, V95, P430, DOI 10.1097/00000539-200208000-00036; Verchere E, 2002, J NEUROSURG ANESTH, V14, P96, DOI 10.1097/00008506-200204000-00002; Warner DS, 1999, ANESTH ANALG, V89, pS33; Warner DS, 1996, ANESTH ANALG, V83, P348, DOI 10.1097/00000539-199608000-00025	11	8	8	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	JUN	2005	22	6					438	441		10.1017/S0265021505000748			4	Anesthesiology	Anesthesiology	941YA	WOS:000230248900006	15991506				2020-06-30	J	Esmaoglu, A; Mizrak, A; Akin, A; Turk, Y; Boyaci, A				Esmaoglu, A; Mizrak, A; Akin, A; Turk, Y; Boyaci, A			Addition of dexmedetomidine to lidocaine for intravenous regional anaesthesia	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article; Proceedings Paper	Euroanaesthesia 2004 Meeting	JUN 05-08, 2004	Lisbon, PORTUGAL			anaesthesia conduction, intravenous regional block; anaesthetics local, lidocaine; dexmedetomidine	ADMINISTERED DEXMEDETOMIDINE; ABDOMINAL HYSTERECTOMY; TOURNIQUET PAIN; CLONIDINE; PRILOCAINE; FENTANYL; AGONISTS; RATS	Background and objective: The aim of this study was to determine the duration of onset and regression time of sensory and motor blocks, the quality of anaesthesia and postoperative analgesia by the addition of dexmedetomidine to local anaesthetic solution in intravenous regional anaesthesia (IVRA). Methods: Forty patients scheduled for elective hand surgery participated in this prospective randomized double-blind study. The IVRA was achieved using 3 mg kg(-1) lidocaine diluted with saline to a total volume of 40 mL in the control group or 1 mu g kg(-1) of dexmedetomidine + 3 mg kg(-1) lidocaine diluted with saline to a total volume of 40 mL in the dexmedetomidine group. The onset and regression times for sensory and motor blocks were recorded. Qualities of anaesthesia, intraoperative and postoperative analgesic requirements were noted. Results: There was no difference between the groups with, respect to sensory and motor blocks, onset and regression time. The quality of anaesthesia was better in the dexmedetomidine group than the control group and the difference was statistically significant. Intraoperative and postoperative analgesic requirements were greater in the control group than in the dexmedetomidine group. Conclusions: Addition of dexmedetomidine to local anaesthetic solution in IVRA improved the quality of anaesthesia and decreased analgesic requirements, but had no effect on the sensory and motor blocks onset and regression times.	Erciyes Univ, Fac Med, Dept Anaesthesiol & Reanimat, Kayseri, Turkey; Erciyes Univ, Fac Med, Dept Orthoped Surg & Traumatol, Kayseri, Turkey	Esmaoglu, A (reprint author), Alpaslan Mahallesi,Esref Bitlis Bulvari,Imaj Site, Kayseri, Turkey.	aliye@operamail.com					AHO M, 1992, ANESTH ANALG, V75, P940; AHO M, 1991, ANESTHESIOLOGY, V74, P997, DOI 10.1097/00000542-199106000-00005; AHO MS, 1991, ANESTH ANALG, V73, P112; ARMSTRONG P, 1991, ANAESTHESIA, V46, P278, DOI 10.1111/j.1365-2044.1991.tb11496.x; ARMSTRONG P, 1990, ANAESTHESIA, V45, P935, DOI 10.1111/j.1365-2044.1990.tb14622.x; Bhana N, 2000, DRUGS, V59, P263, DOI 10.2165/00003495-200059020-00012; Corpataux JB, 1997, ANESTH ANALG, V84, P1081, DOI 10.1097/00000539-199705000-00023; Fragen RJ, 1999, J CLIN ANESTH, V11, P466, DOI 10.1016/S0952-8180(99)00081-1; GAUMANN DM, 1992, ANESTH ANALG, V74, P719; Gentili M, 1999, ANESTH ANALG, V88, P1327, DOI 10.1097/00000539-199906000-00024; GUPTA A, 1993, REGION ANESTH, V18, P250; KALLIO A, 1989, CLIN PHARMACOL THER, V46, P33, DOI 10.1038/clpt.1989.103; Kamibayashi T, 2000, ANESTHESIOLOGY, V93, P1345, DOI 10.1097/00000542-200011000-00030; Lurie SD, 2000, REGION ANESTH PAIN M, V25, P502, DOI 10.1053/rapm.2000.8460; Memis D, 2004, ANESTH ANALG, V98, P835; Rabin BC, 1996, ANESTHESIOLOGY, V85, P565, DOI 10.1097/00000542-199609000-00016; Reuben SS, 1999, ANESTHESIOLOGY, V91, P654, DOI 10.1097/00000542-199909000-00015; REUBEN SS, 1995, ANESTH ANALG, V81, P110, DOI 10.1097/00000539-199507000-00022; SALMENPERA MT, 1994, ANESTHESIOLOGY, V80, P837, DOI 10.1097/00000542-199404000-00017; SALONEN M, 1992, ANESTHESIOLOGY, V76, P1004, DOI 10.1097/00000542-199206000-00022; SATO J, 1991, SCIENCE, V251, P1608, DOI 10.1126/science.2011742	21	37	42	2	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	JUN	2005	22	6					447	451		10.1017/S0265021505000761			5	Anesthesiology	Anesthesiology	941YA	WOS:000230248900008	15991508				2020-06-30	J	Sanli, S; Yegin, A; Kayacan, N; Yilmaz, M; Coskunfirat, N; Karsli, B				Sanli, S; Yegin, A; Kayacan, N; Yilmaz, M; Coskunfirat, N; Karsli, B			Effects of hyperbaric spinal ropivacaine for caesarean section: with or without fentanyl	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthesia obstetrical; caesarean section, anaesthesia; anaesthesia spinal; anaesthetics local, ropivacaine; analgesics opioid, fentanyl	INTRATHECAL FENTANYL; 0.5-PERCENT BUPIVACAINE; PROLONGING RECOVERY; AMBULATORY SURGERY; SUBARACHNOID BLOCK; ANESTHESIA; DELIVERY; SUFENTANIL; BARICITY; STUDY/	Background and objective: Adding various opioids to the local anaesthetic solution administrated intrathecally improves the analgesic potency of spinal analgesia. The purpose of this study was to evaluate the efficacy and safety of intrathecal fentanyl 10 mu g added to 15 mg hyperbaric ropivacaine in patients undergoing caesarean section under spinal anaesthesia. Methods: Thirty-seven healthy, full-term parturients were randomly assigned into two groups: Group S (saline group, n = 17) received 15 mg hyperbaric ropivacaine in 2.5 mL + 0.5 mL saline; Group F (fentanyl group, n = 20) received 15 mg hyperbaric ropivacaine in 2.5 mL + 10 mu g fentanyl in 0.5 mL, intrathecally. Characteristics of spinal block, intraoperative quality of spinal anaesthesia, time to first feeling of pain (complete analgesia), time to first request of analgesics postoperatively (effective analgesia), side-effects and fetal outcomes were evaluated. Results: Regression of sensory block to L5 was significantly prolonged in the fentanyl group compared with the saline group (P = 0.001). Time to the first feeling of pain (130.6 +/- 15.8 min vs. 154.3 +/- 31.1 min; P = 0.008) and the first analgesic requirement (161.2 +/- 32.6 min vs. 213.0 +/- 29.3 min; P < 0.001) were significantly shorter in the saline group compared with the fentanyl group. Side-effects, umbilical arterial and venous blood gases did not differ between the groups. Apgar scores were similar in both groups and no infants had an Apgar score <= 7 at 5 min. Conclusions: The addition of fentanyl 10 mu g, to hyperbaric ropivacaine 15 mg, for spinal anaesthesia increased the duration of analgesia in the early postoperative period in patients undergoing caesarean delivery.	Akdeniz Univ, Fac Med, Dept Anaesthesiol, TR-07070 Antalya, Turkey	Sanli, S (reprint author), Akdeniz Univ, Fac Med, Dept Anaesthesiol, TR-07070 Antalya, Turkey.	suatsanli@superonline.com	Karsli, Bilge/C-2468-2016; Yilmaz, Murat/I-6629-2017; yegin, arif/C-2275-2016; Coskunfirat, Nesil/C-4777-2016	Coskunfirat, Nesil/0000-0003-0179-0043			BANNISTER J, 1990, BRIT J ANAESTH, V64, P232, DOI 10.1093/bja/64.2.232; BELZARENA SD, 1992, ANESTH ANALG, V74, P653; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; BROWN DT, 1980, BRIT J ANAESTH, V52, P589, DOI 10.1093/bja/52.6.589; CHAMBERS WA, 1981, BRIT J ANAESTH, V53, P279, DOI 10.1093/bja/53.3.279; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; Chung CJ, 2002, REGION ANESTH PAIN M, V27, P600, DOI 10.1053/rapm.2002.36455; Chung CJ, 2001, ANESTH ANALG, V93, P157; Dahlgren G, 1997, ANESTH ANALG, V85, P1288, DOI 10.1097/00000539-199712000-00020; Gautier PE, 1999, ANESTHESIOLOGY, V91, P1239, DOI 10.1097/00000542-199911000-00013; Goel S, 2003, EUR J ANAESTH, V20, P294, DOI 10.1097/00003643-200304000-00004; Khaw KS, 2002, ANESTH ANALG, V94, P680, DOI 10.1097/00000539-200203000-00037; Khaw KS, 2001, ANESTHESIOLOGY, V95, P1346, DOI 10.1097/00000542-200112000-00011; LIU S, 1995, ANESTH ANALG, V80, P730, DOI 10.1097/00000539-199504000-00014; Liu SS, 1997, REGION ANESTH, V22, P500; McClellan KJ, 2000, DRUGS, V60, P1065, DOI 10.2165/00003495-200060050-00007; MOLLER IW, 1984, BRIT J ANAESTH, V56, P1191, DOI 10.1093/bja/56.11.1191; PHELAN DM, 1984, ANAESTH INTENS CARE, V12, P101, DOI 10.1177/0310057X8401200202; Sarvela PJ, 1999, ANESTH ANALG, V89, P1257, DOI 10.1213/00000539-199911000-00033; Shende D, 1998, ANAESTHESIA, V53, P706, DOI 10.1046/j.1365-2044.1998.329-az0482.x; Soni AK, 2001, CAN J ANAESTH, V48, P677, DOI 10.1007/BF03016202; Stocks GM, 2001, ANESTHESIOLOGY, V94, P593, DOI 10.1097/00000542-200104000-00011; VANKLEEF JW, 1994, ANESTH ANALG, V78, P1125; VARRASSI G, 1992, ANAESTHESIA, V47, P558, DOI 10.1111/j.1365-2044.1992.tb02323.x; Whiteside JB, 2001, BRIT J ANAESTH, V86, P241, DOI 10.1093/bja/86.2.241; Yegin A, 2005, ACTA ANAESTH SCAND, V49, P401, DOI 10.1111/j.1399-6576.2005.00607.x	26	7	9	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	JUN	2005	22	6					457	461		10.1017/S0265021505000785			5	Anesthesiology	Anesthesiology	941YA	WOS:000230248900010	15991510				2020-06-30	J	Delogu, G; Antonucci, A; Signore, M; Marandola, M; Tellan, G; Ippoliti, F				Delogu, G; Antonucci, A; Signore, M; Marandola, M; Tellan, G; Ippoliti, F			Plasma levels of IL-10 and nitric oxide under two different anaesthesia regimens	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						general anaesthesia; interleukins, interleukin-10; surgery, stress response; nitric oxide	CENTRAL-NERVOUS-SYSTEM; ARGINASE ACTIVITY; SURGERY; SYNTHASE; TRAUMA; INTERLEUKIN-10; BALANCE; CELLS	Background and objective: An alteration in production of both interleukin-10 (IL-10) and nitric oxide (NO) has been found following surgical/anaesthesia trauma. It is also suggested that IL-10 could be an important factor in regulating NO metabolism during the postoperative period. Furthermore, NO seems to play a crucial role in the anaesthetic state. The purpose of this study was to investigate plasma levels of IL-10 and NO following surgery, any possible correlation between these two variables and whether anaesthesia technique could influence NO and IL-10 circulating concentrations. Methods: Thirty-two patients scheduled to undergo elective major surgery were enrolled in the study and allocated into two groups to receive two different techniques of anaesthesia, total intravenous (i.v. anaesthesia (Group I) and inhalational anaesthesia (Group II). Blood samples were drawn before (t(0)), at the end (t(1)) of operation and after 24 h (t(2)). Plasma IL-10 and NO levels were measured by using an enzyme-linked-immunosorbent assay (ELISA) and a total NO assay kit, respectively. Results: In both patient groups there was a significant decrease of plasma NO levels at the end of surgery (30.35 +/- 2.70 mmol L-1 at t(0) to 13.76 +/- 1.51 mmol L-1 at t(1) in Group I, P < 0.0001; 28.23 +/- 2.50 mmol L-1 at t(o) to 11.38 +/- 0.95 mmol L-1 at t(1) in Group II, P < 0.0001). This reduction remained at 24 h postoperatively (14.33 +/- 1.52 mmol L-1 in Group I, P < 0.0001; 12.52 +/- 1.11 mmol L-1 in Group II, P < 0.0001, both vs. t(o)). There was an increase in IL-10 concentrations (26.35 +/- 3.42 pg mL(-1) and 75.39 +/- 8.33 pg mL(-1) at t(1) and t(2), respectively, vs. 4.93 +/- 0.31 pg mL(-1) at t(o), P = 0.03 and P < 0.0001, respectively, in Group I; 26.18 +/- 3.22 pg mL(-1) and 69.91 +/- 7.33 pg mL(-1) at t(1) and t(2), respectively, vs, 5.50 +/- 0.33 pg mL(-1) at t(o), P = 0.02 and P < 0.0001, respectively, in Group II No relationship was found between circulating IL-10 and NO. Conclusions: During the postoperative period, IL-10 overproduction does not correlate with the decrease in systemic NO concentration.	Univ Roma La Sapienza, Policlin Umberto I, Dept Anaesthesia & Intens Care, I-00161 Rome, Italy; Ist Super Sanita, Dept Haematol Oncol & Mol Med, I-00161 Rome, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy	Delogu, G (reprint author), Univ Roma La Sapienza, Policlin Umberto I, Dept Anaesthesia & Intens Care, Vle Policlin 155, I-00161 Rome, Italy.	giovanna.delogu@uniromal.it	Signore, Michele/J-8563-2016	Signore, Michele/0000-0002-0262-842X; TELLAN, GUGLIELMO/0000-0002-4129-3300			Bernard AC, 2000, SURGERY, V127, P412, DOI 10.1067/msy.2000.104115; Bernard AC, 2001, SHOCK, V15, P215, DOI 10.1097/00024382-200115030-00009; Chang CK, 2002, SURG LAPARO ENDO PER, V12, P247, DOI 10.1097/00129689-200208000-00009; Decker D, 1996, SURGERY, V119, P316, DOI 10.1016/S0039-6060(96)80118-8; Delogu G, 2001, J TRAUMA, V51, P92, DOI 10.1097/00005373-200107000-00015; Fujioka S, 2000, SURG TODAY, V30, P871, DOI 10.1007/s005950070036; GALLEY HF, 1995, BRIT J ANAESTH, V75, P326, DOI 10.1093/bja/75.3.326; Galley HF, 2000, BRIT J ANAESTH, V84, P141; Galley HF, 2001, BRIT J ANAESTH, V86, P388, DOI 10.1093/bja/86.3.388; Harbrecht BG, 1996, ARCH SURG-CHICAGO, V131, P1266; Helmy SAK, 1999, ANAESTHESIA, V54, P733, DOI 10.1046/j.1365-2044.1999.00947.x; Kato M, 1998, J CLIN ANESTH, V10, P184, DOI 10.1016/S0952-8180(97)00264-X; Lyons A, 1997, ANN SURG, V226, P450, DOI 10.1097/00000658-199710000-00006; Munder M, 1998, J IMMUNOL, V160, P5347; Nijveldt RJ, 2000, EUR J CLIN NUTR, V54, P615, DOI 10.1038/sj.ejcn.1601062; Ochoa JB, 2000, SURGERY, V127, P419, DOI 10.1067/msy.2000.104745; Satoi S, 1998, J LAB CLIN MED, V131, P236, DOI 10.1016/S0022-2143(98)90095-6; TANJOH K, 1995, SURG TODAY, V25, P774, DOI 10.1007/BF00311451; Tsuei BJ, 2001, J TRAUMA, V51, P497, DOI 10.1097/00005373-200109000-00012	19	10	10	0	3	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	JUN	2005	22	6					462	466		10.1017/S0265021505000797			5	Anesthesiology	Anesthesiology	941YA	WOS:000230248900011	15991511				2020-06-30	J	Vansteensel, MJ; Magnone, MC; van Oosterhout, F; Baeriswyl, S; Albrecht, U; Albus, H; Dahan, A; Meijer, JH				Vansteensel, MJ; Magnone, MC; van Oosterhout, F; Baeriswyl, S; Albrecht, U; Albus, H; Dahan, A; Meijer, JH			The opioid fentanyl affects light input, electrical activity and Per gene expression in the hamster suprachiasmatic nuclei	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						addiction; circadian; electrophysiology; entrainment; pain	CIRCADIAN ACTIVITY RHYTHMS; INDUCED PHASE ADVANCES; MESSENGER-RNA EXPRESSION; NEUROPEPTIDE-Y; RECEPTOR AGONISTS; CLOCK GENES; IMMUNOHISTOCHEMICAL LOCALIZATION; COCAINE SENSITIZATION; LOCOMOTOR-ACTIVITY; SYRIAN-HAMSTER	The suprachiasmatic nuclei (SCN) contain a major circadian pacemaker, which is regulated by photic and nonphotic stimuli. Although enkephalins are present in the SCN, their role in phase regulation of the pacemaker is largely unknown. The opioid agonist fentanyl, a homologue of morphine, is an addictive drug that induces phase shifts of circadian rhythms in hamsters. We observed that these phase shifts are blocked by naloxone, which is a critical test for true opioid receptor involvement, and conclude that opioid receptors are the sole mediators of the actions of fentanyl on the circadian timing system. A strong interaction between opioids and light input was shown by the ability of fentanyl and light to completely block each other's phase shifts of behavioural activity rhythms. Neuronal ensemble recordings in vitro provide first evidence that SCN cells show direct responses to fentanyl and react with a suppression of firing rate. Moreover, we show that fentanyl induces a strong attenuation of light-induced Syrian hamster Period 1 (shPer1) gene expression during the night. During the subjective day, we found no evidence for a role of shPer1 in mediation of fentanyl-induced phase shifts. Based on the present results, however, we cannot exclude the involvement of shPer2. Our data indicate that opioids can strongly modify the photic responsiveness of the circadian pacemaker and may do so via direct effects on SCN electrical activity and regulation of Per genes. This suggests that the pathways regulating addictive behaviour and the circadian clock intersect.	Leiden Univ, Dept Neurophysiol, Med Ctr, NL-2300 RC Leiden, Netherlands; Univ Fribourg, Dept Med, Div Biochem, CH-1700 Fribourg, Switzerland; Leiden Univ, Med Ctr, Dept Anaesthesiol, NL-2300 RC Leiden, Netherlands	Meijer, JH (reprint author), Leiden Univ, Dept Neurophysiol, Med Ctr, Wassenaarseweg 62,POB 9604, NL-2300 RC Leiden, Netherlands.	J.H.Meijer@LUMC.nl	Dahan, Albert/B-8845-2008; Albrecht, Urs/A-9831-2011; Vansteensel, Mariska/K-8015-2019	Dahan, Albert/0000-0003-3161-3945; Albrecht, Urs/0000-0002-0663-8676; Vansteensel, Mariska/0000-0002-9252-5116			Abarca C, 2002, P NATL ACAD SCI USA, V99, P9026, DOI 10.1073/pnas.142039099; ALBERS HE, 1984, NEUROSCI LETT, V50, P163, DOI 10.1016/0304-3940(84)90480-4; Albrecht U, 2001, J BIOL RHYTHM, V16, P100, DOI 10.1177/074873001129001791; Albrecht U, 2002, J APPL PHYSIOL, V92, P1348, DOI 10.1152/japplphysiol.00759.2001; Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; ALBRECHT U, 1998, HUMAN GENOME METHODS, P93; Allen CN, 1999, J NEUROSCI, V19, P2152; Andretic R, 1999, SCIENCE, V285, P1066, DOI 10.1126/science.285.5430.1066; ARVIDSSON U, 1995, P NATL ACAD SCI USA, V92, P5062, DOI 10.1073/pnas.92.11.5062; BERKOWITZ BA, 1975, J PHARMACOL EXP THER, V195, P499; BIELLO SM, 1995, P ROY SOC B-BIOL SCI, V259, P179, DOI 10.1098/rspb.1995.0026; Byku M, 2000, BRAIN RES, V873, P189, DOI 10.1016/S0006-8993(00)02304-0; Byku M, 2000, NEUROREPORT, V11, P1449, DOI 10.1097/00001756-200005150-00019; Byku M, 2000, BRAIN RES, V857, P1, DOI 10.1016/S0006-8993(99)02290-8; CHEN JC, 1993, LIFE SCI, V52, P389, DOI 10.1016/0024-3205(93)90152-S; Cox EH, 1998, J PHARMACOL EXP THER, V284, P1095; Cutler DJ, 1999, BRAIN RES BULL, V50, P119, DOI 10.1016/S0361-9230(99)00069-6; Dahan A, 2001, ANESTHESIOLOGY, V94, P824, DOI 10.1097/00000542-200105000-00021; DESJARDINS GC, 1990, BRAIN RES, V536, P114; DEVRIES MJ, 1993, BRAIN RES, V612, P231, DOI 10.1016/0006-8993(93)91665-F; DEVRIES MJ, 1994, BRAIN RES, V642, P206, DOI 10.1016/0006-8993(94)90923-7; Ding JM, 1997, J NEUROSCI, V17, P667; Ding YQ, 1996, J COMP NEUROL, V367, P375; DUGGAN AW, 1983, PHARMACOL REV, V35, P219; Edelstein K, 2003, NEUROSCIENCE, V118, P253, DOI 10.1016/S0306-4522(02)00908-9; Ehlen JC, 2001, J NEUROSCI, V21, P5351, DOI 10.1523/JNEUROSCI.21-14-05351.2001; Fukuhara C, 2001, NEUROSCI LETT, V314, P119, DOI 10.1016/S0304-3940(01)02304-7; GEORGE SR, 1994, BIOCHEM BIOPH RES CO, V205, P1438, DOI 10.1006/bbrc.1994.2826; Gillette MU, 2002, CELL TISSUE RES, V309, P99, DOI 10.1007/s00441-002-0576-1; Hamada T, 2004, NEUROSCI LETT, V362, P87, DOI 10.1016/j.neulet.2004.02.061; Horikawa K, 2000, J NEUROSCI, V20, P5867; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; MANSOUR A, 1994, J COMP NEUROL, V350, P412, DOI 10.1002/cne.903500307; Marchant EG, 1995, NEUROREPORT, V7, P209, DOI 10.1097/00001756-199512290-00050; Masubuchi S, 2000, EUR J NEUROSCI, V12, P4206, DOI 10.1111/j.1460-9568.2000.01313.x; Matthes HWD, 1998, J NEUROSCI, V18, P7285; Maywood E. S., 2001, Gene Expression Patterns, V1, P27, DOI 10.1016/S1567-133X(01)00005-9; Maywood ES, 2002, EUR J NEUROSCI, V15, P216, DOI 10.1046/j.0953-816x.2001.01852.x; Maywood ES, 1999, P NATL ACAD SCI USA, V96, P15211, DOI 10.1073/pnas.96.26.15211; Meijer JH, 2003, J BIOL RHYTHM, V18, P235, DOI [10.1177/0748730403018003006, 10.1177/0748730403253370]; MEIJER JH, 1992, BRAIN RES, V598, P257, DOI 10.1016/0006-8993(92)90191-B; Meijer JH, 2000, BRAIN RES, V868, P135, DOI 10.1016/S0006-8993(00)02317-9; MEIJER JH, 2004, VISUAL NEUROSCIENCES, V1, P625; Mendoza JY, 2004, NEUROSCIENCE, V127, P529, DOI 10.1016/j.neuroscience.2004.05.026; Miller JD, 1996, SLEEP, V19, P641, DOI 10.1093/sleep/19.8.641; MINAMI M, 1995, NEUROSCI RES, V23, P121, DOI 10.1016/0168-0102(95)00933-K; MISRA AL, 1976, J PHARMACOL EXP THER, V196, P257; Mistlberger RE, 1998, BRAIN RES, V786, P31, DOI 10.1016/S0006-8993(97)01269-9; Moga MM, 1997, J COMP NEUROL, V389, P508, DOI 10.1002/(SICI)1096-9861(19971222)389:3<508::AID-CNE11>3.0.CO;2-H; MORIN LP, 1994, BRAIN RES REV, V19, P102, DOI 10.1016/0165-0173(94)90005-1; Moriya T, 2000, MOL PHARMACOL, V58, P1554; MROSOVSKY N, 1988, J COMP PHYSIOL A, V162, P35, DOI 10.1007/BF01342701; Mrosovsky N, 1996, BIOL REV, V71, P343, DOI 10.1111/j.1469-185X.1996.tb01278.x; Nikaido T, 2001, MOL PHARMACOL, V59, P894; Obrietan K, 1998, NAT NEUROSCI, V1, P693; ONeill SJ, 1997, J PHARMACOL EXP THER, V282, P271; Palazzi E, 1996, J NEUROCHEM, V67, P138; Pickard GE, 1996, J NEUROSCI, V16, P8208; Poirel VJ, 2003, NEUROSCIENCE, V120, P745, DOI 10.1016/S0306-4522(03)00344-0; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; REA MA, 1994, J NEUROSCI, V14, P3635; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Schaap J, 2001, EUR J NEUROSCI, V13, P1955, DOI 10.1046/j.0953-816x.2001.01561.x; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Spanagel R, 2005, NAT MED, V11, P35, DOI 10.1038/nm1163; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Takahashi J.S., 2001, HDB BEHAV NEUROBIOLO, V12; Tierno A, 2002, BRAIN RES, V937, P66, DOI 10.1016/S0006-8993(02)02468-X; TOMINAGA K, 1992, EUR J PHARMACOL, V214, P79, DOI 10.1016/0014-2999(92)90099-P; Vansteensel MJ, 2003, J BIOL RHYTHM, V18, P297, DOI 10.1177/0748730403254283; Wakamatsu H, 2001, NEUROREPORT, V12, P127, DOI 10.1097/00001756-200101220-00033; Weber ET, 1997, NEUROSCI LETT, V231, P159, DOI 10.1016/S0304-3940(97)00559-4; WEE BEF, 1989, PHARMACOL BIOCHEM BE, V32, P901, DOI 10.1016/0091-3057(89)90056-7; Yannielli PC, 2002, NEUROSCIENCE, V112, P677, DOI 10.1016/S0306-4522(02)00100-8; Yokota S, 2000, BRIT J PHARMACOL, V131, P1739, DOI 10.1038/sj.bjp.0703735; Yuferov V, 2003, SYNAPSE, V48, P157, DOI 10.1002/syn.10198; Zaveri N, 2001, EUR J PHARMACOL, V428, P29, DOI 10.1016/S0014-2999(01)01282-1	78	25	26	1	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	JUN	2005	21	11					2958	2966		10.1111/j.1460-9568.2005.04131.x			9	Neurosciences	Neurosciences & Neurology	939DR	WOS:000230053100007	15978007				2020-06-30	J	Chelly, JE				Chelly, JE			An iontophoretic, fentanyl HCl patient-controlled transdermal system for acute postoperative pain management	EXPERT OPINION ON PHARMACOTHERAPY			English	Review						analgesia; fentanyl; iontophoresis; needle free; noninvasive; patient-controlled analgesia; postoperative pain; transdermal	CONTROLLED ANALGESIA; EFFICACY; PHARMACOKINETICS; MECHANISMS; MORPHINE; SAFETY	Patient-controlled modalities using intravenous or epidural routes have dramatically improved postoperative pain management. However, acute postoperative pain continues to be undermanaged. Intravenous patient-controlled analgesia (PCA), the current standard of care for acute postoperative pain management, requires the patient to be attached to a staff-programmed pump apparatus via an intravenous catheter and tubing, rendering it invasive and mobility-limiting. An innovative, needle-free, iontophoretic, fentanyl HCl patient-controlled transdermal system (PCTS) is being developed for acute postoperative pain management. Fentanyl HCl PCTS is a compact, self-contained system that is easily applied to the upper outer arm or chest. It provides pain relief therapeutically equivalent to that of a standard regimen of morphine intravenous PCA, with pharmacokinetics similar to those of intravenous fentanyl infusion. Fentanyl HCl PCTS may be an effective, non-invasive alternative to currently available PCA modalities.	UPMC, Shadyside Hosp, Dept Anesthesiol, Posner Pain Ctr, Pittsburgh, PA 15232 USA	Chelly, JE (reprint author), UPMC, Shadyside Hosp, Dept Anesthesiol, Posner Pain Ctr, Suite M140,5230 Ctr Ave, Pittsburgh, PA 15232 USA.	ChelJE@anes.upmc.edu					ABBOTT PCA, 1997, HLTH DEVICES, V26, P389; *AG HLTH CAR POL R, 1992, AHCPR PUB; *AM PAIN SOC, 2003, [No title captured]; [Anonymous], 1979, Pain, V6, P249; Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; ASHBURN MA, 1992, J PAIN SYMPTOM MANAG, V7, P27, DOI 10.1016/0885-3924(92)90104-P; Ashburn MA, 2004, ANESTHESIOLOGY, V100, P1573; Austrup ML, 1999, SURG CLIN N AM, V79, P253, DOI 10.1016/S0039-6109(05)70382-0; BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; Bardiau FM, 1999, J CLIN ANESTH, V11, P583, DOI 10.1016/S0952-8180(99)00101-4; Barry BW, 2001, EUR J PHARM SCI, V14, P101, DOI 10.1016/S0928-0987(01)00167-1; Bertolucci L E, 1982, J Orthop Sports Phys Ther, V4, P103; BEZZANT JL, 1988, J AM ACAD DERMATOL, V19, P869, DOI 10.1016/S0190-9622(88)70247-9; Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; BROWN CR, 1998, 17 ANN SCI M AM PAIN; Campbell L, 1998, Br J Nurs, V7, P1364; Campbell L., 1998, BR J NURS, V7, P1372; Campbell L., 1998, BR J NURS, V7, P1368; Camu F, 1998, ANESTH ANALG, V87, P890, DOI 10.1097/00000539-199810000-00027; Carr DB, 1998, J CLIN ANESTH, V10, P77, DOI 10.1016/S0952-8180(97)00227-4; Chauvin M, 2003, EUR J ANAESTH, V20, P3; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; COLWELL CW, 1995, J BONE JOINT SURG AM, V77A, P726, DOI 10.2106/00004623-199505000-00009; Curdy C, 2001, J PHARM PHARMACOL, V53, P769, DOI 10.1211/0022357011776117; Gupta SK, 2005, CLIN PHARMACOKINET, V44, P25, DOI 10.2165/00003088-200544001-00005; HANKIN C, 2005, [No title captured]; Horlocker Terese T., 2004, Regional Anesthesia and Pain Medicine, V29, P1, DOI 10.1016/j.rapm.2003.12.006; Horlocker TT, 2001, THROMB RES, V101, pV141; *JOINT COMM ACCR H, 2000, PAIN ASS MAN ORG APP; Kearns GL, 2003, PEDIATRICS, V112, P578, DOI 10.1542/peds.112.3.578; Kehlet H, 1997, BRIT J ANAESTH, V78, P606; Lebovits AH, 2001, PAIN MED, V2, P280, DOI 10.1046/j.1526-4637.2001.01051.x; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Nirschl RP, 2003, AM J SPORT MED, V31, P189; OWEN H, 1989, ANAESTHESIA, V44, P7, DOI 10.1111/j.1365-2044.1989.tb11087.x; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Ready LB, 1999, REGION ANESTH PAIN M, V24, P499, DOI 10.1016/S1098-7339(99)90038-X; READY LB, 1995, ANESTHESIOLOGY, V82, P1071; Sathyan G, 2005, CLIN PHARMACOKINET, V44, P7, DOI 10.2165/00003088-200544001-00003; Sathyan S, 2005, CLIN PHARMACOKINET, V44, P17, DOI 10.2165/00003088-200544001-00004; Shang AB, 2003, DRUGS, V63, P855, DOI 10.2165/00003495-200363090-00002; Shapiro A, 2003, J CLIN ANESTH, V15, P345, DOI 10.1016/S0952-8180(03)00067-9; SINATRA RS, 2002, J AM ACAD ORTHOP SUR, V10, P117; SMYTHE M, 1994, AM J HOSP PHARM, V51, P1433, DOI 10.1093/ajhp/51.11.1433; Stadler M, 2004, J CLIN ANESTH, V16, P159, DOI 10.1016/j.jclinane.2003.06.002; Vicente KJ, 2003, CAN J ANAESTH, V50, P328, DOI 10.1007/BF03021027; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Viscusi ER, 2005, REGION ANESTH PAIN M, V30, P292, DOI 10.1016/j.rapm.2004.12.002; VISCUSI ER, 2003, ANN M AM SOC AN SAN; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x; WASYLAK TJ, 1990, CAN J ANAESTH, V37, P726, DOI 10.1007/BF03006529; 1920, HLTH DEVICES, V31, P342; 1999, HLTH DEVICES, V28, P466	54	19	20	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1465-6566	1744-7666		EXPERT OPIN PHARMACO	Expert Opin. Pharmacother.	JUN	2005	6	7					1205	1214		10.1517/14656566.6.7.1205			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	951QI	WOS:000230945100014	15957973				2020-06-30	J	Kussman, BD; Zurakowski, D; Sullivan, L; McGowan, FX; Davis, PJ; Laussen, PC				Kussman, BD; Zurakowski, D; Sullivan, L; McGowan, FX; Davis, PJ; Laussen, PC			Evaluation of plasma fentanyl concentrations in infants during cardiopulmonary bypass with low-volume circuits	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						fentanyl; cardiopulmonary bypass; cardiac surgery; hypothermia; Bispectral Index; electroencephalography; awareness; pediatric	BISPECTRAL INDEX; CARDIAC-SURGERY; ANESTHESIA; EEG; PROPOFOL; HYPOTHERMIA; CHILDREN; SEVOFLURANE; ISOFLURANE; SUFENTANIL	Objective: The purpose of the study was to measure changes in plasma fentanyl concentrations during infant cardiac surgery using a bypass circuit with low priming volume and to examine the relation of plasma fentanyl concentration and temperature to Bispectral Index (BIS) as an index of conscious level during infant cardiac surgery. Design: Prospective cohort study. Setting: Tertiary care, academic children's hospital. Participants: Fifteen neonates and infants undergoing cardiac surgery with hypothermic cardiopulmonary bypass (CPB). Interventions: Patients were anesthetized with fentanyl, receiving a 30 mu g/kg bolus for induction immediately followed by continuous infusion of 0.3 mu g/kg/min until skin closure. Measurements and Main Results: Intraoperative data and total plasma fentanyl concentration were measured at pre-induction; 30 minutes postinduction; sternotomy; aortic cannulation; at 4, 30, and 60 minutes on CPB; and at 1 and 30 minutes off CPB. At the onset of CPB, fentanyl declined from 15 +/- 6 to 11 +/- 5 ng/mL (p < 0.01), increasing to 16 +/- 5 ng/mL (p < 0.01) at 30 minutes on CPB and maintaining a similar level until 30 minutes off CPB. BIS decreased from 88 +/- 20 to 42 +/- 11 (p = 0.02) with induction, declined further during cooling to 9 +/- 11 at the nadir temperature (p < 0.001), and increased during rewarming to 29 +/- 9 at 1 minute (p < 0.001) and 35 10 at 30 minutes off CPB (p < 0.01). Because of wide individual variation in BIS, there was no significant correlation between fentanyl and BIS and temperature. Conclusions: There was minimal variability in the plasma fentanyl concentration using a low-volume bypass circuit and constant infusion of fentanyl during surgery. There appears to be minimal utility for using BIS during infant cardiac surgery with no relationship between fentanyl concentration, temperature, and BIS established. (c) 2005 Elsevier Inc. All rights reserved.	Childrens Hosp Boston, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; Childrens Hosp Boston, Dept Orthopaed Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Anaesthesia, Boston, MA 02115 USA; Univ Pittsburgh, Dept Anesthesia, Pittsburgh, PA USA	Kussman, BD (reprint author), Childrens Hosp Boston, Dept Anesthesiol Perioperat & Pain Med, 300 Longwood Ave, Boston, MA 02115 USA.	barry.kussman@childrens.harvard.edu					ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; ANAND KJS, 1990, ANESTHESIOLOGY, V73, P661, DOI 10.1097/00000542-199010000-00012; ANTOGNINI JF, 1993, ANESTHESIOLOGY, V78, P1152, DOI 10.1097/00000542-199306000-00020; ARMITAGE P, 2002, STAT METHODS MED RES, P36; Bannister CF, 2001, ANESTH ANALG, V92, P877; Barr G, 2000, ACTA ANAESTH SCAND, V44, P807, DOI 10.1034/j.1399-6576.2000.440707.x; BASHEIN G, 1992, ANESTHESIOLOGY, V76, P878, DOI 10.1097/00000542-199206000-00003; BLAIR E, 1965, SURGERY, V58, P607; Davidson AJ, 2001, ANESTH ANALG, V93, P326, DOI 10.1097/00000539-200108000-00017; Degoute CS, 2001, BRIT J ANAESTH, V86, P209, DOI 10.1093/bja/86.2.209; Denman WT, 2000, ANESTH ANALG, V90, P872, DOI 10.1213/00000539-200004000-00018; Doi M, 1997, ANAESTHESIA, V52, P1048, DOI 10.1111/j.1365-2044.1997.229-az0364.x; Driessen JJ, 1999, EUR J ANAESTH, V16, P622, DOI 10.1046/j.1365-2346.1999.00551.x; England MR, 1999, ANESTHESIOLOGY, V91, P1947, DOI 10.1097/00000542-199912000-00050; Flaishon R, 1997, ANESTHESIOLOGY, V86, P613, DOI 10.1097/00000542-199703000-00013; Gan TJ, 1997, ANESTHESIOLOGY, V87, P808, DOI 10.1097/00000542-199710000-00014; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; HICKEY PR, 1984, ANESTH ANALG, V63, P117; HUG CC, 1990, ANESTHESIOLOGY, V73, P1, DOI 10.1097/00000542-199007000-00001; Katoh T, 1999, ANESTHESIOLOGY, V91, pU175; Kearse LA, 1998, ANESTHESIOLOGY, V88, P25, DOI 10.1097/00000542-199801000-00007; KOREN G, 1984, ANESTH ANALG, V63, P577; Kussman BD, 2001, PAEDIATR ANAESTH, V11, P663, DOI 10.1046/j.1460-9592.2001.00740.x; Laussen PC, 2001, PAEDIATR ANAESTH, V11, P567, DOI 10.1046/j.1460-9592.2001.00728.x; LEVY WJ, 1984, ANESTHESIOLOGY, V60, P291, DOI 10.1097/00000542-198404000-00004; Liu J, 1996, ANESTHESIOLOGY, V84, P64, DOI 10.1097/00000542-199601000-00007; Liu MZ, 2001, ANESTHESIOLOGY, V94, P429, DOI 10.1097/00000542-200103000-00011; Luks AM, 1998, J PHARMACOL EXP THER, V284, P136; Mathew JP, 2001, J CLIN ANESTH, V13, P301, DOI 10.1016/S0952-8180(01)00275-6; McPhee SJ, 2003, PEDIATRICS, V111, P1278, DOI 10.1542/peds.111.6.1278; MURRAY A, 1986, ANAESTHESIA, V41, P173, DOI 10.1111/j.1365-2044.1986.tb13175.x; PHILBIN DM, 1990, ANESTHESIOLOGY, V73, P5, DOI 10.1097/00000542-199007000-00002; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; RUSS W, 1987, ACTA ANAESTH SCAND, V31, P111, DOI 10.1111/j.1399-6576.1987.tb02531.x; Schmidlin D, 2001, BRIT J ANAESTH, V86, P769, DOI 10.1093/bja/86.6.769; Sebel PS, 1997, ANESTH ANALG, V84, P891, DOI 10.1097/00000539-199704000-00035; Todd MM, 1998, ANESTHESIOLOGY, V89, P815, DOI 10.1097/00000542-199810000-00002; Volpe JJ, 2001, NEUROLOGY NEWBORN, P134; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1	39	15	15	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770	1532-8422		J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	JUN	2005	19	3					316	321		10.1053/j.jvca.2005.03.008			6	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	940MJ	WOS:000230148300008	16130057				2020-06-30	J	Zeyneloglu, P; Donmez, A; Bilezikci, B; Mercan, S				Zeyneloglu, P; Donmez, A; Bilezikci, B; Mercan, S			Effects of ketamine on serum and tracheobronchial aspirate interleukin-6 levels in infants undergoing cardiac surgery	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						pediatric cardiac surgery; interleukin-6; ketamine; tracheobronchial aspirate	BRONCHOALVEOLAR LAVAGE FLUID; CARDIOPULMONARY BYPASS; INFLAMMATORY RESPONSE; NEUTROPHIL ACTIVATION; CYTOKINE PRODUCTION; PLASMA; MEDIATORS; PULMONARY; CIRCUITS; CHILDREN	Objective: Corrective surgery for congenital heart defects in children frequently requires cardiopulmonary bypass (CPB). Serum and bronchoalveolar levels of interleukin-6 (IL-6) may be useful in assessing the severity of the systemic inflammatory response after CPB. In the present study, the authors aimed to compare the effects of ketamine anesthesia and isoflurane anesthesia with respect to serum and tracheobronchial aspirate (TBA) IL-6 levels in infants undergoing CPB for cardiac surgery. Design: Prospective and randomized controlled study. Setting: University-based teaching hospital. Participants: Thirty-four infants aged 2 to 24 months were randomized into 2 groups. Interventions: In group K (n = 17), anesthesia was induced with intravenous (IV) ketamine, 1 to 2 mg/kg, and fentanyl, 1 to 2 mu g/kg, and was maintained with infusions of ketamine, 25 to 75 mu g/kg/min, and fentanyl, 10 mu g/kg/h. In group I (n = 17), induction was achieved with IV thiopental sodium, 3 to 5 mg/kg, and fentanyl, 1 to 2 mu g/kg, and was maintained with 1% isoflurane and fentanyl, 10 mu g/kg/h. Blood and TBA samples were obtained at 6 and 4 stages, respectively. Measurements and Main Results: Serum IL-6 and TBA IL-6 levels were similar in the 2 groups at all stages (p > 0.05). Conclusion: The present results show that ketamine anesthesia does not provide superiority over isoflurane anesthesia with respect to serum and TBA IL-6 levels. (c) 2005 Elsevier Inc. All rights reserved.	Baskent Univ, Fac Med, Dept Anesthesiol, TR-06490 Ankara, Turkey; Baskent Univ, Fac Med, Dept Pathol, TR-06490 Ankara, Turkey; Baskent Univ, Fac Med, Dept Cardiovasc Surg, TR-06490 Ankara, Turkey	Zeyneloglu, P (reprint author), Manolya Blok 24, TR-06530 Ankara, Turkey.	pinar_bz@hotmail.com					Brix-Christensen V, 2001, ACTA ANAESTH SCAND, V45, P671, DOI 10.1034/j.1399-6576.2001.045006671.x; CRUICKSHANK AM, 1990, CLIN SCI, V79, P161, DOI 10.1042/cs0790161; Doughty LA, 1996, CRIT CARE MED, V24, P1137, DOI 10.1097/00003246-199607000-00012; DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M; ELHABBAL MH, 1995, CARDIOVASC RES, V29, P102, DOI 10.1016/S0008-6363(96)88553-1; Fransen E, 1999, CHEST, V116, P1233, DOI 10.1378/chest.116.5.1233; Fujita M, 2002, ARTIF ORGANS, V26, P1020, DOI 10.1046/j.1525-1594.2002.07017.x; Gilliland HE, 1999, ANESTH ANALG, V89, P1188, DOI 10.1213/00000539-199911000-00019; GRIGG J, 1992, EUR RESPIR J, V5, P727; Hauser GJ, 1998, INTENS CARE MED, V24, P481, DOI 10.1007/s001340050600; Hill GE, 1997, J CARDIOTHOR VASC AN, V11, P367, DOI 10.1016/S1053-0770(97)90107-5; Kawasaki T, 1999, ANESTH ANALG, V89, P665; Kiehl MG, 1998, CRIT CARE MED, V26, P1194, DOI 10.1097/00003246-199807000-00019; KOTANI N, 1995, ANESTH ANALG, V81, P1255, DOI 10.1097/00000539-199512000-00023; Kotani N, 2000, ANESTH ANALG, V90, P1039, DOI 10.1097/00000539-200005000-00008; Lodge AJ, 1999, J THORAC CARDIOV SUR, V117, P515, DOI 10.1016/S0022-5223(99)70331-4; MCBRIDE WT, 1995, BRIT J ANAESTH, V75, P724, DOI 10.1093/bja/75.6.724; McBride WT, 1996, CYTOKINE, V8, P724, DOI 10.1006/cyto.1996.0096; Roytblat L, 1998, ANESTH ANALG, V87, P266, DOI 10.1097/00000539-199808000-00006; Sablotzki A, 1999, THORAC CARDIOV SURG, V47, P26, DOI 10.1055/s-2007-1013104; Schutte H, 1996, EUR RESPIR J, V9, P1858, DOI 10.1183/09031936.96.09091858; Tonnesen E, 1996, INT J CARDIOL, V53, pS1, DOI 10.1016/0167-5273(96)02568-5; Wan S, 1997, ANN THORAC SURG, V63, P269; Wang MJ, 1996, ANN THORAC SURG, V61, P651, DOI 10.1016/0003-4975(95)00974-4; Williams HJ, 1998, PERFUSION-UK, V13, P322, DOI 10.1177/026765919801300507; ZANETTI G, 1992, J IMMUNOL, V148, P1890; Zilberstein G, 2002, ANESTH ANALG, V95, P531, DOI 10.1097/00000539-200209000-00005	27	12	12	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770	1532-8422		J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	JUN	2005	19	3					329	333		10.1053/j.jvca.2005.03.010			5	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	940MJ	WOS:000230148300010	16130059				2020-06-30	J	Ferrandis, R; Belda, J; Llau, JV; Belda, C; Bahamonde, JA				Ferrandis, R; Belda, J; Llau, JV; Belda, C; Bahamonde, JA			Anesthesia for cardiac surgery on a patient with stiff person syndrome	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						stiff person syndrome; cardiac surgery; perioperative care; anesthetic management	ETOMIDATE		Univ Valencia, Hosp Clin, Serv Anestesiol & Reanimac, Dept Anesthesia & Crit Care, E-46010 Valencia, Spain; Univ Valencia, Hosp Clin, Dept Cardiovasc Surg, E-46010 Valencia, Spain	Ferrandis, R (reprint author), Univ Valencia, Hosp Clin, Serv Anestesiol & Reanimac, Dept Anesthesia & Crit Care, Av Blasco Ibanez 17, E-46010 Valencia, Spain.	raquelferrandis@ono.com		Ferrandis, Raquel/0000-0002-5394-991X; Llau, Juan V./0000-0002-9322-5959			CARLOS R, 1979, BRIT J ANAESTH, V51, P1159, DOI 10.1093/bja/51.12.1159; DALAKAS MC, 1999, ANN INTERN MED, V131, P529; DATHIS F, 1991, ENCY MED CHIR ANESTH, P1; Hall AC, 2004, ANESTH ANALG, V98, P1297, DOI 10.1213/01.ANE.0000111108.78745.AD; Haslam N, 2002, ANAESTHESIA, V57, P298, DOI 10.1111/j.1365-2044.2002.2520_24.x; JOHNSON JO, 1995, ANESTH ANALG, V80, P612, DOI 10.1097/00000539-199503000-00032; LORISH TR, 1989, MAYO CLIN PROC, V64, P629, DOI 10.1016/S0025-6196(12)65339-7; LUCIEN M, 1999, ANN INTERN MED, V131, P526; MOERSCH FP, 1956, P STAFF M MAYO CLIN, V31, P421; Murphy C, 2000, PAEDIATR ANAESTH, V10, P567, DOI 10.1046/j.1460-9592.2000.00573.x; Nishikawa K, 2003, ANESTHESIOLOGY, V99, P678, DOI 10.1097/00000542-200309000-00024; Obara M, 2002, ANAESTHESIA, V57, P511; ZACHARIAS M, 1979, BRIT J ANAESTH, V51, P127, DOI 10.1093/bja/51.2.127	13	4	5	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	1053-0770			J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	JUN	2005	19	3					370	372		10.1053/j.jvca.2005.03.018			3	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	940MJ	WOS:000230148300019	16130068				2020-06-30	J	Vetrugno, L; Cheli, G; Bassi, F; Giordano, F				Vetrugno, L; Cheli, G; Bassi, F; Giordano, F			Cardiac anesthesia management of a patient with Bartter's syndrome	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						Burner's syndrome; anesthesia; hypokalemia; alkalosis; coronary artery bypass	DEFECT		SM Misericordia Hosp, Dept Cardiothorac Anesthesia & Postsurg Transplan, Udine, Italy	Vetrugno, L (reprint author), Via G Freschi 33,CAP, I-33100 Udine, Italy.	vetrugnoluigi@katamail.com	Vetrugno, Luigi/AAF-4198-2020	Vetrugno, Luigi/0000-0003-3745-8368			ABSTON PA, 1981, ANESTH ANALG, V60, P764; AVA R, 1988, ACTA MED SCAND, V224, P165; BARTTER FC, 1962, AM J MED, V33, P811, DOI 10.1016/0002-9343(62)90214-0; BEHRMAN RE, 2000, NELSON TXB PEDIAT, P1601; Brimacombe J R, 1993, AANA J, V61, P193; Chenoweth D, 1987, AANA J, V55, P434; CLIVE DM, 1990, PROSTAG LEUKOTR ESS, V41, P251, DOI 10.1016/0952-3278(90)90138-B; HIGA K, 1993, J CLIN ANESTH, V5, P321, DOI 10.1016/0952-8180(93)90127-Z; KANNAN S, 1995, CAN J ANAESTH, V42, P808, DOI 10.1007/BF03011183; Kim JY, 2000, YONSEI MED J, V41, P662, DOI 10.3349/ymj.2000.41.5.662; NISHIKAWA T, 1985, CAN ANAESTH SOC J, V32, P646, DOI 10.1007/BF03011413; Proesmans W, 1997, EUR J PEDIATR, V156, P669, DOI 10.1007/s004310050688; Rodriguez-Soriano J, 1998, PEDIATR NEPHROL, V12, P315, DOI 10.1007/s004670050461; Roelofse J A, 1997, Anesth Prog, V44, P71; Schachter AD, 1998, PEDIATR NEPHROL, V12, P775, DOI 10.1007/s004670050545; Seto A, 1999, Masui, V48, P434; STOFF JS, 1980, AM J MED, V68, P171, DOI 10.1016/0002-9343(80)90351-4; Vantyghem MC, 1999, ANN ENDOCRINOL-PARIS, V60, P465; VITEZ TS, 1985, ANESTHESIOLOGY, V63, P130, DOI 10.1097/00000542-198508000-00002; WATSON ML, 1983, LANCET, V13, P38	20	1	2	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	1053-0770			J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	JUN	2005	19	3					373	376		10.1053/j.jvca.2005.03.019			4	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	940MJ	WOS:000230148300020	16130069				2020-06-30	J	Yilmaz, E; Batislam, E; Basar, MM; Tuglu, D; Ozcan, S; Basar, H				Yilmaz, E; Batislam, E; Basar, MM; Tuglu, D; Ozcan, S; Basar, H			Effectiveness of eutectic mixture of local anesthetic cream and occlusive dressing with low dosage of fentanyl for pain control during shockwave lithotripsy	JOURNAL OF ENDOUROLOGY			English	Article; Proceedings Paper	22nd World Congress of Endourology/SWL 20th Basic Research Symposium	NOV 02-05, 2004	Bombay, INDIA				WAVE LITHOTRIPSY; ANALGESIC REQUIREMENT; ALFENTANIL; DICLOFENAC; STONES; EMLA	Background and Purpose: To investigate the effect and usefulness of Eutectic Mixture of Local Anesthetic (EMLA) applied with an occlusive dressing and used simultaneously with a low dose of fentanyl during shockwave lithotripsy (SWL). Patients and Methods: One hundred sixty patients with kidney stones, aged between 19 and 68 years, were randomly, divided into seven groups that were treated as follows: group 1: fentanyl 1 mu g/kg by intravenous infusion (IV); group 2: IV fentanyl 0.25 mu g/kg; group 3: occlusive dressing and IV fentanyl 0.25 mu g/kg; group 4: placebo cream and IV fentanyl 0.25 mu g/kg; group 5: EMLA cream and IV fentanyl 0.25 mu g/kg; group 6: placebo cream and IV fentanyl 0.25 mu g/kg with an occlusive dressing; and group 7: EMLA cream and IV fentanyl 0.25 mu g/kg with an occlusive dressing. The mean arterial pressure (MAP), heart rate, ventilatory rate, and oxygen saturation (SpO(2)) were recorded on all patients. A visual analog scale 0-100 mm (VAS) was used for the evaluation of pain. The skin integrity was inspected to detect any lesions after SWL. Results: The SPO2 in group I was lower statistically than in the other groups. The VAS score in group 7 was clearly lower than in the others in the first, tenth, and twentieth minutes and at the end of SWL. In groups 6 and 7, additional fentanyl doses were lower than in the other groups, but only in group 7 was the total fentanyl dosage low. Skin lesions were not seen only in groups 3, 6, and 7. Conclusion: Use of EMLA and an occlusive dressing with low doses of fentanyl during SWL provides appropriate analgesia with minimal morbidity.	Kirikkale Univ, Tip Fak Urol ABD, TR-71100 Kirikkale, Turkey; Kirikkale Univ, Fac Med, Dept Anesthesiol, TR-71100 Kirikkale, Turkey	Yilmaz, E (reprint author), Kirikkale Univ, Tip Fak Urol ABD, TR-71100 Kirikkale, Turkey.	erdaly69@mynet.com	Tuglu, Devrim/E-4651-2015; Batislam, Ertan/E-2892-2016	Batislam, Ertan/0000-0002-7493-4573			ALDREDTNIELSEN L, ACTA DERMATOL SCAND, V70, P314; Barcena M, 1996, EUR J ANAESTH, V13, P373, DOI 10.1046/j.1365-2346.1996.00961.x; Basar H, 2003, J ENDOUROL, V17, P3, DOI 10.1089/089277903321196706; BIERKENS AF, 1991, J UROLOGY, V146, P287, DOI 10.1016/S0022-5347(17)37772-8; BROMAGE PR, 1995, ANESTH ANALG, V80, P1059, DOI 10.1097/00000539-199505000-00040; CHAUSSY C, 1980, LANCET, V2, P1265; CHAUSSY CG, 1989, J UROLOGY, V141, P782, DOI 10.1016/S0022-5347(17)41010-X; Cohen E, 1998, EUR J CLIN PHARMACOL, V54, P455, DOI 10.1007/s002280050492; DELICHTENBERG MH, 1992, J UROLOGY, V147, P96, DOI 10.1016/S0022-5347(17)37143-4; Ganapathy S, 1996, CAN J ANAESTH, V43, P1030, DOI 10.1007/BF03011905; Gesztesi Z, 2000, ANESTH ANALG, V90, P567, DOI 10.1097/00000539-200003000-00013; Issa MM, 1999, UROLOGY, V54, P625, DOI 10.1016/S0090-4295(99)00231-9; Keller R J, 1994, CRNA, V5, P136; LOENING S, 1987, J UROLOGY, V137, P626, DOI 10.1016/S0022-5347(17)44158-9; MCDONALD PF, 1992, BRIT J ANAESTH, V69, P399, DOI 10.1093/bja/69.4.399; MONK TG, 1991, ANESTH ANALG, V72, P616; MONK TG, 1991, ANESTHESIOLOGY, V74, P1023, DOI 10.1097/00000542-199106000-00009; MONK TG, 1994, ANESTH ANALG, V79, P506; POWER I, 1990, ANAESTHESIA, V45, P916, DOI 10.1111/j.1365-2044.1990.tb14618.x; Salinas AS, 1999, UROL INT, V63, P92, DOI 10.1159/000030425; Schelling G, 1996, J UROLOGY, V155, P43, DOI 10.1016/S0022-5347(01)66534-0; SCHIEBER M, 2000, P SOC PHOTO-OPT INS, V1, P48; TISELIUS HG, 1993, J UROLOGY, V149, P8, DOI 10.1016/S0022-5347(17)35983-9; Tritrakarn T, 2000, ANESTHESIOLOGY, V92, P1049, DOI 10.1097/00000542-200004000-00023; Vickers MD, 1991, SYSTEMIC ANALGESICS, P162; Xavier B, 1996, Actas Urol Esp, V20, P883	26	18	18	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0892-7790	1557-900X		J ENDOUROL	J. Endourol.	JUN	2005	19	5					589	594		10.1089/end.2005.19.589			6	Urology & Nephrology	Urology & Nephrology	944EY	WOS:000230410400014	15989452				2020-06-30	J	Cillo, JE; Finn, R				Cillo, JE; Finn, R			Hemodynamics and oxygen saturation during intravenous sedation for office-based laser-assisted uvuloplasty	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							SLEEP-APNEA; CONSCIOUS SEDATION; DAYTIME SLEEPINESS; RANDOMIZED TRIAL; RISK-FACTORS; SHORT-TERM; UVULOPALATOPLASTY; MIDAZOLAM; PROPOFOL; EFFICACY	Purpose: Patients undergoing office-based laser-assisted uvuloplasty (LAUP) for snoring or mild obstructive sleep apnea are generally obese and have a high Mallampati score. Because avoidance of supplemental oxygen during laser procedures is generally mandated, the potential for intraoperative desaturation is high. This study was designed to look at intraoperative hemodynamic changes, respiration patterns, and oxygen saturations during intravenous sedation with midazolam and fentanyl during LAUP procedures. Materials and Methods: This was a retrospective anesthesia chart review of 15 consecutive patients undergoing midazolam/fentanyl intravenous sedation for office-based LAUP treatment for snoring and/or mild obstructive sleep apnea. Data recorded were noninvasive baseline and intraoperative hemodynamic measurements at 5-minute intervals for systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), pulse pressure (PP), pulse (P), and rate-pressure product (RPP). Data collected were reported as mean values with standard deviation. Statistical analysis using the Student's t test was performed and found significant for P < .05. Results: All changes from baseline were statistically insignificant, SBP (P = .4), DBP (P = .2), NLAP (P = .2), P (P = .1), PP (P = .9), RPP (P = .5), RR (P = .9), and SpO(2) (P = .4), and all within +/- 20% of baseline (range, -5.0% to +7.5%). Conclusion: Midazolam and fentanyl intravenous sedation with local anesthesia maintained intraoperative hemodynamic and oxygenation variables close to baseline for office-based LAUP procedures. (c) 2005 American Association of Oral and Maxillofacial Surgeons.	Univ Texas, SW Med Ctr, Parkland Mem Hosp, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Surg, Div Oral & Maxillofacial Surg, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75235 USA; Vet Adm N Texas Hlth Care Syst, Dallas, TX USA	Cillo, JE (reprint author), 2612 Catalina Way, Irving, TX 75060 USA.						[Anonymous], 2001, CLIN PRACTICE GUIDEL; ARAGON SB, 1985, J ORAL MAXIL SURG, V43, P938, DOI 10.1016/0278-2391(85)90006-0; Benumof JL, 2001, J CLIN ANESTH, V13, P144, DOI 10.1016/S0952-8180(01)00232-X; Bitar G, 2003, PLAST RECONSTR SURG, V111, P150, DOI 10.1097/01.PRS.0000037756.88297.BC; Blumen MB, 2002, OTOLARYNG HEAD NECK, V126, P67, DOI 10.1067/mhn.2002.121017; BOA G, 1997, J APPL PHYSIOL, V83, P95; Byrd HS, 2003, PLAST RECONSTR SURG, V112, P636, DOI 10.1097/01.PRS.0000070976.80666.50; Cepeda MS, 2003, CLIN PHARMACOL THER, V74, P102, DOI 10.1016/S0009-9236(03)00152-8; CLARK RNW, 1986, J ORAL MAXIL SURG, V44, P860, DOI 10.1016/0278-2391(86)90222-3; DIERDORF SF, 2002, ANESTHESIA COEXISTIN, P15; Ferguson KA, 2003, AM J RESP CRIT CARE, V167, P15, DOI 10.1164/rccm.2108050; Fletcher EC, 2000, RESP PHYSIOL, V119, P189, DOI 10.1016/S0034-5687(99)00114-0; GARRY BP, 1990, SEMIN SURG ONCOL, V6, P184, DOI 10.1002/ssu.2980060310; Herford AS, 2000, J CRANIO MAXILL SURG, V28, P213, DOI 10.1054/jcms.2000.0148; Hogenson K D, 1992, J Post Anesth Nurs, V7, P38; Hu FB, 2000, J AM COLL CARDIOL, V35, P308, DOI 10.1016/S0735-1097(99)00540-9; JACKSON I, 1994, J ORAL MAXILLOFAC SU, V52, P24; Johns FR, 1998, J ORAL MAXIL SURG, V56, P1124, DOI 10.1016/S0278-2391(98)90749-2; Jordan AS, 2003, CURR OPIN PULM MED, V9, P459, DOI 10.1097/00063198-200311000-00002; Kim YM, 2001, J KOREAN MED SCI, V16, P62, DOI 10.3346/jkms.2001.16.1.62; KRESPI YP, 1994, J OTOLARYNGOL, V23, P328; LAUIE P, 1983, SLEEP, V6, P312; Liistro G, 2003, EUR RESPIR J, V21, P248, DOI 10.1183/09031936.03.00292403; Lindberg E, 2001, AM J RESP CRIT CARE, V164, P2031, DOI 10.1164/ajrccm.164.11.2102028; Maheshwar AA, 2002, INT J CLIN PRACT, V56, P501; MALLAMPATI SR, 1985, CAN ANAESTH SOC J, V32, P429, DOI 10.1007/BF03011357; MORGAN GE, 1992, CLIN ANAESTHESIOL, P347; Morgan S, 1999, BRIT MED J, V318, P368, DOI 10.1136/bmj.318.7180.368; *NAT COMM SLEEP DI, 1995, REP NAT COMM SLEEP D, V2, P10; Neruntarat C, 2001, OTOLARYNG HEAD NECK, V124, P90, DOI 10.1067/mhn.2001.112203; Netzer NC, 2003, CHEST, V124, P1406, DOI 10.1378/chest.124.4.1406; Nugent AM, 2001, J SLEEP RES, V10, P69, DOI 10.1046/j.1365-2869.2001.00226.x; Pastuovic MN, 1996, J ORAL MAXIL SURG, V54, P943, DOI 10.1016/S0278-2391(96)90387-0; PATEL KF, 1981, ANESTH ANALG, V60, P885; Perrott DH, 2003, J ORAL MAXILLOFAC SU, V61, P995; RODRIGO MRC, 1988, J ORAL MAXIL SURG, V46, P746, DOI 10.1016/0278-2391(88)90184-X; Sandler NA, 2001, J ORAL MAXIL SURG, V59, P603, DOI 10.1053/joms.2001.23366; Sarasin DS, 1996, J ORAL MAXIL SURG, V54, P1187, DOI 10.1016/S0278-2391(96)90348-1; Sharp HR, 2001, J LARYNGOL OTOL, V115, P897, DOI 10.1258/0022215011909521; STOELTING RK, 1994, BASICS ANESTHESIA, P251; Terris DJ, 2002, OTOLARYNG HEAD NECK, V127, P315, DOI 10.1067/mhn.2002.128345; Wang H, 2002, CHINESE MED J-PEKING, V115, P1829; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Zamarron C, 1999, RESP MED, V93, P108, DOI 10.1016/S0954-6111(99)90299-8; Zonato AI, 2003, LARYNGOSCOPE, V113, P973, DOI 10.1097/00005537-200306000-00011	45	5	7	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	JUN	2005	63	6					752	755		10.1016/j.joms.2005.02.004			4	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	932PR	WOS:000229566300006	15944969				2020-06-30	J	Ku, ASW; Rodrigo, CR; To, PCY				Ku, ASW; Rodrigo, CR; To, PCY			Anesthetic management of a child with congenital insensitivity to pain with anhydrosis	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							ANHIDROSIS; IV			Rodrigo, CR (reprint author), Block 1,Flat A8,23 Sha Wan Dr, Hong Kong, Hong Kong, Peoples R China.	rodrigo@hkusua.hku.hk					Amano A, 1998, ORAL SURG ORAL MED O, V86, P425, DOI 10.1016/S1079-2104(98)90368-7; Bodner Lipa, 2002, ASDC J Dent Child, V69, P293; Indo Y, 1996, NAT GENET, V13, P485, DOI 10.1038/ng0896-485; Indo Y, 2002, CLIN AUTON RES S1, V12, P120; KASHTAN HI, 1992, ANESTHESIOLOGY, V76, P140, DOI 10.1097/00000542-199201000-00021; MITAKA C, 1985, ANESTHESIOLOGY, V63, P328, DOI 10.1097/00000542-198509000-00018; MORI S, 1988, MASUI, V47, P356; Nagasako EM, 2003, PAIN, V101, P213, DOI 10.1016/S0304-3959(02)00482-7; Okuda K, 2000, PAEDIATR ANAESTH, V10, P545, DOI 10.1046/j.1460-9592.2000.00542.x; ROSEMBERG S, 1994, PEDIATR NEUROL, V11, P50, DOI 10.1016/0887-8994(94)90091-4; Terada Y, 2001, Masui, V50, P789; Tomioka T, 2002, ANESTH ANALG, V94, P271, DOI 10.1097/00000539-200202000-00008; Verze L, 2000, NEUROLOGY, V55, P126, DOI 10.1212/WNL.55.1.126; YAMAMORI Y, 1995, BRAIN RES, V702, P162, DOI 10.1016/0006-8993(95)01037-7	14	6	8	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	JUN	2005	63	6					848	851		10.1016/j.joms.2005.02.023			4	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	932PR	WOS:000229566300023	15944986				2020-06-30	J	Yassen, A; Olofsen, E; Dahan, A; Danhof, M				Yassen, A; Olofsen, E; Dahan, A; Danhof, M			Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: Role of receptor equilibration kinetics	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							ARTERIOVENOUS CONCENTRATION DIFFERENCES; IN-VIVO; OPIOID RECEPTOR; BINDING; PHARMACOLOGY; MORPHINE; AGENT; ANALGESIA; EFFICACY; AFFINITY	The objective of this investigation was to characterize the pharmacokinetic/pharmacodynamic correlation of buprenorphine and fentanyl for the antinociceptive effect in rats. Data on the time course of the antinociceptive effect following intravenous administration of buprenorphine or fentanyl was analyzed in conjunction with plasma concentrations by nonlinear mixed-effects analysis. For fentanyl, the pharmacokinetics was described on the basis of a two-compartment pharmacokinetic model. For buprenorphine, a three-compartment pharmacokinetic model best described the concentration time course. To explain time dependencies in pharmacodynamics of buprenorphine and fentanyl, a combined effect compartment/receptor binding model was applied. A log logistic probability distribution model is proposed to account for censored tail-flick latencies. The model converged, yielding precise estimates of the parameters characterizing hysteresis. The results show that onset and offset of the antinociceptive effect of both buprenorphine and fentanyl is mainly determined by biophase distribution. The k(eo) was 0.024 min(-1) [95% confidence interval (CI): 0.018-0.030 min(-1)] and 0.123 min(-1) (95% CI: 0.095-0.151 min(-1)) for buprenorphine and fentanyl, respectively. On the other hand, part of the hysteresis in the buprenorphine pharmacodynamics could be explained by slow receptor association/ dissociation kinetics. The k(off) was 0.073 min(-1) (95% CI: 0.042-0.104 min(-1)) and k(on) was 0.023 ml/ng/min (95% CI: 0.013-0.033 ml/ng/min). Fentanyl binds instantaneously to the OP3 receptor because no reasonable values for k(on) and k(off) were obtained with the dynamical receptor model. In contrast to earlier reports in the literature, the findings of this study show that the rate-limiting step in the onset and offset of buprenorphine's antinociceptive effect is distribution to the brain.	Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Pharmacol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Ctr Med, Dept Anesthesiol, Leiden, Netherlands	Danhof, M (reprint author), Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Pharmacol, POB 9502, NL-2300 RA Leiden, Netherlands.	m.danhof@lacdr.leidenuniv.nl	Dahan, Albert/B-8845-2008	Dahan, Albert/0000-0003-3161-3945			BEAL SL, 1999, NONMEM USERS GUIDE N; BOAS RA, 1985, BRIT J ANAESTH, V57, P192, DOI 10.1093/bja/57.2.192; BULLINGHAM RES, 1980, CLIN PHARMACOL THER, V28, P667, DOI 10.1038/clpt.1980.219; Christoph T, 2005, EUR J PHARMACOL, V507, P87, DOI 10.1016/j.ejphar.2004.11.052; Cleton A, 1999, J PHARMACOKINET BIOP, V27, P301, DOI 10.1023/A:1020999114109; COWAN A, 1977, BRIT J PHARMACOL, V60, P547, DOI 10.1111/j.1476-5381.1977.tb07533.x; COWAN A, 1977, BRIT J PHARMACOL, V60, P537, DOI 10.1111/j.1476-5381.1977.tb07532.x; Cox D. R., 1984, ANAL SURVIVAL DATA; Cox EH, 1998, J PHARMACOL EXP THER, V284, P1095; DAMOUR F, 1941, J PHARMACOL EXP THER, V77, P74; DUM JE, 1981, BRIT J PHARMACOL, V74, P627, DOI 10.1111/j.1476-5381.1981.tb10473.x; Ette EL, 2003, J CLIN PHARMACOL, V43, P610, DOI 10.1177/0091270003253624; *FDA, 1999, [No title captured]; GAL TJ, 1989, CLIN PHARMACOL THER, V45, P66, DOI 10.1038/clpt.1989.10; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; JASINSKI DR, 1978, ARCH GEN PSYCHIAT, V35, P501; JUSKO WJ, 1995, J PHARMACOKINET BIOP, V23, P5, DOI 10.1007/BF02353781; Luks AM, 1998, J PHARMACOL EXP THER, V284, P136; Lutfy K, 2003, J NEUROSCI, V23, P10331; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; MOK MS, 1981, J CLIN PHARMACOL, V21, P323, DOI 10.1002/j.1552-4604.1981.tb01774.x; OHTANI M, 1995, J PHARMACOL EXP THER, V272, P505; Sarton E, 2000, ANESTHESIOLOGY, V93, P1245, DOI 10.1097/00000542-200011000-00018; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; SHEINER LB, 1979, CLIN PHARMACOL THER, V25, P358; Shimada S, 1996, BIOL PHARM BULL, V19, P430; STANSKI DR, 1987, ANAESTH INTENS CARE, V15, P23, DOI 10.1177/0310057X8701500105; Tuk B, 1998, J PHARMACOL EXP THER, V284, P202; Tuk B, 1997, J PHARMACOKINET BIOP, V25, P39, DOI 10.1023/A:1025767710234; Van der Graaf PH, 1999, J PHARMACOL EXP THER, V290, P702; VanderGraaf PH, 1997, INT J CLIN PHARM TH, V35, P442; VEROTTA D, 1995, J PHARMACOKINET BIOP, V23, P1, DOI 10.1007/BF02353780; VILLIGER JW, 1982, J NEUROCHEM, V38, P1771, DOI 10.1111/j.1471-4159.1982.tb06662.x; Visser SAG, 2003, J PHARMACOL EXP THER, V304, P88, DOI 10.1124/jpet.102.042341; Visser SAG, 2002, J PHARMACOL EXP THER, V302, P1158, DOI 10.1124/jpet.302.3.1158; WALSH SL, 1994, CLIN PHARMACOL THER, V55, P569, DOI 10.1038/clpt.1994.71; WATSON PJQ, 1982, BRIT J ANAESTH, V54, P37, DOI 10.1093/bja/54.1.37; ZHANG AZ, 1981, LIFE SCI, V29, P843; Zuideveld KP, 2002, J PHARMACOL EXP THER, V303, P1130, DOI 10.1124/jpet.102.036798; Zuideveld KP, 2004, J PHARMACOL EXP THER, V308, P1012, DOI 10.1124/jpet.103.059030	40	82	82	0	7	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	JUN	2005	313	3					1136	1149		10.1124/jpet.104.082560			14	Pharmacology & Pharmacy	Pharmacology & Pharmacy	927OM	WOS:000229203200022	15701707				2020-06-30	J	Angeles, DM; Wycliffe, N; Michelson, D; Holshouser, BA; Deming, DD; Pearce, WJ; Sowers, LC; Ashwal, S				Angeles, DM; Wycliffe, N; Michelson, D; Holshouser, BA; Deming, DD; Pearce, WJ; Sowers, LC; Ashwal, S			Use of opioids in asphyxiated term neonates: Effects on neuroimaging and clinical outcome	PEDIATRIC RESEARCH			English	Article							PEDIATRIC INTENSIVE-CARE; VENTILATORY SUPPORT; PROCEDURAL PAIN; CELL-DEATH; IN-VITRO; RAT; BRAIN; ADENOSINE; PRETERM; NEWBORN	Perinatal asphyxia is a common cause of neurologic morbidity in neonates who are born at term. Asphyxiated neonates are frequently treated with analgesic medications, including opioids, for pain and discomfort associated with their care. On the basis of previous laboratory studies suggesting that opioids may have neuroprotective effects, we conducted a retrospective review of medical records of 52 neonates who were admitted to our neonatal intensive care unit between 1995 and 2002 and had undergone magnetic resonance imaging (MRI) of the brain. Our review revealed that 33% of neonates received morphine or fentanyl. The neonates who received opioids also had experienced hypoxic/ischemic insults of greater magnitude as suggested by higher plasma lactate levels and lower 5-min Apgar scores. It is interesting that the MRI studies of neonates who were treated with opioids during the first week of life demonstrated significantly less brain injury in all regions studied. More important, follow-up studies of a subgroup of opioid-treated neonates whose MRI scans were obtained in the second postnatal week had better long-term neurologic outcomes. Our results suggest that the use of opioids in the first week of life after perinatal asphyxia have no significant long-term detrimental effects and may increase the brain's resistance to hypoxic-ischemic insults.	Loma Linda Univ, Sch Med, Dept Physiol & Pharmacol, Loma Linda, CA 92350 USA; Loma Linda Univ, Dept Nursing, Loma Linda, CA 92350 USA; Loma Linda Univ, Dept Radiol, Loma Linda, CA 92350 USA; Loma Linda Univ, Dept Pediat, Loma Linda, CA 92350 USA; Loma Linda Univ, Dept Perinatal Biol, Loma Linda, CA 92350 USA; Loma Linda Univ, Dept Biochem & Microbiol, Loma Linda, CA 92350 USA	Angeles, DM (reprint author), Loma Linda Univ, Sch Med, Dept Physiol & Pharmacol, Loma Linda, CA 92350 USA.	dangeles@som.ilu.edu		Pearce, William/0000-0002-5331-5677; Angeles, Danilyn M./0000-0002-0997-0295	NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [K01 NR008116]		Anand KJS, 2000, BIOL NEONATE, V77, P69, DOI 10.1159/000014197; Anand KJS, 2004, LANCET, V363, P1673, DOI 10.1016/S0140-6736(04)16251-X; Anand KJS, 1999, ARCH PEDIAT ADOL MED, V153, P331; Anand KJS, 2000, PROG BRAIN RES, V122, P117; ARMSTEAD WM, 1995, J CEREBR BLOOD F MET, V15, P539, DOI 10.1038/jcbfm.1995.67; Ashwal S, 1997, ANN NEUROL, V41, P470, DOI 10.1002/ana.410410410; Barker DP, 1996, ARCH DIS CHILD-FETAL, V75, pF187, DOI 10.1136/fn.75.3.F187; Barkovich AJ, 1998, AM J NEURORADIOL, V19, P143; BENNETT GJ, 2000, J PAIN SYMPTOM MANAG, V19, P2; CHIEN S, 1994, J THORAC CARDIOV SUR, V107, P964; Dominguez KD, 2003, ANN PHARMACOTHER, V37, P473, DOI 10.1345/aph.1C324; du Plessis AJ, 2002, CURR OPIN NEUROL, V15, P151, DOI 10.1097/00019052-200204000-00005; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Green CR, 2003, J PAIN, V4, P29, DOI 10.1054/jpai.2003.5; Hajnal BL, 1999, PEDIATR NEUROL, V21, P788, DOI 10.1016/S0887-8994(99)00101-0; Halimi G, 2000, EUR J PHARMACOL, V398, P217, DOI 10.1016/S0014-2999(00)00275-2; Hamrick SEG, 2003, CURR OPIN NEUROL, V16, P147, DOI 10.1097/00019052-200304000-00005; HATTORI H, 1990, PEDIATR NEUROL, V6, P219, DOI 10.1016/0887-8994(90)90111-D; HEURTEAUX C, 1995, P NATL ACAD SCI USA, V92, P4666, DOI 10.1073/pnas.92.10.4666; Jacobs EA, 2000, PEDIATRICS, V106, P358; JENSEN F, 1993, DEV BRAIN RES, V73, P99, DOI 10.1016/0165-3806(93)90051-B; Kofke WA, 1999, BRAIN RES, V818, P326, DOI 10.1016/S0006-8993(98)01228-1; Lee J, 2004, IMMUNOPHARM IMMUNOT, V26, P17, DOI 10.1081/IPH-120029941; Li H, 2000, EUR J PHARMACOL, V407, P237, DOI 10.1016/S0014-2999(00)00661-0; Lim YJ, 2004, ANESTHESIOLOGY, V100, P562, DOI 10.1097/00000542-200403000-00015; MAYFIELD KP, 1994, J PHARMACOL EXP THER, V268, P683; MAYFIELD KP, 1992, BRAIN RES, V582, P226, DOI 10.1016/0006-8993(92)90137-X; Nelson KB, 2003, NEW ENGL J MED, V349, P1765, DOI 10.1056/NEJMsb035364; OLKKOLA KT, 1995, CLIN PHARMACOKINET, V28, P385, DOI 10.2165/00003088-199528050-00004; PASTERNAK GW, 1993, CLIN NEUROPHARMACOL, V16, P1, DOI 10.1097/00002826-199302000-00001; Pasternak JF, 1998, PEDIATR NEUROL, V18, P391, DOI 10.1016/S0887-8994(98)00002-2; Peart JN, 2003, AM J PHYSIOL-HEART C, V285, pH81, DOI 10.1152/ajpheart.00985.2002; POKELA ML, 1994, PEDIATRICS, V93, P379; Reshef A, 2000, PHARMACOL THERAPEUT, V87, P151, DOI 10.1016/S0163-7258(00)00045-0; RUTHERFORD MA, 2002, [No title captured], P99; Saugstad OD, 1996, PEDIATRICS, V98, P103; Schultz JEJ, 1996, CIRC RES, V78, P1100, DOI 10.1161/01.RES.78.6.1100; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIESJO BK, 1989, MAGNESIUM, V8, P223; Simons SHP, 2003, ARCH PEDIAT ADOL MED, V157, P1058, DOI 10.1001/archpedi.157.11.1058; Simons SHP, 2003, JAMA-J AM MED ASSOC, V290, P2419, DOI 10.1001/jama.290.18.2419; Stevens B, 2003, PAIN, V105, P27, DOI 10.1016/S0304-3959(03)00136-2; Stiene-Martin A, 2001, GLIA, V36, P78, DOI 10.1002/glia.1097; Yamakura T, 1999, ANESTHESIOLOGY, V91, P1053, DOI 10.1097/00000542-199910000-00026; Zhang JH, 2002, AM J PHYSIOL-CELL PH, V282, pC1225, DOI 10.1152/ajpcell.00226.2001; Zhang JH, 2000, BRAIN RES, V885, P143, DOI 10.1016/S0006-8993(00)02906-1	47	27	27	0	4	INT PEDIATRIC RESEARCH FOUNDATION, INC	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA	0031-3998			PEDIATR RES	Pediatr. Res.	JUN	2005	57	6					873	878		10.1203/01.PDR.0000157676.45088.8C			6	Pediatrics	Pediatrics	928TC	WOS:000229293600021	15774841	Bronze			2020-06-30	J	Fodale, V; Pratico, C; Tescione, M; Lucanto, T; Tanania, S; Santamaria, LB				Fodale, V; Pratico, C; Tescione, M; Lucanto, T; Tanania, S; Santamaria, LB			Comparative cost-analysis of a propofol-cisatracurium-based anesthesia with remifentanil or fentanyl for laparoscopic surgery	SURGICAL LAPAROSCOPY ENDOSCOPY & PERCUTANEOUS TECHNIQUES			English	Article						anesthesia; intravenous; costs; fentanyl; laparoscopic surgery; propofol; remifentanil	TOTAL INTRAVENOUS ANESTHESIA; BISPECTRAL INDEX; CONTROLLED INFUSION; CHOLECYSTECTOMY; MAINTENANCE; SEVOFLURANE; EMERGENCE; REGIMENS	To compare the intraoperative costs of intravenous propofol-based anesthesia for laparoscopic cholecystectomy, a total of 42 patients were randomly assigned to receive remifentanil or fentanyl as adjuvant using the bispectral index anesthesia monitoring. The average anesthesia calculated costs per hour (and per minute) were 79.45EURO (1.32EURO) in the fentanyl group and 65.36EURO (1.09EURO) in the remifentanil group. The calculated mean cost per patient was 76.56EURO in the fentanyl group and 58.86EURO in the remifentanil group. In conclusion, for propofol-cisatracurium-based anesthesia for laparoscopic surgery, when applying the bispectral index to guide the administration of hypnotic anesthetic drugs and ensure an adequate and stable depth of anesthesia, the cost of anesthesia is lower using remifentanil as an adjuvant rather than fentanyl. The clinical relevance is that it could be the intravenous anesthesia technique of choice in laparoscopic surgery for cholecystectomy from a cost-minimization standpoint.	Univ Messina, Dept Neurosci Psychiat & Anesthesiol Sci, Policlin Univ G Martino, I-98125 Messina, Italy	Fodale, V (reprint author), Univ Messina, Dept Neurosci Psychiat & Anesthesiol Sci, Policlin Univ G Martino, Via C Valeria, I-98125 Messina, Italy.	vfodale@unime.it	Fodale, Vincenzo/G-5554-2010	Fodale, Vincenzo/0000-0001-9540-5665			Abballe C, 1993, G Chir, V14, P493; BUNIATIAN AA, 2001, ANESTEZIOL REANIMAT, V2, P4; Cunningham AJ, 1998, YALE J BIOL MED, V71, P551; CUNNINGHAM AJ, 1994, SURG ENDOSC-ULTRAS, V8, P1272; Drummond GB, 2002, BRIT J ANAESTH, V88, P384, DOI 10.1093/bja/88.3.384; Hoymork SC, 2003, BRIT J ANAESTH, V91, P773, DOI 10.1093/bja/aeg258; Irwin MG, 2002, ANAESTHESIA, V57, P242, DOI 10.1046/j.0003-2409.2001.02446.x; Joshi GP, 2002, J CLIN ANESTH, V14, P494, DOI 10.1016/S0952-8180(02)00404-X; Koitabashi T, 2002, ANESTH ANALG, V94, P1530, DOI 10.1097/00000539-200206000-00028; Lehmann A, 2002, ANESTH ANALG, V95, P639, DOI 10.1097/00000539-200209000-00027; Ludbrook GL, 2003, ANESTH ANALG, V97, P924, DOI 10.1213/01.ANE.0000077162.24188.A8; Schmidt GN, 2004, ANESTH ANALG, V98, P1346, DOI 10.1213/01.ANE.0000111209.44119.30; Smith I, 2003, CNS DRUGS, V17, P609, DOI 10.2165/00023210-200317090-00001; Struys MMRF, 2002, EUR J ANAESTH, V19, P727; Suttner S, 1999, ANESTH ANALG, V88, P77, DOI 10.1097/00000539-199901000-00015; Takrouri Mohammad Said Maani, 1999, Middle East Journal of Anesthesiology, V15, P39; TAYLOR E, 1992, ANESTHESIOLOGY, V76, P541, DOI 10.1097/00000542-199204000-00009; van Delden PG, 2002, ANAESTHESIA, V57, P212, DOI 10.1046/j.0003-2409.2001.02465.x; Vuyk J, 2003, ADV EXP MED BIOL, V523, P95; Wuesten R, 2001, ANESTHESIOLOGY, V94, P211, DOI 10.1097/00000542-200102000-00008	20	2	2	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1530-4515	1534-4908		SURG LAPARO ENDO PER	Surg. Laparosc. Endosc. Pct. Tech.	JUN	2005	15	3					149	152		10.1097/01.sle.0000166963.64521.09			4	Surgery	Surgery	957NM	WOS:000231376500009	15956899				2020-06-30	J	Gaitan, G; Ahuir, FJ; Herrero, JF				Gaitan, G; Ahuir, FJ; Herrero, JF			Enhancement of fentanyl antinociception by subeffective doses of nitroparacetamol (NCX-701) in acute nociception and in carrageenan-induced monoarthritis	LIFE SCIENCES			English	Article						pain; analgesia; spinal cord; opioids; non-steroidal anti-inflammatory drugs; nitric oxide; wind-up	FULL SPINALIZATION; SPINAL-CORD; WIND-UP; MORPHINE; KETOROLAC; RATS; PAIN; ANALGESIA; REFLEXES; POTENCY	We have reported that subanalgesic doses of new generation non-steroidal anti-inflammatory drugs (NSAIDs) enhance the antinociceptive activity of the mu-opiate fentanyl, and the duration of its effect, in acute nociception. Since this therapy is intended for situations of hyperalgesia, we have compared the antinociceptive activity of fentanyl in the absence and in the presence of subeffective doses of NCX-701 (nitroparacetamol) in normal animals and in animals with carrageenan-induced monoarthritis. Subanalgesic dose of NCX-701 did not modify any of the nociceptive responses on its own but reduced the ID50 of fentanyl more than two-fold in both the normal and sensitized states. When administered alone, full recovery from fentanyl was always observed within 15 to 20 minutes, however, full recovery was not observed in the presence of NCX-701. Naloxone was unable to reverse the effect, suggesting a possible reduction of other opiate-mediated secondary effects. We therefore studied the possibility that combining administration of fentanyl and nitroparacetamol (NCX-701) would reduce the development of acute tolerance to fentanyl in behavioral experiments. Acute tolerance to fentanyl in behavioral nociceptive reflexes was developed within 72 h after the constant infusion of the drug, whereas in animals treated with small doses of NCX-701 tolerance was not observed. In summary, our results, both in normal animals and in animals with hyperalgesia, show that fentanyl antinociception can be strongly potentiated with subanalgesic doses of the NSAID NCX-701 and that the development of acute tolerance to fentanyl in normal animals is prevented by this combination of drugs. (c) 2005 Elsevier Inc. All rights reserved.	Univ Alcala de Henares, Dept Fisiol, Fac Med, Madrid 28871, Spain	Herrero, JF (reprint author), Univ Alcala de Henares, Dept Fisiol, Fac Med, Campus Univ, Madrid 28871, Spain.	juanf.herrero@uah.es		Herrero, Juan F./0000-0003-1986-3482			BOSEK V, 1994, CLIN J PAIN, V10, P314, DOI 10.1097/00002508-199412000-00012; BURNS JW, 1991, BRIT J ANAESTH, V67, P235, DOI 10.1093/bja/67.3.235; Carter BL, 2000, PSYCHOPHARMACOLOGY, V148, P384, DOI 10.1007/s002130050067; Celerier E, 1999, BRAIN RES, V847, P18, DOI 10.1016/S0006-8993(99)01998-8; Gaitan G, 2002, BRIT J PHARMACOL, V135, P393, DOI 10.1038/sj.bjp.0704491; GAITAN G, 2003, 33 ANN M SOC NEUR NE; GILLIES GWA, 1987, ANAESTHESIA, V42, P727, DOI 10.1111/j.1365-2044.1987.tb05317.x; Herrero JF, 2000, PROG NEUROBIOL, V61, P169, DOI 10.1016/S0301-0082(99)00051-9; Herrero JF, 1999, BRAIN RES, V840, P106, DOI 10.1016/S0006-8993(99)01780-1; HERRERO JF, 1991, BRIT J PHARMACOL, V104, P166, DOI 10.1111/j.1476-5381.1991.tb12402.x; LAITINEN J, 1992, ANESTHESIOLOGY, V76, P194, DOI 10.1097/00000542-199202000-00006; Lashbrook JM, 1999, PAIN, V82, P65, DOI 10.1016/S0304-3959(99)00031-7; MALMBERG B, 1993, ANESTHESIOLOGY, V79, P70; MAVES TJ, 1994, ANESTHESIOLOGY, V80, P1094, DOI 10.1097/00000542-199405000-00018; Romero-Sandoval EA, 2003, NEUROPHARMACOLOGY, V45, P412, DOI 10.1016/S0028-3908(03)00193-X; Romero-Sandoval EA, 2002, BRIT J PHARMACOL, V135, P1556, DOI 10.1038/sj.bjp.0704589; Solano R, 1997, J NEUROSCI METH, V73, P135, DOI 10.1016/S0165-0270(96)02220-0; Taylor J, 1998, EUR J PHARMACOL, V351, P39, DOI 10.1016/S0014-2999(98)00298-2; Thornton SR, 2000, PHARMACOL BIOCHEM BE, V65, P563, DOI 10.1016/S0091-3057(99)00262-2	19	11	11	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205	1879-0631		LIFE SCI	Life Sci.	MAY 20	2005	77	1					85	95		10.1016/j.lfs.2004.12.022			11	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	922NI	WOS:000228844200008	15848221				2020-06-30	J	Laferriere, A; Colin-Durand, J; Moss, IR				Laferriere, A; Colin-Durand, J; Moss, IR			Ontogeny of respiratory sensitivity and tolerance to the mu-opioid agonist fentanyl in rat	DEVELOPMENTAL BRAIN RESEARCH			English	Article						rat; development; fentanyl; respiratory control; respiratory depression; minute ventilation; plethysmography	MEDULLA-OBLONGATA; MORPHINE; ANALGESIA; RECEPTOR; DEPRESSION; BRAIN; TEMPERATURE; IMMUNOREACTIVITY; DEPENDENCE; INFUSION	Whereas developmental changes in analgesic sensitivity and tolerance to the mu-opioid agonist fentanyl have been reported, knowledge of respiratory responses to that drug is lacking. Using 7- and 14-day-old (P7, P14) and adult conscious rats, we first established, using whole body plethysmography, the fentanyl dose that decreased minute ventilation by 50% (ED50) at each age. ED50 increased with postnatal age (40, 60 and 120 mu g/kg sc, respectively), indicating a high sensitivity to fentanyl in the youngest rats that decreased with maturation. In separate rat groups of the 3 ages, we injected each ED50 dose, once a day, for several consecutive days, until tolerance was established. Tolerance was defined as a reduction in respiratory depression from 50% to 75% of baseline. All age groups reached tolerance in minute ventilation, respiratory frequency, tidal volume and instantaneous flow (equivalent to respiratory drive). The P 14 rat pups attained tolerance more rapidly (at 2.6 days) than did either the younger (5.1 days) or the adult rats (4.4 days). These results indicate that respiratory sensitivity and tolerance to fentanyl in rat vary in a distinct manner during maturation. (c) 2005 Elsevier B.V. All rights reserved.	McGill Univ, Montreal Childrens Hosp, Dept Pediat & Physiol, Res Inst,Dev Resp Lab, Montreal, PQ H3H 1P3, Canada; McGill Univ, Dept Pediat, Montreal, PQ H3A 2T5, Canada; McGill Univ, Ctr Hlth, Inst Res, Montreal, PQ H3A 2T5, Canada	Moss, IR (reprint author), McGill Univ, Montreal Childrens Hosp, Dept Pediat & Physiol, Res Inst,Dev Resp Lab, Room A-707,2300 Tupper St, Montreal, PQ H3H 1P3, Canada.	Immanuela.Moss@muhc.mcgill.ca					Albrecht E, 1997, PHARMACOL BIOCHEM BE, V58, P189, DOI 10.1016/S0091-3057(96)00480-7; ALESSI NE, 1985, NEUROPEPTIDES, V5, P473, DOI 10.1016/0143-4179(85)90057-5; ANAND KJS, 1990, ANESTHESIOLOGY, V73, P661, DOI 10.1097/00000542-199010000-00012; ARNOLD JH, 1991, J PEDIATR-US, V119, P639, DOI 10.1016/S0022-3476(05)82419-9; AYESTA FJ, 1989, J PHARMACOL EXP THER, V250, P371; AYESTA FJ, 1990, EUR J PHARMACOL, V175, P1, DOI 10.1016/0014-2999(90)90145-V; Barr GA, 1999, ANN NY ACAD SCI, V897, P145, DOI 10.1111/j.1749-6632.1999.tb07886.x; BAYON A, 1979, BRAIN RES, V179, P93, DOI 10.1016/0006-8993(79)90493-1; BOOKER P, 1999, PAEDIATR ANAESTH, P115; Choe CH, 2000, PEDIATR RES, V47, P727, DOI 10.1203/00006450-200006000-00008; Colman AS, 2002, EXP BIOL MED, V227, P377; Cote CJ, 2000, PEDIATRICS, V106, P633, DOI 10.1542/peds.106.4.633; DOBBING J, 1982, [No title captured], P744; DOORLEY BM, 1988, LIFE SCI, V43, P365, DOI 10.1016/0024-3205(88)90114-2; FITZGERALD LW, 1993, SYNAPSE, V14, P154, DOI 10.1002/syn.890140208; FLOREZ J, 1982, LIFE SCI, V31, P1275, DOI 10.1016/0024-3205(82)90360-5; Franck LS, 1998, J PAIN SYMPTOM MANAG, V15, P41, DOI 10.1016/S0885-3924(97)00272-8; Hepburn MJ, 1997, J PHARMACOL EXP THER, V281, P1350; HERKENHAM M, 1987, NEUROSCIENCE, V23, P1, DOI 10.1016/0306-4522(87)90268-5; HOVAV E, 1987, J PHARMACOL EXP THER, V242, P251; Javed RR, 2004, EUR J PHARMACOL, V492, P149, DOI 10.1016/j.ejphar.2004.03.061; Kivell BM, 2004, DEV BRAIN RES, V148, P185, DOI 10.1016/j.devbrainres.2003.12.002; KOKKA N, 1965, J PHARMACOL EXP THER, V148, P386; LING GSF, 1983, EUR J PHARMACOL, V86, P487; LING GSF, 1989, LIFE SCI, V45, P1627, DOI 10.1016/0024-3205(89)90272-5; LING GSF, 1985, J PHARMACOL EXP THER, V232, P149; Liu JG, 2001, BRAIN RES REV, V38, P1, DOI 10.1016/S0165-0173(01)00057-1; Marsh DF, 1997, BRIT J ANAESTH, V79, P787; MCGILLIARD KL, 1978, J PHARMACOL EXP THER, V207, P494; MCGILLIARD KL, 1978, J PHARMACOL EXP THER, V207, P891; Mortola JP, 2000, ANNU REV PHYSIOL, V62, P847, DOI 10.1146/annurev.physiol.62.1.847; Mortola JP, 1998, CAN J PHYSIOL PHARM, V76, P937, DOI 10.1139/cjpp-76-10-11-937; Nestler EJ, 1996, NEURON, V16, P897, DOI 10.1016/S0896-6273(00)80110-5; Pan YX, 2003, BIOCHEM BIOPH RES CO, V301, P1057, DOI 10.1016/S0006-291X(03)00089-5; PARONIS CA, 1992, J PHARMACOL EXP THER, V262, P1; PAZOS A, 1984, EUR J PHARMACOL, V99, P15, DOI 10.1016/0014-2999(84)90427-8; ROERIG SC, 1987, BRAIN RES, V400, P278, DOI 10.1016/0006-8993(87)90627-5; Saarenmaa E, 1999, J PEDIATR-US, V134, P144, DOI 10.1016/S0022-3476(99)70407-5; Sim LJ, 1996, J NEUROSCI, V16, P2684; Takita K, 1998, BRAIN RES, V800, P308, DOI 10.1016/S0006-8993(98)00476-4; Thornton SR, 1998, EUR J PHARMACOL, V363, P113, DOI 10.1016/S0014-2999(98)00783-3; Thornton SR, 1997, J PHARMACOL EXP THER, V281, P514; Thornton SR, 1998, DEV BRAIN RES, V105, P269, DOI 10.1016/S0165-3806(97)00185-5; TRUOG R, 1989, CLIN PERINATOL, V16, P61; VANDENHOOGEN RHWM, 1986, J PHARMACOL EXP THER, V237, P252; WINDH RT, 1995, J PHARMACOL EXP THER, V273, P1361; ZOBRIST RH, 1981, EUR J PHARMACOL, V70, P121, DOI 10.1016/0014-2999(81)90206-5	47	7	7	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-3806			DEV BRAIN RES	Dev. Brain Res.	MAY 12	2005	156	2					210	217		10.1016/j.devbrainres.2005.03.002			8	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	931PU	WOS:000229498200011	16099308				2020-06-30	J	Grubb, TL; Gold, JR; Schlipf, JW; Craig, AM; Walker, KC; Riebold, TW				Grubb, TL; Gold, JR; Schlipf, JW; Craig, AM; Walker, KC; Riebold, TW			Assessment of serum concentrations and sedative effects of fentanyl after transdermal administration at three dosages in healthy llamas	AMERICAN JOURNAL OF VETERINARY RESEARCH			English	Article							ADMINISTERED FENTANYL; PHARMACOKINETICS; ANALGESIA; DOGS; CATS; PHARMACODYNAMICS; MORPHINE; PATCH	Objective-To determine the serum concentrations and sedative effects of fentanyl after transdermal administration at 3 dosages in llamas. Animals-9 healthy adult female llamas (mean age, 8 +/- 3 years; mean weight, 150 +/- 18 kg). Procedure-Llamas were allocated to 1 of 3 groups (3 llamas/group). Fentanyl patches (each providing transdermal delivery of 75 mu g of fentanyl/h) were placed on shaved areas of the antebrachium of all llamas. In group 1, llamas were treated with 1 patch (anticipated fentanyl dosage, 75 mu g/h). In group 2, llamas were treated with 2 patches (anticipated fentanyl dosage, 150 mu g/h). In group 3, llamas were treated with 4 patches (anticipated fentanyl dosage, 300 mu g/h). For each llama, the degree of sedation was assessed by use of a subjective scoring system and a blood sample was collected for determination of serum fentanyl concentration at 12, 24, 36, 48, 60, and 72 hours after patch placement. Results-Following the placement of 4 patches, mean +/- SD serum fentanyl concentration in group 3 llamas reached 0.3 +/- 0.08 ng/mL within 12 hours. This concentration was sustained for 72 hours. In group 2, application of 2 patches provided inconsistent results; in group 1, application of 1 patch rarely provided measurable serum fentanyl concentrations. No llamas became sedated at any time. Conclusions and Clinical Relevance-Results suggest that application of four 75 mu g/h fentanyl patches provides consistent, sustained serum fentanyl concentrations without sedation in llamas. However, the serum concentration of fentanyl that provides analgesia in llamas is not known.	Riverview Anim Clin, Uniontown, WA 99179 USA; Cornell Univ, Coll Vet Med, Dept Clin Sci, Ithaca, NY 14853 USA; Oregon State Univ, Coll Vet Med, Dept Clin Sci, Corvallis, OR 97331 USA; Oregon State Univ, Coll Vet Med, Dept Biomed Sci, Corvallis, OR 97331 USA	Grubb, TL (reprint author), Riverview Anim Clin, 2002 L Schultheis Rd, Uniontown, WA 99179 USA.		Craig, A. Morrie/J-5857-2013				Carroll GL, 2001, J AM VET MED ASSOC, V219, P1263, DOI 10.2460/javma.2001.219.1263; Carroll GL, 1999, AM J VET RES, V60, P986; Dowd G., 1998, Veterinary Surgery, V27, P168; Egger CM, 1998, VET SURG, V27, P159, DOI 10.1111/j.1532-950X.1998.tb00114.x; Foley PL, 2001, COMPARATIVE MED, V51, P239; GRUBB TL, 1993, J AM VET MED ASSOC, V203, P1441; Harvey-Clark CJ, 2000, LAB ANIM-UK, V34, P386, DOI 10.1258/002367700780387750; HOLLEY FO, 1988, BRIT J ANAESTH, V60, P608, DOI 10.1093/bja/60.6.608; Kyles AE, 1998, RES VET SCI, V65, P245, DOI 10.1016/S0034-5288(98)90151-5; Kyles AE, 1996, AM J VET RES, V57, P715; Kyles AE, 1998, COMP CONT EDUC PRACT, V20, P721; Lee DD, 2000, AM J VET RES, V61, P672, DOI 10.2460/ajvr.2000.61.672; Maxwell LK, 2003, EQUINE VET J, V35, P484, DOI 10.2746/042516403775600415; Navarre CB, 2001, J VET PHARMACOL THER, V24, P227, DOI 10.1046/j.1365-2885.2001.00324.x; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P757, DOI 10.1016/S0195-5616(08)70005-6; Pettifer GR, 2003, AM J VET RES, V64, P1557, DOI 10.2460/ajvr.2003.64.1557; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; Sarton E, 2000, ANESTHESIOLOGY, V93, P1245, DOI 10.1097/00000542-200011000-00018; ScherkNixon M, 1996, J AM ANIM HOSP ASSOC, V32, P19, DOI 10.5326/15473317-32-1-19; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Wilkinson AC, 2001, CONTEMP TOP LAB ANIM, V40, P12	21	9	9	0	3	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0002-9645			AM J VET RES	Am. J. Vet. Res.	MAY	2005	66	5					907	909		10.2460/ajvr.2005.66.907			3	Veterinary Sciences	Veterinary Sciences	922CT	WOS:000228814200022	15934620				2020-06-30	J	Lane, S; Evans, P; Arfeen, Z; Misra, U				Lane, S; Evans, P; Arfeen, Z; Misra, U			A comparison of intrathecal fentanyl and diamorphine as adjuncts in spinal anaesthesia for Caesarean section	ANAESTHESIA			English	Article							DOSE-RESPONSE; MORPHINE; ANALGESIA; BUPIVACAINE; DELIVERY; EPINEPHRINE; RELIEF; PAIN	This randomised controlled trial examines the effects of fentanyl and diamorphine, alone and in combination, as adjuncts to spinal anaesthesia for Caesarean section. Ninety-nine women undergoing elective Caesarean section with spinal anaesthesia using 0.5% hyperbaric bupivacaine were randomly allocated to receive fentanyl 15 mu g (F), diamorphine 0.25 mg (D), or fentanyl 15 mu g plus diamorphine 0.25 mg (FD), intrathecally. All women received morphine via a patient controlled analgesia system after surgery. There was no significant difference between the groups in time to achieve a block, discomfort, ephedrine use, nausea and vomiting, pruritus and sedation during surgery. Significant differences were observed in morphine consumption 4, 8, 12 and 24 h after surgery between both F and D groups, and F and FD groups, and also at 2 h between F and FD groups. There was a significant difference in pruritus at 4 h between the F and FD group. Our results suggest that diamorphine alone provides optimum benefits during and after surgery, when used in combination with hyperbaric bupivacaine for Caesarean section.	Sunderland Royal Hosp, Dept Anaesthesia, Sunderland SR4 7TP, Durham, England; St George Hosp, Sydney, NSW 2217, Australia	Misra, U (reprint author), Sunderland Royal Hosp, Dept Anaesthesia, Kayll Rd, Sunderland SR4 7TP, Durham, England.	upma.misra@chs.northy.nhs.uk		Lane, Andrew Stuart/0000-0001-8650-5509			ABBOUD TK, 1988, ANESTH ANALG, V67, P137; ABOULEISH E, 1988, ANESTH ANALG, V67, P370; ABOULEISH E, 1993, ANESTH ANALG, V77, P457; Barkshire K, 2001, INT J OBSTET ANESTH, V10, P4, DOI 10.1054/ijoa.2000.0718; BELZARENA SD, 1992, ANESTH ANALG, V74, P653; Ben-David B, 2000, REGION ANESTH PAIN M, V25, P235, DOI 10.1016/S1098-7339(00)90004-X; Chu C C, 1995, Acta Anaesthesiol Sin, V33, P149; CONNELLY NR, 1994, ANESTH ANALG, V78, P918; Cowan CM, 2002, BRIT J ANAESTH, V89, P452; DENNIS AR, 1995, ANAESTHESIA, V50, P297, DOI 10.1111/j.1365-2044.1995.tb04602.x; HUNT CO, 1989, ANESTHESIOLOGY, V71, P535, DOI 10.1097/00000542-198910000-00009; Husaini SW, 1998, BRIT J ANAESTH, V81, P135; Kelly MC, 1998, ANAESTHESIA, V53, P231, DOI 10.1046/j.1365-2044.1998.00307.x; LANE S, 2002, INT J OBSTET ANAES S, V11; PALMER CM, 1995, REGION ANESTH, V20, P389; Palmer CM, 1999, ANESTHESIOLOGY, V90, P437, DOI 10.1097/00000542-199902000-00018; Shende D, 1998, ANAESTHESIA, V53, P706, DOI 10.1046/j.1365-2044.1998.329-az0482.x; Sibilla C, 1997, INT J OBSTET ANESTH, V6, P43, DOI 10.1016/S0959-289X(97)80051-9; Skilton RWH, 1999, INT J OBSTET ANESTH, V8, P231, DOI 10.1016/S0959-289X(99)80102-2; Swart M, 1997, ANAESTHESIA, V52, P373, DOI 10.1111/j.1365-2044.1997.az0083c.x; Yang T, 1999, CAN J ANAESTH, V46, P856, DOI 10.1007/BF03012975	21	12	12	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	MAY	2005	60	5					453	457		10.1111/j.1365-2044.2005.04175.x			5	Anesthesiology	Anesthesiology	915IG	WOS:000228291300007	15819765				2020-06-30	J	Hammer, GB; Ramamoorthy, C; Cao, H; Williams, GD; Boltz, MG; Kamra, K; Drover, DR				Hammer, GB; Ramamoorthy, C; Cao, H; Williams, GD; Boltz, MG; Kamra, K; Drover, DR			Postoperative analgesia after spinal blockade in infants and children undergoing cardiac surgery	ANESTHESIA AND ANALGESIA			English	Article							OPEN-HEART-SURGERY; TOTAL INTRAVENOUS ANESTHESIA; ARTERY BYPASS-SURGERY; INTRATHECAL MORPHINE; EARLY EXTUBATION; REMIFENTANIL; PROPOFOL; FENTANYL; SUFENTANIL; AGE	The aim of this prospective, randomized, controlled clinical trial was to define the opioid analgesic requirement after a remifentanil (REMI)-based anesthetic with spinal anesthetic blockade (SAB+REMI) or without (REMI) spinal blockade for open-heart surgery in children. We enrolled 45 patients who were candidates for tracheal extubation in the operating room after cardiac surgery. Exclusion criteria included age < 3 mo and > 6 yr, pulmonary hypertension, congestive heart failure, contraindication to SAB, and failure to obtain informed consent. All patients had an inhaled induction with sevoflurane and maintenance of anesthesia with REMI and isoflurane (0.3% end-tidal). In addition, patients assigned to the SAB + REMI group received SAB with tetracaine (0.5-2.0 mg/kg) and morphine (7 mu g/kg). After tracheal extubation in the operating room, patients received fentanyl 0.3 mu g/kg IV every 10 min by patient-controlled analgesia for pain score = 4. Pain scores and fentanyl doses were recorded every hour for 24 h or until the patient was ready for discharge from the intensive care unit. Patients in the SAB+REMI group had significantly lower pain scores (P = 0.046 for the first 8 h; P = 0.05 for 24 h) and received less IV fentanyl (P = 0.003 for the first 8 h; P = 0.004 for 24 h) than those in the REMI group. There were no intergroup differences in adverse effects, including hypotension, bradycardia, highest PaCO2, lowest pH, episodes of oxygen desaturation, pruritus, and vomiting.	Stanford Univ, Med Ctr, Dept Anesthesia, Stanford, CA 94305 USA; Stanford Univ, Med Ctr, Dept Pediat, Stanford, CA 94305 USA	Hammer, GB (reprint author), Stanford Univ, Med Ctr, Dept Anesthesia, 300 Pasteur Dr,Room H3580, Stanford, CA 94305 USA.	ham@Stanford.edu					Bowler I, 2002, J CARDIOTHOR VASC AN, V16, P709, DOI 10.1053/jcan.2002.128414; Chaney MA, 1996, ANESTH ANALG, V83, P215, DOI 10.1097/00000539-199608000-00003; DOHI S, 1979, ANESTHESIOLOGY, V50, P319; Elliott P, 2000, ANESTH ANALG, V91, P58, DOI 10.1097/00000539-200007000-00011; Finkel JC, 2003, PAEDIATR ANAESTH, V13, P48, DOI 10.1046/j.1460-9592.2003.00962.x; Friesen RH, 2003, PAEDIATR ANAESTH, V13, P122, DOI 10.1046/j.1460-9592.2003.00978.x; Goldstein S, 2001, J CARDIOTHOR VASC AN, V15, P158, DOI 10.1053/jcan.2001.21937; Guarracino E, 2003, EUR J ANAESTH, V20, P385, DOI 10.1097/00003643-200305000-00006; Hammer GB, 2000, ANESTH ANALG, V90, P1020, DOI 10.1097/00000539-200005000-00004; Howie MB, 2001, ANESTH ANALG, V92, P1084; JONES SEF, 1984, BRIT J ANAESTH, V56, P137, DOI 10.1093/bja/56.2.137; KOWALEWSKI RJ, 1994, CAN J ANAESTH, V41, P1189, DOI 10.1007/BF03020660; Lehmann A, 1999, J CARDIOTHOR VASC AN, V13, P15, DOI 10.1016/S1053-0770(99)90166-0; Lehmann A, 2000, J CARDIOTHOR VASC AN, V14, P416, DOI 10.1053/jcan.2000.7945; MATHEWS ET, 1980, LANCET, V2, P543; Merkel S I, 1997, Pediatr Nurs, V23, P293; Minto CF, 1997, ANESTHESIOLOGY, V86, P10, DOI 10.1097/00000542-199701000-00004; Olivier P, 2000, J CARDIOTHOR VASC AN, V14, P29, DOI 10.1016/S1053-0770(00)90052-1; Pirat A, 2002, ANESTH ANALG, V95, P1207, DOI 10.1097/00000539-200211000-00017; Royston D, 1995, Eur J Anaesthesiol Suppl, V10, P77; Straka Z, 2002, ANN THORAC SURG, V74, P1544, DOI 10.1016/S0003-4975(02)03934-6; Taylor A, 1996, J CARDIOTHOR VASC AN, V10, P225, DOI 10.1016/S1053-0770(96)80242-4; TOBIAS JD, 1990, CLIN PEDIATR, V29, P44, DOI 10.1177/000992289002900107; Tryba M, 1993, Anasthesiol Intensivmed Notfallmed Schmerzther, V28, P179, DOI 10.1055/s-2007-998902; VANSTRUM GS, 1988, ANESTH ANALG, V67, P261; WHALEY L, 1991, NURSING CARE INFANTS, P1148; Zarate E, 2000, ANESTH ANALG, V91, P283	27	23	23	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAY	2005	100	5					1283	1288		10.1213/01.ANE.0000148698.84881.10			6	Anesthesiology	Anesthesiology	921HR	WOS:000228755400013	15845670				2020-06-30	J	Viscusi, ER; Martin, G; Hartrick, CT; Singla, N; Manvelian, G				Viscusi, ER; Martin, G; Hartrick, CT; Singla, N; Manvelian, G		EREM Study Grp	Forty-eight hours of postoperative pain relief after total hip arthroplasty with a novel, extended-release epidural morphine formulation	ANESTHESIOLOGY			English	Article							PATIENT-CONTROLLED ANALGESIA; REHABILITATION; PREDICTOR; SURGERY	Background. Epidural morphine has proven analgesic efficacy, in the postoperative period and is widely used. This study evaluated the efficacy of extended-release epidural morphine (EREM; DepoDur; Endo Pharmaceuticals Inc., Chadds Ford, PA; SkyePharma, Inc., San Diego, CA) in providing pain relief for 48 h after surgery. Methods: Patients (n = 200) scheduled to undergo total hip arthroplasty were randomized to receive a single dose of 15, 20, or 25 mg EREM or placebo. After surgery and after asking for pain medication, patients had access to intravenous patient-controlled analgesia fentanyl for breakthrough pain as needed. Postoperative intravenous patient-controlled analgesia fentanyl use, time to first postoperative fentanyl use, pain intensity at rest and with activity, patient and surgeon ratings of pain control, and adverse events were recorded. Results: All EREM dosages reduced the mean (+/- SD) fentanyl use versus placebo (510 +/- 708 vs. 2,091 +/- 1,803 mu g; P < 0.0001) and delayed the median time to first dose of fentanyl (21.3 vs. 3.6 h; P < 0.0001). All EREM groups had significantly improved pain control at rest through 48 h postdose (area under the curve [0-48 h]) compared with placebo (P < 0.0005). More EREM-treated patients rated their pain control as good or very good compared with placebo (at 24 h: 90 vs. 65%, P < 0.0001; at 48 h: 83 vs. 67%, P < 0.05). No supplemental analgesia was needed in 25% of EREM-treated patients and 2% of placebo-treated patients at 48 h (P < 0.05). The safety profile of EREM was consistent with that of other epidurally administered opioid analgesics. Conclusions: EREM provided significant postoperative pain relief over a 48-h period after hip surgery, without the need for indwelling epidural catheters.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Anesthesiol, Philadelphia, PA 19107 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; William Beaumont Hosp, Dept Anesthesia, Royal Oak, MI 48072 USA; Huntington Mem Hosp, Dept Anesthesiol, Pasadena, CA USA; SkyePharma Inc, San Diego, CA USA	Viscusi, ER (reprint author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Anesthesiol, 111 S 11th St, Philadelphia, PA 19107 USA.	eugene.viscusi@jefferson.edu					[Anonymous], 2002, Health Devices, V31, P342; BEILIN Y, 1995, ANESTH ANALG, V81, P301; Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; Capdevila X, 1999, ANESTHESIOLOGY, V91, P8, DOI 10.1097/00000542-199907000-00006; Carli F, 2002, ANESTHESIOLOGY, V97, P540, DOI 10.1097/00000542-200209000-00005; DUPEN SL, 1990, ANESTHESIOLOGY, V73, P905, DOI 10.1097/00000542-199011000-00018; Horlocker TT, 2003, REGION ANESTH PAIN M, V28, P172, DOI 10.1053/rapm.2003.50046; Howell SB, 2001, CANCER J, V7, P219; Jain S, 1997, Chest Surg Clin N Am, V7, P773; Liu SS, 1996, ANESTH ANALG, V83, P97, DOI 10.1097/00000539-199607000-00017; Macintyre PE, 1996, PAIN, V64, P357, DOI 10.1016/0304-3959(95)00128-X; Ng JM, 2002, ANN ACAD MED SINGAP, V31, P509; PEGUES DA, 1994, CLIN INFECT DIS, V19, P970, DOI 10.1093/clinids/19.5.970; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; ROSEN MA, 1983, ANESTH ANALG, V62, P666; RUTTER DV, 1981, BRIT J ANAESTH, V53, P915, DOI 10.1093/bja/53.9.915; Salvati EA, 2000, J BONE JOINT SURG AM, V82A, P252; Sarvela J, 2002, ANESTH ANALG, V95, P436, DOI 10.1097/00000539-200208000-00037; SINATRA RS, 2002, J AM ACAD ORTHOP SUR, V10, P117; Singelyn FJ, 1998, ANESTH ANALG, V87, P88, DOI 10.1097/00000539-199807000-00019; Vicente KJ, 2003, CAN J ANAESTH, V50, P328, DOI 10.1007/BF03021027; WEITZ SR, 1995, ANESTHESIOLOGY, V83, P96, DOI 10.1097/00000542-199507000-00012; White PF, 2002, ANESTH ANALG, V94, P577, DOI 10.1097/00000539-200203000-00019	23	83	86	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	MAY	2005	102	5					1014	1022		10.1097/00000542-200505000-00022			9	Anesthesiology	Anesthesiology	920EU	WOS:000228673000021	15851890				2020-06-30	J	Bahn, EL; Holt, KR				Bahn, EL; Holt, KR			Procedural sedation and analgesia: A review and new concepts	EMERGENCY MEDICINE CLINICS OF NORTH AMERICA			English	Review							PEDIATRIC EMERGENCY-DEPARTMENT; PULMONARY ASPIRATION; CLINICAL-TRIAL; PROPOFOL; ETOMIDATE; MIDAZOLAM; CHILDREN; DISLOCATION; REDUCTION; MEDICINE	Providing sedation and analgesia (PSA) to patients to accomplish painful procedures or difficult diagnostic imaging is becoming a standard practice in every emergency department (ED). Emergency physicians (EPs) are called upon daily to provide this service. Despite the emergence as a common procedure, PSA is as yet an evolving area of emergency medicine marked with tradition, unchallenged dogma, and unanswered questions. Heretofore we used the term "conscious sedation" to define the act of giving sedatives and analgesics to patients. This term has since been abandoned for a more precise and meaningful title. Conscious sedation implies an alert patient yet sedated. It is an oxymoron. In addition, it is an imprecise description of the patient. During this procedure patients experience a spectrum of sedation, most of which is not in the "conscious" zone. The term conscious sedation is not recognized by the Joint Commission on Accreditation of Health Care Organizations (JCAHO) as a measurable level of sedation, and has since been abandoned for a more inclusive yet flexible title, "procedural sedation and analgesia" [1]. In 2001, JCAHO created sedation guidelines in an attempt to define the spectrum of procedural sedation and analgesia and provide a qualitative measurement for EPs [2]. The spectrum ranges from minimal sedation to general anesthesia, with defined criteria at each level. Minimal sedation is equivalent to anxiolysis. It is a drug-induced state during which patients respond normally to verbal commands. Respiratory and cardiovascular functions are not affected [2]. Next in the spectrum is moderate sedation/analgesia. This describes a depression of consciousness during which patients respond purposefully to verbal commands, either alone or accompanied by light tactile stimulation. Spontaneous ventilation is adequate, and cardiovascular function is usually maintained [2]. The deeper levels of the spectrum range from "deep sedation" to "general anesthesia." Deep sedation/analgesia describes a depression of consciousness during which patients cannot be easily aroused but respond purposefully following repeated or painful stimuli. Patients may require assistance in maintaining a patent airway and spontaneous ventilation. Cardiovascular function is usually maintained [2]. General anesthesia is the point at which consciousness is lost and the patient is not rousable to stimuli. The patient requires respiratory assistance and cardiovascular function is often impaired [2]. Another level of sedation, which may be placed along with moderate sedation, is dissociative sedation. This is a relatively new description since the introduction of ketamine as a sedative agent. It is characterized as a trance-like cataleptic state induced by a dissociative agent that provides profound analgesia and amnesia. Protective airway reflexes and spontaneous respirations are maintained along with cardiovascular stability [2]. The JCAHO sedation guidelines provide qualitative goals for the EP when he/she is conducting PSA, The ideal is to fulfill all the goals of PSA, which are to alleviate anxiety. minimize physical pain and discomfort, and maximize amnesia. In addition, PSA Should assist in controlling behavior to expedite the procedure while minimizing negative psychologic responses to treatment. Last, the EP strives to maintain safety by minimizing risks and ensuring safe discharge. PSA continues to evolve within emergency medicine. This field of practice is becoming more defined. Clinical dogma is being challenged, resulting in new concepts and application to emergency medicine. Last, EPs are building experience with multiple drugs. which adds to Our armamentarium. By understanding the current and new concepts or PSA. becoming familiar with the pharmacologic agents. and appreciating the spectrum of sedation, the EP can reach his clinical goals.	Madigan Army Med Ctr, Dept Emergency Med, Ft Lewis, WA USA	Bahn, EL (reprint author), Madigan Army Med Ctr, Dept Emergency Med, Ft Lewis, WA USA.	elizabeth_bahn@hotmail.com					Agrawal D, 2003, ANN EMERG MED, V42, P636, DOI 10.1016/S0196-0644(03)00516-X; *AM SOC AN, [No title captured]; Bassett KE, 2003, ANN EMERG MED, V42, P773, DOI 10.1016/S0196-0644(03)00619-X; Burton JH, 2002, ANN EMERG MED, V40, P496, DOI 10.1067/mem.2002.126607; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Chudnofsky CR, 2000, ACAD EMERG MED, V7, P228, DOI 10.1111/j.1553-2712.2000.tb01064.x; CHUDNOFSKY CR, 2002, ROSENS EMERGENCY MED, P2581; Coll-Vinent B, 2003, ANN EMERG MED, V42, P767, DOI 10.1016/S0196-0644(03)00510-9; Cromhout Andries, 2003, Emerg Med (Fremantle), V15, P155, DOI 10.1046/j.1442-2026.2003.00433.x; Frenzel D, 2002, INTENS CARE MED, V28, P178, DOI 10.1007/s00134-001-1183-4; Gill M, 2003, ANN EMERG MED, V41, P234, DOI 10.1067/mem.2003.53; Green SM, 2003, ANN EMERG MED, V42, P792, DOI 10.1016/S0196-0644(03)00746-7; Green SM, 2003, ANN EMERG MED, V42, P647, DOI 10.1016/S0196-0644(03)00636-X; Green SM, 2002, ANN EMERG MED, V39, P433, DOI 10.1067/mem.2002.122770; Green SM, 2002, ACAD EMERG MED, V9, P35, DOI 10.1197/aemj.9.1.35; Guenther E, 2003, ANN EMERG MED, V42, P783, DOI 10.1016/S0196-0644(03)00634-6; GUENTHERSKOKAN E, 2001, CLIN PEDIATR, V40, P663; Havel CJ, 1999, ACAD EMERG MED, V6, P989, DOI 10.1111/j.1553-2712.1999.tb01180.x; *JOINT COMM ACCR H, 2001 SED AN CAR STAN; Keim SM, 2002, PHARMACOTHERAPY, V22, P586, DOI 10.1592/phco.22.8.586.33204; Miner JR, 2003, ACAD EMERG MED, V10, P931, DOI 10.1197/S1069-6563(03)00310-5; Miner JR, 2003, ACAD EMERG MED, V10, P638, DOI 10.1197/aemj.10.6.638; Miner JR, 2002, ACAD EMERG MED, V9, P275, DOI 10.1197/aemj.9.4.275; Muse DA, 2001, CLIN PRACTICE EMERGE, P1761; RAIDOO DM, 1990, BRIT J ANAESTH, V65, P248, DOI 10.1093/bja/65.2.248; ROWOW C, 1998, ANESTHESIOL CLIN N A, V2, P89; Ruth WJ, 2001, ACAD EMERG MED, V8, P13, DOI 10.1111/j.1553-2712.2001.tb00539.x; Vardi A, 2002, CRIT CARE MED, V30, P1231, DOI 10.1097/00003246-200206000-00010; Vinson DR, 2002, ANN EMERG MED, V39, P592, DOI 10.1067/mem.2002.123695; Warner MA, 1999, ANESTHESIOLOGY, V90, P896	30	64	66	0	9	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0733-8627			EMERG MED CLIN N AM	Emerg. Med. Clin. N. Am.	MAY	2005	23	2					503	+		10.1016/j.emc.2004.12.013			16	Emergency Medicine	Emergency Medicine	922HM	WOS:000228827600014	15829394				2020-06-30	J	Bouaggad, A; Bouderka, MA; Abassi, O				Bouaggad, A; Bouderka, MA; Abassi, O			Total intravenous anaesthesia with propofol for myasthenic patients	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Letter							GRAVIS		CHU Ibn Rochd, Dept Anaesthesiol & Intens Care, Casablanca 20000, Morocco	Bouaggad, A (reprint author), CHU Ibn Rochd, Dept Anaesthesiol & Intens Care, Casablanca 20000, Morocco.	Bouaggad@hotmial.com					AZAR I, 1984, ANESTHESIOLOGY, V61, P173, DOI 10.1097/00000542-198408000-00011; DRACHMAN DB, 1994, NEW ENGL J MED, V330, P1797, DOI 10.1056/NEJM199406233302507; ELDAWLATLY AA, 1994, ANAESTH INTENS CARE, V22, P458, DOI 10.1177/0310057X9402200423; O'Flaherty D, 1992, J Clin Anesth, V4, P241; VibyMogensen J, 1996, ACTA ANAESTH SCAND, V40, P59, DOI 10.1111/j.1399-6576.1996.tb04389.x	5	6	7	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	MAY	2005	22	5					393	394		10.1017/S0265021505220677			2	Anesthesiology	Anesthesiology	932DZ	WOS:000229535700015	15918391				2020-06-30	J	Mekis, D; Kamenik, M				Mekis, D; Kamenik, M			Remifentanil and high thoracic epidural anaesthesia: a successful combination for patients with myasthenia gravis undergoing transsternal thymectomy	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Letter									Maribor Teaching Hosp, Dept Anesthesiol Intens Care & Pain Management, Maribor 2000, Slovenia	Mekis, D (reprint author), Maribor Teaching Hosp, Dept Anesthesiol Intens Care & Pain Management, Ljubljanska 5, Maribor 2000, Slovenia.	dmekis@siol.net					Akpolat N, 1997, EUR J ANAESTH, V14, P220, DOI 10.1046/j.1365-2346.1997.00113.x; Baraka AS, 2004, ANESTHESIOLOGY, V100, P460, DOI 10.1097/00000542-200402000-00055; Lorimer M, 1998, ANAESTH INTENS CARE, V26, P210, DOI 10.1177/0310057X9802600216; Manullang J, 1999, ANESTH ANALG, V89, P529, DOI 10.1097/00000539-199908000-00053; Richman DP, 2003, NEUROLOGY, V61, P1652, DOI 10.1212/01.WNL.0000098887.24618.A0; ROSOW C, 1993, ANESTHESIOLOGY, V79, P875; Wilkins K B, 1999, Adv Surg, V32, P105	7	9	10	0	0	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	MAY	2005	22	5					397	399		10.1017/S0265021505250676			3	Anesthesiology	Anesthesiology	932DZ	WOS:000229535700018	15918394				2020-06-30	J	Akin, A; Guler, G; Esmaoglu, A; Bedirli, N; Boyaci, A				Akin, A; Guler, G; Esmaoglu, A; Bedirli, N; Boyaci, A			A comparison of fentanyl-propofol with a ketamine-propofol combination for sedation during endometrial biopsy	JOURNAL OF CLINICAL ANESTHESIA			English	Article						anesthetics; intravenous; biopsy; endometrial; fentanyl; ketamine; propofol; sedation	MONITORED ANESTHESIA CARE; SURGERY	Study Objective: The purpose of this study was to compare the clinical activities of ketamine and fentanyl when used in combination with propofol for outpatients undergoing endometrial biopsy. The investigated parameters were respiration, sedation, recovery rate, side effects, time to discharge, and patient satisfaction. Design: Prospective, randomized, double-blind study. Setting: University hospital. Patients: Forty American Society of Anesthesiologists physical status I and II patients (age range 38-61 years) scheduled for elective endometrial biopsy. Interventions: Patients received intravenous bolus doses of either fentanyl 1 mu g/kg and propofol I mg/kg in (group 1 n = 20) or ketamine 0.5 mg/kg and propofol I mg/kg in (group 2 n = 20). Measurements: Heart rate, systolic and diastolic blood pressure, respiratory rate, and peripheral O-2 saturation were monitored in all patients. Depth of sedation was assessed by the Ramsay sedation score. The Aldrete score was used for postoperative recovery evaluation. The time to Aldrete score >= 8, side effects, and time to discharge were recorded. Main Results: Respiratory depression was observed in 5 patients from group 1 and 1 patient from group 2, but the difference was not significant (P >.05). Nausea, vertigo, and visual disturbances were more frequent in group 2 (P <.05). The time to Aldrete score >= 8 was similar in the 2 groups (6.2 +/- 3.5 minutes in group 1 and 7.0 +/- 3.1 minutes in group 2); the time to discharge was significantly longer in group 2 (71.2 +/- 9.7 minutes in group 1 and 115.2 +/- 25.6 minutes in group 2). Frequency of patient satisfaction was 95% in group 1 and 60% in group 2. Conclusions: Hemodynamic change and degrees of sedation showed that fentanyl-propofol and ketamine-fentanyl combinations can be used safely in patients undergoing endometrial biopsy. However, with regard to side effects and patient satisfaction, the fentanyl-propofol was superior. (c) 2005 Elsevier Inc. All rights reserved.	Erciyes Univ, Sch Med, Dept Anesthesiol, TR-38039 Kayseri, Turkey	Akin, A (reprint author), Alpaslan Mah,Kandilli Sok,Bezciler Sitesi 3,Block, TR-38030 Kayseri, Turkey.	aaynur@erciyes.edu.tr		Bedirli, Nurdan/0000-0003-2624-0259			ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Avramov MN, 1996, ANESTHESIOLOGY, V85, P1283, DOI 10.1097/00000542-199612000-00009; Avramov MN, 1997, ANESTH ANALG, V85, P566, DOI 10.1097/00000539-199709000-00015; Badrinath S, 2000, ANESTH ANALG, V90, P858, DOI 10.1213/00000539-200004000-00016; CHUNG F, 1995, ANESTH ANALG, V80, P896, DOI 10.1097/00000539-199505000-00008; Frey K, 1999, ANESTH ANALG, V89, P317, DOI 10.1097/00000539-199908000-00013; Frizelle HP, 1997, ANESTH ANALG, V84, P1318, DOI 10.1097/00000539-199706000-00026; JAKOBSSON J, 1993, ANAESTHESIA, V48, P1005; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; SADOVE MS, 1971, ANESTH ANAL CURR RES, V50, P452; SaRego MM, 1997, ANESTH ANALG, V85, P1020, DOI 10.1097/00000539-199711000-00012; SMITH C, 1994, ANESTHESIOLOGY, V81, P820, DOI 10.1097/00000542-199410000-00008; SMITH I, 1994, ANESTH ANALG, V79, P313; SMITH I, 1994, ANESTHESIOLOGY, V81, P1005; Suzuki M, 1999, ANESTH ANALG, V89, P98, DOI 10.1097/00000539-199907000-00017; VUKYK J, 1995, ANESTHESIOLOGY, V83, P8; WHITE PF, 1982, ANESTHESIOLOGY, V56, P119, DOI 10.1097/00000542-198202000-00007	17	35	37	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	MAY	2005	17	3					187	190		10.1016/j.jclinane.2004.06.019			4	Anesthesiology	Anesthesiology	934DW	WOS:000229688100008	15896585				2020-06-30	J	Oltmanns, KM; Fehm, HL; Peters, A				Oltmanns, KM; Fehm, HL; Peters, A			Chronic fentanyl application induces adrenocortical insufficiency	JOURNAL OF INTERNAL MEDICINE			English	Article						adrenocortical insufficiency; hypothalamus-pituitary-adrenal axis; opiate; pain	CORTICOTROPIN-RELEASING FACTOR; ENDOGENOUS OPIOID-PEPTIDES; TRANSDERMAL FENTANYL; CHRONIC EXPOSURE; MORPHINE; SECRETION; PAIN; HORMONE; RATS	We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome. Shortly before admission to our hospital, the patient had discontinued his hydrocortisone medication. Adrenal crisis was assumed and during therapy with hydrocortisone infusion, the patient recovered. We suspected an opiate-induced suppression of the hypothalamus-pituitary-adrenal (HPA) axis. Therefore, we gradually reduced the opiate dosage. After 1 week, HPA axis function was markedly improved. We conclude that opiate medication may inhibit - in a life-threatening way - the organism's ability to respond to physical, emotional or metabolic stressors.	Med Univ Lubeck, Dept Neuroendocrinol, D-23538 Lubeck, Germany; Med Univ Lubeck, Dept Psychiat & Psychotherapy, D-23538 Lubeck, Germany; Med Univ Lubeck, Dept Internal Med, D-23538 Lubeck, Germany	Oltmanns, KM (reprint author), Med Univ Lubeck, Dept Neuroendocrinol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	oltmanns@medinf.mu-luebeck.de					Broadbear JH, 2004, PSYCHOPHARMACOLOGY, V176, P398, DOI 10.1007/s00213-004-1891-x; BUCKINGHAM JC, 1982, NEUROENDOCRINOLOGY, V35, P111, DOI 10.1159/000123364; DACKIS CA, 1982, LANCET, V2, P1167; DELITALA G, 1983, NEUROENDOCRINOLOGY, V37, P275, DOI 10.1159/000123558; Drolet G, 2001, PROG NEURO-PSYCHOPH, V25, P729, DOI 10.1016/S0278-5846(01)00161-0; ElDaly ES, 1996, LIFE SCI, V59, P1881, DOI 10.1016/S0024-3205(96)00535-8; GOLD MS, 1981, DRUG ALCOHOL DEPEN, V8, P257, DOI 10.1016/0376-8716(81)90069-7; HOWLETT TA, 1986, ANNU REV PHYSIOL, V48, P527; Katz N, 2002, J PAIN SYMPTOM MANAG, V24, pS38, DOI 10.1016/S0885-3924(02)00411-6; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; MEITES J, 1979, LIFE SCI, V24, P1325, DOI 10.1016/0024-3205(79)90001-8; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Nock B, 1997, J PHARMACOL EXP THER, V282, P1262; Nock B, 1998, J PHARMACOL EXP THER, V286, P875; Sarnyai Z, 2001, PHARMACOL REV, V53, P209; SUEMARU S, 1985, ACTA MED OKAYAMA, V39, P463	16	58	60	0	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0954-6820			J INTERN MED	J. Intern. Med.	MAY	2005	257	5					478	480		10.1111/j.1365-2796.2005.01483.x			3	Medicine, General & Internal	General & Internal Medicine	916PD	WOS:000228396700012	15836666				2020-06-30	J	Stanley, TH				Stanley, TH			Fentanyl	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article; Proceedings Paper	Symposium on Updates of the Clinical Pharmacology of Opioids with Special Attention to Long-Acting Drugs	MAY 03-04, 2003	New York, NY	Janssen Pharmaceut Inc, Barbara Ziegler Palliat Care Program, Ellen P Hermanson Fdn		fentanyl; anesthesiology; pain; lipid soluble	CORONARY-ARTERY SURGERY; HIGH-DOSE FENTANYL; ANESTHETIC INDUCTION; MORPHINE ANESTHESIA; OXYGEN ANESTHESIA; NITROUS-OXIDE; CITRATE PREMEDICATION; CORTISOL RESPONSES; REQUIREMENTS; ALFENTANIL	Fentanyl, a potent lipid-soluble opioid which was first synthesized more than 40 years ago, is still the most popular opioid used in the perioperative period throughout the world. Fentanyl's introduction, versatility, and popularity have resulted in its use in many acute and chronic pain conditions and a multitude of novel delivery systems in the last two decades. In spite of the development of more potent, safer, faster onset, and both shorter and longer lasting alternative opioids, fentanyl remains the mainstay of anesthesiologists and Certified Registered Nurse Anesthetists in the perioperative period, and for many pain physicians throughout the world. (c) 2005 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.	Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA	Stanley, TH (reprint author), Univ Utah, Hlth Sci Ctr, 30 North,1900 East, Salt Lake City, UT 84132 USA.						ARENS JF, 1972, ANESTH ANAL CURR RES, V51, P901; ASHBURN MA, 1989, ANESTHESIOLOGY, V71, P615, DOI 10.1097/00000542-198910000-00026; ASHBURN MA, 1990, CAN J ANAESTH, V37, P856; BAILEY PL, 1984, ANESTH ANALG, V63, P183; BAILEY PL, 1985, ANESTH ANALG, V64, P48; BAILEY PL, 1985, J WILDLIFE MANAGE, V49, P931, DOI 10.2307/3801373; BAILEY PL, 1987, ANESTH ANALG, V66, P542; BENNETT GM, 1979, ANESTH ANALG, V58, P179; BENTHUYSEN JL, 1985, ANESTHESIOLOGY, V62, P205, DOI 10.1097/00000542-198502000-00026; CLARK NJ, 1987, ANESTHESIOLOGY, V66, P130, DOI 10.1097/00000542-198702000-00004; CORSSEN G, 1965, J THORAC CARDIOV SUR, V49, P901, DOI 10.1016/S0022-5223(19)33395-1; CORSSEN G, 1964, ANESTH ANALG, V43, P748; de Castro J, 1979, Acta Anaesthesiol Belg, V30, P5; DECASTRO J, 1959, ANESTH ANALG, V16, P1022; DECASTRO J, 1977, ANESTHESIA VIGILE SU, V1, P87; DELANGE S, 1983, CAN ANAESTH SOC J, V30, P248; DELANGE S, 1981, BRIT J ANAESTH, V53, P1291, DOI 10.1093/bja/53.12.1291; DELANGE S, 1982, ANESTHESIOLOGY, V56, P112, DOI 10.1097/00000542-198202000-00006; DELANGE S, 1982, ANESTH ANALG, V61, P424; EISELE JH, 1975, BRIT J ANAESTH, V47, P937, DOI 10.1093/bja/47.9.937; FITCH W, 1969, BRIT J ANAESTH, V41, P800, DOI 10.1093/bja/41.10.800; FREYE E, 1974, ANESTH ANALG, V53, P40; GOROSZENIUK JC, 1977, ANAESTHESIA, V32, P209; GRELL FL, 1970, ANESTH ANAL CURR RES, V49, P523; Hasbrouck J D, 1970, Ann Thorac Surg, V10, P364; HECKER BR, 1983, ANESTH ANALG, V62, P987; HOLMES CM, 1976, BRIT J ANAESTH, V48, P907, DOI 10.1093/bja/48.9.907; JANSSEN PAJ, 1962, BRIT J ANAESTH, V34, P260, DOI 10.1093/bja/34.4.260; LAPPAS DG, 1981, ANESTHESIOLOGY, V55, pA250; LIU WS, 1984, ANAESTHESIOLOGICA SI, V22, P185; LOWENSTEIN E, 1969, NEW ENGL J MED, V281, P1389, DOI 10.1056/NEJM196912182812503; LOWENSTEIN E, 1971, ANESTHESIOLOGY, V35, P563, DOI 10.1097/00000542-197112000-00001; LUNN JK, 1979, ANESTH ANALG, V58, P390; MCDERMOTT RW, 1974, ANESTHESIOLOGY, V41, P89, DOI 10.1097/00000542-197407000-00025; NAUTA J, 1983, CAN ANAESTH SOC J, V30, P53, DOI 10.1007/BF03007717; NAUTA J, 1982, ANESTH ANALG, V61, P267; NELSON PS, 1989, ANESTHESIOLOGY, V70, P616, DOI 10.1097/00000542-198904000-00011; STANLEY T H, 1986, International Journal of Clinical Monitoring and Computing, V3, P21, DOI 10.1007/BF02916395; Stanley T H, 1988, J Cardiothorac Anesth, V2, P6, DOI 10.1016/0888-6296(88)90140-8; STANLEY TH, 1989, ANESTH ANALG, V69, P328; STANLEY TH, 1988, ANESTHESIOLOGY, V68, P665; STANLEY TH, 1978, ANESTH ANALG, V57, P411; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; STANLEY TH, 1988, BRIT J ANAESTH, V60, pS116, DOI 10.1093/bja/60.suppl_1.116S; STANLEY TH, 1981, CLEVELAND CLIN Q, V48, P22, DOI 10.3949/ccjm.48.1.22; STANLEY TH, 1984, CAN ANAESTH SOC J, V31, P368, DOI 10.1007/BF03015404; STANLEY TH, 1983, ANESTH ANALG, V62, P705; STANLEY TH, 1983, MT SINAI J MED, V50, P308; STANLEY TH, 1973, ANESTHESIOLOGY, V38, P536, DOI 10.1097/00000542-197306000-00006; STANLEY TH, 1985, ANESTHESIOLOGY, V62, P837; STANLEY TH, 1989, ANESTH ANALG, V69, P21; STANLEY TH, 1991, ANESTHESIOLOGY, V74, P388, DOI 10.1097/00000542-199102000-00043; STANLEY TH, 1980, ANESTHESIOLOGY, V53, P250, DOI 10.1097/00000542-198009000-00016; STANLEY TH, 1984, REGIONAL ANAESTHTESI, P154; STANLEY TH, 1984, ANESTH SINICA, V22, P321; STANLEY TH, 1985, P 2 INT C VET AN SAC, P18; STANLEY TH, 1981, ANESTHESIA, P425; STANLEY TH, 1979, P 1979 BOERH COURS A, P53; STANLEY TH, 1986, POSTGRAD MED SP 0828, P51; STANLEY TH, 1981, RES STAFF PHYS   JUL, P67; STOELTING RK, 1973, ANESTHESIOLOGY, V38, P45, DOI 10.1097/00000542-197301000-00012; STRAUER B, 1957, ANESTHESIOLOGY, V18, P623; STRAUER BE, 1972, ANESTHESIOLOGY, V37, P304, DOI 10.1097/00000542-197209000-00006; STREISAND JB, 1989, ANESTH ANALG, V69, P28; STREISAND JB, 1989, CURRENT OPINION ANAE, V2, P456; TARVER SD, 1989, ADV ANESTHESIA, V7, P337	66	32	34	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924			J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	MAY	2005	29	5		S			S67	S71		10.1016/j.jpainsymman.2005.01.009			5	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	935BL	WOS:000229753900008	15907648	Bronze			2020-06-30	J	Ciftci, F; Pocan, S; Karadayi, K; Gulecek, O				Ciftci, F; Pocan, S; Karadayi, K; Gulecek, O			Local versus general anesthesia for external dacryocystorhinostomy in young patients	OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY			English	Article							OUTPATIENT DACRYOCYSTORHINOSTOMY; BLOOD-LOSS; SURGERY; COCAINE	Purpose: To compare the effectiveness, complications, and patient acceptance of local anesthesia with general anesthesia in young patients for external dacryocystorhinostomy (DCR). Methods: Data were prospectively collected over an 8-year period (1996-2004) on young patients (mean age: 22.64 +/- 1.71) undergoing external DCR in Gulhane Military Medical Academy. Patients were randomly allocated in two groups: general anesthesia (GA) and local anesthesia (LA). Of the 480 DCR procedures, 182 were performed with general anesthesia (44 bilateral), 298 were performed with local anesthesia (32 bilateral). Visual analogue scales were recorded in the postoperative 2-hour period. Postoperative nausea and vomiting (PONV), epistaxis, length of hospital stay, and intraoperative bleeding were noted. Results: Patients in both groups reported being comfortable during and immediately after surgery. Only 2 patients in the LA group required additional local anesthetic because of pain. Intraoperative bleeding was lower in the LA group. Analgesic requirement and signs of nausea and vomiting in the GA group were higher in the early postoperative period (p < 0.05). The incidence of PONV was higher (p < 0.05) in the GA group. Postoperative epistaxis was observed in 12 patients in the GA group and just 2 patients in the LA group. Length of hospital stay was 2.29 +/- 0.46 days in the GA group, and 1.23 +/- 0.42 days in the LA group (p < 0.01). Conclusions: Local anesthesia in DCR is safe and comfortable when proper anatomical approach to nerve blocks is performed correctly. Local anesthesia in young patients undergoing external DCR is a good alternative because it is cost-effective and it eliminates the complications of general anesthesia.	GATA Haydarpasa Training Hosp, Gulhane Mil Med Acad, Dept Ophthalmol, Istanbul, Turkey; GATA Haydarpasa Training Hosp, Gulhane Mil Med Acad, Dept Anesthesiol, Istanbul, Turkey	Ciftci, F (reprint author), Cicekei Bostan Sok,C-8 Daire 6, TR-34662 Istanbul, Turkey.	ciftciferda@yahoo.com					AITKENHEAD AR, 1998, TXB ANAESTHESIA ANAE, P487; Caesar RH, 2004, OPHTHAL PLAST RECONS, V20, P57, DOI 10.1097/01.IOP.0000105567.09310.7C; DRESNER SC, 1991, OPHTHALMIC SURG LAS, V22, P222; Duffy M T, 2000, Curr Opin Ophthalmol, V11, P352, DOI 10.1097/00055735-200010000-00011; HOSAL BM, 1995, OPHTHALMIC PLAST REC, V11, P215, DOI 10.1097/00002341-199509000-00009; Hurwitz J J, 1989, Ophthalmic Plast Reconstr Surg, V5, P186; Hurwitz JJ, 2000, CAN J OPHTHALMOL, V35, P18, DOI 10.1016/S0008-4182(00)80104-0; JEONG S, 1999, ANESTHESIA OPHTHALMI, P1131; JORDAN DR, 1991, OPHTHALMIC PLAST REC, V7, P261, DOI 10.1097/00002341-199112000-00005; KRATKY V, 1994, CAN J OPHTHALMOL, V29, P13; Lee KJ, 2003, ANESTHESIA HEAD NECK, P916; MAILER CM, 1982, CAN J OPHTHALMOL, V17, P189; McNab AA, 2002, CLIN EXP OPHTHALMOL, V30, P270, DOI 10.1046/j.1442-9071.2002.00535.x; Melzack R, 1994, TXB PAIN, P337; Meyer DR, 2000, OPHTHAL PLAST RECONS, V16, P201, DOI 10.1097/00002341-200005000-00006; TARBET KJ, 1995, OPHTHALMOLOGY, V102, P1065; Tsirbas A, 2000, CLIN EXP OPHTHALMOL, V28, P22, DOI 10.1046/j.1442-9071.2000.00249.x; WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023	18	15	16	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0740-9303			OPHTHAL PLAST RECONS	Ophthalmic Plast. Reconstr. Surg.	MAY	2005	21	3					201	206		10.1097/01.IOP.0000163317.73873.C9			6	Ophthalmology; Surgery	Ophthalmology; Surgery	935OE	WOS:000229790800007	15942495				2020-06-30	J	Viscusi, ER; Witkowski, TA				Viscusi, ER; Witkowski, TA			Iontophoresis: The process behind noninvasive drug delivery	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Editorial Material							ELECTROTRANSPORT SYSTEM; POSTOPERATIVE ANALGESIA; LIDOCAINE IONTOPHORESIS; TRANSDERMAL FENTANYL; CONTROLLED-TRIAL; PAIN; TOLERABILITY; EFFICACY; MORPHINE; CHILDREN		Thomas Jefferson Univ, Jefferson Med Coll, Dept Anesthesiol, Philadelphia, PA 19107 USA	Viscusi, ER (reprint author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Anesthesiol, 111 S 11th St,Suite G 8490, Philadelphia, PA 19107 USA.	eugene.viscusi@jefferson.edu					ASHBURN MA, 1995, ANESTHESIOLOGY, V82, P1146, DOI 10.1097/00000542-199505000-00009; ASHBURN MA, 1992, J PAIN SYMPTOM MANAG, V7, P27, DOI 10.1016/0885-3924(92)90104-P; Barry BW, 2001, EUR J PHARM SCI, V14, P101, DOI 10.1016/S0928-0987(01)00167-1; Bertolucci L E, 1982, J Orthop Sports Phys Ther, V4, P103; BEZZANT JL, 1988, J AM ACAD DERMATOL, V19, P869, DOI 10.1016/S0190-9622(88)70247-9; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Curdy C, 2001, J PHARM PHARMACOL, V53, P769, DOI 10.1211/0022357011776117; Galinkin JL, 2002, ANESTH ANALG, V94, P1484, DOI 10.1097/00000539-200206000-00020; Gammaitoni AR, 2003, J CLIN PHARMACOL, V43, P111, DOI 10.1177/0091270002239817; Gupta SK, 1998, J CLIN PHARMACOL, V38, P951, DOI 10.1002/j.1552-4604.1998.tb04392.x; Gupta SK, 1998, J PHARM SCI, V87, P976, DOI 10.1021/js970437d; Gupta SK, 1999, J PHARM SCI, V88, P835, DOI 10.1021/js980258b; Kearns GL, 2003, PEDIATRICS, V112, P578, DOI 10.1542/peds.112.3.578; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Nirschl RP, 2003, AM J SPORT MED, V31, P189; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Prausnitz MR, 2004, NAT REV DRUG DISCOV, V3, P115, DOI 10.1038/nrd1304; Rogers Tanya L, 2004, J Pediatr Nurs, V19, P33, DOI 10.1016/j.pedn.2003.09.005; Rose JB, 2002, ANESTH ANALG, V94, P867, DOI 10.1097/00000539-200204000-00017; SATHYAN G, 2005, IN PRESS CLIN PHARMA; Squire S J, 2000, J Pediatr Health Care, V14, P68, DOI 10.1067/mph.2000.103647; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333	22	15	16	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	1098-7339			REGION ANESTH PAIN M	Region. Anesth. Pain Med.	MAY-JUN	2005	30	3					292	294		10.1016/j.rapm.2004.12.002			3	Anesthesiology	Anesthesiology	929EU	WOS:000229325700012	15898033				2020-06-30	J	Park, SY; Moon, SH; Park, MS; Oh, KS; Lee, HM				Park, SY; Moon, SH; Park, MS; Oh, KS; Lee, HM			The effects of ketorolac injected via patient controlled analgesia postoperatively on spinal fusion	YONSEI MEDICAL JOURNAL			English	Article						lumbar spine; spinal fusion; ketorolac	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ISTHMIC SPONDYLOLISTHESIS; SURGERY; CYCLOOXYGENASE-2; INHIBITION; NSAID; RAT	Lumbar spinal fusions have been performed for spinal stability, pain relief and improved function in spinal stenosis, scoliosis, spinal fractures, infectious conditions and other lumbar spinal problems. The success of lumbar spinal fusion depends on multifactors, such as types of bone graft materials, levels and numbers of fusion, spinal instrumentation, electrical stimulation, smoking and some drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs). From January 2000 to December 2001, 88 consecutive patients, who were diagnosed with spinal stenosis or spondylolisthesis, were retrospectively enrolled in this study. One surgeon performed all 88 posterolateral spinal fusions with instrumentation and autoiliac bone graft. The patients were divided into two groups. The first group (n=30) was infused with ketorolac and fentanyl intravenously via patient controlled analgesia (PCA) postoperatively and the second group (n=58) was infused only with fentanyl. The spinal fusion rates and clinical outcomes of the two groups were compared. The incidence of incomplete union or nonunion was much higher in the ketorolac group, and the relative risk was approximately 6 times higher than control group (odds ratio: 5.64). The clinical outcomes, which were checked at least 1 year after surgery, showed strong correlations with the spinal fusion status. The control group (93.1%) showed significantly better clinical results than the ketorolac group (77.6%). Smoking had no effect on the spinal fusion outcome in this study. Even though the use of ketorolac after spinal fusion can reduce the need for morphine, thereby decreasing morphine related complications, ketorolac used via PCA at the immediate postoperative state inhibits spinal fusion resulting in a poorer clinical outcome. Therefore, NSAIDs such as ketorolac, should be avoided after posterolateral spinal fusion.	Yonsei Univ, Coll Med, Dept Orthopaed Surg, Seoul 120752, South Korea; Univ Ulsan, Coll Med, Dept Orthopaed Surg, Seoul, South Korea	Lee, HM (reprint author), Yonsei Univ, Coll Med, Dept Orthopaed Surg, 134 Shinchon Dong, Seoul 120752, South Korea.	hwanlee@yumc.ac.kr	PARK, MOON SOO/AAQ-5767-2020	PARK, MOON SOO/0000-0003-2833-9148			BASSETT CAL, 1962, J BONE JOINT SURG AM, V44, P842, DOI 10.2106/00004623-196244050-00002; BROWN CW, 1986, SPINE, V11, P942, DOI 10.1097/00007632-198611000-00015; Brown KM, 2004, J BONE JOINT SURG AM, V86A, P116, DOI 10.2106/00004623-200401000-00017; CARPENTER MCT, 1996, J BONE JOINT SURG AM, V78, P712; Coloma M, 2000, ANESTH ANALG, V90, P1107, DOI 10.1097/00000539-200005000-00019; DANIEL R, 2003, J BONE JOINT SURG, V85, P632; DEPALMA AF, 1996, CLIN ORTHOP RELAT R, V47, P165; Dimar JR, 1996, SPINE, V21, P1870, DOI 10.1097/00007632-199608150-00006; Gerstenfeld LC, 2003, J ORTHOP RES, V21, P670, DOI 10.1016/S0736-0266(03)00003-2; Glassman SD, 1998, SPINE, V23, P834, DOI 10.1097/00007632-199804010-00020; Glassman SD, 2000, SPINE, V25, P2608, DOI 10.1097/00007632-200010150-00011; Goodman S, 2002, J ORTHOP RES, V20, P1164, DOI 10.1016/S0736-0266(02)00079-7; Hernandez-Palazon J, 2001, ANESTH ANALG, V92, P1473, DOI 10.1097/00000539-200106000-00024; HIROSHI M, 2002, SPINE, V27, P2477; Kim NH, 1999, SPINE, V24, P812, DOI 10.1097/00007632-199904150-00014; KIMNH, 1999, YONSEI MED J, V40, P256; KJAERSGAARDANDERSEN P, 1991, CLIN ORTHOP RELAT R, P78; KWON H, 1997, J KOREAN SPINE SURG, V4, P43; LEBWOHL NH, 1994, INHIBITORY EFFECT IB, P278; LENKE LG, 1992, J SPINAL DISORD, V5, P433, DOI 10.1097/00002517-199212000-00008; Long J, 2002, J BONE JOINT SURG AM, V84A, P1763, DOI 10.2106/00004623-200210000-00004; Martin GJ, 1999, SPINE, V24, P2188, DOI 10.1097/00007632-199911010-00003; Miyamoto H, 2002, SPINE, V27, P2477, DOI 10.1097/00007632-200211150-00011; MOON MS, 1986, J KOREAN ORTHOP ASS, V21, P585; Reuben SS, 2001, ANESTH ANALG, V93, P803, DOI 10.1097/00000539-200109000-00057; SAAG KG, 1994, SPINE, V19, P1530, DOI 10.1097/00007632-199407000-00021; SCOTT DB, 1995, SPINE, V20, P412; SCOTT SR, 1998, ANESTH ANALG, V87, P98; Toth JM, 2000, SPINE, V25, P2580, DOI 10.1097/00007632-200010150-00007; TURNER DM, 1995, J SPINAL DISORD, V8, P206, DOI 10.1097/00002517-199506000-00005	30	30	31	0	5	YONSEI UNIV COLL MEDICINE	SEOUL	50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA	0513-5796	1976-2437		YONSEI MED J	Yonsei Med. J.	APR 30	2005	46	2					245	251		10.3349/ymj.2005.46.2.245			7	Medicine, General & Internal	General & Internal Medicine	922HD	WOS:000228826500009		DOAJ Gold, Green Published			2020-06-30	J	Huynh, NH; Tyrefors, N; Ekman, L; Johansson, M				Huynh, NH; Tyrefors, N; Ekman, L; Johansson, M			Determination of fentanyl in human plasma and fentanyl and norfentanyl in human urine using LC-MS/MS	JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS			English	Article; Proceedings Paper	15th International Symposium on Pharmaceutical and Biomedical Analysis	MAY 02-06, 2004	Florence, ITALY			fentanyl; norfentanyl; LC-MS/MS; plasma; urine; validation	PERFORMANCE LIQUID-CHROMATOGRAPHY; MASS-SPECTROMETRY; ULTRAVIOLET DETECTION; ALFENTANIL; RADIOIMMUNOASSAY; METABOLITES; EXTRACTION	Fentanyl, a potent analgesic drug, has traditionally been used intravenously in surgical or diagnostic operations. Formulations with fentanyl in oral transmucosal delivery system and in transdermal depot-patch have also been developed against breakthrough pain in cancer patients. In this report, LC-MS/MS methods to determine fentanyl in human plasma as well as fentanyl and its main metabolite, norfentanyl, in human urine are presented together with validation data. The validation ranges were 0.020-10.0 and 0.100-50.0 ng/ml for fentanyl in plasma and urine, respectively, and 0.102-153 ng/ml for norfentanyl in urine. Liquid-liquid extraction of the compounds fentanyl, norfentanyl and the deuterated internal standards, fentanyl-d(5) and norfentanyl-d(5) from the matrixes was applied and separation was performed on a reversed phase YMC Pro C-18-column followed by MS/MS detection with electrospray in positive mode. The inter-assay precision (CV%) was better than 4.8% for fentanyl in plasma and 6.2% and 4.7% for fentanyl and norfentanyl, respectively, in urine. The ruggedness of the methods, selectivity, recovery, effect of dilution and long-term stability of the analytes in plasma and urine were investigated. Effect of haemolysis and stability of fentanyl in blood samples were also studied. The methods have been applied for the determination of fentanyl in plasma samples and fentanyl/norfentanyl in urine samples taken for pharmacokinetic evaluation after a single intra-venous (i.v.) dose of 75 mu g fentanyl. (c) 2004 Elsevier B.V. All rights reserved.	Quintiles AB, Analyt Serv, SE-75323 Uppsala, Sweden	Huynh, NH (reprint author), Quintiles AB, Analyt Serv, Strandbodgatan 1, SE-75323 Uppsala, Sweden.	ngoc-hang.huynh@quintiles.com					Bansal R, 1996, J LIQ CHROMATOGR R T, V19, P353, DOI 10.1080/10826079608001220; *CDER CVM DEP HLTH, 2001, GUID IND BIOAN METH; Day J, 2003, J ANAL TOXICOL, V27, P513, DOI 10.1093/jat/27.7.513; Fryirsa B, 1997, J CHROMATOGR B, V688, P79, DOI 10.1016/S0378-4347(97)88058-9; Guitton J, 1997, J CHROMATOGR B, V693, P59, DOI 10.1016/S0378-4347(97)00050-9; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; KUMAR K, 1987, J CHROMATOGR-BIOMED, V419, P464, DOI 10.1016/0378-4347(87)80317-1; Kumar K, 1996, J PHARMACEUT BIOMED, V14, P667, DOI 10.1016/0731-7085(95)01685-6; MICHIELS M, 1977, EUR J CLIN PHARMACOL, V12, P153, DOI 10.1007/BF00645137; PHIPPS JA, 1983, J CHROMATOGR, V272, P392, DOI 10.1016/S0378-4347(00)86145-9; Portier EJG, 1999, J CHROMATOGR B, V723, P313, DOI 10.1016/S0378-4347(98)00518-0; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; Shou WZ, 2001, RAPID COMMUN MASS SP, V15, P466, DOI 10.1002/rcm.255; Valaer AK, 1997, J CHROMATOGR SCI, V35, P461, DOI 10.1093/chromsci/35.10.461; Weng ND, 2002, J PHARMACEUT BIOMED, V28, P1115, DOI 10.1016/S0731-7085(02)00002-X	15	46	50	2	20	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0731-7085	1873-264X		J PHARMACEUT BIOMED	J. Pharm. Biomed. Anal.	APR 29	2005	37	5			SI		1095	1100		10.1016/j.jpba.2004.09.024			6	Chemistry, Analytical; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	933BP	WOS:000229599200036	15862690				2020-06-30	J	Olsen, KS; Juul, N; Cold, GE				Olsen, KS; Juul, N; Cold, GE			Effect of alfentanil on intracranial pressure during propofol-fentanyl anesthesia for craniotomy. A randomized prospective dose-response study	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						alfentanil; anesthesia; cerebral perfusion pressure; intracranial pressure	CEREBROSPINAL-FLUID PRESSURE; SUBDURAL PRESSURE; TACTILE ESTIMATION; ISOFLURANE; SUFENTANIL	The effect of alfentanil on intracranial pressure (ICP) in patients with supratentorial cerebral tumors has only been sparsely examined and with somewhat contradictory results. Thirty-one patients were anesthetized with propofol and fentanyl. After removal of the bone flap a bolus-dose of alfentanil 10 (group 1), 20 (group 2), or 30 mu g kg(-1) (group 3) was administered followed by an infusion of 10, 20, or 30 mu g.kg(-1).h(-1) to patients in groups 1, 2, and 3, respectively. A control group received no alfentanil. Subdural ICP, mean arterial blood pressure (MAP), and cerebral perfusion pressure (CPP) were monitored and arterial and jugular bulb blood were sampled before and every minute for 5 min after the bolus administration of alfentanil and again after 5 min of hyperventilation to be able to calculate cerebral arterio-venous oxygen content difference (AVDO(2)) and carbon dioxide reactivity (CO2-reactivity). No changes in subdural ICP or AVDO(2) from alfentanil in the study period were observed within the groups. However, alfentanil decreased MAP and CPP. The maximum CPP decrease (mean value of each group) was 4 mmHg, 8 mmHg, and 18 mmHg in groups 1, 2, and 3, respectively. There was no difference between groups as regards the CO2-reactivity. We conclude that administration of alfentanil to propofol-fentanyl anesthetized patients with supratentorial cerebral tumors decreases MAP and CPP in a dose-related way, but does not influence subdural ICP, AVDO(2) or the CO2-reactivity.	Univ Copenhagen, Dept Anesthesia & Intens Care, Glostrup Hosp, DK-2600 Glostrup, Denmark; Aarhus Univ Hosp, Dept Neuroanesthesia, DK-8000 Aarhus, Denmark	Olsen, KS (reprint author), Univ Copenhagen, Dept Anesthesia & Intens Care, Glostrup Hosp, DK-2600 Glostrup, Denmark.	kask@glostruphosp.kbhamt.dk	Juul, Niels/AAF-1378-2020				Albanese J, 1999, CRIT CARE MED, V27, P407, DOI 10.1097/00003246-199902000-00050; Bundgaard H, 1998, ACT NEUR S, V71, P276; Bundgaard H, 2000, BRIT J NEUROSURG, V14, P229; Cold GE, 1996, BRIT J NEUROSURG, V10, P69; Coles JP, 2000, J NEUROSURG ANESTH, V12, P15, DOI 10.1097/00008506-200001000-00004; ENDO H, 1977, J NEUROSURG, V46, P271, DOI 10.3171/jns.1977.46.3.0271; FROM RP, 1990, ANESTHESIOLOGY, V73, P896, DOI 10.1097/00000542-199011000-00017; HERRICK IA, 1991, ANESTH ANALG, V72, P359; Jamali S, 1996, ANESTH ANALG, V82, P600, DOI 10.1097/00000539-199603000-00030; Jorgensen HA, 1999, BRIT J NEUROSURG, V13, P449; JUNG R, 1990, ANESTH ANALG, V71, P419; MARKOVITZ BP, 1992, ANESTHESIOLOGY, V76, P71, DOI 10.1097/00000542-199201000-00011; MAYBERG TS, 1993, ANESTHESIOLOGY, V78, P288, DOI 10.1097/00000542-199302000-00012; OLSEN KS, 1994, BRIT J ANAESTH, V72, P66, DOI 10.1093/bja/72.1.66; Rasmussen M, 2004, ANAESTHESIA, V59, P229, DOI 10.1111/j.1365-2044.2004.03604.x; Warner DS, 1996, ANESTH ANALG, V83, P348, DOI 10.1097/00000539-199608000-00025; WERNER C, 1995, ANAESTHESIST, V44, P417, DOI 10.1007/s001010050170	17	2	3	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	APR	2005	49	4					445	452		10.1111/j.1399-6576.2005.00648.x			8	Anesthesiology	Anesthesiology	908FU	WOS:000227773700004	15777290				2020-06-30	J	Prusinkiewicz, C; Lang, S; Tsui, BCH				Prusinkiewicz, C; Lang, S; Tsui, BCH			Lateral cervical epidural catheter placement using nerve stimulation for continuous unilateral upper extremity analgesia following a failed continuous peripheral nerve block	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						axillary block; cervical epidural anesthesia; electrical stimulation	ANESTHESIA; SURGERY; ROPIVACAINE	This case report describes the application of electrical stimulation (Tsui test) to confirm placement of a cervical epidural catheter for postoperative pain management in a patient with a failed brachial plexus block who underwent upper extremity surgery. An epidural catheter was easily advanced under nerve stimulation guidance to the surgical dermatome C4 level without any resistance from the C7-T1 level. Successful analgesia was achieved with a bolus of 2 mg ml(-1) ropivacaine 2 ml and fentanyl 20 mu g, followed by a continuous infusion of 2 mg ml(-1) ropivacaine with 2 mu g ml(-1) of fentanyl at a rate of 2 ml h(-1). This case reminds the clinician that cervical epidural analgesia may serve as an alternative to a difficult continuous peripheral nerve block. Electrical stimulation may also help to confirm cervical epidural catheter placement at the appropriate dermatome to provide effective analgesia with minimal side-effects.	Univ Alberta, Dept Anesthesiol & Pain Med, Edmonton, AB T6G 2G3, Canada; Univ Calgary, Dept Anesthesia, Edmonton, AB, Canada	Tsui, BCH (reprint author), Univ Alberta, Dept Anesthesiol & Pain Med, 8-120 Clin Sci Bldg, Edmonton, AB T6G 2G3, Canada.	btsui@ualberta.ca					BONNET F, 1990, CAN J ANAESTH, V37, P353, DOI 10.1007/BF03005590; Buchheit T, 2000, REGION ANESTH PAIN M, V25, P313, DOI 10.1016/S1098-7339(00)90019-1; FINUCANE B, 1999, COMPLICATIONS REGION, P62; Markham A, 1996, DRUGS, V52, P429, DOI 10.2165/00003495-199652030-00012; McGlade DP, 1997, ANAESTH INTENS CARE, V25, P262, DOI 10.1177/0310057X9702500310; Nystrom UME, 1997, J HAND SURG-AM, V22A, P906; Salinas FV, 2003, REGION ANESTH PAIN M, V28, P79, DOI 10.1053/rapm.2003.50033; Stevens RA, 1998, REGION ANESTH PAIN M, V23, P20, DOI 10.1016/S1098-7339(98)90106-7; Tsui BCH, 2004, REGION ANESTH PAIN M, V29, P189, DOI 10.1016/j.rapm.2004.02.002; Tsui BCH, 1998, CAN J ANAESTH, V45, P640, DOI 10.1007/BF03012093; Tucker GT, 1998, NEURAL BLOCKADE CLIN, P55; WALLACE MS, 2002, TXB REGIONAL ANESTHE, P561; WITTICH DJ, 1984, LARYNGOSCOPE, V94, P615	13	14	15	0	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	APR	2005	49	4					579	582		10.1111/j.1399-6576.2005.00630.x			4	Anesthesiology	Anesthesiology	908FU	WOS:000227773700025	15777311				2020-06-30	J	Goh, PK; Chiu, CL; Wang, CY; Chan, YK; Loo, RL				Goh, PK; Chiu, CL; Wang, CY; Chan, YK; Loo, RL			Randomized double-blind comparison of ketamine-propofol, fentanyl-propofol and propofol-saline on haemodynamics and laryngeal mask airway insertion conditions	ANAESTHESIA AND INTENSIVE CARE			English	Article						ketamine, fentanyl, propofol : blood pressure; heart rate; laryngeal mask airway; insertion	ANESTHESIA; INDUCTION; MIVACURIUM	The aim of this prospective, double-blind, randomized, placebo-controlled clinical trial was to investigate whether the administration of ketamine before induction with propofol improves its associated haemodynamic profile and laryngeal mask airway (LMA) insertion conditions. Ninety adult patients were randomly allocated to receive either ketamine 0.5 mg.kg(-1) (n=30), fentanyl 1 mu g.kg(-1) (n=30) or normal saline (n=30), before induction of anaesthesia with propofol 2.5 mg.kg(-1). Insertion of the LMA was performed 60s after injection of propofol. Arterial blood pressure and heart rate were measured before induction (baseline), immediately after induction, immediately before LMA insertion, immediately after LMA insertion and every minute for three minutes after LMA insertion. Following LMA insertion, the following six subjective endpoints were graded by a blinded anaesthestist using ordinal scales graded 1 to 3: mouth opening, gagging, swallowing, movement, laryngospasm and ease of insertion. Systolic blood pressure was significantly higher following ketamine than either fentanyl (P=0.010) or saline (P=0.0001). The median (interquartile range) summed score describing the overall insertion conditions were similar in the ketamine [median 7 0, interquartile range (6.0-8.0)] and fentanyl groups [median 7.0, interquartile range (6.0-8.0)]. Both appeared significantly better than the saline group [median 8.0, interquartile range (6.75-9.25); P=0.024]. The incidence of prolonged apnoea (> 120s) was higher in the fentanyl group [23.1% (7/30)] compared with the ketamine [63% (2/30)] and saline groups [3.3% (1/30)]. We conclude that the addition of ketamine 0.5 mg.kg(-1) improves haemodynamics when compared to fentanyl 1 mu g.kg(-1), with less prolonged apnoea, and is associated with better LMA insertion conditions than placebo (saline).	Univ Malaya, Med Ctr, Fac Med, Dept Anaesthesia & Intens Care, Kuala Lumpur 50603, Malaysia	Wang, CY (reprint author), Univ Malaya, Med Ctr, Fac Med, Dept Anaesthesia & Intens Care, Kuala Lumpur 50603, Malaysia.		CHAN, YOO KUEN/B-8351-2010; Wang, Chew Yin/F-7573-2010				BRAIN AIJ, 1985, ANAESTHESIA, V40, P356; BRAIN AIJ, 1995, [No title captured]; Brimacombe J, 1996, ACTA ANAESTH SCAND, V40, P201, DOI 10.1111/j.1399-6576.1996.tb04420.x; Cheam EWS, 2000, ANAESTHESIA, V55, P323, DOI 10.1046/j.1365-2044.2000.01214.x; Chiu CL, 2001, ANAESTHESIA, V56, P893, DOI 10.1046/j.1365-2044.2001.02059-4.x; Chui PT, 1998, ANAESTHESIA, V53, P491, DOI 10.1046/j.1365-2044.1998.00321.x; CLAEYS MA, 1988, BRIT J ANAESTH, V60, P3, DOI 10.1093/bja/60.1.3; DUNDEE JW, 1986, ANAESTHESIA, V41, P482, DOI 10.1111/j.1365-2044.1986.tb13271.x; Frizelle HP, 1997, ANESTH ANALG, V84, P1318, DOI 10.1097/00000539-199706000-00026; Furuya A, 2001, EUR J ANAESTH, V18, P88; GUIT JBM, 1991, ANAESTHESIA, V46, P24, DOI 10.1111/j.1365-2044.1991.tb09308.x; HUI TW, 1995, ANESTHESIOLOGY, V82, P641, DOI 10.1097/00000542-199503000-00005; SCANLON P, 1993, CAN J ANAESTH, V40, P816, DOI 10.1007/BF03009250; Sivalingam P, 1999, ANAESTHESIA, V54, P271, DOI 10.1046/j.1365-2044.1999.00663.x; VibyMogensen J, 1996, ACTA ANAESTH SCAND, V40, P59, DOI 10.1111/j.1399-6576.1996.tb04389.x	15	31	34	1	2	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0310-057X	1448-0271		ANAESTH INTENS CARE	Anaesth. Intensive Care	APR	2005	33	2					223	228		10.1177/0310057X0503300211			6	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	926RP	WOS:000229140600011	15960405	Bronze			2020-06-30	J	Tan, SM; Sim, YY; Koay, CK				Tan, SM; Sim, YY; Koay, CK			The ProSeal (TM) laryngeal mask airway size selection in male and female patients in an Asian population	ANAESTHESIA AND INTENSIVE CARE			English	Article						equipment, anaesthesia : airway; laryngeal mask airway	APPROPRIATE SIZE; PRESSURES; CROSSOVER; POSITION	The aim of this study was to investigate if size 5 compared with size 4 ProSeal&TRADE; laryngeal mask airway (PLMA) in Asian men and size 4 compared with size 3 ProSeal&TRADE; laryngeal mask airway (PLMA) in Asian women, would give a better glottic seal. We conducted a randomized crossover study involving 30 male and 30 female patients of Asian origin. Size 4 and size 5 PLMA were studied in men and size 3 and size 4 PLMA were studied in women. The patients were anaesthetized and paralysed and the PLMA was inserted with the introducer The oropharyngeal leak pressure (OLP), ease of insertion, anatomical position, mucosal injury, visibility of cuff in the mouth and volume of air required to achieve an intracuff pressure of 60 cmH(2)O were studied. In male patients, oropharyngeal leak pressure was higher when size 5 PLMA was used (P&LT; 0.001) and there was a higher incidence of mucosal injury (P=0.025). For female patients, oropharyngeal leak pressure was higher with size 4 PLMA (P=0.036) while the number of insertion attempts, anatomical position and mucosal injury were similar The cuff was not visible in the oral cavity in any cases. The mean volume of air required to achieve an intracuff pressure of 60 cmH(2)O was less than the maximum recommended by the manufacturers. The size 5 PLMA in Asian men and size 4 PLMA in Asian women resulted in a more effective glottic seal. The use of size 5 PLMA in Asian men led to increased mucosal injury.	Changi Gen Hosp, Dept Anaesthesia & Surg Intens Care, Singapore 529889, Singapore	Tan, SM (reprint author), Changi Gen Hosp, Dept Anaesthesia & Surg Intens Care, 2 Simei St 3, Singapore 529889, Singapore.						Asai T, 1998, BRIT J ANAESTH, V80, P470, DOI 10.1093/bja/80.4.470; Asai T, 1999, BRIT J ANAESTH, V83, P478; Brimacombe J, 2000, ANESTHESIOLOGY, V93, P104, DOI 10.1097/00000542-200007000-00019; Brimacombe J, 2004, ANESTHESIOLOGY, V100, P25, DOI 10.1097/00000542-200401000-00008; BRIMACOMBE J, 1993, ANESTH ANALG, V76, P457; Brimacombe J, 2002, ANESTHESIOLOGY, V96, P289, DOI 10.1097/00000542-200202000-00011; Brimacombe J, 1996, BRIT J ANAESTH, V77, P295, DOI 10.1093/bja/77.2.295-a; Brimacombe J, 1999, BRIT J ANAESTH, V82, P703; Burgard G, 1996, J CLIN ANESTH, V8, P198, DOI 10.1016/0952-8180(95)00229-4; Evans NR, 2002, BRIT J ANAESTH, V88, P534, DOI 10.1093/bja/88.4.534; Kihara S, 2003, ANESTH ANALG, V97, P280, DOI 10.1213/01.ANE.0000068824.86773.B0; *LAR MASK CO LTD, 2000, LMA PROS INSTR MAN H; Lew K K, 1994, Asian J Aesthet Dent, V2, P35; Moate S J, 2002, Aust Orthod J, V18, P19; Voyagis GS, 1996, ANESTH ANALG, V83, P663, DOI 10.1097/00000539-199609000-00062	15	13	13	0	0	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2021, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	APR	2005	33	2					239	242		10.1177/0310057X0503300214			4	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	926RP	WOS:000229140600014	15960408	Bronze			2020-06-30	J	Ahmad, N; Choy, CY; Ab Aris, E; Balan, S				Ahmad, N; Choy, CY; Ab Aris, E; Balan, S			Preventing the withdrawal response associated with rocuronium injection: A comparison of fentanyl with lidocaine	ANESTHESIA AND ANALGESIA			English	Article							PAIN; BROMIDE	We compared the efficacy of IV fentanyl with IV lidocaine as pretreatment for the prevention of withdrawal response after rocuronium injection. For this prospective, randomized, placebo-controlled, double-blind study we recruited 90 patients aged between 18 and 65 yr, ASA physical status I or II, who had undergone elective surgery requiring general anesthesia and positive pressure ventilation. Patients were randomly allocated to 1 of 3 groups: group F received 2 mL IV fentanyl 50 mu g/ml, (100 jig), group L received 2 mL of preservative-free lidocaine 2% (40 mg), and group P (placebo) received 2 mL of normal saline. The incidence of withdrawal response after rocuronium was 57%, 30%, and 7% in the placebo, lidocaine, and fentanyl groups, respectively. We found a significant reduction in incidence of withdrawal response in both the fentanyl and lidocaine groups when compared with the placebo group (P < 0.05), with the fentanyl group being most effective (P < 0.05). In conclusion, both fentanyl and lidocaine are effective clinical treatments to alleviate the withdrawal response associated with rocuronium injection, with fentanyl being more effective.	Hosp Sultanah Aminah, Johor Baharu, Malaysia	Ahmad, N (reprint author), Hosp Sultanah Aminah, Johor Baharu, Malaysia.	dr_ezalee@time.net.my					ARNDT JO, 1991, J PHYSIOL-LONDON, V440, P467, DOI 10.1113/jphysiol.1991.sp018719; Blunk JA, 2003, EUR J ANAESTH, V20, P245, DOI 10.1097/00003643-200303000-00011; Borgeat A, 1997, BRIT J ANAESTH, V79, P382, DOI 10.1093/bja/79.3.382; Borgeat A, 1997, J CLIN ANESTH, V9, P650, DOI 10.1016/S0952-8180(97)00192-X; Cheong KF, 2000, BRIT J ANAESTH, V84, P106; Dalgleish DJ, 2000, ANAESTHESIA, V55, P828, DOI 10.1046/j.1365-2044.2000.01629-34.x; Joshi GP, 1997, ANESTH ANALG, V84, P228, DOI 10.1097/00000539-199701000-00044; KLEMENT W, 1991, BRIT J ANAESTH, V66, P189, DOI 10.1093/bja/66.2.189; LOCKEY D, 1995, ANAESTHESIA, V50, P474, DOI 10.1111/j.1365-2044.1995.tb06019.x; Memis D, 2002, ANESTH ANALG, V94, P1517, DOI 10.1097/00000539-200206000-00026; MILLER RD, 1999, ANESTHESIA, V1, P383; MOORTHY SS, 1995, ANESTH ANALG, V80, P1067, DOI 10.1097/00000539-199505000-00057; Picard P, 2000, ANESTH ANALG, V90, P963; Shevchenko Y, 1999, ANESTH ANALG, V88, P746, DOI 10.1097/00000539-199904000-00011; Steegers MAH, 1996, ANESTH ANALG, V83, P203, DOI 10.1097/00000539-199607000-00065	15	37	43	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	APR	2005	100	4					987	990		10.1213/01.ANE.0000147790.76114.3A			4	Anesthesiology	Anesthesiology	908MZ	WOS:000227792400014	15781511				2020-06-30	J	Fritz, HG; Holzmayr, M; Walter, B; Moeritz, KU; Lupp, A; Bauer, R				Fritz, HG; Holzmayr, M; Walter, B; Moeritz, KU; Lupp, A; Bauer, R			The effect of mild hypothermia on plasma fentanyl concentration and biotransformation in juvenile pigs	ANESTHESIA AND ANALGESIA			English	Article							BLOOD-FLOW; PHARMACOKINETICS; TEMPERATURE; DISPOSITION; SUFENTANIL; ALFENTANIL; METABOLISM; KINETICS; NEWBORN; SWINE	Therapeutic hypothermia may alter the required dosage of analgesics and sedatives, but no data are available. on the effects of mild hypothermia on plasma fentanyl concentration during continuous, long-term administration. We therefore assessed in a porcine model the effect of prolonged hypothemia on plasma fentanyl concentration during 33 h of continuous fentanyl administration. Seven female piglets (weight: 11.8 +/- 1.1 kg) were anesthetized by IV fentanyl (15 mu g (.) kg(-1) (.) h(-1)) and midazolam (1.0 mg (.) kg(-1) (.) h(-1)). After preparation and stabilization (12 h), the animals were cooled to a core temperature of 31.6 degrees +/- 0.2 degrees C for 6 h and were then rewarmed and kept normothermic at 37.7 degrees +/- 0.3 degrees C for 6 more hours. Plasma fentanyl concentrations were measured by radioimmunoassay, cardiac index by thermodilution, and blood flows of the kidney, spleen, pancreas, stomach, gut, and hepatic artery by a colored microspheres technique. Furthermore, in an additional 4 pigs, temperature dependency of hepatic microsomal cytochrome P450 3A4 (CYP3A4) was determined in vitro by ethylmorphine N-demethylation. Plasma fentanyl concentration increased by 25% +/- 11% (P < 0.05) during hypothermia and remained increased for at least 6 h after rewarming. Hypothermia reduced the cardiac index (41% +/- 15%, P < 0.05), as well as all organ blood flows except the hepatic artery. A strong temperature dependency of CYP3A4 was found (P < 0.01). Mild hypothermia induced a distribution and/or elimination-dependent increase in plasma fentanyl concentration which remained increased for several hours after rewarming. Consequently, a prolonged increase of the plasma fentanyl concentration should be anticipated for appropriate control of the analgesia/sedatives during and early after therapeutic hypothermia.	Univ Jena, Inst Pathophysiol & Pathobiochem, Dept Anesthesiol & Intens Care Med, D-6900 Jena, Germany; Univ Jena, Inst Pathophysiol & Pathobiochem, Dept Pathobiochem, D-6900 Jena, Germany; Univ Jena, Dept Neurosurg, D-6900 Jena, Germany; Univ Jena, Inst Pharmacol & Toxicol, D-6900 Jena, Germany; Ernst Moritz Arndt Univ Greifswald, Inst Pharmacol, Greifswald, Germany	Fritz, HG (reprint author), Martha Maria Hosp Halle Dlau gGmbH, Dept Anesthesiol & Intens Care Med, Roentgenstr 1, D-06120 Halle An Der Saale, Germany.	harald_fritz_2000@yahoo.de					Anzenbacher P, 1998, DRUG METAB DISPOS, V26, P56; Battin MR, 2003, PEDIATRICS, V111, P244, DOI 10.1542/peds.111.2.244; Bjorkman S, 1998, ANESTHESIOLOGY, V88, P657, DOI 10.1097/00000542-199803000-00016; Caldwell JE, 2000, ANESTHESIOLOGY, V92, P84, DOI 10.1097/00000542-200001000-00018; Fritz HG, 2004, J NEUROSURG ANESTH, V16, P43, DOI 10.1097/00008506-200401000-00009; GELMAN S, 1983, ANESTH ANALG, V62, P135; Hindman BJ, 1999, NEUROSURGERY, V44, P23, DOI 10.1097/00006123-199901000-00009; Iida Y, 2001, THER DRUG MONIT, V23, P192, DOI 10.1097/00007691-200106000-00002; KELLEY SD, 1995, ANESTHESIOLOGY, V82, P251, DOI 10.1097/00000542-199501000-00030; KLINGER W, 1977, ACTA BIOL MED GER, V36, P1149; KOREN G, 1987, EUR J CLIN PHARMACOL, V32, P373, DOI 10.1007/BF00543972; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; LESLIE K, 1995, ANESTH ANALG, V80, P1007, DOI 10.1097/00000539-199505000-00027; MCALLISTER RG, 1980, PHARMACOLOGY, V20, P95; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; MCKIRNAN MD, 1986, SWINE CARDIOVASCULAR, P105; MICHIELS M, 1977, EUR J CLIN PHARMACOL, V12, P153, DOI 10.1007/BF00645137; Perez-de-Sa V, 2002, ANESTHESIOLOGY, V97, P1189, DOI 10.1097/00000542-200211000-00024; Russell D, 1997, BRIT J ANAESTH, V79, P456, DOI 10.1093/bja/79.4.456; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; Soliman HM, 2001, BRIT J ANAESTH, V87, P186, DOI 10.1093/bja/87.2.186; Statler KD, 2003, CRIT CARE MED, V31, P1134, DOI 10.1097/01.CCM.0000054864.43122.52; Tateishi T., 1996, Anesthesia and Analgesia, V82, P167, DOI 10.1097/00000539-199601000-00031; TRANQUILLI WJ, 1982, AM J VET RES, V43, P895; Walter B, 1997, BASIC RES CARDIOL, V92, P191, DOI 10.1007/s003950050037	25	68	70	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999	1526-7598		ANESTH ANALG	Anesth. Analg.	APR	2005	100	4					996	1002		10.1213/01.ANE.0000146517.17910.54			7	Anesthesiology	Anesthesiology	908MZ	WOS:000227792400016	15781513				2020-06-30	J	Kakimoto, M; Kawaguchi, M; Yamamoto, Y; Inoue, S; Horiuchi, T; Nakase, H; Sakaki, T; Furuya, H				Kakimoto, M; Kawaguchi, M; Yamamoto, Y; Inoue, S; Horiuchi, T; Nakase, H; Sakaki, T; Furuya, H			Tetanic stimulation of the peripheral nerve before transcranial electrical stimulation can enlarge amplitudes of myogenic motor evoked potentials during general anesthesia with neuromuscular blockade	ANESTHESIOLOGY			English	Article							LOW-DOSE PROPOFOL; POSTEXERCISE FACILITATION; MAGNETIC STIMULATION; KETAMINE/FENTANYL ANESTHESIA; SOMATOSENSORY INPUT; NITROUS-OXIDE; CORTEX; ISOFLURANE; RESPONSES; SINGLE	Background: Neuromuscular blockade can suppress myogenic motor evoked potentials (MEPs). The authors hypothesized that tetanic stimulation (TS) of the peripheral nerve before transcranial stimulation may enhance myogenic MEPs during neuromuscular blockade. in the current study, the authors evaluated MEP augmentations by TS at different levels of duration, posttetanic interval, neuromuscular blockade, and stimulus intensity. Methods: Thirty-two patients undergoing propofol-fentanylnitrous oxide anesthesia were examined. Train-of-five stimulation was delivered to C3-C4, and MEPs were recorded from the abductor hallucis muscle. in study 1, TS with a duration of 1, 3, or 5 s was delivered at 50 Hz to the tibial nerve 1, 3, or 5 s (interval) before transcranial stimulation, and the effects of TS on MEP amplitude were evaluated. In study 2, TS-induced MEP augmentations were evaluated at the neuromuscular blockade level (%T1) of 50% or 5%. In study 3, MEP augmentations by TS at stimulus intensities of 0, 5, 25, and 50 mA were evaluated. Results: The application of TS significantly enlarged the amplitudes of MEPs at the combinations of duration (3, 5 s) and interval (1, 3, 5 s) compared with those without TS. TS-induced MEP augmentations were similarly observed at %T1 of both 50% and 5%. TS-induced MEP augmentations were observed at stimulus intensities of 25 and 50 mA. Conclusions: The results indicate that TS of the peripheral nerve before transcranial stimulation can enlarge the amplitude of MEPs during general anesthesia with neuromuscular blockade. TS of the peripheral nerve can be intraoperatively applied as a method to augment myogenic MEP responses.	Nara Med Univ, Dept Anesthesiol, Kashihara, Nara, Japan; Nara Med Univ, Dept Neurosurg, Kashihara, Nara, Japan	Kawaguchi, M (reprint author), Nara Med Univ, Dept Anesthesiol, Kashihara, Nara, Japan.	drjkawa@naramed-u.ac.jp					ADAMS DC, 1993, ANESTH ANALG, V77, P913; ALI HH, 1976, ANESTHESIOLOGY, V45, P216, DOI 10.1097/00000542-197608000-00009; Balbi P, 2002, MUSCLE NERVE, V25, P448, DOI 10.1002/mus.10066; GWINNUTT CL, 1988, BRIT J ANAESTH, V61, P547, DOI 10.1093/bja/61.5.547; Hamdy S, 1998, NAT NEUROSCI, V1, P64, DOI 10.1038/264; Kaelin-Lang A, 2002, J PHYSIOL-LONDON, V540, P623, DOI 10.1113/jphysiol.2001.012801; KALKMAN CJ, 1995, ANESTHESIOLOGY, V83, P270, DOI 10.1097/00000542-199508000-00006; KALKMAN CJ, 1992, ANESTH ANALG, V75, P584; Kawaguchi M, 2000, SPINE, V25, P974, DOI 10.1097/00007632-200004150-00013; Kawaguchi M, 1996, ANESTH ANALG, V82, P593, DOI 10.1097/00000539-199603000-00029; Kawaguchi M, 1998, J NEUROSURG ANESTH, V10, P131, DOI 10.1097/00008506-199807000-00001; Kawaguchi M, 1996, ANESTHESIOLOGY, V85, P1176, DOI 10.1097/00000542-199611000-00027; Kawaguchi Masahiko, 2004, J Anesth, V18, P18, DOI 10.1007/s00540-003-0201-9; Lotto ML, 2004, J NEUROSURG ANESTH, V16, P32, DOI 10.1097/00008506-200401000-00008; Luft AR, 2002, EXP BRAIN RES, V142, P562, DOI 10.1007/s00221-001-0952-1; Norgaard P, 2000, EXP BRAIN RES, V132, P517, DOI 10.1007/s002219900318; RIDLEY SA, 1988, BRIT J ANAESTH, V60, P31, DOI 10.1093/bja/60.1.31; Saitoh Y, 1999, BRIT J ANAESTH, V83, P340, DOI 10.1093/bja/83.2.340; Sakamoto T, 2001, BRIT J ANAESTH, V86, P395, DOI 10.1093/bja/86.3.395; Samii A, 1996, NEUROLOGY, V46, P1376, DOI 10.1212/WNL.46.5.1376; Sloan TB, 2002, J CLIN NEUROPHYSIOL, V19, P430, DOI 10.1097/00004691-200210000-00006; TANIGUCHI M, 1993, NEUROSURGERY, V32, P219, DOI 10.1227/00006123-199302000-00011; Ubags LH, 1998, NEUROSURGERY, V43, P90, DOI 10.1097/00006123-199807000-00058; van Dongen EP, 1999, ANESTH ANALG, V88, P22, DOI 10.1097/00000539-199901000-00005; van Dongen EP, 2000, ACTA ANAESTH SCAND, V44, P799, DOI 10.1034/j.1399-6576.2000.440705.x; WALL FA, 1988, ACTA ANAESTH BELG, V39, P35	26	24	26	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	APR	2005	102	4					733	738		10.1097/00000542-200504000-00007			6	Anesthesiology	Anesthesiology	910IG	WOS:000227923900006	15791101				2020-06-30	J	Tarakanov, IA; Tikhomirova, LN; Safonov, VA				Tarakanov, IA; Tikhomirova, LN; Safonov, VA			Effect of opioids on mechanoreflexive respiration control	BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE			English	Article						vagotomy; morphine; fentanyl; periodic apneustic respiration; rat	NEURONS; CAT	The effects of opioids (morphine and fentanyl) on the function of mechanoreceptive respiration regulatory loop were demonstrated. In most opioid-treated rats (74% cases) vagotomy was followed by apneustic respiration with inspiration pause. Excess of opioids in rat CNS produced minor disturbances in the respiration rhythm, but in the absence afferent input from the mechanoreceptors of respiratory pathways and lungs, pronounced periodic apneustic respiration with inspiration pauses developed. The opioidergic system is involved in the formation of respiratory rhythm, but had no appreciable effect on transmission of mechanoreceptive nerve pulses from respiratory pathways and the lungs to the respiratory center.	Russian Acad Med Sci, Inst Gen Pathol & Pathol Physiol, Moscow, Russia	Tarakanov, IA (reprint author), Russian Acad Med Sci, Inst Gen Pathol & Pathol Physiol, Moscow, Russia.	inspiration@mtu-net.ru	Tikhomirova, Lyudmila/K-2497-2018; Tarakanov, Igor/K-3641-2018	Tikhomirova, Lyudmila/0000-0002-3601-1401; Tarakanov, Igor/0000-0001-7320-0837			ARMSTEAD WM, 1995, AM J PHYSIOL-HEART C, V268, pH226; BALLANTYNE D, 1986, J PHYSIOL-LONDON, V370, P433, DOI 10.1113/jphysiol.1986.sp015943; BALLANTYNE D, 1984, J PHYSIOL-LONDON, V348, P67, DOI 10.1113/jphysiol.1984.sp015100; LING GSF, 1985, J PHARMACOL EXP THER, V232, P149; MASHKOVSKII MD, 2000, PHYS DRUGS, V1, P147; RICHTER DW, 1992, CONTROL OF BREATHING AND ITS MODELING PERSPECTIVE, P7; RICHTER DW, 1979, PFLUG ARCH EUR J PHY, V380, P245, DOI 10.1007/BF00582903; Sergeev P. V., 1987, RECEPTORS PHYSL ACTI; Tarakanov I. A., 1998, Fiziologiya Cheloveka, V24, P116	9	1	1	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0007-4888	1573-8221		B EXP BIOL MED+	Bull. Exp. Biol. Med.	APR	2005	139	4					388	390		10.1007/s10517-005-0301-7			3	Medicine, Research & Experimental	Research & Experimental Medicine	968OO	WOS:000232172000004	16027860				2020-06-30	J	Jung, BF; Reidenberg, MM				Jung, BF; Reidenberg, MM			Interpretation of opioid levels: Comparison of levels during chronic pain therapy to levels from forensic autopsies	CLINICAL PHARMACOLOGY & THERAPEUTICS			English	Article							CONTROLLED-RELEASE MORPHINE; STEADY-STATE KINETICS; POSTMORTEM TISSUE DISTRIBUTION; ADVANCED CANCER-PATIENTS; FENTANYL-RELATED DEATHS; PLASMA-CONCENTRATIONS; ORAL MORPHINE; DRUG CONCENTRATIONS; MORPHINE-6-GLUCURONIDE CONCENTRATIONS; CONTROLLED SUBSTANCES		Cornell Univ, Weill Med Coll, Div Clin Pharmacol LC 424, Dept Pharmacol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Publ Hlth, New York, NY 10021 USA	Reidenberg, MM (reprint author), Cornell Univ, Weill Med Coll, Div Clin Pharmacol LC 424, Dept Pharmacol, 1300 York Ave, New York, NY 10021 USA.	mmreid@med.cornell.edu					*AM AC PAIN MED AM, 1998, US OP TREATM CHRON P; Andersen G, 2002, J PAIN SYMPTOM MANAG, V23, P161, DOI 10.1016/S0885-3924(01)00398-0; Andersen G, 2002, PALLIATIVE MED, V16, P107, DOI 10.1191/0269216302pm512oa; Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; Anderson DT, 2002, J ANAL TOXICOL, V26, P448, DOI 10.1093/jat/26.7.448; Balikova M, 1998, FORENSIC SCI INT, V94, P201, DOI 10.1016/S0379-0738(98)00077-2; Burrows DL, 2003, J FORENSIC SCI, V48, P683; Burt MJ, 2001, J FORENSIC SCI, V46, P1138; Christrup LL, 1999, J PAIN SYMPTOM MANAG, V18, P164, DOI 10.1016/S0885-3924(99)00068-8; Collins JJ, 1999, J PEDIATR-US, V134, P319, DOI 10.1016/S0022-3476(99)70457-9; Collins SL, 1998, J PAIN SYMPTOM MANAG, V16, P388, DOI 10.1016/S0885-3924(98)00094-3; Cone EJ, 2004, J ANAL TOXICOL, V28, P217, DOI 10.1093/jat/28.4.217; Cook DS, 2000, J CLIN PATHOL, V53, P282, DOI 10.1136/jcp.53.4.282; Davis T, 1993, Hosp J, V9, P85, DOI 10.1300/J011v09n01_07; DEBERNARDI M, 1993, ACTA TOXICOL THER, V14, P209; DOUGLAS S, 1989, ED S PAIN CONTR MED, P59; Drug Enforcement Administration, 2002, J Pain Symptom Manage, V24, P147; Druid H, 1997, J FORENSIC SCI, V42, P79; DRUMMER OH, 1992, AM J FOREN MED PATH, V13, P346, DOI 10.1097/00000433-199212000-00017; DRUMMER OH, 1994, J FORENSIC SCI, V39, P1069; Dyer KR, 1999, CLIN PHARMACOL THER, V65, P685, DOI 10.1016/S0009-9236(99)90090-5; Edinboro LE, 1997, J FORENSIC SCI, V42, P741; ELLISON NM, 1984, CLIN PHARMACY, V3, P614; Faura CC, 1996, J PAIN SYMPTOM MANAG, V11, P95, DOI 10.1016/0885-3924(95)00148-4; *FED STAT MED BOAR, 2005, MOD POL US CONTR SUB; FELBY S, 1974, FORENSIC SCI, V3, P77, DOI 10.1016/0300-9432(74)90010-7; Fitzgibbon D, 2003, PAIN, V106, P309, DOI 10.1016/S0304-3959(03)00318-X; GARRIOTT JC, 1984, J ANAL TOXICOL, V8, P288, DOI 10.1093/jat/8.6.288; Gerostamoulos J, 2000, J FORENSIC SCI, V45, P843; Gilson AM, 2001, J PAIN SYMPTOM MANAG, V21, P227, DOI 10.1016/S0885-3924(00)00263-3; GLEDHILL L, 1999, SAN FRANCISCO C 0219, pA1; HASSELSTROM J, 1991, EUR J CLIN PHARMACOL, V40, P585; Heiskanen TE, 2000, ACTA ONCOL, V39, P941; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Hendra TJ, 1996, BRIT MED J, V313, P481; Herman R. A., 1994, Journal of Burn Care and Rehabilitation, V15, P95, DOI 10.1097/00004630-199403000-00002; HIRAGA K, 1989, JAP J CLIN PHARM THE, V20, P639; Holthe M, 2002, EUR J CLIN PHARMACOL, V58, P353, DOI 10.1007/s00228-002-0490-1; HOSKIN PJ, 1989, ANAESTHESIA, V44, P897, DOI 10.1111/j.1365-2044.1989.tb09143.x; Hunt A, 1999, J PEDIATR-US, V135, P47, DOI 10.1016/S0022-3476(99)70326-4; INTURRISI CE, 1987, CLIN PHARMACOL THER, V41, P392, DOI 10.1038/clpt.1987.47; Joranson DE, 2002, J PAIN SYMPTOM MANAG, V23, P138, DOI 10.1016/S0885-3924(01)00403-1; Kintz P, 2001, FORENSIC SCI INT, V121, P65, DOI 10.1016/S0379-0738(01)00454-6; Klepstad P, 2003, ACTA ANAESTH SCAND, V47, P725, DOI 10.1034/j.1399-6576.2003.00138.x; Klepstad P, 2000, EUR J CLIN PHARMACOL, V55, P713, DOI 10.1007/s002280050003; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; LEVINE B, 1984, J FORENSIC SCI, V29, P655; LEVINE B, 1994, FORENSIC SCI INT, V65, P7, DOI 10.1016/0379-0738(94)90294-1; LOGAN BK, 1987, FORENSIC SCI INT, V35, P189, DOI 10.1016/0379-0738(87)90055-7; Logan BK, 1996, J FORENSIC SCI, V41, P221; MEIER B, 2002, NY TIMES        0101, P14; Mercadante S, 2003, SUPPORT CARE CANCER, V11, P326, DOI 10.1007/s00520-003-0440-1; MONFORTE JR, 1977, J FORENSIC SCI, V22, P718; Moolenaar F, 2000, EUR J CLIN PHARMACOL, V56, P219, DOI 10.1007/s002280000133; MORGAN DJ, 1992, INT J CLIN PHARM TH, V30, P576; Morita T, 2002, J PAIN SYMPTOM MANAG, V23, P107, DOI 10.1016/S0885-3924(01)00392-X; Moriya F, 1999, J FORENSIC SCI, V44, P10; Mucci-LoRusso P, 1998, EUR J PAIN-LONDON, V2, P239, DOI 10.1016/S1090-3801(98)90020-9; NEUMANN PB, 1982, PAIN, V13, P247, DOI 10.1016/0304-3959(82)90014-8; PANNUTI F, 1982, PHARMACOL RES COMMUN, V14, P369, DOI 10.1016/S0031-6989(82)80107-0; PARE EM, 1987, J ANAL TOXICOL, V11, P272, DOI 10.1093/jat/11.6.272; PATERSON SC, 1985, FORENSIC SCI INT, V27, P129, DOI 10.1016/0379-0738(85)90175-6; Poklis A, 1995, FORENSIC SCI INT, V76, P55, DOI 10.1016/0379-0738(95)01797-6; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; PORTENOY RK, 1991, PAIN, V47, P13, DOI 10.1016/0304-3959(91)90005-I; PORTENOY RK, 1992, CLIN PHARMACOL THER, V51, P422, DOI 10.1038/clpt.1992.42; PORTENOY RK, 1991, NEUROLOGY, V41, P1457, DOI 10.1212/WNL.41.9.1457; POULAIN P, 1988, BRIT J ANAESTH, V61, P569, DOI 10.1093/bja/61.5.569; Pounder DJ, 1996, J FORENSIC SCI, V41, P927; PROUTY RW, 1990, J FORENSIC SCI, V35, P243; Quigley C, 2003, PALLIATIVE MED, V17, P185, DOI 10.1191/0269216303pm658oa; REIDENBERG MM, 1988, CLIN PHARMACOL THER, V44, P376, DOI 10.1038/clpt.1988.167; SAVAGE SR, 1996, J PAIN SYMPTOM MANAG, V11, P278; SAWE J, 1983, EUR J CLIN PHARMACOL, V24, P537, DOI 10.1007/BF00609900; Spiller HA, 2003, J FORENSIC SCI, V48, P429; Stambaugh JE, 2001, J CLIN PHARMACOL, V41, P500, DOI 10.1177/00912700122010375; Takahashi M, 2003, PALLIATIVE MED, V17, P673, DOI 10.1191/0269216303pm824oa; TANNER R, 2003, WASHINGTON POST 0727, pA5; THIRLWELL MP, 1989, CANCER, V63, P2275, DOI 10.1002/1097-0142(19890601)63:11<2275::AID-CNCR2820631136>3.0.CO;2-4; TISEO PJ, 1995, PAIN, V61, P47, DOI 10.1016/0304-3959(94)00148-8; WELSH J, 1983, ROYAL SOC MED INT C, P9; Westerling D, 1998, ACTA ANAESTH SCAND, V42, P586, DOI 10.1111/j.1399-6576.1998.tb05171.x; Wilsey B, 2004, AM J EMERG MED, V22, P51, DOI 10.1016/j.ajem.2003.09.005; Wolff K, 2002, THER DRUG MONIT, V24, P457, DOI 10.1097/00007691-200208000-00001	84	27	27	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0009-9236	1532-6535		CLIN PHARMACOL THER	Clin. Pharmacol. Ther.	APR	2005	77	4					324	334		10.1016/j.clpt.2004.10.013			11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	914CQ	WOS:000228202700010	15903130				2020-06-30	J	Martin, J; Parsch, A; Franck, M; Wernecke, KD; Fischer, M; Spies, C				Martin, J; Parsch, A; Franck, M; Wernecke, KD; Fischer, M; Spies, C			Practice of sedation and analgesia in German intensive care units: results of a national survey	CRITICAL CARE			English	Article							CRITICALLY-ILL PATIENTS; LONG-TERM SEDATION; MECHANICAL VENTILATION; EPIDURAL ANALGESIA; GUIDELINES; MANAGEMENT; CLONIDINE; PROTOCOL; MORPHINE; SUPPORT	Introduction Sedation and analgesia are provided by using different agents and techniques in different countries. The goal is to achieve early spontaneous breathing and to obtain an awake and cooperative pain-free patient. It was the aim of this study to conduct a survey of the agents and techniques used for analgesia and sedation in intensive care units in Germany. Methods A survey was sent by mail to 261 hospitals in Germany. The anesthesiologists running the intensive care unit were asked to fill in the structured questionnaire about their use of sedation and analgesia. Results A total of 220 (84%) questionnaires were completed and returned. The RAMSAY sedation scale was used in 8% of the hospitals. A written policy was available in 21% of hospitals. For short-term sedation in most hospitals, propofol was used in combination with sufentanil or fentanyl. For long-term sedation, midazolam/fentanyl was preferred. Clonidine was a common part of up to two-thirds of the regimens. Epidural analgesia was used in up to 68%. Neuromuscular blocking agents were no longer used. Conclusion In contrast to the US 'Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult', our survey showed that in Germany different agents, and frequently neuroaxial techniques, were used.	Hosp Eichert, Dept Anesthesiol Intens Care Med & Pain Therapy, Goppingen, Germany; Univ Hosp Charite, Dept Anesthesiol & Intens Care Med, Berlin, Germany; Univ Hosp Charite, Inst Med Biometr, Berlin, Germany	Martin, J (reprint author), Hosp Eichert, Dept Anesthesiol Intens Care Med & Pain Therapy, Goppingen, Germany.	joerg.martin@email.de		Spies, Claudia/0000-0002-1062-0495			AST PH, 1984, LANCET, V2, P863; Barrientos-Vega R, 2001, CRIT CARE MED, V29, P317, DOI 10.1097/00003246-200102000-00018; Beattie WS, 2001, ANESTH ANALG, V93, P853, DOI 10.1097/00000539-200110000-00010; BION JF, 1987, INTENS CARE MED, V13, P215; BOHRER H, 1990, INTENS CARE MED, V16, P265, DOI 10.1007/BF01705163; BONICA JJ, 1987, ACTA ANAESTH SCAND, V31, P1, DOI 10.1111/j.1399-6576.1987.tb02665.x; Brattebo G, 2002, BRIT MED J, V324, P1386, DOI 10.1136/bmj.324.7350.1386; Breitfeld C, 2003, BRIT J ANAESTH, V91, P218, DOI 10.1093/bja/aeg165; Brodner G, 2001, ANESTH ANALG, V92, P1594, DOI 10.1097/00000539-200106000-00049; BURNS AM, 1992, DRUGS, V43, P507, DOI 10.2165/00003495-199243040-00007; Christensen BV, 1999, INTENS CARE MED, V25, P186, DOI 10.1007/s001340050814; Dahaba AA, 2004, ANESTHESIOLOGY, V101, P640, DOI 10.1097/00000542-200409000-00012; Durbin C G Jr, 1994, New Horiz, V2, P64; Ely EW, 2001, INTENS CARE MED, V27, P1892, DOI 10.1007/s00134-001-1132-2; Hack G, 2000, ANASTH INTENSIVMED, V41, P535; HOLM S, 1979, SCAND J STAT, V6, P65; HUGHES MA, 1992, ANESTHESIOLOGY, V76, P334, DOI 10.1097/00000542-199203000-00003; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; KOEPKE JP, 1989, MINER ELECTROL METAB, V15, P83; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; LEWIS KS, 1994, AM J HOSP PHARM, V51, P1539, DOI 10.1093/ajhp/51.12.1539; MacLaren R, 2000, PHARMACOTHERAPY, V20, P662, DOI 10.1592/phco.20.7.662.35172; Mascia MF, 2000, CRIT CARE MED, V28, P2300, DOI 10.1097/00003246-200007000-00019; MERRIMAN HM, 1981, INTENS CARE MED, V7, P217, DOI 10.1007/BF01702623; MEYER TJ, 1994, CHEST, V105, P1211, DOI 10.1378/chest.105.4.1211; MILLERJONES CMH, 1980, ANAESTHESIA, V35, P1104, DOI 10.1111/j.1365-2044.1980.tb05052.x; Murdoch S, 2000, INTENS CARE MED, V26, P922, DOI 10.1007/s001340051282; Ostermann ME, 2000, JAMA-J AM MED ASSOC, V283, P1451, DOI 10.1001/jama.283.11.1451; Putensen C, 2001, AM J RESP CRIT CARE, V164, P43, DOI 10.1164/ajrccm.164.1.2001078; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Soliman HM, 2001, BRIT J ANAESTH, V87, P186, DOI 10.1093/bja/87.2.186; Tobias JD, 2000, CRIT CARE MED, V28, P2122, DOI 10.1097/00003246-200006000-00079; Tonner Peter H, 2003, Curr Opin Anaesthesiol, V16, P113; TUNG A, 1995, CRIT CARE CLIN, V11, P791; Walder B, 2000, CRIT CARE MED, V28, P2242, DOI 10.1097/00003246-200007000-00010; Walz M, 1999, CHIRURG, V70, P66, DOI 10.1007/s001040050608; WHIPPLE JK, 1995, PHARMACOTHERAPY, V15, P592, DOI 10.1002/j.1875-9114.1995.tb02868.x; Zielmann S, 1995, ANAESTHESIST, V44, pS549	39	56	63	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	APR	2005	9	2					R117	R123		10.1186/cc3035			7	Critical Care Medicine	General & Internal Medicine	905RW	WOS:000227588300010	15774043	DOAJ Gold, Green Published			2020-06-30	J	Ortiz-Gomez, JR; Carrascosa, F; Perez-Cajaraville, JJ; Percaz-Bados, JA; Anez, C				Ortiz-Gomez, JR; Carrascosa, F; Perez-Cajaraville, JJ; Percaz-Bados, JA; Anez, C			Comparative study of intubating conditions at the first minute with suxamethonium, rocuronium and different priming techniques of rocuronium	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthetics, intravenous, propofol; intubation, intratracheal; neuromuscular non-depolarising agents, rocuronium, atracurium; vecuronium, cis-atracurium, mivacurium, neuromuscular depolarizing agents, succinylcholine; neuromuscular blockade, onset	RAPID-SEQUENCE INDUCTION; TRACHEAL INTUBATION; NEUROMUSCULAR BLOCKADE; MUSCLE-RELAXANT; PROPOFOL; VECURONIUM; THIOPENTONE; ETOMIDATE; PRINCIPLE; CHOICE	Background and objective: To evaluate orotracheal intubation conditions after 1 min. Patients and methods: A prospective randomized study with 376 adult American Society of Anesthesiologists (ASA) Grade I-III patients. Each patient received propofol, fentanyl and either suxamethonium (1 mg kg(-1)) or rocuronium. The intubating dose of rocuronium (2 X ED95) was preceded 4 min earlier by saline, or a 0.1 X ED95 priming dose of rocuronium, atracurium, cis-atracurium, vecuronium or mivacurium. Intubating conditions were graded as excellent, good or poor with respect to laryngoscopy, vocal cord position and movement and reaction to intubation and/or cuff inflation. Results: There were significant differences (P < 0.05) in laryngoscopy between suxamethonium and rocuronium primed with saline, atracurium or cis-atracurium. With respect to vocal cord position and movement during intubation, rocuronium without priming differed significantly from all other groups and for reaction to insertion of tracheal tube and/or cuff inflation. Rocuronium without priming differed significantly from all other groups except for rocuronium primed with itself The mivacurium group showed more signs of pre-curarization than other groups (P < 0.05). There were significant differences between rocuronium alone and the other groups when final intubating conditions were compared. Conclusions: Priming rocuronium with 0.1 X ED95 of vecuronium, rocuronium, atracurium or cis-atracurium is a safe technique and did not increase risk of pre-curarization in healthy patients.	Univ Clin, Dept Anesthesiol & Intens Care, Navarra 31008, Spain; Univ Navarra, Sch Med, Dept Anesthesiol, Navarra, Spain; Royal Acad Med & Surg Valladolid, Valladolid, Spain; Joan XXIII Hosp, Dept Anesthesiol, Tarragona, Spain	Ortiz-Gomez, JR (reprint author), Univ Clin, Dept Anesthesiol & Intens Care, Avenida Pio 12, Navarra 31008, Spain.	jortizg@unav.es		Ortiz-Gomez, Jose R./0000-0001-9601-5538			Aziz L, 1997, ANESTH ANALG, V85, P663, DOI 10.1097/00000539-199709000-00032; BOROS M, 1984, BRIT J ANAESTH, V56, P195, DOI 10.1093/bja/56.2.195; CRUL JF, 1995, EUR J ANAESTH, V12, P111; Dobson AP, 1999, ANAESTHESIA, V54, P172, DOI 10.1046/j.1365-2044.1999.00655.x; Dueck MH, 2003, ANESTH ANALG, V96, P449, DOI 10.1097/00000539-200302000-00029; DUKE PC, 1979, CAN ANAESTH SOC J, V26, P201, DOI 10.1007/BF03006982; England AJ, 1997, ANAESTHESIA, V52, P336, DOI 10.1111/j.1365-2044.1997.103-az0100.x; FELDMAN SA, 1994, EUR J ANAESTH, P49; Fuchs-Buder T, 1998, BRIT J ANAESTH, V80, P504, DOI 10.1093/bja/80.4.504; GLASS PSA, 1989, ANESTH ANALG, V68, P127, DOI 10.1213/00000539-198902000-00011; Gomez Aparisi J., 2002, Acta Horticulturae, P101; Griffith KE, 1997, J CLIN ANESTH, V9, P204, DOI 10.1016/S0952-8180(97)00034-2; Kopman AF, 2001, ANESTH ANALG, V93, P1253, DOI 10.1097/00000539-200111000-00042; Lavazais S, 2001, EUR J ANAESTH, V18, P66, DOI 10.1046/j.1365-2346.2001.018s23066.x; Mey JC, 1999, EUR J ANAESTH, V16, P387, DOI 10.1046/j.1365-2346.1999.00503.x; MORTIER E, 1987, Acta Anaesthesiologica Belgica, V38, P83; NAGUIB M, 1994, CAN J ANAESTH, V41, P902, DOI 10.1007/BF03010932; Ortiz-Gomez J R, 2000, Rev Esp Anestesiol Reanim, V47, P157; Plaud B, 2001, ANESTHESIOLOGY, V95, P96, DOI 10.1097/00000542-200107000-00019; REDAI I, 1995, EUR J ANAESTH, V12, P11; Shorten GD, 1997, PAEDIATR ANAESTH, V7, P167, DOI 10.1046/j.1460-9592.1997.d01-49.x; Sieber TJ, 1998, ANESTH ANALG, V86, P1137, DOI 10.1097/00000539-199805000-00044; Skinner HJ, 1998, ANAESTHESIA, V53, P702, DOI 10.1046/j.1365-2044.1998.396-az0506.x; Sparr HJ, 1996, BRIT J ANAESTH, V77, P339; Sparr HJ, 2001, EUR J ANAESTH, V18, P71; Tatsumi K, 1994, Masui, V43, P374; VibyMogensen J, 1996, ACTA ANAESTH SCAND, V40, P59, DOI 10.1111/j.1399-6576.1996.tb04389.x; White PF, 2002, BRIT J ANAESTH, V88, P163, DOI 10.1093/bja/88.2.163; Wong AKH, 1996, ANAESTH INTENS CARE, V24, P224	29	9	13	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	APR	2005	22	4					263	268		10.1017/S026502150500044X			6	Anesthesiology	Anesthesiology	932DY	WOS:000229535600004	15892403				2020-06-30	J	Sivaci, RG; Ermis, S; Ozturk, F				Sivaci, RG; Ermis, S; Ozturk, F			Fentanyl reduces cortisol and blood glucose changes during cataract surgery under retrobulbar anaesthesia	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Letter									Kocatepe Univ, Sch Med, Dept Anesthesiol, TR-03200 Afyon, Turkey; Kocatepe Univ, Sch Med, Dept Ophthalmol, TR-03200 Afyon, Turkey	Sivaci, RG (reprint author), Kocatepe Univ, Sch Med, Dept Anesthesiol, Dumlupinat Mh Turabi Cd Tutuncu Apt B Blok 5-9, TR-03200 Afyon, Turkey.	yasarsivaci@hotmail.com					BARKER JP, 1990, BRIT J ANAESTH, V64, P442, DOI 10.1093/bja/64.4.442; BARKER JP, 1994, BRIT J ANAESTH, V72, P119, DOI 10.1093/bja/72.1.119; BARKER JP, 1991, ANAESTHESIA, V46, P642, DOI 10.1111/j.1365-2044.1991.tb09712.x; BARKER JP, 1993, ANAESTHESIA, V48, P488, DOI 10.1111/j.1365-2044.1993.tb07067.x; Foggitt PS, 2001, J CATARACT REFR SURG, V27, P1651, DOI 10.1016/S0886-3350(01)00859-8; Kiefer RT, 1998, EUR J OPHTHALMOL, V8, P239; RAUCOULESAIME M, 1995, BRIT J ANAESTH, V74, P231, DOI 10.1093/bja/74.2.231	7	1	1	0	1	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	APR	2005	22	4					314	316		10.1017/S0265021505220537			3	Anesthesiology	Anesthesiology	932DY	WOS:000229535600014	15892413				2020-06-30	J	Sprenger, T; Berthele, A; Platzer, S; Boecker, H; Tolle, TR				Sprenger, T; Berthele, A; Platzer, S; Boecker, H; Tolle, TR			What to learn from in vivo opioidergic brain imaging?	EUROPEAN JOURNAL OF PAIN			English	Article						opioids; pain; ligands; PET	POSITRON-EMISSION-TOMOGRAPHY; RECEPTOR-BINDING; PAIN; PET; VOLUNTEERS; RESPONSES; CORTEX	Ligand-PET studies are attracting increasing interest in experimental and clinical research. As the most elaborated of PET techniques, ligand-PET allows the demonstration of receptor distributions, and thus, the delineation of neurochemical pathologies in the disease state. Recent developments are promising that ligand-PET will even allow to characterize dynamic and short-term changes in neurotransmission and will tremendously add to the understanding of neurophysiology on the receptor level. In pain studies, mainly the mu-opioidergic agonist [C-11]-carfentanil and the unspecific opioid receptor antagonist [C-11]-diprenorphine are applied. Utilizing these ligands the thalamus, prefrontal and cingulate cortex, basal ganglia and midbrain structures have been shown to possess high amounts of opioidergic receptors in vivo and it is well accepted, that the receptor density is higher in projections of the medial than those of the lateral pain system. Changes in receptor availability were observed in patients suffering from chronic pain. Rheumatoid arthritis, trigeminal neuralgia and central poststroke pain (CPSP) all lead to decreased ligand binding in pain processing regions during the painful period in comparison to pain free intervals or healthy subjects. These decreases may either be the consequence of increased endogenous release or indicate receptor internalization/down-regulation or loss of neurons carrying these receptors. Recent studies also evidenced [C-11]-carfentanil binding changes due to acute experimental pain. One possible interpretation of these changes is that the PET-ligand might be displaced by endogenous opioidergic ligands. One major region, where this "ligand displacement" was observed, was the thalamus. These findings highlight the importance of the opioidergic system in pain processing and the power of ligand-PET to advance the understanding of pain. (c) 2004 European Federation of Chapters of the International Association for the Study of Pain. Published by Elsevier Ltd. All rights reserved.	Tech Univ Munich, Dept Neurol, D-81675 Munich, Germany; Tech Univ Munich, Dept Nucl Med, D-81675 Munich, Germany	Tolle, TR (reprint author), Tech Univ Munich, Dept Neurol, Moehlstr 28, D-81675 Munich, Germany.	thomas.toelle@neuro.med.tu-muenchen.de	Boecker, Henning/N-7172-2019	Sprenger, Till/0000-0002-5390-819X			Ametamey SM, 2002, NUCL MED BIOL, V29, P227, DOI 10.1016/S0969-8051(01)00293-1; Ametamey SM, 1999, J RECEPT SIGNAL TR R, V19, P129, DOI 10.3109/10799899909036640; Bencherif B, 2002, PAIN, V99, P589, DOI 10.1016/S0304-3959(02)00266-X; Casey KL, 2000, J NEUROPHYSIOL, V84, P525; Duncan J S, 1999, Adv Neurol, V79, P893; Firestone LL, 1996, ANESTH ANALG, V82, P1247, DOI 10.1097/00000539-199606000-00025; FROST JJ, 1993, J RECEPTOR RES, V13, P39, DOI 10.3109/10799899309073644; Hagelberg N, 2002, SYNAPSE, V45, P25, DOI 10.1002/syn.10078; Hiller JM, 1996, NEUROCHEM RES, V21, P1333, DOI 10.1007/BF02532374; JONES AKP, 1994, BRIT J RHEUMATOL, V33, P909; JONES AKP, 1991, NEUROSCI LETT, V126, P25, DOI 10.1016/0304-3940(91)90362-W; Jones AKP, 1999, J CEREBR BLOOD F MET, V19, P803, DOI 10.1097/00004647-199907000-00011; JONES AKP, 1988, J NEUROSCI METH, V23, P121, DOI 10.1016/0165-0270(88)90184-7; Laruelle M, 2000, J CEREBR BLOOD F MET, V20, P423, DOI 10.1097/00004647-200003000-00001; LORENZ J, IN PRESS EUR J PAIN; PERT C, 1976, LIFE SCI, V15, P1849; Petrovic P, 2002, SCIENCE, V295, P1737, DOI 10.1126/science.1067176; Shiue CY, 1997, NUCL MED BIOL, V24, P145, DOI 10.1016/S0969-8051(96)00186-2; SPRENGER T, 2003, J CEREB BLOOD FLO S1, V23, P715; VOGT BA, 1987, J COMP NEUROL, V262, P271, DOI 10.1002/cne.902620208; Wagner KJ, 2001, ANESTHESIOLOGY, V94, P732, DOI 10.1097/00000542-200105000-00008; Willoch F, 2004, PAIN, V108, P213, DOI 10.1016/j.pain.2003.08.014; Zubieta JK, 1999, AM J PSYCHIAT, V156, P842, DOI 10.1176/ajp.156.6.842; Zubieta JK, 2002, J NEUROSCI, V22, P5100, DOI 10.1523/JNEUROSCI.22-12-05100.2002; Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	26	57	59	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801	1532-2149		EUR J PAIN	Eur. J. Pain	APR	2005	9	2					117	121		10.1016/j.ejpain.2004.07.010			5	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	911RV	WOS:000228023200006	15737798				2020-06-30	J	Sahin, AE; Duman, A; Atalik, EK; Ogun, CO; Sahin, TK; Erol, A; Ozergin, U				Sahin, AE; Duman, A; Atalik, EK; Ogun, CO; Sahin, TK; Erol, A; Ozergin, U			The mechanisms of the direct vascular effects of fentanyl on isolated human saphenous veins in vitro	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						fentanyl; vascular effects; K+ channels; nitric oxide; indomethacin; saphenous veins; coronary blood flow; coronary artery surgery	OUABAIN-INDUCED CONTRACTION; PORCINE CORONARY-ARTERY; SMOOTH-MUSCLE-CELLS; RAT AORTA; REMIFENTANIL; SUFENTANIL; ALFENTANIL; CHANNELS; OPIOIDS	Objective: The purpose of this study was to determine the mechanism of the direct effects of fentanyl on human veins in vitro. Design: In vitro, prospective with repeated measures. Setting: University research laboratory. Interventions: Dose-response curves were obtained for cumulative doses of fentanyl (10(-9)-10(-5) mol/L) on saphenous vein strips precontracted with (10(-6) mol/L) 5-hydroxytryptamine incubated with either naloxone (10(-4) mol/L), N omega-nitroL-arginine-methyl ester (L-NAME) (10(-4) mol/L), indomethacin (10(-5) mol/L), glibenclamide (10-4 mol/L), tetraethylammonium (10(-4) mol/L), or ouabain (10(-5) mol/L). Vein strips were also exposed to a Ca++-free solution and 0.1 mmol/L of ethylene glycol-bis-(b-aminoethylether) N,N '-tetraacetic acid; 5-hydroxytryptamine (10(-6) mol/L) was added to the bath before cumulative Ca++ (10(-4)-10(-2) mol/L). The same procedure was repeated in the presence of fentanyl (10-6, 3 x 10-6, or 10-5 mol/L) (p < 0.05 = significant). Measurements and Main Results: Preincubation of vein strips with naloxone, L-NAME, or indomethacin did not influence the relaxant responses to fentanyl (p > 0.05). Tetraethylammonium, glibenclamide, and ouabain reduced the relaxation response to fentanyl (p < 0.05). A stepwise increase in tension was recorded with cumulative doses of Ca++ (p < 0.05). Conclusions: The present results show that fentanyl causes vasodilatation via both endothelium- and opioid receptor-independent mechanisms in the human saphenous vein. The relaxant effects of fentanyl are probably via activation of K+ channel and Na+K+-adenosine trisphosphatase and inhibition of Ca++ channel. (c) 2005 Elsevier Inc. All rights reserved.	Selcuk Univ, Dept Pharmacol, TR-42080 Konya, Turkey; Selcuk Univ, Dept Anesthesia & Intens Care, TR-42080 Konya, Turkey; Selcuk Univ, Dept Publ Hlth, TR-42080 Konya, Turkey; Selcuk Univ, Dept Cardiac Surg, TR-42080 Konya, Turkey	Sahin, AE (reprint author), Selcuk Univ, Dept Pharmacol, TR-42080 Konya, Turkey.	aysesaide@hotmail.com	Sahin, Tahir Kemal/AAQ-6915-2020	Sahin, Tahir Kemal/0000-0002-4836-1759			BARAJASLOPEZ C, 1992, EUR J PHARMACOL, V221, P51, DOI 10.1016/0014-2999(92)90771-U; DAUT J, 1994, J CARDIOVASC ELECTR, V5, P154, DOI 10.1111/j.1540-8167.1994.tb01156.x; Duman A, 2003, J CARDIOTHOR VASC AN, V17, P465, DOI 10.1016/S1053-0770(03)00151-4; FERNANDEZALFONSO MS, 1992, GEN PHARMACOL-VASC S, V23, P439, DOI 10.1016/0306-3623(92)90109-W; Hanouz JL, 2001, ANESTH ANALG, V93, P543, DOI 10.1097/00000539-200109000-00005; HIMPENS B, 1995, J VASC RES, V32, P207, DOI 10.1159/000159095; Hirafuji M, 1999, EUR J PHARMACOL, V380, P163, DOI 10.1016/S0014-2999(99)00532-4; INTRONA RPS, 1995, LIFE SCI, V56, P1265, DOI 10.1016/0024-3205(95)00072-0; Karaki H, 1997, PHARMACOL REV, V49, P157; KARASAWA F, 1993, BRIT J ANAESTH, V71, P877, DOI 10.1093/bja/71.6.877; Klockgether-Radke AP, 2000, ACTA ANAESTH SCAND, V44, P1134, DOI 10.1034/j.1399-6576.2000.440917.x; MARIN J, 1991, EUR J PHARMACOL, V201, P75, DOI 10.1016/0014-2999(91)90325-K; MARIN J, 1988, BRIT J PHARMACOL, V93, P43, DOI 10.1111/j.1476-5381.1988.tb11403.x; Saito W, 1998, LIFE SCI, V62, P2171, DOI 10.1016/S0024-3205(98)00194-5; SHIBATA R, 1990, EUR J PHARMACOL, V190, P147, DOI 10.1016/0014-2999(90)94121-D; WHITE DA, 1990, ANESTH ANALG, V71, P29; YAMANOUE T, 1992, ANESTH ANALG, V74, P889; Yamazumi I, 2001, JPN J PHARMACOL, V87, P268, DOI 10.1254/jjp.87.268	18	8	10	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770	1532-8422		J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	APR	2005	19	2					197	200		10.1053/j.jvca.2005.01.031			4	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	921HH	WOS:000228754400013	15868528				2020-06-30	J	Pihlainen, K; Grigoras, K; Franssila, S; Ketola, R; Kotiaho, T; Kostiainen, R				Pihlainen, K; Grigoras, K; Franssila, S; Ketola, R; Kotiaho, T; Kostiainen, R			Analysis of amphetamines and fentanyls by atmospheric pressure desorption/ionization on silicon mass spectrometry and matrix-assisted laser desorption/ionization mass spectrometry and its application to forensic analysis of drug seizures	JOURNAL OF MASS SPECTROMETRY			English	Article						atmospheric pressure desorption/ionization on silicon; atmospheric pressure matrix-assisted laser desorption/ionization; forensic; amphetamines; fentanyl; 1-(2-phenrthyl)-4-N-propionylanilino)piperidine	DESORPTION-IONIZATION; HUMAN PLASMA; QUANTITATIVE-DETERMINATION; POROUS SILICON; ORAL FLUID; DERIVATIVES; 3-METHYLFENTANYL; DISCRIMINATION; EXTRACTION; DIOS	The suitability of atmospheric pressure desorption/ionization on silicon mass spectrometry (AP-DIOS-MS) and matrix-assisted laser desorption ionization mass spectrometry (AP-MALDI-MS) for the identification of amphetamines and fentanyls in forensic samples was studied. With both ionization techniques, the mass spectra recorded showed abundant protonated molecules, and the background did not disturb the analysis. The use of tandem mass spectrometry (MS/MS) allowed unambiguous identification of the amphetamines and fentanyls. AP-DIOS-MS/MS and AP-MALDI-MS/MS were also successfully applied to the identification of authentic compounds from drug seizures. Common diluents and tablet materials did not disturb the analysis and compounds were unequivocally identified. The limits of detection (LODs) for amphetamines and fentanyls with AP-DIOS-MS/MS were 1-3 pmol, indicating excellent sensitivity of the method. The LODs with AP-MALDI-MS/MS were about 5-10 times higher. Copyright (c) 2005 John Wiley & Sons, Ltd.	Univ Helsinki, Div Pharmaceut Chem, Dept Pharm, FIN-00014 Helsinki, Finland; Aalto Univ, Ctr Microelect, FIN-02015 Espoo, Finland; DDTC, Vikki Drug Discovery Technol Ctr, Dept Pharm, FIN-00014 Helsinki, Finland; Univ Helsinki, Chim Analyt Lab, Dept Chem, FIN-00014 Helsinki, Finland	Kostiainen, R (reprint author), Univ Helsinki, Div Pharmaceut Chem, Dept Pharm, POB 56, FIN-00014 Helsinki, Finland.	risto.kostiainen@helsinki.fi	Kostiainen, Risto K/B-5491-2008; Franssila, Sami/M-2801-2014	Kotiaho, Tapio/0000-0003-0382-8578; Kostiainen, Risto/0000-0003-2454-4574			Arakawa R, 2004, J MASS SPECTROM, V39, P961, DOI 10.1002/jms.631; Borth S, 2000, J MASS SPECTROM, V35, P705, DOI 10.1002/1096-9888(200006)35:6<705::AID-JMS997>3.0.CO;2-3; CHENG MT, 1982, ANAL CHEM, V54, P2204, DOI 10.1021/ac00250a016; COOPER D, 1986, J FORENSIC SCI, V31, P511; Doroshenko VM, 2002, INT J MASS SPECTROM, V221, P39, DOI 10.1016/S1387-3806(02)00893-X; Go EP, 2003, ANAL CHEM, V75, P2504, DOI 10.1021/ac026253n; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; Huikko K, 2003, RAPID COMMUN MASS SP, V17, P1339, DOI 10.1002/rcm.1051; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; Kruse RA, 2001, J MASS SPECTROM, V36, P1317, DOI 10.1002/jms.237; Laiko VV, 2000, ANAL CHEM, V72, P652, DOI 10.1021/ac990998k; Laiko VV, 2002, RAPID COMMUN MASS SP, V16, P1737, DOI 10.1002/rcm.781; Martens-Lobenhoffer J, 2002, J CHROMATOGR B, V769, P227, DOI 10.1016/S1570-0232(01)00569-4; Mortier KA, 2002, J CHROMATOGR B, V779, P321, DOI 10.1016/S1570-0232(02)00400-2; Moyer SC, 2003, INT J MASS SPECTROM, V226, P133, DOI 10.1016/S1387-3806(02)00972-7; Ohta H, 1999, J ANAL TOXICOL, V23, P280, DOI 10.1093/jat/23.4.280; Palleschi L, 2003, J PHARMACEUT BIOMED, V32, P329, DOI 10.1016/S0731-7085(03)00110-9; Pihlainen K, 2004, J CHROMATOGR A, V1033, P91, DOI 10.1016/j.chroma.2003.12.073; Rausberg P, 2003, FORENSIC SCI INT, V136, P96; Shen Z., 2001, ANAL CHEM, V33, P179; Shou WZ, 2001, RAPID COMMUN MASS SP, V15, P466, DOI 10.1002/rcm.255; SUZUKI S, 1986, CHEM PHARM BULL, V34, P1340; SUZUKI S, 1989, FORENSIC SCI INT, V43, P15, DOI 10.1016/0379-0738(89)90117-5; Thomas JJ, 2001, ANAL CHIM ACTA, V442, P183, DOI 10.1016/S0003-2670(01)01107-2; Thomas JJ, 2001, P NATL ACAD SCI USA, V98, P4932, DOI 10.1073/pnas.081069298; Tuomikoski S, 2002, LAB CHIP, V2, P247, DOI 10.1039/b207634a; VANBEVER WF, 1974, J MED CHEM, V17, P1047, DOI 10.1021/jm00256a003; Wei J, 1999, NATURE, V399, P243, DOI 10.1038/20400; Wilkinson R, 2003, SEC TEL INF TECHN, P1; Wood M, 2003, J ANAL TOXICOL, V27, P78, DOI 10.1093/jat/27.2.78	31	28	28	1	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1076-5174	1096-9888		J MASS SPECTROM	J. Mass Spectrom.	APR	2005	40	4					539	545		10.1002/jms.831			7	Biochemical Research Methods; Chemistry, Analytical; Spectroscopy	Biochemistry & Molecular Biology; Chemistry; Spectroscopy	923MF	WOS:000228913300013	15712357				2020-06-30	J	Pandey, CK; Navkar, DV; Giri, PD; Raza, M; Behari, S; Singh, RB; Singh, U; Singh, PK				Pandey, CK; Navkar, DV; Giri, PD; Raza, M; Behari, S; Singh, RB; Singh, U; Singh, PK			Evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar diskectomy - A randomized, double-blind, placebo-controlled study	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						gabapentin; preemptive analgesia; optimal dose; diskectomy	HEAT-CAPSAICIN SENSITIZATION; ABDOMINAL HYSTERECTOMY; MORPHINE CONSUMPTION; HEALTHY-VOLUNTEERS; SURGERY; MODEL	We evaluated the optimal preemptive dose of gabapentin for postoperative pain relief after single-level lumbar diskectomy and its effect on fentanyl consumption during the initial 24 hours in a randomized, double-blinded, placebo-controlled study in 100 patients with American Society of Anesthesiologists physical status I and II. Patients were divided into five groups to receive placebo or gabapentin 300, 600, 900, or 1200 mg 2 hours before surgery. After surgery, patients were transferred to the postanesthesia care unit (PACU). A blinded anesthesiologist recorded the pain scores at time points of 6, 12, 18, and 24 hours in the PACU on a Visual Analog Scale (VAS; 010 cm) at rest. Patients received patient-controlled analgesia (fentanyl 1.0 &mu; g/kg on each demand with lockout interval of 10 minutes); total fentanyl consumption during initial 24 hours was recorded. Data were entered into the statistical software package SPSS 9.0 for analysis (one-way analysis of variance and Student-Newman-Keuls test). Patients who received gabapentin 300 mg had significantly lower VAS score at all time points. They consumed less fentanyl (patients who received placebo processed 1217.5 &PLUSMN; 182.0 versus 987.5 &PLUSMN; 129.6 &mu; g; P &LT; 0.05). Patients who received gabapentin 600, 900, and 1200 mg had lower VAS scores at all time points than patients who received gabapentin 300 mg (P &LT; 0.05). Increasing the dose of gabapentin from 600 to 1200 mg did not decrease the VAS score, nor did the increasing dose of gabapentin significantly decrease fentanyl consumption (702.5, 635, and 626.5 &mu; g). Thus, gabapentin 600 mg is the optimal dose for postoperative pain relief following lumbar diskectomy.	Sanjay Gandhi Postgrad Inst Med Sci, Dept Anaesthesiol, Lucknow 226014, Uttar Pradesh, India; Sanjay Gandhi Postgrad Inst Med Sci, Dept Neurosurg, Lucknow 226014, Uttar Pradesh, India; Sanjay Gandhi Postgrad Inst Med Sci, Dept Biostat, Lucknow 226014, Uttar Pradesh, India	Pandey, CK (reprint author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Anaesthesiol, Lucknow 226014, Uttar Pradesh, India.	ckpandey@sgpgi.ac.in					Dierking G, 2004, ACTA ANAESTH SCAND, V48, P322, DOI 10.1111/j.0001-5172.2004.0329.x; Dirks J, 2002, ANESTHESIOLOGY, V97, P102, DOI 10.1097/00000542-200207000-00015; Dirks J, 2002, ANESTHESIOLOGY, V97, P560, DOI 10.1097/00000542-200209000-00007; Eckhardt K, 2000, ANESTH ANALG, V91, P185, DOI 10.1097/00000539-200007000-00035; Fassoulaki A, 2002, ANESTH ANALG, V95, P985, DOI 10.1097/00000539-200210000-00036; Field MJ, 1997, J PHARMACOL EXP THER, V282, P1242; Gee NS, 1996, J BIOL CHEM, V271, P5768, DOI 10.1074/jbc.271.10.5768; GOA KL, 1993, DRUGS, V46, P409, DOI 10.2165/00003495-199346030-00007; Mao JR, 2000, ANESTH ANALG, V91, P680, DOI 10.1213/00000539-200009000-00034; Pandey CK, 2004, CAN J ANAESTH, V51, P358, DOI 10.1007/BF03018240; Petersen KL, 2001, ANESTHESIOLOGY, V94, P15, DOI 10.1097/00000542-200101000-00008; Rorarius MGF, 2004, PAIN, V110, P175, DOI 10.1016/j.pain.2004.03.023; Taylor CP, 1998, EPILEPSY RES, V29, P233, DOI 10.1016/s0920-1211(97)00084-3; Turan A, 2004, ANESTH ANALG, V99, P375; Turan A, 2004, ANESTH ANALG, V98, P1370, DOI 10.1213/01.ANE.0000108964.70485.B2; Turan A, 2004, ANESTHESIOLOGY, V100, P935, DOI 10.1097/00000542-200404000-00025	16	130	135	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	APR	2005	17	2					65	68		10.1097/01.ana.0000151407.62650.51			4	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	923NI	WOS:000228916200002	15840990				2020-06-30	J	Peters, JWB; Schouw, R; Anand, KJS; van Dijk, M; Duivenvoorden, HJ; Tibboel, D				Peters, JWB; Schouw, R; Anand, KJS; van Dijk, M; Duivenvoorden, HJ; Tibboel, D			Does neonatal surgery lead to increased pain sensitivity in later childhood?	PAIN			English	Article						newborn infant; repetitive pain; biobehavioural pain response; analgesia	RANDOMIZED CONTROLLED-TRIAL; EPIDURAL OPIOID ANALGESIA; BIRTH-WEIGHT INFANTS; PERIPHERAL INFLAMMATION; MAJOR SURGERY; SENSORY HYPERINNERVATION; POSTOPERATIVE PAIN; METABOLIC RESPONSE; NEWBORN-INFANTS; SURGICAL STRESS	Does pain or tissue damage in early life lead to hyperalgesia persisting into childhood? We performed a cross-sectional study in 164 infants to investigate whether major surgery within the first 3 months of life increases pain sensitivity to subsequent surgery and to elucidate whether subsequent surgery in the same dermatome or in a different dermatome leads to differences in pain sensitivity. All infants received standard intraoperative and postoperative pain management, with rescue analgesia guided by a treatment algorithm. Differences in pain sensitivity during surgery were assessed by the intraoperative fentanyl intake and by (nor)epinephrine plasma concentrations. Differences in postoperative pain sensitivity were assessed by the observational pain measures COMFORT and VAS, and by morphine intake and (nor)epinephrine plasma concentrations. Infants previously operated upon in the same dermatome needed more intraoperative fentanyl, had higher COMFORT and VAS scores, had greater (nor)epinephrine plasma concentrations, and needed also more morphine than did infants with no prior surgery. In contrast, infants who previously underwent surgery in another dermatome had only significant higher postoperative analgesic requirements and norepinephrine plasma concentrations in comparison with infants with no prior surgery. These preliminary differences may indicate the occurrence of spinal and supraspinal changes following neonatal surgery. We conclude that the long-term consequences of surgery in early infancy are greater in areas of prior tissue damage and that these effects may portend limited clinical but important neurobiological differences. (c) 2005 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	Erasmus Univ, Med Ctr, Dept Pediat Surg, NL-3000 CB Rotterdam, Netherlands; Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; Arkansas Childrens Hosp, Little Rock, AR 72205 USA; Erasmus Univ, Med Ctr, NIHES, Dept Med Psychol & Psychotherapy, Rotterdam, Netherlands	Peters, JWB (reprint author), Erasmus Univ, Med Ctr, Dept Pediat Surg, POB 2060, NL-3000 CB Rotterdam, Netherlands.	j.peters@erasmusmc.nl	van Dijk, Monique/B-6327-2009; Anand, Kanwaljeet/B-3287-2014	Anand, Kanwaljeet/0000-0001-6498-1483; van Dijk, Monique/0000-0002-9856-0318			ALTMAN DG, 1990, PRACTICAL STAT MED; Alvares D, 2000, Prog Brain Res, V129, P365; Anand KJS, 2000, NAT MED, V6, P971, DOI 10.1038/79658; Anand KJS, 1999, PHYSIOL BEHAV, V66, P627, DOI 10.1016/S0031-9384(98)00338-2; Anand KJS, 2004, J PEDIATR-US, V144, P449, DOI 10.1016/j.jpeds.2003.12.035; Anand KJS, 2001, INTENS CARE MED, V27, P873, DOI 10.1007/s001340100929; ANAND KJS, 1988, J PEDIATR SURG, V23, P297, DOI 10.1016/S0022-3468(88)80193-3; ANDREWS K, 1994, PAIN, V56, P95, DOI 10.1016/0304-3959(94)90154-6; Andrews K, 1999, DEV MED CHILD NEUROL, V41, P696, DOI 10.1017/S0012162299001425; Andrews KA, 2002, PAIN, V100, P35, DOI 10.1016/S0304-3959(02)00288-9; Beland B, 2001, J PAIN, V2, P36, DOI 10.1054/jpai.2001.17697; Bhutta AT, 2002, CLIN PERINATOL, V29, P357, DOI 10.1016/S0095-5108(02)00011-8; Bhutta AT, 2001, PHYSIOL BEHAV, V73, P51, DOI 10.1016/S0031-9384(01)00432-2; Bouwmeester NJ, 2001, BRIT J ANAESTH, V87, P390, DOI 10.1093/bja/87.3.390; BOUWMEESTER NJ, 2003, INTENS CARE MED, V25, P25; Coggeshall RE, 1996, DEV BRAIN RES, V92, P81, DOI 10.1016/0165-3806(95)00207-3; De Lima J, 1999, BRIT J ANAESTH, V83, P662; FITZGERALD M, 1988, DEV MED CHILD NEUROL, V30, P520; FITZGERALD M, 1989, PAIN, V39, P31, DOI 10.1016/0304-3959(89)90172-3; FRAYN KN, 1986, CLIN ENDOCRINOL, V24, P577, DOI 10.1111/j.1365-2265.1986.tb03288.x; Fuller B F, 2000, Clin Nurs Res, V9, P124; Grunau RE, 2001, INFANT BEHAV DEV, V24, P41; Grunau RE, 2001, PEDIATRICS, V107, P105, DOI 10.1542/peds.107.1.105; Grunau RE, 1998, J CHILD PSYCHOL PSYC, V39, P587, DOI 10.1111/1469-7610.00354; JONES MO, 1993, J PEDIATR SURG, V28, P1258, DOI 10.1016/S0022-3468(05)80309-4; Kirk E. R, 1995, EXPT DESIGN PROCEDUR; Kleinbaum D. G., 1988, APPL REGRESSION ANAL; Lidow MS, 2002, PAIN, V99, P377, DOI 10.1016/S0304-3959(02)00258-0; Lidow MS, 2001, NEUROREPORT, V12, P399, DOI 10.1097/00001756-200102120-00042; Liu JG, 2004, EUR J PHARMACOL, V491, P127, DOI 10.1016/j.ejphar.2004.03.042; Marsh D, 1999, PAIN, V82, P33, DOI 10.1016/S0304-3959(99)00029-9; Marsh D, 1999, PAIN, V82, P23, DOI 10.1016/S0304-3959(99)00028-7; MCGRATH PJ, 1985, BEHAV SCALE RATING, V9, P395; Narsinghani U, 2000, LAB ANIMAL, V29, P27; Oberlander TF, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.1.e6; OKUR H, 1995, J PEDIATR SURG, V30, P626, DOI 10.1016/0022-3468(95)90147-7; Peters JWB, 2003, CLIN J PAIN, V19, P353, DOI 10.1097/00002508-200311000-00003; Peters JWB, 2003, PEDIATRICS, V111, P129, DOI 10.1542/peds.111.1.129; Peters JWB, 1999, PAEDIATR ANAESTH, V9, P235, DOI 10.1046/j.1460-9592.1999.00358.x; PLATT MPW, 1990, J PEDIATR SURG, V25, P472, DOI 10.1016/0022-3468(90)90553-L; Rahman W, 1997, PROG PAIN RES MANAG, V8, P783; Ren K, 1997, P NATL ACAD SCI USA, V94, P1471, DOI 10.1073/pnas.94.4.1471; REYNOLDS ML, 1995, J COMP NEUROL, V358, P487, DOI 10.1002/cne.903580403; Ruda MA, 2000, SCIENCE, V289, P628, DOI 10.1126/science.289.5479.628; Tachibana T, 2001, NEUROREPORT, V12, P925, DOI 10.1097/00001756-200104170-00012; Taddio A, 1997, LANCET, V349, P599, DOI 10.1016/S0140-6736(96)10316-0; Taddio A, 2002, JAMA-J AM MED ASSOC, V288, P857, DOI 10.1001/jama.288.7.857; Taylor A, 2000, LANCET, V355, P120, DOI 10.1016/S0140-6736(99)02549-0; van Dijk M, 2002, PAIN, V98, P305, DOI 10.1016/S0304-3959(02)00031-3; van Dijk M, 2000, PAIN, V84, P367, DOI 10.1016/S0304-3959(99)00239-0; Walker CD, 2003, DEV BRAIN RES, V140, P253, DOI 10.1016/S0165-3806(02)00611-9; Walker SM, 2003, PAIN, V105, P185, DOI 10.1016/S0304-3959(03)00201-X; YI DK, 1995, PAIN, V60, P257, DOI 10.1016/0304-3959(94)00119-Y	53	147	154	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	APR	2005	114	3					444	454		10.1016/j.pain.2005.01.014			11	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	914MR	WOS:000228232400016	15777869				2020-06-30	J	Romero, A; Planas, E; Poveda, R; Sanchez, S; Pol, O; Puig, MM				Romero, A; Planas, E; Poveda, R; Sanchez, S; Pol, O; Puig, MM			Anti-exudative effects of opioid receptor agonists in a rat model of carrageenan-induced acute inflammation of the paw	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						oedema; histamine; inflammation; opioid receptor; plasma extravasation	PLASMA EXTRAVASATION; INDUCED EDEMA; MAST-CELLS; MU-OPIATE; VASCULAR-PERMEABILITY; PRIMARY AFFERENT; INFLAMED TISSUE; SENSORY NERVES; COMPOUND 48/80; IMMUNE CELLS	We evaluated the anti-exudative effects (Evan's blue) of mu-, delta- and kappa-opioid receptor agonists in a rat model of carrageenan-induced acute inflammation. The contribution of different components was assessed after the administration of. cyclosporine A, capsaicin, 6-hydroxydopamine, compound 48/80, and specific histamine-receptor antagonists. The results show that the mu-opioid receptor agonists morphine and fentanyl and the delta-opioid receptor agonists DPDPE (enkephalin, [D-Pen(2,5)]) and SNC 80 ((+)-4-[(YR)-alpha((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide) decrease plasma extravasation in a dose-dependent manner, with a biphasic response. The effects were reversed by specific antagonists, and are predominantly mediated by peripheral opioid receptors. The integrity of sensory and sympathetic fibres is essential for the anti-exudative effects of fentanyl and DPDPE. Histamine and functional histamine H-2 and H-3 receptors are required for morphine and fentanyl (but not DPDPE) inhibition of plasma extravasation, suggesting different mechanism for mu- and delta-opioid receptor agonists. The present findings implicate multiple sites and mechanisms in the anti-exudative effects of exogenous opioids. (c) 2005 Elsevier B.V. All rights reserved.	Autonomous Univ Barcelona, Sch Med, Hosp Mar, Dept Anesthesiol, Barcelona 08003, Spain; Univ Barcelona, Dept Pharmacol, Bellvitge Biomed Res Inst, Barcelona, Spain	Puig, MM (reprint author), Autonomous Univ Barcelona, Sch Med, Hosp Mar, Dept Anesthesiol, Paseo Maritimo 25, Barcelona 08003, Spain.	MPuigR@imas.imim.es	Pol, Olga/O-2146-2019; Romero, Asuncion/L-6030-2014; Pol, Olga/C-9194-2011	Pol, Olga/0000-0002-4621-8457; Romero, Asuncion/0000-0002-5182-1672; 			Alebouyeh M, 2002, CYTOKINE, V19, P102, DOI 10.1006/cyto.2002.1947; Amann R, 2002, PHARMACOLOGY, V66, P169, DOI 10.1159/000063800; AMANN R, 1995, EUR J PHARMACOL, V279, P227, DOI 10.1016/0014-2999(95)00169-L; BANKS BEC, 1990, BRIT J PHARMACOL, V99, P350, DOI 10.1111/j.1476-5381.1990.tb14707.x; BARBER A, 1993, EUR J PHARMACOL, V236, P113, DOI 10.1016/0014-2999(93)90233-8; Bigliardi PL, 2002, J RECEPT SIGNAL TR R, V22, P191, DOI 10.1081/RRS-120014595; Binder W, 2001, ANESTHESIOLOGY, V94, P1034, DOI 10.1097/00000542-200106000-00018; Cadet P, 2000, ENDOTHELIUM-NEW YORK, V7, P185, DOI 10.3109/10623320009165316; Catheline G, 1999, EUR J PHARMACOL, V370, P287, DOI 10.1016/S0014-2999(99)00153-3; CODERRE TJ, 1989, J NEUROPHYSIOL, V62, P48; Donahoe RM, 2001, ADV EXP MED BIOL, V493, P89; GAVERIAUX C, 1995, FEBS LETT, V369, P272, DOI 10.1016/0014-5793(95)00766-3; Gomes I, 2004, P NATL ACAD SCI USA, V101, P5135, DOI 10.1073/pnas.0307601101; GREEN PG, 1992, NEUROSCIENCE, V49, P129, DOI 10.1016/0306-4522(92)90080-L; HONG YG, 1995, EUR J PHARMACOL, V277, P21, DOI 10.1016/0014-2999(95)00045-M; ICHINOSE M, 1990, J APPL PHYSIOL, V68, P21; JORIS J, 1990, PAIN, V43, P95, DOI 10.1016/0304-3959(90)90054-H; KARIMIAN M, 1994, NEUROSCI LETT, V166, P39, DOI 10.1016/0304-3940(94)90835-4; Kuzmin A, 2000, J PHARMACOL EXP THER, V295, P1031; LEI YH, 1999, LUNG CELL MOL PHYSL, V20, pL391; LEVINE JD, 1986, NATURE, V323, P158, DOI 10.1038/323158a0; Linardi A, 2000, EUR J PHARMACOL, V399, P235, DOI 10.1016/S0014-2999(00)00375-7; LYNN B, 1990, PAIN, V41, P61, DOI 10.1016/0304-3959(90)91110-5; Machelska H, 1999, J PHARMACOL EXP THER, V290, P354; Maisonneuve IM, 2001, DRUG ALCOHOL DEPEN, V65, P55, DOI 10.1016/S0376-8716(01)00150-8; McDonald DM, 1999, MICROCIRCULATION, V6, P7; OHTSUKI H, 1985, JPN J PHARMACOL, V38, P195, DOI 10.1254/jjp.38.195; OWEN SM, 1994, AGENTS ACTIONS, V41, pC62, DOI 10.1007/BF02007768; Pasternak GW, 2001, LIFE SCI, V68, P2213, DOI 10.1016/S0024-3205(01)01008-6; Pasternak GW, 2001, TRENDS PHARMACOL SCI, V22, P67, DOI 10.1016/S0165-6147(00)01616-3; Planas E, 2000, PHARMACOLOGY, V60, P121, DOI 10.1159/000028356; PLANAS ME, 1995, PAIN, V60, P67, DOI 10.1016/0304-3959(94)00090-2; RANDALL LO, 1957, ARCH INT PHARMACOD T, V111, P409; Richardson JD, 2002, J PHARMACOL EXP THER, V302, P839, DOI 10.1124/jpet.102.032797; Saeed RW, 2000, INT J MOL MED, V6, P673; Salmi P, 2003, EUR J PHARMACOL, V458, P101, DOI 10.1016/S0014-2999(02)02736-X; SCHAFER M, 1994, P NATL ACAD SCI USA, V91, P4219, DOI 10.1073/pnas.91.10.4219; Siney L, 1996, BRIT J PHARMACOL, V117, P1065, DOI 10.1111/j.1476-5381.1996.tb16698.x; STEIN C, 1990, P NATL ACAD SCI USA, V87, P5935, DOI 10.1073/pnas.87.15.5935; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; Suh HW, 1999, NEUROPEPTIDES, V33, P121, DOI 10.1054/npep.1999.0006; Suzuki S, 2001, INT IMMUNOPHARMACOL, V1, P1733, DOI 10.1016/S1567-5769(01)00083-2; SUZUKI T, 1994, LIFE SCI, V54, P203, DOI 10.1016/0024-3205(94)00589-3; TALLANDA RJ, 1986, MANUAL PHARM CALCULA; Taylor BK, 2000, PAIN, V84, P263, DOI 10.1016/S0304-3959(99)00212-2; UDAKA K, 1970, P SOC EXP BIOL MED, V133, P1384; Valle L, 2001, J PHARMACOL EXP THER, V296, P378; WINTER CA, 1962, P SOC EXP BIOL MED, V111, P544; YOSHIHARA S, 1995, AM J RESP CRIT CARE, V151, P1011; Zhang Q, 1998, NEUROSCIENCE, V85, P281, DOI 10.1016/S0306-4522(97)00647-7; Zhou L, 1998, J PHARMACOL EXP THER, V286, P1000	51	41	41	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	MAR 28	2005	511	2-3					207	217		10.1016/j.ejphar.2005.02.004			11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	914DY	WOS:000228206600016	15792790				2020-06-30	J	Karahalil, B; Yagar, S; Bahadir, G; Durak, P; Sardas, S				Karahalil, B; Yagar, S; Bahadir, G; Durak, P; Sardas, S			Diazepam and propofol used as anesthetics during open-heart surgery do not cause chromosomal aberrations in peripheral blood lymphocytes	MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS			English	Article						diazepam; propofol; chromosome aberration; cardiac surgery; total intravenous anesthesia	SISTER-CHROMATID EXCHANGES; MOUSE OOCYTES; CELLS; MITOSIS; DRUGS; VITRO; VIVO	Diazepam is a benzodiazepine with anticonvulsant, anxiolytic, sedative and muscle-relaxing properties. Many aspects of its toxicity have been investigated, including genotoxic and carcinogenic effects in various model systems. However, it is still unclear whether diazepam is in fact a genotoxic agent. Propofol is a rapid-onset, short-acting intravenous anesthetic agent. It is used widely for the induction and maintenance of anesthesia as well as for long-term sedation in intensive care units. There is limited information in the literature on its genotoxic effects. Both drugs are commonly used as anesthetic in patients undergoing open-heart surgery. Therefore, we investigated the possible genotoxic effects of propofol and diazepam in those patients, using a chromosomal aberration (CA) assay. Peripheral blood samples were collected from 45 patients before induction of anesthesia and at the end of the anesthesia with diazepam or propofol. In Group I (n = 24), anesthesia was induced with 0.2 mg kg(-1) diazepam and 10 mu g kg(-1) fentanyl. In Group II (n = 21), anesthesia was induced with 1 mg kg(-1) propofol and 10 mu g kg(-1) fentanyl. Pancuronium bromide (0.1 mg kg(-1)) was administered for skeletal muscle relaxation in both groups. Anesthesia was maintained by diazepam administration at 5 mg kg(-1) in Group I or by continuous propofol administration at 2-4 mg (kg h)(-1) in Group II. All patients received 0.02 mg kg(-1) pancuronium and 5 mu g kg-' fentanyl boluses at 30-40 min intervals for anesthesia maintenance. Body temperature was controlled during bypass in the two groups. We found that the mean frequency of CAs in both groups before and at the end of the anesthesia were not statistically significantly different. Our analysis also indicated that age, smoking habit and gender were not confounding factors. In conclusion, our results indicate that diazepam and propofol do not exert genotoxic effects in blood cells during open-heart surgery. (c) 2004 Elsevier B.V. All rights reserved.	Gazi Univ, Fac Pharm, Dept Toxicol, Hipodrom, TR-06330 Ankara, Turkey; Turkish State Railway Hosp, Anaesthesiol Clin, Ankara, Turkey	Karahalil, B (reprint author), Gazi Univ, Fac Pharm, Dept Toxicol, Hipodrom, TR-06330 Ankara, Turkey.	bensu@gazi.edu.tr	Sardas, Semra/J-2175-2018	Sardas, Semra/0000-0001-5456-8636			ANDERSSON LC, 1981, NATURE, V291, P247, DOI 10.1038/291247a0; ANTOCCIA A, 1991, MUTAGENESIS, V6, P316; BONATTI S, 1992, MUTAGENESIS, V7, P111, DOI 10.1093/mutage/7.2.111; CALLAINI G, 1989, BIOL CELL, V67, P313; Chen TL, 2000, BRIT J ANAESTH, V84, P771; COHEN MM, 1969, J AMER MED ASSOC, V207, P2425, DOI 10.1001/jama.207.13.2425; De la Cruz JP, 1999, ANESTH ANALG, V89, P1050, DOI 10.1097/00000539-199910000-00043; Garza CHL, 1998, ARCH MED RES, V29, P285; Izzo M, 1998, MUTAGENESIS, V13, P445, DOI 10.1093/mutage/13.5.445; Karahalil B, 2002, MUTAT RES-GEN TOX EN, V515, P135, DOI 10.1016/S1383-5718(02)00003-7; Krause TKW, 2003, MUTAT RES-GEN TOX EN, V542, P59, DOI 10.1016/j.mrgentox.2003.08.007; LAFI A, 1988, MUTAGENESIS, V3, P23, DOI 10.1093/mutage/3.1.23; MARCHETTI F, 1994, MUTAT RES, V322, P69, DOI 10.1016/0165-1218(94)90034-5; Peng ZY, 2003, CHINESE MED J-PEKING, V116, P731; POHLOVA H, 1986, MUTAT RES, V174, P213, DOI 10.1016/0165-7992(86)90154-5; PRESTON RJ, 1987, MUTAT RES, V189, P175; SPURCK TP, 1994, J CELL SCI, V107, P2643; STAIGER G R, 1970, Mutation Research, V10, P635, DOI 10.1016/0027-5107(70)90090-4; STAIGER GR, 1969, MUTAT RES, V7, P109, DOI 10.1016/0027-5107(69)90054-2; STENCHEVER MA, 1970, AM J OBSTET GYNECOL, V107, P456, DOI 10.1016/0002-9378(70)90576-4; STENCHEVER MA, 1969, AM J OBSTET GYNECOL, V103, P836, DOI 10.1016/0002-9378(69)90583-3; Tatone C, 1998, HUM REPROD, V13, P430, DOI 10.1093/humrep/13.2.430; Tomioka S, 2000, ACTA ANAESTH SCAND, V44, P1261, DOI 10.1034/j.1399-6576.2000.441013.x; Trapani G, 2000, CURR MED CHEM, V7, P249, DOI 10.2174/0929867003375335; WHITE BJ, 1974, JAMA-J AM MED ASSOC, V230, P414, DOI 10.1001/jama.230.3.414	25	23	24	1	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1383-5718	1879-3592		MUTAT RES-GEN TOX EN	Mutat. Res. Genet. Toxicol. Environ. Mutagen.	MAR 7	2005	581	1-2					181	186		10.1016/j.mrgentox.2004.10.021			6	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	906EE	WOS:000227622500018	15725617				2020-06-30	J	Aouad, MT; Kanazi, GE; Siddik-Sayyid, SM; Gerges, FJ; Rizk, LB; Baraka, AS				Aouad, MT; Kanazi, GE; Siddik-Sayyid, SM; Gerges, FJ; Rizk, LB; Baraka, AS			Preoperative caudal block prevents emergence agitation in children following sevoflurane anesthesia	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						caudal; children; emergence agitation; fentanyl; pain; sevoflurane	PEDIATRIC-PATIENTS; RECOVERY CHARACTERISTICS; HALOTHANE; ANALGESIA; FENTANYL; MYRINGOTOMY; SURGERY	Background: The frequency of emergence agitation in children is increased following sevoflurane anesthesia. However, controversies still exist concerning the exact etiology of this postanesthetic problem. Although this phenomenon is present with adequate pain relief or even following pain-free procedures, pain is still regarded as a major contributing factor. Methods: In a prospective, randomized, double-blind study, we enrolled 48 premedicated and calm 2-6-year-old children undergoing inguinal hernia repair. We assigned children to one of two groups: children assigned to the caudal group (n = 24) received a caudal block to supplement sevoflurane, while children assigned to the fentanyl group (n = 24) received a bolus injection of 1 mug kg(-1) intravenous fentanyl before skin incision to supplement sevoflurane. In the post anesthesia care unit, all children were received by their parent, and the incidence of emergence agitation and pain scores, as well as hemodynamic changes, were compared in both groups. Results: Forty-four children completed the study. In the fentanyl group, 59% of the children were agitated following emergence from anesthesia as compared to 4.5% in the caudal group (P < 0.001). Also, pain scores, mean values of heart rate and blood pressure as well as morphine requirement were significantly higher in the post anesthesia care unit in the fentanyl group compared to the caudal group. Conclusion: Our results show that in children undergoing inguinal hernia repair, pain control with a preoperative caudal block as compared to intraoperative intravenous fentanyl significantly reduces the incidence of emergence agitation and pain scores following sevoflurane anesthesia.	American Univ, Beirut Med Ctr, Dept Anesthesiol, Beirut, Lebanon	Aouad, MT (reprint author), American Univ, Beirut Med Ctr, Dept Anesthesiol, POB 11 0236, Beirut, Lebanon.	mm01@aub.edu.lb					Aono J, 1997, ANESTHESIOLOGY, V87, P1298, DOI 10.1097/00000542-199712000-00006; Aono J, 1999, ACTA ANAESTH SCAND, V43, P542, DOI 10.1034/j.1399-6576.1999.430509.x; Beskow A, 1999, ACTA ANAESTH SCAND, V43, P536, DOI 10.1034/j.1399-6576.1999.430508.x; Cravero J, 2000, PAEDIATR ANAESTH, V10, P419, DOI 10.1046/j.1460-9592.2000.00560.x; Cravero JP, 2000, J CLIN ANESTH, V12, P397, DOI 10.1016/S0952-8180(00)00180-X; Cravero JP, 2003, ANESTH ANALG, V97, P364, DOI 10.1213/01.ANE.0000070227.78670.43; Davis PJ, 1999, ANESTH ANALG, V88, P34, DOI 10.1097/00000539-199901000-00007; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; JOHANNESSON GP, 1995, ACTA ANAESTH SCAND, V39, P546, DOI 10.1111/j.1399-6576.1995.tb04116.x; Johr M, 2002, PAEDIATR ANAESTH, V12, P293, DOI 10.1046/j.1460-9592.2002.00799.x; Kokinsky E, 2003, PAEDIATR ANAESTH, V13, P334, DOI 10.1046/j.1460-9592.2003.00999.x; Lapin SL, 1999, PAEDIATR ANAESTH, V9, P299, DOI 10.1046/j.1460-9592.1999.00351.x; Picard V, 2000, ACTA ANAESTH SCAND, V44, P307, DOI 10.1034/j.1399-6576.2000.440315.x; Schrock CR, 2003, PAEDIATR ANAESTH, V13, P403, DOI 10.1046/j.1460-9592.2003.01078.x; Uezono S, 2000, ANESTH ANALG, V91, P563, DOI 10.1213/00000539-200009000-00012; Voepel-Lewis T, 2003, ANESTH ANALG, V96, P1625, DOI 10.1213/01.ANE.0000062522.21048.61; Weber F, 2003, PAEDIATR ANAESTH, V13, P244, DOI 10.1046/j.1460-9592.2003.01018.x; Welborn LG, 1996, ANESTH ANALG, V83, P917, DOI 10.1097/00000539-199611000-00005; Weldon BC, 2004, ANESTH ANALG, V98, P321, DOI 10.1213/01.ANE.0000096004.96603.08	19	50	55	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAR	2005	49	3					300	304		10.1111/j.1399-6576.2005.00642.x			5	Anesthesiology	Anesthesiology	902WI	WOS:000227387000006	15752392				2020-06-30	J	Rama-Maceiras, P; Ferreira, TA; Molins, N; Sanduende, Y; Bautista, AP; Rey, T				Rama-Maceiras, P; Ferreira, TA; Molins, N; Sanduende, Y; Bautista, AP; Rey, T			Less postoperative nausea and vomiting after propofol plus remifentanil versus propofol plus fentanyl anaesthesia during plastic surgery	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						intravenous anaesthesia; propofol; fentanyl; remifentanil; complications; postoperative nausea and vomiting	COMBINATION; ALFENTANIL; CRANIOTOMY; SUFENTANIL	Background: The effect of different opioids on postoperative nausea and vomiting (PONV) has not been conclusively determined yet, thus the aim of this study was to compare the incidence of PONV in propofol-anaesthetized patients receiving either fentanyl or remifentanil as opioid supplement. Methods: Sixty ASA physical status I and II patients scheduled for plastic surgery gave their written informed consent for this prospective, randomized, double-blind study. Anaesthesia was induced with propofol, rocuronium and fentanyl (n = 30; 2 mug kg(-1)) or remifentanil (n = 30; 1 mug kg(-1)). After tracheal intubation, anaesthesia was maintained with propofol, oxygen in air and an infusion of the opioid studied, which was modified according to clinical criteria. Baseline postoperative analgesia was achieved with intravenous propacetamol + metamizol. Intravenous morphine was given if visual analogic scale (VAS) for pain was greater than or equal to 4 (scale 0-10) and metoclopramide was administered if a patient presented greater than or equal to 2 PONV episodes (nausea or vomiting) in less than 30 min. Postoperatively (2, 12 and 24 h), we registered VAS, rescue morphine consumption, number of patients with episodes of PONV and number of patients requiring metoclopramide. P < 0.05 was considered significant. Results: There were no significant differences between groups in the demographic parameters, ASA physical status, propofol dose, VAS, and rescue morphine requirements. Fourteen patients in the fentanyl group and four in the remifentanil group presented PONV episodes 2-12 h postoperative hours' interval; (P < 0.05). Ten patients in the fentanyl group and four in the remifentanil group presented vomiting episodes in the same period (P < 0.05); and eight patients in the fentanyl group and one in the remifentanil group required metoclopramide; (P < 0.05). The number of postoperative PONV episodes were low, both in the 0-2-h period (n = 2 vs. n = 1, fentanyl and remifentanil, respectively) and in the 12-24-h period (n = 3 vs. n = 1). Conclusion: Propofol + fentanyl anaesthesia resulted in a higher incidence of PONV and requirements of antiemetic drugs in the period between 2 and 12 postoperative hours compared with propofol + remifentanil, in patients undergoing plastic surgery.	Complejo Hosp Univ Juan Canalejo, Dept Anaesthesiol & Perioperat Med, La Coruna 15006, Spain	Rama-Maceiras, P (reprint author), Complejo Hosp Univ Juan Canalejo, Dept Anaesthesiol & Perioperat Med, Xubias Arriba 84, La Coruna 15006, Spain.	prmaceiras@wanadoo.es					Bekker AY, 2000, ANESTH ANALG, V91, P117, DOI 10.1097/00000539-200007000-00022; Bowdle TA, 1996, ANESTH ANALG, V83, P1292, DOI 10.1097/00000539-199612000-00028; Burkle H, 1996, ANESTH ANALG, V83, P646, DOI 10.1097/00000539-199609000-00038; Coles JP, 2000, J NEUROSURG ANESTH, V12, P15, DOI 10.1097/00008506-200001000-00004; Davis PJ, 2000, ANESTH ANALG, V90, P863, DOI 10.1213/00000539-200004000-00017; Eltzschig HK, 2002, ANESTH ANALG, V94, P1173, DOI 10.1097/00000539-200205000-00022; Ewalenko P, 1996, BRIT J ANAESTH, V77, P463, DOI 10.1093/bja/77.4.463; FLACKE JW, 1985, ANESTH ANALG, V64, P897; Guy J, 1997, ANESTHESIOLOGY, V86, P514, DOI 10.1097/00000542-199703000-00002; Jellish WS, 2000, OTOLARYNG HEAD NECK, V122, P222, DOI 10.1016/S0194-5998(00)70243-9; Michalowski P, 1998, ANESTHESIOLOGY, V89, pU129, DOI 10.1097/00000542-199809010-00034; PHITAYAKORN P, 1987, CAN J ANAESTH, V34, P242, DOI 10.1007/BF03015160; Pueyo FJ, 1996, ANESTH ANALG, V83, P117, DOI 10.1097/00000539-199607000-00021; Schuttler J, 1997, ANAESTHESIA, V52, P307, DOI 10.1111/j.1365-2044.1997.24-az0051.x; Tramer MR, 2001, ACTA ANAESTH SCAND, V45, P4, DOI 10.1034/j.1399-6576.2001.450102.x; WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023	16	40	44	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAR	2005	49	3					305	311		10.1111/j.1399-6576.2005.00650.x			7	Anesthesiology	Anesthesiology	902WI	WOS:000227387000007	15752393				2020-06-30	J	Yegin, A; Sanli, S; Hadimioglu, N; Akbas, M; Karsli, B				Yegin, A; Sanli, S; Hadimioglu, N; Akbas, M; Karsli, B			Intrathecal fentanyl added to hyperbaric ropivacaine for transurethral resection of the prostate	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						analgesics; anesthesia; anesthetics; fentanyl; local; opioid; prostatectomy; ropivacaine; spinal	SPINAL-ANESTHESIA; CESAREAN DELIVERY; BUPIVACAINE; SUFENTANIL; LIDOCAINE; SURGERY; LABOR	Background: Our purpose was to evaluate the effect of intrathecal fentanyl 25 mug added to 18 mg of 6 mg ml(-1) hyperbaric ropivacaine on the characteristics of subarachnoid block and postoperative pain relief in patients undergoing TURP surgery. Methods: The patients were randomly assigned into two groups: Group S (saline group, n=16) received 3 ml of 18 mg hyperbaric ropivacaine + 0.5 ml saline - in total, a 3.5-ml volume intrathecally; and Group F (fentanyl group, n=15) received 3 ml of 18 mg hyperbaric ropivacaine + 0.5 ml of 25 mug fentanyl - in total, a 3.5-ml volume intrathecally. In both groups the onset and recovery times of the sensory block, degree and recovery times of the motor block and side-effects were recorded and statistically compared. Results: There was no significant difference between the groups in achieving the highest level of sensory block, and in the times taken to reach the peak level. Regression to L1 was significantly prolonged in the fentanyl group compared with the saline group (P=0.004). Times to the first feeling of pain and the first analgesic requirement were significantly prolonged in the fentanyl group compared with the saline group (P=0.011 and P=0.016, respectively). The frequency of pruritus was significantly higher in the fentanyl group compared with the saline group (P=0.022). Conclusion: Addition of fentanyl 25 mug to hyperbaric ropivacaine 18 mg for spinal anesthesia in patients undergoing TURP may significantly improve the quality and prolong the duration of analgesia, without causing a substantial increase in the frequency of major side-effects.	Akdeniz Univ, Fac Med, Dept Anesthesiol, Div Algol, TR-07070 Antalya, Turkey	Yegin, A (reprint author), Akdeniz Univ, Fac Med, Dept Anesthesiol, Div Algol, TR-07070 Antalya, Turkey.	ayegin@akdeniz.edu.tr	Karsli, Bilge/C-2468-2016; yegin, arif/C-2275-2016				BELZARENA SD, 1992, ANESTH ANALG, V74, P653; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; Buckenmaier CC, 2002, ANESTH ANALG, V95, P1253, DOI 10.1097/00000539-200211000-00028; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; Chung CJ, 2002, REGION ANESTH PAIN M, V27, P600, DOI 10.1053/rapm.2002.36455; Chung CJ, 2001, ANESTH ANALG, V93, P157; Dahlgren G, 1997, ANESTH ANALG, V85, P1288, DOI 10.1097/00000539-199712000-00020; Goel S, 2003, EUR J ANAESTH, V20, P294, DOI 10.1097/00003643-200304000-00004; Kararmaz A, 2003, ANAESTHESIA, V58, P526, DOI 10.1046/j.1365-2044.2003.03153.x; Khaw KS, 2002, ANESTH ANALG, V94, P680, DOI 10.1097/00000539-200203000-00037; Khaw KS, 2001, ANESTHESIOLOGY, V95, P1346, DOI 10.1097/00000542-200112000-00011; LIU S, 1995, ANESTH ANALG, V80, P730, DOI 10.1097/00000539-199504000-00014; Liu SS, 1997, REGION ANESTH, V22, P500; REUBEN SS, 1994, ANESTHESIOLOGY, V81, P1371, DOI 10.1097/00000542-199412000-00011; Shende D, 1998, ANAESTHESIA, V53, P706, DOI 10.1046/j.1365-2044.1998.329-az0482.x; Soni AK, 2001, CAN J ANAESTH, V48, P677, DOI 10.1007/BF03016202; Stocks GM, 2001, ANESTHESIOLOGY, V94, P593, DOI 10.1097/00000542-200104000-00011; VANKLEEF JW, 1994, ANESTH ANALG, V78, P1125; VARRASSI G, 1992, ANAESTHESIA, V47, P558, DOI 10.1111/j.1365-2044.1992.tb02323.x; Whiteside JB, 2001, BRIT J ANAESTH, V86, P241, DOI 10.1093/bja/86.2.241	20	16	16	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAR	2005	49	3					401	405		10.1111/j.1399-6576.2005.00607.x			5	Anesthesiology	Anesthesiology	902WI	WOS:000227387000023	15752409				2020-06-30	J	Ruppen, W; Ruesch, S; Schupfer, G; Christen, P				Ruppen, W; Ruesch, S; Schupfer, G; Christen, P			Propofol and questionable lack of sedation	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Letter									Univ Spital Basel, CH-4031 Basel, Switzerland	Ruppen, W (reprint author), Univ Spital Basel, CH-4031 Basel, Switzerland.	wruppen@freesurf.ch						0	1	1	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAR	2005	49	3					425	425		10.1111/j.1399-6576.2005.00629.x			1	Anesthesiology	Anesthesiology	902WI	WOS:000227387000030	15752416				2020-06-30	J	Galinski, M; Dolveck, F; Borron, SW; Tual, L; Van Laer, V; Lardeur, JY; Lapostolle, F; Adnet, F				Galinski, M; Dolveck, F; Borron, SW; Tual, L; Van Laer, V; Lardeur, JY; Lapostolle, F; Adnet, F			A randomized, double-blind study comparing morphine with fentanyl in prehospital analgesia	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							ACUTE PAIN; POSTOPERATIVE PAIN; EMERGENCY; SEDATION; MANAGEMENT; MIDAZOLAM; MEDICINE; SAFETY; ONSET; CARE	Study Objective: The aim of this study was to compare, by a randomized double-blind method, morphine (M) and fentanyl (F) in a prehospital setting. Methods: Consecutive patients with severe, acute pain defined as a visual analog scale score (VASS) of 60/100 or higher were included. The M group received an initial intravenous M injection of 0.1 mg/kg then of 3 mg every 5 minutes. The F group received an initial intravenous F injection of I mu g/kg then of 30 mu g every 5 minutes. The goal of analgesia was a VASS of 30/100 or lower. The end point was the VASS measured 30 minutes after initial administration (VAS [T30]). Results: There were 26 patients included in the M group and 28 in the F group. Initial VASS(TO) and VASS(T30), mean (95% CI), were 83 (78-88) and 40 (28-52) in the M group and 77 (72-82) and 35 (27-43) in the F group (P = NS). Sixty-two percent of patients in the M group described analgesia as excellent or good vs 76% of those in the F group who did (P = NS). There were no differences in the incidence of side effects in the 2 groups. Conclusion: This study demonstrates that M and F were comparable in treating severe, acute pain in a prehospital setting during the first 30 minutes in spontaneous breathing patients. (c) 2005 Elsevier Inc. All rights reserved.	Hop Avicenne, UPRESEA 3409, Dept Anesthesiol & Intens Care, Samu 93, F-93009 Bobigny, France; R Poincare Hosp, Dept Anesthesiol & Intens Care, Samu 92, F-92380 Garches, France; George Washington Univ, Dept Emergency Med, Washington, DC USA; George Washington Univ, Dept Med, Washington, DC USA; CHRU, Dept Emergency, Samu 59, F-59000 Lille, France; Poitiers Hosp, Dept Anesthesiol & Intens Care, Samu 86, F-86000 Poitiers, France	Galinski, M (reprint author), Hop Avicenne, UPRESEA 3409, Dept Anesthesiol & Intens Care, Samu 93, F-93009 Bobigny, France.	michel.galinski@avc.ap-hop-paris.fr					Adnet F, 2000, ANN FR ANESTH, V19, P56; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; BELPOMME V, 2002, ANN FR ANESTH, V21, pS324; BORZAK S, 1991, Henry Ford Hospital Medical Journal, V39, P206; BRUNS BM, 1992, AM J EMERG MED, V10, P53, DOI 10.1016/0735-6757(92)90127-J; CASAGRANDE JT, 1978, BIOMETRICS, V34, P483, DOI 10.2307/2530613; CHAUVIN M, 1995, ANESTHESIEREANIMATIO, P1; CHAUVIN M, 1995, SOC FRANCAISE ANESTH, P125; CHUDNOFSKY CR, 1989, ANN EMERG MED, V18, P635, DOI 10.1016/S0196-0644(89)80517-7; Claxton AR, 1997, ANESTH ANALG, V84, P509, DOI 10.1097/00000539-199703000-00008; COHEN RI, 1993, ANESTH ANALG, V77, P533; CONSTANT I, 1991, DOULEUR MILIEU CHIRU, P77; Innes G, 1999, J EMERG MED, V17, P145, DOI 10.1016/S0736-4679(98)00135-8; Krauss B, 2000, NEW ENGL J MED, V342, P938, DOI 10.1056/NEJM200003303421306; MELZACK R, 1982, PAIN, V14, P33, DOI 10.1016/0304-3959(82)90078-1; Milojevic K., 2001, Annales Francaises d'Anesthesie et de Reanimation, V20, P745; MITCHELL RWD, 1989, BRIT J ANAESTH, V63, P147, DOI 10.1093/bja/63.2.147; Ricard-Hibon A, 1997, ANN FR ANESTH, V16, P945, DOI 10.1016/S0750-7658(97)82142-9; Ricard-Hibon A, 1999, ANN EMERG MED, V34, P738, DOI 10.1016/S0196-0644(99)70099-5; Silfvast T, 2001, Eur J Emerg Med, V8, P275, DOI 10.1097/00063110-200112000-00005; THADANI U, 1994, CARDIOVASC DRUG THER, V8, P719, DOI 10.1007/BF00877118; Ward KR, 2000, EMERG MED CLIN N AM, V18, P141, DOI 10.1016/S0733-8627(05)70111-5; WHITEHEAD EM, 1992, CLIN PHARMACOL THER, V52, P197, DOI 10.1038/clpt.1992.130; WRIGHT SW, 1990, AM J EMERG MED, V8, P97, DOI 10.1016/0735-6757(90)90192-3	24	58	58	0	6	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0735-6757			AM J EMERG MED	Am. J. Emerg. Med.	MAR	2005	23	2					114	119		10.1016/j.ajem.2004.03.010			6	Emergency Medicine	Emergency Medicine	909HI	WOS:000227850600004	15765326				2020-06-30	J	Yanagawa, Y; Sakamoto, T; Okada, Y; Tuzuki, N; Katoh, H; Hiroshi, N; Shima, K				Yanagawa, Y; Sakamoto, T; Okada, Y; Tuzuki, N; Katoh, H; Hiroshi, N; Shima, K			Intubation without premedication may worsen outcome for unconsciousness patients with intracranial hemorrhage	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							SUBARACHNOID HEMORRHAGE; MANAGEMENT; RISK	To clarify the influence of an intubation maneuver with or without premedication for an intracranial hemorrhage in an unconsciousness patient, we retrospectively analyzed 70 patients who had received intubation for unconsciousness and in whom a nontraumatic intracranial hemorrhage was found by CT over a 6-year period. They were divided into 2 groups, consisting of a drug group (n = 15), wherein drugs were used before intubation, and control group (n = 55), wherein no drugs were used before were intubation. The physical findings on admission, CT findings, Glasgow Outcome Score (GOS) at 3 months from admission were analyzed between the groups. There were no significant differences in the backgrounds of the subjects between the groups. The GOS in the control group was significantly higher than in the drug group (P < .001). In cases of intubation for unconscious patients who may have intracranial hemorrhaging, premedication is considered associated with a more favorable outcome. (c) 2005 Elsevier Inc. All rights reserved.	Natl Def Med Coll, Dept Traumatol & Crit Care Med, Tokorozawa, Saitama 359, Japan; Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama 359, Japan	Yanagawa, Y (reprint author), Natl Def Med Coll, Dept Traumatol & Crit Care Med, 3-2 Namiki, Tokorozawa, Saitama 359, Japan.	yanagawa@me.ndmc.ac.jp					Aoyagi N, 1996, ACTA NEUROCHIR, V138, P12, DOI 10.1007/BF01411717; Assy N, 1999, GASTROINTEST ENDOSC, V49, P690, DOI 10.1016/S0016-5107(99)70283-X; Bozkurt Pervin, 1996, Middle East Journal of Anesthesiology, V13, P405; Clusmann H, 2001, J NEUROL NEUROSUR PS, V71, P175, DOI 10.1136/jnnp.71.2.175; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Inagawa T, 2000, J NEUROSURG, V93, P967, DOI 10.3171/jns.2000.93.6.0967; Kawamura M, 1998, AM J KIDNEY DIS, V31, P991, DOI 10.1053/ajkd.1998.v31.pm9631844; Kazui S, 1997, STROKE, V28, P2370, DOI 10.1161/01.STR.28.12.2370; Kopera M, 1999, Neurol Neurochir Pol, V33, P389; LAVIN P, 1986, ARCH INTERN MED, V146, P66, DOI 10.1001/archinte.146.1.66; Lee KC, 1997, CHUNG HUA I HSUEH TS, V59, P88; MCGILL J, 1998, EMERGEN MED, P15; ROOS YBWEM, 1995, J NEUROL NEUROSUR PS, V58, P622, DOI 10.1136/jnnp.58.5.622; Spiekermann BF, 1996, CAN J ANAESTH, V43, P820, DOI 10.1007/BF03013035; St Louis EK, 1998, NEUROLOGY, V51, P1364, DOI 10.1212/WNL.51.5.1364; WOOD MLB, 1994, ACTA ANAESTH SCAND, V38, P510, DOI 10.1111/j.1399-6576.1994.tb03938.x	16	4	4	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	MAR	2005	23	2					182	185		10.1016/j.ajem.2004.01.009			4	Emergency Medicine	Emergency Medicine	909HI	WOS:000227850600019	15765341				2020-06-30	J	Frazee, BW; Park, RS; Lowery, D; Baire, M				Frazee, BW; Park, RS; Lowery, D; Baire, M			Propofol for deep procedural sedation in the ED	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							PEDIATRIC EMERGENCY-DEPARTMENT; CLINICAL-TRIAL; MIDAZOLAM; CARDIOVERSION	We sought to evaluate the use of propofol (2,6-diisopropylphenol) for ED procedural sedation, particularly when administered in a routine fashion for a variety of indications. Methods: This was a prospective observational study conducted in an urban teaching ED. Propofol was administered by handheld syringe and combined with fentanyl. Measurements included propofol and fentanyl dose, serial vital signs, pulse oximetry, adverse events, and patient and physician satisfaction. Results: One hundred thirty-six subjects (18 to 69 years) were enrolled. Procedures included 82 (60.3%) abscess incision and drainages and 47 (34.6%) orthopedic reductions. Adverse events occurred in 14 cases (10.3%; 95% confidence interval 5.2% to 15.4%), including hypotension in 5, hypoxemia in 7, and apnea in 5. One patient required intubation. Both patient and physician satisfaction were excellent. Conclusions: ED procedural sedation with propofol was effective and well accepted by patients and physicians. However, it produced a significant incidence of hypotension, hypoxemia, and apnea. (c) 2005 Elsevier Inc. All rights reserved.	Alameda Cty Med Ctr, Dept Emergency Med, Oakland, CA 94602 USA; Duke Univ, Med Ctr, Dept Surg, Div Emergency Med, Durham, NC 27708 USA; Washoe City Med Ctr, Dept Emergency Med, Reno, NV 89502 USA	Frazee, BW (reprint author), Alameda Cty Med Ctr, Dept Emergency Med, Highland Campus, Oakland, CA 94602 USA.						Bassett KE, 2003, ANN EMERG MED, V42, P773, DOI 10.1016/S0196-0644(03)00619-X; Coll-Vinent B, 2003, ANN EMERG MED, V42, P767, DOI 10.1016/S0196-0644(03)00510-9; CRAWFORD M, 1993, BRIT J ANAESTH, V70, P419, DOI 10.1093/bja/70.4.419; GALE DW, 1993, CRIT CARE MED, V21, P1509, DOI 10.1097/00003246-199310000-00019; Godambe SA, 2003, PEDIATRICS, V112, P116, DOI 10.1542/peds.112.1.116; Green SM, 1999, ACAD EMERG MED, V6, P975, DOI 10.1111/j.1553-2712.1999.tb01176.x; Green SM, 2003, ANN EMERG MED, V42, P792, DOI 10.1016/S0196-0644(03)00746-7; Havel CJ, 1999, ACAD EMERG MED, V6, P989, DOI 10.1111/j.1553-2712.1999.tb01180.x; Miner JR, 2003, ACAD EMERG MED, V10, P931, DOI 10.1197/S1069-6563(03)00310-5; Miner JR, 2002, ACAD EMERG MED, V9, P275, DOI 10.1197/aemj.9.4.275; REVES JG, 2000, NON BARBITUATE INTRA, P249; RODRIGO MRC, 1989, BRIT DENT J, V166, P75, DOI 10.1038/sj.bdj.4806713; SHORT TG, 1991, BRIT J ANAESTH, V67, P539, DOI 10.1093/bja/67.5.539; Skokan EG, 2001, CLIN PEDIATR, V40, P663, DOI 10.1177/000992280104001204; Swanson ER, 1996, ACAD EMERG MED, V3, P234, DOI 10.1111/j.1553-2712.1996.tb03426.x; Vargo JJ, 2002, GASTROENTEROLOGY, V123, P8, DOI 10.1053/gast.2002.34232; Wagner HJ, 1996, J VASC INTERV RADIOL, V7, P673, DOI 10.1016/S1051-0443(96)70827-8; 2002, DIPRIVAN PROPOFOL PR, P667	18	40	41	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0735-6757			AM J EMERG MED	Am. J. Emerg. Med.	MAR	2005	23	2					190	195		10.1016/j.ajem.2004.05.008			6	Emergency Medicine	Emergency Medicine	909HI	WOS:000227850600021	15765343				2020-06-30	J	Cao, WH; Morrison, SF				Cao, WH; Morrison, SF			Brown adipose tissue thermogenesis contributes to fentanyl-evoked hyperthermia	AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY			English	Article						renal sympathetic nerve; heart rate; arterial pressure; mu-opioid receptor; naloxone; raphe pallidus; dorsomedial hypothalamus; rostral ventrolateral medulla	ROSTRAL VENTROLATERAL MEDULLA; KAPPA-OPIOID RECEPTOR; DORSOMEDIAL HYPOTHALAMIC NUCLEUS; RAPHE PALLIDUS; BODY-TEMPERATURE; PREOPTIC AREA; HEART-RATE; RAT-BRAIN; PHARMACOLOGICAL CHARACTERIZATION; IONTOPHORETIC APPLICATION	mu-Opioid receptor activation increases body temperature and affects cardiovascular function. In the present study, fentanyl was administered intravenously [100 mug/kg (300 nmol/kg) iv] and intracerebroventricularly [3.4 mug (10 nmol) in 10 mul icv] in urethane-chloralose-anesthetized, artificially ventilated rats. Increases in brown adipose tissue (BAT) sympathetic nerve activity (SNA) (peak, +326% of control), BAT temperature (peak, +0.8degreesC), renal SNA (peak, +146% of control), and heart rate (HR; peak, +32 beats/min) produced by intravenous fentanyl were abolished by premamillary transection of the neuraxis but were mimicked by intracerebroventricular administration of fentanyl, which also increased arterial pressure (AP; peak, +12 mmHg). Pretreatment with the opioid antagonist naloxone (100 nmol in 10 mul icv) eliminated the intracerebroventricular fentanyl-evoked responses. Microinjection of glycine (0.5 M, 60 nl) to inhibit local neurons in the rostral raphe pallidus (RPa) selectively reversed the intracerebroventricular fentanyl-evoked increases in BAT SNA and HR, while the fentanyl-evoked excitation in RSNA, the pressor responses, and the tachycardic responses were reversed by inhibition of neurons in the rostral ventrolateral medulla (RVLM). Prior inhibition of neurons in the dorsomedial hypothalamus eliminated the intracerebroventricular fentanyl-evoked increases in BAT SNA, BAT temperature, and HR, but not those in RSNA or AP. These results indicate that activation of central mu-opioid receptors with fentanyl can elicit BAT thermogenesis and cardiovascular stimulation through excitation of the sympathetic outflows to BAT, kidney, and heart. Activation of neurons in the rostral RPa and RVLM are essential for the increases in BAT thermogenesis and renal sympathoexcitation, respectively, induced by activation of central mu-opioid receptors. BAT thermogenesis could contribute to fentanyl-evoked hyperthermia, particularly in infants where BAT plays a significant role in thermoregulation.	Oregon Hlth & Sci Univ, Inst Neurol Sci, Beaverton, OR 97006 USA	Morrison, SF (reprint author), Oregon Hlth & Sci Univ, Inst Neurol Sci, 505 NW 185th Ave, Beaverton, OR 97006 USA.	morrisos@ohsu.edu			NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK 20378, DK 57838]; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 40987]		ADLER MW, 1988, ANNU REV PHARMACOL, V28, P429, DOI 10.1146/annurev.pa.28.040188.002241; Adler MW, 1993, HDB EXPT PHARM, P205; Aicher SA, 2001, J COMP NEUROL, V433, P34, DOI 10.1002/cne.1123; AKIL H, 1984, ANNU REV NEUROSCI, V7, P223, DOI 10.1146/annurev.ne.07.030184.001255; Bamshad M, 1999, AM J PHYSIOL-REG I, V276, pR1569; Benamar K, 2000, EUR J PHARMACOL, V401, P161, DOI 10.1016/S0014-2999(00)00424-6; Boulant JA, 2000, CLIN INFECT DIS, V31, pS157, DOI 10.1086/317521; BROWN DL, 1984, AM J PHYSIOL, V247, P1009, DOI 10.1152/ajpregu.1984.247.6.R1009; Campos RR, 1999, AM J PHYSIOL-REG I, V276, pR1102; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Cano G, 2003, J COMP NEUROL, V460, P303, DOI 10.1002/cne.10643; Cao WH, 2004, NEUROSCIENCE, V126, P229, DOI 10.1016/j.neuroscience.2004.03.013; Cao WH, 2003, BRAIN RES, V980, P1, DOI 10.1016/S0006-8993(03)02981-0; Chen XH, 1996, DRUG ALCOHOL DEPEN, V43, P119, DOI 10.1016/S0376-8716(96)01295-1; COX B, 1976, EUR J PHARMACOL, V36, P33, DOI 10.1016/0014-2999(76)90253-3; DAMPNEY RAL, 1994, PHYSIOL REV, V74, P323; Fontes MAP, 2001, AM J PHYSIOL-HEART C, V280, pH2891; GELLER EB, 1983, J PHARMACOL EXP THER, V225, P391; GILLAN MGC, 1982, BRIT J PHARMACOL, V77, P461, DOI 10.1111/j.1476-5381.1982.tb09319.x; Griffioen KJS, 2004, BRAIN RES, V1007, P109, DOI 10.1016/j.brainres.2004.02.010; Guyenet PG, 2002, CLIN EXP PHARMACOL P, V29, P238, DOI 10.1046/j.1440-1681.2002.03636.x; HANDLER CM, 1992, PHARMACOL BIOCHEM BE, V43, P1209, DOI 10.1016/0091-3057(92)90504-9; Hermann DM, 1997, J CHEM NEUROANAT, V13, P1, DOI 10.1016/S0891-0618(97)00019-7; Horiuchi J, 2004, AM J PHYSIOL-REG I, V287, pR824, DOI 10.1152/ajpregu.00221.2004; JAMES IF, 1984, MOL PHARMACOL, V25, P337; JANSEN ASP, 1995, BRAIN RES, V683, P1, DOI 10.1016/0006-8993(95)00276-V; LIN MT, 1984, NEUROPHARMACOLOGY, V23, P591, DOI 10.1016/0028-3908(84)90035-2; Madden CJ, 2004, AM J PHYSIOL-REG I, V286, pR320, DOI 10.1152/ajpregu.00515.2003; Madden CJ, 2003, NEUROSCIENCE, V122, P5, DOI 10.1016/S0306-4522(03)00527-X; MANSOUR A, 1995, J CHEM NEUROANAT, V8, P283, DOI 10.1016/0891-0618(95)00055-C; MARTIN GE, 1978, BRAIN RES, V145, P127, DOI 10.1016/0006-8993(78)90801-6; MATSUDA T, 1992, J PHYSIOL-LONDON, V454, P197, DOI 10.1113/jphysiol.1992.sp019260; MCALLEN RM, 1994, AM J PHYSIOL-REG I, V267, pR935; MENG F, 1993, P NATL ACAD SCI USA, V90, P9954, DOI 10.1073/pnas.90.21.9954; Milner TA, 2001, BRAIN RES, V917, P1, DOI 10.1016/S0006-8993(01)02827-X; Miyawaki T, 2002, NEUROSCIENCE, V109, P133, DOI 10.1016/S0306-4522(01)00439-0; Moriwaki A, 1996, NEUROCHEM RES, V21, P1315, DOI 10.1007/BF02532373; Morrison SF, 1999, AM J PHYSIOL-REG I, V276, pR962; Morrison SF, 2001, AM J PHYSIOL-REG I, V281, pR683; Morrison SF, 1999, AM J PHYSIOL-REG I, V276, pR290; Morrison SR, 2004, NEWS PHYSIOL SCI, V19, P67, DOI 10.1152/nips.01502.2003; Nakamura K, 2002, J NEUROSCI, V22, P4600, DOI 10.1523/JNEUROSCI.22-11-04600.2002; ROSS CA, 1984, J NEUROSCI, V4, P474; Salmi P, 2003, EUR J PHARMACOL, V458, P101, DOI 10.1016/S0014-2999(02)02736-X; Samuels BC, 2004, AM J PHYSIOL-REG I, V287, pR472, DOI 10.1152/ajpregu.00667.2003; Samuels BC, 2002, J PHYSIOL-LONDON, V538, P941, DOI 10.1113/jphysiol.2001.013302; SPENCER RL, 1988, J PHARMACOL EXP THER, V246, P92; Sun SY, 1996, GEN PHARMACOL, V27, P1187, DOI 10.1016/S0306-3623(96)00055-9; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TerHorst GJ, 1996, EUR J NEUROSCI, V8, P2029, DOI 10.1111/j.1460-9568.1996.tb00723.x; THOMPSON RC, 1993, NEURON, V11, P903, DOI 10.1016/0896-6273(93)90120-G; THORNHILL JA, 1984, J PHARMACOL EXP THER, V231, P422; Vuckovic S, 1998, JPN J PHARMACOL, V78, P523, DOI 10.1254/jjp.78.523; Wilson JR, 1996, PHARMACOL BIOCHEM BE, V54, P317, DOI 10.1016/0091-3057(95)02124-8; Xin L, 1997, J PHARMACOL EXP THER, V281, P499; Yakimova KS, 1996, NEUROSCI LETT, V218, P115, DOI 10.1016/S0304-3940(96)13133-5; Zaretskaia MV, 2003, NEUROSCI LETT, V340, P1, DOI 10.1016/S0304-3940(03)00047-8; Zaretskaia MV, 2002, BRAIN RES, V928, P113, DOI 10.1016/S0006-8993(01)03369-8	58	28	28	0	1	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6119	1522-1490		AM J PHYSIOL-REG I	Am. J. Physiol.-Regul. Integr. Comp. Physiol.	MAR	2005	288	3					R723	R732		10.1152/ajpregu.00669.2004			10	Physiology	Physiology	895AJ	WOS:000226832800025	15576661				2020-06-30	J	Ambrisko, TD; Hikasa, Y; Sato, K				Ambrisko, TD; Hikasa, Y; Sato, K			Influence of medetomidine on stress-related neurohormonal and metabolic effects caused by butorphanol, fentanyl, and ketamine administration in dogs	AMERICAN JOURNAL OF VETERINARY RESEARCH			English	Article							SYMPATHO-ADRENAL OUTFLOW; PLASMA-CATECHOLAMINES; CONSCIOUS RABBITS; OPIOID-PEPTIDES; MORPHINE; ANESTHESIA; HYPERGLYCEMIA; HYPERTENSION; GUIDELINES; ADVANTAGES	Objective-To examine stress-related neurohormonal and metabolic effects of butorphanol, fentanyl, and ketamine administration alone and in combination with medetomidine in dogs. Animals-10 Beagles. Procedure-5 dogs received either butorphanol (0.1 mg/kg), fentanyl (0.01 mg/kg), or ketamine (10 mg/kg) IM in a crossover design. Another 5 dogs received either medetomidine (0.02 mg/kg) and butorphanol (0.1 mg/kg), medetomidine and fentanyl (0.01 mg/kg), medetomidine and ketamine (10 mg/kg), or medetomidine and saline (0.9% NaCl) solution (0.1 mL/kg) in a similar design. Blood samples were obtained for 6 hours following the treatments. Norepinephrine, epinephrine, cortisol, glucose, insulin, and nonesterified fatty acid concentrations were determined in plasma. Results-Administration of butorphanol, fentanyl, and ketamine caused neurchormonal and metabolic changes similar to stress, including increased plasma epinephrine, cortisol, and glucose concentrations. The hyperglycemic effect of butorphanol was not significant. Ketamine caused increased norepinephrine concentration. Epinephrine concentration was correlated with glucose concentration in the butorphanol and fentanyl groups but not in the ketamine groups, suggesting an important difference between the mechanisms of the hyperglycemic effects of these drugs. Medetomidine prevented most of these effects except for hyperglycemia. Plasma glucose concentrations were lower in the combined sedation groups than in the medetomidine-saline solution group. Conclusions and Clinical Relevance-Opioids or ketamine used alone may cause changes in stress-related biochemical variables in plasma. Medetomidine prevented or blunted these changes. Combined sedation provided better hormonal and metabolic stability than either component alone. We recommend using medetomidine-butorphanol or medetomidine-ketamine combinations for sedation or anesthesia of systemically healthy dogs.	Tottori Univ, Fac Agr, Dept Vet Internal Med, Tottori 6808553, Japan	Ambrisko, TD (reprint author), Univ Penn, Sch Vet Med, Dept Clin Studies, Philadelphia, PA 19104 USA.						Adamson C, 1997, Md Med J, V46, P530; Ambrisko TD, 2003, CAN J VET RES, V67, P64; Ambrisko TD, 2002, CAN J VET RES, V66, P42; BARAKA A, 1973, ANESTH ANALG, V52, P198; Benson GJ, 2000, VET SURG, V29, P85, DOI 10.1111/j.1532-950X.2000.00085.x; BOULOUX P, 1985, ANN CLIN BIOCHEM, V22, P194, DOI 10.1177/000456328502200217; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; DOENICKE A, 1992, ANAESTHESIST, V41, P597; FELDBERG W, 1972, BRIT J PHARMACOL, V46, P602, DOI 10.1111/j.1476-5381.1972.tb06887.x; FELDBERG W, 1974, J PHYSIOL-LONDON, V238, P487, DOI 10.1113/jphysiol.1974.sp010539; Gaynor JS, 2002, HDB VET PAIN MANAGEM, P49; GUNION MW, 1991, AM J PHYSIOL, V261, pR70; HARTSFIELD SM, 1992, VET CLIN N AM-SMALL, V22, P266, DOI 10.1016/S0195-5616(92)50604-0; HOEHE M, 1993, PSYCHONEUROENDOCRINO, V18, P141, DOI 10.1016/0306-4530(93)90065-S; Hogger P, 2000, EUR J CLIN PHARMACOL, V56, P463, DOI 10.1007/s002280000175; HUSTVEIT O, 1995, PHARMACOL TOXICOL, V77, P355, DOI 10.1111/j.1600-0773.1995.tb01041.x; KIRITSYROY JA, 1986, J PHARMACOL EXP THER, V239, P814; Kohrs R, 1998, ANESTH ANALG, V87, P1186, DOI 10.1097/00000539-199811000-00039; MAY CN, 1989, CLIN SCI, V76, P431, DOI 10.1042/cs0760431; MAY CN, 1988, CLIN SCI, V75, P71, DOI 10.1042/cs0750071; MOLINA PE, 1994, ADV NEUROIMMUNOL, V4, P105, DOI 10.1016/S0960-5428(05)80005-1; RADOSEVICH PM, 1984, J CLIN INVEST, V74, P1473, DOI 10.1172/JCI111560; Slingsby LS, 2000, RES VET SCI, V69, P147, DOI 10.1053/rvsc.2000.0406; TABORSKY GJ, 1981, ENDOCRINOLOGY, V109, P319, DOI 10.1210/endo-109-1-319; Thomson I R, 1988, J Cardiothorac Anesth, V2, P18, DOI 10.1016/0888-6296(88)90142-1; TVERSKOY M, 1994, ANESTH ANALG, V78, P205, DOI 10.1213/00000539-199402000-00002; Vaisanen M, 2002, AM J VET RES, V63, P969, DOI 10.2460/ajvr.2002.63.969; VANLOON GR, 1981, BRAIN RES, V204, P236, DOI 10.1016/0006-8993(81)90671-5; Wagner AE, 2002, J AM VET MED ASSOC, V221, P72, DOI 10.2460/javma.2002.221.72; WILSON DV, 1992, VET CLIN N AM-SMALL, V22, P269, DOI 10.1016/S0195-5616(92)50606-4	30	38	39	0	4	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0002-9645			AM J VET RES	Am. J. Vet. Res.	MAR	2005	66	3					406	412		10.2460/ajvr.2005.66.406			7	Veterinary Sciences	Veterinary Sciences	902XS	WOS:000227390600007	15822583				2020-06-30	J	Apfel, CC; Bacher, A; Biedler, A; Danner, K; Danzeisen, O; Eberhart, LHJ; Forst, H; Fritz, G; Hergert, M; Frings, G; Goebel, A; Hopf, HB; Kerger, H; Kranke, R; Lange, M; Mertzlufft, F; Motsch, J; Paura, A; Roewer, N; Schneider, E; Stoecklein, K; Wermelt, J; Zernak, C				Apfel, CC; Bacher, A; Biedler, A; Danner, K; Danzeisen, O; Eberhart, LHJ; Forst, H; Fritz, G; Hergert, M; Frings, G; Goebel, A; Hopf, HB; Kerger, H; Kranke, R; Lange, M; Mertzlufft, F; Motsch, J; Paura, A; Roewer, N; Schneider, E; Stoecklein, K; Wermelt, J; Zernak, C			A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. Results of the International Multicenter Protocol to assess the single and combined benefits of antiemetic strategies in a controlled clinical trial of a 2x2x2x2x2x2 factorial design (IMPACT)	ANAESTHESIST			German	Article						postoperative nausea and vomiting; prophylaxis; antiemetics; volatile anesthetics; propofol; nitrous oxide	COST-EFFECTIVENESS; DROPERIDOL; ANESTHESIA; ONDANSETRON; EFFICACY; SURGERY; DEXAMETHASONE; METAANALYSIS; MANAGEMENT; EMPHYSEMA	Background. Untreated, one third of patients who undergo surgery will have postoperative nausea and vomiting. Although many trials have been conducted, the relative benefits of prophylactic antiemetic interventions given alone or in combination remain unknown. Methods. In a randomized, controlled trial of factorial design, 5,199 patients at high risk for postoperative nausea and vomiting were randomly assigned to 1 of 64 possible combinations of 6 prophylactic interventions: 1) 4 mg of ondansetron or no ondansetron; 2) 4 mg of dexamethasone or no dexamethasone; 3) 1.25 mg of droperidol or no drope ridol; 4) propofol or a volatile anesthetic; 5) nitrogen or nitrous oxide; 6) remifentanil or fentanyl. The primary aim parameter was nausea and vomiting within 24 h after surgery, which was evaluated blindly. Results. Ondansetron, dexamethasone, and droperidol each reduced the risk of postoperative nausea and vomiting by about 26%, propofol reduced the risk by 19%, and nitrogen by 12%. The risk reduction with both of these agents (i.e., total intravenous anesthesia) was thus similar to that observed with each of the antiemetics alone. All the interventions acted independently of each other and independently of the patients' baseline risk. Consequently, the relative risks associated with the combined interventions could be estimated by multiplying the relative risks associated with each intervention. However, absolute risk reduction was a critical function of patients' baseline risk. Conclusions. Because antiemetic interventions are similarly effective and act independently, the safest or least expensive should be used first. Prophylaxis is rarely warranted in low-risk patients, moderate-risk patients may benefit from a single intervention, and multiple interventions should be reserved for high-risk patients.	Univ Louisville, Dept Anesthesiol & Perioperat Med, Louisville, KY 40202 USA; Univ Louisville, Outcomes Res Inst, Louisville, KY 40202 USA; Univ Wurzburg, Klin & Poliklin Anaesthesiol, D-97070 Wurzburg, Germany; Univ Vienna, Klin Anasthesie & Allgemeine Intensivmed, Vienna, Austria; Univ Saarlandes Kliniken, Klin Anaesthesiol Intensivmed & Schmerztherapie, Homburg, Germany; Westpfalz Klinikum Kaiserslautern, Inst Anasthesiol & Notfallmed, Kaiserslautern, Germany; Univ Freiburg Klinikum, Anasthesiol Univ Klin, Freiburg, Germany; Univ Klin Marburg, Interdisziplinares Zentrum, Abr Anasthesie & Intensivtherapie, Marburg, Germany; Zentrum Klinikum Augsburg, Klin Anasthesiol & Operat Intensivmed, Augsburg, Germany; Univ Klin Charite, Klin Anasthesiol & Operat Intensivmed, Berlin, Germany; Klinikum Schwerin, Klin Anasthesiol & Intensivtherapie, Schwerin, Germany; Wedau Kliniken, Abt Anasthesie, Duisburg, Germany; Eichhof Krankenhaus, Abt Anasthesie, Lauterbach, Germany; Kreisklin Langen, Abt Anasthesie, Langen, Germany; Univ Klin Mannheim, Klin Anasthesiol & Intensivmed, Mannheim, Germany; Waldkrankenhaus Rudolf Elle, Abt Anasthesie, Eisenberg, Germany; Bodelschwingsche Anstalten Bethel, Klin Anasthesiol & Operat Intensivmed, Bielefeld, Germany; Univ Klinikum Heidelberg, Anasthesiol Klin, Heidelberg, Germany; Klinikum Luneburg, Abt Anasthesie, Luneburg, Germany; Univ Klinikum Tubingen, Klin Anasthesiol & Transfus Med, Tubingen, Germany; Allgemeines Krankenhaus Altona, Anaesthesiol & Operat Intens Med Abt, Hamburg, Germany; Kreiskrankenhauses, Anaesthesiol & Operat Intens Med Abt, Garmisch Partenkirchen, Germany	Apfel, CC (reprint author), Univ Louisville, Dept Anesthesiol & Perioperat Med, Suite 21-,501 E Broadway, Louisville, KY 40202 USA.	apfel@ponv.org					Apfel CC, 2002, BRIT J ANAESTH, V88, P234, DOI 10.1093/bja/88.2.234; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Apfel CC, 2003, CONTROL CLIN TRIALS, V24, P736, DOI 10.1016/S0197-2456(03)00107-7; Apfel CC, 2002, ACTA ANAESTH SCAND, V46, P921, DOI 10.1034/j.1399-6576.2002.460801.x; Apfel CC, 2002, BRIT J ANAESTH, V88, P659, DOI 10.1093/bja/88.5.659; BREMNER WGM, 1993, BRIT J ANAESTH, V71, P296, DOI 10.1093/bja/71.2.296; Darkow T, 2001, PHARMACOTHERAPY, V21, P540, DOI 10.1592/phco.21.6.540.34543; Divatia JV, 1996, ANESTHESIOLOGY, V85, P1055, DOI 10.1097/00000542-199611000-00014; Gan TJ, 2002, JAMA-J AM MED ASSOC, V287, P1233, DOI 10.1001/jama.287.10.1233; Gan TJ, 2002, ANESTHESIOLOGY, V97, P287, DOI 10.1097/00000542-200207000-00059; Gan TJ, 2003, ANESTH ANALG, V97, P62, DOI 10.1213/01.ANE.0000068580.00245.95; GOLD BS, 1989, JAMA-J AM MED ASSOC, V262, P3008, DOI 10.1001/jama.262.21.3008; Henzi I, 2000, ANESTH ANALG, V90, P186, DOI 10.1097/00000539-200001000-00038; Hill RP, 2000, ANESTHESIOLOGY, V92, P958, DOI 10.1097/00000542-200004000-00012; Koivuranta M, 1997, ANAESTHESIA, V52, P443, DOI 10.1111/j.1365-2044.1997.117-az0113.x; Kovac AL, 1999, J CLIN ANESTH, V11, P453, DOI 10.1016/S0952-8180(99)00067-7; Kovac AL, 2000, DRUGS, V59, P213, DOI 10.2165/00003495-200059020-00005; Lim BSL, 1999, ANAESTH INTENS CARE, V27, P371, DOI 10.1177/0310057X9902700407; Liu K, 1999, ANESTH ANALG, V89, P1316, DOI 10.1213/00000539-199911000-00046; Macario A, 1999, ANESTH ANALG, V89, P652, DOI 10.1097/00000539-199909000-00022; MELNICK B, 1989, ANESTH ANALG, V69, P748; Pierre S, 2002, CAN J ANAESTH, V49, P237, DOI 10.1007/BF03020521; Schumann R, 1999, ANESTH ANALG, V89, P796; Scuderi PE, 2000, ANESTH ANALG, V91, P1408, DOI 10.1097/00000539-200012000-00020; Sinclair DR, 1999, ANESTHESIOLOGY, V91, P109, DOI 10.1097/00000542-199907000-00018; Sneyd JR, 1998, EUR J ANAESTH, V15, P433, DOI 10.1097/00003643-199807000-00009; Tang J, 1998, ANESTH ANALG, V86, P274, DOI 10.1097/00000539-199802000-00010; Tramer MR, 2001, ACTA ANAESTH SCAND, V45, P4, DOI 10.1034/j.1399-6576.2001.450102.x; WANG Y, 2000, P SOC PHOTO-OPT INS, V1, P136; Watcha Mehernoor F, 2002, Anesthesiol Clin North Am, V20, P709; Watcha MF, 2000, ANESTHESIOLOGY, V92, P931, DOI 10.1097/00000542-200004000-00007	31	25	25	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0003-2417	1432-055X		ANAESTHESIST	Anaesthesist	MAR	2005	54	3					201	209		10.1007/s00101-005-0803-8			9	Anesthesiology	Anesthesiology	913HA	WOS:000228141000003	15731931				2020-06-30	J	Goodwin, RC; Amjadi, F; Parker, RD				Goodwin, RC; Amjadi, F; Parker, RD			Short-term analgesic effects of intra-articular injections after knee arthroscopy	ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY			English	Article						pre; emptive; analgesia; knee; postoperative; pain	PAIN RELIEF; PREEMPTIVE ANALGESIA; POSTOPERATIVE PAIN; BUPIVACAINE LEVELS; MORPHINE; SURGERY	Purpose: To study the effects of 3 different intra-articular analgesic combinations on postoperative pain, and whether the timing of the injection, either preoperative or postoperative, had an effect on postoperative analgesia. Type of Study: Prospective, randomized, double-blind clinical trial. Methods: Patients undergoing knee arthroscopy performed by a single surgeon under general anesthesia were randomized into 6 study groups. Each patient received an intra-articular injection 20 minutes before incision and at the end of the procedure. One injection contained the study medications, and the other contained normal saline solution (placebo). The patients, surgeon, and data collection personnel were blinded to the contents of the injections. Outcome measures included visual analogue pain scores at 0, 60, and 120 minutes after the procedure, and total recovery room fentanyl consumption. Results: Fifty patients successfully completed the study protocol. Patients receiving combinations of morphine, bupivacaine, and epinephrine or bupivacaine and epinephrine yielded lower pain scores and narcotics consumption than patients receiving epinephrine alone, which was statistically significant irrespective of the timing of injection (P < .0001). Patients receiving the study medication preoperatively had significantly lower pain scores at the first measurement (t = 0) than those receiving the study medication postoperatively (P = .0343). There was no statistically significant effect of timing of the treatment medication administration at either 60 or 120 minutes postoperatively. Comparison of fentanyl consumption between groups receiving the treatment medication preoperatively versus postoperatively showed no significant difference. Conclusions: The combination of morphine, bupivacaine, and epinephrine, as well as the combination of bupivacaine and epinephrine provide excellent postoperative pain control when used either preoperatively or postoperatively in knee arthroscopy. There was a trend that patients receiving preoperative analgesic injections experienced superior pain control than did those injected postoperatively. Level of Evidence: Level I, Randomized Controlled Trial.	Cleveland Clin Fdn, Dept Orthopaed Surg, Sect Sports Med, Cleveland, OH 44195 USA; Cedars Sinai Med Ctr, Dept Orthopaed Surg, Los Angeles, CA 90048 USA	Parker, RD (reprint author), Cleveland Clin Fdn, Dept Orthopaed Surg, Sect Sports Med, A41,9500 Euclid Ave, Cleveland, OH 44195 USA.	parkerr@ccf.org					ATES Y, 1994, ARTHROSCOPY, V10, P108, DOI 10.1016/S0749-8063(05)80302-0; CHIRWA S S, 1989, Arthroscopy, V5, P33, DOI 10.1016/0749-8063(89)90087-X; GEUTJENS G, 1994, ARTHROSCOPY, V10, P299, DOI 10.1016/S0749-8063(05)80116-1; HENDERSON RC, 1990, AM J SPORT MED, V18, P614, DOI 10.1177/036354659001800610; Hoher J, 1997, ARTHROSCOPY, V13, P210, DOI 10.1016/S0749-8063(97)90156-0; JOSHI GP, 1992, J BONE JOINT SURG BR, V74, P749; KAEDING C C, 1990, Arthroscopy, V6, P33, DOI 10.1016/0749-8063(90)90094-T; Kalso E, 1997, PAIN, V71, P127, DOI 10.1016/S0304-3959(97)03344-7; KHOURY GF, 1992, ANESTHESIOLOGY, V77, P263, DOI 10.1097/00000542-199208000-00007; Kissin I, 1996, ANESTHESIOLOGY, V84, P1015, DOI 10.1097/00000542-199605000-00001; Lundin O, 1998, ARTHROSCOPY, V14, P192, DOI 10.1016/S0749-8063(98)70040-4; MEINIG RP, 1988, AM J SPORT MED, V16, P295, DOI 10.1177/036354658801600317; MILLIGAN KA, 1988, ANAESTHESIA, V43, P563, DOI 10.1111/j.1365-2044.1988.tb06688.x; OSBORNE D, 1993, [No title captured], V9, P77; SAUNDERS B, 1988, Arthroscopy, V4, P90, DOI 10.1016/S0749-8063(88)80071-9; SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5; SORENSEN T S, 1991, Arthroscopy, V7, P364; STEIN C, 1993, LANCET, V342, P321, DOI 10.1016/0140-6736(93)91471-W; STEIN C, 1991, NEW ENGL J MED, V325, P1123, DOI 10.1056/NEJM199110173251602; WASEDUV G, 1990, ARTHROSCOPY, V6, P40; WEIKER GG, 1991, AM J SPORT MED, V19, P499, DOI 10.1177/036354659101900514; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026	22	14	16	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0749-8063	1526-3231		ARTHROSCOPY	Arthroscopy	MAR	2005	21	3					307	312		10.1016/j.arthro.2004.11.015			6	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	906MG	WOS:000227645700009	15756184				2020-06-30	J	Rohm, KD; Suttner, SW; Boldt, J; Schollhorn, TAH; Piper, SN				Rohm, KD; Suttner, SW; Boldt, J; Schollhorn, TAH; Piper, SN			RETRACTED: Insignificant effect of desflurane-fentanyl-thipental on hepatocellular integrity - a comparison with total intravenous anaesthesia using propofol-remifentanil (Retracted article. See vol. 28, pg. 468, 2011)	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article; Retracted Publication						anaesthetics, desflurane, propofol; opioids, remifentanil; anaesthesia, intravenous, inhalational; glutathione transferase, alpha, hepatic; transaminases, alanine aminotransaminase, aspartate aminotransaminase	GLUTATHIONE-S-TRANSFERASE; INDOCYANINE GREEN CLEARANCE; PROLONGED ANESTHESIA; SEVOFLURANE ANESTHESIA; PLASMA-CONCENTRATIONS; INHALED ANESTHETICS; HEPATIC-FUNCTION; ISOFLURANE; HALOTHANE; HYPOTENSION	Background and objective: Inhalational anaesthetics have been associated with hepatotoxicity. Even desflurane, with its low solubility in blood and tissues, and its minimal hepatic biotransformation, is known to affect hepatic integrity. The effects of propofol on hepatic function are, however, a matter of controversy. Alpha-glutathione S-transferase (alpha-GST), a sensitive and specific biomarker for hepatic integrity, was measured to assess the influence of total intravenous anaesthesia (TIVA) with propofol vs. anaesthesia with desflurane. Methods: Forty-two patients scheduled for elective prostatectomy were randomly allocated to receive either desflurane, fentanyl and thiopental (desflurane group) or propofol and remifentanil (TIVA group). Depth of anaesthesia was guided by bispectral. index. Plasma concentrations of alpha-GST and aminotransferases were measured before induction of anaesthesia (T0), at the end of surgery (T1), as well as 2 h (T2) and 24 h (T3) postoperatively. Haemodynamic parameters and bispectral index values were documented. Results: alpha-GST increased significantly in the desflurane group from TO (3.0 +/- 2.2 mu g L-1) to T1 and T2 (5.5 +/- 4.3 and 5.6 +/- 3.7 mu g L-1, respectively), whereas no changes were seen in the TIVA group. alpha-GST values above the normal upper limit (>7.5 mu g L-1) were seen in 24% of the patients receiving desflurane. Aminotransferases remained unchanged in both groups throughout the study period. Conclusions: The use of propofol as part of a TIVA regimen seems to have no influence on hepatocellular function during and after surgery. In contrast, patients receiving desflurane showed a transient slight, but significant, increase of alpha-GST to above the normal upper limit after anaesthesia, although this was without further clinical relevance.	Klinikum Ludwigshafen, Dept Anaesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany	Rohm, KD (reprint author), Klinikum Ludwigshafen, Dept Anaesthesiol & Intens Care Med, Bremserstr 79, D-67063 Ludwigshafen, Germany.	k.d.roehm@t-online.de					ALDRIDGE LM, 1993, CLIN CHEM ENZYMOLOGY, V5, P195; ALLAN LG, 1987, LANCET, V1, P771; Armbruster K, 1997, ANESTH ANALG, V84, P271, DOI 10.1097/00000539-199702000-00007; Bao YP, 1998, BRIT J ANAESTH, V81, P584, DOI 10.1093/bja/81.4.584; Bauer C, 1995, Anasthesiol Intensivmed Notfallmed Schmerzther, V30, P226, DOI 10.1055/s-2007-996480; BECKETT GJ, 1987, J CLIN BIOCHEM NUTR, V2, P1; BECKETT GJ, 1993, ADV CLIN CHEM, V30, P281, DOI 10.1016/S0065-2423(08)60198-5; BECKETT GJ, 1985, GUT, V26, P26, DOI 10.1136/gut.26.1.26; Chen TL, 2000, BRIT J ANAESTH, V84, P771; EGER EI, 1994, ANESTHESIOLOGY, V80, P906, DOI 10.1097/00000542-199404000-00024; Fukushima M, 1999, Masui, V48, P1105; HARTMAN JC, 1992, CAN J ANAESTH, V39, P877, DOI 10.1007/BF03008300; HOWIE AF, 1992, CLIN CHEM, V38, P476; HUSSEY AJ, 1988, BRIT J ANAESTH, V60, P130, DOI 10.1093/bja/60.2.130; Johansen JW, 2000, ANESTHESIOLOGY, V93, P1336, DOI 10.1097/00000542-200011000-00029; KENNA JG, 1995, ANESTH ANALG, V81, pS51, DOI 10.1097/00000539-199512001-00008; KENNA JG, 1994, ANAESTH PHARM REV, V2, P29; KOBLIN DD, 1992, ANESTH ANALG, V75, pS10; MURRAY JM, 1992, BRIT J ANAESTH, V69, P643, DOI 10.1093/bja/69.6.643; MURRAY JM, 1994, BRIT J ANAESTH, V72, P599, DOI 10.1093/bja/72.5.599; MURRAY JM, 1992, BRIT J ANAESTH, V68, P168, DOI 10.1093/bja/68.2.168; Piper SN, 2003, ANASTH INTENSIV NOTF, V38, P781; Ray DC, 1996, BRIT J ANAESTH, V77, P404; Ray DC, 2002, BRIT J ANAESTH, V88, P285, DOI 10.1093/bja/88.2.285; RAY DC, 1991, BRIT J ANAESTH, V67, P84, DOI 10.1093/bja/67.1.84; Schindler E, 1996, Anasthesiol Intensivmed Notfallmed Schmerzther, V31, P344, DOI 10.1055/s-2007-995933; Schmidt CC, 1999, ANAESTHESIA, V54, P1207, DOI 10.1046/j.1365-2044.1999.01105.x; Shimono H, 2003, ANESTH ANALG, V97, P442, DOI 10.1213/01.ANE.0000067407.25527.B7; Suttner SW, 1999, ANESTH ANALG, V89, P1371, DOI 10.1097/00000539-199912000-00008; Suttner SW, 2000, ANESTH ANALG, V91, P206, DOI 10.1097/00000539-200007000-00039; TAIVAINEN T, 1994, BRIT J ANAESTH, V73, P590, DOI 10.1093/bja/73.5.590; TIAINEN P, 1995, ACTA ANAESTH SCAND, V39, P840, DOI 10.1111/j.1399-6576.1995.tb04181.x; TIANINEN P, 1998, BRIT J ANAESTH, V80, P87	33	12	12	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	MAR	2005	22	3					209	214		10.1017/S0265021505000360			6	Anesthesiology	Anesthesiology	922VV	WOS:000228868900008	15852994				2020-06-30	J	Cigada, M; Pezzi, A; Di Mauro, P; Marzorati, S; Noto, A; Valdambrini, F; Zaniboni, M; Astori, M; Iapichino, G				Cigada, M; Pezzi, A; Di Mauro, P; Marzorati, S; Noto, A; Valdambrini, F; Zaniboni, M; Astori, M; Iapichino, G			Sedation in the critically ill ventilated patient: possible role of enteral drugs	INTENSIVE CARE MEDICINE			English	Article						critical care; enteral sedation; hydroxyzine; midazolam; propofol	INTENSIVE-CARE-UNIT; MECHANICAL VENTILATION	Objective: Sedation by the enteral route is unusual in intensive medicine. We analysed the feasibility/efficacy of long-term enteral sedation in ventilated critically ill patients. Design: Prospective interventional cohort study. Setting: General ICU. Patients and participants: Forty-two patients needing ventilation and sedation for at least 4 days. Interventions: At admission, sedation was induced with propofol or midazolam. Enteral hydroxyzine (+/- enteral lorazepam) was added in all patients within the second day. Intravenous drugs were gradually withdrawn, trying to maintain only enteral sedation after the initial 48 h. Analgesia was provided with continuous IV fentanyl. Measurements and results: Sedation level was assessed evaluating, on a daily basis, patients' compliance to the invasive care and comparing observed vs planned Ramsay scores three times a day. Excluding the first 2 days of patient-stabilisation and fast titration of sedation level, 577 days with ventilatory support were analysed. In 460 days (79.7%) total enteral sedation was given. This percentage rose to 94.2% when the requested Ramsay was 2 (347 days). Daily sedation was judged as adequate in 82.8% of days of total enteral sedation. Thirty-one patients had total enteral as the exclusive route of sedation. Conclusions: After 24-48 h, enteral sedation may replace, totally/in part, IV sedation in ventilated patients. Total enteral sedation easily fits the target when a Ramsay score 2 is planned. When a deeper sedation is needed, a mixed regimen is effective and lowers IV drug dosages. No side effects were reported.	Univ San Paolo, Ist Anestesiol & Rianimaz, Univ Studi Milano, I-20142 Milan, Italy	Cigada, M (reprint author), Univ San Paolo, Ist Anestesiol & Rianimaz, Univ Studi Milano, Azienda Osped Polo,Via A Rudini 8, I-20142 Milan, Italy.	marcocigada@yahoo.it					Arenas-Lopez S, 2004, INTENS CARE MED, V30, P1625, DOI 10.1007/s00134-004-2319-0; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; Cigada M, 2003, INTENS CARE MED, V29, pS24; Durbin C G Jr, 1994, New Horiz, V2, P64; IAPICHINO G, 1989, ANESTESIA RIANIMAZIO, V30, P75; IPAPICHINO G, 1983, JPEN, V7, P50; Izurieta R, 2002, CRIT CARE MED, V30, P2644, DOI 10.1097/00003246-200212000-00006; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Joint Commission on Accreditation of Healthcare Organizations (JCAHO), 2001, COMPR ACCR MAN LONG; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; LAURIA JI, 1968, ANESTH ANAL CURR RES, V47, P378; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lugo RA, 1999, CRIT CARE MED, V27, P417, DOI 10.1097/00003246-199902000-00052; MAZZEO AJ, 1995, CRIT CARE CLIN, V11, P937; Ostermann ME, 2000, JAMA-J AM MED ASSOC, V283, P1451, DOI 10.1001/jama.283.11.1451; PEREZ JE, 1999, CHEST S2, V116, pS278; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Revelly JP, 2001, INTENS CARE MED, V27, P540, DOI 10.1007/s001340100855	19	20	23	0	1	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	MAR	2005	31	3					482	486		10.1007/s00134-005-2559-7			5	Critical Care Medicine	General & Internal Medicine	903SM	WOS:000227445900023	15714324				2020-06-30	J	Sah, N; Vallejo, MC; Ramanathan, S; Golebiewski, K				Sah, N; Vallejo, MC; Ramanathan, S; Golebiewski, K			Bupivacaine versus L-bupivacaine for labor analgesia via combined spinal-epidural: A randomized, double-blinded study	JOURNAL OF CLINICAL ANESTHESIA			English	Article						bupivacaine; verbal analog score; combined spinal-epidural	RACEMIC BUPIVACAINE; CESAREAN-SECTION; RATING-SCALE; LEVOBUPIVACAINE; ROPIVACAINE; SUFENTANIL; POTENCIES; FENTANYL; PAIN	Study objective: To compare the intensity and duration of motor block and the duration of sensory block with racemic bupivacaine and L-bupivacaine for combined spinal-epidural analgesia, as previous studies have shown contradictory results. Design: A prospective, randomized, double-blinded study. Setting: Birth Center at Magee-Womens Hospital, Pittsburgh, Pa. Patients: Multiparous American Society of Anesthesiologists physical status I and II patients requesting labor analgesia. There were 2 groups: group A with 34 patients and group B with 33. Interventions: Group A received a mixture of 2.5 mg of racemic bupivacaine and 25 mu g of fentanyl into the subarachnoid space. Group B received 2.5 mu g of intrathecal L-bupivacaine and 25 mu g of fentanyl. Pain verbal analog score (VAS, 0-10) scores and Bromage scores were recorded at 5, 15, 30, and every 30 minutes thereafter until the VAS increased to 3 or higher, at which time the epidural block was activated with 0.125% bupivacaine and fentanyl. Patients' vital signs and fetal heart rate were monitored for 30 minutes after the block. Main results: None of the patients in both groups had any demonstrable motor block. The median VAS decreased from 7 to 0 in 5 minutes in group A and from 7.5 to 0 in group B. The average durations of sensory block in groups A and B were 114.85 +/- 26.27 and 101.9 +/- 35.20 minutes (P = NS), respectively. Conclusion: Contrary to earlier studies, we did not find any difference in the intensity and duration of sensory or motor blocks between racemic bupivacaine and L-bupivacaine. Based on our findings in the parturient population studied, we conclude that L-bupivacaine does not offer any advantages over racemic bupivacaine when used for combined spinal-epidural for labor analgesia. (c) 2005 Elsevier Inc. All rights reserved.	Magee Womens Hosp, Dept Anesthesia, Pittsburgh, PA 15213 USA	Sah, N (reprint author), Magee Womens Hosp, Dept Anesthesia, Pittsburgh, PA 15213 USA.	sahxnb@anes.upmc.edu	Vallejo, Manuel C/X-5544-2019	Vallejo, Manuel C/0000-0002-1240-3670			Bardsley H, 1998, BRIT J CLIN PHARMACO, V46, P245, DOI 10.1046/j.1365-2125.1998.00775.x; Beilin Y, 2003, ANESTH ANALG, V96, P1794, DOI 10.1213/01.ANE.0000061581.23351.29; Bijur PE, 2003, ACAD EMERG MED, V10, P390, DOI 10.1111/j.1553-2712.2003.tb01355.x; Camorcia M, 2003, EUR J ANAESTH, V20, P636, DOI 10.1097/00003643-200308000-00008; Cox CR, 1998, BRIT J ANAESTH, V80, P594; Faccenda KA, 2003, REGION ANESTH PAIN M, V28, P394, DOI 10.1016/S1098-7339(03)00223-2; Foster RH, 2000, DRUGS, V59, P551, DOI 10.2165/00003495-200059030-00013; Gautier P, 2003, BRIT J ANAESTH, V91, P684, DOI 10.1093/bja/aeg251; Huang YF, 1998, ANESTH ANALG, V86, P797, DOI 10.1097/00000539-199804000-00023; Kanai Y, 1999, REGION ANESTH PAIN M, V24, P444, DOI 10.1016/S1098-7339(99)90012-3; Lacassie HJ, 2003, ANESTH ANALG, V97, P1509, DOI 10.1213/01.ANE.0000083375.48151.FF; Lyons G, 1998, BRIT J ANAESTH, V81, P899; Morrison SG, 2000, ANESTH ANALG, V90, P1308, DOI 10.1097/00000539-200006000-00009; Robinson AP, 2001, ANESTH ANALG, V92, P410, DOI 10.1213/00000539-200102000-00025; Stocks GM, 2001, ANESTHESIOLOGY, V94, P593, DOI 10.1097/00000542-200104000-00011; Vercauteren MP, 2001, ANESTH ANALG, V93, P996, DOI 10.1097/00000539-200110000-00040	16	5	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180			J CLIN ANESTH	J. Clin. Anesth.	MAR	2005	17	2					91	95		10.1016/j.jclinane.2004.05.004			5	Anesthesiology	Anesthesiology	920AW	WOS:000228660400003	15809123				2020-06-30	J	Green, T; Gidron, Y; Friger, M; Almog, Y				Green, T; Gidron, Y; Friger, M; Almog, Y			Relative-assessed psychological factors predict sedation requirement in critically ill patients	PSYCHOSOMATIC MEDICINE			English	Article						sedation; mechanical ventilation; psychological predictors; ICU	SPOUSE RATINGS; BLOOD-PRESSURE; HOSTILITY; ANALGESICS; MIDAZOLAM; EFFICACY; DISEASE	Objective: Sedation is frequently required in critically ill, mechanically ventilated patients. Sedation and analgesia requirements may vary substantially among patients. This study examined whether psychological factors predict amount of sedation requirements beyond the effects of other biomedical parameters. Methods: This Study used a prospective correlative design in ail eight-bed medical intensive care unit at a tertiary university hospital. Fifty-five adult patients requiring mechanical ventilation were included. We evaluated by questionnaires three psychological factors of patients-hostility, anxiety and desire for control (DC)-as completed by patients' relatives at entry to the intensive care unit. Daily doses of sedatives required were monitored. The primary outcome measurement was midazolam dose expressed in mg/kg/h. Results: There was a statistically significant correlation between psychological factors and midazolam dose (mg/kg/h): r values = 0.40 for anxiety, 0.43 for hostility, and 0.46 for DC. Age and pulmonary edema were inversely related to midazolam requirements, whereas smoking, chronic obstructive pulmonary disease, fentanyl dose, and therapeutic intervention scoring system were positively correlated with midazolam doses. In a multiple regression. DC accounted for an additional and significant 5.4% of the variance in midazolam after controlling statistically for the effects of the significant background and biomedical predictors. In the final regression equation, DC and fentanyl were the only significant factors associated with higher sedation requirement. Conclusion: Premorbid psychological profile independently predicts sedation requirement in critically ill, mechanically ventilated patients. Early identification of such a profile may help in sedation management and patient care. The possible mechanisms and clinical implications are discussed.	Ben Gurion Univ Negev, Med Intens Care Unit, Soroka Univ Med Ctr, Fac Hlth Sci, IL-84101 Beer Sheva, Israel; Ben Gurion Univ Negev, Dept Epidemiol, Soroka Univ Med Ctr, Fac Hlth Sci, IL-84101 Beer Sheva, Israel; Univ Southampton, Sch Psychol, Southampton, Hants, England	Almog, Y (reprint author), Ben Gurion Univ Negev, Med Intens Care Unit, Soroka Univ Med Ctr, Fac Hlth Sci, POB 151, IL-84101 Beer Sheva, Israel.	almogya@bgumail.bgu.ac.il					BURGER JM, 1984, J PERS, V52, P71, DOI 10.1111/j.1467-6494.1984.tb00551.x; BURGER JM, 1979, DESIRABILITY CONTROL; Cohen IL, 2002, CRIT CARE MED, V30, pS97, DOI 10.1097/00003246-200201002-00001; Gidron Y, 2002, NEUROREPORT, V13, P139, DOI 10.1097/00001756-200201210-00032; Gidron Y, 2003, BRAIN BEHAV IMMUN, V17, P310, DOI 10.1016/S0889-1591(03)00061-8; Gidron Y, 2001, J BEHAV MED, V24, P1, DOI 10.1023/A:1005631819744; Hammerlein A, 1998, CLIN PHARMACOKINET, V35, P49; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; KANTO JH, 1985, PHARMACOTHERAPY, V5, P138; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNEIP RC, 1993, HEALTH PSYCHOL, V12, P301, DOI 10.1037/0278-6133.12.4.301; Knight SJ, 2001, UROLOGY, V57, P275, DOI 10.1016/S0090-4295(00)00934-1; Krantz DS, 1999, AM J CARDIOL, V84, P1292, DOI 10.1016/S0002-9149(99)00560-3; KRANTZ DS, 1982, PSYCHOSOM MED, V44, P273, DOI 10.1097/00006842-198207000-00005; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Lefering R, 1996, LANGENBECK ARCH CHIR, P318; MAGNI G, 1986, PSYCHOSOMATICS, V27, P362, DOI 10.1016/S0033-3182(86)72687-X; MARTEAU TM, 1994, BRIT J CLIN PSYCHOL, V33, P1; MICHALK S, 1988, INTENS CARE MED, V15, P37; Miranda DR, 1996, CRIT CARE MED, V24, P64, DOI 10.1097/00003246-199601000-00012; Pochard F, 1995, Clin Intensive Care, V6, P57, DOI 10.1080/714028873; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Rozanski A, 1999, CIRCULATION, V99, P2192, DOI 10.1161/01.CIR.99.16.2192; SIEBER WJ, 1992, BRAIN BEHAV IMMUN, V6, P141, DOI 10.1016/0889-1591(92)90014-F; Watling SM, 1997, ANN PHARMACOTHER, V31, P148, DOI 10.1177/106002809703100202; Watson D, 2000, J PERS SOC PSYCHOL, V78, P546, DOI 10.1037/0022-3514.78.3.546	26	1	2	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0033-3174	1534-7796		PSYCHOSOM MED	Psychosom. Med.	MAR-APR	2005	67	2					295	300		10.1097/01.psy.0000156928.12980.99			6	Psychiatry; Psychology; Psychology, Multidisciplinary	Psychiatry; Psychology	909UF	WOS:000227885500020	15784797				2020-06-30	J	Walsh, D				Walsh, D			Advances in opioid therapy and formulations	SUPPORTIVE CARE IN CANCER			English	Review						opioids; formulations; drug delivery systems; dosing strategies	CONTROLLED-RELEASE OXYCODONE; PATIENT-CONTROLLED ANALGESIA; RANDOMIZED CONTROLLED-TRIAL; DRUG-DELIVERY SYSTEM; CANCER PAIN; ORAL MORPHINE; DOUBLE-BLIND; TRANSDERMAL FENTANYL; DIABETIC-NEUROPATHY; CLINICAL-TRIAL	Newly developed opioid analgesics and drug delivery systems may provide pain relief for patients intolerant of morphine. Long-acting oral opioids supply satisfactory analgesia at more convenient dosing intervals. Implantable pumps can provide full analgesic doses of opioids both subcutaneously and intrathecally over extended time periods. Optimal opioid use should rely on individualized dose-finding approaches to enhance pain relief while limiting drug-related side effects and avoiding the common problems associated with opioid prescription in clinical practice.	Cleveland Clin Fdn, Cleveland, OH 44195 USA; Cleveland Clin, Taussig Canc Ctr, Harry R Horvitz Ctr Palliat Med, Cleveland, OH 44106 USA	Walsh, D (reprint author), Cleveland Clin Fdn, 9500 Euclid Ave,M76, Cleveland, OH 44195 USA.	walsht@ccf.org		Walsh, Declan/0000-0002-9310-1729			Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; BEAVER WT, 1977, J CLIN PHARMACOL, V17, P186, DOI 10.1177/009127007701700402; Blumstein HA, 2003, ACAD EMERG MED, V10, P211, DOI 10.1197/aemj.10.3.211; Brant J M, 2001, Clin J Oncol Nurs, V5, P163; Broomhead A, 1997, J PAIN SYMPTOM MANAG, V14, P63, DOI 10.1016/S0885-3924(97)00012-2; Bruera E, 1998, J CLIN ONCOL, V16, P3222, DOI 10.1200/JCO.1998.16.10.3222; Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542; Cheville A, 2001, J BONE JOINT SURG AM, V83A, P572, DOI 10.2106/00004623-200104000-00013; CREWS JC, 1990, CRIT CARE CLIN, V6, P315; CUNDIFF D, 1989, CANCER, V63, P2355, DOI 10.1002/1097-0142(19890601)63:11<2355::AID-CNCR2820631147>3.0.CO;2-#; DAUT RL, 1982, CANCER-AM CANCER SOC, V50, P1913, DOI 10.1002/1097-0142(19821101)50:9<1913::AID-CNCR2820500944>3.0.CO;2-R; Davis MP, 2003, SUPPORT CARE CANCER, V11, P84, DOI 10.1007/s00520-002-0385-9; DAVIS MP, 2003, J TERMINAL ONCOL, V2, P89; DESTOUTZ ND, 1995, J PAIN SYMPTOM MANAG, V10, P378, DOI 10.1016/0885-3924(95)90924-C; Donnelly S, 2002, SUPPORT CARE CANCER, V10, P13, DOI 10.1007/s005200100274; *DUR CORP, 2001, DUROS TECHN PLATF; GABRAIL NY, 2003, SUPPORT CARE CANCER, V11, P396; GALER BS, 1992, PAIN, V49, P87, DOI 10.1016/0304-3959(92)90192-E; Gimbel JS, 2003, NEUROLOGY, V60, P927, DOI 10.1212/01.WNL.0000057720.36503.2C; GOURLAY GK, 1986, PAIN, V25, P297, DOI 10.1016/0304-3959(86)90234-4; HANKS GW, 1989, CANCER, V63, P2378, DOI 10.1002/1097-0142(19890601)63:11<2378::AID-CNCR2820631150>3.0.CO;2-8; Hanks GW, 1996, BRIT MED J, V312, P823; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Heiskanen T, 1997, PAIN, V73, P37, DOI 10.1016/S0304-3959(97)00072-9; Howell SB, 2001, CANCER J, V7, P219; Inturrisi CE, 2002, CLIN J PAIN, V18, pS3, DOI 10.1097/00002508-200207001-00002; Joshi GP, 1999, ANESTHESIOLOGY, V90, P1007, DOI 10.1097/00000542-199904000-00013; Kochhar Romeen, 2003, Oncology (Williston Park), V17, P571; MCILWAIN H, 2003, AM PAIN SOC 22 ANN S; Mucci-LoRusso P, 1998, EUR J PAIN-LONDON, V2, P239, DOI 10.1016/S1090-3801(98)90020-9; Mystakidou K, 2002, ONCOLOGY-BASEL, V62, P9, DOI 10.1159/000048241; Payne R, 1998, SEMIN ONCOL, V25, P47; Reyes-Gibby CC, 2003, J PAIN SYMPTOM MANAG, V25, P444, DOI 10.1016/S0885-3924(03)00077-0; Ripamonti C, 2001, DRUGS, V61, P955, DOI 10.2165/00003495-200161070-00005; Roth SH, 2000, ARCH INTERN MED, V160, P853, DOI 10.1001/archinte.160.6.853; Seeman P, 2002, CAN J PSYCHIAT, V47, P27; SINATRA RS, 1989, ANESTHESIOLOGY, V70, P585, DOI 10.1097/00000542-198904000-00005; SLATKIN N, 2003, SUPPORT CARE CANCER, V11, P397; SLOAN P, 2002, SUPPORT CARE CANCER, V10, P360; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; Smith TJ, 2002, J CLIN ONCOL, V20, P4040, DOI 10.1200/JCO.2002.02.118; Walsh D, 2000, SEMIN ONCOL, V27, P45; Walsh Declan, 2004, Support Cancer Ther, V1, P157, DOI 10.3816/SCT.2004.n.007; Warfield CA, 1998, CANCER-AM CANCER SOC, V82, P2299, DOI 10.1002/(SICI)1097-0142(19980615)82:12<2299::AID-CNCR1>3.0.CO;2-O; Watson CPN, 2003, PAIN, V105, P71, DOI 10.1016/S0304-3959(03)00160-X; Wong J O, 1997, Acta Anaesthesiol Sin, V35, P25; WRIGHT PMC, 1992, ACTA ANAESTH SCAND, V36, P230, DOI 10.1111/j.1399-6576.1992.tb03455.x; Yaksh TL, 2000, DRUG DELIV, V7, P27, DOI 10.1080/107175400266768	48	7	7	0	2	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0941-4355			SUPPORT CARE CANCER	Support. Care Cancer	MAR	2005	13	3					138	144		10.1007/s00520-004-0743-x			7	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	905IJ	WOS:000227561500002	15599600				2020-06-30	J	Hanks, G; Reid, C				Hanks, G; Reid, C			Contribution to variability in response to opioids	SUPPORTIVE CARE IN CANCER			English	Review						opioids; analgesia; adverse effects; bioavailability; metabolism	INDUCED RESPIRATORY DEPRESSION; CANCER PAIN; CLINICAL PHARMACOKINETICS; MORPHINE GLUCURONIDES; POLYMORPHISM A118G; ANALGESIC LADDER; RENAL-FAILURE; MORPHINE-6-GLUCURONIDE; OXYCODONE; MORPHINE-3-GLUCURONIDE	Opioids are the oldest and most effective agents for the short- and long-term control of severe pain, particularly chronic cancer pain palliation. However, morphine and other opioids display wide variations in pharmacological efficacy and tolerability, and a significant number of patients are unable to achieve adequately controlled pain at doses that do not produce intolerable adverse effects. This article reviews factors that affect the efficacy and tolerability of opioid analgesics and clinical strategies for successful pain mangement.	Univ Bristol, Bristol Haematol & Oncol Ctr, Dept Palliat Med, Bristol BS2 8ED, Avon, England	Hanks, G (reprint author), Univ Bristol, Bristol Haematol & Oncol Ctr, Dept Palliat Med, Horfield Rd, Bristol BS2 8ED, Avon, England.	debbie.ashby@bristol.ac.uk					BARTLETT B, 1995, [No title captured], V3, P1; BARTLETT SE, 1994, PHARMACOL TOXICOL, V75, P73, DOI 10.1111/j.1600-0773.1994.tb00327.x; BARTLETT SE, 1995, LIFE SCI, V57, P609; BEAVER WT, 1977, J CLIN PHARMACOL, V17, P186, DOI 10.1177/009127007701700402; BELL R, 2003, COCHRANE LI; Borgbjerg FM, 1996, PAIN, V64, P123; Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542; COLPAERT FC, 1978, EUR J PHARMACOL, V49, P335, DOI 10.1016/0014-2999(78)90114-0; DESTOUTZ ND, 1995, J PAIN SYMPTOM MANAG, V10, P378, DOI 10.1016/0885-3924(95)90924-C; DICKENSON AH, 1994, CANCER SURV, V21, P5; Gaveriaux-Ruff C, 1999, OPIOIDS PAIN CONTROL, P1; GLARE PA, 1991, THER DRUG MONIT, V13, P1, DOI 10.1097/00007691-199101000-00001; HAGEN NA, 1991, J PAIN SYMPTOM MANAG, V6, P125, DOI 10.1016/0885-3924(91)90961-3; HANKS GW, 1984, LANCET, V1, P1477; HANKS GW, 1987, LANCET, V2, P723; HANKS GW, 1981, ANAESTHESIA, V36, P37, DOI 10.1111/j.1365-2044.1981.tb08596.x; Hawley P, 1998, PALLIATIVE MED, V12, P63, DOI 10.1177/026921639801200114; Heiskanen T, 1998, CLIN PHARMACOL THER, V64, P603, DOI 10.1016/S0009-9236(98)90051-0; Hollt V, 2002, PHARMACOGENETICS, V12, P1, DOI 10.1097/00008571-200201000-00001; HOSKIN PJ, 1989, BRIT J CLIN PHARMACO, V27, P499, DOI 10.1111/j.1365-2125.1989.tb05399.x; INTURRISI CE, 1972, CLIN PHARMACOL THER, V13, P923; JADAD AR, 1995, JAMA-J AM MED ASSOC, V274, P1870, DOI 10.1001/jama.274.23.1870; Kirvela M, 1996, J CLIN ANESTH, V8, P13, DOI 10.1016/0952-8180(95)00092-5; KNAPP RJ, 1989, ADV PAIN RES THER, P247; Lee MA, 2001, PALLIATIVE MED, V15, P26, DOI 10.1191/026921601669626431; LEOW KP, 1992, CLIN PHARMACOL THER, V52, P487, DOI 10.1038/clpt.1992.176; Lotsch J, 2002, PHARMACOGENETICS, V12, P3, DOI 10.1097/00008571-200201000-00002; Ma MK, 2002, AM J HEALTH-SYST PH, V59, P2061, DOI 10.1093/ajhp/59.21.2061; MASSIE MJ, 1983, AM J PSYCHIAT, V140, P1048; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; OSBORNE RJ, 1986, BRIT MED J, V292, P1548, DOI 10.1136/bmj.292.6535.1548; OTTON SV, 1993, CLIN PHARMACOL THER, V53, P401, DOI 10.1038/clpt.1993.43; Pasternak GW, 2001, NEUROSCIENTIST, V7, P220, DOI 10.1177/107385840100700307; Penson RT, 2000, CLIN PHARMACOL THER, V68, P667, DOI 10.1067/mcp.2000.111934; POHLAND A, 1971, J MED CHEM, V14, P194, DOI 10.1021/jm00285a004; PORTENOY RK, 1991, PAIN, V47, P13, DOI 10.1016/0304-3959(91)90005-I; POYHIA R, 1992, BRIT J CLIN PHARMACO, V33, P617, DOI 10.1111/j.1365-2125.1992.tb04090.x; POYHIA R, 1993, J PAIN SYMPTOM MANAG, V8, P63, DOI 10.1016/0885-3924(93)90101-Z; Reid C, 2004, PALLIATIVE MED, V18, P175, DOI 10.1191/0269216304pm897ed; Ripamonti C, 1998, J CLIN ONCOL, V16, P3216, DOI 10.1200/JCO.1998.16.10.3216; SHIMOMURA K, 1971, TOHOKU J EXP MED, V105, P45, DOI 10.1620/tjem.105.45; Trujillo Keith A, 2002, Neurotox Res, V4, P373, DOI 10.1080/10298420290023954; World Health Organization, 1996, CANC PAIN REL GUID O; Wright AWE, 2001, LIFE SCI, V69, P409, DOI 10.1016/S0024-3205(01)01133-X; Wu DF, 1997, DRUG METAB DISPOS, V25, P768; Yashpal K, 2001, PAIN, V94, P17, DOI 10.1016/S0304-3959(01)00337-2; Zheng M, 2002, XENOBIOTICA, V32, P427, DOI 10.1080/00498250110119090	49	31	35	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	MAR	2005	13	3					145	152		10.1007/s00520-004-0730-2			8	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	905IJ	WOS:000227561500003	15761703				2020-06-30	J	Poonawala, T; Levay-Young, BK; Hebbel, RP; Gupta, K				Poonawala, T; Levay-Young, BK; Hebbel, RP; Gupta, K			Opioids heal ischemic wounds in the rat	WOUND REPAIR AND REGENERATION			English	Article							NITRIC-OXIDE SYNTHASE; GROWTH-FACTOR EXPRESSION; ENDOTHELIAL-CELLS; STIMULATES ANGIOGENESIS; OPIATE RECEPTOR; MORPHINE; TISSUE; PROLIFERATION; ACTIVATION; REPAIR	Opioids are sometimes used to treat pain in ulcerative wounds, and it is speculated that pain interferes with the healing process. Because the direct effect of opioids on this process remains unknown, we examined the effect of topically applied opioids on the healing of open ischemic wounds in rats. Topically applied opioids hastened wound closure, particularly in the first 4 days when no healing was initiated in phosphate buffered saline solution-treated wounds. After 1 week of application, fentanyl, hydromorphone, and morphine resulted in 66%, 55%, and 42% wound closure, respectively, as compared to only 15% in control wounds. Opioid-induced healing was accompanied by a 1.5- to 2.5-fold increase in nuclear density in the granulation tissue and 45-87% increase in angiogenesis as compared to phosphate buffered saline solution-treated wounds. Fentanyl showed significantly improved healing compared to morphine and hydromorphone (p < 0.05, fentanyl vs. others). Fentanyl-induced healing was inhibited by the opioid receptor antagonist naloxone, suggesting that peripheral opioid receptor(s) mediate the healing process. Opioids accelerate healing by up-regulating both endothelial and inducible nitric oxide synthase and the vascular endothelial-derived growth factor receptor Flk1 in the wounds. We envision that opioids can be used topically to accelerate wound healing in diverse clinical conditions ranging from surgical incisions to nonhealing ischemic ulcers in pathophysiological conditions and in hospice patients.	Univ Minnesota, Sch Med, Vasc Biol Ctr, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Div Hematol Oncol & Transplantat, Dept Med, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Div Hematol Oncol & Transplantat, Dept Surg, Minneapolis, MN 55455 USA	Gupta, K (reprint author), Univ Minnesota, Sch Med, Vasc Biol Ctr, Mayo Mail Code 480,420 Delaware St SE, Minneapolis, MN 55455 USA.	gupta014@umn.edu			NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL68802, P01 HL055552, HL55552]		Altavilla D, 2001, DIABETES, V50, P667, DOI 10.2337/diabetes.50.3.667; ARNOLD F, 1991, PHARMACOL THERAPEUT, V52, P407, DOI 10.1016/0163-7258(91)90034-J; Bertolucci M, 1996, NEUROREPORT, V7, P1181, DOI 10.1097/00001756-199604260-00017; Bigliardi PL, 2003, J INVEST DERMATOL, V120, P145, DOI 10.1046/j.1523-1747.2003.12018.x; Chen C, 1999, WOUND REPAIR REGEN, V7, P486, DOI 10.1046/j.1524-475X.1999.00486.x; Clark R., 1996, Mezhdunarodnyi Sel'skokhozyaistvennyi Zhurnal, P3; Cuellar B, 2000, PSYCHOPHARMACOLOGY, V148, P66, DOI 10.1007/s002130050026; DUIJVESTIJN AM, 1992, LAB INVEST, V66, P459; Efron PA, 2004, J BURN CARE REHABIL, V25, P149, DOI 10.1097/01.BCR.0000111766.97335.34; Fimiani C, 1999, PROSTAG OTH LIPID M, V57, P23, DOI 10.1016/S0090-6980(98)00068-9; Flock P, 2003, J PAIN SYMPTOM MANAG, V25, P547, DOI 10.1016/S0885-3924(03)00140-4; Galeano M, 2003, DIABETOLOGIA, V46, P546, DOI 10.1007/s00125-003-1064-1; Gallucci RM, 2004, J INVEST DERMATOL, V122, P764, DOI 10.1111/j.0022-202X.2004.22323.x; Gallucci RM, 2001, J INTERF CYTOK RES, V21, P603, DOI 10.1089/10799900152547867; Gottrup F, 2004, WOUND REPAIR REGEN, V12, P129, DOI 10.1111/j.1067-1927.2004.012204.x; GRAY P, 1975, MICROTOMISTS FORMULA; Gupta K, 2002, CANCER RES, V62, P4491; Hong YK, 2004, FASEB J, V18, P1111, DOI 10.1096/fj.03-1179fje; Houghtling RA, 2000, ANN NY ACAD SCI, V917, P771; Howdieshell TR, 2003, SURGERY, V133, P528, DOI 10.1067/msy.2003.128; Howdieshell TR, 1998, ANN SURG, V228, P707, DOI 10.1097/00000658-199811000-00011; Howdieshell TR, 2001, J SURG RES, V96, P173, DOI 10.1006/jsre.2001.6089; Jacobi J, 2004, GENE THER, V11, P302, DOI 10.1038/sj.gt.3302162; Khodorova A, 2003, NAT MED, V9, P1055, DOI 10.1038/nm885; Krajnik M, 1999, PAIN, V80, P121, DOI 10.1016/S0304-3959(98)00211-5; Lee PC, 1999, AM J PHYSIOL-HEART C, V277, pH1600; Lin ZQ, 2003, J LEUKOCYTE BIOL, V73, P713, DOI 10.1189/jlb.0802397; Lysle DT, 1999, J PHARMACOL EXP THER, V288, P502; Magazine HI, 1996, J IMMUNOL, V156, P4845; Manafy M, 2004, ECONTENT, V27, P9; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Matsubayashi Y, 2004, CURR BIOL, V14, P731, DOI 10.1016/j.cub.2004.03.060; Most D, 2002, SURGERY, V132, P866, DOI 10.1067/msy.2002.127422; Mustoe T, 2004, AM J SURG, V187, p65S, DOI 10.1016/S0002-9610(03)00306-4; Nissen NN, 1998, AM J PATHOL, V152, P1445; Persson AI, 2003, MOL CELL NEUROSCI, V23, P360, DOI 10.1016/S1044-7431(03)00061-7; Pollock JS, 2001, SURGERY, V129, P341, DOI 10.1067/msy.2001.111700; Ribeiro MDC, 2004, J PAIN SYMPTOM MANAG, V27, P434, DOI 10.1016/j.jpainsymman.2003.09.011; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Schwentker A, 2003, SURG CLIN N AM, V83, P521, DOI 10.1016/S0039-6109(02)00207-4; Schwentker A, 2002, NITRIC OXIDE-BIOL CH, V7, P1, DOI 10.1016/S1089-8603(02)00002-2; Sharma GD, 2003, J BIOL CHEM, V278, P21989, DOI 10.1074/jbc.M302650200; Stefano GB, 1995, J BIOL CHEM, V270, P30290, DOI 10.1074/jbc.270.51.30290; Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; Suzuki S, 2003, BIOCHEM BIOPH RES CO, V308, P802, DOI 10.1016/S0006-291X(03)01472-4; Tsou R, 2002, WOUND REPAIR REGEN, V10, P222, DOI 10.1046/j.1524-475X.2002.10405.x; Twillman RK, 1999, J PAIN SYMPTOM MANAG, V17, P288, DOI 10.1016/S0885-3924(98)00140-7; Ventura C, 2003, CIRC RES, V92, P617, DOI 10.1161/01.RES.0000065168.31147.5B; Watkins LR, 1995, PAIN, V63, P289, DOI 10.1016/0304-3959(95)00186-7; Weller R, 2003, CLIN EXP DERMATOL, V28, P511, DOI 10.1046/j.1365-2230.2003.01365.x	51	70	73	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1067-1927	1524-475X		WOUND REPAIR REGEN	Wound Repair Regen.	MAR-APR	2005	13	2					165	174		10.1111/j.1067-1927.2005.130207.x			10	Cell Biology; Dermatology; Medicine, Research & Experimental; Surgery	Cell Biology; Dermatology; Research & Experimental Medicine; Surgery	913EA	WOS:000228133200007	15828941				2020-06-30	J	Bradaia, A; Berton, F; Ferrari, S; Luscher, C				Bradaia, A; Berton, F; Ferrari, S; Luscher, C			beta-arrestin2, interacting with phosphodiesterase 4, regulates synaptic release probability and presynaptic inhibition by opioids	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						synaptic transmission; mu-opioid receptors; locus coeruleus; periaqueductal gray; analgesia	BETA-ARRESTIN; CYCLIC-AMP; IN-VITRO; RECEPTOR DESENSITIZATION; POTASSIUM CURRENTS; GABA RELEASE; NEURONS; RAT; MORPHINE; PDE4	Most mu-opioid receptor agonists recruit beta-arrestin2, with some exceptions such as morphine. Surprisingly, however, the acute analgesic effect of morphine is enhanced in the absence of beta-arrestin2. To resolve this paradox, we examined the effects of morphine and fentanyl in acute brain slices of the locus coeruleus and the periaqueductal gray from beta-arrestin2 knockout mice. We report that, in these mice, presynaptic inhibition of evoked inhibitory postsynaptic currents was enhanced, whereas postsynaptic G protein-coupled K+ (Kir3/GIRK) currents were unaffected. The frequency, but not amplitude, of miniature inhibitory postsynaptic currents was increased in beta-arrestin2 knockout mice, indicating a higher release probability compared to WT mice. The increased release probability resulted from increased cAMP levels because of impaired phosphodiesterase 4 function and conferred an enhanced efficacy of morphine to inhibit GABA release. Thus, beta-arrestin2 attenuates presynaptic inhibition by opioids independent of mu-opioid receptor-driven recruitment, which may make beta-arrestin2 a promising target for regulating analgesia.	Univ Geneva, Dept Basic Neurosci, CH-1211 Geneva, Switzerland; Univ Geneva, Neurol Clin, CH-1211 Geneva, Switzerland; Univ Geneva, Dept Med, CH-1211 Geneva, Switzerland; Univ Geneva, Serv Bone Dis, CH-1211 Geneva, Switzerland	Luscher, C (reprint author), Univ Geneva, Dept Basic Neurosci, CH-1211 Geneva, Switzerland.	christian.luscher@medecine.unige.ch	Luscher, Christian/A-2496-2011	Luscher, Christian/0000-0001-7917-4596			Bailey CP, 2003, J NEUROSCI, V23, P10515; Baillie GS, 2003, P NATL ACAD SCI USA, V100, P940, DOI 10.1073/pnas.262787199; Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; Blanchet C, 2003, MOL CELL NEUROSCI, V24, P517, DOI 10.1016/S1044-7431(03)00173-8; Blanchet C, 2002, P NATL ACAD SCI USA, V99, P4674, DOI 10.1073/pnas.072075399; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Bohn LM, 2004, MOL PHARMACOL, V66, P106, DOI 10.1124/mol.66.1.106; Bolger GB, 2003, J BIOL CHEM, V278, P49230, DOI 10.1074/jbc.M303772200; CHAVEZNORIEGA LE, 1994, J NEUROSCI, V14, P310; COHEN GA, 1992, NEURON, V9, P325, DOI 10.1016/0896-6273(92)90171-9; Conti M, 2003, J BIOL CHEM, V278, P5493, DOI 10.1074/jbc.R200029200; Cruz HG, 2004, NAT NEUROSCI, V7, P153, DOI 10.1038/nn1181; Fields H, 2004, NAT REV NEUROSCI, V5, P565, DOI 10.1038/nrn1431; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; Hack SP, 2003, NEUROPHARMACOLOGY, V45, P575, DOI 10.1016/S0028-3908(03)00205-3; Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/BJ20021698; Ingram SL, 1998, J NEUROSCI, V18, P10269; JONES SL, 1986, J NEUROPHYSIOL, V56, P1397; Kaneko M, 2004, J NEUROSCI, V24, P5202, DOI 10.1523/JNEUROSCI.0999-04.2004; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; Miller RJ, 1998, ANNU REV PHARMACOL, V38, P201, DOI 10.1146/annurev.pharmtox.38.1.201; Minnis JG, 2003, NEUROSCIENCE, V119, P33, DOI 10.1016/S0306-4522(03)00135-0; Mitrovic I, 2003, P NATL ACAD SCI USA, V100, P271, DOI 10.1073/pnas.0136822100; Nagy G, 2004, NEURON, V41, P417, DOI 10.1016/S0896-6273(04)00038-8; NICHOLSON D, 1991, PHARMACOL BIOCHEM BE, V38, P753, DOI 10.1016/0091-3057(91)90237-V; O'Donnell JM, 2004, TRENDS PHARMACOL SCI, V25, P158, DOI 10.1016/j.tips.2004.01.003; OSBORNE PB, 1995, BRIT J PHARMACOL, V115, P925, DOI 10.1111/j.1476-5381.1995.tb15899.x; Osborne PB, 1996, J PHYSIOL-LONDON, V490, P383, DOI 10.1113/jphysiol.1996.sp021152; Pan YZ, 2004, BRAIN RES, V997, P67, DOI 10.1016/j.brainres.2003.10.050; Perry SJ, 2002, SCIENCE, V298, P834, DOI 10.1126/science.1074683; REEVES ML, 1987, BIOCHEM J, V241, P535, DOI 10.1042/bj2410535; Robichaud A, 2002, J CLIN INVEST, V110, P1045, DOI 10.1172/JCI200215506; Sakaba T, 2003, NATURE, V424, P775, DOI 10.1038/nature01859; SCANZIANI M, 1992, NEURON, V9, P919, DOI 10.1016/0896-6273(92)90244-8; STUART GJ, 1991, NEUROSCI LETT, V126, P179, DOI 10.1016/0304-3940(91)90548-8; Torrecilla M, 2002, J NEUROSCI, V22, P4328, DOI 10.1523/JNEUROSCI.22-11-04328.2002; Vaughan CW, 1997, J PHYSIOL-LONDON, V498, P463, DOI 10.1113/jphysiol.1997.sp021872; Vaughan CW, 1997, NATURE, V390, P611, DOI 10.1038/37610; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914	40	26	28	0	0	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	FEB 22	2005	102	8					3034	3039		10.1073/pnas.0406632102			6	Multidisciplinary Sciences	Science & Technology - Other Topics	900RQ	WOS:000227232400065	15718284	Green Published, Bronze			2020-06-30	J	Wong, CA; Scavone, BM; Peaceman, AM; McCarthy, RJ; Sullivan, JT; Diaz, NT; Yaghmour, E; Marcus, RJL; Sherwani, SS; Sproviero, MT; Yilmaz, M; Patel, R; Robles, C; Grouper, S				Wong, CA; Scavone, BM; Peaceman, AM; McCarthy, RJ; Sullivan, JT; Diaz, NT; Yaghmour, E; Marcus, RJL; Sherwani, SS; Sproviero, MT; Yilmaz, M; Patel, R; Robles, C; Grouper, S			The risk of cesarean delivery with neuraxial analgesia given early versus late in labor	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SPINAL-EPIDURAL ANALGESIA; NULLIPAROUS WOMEN; INTRAVENOUS MEPERIDINE; TRIAL; PAIN; OXYTOCIN; MORPHINE; OPIOIDS	BACKGROUND: Epidural analgesia initiated early in labor (when the cervix is less than 4.0 cm dilated) has been associated with an increased risk of cesarean delivery. It is unclear, however, whether this increase in risk is due to the analgesia or is attributable to other factors. METHODS: We conducted a randomized trial of 750 nulliparous women at term who were in spontaneous labor or had spontaneous rupture of the membranes and who had a cervical dilatation of less than 4.0 cm. Women were randomly assigned to receive intrathecal fentanyl or systemic hydromorphone at the first request for analgesia. Epidural analgesia was initiated in the intrathecal group at the second request for analgesia and in the systemic group at a cervical dilatation of 4.0 cm or greater or at the third request for analgesia. The primary outcome was the rate of cesarean delivery. RESULTS: The rate of cesarean delivery was not significantly different between the groups (17.8 percent after intrathecal analgesia vs. 20.7 percent after systemic analgesia; 95 percent confidence interval for the difference, -9.0 to 3.0 percentage points; P=0.31). The median time from the initiation of analgesia to complete dilatation was significantly shorter after intrathecal analgesia than after systemic analgesia (295 minutes vs. 385 minutes, P<0.001), as was the time to vaginal delivery (398 minutes vs. 479 minutes, P<0.001). Pain scores after the first intervention were significantly lower after intrathecal analgesia than after systemic analgesia (2 vs. 6 on a 0-to-10 scale, P<0.001). The incidence of one-minute Apgar scores below 7 was significantly higher after systemic analgesia (24.0 percent vs. 16.7 percent, P=0.01). CONCLUSIONS: Neuraxial analgesia in early labor did not increase the rate of cesarean delivery, and it provided better analgesia and resulted in a shorter duration of labor than systemic analgesia.	Northwestern Univ, Feinberg Sch Med, Dept Anesthesiol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Obstet & Gynecol, Chicago, IL 60611 USA	Wong, CA (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Anesthesiol, 251 E Huron,F 5-704, Chicago, IL 60611 USA.	c-wong2@northwestern.edu	McCarthy, Robert J/J-9113-2018	McCarthy, Robert J/0000-0002-0966-5311; Peaceman, Alan/0000-0002-4515-4850; Sullivan, John/0000-0001-5445-708X; Wong, Cynthia/0000-0002-7144-7008			Alexander JM, 2001, ANESTH ANALG, V92, P1524; CAMANN WR, 1991, BRIT J ANAESTH, V67, P565, DOI 10.1093/bja/67.5.565; Cascio M, 1997, CAN J ANAESTH, V44, P605, DOI 10.1007/BF03015443; CHESTNUT DH, 1994, ANESTHESIOLOGY, V80, P1201, DOI 10.1097/00000542-199406000-00006; CHESTNUT DH, 1994, ANESTHESIOLOGY, V80, P1193, DOI 10.1097/00000542-199406000-00005; Gambling DR, 1998, ANESTHESIOLOGY, V89, P1336, DOI 10.1097/00000542-199812000-00010; Goetzl Laura M, 2002, Obstet Gynecol, V100, P177; Halpern SH, 1998, JAMA-J AM MED ASSOC, V280, P2105, DOI 10.1001/jama.280.24.2105; Hess PE, 2001, ANESTH ANALG, V93, P414; Hess PE, 2000, ANESTH ANALG, V90, P881, DOI 10.1213/00000539-200004000-00020; Hughes SC, 1997, INT J OBSTET ANESTH, V6, P145, DOI 10.1016/S0959-289X(97)80077-5; Kowalski WB, 1998, BIOL REPROD, V58, P971, DOI 10.1095/biolreprod58.4.971; Leighton BL, 1999, ANESTHESIOLOGY, V90, P1039, DOI 10.1097/00000542-199904000-00017; LEIGHTON BL, 1999, ANESTHESIOLOGY, V91, P602; Lieberman E, 1997, PEDIATRICS, V99, P415, DOI 10.1542/peds.99.3.415; Luxman D, 1998, INT J OBSTET ANESTH, V7, P161, DOI 10.1016/S0959-289X(98)80004-6; MacArthur C, 2001, LANCET, V358, P19; Mardirosoff C, 2002, BJOG-INT J OBSTET GY, V109, P274, DOI 10.1016/S1470-0328(02)01380-0; Nageotte MP, 1997, NEW ENGL J MED, V337, P1715, DOI 10.1056/NEJM199712113372402; NEUMARK J, 1985, ACTA ANAESTH SCAND, V29, P555, DOI 10.1111/j.1399-6576.1985.tb02253.x; Panni MK, 2003, ANESTHESIOLOGY, V98, P957, DOI 10.1097/00000542-200304000-00024; PETRIE RH, 1993, J MATERNAL FETAL MED, V2, P159; Seyb ST, 1999, OBSTET GYNECOL, V94, P600, DOI 10.1016/S0029-7844(99)00377-4; Sharma SK, 2002, ANESTHESIOLOGY, V96, P546, DOI 10.1097/00000542-200203000-00007; SIVALINGAM T, 1985, BRIT J ANAESTH, V57, P430, DOI 10.1093/bja/57.4.430; THORP JA, 1993, AM J OBSTET GYNECOL, V169, P851, DOI 10.1016/0002-9378(93)90015-B; Tsen LC, 1999, ANESTHESIOLOGY, V91, P920, DOI 10.1097/00000542-199910000-00010; WONG CA, 2002, ANESTHESIOLOGY S1, V96; Yoo KY, 2001, ANESTH ANALG, V92, P1006	29	195	222	2	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2005	352	7					655	665		10.1056/NEJMoa042573			11	Medicine, General & Internal	General & Internal Medicine	897UO	WOS:000227031100004	15716559				2020-06-30	J	Vasilakos, K; Wilson, RJA; Kimura, N; Remmers, JE				Vasilakos, K; Wilson, RJA; Kimura, N; Remmers, JE			Ancient gill and lung oscillators may generate the respiratory rhythm of frogs and rats	JOURNAL OF NEUROBIOLOGY			English	Article						homology; frog; respiration; opioid; coupled oscillators	BULLFROG RANA-CATESBEIANA; ISOLATED BRAIN-STEM; PRE-BOTZINGER COMPLEX; CENTRAL PATTERN GENERATOR; IN-VITRO; NEWBORN RATS; SPINAL-CORD; VENTILATORY ACTIVITY; NEONATAL-RATS; FICTIVE GILL	Though the mechanics of breathing differ fundamentally between amniotes and "lower" vertebrates, homologous rhythm generators may drive air breathing in all lunged vertebrates. In both frogs and rats, two coupled oscillators, one active during the inspiratory (1) phase and the other active during the pre-inspiratory (PreI) phase, have been hypothesized to generate the respiratory rhythm. We used opioids to uncouple these oscillators. In the intact rat, complete arrest of the external rhythm by opioid-induced suppression of the putative I oscillator, that is, pre-Botzinger complex (PBC) oscillator, did not arrest the putative PreI oscillator. In the unanesthetized frog, the comparable PreI oscillator, that is, the putative buccal/ gill oscillator, was refractory to opioids even though the comparable I oscillator, the putative lung oscillator, was arrested. Studies in en bloc brainstem preparations derived from both juvenile frogs and metamorphic tadpoles confirmed these results and suggested that opioids may play a role in the clustering of lung bursts into episodes. As the frog and rat respiratory circuitry produce functionally equivalent motor outputs during lung inflation, these data argue for a close homology between the frog and rat oscillators. We suggest that the respiratory rhythm of all lunged vertebrates is generated by paired coupled oscillators. These may have originated from the gill and lung oscillators of the earliest air breathers. (C) 2004 Wiley Periodicals, Inc.	Univ Calgary, Dept Med, Calgary, AB T2N 4N1, Canada; Jikei Univ, Sch Med, Dept Pharmacol 2, Minato Ku, Tokyo 1058461, Japan	Remmers, JE (reprint author), Univ Calgary, Dept Med, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	jeremmer@ucalgary.ca		Wilson, Richard/0000-0001-9942-4775			Ballanyi K, 1999, PROG NEUROBIOL, V59, P583, DOI 10.1016/S0301-0082(99)00009-X; BOUTILIER RG, 1986, J EXP BIOL, V126, P33; Brainerd E. L., 1999, EXP BIOL ONLINE, V4, P11; BRAINERD EL, 1993, BIOL J LINN SOC, V49, P163, DOI 10.1111/j.1095-8312.1993.tb00896.x; Broch L, 2002, J EXP BIOL, V205, P1161; BROCKHAUS J, 1993, J PHYSIOL-LONDON, V462, P421, DOI 10.1113/jphysiol.1993.sp019562; BURGGREN WW, 1982, RESP PHYSIOL, V47, P151, DOI 10.1016/0034-5687(82)90108-6; BURGGREN WW, 1984, [No title captured], P31; Chatonnet F, 2002, RESP PHYSIOL NEUROBI, V131, P5, DOI 10.1016/S1569-9048(02)00033-2; *DAT AN PROD DIV, 1997, SPLUS 4 GUID STAT; DAVIS J N, 1970, Brain Behavior and Evolution, V93, P851, DOI 10.1093/brain/93.4.851; Druzisky KA, 2001, ZOOL-ANAL COMPLEX SY, V104, P143, DOI 10.1078/0944-2006-00015; Duffin J, 2003, RESP PHYSIOL NEUROBI, V139, P105, DOI 10.1016/S1569-9048(03)00194-0; Farmer CG, 1999, ANNU REV PHYSIOL, V61, P573, DOI 10.1146/annurev.physiol.61.1.573; Galante RJ, 1996, J PHYSIOL-LONDON, V492, P545, DOI 10.1113/jphysiol.1996.sp021328; GANS C, 1969, SCIENCE, V163, P1223, DOI 10.1126/science.163.3872.1223; GANS C, 1970, Forma et Functio, V3, P61; Gdovin MJ, 1998, RESP PHYSIOL, V113, P135, DOI 10.1016/S0034-5687(98)00061-9; Glass L, 1988, CLOCKS CHAOS; Harris MB, 2002, AM J PHYSIOL-REG I, V283, pR417, DOI 10.1152/ajpregu.00513.2001; Hedrick MS, 2001, ADV EXP MED BIOL, V499, P127; Hedrick MS, 1999, COMP BIOCHEM PHYS A, V124, P243, DOI 10.1016/S1095-6433(99)00115-4; Janczewski WA, 2002, J PHYSIOL-LONDON, V545, P1017, DOI 10.1113/jphysiol.2002.023408; Kimura N, 1997, NEUROSCI LETT, V225, P9, DOI 10.1016/S0304-3940(97)00171-7; KINKEAD R, 1994, RESP PHYSIOL, V95, P81, DOI 10.1016/0034-5687(94)90049-3; KOGO N, 1994, J NEUROBIOL, V25, P1067, DOI 10.1002/neu.480250904; Lau C, 2003, ACTA PAEDIATR, V92, P721, DOI 10.1080/08035250310002407; Laurin M, 2002, SYST BIOL, V51, P364, DOI 10.1080/10635150252899815; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; Marder E, 1996, PHYSIOL REV, V76, P687; McCrimmon DR, 2000, BIOESSAYS, V22, P6, DOI 10.1002/(SICI)1521-1878(200001)22:1<6::AID-BIES3>3.0.CO;2-Q; MCDONALD DG, 1980, J EXP BIOL, V84, P273; MCLEAN HA, 1995, J COMP PHYSIOL A, V177, P135; MCMAHON BR, 1969, J EXP BIOL, V51, P407; Mellen NM, 2003, NEURON, V37, P821, DOI 10.1016/S0896-6273(03)00092-8; MEYRAND P, 1991, NATURE, V351, P60, DOI 10.1038/351060a0; Morales RD, 2002, COMP BIOCHEM PHYS A, V132, P477, DOI 10.1016/S1095-6433(02)00093-4; NIEUWENHUYS R, 1998, CENTRAL NERVOUS SYST; O'Donovan MJ, 1998, J NEUROBIOL, V37, P131, DOI 10.1002/(SICI)1097-4695(199810)37:1<131::AID-NEU10>3.0.CO;2-H; Onimaru H, 2003, J NEUROSCI, V23, P1478; ONIMARU H, 1990, PFLUG ARCH EUR J PHY, V417, P425, DOI 10.1007/BF00370663; ONIMARU H, 1987, NEUROSCI LETT, V78, P151, DOI 10.1016/0304-3940(87)90624-0; ONIMARU H, 1989, EXP BRAIN RES, V76, P530, DOI 10.1007/BF00248909; Paxinos G., 1998, RAT BRAIN STEREOTAXI; PEARSON KG, 1992, J NEUROSCI METH, V42, P75, DOI 10.1016/0165-0270(92)90137-3; Peever JH, 1999, RESP PHYSIOL, V117, P97, DOI 10.1016/S0034-5687(99)00059-6; Peever JH, 2001, PFLUG ARCH EUR J PHY, V442, P78, DOI 10.1007/s004240000502; Perry SF, 2001, COMP BIOCHEM PHYS A, V129, P37, DOI 10.1016/S1095-6433(01)00304-X; Rekling JC, 1998, ANNU REV PHYSIOL, V60, P385, DOI 10.1146/annurev.physiol.60.1.385; Remmers JE, 2001, RESP PHYSIOL, V129, P211, DOI 10.1016/S0034-5687(01)00291-2; Richter DW, 2003, RESP PHYSIOL NEUROBI, V139, P121, DOI 10.1016/S1569-9048(03)00196-4; Ruta M, 2003, BIOL REV, V78, P251, DOI 10.1017/S1464793102006103; Saito Y, 2002, J PHYSIOL-LONDON, V544, P183, DOI 10.1113/jphysiol.2002.022566; SAKAKIBARA Y, 1984, JPN J PHYSIOL, V34, P269, DOI 10.2170/jjphysiol.34.269; SELVIN S, 1998, MODERN APPL BIOSTATI; SENN DG, 1972, ACTA ANAT, V82, P525; Shao XM, 1997, J NEUROPHYSIOL, V77, P1853; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; Solomon IC, 2003, J APPL PHYSIOL, V94, P2151, DOI 10.1152/japplphysiol.01192.2002; St-John WM, 1998, PROG NEUROBIOL, V56, P97, DOI 10.1016/S0301-0082(98)00031-8; Straus C, 2003, BIOESSAYS, V25, P182, DOI 10.1002/bies.10224; Straus C, 2000, J NEUROBIOL, V45, P75, DOI 10.1002/1097-4695(20001105)45:2<75::AID-NEU2>3.0.CO;2-5; Straus C, 2000, NEUROSCI LETT, V292, P13, DOI 10.1016/S0304-3940(00)01422-1; SWANSON LW, 1998, BRAIN MAPS STRUCTURE; Szekely G, 1993, Adv Anat Embryol Cell Biol, V128, P1; Takeda S, 2001, ANESTHESIOLOGY, V95, P740, DOI 10.1097/00000542-200109000-00029; TAYLOR AC, 1946, ANAT REC, V94, P7, DOI 10.1002/ar.1090940103; Torgerson CS, 1998, J NEUROPHYSIOL, V80, P2015; Torgerson CS, 1997, J EXP BIOL, V200, P2063; Torgerson CS, 2001, AM J PHYSIOL-REG I, V280, pR921; WEST NH, 1975, CAN J ZOOL, V53, P332, DOI 10.1139/z75-042; Wilson RJA, 1999, J NEUROSCI METH, V87, P175, DOI 10.1016/S0165-0270(99)00005-9; Wilson RJA, 2000, J EXP BIOL, V203, P3505; Wilson RJA, 2002, J PHYSIOL-LONDON, V540, P557, DOI 10.1113/jphysiol.2001.013512; Winmill RE, 2003, J NEUROBIOL, V55, P278, DOI 10.1002/neu.10212	75	63	63	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	0022-3034			J NEUROBIOL	J. Neurobiol.	FEB 15	2005	62	3					369	385		10.1002/neu.20102			17	Neurosciences	Neurosciences & Neurology	891CA	WOS:000226557700008	15551345				2020-06-30	J	Martyr, JW; Stannard, KJD; Gillespie, G				Martyr, JW; Stannard, KJD; Gillespie, G			Spinal-induced hypotension in elderly patients with hip fracture. A comparison of glucose-free bupivacaine with glucose-free bupivacaine and fentanyl	ANAESTHESIA AND INTENSIVE CARE			English	Article						anaesthesia, regional : spinal, hip fracture, elderly; hypotension, fentanyl, bupivacaine, baricity	CEREBROSPINAL-FLUID VOLUME; SUBARACHNOID BLOCK; ANESTHESIA; PRESSURE; REPAIR	Intraoperative hypotension is a common and potentially deleterious event in elderly patients undergoing spinal anaesthesia for repair of hip fractures. The synergism between intrathecal opioids and local anaesthetics may allow a reduction in the dose of local anaesthetic and cause less sympathetic block and hypotension, while still maintaining adequate anaesthesia. We studied 40 elderly patients having either an insertion of a dynamic hip screw or a hemiarthroplasty and compared 9.0 mg glucose-free bupivacame with added fentanyl 20 mu g (group BF) with 11.0 m glucose-free bupivacaine alone (group B). Hypotension was defined as a fall in systolic blood pressure to less than 75% baseline or less than 90 mmHg. The incidence and frequency of hypotension in group BF were less than in group B. Similarly, falls in systolic, diastolic and mean blood pressures were all less in group BF than in group B. However, there were four failed blocks in group BF and one in group B.	Royal Perth Hosp, Dept Anesthesia, Perth, WA 6847, Australia	Martyr, JW (reprint author), Royal Perth Hosp, Dept Anesthesia, Box X2213 GPO, Perth, WA 6847, Australia.						Ben-David B, 2000, ANESTHESIOLOGY, V92, P6, DOI 10.1097/00000542-200001000-00007; Broadbent CR, 2000, ANAESTHESIA, V55, P1122, DOI 10.1046/j.1365-2044.2000.01547-4.x; Carpenter RL, 1998, ANESTHESIOLOGY, V89, P24, DOI 10.1097/00000542-199807000-00007; CRITCHLEY LAH, 1994, BRIT J ANAESTH, V73, P464, DOI 10.1093/bja/73.4.464; Critchley LAH, 1996, ANAESTHESIA, V51, P1139, DOI 10.1111/j.1365-2044.1996.tb15051.x; Critchley LAH, 1999, ANAESTH INTENS CARE, V27, P170, DOI 10.1177/0310057X9902700207; GREENE NM, 1985, ANESTH ANALG, V64, P715; Hogan QH, 1996, ANESTHESIOLOGY, V84, P1341, DOI 10.1097/00000542-199606000-00010; Martyr JW, 2001, ANAESTH INTENS CARE, V29, P501, DOI 10.1177/0310057X0102900509; VARRASSI G, 1992, ANAESTHESIA, V47, P558, DOI 10.1111/j.1365-2044.1992.tb02323.x; WANG C, 1993, ANESTHESIOLOGY, V79, P766, DOI 10.1097/00000542-199310000-00019	11	6	6	0	0	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2021, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	FEB	2005	33	1					64	68		10.1177/0310057X0503300110			5	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	908BY	WOS:000227763400010	15957693	Bronze			2020-06-30	J	Walker, L				Walker, L			Intrathecal midazolam: Adverse effects and sources of bias	ANESTHESIA AND ANALGESIA			English	Letter									Royal Brompton Hosp, Dept Anaesthesia, London SW3 6LY, England	Walker, L (reprint author), Royal Brompton Hosp, Dept Anaesthesia, London SW3 6LY, England.	llwalker@ukonline.co.uk					Tucker AP, 2004, ANESTH ANALG, V98, P1521	1	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	FEB	2005	100	2					604	605		10.1213/01.ANE.0000145328.98283.CE			2	Anesthesiology	Anesthesiology	891FP	WOS:000226567000075	15673920				2020-06-30	J	Richebe, P; Rivat, C; Laulin, JP; Maurette, P; Simonnet, G				Richebe, P; Rivat, C; Laulin, JP; Maurette, P; Simonnet, G			Ketamine improves the management of exaggerated postoperative pain observed in perioperative fentanyl-treated rats	ANESTHESIOLOGY			English	Article							OPIOID-INDUCED HYPERALGESIA; LONG-LASTING HYPERALGESIA; INCISIONAL PAIN; ACUTE TOLERANCE; ANTINOCICEPTIVE TOLERANCE; WITHDRAWAL HYPERALGESIA; REMIFENTANIL INFUSIONS; RAPID DEVELOPMENT; DOSE KETAMINE; ANALGESIA	Background: Although opioids are unsurpassed analgesics, experimental and clinical studies suggest that opioids activate N-Methyl-D-aspartate pronociceptive systems leading to pain hypersensitivity and short-term tolerance. Because it is difficult in humans to differentiate pain from hyperalgesia during the postoperative period, the authors performed experimental studies with fentanyl using the rat incisional pain model for evaluating relations between hyperalgesia and short-term tolerance. Because N-methyl-D-aspartate receptor antagonists oppose both pain hypersensitivity and tolerance induced by opioids, the authors examined the capability of ketamine for improving exaggerated postoperative pain management. Methods: During halothane anesthesia, a hind paw plantar incision was performed in rats receiving four fentanyl subcutaneous injections (100 mug/kg per injection, every 15 min). In some groups, three subcutaneous ketamine injections (10 mg/kg per injection, every 5 h) were performed in saline- or fentanyl-treated rats. one day after surgery, the analgesic effect of morphine (2 mg/kg subcutaneous) was tested. Analgesia, mechanical hyperalgesia, tactile allodynia, and pain score were assessed for several days using the paw pressure vocalization test, the von Frey application test, and the postural disequilibrium test. Results: Fentanyl induced analgesia but also produced exaggerated postoperative pain as indicated by the enhancement of hyperalgesia, allodynia, and weight-bearing decrease after hind paw plantar incision. Ketamine pretreatment prevented such a fentanyl-induced enhancement of postoperative pain and improved its management by morphine. Conclusions: By opposing postoperative pain hypersensitivity and subsequent short-term tolerance induced by perioperative opioid use, ketamine not only improves exaggerated postoperative pain management but also provides better postoperative rehabilitation.	Univ Victor Segalen Bordeaux 2, Lab Homeostasie Allostas Pathol, EA 3666, F-33076 Bordeaux, France; Ctr Hosp Univ, Dept Anesthesie Reanimat 3, Bordeaux, France; Univ Bordeaux 1, Bordeaux, France	Simonnet, G (reprint author), Univ Victor Segalen Bordeaux 2, Lab Homeostasie Allostas Pathol, EA 3666, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	gsimonnet@yahoo.com	RIVAT, Cyril/B-5697-2008; Rivat, Cyril/F-8482-2019	Rivat, Cyril/0000-0002-7491-6113			Angst MS, 2003, PAIN, V106, P49, DOI 10.1016/S0304-3959(03)00276-8; Bilsky EJ, 1996, J PHARMACOL EXP THER, V277, P484; Brennan TJ, 1996, PAIN, V64, P493, DOI 10.1016/0304-3959(95)01441-1; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Celerier E, 2001, J NEUROSCI, V21, P4074, DOI 10.1523/JNEUROSCI.21-11-04074.2001; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; Compton P, 2003, J PAIN, V4, P511, DOI 10.1016/j.jpain.2003.08.003; Cooper DW, 1997, BRIT J ANAESTH, V78, P311; Eisenach JC, 2000, ANESTHESIOLOGY, V92, P308, DOI 10.1097/00000542-200002000-00009; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Guignard B, 2002, ANESTH ANALG, V95, P103, DOI 10.1097/00000539-200207000-00018; Gustorff B, 2002, ANESTH ANALG, V94, P1223, DOI 10.1097/00000539-200205000-00032; Hirota K, 1996, BRIT J ANAESTH, V77, P441, DOI 10.1093/bja/77.4.441; Hood DD, 2003, ANESTH ANALG, V97, P810, DOI 10.1213/01.ANE.0000078811.80093.88; KAYSER V, 1990, BRAIN RES, V508, P329, DOI 10.1016/0006-8993(90)90418-B; Kissin I, 2000, ANESTH ANALG, V91, P110, DOI 10.1097/00000539-200007000-00021; Koppert W, 2003, ANESTHESIOLOGY, V99, P152, DOI 10.1097/00000542-200307000-00025; Koppert W, 2001, ANESTHESIOLOGY, V95, P395, DOI 10.1097/00000542-200108000-00022; Larcher A, 1998, NEUROSCIENCE, V84, P583, DOI 10.1016/S0306-4522(97)00556-3; Laulin JP, 2002, ANESTH ANALG, V94, P1263, DOI 10.1097/00000539-200205000-00040; Laulin JP, 1999, NEUROSCIENCE, V89, P631, DOI 10.1016/S0306-4522(98)00652-6; Laulin JP, 1998, EUR J NEUROSCI, V10, P782, DOI 10.1046/j.1460-9568.1998.00083.x; Le Bars D, 2001, PHARMACOL REV, V53, P597; Li XQ, 2001, ANESTH ANALG, V93, P204; Mao JR, 2002, PAIN, V100, P213, DOI 10.1016/S0304-3959(02)00422-0; McCartney CJL, 2004, ANESTH ANALG, V98, P1385, DOI 10.1213/01.ANE.0000108501.57073.38; *NAT I HLTH, 1999, AN CAR US MAN BETHS; Ossipov MH, 2003, LIFE SCI, V73, P783, DOI 10.1016/S0024-3205(03)00410-7; Rivat C, 2002, ANESTHESIOLOGY, V96, P381, DOI 10.1097/00000542-200202000-00025; RIVAT C, 2002, WORLD C PAIN, V10, P381; Schmid RL, 1999, PAIN, V82, P111, DOI 10.1016/S0304-3959(99)00044-5; Scholz J, 2002, NAT NEUROSCI, V5, P1062, DOI 10.1038/nn942; Schraag S, 1999, ANESTH ANALG, V89, P753, DOI 10.1097/00000539-199909000-00042; Simonnet G, 2003, NEUROREPORT, V14, P1, DOI 10.1097/00001756-200301200-00001; SOLOMON RL, 1980, AM PSYCHOL, V35, P691, DOI 10.1037/0003-066X.35.8.691; Vinik HR, 1998, ANESTH ANALG, V86, P1307, DOI 10.1097/00000539-199806000-00033; WANG Z, 1994, LIFE SCI, V54, P1339; Whiteside GT, 2004, BRIT J PHARMACOL, V141, P85, DOI 10.1038/sj.bjp.0705568; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; Zarate E, 1999, ANESTHESIOLOGY, V90, P956, DOI 10.1097/00000542-199904000-00005	41	83	91	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	FEB	2005	102	2					421	428		10.1097/00000542-200502000-00028			8	Anesthesiology	Anesthesiology	893XV	WOS:000226755300026	15681961				2020-06-30	J	Lennernas, B; Hedner, T; Holmberg, M; Bredenberg, S; Nystrom, C; Lennernas, H				Lennernas, B; Hedner, T; Holmberg, M; Bredenberg, S; Nystrom, C; Lennernas, H			Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain	BRITISH JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						fentanyl; incident pain; pharmacokinetics; sublingual administration	ORAL TRANSMUCOSAL FENTANYL; VARIABILITY; DELIVERY	Aims It is estimated that two-thirds of cancer patients will at some point during their illness experience breakthrough pain. In this study, the pharmacokinetics of a novel sublingual dosage form of fentanyl developed for breakthrough pain was evaluated. Methods Eleven Caucasian patients (seven male and 4 female, aged 34-75 years, median 60 years) with metastatic malignant disease were recruited initially, but three patients withdrew. Prior to the study all patients were on continuous nonfentanyl opiate medication. The study was a double-blind, cross-over trial, consisting of three 1-day treatment periods. A new rapidly dissolving preparation of fentanyl, was administered sublingually in single doses of 100, 200 and 400 mug, respectively, on three separate occasions. Plasma fentanyl concentrations were determined using liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS). Pharmacokinetic parameters were calculated by noncompartment analysis. Tolerability and the occurrence of adverse events were monitored throughout the study by patient questionnaire. Results The data from nine subjects who completed at least two periods were used in the analysis of variance. There were no significant differences between doses (100, 200 and 400 mug) for dose adjusted AUC (F = 0.42, P = 0.6660), dose adjusted C-max (F = 0.08, P = 0.9206) and Tmax (F = 0.94, P = 0.4107). Thus, these parameters showed dose proportionality. The differences (400-100mug) in dose adjusted AUC from the three-period crossover analysis was -0.016 min.ng/ml (t = 0.71, P = 0.8718). Interindividual variability in systemic exposure to fentanyl was fairly small (25-40%), which may be related to a good in vivo biopharmaceutical performance of the sublingual tablet, and a relatively small fraction of the dose being swallowed. The first detectable plasma concentration of fentanyl was observed between 8 and 11 min after administration. t(max) increased from 39.7 +/- 17.4 to 48.7 +/- 26.3 and 56.7 +/- 24.6 min for the 100, 200 and 400 mug doses, respectively. Adverse events were few and did not increase with increasing dose. Conclusion With this rapidly dissolving fentanyl formulation, the first detectable plasma concentration of fentanyl was observed at 8-11 min after administration. The pharmacokinetics of the drug showed dose proportionately. This formulation of fentanyl seemed to be well tolerated by the patients.	Uppsala Univ, Dept Pharm, S-75123 Uppsala, Sweden; Karolinska Hosp, Dept Oncol, S-10401 Stockholm, Sweden; Univ Gothenburg, Sahlgrenska Acad, Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Clin Pharmacol, Gothenburg, Sweden	Lennernas, H (reprint author), Uppsala Univ, Dept Pharm, Box 580, S-75123 Uppsala, Sweden.	Hans.Lennernaes@biof.uu.se					Andrews C, 1983, CLIN ANAESTHESIOL, V1, P97; BOYLE R, 1990, BRIT J CLIN PHARMACO, V30, P405, DOI 10.1111/j.1365-2125.1990.tb03791.x; Cherny N, 2000, J Oncol Manag, V9, P8; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; DOLLERY C, 1991, THERAPEUTIC DRUGS, V1, pF26; Gardner-Nix J, 2001, J PAIN SYMPTOM MANAG, V22, P627, DOI 10.1016/S0885-3924(01)00321-9; Gupta SK, 1999, J PHARM SCI, V88, P835, DOI 10.1021/js980258b; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Mather LE, 1998, BRIT J CLIN PHARMACO, V46, P37, DOI 10.1046/j.1365-2125.1998.00035.x; McMillan C, 2001, Br J Nurs, V10, P860; MCQUAY HJ, 1994, CANCER SURV, V21, P17; Ozdemir V, 2000, PHARMACOGENETICS, V10, P373, DOI 10.1097/00008571-200007000-00001; POYHIA R, 1994, PHARMACOL TOXICOL, V74, P23; ROY SD, 1989, PHARM RES-DORDR, V6, P825, DOI 10.1023/A:1015944018555; ROY SD, 1988, PHARMACEUT RES, V5, P580, DOI 10.1023/A:1015994030251; Strang P, 1998, ACTA ONCOL, V37, P641, DOI 10.1080/028418698429973; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006; Sundell-Bredenberg S, 2001, EUR J PHARM SCI, V12, P285, DOI 10.1016/S0928-0987(00)00176-7; Winiwarter S, 1998, J MED CHEM, V41, P4939, DOI 10.1021/jm9810102; Zhang H, 2002, CLIN PHARMACOKINET, V41, P661, DOI 10.2165/00003088-200241090-00003	21	62	69	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0306-5251	1365-2125		BRIT J CLIN PHARMACO	Br. J. Clin. Pharmacol.	FEB	2005	59	2					249	253		10.1111/j.1365-2125.2004.02264.x			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	891JF	WOS:000226576400017	15676050	Green Published			2020-06-30	J	Pandey, CK; Raza, M; Ranjan, R; Singhal, V; Kumar, M; Lakra, A; Navkar, DV; Agarwal, A; Singh, RB; Singh, U; Singh, PK				Pandey, CK; Raza, M; Ranjan, R; Singhal, V; Kumar, M; Lakra, A; Navkar, DV; Agarwal, A; Singh, RB; Singh, U; Singh, PK			Intravenous lidocaine 0.5 mg.kg(-1) effectively suppresses fentanyl-induced cough	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							TRACHEAL INTUBATION; BOLUS	Purpose: To evaluate the minimal dose of lidocaine required for suppression of fentanyl-induced cough. Methods: 320 ASA I and II patients, non-smokers of both sexes scheduled for elective surgery between the ages of 18 to 60 yr were randomly allocated into four equal groups. The patients were assigned to receive lidocaine 0.5 mg(.)kg(-1) (Group I), 1.0 mg(.)kg(-1)(Group II), 1.5 mg(.)kg(-1) (Group III) or placebo (Group IV) over five seconds, one minute prior to the administration of fentanyl 3 mug(.)kg(-1) in a randomized and double-blind fashion. Any episode of cough was classified as coughing and graded as mild ( 1-2) moderate (3-4) or severe (5 or more). The data were analyzed by test of proportion. Results: Eleven, 12, 11 and 28 patients ( 13.75%, 15%, 13.75% and 35%) had cough in Groups I, II, III and IV respectively (P < 0.05 Groups I, II, III vs IV). There was no significant difference in the incidence and severity of cough among the lidocaine pretreated groups (P > 0.05). Conclusion: The results of our study suggest that iv lidocaine 0.5 mg(.)kg(-1) is the minimal dose required to suppress fentanyl-induced cough when administered one minute prior to fentanyl. Any further increase in the lidocaine dose does not reduce the incidence or severity of fentanyl-induced cough.	Sanjay Gandhi Postgrad Inst Med Sci, Dept Anesthesiol, Lucknow 226014, Uttar Pradesh, India; Sanjay Gandhi Postgrad Inst Med Sci, Dept Biostat, Lucknow 226014, Uttar Pradesh, India	Pandey, CK (reprint author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Anesthesiol, Lucknow 226014, Uttar Pradesh, India.	ckpandey@sgpgi.ac.in					Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; BARAKA A, 1978, ANESTH ANALG, V57, P506; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; Lui PW, 1996, CAN J ANAESTH, V43, P1216; NISHINO T, 1990, BRIT J ANAESTH, V64, P682, DOI 10.1093/bja/64.6.682; Pandey CK, 2004, ANESTH ANALG, V99, P1696, DOI 10.1213/01.ANE.0000136967.82197.82; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; POULTON TJ, 1979, ANESTHESIOLOGY, V50, P470, DOI 10.1097/00000542-197905000-00018; Ricciardolo FLM, 2001, AM J MED, V111, P18, DOI 10.1016/S0002-9343(01)00816-6; SMITH FR, 1973, CHEST, V63, P427, DOI 10.1378/chest.63.3.427; STELLATO C, 1992, ANESTHESIOLOGY, V77, P932, DOI 10.1097/00000542-199211000-00016; Tweed WA, 2001, ANESTH ANALG, V92, P1442; YASUDA I, 1978, ANESTHESIOLOGY, V49, P117, DOI 10.1097/00000542-197808000-00012; YUKIOK H, 1993, ANESTH ANALG, V77, P309, DOI 10.1213/00000539-199377020-00016; YUKIOKA H, 1985, ANESTH ANALG, V64, P1189	15	36	50	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	FEB	2005	52	2					172	175		10.1007/BF03027724			4	Anesthesiology	Anesthesiology	902JP	WOS:000227351400011	15684258	Bronze			2020-06-30	J	Schlimp, CJ; Wiedermann, FJ				Schlimp, CJ; Wiedermann, FJ			Does fentanyl-induced cough justify pretreatment with iv lidocaine 2 mg center dot kg(-1)	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Letter												Wiedermann, Franz Josef/M-2328-2015	Wiedermann, Franz Josef/0000-0003-1421-7262			Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421	1	10	12	0	0	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	FEB	2005	52	2					207	207		10.1007/BF03027731			1	Anesthesiology	Anesthesiology	902JP	WOS:000227351400018	15684266	Bronze			2020-06-30	J	Sittl, R; Likar, R; Nautrup, BP				Sittl, R; Likar, R; Nautrup, BP			Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: Results of a retrospective cohort study	CLINICAL THERAPEUTICS			English	Article						analgesic; buprenorphine; equipotency; fentanyl; transdermal; morphine equivalence	LONG-TERM TREATMENT; ORAL MORPHINE; OPIOIDS; GUIDELINES; MANAGEMENT; DATABASE; THERAPY	Background: The equipotency ratio of transdermal (TD) fentanyl to oral morphine has been established as 1:100, for buprenorphine TD, a ratio of 1:75 has been proposed, although this ratio has not been confirmed in clinical studies. Growing evidence from clinical practice, in which much lower doses of buprenorphine are used, suggests that this conversion ratio may be too high. Objective: The aim of this study was to compare calculated equipotent oral morphine doses of fentanyl TD with equipotent oral morphine doses of buprenorphine TD prescribed in clinical practice. Methods: This retrospective study identified patients with cancer and noncancer pain who had received >= 1 prescription for fentanyl TD or buprenorphine TD (the all-patients groups) from the German IMS Disease Analyzer-mediplus database, which contains all relevant data concerning drug prescriptions from 400 practices in Germany. Also identified were subgroups of the all-patients groups who had received long-term treatment with fentanyl TD or buprenorphine TD and were considered to have similar pain intensity, as they had previously received similar analgesic medication (the identical-cohort groups). Mean prescribed daily doses for the all-patients and identical-cohort groups were calculated based on the distribution of prescribed patch strengths. Because patients could have applied > 1 patch, mean prescribed daily doses were also calculated based on an assumption of double application when appropriate. Equipotent oral morphine doses were estimated using equipotency ratios of 1:1.00 for fentanyl TD and 1:75 for buprenorphine TD. Results: The all-patients groups consisted of 2198 patients with noncancer pain and 2544 patients with cancer pain; the identical-cohort groups consisted of 380 patients with noncancer pain and 496 patients with cancer pain (529 women, 347 men; mean age, 74 years [range, 25-101. years]). Equipotent doses of oral morphine were significantly lower In patients receiving buprenorphine TD compared with those receiving fentanyl TD (P < 0.001). In cancer patients, the equipotent oral morphine doses of fentanyl TD and buprenorphine TD were 130.9 to 138.9 mg and 85.2 to 88.8 mg, respectively; in noncancer patients, the corresponding values were 117.0 to 118.3 mg and 80.2 to 80.9 mg. Based on these results, an equipotency ratio of 1:110 to 1:115 for buprenorphine TD would appear to be more appropriate than the proposed ratio of 1:75. Conclusions: The fact that this retrospective analysis conducted in identical cohorts showed lower calculated equipotent oral morphine doses in the buprenorphine TD groups compared with the fentanyl TD groups calls into question the proposed 1:75 ratio for conversion of buprenorphine TD to equipotent oral morphine doses. Based on the findings of the present study, an equipotency ratio of 1:110 to 1:115 may be more appropriate. However, confirmative data from prospective randomized clinical trials are needed. Copyright (c) 2005 Excerpta Medica, Inc.	Univ Erlangen Nurnberg, Pain Clin, D-91054 Erlangen, Germany; Gen Hosp, Pain Clin, Klagenfurt, Austria; Grunenthal GMBH, Aachen, Germany	Sittl, R (reprint author), Univ Erlangen Nurnberg, Pain Clin, Krankenhausstr 12, D-91054 Erlangen, Germany.	Reinhard.Sittl@kfa.imed.uni-erlangen.de					Ackerman Stacey J, 2003, J Manag Care Pharm, V9, P223; Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; ARMITAGE P, 1994, STAT METHODS MED RES; Brant J M, 2001, Clin J Oncol Nurs, V5, P163; Dietlein G, 2002, INT J CLIN PHARM TH, V40, P130; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Jabary NS, 2000, AM J HYPERTENS, V13, P607, DOI 10.1016/S0895-7061(99)00261-7; *JANS PHARM PROD L, 2001, DUR PACK INS; Kwoh CK, 1996, ARTHRITIS RHEUM-US, V39, P713; Motheral B, 2003, VALUE HEALTH, V6, P90, DOI 10.1046/j.1524-4733.2003.00242.x; Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9; QUIGLEY C, 2004, [No title captured]; SCHUG SA, 1991, DRUGS, V42, P228, DOI 10.2165/00003495-199142020-00005; STURM C, 2003, KRANKENHAUSPHARMAZIE, V24, P7; Vallerand AH, 2003, NURS CLIN N AM, V38, P435, DOI 10.1016/S0029-6465(02)00094-4; World Health Organization, 1990, CANC PAIN REL PALL C; World Health Organization, 1996, CANC PAIN REL; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M; 2003, INT STAT CLASSIFICAT; 2003, TRANST SUMM PROD CHA	23	65	69	0	2	EXCERPTA MEDICA INC	NEW YORK	650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA	0149-2918			CLIN THER	Clin. Ther.	FEB	2005	27	2					225	237		10.1016/j.clinthera.2005.02.012			13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	907BZ	WOS:000227691400010	15811486				2020-06-30	J	Guest, JF; Ruiz, FJ; Russ, J; Das Gupta, R; Mihai, A; Greener, M				Guest, JF; Ruiz, FJ; Russ, J; Das Gupta, R; Mihai, A; Greener, M			A comparison of the resources used in advanced cancer care between two different strong opioids: an analysis of naturalistic practice in the UK	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						cancer; costs; economics; fentanyl; morphine; palliative care; resource use	RELEASE ORAL MORPHINE; QUALITY-OF-LIFE; PALLIATIVE CARE; TRANSDERMAL FENTANYL; ALTERNATIVE OPIOIDS; PAIN; EFFICACY	Objective: To assess the resource implications of using strong opioids in patients with advanced cancer in the UK, based on naturalistic practice, in order to develop the evidence base supporting better management. Design and setting: A modelling study performed from the perspective of the UK's National Health Service (NHS). Study participants and interventions: A data set was created from the DIN-link database comprising 986 patients with advanced cancer who were prescribed either 12-hourly sustained release morphine (SR morphine; MST Continuous) (n = 784) or transdermal fentanyl (Durogesic) (n = 202) as their first strong opioid between 1st January 1998 and 30th September 2000 and died during that period. Methods: Palliative care-related resource use data were obtained from the DIN-link database. Unit costs at 2000/2001 prices were applied to the resource use values to determine the mean NHS cost of palliative care from the start of treatment until death. Results: Patients initially treated with transdermal fentanyl started their strong opioid regime 8.5 years after diagnosis compared to 6.4years after diagnosis in those who started SR morphine. This equates to an overall survival period from diagnosis of 8.8 years and 7.4 years respectively. Nevertheless, the total NHS cost of palliative care was similar between treatment groups, ranging from a mean 008743462 per patient. Hospitalisation accounted for up to 71% of the total cost and opioids accounted for up to a further 17%. Less than one-third of patients received 4-hourly morphine as part of their initial opioid treatment despite UK guidelines recommending that moderate-to-severe pain should always be managed initially with an immediate-release preparation. Additionally, patients who received transdermal fentanyl as part of their initial treatment received significantly more laxative prescriptions than patients who started with SIR morphine. Conclusions: SIR morphine and transdermal fentanyl seem to be used in different situations. The results also confirm previous findings that pain management in cancer patients is often sub-optimal. The low contribution of opioids to the overall costs indicates that this should not be an obstacle to starting this aspect of palliative care earlier in disease progression. This characterisation of the resource implications of using SIR morphine and transdermal fentanyl should enable purchasers and providers to optimise the availability of strong opioids for cancer patients on medical, economic and humanitarian grounds.	CATALYST Hlth Econ Consultants, Northwood HA6 1BN, Middx, England	Guest, JF (reprint author), CATALYST Hlth Econ Consultants, 34B High St, Northwood HA6 1BN, Middx, England.	julian.guest@catalyst-health.co.uk		Guest, Julian F./0000-0003-0162-2007			Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Barnett M, 2001, POSTGRAD MED J, V77, P371, DOI 10.1136/pmj.77.908.371; Berger A, 2003, J PAIN SYMPTOM MANAG, V26, P723, DOI 10.1016/S0885-3924(03)00255-0; Billings JA, 2000, BMJ-BRIT MED J, V321, P555, DOI 10.1136/bmj.321.7260.555; Carey Iain M, 2003, BMC Fam Pract, V4, P14, DOI 10.1186/1471-2296-4-14; Carey IM, 2004, INT J MED INFORM, V73, P443, DOI 10.1016/j.ijmedinf.2004.02.002; CELLA DF, 1995, SEMIN ONCOL, V22, P73; CHISHOLM J, 1990, BRIT MED J, V300, P1092, DOI 10.1136/bmj.300.6732.1092; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; Coyle D, 1999, CRIT REV ONCOL HEMAT, V32, P71, DOI 10.1016/S1040-8428(99)00023-2; *DEP HLTH, 2000, NHS EX NHS CANC PLAN; Ellershaw JE, 2002, J PAIN SYMPTOM MANAG, V24, P398, DOI 10.1016/S0885-3924(02)00507-9; ELLERSHAW JE, 1997, HLTH AGEING, P34; Field G B, 1994, Eur J Cancer Care (Engl), V3, P79, DOI 10.1111/j.1365-2354.1994.tb00018.x; FOLEY KM, 1995, OXFORD TXB PALLIATIV, P148; Guest JF, 1998, PHARMACOECONOMICS, V14, P285, DOI 10.2165/00019053-199814030-00005; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; *HAYM MED LTD, 2000, MONTHL IND MED SPEC; IASP Sub-committee on Taxonomy, 1980, PAIN, V8, P249; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Lickiss JN, 2001, EUR J PAIN, V5, P5, DOI 10.1053/eujp.2001.0273; MELZACK R, 1992, ADV PAIN RES THER, V20, P149; Meuser T, 2001, PAIN, V93, P247, DOI 10.1016/S0304-3959(01)00324-4; MORRIS DB, 1998, ILLNESS CULTURE POST, P107; NETTEN A, 2000, UNIT COSTS HLTH SOCI; *NEWC MED LTD, 2001, RET PRIC CAT; Okkes IM, 2000, FAM PRACT, V17, P101, DOI 10.1093/fampra/17.2.101; Pargeon KL, 1999, J PAIN SYMPTOM MANAG, V18, P358, DOI 10.1016/S0885-3924(99)00097-4; Rankin M A, 1982, Cancer Nurs, V5, P181; *ROYAL COLL PHYS, 2000, PAIN CONTR PRINC PAI; Staats PS, 2004, SOUTH MED J, V97, P129, DOI 10.1097/01.SMJ.0000109215.54052.D8; *STAT OFF, 2000, DRUG TAR; Sykes N, 2003, LANCET ONCOL, V4, P312, DOI 10.1016/S1470-2045(03)01079-9	33	6	6	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.	FEB	2005	21	2					271	280		10.1185/030079904X20312			10	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	910BP	WOS:000227904700011	15801998				2020-06-30	J	Ciardo, A; Garavello, W; Leva, M; Graziano, B; Gaini, RM				Ciardo, A; Garavello, W; Leva, M; Graziano, B; Gaini, RM			Reversed ipsilateral acoustic reflex: A study on subjects treated with muscle relaxants	EAR AND HEARING			English	Article							MIDDLE-EAR REFLEX; TENSOR TYMPANI; PROPOFOL ANESTHESIA; IMPEDANCE-CHANGE; STIMULATION	Objectives: To rule out any possible involvement of the middle ear muscles in the genesis of the reversed ipsilateral acoustic reflex (RIAR). Design: Prospective study to evaluate the effects of muscle relaxants on the RIAR of otosclerotic ears as well as on the acoustic reflex of individuals with normal middle ear function. Admittance recording during ipsilateral acoustic stimulation was performed in patients undergoing pharmacological treatment for surgical procedures. Fentanyl, propofol, and a muscle relaxant were sequentially administered intravenously. Ipsilateral acoustic reflexes were recorded before and after each drug injection. Three patients were affected from otosclerosis, whereas 14 individuals had normal middle ear function. Moreover, the ipsilateral acoustic reflex obtained in normal subjects after their treatment with muscle relaxants was compared with that of 10 otosclerotic patients who were not treated pharmacologically. Results: The RIAR of three otosclerotic ears was not inhibited by muscle relaxants as well as by fentanyl and propofol. Moreover, muscle relaxants, when administered in normal subjects, always induced the block of the stapedial reflex that was replaced by a reversed reflex strictly similar to the RIAR of the 10 otosclerotic patients not treated pharmacologically. Propofol could also induce, in most of the cases, the reduction and in some occasion even the reversal of the stapedial reflex, whereas fentanyl did not affect it significantly. Conclusion: The RIAR does not appear to be related to the contraction of the middle ear muscles.	Osped Bassini, Dept Otolaryngol, Cinisello Balsamo, MI, Italy; Univ Milano Bicocca, DNTB, Dept Otolaryngol, Monza, Italy; Osped Bassini, Dept Anaesthesiol & Intens Therapy, Cinisello Balsamo, MI, Italy	Garavello, W (reprint author), Osped San Gerardo, Dept Otolaryngol, I-20052 Monza, MI, Italy.						BEL J, 1976, AUDIOLOGY, V15, P128; BENNETT M J, 1979, Scandinavian Audiology, V8, P233, DOI 10.3109/01050397909076325; BORG E, 1972, ACTA OTO-LARYNGOL, V74, P163, DOI 10.3109/00016487209128437; BORG E, 1973, BRAIN RES, V49, P101, DOI 10.1016/0006-8993(73)90404-6; BORG E, 1972, ACTA OTOLARYNGOLOGIC, V304, P5; BOSATRA L, 1975, ACTA OTOLARYNGOL STO, V79, P334; CHASSARD D, 1989, BRIT J ANAESTH, V62, P522, DOI 10.1093/bja/62.5.522; Ciardo A, 2003, ACTA OTO-LARYNGOL, V123, P65, DOI 10.1080/0036554021000028068; DJUPESLAND G, 1965, [No title captured], V4, P34, DOI DOI 10.3109/05384916509070162; FELDMAN AS, 1967, J SPEECH HEAR RES, V10, P616, DOI 10.1044/jshr.1003.616; FELDMAN AS, 1965, J SPEECH HEAR RES, V8, P213, DOI 10.1044/jshr.0803.213; Fisher E, 1999, INFANT YOUNG CHILD, V11, P1, DOI 10.1097/00001163-199901000-00004; Fria T, 1975, Can J Otolaryngol, V4, P695; GREISEN O, 1975, ARCH OTOLARYNGOL, V101, P348; Holst HE, 1971, ACTA OTO-LARYNGOL, V182, P73; HORNSTEN EG, 1986, APPL MICROBIOL BIOT, V24, P117; IRVINE DRF, 1976, AUDIOLOGY, V15, P433; KAMERER DB, 1978, LARYNGOSCOPE, V88, P651; KLOCKHOFF I, 1961, Acta Otolaryngol Suppl, V164, P1; KLOCKHOFF I, 1966, ACTA OTOLARYNGOL S S, V164, P63; Lee C, 2003, PHARMACOL THERAPEUT, V98, P143, DOI 10.1016/S0163-7258(03)00030-5; LEHNHARDT E, 1977, LARYNG RHINOL OTOL V, V56, P683; LIDEN G, 1970, Acta Oto-Laryngologica Supplement, V263, P208; McManus MC, 2001, AM J HEALTH-SYST PH, V58, P2287, DOI 10.1093/ajhp/58.23.2287; MENDELSON ES, 1957, J APPL PHYSIOL, V11, P499; METZ OTTO, 1951, ACTA OTO LARYNGOL, V39, P397, DOI 10.3109/00016485109119270; MISURYA VK, 1976, ACTA OTO-LARYNGOL, V82, P410, DOI 10.3109/00016487609120926; MOLLER AR, 1961, ANN OTO RHINOL LARYN, V70, P735, DOI 10.1177/000348946107000309; MURATA K, 1986, HEARING RES, V23, P169, DOI 10.1016/0378-5955(86)90014-6; Ochi K, 2002, LARYNGOSCOPE, V112, P2225, DOI 10.1097/00005537-200212000-00018; PURDIE JAM, 1993, ANAESTHESIA, V48, P192, DOI 10.1111/j.1365-2044.1993.tb06898.x; RAUCHFUSS A, 1987, LARYNGO RHINO OTOL, V66, P131, DOI 10.1055/s-2007-998620; Rawool VW, 1998, ACTA OTO-LARYNGOL, V118, P307, DOI 10.1080/00016489850183377; Ried E, 2000, Acta Otorrinolaringol Esp, V51, P463; RUSSOLO M, 1977, AUDIOLOGY, V16, P373; RUTH RA, 1982, J APPL PHYSIOL, V52, P416; STACH BA, 1984, SCAND AUDIOL, V13, P93, DOI 10.3109/01050398409043046; TAYLOR P, 1995, PHARM BASIS THERAPY, P222; TERKILDSEN K, 1960, Acta Otolaryngol Suppl, V158, P230; Tuba Z, 2002, CURR MED CHEM, V9, P1507, DOI 10.2174/0929867023369466; VANDENBERGE H, 1990, J ANAT, V170, P99; von Wedel H, 1980, Laryngol Rhinol Otol (Stuttg), V59, P548; YONOVITZ A, 1976, ACTA OTOLARYNGOLOGIC, V8, P1	43	4	4	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0196-0202			EAR HEARING	Ear Hear.	FEB	2005	26	1					96	103		10.1097/00003446-200502000-00009			8	Audiology & Speech-Language Pathology; Otorhinolaryngology	Audiology & Speech-Language Pathology; Otorhinolaryngology	895WM	WOS:000226894700009	15692308				2020-06-30	J	Greenwald, MK				Greenwald, MK			Opioid craving and seeking behavior in physically dependent volunteers: Effects of acute withdrawal and drug reinforcement opportunity	EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY			English	Article							CUE-REACTIVITY; RHESUS-MONKEYS; CIGARETTE AVAILABILITY; SMOKING-BEHAVIOR; MORPHINE; COCAINE; HUMANS; MAINTENANCE; ALCOHOL; PIGEONS	This study examined whether acute opioid withdrawal and drug reinforcement opportunity increase opioid craving and seeking behavior. The author used a 3 X 2 within-subject randomized crossover design to assess craving and operant behavioral effects of 3 pretreatments (naloxone 0.1 mg/70 kg, fentanyl 0.75 mg/70 kg, or saline iv) and drug or money reinforcement opportunity in 8 methadone-maintained volunteers. Each pretreatment was paired with response-contingent (15 X fixed-ratio 100) delivery of drug (fentanyl 1.5 mg/70 kg iv) and money (rated equivalent of fentanyl) in different sessions. Naloxone significantly increased opioid craving, withdrawal signs, and symptoms, but not operant behavior, relative to saline and fentanyl pretreatment. However, drug versus money reinforcement opportunity did not significantly increase opioid craving or seeking behavior.	Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Subst Abuse Res Div, Detroit, MI 48207 USA	Greenwald, MK (reprint author), Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Subst Abuse Res Div, Detroit, MI 48207 USA.	mgreen@med.wayne.edu			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R29 DA11079]		Carter BL, 1999, ADDICTION, V94, P327, DOI 10.1046/j.1360-0443.1999.9433273.x; Carter BL, 2001, EXP CLIN PSYCHOPHARM, V9, P183, DOI 10.1037//1064-1297.9.2.183; Childress A R, 1987, NIDA Res Monogr, V76, P137; De Wit H, 2000, ADDICTION, V95, pS165; DROUNGAS A, 1995, ADDICT BEHAV, V20, P657, DOI 10.1016/0306-4603(95)00029-C; Dyer KR, 1999, CLIN PHARMACOL THER, V65, P685, DOI 10.1016/S0009-9236(99)90090-5; Eissenberg T, 1996, J PHARMACOL EXP THER, V276, P449; First M., 1996, STRUCTURED CLIN INTE; Foltin RW, 1997, EXP CLIN PSYCHOPHARM, V5, P404; Gauthier CA, 1998, PSYCHOPHARMACOLOGY, V137, P67, DOI 10.1007/s002130050594; Gerak LR, 1997, J PHARMACOL EXP THER, V281, P799; GOLDBERG HI, 1976, SEMIN ROENTGENOL, V11, P203, DOI 10.1016/0037-198X(76)90052-3; GOLDBERG SR, 1976, J PHARMACOL EXP THER, V199, P278; GOLDBERG SR, 1969, SCIENCE, V166, P1303; GOLDBERG SR, 1971, J PHARMACOL EXP THER, V176, P464; Greenwald MK, 1996, J PHARMACOL EXP THER, V277, P1228; Greenwald MK, 2002, EXP CLIN PSYCHOPHARM, V10, P39, DOI 10.1037//1064-1297.10.1.39; Greenwald MK, 2002, PSYCHOPHARMACOLOGY, V160, P344, DOI 10.1007/s00213-001-0975-0; Greenwald MK, 1999, DRUG ALCOHOL DEPEN, V56, P191, DOI 10.1016/S0376-8716(99)00032-0; GRIFFITHS RR, 1993, BEHAV PHARMACOL, V4, P3; Gupta AK, 1997, ANESTH ANALG, V85, P817, DOI 10.1097/00000539-199710000-00018; Hutchison KE, 2001, PSYCHOPHARMACOLOGY, V155, P27, DOI 10.1007/s002130000629; Juliano LM, 1998, EXP CLIN PSYCHOPHARM, V6, P45, DOI 10.1037/1064-1297.6.1.45; LEANDER JD, 1978, J PHARMACOL EXP THER, V206, P624; MEYER RE, 1976, ARCH GEN PSYCHIAT, V33, P371; MITCHELL SH, 1994, BEHAV PHARMACOL, V5, P159, DOI 10.1097/00008877-199404000-00007; NIAURA R, 1992, ADDICT BEHAV, V17, P557, DOI 10.1016/0306-4603(92)90065-4; *NIDA COMM EP WORK, 2002, EP TRENDS DRUG AB, V1; O'Malley SS, 2002, PSYCHOPHARMACOLOGY, V160, P19, DOI 10.1007/s002130100919; PAYNE TJ, 1991, ADDICT BEHAV, V16, P467, DOI 10.1016/0306-4603(91)90054-L; PERKINS KA, 1992, PSYCHOPHARMACOLOGY, V106, P53, DOI 10.1007/BF02253588; Preston KL, 1997, ADDICTION, V92, P717, DOI 10.1046/j.1360-0443.1997.9267178.x; REISINE T, 1996, [No title captured], P521; RUBONIS AV, 1994, J STUD ALCOHOL, V55, P487, DOI 10.15288/jsa.1994.55.487; SCHOENER E, 1999, NIDA RES MONOGR, V179, P227; Schuster CR, 1995, EXP CLIN PSYCHOPHARM, V3, P424, DOI 10.1037/1064-1297.3.4.424; SHIPLEY BB, 1967, SHIPLEY I LIVING SCA; THOMPSON T, 1964, PSYCHOPHARMACOLOGIA, V5, P87, DOI 10.1007/BF00413045; TIFFANY ST, 1990, ADDICT BEHAV, V15, P531, DOI 10.1016/0306-4603(90)90053-Z; TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147; TIFFANY ST, 1995, UNPUB DEV HEROIN CRA; Volkow ND, 1999, AM J PSYCHIAT, V156, P19, DOI 10.1176/ajp.156.1.19; Wertz JM, 2001, EXP CLIN PSYCHOPHARM, V9, P3, DOI 10.1037//1064-1297.9.1.3	43	16	16	0	4	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1064-1297	1936-2293		EXP CLIN PSYCHOPHARM	Exp. Clin. Psychopharmacol.	FEB	2005	13	1					3	14		10.1037/1064-1297.13.1.3			12	Psychology, Biological; Psychology, Clinical; Pharmacology & Pharmacy; Psychiatry	Psychology; Pharmacology & Pharmacy; Psychiatry	898UD	WOS:000227100800001	15727498				2020-06-30	J	Kostopanagiotou, G; Markantonis, SL; Polydorou, M; Pandazi, A; Kottis, G				Kostopanagiotou, G; Markantonis, SL; Polydorou, M; Pandazi, A; Kottis, G			Recovery and cognitive function after fentanyl or remifentanil administration for carotid endarterectomy	JOURNAL OF CLINICAL ANESTHESIA			English	Article						carotid endarterectomy; cognitive function; fentanyl; recovery; remifentanil	ELECTIVE INPATIENT SURGERY; NITROUS-OXIDE ANESTHESIA; ARTERY SURGERY; FAST-TRACKING; PHARMACOKINETICS; GI87084B; SEVOFLURANE; DESFLURANE; PROPOFOL; CRITERIA	Study Objective: To compare recovery and restoration of cognitive function after fentanyl-propofol or remifentanil-propofol anesthesia administration in patients undergoing carotid endarterectomy. Design: Randomized, double-blind, prospective study. Setting: Department of Anesthesiology, University hospital. Patients: Seventy patients with ASA physical statuses II and III (53 men and 17 women) undergoing elective carotid endarterectomy. Interventions: Anesthetic technique and drugs were identical in the 2 groups, with the exception of remifentanil and fentanyl administration. Induction of anesthesia was obtained with a bolus dose of propofol (1-2 mg/kg), maintenance was achieved with a propofol infusion according to hemodynamics and nitrous oxide/oxygen (FIO2, 0.50). Muscle relaxation was achieved with rocuronium. The remifentanil group received I mu g/kg of remifentanil as a single dose during the-induction of anesthesia and 0.5 mu g/kg per minute as an infusion throughout the procedure. The fentanyl group received 2 mu g/kg of fentanyl as a single dose during the induction of anesthesia. Measurements: Intraoperative hemodynamic adverse events were recorded. All patients were also evaluated with regard to their recovery and the restoration of their cognitive function, recording the immediate recovery times and using the Aldrete score 15 and 60 minutes after surgery and the Hasegawa scale 6 hours after surgery. For evaluation of postoperative pain, the Numeric Pain Scale (0-10) was used. Main Results: Patients receiving remifentanil had significantly (P <.05) fewer episodes of intraoperative hypertension and needed nitroglycerine administration less frequently (P <.05) than those receiving fentanyl. Immediate recovery was significantly earlier (P <.05) with remifentanil (eye opening, 5.1 +/- 1.3 [remifentanil] and 7.2 +/- 3.7 [fentanyl] minutes; extubation time, 5.4 +/- 1.9 [remifentanil] and 7.8 +/- 4.1 [fentanyl] minutes). The Hasegawa Dementia Scale scores 6 hours after surgery and Aldrete scores 15 and 60 minutes after surgery did not differ significantly between the 2 groups. Pain levels were also similar for patients taking remifentanil and fentanyl. Conclusions: Although intraoperative hemodynamics were better preserved and immediate recovery was more rapid with remifentanil, overall postoperative recovery and restoration of cognitive functions as well as postoperative pain intensity seem to be similar for patients receiving remifentanil and for those receiving fentanyl combined with propofol for carotid endarterectomy operations. (c) 2005 Elsevier Inc. All rights reserved.	Univ Athens, Sch Med, Aretaie Hosp, Dept Anesthesiol 1, Athens 15238, Greece; Univ Athens, Sch Med, Attikon Hosp, Dept Anesthesiol 2, Athens 12462, Greece; Univ Athens, Sch Pharm, Lab Biopharmaceut & Pharmacokinet, GR-15771 Athens, Greece	Kostopanagiotou, G (reprint author), Patima Chalandriou, Athens 15238, Greece.	banesthclin@attikonhospital.gr		Pandazi, Ageliki/0000-0002-6187-6431			ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; BACON R, 1995, LANCET, V345, P133, DOI 10.1016/S0140-6736(95)90103-5; Bekker AY, 2000, ANESTH ANALG, V91, P117, DOI 10.1097/00000539-200007000-00022; BENT JM, 1984, ANAESTHESIA, V39, P19, DOI 10.1111/j.1365-2044.1984.tb09447.x; BENTLEY JB, 1982, ANESTH ANALG, V61, P968; Biedler A, 2000, ANAESTHESIST, V49, P286, DOI 10.1007/s001010050830; Breslin DS, 2001, ANAESTHESIA, V56, P114, DOI 10.1046/j.1365-2044.2001.01795.x; Curb JD, 1999, NEUROLOGY, V52, P971, DOI 10.1212/WNL.52.5.971; Doyle PW, 2001, EUR J ANAESTH, V18, P13, DOI 10.1046/j.1365-2346.2001.00763.x; EGAN TD, 1993, ANESTHESIOLOGY, V79, P881, DOI 10.1097/00000542-199311000-00004; GARRIOCH MA, 1993, BRIT J ANAESTH, V71, P569, DOI 10.1093/bja/71.4.569; GLASS PSA, 1993, ANESTH ANALG, V77, P1031; Hogue CW, 1996, ANESTH ANALG, V83, P279, DOI 10.1097/00000539-199608000-00014; ISHIZAKI T, 1980, EUR J CLIN PHARMACOL, V18, P407, DOI 10.1007/BF00636794; Jellish WS, 2003, J NEUROSURG ANESTH, V15, P176, DOI 10.1097/00008506-200307000-00004; Larsen B, 2000, ANESTH ANALG, V90, P168, DOI 10.1097/00000539-200001000-00035; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; PEREIRA IT, 1993, PAIN, V53, P341, DOI 10.1016/0304-3959(93)90230-M; Schuttler J, 1997, ANAESTHESIA, V52, P307, DOI 10.1111/j.1365-2044.1997.24-az0051.x; Thompson JP, 1996, BRIT J ANAESTH, V76, P341; WESTMORELAND CL, 1993, ANESTHESIOLOGY, V79, P893, DOI 10.1097/00000542-199311000-00005; White PF, 1999, J CLIN ANESTH, V11, P78; White PF, 1999, ANESTH ANALG, V88, P1069, DOI 10.1097/00000539-199905000-00018; Wilhelm W, 2001, BRIT J ANAESTH, V86, P44, DOI 10.1093/bja/86.1.44	25	12	16	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	FEB	2005	17	1					16	20		10.1016/j.jclinane.2004.03.008			5	Anesthesiology	Anesthesiology	906JM	WOS:000227637000004	15721724				2020-06-30	J	Overly, FL; Wright, RO; Connor, FA; Jay, GD; Linakis, DG				Overly, FL; Wright, RO; Connor, FA; Jay, GD; Linakis, DG			Bispectral analysis during deep sedation of pediatric oral surgery patients	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article; Proceedings Paper	Annual Meeting of the Pediatric-Academic-Societies/Society-for-Pediatric-Research	MAY 03-06, 2003	SEATTLE, WA	Pediat Acad Soc, Amer Pediat Soc, Soc Pediat Res, Ambulatory Pediat Assoc, Tulane Univ Hlth Sci Ctr, Ctr Cont Educ			INDEX; PROPOFOL; ANESTHESIA; SEVOFLURANE; EMERGENCE; INFANTS	Purpose: Bispectral (BIS) analysis uses electroencephalogram information from a forehead electrode to calculate an index score (0 to 100; 0 = coma; 90 to 100 = awake). This index score correlates with the level of alertness in anesthetized patients. Classically, sedation has been monitored with clinical sedation scales such as the Observer's Assessment of Alertness Sedation Scale (OAA/S): Modified Ramsev, Scale. or a Visual Analog Scale (VAS). Our objective was to determine the correlation between clinical sedation scales and BIS index in pediatric patients undergoing sedation in an outpatient oral surgery surgery setting. Materials and Methods: Prospective cohort study of patients aged 2 to 17 years undergoing outpatient oral surgery office. Sedation was perfonned in the customary manner with the addition of BIS monitoring. Three clinical sedation scores (OAA/S: 5 to 1; 5 = awake, I = unresponsive; Modified Ramsey I to 6; 1-2 = awake, 6 = unresponsive; VAS: 0 to 10; 0 = awake.. 10 = unresponsive were assigned every 5 minutes by an investigator blinded to the BIS index. Data were analyzed using a repeated measures linear regression model. Results: Sixteen subjects undergoing oral surgery, ages 4.5 years to 17 years: were enrolled, mean age 12.6 years +/- 4.3 years (standard deviation). Patients received methohexital in addition to I or more of the following: nitrous oxide, fentanyl, or midazolam. The results Of the longitudinal regression analysis showed a highly significant association between the sedation scales and the BIS index. Conclusion: The BIS monitor may be a useful adjunct in monitoring pediatric patients receiving sedation in the outpatient setting. (C) 2005 American Association of Oral and and Maxillofacial Surgeons.	Rhode Isl Hosp, Hasboro Childrens Hosp, Simulat Ctr, Providence, RI 02903 USA; Brown Med Sch, Providence, RI USA; Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Rhode Isl Hosp, Div Dent Oral & Maxillofacial Surg, Providence, RI USA; Brown Univ, Providence, RI 02912 USA; Rhode Isl Hosp, Dept Emergency Med, Providence, RI USA	Overly, FL (reprint author), Rhode Isl Hosp, Hasboro Childrens Hosp, Simulat Ctr, Potter 1,593 Eddy St, Providence, RI 02903 USA.	foverly@lifespan.org	Jay, Gregory/C-6346-2013	Jay, Gregory/0000-0003-1517-8488			*AAPD, 1998, PEDIAT DENT, V20, P47; *AM AC DRUGS, 1992, PEDIATRICS, V86, P1110; BANNISTER C, 2000, ANESTHESIOL NEWS, V26, P10; BLACK S, 2000, ANESTHESIA, P1329; Bower AL, 2000, GASTROINTEST ENDOSC, V52, P192, DOI 10.1067/mge.2000.107284; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Davidson AJ, 2001, ANESTH ANALG, V93, P326, DOI 10.1097/00000539-200108000-00017; Denman WT, 2000, ANESTH ANALG, V90, P872, DOI 10.1213/00000539-200004000-00018; Doi M, 1997, BRIT J ANAESTH, V78, P180; Gill M, 2003, ANN EMERG MED, V41, P234, DOI 10.1067/mem.2003.53; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; Laussen PC, 2000, ANESTH ANALG, V90, pU138; Liu J, 1997, ANESTH ANALG, V84, P185, DOI 10.1097/00000539-199701000-00033; REGO MMS, 2000, ANESTHESIA, P1460; Religa Zdzislaw Christopher, 2002, Pediatr Dent, V24, P221; Sandler NA, 2000, J ORAL MAXIL SURG, V58, P364, DOI 10.1016/S0278-2391(00)90911-X; Sandler NA, 2001, J ORAL MAXIL SURG, V59, P603, DOI 10.1053/joms.2001.23366; SCHER M, 1999, PEDIAT NEUROLOGY, P142; SIGL JC, 1994, J CLIN MONITOR, V10, P392, DOI 10.1007/BF01618421; Song DJ, 1998, ANESTH ANALG, V87, P1245, DOI 10.1097/00000539-199812000-00006; Strachan AN, 2000, BRIT J ANAESTH, V84, P489; Yli-Hankala A, 1999, ACTA ANAESTH SCAND, V43, P545, DOI 10.1034/j.1399-6576.1999.430510.x	22	17	21	1	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	FEB	2005	63	2					215	219		10.1016/j.joms.2004.07.013			5	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	893GC	WOS:000226706300009	15690290				2020-06-30	J	Furst, S; Riba, P; Friedmann, T; Timar, J; Al-Khrasani, M; Obara, I; Makuch, W; Spetea, M; Schutz, J; Przewlocki, R; Przewlocka, B; Schmidhammer, H				Furst, S; Riba, P; Friedmann, T; Timar, J; Al-Khrasani, M; Obara, I; Makuch, W; Spetea, M; Schutz, J; Przewlocki, R; Przewlocka, B; Schmidhammer, H			Peripheral versus central antinociceptive actions of 6-amino acid-substituted derivatives of 14-O-methyloxymorphone in acute and inflammatory pain in the rat	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article; Proceedings Paper	6th European Opioid ConferenceEACTS Symposium for the Future of Cardiac Surgery	2004JUL 01-02, 2004	Visegrad, HUNGARYFrankfurt, GERMANY	EACTS			OPIOID RECEPTOR AGONISTS; HIGHLY POTENT; BIOLOGICAL EVALUATION; SIGNAL-TRANSDUCTION; MORPHINE ANALGESIA; SYSTEMIC MORPHINE; MODEL; 14-ALKOXYMORPHINANS; 14-METHOXYMETOPON; PHARMACOLOGY	Opioid analgesics with restricted access to the central nervous system represent a new approach to the treatment of severe pain with an improved safety profile. The objective of this study was to investigate the peripheral and central components of the antinociceptive actions of the 6-amino acid conjugates ( glycine, alanine, and phenylalanine) of 14-O-methyloxymorphone. Their antinociceptive activities were compared with those of the centrally penetrating mu-opioid agonists morphine, fentanyl, and 14-O-methyloxymorphone. In the tail-flick test in rats, the 6-amino acid conjugates were 45- to 1170-fold more potent than morphine after i.c.v. administration and 19- to 209-fold after s.c. administration. They showed potencies similar to fentanyl after s.c. administration and were more potent after i.c.v. application. The time course of action was different between s.c. and i.c.v. administration, with significant long-lasting effects after i.c.v. administration. Systemic administration of the peripherally selective opioid antagonist naloxone methiodide antagonized the effects after s.c. but not after i.c.v. administration in the tail-flick test. Subcutaneous 6-amino acid derivatives also elicited antihyperalgesic effects in the formalin test in rats, which were reversed by systemically administered naloxone methiodide. Although morphine exerts its analgesic effects by central and peripheral mechanisms, the investigated new opioids interact primarily with peripheral opioid receptors after s.c. administration. The present data indicate that the 6-amino acid conjugates of 14-O-methyloxymorphone have limited access to the central nervous system and can mediate antinociception at peripheral sites. Also, they might find clinical application when the central actions of opioids are unwanted.	Semmelweis Univ, Fac Med, Dept Pharmacol & Pharmacotherapy, H-1445 Budapest, Hungary; Hungarian Acad Sci, SE Grp Neuropsychopharmacol, Budapest, Hungary; Polish Acad Sci, Inst Pharmacol, Dept Mol Neuropharmacol, Krakow, Poland; Univ Innsbruck, Inst Pharm, Dept Pharmaceut Chem, A-6020 Innsbruck, Austria; Univ Innsbruck, Ctr Mol Biosci Innsbruck, A-6020 Innsbruck, Austria	Furst, S (reprint author), Semmelweis Univ, Fac Med, Dept Pharmacol & Pharmacotherapy, Nagyvarad Ter 4,POB 370, H-1445 Budapest, Hungary.	furzsu@pharma.sote.hu	Riba, Pal/K-5007-2017	Riba, Pal/0000-0002-7886-4816; Schmidhammer, Helmut/0000-0001-8752-5050; Makuch, Wioletta/0000-0002-1579-3643; Spetea, Mariana/0000-0002-2379-5358			ABBOTT FV, 1988, LIFE SCI, V43, P1685, DOI 10.1016/0024-3205(88)90479-1; Aceto MD, 1997, EUR J PHARMACOL, V338, P215, DOI 10.1016/S0014-2999(97)81924-3; BOTROS S, 1989, J MED CHEM, V32, P2068, DOI 10.1021/jm00129a009; BROWN DR, 1985, NEUROPHARMACOLOGY, V24, P181, DOI 10.1016/0028-3908(85)90072-3; DESMEULES JA, 1993, PAIN, V53, P277, DOI 10.1016/0304-3959(93)90224-D; Dorazil-Dudzik M, 2004, ANESTH ANALG, V98, P1566; FIELDS HL, 1980, NATURE, V284, P351, DOI 10.1038/284351a0; FRANCES B, 1992, J PHARMACOL EXP THER, V262, P25; Furst S, 1999, BRAIN RES BULL, V48, P129, DOI 10.1016/S0361-9230(98)00159-2; Furst S., 1995, CURR MED CHEM, V1, P423; FURST Z, 1993, EUR J PHARMACOL, V236, P209, DOI 10.1016/0014-2999(93)90591-5; GUTSTEIN HB, 2001, GOODMAN GILMANS PHAR, P569; Herz A., 1971, ADV DRUG RES, V6, P79; KAYSER V, 1991, BRAIN RES, V560, P237, DOI 10.1016/0006-8993(91)91238-V; King MA, 2003, EUR J PHARMACOL, V459, P203, DOI 10.1016/S0014-2999(02)02821-2; KNOLL J, 1975, J PHARM PHARMACOL, V27, P99, DOI 10.1111/j.2042-7158.1975.tb09416.x; Kolesnikov YA, 1996, J PHARMACOL EXP THER, V279, P502; Mika J, 2001, EUR J PHARMACOL, V415, P31, DOI 10.1016/S0014-2999(01)00814-7; MILLAN MJ, 1987, J NEUROSCI, V7, P77; Nicholson B, 2003, DRUGS, V63, P17, DOI 10.2165/00003495-200363010-00002; Obara I, 2004, NEUROSCI LETT, V360, P85, DOI 10.1016/j.neulet.2004.01.056; Perrot S, 2001, ANESTHESIOLOGY, V94, P870, DOI 10.1097/00000542-200105000-00027; PORTOGHESE PS, 1995, J MED CHEM, V38, P402, DOI 10.1021/jm00003a002; Przewlocki R, 2001, EUR J PHARMACOL, V429, P79, DOI 10.1016/S0014-2999(01)01308-5; Quock RM, 1999, PHARMACOL REV, V51, P503; Reichert JA, 2001, PAIN, V89, P221, DOI 10.1016/S0304-3959(00)00365-1; SCHAFER M, 1995, EUR J PHARMACOL, V279, P165, DOI 10.1016/0014-2999(95)00150-J; SCHMIDHAMMER H, 1984, J MED CHEM, V27, P1575, DOI 10.1021/jm00378a009; SCHMIDHAMMER H, 1990, HELV CHIM ACTA, V73, P1784, DOI 10.1002/hlca.19900730623; Schmidhammer H, 1993, CURR TOP MED CHEM, V1, P261; Schutz J, 2003, HELV CHIM ACTA, V86, P2142, DOI 10.1002/hlca.200390171; Shannon HE, 2002, NEUROPHARMACOLOGY, V42, P253, DOI 10.1016/S0028-3908(01)00173-3; Spetea M, 2004, EUR J PHARMACOL, V483, P301, DOI 10.1016/j.ejphar.2003.10.049; Spetea M, 2003, EUR J NEUROSCI, V18, P290, DOI 10.1046/j.1460-9568.2003.02744.x; Stein C, 1996, J CLIN INVEST, V98, P793, DOI 10.1172/JCI118852; Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908; STEIN C, 1995, ANN MED, V27, P219, DOI 10.3109/07853899509031962; STEIN C, 1989, J PHARMACOL EXP THER, V248, P1269; Tegeder I, 2003, BRAIN, V126, P1092, DOI 10.1093/brain/awg115; Zernig G, 2000, LIFE SCI, V66, P1871, DOI 10.1016/S0024-3205(00)00510-5	40	59	59	0	2	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	FEB	2005	312	2					609	618		10.1124/jpet.104.075176			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	888IJ	WOS:000226367100022	15383636				2020-06-30	J	Robertson, SA; Taylor, PM; Sear, JW; Keuhnel, G				Robertson, SA; Taylor, PM; Sear, JW; Keuhnel, G			Relationship between plasma concentrations and analgesia after intravenous fentanyl and disposition after other routes of administration in cats	JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS			English	Article; Proceedings Paper	8th World Congress of Veterinary Anesthesia	SEP, 2003	Knoxville, TN				LECITHIN ORGANOGEL PLO; INTRANASAL FENTANYL; HEALTHY CATS; PHARMACOKINETICS; BIOAVAILABILITY; ALFENTANIL; PAIN; DOGS; OVARIOHYSTERECTOMY; ONYCHECTOMY	Data allowing rational use of analgesics in cats are limited. Pharmacokinetics and pharmacodynamics of fentanyl were studied in cats. Plasma fentanyl concentrations were measured using radioimmunoassay in a crossover study in six cats after 10 mug/kg (i.v.) or by application of fentanyl in pluronic lecithin organogel (PLO) to the inner ear pinna. On a separate occasion thermal thresholds were measured after i.v. fentanyl (10 mug/kg) or saline. Plasma fentanyl concentrations reached 4.7-8.31 ng/mL 2 min after i.v. administration and were undetectable after 95 min. Fentanyl was not detected in plasma at any time after PLO use. Thermal thresholds did not change following saline administration but were increased above baseline from 5 to 110 min after i.v. fentanyl. In this model a plasma concentration of >1.07 ng/mL was required to provide analgesia. Plasma concentrations were measured in additional cats after intranasal or oral dosing (2 mug/kg) and after 30 mug/kg in PLO gel. After oral and nasal dosing, C-max values were 0.96 and 1.48 ng/mL at 5 and 2 min, respectively. Plasma fentanyl was not detected after application of the higher dose of fentanyl in PLO.	Univ Florida, Coll Vet Med, Dept Large Anim Clin Sci, Gainesville, FL 32610 USA; Taylor Monroe, Little Downham, Ely, England; Univ Oxford, Nuffield Dept Anaesthet, Oxford, England	Robertson, SA (reprint author), Univ Florida, Coll Vet Med, Dept Large Anim Clin Sci, POB 100136, Gainesville, FL 32610 USA.	robertsons@mail.vetmed.ufl.edu	Taylor, Polly/M-3239-2015	Taylor, Polly/0000-0003-1322-3468			ARNDT JO, 1984, ANESTHESIOLOGY, V61, P355, DOI 10.1097/00000542-198410000-00001; BENET LZ, 1979, J PHARM SCI, V68, P1071, DOI 10.1002/jps.2600680845; Ciribassi J, 2003, AM J VET RES, V64, P994, DOI 10.2460/ajvr.2003.64.994; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Dixon MJ, 2002, RES VET SCI, V72, P205, DOI 10.1053/rvsc.2001.0543; Dsida RM, 1998, ANESTH ANALG, V86, P66, DOI 10.1097/00000539-199801000-00013; Egger CM, 2003, VET ANAESTH ANALG, V30, P229, DOI 10.1046/j.1467-2995.2003.00109.x; Franks JN, 2000, J AM VET MED ASSOC, V217, P1013, DOI 10.2460/javma.2000.217.1013; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Gellasch KL, 2002, J AM VET MED ASSOC, V220, P1020, DOI 10.2460/javma.2002.220.1020; Glerum LE, 2001, VET SURG, V30, P351, DOI 10.1053/jvet.2001.24387; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Hoffman SB, 2002, J VET PHARMACOL THER, V25, P189, DOI 10.1046/j.1365-2885.2002.00405.x; KROTSCHECK U, 2003, J VET INTERNAL MED, V17, P408; Kyles AE, 1996, AM J VET RES, V57, P715; Lascelles BDX, 1999, VET REC, V145, P601, DOI 10.1136/vr.145.21.601; Lee DD, 2000, AM J VET RES, V61, P672, DOI 10.2460/ajvr.2000.61.672; LEHMANN K A, 1988, Acta Anaesthesiologica Belgica, V39, P11; Marks SL, 2003, J AM ANIM HOSP ASSOC, V39, P19, DOI 10.5326/0390019; Metz C, 2000, ANESTHESIOLOGY, V92, P1559, DOI 10.1097/00000542-200006000-00012; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; REILLY CS, 1985, ANAESTHESIA, V40, P837, DOI 10.1111/j.1365-2044.1985.tb11043.x; Robertson SA, 2003, VET REC, V152, P675, DOI 10.1136/vr.152.22.675; ScherkNixon M, 1996, J AM ANIM HOSP ASSOC, V32, P19, DOI 10.5326/15473317-32-1-19; SCHUTTLER J, 1984, ANESTHESIOLOGY, V61, P315, DOI 10.1097/00000542-198409000-00010; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; SEAR JW, 2000, BRIT J ANAESTH, V84, P285; Sharar S. R., 2002, Journal of Burn Care & Rehabilitation, V23, P27, DOI 10.1097/00004630-200201000-00006; SPINK RR, 1966, AM J VET RES, V27, P1041; STREISAND JB, 1995, ANESTHESIOLOGY, V82, P759, DOI 10.1097/00000542-199503000-00018; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Waterman AE, 1990, J ASS VET ANAESTH, V17, P20; Wheeler M, 2002, PAEDIATR ANAESTH, V12, P594, DOI 10.1046/j.1460-9592.2002.00949.x; WILLIMANN H, 1992, J PHARM SCI, V81, P871, DOI 10.1002/jps.2600810906; Willis-Goulet HS, 2003, VET DERMATOL, V14, P83, DOI 10.1046/j.1365-3164.2003.00331.x; Wong P, 2003, ANAESTHESIA, V58, P818, DOI 10.1046/j.1365-2044.2003.03295_24.x	36	35	35	0	6	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0140-7783			J VET PHARMACOL THER	J. Vet. Pharmacol. Ther.	FEB	2005	28	1					87	93		10.1111/j.1365-2885.2004.00628.x			7	Pharmacology & Pharmacy; Veterinary Sciences	Pharmacology & Pharmacy; Veterinary Sciences	899GM	WOS:000227132900012	15720520				2020-06-30	J	Yegin, A; Sanli, S; Hadimioglu, N; Sahin, N				Yegin, A; Sanli, S; Hadimioglu, N; Sahin, N			Anesthesia in caudal regression syndrome	PEDIATRIC ANESTHESIA			English	Letter									Akdeniz Univ, Dept Anesthesiol, TR-07070 Antalya, Turkey	Yegin, A (reprint author), Akdeniz Univ, Dept Anesthesiol, Dumlupinar Bulvari, TR-07070 Antalya, Turkey.	ayegin@akdeniz.edu.tr	Sahin, Nursel/F-5388-2016; yegin, arif/C-2275-2016				Adra A, 1994, Obstet Gynecol Surv, V49, P508, DOI 10.1097/00006254-199407000-00028; Cama A, 1996, EUR J PEDIATR SURG, V6, P44; Jaffe R, 1991, FETUS SPINAL ANOMALI, V7561, P1; JONES KL, 1998, SMITHS RECOGNIZABLE, P635; PANG D, 1993, NEUROSURGERY, V32, P755, DOI 10.1227/00006123-199305000-00009; REVES JG, 1994, ANESTHESIA, P247	6	1	1	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	FEB	2005	15	2					174	175		10.1111/j.1460-9592.2005.01509.x			4	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	891GW	WOS:000226570300021	15675942				2020-06-30	J	Breekveldt-Postma, NS; Penning-van Beest, FJA; Herings, RMC				Breekveldt-Postma, NS; Penning-van Beest, FJA; Herings, RMC			Utilisation pattern of fentanyl transdermal system in The Netherlands	PHARMACOEPIDEMIOLOGY AND DRUG SAFETY			English	Article						TTS fentanyl; utilisation pattern; prescription database	CHRONIC NONMALIGNANT PAIN; CHRONIC NONCANCER PAIN; RELEASE ORAL MORPHINE; QUALITY-OF-LIFE; CANCER PAIN; TTS-FENTANYL; EFFICACY; OPIOIDS; PHARMACOKINETICS; THERAPY	Purpose To describe the utilisation pattern of TTS fentanyl in daily practice. Methods A retrospective cohort study was performed with data from the Dutch PHARMO system, including medication and hospital admission records of 850 000 inhabitants of 25 Dutch cities. New starters of TTS fentanyl with at least two consecutive prescriptions in the period of I January 1996 through 31 December 2001 were included in the study cohort. Patients were distinguished in having non-cancer or cancer pain. Results About 61% of the patients suffered from non-cancer pain and 60% used other opioids before start of TTS fentanyl. The majority of the patients used other pain medication during the first treatment episode. Most patients (74%) started treatment with the lowest dose of TTS fentanyl (25 mug/hour), patients with cancer pain more often started with higher doses. About half of the patients changed type of patch during the first treatment episode, 80% of these patients had an increase in dose of TTS fentanyl. Fifty percent of all patients had a first treatment episode of less than 2 months and more than one third did not renew their prescription within two months. The median number of days of use per patch was 2.2 days for all patients. Conclusions The use of TTS fentanyl is limited to a short period of time for a substantial percentage of patients starting treatment. The median duration of use per TTS fentanyl patch i.e. 2.2 days, was lower than the 3 days application period recommended in the summary of product characteristics. Copyright (C) 2004 John Wiley Sons, Ltd.	PHARMO Inst, NL-3508 AE Utrecht, Netherlands; Univ Utrecht, UIPS, Dept Pharmacoepidmiol & Therapy, NL-3508 TB Utrecht, Netherlands	Breekveldt-Postma, NS (reprint author), PHARMO Inst, POB 85222, NL-3508 AE Utrecht, Netherlands.	pharmo@pharmo.nl					Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Bell JR, 1997, MED J AUSTRALIA, V167, P26, DOI 10.5694/j.1326-5377.1997.tb138759.x; Dellemijn PLI, 1998, J PAIN SYMPTOM MANAG, V16, P220, DOI 10.1016/S0885-3924(98)00070-0; Dellemijn PLI, 2001, EUR J PAIN-LONDON, V5, P333, DOI 10.1053/eujp.2001.0240; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Herings RMC, 1993, THESIS UTRECHT U; Joranson DE, 2000, JAMA-J AM MED ASSOC, V283, P1710, DOI 10.1001/jama.283.13.1710; Korte W, 1996, J PAIN SYMPTOM MANAG, V11, P139, DOI 10.1016/0885-3924(95)00162-X; Malkin JD, 2002, J MANAGE CARE PHARM, V8, P132; Menten J, 2002, CURR MED RES OPIN, V18, P488, DOI 10.1185/030079902125001272; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Mystakidou K, 2002, ONCOLOGY-BASEL, V62, P9, DOI 10.1159/000048241; Otis JA, 1999, CONSULT PHARM SA, V14, P19; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; PAYNE R, 1995, ANTI-CANCER DRUG, V6, P50, DOI 10.1097/00001813-199504003-00009; Portenoy RK, 1996, J PAIN SYMPTOM MANAG, V11, P203, DOI 10.1016/0885-3924(95)00187-5; Radbruch L, 2001, PALLIATIVE MED, V15, P309, DOI 10.1191/026921601678320296; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; SOUTHAM MA, 1995, ANTI-CANCER DRUG, V6, P29, DOI 10.1097/00001813-199504003-00005; World Health Organization, 1996, CANC PAIN REL; Zagari MJ, 1996, PHARMACOECONOMICS, V10, P356, DOI 10.2165/00019053-199610040-00005	24	5	5	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-8569	1099-1557		PHARMACOEPIDEM DR S	Pharmacoepidemiol. Drug Saf.	FEB	2005	14	2					129	134		10.1002/pds.1008			6	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	896IR	WOS:000226928300008	15386723				2020-06-30	J	Gaitan, G; Herrero, JF				Gaitan, G; Herrero, JF			Subanalgesic doses of dexketoprofen and HCT-2037 (nitrodexketoprofen) enhance fentanyl antinociception in monoarthritic rats	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						pain; analgesia; spinal cord; opioids; non-steroidal antiinflammatory drugs; nitric oxide; wind-up	SPINAL-CORD; WIND-UP; NOCICEPTIVE REFLEXES; WITHDRAWAL REFLEXES; NITRIC-OXIDE; MORPHINE; KETOROLAC; INHIBITORS; PAIN; NITROPARACETAMOL	Subanalgesic doses of the non-steroidal antiinflammatory drugs (NSAID) dexketoprofen trometamol and nitroparacetamol (NCX-701) enhance mu-opiate fentanyl effect in acute nociception. It is not known if a similar combination of drugs is effective in situations of spinal cord sensitization. The aim of this study was to assess if the enhancement of fentanyl antinociception can be observed in carrageenan-induced monoarthritis, when combined with dexketoprofen (DKT) or nitrodexketoprofen (HCT-2037). Withdrawal reflexes were recorded as single motor units in male Wistar rats anesthetized with alpha-chloralose. Fentanyl was studied alone and in the presence of 0.4, 0.8 mumol/kg of DKT or 0.3 mumol/kg of HCT-2037. In responses to noxious mechanical stimulation, the ID50 of fentanyl was enhanced twofold by 0.8 mumol/kg DKT and more than fourfold by HCT-2037 and no significant recovery was observed 45 min later. DKT 0.4 mumol/kg was, however, very little effective. The opioid antagonist naloxone did not reverse the effect. Enhancement of fentanyl effect on wind-up was only observed with HCT-2037 but not with DKT. We conclude that the combined administration of subanalgesic doses of dexketoprofen derivatives, specially its nitroderivative, and the mu-opiate fentanyl is an effective antinociceptive therapy in situations of articular inflammation involving a naloxone-independent mechanism of action. (C) 2004 Elsevier Inc. All rights reserved.	Univ Alcala de Henares, Fac Med, Dept Fisiol, Madrid 28871, Spain	Herrero, JF (reprint author), Univ Alcala de Henares, Fac Med, Dept Fisiol, Campus Univ, Madrid 28871, Spain.	juanf.herrero@uah.es		Herrero, Juan F./0000-0003-1986-3482			BEAVER WT, 1984, AM J MED, V77, P38, DOI 10.1016/S0002-9343(84)80101-1; BOSEK V, 1994, CLIN J PAIN, V10, P314, DOI 10.1097/00002508-199412000-00012; DUARTE IDG, 1992, EUR J PHARMACOL, V217, P225, DOI 10.1016/0014-2999(92)90881-4; Gaitan G, 2003, EUR J PHARMACOL, V481, P181, DOI 10.1016/j.ejphar.2003.09.024; GAITAN G, 2004, 4 FOR EUR NEUR LISB; GILLIES GWA, 1987, ANAESTHESIA, V42, P727, DOI 10.1111/j.1365-2044.1987.tb05317.x; GRANADOSSOTO V, 1995, EUR J PHARMACOL, V277, P281, DOI 10.1016/0014-2999(95)00123-3; Herrero JF, 2000, PROG NEUROBIOL, V61, P169, DOI 10.1016/S0301-0082(99)00051-9; Herrero JF, 2003, CNS DRUG REV, V9, P227; HERRERO JF, 1991, BRIT J PHARMACOL, V104, P166, DOI 10.1111/j.1476-5381.1991.tb12402.x; LAITINEN J, 1992, ANESTHESIOLOGY, V76, P194, DOI 10.1097/00000542-199202000-00006; MALMBERG AB, 1993, ANESTHESIOLOGY, V79, P270, DOI 10.1097/00000542-199308000-00012; MAVES TJ, 1994, ANESTHESIOLOGY, V80, P1094, DOI 10.1097/00000542-199405000-00018; Mazario J, 2001, NEUROPHARMACOLOGY, V40, P937, DOI 10.1016/S0028-3908(01)00020-X; Mazario J, 1999, BRAIN RES, V816, P512, DOI 10.1016/S0006-8993(98)01203-7; Melis M, 2000, EUR J PHARMACOL, V387, pR1, DOI 10.1016/S0014-2999(99)00799-2; Romero-Sandoval EA, 2002, BRIT J PHARMACOL, V135, P1556, DOI 10.1038/sj.bjp.0704589; Solano R, 1997, J NEUROSCI METH, V73, P135, DOI 10.1016/S0165-0270(96)02220-0; Taylor J, 1998, EUR J PHARMACOL, V351, P39, DOI 10.1016/S0014-2999(98)00298-2	19	9	9	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	FEB	2005	80	2					327	332		10.1016/j.pbb.2004.12.004			6	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	897GN	WOS:000226992100013	15680185				2020-06-30	J	Ishihara, C; Konishi, H; Chiba, M; Minouchi, T; Endo, Y; Yamaji, A				Ishihara, C; Konishi, H; Chiba, M; Minouchi, T; Endo, Y; Yamaji, A			Withdrawal symptom after discontinuation of transdermal fentanyl at a daily dose of 0.6 mg	PHARMACY WORLD & SCIENCE			English	Article						pain control; transdermal fentanyl; withdrawal symptom	MORPHINE; PAIN	Neurophysiologic disorders developed in three patients after discontinuation of transdermal fentanyl (TDF) at a daily dose of 0.6 mg (2.5 mg per a patch), although direct removal of a 2.5 mg patch is permitted by the manufacturer as the formulation has the lowest fentanyl content among all the commercially available patch formulations. These observations indicate that the discontinuation of TDF carries a risk for developing withdrawal symptoms even when using a 2.5 mg patch. To avoid such adverse events, we considered the necessity of gradual reduction in the daily fentanyl requirements. For this purpose, we covered part of the application surface of the patch with an insulating tape, and then increased the covered area in a stepwise manner. There were no apparent withdrawal signs during the procedure described above.	Shiga Univ Med Sci, Dept Hosp Pharm, Otsu, Shiga 52021, Japan; Shiga Univ Med Sci, Dept Surg, Otsu, Shiga 52021, Japan	Konishi, H (reprint author), Shiga Univ Med Sci, Dept Hosp Pharm, Otsu, Shiga 52021, Japan.	konishi@belle.shiga-med.ac.jp					BOVILL JG, 1987, DRUGS, V33, P520, DOI 10.2165/00003495-198733050-00006; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; *JANSS PHARM KK, PROD INF; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; LEHMANN KA, 1992, J PAIN SYMPTOM MANAG, V7, P8; MATOBA M, 2004, RECIPE CANC PAIN MAN; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154	8	2	3	0	2	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0928-1231	1573-739X		PHARM WORLD SCI	Pharm. World Sci.	FEB	2005	27	1					13	15		10.1007/s11096-004-2271-7			3	Pharmacology & Pharmacy	Pharmacology & Pharmacy	899PI	WOS:000227156500004	15861929				2020-06-30	J	Lalley, PM				Lalley, PM			D-1-dopamine receptor blockade slows respiratory rhythm and enhances opioid-mediated depression	RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY			English	Article						dopaminergic respiratory modulation; expiratory neurons; fentanyl; phrenic nerve activity; SCH-23390	NEURONS; NALOXONE; NETWORK; SYSTEM; OUTPUT; CO2	Previous studies indicate that dopamine modulates the excitability of the respiratory network and its susceptibility to depression by exogenous opioids, but the roles of different subtypes of dopamine receptor in these processes are still uncertain. In this study, D-1-dopamine receptor (D1R) involvement in dopaminergic modulation of respiratory rhythm and mu-opioid receptor mediated depression were investigated in pentobarbital-anesthetized cats. Intravenous administration of the D1R blocker SCH-23390 (100-200 mug/kg) slowed phrenic nerve and expiratory neuron respiratory rhythms by prolonging the inspiratory and expiratory phases. Phrenic nerve discharge intensity also increased more gradually during the inspiratory phase. SCH-23390 (150 mug/kg) also enhanced dose-dependent depression of phrenic nerve and expiratory neuron excitability, as well as rhythm disturbances, produced by the mu-opioid receptor agonist fentanyl (2-20 mug/kg, i.v.). The results suggest an important role for the D-1-subtype of receptor in respiratory rhythm modulation, and indicate that this type of receptor participates in dopaminergic compensatory mechanisms directed against opioid-mediated network depression. (C) 2004 Elsevier B.V. All rights reserved.	Univ Wisconsin, Dept Physiol, Med Sci Ctr, Madison, WI 53706 USA	Lalley, PM (reprint author), Univ Wisconsin, Dept Physiol, Med Sci Ctr, 1300 Univ Ave,127 Serv Mem Inst, Madison, WI 53706 USA.	pmalley@facstaff.wisc.edu			NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL65526]		BALDESSARINI RJ, 2001, GOODMAN GILMANS PHAR, P485; BALLANTYNE D, 1986, J PHYSIOL-LONDON, V370, P433, DOI 10.1113/jphysiol.1986.sp015943; Ballantyne D, 2000, J PHYSIOL-LONDON, V525, P567, DOI 10.1111/j.1469-7793.2000.00567.x; Ballanyi K, 1997, J PHYSIOL-LONDON, V504, P127, DOI 10.1111/j.1469-7793.1997.127bf.x; BIANCHI AL, 1995, PHYSIOL REV, V75, P1, DOI 10.1152/physrev.1995.75.1.1; Corne S, 2000, J APPL PHYSIOL, V89, P481; de la Fuente-Fernandez- R, 2002, TRENDS NEUROSCI, V25, P302, DOI 10.1016/S0166-2236(02)02181-1; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; FALLERT M, 1979, ARCH ITAL BIOL, V117, P1; Johnson SM, 1996, J APPL PHYSIOL, V80, P2120; Lalley PM, 1997, J NEUROPHYSIOL, V77, P1119; Lalley PM, 2004, RESP PHYSIOL NEUROBI, V139, P247, DOI 10.1016/j.resp.2003.10.007; Lalley PM, 2003, AM J PHYSIOL-REG I, V285, pR1287, DOI 10.1152/ajpregu.00199.2003; LAUBIE M, 1986, EUR J PHARMACOL, V122, P301, DOI 10.1016/0014-2999(86)90410-3; LAWSON EE, 1979, J APPL PHYSIOL, V47, P1105; LONG S, 1986, PROG NEUROBIOL, V27, P101, DOI 10.1016/0301-0082(86)90007-9; LONG WA, 1983, RESP PHYSIOL, V51, P119, DOI 10.1016/0034-5687(83)90106-8; LUNDBERG D, 1979, EUR J PHARMACOL, V54, P153, DOI 10.1016/0014-2999(79)90417-5; LUNDBERG D, 1982, ACTA PHYSIOL SCAND, V114, P81, DOI 10.1111/j.1748-1716.1982.tb06955.x; MCGILLIARD KL, 1979, EUR J PHARMACOL, V54, P61, DOI 10.1016/0014-2999(79)90408-4; Merrill EG, 1974, ESSAYS NERVOUS SYSTE, P451; Missale C, 1998, PHYSIOL REV, V78, P189; Nattie E, 1999, PROG NEUROBIOL, V59, P299, DOI 10.1016/S0301-0082(99)00008-8; NESTLER EJ, 1994, NEUROPSYCHOPHARMACOL, V11, P77, DOI 10.1038/npp.1994.37; RICHTER DW, 1996, [No title captured], V2, P2079, DOI DOI 10.1007/978-3-642-60946-6_106; RICHTER DW, 1982, J EXP BIOL, V93, P100; SRINIVASAN M, 1991, MOL BRAIN RES, V9, P233; Takita K, 2000, BRAIN RES, V884, P201, DOI 10.1016/S0006-8993(00)02921-8; von Euler C, 1976, Acta Physiol Scand, V96, P324; WATLING A, 2001, SIGMA RBI HDB RECEPT; YOUNES M, 1981, J APPL PHYSIOL, V51, P963	31	11	13	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1569-9048	1878-1519		RESP PHYSIOL NEUROBI	Respir. Physiol. Neuro.	JAN 15	2005	145	1					13	22		10.1016/j.resp.2004.11.001			10	Physiology; Respiratory System	Physiology; Respiratory System	893GS	WOS:000226707900002	15652784				2020-06-30	J	Dong, N; Lu, WC; Chen, NY; Zhu, YC; Chen, KX				Dong, N; Lu, WC; Chen, NY; Zhu, YC; Chen, KX			Using support vector classification for SAR of fentanyl derivatives	ACTA PHARMACOLOGICA SINICA			English	Article						structure-activity relationship; support vector machine; fentanyl derivatives; support vector classification	MACHINES	Aim: To discriminate between fentanyl derivatives with high and low activities. Methods: The support vector classification (SVC) method, a novel approach, was employed to investigate structure-activity relationship (SAR) of fentanyl derivatives based on the molecular descriptors, which were quantum parameters including DeltaE [energy difference between highest occupied molecular orbital energy (HOMO) and lowest empty molecular orbital energy (LUMO)], MR (molecular refractivity) and M-r (molecular weight). Results: By using leave-one-out cross-validation test, the accuracies of prediction for activities of fentanyl derivatives in SVC, principal component analysis (PCA), artificial neural network (ANN) and K-nearest neighbor (KNN) models were 93%, 86%, 57%, and 71%, respectively. The results indicated that the performance of the SVC model was better than those of PCA, ANN, and KNN models for this data. Conclusion: SVC can be used to investigate SAR of fentanyl derivatives and could be a promising tool in the field of SAR research.	Shanghai Univ, Sch Sci, Dept Chem, Lab Chem Data Min, Shanghai 200436, Peoples R China; Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China	Lu, WC (reprint author), Shanghai Univ, Sch Sci, Dept Chem, Lab Chem Data Min, Shanghai 200436, Peoples R China.	wclu@mail.shu.edu.cn					Burbidge R, 2001, COMPUT CHEM, V26, P5, DOI 10.1016/S0097-8485(01)00094-8; Cai YD, 2003, PEPTIDES, V24, P665, DOI 10.1016/S0196-9781(03)00133-5; Cai YD, 2003, PEPTIDES, V24, P629, DOI 10.1016/S0196-9781(03)00100-1; CHEN NY, 2000, PATTERN RECOGNITION; Dash M, 1997, INTELL DATA ANAL, V1, P131, DOI DOI 10.1016/S1088-467X(97)00008-5; Gerak LR, 1999, PHARMACOL BIOCHEM BE, V64, P367, DOI 10.1016/S0091-3057(99)00058-1; MADDOCKS I, 1992, Australian Journal of Hospital Pharmacy, V22, P181; Trotter MWB, 2001, MEAS CONTROL-UK, V34, P235, DOI 10.1177/002029400103400803; Vapnik V, 1998, STAT LEARNING THEORY; Wan V, 2000, NEURAL NETWORKS FOR SIGNAL PROCESSING X, VOLS 1 AND 2, PROCEEDINGS, P775, DOI 10.1109/NNSP.2000.890157; ZHU YC, 1981, ACTA PHARMACOL SINIC, V16, P97; 李国正, 2002, [计算机与应用化学, Computers and Applied Chemistry], V19, P703; 陆文聪, 2002, [计算机与应用化学, Computers and Applied Chemistry], V19, P697; 陈念贻, 2002, [计算机与应用化学, Computers and Applied Chemistry], V19, P673	14	16	17	0	6	ACTA PHARMACOLOGICA SINICA	SHANGHAI	294 TAI-YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA	1671-4083	1745-7254		ACTA PHARMACOL SIN	Acta Pharmacol. Sin.	JAN	2005	26	1					107	112		10.1111/j.1745-7254.2005.00014.x			6	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	889EP	WOS:000226426600016	15659122	Bronze			2020-06-30	J	Malavasi, LM; Augustsson, H; Jensen-Waern, M; Nyman, G				Malavasi, LM; Augustsson, H; Jensen-Waern, M; Nyman, G			The effect of transdermal delivery of fentanyl on activity in growing pigs	ACTA VETERINARIA SCANDINAVICA			English	Article						swine; analgesia; opioids; patch; behaviour; pain; sedation; activity	TILETAMINE-ZOLAZEPAM; CATS; DOGS; ANESTHESIA; BUPRENORPHINE; MEDETOMIDINE; BUTORPHANOL; ISOFLURANE; ANALGESIA; PATCHES	Recently, decreased activity levels have been observed in pigs treated postoperatively with transdermal delivery of fentanyl (TD-fentanyl) after isoflurane anaesthesia. Whether the change in behaviour is related to opioid-induced sedation or to insufficient pain relief remains to be investigated. This study was therefore undertaken to evaluate the effect of TD-fentanyl 50 mu g h(-1) on the activity level with and without isollurane anaesthesia. Eight pigs (25.4 +/- 5.2 kg) were submitted to a cross-over study and given two treatments; 1) fentanyl patch applied after 30 minutes of anaesthesia (treatment A/F) and 2) fentanyl patch without anaesthesia (treatment F). The pigs' behaviour was observed from a video recording instantaneously every 10 minutes for 24 h before treatments and up to 72 h after the patch attachment. Venous blood samples were taken 1, 6, 12, 24, 48 and 72 h after the patch application. The behaviour recordings showed that TD-fentanyl did not produce sedation in any pig, No differences were found between the two treatments in activity level, weight gain or serum fentanyl concentration. This concentration measured after 24 h was 0.27 +/- 0.11 ng ml(-1) and 0.47 +/- 0.40 ng ml(-1) in the A/F and F group, respectively. In conclusion, transdermal delivery of 50 mu g h(-1) fentanyl did not cause inactivity in growing pigs. However, the large variations in serum fentanyl concentration indicate that drug absorption from transdermal patches is unpredictable and sometimes deficient.	Swedish Univ Agr Sci, Fac Vet Med & Anim Sci, Dept Clin Sci, S-75007 Uppsala, Sweden	Malavasi, LM (reprint author), Swedish Univ Agr Sci, Fac Vet Med, Dept Clin Sci, Box 7018, S-75007 Uppsala, Sweden.	Lais.Malavasi@kv.slu.se		Nyman, Gorel/0000-0002-2212-2151; Sassner, Hanna/0000-0002-1460-0328			Bowdle TA, 1998, DRUG SAFETY, V19, P173, DOI 10.2165/00002018-199819030-00002; Branson K. R., 2001, Veterinary pharmacology and therapeutics, P268; Carroll GL, 1999, AM J VET RES, V60, P986; Egger CM, 2003, VET ANAESTH ANALG, V30, P229, DOI 10.1046/j.1467-2995.2003.00109.x; France CP, 1998, PHARMACOL BIOCHEM BE, V59, P295, DOI 10.1016/S0091-3057(97)00417-6; Gellasch KL, 2002, J AM VET MED ASSOC, V220, P1020, DOI 10.2460/javma.2002.220.1020; Gilberto DB, 2003, CONTEMP TOP LAB ANIM, V42, P21; Golden AL, 1998, AM J VET RES, V59, P509; Gonyou HW, 1996, ADVANCES IN SWINE IN BIOMEDICAL RESEARCH, VOLS 1 AND 2, P485; HARVEY CR, 1987, PRINCIPLES PRACTICE, P380; Harvey-Clark CJ, 2000, LAB ANIM-UK, V34, P386, DOI 10.1258/002367700780387750; HELLYER P, 1989, VET SURG, V18, P160, DOI 10.1111/j.1532-950X.1989.tb01063.x; HELLYER P, 1988, VET SURG, V17, P105, DOI 10.1111/j.1532-950X.1988.tb00287.x; KEEGAN RD, 1995, AM J VET RES, V56, P193; LILES JH, 1992, LAB ANIM, V26, P180, DOI 10.1258/002367792780740558; MALAVASI LM, 2004, UNPUB PREOPERATIVE E; MARTIN RF, 1985, INTRO VET PHARM, P130; Nolan A. M., 2001, PAIN MANAGEMENT ANIM, P21; Pettifer GR, 2004, VET ANAESTH ANALG, V31, P109, DOI 10.1111/j.1467-2987.2004.00158.x; Rang H. P., 1996, PHARMACOLOGY, P609; Riviere JE, 2001, ADV DRUG DELIVER REV, V50, P175, DOI 10.1016/S0169-409X(01)00157-0; ROBERTSON SA, 2004, J FELINE MED SURG, P1; ROOZEN AWN, 1995, AM J VET RES, V56, P1225; SANFORD J, 1986, Veterinary Record, V118, P334; SHORT CE, 1999, TXB PAIN, P1007; SWINDLE ME, 2002, TECHNICAL B; Szeitz A, 1996, J CHROMATOGR B, V675, P33, DOI 10.1016/0378-4347(95)00350-9; Thomasy SM, 2004, J VET INTERN MED, V18, P550, DOI 10.1892/0891-6640(2004)18&lt;550:TFCWNA&gt;2.0.CO;2; Wallgren P., 1993, Svensk Veterinartidning, V45, P727; Wilkinson AC, 2001, CONTEMP TOP LAB ANIM, V40, P12	30	14	14	0	12	DANSKE DYRLAEGEFORENING	VANLOSE	ROSENLUNDS ALLE 8, DK-2720 VANLOSE, DENMARK	0044-605X			ACTA VET SCAND	Acta Vet. Scand.		2005	46	3					149	157		10.1186/1751-0147-46-149			9	Veterinary Sciences	Veterinary Sciences	973TJ	WOS:000232545200004	16261927	Green Published, Other Gold			2020-06-30	J	Otto, K; Adams, HA				Otto, K; Adams, HA			Experimental studies on the central analgesic effect of the non-steroidal anti-inflammatory drug carprofen in a sheep model - Preliminary results	ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE			German	Article						carprofen; cerebrospinal fluid; noradrenaline; serotonin; sheep	SPINAL-CORD; MECHANICAL STIMULATION; FORMALIN TEST; PAIN; NOREPINEPHRINE; INHIBITION; RAT; OVARIOHYSTERECTOMY; PHARMACOKINETICS; ANTINOCICEPTION	Objective: To evaluate the effect of the non-steroidal anti-inflammtory drug carprofen on the lumbar cerebrospinal fluid (CSF) concentration of noradrenaline (NA) and serotonin (5-HT) in non-stimulated (Part 1) and surgically stimulated (Part 11) sheep. Methods: In a prospective controlled study the effects of a single intravenous (i.v.) bolus injection of 4 mg/kg carprofen (CARP; n = 14), 0.01 mg/kufentanyl (FENT; n = 12) or 0.9% saline solution (NaCl; n = 13) on lumbar CSF concentrations of NA and 5-HT were evaluated in non-stimulated sheep. In addition. CSF concentrations were evaluated in isoflurane-anaesthetised sheep at different time points T1 (30 min after i. v. treatment with 4 mg/kg carprofen [n = 8] or saline [n = 7], T2 (20 min of constant end-tidal isoflurane concentration of 2.4%) and T3 (during stifle arthroscopy at 2.4% end-tidal isoflurane). Results: CSF concentrations of NA (NaCl: 170.23+/-16.86 pg/ml [x+/-SEM], CARP: 200.79+/-28.94 palmi, FENT: 209.58+/-27.67 pg/ml; p = 0.524) and 5-HT (NaCl: 2752.46+/-413.87 pg/ml, FENT: 2969.08+/-684.05 pg/ml, CARP: 3232.93+/-713.93 pg/ml; p = 0.978) were not significantly different between the three treatment groups of non-stimulated sheep. In the anaesthetised sheep, mean CSF-5-HT at T3 (mNaCl: 6670.25+/-313.63 pg/ml; CARP: 4080.80+/-539.59 pg/ml) was significantly increased compared to T1 (NaCl: 2818.4+/-1104.54 pg/ml, p < 0.001; CARP: 2926.13+/-818.66 pg/ml, p = 0.022) and T2 (NaCl: 2593.67+/-618.89 pg/ml, p = 0.002; CARP: 2724.13+/-395.39 pg/ml, p = 0.012) in both treatment groups. Moreover, mean CSF-5-HT at T3 in the saline group was significantly higher (p = 0.006) compared to the CARP-group. Unlike changes in CSF-5 5-HT, no significant changes in mean CSF-NA were recorded neither within nor between the two treatment groups. Conclusion: During arthroscopy in isoflurane-anaesthetised sheep, surgical stimuli may significantly increase mean CSF-5-HT concentration. This effect can be attenuated by pre-treatment with 4 mg/kg carprofen intravenously. Therefore, the analgesic effects of carprofen may be at least in part mediated by central serotonergic mechanisms.	Hochsch Hannover, Zentrales Tierlab Med, D-30625 Hannover, Germany; Hochsch Hannover, Zentrum Anasthesiol Med, D-30625 Hannover, Germany	Otto, K (reprint author), Hochsch Hannover, Zentrales Tierlab Med, Carl Neuberg Str 1, D-30625 Hannover, Germany.	otto.klaus@mh-hannover.de					AIMONE LD, 1987, PAIN, V31, P123, DOI 10.1016/0304-3959(87)90012-1; Al-Gizawiy MM, 2004, VET ANAESTH ANALG, V31, P164, DOI 10.1111/j.1467-2987.2004.00180.x; Alloui A, 2002, EUR J PHARMACOL, V443, P71, DOI 10.1016/S0014-2999(02)01578-9; Balmer TV, 1998, J SMALL ANIM PRACT, V39, P158, DOI 10.1111/j.1748-5827.1998.tb03623.x; BANNWARTH B, 1993, ANN RHEUM DIS, V52, P1, DOI 10.1136/ard.52.1.1; Bonnefont J, 2003, ANESTHESIOLOGY, V99, P976, DOI 10.1097/00000542-200310000-00034; Bostrom IM, 2002, AM J VET RES, V63, P712, DOI 10.2460/ajvr.2002.63.712; BOUAZIZ H, 1994, ANESTHESIOLOGY, V81, pA988; Brune K, 1994, Drugs, V47 Suppl 5, P21, DOI 10.2165/00003495-199400475-00005; CARSTENS EE, 1987, J AM VET MED ASSOC, V191, P1203; Eisenach JC, 1996, ANESTH ANALG, V82, P621, DOI 10.1097/00000539-199603000-00034; FERREIRA SH, 1980, BRIT J CLIN PHARMACO, V10, pS237, DOI 10.1111/j.1365-2125.1980.tb01806.x; Fox SM, 1997, J AM VET MED ASSOC, V210, P1493; Gebhart G.F., 1992, ANIMAL PAIN, P81; GHIA JN, 1981, ANESTH ANALG, V60, P854; LASCELLES BDX, 1995, J SMALL ANIM PRACT, V36, P535, DOI 10.1111/j.1748-5827.1995.tb02805.x; Lees P, 1996, BRIT VET J, V152, P199, DOI 10.1016/S0007-1935(96)80074-1; LEES P, 1994, EQUINE VET J, V26, P203, DOI 10.1111/j.2042-3306.1994.tb04370.x; MALMBERG AB, 1992, J PHARMACOL EXP THER, V263, P136; Miranda HF, 2003, BRAIN RES BULL, V61, P417, DOI 10.1016/S0361-9230(03)00144-8; Miranda HF, 2001, ANESTH ANALG, V93, P430, DOI 10.1097/00000539-200108000-00039; Pinardi G, 2002, INFLAMM RES, V51, P219, DOI 10.1007/PL00000296; POCKETT S, 1995, ANESTH ANALG, V80, P173, DOI 10.1097/00000539-199501000-00026; Ricketts AP, 1998, AM J VET RES, V59, P1441; Slingsby LS, 2002, J SMALL ANIM PRACT, V43, P286, DOI 10.1111/j.1748-5827.2002.tb00074.x; TONG C, 1993, ANESTHESIOLOGY, V79, pA863; TYCE GM, 1981, J PHYSIOL-LONDON, V314, P513, DOI 10.1113/jphysiol.1981.sp013722; WELSH EM, 1995, PAIN, V60, P159, DOI 10.1016/0304-3959(94)00110-Z; WELSH EM, 1994, RES VET SCI, V57, P285, DOI 10.1016/0034-5288(94)90119-8; WELSH EM, 1992, RES VET SCI, V53, P264, DOI 10.1016/0034-5288(92)90123-J	30	4	4	0	2	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0939-2661			ANASTH INTENSIV NOTF	Anasthesiol. Intensivmed. NotfMed. Schmerzther.	JAN	2005	40	1					25	31		10.1055/s-2004-826201			7	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	893ZW	WOS:000226760600005	15645384				2020-06-30	J	Heinz, A; Reimold, M; Wrase, J; Hermann, D; Croissant, B; Mundle, G; Dohmen, BM; Braus, DH; Schumann, G; Machulla, HJ; Bares, R; Mann, K				Heinz, A; Reimold, M; Wrase, J; Hermann, D; Croissant, B; Mundle, G; Dohmen, BM; Braus, DH; Schumann, G; Machulla, HJ; Bares, R; Mann, K			Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving - A positron emission tomography study using carbon 11-labeled carfentanil	ARCHIVES OF GENERAL PSYCHIATRY			English	Article							ETHANOL-CONSUMPTION; NUCLEUS-ACCUMBENS; BETA-ENDORPHIN; ANA RATS; NALTREXONE; DOPAMINE; BINDING; DEPENDENCE; ADDICTION; PAIN	Background: The pleasant effects of food and alcohol intake are partially mediated by mu-opiate receptors in the ventral striatum, a central area of the brain reward system. Blockade of mu-opiate receptors with naltrexone reduces the relapse risk among some but not all alcoholic individuals. Objective: To test the hypothesis that alcohol craving is pronounced among alcoholic individuals with a high availability of mu-opiate receptors in the brain reward system. Design: Patients and comparison sample. The availability of central mu-opiate receptors was measured in vivo with positron emission tomography (PET) and the radioligand carbon 11-labeled carfentanil in the ventral striatum and compared with the severity of alcohol craving as assessed by the Obsessive Compulsive Drinking Scale (OCDS). Setting: Hospitalized care. Participants: Volunteer sample of 25 male alcohol-dependent inpatients assessed after detoxification of whom 12 underwent PET again 5 weeks later. Control group of 10 healthy men. Main Outcome Measures: After I to 3 weeks of abstinence, the availability of mu-opiate receptors in the ventral striatum, including the nucleus accumbens, was significantly elevated in alcoholic patients compared with healthy controls and remained elevated when 12 alcoholic patients had these levels measured 5 weeks later (P<.05 corrected for multiple testing). Higher availability of mu-opiate receptors in this brain area correlated significantly with the intensity of alcohol craving as assessed by the OCDS. Conclusions: Abstinent alcoholic patients displayed an increase in mu-opiate receptors in the ventral striatum, including the nucleus accumbens, which correlated with the severity of alcohol craving. These findings point to a neuronal correlate of alcohol urges.	Heidelberg Univ, Cent Inst Mental Hlth, Dept Addict Behav & Addict Med, D-68159 Mannheim, Germany; Heidelberg Univ, Cent Inst Mental Hlth, Dept Psychiat, D-68159 Mannheim, Germany; Univ Med Berlin, Dept Psychiat, Charite, Berlin, Germany; Univ Tubingen, Dept Nucl Med, D-72074 Tubingen, Germany; Univ Tubingen, Dept Radiopharm, D-72074 Tubingen, Germany; Univ Tubingen, PET Ctr, D-72074 Tubingen, Germany; Univ Tubingen, Dept Psychiat, D-72074 Tubingen, Germany	Mann, K (reprint author), Heidelberg Univ, Cent Inst Mental Hlth, Dept Addict Behav & Addict Med, J5, D-68159 Mannheim, Germany.	sucht@zi-mannheim.de	Schumann, Gunter/H-1013-2013	Hermann, Derik/0000-0003-4434-1221; Heinz, Andreas/0000-0001-5405-9065			Anton RF, 1996, ARCH GEN PSYCHIAT, V53, P225; Ashburner J, 1997, NEUROIMAGE, V6, P209, DOI 10.1006/nimg.1997.0290; Bencherif B, 2002, PAIN, V99, P589, DOI 10.1016/S0304-3959(02)00266-X; Berrendero F, 2002, J NEUROSCI, V22, P10935; Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; Breiter HC, 2001, NEURON, V30, P619, DOI 10.1016/S0896-6273(01)00303-8; Ciccocioppo R, 2002, NEUROPSYCHOPHARMACOL, V27, P391, DOI 10.1016/S0893-133X(02)00302-0; Cowen MS, 1999, PROG NEURO-PSYCHOPH, V23, P1171, DOI 10.1016/S0278-5846(99)00060-3; DEWAELE JP, 1994, ALCOHOL CLIN EXP RES, V18, P1468; Djouma E, 2002, J PHARMACOL EXP THER, V302, P551, DOI 10.1124/jpet.102.035915; DURCAN MJ, 1992, EUR J PHARMACOL, V224, P151, DOI 10.1016/0014-2999(92)90799-A; Endres CJ, 2003, NUCL MED BIOL, V30, P177, DOI 10.1016/S0969-8051(02)00411-0; Everitt BJ, 2002, J NEUROSCI, V22, P3312; First MB, 1997, STRUCTURED CLIN INTE; FIRST MB, 2001, STUCTURED CLIN INTER; FROST JJ, 1989, J CEREBR BLOOD F MET, V9, P398, DOI 10.1038/jcbfm.1989.59; Gastpar M, 2002, J CLIN PSYCHOPHARM, V22, P592, DOI 10.1097/00004714-200212000-00009; Haber SN, 1999, ANN NY ACAD SCI, V877, P33, DOI 10.1111/j.1749-6632.1999.tb09259.x; Hiller JM, 1996, NEUROCHEM RES, V21, P1333, DOI 10.1007/BF02532374; Kiefer F, 2003, ARCH GEN PSYCHIAT, V60, P92, DOI 10.1001/archpsyc.60.1.92; Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52; Krystal JH, 2001, NEW ENGL J MED, V345, P1734, DOI 10.1056/NEJMoa011127; Laruelle M, 2002, METHODS, V27, P287, DOI 10.1016/S1046-2023(02)00085-3; Logan J, 2000, NUCL MED BIOL, V27, P661, DOI 10.1016/S0969-8051(00)00137-2; Marinelli PW, 2000, LIFE SCI, V66, P1915, DOI 10.1016/S0024-3205(00)00517-8; Mawlawi O, 2001, J CEREBR BLOOD F MET, V21, P1034, DOI 10.1097/00004647-200109000-00002; Narendran R, 2004, SYNAPSE, V52, P188, DOI 10.1002/syn.20013; OMALLEY SS, 1995, PSYCHIAT ANN, V25, P681, DOI 10.3928/0048-5713-19951101-11; Pecina S, 2000, BRAIN RES, V863, P71, DOI 10.1016/S0006-8993(00)02102-8; Pfefferbaum A, 1998, ARCH GEN PSYCHIAT, V55, P905, DOI 10.1001/archpsyc.55.10.905; Reimold M, 2004, EUR J NUCL MED MOL I, V31, P564, DOI 10.1007/s00259-003-1389-5; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; SKINNER HA, 1982, J STUD ALCOHOL, V43, P1157, DOI 10.15288/jsa.1982.43.1157; STOCKWELL T, 1979, BRIT J ADDICT, V74, P79; Varga J, 2002, J CEREBR BLOOD F MET, V22, P240, DOI 10.1097/00004647-200202000-00012; Volkow ND, 1997, NATURE, V386, P827, DOI 10.1038/386827a0; VOLPICELLI JR, 1995, AM J PSYCHIAT, V152, P613; Zhang M, 2002, PSYCHOPHARMACOLOGY, V159, P415, DOI 10.1007/s00213-001-0932-y; Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546; Zubieta JK, 1996, NAT MED, V2, P1225, DOI 10.1038/nm1196-1225; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	41	153	159	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-990X	1538-3636		ARCH GEN PSYCHIAT	Arch. Gen. Psychiatry	JAN	2005	62	1					57	64		10.1001/archpsyc.62.1.57			8	Psychiatry	Psychiatry	886TA	WOS:000226250300007	15630073	Bronze			2020-06-30	J	Rodrigues, ARA; Castro, MSA; Francischi, JN; Perez, AC; Duarte, IDG				Rodrigues, ARA; Castro, MSA; Francischi, JN; Perez, AC; Duarte, IDG			Participation of ATP-sensitive K+ channels in the peripheral antinociceptive effect of fentanyl in rats	BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH			English	Article						peripheral antinociception; fentanyl; K+ channel; mu-opioid receptor agonist; Glibenclamide	ACTIVATED POTASSIUM CHANNELS; OPIOID RECEPTOR AGONISTS; MORPHINE ANALGESIA; SENSORY NERVES; INVOLVEMENT; PHARMACOLOGY; GLIBENCLAMIDE; ENKEPHALINS; MECHANISM; SYSTEM	We examined the effect of several K+ channel blockers such as glibenclamide, tolbutamide, charybdotoxin (ChTX), apamin, tetraethylammonium chloride (TEA), 4-aminopyridine (4-AP), and cesium on the ability of fentanyl, a clinically used selective mu-opioid receptor agonist, to promote peripheral antinociception. Antinociception was measured by the paw pressure test in male Wistar rat: weighing 180-250 g (N = 5 animals per group). Carrageenan (250 mug/ paw) decreased the threshold of responsiveness to noxious pressure ( = 188.1 +/- 5.3 g). This mechanical hyperalgesia was reduced by fentanyl (0.5, 1.5 and 3 mug/paw) in a peripherally mediated and dose-dependent fashion (17.3, 45.3 and 62.6%, respectively). The selective blockers of ATP-sensitive K+ channels glibenclamide (40, 80 and 160 mug/paw) and tolbutamide (80, 160 and 240 mug/paw) dose dependently antagonized the antinociception induced by fentanyl (1.5 mug/paw). In contrast, the effect of fentanyl was unaffected by the large conductance Ca2+-activated K+ channel blocker ChTX (2 mug/paw), the small conductance Ca='-activated K+ channel blocker apamin (10 mug/paw), or the non-specific K+ channel blocker TEA (150 mug/paw), 4-AP (50 mug/paw), and cesium (250 mug/paw). These results extend previously reported data on the peripheral analgesic effect of morphine and fentanyl, suggesting for the first time that the peripheral mu-opioid receptor-mediated antinociceptive effect of fentanyl depends on activation of ATP-sensitive, but not other, K+ channels.	Univ Fed Minas Gerais, ICB, Dept Farmacol, BR-31270100 Belo Horizonte, MG, Brazil	Duarte, IDG (reprint author), Univ Fed Minas Gerais, ICB, Dept Farmacol, Av Antonio Carlos 6627, BR-31270100 Belo Horizonte, MG, Brazil.	dimitri@mono.icb.ufmg.br					Amarante LH, 2004, EUR J PHARMACOL, V494, P155, DOI 10.1016/j.ejphar.2004.05.009; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; BENTLEY GA, 1981, BRIT J PHARMACOL, V73, P325, DOI 10.1111/j.1476-5381.1981.tb10425.x; Cook NS, 1990, POTASSIUM CHANNELS S, P181; DUARTE IDG, 1992, EUR J PHARMACOL, V217, P225, DOI 10.1016/0014-2999(92)90881-4; EDWARDS G, 1993, ANNU REV PHARMACOL, V33, P597, DOI 10.1146/annurev.pa.33.040193.003121; FERREIRA SH, 1979, PROSTAGLANDINS, V18, P191, DOI 10.1016/0090-6980(79)90104-7; FERREIRA SH, 1991, EUR J PHARMACOL, V201, P121, DOI 10.1016/0014-2999(91)90333-L; Garcia M L, 1997, Adv Pharmacol, V39, P425, DOI 10.1016/S1054-3589(08)60078-2; Halliwell JV, 1990, POTASSIUM CHANNELS S, P348; Herz A., 1971, ADV DRUG RES, V6, P79; Hille B, 2001, ION CHANNELS EXCITAB, P131; LEVINE JD, 1989, NEUROSCIENCE, V32, P571, DOI 10.1016/0306-4522(89)90279-0; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675; NORTH RA, 1985, J PHYSIOL-LONDON, V364, P265, DOI 10.1113/jphysiol.1985.sp015743; OCANA M, 1993, BRIT J PHARMACOL, V110, P1049, DOI 10.1111/j.1476-5381.1993.tb13919.x; OCANA M, 1990, EUR J PHARMACOL, V186, P377, DOI 10.1016/0014-2999(90)90466-J; Ocana M, 1996, J PHARMACOL EXP THER, V276, P1136; OCANA M, 1995, BRIT J PHARMACOL, V114, P1296, DOI 10.1111/j.1476-5381.1995.tb13346.x; RAFFA RB, 1994, BRAIN RES, V650, P146, DOI 10.1016/0006-8993(94)90217-8; RANDALL LO, 1957, ARCH INT PHARMACOD T, V113, P233; REEVE HL, 1992, NEUROSCI LETT, V135, P37, DOI 10.1016/0304-3940(92)90130-Y; ROANE DS, 1993, PHARMACOL BIOCHEM BE, V46, P205, DOI 10.1016/0091-3057(93)90341-P; Rodrigues ARA, 2000, BRIT J PHARMACOL, V129, P110, DOI 10.1038/sj.bjp.0703038; ROMEY G, 1984, J PHYSIOL-PARIS, V79, P259; Rosati B, 1998, FEBS LETT, V440, P125, DOI 10.1016/S0014-5793(98)01444-6; Satoh M, 1995, PHARMACOL THERAPEUT, V68, P343, DOI 10.1016/0163-7258(95)02011-X; Savoia G, 2001, Minerva Anestesiol, V67, P206; SMITH TW, 1982, LIFE SCI, V31, P1205, DOI 10.1016/0024-3205(82)90343-5; Soares AC, 2000, EUR J PHARMACOL, V400, P67, DOI 10.1016/S0014-2999(00)00355-1; SOARES AC, 1908, BRIT J PHARMACOL, V134, P127; STEIN C, 1990, P NATL ACAD SCI USA, V87, P5935, DOI 10.1073/pnas.87.15.5935; STEIN C, 1993, ANESTH ANALG, V76, P182; STRETTON D, 1992, P NATL ACAD SCI USA, V89, P1325, DOI 10.1073/pnas.89.4.1325; Vergoni A. V., 1992, LIFE SCI, V50, P135; WILD KD, 1991, EUR J PHARMACOL, V193, P135, DOI 10.1016/0014-2999(91)90215-C; YAKSH TL, 1976, SCIENCE, V192, P1357, DOI 10.1126/science.1273597; Yamazumi I, 2001, JPN J PHARMACOL, V87, P268, DOI 10.1254/jjp.87.268; Yonehara N, 1997, REGUL PEPTIDES, V68, P147, DOI 10.1016/S0167-0115(96)02102-7	40	13	13	0	0	ASSOC BRAS DIVULG CIENTIFICA	RIBEIRAO PRETO	FACULDADE MEDICINA, CASA 10, 14049 RIBEIRAO PRETO, RIBEIRAO PRETO, SP 14049, BRAZIL	0100-879X	1414-431X		BRAZ J MED BIOL RES	Brazilian J. Med. Biol. Res.	JAN	2005	38	1					91	97		10.1590/S0100-879X2005000100014			7	Biology; Medicine, Research & Experimental	Life Sciences & Biomedicine - Other Topics; Research & Experimental Medicine	892PX	WOS:000226663600014	15665994	DOAJ Gold			2020-06-30	J	Deeprose, C; Andrade, J; Harrison, D; Edwards, N				Deeprose, C; Andrade, J; Harrison, D; Edwards, N			Unconscious auditory priming during surgery with propofol and nitrous oxide anaesthesia: a replication	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthesia, depth; analgesics opioid, fentanyl; memory, priming	GENERAL-ANESTHESIA; BISPECTRAL INDEX; IMPLICIT MEMORY; INFORMATION	Background. Priming during anaesthesia has been hard to replicate and the conditions under which it occurs remain poorly understood. We replicated and extended a recent study to determine whether intraoperative priming during propofol and nitrous oxide anaesthesia is a reliable phenomenon, whether it occurs due to awareness during word presentation and whether it is suppressed by a dose of fentanyl at induction. Methods. Words were played through headphones during surgery to 62 patients receiving propofol and nitrous oxide anaesthesia. Thirty-two patients received fentanyl 1.5 mug kg(-1) at induction and 30 received no fentanyl. Neuromuscular blocking drugs were not used. Depth of anaesthesia was measured using the bispectral index (BIS). Anaesthetic variables were recorded at 1 min intervals during word presentation. On recovery, implicit and explicit memory were assessed using an auditory word-stem completion test and a yes-no word-recognition test, respectively. Results. BIS, blood pressure, end-tidal carbon dioxide and heart rate during word presentation did not differ between the study groups. The infusion rate of propofol and the patients' ventilatory frequency were significantly higher in the group not receiving fentanyl. No patient had unprompted explicit recall of surgery, although there was above-zero performance in six patients on the yes-no recognition task (P < 0.05). There was no physiological evidence of awareness during anaesthesia (median mean-BIS = 38 in the no-fentanyl group and 42 in the fentanyl group). There was evidence for priming (mean priming score = 0.09, P < 0.05 in the no-fentanyl study group; mean priming score = 0.07, P < 0.05 in the fentanyl group) even when patients with momentary light anaesthesia (maximum recorded BIS greater than or equal to 60) and/or positive recognition scores were excluded from the analysis. Conclusions. Existing knowledge can be primed by information presented during propofol and nitrous oxide anaesthesia. This priming is evidence of unconscious information processing and not the result of moments of awareness.	Univ Sheffield, Dept Psychol, Sheffield S10 2TP, S Yorkshire, England; No Gen Hosp, Sheffield S5 7AU, S Yorkshire, England	Deeprose, C (reprint author), Univ Sheffield, Dept Psychol, Western Bank, Sheffield S10 2TP, S Yorkshire, England.	c.deeprose@shef.ac.uk	Andrade, Jackie/H-1215-2013; Deeprose, Catherine/G-3459-2012	Andrade, Jackie/0000-0002-6626-7192; 			ANDRADE J, 1995, BRIT J PSYCHOL, V86, P479, DOI 10.1111/j.2044-8295.1995.tb02566.x; ANGEL A, 1993, BRIT J ANAESTH, V71, P148, DOI 10.1093/bja/71.1.148; Deeprose C, 2004, BRIT J ANAESTH, V92, P171, DOI 10.1093/bja/aeh054; Gabrieli JDE, 1998, ANNU REV PSYCHOL, V49, P87, DOI 10.1146/annurev.psych.49.1.87; Ghoneim MM, 1997, ANESTHESIOLOGY, V87, P387, DOI 10.1097/00000542-199708000-00027; Hoymork SC, 2000, ACTA ANAESTH SCAND, V44, P1138, DOI 10.1034/j.1399-6576.2000.440918.x; Kerssens C, 2001, ANESTH ANALG, V92, P1210; Lubke GH, 1999, ANESTHESIOLOGY, V90, P670, DOI 10.1097/00000542-199903000-00007; Russell IF, 1997, BRIT J ANAESTH, V78, P3; Schricker T, 2000, ANESTH ANALG, V90, P450, DOI 10.1097/00000539-200002000-00039; SCHWENDER D, 1994, CONSCIOUS COGN, V3, P129, DOI 10.1006/ccog.1994.1009; SHANKS DR, 1994, BEHAV BRAIN SCI, V17, P367, DOI 10.1017/S0140525X00035032; Struys M, 1998, ANAESTHESIA, V53, P4, DOI 10.1046/j.1365-2044.1998.00279.x; Veselis RA, 1997, ANESTHESIOLOGY, V87, P749, DOI 10.1097/00000542-199710000-00007; Veselis RA, 2004, BRIT J ANAESTH, V92, P161, DOI 10.1093/bja/aeh030; WANG M, 2001, AWARENESS ANESTHESIA	16	42	46	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	JAN	2005	94	1					57	62		10.1093/bja/aeh289			6	Anesthesiology	Anesthesiology	889AK	WOS:000226415700010	15486010	Bronze			2020-06-30	J	Sathyan, G; Jaskowiak, J; Evashenk, M; Gupta, S				Sathyan, G; Jaskowiak, J; Evashenk, M; Gupta, S			Characterisation of the pharmacokinetics of the fentanyl HCl patient-controlled transdermal system (PCTS) - Effect of current magnitude and multiple-day dosing and comparison with IV fentanyl administration	CLINICAL PHARMACOKINETICS			English	Review							CONTROLLED ANALGESIA	Introduction: The fentanyl HCl patient-controlled transdermal system (PCTS) is a self-contained, preprogrammed, noninvasive analgesic delivery system for acute pain management. We carried out three studies with the following objectives: study I to evaluate the relationship between fentanyl absorption and the magnitude of current applied to the system; study II to determine dose-proportionality for the fentanyl HCl PCTS (25 and 40 mu g); and Study III to describe the effects of single- and multiple-day administration on the pharmacokinetics of fentanyl delivered by the PCTS. Methods: All studies were open-label, crossover studies with washout periods between treatments. In study I, randomised participants (n = 36) received three of a potential five fentanyl HCl PCTS prototypes, each of which used a different current magnitude, and each of which was evaluated for 24 hours. In study II, participants (n = 40) received fentanyl (25 mu g) from the PCTS for 23.33 hours, followed by fentanyl (40 mu g) from the PCTS for 23.33 hours. Intravenous (IV) fentanyl (80 mu g/h) was administered intermittently over 24 hours as a reference treatment in Studies I and II. In study III, participants (n = 28) received fentanyl (40 mu g) from the PCTS for 20 hours, followed by fentanyl (40 mu g) from the PCTS for 68 hours. Pharmacokinetic parameters, including maximum serum fentanyl concentration (C-max), time to C-max (t(max)), area under the serum concentration-time curve (AUC) and terminal half-life (t(1/2)), were determined for each treatment. Results: The amount of fentanyl absorbed from the PCTS was linearly dependent on the magnitude of current applied to the system, with a current of 170 mu A resulting in the absorption of 39.5 mu g of fentanyl at hour 23. Mixed-effect ANOVA indicated no significant difference (p > 0.1) in the dose-normalised pharmacokinetics of the fentanyl HCl PCTS 25 and 40 mu g. No significant difference existed between the corrected AUC(0-5) of the fentanyl HCl PCTS during the single- and multiple-day treatment periods (0.40 and 0.54 mu g center dot h/L, respectively; p = 0.133). The system was well tolerated, with headache and mild application site erythema being the most common treatment-related adverse events. Conclusions: A linear relationship exists between the amount of current applied to the fentanyl HCl PCTS and the amount of fentanyl absorbed. There is dose-proportionality in the pharmacokinetics of the fentanyl HCl PCTS 25 and 40 mu g. Multiple-day administration does not affect the pharmacokinetics of the fentanyl HCl PCTS 40 mu g. The system was well tolerated, even after repeated application.	ALZA Corp, Mountain View, CA 94043 USA	Sathyan, G (reprint author), ALZA Corp, 1900 Charlestown Rd, Mountain View, CA 94043 USA.	Gayatri.Sathyan@alza.com					*ALZA CORP, 2001, COMP PHARM FENT SING; Austrup ML, 1999, SURG CLIN N AM, V79, P253, DOI 10.1016/S0039-6109(05)70382-0; BROWN CR, 1998, 17 ANN M AM PAIN SOC; Camu F, 1998, ANESTH ANALG, V87, P890, DOI 10.1097/00000539-199810000-00027; GUPTA S, 1998, J PHARM SCI, V88, P835; Gupta SK, 1998, J CLIN PHARMACOL, V38, P951, DOI 10.1002/j.1552-4604.1998.tb04392.x; Macintyre PE, 2001, BRIT J ANAESTH, V87, P36, DOI 10.1093/bja/87.1.36; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Vicente KJ, 2003, CAN J ANAESTH, V50, P328, DOI 10.1007/BF03021027	9	34	35	0	3	ADIS INTERNATIONAL LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 10, NEW ZEALAND	0312-5963			CLIN PHARMACOKINET	Clin. Pharmacokinet.		2005	44			1			7	15		10.2165/00003088-200544001-00003			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	937QR	WOS:000229941100003	16156111				2020-06-30	J	Sathyan, S; Zomorodi, K; Gidwani, S; Gupta, S				Sathyan, S; Zomorodi, K; Gidwani, S; Gupta, S			The effect of dosing frequency on the pharmacokinetics of a fentanyl HCl patient-controlled transdermal system (PCTS)	CLINICAL PHARMACOKINETICS			English	Review							CONTROLLED-TRIAL	Introduction: The fentanyl HCl patient-controlled transdermal system (PCTS) is a noninvasive, needle-free, credit card-sized drug delivery system designed for the on-demand management of acute pain in a medically supervised setting. The objective of these studies was to determine the effect of dosing frequency on the pharmacokinetics of fentanyl delivered by the PCTS. Methods: All three studies were single-centre, open-label, randomised, crossover studies. The fentanyl HCl PCTS was applied to the upper outer arm of all participants. In the first study, participants (n = 30) received three fentanyl HCl PCTS 25 mu g treatments: two sequential doses hourly for 23.33 hours, six sequential doses every 3 hours for 22 hours, and 72 doses continuously over 12 hours. Participants (n = 31) in the second study received three fentanyl HCl PCTS 40 mu g treatments: two sequential doses hourly over 23.33 hours, six sequential doses every 3 hours over approximately 10 hours, and 80 doses continuously over 13.33 hours. In the third Study, participants (n = 28) received four fentanyl HCl PCTS 40 mu g treatments: 6, 1 8 36 and 80 doses over 1, 3, 6 and 13.33 hours, respectively. Naltrexone was used to block the opioid effects of fentanyl. Pharmacokinetic parameters, including maximum serum fentanyl concentration (C-max), time to C-max (t(max)), area under the serum concentration-time curve (AUC) and terminal half-life (t(1/2)) were determined. Results: In the first study, the dose-normalised AUC (AUC(n)) values for the 2- and 6-dose sequence treatments were not significantly different (p = 0.937), suggesting that the frequency of dosing has little effect on the amount of fentanyl absorbed; however, the AUC(n) for the 72-dose treatment was significantly lower than that of the other treatments (p = 0.001), which were of longer duration. The results of the second study paralleled those from the first, suggesting that the bioavailability of fentanyl delivered by the PCTS increases as a function of time and is likely to be independent of dosing frequency. Results from the third study suggested that approximately 40% of the nominal 40 mu g fentanyl dose is absorbed during the first hour of treatment, with the full nominal dose absorbed after approximately 10 hours. The fentanyl HCl PCTS was well tolerated. Conclusion: The amount of fentanyl absorbed from the PCTS increases as a function of time and is independent of both dosing frequency and total number of doses delivered. The fentanyl HCl PCTS is generally safe and well tolerated.	ALZA Corp, Mountain View, CA 94043 USA	Sathyan, S (reprint author), ALZA Corp, 1900 Charlestown Rd, Mountain View, CA 94043 USA.	Gayatri.Sathyan@alza.com					*ALZA CORP, 2003, DAT FIL; BROWN CR, 1998, 17 ANN SCI M AM PAIN; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; GUPTA S, 1998, J PHARM SCI, V88, P835; Gupta SK, 2005, CLIN PHARMACOKINET, V44, P25, DOI 10.2165/00003088-200544001-00005; Gupta SK, 1998, J CLIN PHARMACOL, V38, P951, DOI 10.1002/j.1552-4604.1998.tb04392.x; Sathyan G, 2005, CLIN PHARMACOKINET, V44, P7, DOI 10.2165/00003088-200544001-00003; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333	8	19	19	0	2	ADIS INTERNATIONAL LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 10, NEW ZEALAND	0312-5963			CLIN PHARMACOKINET	Clin. Pharmacokinet.		2005	44			1			17	24		10.2165/00003088-200544001-00004			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	937QR	WOS:000229941100004	16156112				2020-06-30	J	Gupta, SK; Hwang, S; Southam, M; Sathyan, G				Gupta, SK; Hwang, S; Southam, M; Sathyan, G			Effects of application site and subject demographics on the pharmacokinetics of fentanyl HCl patient-controlled transdermal system (PCTS)	CLINICAL PHARMACOKINETICS			English	Review							EFFICACY; DELIVERY	Introduction: The fentanyl HCl patient-controlled transdermal system (PCTS) is a self-contained, preprogrammed, needle-free system Currently in development for acute pain management in a medically supervised setting. The objectives of these studies were to evaluate skin application sites for the fentanyl HCl PCTS and to evaluate the effect of patient demographics on its pharmacokinetics. Methods: The first study was a randomised, open-label, single-centre, 3-treatment, crossover study in which the fentanyl HCl PCTS was applied to the upper outer arm, lower inner arm or chest of healthy volunteers. Fentanyl 25 mu g was then delivered via this system twice during the first 20 minutes of every hour for 24 hours. The pharmacokinetics of fentanyl were determined and analysed for each application site using ANOVA. The second study was a nonrandomised, nonblind, multicentre, sequential treatment study. Healthy volunteers received fentanyl HCl 40 mu g via the PCTS three times during the first 30 minutes of each hour for 3 hours. After a 5- to 10-day washout period, fentanyl HCl 120 mu g was administered intravenously during the first 30 minutes of each hour for 3 hours as a reference treatment. Pharmacokinetic parameters were determined for the fentanyl HCl PCTS, and results were analysed using ANOVA. Safety and tolerability were evaluated in both studies. Results: Application of the system to the upper outer arm or chest resulted in similar maximum serum concentrations (C-max; 1.193 and 1.176 mu g/L, respectively) and areas under the serum concentration-time Curve (AUC(24-25); 1.033 and 1.015 mu g center dot h/L). However, both C-max and AUC(24-25) were less when the system was applied to the lower inner arm (0.859 mu g/L and 0.757 mu g center dot h/L). Subject age, bodyweight, sex and ethnicity had no significant effect on pharmacokinetic parameters. No serious adverse events were reported in either study during or after administration of the fentanyl HCl PCTS. Conclusion: Fentanyl HCl is comparably absorbed from the PCTS when it is applied to the upper outer arm or chest. The pharmacokinetics of fentanyl HCl delivered by the PCTS are unaffected by sex, age, race or weight.	ALZA Corp, Mountain View, CA 94043 USA	Sathyan, G (reprint author), ALZA Corp, 1900 Charlestown Rd, Mountain View, CA 94043 USA.	Gayatri.Sathyan@alza.com					*ALZA CORP, 2003, DAT FIL; BROWN CR, 1998, 17 ANN SCI M AM PAIN; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Gupta SK, 1998, J CLIN PHARMACOL, V38, P951, DOI 10.1002/j.1552-4604.1998.tb04392.x; GYORY RJ, 1997, TRANSDERMAL ADM CASE, P262; Harrison LI, 2002, J CLIN PHARMACOL, V42, P1134, DOI 10.1177/009127002401382740; MOODIE J, 1998, 17 ANN SCI M AM PAIN; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014	8	26	27	0	1	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0312-5963	1179-1926		CLIN PHARMACOKINET	Clin. Pharmacokinet.		2005	44			1			25	32		10.2165/00003088-200544001-00005			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	937QR	WOS:000229941100005	16156113				2020-06-30	J	Darwish, M; Tempero, K; Kirby, M; Thompson, J				Darwish, M; Tempero, K; Kirby, M; Thompson, J			Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers	CLINICAL PHARMACOKINETICS			English	Review							PERMEABILITY	Background and objectives: Fentanyl effervescent buccal tablets (FEBT) are designed to enhance the rate and efficiency of fentanyl absorption through the buccal mucosa. This study was undertaken to characterise the pharmacokinetics and assess the dose proportionality of FEBT in healthy volunteers within the potential therapeutic dose range. Methods: Twenty-five healthy adults (mean age 33 years) completed a single-dose, randomised, open-label, four-dose, four-period, crossover study of FEBT. They were administered FEBT 200, 500, 810 or 1080 mu g. The subjects in this study were not opioid tolerant; therefore, naltrexone was administered to block any opioid receptor-mediated effects of fentanyl. Venous blood samples for measurement of serum fentanyl concentrations were obtained over 36 hours following dosing. Adverse events were recorded throughout the study. Results: The pharmacokinetics of FEBT were characterised by an absorption phase with a median time to reach maximum serum concentration (t(max)) Of 0.75-0.99 hours that was consistent irrespective of dose. Mean serum fentanyl concentrations exhibited a biexponential decline from peak after FEBT 200 and 500 mu g doses and a triexponential decline after FEBT 810 and 1080 mu g doses. The maximum serum concentration (C-max) of fentanyl was proportional up to and including the 810 mu g dose. The increase in Cmax was 20% less than proportional at the 1080 mu g dose. Systemic exposure to fentanyl, as measured by the area under the serum concentration-time curve from time zero to infinity (AUC(infinity)), increased proportionally with increasing doses of FEBT (200-1080 mu g). No serious adverse events were reported during the study. Conclusion: The pharmacokinetics of FEBT were characterised by a high early fentanyl concentration as a result of absorption across the buccal mucosa of the oral cavity, which results in bypassing first-pass metabolism. This high early tmax contributed to enhanced early systemic fentanyl exposure. Maximum concentration and AUC(infinity) of FEBT increased in a dose-proportional manner from 200 to 810 mu g. This study provides preliminary, pharmacokinetic data for FEBT across the potential therapeutic dose range.	Cephalon Inc, Clin Pharmacol, Frazer, PA USA; CIMA Labs Inc, Eden Prairie, MN USA	Darwish, M (reprint author), 41 Moores Rd, Malvern, PA 19355 USA.	mdarwish@cephalon.com					Barash PG, 2001, CLIN ANESTHESIA; *CTR DRUG EV RES F, GUID IND BIO BIO STU; Eichman JD, 1998, PHARM RES-DORDR, V15, P925, DOI 10.1023/A:1011936901638; Eichman JD, 1997, EUR J PHARM BIOPHARM, V44, P33, DOI 10.1016/S0939-6411(97)00099-4; HILL HF, 1990, PAIN, V43, P69, DOI 10.1016/0304-3959(90)90051-E; HUDSON RJ, 1986, ANESTHESIOLOGY, V64, P334, DOI 10.1097/00000542-198603000-00006; HUG CC, 1981, ANESTHESIOLOGY, V55, P369, DOI 10.1097/00000542-198110000-00006; Lor M, 2005, CLIN PHARMACOL THER, V77, pP76, DOI 10.1016/j.clpt.2004.12.181; PATHER SI, ENHANCED BUCCAL DELI; Smith BP, 2000, PHARMACEUT RES, V17, P1278, DOI 10.1023/A:1026451721686; Stanley TH, 2005, J PAIN SYMPTOM MANAG, V29, pS67, DOI 10.1016/j.jpainsymman.2005.01.009; Sweetman S., 2005, MARTINDALE COMPLETE	12	42	46	0	6	ADIS INTERNATIONAL LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND	0312-5963			CLIN PHARMACOKINET	Clin. Pharmacokinet.		2005	44	12					1279	1286		10.2165/00003088-200544120-00006			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	012RU	WOS:000235357800006	16372825				2020-06-30	J	De Jonghe, B; Bastuji-Garin, S; Fangio, P; Lacherade, JC; Jabot, J; Appere-De-Vecchi, C; Rocha, N; Outin, H				De Jonghe, B; Bastuji-Garin, S; Fangio, P; Lacherade, JC; Jabot, J; Appere-De-Vecchi, C; Rocha, N; Outin, H			Sedation algorithm in critically ill patients without acute brain injury	CRITICAL CARE MEDICINE			English	Article						hypnotics; sedatives; respiration; artificial; consciousness; algorithm; intensive care	INTENSIVE-CARE-UNIT; MECHANICAL VENTILATION; ICU SEDATION; PROLONGED SEDATION; RANDOMIZED TRIAL; DOUBLE-BLIND; MIDAZOLAM; PROPOFOL; DEXMEDETOMIDINE; ACCUMULATION	Objective., To determine whether use of a sedation algorithm to promote a high level of tolerance to the intensive care, environment and preserve consciousness affected time to arousal and duration of mechanical ventilation in patients without acute brain injury. Design: Two-phase, prospective, controlled study. Setting: University-affiliated medical intensive care unit. Patients: Patients without acute brain injury requiring mechanical ventilation for at least 24 hrs. Interventions: During the control phase, sedatives and analgesics were adjusted according to the physician's decision. During the algorithm phase, sedatives and analgesics were adjusted according to an algorithm developed by a multidisciplinary team including nurses and physicians. The algorithm was based on regular assessments of consciousness and tolerance to the intensive care unit environment using the Adaptation to Intensive Care Environment instrument and was designed to achieve tolerance and maintain a high level of consciousness. Standard practices, including weaning from the ventilator, were the same during both study phases. Measurements and Main Results. A total of 102 patients were enrolled (control group, n = 54; algorithm group, n = 48). Median duration of mechanical ventilation was significantly shorter in the algorithm group (4.4 days [interquartile range, 2.1-9.8]) compared with the control group (10.3 days [3.5-17.2], p =.014), representing a 57.3% reduction. In Cox multivariate analysis, the risk of remaining on mechanical ventilation was 0.48 times (95% confidence interval, 0.29-0.78) lower for algorithm patients compared with controls. The median time to arousal was also significantly shorter in patients in the algorithm group (2 days [2-5]) compared with the control group (4 days [2-9], p =.006). Conclusions. The use of a sedation algorithm to promote tolerance to the intensive care environment and preserve consciousness in patients without acute brain injury resulted in a marked decrease in the duration of mechanical ventilation. This reduction was at least partly attributable to a shorter time to arousal after initiation of mechanical ventilation.	Poissy Hosp, Med Intens Care Unit, Poissy, France; Univ Paris 12, Hop Henri Mondor, Dept Publ Hlth, F-94010 Creteil, France	De Jonghe, B (reprint author), Poissy Hosp, Med Intens Care Unit, Poissy, France.		Bastuji-Garin, Sylvie/R-3479-2018	Bastuji-Garin, Sylvie/0000-0001-9855-5183			Barr J, 2001, ANESTHESIOLOGY, V95, P286, DOI 10.1097/00000542-200108000-00007; BarrientosVega R, 1997, CRIT CARE MED, V25, P33, DOI 10.1097/00003246-199701000-00009; BAUER TM, 1995, LANCET, V346, P145, DOI 10.1016/S0140-6736(95)91209-6; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; BYATT CM, 1984, BRIT MED J, V289, P799, DOI 10.1136/bmj.289.6448.799; CARRASCO G, 1993, CHEST, V103, P557, DOI 10.1378/chest.103.2.557; Chevron V, 1998, CRIT CARE MED, V26, P1049, DOI 10.1097/00003246-199806000-00026; COX DR, 1972, J R STAT SOC B, V34, P187; De Jonghe B, 2003, CRIT CARE MED, V31, P2344, DOI 10.1097/01.CCM.0000084850.16444.94; Devlin JW, 1997, ANN PHARMACOTHER, V31, P689, DOI 10.1177/106002809703100604; Diringer MN, 2001, CRIT CARE MED, V29, P1792, DOI 10.1097/00003246-200109000-00023; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; FAGON JY, 1993, INTENS CARE MED, V19, P137, DOI 10.1007/BF01720528; Hall RI, 2001, CHEST, V119, P1151, DOI 10.1378/chest.119.4.1151; HANSENFLASCHEN JH, 1991, JAMA-J AM MED ASSOC, V266, P2870, DOI 10.1001/jama.266.20.2870; Herr DL, 2003, J CARDIOTHOR VASC AN, V17, P576, DOI 10.1016/S1053-0770(03)00200-3; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; MacLaren R, 2000, PHARMACOTHERAPY, V20, P662, DOI 10.1592/phco.20.7.662.35172; MALACRIDA R, 1992, CRIT CARE MED, V20, P1123, DOI 10.1097/00003246-199208000-00010; Ostermann ME, 2000, JAMA-J AM MED ASSOC, V283, P1451, DOI 10.1001/jama.283.11.1451; Papanikolaou P, 2003, J ADV NURS, V44, P128, DOI 10.1046/j.1365-2648.2003.02778.x; PHAM LH, 1991, AM REV RESPIR DIS, V143, P1055, DOI 10.1164/ajrccm/143.5_Pt_1.1055; Santoli F, 2001, INTENS CARE MED, V27, P1141, DOI 10.1007/s001340100998; SHAFER A, 1990, CRIT CARE MED, V18, P1039, DOI 10.1097/00003246-199009000-00024; Sharshar T, 2002, CRIT CARE MED, V30, P2371, DOI 10.1097/00003246-200210000-00031; Soliman HM, 2001, BRIT J ANAESTH, V87, P186, DOI 10.1093/bja/87.2.186; Thel MC, 1997, LANCET, V350, P1272, DOI 10.1016/S0140-6736(97)05048-4; Triltsch AE, 2002, CRIT CARE MED, V30, P1007, DOI 10.1097/00003246-200205000-00009; Tung A, 2001, J CLIN ANESTH, V13, P24, DOI 10.1016/S0952-8180(00)00237-3; Venn RM, 2001, BRIT J ANAESTH, V87, P684, DOI 10.1093/bja/87.5.684; Walder B, 2001, ANESTH ANALG, V92, P975, DOI 10.1097/00000539-200104000-00033; Watling SM, 1997, ANN PHARMACOTHER, V31, P148, DOI 10.1177/106002809703100202	38	147	151	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	JAN	2005	33	1					120	127		10.1097/01.CCM.0000150268.04228.68			8	Critical Care Medicine	General & Internal Medicine	887WN	WOS:000226336300017	15644658				2020-06-30	J	Cortinez, LI; Munoz, HR; De la Fuente, R; Acuna, D; Dagnino, JA				Cortinez, LI; Munoz, HR; De la Fuente, R; Acuna, D; Dagnino, JA			Target-controlled infusion of remifentanil or fentanyl during extra-corporeal shock-wave lithotripsy	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						pharmacology, fentanyl, remifentanil, target-controlled infusion; respiratory depression; surgical procedures, extra-corporeal shock-wave lithotripsy	COMPUTER-CONTROLLED INFUSION; MONITORED ANESTHESIA CARE; ALVEOLAR CONCENTRATION; PHARMACOKINETICS; ALFENTANIL; REDUCTION; DRUG; PUMP	Background and objective: Target-controlled infusions (TCIs) of remifentanil and fentanyl in conscious sedation regimes for extra-corporeal shock-wave lithotripsy have not been reported. We estimated the effect site concentrations of remifentanil and fentanyl needed to obtain adequate analgesia in 50% of patients (EC50) and compared both drugs in terms of intra- and post-procedure complications. Methods: Forty-four adult patients were randomly distributed into two groups: Group R received remifentanil and Group F received fentanyl TCI with initial effect site concentrations of 1.5 and 2 ng mL(-1), respectively. Pain was assessed using a 10-point verbal analogue scale and <3 was considered adequate analgesia. Increments or decrements of 0.5 ng mL(-1) were then introduced for subsequent patients according to Dixon's up and down method. During the rest of the procedure, TO was adjusted to maintain verbal analogue scale <3. Results: Remifentanil and fentanyl EC50 were 2.8 ng mL(-1) (95 % confidence interval (CI): 1.8-3.7 ng mL(-1)) and 2.9 ng mL(-1) (95 % Cl: 1.7-4.1 ng mL(-1)), respectively (n.s.). At EC50, the probability of having a respiratory rate <10 was 4% MIX Cl: 0-57%) for remifentanil and 56%, (95% Cl: 13-92%) for fentanyl. Hypoxaemia, vomiting and sedation were more frequent in Group F during and after the procedure (P < 0.05). Conclusions: A similar EC50 but more respiratory depression, sedation and PONV were found with fentanyl TO than with remifentanil TCI.	Pontificia Univ Catolica Chile, Dept Anesthesiol, Santiago, Chile	Cortinez, LI (reprint author), Pontificia Univ Catolica Chile, Hosp Clin, Dept Anestesiol, Alameda 340, Santiago, Chile.	licorti@med.puc.cl					AUSEMS ME, 1988, ANESTHESIOLOGY, V68, P851, DOI 10.1097/00000542-198806000-00004; Beloeil H, 2002, BRIT J ANAESTH, V89, P567, DOI 10.1093/bja/aef202; BROMAGE PR, 1989, ANESTH ANALG, V68, P363; Chen SW, 1996, EUR J PHARMACOL, V312, P241, DOI 10.1016/0014-2999(96)00571-7; Coloma M, 2000, ANESTH ANALG, V91, P92; Dixon WJ, 1969, INTRO STAT ANAL; Gesztesi Z, 2000, ANESTH ANALG, V90, P567, DOI 10.1097/00000539-200003000-00013; GOLDMAN JM, 1987, ANESTHESIOLOGY, V67, P606, DOI 10.1097/00000542-198710000-00038; Gravenstein D, 2000, Anesthesiol Clin North Am, V18, P953, DOI 10.1016/S0889-8537(05)70203-0; Joo HS, 2001, ANESTH ANALG, V93, P1227, DOI 10.1097/00000539-200111000-00037; Joshi GP, 2002, J CLIN ANESTH, V14, P494, DOI 10.1016/S0952-8180(02)00404-X; Lang E, 1996, ANESTHESIOLOGY, V85, P721, DOI 10.1097/00000542-199610000-00006; MAITRE PO, 1987, ANESTHESIOLOGY, V66, P3, DOI 10.1097/00000542-198701000-00002; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; MCEWAN AI, 1993, ANESTHESIOLOGY, V78, P864, DOI 10.1097/00000542-199305000-00009; Mertens MJ, 2003, BRIT J ANAESTH, V90, P132, DOI 10.1093/bja/aeg046; Minto CF, 1997, ANESTHESIOLOGY, V86, P24, DOI 10.1097/00000542-199701000-00005; Paul M, 2001, ANESTHESIOLOGY, V95, P1362, DOI 10.1097/00000542-200112000-00014; Puchner W, 2002, ACTA ANAESTH SCAND, V46, P350, DOI 10.1034/j.1399-6576.2002.460403.x; Rego MMS, 1999, ANESTH ANALG, V88, P518; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; SHAFER SL, 1992, J PHARMACOKINET BIOP, V20, P147, DOI 10.1007/BF01070999	22	15	19	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	JAN	2005	22	1					56	61		10.1017/S0265021505000128			6	Anesthesiology	Anesthesiology	932DS	WOS:000229535000012	15816575				2020-06-30	J	Thevis, M; Geyer, H; Bahr, D; Schanzer, W				Thevis, M; Geyer, H; Bahr, D; Schanzer, W			Identification of fentanyl, alfentanil, sufentanil, remifentanil and their major metabolites in human urine by liquid chromatography/tandem mass spectrometry for doping control purposes	EUROPEAN JOURNAL OF MASS SPECTROMETRY			English	Article						sport; opioids; doping; liquid chromatography; mass spectrometry; fragmentation; collision-induced dissociation	GAS-CHROMATOGRAPHY; HUMAN PLASMA; QUANTITATIVE-DETERMINATION; PHARMACOLOGICAL-PROPERTIES; THERAPEUTIC-EFFICACY; TRANSDERMAL FENTANYL; PHARMACOKINETICS; NORFENTANYL; BLOOD	Since January 2005, the list of prohibited substances established by the World Anti-Doping Agency prohibits the opioid agent fentanyl as well as its related drugs in professional and amateur sports. Fast, reliable and robust analytical assays are required that allow the sensitive determination of these compounds or respective metabolites in human urine and liquid chromatography interfaced to mass spectrometry has proven to be a suitable and powerful tool for drug testing for several years. A screening and confirmation method was developed that enables the identification of fentanyl, alfentanil, remifentanil and sufentanil as well as their N-dealkylated or de-esterified metabolites utilizing solid-phase extraction of a 2mL urine aliquot followed by LC-electrospray-MS/MS analysis. The procedure was validated in terms of recovery (95.8-104.9%), lower limit of detection (0.5 ng mL(-1)), specificity and interday precision (3.9-19.8%) for the four opioid drugs and the metabolic product norfentanyl. In addition, the mass spectrometric behavior of fentanyl after electrospray ionization and collision-induced dissociation was studied by synthesis and analysis of structurally related compounds and dissociation pathways were proposed allowing the characterization of target analytes and corresponding metabolites.	German Sport Univ Cologne, Inst Biochem, D-50933 Cologne, Germany	Thevis, M (reprint author), German Sport Univ Cologne, Inst Biochem, Carl Dien Weg 6, D-50933 Cologne, Germany.	m.thevis@biochemn.dshs-koeln-de					Bender J, 1999, J PHARMACEUT BIOMED, V21, P559, DOI 10.1016/S0731-7085(99)00151-X; CASY AF, 1988, J PHARM PHARMACOL, V40, P605, DOI 10.1111/j.2042-7158.1988.tb05318.x; Day J, 2003, J ANAL TOXICOL, V27, P513, DOI 10.1093/jat/27.7.513; Egan TD, 1997, WESTERN J MED, V166, P202; EGAN TD, 1995, CLIN PHARMACOKINET, V29, P80, DOI 10.2165/00003088-199529020-00003; EGAN TD, 1993, ANESTHESIOLOGY, V79, P881, DOI 10.1097/00000542-199311000-00004; GOROMARU T, 1984, ANESTHESIOLOGY, V61, P73, DOI 10.1097/00000542-198461010-00013; HAMMARGREN WR, 1988, J ANAL TOXICOL, V12, P183, DOI 10.1093/jat/12.4.183; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Kiricojevic VD, 2002, J SERB CHEM SOC, V67, P793, DOI 10.2298/JSC0212793K; KROMIDAS A, 1999, VALIDIERUNG ANAL; Latasch L, 1989, Acta Anaesthesiol Belg, V40, P113; LIN SN, 1981, J PHARM SCI, V70, P1276, DOI 10.1002/jps.2600701124; Mastronardi P, 2001, Minerva Anestesiol, V67, P332; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MEULDERMANS W, 1987, DRUG METAB DISPOS, V15, P905; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Palleschi L, 2003, J PHARMACEUT BIOMED, V32, P329, DOI 10.1016/S0731-7085(03)00110-9; Pihlainen K, 2005, J MASS SPECTROM, V40, P539, DOI 10.1002/jms.831; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; SELINGER K, 1994, J PHARMACEUT BIOMED, V12, P243, DOI 10.1016/0731-7085(94)90035-3; Shou WZ, 2001, RAPID COMMUN MASS SP, V15, P466, DOI 10.1002/rcm.255; Suh YG, 1998, ARCH PHARM RES, V21, P70, DOI 10.1007/BF03216756; Valaer AK, 1997, J CHROMATOGR SCI, V35, P461, DOI 10.1093/chromsci/35.10.461; VANROOY HH, 1981, J CHROMATOGR, V223, P85, DOI 10.1016/S0378-4347(00)80070-5; *WADA, [No title captured]	27	28	28	1	25	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1469-0667	1751-6838		EUR J MASS SPECTROM	Eur. J. Mass Spectrom.		2005	11	4					419	427		10.1255/ejms.761			9	Physics, Atomic, Molecular & Chemical; Spectroscopy	Physics; Spectroscopy	981HO	WOS:000233078500008	16204809				2020-06-30	J	Doi, M; Morita, K; Mantzaridis, H; Sato, S; Kenny, GNC				Doi, M; Morita, K; Mantzaridis, H; Sato, S; Kenny, GNC			Prediction of responses to various stimuli during sedation: a comparison of three EEG variables	INTENSIVE CARE MEDICINE			English	Article						auditory evoked potentials; Bispectral Index; monitoring of sedation; Ramsay Sedation Score; intensive care; prediction probability	CRITICALLY-ILL PATIENTS; EVOKED POTENTIAL INDEX; SPECTRAL EDGE FREQUENCY; BISPECTRAL INDEX; AGITATION SCALE; MEDIAN FREQUENCY; ICU PATIENTS; ANESTHESIA; MOVEMENT; PROPOFOL	Objective: To compare the ability of the aepEX, a derivative of auditory evoked potentials, the bispectral index, and SEF95% to predict responses to various stimuli. Design: Prospective clinical study. Setting: General Intensive Care Unit in a university hospital. Patients and participants: Forty postsurgical, mechanically ventilated patients. Interventions: Target concentrations of blood propofol were randomly set at 0.5 mug/ml, 1.0 mug/ml, 1.5 mug/ml, and 2.0 mug/ml, with a fixed fentanyl infusion rate between 0.5 mug . kg(-1) . h(-1) and 1.5 mug . kg(-1) . h(-1). Measurements: Depth of sedation was subjectively assessed with the Ramsay Sedation Score. The aepEX was recorded using an auditory evoked potentials system. The bispectral index and SEF95% were measured using an Aspect A- 1000 monitor. Results: The aepEX, bispectral index, and SEF95% correlated with the Ramsay Sedation Score, the Pk value being greatest for the aepEX, followed by the bispectral index. All three variables could predict opening of the eyes in response to verbal commands or a glabellar tap, the aepEX being a better predictor than the bispectral index or SEF95%. All three EEG variables had Pk values > 0.5 in predicting coughing or movement in response to tracheal suction, but they were unable to predict increases in heart rate or systolic blood pressure. Conclusions: The aepEX was the best predictor, followed by bispectral index. Although in most intensive care patients subjective sedation scales are sufficient to assess levels of sedation, the aepEX and bispectral index were potential alternatives to subjective scales when they do not work well in the setting of neuromuscular blockade or may not be sufficiently sensitive to evaluate very deep sedation.	Hamamatsu Univ Sch Med, Dept Anesthesiol & Intens Care, Hamamatsu, Shizuoka 4313192, Japan; Hamamatsu Univ Hosp, Surg Ctr, Hamamatsu, Shizuoka, Japan; Glasgow Royal Infirm, Univ Dept Anaesthesia, Glasgow G4 0SF, Lanark, Scotland	Doi, M (reprint author), Hamamatsu Univ Sch Med, Dept Anesthesiol & Intens Care, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	matdoi@hama-med.ac.jp					Absalom AR, 2001, BRIT J ANAESTH, V87, P778, DOI 10.1093/bja/87.5.778; Doi M, 1999, BRIT J ANAESTH, V82, P203, DOI 10.1093/bja/82.2.203; Doi M, 1997, ANAESTHESIA, V52, P1048, DOI 10.1111/j.1365-2044.1997.229-az0364.x; Doi M, 1997, BRIT J ANAESTH, V78, P180; Frenzel D, 2002, INTENS CARE MED, V28, P178, DOI 10.1007/s00134-001-1183-4; KENNY GNC, 1992, INT J CLIN MONIT COM, V9, P179, DOI 10.1007/BF01145171; Kurita T, 2001, ANESTHESIOLOGY, V95, P364, DOI 10.1097/00000542-200108000-00017; Mantzaridis H, 1997, ANAESTHESIA, V52, P1030, DOI 10.1111/j.1365-2044.1997.185-az0327.x; Mondello Epifanio, 2002, J Clin Monit Comput, V17, P271, DOI 10.1023/A:1021250320103; Nasraway SA, 2002, CRIT CARE MED, V30, P1483, DOI 10.1097/00003246-200207000-00014; RAMSAY MA, 1974, [No title captured], V22, P656; Riker RR, 1999, CRIT CARE MED, V27, P1325, DOI 10.1097/00003246-199907000-00022; RIKER RR, 1994, CRIT CARE MED, V22, P433, DOI 10.1097/00003246-199403000-00013; Riker RR, 2001, INTENS CARE MED, V27, P853, DOI 10.1007/s001340100912; Rundshagen I, 2000, INTENS CARE MED, V26, P1312, DOI 10.1007/s001340000591; SCHLTETAMBUREN AM, 1999, INTENS CARE MED, V25, P377; Simmons LE, 1999, CRIT CARE MED, V27, P1499, DOI 10.1097/00003246-199908000-00016; Smith WD, 1996, ANESTHESIOLOGY, V84, P38, DOI 10.1097/00000542-199601000-00005; Thornton C, 1998, BRIT J ANAESTH, V81, P771, DOI 10.1093/bja/81.5.771; Walder B, 2001, INTENS CARE MED, V27, P107, DOI 10.1007/s001340000761	20	29	29	1	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	JAN	2005	31	1					41	47		10.1007/s00134-004-2516-x			7	Critical Care Medicine	General & Internal Medicine	887NV	WOS:000226313700007	15650862				2020-06-30	J	Dotsikas, Y; Loukas, YL				Dotsikas, Y; Loukas, YL			Application of avidin-biotin technology for the characterization of a model hapten-protein conjugate	JOURNAL OF IMMUNOASSAY & IMMUNOCHEMISTRY			English	Article						hapten-BSA conjugate; electrospray mass spectrometry; HABA; biotin	IONIZATION MASS-SPECTROMETRY; FENTANYL; ELECTROPHORESIS; IMMUNOASSAYS; ANTIBODIES; BINDING; ACID; SITE	A simple method was developed for the rapid characterization of the covalent binding of haptens to proteins such as enzymes, bovine serum albumin (BSA), and other carrier-proteins and antibodies. In the present study, a commercially available fentanyl-BSA conjugate was characterized by a 4'-hydroxyazobenzene-2-carboxylic acid (HABA) dye assay that followed a biotinylation reaction. This protocol allowed the indirect observation of the average hapten number per BSA molecule. Such measurement is useful for optimizing reaction conditions to yield a more precisely defined product for immunological applications. The obtained result was within the limits suggested by the manufacturer of the conjugate.	Univ Athens, Sch Pharm, Dept Pharmaceut Chem, GR-15771 Athens, Greece	Loukas, YL (reprint author), Univ Athens, Sch Pharm, Dept Pharmaceut Chem, GR-15771 Athens, Greece.	loukas@pharm.uoa.gr	Dotsikas, Yannis/I-7745-2018	Dotsikas, Yannis/0000-0003-0882-8286			BARBARAKIS MS, 1991, CLIN CHEM, V37, P87; COLE RB, 1997, ELECTROSPRAY IONIZAT, V55; Dotsikas Y, 2004, ANAL CHIM ACTA, V509, P103, DOI 10.1016/j.aca.2003.12.007; Dotsikas Y, 2002, J PHARMACEUT BIOMED, V29, P487, DOI 10.1016/S0731-7085(02)00076-6; Dotsikas Y, 2002, ANAL CHIM ACTA, V459, P177, DOI 10.1016/S0003-2670(02)00133-2; FENG PCC, 1992, J AGR FOOD CHEM, V40, P211, DOI 10.1021/jf00014a009; GITLIN G, 1987, BIOCHEM J, V242, P923, DOI 10.1042/bj2420923; GOSSLING JP, 2000, IMMUNOASSAYS PRACTIC, V172; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; HENDERSON GL, 1975, J PHARMACOL EXP THER, V192, P489; HERMANSON GT, 1996, BIOCONJUGATE TECHNIQ, V591; KAMPSHOLTZAPPLE C, 1993, J IMMUNOL METHODS, V164, P245, DOI 10.1016/0022-1759(93)90317-Z; LITTLE DP, 1995, J AM CHEM SOC, V117, P6783, DOI 10.1021/ja00130a020; Lundblad RL, 1997, BIOTECHNOL APPL BIOC, V26, P143; METELITZA DI, 1991, BIOCONJUGATE CHEM, V2, P309, DOI 10.1021/bc00011a003; MICHIELS M, 1977, EUR J CLIN PHARMACOL, V12, P153, DOI 10.1007/BF00645137; Morpurgo M, 1999, J BIOCHEM BIOPH METH, V38, P17, DOI 10.1016/S0165-022X(98)00027-X; SHOYAMA Y, 1993, ORG MASS SPECTROM, V28, P987, DOI 10.1002/oms.1210280910; SHULER KR, 1992, J IMMUNOL METHODS, V156, P137, DOI 10.1016/0022-1759(92)90020-T; SIEGEL MM, 1991, ANAL CHEM, V63, P2470, DOI 10.1021/ac00021a016; SIUZDAK G, 1994, P NATL ACAD SCI USA, V91, P11290, DOI 10.1073/pnas.91.24.11290; STRAUB KM, 1994, BIOCONJUGATE CHEM, V5, P194, DOI 10.1021/bc00027a003; Wetzel R, 1990, BIOCONJUGATE CHEM, V1, P114, DOI 10.1021/bc00002a005; WIE SI, 1982, ANAL BIOCHEM, V125, P168, DOI 10.1016/0003-2697(82)90399-2; WILCHEK M, 1988, ANAL BIOCHEM, V171, P1, DOI 10.1016/0003-2697(88)90120-0	25	1	1	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1532-1819	1532-4230		J IMMUNOASS IMMUNOCH	J. Immunoass. Immunoch.		2005	26	4					285	293		10.1080/15321810500220845			9	Biochemical Research Methods; Immunology; Medical Laboratory Technology	Biochemistry & Molecular Biology; Immunology; Medical Laboratory Technology	961PR	WOS:000231674800004	16153013				2020-06-30	J	Zhang, M; Wang, XM; Zhang, DB; Xu, GH; Dong, HW; Yu, YX; Han, JS				Zhang, M; Wang, XM; Zhang, DB; Xu, GH; Dong, HW; Yu, YX; Han, JS			Orphanin FQ antagonizes the inhibition of Ca2+ currents induced by mu-opioid receptors	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						orphanin FQ; ORL1 receptor; single-cell RT-PCR; opioid receptor; calcium channel; patch clamp	ROOT GANGLION NEURONS; CHOLECYSTOKININ-OCTAPEPTIDE REVERSES; NOCICEPTIN/ORPHANIN FQ; MEDIATED INHIBITION; CALCIUM CURRENT; DYNORPHIN-A; IN-VITRO; ORL1; MODULATION; EXPRESSION	Orphanin FQ (OFQ), an endogenous peptide ligand of opioid receptor-like receptors (ORLs), has properties similar tc traditional opioids. This peptide inhibits adenylyl cyclase and voltage-gated calcium channels but stimulates inwardly rectifying potassium channels. Among other actions, however, OFQ also has pharmacological functions that are different from, or even opposite to, those of opioids. For example, OFQ antagonizes the behavioral analgesic effects mediated by kappa- and mu-opioid receptors. In a previous paper, we reported that OFQ antagonizes inhibition of calcium channels mediated by K-opioid receptors. We report here that OFQ also antagonizes the inhibition of calcium channels mediated by mu-opioid receptor. Further, single-cell RT-PCR reveals that the antagonistic effect of OFQ is correlated with the presence of ORL1 mRNA in individual cells.	Peking Univ, Neurosci Res Inst, Beijing, Peoples R China; Capital Univ Med Sic, Dept Physiol, Beijing, Peoples R China; Univ Rochester, Med Ctr, Dept Biostat & Computat Biol, Rochester, NY 14642 USA	Zhang, M (reprint author), Peking Univ, Neurosci Res Inst, Beijing, Peoples R China.	mz35@cornell.edu			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA03983]		AGIUS GM, 1998, J COMP NEUROL, V399, P373; Chin JH, 2002, J PHARMACOL EXP THER, V303, P188, DOI 10.1124/jpet.102.037945; Chiou LC, 2002, NEUROPHARMACOLOGY, V42, P246, DOI 10.1016/S0028-3908(01)00159-9; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; GROSS RA, 1990, P NATL ACAD SCI USA, V87, P7025, DOI 10.1073/pnas.87.18.7025; Harrison LM, 2000, PEPTIDES, V21, P151, DOI 10.1016/S0196-9781(99)00185-0; Knoflach F, 1996, J NEUROSCI, V16, P6657; Lapalu S, 1997, FEBS LETT, V417, P333, DOI 10.1016/S0014-5793(97)01318-5; Liu NJ, 1995, J PHARMACOL EXP THER, V275, P1293; Mogil JS, 1996, NEUROSCI LETT, V214, P131, DOI 10.1016/0304-3940(96)12917-7; MOLLEREAU C, 1994, FEBS LETT, V341, P33, DOI 10.1016/0014-5793(94)80235-1; MOTIN LG, 1995, NEUROSCI LETT, V193, P21, DOI 10.1016/0304-3940(95)11656-H; Ozaki S, 2000, EUR J PHARMACOL, V387, pR17, DOI 10.1016/S0014-2999(99)00822-5; Ozaki S, 2000, EUR J PHARMACOL, V402, P45, DOI 10.1016/S0014-2999(00)00520-3; Polo-Parada L, 1999, J NEUROSCI, V19, P5213; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; SEWARD E, 1991, P ROY SOC B-BIOL SCI, V244, P129, DOI 10.1098/rspb.1991.0061; Vaughan CW, 2001, J PHYSIOL-LONDON, V534, P849, DOI 10.1111/j.1469-7793.2001.00849.x; WANG JB, 1994, FEBS LETT, V348, P75, DOI 10.1016/0014-5793(94)00557-5; WiesenfeldHallin Z, 1996, REGUL PEPTIDES, V65, P23, DOI 10.1016/0167-0115(96)00068-7; Xu T, 1996, BRAIN RES, V730, P207; Yamada S, 2003, BRIT J PHARMACOL, V139, P1462, DOI 10.1038/sj.bjp.0705371; Zhang M, 1998, NEUROREPORT, V9, P2095, DOI 10.1097/00001756-199806220-00034; ZHANG X, 1995, J NEUROSCI, V15, P2733	25	11	11	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.		2005	25	1					21	27		10.1385/JMN:25:1:021			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	924TV	WOS:000229004200003	15781963				2020-06-30	J	Allegaert, K; Devlieger, H; Bulckaert, D; Naulaers, G; Casaer, P; Tibboel, D				Allegaert, K; Devlieger, H; Bulckaert, D; Naulaers, G; Casaer, P; Tibboel, D			Variability in pain expression characteristics in former preterm infants	JOURNAL OF PERINATAL MEDICINE			English	Article						preterm infant; pain expression; pre-emptive analgesia; procedural pain	BIRTH-WEIGHT INFANTS; PROCEDURAL PAIN; INTENSIVE-CARE; CORRECTED AGE; SENSITIVITY; VACCINATION; REACTIVITY; RESPONSES; NEWBORN	Objectives: To document pain expression characteristics in former preterm infants in the first year of life in whom systematic evaluation and treatment of pain was provided. Methods: Data on the Modified Behavioral Pain Scale (MBPS), Visual Analogue Scale (VAS, crying time and heart rate were collected during immunization. The effect of clinical characteristics [postconception and gestational age [PCA], surgery, ventilation, fentanyl, length of stay (LOS)} on bio-behavioral parameters was evaluated. Results: 121 procedures were recorded in 49 infants. GA was 28 (25-32) weeks. PCA was 60 (34-90) weeks. Median MBPS was 8 (2-10), median crying time 44 (0-112) s. Median pre-procedural heart rate was 144 (103-201) and increased to 184 (147-220) afterwards, resulting in a relative increase of 29 (5-99)%. Median VAS score was 7 (1-10). Significant correlations of PCA with pre-procedural heart rate (r= -0.36) and with relative increase in heart rate (r = 0.33) were identified. A correlation of LOS on crying time (r=0.37) was observed. Conclusions: Correlations of PCA with pre-procedural and relative increase in heart rate reflect the maturational decrease in heart rate. LOS had an effect on pain expression, potentially reflecting the impact of cumulative 'minor' procedural pain.	Univ Hosp Gasthuisberg, Dept Pediat, Neonatal Intens Care Unit, B-3000 Louvain, Belgium; Sophias Childrens Hosp, Dept Pediat Surg, Rotterdam, Netherlands	Allegaert, K (reprint author), Univ Hosp Gasthuisberg, Dept Pediat, Neonatal Intens Care Unit, Herestr 49, B-3000 Louvain, Belgium.	karel.allegaert@uz.kuleuven.ac.be	Naulaers, Gunnar/AAC-5022-2019; allegaert, karel/C-3611-2016	allegaert, karel/0000-0001-9921-5105; Naulaers, Gunnar/0000-0003-0735-4808			Allegaert K, 2003, EUR J CLIN PHARMACOL, V59, P87, DOI 10.1007/s00228-003-0585-3; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; Anand KJS, 2001, ARCH PEDIAT ADOL MED, V155, P173, DOI 10.1001/archpedi.155.2.173; BARKER DP, 1995, ARCH DIS CHILD-FETAL, V72, pF47, DOI 10.1136/fn.72.1.F47; Buskila D, 2003, ARCH PEDIAT ADOL MED, V157, P1079, DOI 10.1001/archpedi.157.11.1079; CRAIG KD, 2000, CLIN DEV MED, V152; Grunau RE, 2004, PEDIATRICS, V114, pE77, DOI 10.1542/peds.114.1.e77; Grunau RE, 2001, INFANT BEHAV DEV, V24, P41; Grunau RE, 2001, PEDIATRICS, V107, P105, DOI 10.1542/peds.107.1.105; GRUNAU RVE, 1994, PAIN, V58, P341, DOI 10.1016/0304-3959(94)90128-7; Johnston CC, 1996, DEV MED CHILD NEUROL, V38, P438; Oberlander TF, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.1.e6; Peters JWB, 2003, PEDIATRICS, V111, P129, DOI 10.1542/peds.111.1.129; SIMONS SH, 2002, PEDIATR RES, V54, pA266; Simons SHP, 2003, ARCH PEDIAT ADOL MED, V157, P1058, DOI 10.1001/archpedi.157.11.1058; Taddio A, 1997, LANCET, V349, P599, DOI 10.1016/S0140-6736(96)10316-0; Taddio A, 2002, JAMA-J AM MED ASSOC, V288, P857, DOI 10.1001/jama.288.7.857; TADDIO A, 1994, J PEDIATR-US, V124, P643, DOI 10.1016/S0022-3476(05)83150-6; van Dijk M, 2002, CLIN PERINATOL, V29, P469, DOI 10.1016/S0095-5108(02)00015-5; YEH TS, 1982, CRIT CARE MED, V10, P497, DOI 10.1097/00003246-198208000-00002	20	5	6	1	3	WALTER DE GRUYTER & CO	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0300-5577			J PERINAT MED	J. Perinat. Med.		2005	33	5					442	448		10.1515/JPM.2005.078			7	Obstetrics & Gynecology; Pediatrics	Obstetrics & Gynecology; Pediatrics	969ZE	WOS:000232274200011	16238540				2020-06-30	J	Ikai, A; Riemer, RK; Ramamoorthy, C; Malhatra, S; Cassorla, L; Amir, G; Hanley, FL; Reddy, VM				Ikai, A; Riemer, RK; Ramamoorthy, C; Malhatra, S; Cassorla, L; Amir, G; Hanley, FL; Reddy, VM			Preliminary results of fetal cardiac bypass in nonhuman primates	JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY			English	Article; Proceedings Paper	84th Annual Meeting of the American-Association-for-Thoracic-Surgery	APR 25-MAY 28, 2004	Toronto, CANADA	Amer Assoc Thorac Surg			PLACENTAL DYSFUNCTION; FLOW; ISOFLURANE; INHIBITION; KETAMINE; SURGERY; VOLUME	Objective: Fetal cardiac surgery has potential benefits for treatment of some congenital heart defects. However, placental dysfunction as a result of fetal bypass, fetal stress, and fetal exposure to external milieu needs to be overcome to optimize the outcomes of fetal cardiac bypass. In this study we evaluated the technical feasibility of cardiac bypass in the nonhuman primate fetus and the efficacy of different anesthetic approaches. Methods: Twelve baboon fetuses, average gestation 146 +/- 8 days and weight 696 +/- 1184 g, were used. Three fetuses were excluded from the study because of nuchal cord presentations. The animals were separated into two anesthesia groups: isoflurane (n = 6) and fentanyl and midazolam (n = 3). A miniature roller pump circuit without oxygenator was used for fetal bypass for 30 minutes. No blood transfusion was pet-formed. Fetal blood gas samples were collected before bypass, during bypass, and at 15 and 60 minutes after bypass. Results: All fetuses in the isoflurane group were successfully placed on the cardiac bypass circuit. However, 2 animals in the fentanyl and midazolam group were not placed on the bypass circuit because of sustained elevation in maternal uterine tone. All maternal baboons survived. Of the 6 fetuses in the isoflurane group, 5 survived for 60 minutes; however, placental function continued to deteriorate after bypass (Pao(2) 33 +/- 3 mm Hg before bypass, 23 +/- 6 mm Hg 15 minutes after, and 18 +/- 9 mm Hg 60 minutes after). Conclusion: The technical feasibility of cardiac bypass in nonhuman primate fetuses weighing less than 1000 g was confirmed. Isoflurane anesthesia appears to be superior to fentanyl and midazolam anesthesia for fetal cardiac surgery because of adequate uterine relaxation.	Stanford Univ, Sch Med,Dept Cardiothorac Surg, Div Pediat Cardiac Surg, Falk CVRC, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Anesthesiol, Div Pediat Cardiac Anesthesiol, Stanford, CA 94305 USA; NYU Med Ctr, Dept Surg, New York, NY 10016 USA; Univ Calif San Francisco, Dept Anesthesiol, San Francisco, CA 94143 USA	Reddy, VM (reprint author), Stanford Univ, Sch Med,Dept Cardiothorac Surg, Div Pediat Cardiac Surg, Falk CVRC, 300 Pasteur Dr, Stanford, CA 94305 USA.	vmreddy@Stanford.edu			NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL43357]		BIEHL DR, 1983, CAN ANAESTH SOC J, V30, P581, DOI 10.1007/BF03015226; BISSONNETTE JM, 1973, J APPL PHYSIOL, V35, P355; BOILLOT A, 1995, BRIT J ANAESTH, V75, P761, DOI 10.1093/bja/75.6.761; Carotti A, 2003, J THORAC CARDIOV SUR, V126, P1839, DOI 10.1016/S0022-5223(03)01293-5; ELLINGSON A, 1977, ACTA ANAESTH SCAND, V21, P41, DOI 10.1111/j.1399-6576.1977.tb01191.x; FENTON KN, 1994, J THORAC CARDIOV SUR, V107, P1416, DOI 10.1016/S0022-5223(94)70416-3; Gaiser RR, 1999, SEMIN PERINATOL, V23, P507, DOI 10.1016/S0146-0005(99)80029-9; HAWKINS JA, 1994, ANN THORAC SURG, V57, P293, DOI 10.1016/0003-4975(94)90986-5; Parry AJ, 2000, ANN THORAC SURG, V70, P582, DOI 10.1016/S0003-4975(00)01570-8; Reddy V M, 2001, Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu, V4, P271, DOI 10.1053/tc.2001.24985; Reddy VM, 1999, J THORAC CARDIOV SUR, V117, P343, DOI 10.1016/S0022-5223(99)70432-0; Reddy VM, 1996, ANN THORAC SURG, V62, P393, DOI 10.1016/0003-4975(96)00243-3; Rosen MA, 2001, YONSEI MED J, V42, P669, DOI 10.3349/ymj.2001.42.6.669; SABIK JF, 1994, J THORAC CARDIOV SUR, V107, P116; SABIK JF, 1992, J THORAC CARDIOV SUR, V103, P733; TAGA K, 1990, ANESTHESIOLOGY, V72, P939, DOI 10.1097/00000542-199005000-00025	16	12	15	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-5223	1097-685X		J THORAC CARDIOV SUR	J. Thorac. Cardiovasc. Surg.	JAN	2005	129	1					175	181		10.1016/j.jtcvs.2004.09.003			7	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Cardiovascular System & Cardiology; Respiratory System; Surgery	886HD	WOS:000226216600024	15632840				2020-06-30	J	Greenwald, MK; Roehrs, TA				Greenwald, MK; Roehrs, TA			Mu-opioid self-administration vs passive administration in heroin abusers produces differential EEG activation	NEUROPSYCHOPHARMACOLOGY			English	Article						opioid dependence; self-administration; EEG; fentanyl; naloxone; reinforcement	VENTRAL TEGMENTAL AREA; FREELY MOVING RATS; NUCLEUS-ACCUMBENS; CROSS-TOLERANCE; NEUROTRANSMITTER TURNOVER; NEURONAL RESPONSES; SEEKING BEHAVIOR; MORPHINE; FENTANYL; DRUG	Psychoactive drug self-administration (SA) produces different neurobiological effects than passive administration (PA) in non-human animals; however, such consequences have never been examined in human drug abusers. The present study compared electroencephalographic (EEG) activation produced by intravenous PA and SA of the mu-opioid fentanyl in eight heroin-dependent, methadone-stabilized male participants. In phase 1, participants received cumulative PA of fentanyl (up to 1.5 mg/70 kg; session 1), then bolus PA of placebo and fentanyl 1.5 mg/70 kg (session 2). High-dose fentanyl significantly increased the amplitude of slow-frequency (delta- and theta-band) EEG activity. In phase 2, bolus fentanyl 1.5 mg/70 kg was available for SA, requiring the participant to complete 1500 responses, in each of two sessions after saline or naloxone pretreatment. Delta EEG peak amplitude increases were greater following fentanyl SA than fentanyl PA, primarily over the central midline region, and were attenuated by naloxone pretreatment. The EEG increase and its attenuation by naloxone agree with preclinical evidence and suggest that SA-related EEG responses were mediated by opioid receptors.	Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Subst Abuse Res Div, Detroit, MI 48207 USA; Henry Ford Hosp, Sleep Disorders & Res Ctr, Detroit, MI 48202 USA	Greenwald, MK (reprint author), Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Subst Abuse Res Div, 2761 E Jefferson Ave, Detroit, MI 48207 USA.	mgreen@med.wayne.edu			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R29 DA11079]		AMIT Z, 1976, PSYCHOPHARMACOLOGY, V48, P291, DOI 10.1007/BF00496864; BARTOLETTI M, 1987, NEUROPHARMACOLOGY, V26, P115, DOI 10.1016/0028-3908(87)90197-3; Baylon GJ, 2000, J CLIN PSYCHOPHARM, V20, P597, DOI 10.1097/00004714-200012000-00002; BOVILL JG, 1983, BR J ANAESTH S2, V55, P199; Chang JY, 1997, BRAIN RES, V754, P12, DOI 10.1016/S0006-8993(97)00012-7; Chang JY, 1998, J NEUROSCI, V18, P3098; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; Choe CH, 2000, PEDIATR RES, V47, P727, DOI 10.1203/00006450-200006000-00008; DWORKIN SI, 1995, PSYCHOPHARMACOLOGY, V117, P262, DOI 10.1007/BF02246100; Emmett-Oglesby M.W., 1989, Behav Pharmacol, V1, P3; Fink M., 1971, NARCOTIC DRUGS BIOCH, P452; First M., 1996, STRUCTURED CLIN INTE; GRASING K, 1993, NEUROPHARMACOLOGY, V32, P543, DOI 10.1016/0028-3908(93)90050-D; Greenwald MK, 1996, J PHARMACOL EXP THER, V277, P1228; Greenwald MK, 2002, EXP CLIN PSYCHOPHARM, V10, P39, DOI 10.1037//1064-1297.10.1.39; GREENWALD MK, 1999, NIDA RES MONOGR, V179, P311; GREENWALD MK, 2004, IN PRESS EXP CLIN PS; HEMBY SE, 1995, J PHARMACOL EXP THER, V273, P591; Jacobs EH, 2004, FASEB J, V18, P200, DOI 10.1096/fj.03-0317fje; Jacobs EH, 2003, TRENDS PHARMACOL SCI, V24, P566, DOI 10.1016/j.tips.2003.09.006; Jacobs EH, 2002, FASEB J, V16, P1961, DOI 10.1096/fj.02-0272fje; Kiyatkin EA, 2001, NEUROSCIENCE, V102, P565, DOI 10.1016/S0306-4522(00)00492-9; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Lee RS, 1999, SYNAPSE, V33, P49, DOI 10.1002/(SICI)1098-2396(199907)33:1<49::AID-SYN5>3.3.CO;2-F; *NAT I DRUG AB COM, 2002, EP TRENDS DRUG AB; PHILLIPS RL, 1994, NEUROPSYCHOPHARMACOL, V10, P171, DOI 10.1038/npp.1994.19; Powell KR, 2001, DRUG ALCOHOL DEPEN, V62, P83, DOI 10.1016/S0376-8716(00)00167-8; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; SEBEL PS, 1981, ANESTHESIOLOGY, V55, P203, DOI 10.1097/00000542-198109000-00004; SELF DW, 1995, SYNAPSE, V21, P312, DOI 10.1002/syn.890210405; SHIPLEY BB, 1967, SHIPLEY I LIVING SCA; SMITH JE, 1984, PHARMACOL BIOCHEM BE, V20, P429, DOI 10.1016/0091-3057(84)90282-X; SMITH JE, 1982, PHARMACOL BIOCHEM BE, V16, P509, DOI 10.1016/0091-3057(82)90460-9; SMITH JE, 1980, NATURE, V287, P152, DOI 10.1038/287152a0; SMITH JE, 1984, PHARMACOL BIOCHEM BE, V20, P443, DOI 10.1016/0091-3057(84)90283-1; Thornton SR, 2000, PHARMACOL BIOCHEM BE, V65, P563, DOI 10.1016/S0091-3057(99)00262-2; TORTELLA FC, 1979, J PHARMACOL EXP THER, V210, P174; VOLAVKA J, 1970, NEUROPHARMACOLOGY, V9, P587, DOI 10.1016/0028-3908(70)90009-2; Walker EA, 1997, PSYCHOPHARMACOLOGY, V133, P17, DOI 10.1007/s002130050366; WAUQUIER A, 1984, NEUROPSYCHOBIOLOGY, V11, P203, DOI 10.1159/000118078; WELZL H, 1989, NEUROPHARMACOLOGY, V28, P1017, DOI 10.1016/0028-3908(89)90112-3; YOUNG GA, 1984, NEUROPHARMACOLOGY, V23, P505, DOI 10.1016/0028-3908(84)90022-4	42	28	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	JAN	2005	30	1					212	221		10.1038/sj.npp.1300596			10	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	880WD	WOS:000225819700024	15508021				2020-06-30	J	Madden, J; Ponto, J; Murphy, CM				Madden, J; Ponto, J; Murphy, CM			How does certification validate us as nurses? Respond	ONCOLOGY NURSING FORUM			English	Letter																	0	0	0	0	0	ONCOLOGY NURSING SOCIETY	PITTSBURGH	125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA	0190-535X			ONCOL NURS FORUM	Oncol. Nurs. Forum	JAN	2005	32	1					15	16		10.1188/05.ONF.15-16			2	Oncology; Nursing	Oncology; Nursing	889OW	WOS:000226453300005					2020-06-30	J	Welsh, J; Reid, A; Graham, J; Curto, J; MacLeod, K; O'Neill, C				Welsh, J; Reid, A; Graham, J; Curto, J; MacLeod, K; O'Neill, C			Physicians' knowledge of transdermal fentanyl	PALLIATIVE MEDICINE			English	Article						cancer pain; knowledge; pain control; pharmacology; physicians; transdermal fentanyl	CANCER PAIN; PHARMACOKINETICS; MANAGEMENT; ATTITUDES	Background: Different opioids for use in the control of moderate to severe cancer pain have become widely available. More recently, sophisticated formulations such as transdermal patches have been developed. One example, transdermal fentanyl (TF), has characteristic pharmacokinetics and along with the other opioids, equivalency conversions are often made when changing from or to other opioids. Aim of study: To explore the knowledge of general practitioners (GPs), hospital consultants and oncologists about the pharmacology and use of TF in the management of moderate/severe cancer pain. Method: During 2001 and 2002 a questionnaire survey was carried out. A randomized selection of GPs, hospital consultants and oncologists (n = 1167) from the UK and Ireland were sent a questionnaire and 576 (49%) were returned and evaluated. Results: The results show doctors who had previously prescribed TF are more confident and knowledgeable about the indications and pharmacology of TF than doctors who had never prescribed TF. Overall knowledge and confidence in using TF was poor.	Univ Glasgow, Western Infirm, Dept Palliat Med, Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland; Wishaw Gen Hosp, Wishaw, Scotland; Univ Glasgow, Beatson Labs, Canc Res UK, Glasgow, Lanark, Scotland	Reid, A (reprint author), Univ Glasgow, Western Infirm, Dept Palliat Med, Beatson Oncol Ctr, Dumbarton Rd, Glasgow G11 6NT, Lanark, Scotland.	anne.reid@northglasgow.scot.nhs.uk		Curto Garcia, Jordi/0000-0002-0385-1439			Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; *BRIT NAT FORM, BNFORG213; *CANC, 2001, PAIN MAN SURV 2000; Clarke EB, 1996, J PAIN SYMPTOM MANAG, V11, P18, DOI 10.1016/0885-3924(95)00134-4; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; GOURLAY GK, 1989, PAIN, V37, P193, DOI 10.1016/0304-3959(89)90130-9; *JANSS, 2003, DUR FULL US PRESCR I; *JANSS UK, 2002, SUMM PROD CHAR; LEHMANN KA, 1992, J PAIN SYMPTOM MANAG, V7, P8; Levin ML, 1998, J PAIN SYMPTOM MANAG, V15, P27, DOI 10.1016/S0885-3924(97)00258-3; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; *SCOTT INT GUID NE, 2000, SIGN PUBL, V44; TWYCROSS R, 1998, PALLIATIVE CARE FORM, V1, P107; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M	14	7	7	0	1	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2163	1477-030X		PALLIATIVE MED	Palliat. Med.		2005	19	1					9	16		10.1191/0269216305pm971oa			8	Health Care Sciences & Services; Public, Environmental & Occupational Health; Medicine, General & Internal	Health Care Sciences & Services; Public, Environmental & Occupational Health; General & Internal Medicine	885VF	WOS:000226184500003	15690863				2020-06-30	J	De Conno, F; Ripamonti, C; Brunelli, C				De Conno, F; Ripamonti, C; Brunelli, C			Opioid purchases and expenditure in nine western European countries: 'Are we killing off morphine?'	PALLIATIVE MEDICINE			English	Article						codeine; European countries; fentanyl; morphine; opioid expenditure; opioid purchases; tramadol	CANCER PAIN; OPIOPHOBIA; TRAMADOL	Background: In clinical practice the major role of opioid drugs is the management of malignant and nonmalignant pain. The primary aim of this study is to evaluate the trend in sales of four opioid analgesic drugs (codeine, tramadol, morphine, fentanyl), from wholesalers to community pharmacies, as an indicator of opioid consumption in nine European countries in 2001, 2002 and 2003. Secondary aims are to compare: (a) the amount of each drug purchased by different countries in 2003; (b) the average price for each drug in the different countries in 2003; and (c) the total expenditure for each opioid from 2001 to 2003. Methods: Data from the Statistical Report on drugs purchased by pharmacies was supplied by IMS Health, an internationally accepted information provider for the pharmaceutical and health care industries. Finding: In the period 2001-2003, while the percentage increase of purchases of fentanyl and tramadol was considerable, that of morphine was the lowest in most of the nine countries. The largest consumer of codeine was the UK and of tramadol was Belgium. The consumption of morphine was the lowest reported in all the countries together and was three times lower than that of transdermal fentanyl. There was a high variability in the costs of the opioids among the different countries. In 2003, the total expenditure on fentanyl reached the total expenditure on tramadol, followed by codeine. Morphine presents the lowest expenditure in all nine countries and over all three years. Interpretation: These results open up many questions. What factors influence opioid purchasing and costs in these European countries? It would be interesting to have the answers from those people who know the actual situation in the individual countries.	Natl Canc Inst, Rehabil & Palliat Care Operat Unit, I-20133 Milan, Italy	Ripamonti, C (reprint author), Natl Canc Inst, Rehabil & Palliat Care Operat Unit, Via Venezian 1, I-20133 Milan, Italy.	carla.ripamonti@istitutotumori.mi.it	Ripamonti, Carla/C-4557-2017; Brunelli, Cinzia/B-9361-2017	Ripamonti, Carla/0000-0001-5495-5054; Brunelli, Cinzia/0000-0003-3905-1289			*AM AC PAIN MED AM, 1997, [No title captured]; Brinker A, 2002, AM J PSYCHIAT, V159, P881, DOI 10.1176/appi.ajp.159.5.881; Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542; Chinellato A, 2003, LANCET, V362, P78, DOI 10.1016/S0140-6736(03)13819-6; Genf World Health Organization, 1986, CANC PAIN REL; Hanks GW, 1996, BRIT MED J, V312, P823; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; *INCB, 2004, REP 2003; Jamison RN, 1998, SPINE, V23, P2591, DOI 10.1097/00007632-199812010-00014; Megens AAHP, 1998, J PAIN SYMPTOM MANAG, V15, P253, DOI 10.1016/S0885-3924(97)00371-0; Portenoy RK, 2000, J PAIN SYMPTOM MANAG, V19, pS16; Ripamonti C, 2004, AM J PSYCHIAT, V161, P2326, DOI 10.1176/appi.ajp.161.12.2326; ZENZ M, 1993, LANCET, V341, P1075, DOI 10.1016/0140-6736(93)92425-S; ZYLICZ Z, 1993, LANCET, V341, P1473, DOI 10.1016/0140-6736(93)90915-4; 2003, PRESCRIBE INT, V12, P99	15	71	74	1	6	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2163	1477-030X		PALLIATIVE MED	Palliat. Med.		2005	19	3					179	184		10.1191/0269216305pm1002oa			6	Health Care Sciences & Services; Public, Environmental & Occupational Health; Medicine, General & Internal	Health Care Sciences & Services; Public, Environmental & Occupational Health; General & Internal Medicine	928RA	WOS:000229288200002	15920930				2020-06-30	J	Lidstone, V; Owen, R				Lidstone, V; Owen, R			Physicians' knowledge of transdermal fentanyl	PALLIATIVE MEDICINE			English	Letter									Princess Wales Hosp, Bridgend, Wales	Lidstone, V (reprint author), Princess Wales Hosp, Bridgend, Wales.	victoria@lidstone.net						0	0	0	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2163	1477-030X		PALLIATIVE MED	Palliat. Med.		2005	19	7					566	567		10.1191/0269216305pm1074xx			2	Health Care Sciences & Services; Public, Environmental & Occupational Health; Medicine, General & Internal	Health Care Sciences & Services; Public, Environmental & Occupational Health; General & Internal Medicine	983PL	WOS:000233244500012	16295292				2020-06-30	J	McGregor, A				McGregor, A			Physicians' knowledge of transdermal fentanyl	PALLIATIVE MEDICINE			English	Letter									St Christophers Hospice, London SE26 6DZ, England	McGregor, A (reprint author), St Christophers Hospice, 51-59 Lawrie Pk Rd, London SE26 6DZ, England.	a.mcgregor@stchristophers.org.uk						0	0	0	0	0	HODDER ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	0269-2163			PALLIATIVE MED	Palliat. Med.		2005	19	7					566	566		10.1191/0269216305pm1074xx			1	Health Care Sciences & Services; Public, Environmental & Occupational Health; Medicine, General & Internal	Health Care Sciences & Services; Public, Environmental & Occupational Health; General & Internal Medicine	983PL	WOS:000233244500011	16295291				2020-06-30	J	Turan, M; Bagcivan, I; Gursoy, S; Sarac, B; Duman, M; Kaya, T				Turan, M; Bagcivan, I; Gursoy, S; Sarac, B; Duman, M; Kaya, T			In vitro effects of intravenous anesthetics on the sphincter of Oddi strips of sheep	PANCREATOLOGY			English	Article						endoscopic retrograde cholangiopancreatography fentanyl; meperidine; manometry; midazolam; propofol; sphincter of Oddi; relaxation	ENDOSCOPIC SPHINCTEROTOMY; INTRABILIARY PRESSURE; BILIARY PRESSURE; GUINEA-PIGS; MOTILITY; MEPERIDINE; MIDAZOLAM; MORPHINE; FENTANYL; BUTORPHANOL	Background: Intravenous anesthetics are often used for conscious sedation in endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincter of Oddi (SO) manometry. This study was designed to investigate the direct effects of some intravenous anesthetics on SO in sheep. Methods: In sheep SO rings, changes in isometric tension in response to cumulative concentrations of intravenous anesthetics were determined, and values for E-max (mean maximal inhibition) and pD(2) (i.e. the negative logarithm of the concentration for the half-maximal response, EC50) were compared. Results: Meperidine (10(-)7 to 3x10(-5) M), fentanyl (10(-7) to 3x10(-5) M), midazolam (10(-7) to 3x10(-5) M) and propofol (10(-7) to 3x10(-4) M) induced concentration-dependent relaxations on SO precontracted with carbachol (10(-6) M). E-max and pD(2) values following meperidine, fentanyl and midazolam administration were significantly greater than after propofol (p<0.05). There were no significant differences in E-max and pD(2) values for meperidine, fentanyl and midazolam. Conclusion: These results suggest that meperidine, fentanyl and midazolam are equipotent relaxants in the sheep SO in vitro. The relaxatory effect of propofol was 10 times less potent compared to the above agents, and it can be beneficial during SO manometry in controlled clinical human studies. Copyright (C) 2005 S. Karger AG, Basel and IAP.	Cumhuriyet Univ, Fac Med, Dept Gen Surg, Sivas, Turkey; Cumhuriyet Univ, Fac Med, Dept Pharmacol, Sivas, Turkey; Cumhuriyet Univ, Fac Med, Dept Anesthesiol, Sivas, Turkey	Turan, M (reprint author), Gokcebostan Mah 2 Sok,Hurriyet Apt Daire 2, TR-58070 Sivas, Turkey.	mturan_1999@yahoo.com	Duman, Mustafa/L-8033-2015				ALLESCHER HD, 1993, ENDOSCOPY, V25, P399, DOI 10.1055/s-2007-1010350; ARGUELLES JE, 1979, ANESTH ANALG, V58, P120; Baron T H, 1994, HPB Surg, V7, P297, DOI 10.1155/1994/78764; CLASSEN M, 1974, DEUT MED WOCHENSCHR, V99, P496, DOI 10.1055/s-0028-1107790; COELHO JCU, 1986, ANN SURG, V204, P53, DOI 10.1097/00000658-198607000-00007; Cohen J, 2000, GASTROINTEST ENDOSC, V51, P546, DOI 10.1016/S0016-5107(00)70287-2; CUER JC, 1993, ENDOSCOPY, V25, P384, DOI 10.1055/s-2007-1010345; ECONOMOU G, 1971, GUT, V12, P218, DOI 10.1136/gut.12.3.218; Fazel A, 2002, GASTROINTEST ENDOSC, V55, P637, DOI 10.1067/mge.2002.123272; Freeman Martin L, 2003, Curr Gastroenterol Rep, V5, P145, DOI 10.1007/s11894-003-0084-9; GOFF JS, 1995, DIGEST DIS SCI, V40, P2364, DOI 10.1007/BF02063238; GREENSTEIN AJ, 1972, AM J GASTROENTEROL, V58, P417; Hubbard GP, 2003, ANN PHARMACOTHER, V37, P534, DOI 10.1345/aph.1C108; JONES RM, 1981, ANESTH ANALG, V60, P638; KAWAI K, 1974, GASTROINTEST ENDOSC, V20, P148, DOI 10.1016/S0016-5107(74)73914-1; MCCAMMON RL, 1984, ANESTH ANALG, V63, P139; ROLNY P, 1993, ENDOSCOPY, V25, P381, DOI 10.1055/s-2007-1010344; ROMOSALAS F, 1980, SURG GYNECOL OBSTET, V150, P551; Sherman S, 1996, GASTROINTEST ENDOSC, V44, P239, DOI 10.1016/S0016-5107(96)70158-X; THUNE A, 1990, BRIT J SURG, V77, P992, DOI 10.1002/bjs.1800770911	20	4	5	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1424-3903			PANCREATOLOGY	Pancreatology		2005	5	2-3					215	219		10.1159/000085274			5	Gastroenterology & Hepatology	Gastroenterology & Hepatology	925EP	WOS:000229034600013	15855818				2020-06-30	J	Cherng, CH; Wong, CS				Cherng, CH; Wong, CS			Effect of fentanyl on lidocaine-induced convulsions in mice	PHARMACOLOGY			English	Article						fentanyl; lidocaine; convulsions	GRAND-MAL SEIZURE; SPINAL-ANESTHESIA; RAT HIPPOCAMPUS; MORPHINE; BUPIVACAINE; BRAIN; ONSET	This study was undertaken to examine the effect of fentanyl on lidocaine-induced convulsions in mice. Seventy-five male mice were used and divided into five groups, 15 in each. Convulsions were obtained by lidocaine injection subcutaneously ( 150 mg/kg), in a dose volume of 0.1 ml/10 g body weight over the upper back. The five groups were: ( a) control group: pretreated with normal saline; (b) F50 group: pretreated with fentanyl 50 mu g/kg; (c) F100 group: pretreated with fentanyl 100 mu g/kg; (d) F200 group: pretreated with fentanyl 200 mu g/kg, and ( e) F100+N group: pretreated with fentanyl 100 mu g/kg plus naloxone 1 mg/kg. The pretreatments were given intraperitoneally (i. p.) 5 min prior to lidocaine injection. After lidocaine injection, the latency to the onset of generalized convulsions was observed for 12 min and recorded. The severity of convulsions was assessed and scored as 1 = mild, 2 = moderate, and 3 = severe. The recovery or death of the mice were also recorded. Student's t, Mann-Whitney U, and Fisher's exact tests were used to analyze the data. Compared with the control group (431.7 +/- 37.3 s), the latencies of onset of convulsions in the fentanyl groups were dose-dependently decreased (F50: 331.0 +/- 37.1 s; F100: 240.3 +/- 28.6 s, p < 0.001; F200: 188.7 +/- 19.4 s, p < 0.001), and the decreased latency was reversed by naloxone (F100+ N: 412.9 +/- 34.1 s). Compared with the control group (1.13 +/- 0.19), the severities of convulsions in the fentanyl groups were also increased in a dose-dependent manner (F50: 1.47 +/- 0.19; F100: 1.93 +/- 0.21, p < 0.05; F200: 2.46 +/- 0.17, p < 0.001). Similarly, the increased severity was reversed by naloxone (F100+ N: 1.33 +/- 0.16). There was no death in the control and naloxone-treated groups. The incidences of death were 2/15 in F50 group, 5/15 in F100 group, and 7/15 in the F200 group ( p < 0.05). The results of this study demonstrated that fentanyl potentiates the lidocaine- induced convulsions in a dose-dependent manner in mice, and this effect may be mediated by an opioid mechanism. Copyright (C) 2005 S. Karger AG, Basel.	Tri Serv Gen Hosp, Natl Def Med Ctr, Dept Anesthesiol, Taipei 114, Taiwan	Cherng, CH (reprint author), Tri Serv Gen Hosp, Natl Def Med Ctr, Dept Anesthesiol, 325,Sec 2,Cheng Gung Rd, Taipei 114, Taiwan.	cherng1018@yahoo.com.tw					BARAKA A, 1985, ANESTHESIOLOGY, V62, P206, DOI 10.1097/00000542-198502000-00027; Cherng CH, 2002, ANESTH ANALG, V94, P1614, DOI 10.1097/00000539-200206000-00046; Cherng CH, 2001, REGION ANESTH PAIN M, V26, P523, DOI 10.1053/rapm.2001.27852; DEJONG RH, 1980, ANESTH ANALG, V59, P401; FUKUDA K, 2005, ANESTHESIA, V1, P379; IKONOMIDOUTURSKI C, 1987, NEUROSCIENCE, V20, P671, DOI 10.1016/0306-4522(87)90118-7; KEARSE LA, 1993, ELECTROEN CLIN NEURO, V87, P374, DOI 10.1016/0013-4694(93)90150-T; KOFKE WA, 1992, ANESTH ANALG, V75, P953; Lee DL, 1999, J CARDIOTHOR VASC AN, V13, P200, DOI 10.1016/S1053-0770(99)90088-5; LIU S, 1995, ANESTH ANALG, V80, P730, DOI 10.1097/00000539-199504000-00014; MADISON DV, 1988, J PHYSIOL-LONDON, V398, P123, DOI 10.1113/jphysiol.1988.sp017033; Manninen PH, 1997, CAN J ANAESTH, V44, P463, DOI 10.1007/BF03011931; MODICA PA, 1990, ANESTH ANALG, V70, P303; NAKAO S, 1994, ACTA ANAESTH SCAND, V38, P845, DOI 10.1111/j.1399-6576.1994.tb04016.x; PALMER CM, 1995, REGION ANESTH, V20, P389; PENNING JP, 1992, ANESTHESIOLOGY, V77, P1186, DOI 10.1097/00000542-199212000-00021; RAO TLK, 1982, ANESTH ANALG, V61, P1020; ROSENBERG M, 1986, J ORAL MAXIL SURG, V44, P577, DOI 10.1016/S0278-2391(86)80102-1; SAFWAT AM, 1983, ANESTHESIOLOGY, V59, P78, DOI 10.1097/00000542-198307000-00018; Schoffelmeer ANM, 2001, SYNAPSE, V42, P87, DOI 10.1002/syn.1104; SEO N, 1982, ANESTHESIOLOGY, V57, P451, DOI 10.1097/00000542-198212000-00004; STRIPLING JS, 1982, ELECTROEN CLIN NEURO, V53, P208, DOI 10.1016/0013-4694(82)90025-6; TEMPELHOFF R, 1992, J NEUROSURG, V77, P201, DOI 10.3171/jns.1992.77.2.0201; TOMMASINO C, 1984, ANESTHESIOLOGY, V60, P283, DOI 10.1097/00000542-198404000-00003; WAGMAN IH, 1967, ANESTHESIOLOGY, V28, P155, DOI 10.1097/00000542-196701000-00017; WANG C, 1993, ANESTHESIOLOGY, V79, P766, DOI 10.1097/00000542-199310000-00019; WINKELMULLER M, 1996, J NEUROSURG, V86, P107; ZIEGLGANSBERGER W, 1979, SCIENCE, V205, P415, DOI 10.1126/science.451610	28	6	6	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0031-7012			PHARMACOLOGY	Pharmacology		2005	75	1					1	4		10.1159/000085767			4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	978LZ	WOS:000232876200001	15897677				2020-06-30	J	Chhabra, A; Pandey, R; Khandelwal, M; Subramaniam, R; Gupta, S				Chhabra, A; Pandey, R; Khandelwal, M; Subramaniam, R; Gupta, S			Anesthetic techniques and postoperative emesis in pediatric strabismus surgery	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article						anesthesia; pediatric surgery; strabismus; postoperative complications; vomiting; pain	PROPOFOL ANESTHESIA; ANALGESIC EFFICACY; CONTROLLED TRIAL; KETOROLAC; RECOVERY; FENTANYL; SAFETY; NAUSEA; TONSILLECTOMY; ALFENTANIL	Background and Objectives: Postoperative emesis after pediatric strabismus surgery continues to be a problem, despite the use of antiemetics. The purpose of this study was to identify an anesthetic technique associated with the lowest incidence of vomiting after pediatric strabismus surgery. Methods: A prospective, randomized, double-blind study was conducted to evaluate the effect of intravenous fentanyl, meperidine, or peribulbar block with propofol infusion on emesis in 105 pediatric patients undergoing strabismus surgery. Anesthesia was maintained with nitrous oxide, oxygen, and propofol infusion. Ketorolac 1.0 mg/kg(-1) intramuscular was administered to all patients after induction. Patients were given either a peribulbar block, intravenous fentanyl 2 mug/kg(-1), or intravenous meperidine 1 mg/kg(-1) for perioperative analgesia. The emesis scores were observed for the first 24 hours postoperatively. Results: The incidence of emesis was significantly lower (1 of 35; 2.9%) in the peribulbar group compared with the meperidine group (9 of 35; 25.6%) (P < .01) in the first 24 hours. The fentanyl group had a higher incidence of postoperative vomiting (4 of 35; 11.4%) than did the peribulbar group; the difference, however, was not statistically significant. Conclusion: Among the three techniques, peribulbar block with propofol-based anesthesia is the technique with the lowest incidence of postoperative emesis. Fentanyl-propofol is an equally acceptable alternative; however, meperidine-propofol is associated with a high incidence of postoperative emesis.	All India Inst Med Sci, Dept Anesthesiol & Intens Care, Dr Rajendra Prasad Eye Ctr, New Delhi, India	Chhabra, A (reprint author), House 13,Rd 61, New Delhi 110026, India.	anjolie5@hotmail.com					Apfel CC, 2002, BRIT J ANAESTH, V88, P659, DOI 10.1093/bja/88.5.659; DAVIS DB, 1994, J CATARACT REFR SURG, V20, P327, DOI 10.1016/S0886-3350(13)80586-X; Deb K, 2001, PAEDIATR ANAESTH, V11, P161, DOI 10.1046/j.1460-9592.2001.00623.x; JAKOBSSON J, 1991, ACTA ANAESTH SCAND, V35, P767, DOI 10.1111/j.1399-6576.1991.tb03388.x; KENNY GNC, 1994, ANAESTHESIA, V49, P6, DOI 10.1111/j.1365-2044.1994.tb03576.x; LARSSON S, 1992, ACTA ANAESTH SCAND, V36, P182, DOI 10.1111/j.1399-6576.1992.tb03448.x; MARSHALL CA, 1992, ANAESTHESIA, V47, P461, DOI 10.1111/j.1365-2044.1992.tb02265.x; MENDEL HG, 1995, ANESTH ANALG, V80, P1129, DOI 10.1097/00000539-199506000-00010; MILLAR JM, 1988, ANAESTHESIA, V43, P738, DOI 10.1111/j.1365-2044.1988.tb05743.x; MUNRO HM, 1994, BRIT J ANAESTH, V72, P624, DOI 10.1093/bja/72.6.624; ODDBYMUHRBECK E, 1994, ACTA ANAESTH SCAND, V38, P52, DOI 10.1111/j.1399-6576.1994.tb03837.x; PAWAR D, 1994, ANESTHESIA CHILDREN, P127; REIMER EJ, 1993, CAN J ANAESTH, V40, P927, DOI 10.1007/BF03010094; Romsing J, 1998, ACTA ANAESTH SCAND, V42, P770, DOI 10.1111/j.1399-6576.1998.tb05320.x; Shende D, 1999, ACTA ANAESTH SCAND, V43, P265, DOI 10.1034/j.1399-6576.1999.430305.x; Standl T, 1996, ACTA ANAESTH SCAND, V40, P729, DOI 10.1111/j.1399-6576.1996.tb04519.x; STEWARD DJ, 1975, CAN ANAESTH SOC J, V22, P111, DOI 10.1007/BF03004827; SUTTERS KA, 1995, PAIN, V61, P145, DOI 10.1016/0304-3959(94)00166-C; WATCHA MF, 1991, ANESTHESIOLOGY, V75, P204, DOI 10.1097/00000542-199108000-00006; WEIR PM, 1993, ANESTH ANALG, V76, P760	20	24	24	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1098-7339	1532-8651		REGION ANESTH PAIN M	Region. Anesth. Pain Med.	JAN-FEB	2005	30	1					43	47		10.1016/j.rapm.2004.08.023			5	Anesthesiology	Anesthesiology	897LI	WOS:000227005100004	15690267				2020-06-30	J	Kallio, H; Snall, EVT; Suvanto, SJ; Tuomas, CA; Iivonen, MK; Pokki, JP; Rosenberg, PH				Kallio, H; Snall, EVT; Suvanto, SJ; Tuomas, CA; Iivonen, MK; Pokki, JP; Rosenberg, PH			Spinal hyperbaric ropivacaine-fentanyl for day-surgery	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article						anesthetic techniques; subarachnoid; hyperbaric anesthetic local; ropivacaine; fentanyl	OUTPATIENT KNEE ARTHROSCOPY; INTRATHECAL FENTANYL; CESAREAN DELIVERY; THERMODYNAMIC PROPERTIES; INDUCED PRURITUS; 15 MG; BUPIVACAINE; ANESTHESIA; BLOCK; LIDOCAINE	Background: Adequate intraoperative analgesia combined with faster mobilization might be achieved by replacing hyperbaric ropivacaine partly with fentanyl. Methods: Sixty spinal anesthesia patients were randomized into 2 groups of either fentanyl 20 mug mixed with hyperbaric ropivacaine 10 mg (group FR10) or hyperbaric ropivacaine 15 mg (group R15). Forty-five patients underwent inguinal hernia repair and 15 patients had lower extremity surgery. Sensory block was tested by pinprick, and motor block was tested by use of a modified Bromage scale at 5-minute intervals for 30 minutes, 15-minute intervals for 60 minutes, and at 30-minute intervals until full recovery. Results: The groups did not differ significantly regarding success (27 of 30 [group FR10] and 29 of 30 [group R15]), median onset time (10 [5 to 25] v 10 [5 to 20] minutes) or median duration of T10 sensory block (55 [20 to 115] v 80 [5 to 170] minutes), respectively. Recovery from spinal block was significantly quicker in group FR10 than in group R15, recorded in ability to walk (2.5 hours v3 hours [P = .017]), full motor recovery (1 hour v 1.5 hour [P < .001]), and sensory recovery to S1 (2.5 hours v 3.3 hours [P = .026]). Pruritus occurred in 18 (60 %) of group FR10 v 0 of group RI 5 patients (P < .001). This symptom was mild in all except 1 patient, who received ondansetron 8 mg IV. In the OR, the groups did not differ hemodynamically: 9 (30 %) of the group FR10 and 10 (33 %) of the group R15 patients, respectively, required medication for hypotension and/or bradycardia. Full motor block (Bromage 3) developed less frequently (P < .001) in group FR10 patients than in group R15 patients (1 [3 %] v 14 [47 %]), and the group FR10 patients recovered faster in a median time of 60 v 90 minutes (P < .001). In both groups, sensory and motor blocks were more extensive on the operative side compared with the nonoperative side (P < .001). Conclusion: Faster mobilization but equal onset and duration of analgesia were achieved with intrathecal hyperbaric ropivacaine 10 mg plus fentanyl 20 mug as compared with hyperbaric ropivacaine 15 mg.	Forssa Hosp, Dept Anesthesiol, Forssa, Finland; Forssa Hosp, Dept Surg, Forssa, Finland; Aalto Univ, Lab Chem Engn & Plant Design, Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Anesthesiol & Intens Care Med, Helsinki, Finland	Kallio, H (reprint author), Forssa Hosp, Dept Anesthesiol, POB 42, Forssa, Finland.	helena.kallio@fstky.fi					Ben-David B, 2000, REGION ANESTH PAIN M, V25, P235, DOI 10.1016/S1098-7339(00)90004-X; Ben-David B, 2000, ANESTHESIOLOGY, V92, P6, DOI 10.1097/00000542-200001000-00007; Borgeat A, 1999, ANESTHESIOLOGY, V90, P432, DOI 10.1097/00000542-199902000-00017; Borghi B, 2003, J CLIN ANESTH, V15, P351, DOI 10.1016/S0952-8180(03)00078-3; Buckenmaier CC, 2002, ANESTH ANALG, V95, P1253, DOI 10.1097/00000539-200211000-00028; Casati A, 1998, BRIT J ANAESTH, V81, P355, DOI 10.1093/bja/81.3.355; Casati A, 1998, ANESTH ANALG, V87, P355, DOI 10.1097/00000539-199808000-00022; Casati A, 1999, REGION ANESTH PAIN M, V24, P214, DOI 10.1016/S1098-7339(99)90130-X; Casati A, 2004, REGION ANESTH PAIN M, V29, P4, DOI 10.1016/j.rapm.2003.09.014; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; Chung CJ, 2002, REGION ANESTH PAIN M, V27, P600, DOI 10.1053/rapm.2002.36455; Enk D, 2001, REGION ANESTH PAIN M, V26, P420, DOI 10.1053/rapm.2001.26489; Esmaoglu A, 1998, ACTA ANAESTH SCAND, V42, P1083, DOI 10.1111/j.1399-6576.1998.tb05380.x; Gautier PE, 1999, ANESTHESIOLOGY, V91, P1239, DOI 10.1097/00000542-199911000-00013; Hodgson PS, 1999, ANESTH ANALG, V88, P797, DOI 10.1097/00000539-199904000-00023; Hughes D, 2001, BRIT J ANAESTH, V87, P733, DOI 10.1093/bja/87.5.733; Kallio H, 2004, BRIT J ANAESTH, V93, P664, DOI 10.1093/bja/aeh257; Kallio H, 2004, ANESTH ANALG, V99, P713, DOI 10.1213/01.ANE.0000129976.26455.32; Korhonen AM, 2003, ACTA ANAESTH SCAND, V47, P342, DOI 10.1034/j.1399-6576.2003.00092.x; Lemmon EW, 2000, J PHYS CHEM REF DATA, V29, P331, DOI 10.1063/1.1285884; McLeod GA, 2004, BRIT J ANAESTH, V92, P547, DOI 10.1093/bja/aeh094; Mulroy MF, 2001, REGION ANESTH PAIN M, V26, P252, DOI 10.1053/rapm.2001.22997; Shah MK, 2000, ANAESTHESIA, V55, P1008, DOI 10.1046/j.1365-2044.2000.01618-2.x; Wagner W, 2002, J PHYS CHEM REF DATA, V31, P387, DOI 10.1063/1.1461829	24	21	22	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1098-7339	1532-8651		REGION ANESTH PAIN M	Region. Anesth. Pain Med.	JAN-FEB	2005	30	1					48	54		10.1016/j.rapm.2004.11.002			7	Anesthesiology	Anesthesiology	897LI	WOS:000227005100005	15690268				2020-06-30	J	Stienen, PJ; van den Brom, WE; de Groot, HNM; Venker-van Haagen, AJ; Hellebrekers, LJ				Stienen, PJ; van den Brom, WE; de Groot, HNM; Venker-van Haagen, AJ; Hellebrekers, LJ			Differences between primary somatosensory cortex- and vertex-derived somatosensory-evoked potentials in the rat	BRAIN RESEARCH			English	Article						SEP; somatosensory system; nociception; fentanyl; thiopental; ketamine	C-FIBER INPUT; OPIOID RECEPTORS; FIELD POTENTIALS; DYNAMIC CHANGES; AWAKE RATS; SI; ANESTHESIA; PAIN; DEPTH; TRANSMISSION	The somatosensory-evoked potential (SEP) elicited by high-intensity stimulation potentially provides a reliable indicator of analgesic efficacy since it reflects the level of activation of the nociceptive system. In the present study, components in the 10-30-ms latency range of SEPs recorded over the primary somatosensory cortex (SI-SEPs) and vertex (Vx-SEP) in the rat were characterized and compared. SEPs were elicited by electrical tail-base stimulation, and SI-SEPs and Vx-SEPs were recorded simultaneously. Responses to increasing stimulus intensity and stimulus frequency while awake and responses to bolus injection of fentanyl, thiopental, and ketamine were investigated. The SI-SEP positive component (P) occurring at 12 ms after stimulation (P12) showed a significantly lower intensity threshold and was significantly less affected by increasing stimulus frequency and by administration of the different drugs when compared to the Vx-SEP P15. The fact that a single stimulus modality results in different signal characteristics dependent on the recording site supports the view that different neural mechanisms involved in primary processing of somatosensory information are responsible for the generation of the SI-SEP P12 and Vx-SEP P15, respectively. This differentiation between SI-SEPs and Vx-SEPs potentially has distinct consequences using the SEP to evaluate nociception and analgesia in the rat model. (C) 2004 Elsevier B.V. All rights reserved.	Univ Utrecht, Fac Vet Med, Dept Clin Sci Compan Anim, NL-3508 TD Utrecht, Netherlands; Univ Utrecht, Fac Vet Med, Dept Equine Sci, NL-3508 TD Utrecht, Netherlands	Stienen, PJ (reprint author), Univ Utrecht, Fac Vet Med, Dept Clin Sci Compan Anim, POB 80-154,Yalelaan 8, NL-3508 TD Utrecht, Netherlands.	P.Stienen@vet.uu.nl					ATWEH SF, 1983, BRIT MED BULL, V39, P47, DOI 10.1093/oxfordjournals.bmb.a071789; BERRY MS, 1976, BRAIN RES, V105, P1, DOI 10.1016/0006-8993(76)90919-7; Bromm B, 1998, ELECTROEN CLIN NEURO, V107, P227, DOI 10.1016/S0013-4694(98)00075-3; Casey KL, 2000, J NEUROPHYSIOL, V84, P525; CHAPIN JK, 1984, J COMP NEUROL, V229, P199, DOI 10.1002/cne.902290206; de Bruin NMWJ, 1999, PSYCHOPHARMACOLOGY, V142, P9, DOI 10.1007/s002130050856; de Bruin NMWJ, 2001, BIOL PSYCHOL, V55, P195, DOI 10.1016/S0301-0511(00)00084-3; FEHLINGS MG, 1988, ELECTROEN CLIN NEURO, V69, P65, DOI 10.1016/0013-4694(88)90036-3; FELDMAN RS, 1997, PRINCIPLES NEUROPSYC, P678; Flecknell P.A., 1996, LAB ANIMAL ANAESTHES, P160; Freeman S, 1996, EVOKED POTENTIAL, V100, P362, DOI 10.1016/0168-5597(96)95690-7; Haberham ZL, 1999, LAB ANIM, V33, P47, DOI 10.1258/002367799780578570; Haberham ZL, 2000, BRAIN RES, V873, P287, DOI 10.1016/S0006-8993(00)02504-X; HABERHAM ZL, 2000, THESIS UTRECHT U; Homma Y, 2003, BRAIN RES BULL, V61, P189, DOI 10.1016/S0361-9230(03)00116-3; Jackson ME, 1998, NEUROREPORT, V9, P3379, DOI 10.1097/00001756-199810260-00008; JONES AKP, 1991, NEUROSCI LETT, V126, P25, DOI 10.1016/0304-3940(91)90362-W; KALLIOMAKI J, 1993, BRAIN RES, V622, P271, DOI 10.1016/0006-8993(93)90828-B; Kalliomaki J, 1998, PAIN, V77, P323, DOI 10.1016/S0304-3959(98)00115-8; Koyanagi I, 1996, ELECTROMYOGR MOTOR C, V101, P534, DOI 10.1016/S0013-4694(96)96007-5; Lee JC, 2001, CHINESE J PHYSIOL, V44, P89; LOVICK TA, 1972, J PHYSL, V46, P62; Mantzaridis H, 1997, ANAESTHESIA, V52, P1030, DOI 10.1111/j.1365-2044.1997.185-az0327.x; Millan MJ, 1999, PROG NEUROBIOL, V57, P1, DOI 10.1016/S0301-0082(98)00048-3; Miyazato H, 1999, BRAIN RES, V822, P60, DOI 10.1016/S0006-8993(99)01074-4; MIYAZATO H, 1995, BRAIN RES BULL, V37, P247, DOI 10.1016/0361-9230(95)00003-W; Nusbaum MP, 2004, CURR BIOL, V14, pR247, DOI 10.1016/j.cub.2004.02.059; PEKOE GM, 1982, PAIN, V12, P57, DOI 10.1016/0304-3959(82)90170-1; RAMPIL IJ, 1993, ANESTHESIOLOGY, V78, P707, DOI 10.1097/00000542-199304000-00014; RICHARDS CD, 1983, BRIT J ANAESTH, V55, P201, DOI 10.1093/bja/55.3.201; Salami M, 2003, P NATL ACAD SCI USA, V100, P6174, DOI 10.1073/pnas.0937380100; SAMRA SK, 1987, ANESTHESIOLOGY, V66, P29, DOI 10.1097/00000542-198701000-00006; SCHOUENBORG J, 1986, BRAIN RES, V397, P86, DOI 10.1016/0006-8993(86)91371-5; Shaw FZ, 2003, BRAIN RES, V983, P152, DOI 10.1016/S0006-8993(03)03048-8; Shaw FZ, 2001, BRAIN RES, V911, P105, DOI 10.1016/S0006-8993(01)02686-5; Shaw FZ, 1999, BRAIN RES, V824, P183, DOI 10.1016/S0006-8993(99)01185-3; Shaw N A, 1987, Electromyogr Clin Neurophysiol, V27, P235; Silbert SC, 2003, J NEUROSCI, V23, P34; Stienen PJ, 2003, J NEUROSCI METH, V126, P79, DOI 10.1016/S0165-0270(03)00070-0; TONEMORI N, 1981, ACTA ANAESTH SCAND, V25, P355; VOGT BA, 1995, EXP NEUROL, V135, P83, DOI 10.1006/exnr.1995.1069; WIEDERHOLT WC, 1977, ELECTROEN CLIN NEURO, V42, P456, DOI 10.1016/0013-4694(77)90209-7; Willis WD, 1997, J CLIN NEUROPHYSIOL, V14, P2, DOI 10.1097/00004691-199701000-00002; WOODS JW, 1964, J NEUROPHYSIOL, V27, P635	44	15	15	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	DEC 31	2004	1030	2					256	266		10.1016/j.brainres.2004.10.014			11	Neurosciences	Neurosciences & Neurology	880FW	WOS:000225775400009	15571674				2020-06-30	J	Gil-Gouveia, R; Wilkinson, PA; Kaube, H				Gil-Gouveia, R; Wilkinson, PA; Kaube, H			Severe hemiplegic migraine attack precipitated by fentanyl sedation for esophagogastroscopy	NEUROLOGY			English	Editorial Material							MECHANISMS; AURA		Inst Neurol, Headache Grp, London WC1N 3BG, England; UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England	Kaube, H (reprint author), Inst Neurol, Headache Grp, Queen Sq, London WC1N 3BG, England.	holgerk@ion.ucl.ac.uk	Radovanovic, Ivana/M-3503-2014	Radovanovic, Ivana/0000-0001-7872-4146; Gil-Gouveia, Raquel/0000-0002-4256-4256			Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; Kaube H, 2000, NEUROLOGY, V55, P139, DOI 10.1212/WNL.55.1.139; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; Moskowitz MA, 2004, ANN NEUROL, V55, P276, DOI 10.1002/ana.20035; SPRICK U, 1981, BRAIN RES, V210, P243, DOI 10.1016/0006-8993(81)90897-0; STRAUSS RA, 1989, J ORAL MAXIL SURG, V47, P184, DOI 10.1016/S0278-2391(89)80115-6; Thurlow JA, 1998, EUR J ANAESTH, V15, P610, DOI 10.1046/j.1365-2346.1998.00368.x	7	6	6	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	DEC 28	2004	63	12					2446	2447		10.1212/01.WNL.0000147326.21231.74			2	Clinical Neurology	Neurosciences & Neurology	883KJ	WOS:000226010000057	15623730				2020-06-30	J	Benitez-Rosario, MA; Feria, M; Salinas-Martin, A; Martinez-Castillo, LP; Martin-Ortega, JJ				Benitez-Rosario, MA; Feria, M; Salinas-Martin, A; Martinez-Castillo, LP; Martin-Ortega, JJ			Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain	CANCER			English	Article						transdermal fentanyl; methadone; opioid rotation; opioid neurotoxicity; cancer pain	DOSE RATIO; CLINICAL PHARMACOKINETICS; MORPHINE; MANAGEMENT; ROTATION; DELIRIUM; HALLUCINATIONS; HYDROMORPHONE; STRATEGIES; TOXICITY	BACKGROUND. Patients with cancer often are rotated from other opioids to methadone to improve the balance between analgesia and side effects. To the authors' knowledge, no clear guidelines currently exist for the safe and effective rotation from transdermal fentanyl to methadone. METHODS. The authors evaluated a protocol for switching opioid from transdermal fentanyl to oral methadone in 17 patients with cancer. Reasons for switching were uncontrolled pain (41.1% of patients) and neurotoxic side effects (58.9% of patients). Methadone was initiated 8-24 hours after fentanyl withdrawal, depending on the patient's previous opioid doses (from < 100 mug per hour to > 300 mug per hour). The starting methadone dose was calculated according to a 2-step conversion between transdermal fentanyl:oral morphine (1:100 ratio) and oral morphine: oral methadone (5:1 ratio or 10:1 ratio). The correlation between previous fentanyl dose and the final methadone dose or the fentanyl: methadone dose ratio was assessed by means of Pearson and Spearman correlation coefficients (r), respectively. A Friedman test was used to compare pain intensity before and after the switch and the use of daily rescue doses. RESULTS. Opioid rotation was fully or partially effective in 80% and 20%, respectively, of patients with somatic pain. Neuropathic pain was not affected by opioid switching. Delirium and myoclonus were reverted in 80% and 100% of patients, respectively, after opioid switching. A positive linear correlation was obtained between the fentanyl and methadone doses (Pearson r, 0.851). Previous fentanyl doses were not correlated with the final fentanyl: methadone dose ratios (Spearman r, - 0.327). CONCLUSIONS. The protocol studied provided a safe approach for switching from transdermal fentanyl to oral methadone, improving the balance between analgesia and side effects in patients with cancer. (C) 2004 American Cancer Society.	Univ La Laguna, Fac Med, Dept Pharmacol, Tenerife 38271, Spain; Hosp La Candelaria, Palliat Care Unit, Canary Hlth Serv, Tenerife, Spain; Hosp La Candelaria, Res Unit, Canary Hlth Serv, Tenerife, Spain	Benitez-Rosario, MA (reprint author), Univ La Laguna, Fac Med, Dept Pharmacol, Tenerife 38271, Spain.	mabenitez@comtf.es	Benitez-Rosario, Miguel-Angel/I-3824-2019	Benitez-Rosario, Miguel-Angel/0000-0001-7706-3171			Bruera E, 1996, CANCER, V78, P852, DOI 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T; Bruera Eduardo, 2002, J Palliat Med, V5, P127, DOI 10.1089/10966210252785097; Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542; Daeninck PJ, 1999, ACTA ANAESTH SCAND, V43, P924, DOI 10.1034/j.1399-6576.1999.430910.x; del Rosario MAB, 2002, PALLIATIVE MED, V16, P71, DOI 10.1191/0269216302pm506xx; DEROSARIO MA, 2001, J PAIN S MANAGE, V21, P177; DESTOUTZ ND, 1995, J PAIN SYMPTOM MANAG, V10, P378, DOI 10.1016/0885-3924(95)90924-C; Eap CB, 2002, CLIN PHARMACOKINET, V41, P1153, DOI 10.2165/00003088-200241140-00003; Enting RH, 2002, CANCER-AM CANCER SOC, V94, P3049, DOI 10.1002/cncr.10518; FAINSINGER R, 1993, PAIN, V52, P137, DOI 10.1016/0304-3959(93)90125-9; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Foley KM, 1998, J CLIN ONCOL, V16, P3213, DOI 10.1200/JCO.1998.16.10.3213; Fountain A, 2001, PALLIATIVE MED, V15, P19, DOI 10.1191/026921601674921626; Gorman AL, 1997, NEUROSCI LETT, V223, P5; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; HANKS GWC, 1998, OXFORD TXB PALLIATIV, P311; Indelicato RA, 2002, J CLIN ONCOL, V20, P348, DOI 10.1200/JCO.2002.20.1.348; *JANSS PHARM PROD, DURAG FENT TRANSD SY; JOHNSON J, 1994, DRUG AGING, V5, P431, DOI 10.2165/00002512-199405060-00005; Lawlor P, 1997, PAIN, V72, P79, DOI 10.1016/S0304-3959(97)00018-3; Lawlor PG, 1998, CANCER, V82, P1167, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.3.CO;2-8; Lawlor PG, 2000, ARCH INTERN MED, V160, P786, DOI 10.1001/archinte.160.6.786; Menten J, 2002, CURR MED RES OPIN, V18, P488, DOI 10.1185/030079902125001272; Mercadante S, 1999, J CLIN ONCOL, V17, P3307, DOI 10.1200/JCO.1999.17.10.3307; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; Mercadante S, 2001, J PAIN SYMPTOM MANAG, V21, P338, DOI 10.1016/S0885-3924(01)00250-0; MORLEY JS, 1998, [No title captured], V5, P51; Ripamonti C, 2002, HEMATOL ONCOL CLIN N, V16, P543, DOI 10.1016/S0889-8588(02)00017-5; Ripamonti C, 1998, J CLIN ONCOL, V16, P3216, DOI 10.1200/JCO.1998.16.10.3216; Santiago-Palma J, 2001, CANCER, V92, P1919, DOI 10.1002/1097-0142(20011001)92:7<1919::AID-CNCR1710>3.0.CO;2-G; Tse DMW, 2003, PALLIATIVE MED, V17, P206, DOI 10.1191/0269216303pm696oa; TWYCROSS R, 2004, GUIDELINES USE METHA; Vielvoye-Kerkmeer APE, 2001, J PAIN SYMPTOM MANAG, V22, P635, DOI 10.1016/S0885-3924(01)00327-X	34	44	48	2	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0008-543X	1097-0142		CANCER-AM CANCER SOC	Cancer	DEC 15	2004	101	12					2866	2873		10.1002/cncr.20712			8	Oncology	Oncology	878HK	WOS:000225637200019	15529307				2020-06-30	J	Mills, PC; Magnusson, BM; Cross, SE				Mills, PC; Magnusson, BM; Cross, SE			Investigation of in vitro transdermal absorption of fentanyl from patches placed on skin samples obtained from various anatomic regions of dogs	AMERICAN JOURNAL OF VETERINARY RESEARCH			English	Article							CLINICAL PHARMACOKINETICS; PERCUTANEOUS-ABSORPTION; PENETRATION	Objective-To investigate in vitro transdermal absorption of fentanyl from patches through skin samples obtained from various anatomic regions of dogs. Sample Population-Skin samples from 5 Greyhounds. Procedure-Skin samples from the dogs' thoracic, neck, and groin regions were collected postmortem and frozen. After samples were thawed, circular sections were cut and placed in Franz-type diffusion cells in a water bath (32degreesC). A commercial fentanyl patch, attached to an acetate strip with a circular hole, was applied to each skin sample. Cellulose strips were used as control membranes. Samples of receptor fluid in the diffusion cells were collected at intervals for 48 hours, and fentanyl concentrations were analyzed by use of high-performance liquid chromatography. Results-Mean +/- SD release rate of fentanyl from the patch, defined by its absorption rate through the non-rate-limiting cellulose membrane, was linear during the first 8 hours (2.01 +/- 0.05 pg/cm(2) of cellulose membrane/h) and then decreased. Fentanyl passed through skin from the groin region at a faster rate and with a significantly shorter lag time, compared with findings in neck or thoracic skin samples. Conclusions and Clinical Relevance-In vitro, fentanyl from a patch was absorbed more quickly and to a greater extent through skin collected from the groin region of dogs, compared with skin samples from the thoracic and neck regions. Placement of fentanyl patches in the groin region of dogs may decrease the lag time to achieve analgesia perioperatively; however, in vivo studies are necessary to confirm these findings.	Univ Queensland, Sch Vet Sci, Brisbane, Qld 4072, Australia; Univ Queensland, Princess Alexandra Hosp, So Clin Div, Therapeut Res Unit, Brisbane, Qld 4102, Australia	Mills, PC (reprint author), Univ Queensland, Sch Vet Sci, Brisbane, Qld 4072, Australia.						Egger CM, 1998, VET SURG, V27, P159, DOI 10.1111/j.1532-950X.1998.tb00114.x; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; HUEBER F, 1994, SKIN PHARMACOL, V7, P237, DOI 10.1159/000211300; Kyles AE, 1998, RES VET SCI, V65, P245, DOI 10.1016/S0034-5288(98)90151-5; Kyles AE, 1996, AM J VET RES, V57, P715; Lee DD, 2000, AM J VET RES, V61, P672, DOI 10.2460/ajvr.2000.61.672; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Mills PC, 2004, RES VET SCI, V76, P37, DOI 10.1016/S0034-5288(03)00142-5; MONTEIRORIVIERE NA, 1993, PHARMACEUT RES, V10, P1326, DOI 10.1023/A:1018973814456; Oriba HA, 1996, BRIT J DERMATOL, V134, P229; PLEZIA PM, 1989, PHARMACOTHERAPY, V9, P2; QIAO GL, 1995, J PHARM SCI, V84, P425, DOI 10.1002/jps.2600840408; Roberts MS, 2002, DRUGS PHARM SCI, V119, P89; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; ROY SD, 1990, PHARMACEUT RES, V7, P842, DOI 10.1023/A:1015912932416; Schultheiss P J, 1995, Contemp Top Lab Anim Sci, V34, P75; SHAH VP, 1995, J PHARM SCI, V84, P1139, DOI 10.1002/jps.2600840920; TUR E, 1991, SKIN PHARMACOL, V4, P230; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008	19	30	30	1	13	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0002-9645	1943-5681		AM J VET RES	Am. J. Vet. Res.	DEC	2004	65	12					1697	1700		10.2460/ajvr.2004.65.1697			4	Veterinary Sciences	Veterinary Sciences	874FP	WOS:000225336600015	15631036				2020-06-30	J	Goto, T; Hanne, P; Ishiguro, Y; Ichinose, F; Niimi, Y; Morita, S				Goto, T; Hanne, P; Ishiguro, Y; Ichinose, F; Niimi, Y; Morita, S			Cardiovascular effects of xenon and nitrous oxide in patients during fentanyl-midazolam anaesthesia	ANAESTHESIA			English	Article						anaesthetics, inhalational, inert gases; cardiac function; transoesophageal echocardiography	CARDIAC-FUNCTION; ISOFLURANE; HEMODYNAMICS; SEVOFLURANE; COMBINATION; METABOLISM; HALOTHANE; CURRENTS; KINETICS; HEART	Xenon anaesthesia appears to have minimal haemodynamic effects. The purpose of this randomised prospective study was to compare the cardiovascular effects of xenon and nitrous oxide in patients with known ischaemic heart disease. In 20 patients who were due to undergo coronary artery bypass graft surgery, 30 min following induction of anaesthesia with fentanyl 30 mug.kg(-1) and midazolam 0.1 mg.kg(-1) but prior to the start of surgery, xenon or nitrous oxide 60% was administered for 15 min. The results showed that xenon caused a minimal decrease in the mean arterial pressure (from 81 (7) to 75 (8) mmHg, mean (SD)), but did not affect the systolic function of the left ventricle, as demonstrated by unchanged left ventricular stroke work index (LVSWI) and the fractional area change of the left ventricle (FAC) derived from transoesophageal echocardiography (TOE). However, in contrast, nitrous oxide was found to decrease the mean arterial pressure (from 81 (8) to 69 (7) mmHg), the LVSWI, and the FAC. The cardiac index, central venous and pulmonary artery occlusion pressures, systemic and pulmonary vascular resistances, and the TOE-derived E/A ratio through the mitral valve were unchanged by xenon or nitrous oxide. We conclude that xenon provides improved haemodynamic stability compared with nitrous oxide, conserving the left ventricular systolic function.	Teikyo Univ, Sch Med, Dept Anaesthesia & Crit Care, Itabashi Ku, Tokyo 1738605, Japan; Univ Hosp Schleswig Holstein, Dept Anaesthesiol & Intens Care Med, D-24105 Kiel, Germany; Massachusetts Gen Hosp, Dept Anaesthesia & Crit Care, Boston, MA 02114 USA; Teikyo Univ, Ichihara Hosp, Ichihara, Chiba 2990111, Japan	Goto, T (reprint author), Teikyo Univ, Sch Med, Dept Anaesthesia & Crit Care, Itabashi Ku, 2-11-1 Kaga, Tokyo 1738605, Japan.	takigoto@med.teikyo-u.ac.jp					Bedi A, 2003, CRIT CARE MED, V31, P2470, DOI 10.1097/01.CCM.0000089934.66049.76; BOOMSMA F, 1990, ANAESTHESIA, V45, P273, DOI 10.1111/j.1365-2044.1990.tb14731.x; CARTON EG, 1992, ANESTH ANALG, V74, P575; CULLEN SC, 1969, ANESTHESIOLOGY, V31, P305, DOI 10.1097/00000542-196910000-00003; Dingley J, 2001, ANAESTHESIA, V56, P829, DOI 10.1046/j.1365-2044.2001.02139.x; EBERT TJ, 1989, ANESTH ANALG, V69, P444; Goto T, 2001, ANESTHESIOLOGY, V94, P782, DOI 10.1097/00000542-200105000-00015; Goto T, 2000, ANESTHESIOLOGY, V93, P1188, DOI 10.1097/00000542-200011000-00009; GREENBLATT DJ, 1984, ANESTHESIOLOGY, V61, P27, DOI 10.1097/00000542-198461010-00006; Hettrick DA, 1998, ANESTHESIOLOGY, V89, P1166, DOI 10.1097/00000542-199811000-00017; Huneke R, 2001, ANESTHESIOLOGY, V95, P999; Ishiguro Y, 2000, J CLIN ANESTH, V12, P196, DOI 10.1016/S0952-8180(00)00139-2; LUTTROPP HH, 1993, ANAESTHESIA, V48, P1045; Marx T, 1997, BRIT J ANAESTH, V78, P326; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; MOFFITT EA, 1984, ANESTH ANALG, V63, P1071; Nakata Y, 1999, ANESTHESIOLOGY, V90, P406, DOI 10.1097/00000542-199902000-00013; Nakayama H, 2002, CAN J ANAESTH, V49, P375, DOI 10.1007/BF03017325; Preckel B, 2002, BRIT J ANAESTH, V88, P264, DOI 10.1093/bja/88.2.264; Rossaint R, 2003, ANESTHESIOLOGY, V98, P6, DOI 10.1097/00000542-200301000-00005; Sanders RD, 2003, BRIT J ANAESTH, V91, P709, DOI 10.1093/bja/aeg232; Stowe DF, 2000, ANESTHESIOLOGY, V92, P516, DOI 10.1097/00000542-200002000-00035; STOWE DF, 1990, ANESTHESIOLOGY, V73, P1220, DOI 10.1097/00000542-199012000-00021	23	31	39	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0003-2409			ANAESTHESIA	Anaesthesia	DEC	2004	59	12					1178	1183		10.1111/j.1365-2044.2004.03900.x			6	Anesthesiology	Anesthesiology	872HC	WOS:000225197300007	15549976				2020-06-30	J	Agarwal, A; Pandey, R; Dhiraaj, S; Singh, PK; Raza, M; Pandey, CK; Gupta, D; Choudhury, A; Singh, U				Agarwal, A; Pandey, R; Dhiraaj, S; Singh, PK; Raza, M; Pandey, CK; Gupta, D; Choudhury, A; Singh, U			The effect of epidural bupivacaine on induction and maintenance doses of propofol (evaluated by bispectral index) and maintenance doses of fentanyl and vecuronium	ANESTHESIA AND ANALGESIA			English	Article							ANESTHETIC REQUIREMENTS; LOCAL-ANESTHETICS; SKIN INCISION; BLOCK; CONSCIOUSNESS; ALFENTANIL; LIGNOCAINE	The growing interest in combining local and general anesthesia has led to studies investigating possible interactions between general anesthesia and local anesthetics administered via spinal, epidural, IV, or IM routes. However, no study has evaluated the effect of local anesthetics on all three components of balanced anesthesia, i.e., hypnosis, analgesia, and muscle relaxation. In this prospective, randomized, double-blind study, we investigated the effect of epidural bupivacaine on the dose requirement of propofol (as evaluated by using the bispectral index [BIS]), fentanyl, and vecuronium for general anesthesia. This study consisted of 30 adults, ASA physical status I and 11, undergoing Whipple's pancreaticoduodenectomy for periampullary carcinoma lasting >4 h. An epidural catheter was placed between T9-10. Depending on the group allocation, 10 mL of the study drug was administered as a bolus followed by an infusion at 6 mL/h via the epidural catheter. Patients were divided into 2 groups of 15 each. Patients in the control group received epidural normal saline whereas those in the bupivacaine group received epidural bupivacaine 0.1%. Induction of anesthesia was performed with IV fentanyl 2 mug/kg and propofol titrated to achieve BIS between 40-50. Endotracheal intubation was facilitated by the IV administration of vecuronium 0.1 mg/kg and patient's lungs were ventilated with 66% nitrous oxide in oxygen. After intubation, infusion of propofol 1% was titrated to maintain BIS between 40-50. Inadequate analgesia was defined as an increase in systolic blood pressure and/or heart rate by >20% of baseline values in response to surgical stimulus and was treated with bolus fentanyl 0.5 mug/kg. Neuromuscular monitoring was used to assess the need for additional doses of vecuronium. Data were analyzed by using the Student's t-test and P less than or equal to0.05 was considered significant. The requirement of propofol for induction and maintenance of anesthesia in the bupivacaine group was 1.3 +/- 0.3 mg/kg and 2.4 +/- 0.9 mg . kg(-1) . h(-1), respectively, compared with 2.4 +/- 0.6 mg/kg and 4.4 +/- 1.6 mg . kg(-1) . h(-1) observed in the control group (P <0.05). Significant reduction was also observed in the requirement of vecuronium and fentanyl during maintenance in the bupivacaine group (P <0.05). We conclude that epidural bupivacaine given before induction of anesthesia reduces the requirement of propofol, fentanyl, and vecuronium during general anesthesia.	Sanjay Gandhi Postgrad Inst Med Sci, Dept Anesthesia, Lucknow 226014, Uttar Pradesh, India; Sanjay Gandhi Postgrad Inst Med Sci, Dept Biostat, Lucknow 226014, Uttar Pradesh, India	Agarwal, A (reprint author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Anesthesia, Type 4-48, Lucknow 226014, Uttar Pradesh, India.	aagarwal@sgpgi.ac.in					Bailey P.L., 2000, ANESTHESIA, P273; BENDAVID B, 1995, ANESTH ANALG, V81, P525, DOI 10.1097/00000539-199509000-00017; BenShlomo I, 1997, BRIT J ANAESTH, V78, P375; Eappen S, 1998, ANESTHESIOLOGY, V88, P1036, DOI 10.1097/00000542-199804000-00024; GLASS PSA, 1997, J CLIN ANESTH, V9, P185; HIMES RS, 1977, ANESTHESIOLOGY, V47, P437, DOI 10.1097/00000542-197711000-00010; Hodgson PS, 1999, ANESTHESIOLOGY, V91, P1687, DOI 10.1097/00000542-199912000-00021; Iselin-Chaves IA, 1998, ANESTH ANALG, V87, P949; Katoh T, 1998, ANESTHESIOLOGY, V88, P18, DOI 10.1097/00000542-199801000-00006; KORDAS M, 1970, J PHYSIOL-LONDON, V209, P689, DOI 10.1113/jphysiol.1970.sp009186; LANIER WL, 1994, ANESTHESIOLOGY, V80, P392, DOI 10.1097/00000542-199402000-00019; MORGAN RGE, 1996, CLIN ANAESTHESIOL, P193; Nonaka Akihiko, 2002, Masui, V51, P880; Nordmark J, 1997, NEUROREPORT, V8, P465, DOI 10.1097/00001756-199701200-00018; REVES J.G., 2000, ANESTHESIA, P228; Senturk M, 2002, BRIT J ANAESTH, V89, P849, DOI 10.1093/bja/aef287; SMITH C, 1994, ANESTHESIOLOGY, V81, P820, DOI 10.1097/00000542-199410000-00008; TELIVUO L, 1970, ANAESTHESIA, V25, P30, DOI 10.1111/j.1365-2044.1970.tb00156.x; Tverskoy M, 1996, REGION ANESTH, V21, P209; Tverskoy M, 1996, ANAESTHESIA, V51, P652; Tverskoy M, 1997, BRIT J ANAESTH, V79, P798; USUBIAGA JE, 1968, J PHARMACOL EXP THER, V159, P353; VUYK J, 1995, ANESTHESIOLOGY, V83, P8, DOI 10.1097/00000542-199507000-00003	23	31	37	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	DEC	2004	99	6					1684	1688		10.1213/01.ANE.0000136422.70531.5A			5	Anesthesiology	Anesthesiology	874HN	WOS:000225341600020	15562054				2020-06-30	J	Pandey, CK; Raza, M; Ranjan, R; Lakra, A; Agarwal, A; Singh, U; Singh, RB; Singh, PK				Pandey, CK; Raza, M; Ranjan, R; Lakra, A; Agarwal, A; Singh, U; Singh, RB; Singh, PK			Intravenous lidocaine suppresses fentanyl-induced coughing: A double-blind, prospective, randomized placebo-controlled study	ANESTHESIA AND ANALGESIA			English	Article							TRACHEAL INTUBATION; BOLUS	IV lidocaine is effective in suppressing the cough reflex of tracheal intubation, extubation, bronchography, bronchoscopy, and laryngoscopy. We investigated this effect of lidocaine on fentanyl-induced cough in 502 patients of ASA physical status I and II scheduled for elective surgery. The patients were assigned to 2 equal groups to receive either lidocaine 1.5 mg/kg or placebo (0.9% saline) over 5 s 1 min before the administration of fentanyl 3 mug/kg in a randomized and double-blind fashion. Coughs were classified as coughing and graded as mild (1-2), moderate (3-4), or severe (5 or more). The results of the study suggest that IV lidocaine 1.5 mg/kg, when administered 1 min before fentanyl, is significantly effective in suppressing fentanyl-induced cough compared to placebo (0.9% saline) (218 versus 165 patients) (P < 0.002) but without affecting the severity of cough (P > 0.05).	Sanjay Gandhi Postgrad Inst Med Sci, Dept Anaesthesiol & Biostat, Lucknow 226014, Uttar Pradesh, India	Pandey, CK (reprint author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Anaesthesiol, Lucknow 226014, Uttar Pradesh, India.	ckpandey@sgpgi.ac.in					Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; BARAKA A, 1978, ANESTH ANALG, V57, P506; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; Lui PW, 1996, CAN J ANAESTH, V43, P1216; NISHINO T, 1990, BRIT J ANAESTH, V64, P682, DOI 10.1093/bja/64.6.682; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; POULTON TJ, 1979, ANESTHESIOLOGY, V50, P470, DOI 10.1097/00000542-197905000-00018; SMITH FR, 1973, CHEST, V63, P427, DOI 10.1378/chest.63.3.427; STELLATO C, 1992, ANESTHESIOLOGY, V77, P932, DOI 10.1097/00000542-199211000-00016; Tweed WA, 2001, ANESTH ANALG, V92, P1442; YASUDA I, 1978, ANESTHESIOLOGY, V49, P117, DOI 10.1097/00000542-197808000-00012; YUKIOK H, 1993, ANESTH ANALG, V77, P309, DOI 10.1213/00000539-199377020-00016; YUKIOKA H, 1985, ANESTH ANALG, V64, P1189	13	46	68	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	DEC	2004	99	6					1696	1698		10.1213/01.ANE.0000136967.82197.82			3	Anesthesiology	Anesthesiology	874HN	WOS:000225341600022	15562056				2020-06-30	J	Studenov, AR; Jivan, S; Adam, MJ; Ruth, TJ; Buckley, KR				Studenov, AR; Jivan, S; Adam, MJ; Ruth, TJ; Buckley, KR			Studies of the mechanism of the in-loop synthesis of radiopharmaceuticals	APPLIED RADIATION AND ISOTOPES			English	Article						[C-11]methyliodide; [C-11]carfentanil; [C-11]SCH23390; [C-11]DTBZ; in-loop radiosynthesis; positron emission tomography	C-11; DIHYDROTETRABENAZINE; RADIOTRACER; BINDING	A series of experiments were performed to better understand the mechanism of the In-loop [C-11]CH3I-methylation. The timing of [C-11]CH3I delivery is critical for the high yield of radiolabeling, since in-loop radioactivity trapping is reversible. Trapped radioactivity escapes faster from a Tefzel loop compared to a PEEK- or stainless steel loop. Up to 50% of delivered radioactivity may be concentrated at the loop origin (representing 8.1% of the total loop volume). A five-fold reduction of the reaction solvent volume and/or precursor amount may lead to a decrease of the product radiochemical yield either by lowering the in-loop radioactivity trapping or by diminishing conversion of [C-11]CH3I into the product. (C) 2004 Elsevier Ltd. All rights reserved.	TRIUMF, PET Grp, Vancouver, BC V6T 2A3, Canada	Studenov, AR (reprint author), TRIUMF, PET Grp, 4004 Wesbrook Mall, Vancouver, BC V6T 2A3, Canada.	studenov@triumf.ca					ADAM MJ, 1999, RADIOPHARM S, V42, pS445; Buckley KR, 2000, RADIOCHIM ACTA, V88, P201, DOI 10.1524/ract.2000.88.3-4.201; BURGERJON JJ, 1979, [No title captured]; DANNALS RF, 1985, INT J APPL RADIAT IS, V36, P303, DOI 10.1016/0020-708X(85)90089-4; HALLDIN C, 1986, APPL RADIAT ISOTOPES, V37, P1039; Iwata R, 2002, J LABELLED COMPD RAD, V45, P271, DOI 10.1002/jlcr.557; Iwata R, 2001, APPL RADIAT ISOTOPES, V55, P17, DOI 10.1016/S0969-8043(00)00368-7; Jewett DM, 1997, NUCL MED BIOL, V24, P197, DOI 10.1016/S0969-8051(96)00213-2; Jewett DM, 2001, NUCL MED BIOL, V28, P733, DOI 10.1016/S0969-8051(01)00226-8; KILBOURN M, 1995, EUR J PHARMACOL, V278, P249, DOI 10.1016/0014-2999(95)00162-E; Klein ATJ, 2001, APPL RADIAT ISOTOPES, V55, P309, DOI 10.1016/S0969-8043(01)00064-1; Larsen P., 1995, Journal of Labelled Compounds and Radiopharmaceuticals, V37, P73; Link Jeanne M., 1995, Journal of Labelled Compounds and Radiopharmaceuticals, V37, P76; Link JM, 1997, NUCL MED BIOL, V24, P93, DOI 10.1016/S0969-8051(96)00181-3; Link JM, 1999, ANAL CHEM, V71, P2700, DOI 10.1021/ac981401o; Maguire RP, 1997, IEEE T NUCL SCI, V44, P26, DOI 10.1109/23.554819; Martinez D.M., 2001, SCI PAPERMAKING, P225; RAVERT HT, 1987, APPL RADIAT ISOTOPES, V38, P305; Studenov AR, 2003, J LABELLED COMPD RAD, V46, P837, DOI 10.1002/jlcr.722; Wilson AA, 2000, NUCL MED BIOL, V27, P529, DOI 10.1016/S0969-8051(00)00132-3; ZEISLER SK, 1994, APPL RADIAT ISOTOPES, V45, P377, DOI 10.1016/0969-8043(94)90054-X	21	13	14	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0969-8043			APPL RADIAT ISOTOPES	Appl. Radiat. Isot.	DEC	2004	61	6					1195	1201		10.1016/j.apradiso.2004.05.051			7	Chemistry, Inorganic & Nuclear; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging	Chemistry; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging	862OP	WOS:000224500800011	15388110				2020-06-30	J	Pandey, CK; Sahay, S; Gupta, D; Ambesh, SP; Singh, RB; Raza, M; Singh, U; Singh, PK				Pandey, CK; Sahay, S; Gupta, D; Ambesh, SP; Singh, RB; Raza, M; Singh, U; Singh, PK			Preemptive gabapentin decreases postoperative pain after lumbar discoidectomy	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							HEAT-CAPSAICIN SENSITIZATION; HEALTHY-VOLUNTEERS; NEUROPATHIC PAIN; RAT MODEL; ANALGESIA; MORPHINE	Purpose: We investigated whether the preemptive use of gabapentin, a structural analogue of gamma amino butyric acid could reduce postoperative pain and fentanyl consumption in patients after single-level lumbar discoidectomy. Methods: Fifty-six ASA I and II patients were randomly allocated into two equal groups to receive either gabapentin 300 mg or placebo two hours before surgery. After surgery, the pain was assessed on a visual analogue scale (VAS) at intervals of 0-6, 6-12, 12-18, and 18-24 hr at rest. Total fentanyl consumption in the first 24 hr after surgery was also recorded. Fentanyl 2 mug(.)kg(-1) intravenously was used to treat postoperative pain on patients' demand. Results: Patients in the gabapentin group had significantly lower VAS scores at all time intervals of 0-6, 6-12, 12-18, and 18-24 hr than those in the placebo group (3.5 +/- 2.3, 3.2 +/- 2.1, 1.8 +/- 1.7, 1.2 +/- 1.3 vs 6.1 +/- 1.7, 4.4 +/- 1.2, 3.3 +/- 1.1, 2.1 +/- 1.2; P < 0,05). The total fentanyl consumed after surgery in the first 24 hr in the gabapentin group (233.5 +/- 141.9, mean + SD) was significantly less than in the placebo group (359.6 +/- 104.1; P < 0.05). Conclusion: Preemptive gabapentin 300 mg po significantly decreases the severity of pain postoperatively in patients who undergo single-level lumbar discoidectomy.	Sanjay Gandhi Postgrad Inst Med Sci, Dept Anaesthesiol, Lucknow 226014, Uttar Pradesh, India; Sanjay Gandhi Postgrad Inst Med Sci, Dept Biostat, Lucknow 226014, Uttar Pradesh, India	Pandey, CK (reprint author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Anaesthesiol, Lucknow 226014, Uttar Pradesh, India.	ckpandey@sgpgi.ac.in					Abdi S, 1998, ANESTH ANALG, V87, P1360, DOI 10.1097/00000539-199812000-00027; Dirks J, 2002, ANESTHESIOLOGY, V97, P102, DOI 10.1097/00000542-200207000-00015; Dirks J, 2002, ANESTHESIOLOGY, V97, P560, DOI 10.1097/00000542-200209000-00007; Eckhardt K, 2000, ANESTH ANALG, V91, P185, DOI 10.1097/00000539-200007000-00035; Fassoulaki A, 2002, ANESTH ANALG, V95, P985, DOI 10.1097/00000539-200210000-00036; Feng Y, 2003, ANESTHESIOLOGY, V98, P729, DOI 10.1097/00000542-200303000-00023; Field MJ, 1997, J PHARMACOL EXP THER, V282, P1242; Gilron I, 2002, ANESTHESIOLOGY, V97, P537, DOI 10.1097/00000542-200209000-00004; GOA KL, 1993, DRUGS, V46, P409, DOI 10.2165/00003495-199346030-00007; Kissin I, 1996, ANESTHESIOLOGY, V84, P1015, DOI 10.1097/00000542-199605000-00001; Kissin I, 2000, ANESTHESIOLOGY, V93, P1138, DOI 10.1097/00000542-200010000-00040; Mao JR, 2000, ANESTH ANALG, V91, P680, DOI 10.1213/00000539-200009000-00034; Nicholson B, 2000, ACTA NEUROL SCAND, V101, P359, DOI 10.1034/j.1600-0404.2000.0006a.x; Pandey CK, 2002, ANESTH ANALG, V95, P1719, DOI 10.1097/00000539-200212000-00046; Petersen KL, 2001, ANESTHESIOLOGY, V94, P15, DOI 10.1097/00000542-200101000-00008; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026	16	85	87	0	1	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	DEC	2004	51	10					986	989		10.1007/BF03018484			4	Anesthesiology	Anesthesiology	880QG	WOS:000225803700006	15574547				2020-06-30	J	Al-Refai, A; Gunka, V; Douglas, J				Al-Refai, A; Gunka, V; Douglas, J			Spinal anesthesia for Cesarean section in a parturient with long QT syndrome	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							T INTERVAL SYNDROME; SURGERY; JERVELL; UPDATE; HEART	Purpose: To report the first use of spinal anesthesia for Cesarean section (CS) in a parturient with a long QT syndrome (LQTS) and an automatic implantable cardiac defibrillator (AICD). Although both general and epidural anesthesia have been described for CS in patients with LQTS, there are no previous case reports on the use of spinal anesthesia. The clinical features, diagnosis, treatment and anesthetic management of LQTS are discussed. Clinical features: A 31-yr-old woman, gravida 2 para I known to have LQTS and an AICD, presented in labour at 35 weeks gestation, three weeks before her scheduled CS. Her previous delivery by CS under spinal anesthesia at our institution was uneventful. On this occasion, we elected to administer spinal anesthesia because she was asymptomatic (no arrhythmia or cardiac arrest) for the last few years, was hemodynamically stable, and had received uneventful spinal anesthesia before. Conclusion: Spinal anesthesia was used safely for CS in this parturient with LQTS.	BC Womens Hosp, Dept Anesthesia, Vancouver, BC V6H 3N1, Canada	Gunka, V (reprint author), BC Womens Hosp, Dept Anesthesia, 4500 Oak St, Vancouver, BC V6H 3N1, Canada.	vgunka@cw.bc.ca					Ackerman MJ, 1998, MAYO CLIN PROC, V73, P250, DOI 10.4065/73.3.250; Booker PD, 2003, BRIT J ANAESTH, V90, P349, DOI 10.1093/bja/aeg061; Eagle KA, 2002, ANESTH ANALG, V94, P1052, DOI 10.1097/00000539-200205000-00002; ELDAR M, 1992, J AM COLL CARDIOL, V20, P830, DOI 10.1016/0735-1097(92)90180-U; FRESHWATER JV, 1984, BRIT J ANAESTH, V56, P655, DOI 10.1093/bja/56.6.655; GARSON A, 1993, CIRCULATION, V87, P1866, DOI 10.1161/01.CIR.87.6.1866; Kuenszberg E, 2000, EUR J ANAESTH, V17, P662, DOI 10.1046/j.1365-2346.2000.00739.x; MANGAR D, 1991, CAN J ANAESTH, V38, P616, DOI 10.1007/BF03008198; PALKAR NV, 1986, BRIT J ANAESTH, V58, P575, DOI 10.1093/bja/58.5.575; RYAN H, 1988, CAN J ANAESTH, V35, P422, DOI 10.1007/BF03010867; SCHMELING WT, 1991, ANESTH ANALG, V72, P137, DOI 10.1213/00000539-199102000-00001; SCHWARTZ PJ, 1993, CIRCULATION, V88, P782, DOI 10.1161/01.CIR.88.2.782; SCHWARTZ PJ, 1985, AM HEART J, V109, P399, DOI 10.1016/0002-8703(85)90626-X; Swenerton JE, 1998, OBSTET ANAESTHESIA U, P39; TRANKINA MF, 2002, ASA NEWSLETTER, V66; Wilde AAM, 2002, J CARDIOVASC ELECTR, V13, pS110, DOI 10.1111/j.1540-8167.2002.tb01963.x	16	18	18	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	DEC	2004	51	10					993	996		10.1007/BF03018486			4	Anesthesiology	Anesthesiology	880QG	WOS:000225803700008	15574549				2020-06-30	J	Crystal, GJ; Metwally, AA; Salem, MR				Crystal, GJ; Metwally, AA; Salem, MR			Isoflurane preserves central nervous system blood flow during intraoperative cardiac tamponade in dogs	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							CORONARY CIRCULATION; ANESTHETIZED DOGS; NITRIC-OXIDE; KETAMINE; METABOLISM; MIDAZOLAM; RESPONSES; FENTANYL	Purpose: The present study tested the hypothesis that the anesthetic technique will influence the changes in regional blood flow (RBF) during intraoperative cardiac tamponade, Methods: Twenty-four dogs were divided into three equal groups: Group I, anesthesia was maintained with ketamine (25 mg(.)kg(-1.)hr(-1)); Group II, with fentanyl and midazolam (F-M; 10 mug(.)kg(-1.)hr(-1) and 0.5 mg(.)kg(-1.)hr(-1), respectively); Group III with I minimum alveolar concentration (MAC; 1.4%) isoflurane. Radioactive microspheres were used to measure RBF in myocardium, brain, spinal cord, abdominal viscera, skeletal muscle and skin. Cardiac output (CO) was measured by thermodilution and arterial pressure with a catheter situated in the thoracic aorta. Catheters were introduced into the pericardial cavity to infuse isotonic saline and to measure intrapericardial pressure (IPP). Measurements were obtained under control conditions and during tamponade, as defined by an increase in I PP sufficient to reduce mean arterial pressure by 40%. Results: Tamponade caused decreases in CO and RBF that were comparable under the three anesthetics, except that RBF in subcortical regions of the brain and in the spinal cord were maintained under isoflurane but decreased under ketamine or F-M. Conclusions: In dogs, intraoperative cardiac tamponade caused comparable changes in RBF under the different anesthetic techniques except that autoregulation was effective in maintaining RBF within the central nervous system only under isoflurane anesthesia. Our findings provide no compelling reason to recommend one anesthetic over the others for maintenance of anesthesia in situations with increased risk for intraoperative cardiac tamponade. However, they cannot be extrapolated to anesthesia induction in the presence of cardiac tamponade.	Illinois Masonic Med Ctr, Dept Anesthesiol, Chicago, IL 60657 USA; Univ Chicago, Coll Med, Dept Anesthesiol, Chicago, IL 60637 USA; Univ Chicago, Coll Med, Dept Physiol & Biophys, Chicago, IL 60637 USA	Crystal, GJ (reprint author), Illinois Masonic Med Ctr, Dept Anesthesiol, 836 W Wellington Ave, Chicago, IL 60657 USA.	gcrystal@uic.edu					ALTURA BM, 1980, FED PROC, V39, P1584; BERNATH GA, 1987, CIRC RES, V60, P72, DOI 10.1161/01.RES.60.1.72; BLAISE GA, 1990, ANESTHESIOLOGY, V72, P535, DOI 10.1097/00000542-199003000-00023; BRIAN JE, 1990, J NEUROSURG ANESTH, V2, P122, DOI 10.1097/00008506-199006000-00010; BROWN DV, 2001, CARDIAC ANESTHESIA P, P857; COGSWELL TL, 1986, AM J PHYSIOL, V251, pR916; Crystal GJ, 1999, J APPL PHYSIOL, V86, P1944; CRYSTAL GJ, 1989, AM J PHYSIOL, V257, pH726; CRYSTAL GJ, 1989, P SOC EXP BIOL MED, V191, P396; CRYSTAL GJ, 1994, ANESTHESIOLOGY, V81, P209, DOI 10.1097/00000542-199407000-00027; FLEISCHER JE, 1988, ANESTHESIOLOGY, V68, P234, DOI 10.1097/00000542-198802000-00010; FUKUDA S, 1983, ANESTH ANALG, V62, P553; Jiha JG, 1996, ANESTH ANALG, V82, P664, DOI 10.1097/00000539-199603000-00041; KAZAMA T, 1988, ANESTHESIOLOGY, V68, P435, DOI 10.1097/00000542-198803000-00020; MARTY J, 1986, ANESTHESIOLOGY, V64, P206, DOI 10.1097/00000542-198602000-00013; MATTILA I, 1984, ACTA ANAESTH SCAND, V58, P236; MCPHERSON RW, 1988, ANESTHESIOLOGY, V69, P493, DOI 10.1097/00000542-198810000-00008; MICHENFELDER JD, 1971, BRIT J ANAESTH, V43, P630, DOI 10.1093/bja/43.7.630; OREN RE, 1987, STROKE, V18, P441, DOI 10.1161/01.STR.18.2.441; PAGEL PS, 1992, ANESTHESIOLOGY, V76, P564, DOI 10.1097/00000542-199204000-00013; SEYDE WC, 1984, ANESTHESIOLOGY, V61, P686, DOI 10.1097/00000542-198412000-00010; Shaneweise JS, 2000, ANESTHESIA, P1753; SMITH G, 1979, ANAESTHESIA, V34, P555, DOI 10.1111/j.1365-2044.1979.tb06341.x; Swanton BJ, 2003, ANESTH ANALG, V97, P654, DOI 10.1213/01.ANE.0000074234.13373.E7; WARREN TW, 1986, CARDIOVASCULAR ACTIO, P3; WHITE PF, 1982, ANESTHESIOLOGY, V56, P119, DOI 10.1097/00000542-198202000-00007; ZAR JH, 1974, BIOSTATISTICAL ANAL	27	1	1	0	0	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	DEC	2004	51	10					1011	1017		10.1007/BF03018490			7	Anesthesiology	Anesthesiology	880QG	WOS:000225803700012	15574553				2020-06-30	J	Mastronicola, D; Arcuri, E; Arese, M; Bacchi, A; Mercadante, S; Cardelli, P; Citro, G; Sarti, P				Mastronicola, D; Arcuri, E; Arese, M; Bacchi, A; Mercadante, S; Cardelli, P; Citro, G; Sarti, P			Morphine but not fentanyl and methadone affects mitochondrial membrane potential by inducing nitric oxide release in glioma cells	CELLULAR AND MOLECULAR LIFE SCIENCES			English	Article						cytochrome oxidase; nitrosative stress; opioid responsiveness; bioenergetics; antinociceptive drug; radicals	MU-OPIOID RECEPTOR; SIGNALING MOLECULE; RESPIRATION; INHIBITION; MODULATION; EXPRESSION; ATP; CHANNELS; SYNTHASE; ENZYME	We have observed that treatment of human glioma cells with morphine in the nanomolar range of concentration affects the mitochondrial membrane potential. The effect is specific to morphine and is mediated by naloxone-sensitive receptors, and is thus better observed on glioma cells treated with desipramine; moreover, the mitochondrial impairment is not inducible by fentanyl or methadone treatment and is prevented by the nitric oxide (NO) synthase inhibitor L-NAME. We conclude that in cultured glioma cells, the morphine-induced NO release decreases the mitochondrial membrane potential, as one might expect based on the rapid inhibition of the respiratory chain by NO. The identification of new intra-cellular pathways involved in the mechanism of action of morphine opens additional hypotheses, providing a novel rationale relevant to the therapy and toxicology of opioids.	Univ Roma La Sapienza, Dept Biochem A Rossi Fanelli, I-00185 Rome, Italy; Univ Roma La Sapienza, Fac Med 2, S Andrea Hosp, Ctr Adv Mol Diag DIMA, Rome, Italy; Regina Elena Inst Canc Res, I-00100 Rome, Italy; Canc Ins Maddalena, Div Pain Therapy & Palliat Care, Palermo, Italy; Univ Roma Tor Vergata, Dept Odontostomatol, Rome, Italy	Sarti, P (reprint author), Univ Roma La Sapienza, Dept Biochem A Rossi Fanelli, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	paolo.sarti@uniroma1.it	Sarti, Paolo/D-2946-2009	Sarti, Paolo/0000-0002-8219-4827; ARESE, Marzia/0000-0002-6140-2287			Almeida A, 2001, P NATL ACAD SCI USA, V98, P15294, DOI 10.1073/pnas.261560998; Almeida A, 2004, NAT CELL BIOL, V6, P45, DOI 10.1038/ncb1080; BARG J, 1991, PEPTIDES, V12, P845, DOI 10.1016/0196-9781(91)90144-E; Bell RM, 2003, CARDIOVASC RES, V57, P405, DOI 10.1016/S0008-6363(02)00675-2; Bilfinger TV, 1998, INT J CARDIOL, V64, pS61, DOI 10.1016/S0167-5273(98)00037-0; Bohn LM, 1998, J NEUROCHEM, V70, P1819; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Brown GC, 2001, BBA-BIOENERGETICS, V1504, P46, DOI 10.1016/S0005-2728(00)00238-3; Brunori M, 1999, CELL MOL LIFE SCI, V56, P549, DOI 10.1007/s000180050452; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; DAVIS S, 1985, J BIOL CHEM, V260, P3844; Di Francesco P, 1998, LIFE SCI, V63, P2167, DOI 10.1016/S0024-3205(98)00497-4; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Ghosh DK, 2003, FRONT BIOSCI, V8, pD193, DOI 10.2741/959; Giulivi C, 2003, FREE RADICAL BIO MED, V34, P397, DOI 10.1016/S0891-5849(02)01298-4; Guzik TJ, 2003, J PHYSIOL PHARMACOL, V54, P469; Ignarro LJ, 1999, BIOSCIENCE REP, V19, P51, DOI 10.1023/A:1020150124721; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; KORZENIEWSKI C, 1983, J IMMUNOL METHODS, V64, P313, DOI 10.1016/0022-1759(83)90438-6; Kvam TM, 2004, J MOL MED, V82, P250, DOI 10.1007/s00109-003-0514-z; Liang BT, 1999, CIRC RES, V84, P1396; Lim YJ, 2004, ANESTHESIOLOGY, V100, P562, DOI 10.1097/00000542-200403000-00015; Liu CL, 2003, LIVER TRANSPLANT, V9, P863, DOI 10.1053/jlts.2003.50163; LORENTZ M, 1988, BRAIN RES, V445, P157, DOI 10.1016/0006-8993(88)91086-4; McPherson BC, 2001, CIRCULATION, V103, P290; Mercadante S, 2003, J PAIN SYMPTOM MANAG, V26, P769, DOI 10.1016/S0885-3924(03)00258-6; Nemmani KVS, 2004, PAIN, V109, P274, DOI 10.1016/j.pain.2004.01.035; PASTERNAK GW, 1995, NEUROPSYCHOPHARMACOL, V13, P309, DOI 10.1016/0893-133X(95)00084-Q; Poderoso JJ, 1999, J BIOL CHEM, V274, P37709, DOI 10.1074/jbc.274.53.37709; Quillan JM, 2002, J PHARMACOL EXP THER, V302, P1002, DOI 10.1124/jpet.302.3.1002; Reed P W, 1979, Methods Enzymol, V55, P435; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Sarti P, 2003, FREE RADICAL BIO MED, V34, P509, DOI 10.1016/S0891-5849(02)01326-6; Sarti P, 1999, FASEB J, V13, P191; Schultz JE, 2001, PHARMACOL THERAPEUT, V89, P123, DOI 10.1016/S0163-7258(00)00106-6; Shah AM, 2004, HEART, V90, P486, DOI 10.1136/hrt.2003.029389; Stefano GB, 2004, J PHYSIOL PHARMACOL, V55, P279; Stefano GB, 2001, INT J IMMUNOPATH PH, V14, P129; Stefano GB, 1995, J BIOL CHEM, V270, P30290, DOI 10.1074/jbc.270.51.30290; Stefano GB, 1996, J BIOL CHEM, V271, P19238, DOI 10.1074/jbc.271.32.19238; Stern JE, 2004, PROG BIOPHYS MOL BIO, V84, P197, DOI 10.1016/j.pbiomolbio.2003.11.015; Tseng L, 2000, J SOC GYNECOL INVEST, V7, P343, DOI 10.1016/S1071-5576(00)00081-2; WOOD J, 1994, NEUROPHARMACOLOGY, V33, P1235, DOI 10.1016/0028-3908(94)90022-1	45	19	20	0	1	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	1420-682X	1420-9071		CELL MOL LIFE SCI	Cell. Mol. Life Sci.	DEC	2004	61	23					2991	2997		10.1007/s00018-004-4371-x			7	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	876WH	WOS:000225528700011	15583861				2020-06-30	J	Bell, JK; Laasch, HU; Wilbraham, L; England, RE; Morris, JA; Martin, DF				Bell, JK; Laasch, HU; Wilbraham, L; England, RE; Morris, JA; Martin, DF			Bispectral index monitoring for conscious sedation in intervention: better, safer, faster	CLINICAL RADIOLOGY			English	Article						anaesthesia; drugs, side effects; EEG; interventional procedures; monitoring; sedation	GASTROINTESTINAL ENDOSCOPY; MIDAZOLAM; PROPOFOL; ALFENTANIL; DEPTH	The aim of this study was to compare subjective (Ramsay sedation score, RSS) with objective electroencephalogram -based bispectral index (BIS) assessment, and to validate the appropriate BIS range for measurement of conscious sedation in interventional procedures. MATERIALS AND METHODS: One hundred patients undergoing sedo-analgesia (midazolam and fentanyl) for interventional gastrointestinal procedures were divided into two groups. In group A (n = 30) sedation was guided by the RSS with the operator blinded to the BIS recording. In group B (n = 70) the operator titrated intravenous sedation to maintain an optimal BIS, predetermined from the results in group A. Recovery time, procedure duration, physiological parameters and unplanned events were recorded in both groups. RESULTS: There was a significant correlation between the BIS and RSS (p < 0.001). BIS values of 87.2 and 80.9 corresponded to an RSS of 3 and 4, respectively. The optimal BIS Level was defined as 80-85. Fifty-seven point five percent of readings were within this range in group B compared with 26.5% in group A (p < 0.001). Sedation approaching general anaesthesia (BIS < 60) occurred in 5.5% of patients in group A but not in group B. Mean recovery time, duration of procedure, midazolam and fentanyl doses were significantly reduced in group B. Unplanned events were reduced from 27 to 17%, but this was not statistically significant (p = 0.29). CONCLUSION: BIS monitoring enables more effective titration of sedatives to maintain a suitable level of consciousness, whilst reducing procedure time. The BIS offers an objective, safe and reliable measure of sedation, without disturbing either patient or operator. BIS monitoring raises the standard of patient care, and in our view, should be used to augment standard assessment. (C) 2004 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.	S Manchester Univ, Hosp NHS Trust, Acad Dept GI Radiol, Manchester M23 9LT, Lancs, England; S Manchester Univ, Hosp NHS Trust, Dept Med Stat, Manchester M23 9LT, Lancs, England; Univ Cent Lancashire, Preston PR1 2HE, Lancs, England	Martin, DF (reprint author), S Manchester Univ, Hosp NHS Trust, Acad Dept GI Radiol, Southmoor Rd, Manchester M23 9LT, Lancs, England.	derrick.martin@smtr.nhs.uk					[Anonymous], 1995, GASTROINTEST ENDOSC, V42, P626; Arepally A, 2001, CARDIOVASC INTER RAD, V24, P185, DOI 10.1007/s002700002549; ARROWSMITH JB, 1991, GASTROINTEST ENDOSC, V37, P421, DOI 10.1016/S0016-5107(91)70773-6; AVRAMOV MN, 1995, CRIT CARE CLIN, V11, P803; BARNETT TP, 1971, SCIENCE, V172, P401, DOI 10.1126/science.172.3981.401; BELL GD, 1987, BRIT J CLIN PHARMACO, V23, P241, DOI 10.1111/j.1365-2125.1987.tb03037.x; Bower AL, 2000, GASTROINTEST ENDOSC, V52, P192, DOI 10.1067/mge.2000.107284; CHARLTON JE, 1995, BRIT MED J, V310, P886, DOI 10.1136/bmj.310.6984.886; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Gan TJ, 1997, ANESTHESIOLOGY, V87, P808, DOI 10.1097/00000542-199710000-00014; LIEBERMAN DA, 1985, GASTROENTEROLOGY, V88, P468, DOI 10.1016/0016-5085(85)90508-6; Liu J, 1996, ANESTHESIOLOGY, V84, P64, DOI 10.1097/00000542-199601000-00007; Marriott P, 2004, CLIN RADIOL, V59, P180, DOI 10.1016/j.crad.2003.07.001; McCune WS, 1988, ENDOSCOPY, V34, P277; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; RANG HP, 1999, PHARMACOLOGY, P528; *ROY COLL AN, 2001, IMPL ENS SAF SED PRA; Sebel PS, 1997, ANESTH ANALG, V84, P891, DOI 10.1097/00000539-199704000-00035; Shah N, 1996, ANESTHESIOLOGY, V85, pA469; Skelly A., 1996, INTERVENTIONAL RADIO, P3; Smith WD, 1996, ANESTHESIOLOGY, V84, P38, DOI 10.1097/00000542-199601000-00005; VERNON JM, 1995, ANESTH ANALG, V80, P780, DOI 10.1097/00000539-199504000-00023; VESELIS RA, 1991, J CLIN MONITOR, V7, P259, DOI 10.1007/BF01619271; Waring JP, 2003, GASTROINTEST ENDOSC, V58, P317, DOI 10.1067/S0016-5107(03)00001-4; Wehrmann T, 2002, GASTROINTEST ENDOSC, V56, P817, DOI 10.1067/mge.2002.129603	25	45	47	0	3	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	0009-9260	1365-229X		CLIN RADIOL	Clin. Radiol.	DEC	2004	59	12					1106	1113		10.1016/j.crad.2004.04.008			8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	876ET	WOS:000225479800007	15556593				2020-06-30	J	Pavelka, K; Le Loet, X; Bjorneboe, O; Herrero-Beaumont, G; Richarz, U				Pavelka, K; Le Loet, X; Bjorneboe, O; Herrero-Beaumont, G; Richarz, U			Benefits of transdermal fentanyl in patients with rheumatoid arthritis or with osteoarthritis of the knee or hip: An open-label study to assess pain control	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						opioids; osteoarthritis; pain control; rheumatoid arthritis; transdermal fentanyl	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CHRONIC NONMALIGNANT PAIN; CHRONIC NONCANCER PAIN; CONTROLLED-RELEASE CODEINE; DOUBLE-BLIND; MEDICAL-MANAGEMENT; NEUROPATHIC PAIN; RANDOMIZED-TRIAL; ORAL MORPHINE; BACK-PAIN	Objectives: To evaluate the effectiveness and safety of transdermal fentanyl (TDF) for the treatment of pain associated with rheumatoid arthritis (RA) or osteoarthritis of the knee or hip (OA), which was not adequately controlled by non-opioid analgesics and/or weak opioids. Methods: The study design incorporated a 1 week run-in period when current analgesic medications were optimised, a 28-day treatment period and a 1-week taper-off period. Patients with RA (n = 104) and OA (n = 159) started treatment with TDF 25 mug/h. Patches were replaced every 72 h, with the option to up-titrate until adequate pain control was achieved. Metoclopramide was taken during the first treatment week and as needed thereafter. Results: 203 patients completed the treatment phase, 90 entered the taper-off phase. 25 mug/h was the most frequently used maximum dose (51%). Pain control was increased from 4% to 29% of patients during run-in. The number of patients reaching adequate pain control in the first treatment week was increased to 75%, and increased further to 88% on day 28 and to 80% at endpoint. From baseline (screening) to endpoint, there were significant reductions in pain (p < 0.001) on the Wisconsin Brief Pain Inventory, and significant improvements in quality of life (Short-Form-36: physical p < 0.001; mental health p < 0.05). Eighty per cent of the patients (n = 134) assessed the treatment favourably; nausea and vomiting were the most common adverse events, mainly occurring at treatment initiation. Efficacy of metoclopramide appeared limited. TDF could be initiated in patients pre-treated with non-opioid analgesics or weak opioids and tapered off without major complications. Conclusions: TDF significantly improved pain control and quality of life, and was well tolerated in patients with RA or knee/hip OA who continued to experience pain on their current analgesic treatment. Treatment could be discontinued without issues. Nausea and vomiting was usually mild during treatment initiation. Patients' well being could be further accommodated by optimising prophylactic treatment.	Janssen Cilag Europe Middle E Asia, CH-6341 Baar, Switzerland; Fdn Jimenez Diaz, E-28040 Madrid, Spain; Martina Hansens Hosp, Sandviken, Sweden; CHR Rouen, Rouen, France; Inst Rheumatol, Prague, Czech Republic	Richarz, U (reprint author), Janssen Cilag Europe Middle E Asia, Sihlbruggstr 111, CH-6341 Baar, Switzerland.	uricharz@jacgb.jnj.com	Vlak, Tonko/H-4906-2017; Pavelka, Karel/E-6578-2017	Vlak, Tonko/0000-0001-5415-7124; Pavelka, Karel/0000-0003-1952-8422; Herrero-Beaumont, Gabriel/0000-0002-3241-991X			Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; ALLAN LA, 2003, 4 C EFIC CZECH REP P; ALLEN L, 2001, BMJ-BRIT MED J, V322, P1154; *AM PAIN SOC, 2002, GUID MAN PAIN OST RH; Anderson K O, 1994, Arthritis Care Res, V7, P64, DOI 10.1002/art.1790070204; ANON, 1997, PAIN FORUM, V6, P77; ARKINSTALL W, 1995, PAIN, V62, P169, DOI 10.1016/0304-3959(94)00262-D; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; *ARTH RES CAMP, FACTF ARTHR GLANC AR; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Bellamy N, 1996, ARTHRITIS RHEUM, V39, P357, DOI 10.1002/art.1780390302; Berliner M, 2002, AKTUEL RHEUMATOL, V27, P230, DOI 10.1055/s-2002-34640; Bierma-Zeinstra S, 1999, J RHEUMATOL, V26, P1129; Buckelew S P, 1989, Arthritis Care Res, V2, P136, DOI 10.1002/anr.1790020408; Caldwell JR, 1999, J RHEUMATOL, V26, P862; Caldwell JR, 2002, J PAIN SYMPTOM MANAG, V23, P278, DOI 10.1016/S0885-3924(02)00383-4; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; CLIVE DM, 1984, NEW ENGL J MED, V310, P563, DOI 10.1056/NEJM198403013100905; Creamer P, 1997, LANCET, V350, P503, DOI 10.1016/S0140-6736(97)07226-7; Dellemijn PLI, 1997, LANCET, V349, P753, DOI 10.1016/S0140-6736(96)09024-1; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; GILLINGS D, 1991, DRUG INF J, V25, P411, DOI DOI 10.1177/009286159102500311; Gonzales G R, 1993, Arthritis Care Res, V6, P223, DOI 10.1002/art.1790060409; Graziotti PJ, 1997, MED J AUSTRALIA, V167, P30, DOI 10.5694/j.1326-5377.1997.tb138760.x; Griessinger N, 2003, DRUG AGING, V20, P571, DOI 10.2165/00002512-200320080-00003; Hawkey CJ, 1999, LANCET, V353, P307, DOI 10.1016/S0140-6736(98)12154-2; HITCHCOCK LS, 1994, J PAIN SYMPTOM MANAG, V9, P312, DOI 10.1016/0885-3924(94)90190-2; HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1541, DOI 10.1002/art.1780381104; HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1535, DOI 10.1002/art.1780381103; HOLMAN GH, 1997, CLIN GERIATR MED, V5, P21; JADAD AR, 1992, LANCET, V339, P1367, DOI 10.1016/0140-6736(92)91194-D; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; JOHNSON AG, 1994, ANN INTERN MED, V121, P289, DOI 10.7326/0003-4819-121-4-199408150-00011; Kalso E, 2003, EUR J PAIN, V7, P381, DOI 10.1016/S1090-3801(02)00143-X; Knott L, 2000, CURR MED RES OPIN, V16, P147, DOI 10.1185/0300799009117019; McQuay H, 1999, LANCET, V353, P2229, DOI 10.1016/S0140-6736(99)03528-X; Milligan K, 2001, J PAIN, V2, P197, DOI 10.1054/jpai.2001.25352; Moulin DE, 1996, LANCET, V347, P143, DOI 10.1016/S0140-6736(96)90339-6; Peloso PM, 2000, J RHEUMATOL, V27, P764; Pendleton A, 2000, ANN RHEUM DIS, V59, P936, DOI 10.1136/ard.59.12.936; PERNEGER TV, 1994, NEW ENGL J MED, V331, P1675, DOI 10.1056/NEJM199412223312502; Pinals RS, 1996, DRUGS, V52, P14, DOI 10.2165/00003495-199600523-00004; Portenoy RK, 1996, J LAW MED ETHICS, V24, P296, DOI 10.1111/j.1748-720X.1996.tb01871.x; Portenoy RK, 2000, J PAIN SYMPTOM MANAG, V19, pS16; Ringe JD, 2002, RHEUMATOL INT, V22, P199, DOI 10.1007/s00296-002-0217-8; Rodriguez LAG, 2001, EPIDEMIOLOGY, V12, P570; SCHUG SA, 1991, DRUGS, V42, P228, DOI 10.2165/00003495-199142020-00005; Simpson RK, 1997, J PAIN SYMPTOM MANAG, V14, P218, DOI 10.1016/S0885-3924(97)00183-8; THEODORIDIS T, 2002, Z ORTHOP, V140, P217; WANG C, 1965, PHYSL PHARM 2, P255; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Watson CPN, 1998, NEUROLOGY, V50, P1837; Wollheim FA, 1996, DRUGS, V52, P27, DOI 10.2165/00003495-199600523-00006	53	14	16	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.	DEC	2004	20	12					1967	1977		10.1185/030079904X14120			11	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	894ZF	WOS:000226829400015	15701214				2020-06-30	J	Gurbet, A; Goren, S; Sahin, S; Uckunkaya, N; Korfali, G				Gurbet, A; Goren, S; Sahin, S; Uckunkaya, N; Korfali, G			Comparison of analgesic effects of morphine, fentanyl, and remifentanil with intravenous patient-controlled analgesia after cardiac surgery	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						cardiac surgery; postoperative analgesia; morphine; fentanyl; remifentanil	EARLY POSTOPERATIVE ANALGESIA; PULMONARY COMPLICATIONS; PAIN; ALFENTANIL	Objective: The purpose of this study was to compare the analgesic effects of remifentanil with 2 other opioid agents, morphine and fentanyl, after cardiac surgery. Design: Prospective, randomized, and double-blinded study. Settings: This study was performed at Uludag University hospital. Participants: Seventy-five patients undergoing off-pump coronary artery bypass surgery were included in the study. Interventions: Anesthesia was standardized. Cases were randomized into 3 groups consisting of 25 patients in each. Groups M, F, and R were given morphine HCl (1 mg/mL) with an infusion rate of 0.3 mg/h and 1-mg bolus doses; fentanyl (50 mug/mL.) with an infusion rate of 1 mug/kg/h and 10-mug bolus; and, remifentanil (50 mug/mL) with an infusion rate of 0.05 mug/kg/min and 0.5-mug/kg bolus, respectively. Continuous infusion was started immediately after the completion of the surgery. Measurements and Main Results: Pain was assessed by using a visual analog scale (0-10), and sedation was assessed with the Ramsey sedation score (1-6) 30 minutes, 1, 2, 4, 12, and 24 hours after extubation. The number of boluses and demands, time to extubation, and side effects were analyzed. Visual analog scale, sedation scores, and mean extubation times were similar in all groups. Total number of boluses and demands were statistically more in the remifentanil group. Regarding the side effects, nausea and vomiting was higher in group M (p < 0.05), whereas itching was prominent in group F (p < 0.05). Conclusions: Despite the different durations of these 3 opioid agents, the infusion dose of remifentanil was as effective as morphine and fentanyl after OPCAB surgery with fewer side effects. (C) 2004 Elsevier Inc. All rights reserved.	Uludag Univ, Dept Anesthesiol, Bursa, Turkey	Gurbet, A (reprint author), Uludag Univ, Typ Fak, Anesteziyol Ve Reanimasyon AD, TR-16059 Bursa, Turkey.	agurbet@uludag.edu.tr					BENUMOF JL, 1994, ANESTHESIA, V2, P1722; Bowdle TA, 1996, ANESTH ANALG, V83, P1292, DOI 10.1097/00000539-199612000-00028; Brown D L, 1990, J Cardiothorac Anesth, V4, P368, DOI 10.1016/0888-6296(90)90048-K; CUNNINGHAM FE, 1995, ANESTHESIOLOGY, V83, pA376; EASTRIDGE CE, 1991, ANN THORAC SURG, V51, P56, DOI 10.1016/0003-4975(91)90448-Y; FELDMAN PL, 1991, J MED CHEM, V34, P2202, DOI 10.1021/jm00111a041; GLASS PSA, 1993, ANESTH ANALG, V77, P1031; GUILLEN F, 2001, EUR ASS CARD AN EACT, P82; Gust R, 1999, CRIT CARE MED, V27, P2218, DOI 10.1097/00003246-199910000-00025; JAYR C, 1988, SURGERY, V104, P57; KALSO E, 1992, ACTA ANAESTH SCAND, V36, P96, DOI 10.1111/j.1399-6576.1992.tb03430.x; Mailis A, 2000, ANN THORAC SURG, V69, P1455, DOI 10.1016/S0003-4975(00)01186-3; MANGANO DT, 1992, ANESTHESIOLOGY, V76, P331; Michelsen LG, 1996, ANESTHESIOLOGY, V84, P865, DOI 10.1097/00000542-199604000-00014; MOORE R, 1994, CHEST, V106, P1339, DOI 10.1378/chest.106.5.1339; Mueller XM, 2000, CHEST, V118, P391, DOI 10.1378/chest.118.2.391; PARIS A, 2001, EUR ASS CARD AN EACT, P68; PFLUG AE, 1974, ANESTHESIOLOGY, V41, P8, DOI 10.1097/00000542-197407000-00003; Rady MY, 1997, CRIT CARE MED, V25, P1831, DOI 10.1097/00003246-199711000-00021; RAMSEY MA, 1994, [No title captured], V2, P656; Roelants F, 2001, CAN J ANAESTH, V48, P175, DOI 10.1007/BF03019731; Schraag S, 1998, BRIT J ANAESTH, V81, P365, DOI 10.1093/bja/81.3.365; Schuttler J, 1997, ANAESTHESIA, V52, P307, DOI 10.1111/j.1365-2044.1997.24-az0051.x; SECHZER P H, 1968, Anesthesiology (Hagerstown), V29, P209, DOI 10.1097/00000542-196801000-00104	24	31	36	0	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	1053-0770			J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	DEC	2004	18	6					755	758		10.1053/j.jvca.2004.08.014			4	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	896EI	WOS:000226917000013	15650986				2020-06-30	J	Celiker, V; Basgul, E; Karagoz, AH; Dal, D				Celiker, V; Basgul, E; Karagoz, AH; Dal, D			Anesthesia in a patient with nasopharyngeal angiofibroma and hemophilia A	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Letter									Univ Hacettepe, Dept Anesthesiol & Reanimatol, TR-06100 Ankara, Turkey	Celiker, V (reprint author), Univ Hacettepe, Dept Anesthesiol & Reanimatol, TR-06100 Ankara, Turkey.						Ezri T, 2003, J CARDIOTHOR VASC AN, V17, P622, DOI 10.1016/S1053-0770(03)00207-6; Ozturk MA, 1999, HAEMOPHILIA, V5, P207	2	1	1	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	1053-0770			J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	DEC	2004	18	6					819	819		10.1053/j.jvca.2004.08.030			1	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	896EI	WOS:000226917000029	15651002				2020-06-30	J	Mutlow, A; Isaza, R; Carpenter, JW; Koch, DE; Hunter, RP				Mutlow, A; Isaza, R; Carpenter, JW; Koch, DE; Hunter, RP			Pharmacokinetics of carfentanil and naltrexone in domestic goats (Capra hircus)	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Article						Carfentanil; naltrexone; phamacokinetics; immobilization; renarcotization; goat	IMMOBILIZATION; DISPOSITION; METABOLISM; HYDROCHLORIDE; ETORPHINE; NALOXONE; CITRATE	Using a crossover study design. the pharmacokinetics of carfentanil and naltrexone, after i.v.. i.m.. and s.c. administration were determined in eight domestic goats (Capra hircus). Serial blood samples were taken up to 120 hr after carfentanil administration, and the plasma drug concentrations were determined using liquid chromatography and mass spectroscopy. All goats were immobilized with 40 mug/kg carfentanil i.m., although the resulting neurologic effects varied considerably. Plasma profiles showed rapid carfentanil absorption and a simple biphasic decline for 12-48 hr. Naltrexone given at 100 mg naltrexone/mg carfentanil 30 min after carfentanil administration produced rapid reversal of immobilization after all routes of administration. Variable fluctuations in the naltrexone plasma concentrations during the first 2.5-3.5 hr were observed. followed by a more consistent biphasic decline. The time to standing was significantly shorter after i.v. compared with s.c. naltrexone. although the time difference (1 min) had little clinical relevance. No statistically significant differences between the naltrexone, pharmacokinetic parameters measured for the three routes of naltrexone administration were identified. although the recoveries after i.m. administration were, subjectively, the smoothest. The carfentanil half-life did not differ significantly in the goats given naltrexone by different routes. Although it is currently recommended that the naltrexone dose be divided into s.c. and i.v. portions, this practice does not appear to offer any benefit.	Kansas State Univ, Zool Pharmacol Lab, Dept Clin Sci, Coll Vet Med, Manhattan, KS 66506 USA; Kansas State Univ, Coll Vet Med, Dept Anat & Physiol, Manhattan, KS 66506 USA; Rolling Hills Zoo, Salina, KS 67401 USA	Mutlow, A (reprint author), Kansas State Univ, Zool Pharmacol Lab, Dept Clin Sci, Coll Vet Med, Manhattan, KS 66506 USA.		Hunter, Robert P/A-2306-2008	Hunter, Robert P/0000-0003-1224-2376			Allen JL, 1996, J ZOO WILDLIFE MED, V27, P496; ALLEN JL, 1989, J ZOO WILDLIFE MED, V20, P423; BLUMBERG H, 1974, NARCOTIC ANTAGONISTS, V8, P33; CONE EJ, 1974, DRUG METAB DISPOS, V2, P506; GIBALDI M, 1982, PHARMACOKINETICS; HAIGH JC, 1991, J ZOO WILDLIFE MED, V22, P318; HAIGH JC, 1995, J WILDLIFE DIS, V31, P37, DOI 10.7589/0090-3558-31.1.37; HAIGH JC, 1990, J ZOO WILDLIFE MED, V21, P319; HEARD DJ, 1990, J ZOO WILDLIFE MED, V21, P166; Heard DJ, 1996, AM J VET RES, V57, P87; Hunter RP, 2003, J CHROMATOGR B, V793, P351, DOI 10.1016/S1570-0232(03)00351-9; LEE MC, 1988, J NUCL MED, V29, P1207; Mason BJ, 2002, NEUROPSYCHOPHARMACOL, V27, P596, DOI 10.1016/S0893-133X(02)00368-8; MEYER MC, 1984, J CLIN PSYCHIAT, V45, P15; Miller MW, 1996, J WILDLIFE DIS, V32, P234, DOI 10.7589/0090-3558-32.2.234; PACE NL, 1979, J PHARMACOL EXP THER, V208, P254; Porter SJ, 2002, ADDICT BIOL, V7, P219, DOI 10.1080/135562102200120442; RESNICK RB, 1974, AM J PSYCHIAT, V131, P646; RIVIERE JE, 1999, COMP PHARMACOKINETIC; Sleeman JM, 1997, J ZOO WILDLIFE MED, V28, P158; VEREBEY K, 1976, CLIN PHARMACOL THER, V20, P315; VEREBEY K, 1975, AM J DRUG ALCOHOL AB, V2, P357, DOI 10.3109/00952997509005661; WALL ME, 1984, DRUG METAB DISPOS, V12, P677; WALL ME, 1981, DRUG METAB DISPOS, V9, P369	24	11	13	0	10	AMER ASSOC ZOO VETERINARIANS	MEDIA	6 NORTH PENNELL ROAD, MEDIA, PA 19063 USA	1042-7260			J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	DEC	2004	35	4					489	496		10.1638/03-074			8	Veterinary Sciences	Veterinary Sciences	889NR	WOS:000226450200007	15732589				2020-06-30	J	O'Hara, JF; Cywinski, JB; Tetzlaff, JE; Xu, M; Gurd, AR; Andrish, JT				O'Hara, JF; Cywinski, JB; Tetzlaff, JE; Xu, M; Gurd, AR; Andrish, JT			The effect of epidural vs intravenous analgesia for posterior spinal fusion surgery	PEDIATRIC ANESTHESIA			English	Article						scoliosis; epidural analgesia; pain; spinal fusion; postoperative recovery	PATIENT-CONTROLLED ANALGESIA; POSTOPERATIVE PAIN; MORPHINE; RELIEF; ADOLESCENTS; CHILDREN	Background: The study objective was to compare epidural vs intravenous postoperative analgesia in posterior spinal fusion surgery patients. Methods: This prospective, double-blinded, randomized study was performed in a tertiary care teaching hospital involving 31 American Society of Anesthesiologists physical status I and II adolescent/young adult patients scheduled for elective posterior spinal fusion surgery for idiopathic scoliosis. Patients were divided into three treatment groups according to the epidural solution infused: group 1 (n = 10) 0.1% bupivacaine + 5 mug.ml(-1) fentanyl; group 2 (n = 12) 0.0625% bupivacaine + 5 mug.ml(-1) fentanyl; group 3 (n = 9) 0.9% sodium chloride (placebo). During general anesthesia all patients received a directly placed midthoracic epidural catheter with a set infusion rate followed by morphine sulfate intravenous patient-controlled analgesic device postoperatively. Morphine sulfate usage and visual analog scores were evaluated at 4 h intervals postoperatively for up to 96 h. Postoperative time to liquids, solid food, ambulation, length of stay, discontinuation of Foley catheter, and side effects were recorded. Results: No consistent difference was detected on intravenous morphine dose usage, visual analog scores, or estimated pain scale over the whole follow-up period. No difference was observed in the epidural groups in time to oral intake of liquids or solids, ambulation, bowel sounds, or length of stay when compared with placebo. Conclusions: By evaluating morphine sulfate usage between groups, the analgesic effectiveness of continuous thoracic epidural analgesia bupivacaine and fentanyl doses used revealed no significant improvement over intravenous morphine sulfate analgesia alone in patients after posterior spinal fusion surgery.	Cleveland Clin Fdn, Dept Gen Anesthesiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Biostat & Epidemiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Orthopaed Surg, Cleveland, OH 44195 USA	O'Hara, JF (reprint author), Cleveland Clin Fdn, Dept Gen Anesthesiol E31, 9500 Euclid Ave, Cleveland, OH 44195 USA.	oharaj@ccf.org					AMARANATH L, 1989, CLIN ORTHOP RELAT R, V249, P223; Arms DM, 1998, ORTHOPEDICS, V21, P539; Cassady JF, 2000, REGION ANESTH PAIN M, V25, P246; Cohen BE, 1997, SPINE, V22, P1892, DOI 10.1097/00007632-199708150-00016; DELEONCASASOLA OA, 1994, REGION ANESTH, V19, P307; GOODARZI M, 1993, J PEDIATR ORTHOPED, V13, P663; JOHNSON RG, 1989, SPINE, V14, P363, DOI 10.1097/00007632-198904000-00003; LOPER KA, 1989, ANESTH ANALG, V68, P350; LOPER KA, 1989, ANESTH ANALG, V69, P826; MURPHY DF, 1984, ACTA ANAESTH SCAND, V28, P144, DOI 10.1111/j.1399-6576.1984.tb02030.x; NAULTY JS, 1989, CLIN J PAIN, V5, pS16, DOI 10.1097/00002508-198903001-00006; PURNELL RJ, 1982, ANAESTHESIA, V37, P1115, DOI 10.1111/j.1365-2044.1982.tb01758.x; RAY CD, 1983, NEUROSURGERY, V13, P388, DOI 10.1227/00006123-198310000-00007; Shaw BA, 1996, J PEDIATR ORTHOPED, V16, P374, DOI 10.1097/01241398-199605000-00016	14	34	34	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	DEC	2004	14	12					1009	1015		10.1111/j.1460-9592.2004.01387.x			7	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	878HM	WOS:000225637400008	15601351				2020-06-30	J	Bouchut, JC; Mallet, E				Bouchut, JC; Mallet, E			Weaning directly from high frequency oscillatory ventilation: the 'open lung' strategy expanded to weaning?	PEDIATRIC ANESTHESIA			English	Letter							RESPIRATORY SYNCYTIAL VIRUS		Hop St Pierre, La Reunion, France	Bouchut, JC (reprint author), Hop St Pierre, La Reunion, France.	jean-christophe.bouchut@chu-lyon.fr					Arnold J H, 2000, Pediatr Crit Care Med, V1, P93, DOI 10.1097/00130478-200010000-00001; Duval ELIM, 1999, RESP MED, V93, P435, DOI 10.1053/rmed.1999.0578; Hammer J, 1997, PEDIATR PULM, V23, P176, DOI 10.1002/(SICI)1099-0496(199703)23:3<176::AID-PPUL2>3.0.CO;2-M; Leclerc F., 2001, Pediatr Crit Care Med, V2, P197, DOI 10.1097/00130478-200107000-00002; Medbo S, 1997, ACTA PAEDIATR, V86, P766, DOI 10.1111/j.1651-2227.1997.tb08584.x; Seller L, 2001, Respir Care, V46, P263	6	1	1	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	DEC	2004	14	12					1030	1031		10.1111/j.1460-9592.2004.01449.x			2	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	878HM	WOS:000225637400013	15601356				2020-06-30	J	Rubin, JT; Towbin, RB; Bartko, M; Baskin, KM; Cahill, AM; Kaye, RD				Rubin, JT; Towbin, RB; Bartko, M; Baskin, KM; Cahill, AM; Kaye, RD			Oral and intravenous caffeine for treatment of children with post-sedation paradoxical hyperactivity	PEDIATRIC RADIOLOGY			English	Article						adverse event; sedation; hyperactivity; caffeine		Background: Paradoxical hyperactivity (PH) is a known complication of sedation in children, especially with barbiturates such as pentobarbital. The accompanying inconsolable irritability and agitation, similar to behaviors reported in children with attention deficit hyperactivity disorder (ADHD), is uncomfortable for the child and anxiety-provoking for parents and health-care workers. Our objective was to describe our experience with oral (PO) and intravenous (IV) caffeine as a treatment for sedation-induced PH. Materials and methods: From January 2000 to April 2003, 19,894 children were sedated in our institution for radiology procedures. Of these, 360 children were diagnosed with PH. A total of 229 children exhibiting symptoms of PH after sedative administration were treated with PO caffeine (n = 88; 43 boys, 45 girls; mean age 4.5 years, mean weight 18.7 kg) or IV caffeine (n = 13 1; 73 boys, 58 girls; mean age 4.8 years, mean weight 20.1 kg) or both (n = 10; 8 boys, 2 girls; mean age 5.0 years, mean weight 19.9 kg). A positive effect was defined as a decrease in agitation, crying, or hyperactivity within 40 min of caffeine administration. A control group (n = 45) was obtained from those 141 children who experienced post-sedation PH but were not treated with caffeine, and matched for age and sex with samples of children treated with IV caffeine (n = 45) and PO caffeine (n = 45). Results: Children treated intravenously received the equivalent of 20 mg/kg caffeine citrate (to a maximum of 200 mg). Of those treated with TV caffeine, 82/131 (63%) showed a positive effect, and returned to baseline behavioral status after an average of 33 min (SD = 23 min). The untreated control group required a significantly longer time to recover (P < 0.01) than those treated with IV caffeine. Children treated orally received approximately 1.0-2.5 mg/kg caffeine in Mountain Dew (Pepsi-Cola Company), and 36/88 (41%) showed a positive effect and returned to baseline behavioral status after an average of 42 min (SD = 27 min). Of the 10 children treated with both PO and IV caffeine, 6 showed a positive effect. There was no significant difference in recovery time between the untreated control group and either the matched orally treated group or the group treated with both IV and PO caffeine. No complications occurred after caffeine administration. Conclusion: IV caffeine appears to be an effective treatment for PH in children with sedation-induced PH. Further controlled prospective study is needed to determine the optimum dose and route of administration and to compare efficacy with other potential drug classes.	Childrens Hosp Philadelphia, Dept Radiol, Philadelphia, PA 19104 USA	Baskin, KM (reprint author), Childrens Hosp Philadelphia, Dept Radiol, 34th St & Civic Ctr Blvd, Philadelphia, PA 19104 USA.	baskin@E-mail.chop.edu		Baskin, Kevin/0000-0001-8928-9688			Adesman Andrew R., 2001, Prim Care Companion J Clin Psychiatry, V3, P66; Bunt C, 2000, PEDIATR RADIOL, V30, P204, DOI 10.1007/s002470050047; Castellanos FX, 2002, FOOD CHEM TOXICOL, V40, P1235, DOI 10.1016/S0278-6915(02)00097-2; Karian VE, 1999, PEDIATR RADIOL, V29, P869, DOI 10.1007/s002470050715; Leung AKC, 2003, ADV THER, V20, P305, DOI 10.1007/BF02849796; SCHECHTER MD, 1985, J CLIN PHARMACOL, V25, P276, DOI 10.1002/j.1552-4604.1985.tb02838.x; SLOVIS TL, 1993, PEDIATR RADIOL, V23, P345, DOI 10.1007/BF02011953; STRAIN JD, 1988, AM J ROENTGENOL, V151, P975, DOI 10.2214/ajr.151.5.975	8	13	13	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0301-0449	1432-1998		PEDIATR RADIOL	Pediatr. Radiol.	DEC	2004	34	12					980	984		10.1007/s00247-004-1303-8			5	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	881JV	WOS:000225864700009	15365651				2020-06-30	J	Trujillo, KA; Kubota, KS; Warmoth, KP				Trujillo, KA; Kubota, KS; Warmoth, KP			Continuous administration of opioids produces locomotor sensitization	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						opioid; sensitization; locomotor; tolerance; analgesia; addiction	BEHAVIORAL SENSITIZATION; INCENTIVE-SENSITIZATION; MORPHINE-TOLERANCE; COCAINE; INTERMITTENT; AMPHETAMINE; INDUCTION; DOPAMINE; RATS; STIMULATION	Sensitization, a behavioral phenomenon characterized by an escalating pattern of drug response following repeated administration, is thought to be involved in the development of addiction. Research on certain drugs of abuse, most notably the psychomotor stimulants amphetamine and cocaine, suggests that two factors are important to the development of sensitization: (1) drugs must be administered intermittently, rather than continuously, and (2) drugs must be administered in association with specific environmental cues. The present studies were performed to determine if the same requirements exist for opioid sensitization. If sensitization occurs following continuous infusion of the drugs, then neither intermittent administration nor specific environmental cues can be critical. Morphine was administered continuously with pellets (2x75 mg) or osmotic pumps (20 mg/kg/day), and fentanyl was administered continuously with osmotic pumps (0.2 mg/kg/day) to male Sprague-Dawley rats. Continuous infusion of either morphine or fentanyl led to an escalating pattern of activity that is characteristic of sensitization to the locomotor effects of the drugs. The escalation of activity was evident across different measures of activity, and persisted beyond continuous administration. The results suggest that, unlike sensitization to cocaine or amphetamine, intermittent administration and environmental specificity are not critical to opioid sensitization. These findings may have implications for the treatment of pain and addiction. (C) 2004 Elsevier Inc. All rights reserved.	Calif State Univ San Marcos, Dept Psychol, San Marcos, CA 92096 USA; Calif State Univ San Marcos, Off Biomed Res & Training, San Marcos, CA 92096 USA	Trujillo, KA (reprint author), Calif State Univ San Marcos, Dept Psychol, San Marcos, CA 92096 USA.	keith@csusm.edu			NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 59833]		Anagnostaras SG, 2002, NEUROPSYCHOPHARMACOL, V26, P703, DOI 10.1016/S0893-133X(01)00402-X; Badiani A, 2000, PSYCHOPHARMACOLOGY, V151, P273, DOI 10.1007/s002130000447; BERGE OG, 1981, NEUROPHARMACOLOGY, V20, P653, DOI 10.1016/0028-3908(81)90112-X; Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9; Carey RJ, 1998, BEHAV BRAIN RES, V92, P67, DOI 10.1016/S0166-4328(97)00126-5; Crombag HS, 2000, BEHAV BRAIN RES, V116, P1, DOI 10.1016/S0166-4328(00)00243-6; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; GOLD LH, 1994, EUR J PHARMACOL, V253, P45, DOI 10.1016/0014-2999(94)90755-2; GUTSTEIN HB, 1993, BRAIN RES, V626, P332, DOI 10.1016/0006-8993(93)90597-G; Izenwasser S, 2002, PHARMACOL BIOCHEM BE, V73, P877, DOI 10.1016/S0091-3057(02)00942-5; Izenwasser S, 1999, BEHAV BRAIN RES, V99, P201, DOI 10.1016/S0166-4328(98)00104-1; JOHANSSON EK, 1992, EUR J DRUG METAB PH, V17, P155, DOI 10.1007/BF03188784; Kalivas PW, 1998, J PSYCHOPHARMACOL, V12, P49, DOI 10.1177/026988119801200107; KHALLOUKBOUSSELMAME R, 1994, EUR NEUROPSYCHOPHARM, V4, P137, DOI 10.1016/0924-977X(94)90007-8; KING GR, 1994, PHARMACOL BIOCHEM BE, V49, P883, DOI 10.1016/0091-3057(94)90238-0; KING GR, 1994, PHARMACOL BIOCHEM BE, V47, P451, DOI 10.1016/0091-3057(94)90142-2; Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0; Kunko PM, 1998, J PHARMACOL EXP THER, V285, P277; MELCHIORRI P, 1992, P NATL ACAD SCI USA, V89, P3696, DOI 10.1073/pnas.89.9.3696; NELSON LR, 1978, NEUROPHARMACOLOGY, V17, P1081, DOI 10.1016/0028-3908(78)90045-X; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; NIELSEN EB, 1981, PHARMACOL BIOCHEM BE, V15, P161, DOI 10.1016/0091-3057(81)90171-4; PERT A, 1990, NIDA RES MG, V97, P208; Pollock J, 1996, PHARMACOL BIOCHEM BE, V53, P67, DOI 10.1016/0091-3057(95)00199-9; POST RM, 1980, LIFE SCI, V26, P1275, DOI 10.1016/0024-3205(80)90085-5; REITH MEA, 1987, J PHARMACOL EXP THER, V243, P281; Robinson TE, 2001, ADDICTION, V96, P103, DOI 10.1046/j.1360-0443.2001.9611038.x; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; ROBINSON TE, 1986, BRAIN RES REV, V11, P157, DOI 10.1016/0165-0173(86)90002-0; Robinson TE, 1998, NEUROSCI BIOBEHAV R, V22, P347, DOI 10.1016/S0149-7634(97)00020-1; Robinson TE, 2002, ANNU REV PSYCHOL, V14, P14; STEWART J, 1993, BEHAV PHARMACOL, V4, P289; Stewart J, 1988, SENSITIZATION NERVOU, P207; TRUJILLO KA, 1991, SCIENCE, V251, P85, DOI 10.1126/science.1824728; TRUJILLO KA, 1994, BRAIN RES, V633, P178, DOI 10.1016/0006-8993(94)91538-5; Vanderschuren LJMJ, 2000, PSYCHOPHARMACOLOGY, V151, P99, DOI 10.1007/s002130000493; Wolf ME, 1998, PROG NEUROBIOL, V54, P679, DOI 10.1016/S0301-0082(97)00090-7; YOBURN BC, 1985, J PHARMACOL EXP THER, V235, P282	38	17	19	2	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	DEC	2004	79	4					661	669		10.1016/j.pbb.2004.09.017			9	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	881YV	WOS:000225906400008	15582674				2020-06-30	J	Burkle, CM; Harrison, BA; Koenig, LF; Decker, PA; Warner, DO; Gastineau, DA				Burkle, CM; Harrison, BA; Koenig, LF; Decker, PA; Warner, DO; Gastineau, DA			Morbidity and mortality of deep sedation in outpatient bone marrow biopsy	AMERICAN JOURNAL OF HEMATOLOGY			English	Article						anesthesiology; hematology; bone marrow biopsy	AMBULATORY SURGERY; ANESTHESIA; PAIN; ASPIRATION; PREDICTORS	Deep sedation is being provided at an increasing rate for patients undergoing bone marrow biopsy and aspiration (BMBA). The aim of this study was to establish the safety of deep sedation used for adults undergoing BMBA. A nonrandomized database analysis and retrospective review of patient records from January 1997 to December 2000 was performed; 5,811 patients were identified as having undergone their first outpatient BMBA. Outcome measures included 30-day mortality and same-day hospital admission; surrogate measures included need for a surgical procedure or receipt of red blood cells within the 48 hr following the BMBA. Patients who received intravenously administered midazolam, fentanyl, and propofol for maintenance of deep sedation plus infiltration of a local anesthetic (n=2,604; 45%) comprised the deep sedation group; those who received infiltration of a local anesthetic but no intravenous sedation or analgesia (n=3,207; 55%) comprised the local anesthesia group. Patients in the deep sedation group compared to those in the local anesthesia group were less likely to die within 30 days (0.69% vs. 1.34%, P=0.018) and less likely to receive red blood cells (1.27% vs. 2.25%, P=0.006). No other differences between the groups were found. Although the study was retrospective and nonrandomized, the results suggest that the use of deep sedation for outpatient BMBA is as safe as using local anesthesia. (C) 2004 Wiley-Liss, Inc.	Mayo Clin, Coll Med, Dept Anesthesiol, Rochester, MN 55905 USA; Mayo Clin Jacksonville, Coll Med, Dept Anesthesiol, Jacksonville, FL 32224 USA; Mayo Clin, Coll Med, Div Biostat, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Hematol, Rochester, MN 55905 USA	Burkle, CM (reprint author), Mayo Clin, Coll Med, Dept Anesthesiol, 200 1st St SW, Rochester, MN 55905 USA.	burkle.christopher@mayo.edu					*AM SOC AN, 2004, JCAHO COMPL TOOL KIT; Bain BJ, 2003, BRIT J HAEMATOL, V121, P949, DOI 10.1046/j.1365-2141.2003.04329.x; Bain BJ, 2001, J CLIN PATHOL, V54, P737, DOI 10.1136/jcp.54.10.737; Bain BJ, 2001, J CLIN PATHOL, V54, P657, DOI 10.1136/jcp.54.9.657; Birkmeyer JD, 2001, SURGERY, V130, P415, DOI 10.1067/msy.2001.117139; CHENEY FW, 1989, JAMA-J AM MED ASSOC, V261, P1599, DOI 10.1001/jama.261.11.1599; DUNCAN PG, 1992, CAN J ANAESTH, V39, P440, DOI 10.1007/BF03008707; Dunlop TJ, 1999, SOUTHERN MED J, V92, P477, DOI 10.1097/00007611-199905000-00005; Eger EI, 2000, PHARMACOECONOMICS, V17, P245, DOI 10.2165/00019053-200017030-00003; GUPTA S, 1992, POSTGRAD MED J, V68, P770, DOI 10.1136/pgmj.68.803.770; Gupta V L, 1998, PRINCIPLES PRACTICE, P1260; Inturrisi CE, 2002, CLIN J PAIN, V18, pS3, DOI 10.1097/00002508-200207001-00002; Johnston JA, 2003, ARCH INTERN MED, V163, P1705, DOI 10.1001/archinte.163.14.1705; MACKAY P, 2002, AUST NZ COLL ANAESTH, P1; Mainwaring CJ, 1996, CLIN LAB HAEMATOL, V18, P285; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; MILLIGAN DW, 1987, J CLIN PATHOL, V40, P696, DOI 10.1136/jcp.40.6.696; NATOF HE, 1980, JAMA-J AM MED ASSOC, V244, P1116, DOI 10.1001/jama.244.10.1116; PUSCHEL K, 1985, DEUT MED WOCHENSCHR, V110, P1611, DOI 10.1055/s-2008-1069055; Ryan D., 2001, WILLIAMS HEMATOLOGY, P17; RYAN DH, 2000, HEMATOLOGY BASIC PRI, P2460; Sprung J, 2003, ANESTHESIOLOGY, V99, P259, DOI 10.1097/00000542-200308000-00006; STOELTING RK, 1999, PHARM PHYSL ANAESTHE, P126; Tesniere Antoine, 2003, Anesthesiol Clin North Am, V21, P273, DOI 10.1016/S0889-8537(02)00081-0; Vanhelleputte PA, 2003, J PAIN SYMPTOM MANAG, V26, P860, DOI 10.1016/S0885-3924(03)00312-9; WARNER MA, 1993, JAMA-J AM MED ASSOC, V270, P1437, DOI 10.1001/jama.270.12.1437; Wolanskyj A P, 2000, Clin Lymphoma, V1, P154, DOI 10.3816/CLM.2000.n.014	27	15	16	0	4	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0361-8609			AM J HEMATOL	Am. J. Hematol.	NOV	2004	77	3					250	256		10.1002/ajh.20185			7	Hematology	Hematology	866MO	WOS:000224777800007	15495252				2020-06-30	J	Wheeler, M; Birmingham, PK; Lugo, RA; Heffner, CL; Cote, CJ				Wheeler, M; Birmingham, PK; Lugo, RA; Heffner, CL; Cote, CJ			The pharmacokinetics of the intravenous formulation of fentanyl citrate administered orally in children undergoing general anesthesia	ANESTHESIA AND ANALGESIA			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 12-16, 2002	ORLANDO, FL	Amer Soc Anesthesiologists				The bioavailability of oral transmucosal fentanyl citrate (OTFC) in children is similar to that of fentanyl solution administered orally to adults. We hypothesized that administering an oral fentanyl solution to children would result in similar fentanyl plasma concentrations and pharmacokinetic variables as administering comparable doses of OTFC. In this pilot study, 10 healthy children requiring postoperative analgesia were enrolled. Each received the undiluted IV fentanyl formulation orally (approximately 10-15 mug/kg; maximum, 400 mug). Venous blood samples were collected from 15 to 600 min after administration. Pharmacokinetic variables were determined using non-compartmental analysis and were compared with a previously studied population of children who received a similar dose of OTFC. Pharmacokinetic variables for the orally administered W fentanyl formulation were as follows: time to reach peak concentration = 1.7 +/- 1.6 h, peak concentration = 1.83 +/- 1.19 ng/mL, half-life 4.7 +/- 2.8 h, area under the plasma concentration time curve = 6.46 +/- 3.96 h (.) ng(-1) (.) mL(-1), apparent oral volume of distribution (V/F) = 17.5 +/- 7.2 L/kg, apparent oral clearance (CL/F) = 3.33 +/- 2.25 L (.) kg(-1) (.) h(-1). Although both OTFC and orally administered IV fentanyl resulted in similar pharmacokinetic variables and plasma concentrations for a given dose, there was marked interpatient variability, particularly in the early hours after oral administration of the IV formulation of fentanyl. This suggests that this method of administration be used with caution until further data are available.	Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Univ Utah, Coll Pharm, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Salt Lake City, UT 84112 USA; Childrens Mem Hosp, Dept Pediat, Chicago, IL 60614 USA; Childrens Mem Hosp, Dept Anesthesiol, Chicago, IL 60614 USA	Wheeler, M (reprint author), Childrens Mem Hosp, Dept Pediat Anesthesiol, 2300 Childrens Plaza, Chicago, IL 60614 USA.	mwheeler@northwestern.edu					*CEPH INC, 2003, ACT BRAND OR TRANSM; Dsida RM, 1998, ANESTH ANALG, V86, P66, DOI 10.1097/00000539-199801000-00013; Egan TD, 2000, ANESTHESIOLOGY, V92, P665, DOI 10.1097/00000542-200003000-00009; GARIELSSON J, 2001, PHARMACOKINETIC PHAR; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; STOECKEL H, 1979, BRIT J ANAESTH, V51, P741, DOI 10.1093/bja/51.8.741; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; TAEGER K, 1988, BRIT J ANAESTH, V61, P425, DOI 10.1093/bja/61.4.425; Wheeler M, 2002, PAEDIATR ANAESTH, V12, P594, DOI 10.1046/j.1460-9592.2002.00949.x	9	11	13	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2004	99	5					1347	1351		10.1213/01.ANE.0000132777.00967.A3			5	Anesthesiology	Anesthesiology	865ED	WOS:000224684400014	15502029				2020-06-30	J	Shiga, Y; Minami, K; Segawa, K; Uezono, Y; Shiraishi, M; Sata, T; Yamamoto, C; Sung-Teh, K				Shiga, Y; Minami, K; Segawa, K; Uezono, Y; Shiraishi, M; Sata, T; Yamamoto, C; Sung-Teh, K			The inhibition of aortic smooth muscle cell proliferation by the intravenous anesthetic ketamine	ANESTHESIA AND ANALGESIA			English	Article							PROTEIN-KINASE-C; SELECTIVE INHIBITOR; PHARMACOKINETICS; POTENT	Smooth muscle cell (SMC) proliferation has been recognized as central to the pathology of both major forms of vascular disease, atherosclerosis and hypertension. Recently, we reported that ketamine inhibits rat mesangial cell proliferation, suggesting that ketamine inhibits cell growth. Although the IV anesthetic ketamine has been widely used clinically, the exact effects of ketamine on vascular SMC proliferation have not been studied. In this study, we investigated the effects of ketamine on vascular SMC proliferation. Ketamine inhibited [3(H)]thymidine incorporation and decreased the number of SMCs in a concentration-dependent manner (10-200 muM); neither propofol nor fentanyl inhibited [H-3]thymidine incorporation into human aortic SMCs. The protein kinase C (PKC) inhibitor GF109203X abolished the ketamine-induced inhibition of [H-3]thymidine incorporation into SMC, but the inhibition was not affected by either the protein kinase A inhibitor H-89 or the protein kinase G inhibitor KT5823. A histological analysis demonstrated the inhibitory effect of ketamine on the intimal thickening of the balloon-injured rat aorta. Based on these results, ketamine inhibits SMCs at clinical concentrations via the PKC pathway. Our results indicate that ketamine might prevent the proliferation of SMCs clinically.	Univ Occupat & Environm Hlth, Sch Med, Dept Anesthesiol, Kitakyushu, Fukuoka 8078555, Japan; Kitakyushu Inst Biophys, Fukuoka, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Pharmacol, Nagasaki 852, Japan	Minami, K (reprint author), Univ Occupat & Environm Hlth, Sch Med, Dept Anesthesiol, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.	kminami@med.uoeh-u.ac.jp					Bowdle TA, 1998, ANESTHESIOLOGY, V88, P82, DOI 10.1097/00000542-199801000-00015; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CLOWES AW, 1983, LAB INVEST, V49, P327; IDVALL J, 1979, BRIT J ANAESTH, V51, P1167, DOI 10.1093/bja/51.12.1167; Jimi N, 1997, ANESTH ANALG, V84, P190, DOI 10.1097/00000539-199701000-00034; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KHARASCH ED, 1995, PHARM BASIS ANESTHES, P357; Kudoh A, 2002, ANESTH ANALG, V94, P552, DOI 10.1097/00000539-200203000-00013; Minami K, 1997, J PHARMACOL EXP THER, V281, P1136; Okamoto T, 2003, ANESTH ANALG, V97, P104, DOI 10.1213/01.ANE.0000066260.99680.11; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WIEBER J, 1975, ANAESTHESIST, V24, P260	14	2	2	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2004	99	5					1408	1412		10.1213/01.ANE.0000132977.84091.B5			5	Anesthesiology	Anesthesiology	865ED	WOS:000224684400024	15502039				2020-06-30	J	Halpern, SH; Muir, H; Breen, TW; Campbell, DC; Barrett, J; Liston, R; Blanchard, JW				Halpern, SH; Muir, H; Breen, TW; Campbell, DC; Barrett, J; Liston, R; Blanchard, JW			A multicenter randomized controlled trial comparing patient-controlled epidural with intravenous analgesia for pain relief in labor	ANESTHESIA AND ANALGESIA			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Obstetric-Anesthesia-and-Perinatology (SOAP)	MAY 31-JUN 04, 2000	MONTREAL, CANADA	Soc Obstet Anesthesia & Perinatol			CESAREAN DELIVERY; PETHIDINE; BLOCK	In this multicenter, randomized, controlled trial, we sought to determine whether patient-controlled epidural analgesia (PCEA) for labor affected the incidence of cesarean delivery when compared with patient-controlled IV opioid analgesia (PCIA). Healthy, term nulliparous patients in 4 Canadian institutions were randomly assigned to receive PCIA with fentanyl (n = 118) or PCEA with 0.08% bupivacaine and fentanyl 1.6 mug/mL (n = 124). There was no difference in the incidence of cesarean delivery-10.2% (12 of 118) versus 9.7% (12 of 124)-or instrumental vaginal delivery-21.2% (25 of 118) versus 29% (36 of 124)-between groups. The duration of the second stage of labor was increased in the PCEA group by a median of 23 min (P = 0.02). Fifty-one patients (43%) in the PCIA group received epidural analgesia: 39 (33%) because of inadequate pain relief and 12 (10%) to facilitate operative delivery. Patients in the PCIA group required more antiemetic therapy (17% versus 6.4%; P = 0.01) and had more sedation (39% versus 5%; P < 0.001). Maternal mean pain and satisfaction with analgesia scores were better in the PCEA group (P < 0.001 and P = 0.02, respectively). More neonates in the PCIA group required active resuscitation (52% versus 31%; P = 0.001) and naloxone (17% versus 3%; P < 0.001). These observations support the hypothesis that PCEA does not result in an increased incidence of obstetrical intervention compared with PCIA. PCEA provides superior analgesia and less maternal and neonatal sedation compared with PCIA.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Anesthesia, Toronto, ON M5S 1B2, Canada; Univ Toronto, Dept Obstet & Gynaecol, Toronto, ON, Canada; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Univ Saskatchewan, Royal Univ Hosp, Dept Anesthesia, Coll Med, Saskatoon, SK, Canada; Univ British Columbia, Dept Obstet & Gynaecol, British Columbia Womens Hosp, Vancouver, BC V5Z 1M9, Canada; Dalhousie Univ, Dept Math & Stat, Stat Consulting Serv, Halifax, NS, Canada	Halpern, SH (reprint author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Anesthesia, 76 Grenville St, Toronto, ON M5S 1B2, Canada.	stephen.halpern@sw.ca	Halpern, Stephen H/K-8304-2012				[Anonymous], 2002, INT J GYNECOL OBSTET, V78, P321; Bofill JA, 1997, AM J OBSTET GYNECOL, V177, P1465, DOI 10.1016/S0002-9378(97)70092-9; BREEN TW, 1993, ANESTH ANALG, V77, P919; Clark A, 1998, AM J OBSTET GYNECOL, V179, P1527, DOI 10.1016/S0002-9378(98)70019-5; Howell CJ, 2001, BRIT J OBSTET GYNAEC, V108, P27, DOI 10.1016/S0306-5456(00)00012-7; Jain S, 2003, INT J GYNECOL OBSTET, V83, P19, DOI 10.1016/S0020-7292(03)00201-7; Leighton BL, 2002, AM J OBSTET GYNECOL, V186, pS69, DOI 10.1067/mob.2002.121813; Lieberman E, 2002, AM J OBSTET GYNECOL, V186, pS31, DOI 10.1067/mob.2002.122522; Loughnan BA, 2000, BRIT J ANAESTH, V84, P715; Nikkola EM, 1997, CAN J ANAESTH, V44, P1248, DOI 10.1007/BF03012771; PHILIPSEN T, 1989, EUR J OBSTET GYN R B, V30, P27, DOI 10.1016/0028-2243(89)90090-7; ROBINSON JO, 1980, ANAESTHESIA, V35, P1173, DOI 10.1111/j.1365-2044.1980.tb05074.x; Sharma SK, 1997, ANESTHESIOLOGY, V87, P487, DOI 10.1097/00000542-199709000-00006; Sharma SK, 2000, CURR ANESTHESIOL REP, V2, P18; THORP JA, 1993, AM J OBSTET GYNECOL, V169, P851, DOI 10.1016/0002-9378(93)90015-B	15	67	74	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2004	99	5					1532	1538		10.1213/01.ANE.0000136850.08972.07			7	Anesthesiology	Anesthesiology	865ED	WOS:000224684400045	15502060				2020-06-30	J	Schricker, T; Meterissian, S; Wykes, L; Eberhart, L; Lattermann, R; Carli, F				Schricker, T; Meterissian, S; Wykes, L; Eberhart, L; Lattermann, R; Carli, F			Postoperative protein sparing with epidural analgesia and hypocaloric dextrose	ANNALS OF SURGERY			English	Article							TOTAL PARENTERAL-NUTRITION; INSULIN-RESISTANCE; NITROGEN-BALANCE; GROWTH-HORMONE; GLUCOSE; METABOLISM; OXIDATION; SURGERY; STRATEGIES; INFUSION	Objective: We examined the hypothesis that epidural analgesia prevents the increase in amino acid oxidation after elective colorectal surgery in patients receiving hypocaloric infusion of dextrose. Summary Background Data: Increased oxidative protein loss after surgery may adversely affect postoperative outcome. We have previously shown that effective segmental pain relief by epidural analgesia improves postoperative substrate utilization, resulting in less protein catabolism. Methods: We randomly allocated 10 patients to receive general anesthesia combined with epidural analgesia using bupivacaine/fentanyl and 10 to receive general anesthesia followed by patient-controlled analgesia with intravenous morphine. All patients received a peripheral 72-hour infusion of dextrose 10% from the day before until the second day after surgery. The dextrose infusion rate was adjusted to provide 50% of the patients' resting energy expenditure. The primary end point was whole-body leucine oxidation as determined by a stable isotope tracer technique (L-[1-C-13]leucine). Results: In the intravenous analgesia group, leucine oxidation increased from 19 +/- 4 to 28 +/- 6 mumol kg(-1) h(-1) after surgery. Epidural analgesia prevented this increase of leucine oxidation (preoperative 21 +/- 6 mumol kg(-1) h(-1), postoperative 21 +/- 5 mumol kg(-1) h(-1)). This difference was statistically significant (P = 0.01; analysis of variance for repeated measures). Conclusion: Perioperative epidural analgesia and hypocaloric dextrose infusion suppress the postoperative increase in amino acid oxidation, thereby saving more than 100 g of lean body mass per day.	McGill Univ, Dept Anaesthesia, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Surg, Montreal, PQ H3A 2T5, Canada; McGill Univ, Sch Dietet & Human Nutr, Montreal, PQ, Canada; Univ Marburg, Dept Anesthesia & Intens Care Med, Marburg, Germany	Schricker, T (reprint author), McGill Univ, Royal Victoria Hosp, Dept Anaesthesia, 687 Pine Ave W,Room S5-05, Montreal, PQ H3A 1A1, Canada.	thomas.schricker@mcgill.ca					Ang B, 2000, NUTRITION, V16, P221, DOI 10.1016/S0899-9007(99)00288-9; Barratt SM, 2002, REGION ANESTH PAIN M, V27, P15, DOI 10.1053/rapm.2002.27850; Basse L, 2002, BRIT J SURG, V89, P446, DOI 10.1046/j.0007-1323.2001.02044.x; Carli F, 2002, ANESTHESIOLOGY, V97, P540, DOI 10.1097/00000542-200209000-00005; Carli F, 1997, METABOLISM, V46, P23, DOI 10.1016/S0026-0495(97)90162-1; CARLI F, 1991, BRIT J ANAESTH, V67, P729, DOI 10.1093/bja/67.6.729; CHANDRA RK, 1983, LANCET, V1, P688; Chang DW, 1998, SHOCK, V10, P155, DOI 10.1097/00024382-199809000-00001; CROWE PJ, 1984, BRIT J SURG, V71, P635, DOI 10.1002/bjs.1800710828; Felbinger TW, 2000, ANASTH INTENSIVMED, V41, P509; FRAYN KN, 1983, J APPL PHYSIOL, V55, P628; GREENBERG GR, 1976, NEW ENGL J MED, V294, P1411, DOI 10.1056/NEJM197606242942601; Greisen J, 2001, ANESTHESIOLOGY, V95, P578, DOI 10.1097/00000542-200109000-00007; Hart DW, 2001, CRIT CARE MED, V29, P1318, DOI 10.1097/00003246-200107000-00004; Heyland DK, 1998, JAMA-J AM MED ASSOC, V280, P2013, DOI 10.1001/jama.280.23.2013; HOUGHTON A, 1978, BRIT J ANAESTH, V50, P495, DOI 10.1093/bja/50.5.495; KEHLET H, 1988, NEUROL BLOCKADE CLIN, P219; LJUNGQVIST O, 1994, J AM COLL SURGEONS, V178, P329; MAMER OA, 1988, METHOD ENZYMOL, V166, P27, DOI 10.1016/S0076-6879(88)66008-3; MATTHEWS DE, 1980, AM J PHYSIOL, V238, pE473; NORDENSTROM J, 1983, ANN SURG, V197, P27, DOI 10.1097/00000658-198301001-00005; PONTING GA, 1988, LANCET, V1, P438; Schricker T, 2000, AM J PHYSIOL-ENDOC M, V279, pE646; STEHLE P, 1989, LANCET, V1, P231; THORELL A, 1994, BRIT J SURG, V81, P59, DOI 10.1002/bjs.1800810120; UCHIDA I, 1988, BRIT J SURG, V75, P557, DOI 10.1002/bjs.1800750618; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; VEDRINNE C, 1989, ANESTH ANALG, V69, P354; WARD HC, 1987, ANN SURG, V206, P56, DOI 10.1097/00000658-198707000-00009; WILLIFORD WO, 1991, NEW ENGL J MED, V325, P525; WILMORE DW, 1991, NEW ENGL J MED, V325, P695, DOI 10.1056/NEJM199109053251005	31	28	31	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	NOV	2004	240	5					916	921		10.1097/01.sla.0000143249.93856.66			6	Surgery	Surgery	865YD	WOS:000224739200025	15492576	Green Published			2020-06-30	J	Forster, JG; Rosenberg, PH				Forster, JG; Rosenberg, PH			Small dose of clonidine mixed with low-dose ropivacaine and fentanyl for epidural analgesia after total knee arthroplasty	BRITISH JOURNAL OF ANAESTHESIA			English	Article; Proceedings Paper	Euroanaesthesia 2004 Meeting	JUN 05-08, 2004	Lisbon, PORTUGAL			anaesthetic techniques, epidural, lumbar; anaesthetics, local, ropivacaine; analgesia, postoperative; analgesics opioid, fentanyl; clonidine	ENHANCES POSTOPERATIVE ANALGESIA; INTRATHECAL CLONIDINE; EXTRADURAL CLONIDINE; HIP-REPLACEMENT; DOUBLE-BLIND; MORPHINE; BUPIVACAINE; EFFICACY; PAIN; METAANALYSIS	Background. We studied whether a small dose of clonidine added to a ropivacaine-fentanyl mixture improves epidural analgesia without provoking side effects typically related to larger amounts of epidural clonidine. Methods. In this randomized, double-blinded study, patients (less than or equal to85 yr, ASA I-III) underwent total knee arthroplasty (TKA) performed under spinal anaesthesia. After the operation, patients received an epidural infusion consisting of ropivacaine 2 mg ml(-1) and fentanyl 5 mug ml(-1) either without (Group RF, n=33) or with clonidine 2 mug ml(-1) (Group RFC, n=36). The infusion rate was adjusted within the range 3-7 ml h(-1). Results. Average rate of infusion was slightly smaller in Group RFC than in Group RF (mean (sd) 4.7 (0.72) vs 5.2 (0.8) ml h(-1), P=0.004). Compared with the RF group, patients in the RFC group required significantly less rescue pain medication, that is i.m. oxycodone (median (25th, 75th percentile) 0 (0, 7) vs 7 (0, 12) mg, P=0.027). Arterial pressure and heart rate were slightly lower in Group RFC throughout the study period (mean difference between the groups 5 mm Hg (P<0.002) and 3 min(-1) (P=0.12), respectively). The groups did not differ statistically with respect to nausea, motor block, and sedation. Conclusions. The small amount of clonidine added to the low-dose ropivacaine-fentanyl mixture reduced the need for opioid rescue pain medication after TKA. Clonidine slightly decreased arterial pressure and heart rate without jeopardizing haemodynamics. Otherwise, the side effect profiles were comparable in both groups.	Univ Helsinki, Cent Hosp, Dept Anaesthesiol & Intens Care Med, FIN-00029 Helsinki, Finland	Forster, JG (reprint author), Univ Helsinki, Cent Hosp, Dept Anaesthesiol & Intens Care Med, PB 340, FIN-00029 Helsinki, Finland.	johannes.forster@hus.fi		Forster, Johannes Georg/0000-0001-5344-9926			Armand S, 1998, BRIT J ANAESTH, V81, P126; Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; BONNET F, 1989, BRIT J ANAESTH, V63, P465, DOI 10.1093/bja/63.4.465; Bromage P R, 1965, Acta Anaesthesiol Scand Suppl, V16, P55; DeKock M, 1997, ANESTHESIOLOGY, V86, P285, DOI 10.1097/00000542-199702000-00003; Eisenach JC, 1996, ANESTHESIOLOGY, V85, P655, DOI 10.1097/00000542-199609000-00026; GRACE D, 1995, ANESTH ANALG, V80, P86, DOI 10.1097/00000539-199501000-00015; JapundzicZigon N, 1997, PHARMACOL RES, V35, P287, DOI 10.1006/phrs.1997.0133; Khasawinah Tariq A, 2003, Am J Ther, V10, P303, DOI 10.1097/00045391-200307000-00012; Milligan KR, 2000, ANESTH ANALG, V91, P393, DOI 10.1097/00000539-200008000-00030; MOGENSEN T, 1992, ANESTH ANALG, V75, P607; MOTSCH J, 1990, ANESTHESIOLOGY, V73, P1067, DOI 10.1097/00000542-199012000-00002; MURATA K, 1989, ANESTH ANALG, V69, P185; Oddby-Muhrbeck E, 2002, ANESTHESIOLOGY, V96, P1109, DOI 10.1097/00000542-200205000-00013; Paech MJ, 2002, ANESTH ANALG, V95, P1396, DOI 10.1097/00000539-200211000-00054; Paech MJ, 1997, ANESTH ANALG, V84, P1323, DOI 10.1097/00000539-199706000-00027; Sites BD, 2003, ANESTH ANALG, V96, P1083, DOI 10.1213/01.ANE.0000055651.24073.59; SOLOMON RE, 1994, ANESTH ANALG, V78, P1164; Svedberg KO, 2002, J CLIN PHARM THER, V27, P39, DOI 10.1046/j.1365-2710.2002.00386.x; Tryba Michael, 2002, Curr Opin Anaesthesiol, V15, P511, DOI 10.1097/00001503-200210000-00007; WILLIAMSRUSSO P, 1992, J AM GERIATR SOC, V40, P759, DOI 10.1111/j.1532-5415.1992.tb01846.x; WULF H, 1994, J PAIN SYMPTOM MANAG, V9, P308, DOI 10.1016/0885-3924(94)90189-9; YAKSH TL, 1981, ANESTHESIOLOGY, V54, P451, DOI 10.1097/00000542-198106000-00004	23	33	33	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	NOV	2004	93	5					670	677		10.1093/bja/aeh259			8	Anesthesiology	Anesthesiology	860RL	WOS:000224360600011	15377579	Bronze			2020-06-30	J	Upton, RN; Grant, C; Martinez, AM; Ludbrook, GL				Upton, RN; Grant, C; Martinez, AM; Ludbrook, GL			Recirculatory model of fentanyl disposition with the brain as the target organ	BRITISH JOURNAL OF ANAESTHESIA			English	Article						brain, cerebral blood flow; heart, cardiac output; pharmacokinetics, brain; pharmacokinetics, fentanyl; pharmacokinetics, lung; pharmacokinetics, models	CEREBRAL-BLOOD-FLOW; DOPPLER VENOUS OUTFLOW; ACID-BASE CHANGES; PHYSIOLOGICAL MODEL; CONSCIOUS SHEEP; COMPARATIVE PHARMACODYNAMICS; TISSUE DISTRIBUTION; DOSE REQUIREMENTS; DRUG DISPOSITION; ANESTHETIZED DOG	Background. The factors affecting the concentrations of fentanyl in the brain after intravenous administration have not been completely quantified. Methods. A model integrating the role of brain, lung and systemic kinetics was developed based on data from conscious instrumented sheep. Brain kinetics were inferred from arterio-sagittal sinus concentration gradients and cerebral blood flow, and lung kinetics from the pulmonary artery-aortic gradient and cardiac output. The best models of the lung and brain were incorporated into a recirculatory model of the whole-body disposition of fentanyl. The validity of the model structure was tested by its ability to describe published data on the effect of hypo-, normo- and hypercarbia on the blood and brain concentrations of fentanyl in anaesthetized dogs. Results. The cerebral kinetics of fentanyl were consistent with partial membrane limitation: the time to 50% equilibration with arterial blood was 10.0 min. Lung kinetics had two distinct components: a shallow compartment that was 50% equilibrated with blood in 0.72 min, and a loss term probably representing sequestration. Despite its simplicity, the recirculatory model was an adequate description of the sheep data. The dog data could be described if cerebral blood flow and cardiac output in the model were allowed to differ between hypo-, normo- and hypercarbic states. The required flow changes were in good agreement with the known effect of these states in the dog. Conclusions. A recirculatory model with the brain as a target organ defined the quantitative relationship between the brain concentrations of fentanyl and the circulatory state.	Royal Adelaide Hosp, Dept Anaesthesia & Intens Care, Adelaide, SA 5005, Australia; Univ Adelaide, Adelaide, SA 5005, Australia	Upton, RN (reprint author), Royal Adelaide Hosp, Dept Anaesthesia & Intens Care, Adelaide, SA 5005, Australia.	richard.upton@adelaide.edu.au	Upton, Richard N/G-4727-2011	Upton, Richard N/0000-0001-9996-4886			AINSLIE SG, 1979, ANESTHESIOLOGY, V51, P293, DOI 10.1097/00000542-197910000-00003; BJORKMAN S, 1993, J PHARMACOKINET BIOP, V21, P255, DOI 10.1007/BF01059779; BJORKMAN S, 1990, ANESTHESIOLOGY, V72, P865, DOI 10.1097/00000542-199005000-00017; Bjorkman S, 1998, ANESTHESIOLOGY, V88, P657, DOI 10.1097/00000542-199803000-00016; CARSON SAA, 1965, J APPL PHYSIOL, V20, P948; CUTLER DJ, 1979, J PHARMACOKINET BIOP, V7, P101, DOI 10.1007/BF01059445; Doolette DJ, 1998, J PHARMACOKINET BIOP, V26, P649, DOI 10.1023/A:1020798806704; Doolette DJ, 1999, CLIN EXP PHARMACOL P, V26, P736, DOI 10.1046/j.1440-1681.1999.03109.x; EBLING WF, 1990, ANESTHESIOLOGY, V72, P650, DOI 10.1097/00000542-199004000-00013; Grant C, 1996, AUST VET J, V73, P129, DOI 10.1111/j.1751-0813.1996.tb10004.x; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; HESS R, 1971, J PHARMACOL EXP THER, V179, P474; Huang YF, 1998, J PHARMACOL EXP THER, V284, P1048; Huang YF, 2003, J PHARM SCI, V92, P180, DOI 10.1002/jps.10273; KONTO HA, 1965, AM J PHYSIOL, V208, P139; KREJCIE TC, 1994, J PHARMACOL EXP THER, V269, P609; KUMAR K, 1987, J CHROMATOGR-BIOMED, V419, P464, DOI 10.1016/0378-4347(87)80317-1; LEYSEN JE, 1983, EUR J PHARMACOL, V87, P209, DOI 10.1016/0014-2999(83)90331-X; LIVINGSTON A, 1991, ACTA VET SCAND S, V87, P170; Ludbrook GL, 1997, BRIT J ANAESTH, V79, P505, DOI 10.1093/bja/79.4.505; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MCPHERSON RW, 1989, ANESTHESIOLOGY, V70, P843, DOI 10.1097/00000542-198905000-00022; ROERIG DL, 1989, ANESTHESIOLOGY, V71, P62, DOI 10.1097/00000542-198907000-00012; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; TAEGER K, 1988, BRIT J ANAESTH, V61, P425, DOI 10.1093/bja/61.4.425; Thompson SJ, 2000, ANESTHESIOLOGY, V92, P1392, DOI 10.1097/00000542-200005000-00030; UPTON R, 1994, J CEREBR BLOOD F MET, V14, P680, DOI 10.1038/jcbfm.1994.85; Upton RN, 1999, BRIT J ANAESTH, V82, P890; Upton RN, 1997, ANESTHESIOLOGY, V86, P1317, DOI 10.1097/00000542-199706000-00013; Upton RN, 1996, BRIT J ANAESTH, V77, P764; Upton RN, 1997, BRIT J ANAESTH, V79, P497, DOI 10.1093/bja/79.4.497; Upton RN, 2000, ANESTHESIOLOGY, V93, P1085, DOI 10.1097/00000542-200010000-00033; Upton RN, 1999, CLIN EXP PHARMACOL P, V26, P381, DOI 10.1046/j.1440-1681.1999.03048.x; Upton RN, 1997, CLIN PHARMACOKINET, V33, P225, DOI 10.2165/00003088-199733030-00005; Upton RN, 2003, BRIT J ANAESTH, V90, P750, DOI 10.1093/bja/aeg131; Upton RN, 1999, J PHARMACOL EXP THER, V290, P694; Upton RN, 2000, J PHARM PHARMACOL, V52, P181, DOI 10.1211/0022357001773832; WEISS M, 1979, EUR J CLIN PHARMACOL, V16, P287, DOI 10.1007/BF00608408; WOOD M, 1990, DRUGS ANESTHESIA PHA, P129	42	13	13	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	NOV	2004	93	5					687	697		10.1093/bja/aeh261			11	Anesthesiology	Anesthesiology	860RL	WOS:000224360600014	15377588	Bronze			2020-06-30	J	Avitsian, R; Borkowski, R; Tetzlaff, J				Avitsian, R; Borkowski, R; Tetzlaff, J			Difficulties in anesthetizing a 106-yr-old patient for total hip replacement	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Letter																ALLEN SJ, 1986, CLIN ANAESTHESIOL, V4, P899; Amar D, 2002, ANESTHESIOLOGY, V96, P352, DOI 10.1097/00000542-200202000-00021; DETSKY AS, 1986, ARCH INTERN MED, V146, P2131, DOI 10.1001/archinte.146.11.2131; Sprung J, 1999, ANESTH ANALG, V89, P384; Tessler MJ, 1999, REGION ANESTH PAIN M, V24, P126	5	0	0	0	0	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	NOV	2004	51	9					942	942		10.1007/BF03018897			1	Anesthesiology	Anesthesiology	874BD	WOS:000225325000019	15525625				2020-06-30	J	Fedder, A; Dall, R; Laurberg, S; Rodt, SA				Fedder, A; Dall, R; Laurberg, S; Rodt, SA			Epidural anaesthesia with bupivacaine does not cause increased oedema in small gut anatomoses in pigs	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthesia; epidural; bupivacaine; opioids; adverse effects; anastomosis surgical; adverse effects; anastomotic breakdown; oedema; local tissue; intestine; mesentery; inflammation; swine	ANASTOMOTIC LEAKAGE; FLUID; ANALGESIA; PERMEABILITY; RISK	Background and objective: Epidural analgesia is widely used for abdominal surgery due to the properties of 'stress-free' anaesthesia and superior pain control. Nevertheless, sympathomimetics are known to antagonize inflammation. The present study was performed to investigate if epidural local anaesthetics caused increased local oedema formation. Methods: Thirty Dansk Landrace pigs were randomized into three groups: epidural bupivacaine, epidural morphine or intravenous (i.v.) fentanyl. All animals were anaesthetized with isoflurane and i.v. midazolam and received an identical fluid regimen. Six small bowel resections were performed over a 3-h period and during the following 3 h the anastomoses were resected. Primary end-points were water content in small bowel and mesentery samples before and after gut anastomosis, lymph flow and urine production. Results: The water content in the small bowel samples was not changed by surgery or by the different anaesthetic protocols. In the mesenteric tissue, there was a highly significant increase in water content of the postanastomotic samples compared to pre-anastomotic samples (P < 0.001) and a significant time treatment interaction was revealed (P < 0.05) suggesting an increase in oedema formation in the epidural local anaesthetic group. Lymph flow did not change during the experiments and there were no significant differences between the groups (P = 0.80). The mean total urine output was 44% higher in the epidural morphine group compared to the local anaesthetic group (P = 0.17). Conclusions: Surgery did not increase gut wall water content, but acute oedema formation resulted in the peri-resectional mesenterial tissue, more prominently so in the bupivacaine group.	Aarhus Univ Hosp, Unit Colorectal Surg, Aarhus, Denmark; Aarhus Univ Hosp, Dept Anaesthesiol, Aarhus, Denmark	Rodt, SA (reprint author), Aarhus Kommune Hosp, Tage Hansens Gade 2, DK-8000 Aarhus C, Denmark.	svein.rodt@aas.auh.dk					Adolphs J, 2003, ANESTHESIOLOGY, V99, P685, DOI 10.1097/00000542-200309000-00025; AUKLAND K, 1993, PHYSIOL REV, V73, P1, DOI 10.1152/physrev.1993.73.1.1; Benoit Joseph N., 1994, P1669; Brandstrup B, 2003, ANN SURG, V238, P641, DOI 10.1097/01.sla.0000094387.50865.23; Brown DL, 2000, ANESTHESIA, P1491; Gaarden M., 1997, Acta Anaesthesiologica Scandinavica, V41, P184; Holte K, 2002, BRIT J ANAESTH, V89, P622, DOI 10.1093/bja/aef220; Holte K, 2002, Minerva Anestesiol, V68, P152; Holte K, 2001, REGION ANESTH PAIN M, V26, P111, DOI 10.1053/rapm.2001.21241; JOHANSSON K, 1988, BRIT J SURG, V75, P73, DOI 10.1002/bjs.1800750127; KEHLET H, 1989, BRIT J ANAESTH, V63, P189, DOI 10.1093/bja/63.2.189; LIU S, 1995, ANESTHESIOLOGY, V82, P1474, DOI 10.1097/00000542-199506000-00019; MARCINIAK DL, 1978, AM J PHYSIOL, V234, pH180; MELLANDER S, 1968, PHARMACOL REV, V20, P117; MINNEAR FL, 1993, J APPL PHYSIOL, V75, P1171; MOLNAR R, 1998, CLIN ANAESTHESIA PRO, P242; RANDALL HT, 1976, SURG CLIN N AM, V56, P1019; RIPPE B, 1978, ACTA PHYSIOL SCAND, V103, P252, DOI 10.1111/j.1748-1716.1978.tb06212.x; Rullier E, 1998, BRIT J SURG, V85, P355; STEINHELPER ME, 1989, J BIOL CHEM, V264, P10976; Tighe D, 1996, New Horiz, V4, P426	21	5	6	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	NOV	2004	21	11					864	870		10.1017/S0265021504000201			7	Anesthesiology	Anesthesiology	894TF	WOS:000226813800006	15717702				2020-06-30	J	Macdowell, AD; Robinson, AHN; Hill, DJ; Villar, RN				Macdowell, AD; Robinson, AHN; Hill, DJ; Villar, RN			Is epidural anaesthesia acceptable at total hip arthroplasty? A study of the rates of urinary catheterisation	JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME			English	Article							BUPIVACAINE; THROMBOSIS	Epidural anaesthesia, with and without opiate, is widely used in total hip arthroplasty (THA). It may cause urinary retention, leading to catheterisation, and a subsequent increase in the likelihood of deep infection. We investigated prospectively the rate of urinary catheterisation in patients after THA performed under general anaesthesia, with or without peri-operative fentanyl and bupivacaine opiate epidural anaesthesia. Of 173 patients, 75 received general anaesthesia alone and 98 both general and epidural management. The post-operative rate of catheterisation was 14.7% in those who received general anaesthesia alone and 13.3% in those who received both. Our findings suggest that the rate of post-operative urinary catheterisation does not increase when general anaesthesia is supplemented by epidural anaesthesia using fentanyl and bupivicaine.	Addenbrookes Hosp, Dept Orthopaed, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Dept Anaesthesia, Cambridge CB2 2QQ, England	Villar, RN (reprint author), BUPA Cambridge Lea Hosp, Cambridge Hip & Knee Unit, Cambridge CB4 9EL, England.		MacDowell, Alastair/K-4211-2012				AXELSSON K, 1989, ANESTH ANALG, V69, P739; Brinker MR, 1997, ORTHOPEDICS, V20, P109; BROMAGE PR, 1969, CAN ANAESTH SOC J, V16, P37, DOI 10.1007/BF03005776; Dalldorf P G, 1994, J Arthroplasty, V9, P611, DOI 10.1016/0883-5403(94)90114-7; Dauphin A, 1997, J CLIN ANESTH, V9, P200, DOI 10.1016/S0952-8180(97)00035-4; Gedney JA, 1998, ANAESTHESIA, V53, P1148, DOI 10.1046/j.1365-2044.1998.00636.x; REIZ S, 1981, ACTA ANAESTH SCAND, V25, P111, DOI 10.1111/j.1399-6576.1981.tb01619.x; SHARROCK NE, 1991, J BONE JOINT SURG AM, V73A, P502, DOI 10.2106/00004623-199173040-00004; WALTS LF, 1985, CLIN ORTHOP RELAT R, P280; WILLIAMS A, 1995, J ROY SOC MED, V88, P699; WROBLEWSKI BM, 1980, CLIN ORTHOP RELAT R, P209	11	17	18	0	0	BRITISH EDITORIAL SOC BONE JOINT SURGERY	LONDON	22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND	0301-620X			J BONE JOINT SURG BR	J. Bone Joint Surg.-Br. Vol.	NOV	2004	86B	8					1115	1117		10.1302/0301-620X.86B8.14240			3	Orthopedics; Surgery	Orthopedics; Surgery	873IL	WOS:000225273000005	15568522				2020-06-30	J	Hofmeister, EH; Egger, CM				Hofmeister, EH; Egger, CM			Transdermal fentanyl patches in small animals	JOURNAL OF THE AMERICAN ANIMAL HOSPITAL ASSOCIATION			English	Article							ADMINISTERED FENTANYL; SERUM CONCENTRATIONS; DOGS; CATS; PHARMACOKINETICS; ANALGESIA; PLASMA; SYSTEM; OVARIOHYSTERECTOMY; BUTORPHANOL	Fentanyl citrate is a potent opioid that can be delivered by the transdermal route in cats and dogs. Publications regarding transdermal fentanyl patches were obtained and systematically reviewed. Seven studies in cats and seven studies in dogs met the criteria for inclusion in this review. Dogs achieved effective plasma concentrations approximately 24 hours after patch application. Cats achieved effective plasma concentrations 7 hours after patch application. In dogs, transdermal fentanyl produced analgesia for up to 72 hours, except for the immediate 0- to 6-hour postoperative period. In cats, transdermal fentanyl produced analgesia equivalent to intermittent butorphanol administration for up to 72 hours following patch application.	Univ Georgia, Coll Vet Med, Dept Small Anim Med & Surg, Athens, GA 30602 USA; Univ Tennessee, Coll Vet Med, Dept Small Anim Clin Sci, Knoxville, TN 37996 USA	Hofmeister, EH (reprint author), Univ Georgia, Coll Vet Med, Dept Small Anim Med & Surg, Athens, GA 30602 USA.		Holtet, Astrid/B-9316-2012				BAILEY PL, 1987, ANESTH ANALG, V66, P542; BROOME IJ, 1995, ANAESTHESIA, V50, P300, DOI 10.1111/j.1365-2044.1995.tb04603.x; Chalmers I., 1995, SYSTEMATIC REV; CHANG SK, 1993, PHARMACEUT RES, V10, P152, DOI 10.1023/A:1018901903243; Davidson CD, 2004, JAVMA-J AM VET MED A, V224, P700, DOI 10.2460/javma.2004.224.700; DYSON DH, 1990, VET SURG, V19, P398, DOI 10.1111/j.1532-950X.1990.tb01217.x; Egger CM, 2003, VET ANAESTH ANALG, V30, P229, DOI 10.1046/j.1467-2995.2003.00109.x; EGGER CM, 1998, VET SURG, V27, P156; Flannagan LM, 1996, J FORENSIC SCI, V41, P320; Franks JN, 2000, J AM VET MED ASSOC, V217, P1013, DOI 10.2460/javma.2000.217.1013; FUNG DL, 1980, J CLIN PHARMACOL, V20, P652, DOI 10.1002/j.1552-4604.1980.tb01682.x; Gellasch KL, 2002, J AM VET MED ASSOC, V220, P1020, DOI 10.2460/javma.2002.220.1020; Glerum LE, 2001, VET SURG, V30, P351, DOI 10.1053/jvet.2001.24387; Greenhalgh T, 1997, BRIT MED J, V315, P672, DOI 10.1136/bmj.315.7109.672; GUPTA SK, 1992, [No title captured], V7, P17; HARDIE EM, 1998, CURRENT TECHNIQUES S, P3; Hellyer PW, 2001, AM J VET RES, V62, P555, DOI 10.2460/ajvr.2001.62.555; HENGSTMANN JH, 1980, BRIT J ANAESTH, V52, P1021, DOI 10.1093/bja/52.10.1021; HESS R, 1972, EUR J CLIN PHARMACOL, V4, P137, DOI 10.1007/BF00561135; HUG CC, 1979, ANESTHESIOLOGY, V50, P342, DOI 10.1097/00000542-197904000-00011; Hwang S., 1991, TRANSDERMAL FENTANYL, P1; KlockgetherRadke A, 1997, ANAESTHESIST, V46, P428, DOI 10.1007/s001010050420; KRAHWINKEL DJ, 1975, AM J VET RES, V36, P1211; Kyles AE, 1998, RES VET SCI, V65, P245, DOI 10.1016/S0034-5288(98)90151-5; Kyles AE, 1996, AM J VET RES, V57, P715; Lee DD, 2000, AM J VET RES, V61, P672, DOI 10.2460/ajvr.2000.61.672; Lemke KA, 1996, J AM VET MED ASSOC, V209, P776; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MICHIELS M, 1977, EUR J CLIN PHARMACOL, V12, P153, DOI 10.1007/BF00645137; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P757, DOI 10.1016/S0195-5616(08)70005-6; Pettifer GR, 2004, VET ANAESTH ANALG, V31, P109, DOI 10.1111/j.1467-2987.2004.00158.x; Pettifer GR, 2003, AM J VET RES, V64, P1557, DOI 10.2460/ajvr.2003.64.1557; PLEZIA PM, 1989, PHARMACOTHERAPY, V9, P2; PLUMB DC, 1999, VET DRUG HDB; RIVIERE JE, 1991, J PHARM SCI, V80, P615, DOI 10.1002/jps.2600800702; Riviere JE, 2001, ADV DRUG DELIVER REV, V50, P175, DOI 10.1016/S0169-409X(01)00157-0; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; ROSE PG, 1993, ANESTH ANALG, V77, P390, DOI 10.1213/00000539-199377020-00029; ROY SD, 1988, PHARMACEUT RES, V5, P580, DOI 10.1023/A:1015994030251; ScherkNixon M, 1996, J AM ANIM HOSP ASSOC, V32, P19, DOI 10.5326/15473317-32-1-19; Schuh KJ, 1999, PSYCHOPHARMACOLOGY, V145, P162, DOI 10.1007/s002130051045; Schultheiss P J, 1995, Contemp Top Lab Anim Sci, V34, P75; SOUTHAM MA, 1995, ANTI-CANCER DRUG, V6, P29, DOI 10.1097/00001813-199504003-00005; STOELTING RK, 1999, [No title captured]; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; TERENIUS L, 1974, J PHARM PHARMACOL, V26, P146, DOI 10.1111/j.2042-7158.1974.tb09245.x; THURMAN JC, 1996, [No title captured]; Welch JA, 2002, J VET EMERG CRIT CAR, V12, P81, DOI 10.1046/j.1435-6935.2002.00021.x; Yerasi AB, 1997, AM J HEALTH-SYST PH, V54, P85, DOI 10.1093/ajhp/54.1.85	50	48	48	1	18	AMER ANIMAL HOSPITAL ASSOC	LAKEWOOD	PO BOX 150899, LAKEWOOD, CO 80215-0899 USA	0587-2871			J AM ANIM HOSP ASSOC	J. Am. Anim. Hosp. Assoc.	NOV-DEC	2004	40	6					468	478		10.5326/0400468			11	Veterinary Sciences	Veterinary Sciences	054HU	WOS:000238368200006	15533967				2020-06-30	J	Costi, D; van der Walt, JH				Costi, D; van der Walt, JH			General anesthesia in an infant with X-linked myotubular myopathy	PEDIATRIC ANESTHESIA			English	Article						myopathy; X-linked myotubular myopathy; Nissen's fundoplication; relaxants; nondepolarizing	INDUCED CARDIAC-ARREST; NEUROMUSCULAR BLOCKADE; CENTRONUCLEAR MYOPATHY; CONGENITAL MYOPATHIES; MUSCULAR-DYSTROPHY; CHILDREN; MUSCLE; SUCCINYLCHOLINE; REMIFENTANIL; VECURONIUM	We present a 20-week-old infant with the X-linked form of myotubular myopathy who required anesthesia for a Nissen fundoplication procedure where the response to nondepolarizing neuromuscular blockade was evaluated.	Womens & Childrens Hosp, Dept Paediat Anaesthesia, Adelaide, SA 5006, Australia	Costi, D (reprint author), Womens & Childrens Hosp, Dept Paediat Anaesthesia, 72 King William Rd, Adelaide, SA 5006, Australia.	costid@wch.sa.gov.au					Al-Ruwaishid A, 2003, BRAIN DEV-JPN, V25, P62, DOI 10.1016/S0387-7604(02)00151-1; Breslin D, 2000, ANAESTHESIA, V55, P471; Dorchies OM, 2001, NEUROMUSCULAR DISORD, V11, P736, DOI 10.1016/S0960-8966(01)00221-8; Erhan E, 2003, EUR J ANAESTH, V20, P37, DOI 10.1097/00003643-200301000-00007; GENEVER EE, 1971, BRIT J ANAESTH, V43, P984, DOI 10.1093/bja/43.10.984; Gottschalk A, 1998, ANESTHESIOLOGY, V89, P1018, DOI 10.1097/00000542-199810000-00026; Herman GE, 1999, J PEDIATR-US, V134, P206, DOI 10.1016/S0022-3476(99)70417-8; Jungbluth H, 2003, EUR J PAEDIATR NEURO, V7, P23, DOI 10.1016/S1090-3798(02)00136-8; McEntagart M, 2002, NEUROMUSCULAR DISORD, V12, P939, DOI 10.1016/S0960-8966(02)00153-0; MEAKIN G, 1988, BRIT J ANAESTH, V60, P171, DOI 10.1093/bja/60.2.171; MERETOJA OA, 1988, ACTA ANAESTH SCAND, V32, P614, DOI 10.1111/j.1399-6576.1988.tb02797.x; PRICE SR, 1995, PAEDIATR ANAESTH, V5, P267, DOI 10.1111/j.1460-9592.1995.tb00298.x; QUINN RD, 1992, ANN THORAC SURG, V53, P1114, DOI 10.1016/0003-4975(92)90403-Q; Ririe DG, 1998, ANESTHESIOLOGY, V88, P351, DOI 10.1097/00000542-199802000-00013; ROSENBERG H, 1992, ANESTHESIOLOGY, V77, P1054, DOI 10.1097/00000542-199211000-00040; SPIRO AJ, 1966, ARCH NEUROL-CHICAGO, V14, P1, DOI 10.1001/archneur.1966.00470070005001; SULLIVAN M, 1994, CAN J ANAESTH, V41, P497, DOI 10.1007/BF03011544; Taratuto AL, 2002, CURR OPIN NEUROL, V15, P553, DOI 10.1097/00019052-200210000-00006; Tobias J. D., 1994, PAEDIATR ANAESTH, V4, P57; Tokarz A, 2002, EUR J ANAESTH, V19, P842; WIESEL S, 1991, ANESTH ANALG, V72, P696	21	6	6	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	NOV	2004	14	11					964	968		10.1111/j.1460-9592.2004.01307.x			5	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	864TD	WOS:000224654900013	15500500				2020-06-30	J	Broadbear, JH; Winger, G; Woods, JH				Broadbear, JH; Winger, G; Woods, JH			Self-administration of fentanyl, cocaine and ketamine: effects on the pituitary-adrenal axis in rhesus monkeys	PSYCHOPHARMACOLOGY			English	Article; Proceedings Paper	63rd Annual Scientific Meeting of the CPDD	JUN, 2001	Scottsdale, AZ	CPDD		rhesus monkey; cocaine; fentanyl; ketamine; self-administration; adrenocorticotropin; cortisol; reinforcement; behavior	CORTICOTROPIN-RELEASING-FACTOR; PLASMA-CORTICOSTERONE LEVELS; MET-ENKEPHALIN ANALOG; CORTISOL SECRETION; BETA-ENDORPHIN; MACACA-MULATTA; ANTERIOR-PITUITARY; HORMONE-SECRETION; RATS; ACTH	Rationale: Drugs of abuse can affect the functioning of the hypothalamic-pituitary-adrenal (HPA) axis. Acute administration of drugs that serve as reinforcers have been observed to stimulate the rat HPA axis, leading to the suggestion that these stimulatory effects may contribute to the development of drug-maintained behaviors. Objectives: To determine whether reinforcing drugs that are dissimilar with respect to their mechanisms of action have similar effects on HPA axis activity at doses that are self-administered. Rhesus monkeys were randomly assigned to self-administer the mu-opioid agonist fentanyl, the psychomotor stimulant cocaine, or the NMDA antagonist ketamine. Methods: Each monkey was trained to press a lever in order to receive an intravenous injection of drug or saline. Blood samples were obtained before, during, and after the self-administration sessions and assayed for ACTH and cortisol by radioimmunoassay. Results: Fentanyl, cocaine, and ketamine were each self-administered across a range of doses. However, the three drugs differed in their effects on ACTH and cortisol. Cocaine stimulated ACTH and cortisol secretion, a finding that is consistent with previous rat and primate studies. Self-administration of both fentanyl and ketamine inhibited HPA axis activity. HPA inhibition by fentanyl is consistent with other monkey and human studies, and contrasts with the stimulatory effects of mu-opioids in rodents. The inhibitory effect of ketamine on ACTH and cortisol secretion contrasts with findings in the few primate studies that have evaluated NMDA antagonists. Neither fentanyl nor cocaine, at doses that maintained maximum rates of responding, produced significant changes in ACTH and cortisol levels. Conclusions: There appears to be little commonality between different classes of abused drugs and their effects on the HPA axis, which calls into question the necessity for HPA axis stimulation in the reinforcement of drug- maintained behavior.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Psychol, Ann Arbor, MI USA	Broadbear, JH (reprint author), Monash Univ, Dept Physiol, Bldg 13F, Clayton, Vic 3800, Australia.	jillian.broadbear@med.monash.edu.au	Broadbear, Jillian/A-6864-2011	Broadbear, Jillian/0000-0003-3342-5868	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 00254, DA 09161]		ADAMS HA, 1992, ANAESTHESIST, V41, P588; ALLOLIO B, 1986, J CLIN ENDOCR METAB, V63, P1427, DOI 10.1210/jcem-63-6-1427; ALLOLIO B, 1987, ACTA ENDOCRINOL-COP, V114, P509, DOI 10.1530/acta.0.1140509; Broadbear JH, 1999, J PHARMACOL EXP THER, V289, P1641; Broadbear JH, 1999, J PHARMACOL EXP THER, V290, P1347; CALOGERO AE, 1989, BRAIN RES, V505, P7, DOI 10.1016/0006-8993(89)90109-1; DELITALA G, 1983, NEUROENDOCRINOLOGY, V37, P275, DOI 10.1159/000123558; ELVIDGE H, 1976, J ENDOCRINOL, V70, P325, DOI 10.1677/joe.0.0700325; GAILLARD RC, 1981, CLIN ENDOCRINOL, V14, P471, DOI 10.1111/j.1365-2265.1981.tb00636.x; Galici R, 2000, EUR J PHARMACOL, V387, P59, DOI 10.1016/S0014-2999(99)00780-3; GARLAND EJ, 1990, HORM RES, V34, P249; GARLAND EJ, 1989, PSYCHONEUROENDOCRINO, V14, P397, DOI 10.1016/0306-4530(89)90009-7; GAY VL, 1987, ENDOCRINOLOGY, V120, P2289, DOI 10.1210/endo-120-6-2289; Goeders NE, 1996, BRAIN RES, V722, P145, DOI 10.1016/0006-8993(96)00206-5; GOEDERS NE, 1994, PSYCHOPHARMACOLOGY, V114, P63, DOI 10.1007/BF02245445; Goeders NE, 2000, NEUROPSYCHOPHARMACOL, V23, P577, DOI 10.1016/S0893-133X(00)00148-2; HAYES AG, 1985, EUR J PHARMACOL, V116, P75, DOI 10.1016/0014-2999(85)90186-4; HEESCH CM, 1995, AM J MED SCI, V310, P61, DOI 10.1097/00000441-199508000-00004; HOTTA M, 1991, LIFE SCI, V48, P1483, DOI 10.1016/0024-3205(91)90186-F; IYENGAR S, 1990, NEUROPHARMACOLOGY, V29, P299, DOI 10.1016/0028-3908(90)90017-L; JEZOVA D, 1991, NEUROENDOCRINOLOGY, V54, P488; KOEK W, 1989, J PHARMACOL EXP THER, V250, P1019; Lu L, 2003, J NEUROCHEM, V84, P1378, DOI 10.1046/j.1471-4159.2003.01635.x; MENDELSON JH, 1989, J CLIN ENDOCR METAB, V69, P1256, DOI 10.1210/jcem-69-6-1256; MOLDOW RL, 1987, PEPTIDES, V8, P819, DOI 10.1016/0196-9781(87)90065-9; NADER MA, 1989, PEPTIDES, V10, P1199, DOI 10.1016/0196-9781(89)90013-2; PECHNICK RN, 1993, ANN REV PHARM TOXICO, V32, P353; PIAZZA PV, 1991, P NATL ACAD SCI USA, V88, P2088, DOI 10.1073/pnas.88.6.2088; Piazza PV, 1996, ANNU REV PHARMACOL, V36, P359, DOI 10.1146/annurev.pa.36.040196.002043; REYES A, 1990, ENDOCRINOLOGY, V127, P724; RITTMASTER RS, 1985, J CLIN ENDOCR METAB, V60, P891, DOI 10.1210/jcem-60-5-891; RIVIER C, 1987, BRAIN RES, V422, P403, DOI 10.1016/0006-8993(87)90953-X; Sarnyai Z, 2001, PHARMACOL REV, V53, P209; SETCHELL KDR, 1975, J ENDOCRINOL, V67, P241, DOI 10.1677/joe.0.0670241; Shaham Y, 1998, PSYCHOPHARMACOLOGY, V137, P184, DOI 10.1007/s002130050608; SHAHAM Y, 1994, PSYCHOPHARMACOLOGY, V114, P523, DOI 10.1007/BF02249346; TALLARIDA RJ, 1987, MANUAL PHARM CALCULA; VESCOVI PP, 1992, HORM RES, V37, P221, DOI 10.1159/000182316; Ward AS, 1998, BEHAV PHARMACOL, V9, P577, DOI 10.1097/00008877-199811000-00013	39	44	45	0	2	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0033-3158			PSYCHOPHARMACOLOGY	Psychopharmacology	NOV	2004	176	3-4					398	406		10.1007/s00213-004-1891-x			9	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	870IN	WOS:000225050900020	15114434				2020-06-30	J	Herrero-Beaumont, G; Bjorneboe, O; Richarz, U				Herrero-Beaumont, G; Bjorneboe, O; Richarz, U			Transdermal fentanyl for the treatment of pain caused by rheumatoid arthritis	RHEUMATOLOGY INTERNATIONAL			English	Article						analgesia; fentanyl; opioids; pain; rheumatoid arthritis	CHRONIC NONCANCER PAIN; QUALITY-OF-LIFE; OSTEOARTHRITIS; RELEASE; OPIOIDS; TRIAL; KNEE; RECOMMENDATIONS; DISABILITY; MANAGEMENT	This study evaluated transdermal fentanyl (TDF) for the treatment of pain from rheumatoid arthritis (RA) which was not adequately controlled by nonopioid analgesics and/or weak opioids. Following I week of optimization of current analgesic medication, patients (n = 104) started 28-day treatment with 25 mug/h of TDF, with the option to up-titrate until adequate pain control was achieved. Metoclopramide was taken during the 1st week and as needed thereafter. Eighty-four patients completed the treatment phase, and 42 entered the 1-week tapering-off phase. The most frequently used maximum dose was 25 mug/h. The number of patients with pain control increased, particularly in the 1st week of treatment (33% to 77%), to 88% on day 28. From baseline to endpoint, there were reductions in pain (P<0.001), including in "pain right now" at 24 h, and in degree of pain (mean reduction from "severe" to, "moderate"), improvements in function (majority of items in the Health Assessment Questionnaire) (P<0.001), and in quality of life (Short Form 36 physical P < 0.001, mental P < 0.05). Treatment was assessed favorably: greater than or equal to78% would recommend it. Transdermal fentanyl should be considered in treatment programs for patients with RA.	Janssen Cilag Europe Middle E & Asia, CH-6341 Baar, Switzerland; Fdn Jimenez Diaz, E-28040 Madrid, Spain; Martina Hansens Hosp, Sandvika, Norway	Richarz, U (reprint author), Janssen Cilag Europe Middle E & Asia, Sihlbruggstr 111, CH-6341 Baar, Switzerland.	urichar1@jacch.jnj.com		Herrero-Beaumont, Gabriel/0000-0002-3241-991X			Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; ALLAN LA, 2003, 4 C EFIC PRAG 2 6 SE; ALLEN L, 2001, BMJ-BRIT MED J, V322, P1154; *AM PAIN SOC, 2002, GUID MAN PAIN OST RH; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Babul N, 2004, J PAIN SYMPTOM MANAG, V28, P59, DOI 10.1016/j.jpainsymman.2003.11.006; Berliner M, 2002, AKTUEL RHEUMATOL, V27, P230, DOI 10.1055/s-2002-34640; Blomqvist P, 2000, J RHEUMATOL, V27, P1171; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Dellemijn PLI, 1998, J PAIN SYMPTOM MANAG, V16, P220, DOI 10.1016/S0885-3924(98)00070-0; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; Graziotti PJ, 1997, MED J AUSTRALIA, V167, P30, DOI 10.5694/j.1326-5377.1997.tb138760.x; Griessinger N, 2003, DRUG AGING, V20, P571, DOI 10.2165/00002512-200320080-00003; Haddox JD, 1997, PAIN FORUM, V6, P77; Kalso E, 2003, EUR J PAIN, V7, P381, DOI 10.1016/S1090-3801(02)00143-X; Knott L, 2000, CURR MED RES OPIN, V16, P147, DOI 10.1185/0300799009117019; Kosinski M, 2000, ARTHRITIS RHEUM, V43, P1478, DOI 10.1002/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M; MARKENSON JA, 1991, SEMIN ARTHRITIS RHEU, V21, P4, DOI 10.1016/0049-0172(91)90046-3; PAVELKA K, UNPUB CURR MED RES O; Peloso PM, 2000, J RHEUMATOL, V27, P764; Pendleton A, 2000, ANN RHEUM DIS, V59, P936, DOI 10.1136/ard.59.12.936; Portenoy RK, 2000, J PAIN SYMPTOM MANAG, V19, pS16; Roth SH, 2000, ARCH INTERN MED, V160, P853, DOI 10.1001/archinte.160.6.853; SCHUG SA, 1991, DRUGS, V42, P228, DOI 10.2165/00003495-199142020-00005; SHERRER YS, 1986, ARTHRITIS RHEUM, V29, P494, DOI 10.1002/art.1780290406; Simpson RK, 1997, J PAIN SYMPTOM MANAG, V14, P218, DOI 10.1016/S0885-3924(97)00183-8; VANDERHEIDE A, 1995, J RHEUMATOL, V22, P1466; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	28	7	7	0	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8172	1437-160X		RHEUMATOL INT	Rheumatol. Int.	NOV	2004	24	6					325	332		10.1007/s00296-004-0520-7			8	Rheumatology	Rheumatology	874SM	WOS:000225370100003	15480678				2020-06-30	J	Mercadante, S; Villari, P; Ferrera, P; Casuccio, A				Mercadante, S; Villari, P; Ferrera, P; Casuccio, A			Addition of a second opioid may improve opioid response in cancer pain: preliminary data	SUPPORTIVE CARE IN CANCER			English	Article						cancer pain; opioids; tolerance; switching	MORPHINE-TOLERANCE; CLINICAL-ASPECTS; HYPERALGESIA; CONVERSION; MECHANISMS; METHADONE; TOXICITY; ROTATION	Recent experimental data suggest a possible use of an opioid combination to improve analgesia. In cancer patients, a rapid opioid escalation due to either worsening of the pain condition or the development of tolerance is a critical phase, as this condition is associated with a negative prognosis. The aim of this study was to assess the effects of adding a second opioid at low doses in patients with a poor analgesic benefit after dose escalation. Fourteen patients receiving strong opioids who had increased their dosage more than 100% in the last week unsuccessfully were randomly chosen to add a second opioid to the first using an initial equivalent dosage of 20% of the previous therapy. The dose of the second opioid was then changed according to the clinical situation to obtain an acceptable pain control with minimal adverse effects. Pain and symptoms associated with opioid therapy were assessed, and an opioid escalation index (OEI) was calculated at weekly intervals. OEI significantly decreased after adding the second opioid, and this trend was also maintained for the following weeks. Similarly, pain intensity was significantly improved and maintained at acceptable levels for the following weeks. The second opioid did not induce significant opioid-related adverse effects. The opioid combination was able to break opioid escalation in patients with pain syndromes with a poor response to the previous opioid. It allowed for a regaining of analgesia, regardless of the opioid combination used. These preliminary observations should be confirmed in further studies.	La Maddalena Canc Ctr, Palliat Med Chair Anesthesia Intens Care & Emerge, Anesthesia & Intens Care Unit, Palermo, Italy; La Maddalena Canc Ctr, Palliat Med Chair Anesthesia, Pain Relief & Palliat Care Unit, Palermo, Italy; Univ Palermo, Dept Hyg & Microbiol, Palermo, Italy	Mercadante, S (reprint author), Via San Lorenzo Colli 312, I-90146 Palermo, Italy.	terapiadeldolore@la-maddalena.it	casuccio, alessandra/B-1730-2013	casuccio, alessandra/0000-0002-5676-9535			Anderson R, 2001, J PAIN SYMPTOM MANAG, V21, P397, DOI 10.1016/S0885-3924(01)00271-8; BRUERA E, 1989, PAIN, V37, P203, DOI 10.1016/0304-3959(89)90131-0; Daeninck PJ, 1999, ACTA ANAESTH SCAND, V43, P924, DOI 10.1034/j.1399-6576.1999.430910.x; DESTOUTZ ND, 1995, J PAIN SYMPTOM MANAG, V10, P378, DOI 10.1016/0885-3924(95)90924-C; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Eisinger DA, 2002, J NEUROSCI, V22, P10192; GOURLAY GK, 1986, PAIN, V25, P297, DOI 10.1016/0304-3959(86)90234-4; He L, 2002, CELL, V108, P271, DOI 10.1016/S0092-8674(02)00613-X; Mao JR, 2002, PAIN, V100, P213, DOI 10.1016/S0304-3959(02)00422-0; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; Mercadante S, 1999, J CLIN ONCOL, V17, P3307, DOI 10.1200/JCO.1999.17.10.3307; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; Mercadante S, 2003, J PAIN SYMPTOM MANAG, V26, P769, DOI 10.1016/S0885-3924(03)00258-6; Mercadante S, 2001, J PAIN SYMPTOM MANAG, V21, P255, DOI 10.1016/S0885-3924(00)00236-0; Mercadante S, 1999, J PAIN SYMPTOM MANAG, V18, P347, DOI 10.1016/S0885-3924(99)00099-8; MERCADANTE S, 2001, TOPICS PALLIATIVE CA, P213; PORTENOY RK, 1994, CANCER SURV, V21, P49; Ross FB, 2000, PAIN, V84, P421, DOI 10.1016/S0304-3959(99)00230-4; SJOGREN P, 1994, PAIN, V59, P313, DOI 10.1016/0304-3959(94)90084-1	19	39	41	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	NOV	2004	12	11					762	766		10.1007/s00520-004-0650-1			5	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	872CW	WOS:000225185000004	15206014				2020-06-30	J	Bai, SJ; Koo, BN; Kim, JH; Doh, PS; Kim, KH; Shin, YS				Bai, SJ; Koo, BN; Kim, JH; Doh, PS; Kim, KH; Shin, YS			Comparison of continuous epidural and intravenous analgesia for postoperative pain control in pediatric lower extremity surgery	YONSEI MEDICAL JOURNAL			English	Article						children; epidural analgesia; intravenous analgesia; lidocaine; fentanyl	HYPNOTIC REQUIREMENTS; REGIONAL ANESTHESIA; SPINAL-ANESTHESIA; CAUDAL ANESTHESIA; CHILDREN; BUPIVACAINE; LIDOCAINE; BLOCK; CATHETERS; MIDAZOLAM	In recent years epidural anesthesia and analgesia techniques were used in pediatric surgery owing to the development of pediatric epidural catheter needles. And the need of postoperative pain control in pediatric patients is also increasing. We compared combined general-epidural anesthesia and analgesia technique with intravenous fentanyl analgesia after general anesthesia for postoperative analgesic effect and complications in these pediatric patients. We randomly allocated 91 pediatric patients undergoing lower extremities surgery into epidural lidocaine group (n=61) and IV fentanyl group (n=30). During the operation, end-tidal sevoflurane concentration (ETsev) was controlled to maintain the blood pressure and heart rate within 10% of preoperative value. At the postoperative period, Parent Visual Analog Scale (PVAS), Objective Pain Score (OPS) and the incidence of nausea/vomiting were checked immediately, 6 hours and 24 hours after the patient's arrival at general ward. ETsev was significantly low in epidural lidocaine group (p < 0.05). Compare to IV fentanyl group, epidural lidocaine group had significantly lower OPSs at 6 hours after arrival. Epidural lidocaine group had significantly lower PVASs immediately, 6 hrs and 24 hours after arrival. There was no significant difference in the incidence of postoperative nausea and vomiting. A combined general-epidural anesthesia technique significantly reduces intraoperative end-tidal sevoflurane concentration compared to general anesthesia alone. And continuous patient-controlled epidural analgesia reduces postoperative pain scores significantly more than continuous patient-controlled IV fentanyl analgesia without any serious complications in pediatric lower extremity surgery.	Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Seoul 120752, South Korea; St Marys Hosp, Dept Anesthesiol, Galesburg, IL 61401 USA	Shin, YS (reprint author), Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, 134 Shinchon Dong, Seoul 120752, South Korea.	ysshin@yumc.yonsei.ac.kr					Birmingham PK, 2003, ANESTH ANALG, V96, P686, DOI 10.1213/01.ANE.0000047209.18191.9E; CAMPBELL MF, 1933, [No title captured], V30, P245; DALENS B, 1986, ANESTH ANALG, V65, P1069; Gentili M, 1998, BRIT J ANAESTH, V81, P970; GRECO CD, 2002, PEDIAT ANESTHESIA, P749; HANNALLAH RS, 1987, ANESTHESIOLOGY, V66, P832, DOI 10.1097/00000542-198706000-00023; Hodgson PS, 1999, ANESTHESIOLOGY, V91, P1687, DOI 10.1097/00000542-199912000-00021; Hodgson PS, 2001, ANESTHESIOLOGY, V94, P799, DOI 10.1097/00000542-200105000-00018; INAGAKI Y, 1994, ANESTH ANALG, V79, P368; Ivani G, 2002, REGION ANESTH PAIN M, V27, P157, DOI 10.1053/rapm.2002.30706; Kelly AM, 2002, PEDIATR EMERG CARE, V18, P159, DOI 10.1097/00006565-200206000-00002; Kost-Byerly S, 1998, ANESTH ANALG, V86, P712, DOI 10.1097/00000539-199804000-00007; LANIER WL, 1994, ANESTHESIOLOGY, V80, P392, DOI 10.1097/00000542-199402000-00019; LENOX WC, 1995, ANESTHESIOLOGY, V83, P1112, DOI 10.1097/00000542-199511000-00026; LLOYDTHOMAS AR, 1990, BRIT J ANAESTH, V64, P85, DOI 10.1093/bja/64.1.85; McNeely JK, 1997, REGION ANESTH, V22, P428, DOI 10.1016/S1098-7339(97)80028-4; Memis D, 2003, PAEDIATR ANAESTH, V13, P324, DOI 10.1046/j.1460-9592.2003.01020.x; Pollock JE, 2000, ANESTHESIOLOGY, V93, P728, DOI 10.1097/00000542-200009000-00022; Reinoso-Barbero F, 2002, CAN J ANAESTH, V49, P67, DOI 10.1007/BF03020421; Suresh Santhanam, 2002, Anesthesiol Clin North Am, V20, P83, DOI 10.1016/S0889-8537(03)00056-7; TVERSKOY M, 1994, J CLIN ANESTH, V6, P487, DOI 10.1016/0952-8180(94)90089-2; Tverskoy M, 1996, REGION ANESTH, V21, P209; Uguralp S, 2002, J PEDIATR SURG, V37, P610, DOI 10.1053/jpsu.2002.31619; Van Boerum DH, 2000, SPINE, V25, P2355, DOI 10.1097/00007632-200009150-00014; Verghese ST, 2002, ANESTH ANALG, V95, P1219, DOI 10.1097/00000539-200211000-00019; WOOD CE, 1994, CAN J ANAESTH, V41, P613, DOI 10.1007/BF03010002	26	4	5	0	1	YONSEI UNIV COLL MEDICINE	SEOUL	50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA	0513-5796	1976-2437		YONSEI MED J	Yonsei Med. J.	OCT 31	2004	45	5					789	795		10.3349/ymj.2004.45.5.789			7	Medicine, General & Internal	General & Internal Medicine	868FL	WOS:000224899400003	15515187	Bronze			2020-06-30	J	Biricik, HS; Ceylan, C; Sakar, M				Biricik, HS; Ceylan, C; Sakar, M			Effects of pethidine and fentanyl on tear production in dogs	VETERINARY RECORD			English	Article							ANESTHESIA; SEDATION		Harran Univ, Fac Med Vet, Dept Surg, TR-63300 Sanliurfa, Turkey	Biricik, HS (reprint author), Harran Univ, Fac Med Vet, Dept Surg, TR-63300 Sanliurfa, Turkey.						BROCK N, 1995, CAN VET J, V36, P474; CROSS DA, 1977, ANESTH ANALG, V56, P35; DARTT DA, 1994, ADV EXP MED BIOL, V350, P1; Dodam John Richard, 1998, Veterinary Ophthalmology, V1, P57; Hall LL, 2000, COMMUNITY MENT HLT J, V36, P427, DOI 10.1023/A:1001917114105; LUDDERS JW, 1979, J AM VET MED ASSOC, V175, P585; SEVERIN GA, 1995, VET OPHTHALMOLOGY NO, P223; Smith LJ, 2001, J AM VET MED ASSOC, V218, P1101, DOI 10.2460/javma.2001.218.1101; SOONTORNVIPART K, 2003, ONLINE J VET RES, V1, P10; TAYLOR PM, 1986, J SMALL ANIM PRACT, V27, P325, DOI 10.1111/j.1748-5827.1986.tb02144.x; THORIG I, 1983, DOC OPHTHALMOL, V56, P35; THORIG L, 1984, DOC OPHTHALMOL, V58, P307, DOI 10.1007/BF00153632; TOBIN T, 1979, J EQUINE MED SURG, V3, P284; TRIPHATI RC, 1975, CONTACT LENS PRACTIC, P24; VANHAERINGEN NJ, 1981, SURV OPHTHALMOL, V26, P84, DOI 10.1016/0039-6257(81)90145-4; WILSON DV, 1992, VET CLIN N AM-SMALL, V22, P269, DOI 10.1016/S0195-5616(92)50606-4	16	4	4	0	6	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON W1M 0AT, ENGLAND	0042-4900			VET REC	Vet. Rec.	OCT 30	2004	155	18					564	565		10.1136/vr.155.18.564			2	Veterinary Sciences	Veterinary Sciences	878OJ	WOS:000225655800018	15559424				2020-06-30	J	Gao, C; Chen, LW; Tao, YM; Chen, J; Xu, XJ; Zhang, GY; Chi, ZQ				Gao, C; Chen, LW; Tao, YM; Chen, J; Xu, XJ; Zhang, GY; Chi, ZQ			Colocalization of phosphorylated CREB with calcium/calmodulin-dependent protein kinase IV in hippocampal neurons induced by ohmfentanyl stereoisomers	BRAIN RESEARCH			English	Article						ohmfentanyl stereoisomer; cAMP response element-binding protein; Ca2+/calmodulin-dependent protein kinase IV; hippocampal neuron; opioids dependence; phosphorylation	ELEMENT-BINDING PROTEIN; OHMEFENTANYL STEREOISOMERS; ANALGESIC ACTIVITY; OPIOID RECEPTORS; CHRONIC MORPHINE; RAT HIPPOCAMPUS; GENE-EXPRESSION; ADDICTION; MECHANISMS; MICE	The transcription factor cAMP response element-binding protein (CREB) plays an important role in opioids dependence. To better understand the role of CREB in opioids dependence and underlying signal pathways, we compared the effects of three ohmfentanyl stereoisomers ((-)-cis-(3R,4S,2' R) OMF (179202), (+)-cis-(3R,4S,2' S) OMF (179204), (-)-cis-(3S,4S,2' R) OMF (179203)) and morphine on CREB phosphorylation and the expression of Ca2+/calmodulin-dependent protein kinase IV (CaMKIV) in hippocampus derived from mice which displayed conditioned place preference (CPP) behavior by Western blot, and immunohistochemistry analyses. Moreover, we studied the effects of OMF and morphine on CREB phosphorylation and colocalization of phosphorylated CREB (P-CREB) with CaMKIV in cultured rat hippocampal neurons by Western blot, and confocal fluorescence microscopy analyses. The results showed that 179202, 179204 or morphine, which could induce CPP, enhanced CREB phosphorylation and the expression of CaMKIV in hippocampus from CPP mice without affecting total CREB protein level. The CREB phosphorylation of cultured hippocampal neurons was also enhanced and reached its peak level at 30 min upon exposure to 179202 (100 nM), 179204 (100 nM) or morphine (1 muM), while the total CREB protein level was not altered. KN-62 (10 muM), an inhibitor of CaM kinases, prevented CREB phosphorylation induced by morphine, 179202, and 179204 without change of total CREB level. The results of confocal fluorescence microscopy further demonstrated that the activated CREB (P-CREB) was colocalized with CaMKIV in nucleus. 179203, which could not induce CPP, failed to increase the CREB phosphorylation and the colocalization of P-CREB with CaMKIV both in hippocampus from CPP mice and in cultured hippocampal neurons. This is the first evidence to suggest that the increased CREB phosphorylation via CaMKIV signal pathway in hippocampus is relevant to opioids psychological dependence. (C) 2004 Elsevier B.V. All rights reserved.	Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China; Xuzhou Med Coll, Res Ctr Biochem & Mol Biol, Xuzhou 221002, Jiangsu, Peoples R China	Chi, ZQ (reprint author), Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Mat Med, 555 Zuchongzhi Rd,Zhangjiang Hitech Pk, Shanghai 201203, Peoples R China.	zqchi@mail.shcnc.ac.cn					Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9; Bilecki W, 2000, EUR J PHARMACOL, V390, P1, DOI 10.1016/S0014-2999(00)00018-2; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Blendy JA, 1998, J MOL MED-JMM, V76, P104, DOI 10.1007/s001090050197; Brine GA, 1997, CURR MED CHEM, V4, P247; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; Fan GH, 1999, MOL PHARMACOL, V56, P39; Gao C, 1999, ACTA PHARMACOL SIN, V20, P991; Gao C, 2003, ACTA PHARMACOL SIN, V24, P1253; GUITART X, 1992, J NEUROCHEM, V58, P1168, DOI 10.1111/j.1471-4159.1992.tb09377.x; Guo GW, 2000, LIFE SCI, V67, P113, DOI 10.1016/S0024-3205(00)00617-2; Hawes BE, 1998, J NEUROCHEM, V71, P1024; Hyman SE, 1996, SCIENCE, V273, P611, DOI 10.1126/science.273.5275.611; Jin WQ, 1996, ACTA PHARM SINIC, V17, P421; Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7; LaneLadd SB, 1997, J NEUROSCI, V17, P7890; Lin KD, 1999, BIOTECHNIQUES, V26, P318, DOI 10.2144/99262rr02; Liu JG, 2001, BRAIN RES REV, V38, P1, DOI 10.1016/S0165-0173(01)00057-1; Lou LG, 1999, MOL PHARMACOL, V55, P557; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maldonado R, 1996, SCIENCE, V273, P657, DOI 10.1126/science.273.5275.657; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Matthies H, 2000, NEUROPHARMACOLOGY, V39, P952, DOI 10.1016/S0028-3908(99)00203-8; Misra K, 2001, NEUROREPORT, V12, P4133, DOI 10.1097/00001756-200112210-00054; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; Nestler EJ, 2001, SCIENCE, V292, P2266, DOI 10.1126/science.1063024; Przewlocki R, 1999, J NEUROSCI, V19, P9705; Robbins TW, 1996, CURR OPIN NEUROBIOL, V6, P228, DOI 10.1016/S0959-4388(96)80077-8; Shaw-Lutchman TZ, 2002, J NEUROSCI, V22, P3663; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SUZUKI T, 1993, BRAIN RES, V602, P45, DOI 10.1016/0006-8993(93)90239-J; Walters CL, 2001, J NEUROSCI, V21, P9438, DOI 10.1523/JNEUROSCI.21-23-09438.2001; Wang DX, 2000, J NEUROCHEM, V74, P1418, DOI 10.1046/j.1471-4159.2000.0741418.x; WANG ZX, 1995, J MED CHEM, V38, P3652, DOI 10.1021/jm00018a026; Williams JT, 2001, PHYSIOL REV, V81, P299	36	10	12	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 22	2004	1024	1-2					25	33		10.1016/j.brainres.2004.06.084			9	Neurosciences	Neurosciences & Neurology	864WX	WOS:000224664800003	15451364				2020-06-30	J	Scheffold, N; Heinz, B; Albrecht, H; Pickert, A; Cyran, J				Scheffold, N; Heinz, B; Albrecht, H; Pickert, A; Cyran, J			Strychnine poisoning	DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT			German	Article							INTOXICATION	History and admission findings: A 46-year-old man presented two hours after ingestion of about 250 mg strychnine with severe violent, generalized convulsions, triggered by external stimuli. During the convulsion-free periods there were no abnormal signs in the physical examination. Investigation: The presence of strychnine was confirmed by urine analysis with gas chromatography-mass spectrometry. Treatment and course: Because diazepam as anticonvulsant of choice was not effective in abating the convulsions the patient was intubated. A combination with midazolam, fentanil and pancuronium was effective in controlling the convulsions. The patient was discharged from ICU on day three. Conclusion: Fatal outcome of strychnine poisoning demands an aggressive management with early intubation, control of muscle tremors and prevention of rhabdomyolisis and renal failure.	Univ Heidelberg, Akad Lehrkrankenhaus, SLK Kliniken Heilbronn GmbH, Med Klin 1,Schwepunkt Kardiol, D-74078 Heilbronn, Germany; Univ Heidelberg, Klinikum, SLK Kliniken Heilbronn GmbH, Inst Lab Med, D-74078 Heilbronn, Germany	Scheffold, N (reprint author), Univ Heidelberg, Akad Lehrkrankenhaus, SLK Kliniken Heilbronn GmbH, Med Klin 1,Schwepunkt Kardiol, Gesundbrunnen 20-74, D-74078 Heilbronn, Germany.	Norbert.Scheffold@Klinikum-Heilbronn.de					AIKMAN J, 1930, JAMA-J AM MED ASSOC, V30, P1661; BOYD RE, 1983, AM J MED, V74, P507, DOI 10.1016/0002-9343(83)90999-3; CALLAGHAN WG, 1982, CLIN RES ED, V285, P478; Campbell C H, 1968, Med J Aust, V2, P1; Cotten M S, 1966, J Miss State Med Assoc, V7, P466; DECKER WJ, 1982, VET HUM TOXICOL, V24, P161; FINK JL, 1985, LAWS GOVERNING PHARM, P1890; HEISER JM, 1992, J TOXICOL-CLIN TOXIC, V30, P269, DOI 10.3109/15563659209038638; LAMBERT JR, 1981, CAN MED ASSOC J, V1, P1268; LAPPENBERGERPEL.M, 1995, EINFACHE TOXIKOLOGIS, P155; MARON BJ, 1971, J PEDIATR-US, V78, P697, DOI 10.1016/S0022-3476(71)80480-8; NORRIS JC, 1937, AM J CLIN PATHOL, V7, P531; Oberpaur B, 1999, PEDIATR EMERG CARE, V15, P264; PERPER JA, 1985, J FORENSIC SCI, V30, P1248; PFLEGER K, 1992, MASS SPECTRAL GC DAT; SGARAGLI GP, 1973, CLIN TOXICOL, V6, P533, DOI 10.3109/15563657308991052; SMITH B A, 1990, Journal of Emergency Medicine, V8, P321, DOI 10.1016/0736-4679(90)90013-L; TEITELBAUM DT, 1970, CLIN TOXICOL, V3, P267, DOI 10.3109/15563657008990475; Weiss S, 1922, J PHARMACOL EXP THER, V19, P419; WINEK CL, 1986, J ANAL TOXICOL, V10, P120, DOI 10.1093/jat/10.3.120; Wood DM, 2002, CRIT CARE, V6, P456, DOI 10.1186/cc1549	21	2	2	0	13	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0012-0472			DEUT MED WOCHENSCHR	Dtsch. Med. Wochenschr.	OCT 15	2004	129	42					2236	2238		10.1055/s-2004-831869			3	Medicine, General & Internal	General & Internal Medicine	862KA	WOS:000224488300003	15483758				2020-06-30	J	Lessa, MA; Rodrigues, E; Tibirica, E				Lessa, MA; Rodrigues, E; Tibirica, E			Cardioprotective action of fentanyl in a model of central sympathetic overactivity in rabbits: antiarrhythmic and anti-ischemic effects	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						anesthesia; autonomic nervous system; myocardial ischemia; opioids; ventricular arrhythmia	MYOCARDIAL OXYGEN-DEMAND; NITRIC-OXIDE SYNTHASE; CORONARY VASOCONSTRICTION; VENTRICULAR-ARRHYTHMIAS; SUDDEN-DEATH; HEART-RATE; ISCHEMIA; INHIBITION; RAT; MECHANISMS	Background: Sympathetic overactivity resulting from perioperative noxious stimuli elicits hyperdynamic cardiovascular responses that may lead to myocardial ischemia and/or ventricular arrhythmia, especially in patients presenting with coronary artery disease. In the present study we investigated the cardioprotective effects of clinically relevant doses of fentanyl in an experimental model of sympathetic overactivity associated with myocardial ischemia in anesthetized rabbits. Methods: Central sympathetic stimulation was achieved through intracerebroventricular (i.c.v.) injection of L-glutamate (10 mumol), with simultaneous inhibition of nitric oxide (NO) synthesis through i.v. administration of N(omega)-nitro-l-arginine methyl ester (L-NAME; 40 mg kg(-1)). Results: L-glutamate triggered ventricular arrhythmia and electrocardiographic alterations indicative of myocardial ischemia. The intravenous administration of fentanyl (5, 10 or 50 mug kg(-1)) reduced the incidence of ST-segment shift (70, 20 and 10%, respectively, vs. 66.7% in controls) as well as of T-wave inversion from 58.3% to 30, 20 and 10%, respectively. The total number of ventricular premature complexes per minute fell from 65.2 +/- 16 in the control group to 6.8 +/- 3, 3.5 +/- 2 and 2.6 +/- 1.5, respectively. The occurrence of ventricular tachycardia and bigeminy was completely abolished by fentanyl. Finally, the i.v. administration of fentanyl did not induce significant hemodynamic effects (except for dP/dt(max) in the 50 mug kg(-1)-dose). Conclusion: Fentanyl elicits significant cardioprotective effects in a model of arrhythmia resulting from the association of central sympathetic overactivity with myocardial ischemia in rabbits, independently from its systemic hemodynamic actions.	Fiocruz MS, Inst Oswaldo Cruz, Dept Fisiol & Farmacodinam, BR-21045900 Rio De Janeiro, Brazil	Tibirica, E (reprint author), Fiocruz MS, Inst Oswaldo Cruz, Dept Fisiol & Farmacodinam, Av Brazil 4365,CP 926, BR-21045900 Rio De Janeiro, Brazil.	etibi@ioc.fiocruz.br					Airaksinen KEJ, 1999, ANN MED, V31, P240, DOI 10.3109/07853899908995886; AMRANI M, 1992, J PHYSIOL-LONDON, V456, P681, DOI 10.1113/jphysiol.1992.sp019361; Bailey P.L., 2000, ANESTHESIA, P273; BILLMAN GE, 1982, CIRCULATION, V66, P874, DOI 10.1161/01.CIR.66.4.874; Brook RD, 2000, AM J HYPERTENS, V13, p112S, DOI 10.1016/S0895-7061(00)00228-4; Catelli M, 2003, BRAZ J MED BIOL RES, V36, P85, DOI 10.1590/S0100-879X2003000100012; Coda BA, 2001, CLIN ANESTH, P345; FLACKE JW, 1983, ANESTH ANALG, V62, P305; FLACKE JW, 1985, ANESTH ANALG, V64, P1053; GARDINER SM, 1993, BRIT J PHARMACOL, V110, P1457, DOI 10.1111/j.1476-5381.1993.tb13985.x; Grabe-Guimaraes A, 1999, CLIN AUTON RES, V9, P83, DOI 10.1007/BF02311764; Hobbs AJ, 1999, ANNU REV PHARMACOL, V39, P191, DOI 10.1146/annurev.pharmtox.39.1.191; HUMPHRIES RG, 1991, BRIT J PHARMACOL, V102, P565, DOI 10.1111/j.1476-5381.1991.tb12212.x; Kato R, 2002, CAN J ANAESTH, V49, P777, DOI 10.1007/BF03017409; KELM M, 1990, CIRC RES, V66, P1561, DOI 10.1161/01.RES.66.6.1561; Komatsu T, 1992, J Cardiothorac Vasc Anesth, V6, P444, DOI 10.1016/1053-0770(92)90011-U; Kubler W, 1996, HEART, V75, P330, DOI 10.1136/hrt.75.4.330; LATSON TW, 1992, J CLIN ANESTH, V4, P265, DOI 10.1016/0952-8180(92)90127-M; LAUBIE M, 1983, EUR J PHARMACOL, V91, P431, DOI 10.1016/0014-2999(83)90167-X; Moreno H, 1997, CLIN EXP PHARMACOL P, V24, P349, DOI 10.1111/j.1440-1681.1997.tb01200.x; Murphy DB, 1999, J CARDIOVASC PHARM, V33, P122, DOI 10.1097/00005344-199901000-00018; PEROUTKA SJ, 1980, SCIENCE, V208, P610, DOI 10.1126/science.6102801; Pomposiello S, 1997, J CARDIOVASC PHARM, V30, P599, DOI 10.1097/00005344-199711000-00010; Pugsley MK, 2002, PHARMACOL THERAPEUT, V93, P51, DOI 10.1016/S0163-7258(02)00165-1; SAWYER CH, 1954, J COMP NEUROL, V101, P801, DOI 10.1002/cne.901010307; SCHULTZ JEJ, 1995, AM J PHYSIOL-HEART C, V268, pH2157, DOI 10.1152/ajpheart.1995.268.5.H2157; Schutt K, 2001, ZBL GYNAKOL, V123, P37, DOI 10.1055/s-2001-12024; SITSAPESAN R, 1989, BRIT J PHARMACOL, V97, P795, DOI 10.1111/j.1476-5381.1989.tb12018.x; SONNTAG M, 1992, PFLUG ARCH EUR J PHY, V420, P194, DOI 10.1007/BF00374990; TIBIRICA E, 1995, BRIT J PHARMACOL, V115, P1331, DOI 10.1111/j.1476-5381.1995.tb15045.x; Vanhoutte PM, 2003, CIRC J, V67, P572; VANOLI E, 1990, BASIC RES CARDIOL, V85, P305; Wittert G, 1996, BIOCHEM BIOPH RES CO, V218, P877, DOI 10.1006/bbrc.1996.0156; ZUNKIN RS, 1981, LIFE SCI, V29, P2681	34	11	14	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	OCT	2004	48	9					1115	1122		10.1111/j.1399-6576.2004.00472.x			8	Anesthesiology	Anesthesiology	852GP	WOS:000223743900008	15352957				2020-06-30	J	Fannelop, T; Dahle, GO; Matre, K; Segadal, L; Grong, K				Fannelop, T; Dahle, GO; Matre, K; Segadal, L; Grong, K			An anaesthetic protocol in the young domestic pig allowing neuromuscular blockade for studies of cardiac function following cardioplegic arrest and cardiopulmonary bypass	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						anaesthesia; cardiac function; muscular paralysis; swine	RESPONSES; ISCHEMIA; WARM	Background: Neuromuscular blockade should, for ethical reasons, not be allowed in animal experiments unless the use is strongly motivated. Beforehand, the anaesthetic protocol must be documented without muscle relaxation in the species studied. Documentation is difficult to obtain from the scientific literature. When focusing on cardiac function over time, in particular, the ideal anaesthetic protocol should cause no or minor alterations in cardiac variables. Methods: We intended to document an anaesthetic protocol involving ventilation with N2O combined with loading doses and continuous infusions of pentobarbital, fentanyl and midazolam in seven pigs by applying potentially painful stimuli every 15 min for 7 h. Subsequently, left ventricular global and regional function was studied with conductance catheter and strain rate imaging by echocardiography in eight pigs with pancuronium included. Results: Pigs without pancuronium were completely immobilized and unresponsive to potentially painful stimuli and sternotomy, with no accumulation or degradation of anaesthetic agents. With pancuronium included, left ventricular preload gradually decreased together with reduction of cardiac index from 3.52 +/- 0.14 at 2 h to 2.84 +/- 0.11 L min(-1) . m(-2) (+/-SEM) after 7 h of observation. Preload recruitable stroke work decreased after 7 h, whereas peak systolic strain in the anterior left ventricular wall and load-independent indices of diastolic function were not significantly altered. Conclusion: In specific experimental protocols, the anaesthetic protocol described could allow the use of muscular paralysis in young domestic pigs, for instance when involving hypothermic cardiopulmonary bypass, cardioplegic arrest and reperfusion.	Univ Bergen, Dept Surg Sci, Surg Res Lab, Bergen, Norway; Univ Bergen, Inst Med, Bergen, Norway	Fannelop, T (reprint author), Univ Bergen, Haukeland Univ Hosp, Dept Surg Sci, Surg Res Lab, N-5021 Bergen, Norway.	tfan@haukeland.no					Antognini JF, 2002, BRIT J ANAESTH, V89, P156, DOI 10.1093/bja/aef156; ATKINSON RS, 1982, GEN ANAESTHESIA REGI, P168; BAAN J, 1984, CIRCULATION, V70, P812, DOI 10.1161/01.CIR.70.5.812; Baan J., 1989, Automedica, V11, P357; Bogaert J, 2001, AM J PHYSIOL-HEART C, V280, pH610; Boston US, 2001, ANN THORAC SURG, V71, P260, DOI 10.1016/S0003-4975(00)01883-X; Chai PJ, 1999, ANN THORAC SURG, V67, P731, DOI 10.1016/S0003-4975(99)00096-X; Cruccu G, 1997, NEUROSCI LETT, V222, P33, DOI 10.1016/S0304-3940(97)13335-3; Diegeler A, 2000, CIRCULATION, V102, P95; Driessen JJ, 1999, EUR J ANAESTH, V16, P622, DOI 10.1046/j.1365-2346.1999.00551.x; Drummond JC, 1996, ANESTHESIOLOGY, V85, P697, DOI 10.1097/00000542-199610000-00001; Elvenes OP, 2000, ANN THORAC SURG, V69, P1799, DOI 10.1016/S0003-4975(00)01107-3; Ericsson AB, 1999, ANN THORAC SURG, V68, P454, DOI 10.1016/S0003-4975(99)00759-6; ERICSSON AB, 2000, THESIS KONGL CAROLIN; Fujinaga M, 2002, MOL NEUROBIOL, V25, P167, DOI 10.1385/MN:25:2:167; Heier T, 1996, ACTA ANAESTH SCAND, V40, P1073, DOI 10.1111/j.1399-6576.1996.tb05569.x; *I LAB AN RES COMM, 1996, GUID CAR US LAB AN, P64; Irish C L, 1991, J Cardiothorac Vasc Anesth, V5, P132, DOI 10.1016/1053-0770(91)90324-M; Moon PF, 1996, VET CLIN N AM-FOOD A, V12, P663, DOI 10.1016/S0749-0720(15)30392-3; Murray DR, 1996, CIRC RES, V78, P154, DOI 10.1161/01.RES.78.1.154; Perez-de-Sa V, 2003, ANESTH ANALG, V97, P972, DOI 10.1213/01.ANE.0000081788.79516.CB; Schertel ER, 1998, THORAC CARDIOV SURG, V46, P248, DOI 10.1055/s-2007-1013081; Sellgren J, 2003, ACTA ANAESTH SCAND, V47, P541, DOI 10.1034/j.1399-6576.2003.00084.x; Steendijk P, 2001, AM J PHYSIOL-HEART C, V281, pH755; Swindle M M, 1988, J Invest Surg, V1, P65, DOI 10.3109/08941938809141077; Valen G, 2004, EUR J CARDIO-THORAC, V25, P69, DOI 10.1016/S1010-7940(03)00672-9; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1	27	22	22	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	OCT	2004	48	9					1144	1154		10.1111/j.1399-6576.2004.00464.x			11	Anesthesiology	Anesthesiology	852GP	WOS:000223743900012	15352961				2020-06-30	J	Nishikawa, K; Kanaya, N; Kawamata, M; Namiki, A				Nishikawa, K; Kanaya, N; Kawamata, M; Namiki, A			Left ventricular mechanical performance in elderly patients after induction of anaesthesia. A comparison of inhalational induction with sevoflurane and intravenous induction with fentanyl and propofol	ANAESTHESIA			English	Article						anaesthetics, propofol, sevoflurane; analgesics, fentanyl; ventricular function; age factors	EFFECTIVE ARTERIAL ELASTANCE; BAROREFLEX CONTROL; HEART-RATE; INDEX	We investigated changes in left ventricular mechanical performance in 40 patients aged > 70 years in whom anaesthesia had been induced with sevoflurane or with fentanyl and propofol. The ratio of ventricular contractility to arterial properties, which reflects left ventricular performance, was estimated from the ratio of ventricular end-systolic elastance to effective arterial elastance. This ratio decreased after induction in both groups, the magnitude of the decrease being significantly greater in the fentanyl/propofol group than in the sevoflurane group. Decreases in mean arterial pressure after induction of anaesthesia in the two groups were similar, whereas the magnitude of the decrease in heart rate in the sevoflurane group was greater than that in the fentanyl/propofol group. Sevoflurane may therefore be preferable to fentanyl and propofol for induction of anaesthesia in elderly patients because of its lesser effect on left ventricular performance.	Sapporo Med Univ, Sch Med, Dept Anaesthesiol, Chuo Ku, Sapporo, Hokkaido 0608543, Japan	Nishikawa, K (reprint author), Sapporo Med Univ, Sch Med, Dept Anaesthesiol, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan.	nkouki@sapmed.ac.jp					ASANOI H, 1989, CIRC RES, V65, P483, DOI 10.1161/01.RES.65.2.483; BURKHOFF D, 1991, AM J PHYSIOL, V260, pH569; Eger EI, 2001, ANESTH ANALG, V93, P947, DOI 10.1097/00000539-200110000-00029; FREEMAN GL, 1990, J CLIN INVEST, V86, P1278, DOI 10.1172/JCI114835; GOODCHILD CS, 1989, BRIT J ANAESTH, V63, P87, DOI 10.1093/bja/63.1.87; Hayashi K, 2000, ANESTHESIOLOGY, V92, P1769, DOI 10.1097/00000542-200006000-00037; HAYASHIDA K, 1992, CIRC RES, V71, P481, DOI 10.1161/01.RES.71.3.481; Hettrick DA, 1997, ANESTHESIOLOGY, V86, P1088, DOI 10.1097/00000542-199705000-00012; Kanaya N, 2003, ANESTHESIOLOGY, V98, P34, DOI 10.1097/00000542-200301000-00009; Kanaya N, 1998, ANESTHESIOLOGY, V89, P1532, DOI 10.1097/00000542-199812000-00033; KELLY RP, 1992, CIRCULATION, V86, P513, DOI 10.1161/01.CIR.86.2.513; Lennander O, 1996, BRIT J ANAESTH, V77, P399; Mesec A, 1993, Clin Auton Res, V3, P339, DOI 10.1007/BF01827336; MILLER DK, 1988, BRIT MED J, V297, P672, DOI 10.1136/bmj.297.6649.672; Moore PG, 2000, CLIN EXP PHARMACOL P, V27, P1028, DOI 10.1046/j.1440-1681.2000.03371.x; MULIER JP, 1991, ANESTH ANALG, V72, P28; Nagasaki G, 2001, ANESTH ANALG, V93, P1127, DOI 10.1097/00000539-200111000-00012; ROBOTHAM JL, 1991, ANESTHESIOLOGY, V74, P172, DOI 10.1097/00000542-199101000-00026; ROUBY JJ, 1991, ANESTHESIOLOGY, V75, P32, DOI 10.1097/00000542-199107000-00007; SUNAGAWA K, 1985, AM J PHYSIOL, V248, pH477; SUNAGAWA K, 1985, CIRC RES, V56, P586, DOI 10.1161/01.RES.56.4.586	21	11	13	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	OCT	2004	59	10					948	953		10.1111/j.1365-2044.2004.03798.x			6	Anesthesiology	Anesthesiology	854LN	WOS:000223904700003	15488051				2020-06-30	J	Priston, MJ; Hughes, JM; Santillo, M; Christie, IW				Priston, MJ; Hughes, JM; Santillo, M; Christie, IW			Stability of an epidural analgesic admixture containing epinephrine, fentanyl and bupivacaine	ANAESTHESIA			English	Article						analgesia, epidural; analgesics, fentanyl; local anaesthetics, bupivacaine; drug stability	MAJOR SURGERY; DOUBLE-BLIND; ADRENALINE; INFUSION; MIXTURES	The addition of epinephrine to solutions containing fentanyl and bupivacaine for epidural infusion has been shown to improve the quality of analgesia. However, this admixture is not available commercially in the United Kingdom. Moreover, stability data applicable to UK practice for this admixture are limited. This study investigated the stability of fentanyl 2 mug.ml(-1) plus bupivacaine 1 mg.ml(-1) in PVC bags with and without epinephrine 2 mug.ml(-1) over a period of 184 days both at room temperature and at 4 degreesC. All infusions were found to be stable over the study period (> 90% remaining) using stability-indicating High Performance Liquid Chromatography (HPLC) methods, with no changes in physical appearance or pH (range 4.5-4.2). The infusions were prepared using standard pharmaceutical products, so facilitating the batch preparation of epinephrine, fentanyl and bupivacaine epidural solutions by hospital pharmacy departments.	Derriford Hosp, Dept Pharm, Plymouth PL6 8DH, Devon, England; Univ Plymouth, Plymouth PL4 8AA, Devon, England; Univ Exeter, Peninsula Med Sch, Exeter EX4 4QJ, Devon, England; Derriford Hosp, Dept Anaesthesia, Plymouth PL6 8DH, Devon, England	Priston, MJ (reprint author), Derriford Hosp, Dept Pharm, Plymouth PL6 8DH, Devon, England.	mel.priston@phnt.swest.nhs.uk	Rose, Rebecca J/B-7812-2011				ALLEN LV, 1993, AM J HOSP PHARM, V50, P714, DOI 10.1093/ajhp/50.4.714; Bannon L, 2001, ANAESTHESIA, V56, P1021, DOI 10.1046/j.1365-2044.2001.02279-34.x; CONNORS KA, 1986, CHEM STABILITY PHARM; Curatolo M, 2002, ANESTH ANALG, V94, P1381, DOI 10.1097/00000539-200206000-00001; DAWSON PJ, 1992, BRIT J ANAESTH, V68, P414, DOI 10.1093/bja/68.4.414; Kjonniksen I, 2000, ACTA ANAESTH SCAND, V44, P864, DOI 10.1034/j.1399-6576.2000.440713.x; NEWTON DW, 1981, AM J HOSP PHARM, V38, P1314, DOI 10.1093/ajhp/38.9.1314; Niemi G, 1998, ACTA ANAESTH SCAND, V42, P897, DOI 10.1111/j.1399-6576.1998.tb05348.x; Niemi G, 2003, ACTA ANAESTH SCAND, V47, P439, DOI 10.1034/j.1399-6576.2003.00077.x; PARKER E A, 1969, Hospital Pharmacy, V4, P14; Sakaguchi Y, 2000, ANAESTH INTENS CARE, V28, P522, DOI 10.1177/0310057X0002800506; YAU G, 1990, ANAESTHESIA, V45, P1020, DOI 10.1111/j.1365-2044.1990.tb14878.x	12	8	11	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0003-2409			ANAESTHESIA	Anaesthesia	OCT	2004	59	10					979	983		10.1111/j.1365-2044.2004.03803.x			5	Anesthesiology	Anesthesiology	854LN	WOS:000223904700008	15488056				2020-06-30	J	Morin, AM; Vasters, FG; Wulf, H; Geldner, G; Kratz, C; Hedderich, U; Kussin, A; Eisenhardt, G; Eberhart, LHJ				Morin, AM; Vasters, FG; Wulf, H; Geldner, G; Kratz, C; Hedderich, U; Kussin, A; Eisenhardt, G; Eberhart, LHJ			Does fentanyl or midazolam improve patient's comfort and cooperation when given for regional catheter placement? A randomized, controlled and double-blind trial	ANAESTHESIST			German	Article						intravenous fentanyl; intravenous midazolam; regional anaesthesia; patient's acceptance and cooperation; amnesia	ORAL PREMEDICATION; RETROBULBAR ANESTHESIA; LOCAL-ANESTHESIA; PROPOFOL; SURGERY; SEDATION	Background. The procedure of placing a catheter for continuous regional anaesthesia is often associated with fear and pain in the patient. Thus, we evaluated the use of midazolam and fentanyl to improve patient's comfort and cooperation. Methods. After an oral dose of 20 mg clorazepate, 174 patients receiving peripheral nerve catheters for regional anaesthesia Where randomized into 3-groups to receive either intravenous placebo, 3 mg midazolam or 0.1 mg fentanyl immediately before catheter placement in a double-blind manner. Stepwise regression analysis was used to identify factors associated with patient's assessment of subjective discomfort (measured using a VAS 0-10) during the procedure. Amnesia was evaluated 24 h later. The anaesthetist rated patient's cooperation during catheter placement. Results. Female sex and longer duration of catheter placement had significant negative impact on patient's comfort, whereas fentany showed an improvement. Age, body mass index, midazolam and the type of catheter had no influence. The following day 27% of the midazolam group, 6% of the placebo group and 9% of the fentanyl patients did not remember catheter placement. Patient's cooperation was poor in 26% of the midazolam patients but only in 9% of the placebo and 3% of the patients receiving fentanyl. Of the placebo patients 18.4% had to be supplemented with fentanyl because they found the procedure of catheter placement unbearable.-No side-effects occurred in either group. Conclusion. As patient's comfort and cooperation were significantly improved by fentanyl, We recommend fentanyl to facilitate catheter placement for regional anaesthesia.	Klinikum Philipps Univ Marburg, Klin Anasthesie & Intens Therapie, D-35043 Marburg, Germany	Morin, AM (reprint author), Klinikum Philipps Univ Marburg, Klin Anasthesie & Intens Therapie, Baldingerstr, D-35043 Marburg, Germany.	a.morin@web.de					Baris S, 2001, CAN J CARDIOL, V17, P277; Beer GM, 2001, PLAST RECONSTR SURG, V108, P637, DOI 10.1097/00006534-200109010-00006; Heine GH, 2003, BRIT J OPHTHALMOL, V87, P1020, DOI 10.1136/bjo.87.8.1020; LANZ E, 1987, ANAESTHESIST, V36, P197; McHardy FE, 2000, CAN J ANAESTH, V47, P211, DOI 10.1007/BF03018914; SENN P, 1993, KLIN MONATSBL AUGENH, V202, P528, DOI 10.1055/s-2008-1045639; TWERSKY RS, 1993, ANESTHESIOLOGY, V78, P51, DOI 10.1097/00000542-199301000-00009; Veselis RA, 1997, ANESTHESIOLOGY, V87, P749, DOI 10.1097/00000542-199710000-00007; Weindler J, 1996, KLIN MONATSBL AUGENH, V208, P410, DOI 10.1055/s-2008-1035255; Weindler J, 1996, ANAESTHESIST, V45, P826, DOI 10.1007/s001010050317; YIP ASB, 1992, AM J CARDIOL, V70, P593, DOI 10.1016/0002-9149(92)90197-7	11	0	0	0	0	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0003-2417			ANAESTHESIST	Anaesthesist	OCT	2004	53	10					944	+		10.1007/s00101-004-0735-8			5	Anesthesiology	Anesthesiology	867VZ	WOS:000224872000004	15316642				2020-06-30	J	Sia, S; Pelusio, F; Barbagli, R; Rivituso, C				Sia, S; Pelusio, F; Barbagli, R; Rivituso, C			Analgesia before performing a spinal block in the sifting position in patients with femoral shaft fracture: A comparison between femoral nerve block and intravenous fentanyl	ANESTHESIA AND ANALGESIA			English	Article							3-IN-ONE	We conducted this prospective, randomized study to compare the analgesic effect of femoral nerve block and IV fentanyl administration when given to facilitate the sitting position for spinal anesthesia in patients under for femoral shaft fracture. Five minutes going surgery before the placement of spinal block, group FEM patients (n = 10) received a femoral nerve block with lidocaine 1.5% 15 mL, and group IVA patients (n = 10) received IV fentanyl 3 mug/kg. Visual analog scale values during positioning (median and range) were lower in group FEM: 0.5 (0-1) versus 3 (2-6) (P < 0.001). Time to perform spinal anesthesia (mean +/- so) was shorter in group FEM: 1.8 +/- 0.7 min versus 3.0 +/- 1.1 min (P < 0.05). Quality of patient positioning for spinal anesthesia (0 = not satisfactory, 1 = satisfactory, 2 = good, and 3 = optimal) (median and range) was higher in group FEM: 3 (2-3) versus 1.5 (1-3) (P < 0.005). Patient acceptance was less in group IVA (P < 0.05). In one group IVA patient, an oxygen saturation <90% was recorded during the procedure. We conclude that femoral nerve block is more advantageous than IV administration of fentanyl to facilitate the sitting position for spinal anesthesia in patients undergoing surgery for femoral shaft fractures.	Azienda Osped Careggi, Ctr Traumatol Ortoped, Dept Anesthesiol, Florence, Italy	Sia, S (reprint author), Univ Florence, Via Santelli,41, I-50134 Florence, Italy.	sia3@interfree.it					BAILEY PL, 2000, INTRAVENOUS OPIOID A, P273; Barriot P, 1988, JEUR, V1, P21; Capdevila X, 1998, J CLIN ANESTH, V10, P606, DOI 10.1016/S0952-8180(98)00097-X; Capdevila X, 1998, ANESTH ANALG, V86, P1039, DOI 10.1097/00000539-199805000-00025; Lopez S, 2003, REGION ANESTH PAIN M, V28, P203, DOI 10.1053/rapm.2003.50134; MCGLONE R, 1987, ARCH EMERG MED, V4, P163; TARR AJ, 2001, ROCKWOOD GREENS FRAC, P1683; Urbanek B, 2003, ANESTH ANALG, V97, P888, DOI 10.1213/01.ANE.0000072705.86142.5D	8	30	30	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	OCT	2004	99	4					1221	1224		10.1213/01.ANE.0000134812.00471.44			4	Anesthesiology	Anesthesiology	856IW	WOS:000224039900049	15385380				2020-06-30	